PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	NODWELL, JR; GREENBLATT, J				NODWELL, JR; GREENBLATT, J			RECOGNITION OF BOXA ANTITERMINATOR RNA BY THE ESCHERICHIA-COLI ANTITERMINATION FACTORS NUSB AND RIBOSOMAL-PROTEIN S10	CELL			English	Article							ESCHERICHIA-COLI; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; ANTI-TERMINATION; NUCLEOTIDE-SEQUENCE; GENE PROTEIN; TRANSCRIPTION; REGION; SITE; OPERON	The boxA sequences of the E. coli ribosomal RNA (rrn) operons are sufficient to cause RNA polymerase to read through Rho-dependent transcriptional terminators. We show that a complex of the transcription antitermination factors NusB and ribosomal protein S10 interacts specifically with box A RNA. Neither Nus B nor S10 binds boxA RNA on its own, and neither NusA nor NusG affects the interaction of the NusB-S10 complex with boxA RNA. Mutations in boxA that impair its anti-termination activity compromise its interaction with NusB and S10, suggesting that ribosomal protein S10 regulates the synthesis of ribosomal RNA in bacteria. RNA containing the closely related boxA sequence from the bacteriophage lambda nutR site is not stably bound by NusB and S10. This probably explains why antitermination in phage lambda depends on the phage lambda N protein and the boxB component of the nut site, in addition to boxA.			NODWELL, JR (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.							ALBRECHTSEN B, 1990, J MOL BIOL, V213, P123, DOI 10.1016/S0022-2836(05)80125-1; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BREWSTER JM, 1981, J BACTERIOL, V148, P897, DOI 10.1128/JB.148.3.897-903.1981; DOELLING JH, 1989, NUCLEIC ACIDS RES, V17, P5565, DOI 10.1093/nar/17.14.5565; FRANKLIN NC, 1985, J MOL BIOL, V181, P75, DOI 10.1016/0022-2836(85)90325-0; FRIEDMAN DI, 1990, GENE DEV, V4, P2210, DOI 10.1101/gad.4.12a.2210; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; FRIEDMAN DI, 1976, VIROLOGY, V73, P119, DOI 10.1016/0042-6822(76)90066-0; GEORGOPOULOS CP, 1980, MOL GEN GENET, V179, P55, DOI 10.1007/BF00268446; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GREENBLATT J, 1984, CAN J BIOCHEM CELL B, V62, P79, DOI 10.1139/o84-012; GREENBLATT J, 1987, RNA POLYM REGULATION, P357; HOLBEN WE, 1984, P NATL ACAD SCI-BIOL, V81, P6789, DOI 10.1073/pnas.81.21.6789; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; HSIAO KC, 1991, NUCLEIC ACIDS RES, V19, P2787, DOI 10.1093/nar/19.10.2787; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LI J, 1992, J BIOL CHEM, V267, P6012; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; MASON S, 1992, IN PRESS J BIOL CHEM; MASON SW, 1991, GENE DEV, V5, P1504, DOI 10.1101/gad.5.8.1504; MASON SW, 1992, J MOL BIOL, V223, P55, DOI 10.1016/0022-2836(92)90715-V; MORGAN EA, 1986, J BACTERIOL, V168, P1; MORGAN EA, 1980, CELL, V21, P257, DOI 10.1016/0092-8674(80)90133-6; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OLINS PO, 1981, CELL, V26, P205, DOI 10.1016/0092-8674(81)90303-2; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; OLSON ER, 1982, CELL, V31, P61, DOI 10.1016/0092-8674(82)90405-6; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; SALSTROM JS, 1978, J MOL BIOL, V124, P195, DOI 10.1016/0022-2836(78)90156-0; SCHAUER AT, 1987, J MOL BIOL, V194, P679, DOI 10.1016/0022-2836(87)90245-2; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SHARROCK RA, 1984, J BACTERIOL, V163, P704; SWINDLE J, 1988, J BIOL CHEM, V263, P10229; WHALEN W A, 1990, New Biologist, V2, P975; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4515	42	132	135	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					261	268		10.1016/0092-8674(93)90665-D	http://dx.doi.org/10.1016/0092-8674(93)90665-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	7678781				2022-12-01	WOS:A1993KK03800010
J	KORPI, ER; KLEINGOOR, C; KETTENMANN, H; SEEBURG, PH				KORPI, ER; KLEINGOOR, C; KETTENMANN, H; SEEBURG, PH			BENZODIAZEPINE-INDUCED MOTOR IMPAIRMENT LINKED TO POINT MUTATION IN CEREBELLAR GABA(A) RECEPTOR	NATURE			English	Article							ANT RAT LINE; <H-3>RO 15-4513; PLASMID DNA; CELLS; SENSITIVITY; CHANNELS; BINDING; INVERSE; BRAIN	THE selectively outbred alcohol-non-tolerant (ANT) rat line1 is highly susceptible to impairment of postural reflexes by benzodiazepine agonists2 such as diazepam. ANT cerebella are generally devoid3 of diazepam-insensitive high-affinity binding of the benzodiazepine [H-3]Ro15-4513 (refs 4, 5), whereas in non-selected strains such binding marks a granule-cell-specific GABA(A) (gamma-aminobutyric acid) receptor containing the alpha6 subunit5,6. A critical determinant for diazepam insensitivity of this 'wild-type' cerebellar GABA(A) receptor is an arginine residue7 in alpha6 position 100, where other alpha subunits carry a histidine8. Here we report that the alpha6 gene of ANT rats is expressed at wild-type levels but carries a point mutation generating an arginine-to-glutamine substitution at position 100. In consequence, alpha6(Q100)beta2gamma2 receptors show diazepam-mediated potentiation of GABA-activated currents and diazepam-sensitive binding of [H-3]Ro15-4513. Our results suggest that cerebellar motor control may be a distinct behavioural correlate of the alpha6-subunit-containing GABA(A) receptor subtype.	ALKO LTD,BIOMED RES CTR,SF-00101 HELSINKI,FINLAND; UNIV HEIDELBERG,DEPT NEUROBIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	KORPI, ER (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY.		Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Eriksson K., 1981, DEV ANIMAL MODELS PH, P87; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS RA, 1989, FASEB J, V3, P1689, DOI 10.1096/fasebj.3.6.2467834; HELLEVUO K, 1989, PHARMACOL BIOCHEM BE, V34, P399, DOI 10.1016/0091-3057(89)90333-X; KLEINGOOR C, 1991, NEUROSCI LETT, V130, P169, DOI 10.1016/0304-3940(91)90389-B; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MALMINIEMI O, 1989, EUR J PHARMACOL, V169, P53, DOI 10.1016/0014-2999(89)90816-9; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; ROTHSTEIN JD, 1992, J NEUROCHEM, V58, P2102, DOI 10.1111/j.1471-4159.1992.tb10952.x; SANGAMESWARAN L, 1985, P NATL ACAD SCI USA, V82, P5560, DOI 10.1073/pnas.82.16.5560; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TUOMINEN K, 1991, PHARMACOL BIOCHEM BE, V40, P409, DOI 10.1016/0091-3057(91)90572-J; UUSIOUKARI M, 1990, J NEUROCHEM, V54, P1980, DOI 10.1111/j.1471-4159.1990.tb04901.x; UUSIOUKARI M, 1991, ALCOHOL CLIN EXP RES, V15, P241, DOI 10.1111/j.1530-0277.1991.tb01864.x; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y; WISDEN W, 1992, J NEUROSCI, V12, P1040	24	220	224	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					356	359		10.1038/361356a0	http://dx.doi.org/10.1038/361356a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678923				2022-12-01	WOS:A1993KJ59000059
J	PFEIFER, JD; WICK, MJ; ROBERTS, RL; FINDLAY, K; NORMARK, SJ; HARDING, CV				PFEIFER, JD; WICK, MJ; ROBERTS, RL; FINDLAY, K; NORMARK, SJ; HARDING, CV			PHAGOCYTIC PROCESSING OF BACTERIAL-ANTIGENS FOR CLASS-I MHC PRESENTATION TO T-CELLS	NATURE			English	Article							MEMBRANE PROTEIN; LYMPHOCYTES-T; SALMONELLA; INDUCTION; MOLECULES; TOPOLOGY; SURFACE; EPITOPE; INVIVO	CLASS I major histocompatibility complex (MHC) molecules present antigens that are produced within the presenting cell or penetrate from the vacuolar system into the cytosol for processing. Most studies of exogenous antigen processing have used soluble antigens, which are not efficiently presented by class I MHC molecules1 and do not elicit CD8 T-cell responses in vivo. But particulate antigen preparations with no known mechanism for cytosolic penetration can also elicit CD8 T-cell responses in vivo2-7. We report here that phagocytosis of bacteria with no mechanism for cytosolic penetration also results in presentation of bacterial antigens by class I MHC molecules. Moreover, this mechanism is resistant to cycloheximide and Brefeldin A, which block the classical class I processing pathway. These results suggest a novel vacuolar class I processing pathway for exogenous phagocytic antigens.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; ARNQVIST A, 1992, MOL MICROBIOL, V6, P2443; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRUNT LM, 1990, J IMMUNOL, V145, P3540; BURGERT HG, 1989, J EXP MED, V170, P1887, DOI 10.1084/jem.170.6.1887; CARBONE FR, 1989, J EXP MED, V169, P603, DOI 10.1084/jem.169.3.603; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; COLLINS DS, 1992, J IMMUNOL, V148, P3336; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FARRELL JP, 1989, J IMMUNOL, V142, P2052; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; GAO XM, 1992, INFECT IMMUN, V60, P3780, DOI 10.1128/IAI.60.9.3780-3789.1992; GOODING LR, 1980, J IMMUNOL, V124, P1258; GRANT EP, 1992, J IMMUNOL, V148, P13; HARDING CV, 1992, EUR J IMMUNOL, V22, P1865, DOI 10.1002/eji.1830220728; HARDING CV, 1991, J IMMUNOL, V147, P2860; HARDING CV, 1991, J IMMUNOL, V147, P767; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MCREYNOLDS L, 1978, NATURE, V273, P723, DOI 10.1038/273723a0; MISRA R, 1988, J BACTERIOL, V170, P528, DOI 10.1128/jb.170.2.528-533.1988; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; PFEIFER JD, 1992, J IMMUNOL, V149, P2576; REDDY R, 1992, J IMMUNOL, V148, P1585; ROCK KL, 1990, SCIENCE, V249, P918, DOI 10.1126/science.2392683; SARMIENTO M, 1982, IMMUNOL REV, V68, P133; SMITH JD, 1992, P NATL ACAD SCI USA, V89, P7767, DOI 10.1073/pnas.89.16.7767	31	561	586	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					359	362		10.1038/361359a0	http://dx.doi.org/10.1038/361359a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	7678924				2022-12-01	WOS:A1993KJ59000060
J	KUBESCH, P; DORK, T; WULBRAND, U; KALIN, N; NEUMANN, T; WULF, B; GEERLINGS, H; WEISSBRODT, H; VONDERHARDT, H; TUMMLER, B				KUBESCH, P; DORK, T; WULBRAND, U; KALIN, N; NEUMANN, T; WULF, B; GEERLINGS, H; WEISSBRODT, H; VONDERHARDT, H; TUMMLER, B			GENETIC-DETERMINANTS OF AIRWAYS COLONIZATION WITH PSEUDOMONAS-AERUGINOSA IN CYSTIC-FIBROSIS	LANCET			English	Article							POLYMERASE CHAIN-REACTION; DELTA-F508 MUTATION; DNA; IDENTIFICATION; PATHOGENESIS; DISEASE	Exocrine pancreatic insufficiency and lung infection with Pseudomonas aeruginosa are major features of cystic fibrosis (CF). This monogenic disease is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. 267 children and adolescents with CF who were regularly seen at the same centre were assessed for an association of the CFTR mutation genotype with exocrine pancreatic function and the age of onset of chronic colonisation with P aeruginosa. The major mutation DELTAF508 accounted for 74% of CF alleles; 33 further CFTR mutations had been detected on the CF chromosomes of the study population by June, 1992. With the exception of DELTAF508/R347P compound heterozygotes, patients of the same mutation genotype were either pancreas insufficient (PI) or pancreas sufficient (PS). The age-specific colonisation rates with P aeruginosa were significantly lower in PS than in PI patients. The missense and splice site mutations that are ''mild'' CF alleles with respect to exocrine pancreatic function were also ''low risk'' alleles for the acquisition of P aeruginosa. On the other hand, the proportion of P aeruginosa-positive patients increased most rapidly in the PI DELTAF508 compound heterozygotes who were carrying a termination mutation in the nucleotide binding fold-encoding exons. Pancreatic status and the risk of chronic airways' colonisation with P aeruginosa are predisposed by the CFTR mutation genotype and can be differentiated by the type and location of the mutations in the CFTR gene.	HANNOVER MED SCH, DEPT BIOPHYS CHEM,BIOPHYS CHEM ABT, ZENTRUM BIOCHEM 2,KONSTANTY GUTSCHOW STR 8, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT PAEDIAT RESP DIS, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT BIOMETRY, W-3000 HANNOVER 61, GERMANY; HANNOVER MED SCH, DEPT MED MICROBIOL, W-3000 HANNOVER 61, GERMANY	Hannover Medical School; Hannover Medical School; Hannover Medical School; Hannover Medical School			Dörk, Thilo/J-8620-2012	Dörk, Thilo/0000-0002-9458-0282				BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; CLAUSTRES M, 1992, GENOMICS, V13, P907, DOI 10.1016/0888-7543(92)90187-W; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DORK T, 1992, HUM GENET, V88, P417, DOI 10.1007/BF00215676; FANEN P, 1992, GENOMICS, V13, P770, DOI 10.1016/0888-7543(92)90152-I; GEOKAS MC, 1979, AM J PHYSIOL, V236, pE77, DOI 10.1152/ajpendo.1979.236.1.E77; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HOIBY N, 1989, ACTA PAEDIATR SCAND, V78, P395, DOI 10.1111/j.1651-2227.1989.tb11099.x; HOIBY N, 1986, ANNU REV MICROBIOL, V40, P29, DOI 10.1146/annurev.mi.40.100186.000333; JOHANSEN HK, 1991, LANCET, V337, P631, DOI 10.1016/0140-6736(91)92449-C; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS J, 1990, AM J HUM GENET, V46, P395; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; Suter S, 1989, Antibiot Chemother (1971), V42, P158; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; Tsui L C, 1991, Adv Hum Genet, V20, P153; TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265; VANDEKAMER JH, 1949, J BIOL CHEM, V177, P347; ZEITLIN PL, 1992, P NATL ACAD SCI USA, V89, P344, DOI 10.1073/pnas.89.1.344; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	31	83	83	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 23	1993	341	8839					189	193		10.1016/0140-6736(93)90062-L	http://dx.doi.org/10.1016/0140-6736(93)90062-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ219	7678316				2022-12-01	WOS:A1993KJ21900001
J	DUCHESNE, M; SCHWEIGHOFFER, F; PARKER, F; CLERC, F; FROBERT, Y; THANG, MN; TOCQUE, B				DUCHESNE, M; SCHWEIGHOFFER, F; PARKER, F; CLERC, F; FROBERT, Y; THANG, MN; TOCQUE, B			IDENTIFICATION OF THE SH3 DOMAIN OF GAP AS AN ESSENTIAL SEQUENCE FOR RAS-GAP MEDIATED SIGNALING	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPASE-C; P21 GTPASE; BINDING; PHOSPHORYLATION; PURIFICATION; RECEPTORS; INDUCTION	Guanosine triphosphatase activating protein (GAP) is an essential component of Ras signaling pathways. GAP functions in different cell types as a deactivator and a transmitter of cellular Ras signals. A domain (amino acids 275 to 351) encompassing the Src homology region 3 (SH3) of GAP was found to be essential for GAP signaling. A monoclonal antibody was used to block germinal vesicle breakdown (GVBD) induced by the oncogenic protein Ha-ras Lys12 in Xenopus oocytes. The monoclonal antibody, which was found to recognize the peptide containing amino acids 275 to 351 within the amino-terminal domain of GAP, did not modify the stimulation of the Ha-Ras-GTPase by GAP. Injection of peptides corresponding to amino acids 275 to 351 and 317 to 326 blocked GVBD induced by insulin or by Ha-Ras Lys12 but not that induced by progesterone. These findings confirm that GAP is an effector for Ras in Xenopus oocytes and that the SH3 domain is essential for signal transduction.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,13 QUAI JULES GUESDE,BP 14,F-94403 VITRY,FRANCE; CEA,CTR ETUD SACLAY,DRIPP,SERV PHARMACOL & IMMUNOL,F-91191 GIF SUR YVETTE,FRANCE; HOP ST ANTOINE,INSERM,U245,F-75571 PARIS 11,FRANCE	Sanofi-Aventis; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite								BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAI S, 1984, DEV BIOL, V100, P214; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	25	134	146	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					525	528		10.1126/science.7678707	http://dx.doi.org/10.1126/science.7678707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	7678707				2022-12-01	WOS:A1993KJ07900038
J	SEUBERT, P; OLTERSDORF, T; LEE, MG; BARBOUR, R; BLOMQUIST, C; DAVIS, DL; BRYANT, K; FRITZ, LC; GALASKO, D; THAL, LJ; LIEBERBURG, I; SCHENK, DB				SEUBERT, P; OLTERSDORF, T; LEE, MG; BARBOUR, R; BLOMQUIST, C; DAVIS, DL; BRYANT, K; FRITZ, LC; GALASKO, D; THAL, LJ; LIEBERBURG, I; SCHENK, DB			SECRETION OF BETA-AMYLOID PRECURSOR PROTEIN CLEAVED AT THE AMINO TERMINUS OF THE BETA-AMYLOID PEPTIDE	NATURE			English	Article							ALZHEIMERS-DISEASE; DOMAIN; IDENTIFICATION; MUTATION; GENE	THE accumulation in brain of senile plaques containing beta-amyloid protein (Abeta) is a defining feature of Alzheimer's disease1-3. The amyloid precursor protein (APP)4 from which Abeta is derived is subject to several genetic mutations which segregate with rare familial forms of the disease, resulting in early onset of dementia and plaque formation5-9, suggesting that APP metabolism plays a causal role in the disease. Various cell types have been shown to release a soluble form of Abeta, thus allowing for the in vitro study of Abeta generation10-12. We report here evidence that a substantial portion of the APP secreted by human mixed brain cell cultures, as well as that present in cerebrospinal fluid, is of a novel form cleaved precisely at the amino terminus of Abeta, suggesting that a secretory pathway is involved in Abeta genesis.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	SEUBERT, P (corresponding author), ATHENA NEUROSCI INC,800F GATEWAY BLVD,SAN FRANCISCO,CA 94080, USA.							ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kennedy Hilary, 1992, Neurodegeneration, V1, P59; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PULLIAM L, 1984, J VIROL METHODS, V9, P301, DOI 10.1016/0166-0934(84)90056-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WONG CW, 1985, P NATL ACAD SCI USA, V82, P8729, DOI 10.1073/pnas.82.24.8729	26	510	546	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					260	263		10.1038/361260a0	http://dx.doi.org/10.1038/361260a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	7678698				2022-12-01	WOS:A1993KH61400060
J	WHITE, RE; LEE, AB; SHCHERBATKO, AD; LINCOLN, TM; SCHONBRUNN, A; ARMSTRONG, DL				WHITE, RE; LEE, AB; SHCHERBATKO, AD; LINCOLN, TM; SCHONBRUNN, A; ARMSTRONG, DL			POTASSIUM CHANNEL STIMULATION BY NATRIURETIC PEPTIDES THROUGH CGMP-DEPENDENT DEPHOSPHORYLATION	NATURE			English	Article							CA-2+-ACTIVATED K+ CHANNELS; ANTERIOR-PITUITARY-CELLS; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; CALCIUM CHANNELS; CYCLIC-GMP; MODULATION; PHOSPHATASES; RECEPTOR; CYCLASE	NATRIURETIC peptides inhibit the release and action of many hormones through cyclic guanosine monophosphate (cGMp)1,2, but the mechanism of cGMP action is unclear3. In frog ventricular muscle and guinea-pig hippocampal neurons, cGMP inhibits voltage-activated Ca2+ currents by stimulating phosphodiesterase activity and reducing intracellular cyclic AMP4,5; however, this mechanism is not involved in the action of cGMP on other channels6 or on Ca2+ channels in other cells7,8. Natriuretic peptide receptors in the rat pituitary also stimulate guanylyl cyclase activity but inhibit secretion by increasing membrane conductance to potassium9,10. In an electrophysiological study on rat pituitary tumour cells11, we identified the large-conductance, calcium- and voltage-activated potassium channels (BK) as the primary target of another inhibitory neuropeptide, somatostatin. Here we report that atrial natriuretic peptide also stimulates BK channel activity in GH4C1 cells through protein dephosphorylation. Unlike somatostatin, however, the effect of atrial natriuretic peptide on BK channel activity is preceded by a rapid and potent stimulation of cGMP production and requires cGMP-dependent protein kinase activity. Protein phosphatase activation by cGMP-dependent kinase could explain the inhibitory effects of natriuretic peptides on electrical excitability and the antagonism of cGMP and cAMP in many systems12.	NIEHS, CELLULAR & MOLEC PHARMACOL LAB, RES TRIANGLE PK, NC 27709 USA; UNIV ALABAMA, DEPT PATHOL, BIRMINGHAM, AL 35294 USA; UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Alabama System; University of Alabama Birmingham; University of Texas System								ANTONI FA, 1990, J ENDOCRINOL, V126, P183, DOI 10.1677/joe.0.1260183; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DAYANITHI G, 1990, J ENDOCRINOL, V125, P39, DOI 10.1677/joe.0.1250039; DOERNER D, 1988, NEURON, V1, P693, DOI 10.1016/0896-6273(88)90168-7; DORFINGER LJ, 1983, ENDOCRINOLOGY, V13, P1541; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; Goldberg N D, 1973, Adv Cyclic Nucleotide Res, V3, P155; GOY MF, 1991, TRENDS NEUROSCI, V14, P293, DOI 10.1016/0166-2236(91)90140-P; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; KORN SJ, 1989, J GEN PHYSIOL, V94, P789, DOI 10.1085/jgp.94.5.789; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; OHYA Y, 1989, PFLUG ARCH EUR J PHY, V414, P257, DOI 10.1007/BF00584624; ONO K, 1992, J PHYSIOL-LONDON, V454, P673, DOI 10.1113/jphysiol.1992.sp019286; REINHART PH, 1991, J NEUROSCI, V11, P1627; SCHONBRUNN A, 1990, METABOLISM, V39, P96, DOI 10.1016/0026-0495(90)90221-W; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SIKDAR SK, 1989, BRAIN RES, V496, P113, DOI 10.1016/0006-8993(89)91057-3; STEINER AL, 1979, METHOD HORM RADIOIMM, P3; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; TOHSE N, 1991, CIRC RES, V69, P325, DOI 10.1161/01.RES.69.2.325; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WILLIAMS DL, 1988, P NATL ACAD SCI USA, V85, P9360, DOI 10.1073/pnas.85.23.9360	31	241	252	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					263	266		10.1038/361263a0	http://dx.doi.org/10.1038/361263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	7678699				2022-12-01	WOS:A1993KH61400061
J	TOWNSEND, SE; ALLISON, JP				TOWNSEND, SE; ALLISON, JP			TUMOR REJECTION AFTER DIRECT COSTIMULATION OF CD8+ T-CELLS BY B7-TRANSFECTED MELANOMA-CELLS	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CLASS-I; ACTIVATION ANTIGEN-B7; INTERLEUKIN-2; GENERATION; PROLIFERATION; RECOGNITION; EXPRESSION; RESPONSES; PEPTIDES	A variety of tumors are potentially immunogenic but do not stimulate an effective anti-tumor immune response in vivo. Tumors may be capable of delivering antigen-specific signals to T cells, but may not deliver the costimulatory signals necessary for full activation of T cells. Expression of the costimulatory ligand B7 on melanoma cells was found to induce the rejection of a murine melanoma in vivo. This rejection was mediated by CD8+ T cells; CD4+ T cells were not required. These results suggest that B7 expression renders tumor cells capable of effective antigen presentation, leading to their eradication in vivo.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley				Allison, James/0000-0001-8980-5697	NATIONAL CANCER INSTITUTE [R01CA057986] Funding Source: NIH RePORTER; NCI NIH HHS [CA57986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTH RJ, 1990, J IMMUNOL, V144, P1531; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CANTOR H, 1975, J EXP MED, V141, P1390, DOI 10.1084/jem.141.6.1390; DONAWHO C, 1990, CANCER COMMUN, V2, P101, DOI 10.3727/095535490820874597; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GREENBERG PD, 1981, J IMMUNOL, V126, P2100; GROSS JA, 1992, J IMMUNOL, V149, P380; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HARDING FR, UNPUB; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JENKINS MK, 1988, J IMMUNOL, V140, P3324; JENKINS MK, 1991, J IMMUNOL, V147, P2461; KAHN M, 1991, J IMMUNOL, V146, P3235; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; LARSEN CP, 1992, J EXP MED, V176, P1215, DOI 10.1084/jem.176.4.1215; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MIZUOCHI T, 1986, J EXP MED, V163, P603, DOI 10.1084/jem.163.3.603; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423; SCHREIBER H, 1988, ANNU REV IMMUNOL, V6, P465; SPRENT J, 1985, J EXP MED, V162, P2068, DOI 10.1084/jem.162.6.2068; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; VONBOEHMER H, 1984, J IMMUNOL, V133, P59; VONBOEHMER H, 1983, EUR J IMMUNOL, V13, P176, DOI 10.1002/eji.1830130216; WAGNER H, 1978, J EXP MED, V148, P1523, DOI 10.1084/jem.148.6.1523	36	1179	1288	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					368	370		10.1126/science.7678351	http://dx.doi.org/10.1126/science.7678351			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	7678351				2022-12-01	WOS:A1993KG62400034
J	VERMA, A; HIRSCH, DJ; GLATT, CE; RONNETT, GV; SNYDER, SH				VERMA, A; HIRSCH, DJ; GLATT, CE; RONNETT, GV; SNYDER, SH			CARBON-MONOXIDE - A PUTATIVE NEURAL MESSENGER	SCIENCE			English	Article							NITRIC-OXIDE SYNTHESIS; HEME OXYGENASE; RAT-BRAIN; GUANYLATE-CYCLASE; SMOOTH-MUSCLE; ACTIVATION; RELAXATION; MECHANISM; RNA; VASODILATION	Carbon monoxide, an activator of guanylyl cyclase, is formed by the action of the enzyme heme oxygenase. By in situ hybridization in brain slices, discrete neuronal localization of messenger RNA for the constitutive form of heme oxygenase throughout the brain has been demonstrated. This localization is essentially the same as that for soluble guanylyl cyclase messenger RNA, In primary cultures of olfactory neurons, zinc protoporphyrin-9, a potent selective inhibitor of heme oxygenase, depletes endogenous guanosine 3',5'-monophosphate (cGMP). Thus, carbon monoxide, like nitric oxide, may be a physiologic regulator of cGMP. These findings, together with the neuronal localizations of heme oxygenase, suggest that carbon monoxide may function as a neurotransmitter.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; WALTER REED ARMY MED CTR,DEPT NEUROL,WASHINGTON,DC 20307; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Verma, Ajay/0000-0001-7715-0443	NIDA NIH HHS [DA00266] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline; NINDS NIH HHS [NS02131] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADEAGBO ASO, 1990, J PHARMACOL EXP THER, V252, P875; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNE B, 1987, MOL PHARMACOL, V32, P497; CHERNICK RJ, 1989, HEPATOLOGY, V10, P365, DOI 10.1002/hep.1840100320; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6388; DIFIGLIA M, 1990, HUMAN NERVOUS SYSTEM, P1115; DIGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485; EWING JF, 1991, P NATL ACAD SCI USA, V88, P5364, DOI 10.1073/pnas.88.12.5364; FURCHGOTT RF, 1991, BLOOD VESSELS, V28, P52; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GRASER T, 1990, BIOMED BIOCHIM ACTA, V49, P293; HOKFELT T, 1984, SCIENCE, V225, P1326, DOI 10.1126/science.6147896; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KASA P, 1986, PROG NEUROBIOL, V26, P211, DOI 10.1016/0301-0082(86)90016-X; KOLBRIDE P, 1979, J GEN PHYSIOL, V79, P415; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKANE M, 1983, BRAIN RES, V273, P9, DOI 10.1016/0006-8993(83)91088-0; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; RAMOS KS, 1989, BIOCHEM PHARMACOL, V38, P1368, DOI 10.1016/0006-2952(89)90347-X; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; ROSS CA, 1989, P NATL ACAD SCI USA, V86, P2923, DOI 10.1073/pnas.86.8.2923; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SUN Y, 1990, J BIOL CHEM, V265, P8212; SUNDERMAN FW, 1958, CLIN CHEM NY, V28, P2026; UTZ J, 1991, BIOCHEM PHARMACOL, V41, P1195, DOI 10.1016/0006-2952(91)90658-R; VEDERNIKOV YP, 1989, BIOMED BIOCHIM ACTA, V48, P601; Verma A., UNPUB; WEING JF, 1992, J NEUROCHEM, V58, P1140; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7794	43	1356	1431	0	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					381	384		10.1126/science.7678352	http://dx.doi.org/10.1126/science.7678352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	7678352				2022-12-01	WOS:A1993KG62400038
J	COOPER, HM; HERBIN, M; NEVO, E				COOPER, HM; HERBIN, M; NEVO, E			OCULAR REGRESSION CONCEALS ADAPTIVE PROGRESSION OF THE VISUAL-SYSTEM IN A BLIND SUBTERRANEAN MAMMAL	NATURE			English	Article							MOLE RAT; RETINAL PROJECTIONS; SPALAX-EHRENBERGI; ALBINO-RAT; NUCLEUS; MELATONIN; VASOPRESSIN; PATHWAY; HAMSTER; BRAIN	THE mole rat, Spalax ehrenberghi, is an extreme example of natural visual degeneration in mammals: visual pathways are regressed and incomplete1, and the absence of visual cortical potentials or an overt behavioural response to light have led to the conclusion that Spalax is completely blind2-4. But structural and molecular investigations of the atrophied, subcutaneous eye suggest a functional role for the retina in light perception5,6, and entrainment of circadian locomotor and thermoregulatory rhythms by ambient light demonstrates a capacity for photoperiodic detection2,7-9. We report here that severe regression of thalamic and tectal structures involved in form and motion perception is coupled to a selective hypertrophy of structures subserving photoperiodic functions. As an alternative to the prevalent view that ocular regression results from negative or nonselective evolutionary processes10-12, the differential reduction and expansion of visual structures in Spalax can be explained as an adaptive response to the underground environment.	MUSEUM NATL HIST NAT, ANAT COMPAREE LAB, F-75005 PARIS, FRANCE; UNIV HAIFA, INST EVOLUT, HAIFA, ISRAEL	Museum National d'Histoire Naturelle (MNHN); University of Haifa	COOPER, HM (corresponding author), INSERM, U371, F-69500 BRON, FRANCE.		COOPER, HOWARD/M-7304-2014					BALKEMA GW, 1990, VISUAL NEUROSCI, V4, P593; BELTRAMINO C, 1980, NEUROENDOCRINOLOGY, V30, P238, DOI 10.1159/000123007; BRACE CL, 1963, AM NAT, V97, P39, DOI 10.1086/282252; BRONCHTI G, 1991, DEV BRAIN RES, V58, P159, DOI 10.1016/0165-3806(91)90002-Z; Cassone VM, 1988, J BIOL RHYTHM, V3, P71, DOI 10.1177/074873048800300106; Cei G., 1946, MONITORE ZOOL ITALIANO, V55, P69; COLLIN JP, 1981, PINEAL GLAND, V1, P27; COOPER AM, 1990, NEUROSCIENCE, V35, P335, DOI 10.1016/0306-4522(90)90087-K; COOPER HM, 1989, BRAIN RES, V477, P350, DOI 10.1016/0006-8993(89)91426-1; COOPER HM, IN PRESS J COMP NEUR; COOPER KE, 1979, J PHYSIOL-LONDON, V295, P33, DOI 10.1113/jphysiol.1979.sp012953; DEJONG WW, 1990, PROG CLIN BIOL RES, V335, P383; HAIM A, 1983, J EXP BIOL, V107, P59; HEIL P, 1991, NEUROREPORT, V2, P735, DOI 10.1097/00001756-199112000-00001; HETH G, 1986, J EXP ZOOL, V238, P1, DOI 10.1002/jez.1402380102; KASTING NW, 1983, BRAIN RES, V258, P127, DOI 10.1016/0006-8993(83)91237-4; KUDO M, 1988, NEUROSCI LETT, V93, P176, DOI 10.1016/0304-3940(88)90077-8; LEVINE JD, 1991, J COMP NEUROL, V306, P344, DOI 10.1002/cne.903060210; LUND RD, 1965, EXP NEUROL, V13, P302, DOI 10.1016/0014-4886(65)90118-4; MAGNIN M, 1989, BRAIN RES, V488, P390, DOI 10.1016/0006-8993(89)90737-3; MEIJER JH, 1989, PHYSIOL REV, V69, P671, DOI 10.1152/physrev.1989.69.3.671; NECKER R, 1992, NEUROREPORT, V3, P505, DOI 10.1097/00001756-199206000-00012; NELSON DE, 1991, J PHYSIOL-LONDON, V439, P115, DOI 10.1113/jphysiol.1991.sp018660; NEVO E, 1991, EVOLUTIONARY BIOL, V1, P1; PEVET P, 1984, J EXP ZOOL, V232, P41, DOI 10.1002/jez.1402320106; PEVET P, 1987, FUNDAMENTALS CLIN PI, P221; PICKARD GE, 1982, J COMP NEUROL, V211, P65, DOI 10.1002/cne.902110107; RADO R, 1988, ISR J ZOOL, V35, P105; SANYAL S, 1990, INVEST OPHTH VIS SCI, V31, P1398; SUGITA S, 1983, EXP NEUROL, V82, P413, DOI 10.1016/0014-4886(83)90413-2; TOGA AW, 1981, J COMP NEUROL, V199, P443, DOI 10.1002/cne.901990402; WEAVER DR, 1989, J NEUROSCI, V9, P2581; WILKENS H, 1971, EVOLUTION, V25, P530, DOI 10.1111/j.1558-5646.1971.tb01913.x; WRIGHT S, 1964, AM NAT, V98, P65, DOI 10.1086/282301	34	166	169	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					156	159		10.1038/361156a0	http://dx.doi.org/10.1038/361156a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678449				2022-12-01	WOS:A1993KG46600060
J	FEIGENSPAN, A; WASSLE, H; BORMANN, J				FEIGENSPAN, A; WASSLE, H; BORMANN, J			PHARMACOLOGY OF GABA RECEPTOR CL- CHANNELS IN RAT RETINAL BIPOLAR CELLS	NATURE			English	Article							GAMMA-AMINOBUTYRIC-ACID; GLYCINE RECEPTOR; PATCH-CLAMP; FUNCTIONAL EXPRESSION; MEMBRANE PATCHES; XENOPUS OOCYTES; SUBUNIT; CURRENTS; BICUCULLINE; STRYCHNINE	Gamma-AMINOBUTYRIC acid (GABA), a major inhibitory neurotransmitter in the mammalian nervous system, is known to operate bicuculline-sensitive Cl- channels through GABA(A) receptors and bicuculline-insensitive cation channels through GABA(B) receptors1,2. Recent observations indicate that the retina may contain GABA receptors with unusual pharmacological properties3-5. Here we report that GABA gates bicuculline-insensitive Cl- channels in rod bipolar cells of the rat retina, which were not modulated by flunitrazepam, pentobarbital and alphaxalone and were only slightly blocked by picrotoxinin. Moreover, the GABA(B) receptor agonist baclofen, and the antagonist 2-hydroxysaclofen had no effect. The underlying single-channel conductance was 7 pS and the open time 150 ms. These values are clearly different from those obtained for GABA(A) receptor channels recorded in other neurons of the same preparation, and in other parts of the brain1,6-8. The bicuculline- and baclofen-insensitive GABA receptors were activated selectively by the GABA analogue cis-4-aminocrotonic acid (CACA)9. Hence they may be similar to those receptors termed GABA(C) receptors10.	MAX PLANCK INST HIRNFORSCH,DEUTSCHORDENSTR 46,W-6000 FRANKFURT 71,GERMANY	Max Planck Society			Bormann, Joachim/E-6214-2011					Becker C.-M., 1992, HDB EXPT PHARM, V102, P539; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; DREW CA, 1984, NEUROSCI LETT, V52, P317, DOI 10.1016/0304-3940(84)90181-2; FEIGENSPAN A, IN PRESS VISUAL NEUR; GAHWILER BH, 1984, NEUROSCIENCE, V11, P751, DOI 10.1016/0306-4522(84)90192-1; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JOHNSTON GA, 1975, J NEUROCHEM, V24, P157, DOI 10.1111/j.1471-4159.1975.tb07642.x; KARSCHIN A, 1990, J NEUROPHYSIOL, V63, P860, DOI 10.1152/jn.1990.63.4.860; LIPTON SA, 1989, VISUAL NEUROSCI, V3, P275, DOI 10.1017/S0952523800010026; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; PRIBILLA I, IN PRESS EMBO J; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; SHIRASAKI T, 1991, BRAIN RES, V561, P77, DOI 10.1016/0006-8993(91)90751-G; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; SUZUKI S, 1990, J PHYSIOL-LONDON, V421, P645, DOI 10.1113/jphysiol.1990.sp017967; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; YEH HH, 1990, VISUAL NEUROSCI, V4, P349, DOI 10.1017/S0952523800004557	26	360	365	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					159	162		10.1038/361159a0	http://dx.doi.org/10.1038/361159a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	7678450				2022-12-01	WOS:A1993KG46600061
J	CARR, TW				CARR, TW			NATURAL-HISTORY OF PROSTATE-CANCER	LANCET			English	Editorial Material											CARR, TW (corresponding author), SOUTHEND HOSP,DEPT UROL,ESSEX,ENGLAND.							ANDREWS GS, 1949, J CLIN PATHOL, V2, P197, DOI 10.1136/jcp.2.3.197; CARR TW, 1988, LANCET, V1, P776; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FAIR WR, 1992, PROSTATE S, V4, P79; FRANKS LM, 1956, LANCET, V2, P1037; GEORGE NJR, 1988, LANCET, V1, P494; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; HANKS GE, 1988, LANCET, V2, P217; JOHANSSON JE, 1989, LANCET, V1, P799; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LERNER SP, 1991, J UROLOGY, V146, P1040, DOI 10.1016/S0022-5347(17)37997-1; Madsen P O, 1988, Scand J Urol Nephrol Suppl, V110, P95; WHITMORE WF, 1991, CANCER, V67, P1092	13	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					91	92		10.1016/0140-6736(93)92565-B	http://dx.doi.org/10.1016/0140-6736(93)92565-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	7678121				2022-12-01	WOS:A1993KF87000012
J	DEBELDER, AJ; RADOMSKI, MW; WHY, HJF; RICHARDSON, PJ; BUCKNALL, CA; SALAS, E; MARTIN, JF; MONCADA, S				DEBELDER, AJ; RADOMSKI, MW; WHY, HJF; RICHARDSON, PJ; BUCKNALL, CA; SALAS, E; MARTIN, JF; MONCADA, S			NITRIC-OXIDE SYNTHASE ACTIVITIES IN HUMAN MYOCARDIUM	LANCET			English	Note								Myocardial constitutive and inducible nitric oxide (NO) synthase activities were measured in right ventricular tissue from 17 patients with dilated cardiomyopathy (DCM). A significant activity of inducible enzyme was accompanied by a low activity of the constitutive NO synthase. Thus, the myocardium has the capacity to express both NO synthases. NO may have a physiological as well as a pathological role in the human myocardium.	WELLCOME RES LABS,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT CARDIOL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON WC2R 2LS,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London			Salas, Eduardo/AAL-4836-2020	Salas, Eduardo/0000-0002-6837-2471; bucknall, clifford/0000-0003-0662-5856				MONCADA S, 1991, PHARMACOL REV, V43, P109; OLSEN EGJ, 1979, AM HEART J, V98, P385, DOI 10.1016/0002-8703(79)90052-8; PALMER RMJ, 1992, BRIT J PHARMACOL, V105, P11, DOI 10.1111/j.1476-5381.1992.tb14202.x; RICHARDSON PJ, 1990, CURR OPIN CARDIOL, V5, P306, DOI 10.1097/00001573-199006000-00009; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SMITH JA, 1991, J PHYSIOL-LONDON, V439, P1; SMITH JC, 1992, CIRC RES, V70, P856	8	325	325	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 9	1993	341	8837					84	85		10.1016/0140-6736(93)92559-C	http://dx.doi.org/10.1016/0140-6736(93)92559-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF870	7678120				2022-12-01	WOS:A1993KF87000006
J	HOWARD, PK; SEFTON, BM; FIRTEL, RA				HOWARD, PK; SEFTON, BM; FIRTEL, RA			TYROSINE PHOSPHORYLATION OF ACTIN IN DICTYOSTELIUM ASSOCIATED WITH CELL-SHAPE CHANGES	SCIENCE			English	Article							BINDING PROTEINS; GENE-EXPRESSION; DISCOIDEUM; CHEMOTAXIS; IDENTIFICATION; POLYMERIZATION; MECHANISMS; MOTILITY; MULTIPLE; GROWTH	When Dictyostelium cells that have initiated their developmental program upon starvation are returned to growth medium, there is a rapid and transient de novo tyrosine phosphorylation of a 43-kilodalton protein. This protein was found to be actin. Most of the phosphorylation occurred in a single, minor acidic isoform of actin. Developing cells that had been returned to growth medium lost their pseudopod extensions, became round, and had reduced adhesion to the substratum. These effects occurred with kinetics that matched the increase in tyrosine phosphorylation of actin. In mutant cell lines in which the gene for the phosphotyrosine phosphatase PTP1 had been disrupted, tyrosine phosphorylation of actin was rapid and more prolonged. These cells responded with proportionally accelerated kinetics of cell rounding. Cell lines overexpressing PTP1 had diminished amplitude and duration of actin tyrosine phosphorylation and exhibited diminished cell-shape change and an accelerated return to the extended cell-shape morphology seen in starved cells.	UNIV CALIF SAN DIEGO, DEPT BIOL, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; SALK INST BIOL SCI, MOLEC BIOL & VIROL LAB, SAN DIEGO, CA 92186 USA	University of California System; University of California San Diego; Salk Institute								AMATO PA, 1983, J CELL BIOL, V96, P750, DOI 10.1083/jcb.96.3.750; AMBROS VR, 1975, P NATL ACAD SCI USA, V72, P3144, DOI 10.1073/pnas.72.8.3144; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cellbio.4.1.649; FARMER SR, 1989, CELL SHAPE DETERMINA, P173; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FUTRELLE RP, 1982, J CELL BIOL, V92, P807, DOI 10.1083/jcb.92.3.807; GARRELS JI, 1976, CELL, V9, P793, DOI 10.1016/0092-8674(76)90142-2; GERISCH G, 1982, ANNU REV PHYSIOL, V44, P535, DOI 10.1146/annurev.ph.44.030182.002535; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HOWARD P, UNPUB; HOWARD PK, 1992, CELL, V71, P637, DOI 10.1016/0092-8674(92)90597-6; KABSCH W, 1992, ANNU REV BIOPH BIOM, V21, P49, DOI 10.1146/annurev.bb.21.060192.000405; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; MACLEOD C, 1980, DEV BIOL, V76, P263, DOI 10.1016/0012-1606(80)90378-4; MARIN FT, 1976, DEV BIOL, V48, P110, DOI 10.1016/0012-1606(76)90050-6; MCKEOWN M, 1981, J MOL BIOL, V151, P593, DOI 10.1016/0022-2836(81)90425-3; MCKEOWN M, 1981, COLD SPRING HARB SYM, V46, P495; MCROBBIE SJ, 1983, BIOCHEM BIOPH RES CO, V115, P351, DOI 10.1016/0006-291X(83)91011-2; MCROBBIE SJ, 1986, CRC CR REV MICROBIOL, V13, P335, DOI 10.3109/10408418609108742; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MELAMED I, 1991, BIOCHEM BIOPH RES CO, V176, P1424, DOI 10.1016/0006-291X(91)90445-D; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; ROMANS P, 1985, J MOL BIOL, V186, P337, DOI 10.1016/0022-2836(85)90109-3; SCHWEIGER A, 1992, J CELL SCI, V102, P601; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SIMPSON PA, 1984, J CELL BIOL, V99, P287, DOI 10.1083/jcb.99.1.287; SONOBE S, 1986, J BIOL CHEM, V261, P4837; WATTS RG, 1991, CELL MOTIL CYTOSKEL, V19, P159, DOI 10.1002/cm.970190304; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0	35	108	109	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 8	1993	259	5092					241	244		10.1126/science.7678470	http://dx.doi.org/10.1126/science.7678470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678470				2022-12-01	WOS:A1993KF71900035
J	POPOV, S; BROWN, A; POO, MM				POPOV, S; BROWN, A; POO, MM			FORWARD PLASMA-MEMBRANE FLOW IN GROWING NERVE PROCESSES	SCIENCE			English	Article							NEURONS; GROWTH; ELONGATION; MOVEMENTS; CULTURE	Nerve growth requires addition of new plasma membrane material, which is generally believed to occur at the growth cone. Local incorporation of a fluorescent lipid analog into the plasma membrane of fast-growing Xenopus neurites revealed an anterograde bulk membrane flow that correlated with neurite elongation. The rate of membrane flow depended on the position of the labeled membrane segment along the neurite, increasing with distance from the soma. This result suggests that new membrane in growing Xenopus neurites is added not at the growth cone but at the cell body and along the neurite.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University			brown, abraham/R-8823-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts B., 1989, MOL BIOL CELL; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BRAY D, 1973, J CELL BIOL, V56, P702, DOI 10.1083/jcb.56.3.702; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; FORSCHER P, 1992, NATURE, V357, P515, DOI 10.1038/357515a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; OKABE S, 1992, J CELL BIOL, V117, P105, DOI 10.1083/jcb.117.1.105; POPOV S, 1992, J NEUROSCI, V12, P77; REINSCH SS, 1991, J CELL BIOL, V115, P365, DOI 10.1083/jcb.115.2.365; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; TABTI N, 1991, CULTURING NERVE CELL; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TANK DW, 1982, J CELL BIOL, V92, P207, DOI 10.1083/jcb.92.1.207	16	68	69	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					244	246		10.1126/science.7678471	http://dx.doi.org/10.1126/science.7678471			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678471				2022-12-01	WOS:A1993KF71900036
J	ZAGHOUANI, H; STEINMAN, R; NONACS, R; SHAH, H; GERHARD, W; BONA, C				ZAGHOUANI, H; STEINMAN, R; NONACS, R; SHAH, H; GERHARD, W; BONA, C			PRESENTATION OF A VIRAL T-CELL EPITOPE EXPRESSED IN THE CDR3 REGION OF A SELF IMMUNOGLOBULIN MOLECULE	SCIENCE			English	Article							DENDRITIC CELLS; LYMPHOCYTES-T; GENE SEGMENTS; FC-RECEPTORS; ANTIGEN; CHAIN; RECOGNITION; SURFACE	Synthetic peptides corresponding to microbial epitopes stimulate T cell immunity but their immunogenicity is poor and their half-lives are short. A viral epitope inserted into the complementarity-determining region 3 (CDR3) loop of the heavy chain of a self immunoglobulin (Ig) molecule was generated from the Ig context and was presented by I-E(d) class II molecules to virus-specific, CD4+ T cells. Chimeric Ig-peptide was presented 100 to 1000 times more efficiently than free synthetic peptide and was able to prime virus-specific T cells in vivo. These features suggest that antigenized Ig can provide an improved and safe vaccine for the presentation of microbial and other peptides.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021; WISTAR INST,PHILADELPHIA,PA 19104	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rockefeller University; The Wistar Institute			Steinman, Ralph/F-7729-2012		NIAID NIH HHS [AI24460, AI18316, AI13013] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI013013, R01AI018316, P01AI024460, R01AI013013] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEGAY M, 1992, J VIROL, V66, P1199, DOI 10.1128/JVI.66.2.1199-1201.1992; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; CHIMINI G, 1989, J EXP MED, V169, P297, DOI 10.1084/jem.169.1.297; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; FREIMUTH P, 1990, RES MICROBIOL, V141, P995, DOI 10.1016/0923-2508(90)90139-H; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HABERMAN AM, 1990, J IMMUNOL, V145, P3087; HAN YS, 1991, J EXP MED, V174, P733; INABA K, 1990, J EXP MED, V172, P631, DOI 10.1084/jem.172.2.631; MOSMANN TJ, 1983, IMMUNOL METHODS, V66, P55; NUSSENZWEIG MC, 1980, J EXP MED, V151, P1196, DOI 10.1084/jem.151.5.1196; NUSSENZWEIG MC, 1981, J EXP MED, V154, P168, DOI 10.1084/jem.154.1.168; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; RATHBUN GA, 1988, J MOL BIOL, V202, P383, DOI 10.1016/0022-2836(88)90272-0; ROMANI N, 1989, J EXP MED, V169, P1153, DOI 10.1084/jem.169.3.1153; SANZ I, 1987, P NATL ACAD SCI USA, V84, P1085, DOI 10.1073/pnas.84.4.1085; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; UNKELESS JC, 1981, ADV IMMUNOL, V31, P247, DOI 10.1016/S0065-2776(08)60922-0; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; ZAGHOUANI H, 1992, J IMMUNOL, V148, P3604; ZAGHOUANI H, UNPUB	25	112	128	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 8	1993	259	5092					224	227		10.1126/science.7678469	http://dx.doi.org/10.1126/science.7678469			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF719	7678469				2022-12-01	WOS:A1993KF71900030
J	HSU, YT; MOLDAY, RS				HSU, YT; MOLDAY, RS			MODULATION OF THE CGMP-GATED CHANNEL OF ROD PHOTORECEPTOR CELLS BY CALMODULIN	NATURE			English	Article							FREE CALCIUM-CONCENTRATION; CYCLIC-GMP CASCADE; OUTER SEGMENTS; RETINAL RODS; GUANYLATE-CYCLASE; BINDING-PROTEINS; CONDUCTANCE; MEMBRANES; ADAPTATION; MECHANISM	PHOTOBLEACHING of rhodopsin in rod photoreceptors activates the visual cascade system leading to a decrease in cyclic GMP and the closure of cGMP-gated channels in the rod outer segment plasma membrane1-4. Calcium plays an important role in the recovery of the rod outer segment to its dark state by regulating the resynthesis of cGMP by guanylate cyclase5-7. Here we report that calmodulin, a Ca2+-binding protein present in the rod outer segment8,9, increases the apparent Michaelis constant of the channel for cGMP. This results in a decrease in the rate of cation influx into the rod outer segment by two- to sixfold at low cGMP concentrations and has the effect of increasing the sensitivity of the channel to small changes in cGMP levels during phototransduction. Biochemical studies indicate that calcium-calmodulin binds to a protein of M(r) 240K which is tightly associated with the channel10. On the basis of these studies, Ca2+ is suggested to play a central role in photorecovery and light adaptation, not only by regulating guanylate cyclase, possibly through recoverin6,7, but also by modulating the cGMP-gated channel through calmodulin interaction with the 240K protein.	UNIV BRITISH COLUMBIA, FAC MED, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA	University of British Columbia								CARETTA A, 1988, EUR J BIOCHEM, V177, P139, DOI 10.1111/j.1432-1033.1988.tb14354.x; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; COTE RH, 1986, J BIOL CHEM, V261, P2965; DLZHOOR AM, 1991, SCIENCE, V251, P915; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GLENNEY JR, 1982, P NATL ACAD SCI-BIOL, V79, P4002, DOI 10.1073/pnas.79.13.4002; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KAUPP UB, 1992, REV PHYSL, V54, P153; KAWAMURA S, 1991, NATURE, V349, P420, DOI 10.1038/349420a0; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOHNKEN RE, 1981, J BIOL CHEM, V256, P2517; KORENBROT JI, 1989, VISION RES, V29, P939, DOI 10.1016/0042-6989(89)90108-9; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; NAGAO S, 1987, BIOCHEMISTRY-US, V26, P1659, DOI 10.1021/bi00380a026; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P695, DOI 10.1113/jphysiol.1988.sp016942; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; OGAWA Y, 1984, J BIOCHEM-TOKYO, V95, P19, DOI 10.1093/oxfordjournals.jbchem.a134584; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; RATTO GM, 1988, J NEUROSCI, V8, P3240; SCHNETKAMP PPM, 1990, J GEN PHYSIOL, V96, P517, DOI 10.1085/jgp.96.3.517; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TORRE V, 1986, P NATL ACAD SCI USA, V83, P7109, DOI 10.1073/pnas.83.18.7109; WONG S, 1986, BIOCHEMISTRY-US, V25, P6294, DOI 10.1021/bi00368a069; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289	30	326	329	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 7	1993	361	6407					76	79		10.1038/361076a0	http://dx.doi.org/10.1038/361076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7678445				2022-12-01	WOS:A1993KF71800052
J	STOUTHAMER, R; BREEUWER, JAJ; LUCK, RF; WERREN, JH				STOUTHAMER, R; BREEUWER, JAJ; LUCK, RF; WERREN, JH			MOLECULAR-IDENTIFICATION OF MICROORGANISMS ASSOCIATED WITH PARTHENOGENESIS	NATURE			English	Article							TRICHOGRAMMA HYMENOPTERA; DROSOPHILA-SIMULANS; INCOMPATIBILITY; POPULATIONS; MORMONIELLA	CYTOPLASMICALLY inherited microorganisms are widespread in insects and have been implicated as causes of female parthenogenesis (females developing from unfertilized eggs) and cytoplasmic incompatibility1-15. Normal sexual reproduction can be restored by treatment with antibiotics1-4. Sequence analysis of the DNA encoding 16S ribosomal RNA has shown that cytoplasmic incompatibility bacteria from diverse insect taxa are closely related (they share >95% sequence similarity) and belong to the alpha subdivision of Proteobacteria5-7. Here we show that parthenogenesis-associated bacteria from parasitoid Hymenoptera also fall into this bacterial group, having up to 99% sequence similarity to some incompatibility microorganisms. Both incompatibility and parthenogenesis microorganisms alter host chromosome behaviour during early mitotic divisions of the egg13-17. Incompatibility bacteria act by interfering with paternal chromosome incorporation in fertilized eggs, whereas parthenogenesis bacteria prevent segregation of chromosomes in unfertilized eggs. These traits are adaptive for the microorganisms. On the basis of their sequence similarities, we conclude that parthenogenesis bacteria and cytoplasmic incompatibility bacteria form a monophyletic group of microorganisms that 'specialize' in manipulating chromosome behaviour and reproduction of insects.	UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT ENTOMOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside	STOUTHAMER, R (corresponding author), AGR UNIV WAGENINGEN,DEPT ENTOMOL,POB 8031,6700 EH WAGENINGEN,NETHERLANDS.			Werren, John/0000-0001-9353-2070				ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; CASPARI E, 1959, EVOLUTION, V13, P568, DOI 10.1111/j.1558-5646.1959.tb03045.x; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; JOST E, 1970, ROUX ARCH DEV BIOL, V166, P173, DOI 10.1007/BF00576992; KELLEN WR, 1981, J INVERTEBR PATHOL, V37, P273, DOI 10.1016/0022-2011(81)90087-2; LANE D.J., 1991, 16S 23S RRNA SEQUENC, P115, DOI DOI 10.1007/S00227-012-2133-0; LEGNER EF, 1985, CAN ENTOMOL, V117, P383, DOI 10.4039/Ent117383-3; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; RICHARDSON PM, 1987, J INVERTEBR PATHOL, V50, P176, DOI 10.1016/0022-2011(87)90080-2; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1985, J HERED, V76, P21, DOI 10.1093/oxfordjournals.jhered.a110011; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; STOUTHAMER R, 1990, P NATL ACAD SCI USA, V87, P2424, DOI 10.1073/pnas.87.7.2424; STOUTHAMER R, 1990, ANN ENTOMOL SOC AM, V83, P475, DOI 10.1093/aesa/83.3.475; STOUTHAMER R, IN PRESS J INVERT PA; SWOFFORD DL, 1990, PAUP V30; VANVLIET AHM, 1992, INT J SYST BACTERIOL, V42, P494, DOI 10.1099/00207713-42-3-494; WADE MJ, 1985, SCIENCE, V278, P527; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YEN JH, 1973, J INVERTEBR PATHOL, V22, P242, DOI 10.1016/0022-2011(73)90141-9; ZCHORIFEIN E, 1992, EXPERIENTIA, V48, P102, DOI 10.1007/BF01923619	27	396	437	1	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					66	68		10.1038/361066a0	http://dx.doi.org/10.1038/361066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7538198				2022-12-01	WOS:A1993KF71800049
J	TANAKA, Y; ADAMS, DH; HUBSCHER, S; HIRANO, H; SIEBENLIST, U; SHAW, S				TANAKA, Y; ADAMS, DH; HUBSCHER, S; HIRANO, H; SIEBENLIST, U; SHAW, S			T-CELL ADHESION INDUCED BY PROTEOGLYCAN-IMMOBILIZED CYTOKINE MIP-1-BETA	NATURE			English	Article							LYMPHOCYTES-T; CD44; PROTEIN; ACTIVATION; RECEPTOR; FAMILY; GLYCOSAMINOGLYCANS; HYALURONATE; MOLECULE-1; ADHERENCE	LYMPHOCYTE migration from blood into tissue depends on integrin-mediated adhesion to endothelium1-4. Adhesion requires not only integrin ligands on the endothelium, but also activation signals because T-cell integrins cannot bind well until they are activated. The physiological 'triggers' for T-cell adhesion are unknown, but cytokines may be good candidates as they are released during inflammation and trigger adhesion in neutrophils and monocytes2,5,6. We have identified a cytokine, macrophage inflammatory protein-1beta (MIP-1beta),that induces both chemotaxis and adhesion of T cells; MIP-1beta is most effective at augmenting adhesion of CD8+ T cells to the vascular cell adhesion molecule VCAM-1. We reasoned that, as cytokines in vivo will be rapidly washed away, MIP-1beta might be bound to endothelial surfaces and so induce adhesion in its immobilized form. Here we show that: (1) MIP-1beta is present on lymph node endothelium; (2) immobilized MIP-1beta induces binding of T cells to VCAM-1 in vitro. MIP-1beta was immobilized by binding to proteoglycan: a conjugate of heparin with bovine serum albumin and cellular proteoglycan CD44 were both effective. We propose that MIP-1beta and other cytokines with glycosaminoglycan-binding sites will bind to and be presented by endothelial proteoglycans to trigger adhesion selectively not only of lymphocyte subsets, but also of other cell types.	UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	University of Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	TANAKA, Y (corresponding author), NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892, USA.		Adams, David H/C-9092-2009	Adams, David H/0000-0001-6776-0336				ADAMS DH, 1991, J IMMUNOL, V147, P609; ADAMS DH, 1989, LANCET, V2, P1122; ARNAOUT MA, 1986, J CLIN INVEST, V78, P591; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HORGAN KJ, 1991, CURRENT PROTOCOLS IM; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALS ST, 1989, J IMMUNOL, V143, P851; PARDI R, 1992, IMMUNOL TODAY, V13, P224, DOI 10.1016/0167-5699(92)90159-5; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SHAW LM, 1989, J EXP MED, V169, P303, DOI 10.1084/jem.169.1.303; SHERRY B, 1988, J EXP MED, V168, P2251, DOI 10.1084/jem.168.6.2251; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; TANAKA Y, IN PRESS IMMUN TODAY; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	40	801	814	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 7	1993	361	6407					79	82		10.1038/361079a0	http://dx.doi.org/10.1038/361079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KF718	7678446				2022-12-01	WOS:A1993KF71800053
J	OESTERLING, JE; MARTIN, SK; BERGSTRALH, EJ; LOWE, FC				OESTERLING, JE; MARTIN, SK; BERGSTRALH, EJ; LOWE, FC			THE USE OF PROSTATE-SPECIFIC ANTIGEN IN STAGING PATIENTS WITH NEWLY DIAGNOSED PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE; CARCINOMA; SCINTIGRAPHY; SCANS	Objective.-To assess the need for obtaining radionuclide bone scans in the staging evaluation of patients with newly diagnosed, untreated prostate cancer. This determination was made on the basis of presenting prostate-specific antigen (PSA) levels. Design.-Retrospective review. Participants.-The medical records of 2064 consecutive patients with prostate cancer who were evaluated at the Mayo Clinic in Rochester, Minn, from January 1989 through December 1990 were reviewed. Eight hundred fifty-two patients with newly diagnosed, untreated disease and a serum PSA concentration less than 20.0 mug/L at presentation comprised the study population. Main Outcome Measure.-The rate of false-negative results associated with using the serum PSA concentration to predict bone scan findings. Results.-Five hundred sixty-one patients had a serum PSA concentration of 10.0 mug/L or less; only three had an abnormal bone scan result, and one had an indeterminate scan result. Of the 467 men whose PSA value was 8.0 mug/L or less (two times the upper limit of the reference range), none had bone scan results that were either abnormal or indeterminate. The rate of false-negative results for an abnormal bone scan result was 0% with a serum PSA value of 8.0 mug/L or less and 0.5% with a cutoff level of 10.0 mug/L. The 95% upper confidence limit for the rate of false-negative results for all PSA cutoff levels less than 20.0 mug/L was less than 2%. Conclusions.-For patients with newly diagnosed, untreated prostate cancer, a serum PSA concentration of 10.0 mug/L or less, and no skeletal symptoms, a staging radionuclide bone scan does not appear to be necessary. This clinical situation applies to 39% of all patients presenting with newly diagnosed prostate cancer. Since more than 130 000 new cases are diagnosed each year, approximately 50 000 patients are affected annually. If the $600 staging bone scan were eliminated for these patients, a significant economic savings to the health care system in this country would be effected.	MAYO CLIN & MAYO FDN,BIOSTAT SECT,ROCHESTER,MN 55905; ST LUKES ROOSEVELT HOSP,DEPT UROL,NEW YORK,NY; COLUMBIA UNIV COLL PHYS & SURG,DEPT UROL,NEW YORK,NY 10032	Mayo Clinic; Mount Sinai St. Luke's; Mount Sinai West; Columbia University	OESTERLING, JE (corresponding author), MAYO CLIN & MAYO FDN,DEPT UROL,200 1ST ST SW,ROCHESTER,MN 55905, USA.							BERGER GL, 1981, J UROLOGY, V125, P637, DOI 10.1016/S0022-5347(17)55144-7; CATALONA WJ, 1984, PROSTATE CANCER; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8; LINDNER A, 1982, J UROLOGY, V128, P1181, DOI 10.1016/S0022-5347(17)53412-6; MCGREGOR B, 1978, BRIT J UROL, V50, P178, DOI 10.1111/j.1464-410X.1978.tb02798.x; MERRICK MV, 1985, BRIT J UROL, V57, P715, DOI 10.1111/j.1464-410X.1985.tb07039.x; ODONOGHUE EPN, 1978, BRIT J UROL, V50, P172, DOI 10.1111/j.1464-410X.1978.tb02797.x; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PAULSON DF, 1988, DIAGNOSIS MANAGEMENT, P417; ROCK RC, 1987, CLIN CHEM, V33, P2257; ROSEN PR, 1984, J NUCL MED, V25, P289; SCHAFFER DL, 1976, RADIOLOGY, V121, P431, DOI 10.1148/121.2.431; UTZ DC, 1969, J AMER MED ASSOC, V209, P1701, DOI 10.1001/jama.209.11.1701; 1992, CANCER FACTS FIGURES	14	185	191	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 6	1993	269	1					57	60						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF026	7677962				2022-12-01	WOS:A1993KF02600027
J	ADAMS, SA; ROBSON, SC; GATHIRAM, V; JACKSON, TFHG; PILLAY, TS; KIRSCH, RE; MAKGOBA, MW				ADAMS, SA; ROBSON, SC; GATHIRAM, V; JACKSON, TFHG; PILLAY, TS; KIRSCH, RE; MAKGOBA, MW			IMMUNOLOGICAL SIMILARITY BETWEEN THE 170 KD AMEBIC ADHERENCE GLYCOPROTEIN AND HUMAN BETA-2 INTEGRINS	LANCET			English	Note							GALACTOSE-BINDING LECTIN; ENTAMOEBA-HISTOLYTICA; ANTIBODIES	Amoebiasis is an important cause of morbidity and mortality in developing countries. Virulence of Entamoeba histolytica depends on the trophozoite's being able to bind to colonic epithelium; binding is mediated by the 170 kD subunit of a 260 kD lectin. We found, by microcytofluorometry and western blotting studies, that this 170 kD subunit protein shares an epitope with human beta2 integrins-a subfamily of cell-surface glycoproteins expressed exclusively on leucocytes and involved in many adhesive and signalling interactions. The immunological similarity between these proteins may explain the trophozoite's ability to bind to and invade colonic epithelium.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,DIV MOLEC ENDOCRINOL,DU CANE RD,LONDON W12 0NN,ENGLAND; UNIV CAPE TOWN,SCH MED,MRC,LIVER RES CTR,CAPE TOWN,SOUTH AFRICA; UNIV NATAL,MRC,DURBAN,SOUTH AFRICA; UNIV NATAL,DEPT MED,DURBAN,SOUTH AFRICA	Imperial College London; University of Cape Town; University of Kwazulu Natal; University of Kwazulu Natal			Robson, Simon C./AAA-8537-2021	pillay, tahir/0000-0002-9982-9710	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHADEE K, 1987, J CLIN INVEST, V80, P1245, DOI 10.1172/JCI113199; JOYCE MP, 1988, AM J TROP MED HYG, V35, P159; MANN BJ, 1991, P NATL ACAD SCI USA, V88, P3248, DOI 10.1073/pnas.88.8.3248; PETRI WA, 1989, J BIOL CHEM, V264, P3007; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1990, J IMMUNOL, V144, P4803; RAVDIN JI, 1990, J INFECT DIS, V162, P768, DOI 10.1093/infdis/162.3.768; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walsh J.A., 1988, P93	10	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					17	19		10.1016/0140-6736(93)92483-A	http://dx.doi.org/10.1016/0140-6736(93)92483-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	7678048				2022-12-01	WOS:A1993KF02700006
J	HOTAMISLIGIL, GS; SHARGILL, NS; SPIEGELMAN, BM				HOTAMISLIGIL, GS; SHARGILL, NS; SPIEGELMAN, BM			ADIPOSE EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA - DIRECT ROLE IN OBESITY-LINKED INSULIN RESISTANCE	SCIENCE			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; LIPOPROTEIN-LIPASE ACTIVITY; SERINE PROTEASE HOMOLOG; SKELETAL-MUSCLE; MESSENGER-RNA; DECREASED EXPRESSION; 3T3-L1 ADIPOCYTES; DIABETES-MELLITUS; LIPID-METABOLISM; GENE-EXPRESSION	Tumor necrosis factor-alpha (TNF-alpha) has been shown to have certain catabolic effects on fat cells and whole animals. An induction of TNF-alpha messenger RNA expression was observed in adipose tissue from four different rodent models of obesity and diabetes. TNF-alpha protein was also elevated locally and systemically. Neutralization of TNF-alpha in obese fa/fa rats caused a significant increase in the peripheral uptake of glucose in response to insulin. These results indicate a role for TNF-alpha in obesity and particularly in the insulin resistance and diabetes that often accompany obesity.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 42539] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEISEL WR, 1975, ANNU REV MED, V26, P9, DOI 10.1146/annurev.me.26.020175.000301; BELL GI, 1991, DIABETES, V40, P413, DOI 10.2337/diabetes.40.4.413; BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BJORNTORP P, 1991, DIABETES CARE, V14, P1132, DOI 10.2337/diacare.14.12.1132; CAMERON DP, 1978, CLIN EXP PHARMACOL P, V5, P41, DOI 10.1111/j.1440-1681.1978.tb00650.x; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOY LN, 1992, J BIOL CHEM, V267, P12736; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; COLEMAN DL, 1982, DIABETES, V31, P1; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DINARELLO CA, 1987, IMMUNOL LETT, V16, P227, DOI 10.1016/0165-2478(87)90151-9; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; DOHM GL, 1991, AM J PHYSIOL, V260, pE459, DOI 10.1152/ajpendo.1991.260.3.E459; FEINGOLD KR, 1989, J CLIN INVEST, V83, P1116, DOI 10.1172/JCI113991; FEINGOLD KR, 1987, J CLIN INVEST, V80, P184, DOI 10.1172/JCI113046; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FRAKER DL, 1989, AM J PHYSIOL, V256, pE725, DOI 10.1152/ajpendo.1989.256.6.E725; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRUNFELD C, 1989, J LIPID RES, V30, P579; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; HANDBERG A, 1990, DIABETOLOGIA, V33, P625, DOI 10.1007/BF00400207; HOTAMISLIGIL GS, UNPUB; KAHN BB, 1989, J CLIN INVEST, V84, P404, DOI 10.1172/JCI114180; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1988, J LIPID RES, V29, P909; KETTELHUT IC, 1988, J CLIN INVEST, V81, P1384, DOI 10.1172/JCI113467; KOIVISTO VA, 1989, DIABETES, V38, P641, DOI 10.2337/diabetes.38.5.641; KUNKEL SL, 1989, CRIT REV IMMUNOL, V9, P93; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LARDY H, 1990, ANNU REV BIOCHEM, V59, P689, DOI 10.1146/annurev.biochem.59.1.689; LE JM, 1987, LAB INVEST, V56, P234; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LONNROTH P, 1991, J INTERN MED, V229, P23; Maniatis T, 1989, DECONTAMINATION DILU; MESZAROS K, 1987, BIOCHEM BIOPH RES CO, V149, P1, DOI 10.1016/0006-291X(87)91596-8; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MULLEN BJ, 1990, P SOC EXP BIOL MED, V193, P318; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PATTON JS, 1987, J CLIN INVEST, V80, P1587, DOI 10.1172/JCI113245; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PLATA-SALAMAN C R, 1989, Brain Behavior and Immunity, V3, P193, DOI 10.1016/0889-1591(89)90036-6; PRICE SR, 1986, ARCH BIOCHEM BIOPHYS, V251, P738, DOI 10.1016/0003-9861(86)90384-X; REAVEN GM, 1988, AM J MED, V85, P106, DOI 10.1016/0002-9343(88)90402-0; REY DA, 1987, AM J PHYSIOL, V253, pR794; RODBELL M, 1964, J BIOL CHEM, V239, P375; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SEMB H, 1987, J BIOL CHEM, V262, P8390; SHAFRIR E, 1990, DIABETES MELLITUS TH, P299; SHARGILL NS, UNPUB; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; Snick JV, 1990, ANNU REV IMMUNOL, V8, P253; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; STEPHENS JM, 1992, BIOCHEM BIOPH RES CO, V183, P417, DOI 10.1016/0006-291X(92)90497-9; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TENG MN, 1991, P NATL ACAD SCI USA, V88, P3535, DOI 10.1073/pnas.88.9.3535; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TRUETT GE, 1991, P NATL ACAD SCI USA, V88, P7806, DOI 10.1073/pnas.88.17.7806; WASSERMANN F., 1965, HANDBOOK PHYSIOL, V5, P87	80	5648	5900	20	558	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 1	1993	259	5091					87	91		10.1126/science.7678183	http://dx.doi.org/10.1126/science.7678183			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE601	7678183				2022-12-01	WOS:A1993KE60100035
J	ALTER, MJ; MARGOLIS, HS; KRAWCZYNSKI, K; JUDSON, FN; MARES, A; ALEXANDER, WJ; HU, PY; MILLER, JK; GERBER, MA; SAMPLINER, RE; MEEKS, EL; BEACH, MJ				ALTER, MJ; MARGOLIS, HS; KRAWCZYNSKI, K; JUDSON, FN; MARES, A; ALEXANDER, WJ; HU, PY; MILLER, JK; GERBER, MA; SAMPLINER, RE; MEEKS, EL; BEACH, MJ			THE NATURAL-HISTORY OF COMMUNITY-ACQUIRED HEPATITIS-C IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; ACUTE NON-A; CHRONIC LIVER-DISEASE; POSTTRANSFUSION HEPATITIS; VIRAL-HEPATITIS; VIRUS-INFECTION; EPIDEMIOLOGY; TRANSMISSION; ANTIBODIES; REGIONS	Background. Chronic liver disease develops in more than half of patients with post-transfusion hepatitis C, but little is known about the natural history of community-acquired hepatitis C. Methods. In 1985 and 1986 we identified adults with acute non-A, non-B hepatitis in four counties in the United States and followed them prospectively. We used three markers to detect hepatitis C virus (HCV) infection in stored samples of serum: antibody to HCV (anti-HCV) detected by second-generation serologic assays; HCV RNA detected by polymerase-chain-reaction assay; and antibody to HCV antigen (anti-HCVAg) detected by fluorescent-antibody-blocking assay. Results. Of 130 patients with non-A, non-B hepatitis, 106 (82 percent) had HCV infection, 93 were positive for anti-HCV, and 13 were positive only for HCV RNA or anti-HCVAg. Chronic hepatitis developed in 60 (62 percent) of 97 HCV-infected patients followed for 9 to 48 months, with no relation to the risk factors for infection. Ten of the 30 patients who had liver biopsies had chronic active hepatitis. In samples collected 42 to 48 months after the onset of hepatitis, HCV RNA was detected in 12 of 13 tested patients with chronic hepatitis and in all 15 tested patients with hepatitis that had resolved. Anti-HCV persisted in all but two of the initially positive patients, for a rate of antibody loss of 0.6 per 100 person-years. Conclusions. Patients with community-acquired hepatitis C have a high rate of chronic hepatitis. HCV may be a major cause of chronic liver disease in the United States, and in most patients HCV infection seems to persist for at least several years, even in the absence of active liver disease.	DENVER PUBL HLTH, DENVER, CO USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; TACOMA PIERCE CTY DEPT HLTH, TACOMA, WA USA; JEFFERSON CTY DEPT HLTH, BIRMINGHAM, AL USA; PINELLAS CTY DEPT HLTH, ST PETERSBURG, FL USA; TULANE UNIV, SCH MED, DEPT PATHOL, NEW ORLEANS, LA 70112 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT MED, TUCSON, AZ 85724 USA; VET AFFAIRS MED CTR, TUCSON, AZ USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tulane University; University of Arizona; University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	ALTER, MJ (corresponding author), CTR DIS CONTROL, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA.				PHS HHS [224-85-1001, 224-90-1002] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; [Anonymous], 1977, LANCET, V2, P914; BEACH MJ, 1992, J MED VIROL, V36, P226, DOI 10.1002/jmv.1890360314; BORTOLOTTI F, 1991, J HEPATOL, V12, P176, DOI 10.1016/0168-8278(91)90935-5; BRADLEY DW, 1983, J INFECT DIS, V148, P254, DOI 10.1093/infdis/148.2.254; GERBER MA, 1992, MODERN PATHOL, V5, P483; HAN JH, 1991, P NATL ACAD SCI USA, V88, P1711, DOI 10.1073/pnas.88.5.1711; INOUE Y, 1991, NATURE, V353, P609, DOI 10.1038/353609a0; KRAWCZYNSKI K, 1992, GASTROENTEROLOGY, V103, P622, DOI 10.1016/0016-5085(92)90856-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MATHIESON RD, 1986, AM J CLIN PATHOL, V85, P353, DOI 10.1093/ajcp/85.3.353; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; MIMMS L, 1990, LANCET, V336, P1590, DOI 10.1016/0140-6736(90)93377-2; NAGATA A, 1985, AM J GASTROENTEROL, V80, P298; NORKRANS G, 1979, SCAND J INFECT DIS, V11, P259, DOI 10.3109/inf.1979.11.issue-4.01; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; RIESTRA S, 1990, ANN INTERN MED, V113, P411; SAMPLINER RE, 1984, J MED VIROL, V13, P125, DOI 10.1002/jmv.1890130203; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TREMOLADA F, 1991, ANN INTERN MED, V114, P277, DOI 10.7326/0003-4819-114-4-277; 1986, MMWR MORB MORTAL WKL, V35, P655	29	1540	1573	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1899	1905		10.1056/NEJM199212313272702	http://dx.doi.org/10.1056/NEJM199212313272702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1280771				2022-12-01	WOS:A1992KE50500002
J	CONVERSE, RL; JACOBSEN, TN; TOTO, RD; JOST, CMT; COSENTINO, F; FOUADTARAZI, F; VICTOR, RG				CONVERSE, RL; JACOBSEN, TN; TOTO, RD; JOST, CMT; COSENTINO, F; FOUADTARAZI, F; VICTOR, RG			SYMPATHETIC OVERACTIVITY IN PATIENTS WITH CHRONIC-RENAL-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOPAMINE-BETA-HYDROXYLASE; BLOOD-PRESSURE; ANGIOTENSIN-II; RENIN-ACTIVITY; NERVE ACTIVITY; PLASMA-RENIN; HEMODIALYSIS; NOREPINEPHRINE; HYPERTENSION; MECHANISMS	Background. Hypertension is a frequent complication of chronic renal failure, but its causes are not fully understood. There is indirect evidence that increased activity of the sympathetic nervous system might contribute to hypertension in patients with end-stage renal disease, but sympathetic-nerve discharge has not been measured directly in patients or animals with chronic renal failure. Methods. We recorded the rate of postganglionic sympathetic nerve discharge to the blood vessels in skeletal muscle by means of microelectrodes inserted into the peroneal nerve in 18 patients with native kidneys who were undergoing long-term treatment with hemodialysis (ot whom 14 had hypertension), 5 patients receiving hemodialysis who had undergone bilateral nephrectomy (of whom 1 had hypertension), and 11 normal subjects. Results. The mean (+/-SE) rate of sympathetic-nerve discharge was 2.5 times higher in the patients receiving hemodialysis who had not undergone nephrectomy than in the normal subjects (58+/-3 vs. 23+/-3 bursts per minute, P<0.01). In contrast, the rate of sympathetic-nerve discharge was similar in the patients receiving hemodialysis who had undergone bilateral nephrectomy (21+/-6 bursts per minute) and the normal subjects. The rate of sympathetic-nerve discharge in the patients receiving hemodialysis who had not undergone nephrectomy was also significantly higher (P<0.01) than that in the patients with bilateral nephrectomy, and it was accompanied in the former group by higher values for vascular resistance in the calf (45+/-4 vs. 22+/-4 units, P<0.05) and mean arterial pressure (106+/-4 vs. 76+/-14 mm Hg, P<0.05). The rate of sympathetic-nerve discharge was not correlated with either plasma norepinephrine concentrations or plasma renin activity. Conclusions. Chronic renal failure may be accompanied by reversible sympathetic activation, which appears to be mediated by an afferent signal arising in the failing kidneys.	UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED,DIV CARDIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; CLEVELAND CLIN EDUC FDN, RES INST, CLEVELAND, OH 44106 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cleveland Clinic Foundation			Toto, Robert/AAQ-3336-2021		FIC NIH HHS [1-F05-TW04494-01] Funding Source: Medline; NHLBI NIH HHS [5-T32-HL07360-13, R0-1 HL44010] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004494] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044010, T32HL007360] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON EA, 1989, HYPERTENSION, V14, P177, DOI 10.1161/01.HYP.14.2.177; BRAVO EL, 1975, NEW ENGL J MED, V292, P66, DOI 10.1056/NEJM197501092920203; CAMPESE VM, 1981, KIDNEY INT, V20, P246, DOI 10.1038/ki.1981.127; CORDER CN, 1980, NEPHRON, V25, P267, DOI 10.1159/000181855; CUCHE JL, 1986, KIDNEY INT, V30, P566, DOI 10.1038/ki.1986.222; DELIUS W, 1972, ACTA PHYSIOL SCAND, V84, P82, DOI 10.1111/j.1748-1716.1972.tb05158.x; DIBONA GF, 1982, REV PHYSIOL BIOCH P, V94, P75, DOI 10.1007/BFb0031333; ESPOSTI ED, 1985, CLIN SCI, V69, P51, DOI 10.1042/cs0690051; FABER JE, 1985, CIRC RES, V57, P676, DOI 10.1161/01.RES.57.5.676; FERRARIO CM, 1972, CIRC RES, V30, P257, DOI 10.1161/01.RES.30.3.257; Heidbreder E, 1986, Contrib Nephrol, V50, P14; HENRICH WL, 1977, KIDNEY INT, V12, P279, DOI 10.1038/ki.1977.112; Katholi R E, 1984, J Hypertens, V2, P349; KATHOLI RE, 1982, J CLIN INVEST, V69, P55, DOI 10.1172/JCI110441; LAKE CR, 1979, CARDIOVASC MED, V4, P1099; LAZARUS JM, 1973, CIRCULATION, V47, P1015, DOI 10.1161/01.CIR.47.5.1015; LILLEY JJ, 1976, J CLIN INVEST, V57, P1190, DOI 10.1172/JCI108387; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; MARK AL, 1985, CIRC RES, V57, P461, DOI 10.1161/01.RES.57.3.461; Mark AL., 1983, HDB PHYSL SECTION 2, VVol. 3 Part 2, P795; MCGRATH BP, 1977, KIDNEY INT, V12, P294, DOI 10.1038/ki.1977.114; NIES AS, 1979, J LAB CLIN MED, V94, P395; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; RECORDATI G, 1981, J AUTONOM NERV SYST, V3, P237, DOI 10.1016/0165-1838(81)90066-7; ROSTAND SG, 1991, J AM SOC NEPHROL, V2, P1053; SCHAEFER RM, 1988, AM J NEPHROL, V8, P449, DOI 10.1159/000167652; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; Siggaard-Andersen J, 1970, DANISH MED B      S1, V17, P1; SMOGORZEWSKI M, 1989, KIDNEY INT, V36, P458, DOI 10.1038/ki.1989.217; STEIN RD, 1984, AM J PHYSIOL, V246, pR13, DOI 10.1152/ajpregu.1984.246.1.R13; SUZUKI H, 1983, HYPERTENSION, V5, pI139, DOI 10.1161/01.HYP.5.2_Pt_2.I139; TEXTOR SC, 1981, HYPERTENSION, V3, P294, DOI 10.1161/01.HYP.3.3.294; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; WALLIN BG, 1979, HYPERTENSION, V1, P67, DOI 10.1161/01.HYP.1.2.67; WALLIN BG, 1973, CIRC RES, V33, P9, DOI 10.1161/01.RES.33.1.9; Weidmann P, 1987, Contrib Nephrol, V54, P159; WHITE RP, 1976, T AM SOC ART INT ORG, V22, P420; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122; ZUCCHELLI P, 1988, SEMIN NEPHROL, V8, P163; ZUCCHELLI P, 1992, OXFORD TXB CLIN NEPH, V2, P1458	40	898	1019	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1912	1918		10.1056/NEJM199212313272704	http://dx.doi.org/10.1056/NEJM199212313272704			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1454086				2022-12-01	WOS:A1992KE50500004
J	LICHTMAN, SW; PISARSKA, K; BERMAN, ER; PESTONE, M; DOWLING, H; OFFENBACHER, E; WEISEL, H; HESHKA, S; MATTHEWS, DE; HEYMSFIELD, SB				LICHTMAN, SW; PISARSKA, K; BERMAN, ER; PESTONE, M; DOWLING, H; OFFENBACHER, E; WEISEL, H; HESHKA, S; MATTHEWS, DE; HEYMSFIELD, SB			DISCREPANCY BETWEEN SELF-REPORTED AND ACTUAL CALORIC-INTAKE AND EXERCISE IN OBESE SUBJECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLY-LABELED-WATER; ENERGY-EXPENDITURE; BODY-WEIGHT; SMALL EATERS; HUMANS; WOMEN; VALIDATION; ADULTS; FOOD; MEN	Background and Methods. Some obese subjects repeatedly fail to lose weight even though they report restricting their caloric intake to less than 1200 kcal per day. We studied two explanations for this apparent resistance to diet - low total energy expenditure and underreporting of caloric intake - in 224 consecutive obese subjects presenting for treatment. Group 1 consisted of nine women and one man with a history of diet resistance in whom we evaluated total energy expenditure and its main thermogenic components and actual energy intake for 14 days by indirect calorimetry and analysis of body composition. Group 2, subgroups of which served as controls in the various evaluations, consisted of 67 women and 13 men with no history of diet resistance. Results. Total energy expenditure and resting metabolic rate in the subjects with diet resistance (group 1) were within 5 percent of the predicted values for body composition, and there was no significant difference between groups 1 and 2 in the thermic effects of food and exercise. Low energy expenditure was thus excluded as a mechanism of self-reported diet resistance. In contrast, the subjects in group 1 underreported their actual food intake by an average (+/-SD) of 47+/-16 percent and overreported their physical activity by 51+/-75 percent. Although the subjects in group 1 had no distinct psychopathologic characteristics, they perceived a genetic cause for their obesity, used thyroid medication at a high frequency, and described their eating behavior as relatively normal (all P<0.05 as compared with group 2). Conclusions. The failure ot some obese subjects to lose weight while eating a diet they report as low in calories is due to an energy intake substantially higher than reported and an overestimation ot physical activity, not to an abnormality in thermogenesis.	COLUMBIA UNIV COLL PHYS & SURG, ST LUKES ROOSEVELT HOSP CTR, OBES RES CTR, DEPT MED, NEW YORK, NY 10032 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT SURG, NEW YORK, NY 10021 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital			González, Adela M Gómez/D-2863-2012; Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425	NCRR NIH HHS [RR00047] Funding Source: Medline; NIDDK NIH HHS [P01-DK42618, DK-26687] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042618, P30DK026687] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; BOUCHARD C, 1983, AM J CLIN NUTR, V37, P461, DOI 10.1093/ajcn/37.3.461; CLARK D, 1992, BRIT J NUTR, V68, P31, DOI 10.1079/BJN19920064; DIEM K, 1962, DOCUMENTA GEIGY SCI, P631; Dwyer JT., 1988, MODERN NUTR HLTH DIS, V7, P887; GAESSER GA, 1975, J APPL PHYSIOL, V38, P1132, DOI 10.1152/jappl.1975.38.6.1132; GEORGE V, 1989, INT J OBESITY, V13, P43; GEORGE V, 1991, AM J CLIN NUTR, V53, P425, DOI 10.1093/ajcn/53.2.425; GOLDMAN RF, 1961, TECHNIQUES MEASURING, P79; Graham J.R., 1987, MMPI PRACTICAL GUIDE; HADIGAN CM, 1992, INT J EAT DISORDER, V12, P107, DOI 10.1002/1098-108X(199207)12:1&lt;107::AID-EAT2260120115&gt;3.0.CO;2-Y; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P52, DOI 10.1093/ajcn/52.1.52; KUSHNER RF, 1990, AM J CLIN NUTR, V52, P219, DOI 10.1093/ajcn/52.2.219; LUSK G, 1928, ELEMENTS SCI NUTRITI; MERTZ W, 1991, AM J CLIN NUTR, V54, P291, DOI 10.1093/ajcn/54.2.291; Newburgh LH, 1930, ANN INTERN MED, V3, P815, DOI 10.7326/0003-4819-3-8-815; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; PRENTICE AM, 1985, LANCET, V1, P1419; PRENTICE AM, 1988, P NUTR SOC, V47, P259, DOI 10.1079/PNS19880043; PRENTICE AM, 1990, IDECG WORKING GROUP; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; RAVUSSIN E, 1989, AM J CLIN NUTR, V49, P968, DOI 10.1093/ajcn/49.5.968; ROBERTS SB, 1988, NEW ENGL J MED, V318, P461, DOI 10.1056/NEJM198802253180801; SCHOELLER DA, 1986, AM J PHYSIOL, V250, pR823, DOI 10.1152/ajpregu.1986.250.5.R823; SCHOELLER DA, 1988, J NUTR, V118, P1278, DOI 10.1093/jn/118.11.1278; SCHOELLER DA, 1990, NUTR REV, V48, P373, DOI 10.1111/j.1753-4887.1990.tb02882.x; SCHOELLER DA, 1991, ANNU REV NUTR, V11, P355, DOI 10.1146/annurev.nu.11.070191.002035; SEGAL KR, 1985, J CLIN INVEST, V76, P1107, DOI 10.1172/JCI112065; SEGAL KR, 1990, METABOLISM, V39, P985, DOI 10.1016/0026-0495(90)90312-Z; Siri W.E., 1956, ADV BIOL MED PHYS, P239, DOI DOI 10.1016/B978-1-4832-3110-5.50011-X; Spitzer R.L., 1990, STRUCTURED CLIN INTE; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; WELLE S, 1992, AM J CLIN NUTR, V55, P14, DOI 10.1093/ajcn/55.1.14; YELLOWLEES PM, 1988, BRIT MED J, V296, P1689, DOI 10.1136/bmj.296.6638.1689; 1987, DSM3R AM PSYCH ASS; 1985, ANN INTERN MED, V103, P977	38	940	946	0	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1893	1898		10.1056/NEJM199212313272701	http://dx.doi.org/10.1056/NEJM199212313272701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1454084	Bronze			2022-12-01	WOS:A1992KE50500001
J	MIRALLES, GD; OFALLON, JR; TALLEY, NJ				MIRALLES, GD; OFALLON, JR; TALLEY, NJ			PLASMA-CELL DYSCRASIA WITH POLYNEUROPATHY - THE SPECTRUM OF POEMS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL-NERVE MYELIN; MONOCLONAL GAMMOPATHY; OSTEOSCLEROTIC MYELOMA; SKIN CHANGES; NEUROPATHY; PARAPROTEINEMIA; FEATURES; ANTIBODY; TISSUE	Background. The POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome and osteosclerotic myeloma (polyneuropathy and sclerotic bone lesions) may both be manifestations of plasma-cell dyscrasia, but the interrelation of these diseases is not clear. We therefore set out to define the clinical spectrum of disease in patients with plasma-cell dyscrasia and polyneuropathy who have the complete or incomplete form of the POEMS syndrome or osteosclerotic myeloma. Methods. Among 2714 patients with plasma-cell dyscrasia who were identified between 1973 and 1989, we reviewed the cases of those with polyneuropathy and plasma-cell dyscrasia who fulfilled the criteria for the POEMS syndrome or osteosclerotic myeloma. Results. Thirty-eight patients (1.4 percent) with a median age of 51 years were identified, 22 of whom were male. By definition, all had polyneuropathy (37 combined sensorimotor, and 1 primarily motor). Other findings included osteosclerotic bone lesions (82 percent), skin abnormalities (58 percent), lymphadenopathy (42 percent), papilledema (37 percent), peripheral edema (29 percent), hepatomegaly (24 percent), splenomegaly (21 percent), and ascites (11 percent). Thirty-three patients (87 percent) had an abnormal M protein in serum or urine (17 had IgA-lambda and 12 IgG-lambda). Five patients fulfilled all the criteria for the POEMS syndrome. The estimated five-year survival in the 38 patients was 60 percent, which was significantly better than the 20 percent survival in 869 patients with multiple myeloma (P<0.05). The clinical course was similar among the patients with the complete form of the POEMS syndrome and those with the incomplete form. Conclusions. Plasma-cell dyscrasia with polyneuropathy is a rare multisystem disease that often presents with osteosclerotic bone lesions. The differentiation of the POEMS syndrome from so-called osteosclerotic myeloma with peripheral neuropathy appears to have no clinical value.	MAYO CLIN & MAYO FDN, DIV GASTROENTEROL & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, CANC STAT UNIT, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic			Talley, Nicholas J/D-5399-2013	Talley, Nicholas J/0000-0003-2537-3092				AGUAYO A, 1964, J NEUROL NEUROSUR PS, V27, P562, DOI 10.1136/jnnp.27.6.562; BARDWICK PA, 1980, MEDICINE, V59, P311, DOI 10.1097/00005792-198007000-00006; BESINGER UA, 1981, SCIENCE, V213, P1027, DOI 10.1126/science.7268405; BRAUN PE, 1982, J NEUROCHEM, V39, P1261, DOI 10.1111/j.1471-4159.1982.tb12563.x; CROW RS, 1956, BRIT MED J, V2, P802, DOI 10.1136/bmj.2.4996.802; DRIEDGER H, 1980, MEDICINE, V59, P301, DOI 10.1097/00005792-198007000-00005; DYCK PJ, 1991, NEW ENGL J MED, V325, P1482, DOI 10.1056/NEJM199111213252105; EVISON G, 1967, BRIT J RADIOL, V40, P81, DOI 10.1259/0007-1285-40-470-81; HAFLER DA, 1986, NEUROLOGY, V36, P75, DOI 10.1212/WNL.36.1.75; JULIEN J, 1978, ARCH NEUROL-CHICAGO, V35, P423, DOI 10.1001/archneur.1978.00500310025005; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLY JJ, 1981, NEUROLOGY, V31, P24, DOI 10.1212/WNL.31.1.24; KELLY JJ, 1983, NEUROLOGY, V33, P202, DOI 10.1212/WNL.33.2.202; KOJIMA M, 1983, JPN J CLIN ONCOL, V13, P557; KYLE RA, 1975, MAYO CLIN PROC, V50, P29; KYLE RA, 1976, MONOCLONAL GAMMOPATH; LATOV N, 1980, NEW ENGL J MED, V303, P618, DOI 10.1056/NEJM198009113031105; LATOV N, 1981, NEUROLOGY, V31, P1530, DOI 10.1212/WNL.31.12.1530; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mayo C M, 1968, Trans Am Neurol Assoc, V93, P240; MEIER C, 1985, J NEUROL, V232, P204, DOI 10.1007/BF00313781; MONACO S, 1990, NEW ENGL J MED, V322, P649, DOI 10.1056/NEJM199003083221002; MORLEY JB, 1967, J NEUROL NEUROSUR PS, V30, P432, DOI 10.1136/jnnp.30.5.432; MYERS BM, 1991, AM J MED, V90, P646; NAKANISHI T, 1984, NEUROLOGY, V34, P712, DOI 10.1212/WNL.34.6.712; ODELBERGJOHNSON O, 1959, ACTA RADIOL, V52, P139, DOI 10.3109/00016925909171139; REITAN JB, 1980, ACTA MED SCAND, V208, P137; REULECKE M, 1988, NEUROLOGY, V38, P614, DOI 10.1212/WNL.38.4.614; SEMBLE EL, 1986, ARTHRITIS RHEUM, V29, P286, DOI 10.1002/art.1780290218; SHELLEY WB, 1987, ARCH DERMATOL, V123, P85, DOI 10.1001/archderm.123.1.85; Shimpo S, 1968, Nihon Rinsho, V26, P2444; Silberstein L E, 1985, J Clin Apher, V2, P253, DOI 10.1002/jca.2920020309; TAKATSUKI K, 1983, JPN J CLIN ONCOL, V13, P543; TRENTHAM DE, 1976, ANN INTERN MED, V84, P271, DOI 10.7326/0003-4819-84-3-271; WALDENSTROM JG, 1978, ACTA MED SCAND, V203, P297; WIERNIK PH, 1991, NEOPLASTIC DISEASES	36	216	222	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1919	1923		10.1056/NEJM199212313272705	http://dx.doi.org/10.1056/NEJM199212313272705			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1333569				2022-12-01	WOS:A1992KE50500005
J	SEEFF, LB; BUSKELLBALES, Z; WRIGHT, EC; DURAKO, SJ; ALTER, HJ; IBER, FL; HOLLINGER, FB; GITNICK, G; KNODELL, RG; PERRILLO, RP; STEVENS, CE; HOLLINGSWORTH, CG				SEEFF, LB; BUSKELLBALES, Z; WRIGHT, EC; DURAKO, SJ; ALTER, HJ; IBER, FL; HOLLINGER, FB; GITNICK, G; KNODELL, RG; PERRILLO, RP; STEVENS, CE; HOLLINGSWORTH, CG			LONG-TERM MORTALITY AFTER TRANSFUSION-ASSOCIATED NON-A-HEPATITIS, NON-B-HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALCOHOLIC LIVER-DISEASE; C VIRUS; HEPATOCELLULAR-CARCINOMA; POSTTRANSFUSION HEPATITIS; FOLLOW-UP; VIRAL-HEPATITIS; PREVALENCE; ANTIBODIES; CIRRHOSIS; EFFICACY	Background. Acute non-A, non-B hepatitis after blood transfusion often progresses to chronic hepatitis and sometimes culminates in cirrhosis or even hepatocellular carcinoma. However, the frequency of these sequelae and their effects on mortality are not known. Methods. We traced patients with transfusion-related non-A, non-B hepatitis who had been identified in five major prospective studies conducted in the United States between 1967 and 1980. We matched each patient with two control subjects (identified as the first and second controls) who received transfusions but who did not have hepatitis. The mortality rates in the three groups were determined with use of data from the National Death index and Social Security Death Tapes. Cause-specific mortality was determined by reviewing death certificates. Results. Vital status was established for over 94 percent of the 568 patients who had had non-A, non-B hepatitis and the two control groups (526 first controls and 458 second controls). After an average follow-up of 18 years, the estimate by life-table analysis of mortality from all causes was 51 percent for those with transfusion-associated non-A, non-B hepatitis, as compared with 52 percent for the first controls and 50 percent for the second controls. The survival curves for the three groups were virtually the same. Mortality related to liver disease was 3.3, 1.1, and 2.0 percent, respectively, among the three groups (P = 0.033 for the comparison of the group with non-A, non-B hepatitis with the combined control group). Seventy-one percent of the deaths related to liver disease occurred among patients with chronic alcoholism. Conclusions. In this long-term follow-up study, there was no increase in mortality from all causes after transfusion-associated non-A, non-B hepatitis, although there was a small but statistically significant increase in the number of deaths related to liver disease.	GEORGETOWN UNIV, SCH MED, WASHINGTON, DC USA; GEORGE WASHINGTON UNIV, CTR BIOSTAT, ROCKVILLE, MD USA; WESTAT CORP, ROCKVILLE, MD USA; NIH, BLOOD BANK, BETHESDA, MD 20892 USA; VET AFFAIRS MED CTR, HINES, IL USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA; NEW YORK BLOOD CTR, NEW YORK, NY 10021 USA; NHLBI, BETHESDA, MD 20892 USA	Georgetown University; George Washington University; Westat; National Institutes of Health (NIH) - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Maryland; University of Maryland Baltimore; Washington University (WUSTL); New York Blood Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	SEEFF, LB (corresponding author), VET AFFAIRS MED CTR, 50 IRVING ST NW, WASHINGTON, DC 20422 USA.		Hollinger, F Blaine/AAY-3323-2021		NHLBI NIH HHS [N01-HB-87047] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB087047] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; AACH RD, 1981, NEW ENGL J MED, V304, P989, DOI 10.1056/NEJM198104233041701; ALTER HJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P396; Alter HJ, 1978, VIRAL HEPATITIS, P359; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; BERMAN M, 1979, ANN INTERN MED, V91, P1, DOI 10.7326/0003-4819-91-1-1; CALDWELL SH, 1991, AM J GASTROENTEROL, V86, P1219; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Cochran W.G, 1957, STAT METHODS, V6th ed; COLOMBO M, 1989, LANCET, V2, P1006; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; ECOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021; FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502; GILLIAM JH, 1984, ANN INTERN MED, V101, P794, DOI 10.7326/0003-4819-101-6-794; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KNODELL RG, 1976, LANCET, V1, P557; KORETZ RL, 1985, GASTROENTEROLOGY, V88, P1251, DOI 10.1016/S0016-5085(85)80087-1; MATTSSON L, 1988, LIVER, V8, P184; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; NOGUCHI O, 1991, LIVER, V11, P225; PERCY C, 1990, PUBLIC HEALTH REP, V105, P361; PRINCE AM, 1974, LANCET, V2, P241; RAKELA J, 1979, GASTROENTEROLOGY, V77, P1200; REALDI G, 1982, GUT, V23, P270, DOI 10.1136/gut.23.4.270; SEEFF LB, 1977, GASTROENTEROLOGY, V72, P111; SEEFF LB, 1978, VIRAL HEPATITIS, P371; TANAKA K, 1991, CANCER RES, V51, P2842; WEJSTAL R, 1987, SCAND J GASTROENTERO, V22, P1115, DOI 10.3109/00365528708991968; 1978, BMJ, V2, P1063; 1985, SAS USERS GUIDE BASI	33	673	678	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 31	1992	327	27					1906	1911		10.1056/NEJM199212313272703	http://dx.doi.org/10.1056/NEJM199212313272703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE505	1454085				2022-12-01	WOS:A1992KE50500003
J	AFZALPURKAR, RG; SCHILLER, LR; LITTLE, KH; SANTANGELO, WC; FORDTRAN, JS				AFZALPURKAR, RG; SCHILLER, LR; LITTLE, KH; SANTANGELO, WC; FORDTRAN, JS			THE SELF-LIMITED NATURE OF CHRONIC IDIOPATHIC DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTESTINAL PERFUSION; INGESTION	Background. Little is known about the clinical presentation and natural history of previously healthy patients in whom chronic idiopathic diarrhea develops. Methods. We reviewed the case records of 152 patients with chronic diarrhea who had no history of gastrointestinal surgery and who were evaluated in detail as part of a chronic-diarrhea protocol from 1985 to 1990. Patients were considered to have chronic idiopathic diarrhea if they had persistently loose stools for more than four weeks, no systemic illness, and no identifiable cause of diarrhea. Results. Seventeen patients (10 men and 7 women) ranging in age from 33 to 72 years met the criteria for chronic idiopathic diarrhea. Each patient had a history of a relatively abrupt onset of symptoms, often soon after returning home from a trip, starting two to seven months before evaluation. Their diarrhea did not occur during a local outbreak of diarrhea, and other family members did not become ill. Stool frequency ranged from 5 to 25 movements per day, stool weights ranged from 417 to 1480 g per day, and fecal electrolyte and osmolality values were consistent with a diagnosis of secretory diarrhea. The results of biopsies of the small intestine and colon were normal, as were small-bowel roentgenograms. Extensive studies for infectious causes of diarrhea were negative, and no patient responded to antibiotic therapy. In every patient the diarrhea stopped without specific therapy after 7 to 31 months (mean, 15) and did not recur during a follow-up period averaging 38 months. Conclusions. Sporadic idiopathic chronic diarrhea is a recognizable syndrome that can last many months, but is self-limited.	BAYLOR UNIV,MED CTR,DEPT INTERNAL MED,3500 GASTON AVE,DALLAS,TX 75246	Baylor University; Baylor University Medical Center	FORDTRAN, JS (corresponding author), BAYLOR UNIV,MED CTR,DEPT INTERNAL MED,3500 GASTON AVE,DALLAS,TX 75246, USA.				NIDDK NIH HHS [R01-DK37172-07] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; FINE KD, 1991, NEW ENGL J MED, V324, P1012, DOI 10.1056/NEJM199104113241502; FINE KD, 1989, GASTROINTESTINAL DIS, P290; FORDTRAN JS, 1986, CLIN GASTROENTEROL, V15, P477; GORBACH SL, 1989, GASTROINTESTINAL DIS, P1191; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; JANDA RC, 1991, GASTROENTEROLOGY, V100, P458, DOI 10.1016/0016-5085(91)90216-8; KREJS GJ, 1977, AM J DIG DIS, V22, P280, DOI 10.1007/BF01072184; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; PARSONNET J, 1989, ANN INTERN MED, V110, P985, DOI 10.7326/0003-4819-110-12-985; READ NW, 1982, DIGEST DIS SCI, V27, P193, DOI 10.1007/BF01296914; Schiller LA, 1991, DIARRHEAL DISEASES, P219; TOSKES PP, 1989, GASTROINTESTINAL DIS, P1289	13	47	51	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1849	1852		10.1056/NEJM199212243272605	http://dx.doi.org/10.1056/NEJM199212243272605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1448122				2022-12-01	WOS:A1992KD71400005
J	BOSENBERG, MW; PANDIELLA, A; MASSAGUE, J				BOSENBERG, MW; PANDIELLA, A; MASSAGUE, J			THE CYTOPLASMIC CARBOXY-TERMINAL AMINO-ACID SPECIFIES CLEAVAGE OF MEMBRANE TGF-ALPHA INTO SOLUBLE GROWTH-FACTOR	CELL			English	Article							STIMULATING FACTOR CSF-1; CELL-SURFACE; KIT LIGAND; MOLECULAR-CLONING; FACTOR RECEPTORS; PLASMA-MEMBRANE; SI-LOCUS; PRECURSOR; TRANSMEMBRANE; PROTEIN	Membrane-anchored transforming growth factor a (proTGFalpha) belongs to a group of transmembrane proteins whose extracellular domains are selectively cleaved and released into the medium. We demonstrate that the carboxy-terminal valine in the cytoplasmic tail of proTGFalpha is required for cleavage of the growth factor ectodomain in response to various activators. This cleavage process occurs outside Golgi or lysosomal locations, affects cell surface proTGFalpha, and requires little or no membrane traffic. We propose that cleavage and release of proTGFalpha ectodomain involve a specialized proteolytic system and depend on the recognition of a simple and specific determinant located in the proTGFalpha cytoplasmic tail.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	BOSENBERG, MW (corresponding author), MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.		Pandiella, Atanasio/O-5180-2014	Pandiella, Atanasio/0000-0002-4704-8971; Massague, Joan/0000-0001-9324-8408				ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BERNSTEIN SE, 1960, MOUSE NEWS LETT, V23, P33; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KISHIMOTO TE, 1989, SCIENCE, V245, P1338; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PORTEU F, 1991, J BIOL CHEM, V266, P18846; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; Sambrook J., 1989, MOL CLONING LAB MANU; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STEIN J, 1991, ONCOGENE, V6, P601; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	50	130	133	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1157	1165		10.1016/S0092-8674(05)80064-9	http://dx.doi.org/10.1016/S0092-8674(05)80064-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473151				2022-12-01	WOS:A1992KE60400010
J	BULTMAN, SJ; MICHAUD, EJ; WOYCHIK, RP				BULTMAN, SJ; MICHAUD, EJ; WOYCHIK, RP			MOLECULAR CHARACTERIZATION OF THE MOUSE AGOUTI LOCUS	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LIMB DEFORMITY; SEQUENCE-ANALYSIS; GENE; RECOMBINATION; MUTATIONS; MICE; ORGANIZATION; TRANSCRIPTS; CLEAVAGE	The agouti (a) locus acts within the microenvironment of the hair follicle to regulate coat color pigmentation in the mouse. We have characterized a gene encoding a novel 131 amino acid protein that we propose is the one gene associated with the agouti locus. This gene is normally expressed in a manner consistent with a locus function, and, more importantly, its structure and expression are affected by a number of representative alleles in the agouti dominance hierarchy. In addition, we found that the pleiotropic effects associated with the lethal yellow (A(y)) mutation, which include pronounced obesity, diabetes, and the development of neoplasms, are accompanied by deregulated overexpression of the agouti gene in numerous tissues of the adult animal.	UNIV TENNESSEE,SCH BIOMED SCI,DIV BIOL,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville	BULTMAN, SJ (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831, USA.		Woychik, Richard P/C-8345-2019	Woychik, Richard P/0000-0001-8196-1732	NIEHS NIH HHS [IAG 222Y01-ES-10067] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R13ES010067] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel FM., 1988, CURRENT PROTOCOLS MO; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BULTMAN SJ, 1991, P NATL ACAD SCI USA, V88, P8062, DOI 10.1073/pnas.88.18.8062; CALARCO PG, 1976, J EMBRYOL EXP MORPH, V35, P73; CARPENTER KJ, 1958, AM J PHYSIOL, V193, P499, DOI 10.1152/ajplegacy.1958.193.3.499; Castle WE, 1910, SCIENCE, V32, P868, DOI 10.1126/science.32.833.868; Cuenot L., 1905, ARCH ZOOL EXP GEN, V3, P123; DERINGER MK, 1970, J NATL CANCER I, V45, P1205; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEXTER TM, 1977, NATURE, V269, P412, DOI 10.1038/269412a0; DICKERSON GE, 1947, SCIENCE, V105, P496, DOI 10.1126/science.105.2732.496-a; Dunn LC, 1928, P NATL ACAD SCI USA, V14, P816, DOI 10.1073/pnas.14.10.816; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EATON GJ, 1963, GENETICA, V34, P155, DOI 10.1007/BF01664187; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FENTON PF, 1951, P SOC EXP BIOL MED, V77, P420, DOI 10.3181/00379727-77-18800; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GRANHOLM NH, 1986, J REPROD FERTIL, V76, P279, DOI 10.1530/jrf.0.0760279; Green M. C., 1989, GENETIC VARIANTS STR, P17; HELLERSTROM C, 1963, METABOLISM, V12, P527; HESTON WE, 1961, J NATL CANCER I, V26, P969; Heston WE, 1942, J NATL CANCER I, V3, P303; HESTON WE, 1962, J NATL CANCER I, V29, P197; HESTON WE, 1947, J NATL CANCER I, V7, P463; HESTON WE, 1963, J NATL CANCER I, V31, P189; HOLLANDER W. F., 1956, JOUR HEREDITY, V47, P221; KOBORI JA, 1986, SCIENCE, V234, P173, DOI 10.1126/science.3018929; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBO RV, 1983, P NATL ACAD SCI-BIOL, V80, P4808, DOI 10.1073/pnas.80.15.4808; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MAYER TC, 1968, DEV BIOL, V18, P62, DOI 10.1016/0012-1606(68)90023-7; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; PAPAIOANNOU V, 1979, J EMBRYOL EXP MORPH, V52, P153; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PLOCHER TA, 1976, METABOLISM, V25, P593, DOI 10.1016/0026-0495(76)90013-5; Robertson GG, 1942, J EXP ZOOL, V89, P197, DOI 10.1002/jez.1400890203; RUSSELL LB, 1963, GENETICS, V48, P907; SAKURAI T, 1975, DEV BIOL, V47, P466, DOI 10.1016/0012-1606(75)90301-2; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; Silvers W. K., 1979, COAT COLORS MICE, P6; SILVERS WK, 1961, SCIENCE, V134, P368, DOI 10.1126/science.134.3476.368; SILVERS WK, 1958, J EXP ZOOL, V137, P189, DOI 10.1002/jez.1401370110; SILVERS WK, 1955, J EXP ZOOL, V130, P199, DOI 10.1002/jez.1401300203; SILVERS WK, 1958, J EXP ZOOL, V137, P181, DOI 10.1002/jez.1401370109; SIRACUSA LD, 1987, GENETICS, V117, P93; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEUCHI T, 1989, Journal of Investigative Dermatology, V92, p239S, DOI 10.1111/1523-1747.ep13075730; TRECO D, 1985, MOL CELL BIOL, V5, P2029, DOI 10.1128/MCB.5.8.2029; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLFF GL, 1986, J HERED, V77, P151, DOI 10.1093/oxfordjournals.jhered.a110206; WOYCHIK RP, 1990, P NATL ACAD SCI USA, V87, P2588, DOI 10.1073/pnas.87.7.2588; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0	65	673	711	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1195	1204		10.1016/S0092-8674(05)80067-4	http://dx.doi.org/10.1016/S0092-8674(05)80067-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473152				2022-12-01	WOS:A1992KE60400013
J	CAPLAN, AJ; CYR, DM; DOUGLAS, MG				CAPLAN, AJ; CYR, DM; DOUGLAS, MG			YDJ1P FACILITATES POLYPEPTIDE TRANSLOCATION ACROSS DIFFERENT INTRACELLULAR MEMBRANES BY A CONSERVED MECHANISM	CELL			English	Article							HEAT-SHOCK PROTEINS; PREPRO-ALPHA-FACTOR; MITOCHONDRIAL PRECURSOR POLYPEPTIDES; POST-TRANSLATIONAL TRANSLOCATION; YEAST SECRETORY PATHWAY; ESCHERICHIA-COLI DNAJ; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CARBOXYPEPTIDASE-Y; STRESS PROTEINS	The role of S. cerevisiae YDJ1 protein (YDJ1p) in polypeptide translocation across membranes has been examined. A conditional ydj1 mutant strain (ydj1-151TS) is defective for import of several polypeptides into mitochondria and alpha factor into the endoplasmic reticulum at 37-degrees-C. These defects are suppressed by E. coli dnaJ or overexpression of S. cerevisiae SIS1 proteins. A different ydj1 mutant, which cannot be farnesylated (ydj1-S406), displays similar transport defects to the ydj1-151 strain. Furthermore, the ability of purified ydj1-151p to stimulate the ATPase activity of hsp70SSA1 was greatly diminished compared with the wild-type protein. Together, these data suggest that YDJ1p functions in polypeptide translocation in a conserved manner, probably acting at organelle membranes and in association with hsp70 proteins.			CAPLAN, AJ (corresponding author), UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA.		Caplan, Avrom/GPT-0824-2022	Cyr, Douglas/0000-0002-4928-3414	NIGMS NIH HHS [GM35367, GM41758] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041758] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10699; ALTMAN E, 1991, EMBO J, V10, P239, DOI 10.1002/j.1460-2075.1991.tb07943.x; ANG D, 1991, J BIOL CHEM, V266, P24233; ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BLUMBERG H, 1991, NATURE, V349, P627, DOI 10.1038/349627a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIMURA T, 1989, J BIOL CHEM, V264, P3183; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Leung DW, 1989, TECHNIQUE, V1, P11; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MACCECCHINI ML, 1979, P NATL ACAD SCI USA, V76, P343, DOI 10.1073/pnas.76.1.343; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; REID GA, 1982, J BIOL CHEM, V257, P3056; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHERER PE, 1990, EMBO J, V9, P4315, DOI 10.1002/j.1460-2075.1990.tb07880.x; Sherman F., 1986, METHODS YEAST GENETI; SHERMAN MY, 1992, EMBO J, V11, P71; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	65	233	236	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1143	1155		10.1016/S0092-8674(05)80063-7	http://dx.doi.org/10.1016/S0092-8674(05)80063-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473150				2022-12-01	WOS:A1992KE60400009
J	CHEN, LP; ASHE, S; BRADY, WA; HELLSTROM, I; HELLSTROM, KE; LEDBETTER, JA; MCGOWAN, P; LINSLEY, PS				CHEN, LP; ASHE, S; BRADY, WA; HELLSTROM, I; HELLSTROM, KE; LEDBETTER, JA; MCGOWAN, P; LINSLEY, PS			COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-CELLS; INTERLEUKIN-2 PRODUCTION; GENE-TRANSFER; ANTIGEN; ACTIVATION; RECEPTOR; SIGNAL; TUMORIGENICITY; RECOGNITION	Interaction of the B7 molecule on antigen-presenting cells with its receptors CD28 and CTLA-4 on T cells provides costimulatory signals for T cell activation. We have studied the effects of B7 on antitumor immunity to a murine melanoma that expresses a rejection antigen associated with the E7 gene product of human papillomavirus 16. While this E7+ tumor grows progressively in immunocompetent hosts, cotransfection of its cells with B7 led to tumor regression by a B7-dependent immune response mediated by CD8+ cytolytic T lymphocytes. The immune response induced by E7+B7+ tumor cells also caused regression of E7+B7-tumors at distant sites and was curative for established E7+B7- micrometastases. Our findings suggest that increasing T cell costimulation through the CD28 and CTLA-4 receptors may have therapeutic usefulness for generating immunity against tumors expressing viral antigens.			CHEN, LP (corresponding author), BRISTOL MYERS SQUIBB, PHARMACEUT RES INST, SEATTLE, WA 98121 USA.							AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1992, J IMMUNOL, V149, P1115; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOON T, 1992, ADV CANCER RES, V58, P177, DOI 10.1016/S0065-230X(08)60295-X; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CHEN L, 1992, J IMMUNOL, V148, P2617; CHEN LP, 1991, P NATL ACAD SCI USA, V88, P110, DOI 10.1073/pnas.88.1.110; DAMLE NK, 1992, J IMMUNOL, V148, P1985; ELLIOTT BE, 1989, ADV CANCER RES, V53, P181; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FELL HP, 1992, J BIOL CHEM, V267, P15552; FIDLER IJ, 1981, CANCER RES, V41, P3266; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Hellstrom K., 1991, BIOL THERAPY CANCER, P35; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JENKINS MK, 1991, J IMMUNOL, V147, P2461; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNG G, 1987, P NATL ACAD SCI USA, V84, P4611, DOI 10.1073/pnas.84.13.4611; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LEY V, 1991, EUR J IMMUNOL, V21, P851, DOI 10.1002/eji.1830210350; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; LIU Y, 1992, J EXP MED, V175, P437, DOI 10.1084/jem.175.2.437; MELIEF CJM, 1992, ADV CANCER RES, V58, P143, DOI 10.1016/S0065-230X(08)60294-8; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NIJHUIS EWP, 1990, CANCER IMMUNOL IMMUN, V32, P245, DOI 10.1007/BF01741708; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OTTEN GR, 1991, SCIENCE, V251, P1228, DOI 10.1126/science.1900952; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; TAN R, 1992, IN PRESS J IMMUNOL; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; VANSEVENTER GA, 1991, CURR OPIN IMMUNOL, V3, P294, DOI 10.1016/0952-7915(91)90027-X; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; YANG L, 1992, CURR OPIN IMMUNOL, V4, P265, DOI 10.1016/0952-7915(92)90075-P	52	1038	1157	5	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1093	1102		10.1016/S0092-8674(05)80059-5	http://dx.doi.org/10.1016/S0092-8674(05)80059-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335364				2022-12-01	WOS:A1992KE60400005
J	DEVARY, Y; GOTTLIEB, RA; SMEAL, T; KARIN, M				DEVARY, Y; GOTTLIEB, RA; SMEAL, T; KARIN, M			THE MAMMALIAN ULTRAVIOLET RESPONSE IS TRIGGERED BY ACTIVATION OF SRC TYROSINE KINASES	CELL			English	Article							NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE; C-JUN; IONIZING-RADIATION; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; UV RESPONSE; DNA DAMAGE	Exposure of mammalian cells to DNA-damaging agents induces the ultraviolet (UV) response, involving transcription factor AP-1, composed of Jun and Fos proteins. We investigated the mechanism by which UV irradiation induces the c-jun gene. The earliest detectable step was activation of Src tyrosine kinases, followed by activation of Ha-Ras and Raf-1. The response to UV was blocked by tyrosine kinase inhibitors and dominant negative mutants of v-src, Ha-ras, and raf-1. This signaling cascade leads to increased phosphorylation of c-Jun on two serine residues that potentiate its activity. These results strongly suggest that the UV response is initiated at or near the plasma membrane rather than the nucleus. The response may be elicited by oxidative stress, because it is inhibited by elevation of intracellular glutathione. Using tyrosine kinase inhibitors, we demonstrate that the UV response has a protective function.	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	DEVARY, Y (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Gottlieb, Roberta/0000-0002-1432-006X				AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1985, DNA REPAIR; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EISEMAN E, 1992, NATURE, V355, P78; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRILING RS, 1991, P NATL ACAD SCI USA, V87, P6258; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MUSTELIN T, 1990, ONCOGENE, V5, P809; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Romerdahl C A, 1989, Cancer Commun, V1, P209; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHIMM DS, 1992, RADIAT RES, V129, P149, DOI 10.2307/3578151; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4	71	865	886	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1081	1091		10.1016/S0092-8674(05)80058-3	http://dx.doi.org/10.1016/S0092-8674(05)80058-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473146				2022-12-01	WOS:A1992KE60400004
J	ELLENBERGER, TE; BRANDL, CJ; STRUHL, K; HARRISON, SC				ELLENBERGER, TE; BRANDL, CJ; STRUHL, K; HARRISON, SC			THE GCN4 BASIC REGION LEUCINE ZIPPER BINDS DNA AS A DIMER OF UNINTERRUPTED ALPHA-HELICES - CRYSTAL-STRUCTURE OF THE PROTEIN-DNA COMPLEX	CELL			English	Article							TRANSCRIPTIONAL ACTIVATOR PROTEIN; LAMBDA-REPRESSOR; 2.8-A RESOLUTION; COILED COIL; FOS; JUN; RECOGNITION; DOMAIN; YEAST; SITE	The yeast transcriptional activator GCN4 is 1 of over 30 identified eukaryotic proteins containing the basic region leucine zipper (bZIP) DNA-binding motif. We have determined the crystal structure of the GCN4 bZIP element complexed with DNA at 2.9 angstrom resolution. The bZIP dimer is a pair of continuous alpha helices that form a parallel coiled coil over their carboxy-terminal 30 residues and gradually diverge toward their amino termini to pass through the major groove of the DNA-binding site. The coiled-coil dimerization interface is oriented almost perpendicular to the DNA axis, giving the complex the appearance of the letter T. There are no kinks or sharp bends in either bZIP monomer. Numerous contacts to DNA bases and phosphate oxygens are made by basic region residues that are conserved in the bZIP protein family. The details of the bZIP dimer interaction with DNA can explain recognition of the AP-1 site by the GCN4 protein.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute	ELLENBERGER, TE (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.							BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1990, X PLORV 2 1 MANUAL; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; COHEN DR, 1990, ONCOGENE, V5, P929; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAPTEIN R, 1991, CURR OPIN STRUC BIOL, V2, P109; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; OAKLEY MG, 1990, SCIENCE, V248, P847, DOI 10.1126/science.2111578; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELLERS JW, 1989, NATURE, V341, P74, DOI 10.1038/341074a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P6019, DOI 10.1073/pnas.81.19.6019; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	54	864	898	1	44	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1223	1237		10.1016/S0092-8674(05)80070-4	http://dx.doi.org/10.1016/S0092-8674(05)80070-4			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473154				2022-12-01	WOS:A1992KE60400016
J	GROSS, E; GOLDBERG, D; LEVITZKI, A				GROSS, E; GOLDBERG, D; LEVITZKI, A			PHOSPHORYLATION OF THE SACCHAROMYCES-CEREVISIAE CDC25 IN RESPONSE TO GLUCOSE RESULTS IN ITS DISSOCIATION FROM RAS	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; EXCHANGE; KINASE	IN the yeast Sacchromyces cerevisiae, addition of glucose to starved cells triggers a transient rise in the intracellular level of cyclic AMP that induces a protein phosphorylation cascade1. The glucose signal is processed by the Cdc25/Ras/adenylyl cyclase pathway2, where the role of Cdc25 is to catalyse the GDP-GTP exchange on Ras3. The molecular mechanisms involved in the regulation of the activity of Cdc25 are unknown. We report here the use of highly selective anti-Cdc25 antibodies4 to demonstrate that Cdc25 is a phospho protein and that in response to glucose it is hyperphosphorylated, within seconds, by the cyclic AMP-dependent protein kinase. It is also demonstrated that, concomitantly with hyperphosphorylation, Cdc25 partially relocalizes to the cytoplasm, reducing its accessibility to membrane-bound Ras. These results are of general significance because of the highly conserved sequence of Ras-guanyl nucleotide exchange factors from yeasts to mammals.	HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	LEVITZKI, A (corresponding author), HEBREW UNIV JERUSALEM, ALEXANDER SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL.							CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; DUFAU ML, 1977, P NATL ACAD SCI USA, V74, P3419, DOI 10.1073/pnas.74.8.3419; ENGELBERG D, 1989, CELL SIGNAL, V1, P1, DOI 10.1016/0898-6568(89)90015-6; ERASO P, 1985, FEBS LETT, V191, P51, DOI 10.1016/0014-5793(85)80991-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GROSS E, 1992, MOL CELL BIOL, V12, P2653, DOI 10.1128/MCB.12.6.2653; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MBONYI K, 1990, MOL CELL BIOL, V10, P4518, DOI 10.1128/MCB.10.9.4518; MUNDER T, 1989, FEBS LETT, V242, P341, DOI 10.1016/0014-5793(89)80498-3; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; RUBIN GM, 1973, J BIOL CHEM, V248, P3860; SCHOMERUS C, 1990, MOL GEN GENET, V223, P426, DOI 10.1007/BF00264449; SEGAL M, IN PRESS J BIOL CHEM; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7	18	79	79	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					762	765		10.1038/360762a0	http://dx.doi.org/10.1038/360762a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334534				2022-12-01	WOS:A1992KE47200041
J	GRUNDER, S; THIEMANN, A; PUSCH, M; JENTSCH, TJ				GRUNDER, S; THIEMANN, A; PUSCH, M; JENTSCH, TJ			REGIONS INVOLVED IN THE OPENING OF CIC-2 CHLORIDE CHANNEL BY VOLTAGE AND CELL-VOLUME	NATURE			English	Article							INACTIVATION; MECHANISMS; EXPRESSION	REGULATION of cell volume is essential for every cell and is accomplished by the regulated loss or gain of intracellular ions or other osmolytes1-4. Regulatory volume decrease often involves the parallel activation of potassium and chloride channels5-10. Overexpression of P-glycoprotein leads to volume-activated Cl-currents11,12 but its physiological importance for volume regulation is unclear13. ClC-2 is a ubiquitously expressed Cl- channel14 activatable by non-physiologically strong hyperpolarization. We now show that ClC-2 can be activated by extracellular hypotonicity, which suggests that it has a widespread role in volume regulation. Domains necessary for activation by both voltage and volume are localized to the amino terminus. Mutations in an 'essential' region lead to constitutively open channels unresponsive to medium tonicity, whereas deletions in a 'modulating' region produce partially opened channels responsive to both hypo- and hypertonicity. These domains can be transplanted to different regions of the protein without loss of function.	UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	University of Hamburg	JENTSCH, TJ (corresponding author), UNIV HAMBURG,ZMNH,CTR MOLEC NEUROBIOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Gründer, Stefan/I-2495-2019	Gründer, Stefan/0000-0002-7635-9883; Jentsch, Thomas/0000-0002-3509-2553; Pusch, Michael/0000-0002-8644-8847				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUER CK, 1991, P NATL ACAD SCI USA, V88, P11052, DOI 10.1073/pnas.88.24.11052; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DUBINSKY WP, 1992, P NATL ACAD SCI USA, V89, P1770, DOI 10.1073/pnas.89.5.1770; FOSTER CD, 1992, NEURON, V9, P229, DOI 10.1016/0896-6273(92)90162-7; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KUNZELMANN K, 1992, PFLUG ARCH EUR J PHY, V421, P238, DOI 10.1007/BF00374833; MCEWAN GTA, 1992, FEBS LETT, V304, P233, DOI 10.1016/0014-5793(92)80626-R; MONTROSERAFIZADEH C, 1990, ANNU REV PHYSIOL, V52, P761; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TORO L, 1992, NEURON, V9, P237, DOI 10.1016/0896-6273(92)90163-8; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; WEISS H, 1992, J MEMBRANE BIOL, V126, P109; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	28	380	389	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					759	762		10.1038/360759a0	http://dx.doi.org/10.1038/360759a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334533				2022-12-01	WOS:A1992KE47200040
J	LEVERETTE, RD; ANDREWS, MT; MAXWELL, ES				LEVERETTE, RD; ANDREWS, MT; MAXWELL, ES			MOUSE U14 SNRNA IS A PROCESSED INTRON OF THE COGNATE HSC70 HEAT-SHOCK PREMESSENGER RNA	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; PROTEIN; GENE; NUCLEAR; CELLS; U3; EXPRESSION; SEQUENCE	U14 snRNA is a small nucleolar RNA species essential for eukaryotic pre-rRNA processing. We have previously shown that the mouse U14 snRNA genes are positioned within introns 5, 6, and 8 on the coding strand of the constitutively expressed cognate hsc70 heat shock gene. This genomic organization suggested the possibility that U14 snRNAs are transcribed as part of the hsc70 pre-mRNA and then excised from the intron to yield mature U14 snRNA species. To test this hypothesis directly, we have microinjected Xenopus oocytes with hsc70 pre-mRNA transcripts possessing intron 5 and the encoded U14 snRNA sequence. Processing results demonstrate that, in addition to the splicing of upstream and downstream exons, a mature 87 nt U14 snRNA is excised from the intron. Accurate excision of U14 snRNA from hsc70 intron 5 can occur in the absence of splicing. These results demonstrate a biosynthetic pathway for an snRNA species and provide a novel example of a eukaryotic pre-mRNA intron that is processed to produce a stable, biologically functional RNA species.	N CAROLINA STATE UNIV,DEPT GENET,RALEIGH,NC 27695	University of North Carolina; North Carolina State University	LEVERETTE, RD (corresponding author), N CAROLINA STATE UNIV,DEPT BIOCHEM,RALEIGH,NC 27695, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD024673] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-24673] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; HANAHAN D, 1983, METHOD ENZYMOL, V100, P333; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; JARMOLOWSKI A, 1990, EMBO J, V9, P4503, DOI 10.1002/j.1460-2075.1990.tb07901.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LAMBOWITZ AM, 1989, CELL, V56, P323, DOI 10.1016/0092-8674(89)90232-8; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIU J, 1990, NUCLEIC ACIDS RES, V18, P6565, DOI 10.1093/nar/18.22.6565; MAXWELL ES, 1986, P NATL ACAD SCI USA, V83, P7261, DOI 10.1073/pnas.83.19.7261; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Sambrook J., 1989, MOL CLONING LAB MANU; SHANAB GM, 1991, NUCLEIC ACIDS RES, V19, P4891, DOI 10.1093/nar/19.18.4891; SHANAB GM, 1992, EUR J BIOCHEM, V206, P391, DOI 10.1111/j.1432-1033.1992.tb16939.x; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; TRINHROHLIK Q, 1988, NUCLEIC ACIDS RES, V16, P521; TYC K, 1989, EMBO J, V8, P3113, DOI 10.1002/j.1460-2075.1989.tb08463.x; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZAGORSKI J, 1988, MOL CELL BIOL, V8, P3282, DOI 10.1128/MCB.8.8.3282	25	94	96	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1215	1221		10.1016/S0092-8674(05)80069-8	http://dx.doi.org/10.1016/S0092-8674(05)80069-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1282084				2022-12-01	WOS:A1992KE60400015
J	LI, L; JAMES, G; HELLERHARRISON, R; CZECH, MP; OLSON, EN				LI, L; JAMES, G; HELLERHARRISON, R; CZECH, MP; OLSON, EN			FGF INACTIVATES MYOGENIC HELIX-LOOP-HELIX PROTEINS THROUGH PHOSPHORYLATION OF A CONSERVED PROTEIN-KINASE-C SITE IN THEIR DNA-BINDING DOMAINS	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; FIBROBLAST GROWTH-FACTOR; H-RAS ONCOGENE; GENE-EXPRESSION; MYC HOMOLOGY; ACTIVATION; MYOD1; DIFFERENTIATION; SEQUENCE; REGION	Myogenin belongs to a family of myogenic helix-loop-helix (HLH) proteins that activate muscle transcription through binding to a conserved DNA sequence associated with numerous muscle-specific genes. Fibroblast growth factor (FGF) inhibits myogenesis by inactivating myogenic HLH proteins. We show that activated protein kinase C (PKC) can substitute for FGF and inhibit transcriptional activity of myogenic HLH proteins. In transfected cells, FGF induces phosphorylation of a conserved site in the DNA-binding domain of myogenin. This site is phosphorylated by PKC in vivo and in vitro and mediates repression of the myogenic program through a loss in DNA binding activity. A myogenin mutant lacking the PKC phosphorylation site is not repressed by FGF, confirming this site as a molecular target for FGF-dependent repression of muscle transcription. These results establish a direct link between the signal transduction pathways that inhibit myogenesis and the transcription factors directly activating muscle-specific genes.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	LI, L (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.				NIAMS NIH HHS [AR 39849, AR 40339] Funding Source: Medline; NIDDK NIH HHS [DK 30648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039849, R01AR040339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUANNO S, 1990, CANCER RES, V50, P3377; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COHEN R, 1977, NATURE, V266, P538, DOI 10.1038/266538a0; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIAS P, 1990, AM J PATHOL, V137, P1283; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Gorman C., 1985, DNA CLONING, V2; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIM SJ, 1992, J BIOL CHEM, V267, P15140; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OLSON EN, 1992, IN PRESS DEV BIOL; RAPP UR, 1991, ONCOGENE, V6, P495; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TONIN PN, 1991, CANCER RES, V51, P5100; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VINSON CR, 1992, NEW BIOL, V4, P396; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZHU YY, 1991, J CELL BIOL, V115, P745, DOI 10.1083/jcb.115.3.745	66	321	324	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1181	1194		10.1016/S0092-8674(05)80066-2	http://dx.doi.org/10.1016/S0092-8674(05)80066-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335366				2022-12-01	WOS:A1992KE60400012
J	LIN, CJ; LIN, SC; CHANG, CP; ROSENFELD, MG				LIN, CJ; LIN, SC; CHANG, CP; ROSENFELD, MG			PIT-1-DEPENDENT EXPRESSION OF THE RECEPTOR FOR GROWTH-HORMONE RELEASING-FACTOR MEDIATES PITUITARY CELL-GROWTH	NATURE			English	Article							PANCREATIC-ISLET TUMOR; SOMATOSTATIN GENE; MESSENGER-RNA; TRANSCRIPTION; MICE; CREB; PHOSPHORYLATION; HYPERPLASIA; MUTATIONS; DWARFISM	IN Snell (dw) and Jackson (dw(J)) dwarf mice, mutations in the gene encoding Pit-1, a tissue-specific POU-domain transcription factor, lead to the absence of somatotroph, lactotroph and thyrotroph cells1-6. Pre-somatotroph proliferation is stimulated by increased intracellular levels of cyclic AMP, normally induced by growth hormone releasing factor (GRF; refs 7-17). Here we report the cloning of mouse and rat complementary DNAs encoding a new member of the seven-transmembrane-helix, G-protein-coupled receptor family restricted to the pituitary gland, which mediates increases in intracellular cAMP and cAMP-dependent gene transcription in response to GRF. The receptor is expressed in a spatial and temporal pattern corresponding precisely to growth hormone gene expression, and neither is expressed in dw/dw mice. The pituitary hypoplasia in these mice thus appears to be due, at least in part, to the absence of GRF receptor, which is in turn due to the absence of functional Pit-1.	UNIV CALIF SAN DIEGO,SCH & DEPT MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	LIN, CJ (corresponding author), UNIV CALIF SAN DIEGO,SCH & DEPT MED,HOWARD HUGHES MED INST,9500 GILMAN DR,LA JOLLA,CA 92093, USA.		Lin, SC/G-4666-2010					BAIRD A, 1984, REGUL PEPTIDES, V10, P23, DOI 10.1016/0167-0115(84)90049-1; BILEZIKJIAN LM, 1983, ENDOCRINOLOGY, V113, P1726, DOI 10.1210/endo-113-5-1726; BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; COLLINS S, 1992, TRENDS BIOCHEM SCI, V17, P37, DOI 10.1016/0968-0004(92)90425-9; EICHER EM, 1976, J HERED, V67, P87, DOI 10.1093/oxfordjournals.jhered.a108682; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; FROHMAN LA, 1986, ENDOCR REV, V7, P236; GICK GG, 1984, P NATL ACAD SCI-BIOL, V81, P1553, DOI 10.1073/pnas.81.5.1553; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; ISHIHARA T, 1992, NEURON, V8, P815; ISHIKAWA K, 1986, NEUROENDOCRINOLOGY, V43, P537, DOI 10.1159/000124579; JUPPNER H, 1991, SCIENCE, P1022; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; MAYO KE, 1988, MOL ENDOCRINOL, V2, P606, DOI 10.1210/mend-2-7-606; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; RIVIER J, 1982, NATURE, V300, P276, DOI 10.1038/300276a0; ROUSE M, 1982, CELL TISSUE RES, V223, P415; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT H, 1985, NATURE, V313, P487, DOI 10.1038/313487a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; THORNER MO, 1982, J CLIN INVEST, V70, P965, DOI 10.1172/JCI110708; WILSON DB, 1986, ANAT EMBRYOL, V174, P277, DOI 10.1007/BF00824343; YASHIRO T, 1988, CELL TISSUE RES, V251, P249, DOI 10.1007/BF00215832	35	287	300	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					765	768		10.1038/360765a0	http://dx.doi.org/10.1038/360765a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1334535				2022-12-01	WOS:A1992KE47200042
J	MARSHALL, H; NONCHEV, S; SHAM, MH; MUCHAMORE, I; LUMSDEN, A; KRUMLAUF, R				MARSHALL, H; NONCHEV, S; SHAM, MH; MUCHAMORE, I; LUMSDEN, A; KRUMLAUF, R			RETINOIC ACID ALTERS HINDBRAIN HOX CODE AND INDUCES TRANSFORMATION OF RHOMBOMERES 2-3 INTO A 4-5 IDENTITY	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; MOUSE HINDBRAIN; EXPRESSION; SEGMENTATION; DISRUPTION; VERTEBRAE; DEFECTS; HOX-1.1; EMBRYOS; HOX-2.9	IT has been suggested that Hox genes play an important part in the patterning of limbs1-3, vertebrae4-6 and craniofacial structures5,7-9 by providing an ordered molecular system of positional values, termed the Hox code10,11. Little is known about the nature of the signals that govern the establishment and regulation of Hox genes, but retinoic acid can affect the expression of these genes in cell lines12-14 and in embryonic tissues2,11,15-17. On the basis of experimental and clinical evidence, the hindbrain and branchial region of the head are particularly sensitive to the effects of retinoic acid 15,18-21, but the phenotypes are complex and hard to interpret, and how and if they relate to Hox expression has not been clear. Here we follow the changes induced by retinoic acid to hindbrain segmentation and the branchial arches using transgenic mice which contain lacZ reporter genes that reveal the endogenous segment-restricted expression of the Hox-B1 (Hox-2.9), Hox-B2(Hox-2.8) and Krox-20 genes. Our results show that these genes rapidly respond to exposure to retinoic acid at preheadfold stages and undergo a progressive series of changes in segmental expression that are associated with specific phenotypes in hindbrain of first branchial arch. Together the molecular and anatomical alterations indicate that retinoic acid has induced changes in the hindbrain Hox code which result in the homeotic transformation of rhombomeres (r) 2/3 to an r4/5 identity. A main feature of this rhombomeric phenotype is that the trigeminal motor nerve is transformed to a facial identity. Furthermore, in support of this change in rhombomeric identity, neural crest cells derived from r2/3 also express posterior Hox markers suggesting that the retinoic acid-induced transformation extends to multiple components of the first branchial arch.	NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV ANAT & CELL BIOL,MRC,LONDON SE1 9RT,ENGLAND	MRC National Institute for Medical Research; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	KRUMLAUF, R (corresponding author), NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.		Krumlauf, Robb/AAH-5012-2019; Lumsden, Andrew/C-5146-2009; Sham, Mai Har/AAX-3781-2020	Krumlauf, Robb/0000-0001-9102-7927; Sham, Mai Har/0000-0003-1179-7839; Muchamore, Ian/0000-0003-2121-1539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CANLON R, 1992, DEVELOPMENT, V116, P357; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DOLE P, 1989, NATURE, V342, P767; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; Hogan B., 1986, MANIPULATING MOUSE E; HOLDER N, 1991, DEVELOPMENT, V113, P1159; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Morris G. M., 1978, DEV MAMMALS, V3, P363; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PAPALOPULU N, 1991, NUCLEIC ACIDS RES, V19, P5497, DOI 10.1093/nar/19.20.5497; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SHAM MH, IN PRESS CELL; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0	32	427	433	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					737	741		10.1038/360737a0	http://dx.doi.org/10.1038/360737a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1361214				2022-12-01	WOS:A1992KE47200033
J	OPPENHEIM, RW; YIN, QW; PREVETTE, D; YAN, Q				OPPENHEIM, RW; YIN, QW; PREVETTE, D; YAN, Q			BRAIN-DERIVED NEUROTROPHIC FACTOR RESCUES DEVELOPING AVIAN MOTONEURONS FROM CELL-DEATH	NATURE			English	Article							EMBRYO SPINAL-CORD; NERVE GROWTH-FACTOR; CHICK-EMBRYO; RETROGRADE TRANSPORT; MOTOR NEURONS; MESSENGER-RNA; SURVIVAL; NGF; MUSCLE; DEGENERATION	DURING normal vertebrate development, about half of spinal motoneurons are lost by a process of naturally occurring or programmed cell death1,2. Additional developing motoneurons degenerate after the removal of targets3,4 or afferents5. Naturally occurring motoneuron death as well as motoneuron death after loss of targets or after axotomy can. be prevented by in vivo treatment with putative target (muscle) derived or other neurotrophic agents6-8. Motoneurons can also be prevented from dying in vitro9-12 and in vivo (Y.Q.-W., R.W., D.P., J. Johnson and L. Van Eldik, unpublished data and refs 7, 13, 14) by treatment with central nervous system extracts (brain or spinal cord) and purified central nervous system and glia-derived proteins. Here we report that in vivo treatment of chick embryos with brain-derived neurotrophic factor rescues motoneurons from naturally occurring cell death. Furthermore, in vivo treatment with brain-derived neurotrophic factor (and nerve growth factor) also prevents the induced death of motoneurons that occurs following the removal of descending afferent input(deafferentation)5. These data indicate that members of the neurotrophin family can promote the survival of developing avian motoneurons.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,NEUROSCI PROGRAM,WINSTON SALEM,NC 27103; AMGEN INC,AMGEN CTR,NEUROBIOL PROGRAM,THOUSAND OAKS,CA 91320	Wake Forest University; Wake Forest Baptist Medical Center; Amgen	OPPENHEIM, RW (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROBIOL & ANAT,WINSTON SALEM,NC 27103, USA.							ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BHATTACHARYYA A, IN PRESS J NEUROBIOL; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; DOHRMANN U, 1987, DEV BIOL, V124, P145, DOI 10.1016/0012-1606(87)90467-2; DOHRMANN U, 1986, DEV BIOL, V188, P20; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; HAMBURGER V, 1958, AM J ANAT, V102, P465; HOFER MM, 1988, NATURE, V331, P361; HULST JR, 1986, DEV BRAIN RES, V25, P153, DOI 10.1016/0165-3806(86)90164-1; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARCHETTI D, 1991, DEV BIOL, V148, P306, DOI 10.1016/0012-1606(91)90339-5; OKADO N, 1984, J NEUROSCI, V4, P1639; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; OPPENHEIM RW, 1978, J COMP NEUROL, V177, P87, DOI 10.1002/cne.901770107; OPPENHEIM RW, 1988, SCIENCE, V240, P919, DOI 10.1126/science.3363373; OPPENHEIM RW, 1989, DEV BIOL, V133, P468, DOI 10.1016/0012-1606(89)90050-X; OPPENHEIM RW, IN PRESS J NEUROSCI; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; WAYNE DB, 1988, DEV BIOL, V127, P220, DOI 10.1016/0012-1606(88)90203-5; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1988, NEURON, V1, P335	28	445	462	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					755	759		10.1038/360755a0	http://dx.doi.org/10.1038/360755a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465146				2022-12-01	WOS:A1992KE47200038
J	REICHMANN, E; SCHWARZ, H; DEINER, EM; LEITNER, I; EILERS, M; BERGER, J; BUSSLINGER, M; BEUG, H				REICHMANN, E; SCHWARZ, H; DEINER, EM; LEITNER, I; EILERS, M; BERGER, J; BUSSLINGER, M; BEUG, H			ACTIVATION OF AN INDUCIBLE C-FOSER FUSION PROTEIN CAUSES LOSS OF EPITHELIAL POLARITY AND TRIGGERS EPITHELIAL-FIBROBLASTOID CELL CONVERSION	CELL			English	Article							CANINE KIDNEY-CELLS; ADHESION MOLECULE UVOMORULIN; HEPATOCYTE GROWTH-FACTOR; HUMAN ESTROGEN-RECEPTOR; MESENCHYME-LIKE CELLS; TRANSCRIPTIONAL ACTIVATION; CYTOSKELETAL PROTEINS; GENE-EXPRESSION; BINDING-SITE; TRANSFORMATION	As a novel approach to studying the modulation of the polarized epithelial phenotype, we have expressed c-Fos and c-Myc estrogen receptor fusion proteins (c-FosER and c-MycER) in mammary epithelial cells. The hybrid proteins could be activated by estrogen for defined time periods and after the cells had achieved their fully polarized organization. Activation of c-MycER deregulated proliferation but did not affect epithelial polarity. Short-term activation of c-FosER induced the reversible loss of morphological and functional cell polarity. In contrast, long-term stimulation of c-FosER caused the cells to depolarize irreversibly, to invade collagen gels, and to undergo epithelial-fibroblastoid cell conversion. Our data suggest that Fos proteins are important in modulating the epithelial phenotype both in normal tissue development and in invasive processes.	MAX PLANCK INST ENTWICKLUNGSBIOL,W-7400 TUBINGEN,GERMANY; ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	REICHMANN, E (corresponding author), FORSCHUNGSINST MOLEK PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; ASCH HL, 1985, DEV BIOL, V107, P470, DOI 10.1016/0012-1606(85)90328-8; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1984, CELL, V36, P259; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANKE WW, 1981, EXP CELL RES, V134, P345, DOI 10.1016/0014-4827(81)90435-3; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBURG G, 1986, DEV BIOL, V115, P363, DOI 10.1016/0012-1606(86)90256-3; GREENBURG G, 1988, DEVELOPMENT, V102, P605; GRIFFITHS G, 1993, IN PRESS FINE STRUCT; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Hay E.D., 1990, Seminars in Developmental Biology, V1, P347; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KANDJIAN EW, 1986, MOL BIOL REP, V11, P107; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KEMLER R, 1989, BIOESSAYS, V11, P88, DOI 10.1002/bies.950110403; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MARGUET D, 1992, J BIOL CHEM, V267, P2200; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKWALD RR, 1979, DEV BIOL, V69, P634, DOI 10.1016/0012-1606(79)90317-8; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MULLIN JM, 1988, J CELL PHYSIOL, V134, P357, DOI 10.1002/jcp.1041340306; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; OJAKIAN GK, 1981, CELL, V23, P95, DOI 10.1016/0092-8674(81)90274-9; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SANFORD KK, 1961, JNCI-J NATL CANCER I, V26, P1139; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SONNENBERG A, 1986, CANCER RES, V46, P5913; STRANGE R, 1991, CELL GROWTH DIFFER, V2, P549; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRELSTAD RL, 1982, DEV BIOL, V92, P27, DOI 10.1016/0012-1606(82)90147-6; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZUK A, 1989, J CELL BIOL, V108, P903, DOI 10.1083/jcb.108.3.903; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	69	234	244	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1103	1116		10.1016/S0092-8674(05)80060-1	http://dx.doi.org/10.1016/S0092-8674(05)80060-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473147				2022-12-01	WOS:A1992KE60400006
J	SABIA, PJ; POWERS, ER; RAGOSTA, M; SAREMBOCK, IJ; BURWELL, LR; KAUL, S				SABIA, PJ; POWERS, ER; RAGOSTA, M; SAREMBOCK, IJ; BURWELL, LR; KAUL, S			AN ASSOCIATION BETWEEN COLLATERAL BLOOD-FLOW AND MYOCARDIAL VIABILITY IN PATIENTS WITH RECENT MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TWO-DIMENSIONAL ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; PHASE-I THROMBOLYSIS; 12-MONTH FOLLOW-UP; CONTRAST ECHOCARDIOGRAPHY; CORONARY-ARTERY; TIMI TRIAL; REPERFUSION; SIZE; OCCLUSION	Background. We hypothesized that successful reperfusion of an occluded infarct-related coronary artery even late after acute myocardial infarction would result in improved regional wall motion and that such improvement might be related to the presence of collateral blood flow within the infarct bed. Methods. We assessed regional wall motion by two-dimensional echocardiography at base line and one month after angioplasty was attempted in the occluded infarct-related artery in 43 patients who had had a myocardial infarction two days to five weeks earlier. A wall-motion score was assigned to each patient on a five-point scale (from 1 [normal function] to 5 [dyskinesia]). The percentage of the infarct bed perfused by collateral flow was assessed with myocardial contrast echocardiography. Results. In the 41 patients who had abnormal wall motion at base line, improvement in function was noted in 25 (78 percent) of the 32 in whom angioplasty was successful, as compared with only 1 (11 percent) of the 9 in whom it was unsuccessful (P<0.001). The percentage of the infarct bed supplied by collateral flow at base line was directly correlated with wall function and inversely correlated with the wall-motion score one month after successful angioplasty (r = -0.64, P<0.001). Among the patients in whom angioplasty was successful, the 23 in whom >50 percent of the infarct bed was supplied by collateral flow had better wall motion (P<0.001) and greater improvement in wall motion at one month (P = 0.004) than the 9 in whom less-than-or-equal-to 50 percent of the bed was supplied by collateral flow. The degree of improvement in function was not influenced by the length of time between the infarction and the attempted angioplasty. Conclusions. The myocardium remains viable for a prolonged period in many patients with acute infarction and an occluded infarct-related artery. Viability appears to be associated with the presence of collateral blood flow within the infarct bed.	UNIV VIRGINIA, SCH MED, DEPT MED, DIV CARDIOL, BOX 158, CHARLOTTESVILLE, VA 22908 USA	University of Virginia	POWERS, ER (corresponding author), UNIV VIRGINIA, SCH MED, DEPT MED, DIV CARDIOL, BOX 158, CHARLOTTESVILLE, VA 22908 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001833, R29HL038345] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08-HL01833, R29-HL38345] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COHEN MV, 1985, CORONARY COLLATERALS, P1; Cohen MV, 1985, CORONARY COLLATERALS, P93; DALEN JE, 1988, AM J CARDIOL, V62, P179, DOI 10.1016/0002-9149(88)90208-1; FINCI L, 1990, AM J CARDIOL, V66, P660, DOI 10.1016/0002-9149(90)91125-P; FORCE T, 1988, J AM COLL CARDIOL, V11, P192, DOI 10.1016/0735-1097(88)90189-1; GENSINI GG, 1969, AM J CARDIOL, V24, P393, DOI 10.1016/0002-9149(69)90434-2; GOHLKE H, 1991, AM J CARDIOL, V67, P1165, DOI 10.1016/0002-9149(91)90920-G; Gorlin R, 1976, Major Probl Intern Med, V11, P59; GRILL HP, 1990, J AM COLL CARDIOL, V16, P1594, DOI 10.1016/0735-1097(90)90306-A; HABIB GB, 1991, CIRCULATION, V83, P739, DOI 10.1161/01.CIR.83.3.739; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; KAUL S, 1989, J AM COLL CARDIOL, V13, P468, DOI 10.1016/0735-1097(89)90528-7; KAUL S, 1985, J AM COLL CARDIOL, V6, P825, DOI 10.1016/S0735-1097(85)80490-3; KAUL S, 1986, J AM COLL CARDIOL, V7, P383, DOI 10.1016/S0735-1097(86)80509-5; KAUL S, 1991, J AM COLL CARDIOL, V17, P1403, DOI 10.1016/S0735-1097(10)80154-8; KAUL S, 1987, CIRC RES, V61, P77, DOI 10.1161/01.RES.61.1.77; KELLER MW, 1988, J AM COLL CARDIOL, V12, P1039, DOI 10.1016/0735-1097(88)90474-3; KENNEDY JW, 1985, NEW ENGL J MED, V312, P1073, DOI 10.1056/NEJM198504253121701; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; LANG RM, 1986, J AM COLL CARDIOL, V8, P232, DOI 10.1016/S0735-1097(86)80118-8; LIM YJ, 1990, AM J CARDIOL, V66, P556, DOI 10.1016/0002-9149(90)90481-F; MOOD AM, 1963, INTRO THEORY STATIST; MOORE CA, 1986, J AM COLL CARDIOL, V8, P1066, DOI 10.1016/S0735-1097(86)80383-7; Mulvihill DA, 1931, NEW ENGL J MED, V204, P1032, DOI 10.1056/NEJM193105142042003; REIMER KA, 1979, LAB INVEST, V40, P633; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; SABIA PJ, 1992, CIRCULATION, V85, P2080, DOI 10.1161/01.CIR.85.6.2080; SAITO Y, 1985, AM J CARDIOL, V55, P1259, DOI 10.1016/0002-9149(85)90485-0; SCHAPER W, 1979, BASIC RES CARDIOL, V74, P46, DOI 10.1007/BF01907684; SCHAPER W, 1971, COLLATERAL CIRCULATI, P155; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SCHRODER R, 1989, AM J CARDIOL, V64, P878, DOI 10.1016/0002-9149(89)90835-7; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; SPOTNITZ WD, 1990, AM J CARDIOL, V65, P1259, DOI 10.1016/0002-9149(90)90984-9; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; TOPOL EJ, 1992, CIRCULATION, V85, P2090, DOI 10.1161/01.CIR.85.6.2090; TOUCHSTONE DA, 1989, J AM COLL CARDIOL, V13, P1506, DOI 10.1016/0735-1097(89)90340-9; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905	42	475	485	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 24	1992	327	26					1825	1831		10.1056/NEJM199212243272601	http://dx.doi.org/10.1056/NEJM199212243272601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD714	1448120				2022-12-01	WOS:A1992KD71400001
J	SENDTNER, M; HOLTMANN, B; KOLBECK, R; THOENEN, H; BARDE, YA				SENDTNER, M; HOLTMANN, B; KOLBECK, R; THOENEN, H; BARDE, YA			BRAIN-DERIVED NEUROTROPHIC FACTOR PREVENTS THE DEATH OF MOTONEURONS IN NEWBORN RATS AFTER NERVE-SECTION	NATURE			English	Article							SPINAL-CORD MOTONEURONS; GROWTH-FACTOR; MESSENGER-RNA; EXPRESSION; SURVIVAL; NGF; NEURONS; AXOTOMY; CNTF; BDNF	MOTONEURONS innervating the skeletal musculature were among the first neurons shown to require the presence of their target cells to develop appropriately1,2. But the characterization of molecules allowing motoneuron survival has been difficult. Ciliary neurotrophic factor prevents the death of motoneurons3-6, but its gene is not expressed during development7. Although the presence of a neurotrophin receptor on developing motoneurons8-10 has suggested a role for neurotrophins, none could be shown to promote motoneuron survival in vitro3. We report here that brain-derived neurotrophic factor can prevent the death of axotomized motoneurons in newborn rats, suggesting a role for this neurotrophin for motoneuron survival in vivo.			SENDTNER, M (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM & NEUROBIOCHEM,W-8033 MARTINSRIED,GERMANY.		Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012; Barde, Yves/F-6019-2011	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Barde, Yves/0000-0002-7627-461X				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; GOTZ R, 1992, EUR J BIOCHEM, V204, P745, DOI 10.1111/j.1432-1033.1992.tb16689.x; Gudden B., 1870, ARCHIV PSYCHIAT NERV, V2, P693; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Oppenheim R. W., 1981, STUDIES DEV NEUROBIO, P74; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RAIVICH G, 1985, EMBO J, V4, P637, DOI 10.1002/j.1460-2075.1985.tb03677.x; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Shorey ML, 1909, J EXP ZOOL, V7, P25, DOI 10.1002/jez.1400070103; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; SUDA K, 1978, P NATL ACAD SCI USA, V75, P4042, DOI 10.1073/pnas.75.8.4042; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1988, NEURON, V1, P335	23	682	704	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					757	759		10.1038/360757a0	http://dx.doi.org/10.1038/360757a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465147	Green Submitted			2022-12-01	WOS:A1992KE47200039
J	SHEN, JC; RIDEOUT, WM; JONES, PA				SHEN, JC; RIDEOUT, WM; JONES, PA			HIGH-FREQUENCY MUTAGENESIS BY A DNA METHYLTRANSFERASE	CELL			English	Article							HEAT-INDUCED DEAMINATION; CYTOSINE METHYLTRANSFERASES; CPG DINUCLEOTIDE; CELLS; 5-METHYLCYTOSINE; RESTRICTION; METHYLATION; MECHANISM; MOUSE; MODEL	Hpall methylase (M. Hpall), an example of a DNA (cytosine-5)-methyltransferase, was found to induce directly a high frequency of C-U transition mutations in double-stranded DNA. A mutant pSV2-neo plasmid, constructed with an inactivating T-->C transition mutation creating a CCGG site, was incubated with M. Hpall in the absence of S-adenosylmethionine (SAM). This caused an approximately 10(4)-fold increase in the rate of reversion when the mutant neo plasmid was transformed into bacteria lacking uracil-DNA glycosylase. The mutation frequency was very sensitive to SAM concentration and was reduced to background when the concentration of the methyl donor exceeded 300 nM. The data support current models for the formation of a covalent complex between the methyltransferase and cytosine. They also suggest that the occurrence of mutational hot spots at CpG sites may not always be due to spontaneous deamination of 5-methylcytosine, but might also be initiated by enzymatic deamination of cytosine and proceed through a C-->U-->T pathway.			SHEN, JC (corresponding author), UNIV SO CALIF,SCH MED,KENNETH NORRIS JR COMPREHENS CANC CTR,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033, USA.				NATIONAL CANCER INSTITUTE [R35CA049758] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA49758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DUNCAN B, 1984, ENZYMES, P565; EHRLICH M, 1986, BIOSCIENCE REP, V6, P387, DOI 10.1007/BF01116426; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FEINBERG AP, 1988, CANCER RES, V48, P1159; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FRIEDMAN S, 1985, J BIOL CHEM, V260, P5698; GUNTHERT U, 1981, J BIOL CHEM, V256, P9346; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; Maniatis T., 1982, MOL CLONING; MONK M, 1991, DEVELOPMENT, V112, P189; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Sambrook J., 1989, MOL CLONING LAB MANU; SANTI DV, 1983, CELL, V33, P9, DOI 10.1016/0092-8674(83)90327-6; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHAPIRO R, 1966, BIOCHEMISTRY-US, V5, P2358, DOI 10.1021/bi00871a026; SHEN JC, 1992, NUCLEIC ACIDS RES, V20, P5119, DOI 10.1093/nar/20.19.5119; SIMON D, 1978, NUCLEIC ACIDS RES, V5, P2153, DOI 10.1093/nar/5.6.2153; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; STEINBERG RA, 1992, MOL CELL BIOL, V12, P767, DOI 10.1128/MCB.12.2.767; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; WU JC, 1987, J BIOL CHEM, V262, P4778	39	252	255	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1073	1080		10.1016/S0092-8674(05)80057-1	http://dx.doi.org/10.1016/S0092-8674(05)80057-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473145				2022-12-01	WOS:A1992KE60400003
J	SIEGFRIED, E; CHOU, TB; PERRIMON, N				SIEGFRIED, E; CHOU, TB; PERRIMON, N			WINGLESS SIGNALING ACTS THROUGH ZESTE-WHITE 3, THE DROSOPHILA HOMOLOG OF GLYCOGEN-SYNTHASE KINASE-3, TO REGULATE ENGRAILED AND ESTABLISH CELL FATE	CELL			English	Article							SEGMENT-POLARITY GENE; SITE-SPECIFIC RECOMBINATION; PROTEIN-KINASE; SPATIAL-DISTRIBUTION; MULTIPLE FUNCTIONS; MOLECULAR-CLONING; LETHAL MUTATIONS; NERVOUS-SYSTEM; PATCHED GENE; EXPRESSION	Intrasegmental patterning in the Drosophila embryo is regulated by cell-cell communication. One of the signaling pathways that operates to specify positional information throughout the segment is mediated by the wingless (wg) protein, which is the homolog of the proto-oncogene Wnt-1. The early role of wg is to stabilize engrailed (en) expression by initiating a phase of en autoregulation in the adjacent more posterior cells. Here, we report that the segment polarity gene zeste-white 3 (zw3; also known as shaggy) acts as a repressor of en autoregulation. Genetic epistasis experiments indicate that wg signaling operates by inactivating the zw3 repression of en autoactivation. In addition, we demonstrate that zw3 encodes the Drosophila homolog of mammalian glycogen synthase kinase-3.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	SIEGFRIED, E (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.		Chou, Tze-Bin/S-1188-2017	Chou, Tze-Bin/0000-0003-2453-0164; Perrimon, Norbert/0000-0001-7542-472X				AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHOU TB, 1992, GENETICS, V131, P643; DEGROOT RP, 1992, IN PRESS ONCOGENE; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, IN PRESS NATURE; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; FRASCH M, 1988, GENE DEV, V2, P1824, DOI 10.1101/gad.2.12b.1824; GAY NJ, 1988, NUCLEIC ACIDS RES, V16, P6637, DOI 10.1093/nar/16.14.6637; GERGEN J P, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P49; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GOODMAN CS, 1984, SCIENCE, V225, P1271, DOI 10.1126/science.6474176; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, IN PRESS DEVELOPMENT; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTSON HM, 1988, GENETICS, V118, P461; SAKSELA K, 1992, ONCOGENE, V7, P347; Sambrook J., 1989, MOL CLONING LAB MANU; SHANNON MP, 1972, GENETICS, V72, P615; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SIMPSON P, 1989, DEVELOPMENT, V106, P57; Spradling AC, 1986, P ELEMENT MEDIATED T, P175; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	74	368	375	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1167	1179		10.1016/S0092-8674(05)80065-0	http://dx.doi.org/10.1016/S0092-8674(05)80065-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1335365				2022-12-01	WOS:A1992KE60400011
J	TARDIEUX, I; WEBSTER, P; RAVESLOOT, J; BORON, W; LUNN, JA; HEUSER, JE; ANDREWS, NW				TARDIEUX, I; WEBSTER, P; RAVESLOOT, J; BORON, W; LUNN, JA; HEUSER, JE; ANDREWS, NW			LYSOSOME RECRUITMENT AND FUSION ARE EARLY EVENTS REQUIRED FOR TRYPANOSOME INVASION OF MAMMALIAN-CELLS	CELL			English	Article							PLASMA-MEMBRANE; ACTIN-FILAMENTS; LISTERIA-MONOCYTOGENES; TOXOPLASMA-GONDII; HUMAN-NEUTROPHILS; EPITHELIAL-CELLS; XENOPUS OOCYTES; PROTEIN-KINASE; CYCLE CONTROL; HELA-CELLS	Trypanosoma cruzi invades most nucleated cells by a mechanism distinct from classical phagocytosis. Although parasites enter at the lysosome-poor peripheral cell margins, lysosomal markers are immediately incorporated into the parasitophorous vacuole. No accumulation of polymerized actin was detected around recently internalized parasites, and disruption of microfilaments significantly facilitated invasion. Lysosomes were observed to aggregate at the sites of trypanosome attachment and to fuse with the vacuole at early stages of its formation. Experimentally induced, microtubule-dependent movement of lysosomes from the perinuclear area to the cell periphery enhanced entry. Conditions that deplete cells of peripheral lysosomes or interfere with lysosomal fusion capacity inhibited invasion. These observations reveal a novel mechanism for cell invasion: recruitment of lysosomes for fusion at the site of parasite internalization.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Yale University; Yale University; Washington University (WUSTL)	TARDIEUX, I (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,INFECT DIS SECT,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020; Tardieux, Isabelle/G-4733-2014; Heuser, John/H-5940-2012	Tardieux, Isabelle/0000-0002-5677-7463; Andrews, Norma/0000-0002-0611-2412; Boron, Walter/0000-0003-4741-7287; Webster, Paul/0000-0002-1980-6931	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027260, R01AI032056] Funding Source: NIH RePORTER; NIAID NIH HHS [R29AI27260, R01AI32056] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ANDREWS NW, 1987, EXP PARASITOL, V64, P474, DOI 10.1016/0014-4894(87)90062-2; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; BARON R, 1990, J CELL SCI, V97, P439; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BOYLES J, 1981, CELL, V24, P905, DOI 10.1016/0092-8674(81)90116-1; CARVALHO T M U D, 1989, Cell Structure and Function, V14, P383; CERIOTTI A, 1989, J CELL BIOL, V109, P1439, DOI 10.1083/jcb.109.4.1439; CLERC P, 1987, INFECT IMMUN, V55, P2681, DOI 10.1128/IAI.55.11.2681-2688.1987; COHN ZA, 1969, J EXP MED, V129, P201, DOI 10.1084/jem.129.1.201; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; DVORAK JA, 1981, SCIENCE, V214, P1034, DOI 10.1126/science.7029713; FERRIS AL, 1987, J CELL BIOL, V105, P2703, DOI 10.1083/jcb.105.6.2703; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HALL BF, 1992, J EXP MED, V176, P313, DOI 10.1084/jem.176.2.313; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; KNAPP PE, 1990, J CELL SCI, V95, P433; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEY V, 1990, J EXP MED, V171, P401, DOI 10.1084/jem.171.2.401; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LYNCH TJ, 1986, J BIOL CHEM, V261, P4212; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MEIRELLES MNL, 1983, J SUBMICR CYTOL PATH, V17, P327; MILDER R, 1980, PARASITOLOGY, V80, P139, DOI 10.1017/S0031182000000597; MONTGOMERY RR, 1991, J IMMUNOL, V147, P3087; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NOGUEIRA N, 1976, J EXP MED, V143, P1402, DOI 10.1084/jem.143.6.1402; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PERRIN D, 1992, J CELL BIOL, V116, P127, DOI 10.1083/jcb.116.1.127; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; PRYZWANSKY KB, 1979, CELL, V18, P1025, DOI 10.1016/0092-8674(79)90215-0; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SALAS PJI, 1986, J CELL BIOL, V102, P1853, DOI 10.1083/jcb.102.5.1853; SCHENKMAN S, 1988, CELL, V55, P157, DOI 10.1016/0092-8674(88)90018-9; SCHENKMAN S, 1991, INFECT IMMUN, V59, P645, DOI 10.1128/IAI.59.2.645-654.1991; SCHENKMAN S, 1992, J CELL SCI, V101, P895; SHROER TA, 1989, CELL, V56, P937; SHROER TR, 1988, J CELL BIOL, V107, P1785; SIBLEY LD, 1985, NATURE, V315, P416, DOI 10.1038/315416a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	64	314	323	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 24	1992	71	7					1117	1130		10.1016/S0092-8674(05)80061-3	http://dx.doi.org/10.1016/S0092-8674(05)80061-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473148				2022-12-01	WOS:A1992KE60400007
J	VANKAER, L; ASHTONRICKARDT, PG; PLOEGH, HL; TONEGAWA, S				VANKAER, L; ASHTONRICKARDT, PG; PLOEGH, HL; TONEGAWA, S			TAP1 MUTANT MICE ARE DEFICIENT IN ANTIGEN PRESENTATION, SURFACE CLASS-I MOLECULES, AND CD4-8+ T-CELLS	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; H-2-DEFICIENT LYMPHOMA VARIANTS; LYMPHOCYTES-T; ENDOPLASMIC-RETICULUM; LYMPHOBLASTOID-CELLS; SELF-PEPTIDES; MHC MOLECULES; H-2 ANTIGENS; EXPRESSION; PROTEINS	The transporter associated with the antigen processing 1 (TAP1) gene encodes a subunit for a transporter, presumed to be involved in the delivery of peptides across the endoplasmic reticulum membrane to class I molecules. We have generated mice with a disrupted TAP1 gene using embryonic stem cell technology. TAP1-deficient mice are defective in the stable assembly and intracellular transport of class I molecules and consequently show severely reduced levels of surface class I molecules. These properties are strikingly similar to those described for the TAP2 mutant cell line RMA-S. Cells from the TAP1-deficient mice are unable to present cytosolic antigens to class I-restricted cytotoxic T cells. As predicted from the near absence of class I surface expression, TAP1-deficient mice lack CD4-8+ T cells.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	VANKAER, L (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Van Kaer, Luc/H-1033-2015	Van Kaer, Luc/0000-0001-5275-2309				AOSAI F, 1991, EUR J IMMUNOL, V21, P2767, DOI 10.1002/eji.1830211118; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BODMER JG, 1992, IMMUNOGENETICS, V36, P135, DOI 10.1007/BF00661090; BOEHMER HV, 1978, P NATL ACAD SCI USA, V75, P2439, DOI 10.1073/pnas.75.5.2439; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BUCHMEIER MJ, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FINK PJ, 1978, J EXP MED, V148, P766, DOI 10.1084/jem.148.3.766; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, IMMUNOGENETICS, V32, P440; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NEEFJES JJ, 1992, EUR J IMMUNOL, V22, P1609, DOI 10.1002/eji.1830220639; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, COLD SH Q B, V54, P299; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; van Bleek G M, 1992, Trends Cell Biol, V2, P202, DOI 10.1016/0962-8924(92)90247-K; WALDEN PR, 1990, P NATL ACAD SCI USA, V87, P9015, DOI 10.1073/pnas.87.22.9015; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL RM, 1978, NATURE, V271, P251, DOI 10.1038/271251a0	58	616	624	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1205	1214						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473153				2022-12-01	WOS:A1992KE60400014
J	WANG, ZQ; OVITT, C; GRIGORIADIS, AE; MOHLESTEINLEIN, U; RUTHER, U; WAGNER, EF				WANG, ZQ; OVITT, C; GRIGORIADIS, AE; MOHLESTEINLEIN, U; RUTHER, U; WAGNER, EF			BONE AND HEMATOPOIETIC DEFECTS IN MICE LACKING C-FOS	NATURE			English	Article							TRANSGENIC MICE; PROTO-ONCOGENE; EXPRESSION; TUMORS; MOUSE; CELLS; RAT	THE proto-oncogene c-fos is the cellular homologue of v-fos originally isolated from murine osteosarcoma1. Fos protein is a major component of the AP-1 transcription factor complex, which includes members of the jun family2. Stable expression of c-fos in mice has been demonstrated in developing bones and teeth, haematopoietic cells, germ cells and in the central nervous system3-11. It has been proposed that c-fos has an important role in signal transduction, cell proliferation and differentiation12-15. We have previously demonstrated that overexpression of c-fos in transgenic and chimaeric mice specifically affects bone, cartilage and haematopoietic cell development16-20. To understand better the function of c-fos in vivo, we used gene targeting in embryonic stem cells to generate cells and mice lacking c-fos. Here we report that heterozygous fos +/- mice appear normal, although females exhibit a distorted transmission frequency. All homozygous fos -/- mice are growth-retarded, develop osteopetrosis with deficiencies in bone remodelling and tooth eruption, and have altered haematopoiesis. These data define the c-Fos protein as an essential molecule for the development of specific cellular compartments.	EMBL, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	WANG, ZQ (corresponding author), IMP, MOLEC PATHOL RES INST, DR BOHR GASSE 7, A-1030 VIENNA, AUSTRIA.			Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CAUBET JF, 1988, BIOL CELL, V64, P101, DOI 10.1016/0248-4900(88)90100-1; COHEN DR, IN PRESS ONCOGENE; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; Green MC., 1989, GENETIC VARIANTS STR, P12; HILBERG F, 1992, ONCOGENE, V7, P2371; JONES KL, 1988, SMITHS RECOGNIZABLE, P353; MARKS SC, 1989, AM J ANAT, V186, P325, DOI 10.1002/aja.1001860402; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; PELTOHUIKKO M, 1991, ACTA PHYSIOL SCAND, V141, P283, DOI 10.1111/j.1748-1716.1991.tb09080.x; Revell P. A., 1986, PATHOLOGY BONE; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAO S, 1991, INT IMMUNOL, V3, P369, DOI 10.1093/intimm/3.4.369; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x	30	802	824	1	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 24	1992	360	6406					741	745		10.1038/360741a0	http://dx.doi.org/10.1038/360741a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465144				2022-12-01	WOS:A1992KE47200034
J	WICHMANN, H; HENGST, L; GALLWITZ, D				WICHMANN, H; HENGST, L; GALLWITZ, D			ENDOCYTOSIS IN YEAST - EVIDENCE FOR THE INVOLVEMENT OF A SMALL GTP-BINDING PROTEIN (YPT7P)	CELL			English	Article							EPITHELIAL-CELL LINE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; VACUOLAR BIOGENESIS; MOLECULAR-CLONING; PLASMA-MEMBRANE; YPT1/SEC4-RELATED CDNAS; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; MUTATIONAL ANALYSIS	From the budding yeast S. cerevisiae, we have cloned a gene, YPT7, that encodes a GTP-binding protein belonging to the Ypt family of ras-related proteins. The 208 amino acid protein shares identical effector domain and C-terminal sequences with the mammalian Rab7 protein. YPT7 gene disruption did not impair cellular growth at temperatures ranging from 17-degrees-C to 37-degrees-C. ypt7 null mutants are characterized by highly fragmented vacuoles and differential defects of vacuolar protein transport and maturation. The uptake of alpha factor pheromone by wild-type and Ypt7p-deficient cells was found to be indistinguishable, but in mutant cells lacking Ypt7p, degradation of the endocytosed pheromone was severely inhibited. Our findings suggest a role of Ypt7p in protein transport between endosome-like compartments.			WICHMANN, H (corresponding author), MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, W-3400 GOTTINGEN, GERMANY.			Hengst, Ludger/0000-0002-0605-0223				BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Griffiths G, 1991, Trends Cell Biol, V1, P5, DOI 10.1016/0962-8924(91)90047-D; GUTHRIE C, 1991, METH ENZYMOL, V194; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HERMAN PK, 1991, EMBO J, V10, P4049, DOI 10.1002/j.1460-2075.1991.tb04981.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAWETZ SA, 1989, NUCLEIC ACIDS RES, V17, P819, DOI 10.1093/nar/17.2.819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; MAKAROW M, 1985, EMBO J, V4, P1861, DOI 10.1002/j.1460-2075.1985.tb03861.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MECHLER B, 1987, EMBO J, V6, P2157, DOI 10.1002/j.1460-2075.1987.tb02483.x; MIYAKE S, 1990, EMBO J, V9, P1417, DOI 10.1002/j.1460-2075.1990.tb08257.x; Murphy R F, 1991, Trends Cell Biol, V1, P77, DOI 10.1016/0962-8924(91)90022-2; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; PRESTON RA, 1987, J CELL BIOL, V105, P1981, DOI 10.1083/jcb.105.5.1981; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; RAYMOND CK, 1992, IN PRESS INT REV CYT; REID GA, 1983, METHOD ENZYMOL, V97, P324; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Stevens B J, 1979, Methods Enzymol, V56, P718; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WAGNER P, 1992, METHOD ENZYMOL, V219, P369; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WOOLFORD CA, 1990, GENETICS, V125, P739; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	79	210	213	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 24	1992	71	7					1131	1142		10.1016/S0092-8674(05)80062-5	http://dx.doi.org/10.1016/S0092-8674(05)80062-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KE604	1473149				2022-12-01	WOS:A1992KE60400008
J	WOLFE, JH; SANDS, MS; BARKER, JE; GWYNN, B; ROWE, LB; VOGLER, CA; BIRKENMEIER, EH				WOLFE, JH; SANDS, MS; BARKER, JE; GWYNN, B; ROWE, LB; VOGLER, CA; BIRKENMEIER, EH			REVERSAL OF PATHOLOGY IN MURINE MUCOPOLYSACCHARIDOSIS TYPE-VII BY SOMATIC-CELL GENE-TRANSFER	NATURE			English	Article							BETA-GLUCURONIDASE DEFICIENCY; HEMATOPOIETIC STEM-CELLS; INVITRO; MOUSE; THERAPY; CDNA	AN inherited deficiency of beta-glucuronidase in humans1, mice2 and dogs3 causes mucopolysaccharidosis VII (Sly syndrome), a progressive degenerative disease that reduces lifespan (to an average of 5 months in mice2) and results from lysosomal storage of undegraded glycosaminoglycans in the spleen, liver, kidney, cornea, brain and skeletal system1-4. Bone marrow transplantation in mutant mice provides a source of normal enzyme ('cross-correction'5), which substantially improves the clinical condition and extends the average lifespan to 18 months6. Gene therapy by transfer of a beta-glucuronidase gene into mutant haematopoietic stem cells is an alternative approach7,8, but it is not known whether the low expression of vector-transferred genes in vivo9,10 would be sufficiently effective. Here we show that retroviral vector-mediated transfer of the gene to mutant stem cells results in long-term expression of low levels of beta-glucuronidase which partially corrects the disease by reducing lysosomal storage in liver and spleen.	UNIV PENN,SCH VET MED,PHILADELPHIA,PA 19104; ST LOUIS UNIV,SCH MED,ST LOUIS,MO 63104	University of Pennsylvania; Saint Louis University	WOLFE, JH (corresponding author), JACKSON LAB,BAR HARBOR,ME 04609, USA.			Sands, Mark/0000-0002-5559-0832				BARKER JE, 1983, BLOOD, V62, P827; BARKER JE, IN PRESS EXPL HEMAT; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BIRKENMEIER EH, 1991, BLOOD, V78, P3081; BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; FRASER CC, 1990, BLOOD, V76, P1071; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; NEUFELD EF, 1970, SCIENCE, V169, P141, DOI 10.1126/science.169.3941.141; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; SMITH BF, 1990, MOL CELL BIOL, V10, P3268, DOI 10.1128/MCB.10.6.3268; STRAMM LE, 1990, EXP EYE RES, V50, P521, DOI 10.1016/0014-4835(90)90041-R; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VOGLER CA, 1991, AM J PATHOL, V136, P207; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	22	211	214	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					749	753		10.1038/360749a0	http://dx.doi.org/10.1038/360749a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1465145				2022-12-01	WOS:A1992KE47200036
J	YAN, Q; ELLIOTT, J; SNIDER, WD				YAN, Q; ELLIOTT, J; SNIDER, WD			BRAIN-DERIVED NEUROTROPHIC FACTOR RESCUES SPINAL MOTOR NEURONS FROM AXOTOMY-INDUCED CELL-DEATH	NATURE			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; RETROGRADE TRANSPORT; CORD MOTONEURONS; DEVELOPING RATS; FACTOR FAMILY; TRKB; NGF; EXPRESSION; MEMBER	CURRENT ideas about the dependence of neurons on target-derived growth factors were formulated on the basis of experiments involving neurons with projections to the periphery1,2. Nerve growth factor (NGF) and recently identified members of the NGF family of neuronal growth factors, known as neurotrophins, are thought to regulate survival of sympathetic and certain populations of sensory ganglion cells during development3-8. Far less is known about factors that regulate the survival of spinal and cranial motor neurons, which also project to peripheral targets. NGF has not been shown to influence motor neuron survival9,10, and whether the newly identified neurotrophins promote motor neuron survival is unknown. We show here that brain-derived neurotrophic factor (BDNF) is retrogradely transported by motor neurons in neonatal rats and that local application of BDNF to transected sciatic nerve prevents the massive death of motor neurons that normally follows axotomy in the neonatal period. These results show that BDNF has survival-promoting effects on motor neurons in vivo and suggest that BDNF may influence motor neuron survival during development.	WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL SURG NEUROL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	YAN, Q (corresponding author), AMGEN INC,AMGEN CTR,NEUROBIOL PROGRAM,THOUSAND OAKS,CA 91320, USA.							ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; KASHIHARA Y, 1987, J PHYSIOL-LONDON, V386, P135, DOI 10.1113/jphysiol.1987.sp016526; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P229; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; OPPENHEIM RW, 1982, J COMP NEUROL, V210, P174, DOI 10.1002/cne.902100208; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WAYNE DB, 1988, DEV BIOL, V127, P220, DOI 10.1016/0012-1606(88)90203-5; YAN Q, 1988, NEURON, V1, P335; YAN Q, 1988, J NEUROSCI, V8, P3481; YAN Q, 1991, Society for Neuroscience Abstracts, V17, P1119	31	633	680	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 24	1992	360	6406					753	755		10.1038/360753a0	http://dx.doi.org/10.1038/360753a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KE472	1281520				2022-12-01	WOS:A1992KE47200037
J	ERNST, P; SPITZER, WO; SUISSA, S; COCKCROFT, D; HABBICK, B; HORWITZ, RI; BOIVIN, JF; MCNUTT, M; BUIST, AS				ERNST, P; SPITZER, WO; SUISSA, S; COCKCROFT, D; HABBICK, B; HORWITZ, RI; BOIVIN, JF; MCNUTT, M; BUIST, AS			RISK OF FATAL AND NEAR-FATAL ASTHMA IN RELATION TO INHALED CORTICOSTEROID USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LONG-TERM TREATMENT; BUDESONIDE; RESPONSIVENESS; TERBUTALINE	Objective.-To examine the relationship between patterns of use of inhaled beclomethasone dipropionate and the risk of fatal and near-fatal asthma. Design.-Nested case-control analysis of a historical cohort; a further analysis. Setting.-The 12 301 residents of Saskatchewan aged 5 to 54 years who were dispensed 10 or more asthma drugs from 1978 to 1987. Patients.-The 129 persons who experienced asthma death (n=44) and near-death (n=85) and their 655 controls matched as to age and date of entry into the cohort, with the additional matching criteria of at least one hospitalization for asthma in the prior 2 years, region of residence, and having received social assistance. Main Outcome.-Life-threatening attacks of asthma defined as death due to asthma or the occurrence of hypercarbia, intubation, and mechanical ventilation during an acute attack of asthma. Results.-After accounting for the risk associated with use of other medications and adjustment for markers of risk of adverse events related to asthma, subjects who had been dispensed, on average, one or more metered-dose inhalers of beclomethasone per month over a 1-year period had a significantly lower risk of fatal and near-fatal asthma (odds ratio, 0.1; 95% confidence interval, 0.02 to 0.6). Conclusion.-These data support recent guidelines from several countries that recommend the use of inhaled corticosteroids in moderate and severe asthma.	MONTREAL GEN HOSP,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3G 1A4,QUEBEC,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3A 2T5,QUEBEC,CANADA; UNIV SASKATCHEWAN,DEPT MED,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; UNIV SASKATCHEWAN,DEPT COMMUNITY HLTH & EPIDEMIOL,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA; YALE UNIV,SCH MED,NEW HAVEN,CT 06510; SASKATCHEWAN DEPT HLTH,LAB & DIS CONTROL SERV BRANCH,HE ROBERTSON LAB,REGINA,SASKATCHEWAN,CANADA; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT PHYSIOL,PORTLAND,OR 97201	McGill University; McGill University; McGill University; University of Saskatchewan; University of Saskatchewan; Yale University; Oregon Health & Science University; Oregon Health & Science University	ERNST, P (corresponding author), RESP EPIDEMIOL UNIT,1110 PINE AVE W,MONTREAL H3A 1A3,QUEBEC,CANADA.							[Anonymous], 1990, BMJ, V301, P651; BRESLOW NE, 1980, STATISTICAL METHODS, P1; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; JENKINS CR, 1988, THORAX, V43, P378, DOI 10.1136/thx.43.5.378; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAND LM, 1989, PHARMACOEPIDEM DR S, P189; TOOGOOD JH, 1985, BRONCHIAL ASTHMA MEC, P698; WEST R, 1987, AM J PREV MED S2, V4, P25; 1991, 913042 DEP HLTH HUM	15	210	214	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3462	3464		10.1001/jama.268.24.3462	http://dx.doi.org/10.1001/jama.268.24.3462			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460737				2022-12-01	WOS:A1992KC83900035
J	KAPUR, S; MIECZKOWSKI, T; MANN, JJ				KAPUR, S; MIECZKOWSKI, T; MANN, JJ			ANTIDEPRESSANT MEDICATIONS AND THE RELATIVE RISK OF SUICIDE ATTEMPT AND SUICIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DATA-COLLECTION-SYSTEM; DOUBLE-BLIND; DISORDERS; AMITRIPTYLINE; FLUVOXAMINE; TOXICITY; OVERDOSE; DEPRESSION; FLUOXETINE; MIANSERIN	Objective.-Suicide by drug overdose is a major public health problem, and antidepressant medications are the most common agent involved. European studies suggest differences in the rates of suicide by overdose among antidepressants, but no reports have been published for the United States. We estimated the comparative risks of suicide attempts and suicides, and the relative risk of fatality in the event of an overdose for the major antidepressants currently marketed in the United States. Data Sources.-Information regarding suicide attempts and suicides by antidepressant overdose was obtained from the published reports of the Drug Abuse and Warning Network and the annual report of the American Association of Poison Control Centers, and corrected for differences in total annual prescriptions using data from the National Prescription Audit. Results.-The risk of a suicide attempt did not appear to differ among antidepressants. The tricyclic antidepressants were associated with a higher rate of death in the event of an overdose than the newer nontricyclic antidepressants in both the annual report of the American Association of Poison Control Centers and the Drug Abuse and Warning Network data. The chance of death after an overdose was greater for desipramine hydrochloride than for other tricyclics. Conclusion.-The higher risk of suicide with tricyclics vs nontricyclics may be explained by a higher rate of death from overdose rather than more suicide attempts. Tricyclics carry the risk of greater cardiotoxicity. The basis for the even higher rate of death/overdose of desipramine is not known and requires further research. If these findings are replicated in a case-control study design, they have important implications for the choice of an antidepressant for the depressed patient at risk for suicidal behavior.	UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC	MANN, JJ (corresponding author), UNIV PITTSBURGH,WESTERN PSYCHIAT INST & CLIN,SCH MED,PITTSBURGH,PA 15213, USA.		anand, amit/A-7222-2009	Kapur, Shitij/0000-0002-2231-2924; Santibanez, Tammy A./0000-0002-5784-7427	NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH046745, P50MH046745] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-46745] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Asberg M., 1987, PSYCHOPHARMACOLOGY 3, P655; BALDESSARINI RJ, 1989, J CLIN PSYCHIAT, V50, P117; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEAUMONT G, 1989, BRIT J PSYCHIAT, V154, P454, DOI 10.1192/bjp.154.4.454; BRENT DA, 1988, AM PSYCHIATRIC REV P, V7, P353; BROADHEAD WE, 1991, J FAM PRACTICE, V33, P24; BULIK CM, 1990, J AFFECT DISORDERS, V18, P29, DOI 10.1016/0165-0327(90)90114-N; CASSIDY S, 1987, BRIT MED J, V295, P1021, DOI 10.1136/bmj.295.6605.1021; COCCARO EF, 1989, ARCH GEN PSYCHIAT, V46, P587; COLE JO, 1990, J CLIN PSYCHIAT, V51, P21; CROME P, 1979, J ROY SOC MED, V72, P649, DOI 10.1177/014107687907200905; DAMLUJI NF, 1988, J CLIN PSYCHOPHARM, V8, P347; DEWILDE J, 1991, ACTA PSYCHIAT SCAND, P89; GALLANT DM, 1987, PSYCHOPATHOLOGY, V20, P75, DOI 10.1159/000284526; GONELLA G, 1990, CURR MED RES OPIN, V12, P177, DOI 10.1185/03007999009111499; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HALPER JP, 1988, BRIT J PSYCHIAT, V153, P87, DOI 10.1192/S0007125000297341; HANZLICK R, 1989, AM J FOREN MED PATH, V10, P326, DOI 10.1097/00000433-198912000-00009; INMAN WHW, 1988, LANCET, V2, P90; KING LA, 1985, HUM TOXICOL, V4, P273, DOI 10.1177/096032718500400307; KING RA, 1991, J AM ACAD CHILD PSY, V30, P179, DOI 10.1097/00004583-199103000-00003; LEONARD BE, 1986, LANCET, V2, P1105; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LITOVITZ TL, 1990, AM J EMERG MED, V8, P394, DOI 10.1016/0735-6757(90)90234-Q; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; MANN JJ, 1989, PSYCHOPHARMACOL BULL, V25, P407; MANN JJ, 1989, BRIT J PSYCHIAT, V155, P7, DOI 10.1192/S000712500029171X; MONTGOMERY SA, 1981, ACTA PSYCHIAT SCAND, V63, P314, DOI 10.1111/j.1600-0447.1981.tb00735.x; MONTGOMERY SA, 1987, PSYCHOPHARMACOLOGY, V92, P265; MONTGOMERY SA, 1989, ACTA PSYCHIAT SCAND, V80, P47, DOI 10.1111/j.1600-0447.1989.tb03046.x; MULLIN JM, 1988, BRIT J CLIN PRACT, V42, P51; NATHAN RS, 1990, J CLIN PSYCHIAT, V51, P367; PEREZ A, 1990, CURR MED RES OPIN, V12, P234, DOI 10.1185/03007999009111652; POLLACK MH, 1987, J CLIN PSYCHIAT, V48, P3; ROTTERSTOL N, 1989, ACTA PSYCHIATR S354, V80, P61; ROULLION F, 1989, ENCEPHALE, V15, P527; SACCHETTI E, 1991, SEROTONIN RELATED PS, P47; SOLOFF PH, 1987, PSYCHOPHARMACOL BULL, V23, P177; SOLOFF PH, 1986, AM J PSYCHIAT, V143, P1603; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; VUORI E, 1989, ACTA PSYCHIAT SCAND, V80, P55, DOI 10.1111/j.1600-0447.1989.tb03047.x; WAKELIN JS, 1988, ADV BIOL PSYCHIAT, V17, P70; 1989, STAT ABSTR US 1989; 1990, NIDA STATISTICAL SER, V1	44	162	164	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3441	3445		10.1001/jama.268.24.3441	http://dx.doi.org/10.1001/jama.268.24.3441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460734				2022-12-01	WOS:A1992KC83900031
J	MICHAELS, D; LEVINE, C				MICHAELS, D; LEVINE, C			ESTIMATES OF THE NUMBER OF MOTHERLESS YOUTH ORPHANED BY AIDS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WOMEN; MORTALITY; HISPANICS; EPIDEMIC; IMPACT	Objective.-To estimate the number of youth in the United States who have been or will be left motherless by the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic, in order to project the need for family supports, age-appropriate foster and congregate care, and mental health and social services. Design.-Orphans are defined as youth whose mothers (the usual caregiving parent) die of HIV/AIDS-related causes. A mathematical model was constructed to estimate the number of such motherless youth. Cumulative fertility rates were applied to the number of reported AIDS deaths (1981 through 1990) and projected deaths (1991 through 1995) of adult women less than 50 years old. The results were adjusted for underreporting of HIV/AIDS-related mortality, pediatric AIDS deaths, infant mortality, ethnic and racial variation in fertility, and decreased fertility associated with late-stage HIV disease. Estimates were made for the number who were children (less than 13 years of age), adolescents (1 3 to 17 years of age), or young adults (1 8 years of age or older) at the time of their mothers' death. Results.-By the end of 1995, maternal deaths caused by the HIV/AIDS epidemic will have orphaned an estimated 24 600 children and 21 000 adolescents in the United States; unless the course of the epidemic changes dramatically, by the year 2000, the overall number of motherless children and adolescents will exceed 80000. In 1991, an estimated 13% of US children and 9% of adolescents whose mothers died of all causes were children of women who died of HIV/AIDS-related diseases. These proportions will surpass 17% and 12%, respectively, by 1995. The vast majority of these motherless youth will come from poor communities of color. Conclusions.-A large and rapidly growing number of American youth are being orphaned by the HIV/AIDS epidemic. Unless increased attention and resources are devoted to this vulnerable population, a social catastrophe is unavoidable.	ORPHAN PROJECT,121 AVE AMER,6TH FL,NEW YORK,NY 10013; CUNY,SCH MED,SOPHIE DAVIS SCH BIOMED EDUC,DEPT COMMUNITY HLTH & SOCIAL MED,NEW YORK,NY 10021	City University of New York (CUNY) System; Sophie Davis School of Biomedical Education	LEVINE, C (corresponding author), ORPHAN PROJECT,121 AVE AMER,6TH FL,NEW YORK,NY 10013, USA.			Michaels, David/0000-0001-8558-7733				BENNETT JV, 1991, AM J DIS CHILD, V145, P1242, DOI 10.1001/archpedi.1991.02160110034016; BOYLAN L, 1991, EPIDEMIOL REV, V13, P143, DOI 10.1093/oxfordjournals.epirev.a036067; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BUEHLER JW, 1992, AM J PUBLIC HEALTH, V82, P1500, DOI 10.2105/AJPH.82.11.1500; CALDWELL MB, 1992, PEDIATRICS, V90, P482; CARPENTER CCJ, 1991, MEDICINE, V70, P307, DOI 10.1097/00005792-199109000-00003; Carr J N, 1975, Pediatr Ann, V4, P65, DOI 10.3928/0090-4481-19750701-11; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; DEREN S, 1986, 50 NEW YORK STATE DI; DRUCKER E, 1991, AIDS READER; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; MENENDEZ BS, 1990, J ACQ IMMUN DEF SYND, V3, P644; PIVNICK A, 1991, MED ANTHROPOL Q, V5, P153, DOI 10.1525/maq.1991.5.2.02a00030; PREBLE EA, 1990, SOC SCI MED, V31, P671, DOI 10.1016/0277-9536(90)90249-R; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; RUMLEY RL, 1991, AIDS, V5, P1373, DOI 10.1097/00002030-199111000-00015; SELIK RM, 1989, AM J PUBLIC HEALTH, V79, P836, DOI 10.2105/AJPH.79.7.836; 1991, AIDS MICROFICHE DATA; 1992, AIDS SURVEILLANCE UP; 1991, 1991 M AIDS ORPH AFR, P5; 1989, SUMMARY VITAL STATIS; 1992, HIV AIDS SURVEILANCE, P1; 1991, MONTHLY VITAL STA S1, V40, P1; 1992, MMWR, V41, P28; 1991, LANCET, V337, P253; 1992, MMWR, V41, P121; 1992, MONTHLY VITAL STA S2, V40, P1; 1990, MMWR, V39, P1; 1991, VITAL STATISTICS US, V2	30	111	111	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3456	3461		10.1001/jama.268.24.3456	http://dx.doi.org/10.1001/jama.268.24.3456			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KC839	1460736				2022-12-01	WOS:A1992KC83900034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW ANTIARRHYTHMIC APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-01	WOS:A1992KC83900008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONTRACEPTIVE INJECTION APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-01	WOS:A1992KC83900007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PRESCRIPTION DRUG-USER FEE STATUTE ENACTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3418	3418		10.1001/jama.268.24.3418	http://dx.doi.org/10.1001/jama.268.24.3418			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460725				2022-12-01	WOS:A1992KC83900006
J	SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM				SKOBELOFF, EM; SPIVEY, WH; STCLAIR, SS; SCHOFFSTALL, JM			THE INFLUENCE OF AGE AND SEX ON ASTHMA ADMISSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe demographic data from a large population of asthmatic patients to define the role of age and sex as risk factors for asthma admission. Design.-A retrospective review of all asthma admissions as defined by international Classification of Diseases, Ninth Revision, code 493.0. Source.-All medical-surgical admissions from 67 hospitals in five counties of southeastern Pennsylvania from 1986 through 1989. Results.-Patients admitted for asthma treatment (33 269) were reviewed. In the 0- to 5-year-old and 6- to 10-year-old age groups, males were admitted nearly twice as often as age-identical females. In the 11- to 20-year-old age group, admissions for males and females were nearly identical. Between 20 and 50 years of age, the female-to-male ratio was nearly 3:1. Thereafter, females were admitted for asthma at a rate of about 2.5:1 when compared with their age-equivalent male counterparts. Length of stay increased proportionally as the patient age increased. After 30 years of age, the length of stay was slightly greater for females than males. Conclusions.-There is a much higher rate of admission for prepubertal males than females. However, there is a higher incidence of asthma admissions for adult females than adult male asthmatic patients, and female asthmatic patients experience longer hospital stays per admission as well. These data indicate that adult females are more severely affected by asthma and raise the possibility that hormonal or biochemical differences related to sex may play a role in the pathophysiology of asthma.	MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129	Drexel University	SPIVEY, WH (corresponding author), MED COLL PENN,DEPT EMERGENCY MED,DIV RES,3300 HENRY AVE,PHILADELPHIA,PA 19129, USA.							ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V107, P641, DOI 10.1016/S0002-9378(16)33953-9; ABDULKARIM RW, 1970, AM J OBSTET GYNECOL, V108, P1098, DOI 10.1016/0002-9378(70)90459-X; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; ELIASSON O, 1987, J ALLERGY CLIN IMMUN, V79, P909, DOI 10.1016/0091-6749(87)90240-5; ELIASSON O, 1985, American Review of Respiratory Disease, V131, pA110; JOHANSSON U, 1981, J PHARM PHARMACOL, V33, P353, DOI 10.1111/j.2042-7158.1981.tb13802.x; Kohler Po, 1986, CLIN ENDOCRINOLOGY; KONNO A, 1986, ORL J OTO-RHINO-LARY, V48, P45, DOI 10.1159/000275841; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MOAWAD AH, 1982, AM J OBSTET GYNECOL, V144, P608, DOI 10.1016/0002-9378(82)90235-6; ROCHE WR, 1989, LANCET, V1, P52; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; VIDIC B, 1978, CYTOBIOLOGIE, V18, P10; WILKINSON L, 1988, SYSTAT SYSTEM STATIS; 1990, 1988 SUMMARY NATIONA, V185, P1; 1991, JAMA-J AM MED ASSOC, V266, P559; 1991, 913042 DEP HLTH HUM; 1991, 1990 GENERAL POPULAT; 1980, PHS801260 DEP HLTH H	19	284	285	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1992	268	24					3437	3440		10.1001/jama.268.24.3437	http://dx.doi.org/10.1001/jama.268.24.3437			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC839	1460733				2022-12-01	WOS:A1992KC83900030
J	BARBIR, M; KUSHWAHA, S; HUNT, B; MACKEN, A; THOMPSON, GR; MITCHELL, A; ROBINSON, D; YACOUB, M				BARBIR, M; KUSHWAHA, S; HUNT, B; MACKEN, A; THOMPSON, GR; MITCHELL, A; ROBINSON, D; YACOUB, M			LIPOPROTEIN(A) AND ACCELERATED CORONARY-ARTERY DISEASE IN CARDIAC TRANSPLANT RECIPIENTS	LANCET			English	Article								High concentrations of serum lipoprotein(a) (Lp(a)) are associated with an increased risk of atherosclerotic vascular disease in the non-transplanted population. However its relation with accelerated coronary artery disease (CAD) in cardiac transplant recipients has not been reported. We measured serum Lp(a) in 130 cardiac transplant recipients undergoing routine follow-up, which included annual coronary angiography. The median Lp (a) concentration in 33 patients with CAD was 71 mg/dl, which was significantly higher than the corresponding value of 22 mg/dL in the 97 patients without CAD (p = 0.0006). Multivariant analysis showed the serum Lp(a) value to be a higher significant risk factor for CAD irrespective of the other factors included in the regression analysis. Thus a high concentration of serum Lp(a) is an important, independent risk factor for the development of accelerated CAD in transplant recipients.	HAREFIELD HOSP,THORAC & CARDIAC SURG UNIT,UXBRIDGE UB9 6JH,MIDDX,ENGLAND; HAMMERSMITH HOSP,MRC LIPOPROT TEAM,LONDON W12 0HS,ENGLAND; UNIV SUSSEX,SCH MATH & PHYS SCI,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London; University of Sussex	YACOUB, M (corresponding author), HAREFIELD HOSP,THORAC & CARDIAC SURG UNIT,UXBRIDGE UB9 6JH,MIDDX,ENGLAND.							ALONSO DR, 1977, AM J PATHOL, V87, P415; Altman DG, 1991, PRACTICAL STATISTICS; BARBIR M, 1991, INT J CARDIOL, V32, P51, DOI 10.1016/0167-5273(91)90043-O; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2; DUNN MJ, 1992, LANCET, V339, P1566, DOI 10.1016/0140-6736(92)91832-S; GAO SZ, 1989, AM J CARDIOL, V64, P1093, DOI 10.1016/0002-9149(89)90858-8; GENEST J, 1991, AM J CARDIOL, V67, P1039, DOI 10.1016/0002-9149(91)90862-F; HESS ML, 1983, CIRCULATION, V68, P94; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; HOFF HF, 1988, CIRCULATION, V77, P1238, DOI 10.1161/01.CIR.77.6.1238; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; SCHROEDER JS, 1986, NEW ENGL J MED, V315, P961, DOI 10.1056/NEJM198610093151511; SCOTT J, 1991, BRIT MED J, V303, P663, DOI 10.1136/bmj.303.6804.663; STEINBERG D, 1989, NEW ENGL J MED, V320, P1915; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827; WINTER GL, 1990, J HEART TRANSPLANT, V9, P367	16	77	79	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1500	1502		10.1016/0140-6736(92)92756-6	http://dx.doi.org/10.1016/0140-6736(92)92756-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361597				2022-12-01	WOS:A1992KD06900005
J	BRANCA, F; ROBINS, SP; FERROLUZZI, A; GOLDEN, MHN				BRANCA, F; ROBINS, SP; FERROLUZZI, A; GOLDEN, MHN			BONE TURNOVER IN MALNOURISHED CHILDREN	LANCET			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; URINARY-EXCRETION; COLLAGEN; GROWTH; MALNUTRITION; CROSSLINKS; MARKERS; AGE	Pyridinoline (PYD) and deoxypyridinoline (DPD) are cross-linking aminoacids of collagen that are located mainly in bone and cartilage. When bone matrix is resorbed these cross-links are quantitatively excreted in the urine and therefore represent specific markers. We have measured the urinary excretion rate of PYD and DPD in 46 severely malnourished boys to assess their skeletal turnover and to relate this to their subsequent rate of growth. The children were aged 13 months (SD 6), and height-for-age was -3.6 (1.6) Z-score, and weight-for-height was -2.4 (0.8) Z-score. PYD excretion when malnourished and after "recovery" was 11.2 (4.6) nmol h-1m-2 and 32.2 (10.8) nmol h-1m-2 and DPD excretion was 2.6 (1.3) nmol h-1m-2 and 7.5 (3.0) nmol h-1m-2, respectively. The ratio of the two cross-links did not change with recovery. These data show that cartilage and bone turnover is much lower in the malnourished than in the recovered child. There was no difference in the degree of depression of turnover between the children with marasmus, marasmic-kwashiorkor, or kwashiorkor. The rate of height gain during recovery was significantly related to cross-link excretion, age, and weight-for-height on admission. These three factors accounted for 44% of the variance in the height velocity of the children. PYD and DPD excretion rate could be used to assess therapeutic interventions designed to alleviate stunting.	UNIV W INDIES,TROP METAB RES UNIT,KINGSTON 7,JAMAICA; IST NAZL NUTR,ROME,ITALY; ROWETT RES INST,BUCKSBURN AB2 9SB,ABERDEEN,SCOTLAND	University West Indies Mona Jamaica; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); University of Aberdeen	GOLDEN, MHN (corresponding author), UNIV ABERDEEN,DEPT MED & THERAPEUT,ABERDEEN AB9 2ZD,SCOTLAND.		Golden, Michael/AAB-8989-2020	Golden, Michael/0000-0002-4039-7538	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKAMAGUNA AI, 1986, PEDIATR RADIOL, V16, P40, DOI 10.1007/BF02387503; BAUMGARTNER RN, 1986, AM J CLIN NUTR, V43, P711, DOI 10.1093/ajcn/43.5.711; BEARDSWORTH LJ, 1990, J BONE MINER RES, V5, P671; BLACK D, 1988, ANAL BIOCHEM, V169, P197, DOI 10.1016/0003-2697(88)90274-6; BROWN KH, 1982, AM J CLIN NUTR, V36, P303; COOPER ES, 1990, EUR J CLIN NUTR, V44, P285; DELMAS PD, 1991, J BONE MINER RES, V6, P639; EASTELL R, 1990, 3RD P INT S OST AALB, P469; EYRE DR, 1988, BIOCHEM J, V252, P495, DOI 10.1042/bj2520495; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; GARN SM, 1981, AM J ROENTGENOL, V137, P231, DOI 10.2214/ajr.137.2.231; GOLDEN M, 1977, AM J CLIN NUTR, V30, P1345, DOI 10.1093/ajcn/30.8.1345; GOLDEN MHN, 1981, TRACE ELEMENT METABO, V4, P69; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HEIKENS GT, 1989, EUR J CLIN NUTR, V43, P145; Himes J H, 1978, World Rev Nutr Diet, V28, P143; JACKSON AA, 1987, OXFORD TXB MED; LAMPL M, 1978, ANN HUM BIOL, V5, P219, DOI 10.1080/03014467800002841; PICOU D, 1966, CLIN SCI, V30, P345; PICOU D, 1965, CLIN SCI, V29, P517; PRUDHON C, 1991, CR ACAD SCI III-VIE, V313, P233; ROBINS SP, 1988, BAILLIERE CLIN RHEUM, V2, P1, DOI 10.1016/S0950-3579(88)80003-7; ROBINS SP, 1991, EUR J CLIN INVEST, V21, P310, DOI 10.1111/j.1365-2362.1991.tb01375.x; TROTTER M, 1970, AM J PHYS ANTHROPOL, V33, P313, DOI 10.1002/ajpa.1330330305; WALKER SP, 1988, EUR J CLIN NUTR, V42, P395; Wellcome Trust Working Party, 1970, LANCET, V2, P302; WHITEHEAD RG, 1965, LANCET, V2, P567; WILKINSON L, 1990, SYSTAT SYSTEM STATIS	28	61	61	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1493	1496		10.1016/0140-6736(92)92754-4	http://dx.doi.org/10.1016/0140-6736(92)92754-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361595				2022-12-01	WOS:A1992KD06900003
J	BREATHNACH, AS; JENKINS, DR; PEDLER, SJ				BREATHNACH, AS; JENKINS, DR; PEDLER, SJ			STETHOSCOPES AS POSSIBLE VECTORS OF INFECTION BY STAPHYLOCOCCI	BRITISH MEDICAL JOURNAL			English	Article											BREATHNACH, AS (corresponding author), ROYAL VICTORIA INFIRM,DEPT CLIN MICROBIOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							AYCLIFF GA, 1992, CONTROL HOSPITAL INF, P78; AYCLIFFE GA, 1990, J HOSP INFECT, V16, P351; GERKEN A, 1972, LANCET, V1, P1214; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; Waldvogel F. A., 1990, PRINCIPLES PRACTICES, P1489	5	58	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1573	1574		10.1136/bmj.305.6868.1573	http://dx.doi.org/10.1136/bmj.305.6868.1573			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286393	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992KD77100030
J	CLEMONS, MJ; CLEMONS, KR; SKINNER, R				CLEMONS, MJ; CLEMONS, KR; SKINNER, R			MEDICINE - THE HEARING PROFESSION	BRITISH MEDICAL JOURNAL			English	Article									ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; UNIV BRISTOL,BRISTOL BS8 1TH,ENGLAND	Newcastle University - UK; University of Bristol	SKINNER, R (corresponding author), ROYAL VICTORIA INFIRM,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							WALTERS S, 1988, BRIT MED J, V297, P1665	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1568	1569		10.1136/bmj.305.6868.1568	http://dx.doi.org/10.1136/bmj.305.6868.1568			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286390	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992KD77100027
J	GODLEE, F				GODLEE, F			MEDICINAL-PLANTS - ANOTHER MANS POISON	BRITISH MEDICAL JOURNAL			English	Article																		FELLOWS LE, 1922, NEW DRUGS NATURAL SO; FLINT M, 1991, BIOL RESOURCES DEV C; SCALISE JA, 1988, VET HUM TOXICOL, V30, P426	3	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1583	1585		10.1136/bmj.305.6868.1583	http://dx.doi.org/10.1136/bmj.305.6868.1583			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286403	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992KD77100042
J	MCBRIDE, D; GILL, F; PROOPS, D; HARRINGTON, M; GARDINER, K; ATTWELL, C				MCBRIDE, D; GILL, F; PROOPS, D; HARRINGTON, M; GARDINER, K; ATTWELL, C			NOISE AND THE CLASSICAL MUSICIAN	BRITISH MEDICAL JOURNAL			English	Article							HEARING	Objectives-To test the hypothesis that noise exposure may cause hearing loss in classical musicians. Design-Comparison of hearing levels between two risk groups identified during the study by measuring sound levels. Setting-Symphony orchestra and occupational health department in the west Midlands, Main outcome measures-Hearing level as measured by clinical pure tone audiometry. Results-Trumpet and piccolo players received a noise dose of 160% and 124%, respectively, over mean levels during part of the study. Comparison of the hearing levels of 18 woodwind and brass musicians with 18 string musicians matched for age and sex did not show a significant difference in hearing, the mean difference in the hearing levels at the high (2, 4, and 8 KHz) audiometric frequencies being 1.02 dB (95% confidence interval -2.39 to 4.43). Conclusions-This study showed that there is a potential for occupational hearing loss in classical orchestral musicians.	QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham	MCBRIDE, D (corresponding author), UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		McBride, David I/F-9664-2010	McBride, David I/0000-0001-5531-7687				Axelsson A, 1981, Acta Otolaryngol Suppl, V377, P3; Burns W, 1973, J Soc Occup Med, V23, P86; RABINOWITZ J, 1982, MED HYG, V40, P1; ROYSTER JD, 1991, J ACOUST SOC AM, V89, P2793, DOI 10.1121/1.400719; SANTUCCI M, 1990, MED PROBL PERFORM AR, V5, P136; SATALOFF RT, 1991, AM J OTOL, V12, P122; 1989, NOISE WORK REGULATIO	7	44	49	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1561	1563		10.1136/bmj.305.6868.1561	http://dx.doi.org/10.1136/bmj.305.6868.1561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	KD771	1286387	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992KD77100024
J	NEWENS, AJ; JARVIS, SN; GEORGE, R				NEWENS, AJ; JARVIS, SN; GEORGE, R			HOW TO GAIN WEIGHT BY LOOKING UP	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND; GATESHEAD HLTH AUTHOR,GATESHEAD NE8 3EP,ENGLAND	Newcastle University - UK	JARVIS, SN (corresponding author), UNIV NEWCASTLE UPON TYNE,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.							BARELL V, 1988, AM J EPIDEMIOL, V128, P218, DOI 10.1093/oxfordjournals.aje.a114944; Townsend P, 1988, HLTH DEPRIVATION INE; 1977, MANUAL INT STATISTIC, V1	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1576	1577		10.1136/bmj.305.6868.1576	http://dx.doi.org/10.1136/bmj.305.6868.1576			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286396	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992KD77100033
J	OVEREND, A; HALL, WW; GODWIN, PGR				OVEREND, A; HALL, WW; GODWIN, PGR			DOES EARWAX LOSE ITS PATHOGENS ON YOUR AURISCOPE OVERNIGHT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To describe the organisms cultured from general practitioners' auriscope earpieces; and to explore general practitioners' perceptions of the possibility of cross infection from contaminated auriscope earpieces and of how their auriscope earpieces are cleaned. Design-Microbiological survey of auriscope ear-pieces in two general practices and a semistructured questionnaire sent to 105 general practitioners. Setting-General practitioners served by one district general hospital microbiology laboratory in the north of England. Results-Organisms were cultured from 41 (93%) of 44 auriscope earpieces, of which 14 (32%) carried potential pathogens; four (9%) were heavily contaminated. Of the 85 (81%) general practitioners who responded, 72 (85%) believed that contaminated auriscope earpieces could cause serious infection, 66 (78%) did not clean earpieces between patients, and 70 (82%) thought that patients would mind if they knew that dirty earpieces were used. Conclusions-Almost a third of auriscope ear-pieces were contaminated by pathogenic bacteria. Although general practitioners suspected this, most did not ensure that a clean earpiece was used for each patient.	TOWNHEAD SURG,SETTLE BD24 9JA,N YORKSHIRE,ENGLAND; AIREDALE DIST GEN HOSP,KEIGHLEY,W YORKSHIRE,ENGLAND		HALL, WW (corresponding author), TOWNHEAD SURG,SETTLE BD24 9JA,N YORKSHIRE,ENGLAND.							AYLIFFE GAJ, 1992, CONTROL HOSPITAL INF; BROOK I, 1985, AM J OTOLARYNG, V6, P111, DOI 10.1016/S0196-0709(85)80048-X; CASSISI N, 1977, ANN OTO RHINOL LARYN, V86, P1; CHAI TJ, 1980, CHEMOTHERAPY, V18, P638; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; LENNETTE EH, 1980, MANUAL CLIN MICROBIO; MARCY SM, 1985, PEDIATR INFECT DIS J, V4, P192; MARCY SM, 1985, PEDIATR INFECT DIS J, V4, pS27, DOI 10.1097/00006454-198505010-00007; Roethlisberger F.J., 1939, MANAGEMENT WORKER; Rosenstock I., 1979, HEALTH PSYCHOL, P161; SHETH KJ, 1986, PEDIATRICS, V77, P920; STONE M, 1984, ANN OTO RHINOL LARYN, V93, P183, DOI 10.1177/000348948409300217; 1992, PRACTICE PLUS DIAGNO; 1990, INTRUCTION LEAFLET D	14	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1571	1573		10.1136/bmj.305.6868.1571	http://dx.doi.org/10.1136/bmj.305.6868.1571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286392	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992KD77100029
J	PITHIE, AD; CHICKSEN, B				PITHIE, AD; CHICKSEN, B			FINE-NEEDLE EXTRATHORACIC LYMPH-NODE ASPIRATION IN HIV-ASSOCIATED SPUTUM-NEGATIVE TUBERCULOSIS	LANCET			English	Note							UGANDA; AIDS	HIV-associated tuberculosis is increasingly seen in Zimbabwe and other developing countries. The clinical and radiological features are often atypical, and diagnostic confusion may arise when sputum smears are negative. Patients with suspected intrathoracic tuberculosis frequently have palpable extrathoracic lymph nodes. In this study, Ziehl-Neelsen staining of aspirates from extrathoracic lymph nodes revealed acid-fast bacilli in 20 (71%) of 28 patients with suspected tuberculosis, and 20 (87%) of 23 patients in whom a final diagnosis of tuberculosis was made Aspiration is simple, rapid, and cheap and may be of value in the diagnosis of tuberculosis, especially in developing countries with limited diagnostic and therapeutic resources.	UNIV ZIMBABWE,DEPT MED,HARARE,ZIMBABWE	University of Zimbabwe	PITHIE, AD (corresponding author), E BIRMINGHAM HOSP NHS TRUST,DEPT INFECT & TROP MED,BORDESLEY GREEN E,BIRMINGHAM B9 5ST,ENGLAND.							ELLIOTT AM, 1990, BRIT MED J, V301, P412, DOI 10.1136/bmj.301.6749.412; GOODGAME RW, 1990, NEW ENGL J MED, V323, P383, DOI 10.1056/NEJM199008093230605; HARRIES AD, 1990, LANCET, V335, P387, DOI 10.1016/0140-6736(90)90216-R; MASON PR, 1992, 1ST AFR IMM C HAR; MORRISSEY AB, 1992, J ACQ IMMUN DEF SYND, V5, P477; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; OKELLO DO, 1990, J INFECT DIS, V162, P208, DOI 10.1093/infdis/162.1.208; PERRONNE C, 1992, TUBERCLE LUNG DIS, V73, P39, DOI 10.1016/0962-8479(92)90078-X; VOETBERG A, 1991, LANCET, V337, P56, DOI 10.1016/0140-6736(91)93380-R; 1987, MMWR S, V36, pS1	10	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1504	1505		10.1016/0140-6736(92)92758-8	http://dx.doi.org/10.1016/0140-6736(92)92758-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361599				2022-12-01	WOS:A1992KD06900007
J	RINTALA, M; MUSTAJOKI, P				RINTALA, M; MUSTAJOKI, P			COULD MANNEQUINS MENSTRUATE	BRITISH MEDICAL JOURNAL			English	Article							MENARCHE		UNIV HELSINKI,CENT HOSP,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki; Helsinki University Central Hospital	MUSTAJOKI, P (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT MED 3,SF-00290 HELSINKI 29,FINLAND.							FRISCH RE, 1985, PERSPECT BIOL MED, V28, P611; PATTON GC, 1990, PSYCHOL MED, V20, P383, DOI 10.1017/S0033291700017700; SCOTT EC, 1982, J ADOLESCENT HEALTH, V2, P249, DOI 10.1016/S0197-0070(82)80059-4; SMITH DP, 1977, AM J CLIN NUTR, V30, P560, DOI 10.1093/ajcn/30.4.560; STEINKAMP RC, 1965, J CHRON DIS, V18, P1291, DOI 10.1016/0021-9681(65)90162-1	5	14	14	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1575	1576		10.1136/bmj.305.6868.1575	http://dx.doi.org/10.1136/bmj.305.6868.1575			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286395	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992KD77100032
J	SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C				SALAMA, A; BERGHOFER, H; MUELLERECKHARDT, C			RED-BLOOD-CELL TRANSFUSION IN WARM-TYPE AUTOIMMUNE HEMOLYTIC-ANEMIA	LANCET			English	Article							HEMOLYTIC-ANEMIA; AUTOANTIBODIES	Blood transfusions are regarded as hazardous in patients with warm-type autoimmune haemolytic anaemia (AIHA) because of potential intensification of haemolysis and a presumed high incidence of alloimmunisation. We have retrospectively analysed data of 79 multitransfused patients (74 adults, 5 children) with detectable warm autoantibodies and transitory or persisting haemolytic anaemia. All patients had received blood transfusions on at least two occasions. Patients were reexamined at least twice within the first 6 months of transfusion (duration of follow-up 6 months-12 years). 53 patients had received blood transfusions because of decompensated AIHA, all of whom presented with detectable autoantibodies against red blood cells. None of these patients had transfusion-related alloimmunisation or a definite increase in haemolysis, even when the transfused red cells were serologically incompatible because of free serum autoantibodies. The other 26 patients had no signs of AIHA at presentation (negative direct and indirect antiglobulin test), but received blood transfusions for anaemia due to various other causes. 23 of these 26 patients went on to develop alloantibodies as well as autoantibodies upon transfusion, and 3 patients developed autoantibodies alone. Our findings do not support the generally accepted notion that transfusion therapy should be avoided in AIHA patients. Rather, they indicate that the incidence of alloimmunisation as well as adverse haemolytic transfusion reactions are less common in AIHA patients than in other multitransfused patients.	UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY; UNIV GIESSEN,DEPT INTERNAL MED,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen; Justus Liebig University Giessen	MUELLERECKHARDT, C (corresponding author), UNIV GIESSEN,INST CLIN IMMUNOL & TRANSFUS MED,LANGHANSSTR 7,W-6300 GIESSEN,GERMANY.							BELL CA, 1973, AM J CLIN PATHOL, V60, P903; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; CROOKSTON JH, 1975, ARCH INTERN MED, V135, P1314, DOI 10.1001/archinte.135.10.1314; HABIBI B, 1974, AM J MED, V56, P61, DOI 10.1016/0002-9343(74)90751-7; ISSITT P, 1985, APPLIED BLOOD GROUP; LEDDY JP, 1970, J IMMUNOL, V105, P677; NESS PM, 1990, TRANSFUSION, V30, P688, DOI 10.1046/j.1537-2995.1990.30891020325.x; Petz LD, 1980, ACQUIRED IMMUNE HEMO; PIROFSKY B, 1975, CLIN HAEMATOL, V4, P167; ROSENFIELD RE, 1976, SEMIN HEMATOL, V13, P311; SALAMA A, 1987, BRIT J HAEMATOL, V65, P67, DOI 10.1111/j.1365-2141.1987.tb06137.x; SALAMA A, 1984, TRANSFUSION, V24, P188, DOI 10.1046/j.1537-2995.1984.24384225018.x; WALLHERMFECHTEL MA, 1984, TRANSFUSION, V24, P482, DOI 10.1046/j.1537-2995.1984.24685066805.x	13	53	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1515	1517		10.1016/0140-6736(92)92766-9	http://dx.doi.org/10.1016/0140-6736(92)92766-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361607				2022-12-01	WOS:A1992KD06900015
J	SIMOES, EAF; MCGRATH, EJ				SIMOES, EAF; MCGRATH, EJ			RECOGNITION OF PNEUMONIA BY PRIMARY HEALTH-CARE WORKERS IN SWAZILAND WITH A SIMPLE CLINICAL ALGORITHM	LANCET			English	Note								In developing countries primary health care workers are being trained to manage and treat acute respiratory infections with a protocol developed by the WHO. We tested the ability of nurses and nursing assistants in Swaziland to recognise the signs and symptoms of pneumonia; with the results of a paediatrician's examination as "gold standard", sensitivities and specificities were calculated. Danger signs of stridor and abnormal sleepiness were poorly recognised (sensitivity 0-50%) by the health care workers, as was audible wheeze. Severe undernutrition, tachypnoea, and chest wall indrawing were well recognised. Overall, the recognition of pneumonia was good (sensitivity 71-83%, specificity 84-85%). These findings highlight topics for emphasis in training.	MINIST HLTH, MBABANE, SWAZILAND		SIMOES, EAF (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, 4200 E 9TH AVE, BOX C-227, DENVER, CO 80262 USA.							BANG AT, 1990, LANCET, V336, P201, DOI 10.1016/0140-6736(90)91733-Q; CHERIAN T, 1990, AM J DIS CHILD, V144, P1026, DOI 10.1001/archpedi.1990.02150330086028; CHERIAN T, 1988, LANCET, V2, P125; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; Leowski J, 1986, World Health Stat Q, V39, P138; MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004; SIMOES EAF, 1991, ARCH DIS CHILD, V66, P1199, DOI 10.1136/adc.66.10.1199; SNEDECOR GW, 1980, STATISTICAL METHODS, P121; 1992, ACUTE RESPIRATORY IN; 1990, SUPERVISORY SKILLS M	10	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 19	1992	340	8834-5					1502	1503		10.1016/0140-6736(92)92757-7	http://dx.doi.org/10.1016/0140-6736(92)92757-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361598				2022-12-01	WOS:A1992KD06900006
J	TAYLOR, S				TAYLOR, S			CONFESSIONS OF A BENEDICTINE DRINKER	BRITISH MEDICAL JOURNAL			English	Article											TAYLOR, S (corresponding author), ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							DEQUINCEY T, CONFESSIONS ENGLISH	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 19	1992	305	6868					1585	1586		10.1136/bmj.305.6868.1585	http://dx.doi.org/10.1136/bmj.305.6868.1585			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD771	1286404	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992KD77100043
J	TRAVIS, SPL; MCGRATH, JA; TURNBULL, AJ; SCHOFIELD, OM; CHAN, O; OCONNOR, AF; MAYOU, B; EADY, RAJ; THOMPSON, RPH				TRAVIS, SPL; MCGRATH, JA; TURNBULL, AJ; SCHOFIELD, OM; CHAN, O; OCONNOR, AF; MAYOU, B; EADY, RAJ; THOMPSON, RPH			ORAL AND GASTROINTESTINAL MANIFESTATIONS OF EPIDERMOLYSIS-BULLOSA	LANCET			English	Note							MONOCLONAL-ANTIBODY; DIAGNOSIS	The mouth, oesophagus, and anus are often involved in dystrophic and junctional epidermolysis bullosa, but the frequency is unknown. Among 246 patients with epidermolysis bullosa, dysphagia developed in 76% of those with recessive dystrophic, in 20% of those with dominant dystrophic, in 15% of those with junctional, and in 2% of those with simplex forms. Lingual adhesions or microstomia occurred in dystrophic epidermolysis bullosa only, but were eight times more common in recessive than in dominant subtypes. These lesions are provoked by the trauma of eating and further reduce food intake, which exacerbates constipation caused by anal blisters and results in malnutrition. Management requires specialised multidisciplinary care.	ST THOMAS HOSP,GASTROINTESTINAL LAB,LONDON SE1,ENGLAND; ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT RADIOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT OTOLARYNGOL,LONDON SE1,ENGLAND; ST THOMAS HOSP,DEPT PLAST SURG,LONDON SE1,ENGLAND		TRAVIS, SPL (corresponding author), RADCLIFFE INFIRM,GASTROENTEROL UNIT,OXFORD OX2 6HE,ENGLAND.		McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Travis, Simon/0000-0002-2690-4361				COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FEURLE GE, 1984, GASTROENTEROLOGY, V87, P1376; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FOX T, 1879, LANCET, V1, P765; GRYBOSKI JD, 1988, ARCH DERMATOL, V124, P746, DOI 10.1001/archderm.124.5.746; HEAGERTY AHM, 1986, LANCET, V1, P860; HEAGERTY AHM, 1986, BRIT J DERMATOL, V115, P125, DOI 10.1111/j.1365-2133.1986.tb05707.x; NOWAK AJ, 1988, ARCH DERMATOL, V124, P742, DOI 10.1001/archderm.124.5.742; PEARSON RW, 1988, ARCH DERMATOL, V124, P718, DOI 10.1001/archderm.124.5.718; RYYNANEN M, 1992, J CLIN INVEST, V89, P974, DOI 10.1172/JCI115680; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P374, DOI 10.1111/1523-1747.ep12265460; TIDMAN MJ, 1988, CLIN EXP DERMATOL, V13, P279, DOI 10.1111/j.1365-2230.1988.tb00702.x	12	34	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 19	1992	340	8834-5					1505	1506		10.1016/0140-6736(92)92759-9	http://dx.doi.org/10.1016/0140-6736(92)92759-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KD069	1361600				2022-12-01	WOS:A1992KD06900008
J	ARTHUR, LO; BESS, JW; SOWDER, RC; BENVENISTE, RE; MANN, DL; CHERMANN, JC; HENDERSON, LE				ARTHUR, LO; BESS, JW; SOWDER, RC; BENVENISTE, RE; MANN, DL; CHERMANN, JC; HENDERSON, LE			CELLULAR PROTEINS BOUND TO IMMUNODEFICIENCY VIRUSES - IMPLICATIONS FOR PATHOGENESIS AND VACCINES	SCIENCE			English	Article							T4 MOLECULE; CELLS; ANTIGENS; MHC; BETA-2-MICROGLOBULIN; RECEPTOR; COMPLEX; HIV; HISTOCOMPATIBILITY; ASSOCIATION	Cellular proteins associated with immunodeficiency viruses were identified by determination of the amino acid sequence of the proteins and peptides present in sucrose density gradient-purified human immunodeficiency virus (HIV)-1, HIV-2, and simian immunodeficiency virus (SIV). Beta2 microglobulin (beta2m) and the alpha and beta chains of human lymphocyte antigen (HLA) DR were present in virus preparations at one-fifth the concentration of Gag on a molar basis. Antisera to HLA DR, beta2m, as well as HLA class I precipitated intact viral particles, suggesting that these cellular proteins were physically associated with the surface of the virus. Antisera to class I, beta2m, and HLA DR also inhibited infection of cultured cells by both HIV-1 and SIV. The specific, selective association of these cellular proteins in a physiologically relevant manner has major implications for our understanding of the infection process and the pathogenesis of immunodeficiency viruses and should be considered in the design of vaccines.	NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; INSERM,UNITE RECH RETROVIRUS & MALAD ASSOCIEES,F-13273 MARSEILLE 9,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Institut National de la Sante et de la Recherche Medicale (Inserm)	ARTHUR, LO (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702, USA.		Bess, Jr., Julian/B-5343-2012		NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; BENVENISTE RE, UNPUB; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BESS JW, UNPUB; CHERMANN JC, UNPUB; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FERNANDEZLARSSON R, 1992, P NATL ACAD SCI USA, V89, P2223, DOI 10.1073/pnas.89.6.2223; GELDERBLOM H, 1987, Z NATURFORSCH C, V42, P1328; GELDERBLOM HR, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P50; HENDERSON LE, 1988, SCIENCE, V241, P199, DOI 10.1126/science.3388031; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HENDERSON LE, 1990, J MED PRIMATOL, V19, P411; HENDERSON LE, 1987, J VIROL, V61, P629, DOI 10.1128/JVI.61.2.629-632.1987; HOXIE JA, 1987, HUM IMMUNOL, V18, P39, DOI 10.1016/0198-8859(87)90111-X; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KANNAGI M, 1987, J VIROL, V61, P1421, DOI 10.1128/JVI.61.5.1421-1426.1987; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KUBOTA K, 1984, J IMMUNOL, V133, P3203; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; MANN DL, 1988, J IMMUNOL, V141, P1131; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; SCHMIDT W, 1981, IMMUNOGENETICS, V13, P483, DOI 10.1007/BF00343716; SCHOLS D, 1992, VIROLOGY, V189, P374, DOI 10.1016/0042-6822(92)90719-6; SHEPPARD HW, 1992, J ACQ IMMUN DEF SYND, V5, P143; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; WRIGHTHAM M, 1991, CLIN EXP IMMUNOL, V85, P75, DOI 10.1111/j.1365-2249.1991.tb05685.x	32	494	511	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1935	1938		10.1126/science.1470916	http://dx.doi.org/10.1126/science.1470916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470916				2022-12-01	WOS:A1992KD08800031
J	DANIEL, MD; KIRCHHOFF, F; CZAJAK, SC; SEHGAL, PK; DESROSIERS, RC				DANIEL, MD; KIRCHHOFF, F; CZAJAK, SC; SEHGAL, PK; DESROSIERS, RC			PROTECTIVE EFFECTS OF A LIVE ATTENUATED SIV VACCINE WITH A DELETION IN THE NEF GENE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; CONFERS PROTECTION; RHESUS-MONKEYS; CHIMPANZEES; MACAQUES; INFECTION; IMMUNIZATION; CHALLENGE	Vaccine protection against the human immunodeficiency virus (HIV) and the related simian immunodeficiency virus (SIV) in animal models is proving to be a difficult task. The difficulty is due in large part to the persistent, unrelenting nature of HIV and SIV infection once infection is initiated. SIV with a constructed deletion in the auxiliary gene nef replicates poorly in rhesus monkeys and appears to be nonpathogenic in this normally susceptible host. Rhesus monkeys vaccinated with live SIV deleted in nef were completely protected against challenge by intravenous inoculation of live, pathogenic SIV. Deletion of nef or of multiple genetic elements from HIV may provide the means for creating a safe, effective, live attenuated vaccine to protect against acquired immunodeficiency syndrome (AIDS).	HARVARD UNIV,NEW ENGLAND REG PRIMATE RES CTR,SCH MED,1 PINE HILL DR,BOX 9102,SOUTHBOROUGH,MA 01772	Harvard University			Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025328, R01AI025328] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25328, AI26463, AI26507] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTHUR LO, 1989, J VIROL, V63, P5046, DOI 10.1128/JVI.63.12.5046-5053.1989; Bruck C., COMMUNICATION; BURNS DPW, 1991, J VIROL, V65, P1843, DOI 10.1128/JVI.65.4.1843-1854.1991; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1293; Cranage M P, 1992, Nature, V355, P685, DOI 10.1038/355685a0; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, UNPUB; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; EMINI EA, 1990, AIDS RES HUM RETROV, V6, P1247, DOI 10.1089/aid.1990.6.1247; GIBBS JS, UNPUB; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; GIRARD M P, 1990, AIDS (London), V4, pS143; HU SL, 1987, NATURE, V328, P721, DOI 10.1038/328721a0; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; HU SMK, COMMUNICATION; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; LEGRAND R, 1992, NATURE, V355, P684; LEWIS MA, UNPUB; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; REGIER DA, 1990, AIDS RES HUM RETROV, V6, P1221, DOI 10.1089/aid.1990.6.1221; RUANO G, 1989, NUCLEIC ACIDS RES, V17, P5407, DOI 10.1093/nar/17.13.5407; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; YILMA T, COMMUNICATION	26	964	998	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1938	1941		10.1126/science.1470917	http://dx.doi.org/10.1126/science.1470917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470917				2022-12-01	WOS:A1992KD08800032
J	DEVANE, WA; HANUS, L; BREUER, A; PERTWEE, RG; STEVENSON, LA; GRIFFIN, G; GIBSON, D; MANDELBAUM, A; ETINGER, A; MECHOULAM, R				DEVANE, WA; HANUS, L; BREUER, A; PERTWEE, RG; STEVENSON, LA; GRIFFIN, G; GIBSON, D; MANDELBAUM, A; ETINGER, A; MECHOULAM, R			ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR	SCIENCE			English	Article							RAT-BRAIN; LOCALIZATION	Arachidonylethanolamide, an arachidonic acid derivative in porcine brain, was identified in a screen for endogenous ligands for the cannabinoid receptor. The structure of this compound, which has been named "anandamide," was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and was confirmed by synthesis. Anandamide inhibited the specific binding of a radiolabeled cannabinoid probe to synaptosomal membranes in a manner typical of competitive ligands and produced a concentration-dependent inhibition of the electrically evoked twitch response of the mouse vas deferens, a characteristic effect of psychotropic cannabinoids. These properties suggest that anandamide may function as a natural ligand for the cannabinoid receptor.	HEBREW UNIV JERUSALEM,FAC MED,DEPT NAT PROD,IL-91120 JERUSALEM,ISRAEL; UNIV ABERDEEN MARISCHAL COLL,DEPT BIOMED SCI,ABERDEEN AB9 1AS,SCOTLAND; TECHNION ISRAEL INST TECHNOL,DEPT CHEM,IL-32000 HAIFA,ISRAEL	Hebrew University of Jerusalem; University of Aberdeen; Technion Israel Institute of Technology			Pertwee, Roger Guy/E-1312-2011	Pertwee, Roger/0000-0003-3227-2783	NIDA NIH HHS [DA 6481] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006481] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BACHUR NR, 1965, J BIOL CHEM, V240, P1019; BURSTEIN S, 1992, MARIJUANA CANNABINOI, P73; CHRISTIE WW, 1982, LIPID ANAL, P81; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1989, THESIS ST LOUIS U ST; DEVANE WA, 1991, 5TH P NORD NEUR M, P198; DEVANE WA, UNPUB; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FAIRBAIRN JW, 1981, BRIT J PHARMACOL, V72, P401, DOI 10.1111/j.1476-5381.1981.tb10990.x; FROST DJ, 1971, ANAL CHEM, V43, P1316, DOI 10.1021/ac60304a048; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; Howlett A., 1992, MARIJUANA CANNABINOI, P35; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MECHOULAM R, 1992, MARIJUANA CANNABINOI, P1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERTWEE RG, 1992, BRIT J PHARMACOL, V105, P980, DOI 10.1111/j.1476-5381.1992.tb09088.x; PERTWEE RG, 1988, PHARMACOL THERAPEUT, V36, P189, DOI 10.1016/0163-7258(88)90106-4; PERTWEE RG, 1992, MARIJUANA CANNABINOI, P165; SKLENOVSKY A, 1989, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V122, P83; SWEELEY CC, 1969, METHOD ENZYMOL, V14, P254; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z; Wenker H, 1935, J AM CHEM SOC, V57, P1079, DOI 10.1021/ja01309a034	29	4296	4466	3	287	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1946	1949		10.1126/science.1470919	http://dx.doi.org/10.1126/science.1470919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470919				2022-12-01	WOS:A1992KD08800035
J	GRANT, SGN; ODELL, TJ; KARL, KA; STEIN, PL; SORIANO, P; KANDEL, ER				GRANT, SGN; ODELL, TJ; KARL, KA; STEIN, PL; SORIANO, P; KANDEL, ER			IMPAIRED LONG-TERM POTENTIATION, SPATIAL-LEARNING, AND HIPPOCAMPAL DEVELOPMENT IN FYN MUTANT MICE	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; ASPARTATE RECEPTOR ANTAGONIST; RAT-BRAIN; SYNAPTIC TRANSMISSION; NITRIC-OXIDE; C-SRC; SELECTIVE IMPAIRMENT; KINASE-ACTIVITY; PDGF RECEPTOR; GROWTH-FACTOR	Mice with mutations in four nonreceptor tyrosine kinase genes, fyn, src, yes, and abl, were used to study the role of these kinases in long-term potentiation (LTP) and in the relation of LTP to spatial learning and memory. All four kinases were expressed in the hippocampus. Mutations in src, yes, and abl did not interfere with either the induction or the maintenance of LTP. However, in fyn mutants, LTP was blunted even though synaptic transmission and two short-term forms of synaptic plasticity, paired-pulse facilitation and post-tetanic potentiation, were normal. In parallel with the blunting of LTP, fyn mutants showed impaired spatial learning, consistent with a functional link between LTP and learning. Although fyn is expressed at mature synapses, its lack of expression during development resulted in an increased number of granule cells in the dentate gyrus and of pyramidal cells in the CA3 region. Thus, a common tyrosine kinase pathway may regulate the growth of neurons in the developing hippocampus and the strength of synaptic plasticity in the mature hippocampus.	BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	GRANT, SGN (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Grant, Seth/0000-0001-8732-8735	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008702] Funding Source: NIH RePORTER; NIA NIH HHS [AG08702] Funding Source: Medline; NICHD NIH HHS [HD24875] Funding Source: Medline; NIMH NIH HHS [MH45923] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOSS BD, 1987, BRAIN RES, V406, P280, DOI 10.1016/0006-8993(87)90793-1; BROWN TH, 1991, LONG TERM POTENTIATI, P357; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; CUDMORE SB, 1991, J NEUROCHEM, V57, P1240, DOI 10.1111/j.1471-4159.1991.tb08285.x; DAVIS RL, 1991, TRENDS GENET, V7, P224, DOI 10.1016/0168-9525(91)90369-2; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1989, BEHAV NEUROSCI, V103, P1207, DOI 10.1037/0735-7044.103.6.1207; ESPINO PC, 1990, ONCOGENE, V5, P283; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GURD JW, 1982, J NEUROCHEM, V39, P1117, DOI 10.1111/j.1471-4159.1982.tb11504.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANNIG G, 1991, ONCOGENE, V6, P361; HARVEY J, 1992, NEUROSCI LETT, V139, P197, DOI 10.1016/0304-3940(92)90551-H; HEISENBERG M, 1989, PROGR ZOOLOGY, P3; HSI ED, 1989, J BIOL CHEM, V264, P10836; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNOVSKY MJ, 1969, HISTOCHEM CYTOCHEM, V112, P219; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPP HP, 1989, EXPERIENTIA, V45, P845, DOI 10.1007/BF01954059; LOMO T, 1966, ACTA PHYSIOL SCAND, VS 68, P128; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MORRIS RGM, 1985, COLD SPRING HARB SYM, V50, P161; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; ODELL TJ, UNPUB; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SORIANO P, UNPUB; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; UPCHURCH M, 1989, BEHAV NEUROSCI, V103, P1251, DOI 10.1037/0735-7044.103.6.1251; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; WOOLSEY TA, 1971, BRAIN RES, V26, P259; ZHAO YH, 1991, ONCOGENE, V6, P1725	69	950	973	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1903	1910		10.1126/science.1361685	http://dx.doi.org/10.1126/science.1361685			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1361685				2022-12-01	WOS:A1992KD08800022
J	GREEN, R; SZOSTAK, JW				GREEN, R; SZOSTAK, JW			SELECTION OF A RIBOZYME THAT FUNCTIONS AS A SUPERIOR TEMPLATE IN A SELF-COPYING REACTION	SCIENCE			English	Article							GROUP-I INTRONS; COMPLEMENTARY-STRAND RNA; DNA; TETRAHYMENA; INVITRO; BACTERIOPHAGE-T4; POLYMERASE; LIGANDS	The sunY ribozyme is derived from a self-splicing RNA group I intron. This ribozyme was chosen as a starting point for the design of a self-replicating RNA because of its small size. As a means of facilitating the self-replication process, the size of this ribozyme was decreased by the deletion of nonconserved structural domains; however, when such deletions were made, there were severe losses of enzymatic activity. In vitro genetic selection was used to identify mutations that reactivate a virtually inactive sunY deletion mutant. A selected mutant with five substitution mutations scattered throughout the primary sequence showed greater catalytic activity than the original ribozyme under the selection conditions. The sunY ribozyme and its small selected variant can both catalyze template-directed oligonucleotide assembly. The small size and reduced secondary structure of the selected variant results in an enhancement, relative to that of the original ribozyme, of its rate of self-copying. This engineered ribozyme is able to function effectively both as a catalyst and as a template in self-copying reactions.			GREEN, R (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA.							BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; DOUDNA JA, 1989, MOL CELL BIOL, V9, P5480, DOI 10.1128/MCB.9.12.5480; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; GREEN R, 1991, Methods (Orlando), V2, P75, DOI 10.1016/S1046-2023(05)80127-6; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1992, GENE DEV, V6, P1372; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MITCHELL MJ, 1990, NUCLEIC ACIDS RES, V18, P5321, DOI 10.1093/nar/18.17.5321; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121	18	107	147	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1910	1915		10.1126/science.1470913	http://dx.doi.org/10.1126/science.1470913			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470913				2022-12-01	WOS:A1992KD08800023
J	MAZUR, P; COLE, KW; HALL, JW; SCHREUDERS, PD; MAHOWALD, AP				MAZUR, P; COLE, KW; HALL, JW; SCHREUDERS, PD; MAHOWALD, AP			CRYOBIOLOGICAL PRESERVATION OF DROSOPHILA EMBRYOS	SCIENCE			English	Article							MOUSE EMBRYOS; MELANOGASTER EMBRYOS; SURVIVAL; PERMEABILIZATION; FROZEN; EGGS	The inability to cryobiologically preserve the fruit fly Drosophila melanogaster has required that fly stocks be maintained by frequent transfer of adults. This method is costly in terms of time and can lead to loss of stocks. Traditional slow freezing methods do not succeed because the embryos are highly sensitive to chilling. With the procedures described here, 68 percent of precisely staged 15-hour Oregon R (wild-type) embryos hatch after vitrification at -205-degrees-C, and 40 percent of the resulting larvae develop into normal adult flies. These embryos are among the most complex organisms successfully preserved by cryobiology.	UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE NATL LAB,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Chicago	MAZUR, P (corresponding author), UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,DIV BIOL,OAK RIDGE,TN 37831, USA.				NICHD NIH HHS [HD17607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017607] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON KV, 1981, DEV BIOL, V82, P127, DOI 10.1016/0012-1606(81)90434-6; Ashburner M., 1978, GENETICS BIOL DROS A, P1; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; EDGLEY M, 1988, CAENORHABDITIS GENET; Hadley N.F., 1986, SCI AM, V254, P104; LIMBOURG B, 1973, DEV BIOL, V35, P382, DOI 10.1016/0012-1606(73)90034-1; LYNCH DV, 1989, CRYOBIOLOGY, V26, P445, DOI 10.1016/0011-2240(89)90069-2; MAZUR P, 1992, CRYOBIOLOGY, V29, P210, DOI 10.1016/0011-2240(92)90021-S; MAZUR P, 1992, CRYOBIOLOGY, V29, P39, DOI 10.1016/0011-2240(92)90005-M; MAZUR P, 1990, CELL BIOPHYS, V17, P53, DOI 10.1007/BF02989804; MAZUR P, IN PRESS CRYOBIOLOGY; MYERS S P, 1990, Cryobiology, V27, P651; MYERS SP, 1988, CRYOBIOLOGY, V25, P544, DOI 10.1016/0011-2240(88)90401-4; MYERS SP, 1989, CRYOBIOLOGY, V26, P472, DOI 10.1016/0011-2240(89)90071-0; RALL WF, 1987, CRYOBIOLOGY, V24, P387, DOI 10.1016/0011-2240(87)90042-3; RAMINANI LN, 1975, J INSECT MORPHOL EMB, V4, P517; SCHNEIDER U, 1983, BIOL REPROD, V29, P121, DOI 10.1095/biolreprod29.1.121; SCHREUDERS PD, IN PRESS CRYOBIOLOGY; STEPONKUS PL, 1990, NATURE, V345, P170, DOI 10.1038/345170a0; STEPONKUS PL, IN PRES CRYOBIOLOGY; STRONGGUNDERSON JM, 1989, ENVIRON ENTOMOL, V18, P756, DOI 10.1093/ee/18.5.756; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHITTINGHAM DG, 1972, SCIENCE, V178, P411, DOI 10.1126/science.178.4059.411; Wieschaus E., 1986, P199; ZALOKAR M, 1977, EMBO WORKSHOP GIF SU	25	153	166	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1932	1935		10.1126/science.1470915	http://dx.doi.org/10.1126/science.1470915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470915				2022-12-01	WOS:A1992KD08800030
J	PAPAVASSILIOU, AG; TREIER, M; CHAVRIER, C; BOHMANN, D				PAPAVASSILIOU, AG; TREIER, M; CHAVRIER, C; BOHMANN, D			TARGETED DEGRADATION OF C-FOS, BUT NOT V-FOS, BY A PHOSPHORYLATION-DEPENDENT SIGNAL ON C-JUN	SCIENCE			English	Article							DNA-BINDING DOMAIN; ACTIVATION; TRANSCRIPTION; ONCOGENES; CELLS	The proto-oncogene products c-Fos and c-Jun heterodimerize through their leucine zippers to form the AP-1 transcription factor. The transcriptional activity of the heterodimer is regulated by signal-dependent phosphorylation and dephosphorylation events. The stability of c-Fos was found to also be controlled by intracellular signal transduction. In transient expression and in vitro degradation experiments, the stability of c-Fos was decreased when the protein was dimerized with phosphorylated c-Jun. c-Jun protein isolated from phorbol ester-induced cells did not target c-Fos for degradation, which suggests that c-Fos is transiently stabilized after stimulation of cell growth. v-Fos protein, the retroviral counterpart of c-Fos, was not susceptible to degradation targeted by c-Jun.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAM, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Karamouzis, Michalis/AAD-2860-2020; Treier, Mathias/AAD-6388-2021					BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOHMANN D, UNPUB; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CURRAN T, 1987, ONCOGENE, V2, P79; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PAPAVASSILIOU AG, UNPUB; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0	25	104	104	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1941	1944		10.1126/science.1470918	http://dx.doi.org/10.1126/science.1470918			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470918				2022-12-01	WOS:A1992KD08800033
J	SHERMAN, DR; GUINN, B; PERDOK, MM; GOLDBERG, DE				SHERMAN, DR; GUINN, B; PERDOK, MM; GOLDBERG, DE			COMPONENTS OF STEROL BIOSYNTHESIS ASSEMBLED ON THE OXYGEN-AVID HEMOGLOBIN OF ASCARIS	SCIENCE			English	Article							SQUALENE EPOXIDASE; RAT-LIVER	The parasitic nematode Ascaris infests a billion people worldwide. Much of its proliferative success is due to prodigious egg production, up to 10(6) sterol-replete eggs per day. Sterol synthesis requires molecular oxygen for squalene epoxidation, yet oxygen is scarce in the intestinal folds the worms inhabit. Ascaris has an oxygen-avid hemoglobin in the perienteric fluid that bathes its reproductive organs. Purified hemoglobin contained tightly bound squalene and functioned as an NADPH-dependent, ferrihemoprotein reductase. All components of the squalene epoxidation reaction-squalene, oxygen, NADPH, and NADPH-dependent reductase-are assembled on the hemoglobin. This molecule may thus function in sterol biosynthesis.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; JEWISH HOSP ST LOUIS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)					NCRR NIH HHS [RR-00954] Funding Source: Medline; NIADDK NIH HHS [AM-20579] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM020579] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barrett J., 1981, BIOCH PARASITIC HELM; BRYANT C, 1978, ADV PARASIT, V16, P3111; Bunn HFL, 1986, HEMOGLOBIN MOL GENET; CHEAH KS, 1975, BIOCHIM BIOPHYS ACTA, V387, P107, DOI 10.1016/0005-2728(75)90055-9; CROMPTON DWT, 1986, T ROY SOC TROP MED H, V80, P697, DOI 10.1016/0035-9203(86)90368-8; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; Dresselhaus M., 1974, Getreide, Mehl und Brot, V28, P137; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; HAMADA K, 1963, J BIOCHEM-TOKYO, V53, P484, DOI 10.1093/oxfordjournals.jbchem.a127727; HAMADA K, 1962, J BIOCHEM-TOKYO, V52, P290, DOI 10.1093/oxfordjournals.jbchem.a127616; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; LEE DL, 1965, EXP PARASITOL, V16, P392, DOI 10.1016/0014-4894(65)90062-7; MBAYA B, 1987, BIOCHEM BIOPH RES CO, V147, P556, DOI 10.1016/0006-291X(87)90967-3; OKAZAKI T, 1967, BIOCHIM BIOPHYS ACTA, V140, P258, DOI 10.1016/0005-2795(67)90466-7; ONO T, 1985, METHOD ENZYMOL, V110, P375; PAWLOWSKI ZS, 1982, REV INFECT DIS, V4, P806; SHERMAN DH, UNPUB; SMITH MH, 1963, PROC R SOC SER B-BIO, V157, P234, DOI 10.1098/rspb.1963.0007; STEPHENSON LS, 1980, PARASITOLOGY, V81, P221, DOI 10.1017/S0031182000055177; WARREN K, 1988, BIOL PARASITISM; Warren K, 1989, TROPICAL GEOGRAPHICA; WEBER RE, 1980, AM ZOOL, V20, P79; WITTENBE.BA, 1965, BIOCHIM BIOPHYS ACTA, V111, P485, DOI 10.1016/0304-4165(65)90058-9; YAMAMOTO S, 1970, J BIOL CHEM, V245, P1670	25	23	24	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1930	1932		10.1126/science.1470914	http://dx.doi.org/10.1126/science.1470914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470914				2022-12-01	WOS:A1992KD08800029
J	VAUX, DL; WEISSMAN, IL; KIM, SK				VAUX, DL; WEISSMAN, IL; KIM, SK			PREVENTION OF PROGRAMMED CELL-DEATH IN CAENORHABDITIS-ELEGANS BY HUMAN BCL-2	SCIENCE			English	Article							CHROMOSOMAL BREAKPOINT; GENE-EXPRESSION; B-CELLS; NEMATODE; TRANSLOCATION; SURVIVAL; CLONING; PROTEIN; LOCUS	Programmed cell death is a physiological process that eliminates unwanted cells. The bcl-2 gene regulates programmed cell death in mammalian cells, but the way it functions is not known. Expression of the human bcl-2 gene in the nematode Caenorhabditis elegans reduced the number of programmed cell deaths, suggesting that the mechanism of programmed cell death controlled by bcl-2 in humans is the same as that in nematodes.			VAUX, DL (corresponding author), STANFORD UNIV, MED CTR, DEPT DEV BIOL, STANFORD, CA 94305 USA.		Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUX DL, 1992, INT IMMUNOL, V4, P821; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P29; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JONES D, 1986, J BIOL CHEM, V261, P2006; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	27	517	545	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 18	1992	258	5090					1955	1957		10.1126/science.1470921	http://dx.doi.org/10.1126/science.1470921			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470921				2022-12-01	WOS:A1992KD08800038
J	YANG, G; MASLAND, RH				YANG, G; MASLAND, RH			DIRECT VISUALIZATION OF THE DENDRITIC AND RECEPTIVE-FIELDS OF DIRECTIONALLY SELECTIVE RETINAL GANGLION-CELLS	SCIENCE			English	Article							CHOLINERGIC AMACRINE CELLS; RABBIT RETINA; MAMMALIAN RETINA; GABA-LIKE; NEURONS; ACETYLCHOLINE; MORPHOLOGY; IMMUNOREACTIVITY; DECARBOXYLASE; RESPONSES	Optical methods were used to locate the cell bodies of directionally selective ganglion cells in isolated rabbit retinas. These neurons detect the direction in which images move across the retinal surface and transmit that information to the brain. The receptive field of each identified cell was determined, after which the cell was injected with Lucifer yellow. An image of the receptive field border was then projected onto the fluorescent image of the dendrites, allowing precise comparison between them. The size of the receptive field matched closely the size of the dendritic arbor of that cell. This result restricts the types of convergence that can be postulated in modeling the mechanism of retinal directional selectivity.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROSURG,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NEI NIH HHS [R37-EY01075] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY001075] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES A, 1981, J NEUROCHEM, V37, P867, DOI 10.1111/j.1471-4159.1981.tb04473.x; AMTHOR FR, 1989, J COMP NEUROL, V280, P97, DOI 10.1002/cne.902800108; AMTHOR FR, 1984, BRAIN RES, V298, P187, DOI 10.1016/0006-8993(84)91167-3; ARIEL M, 1982, J PHYSIOL-LONDON, V324, P161, DOI 10.1113/jphysiol.1982.sp014105; BARLOW HB, 1965, J PHYSIOL-LONDON, V178, P477, DOI 10.1113/jphysiol.1965.sp007638; BLOOMFIELD SA, 1992, J NEUROPHYSIOL, V68, P711, DOI 10.1152/jn.1992.68.3.711; BLOOMFIELD SA, 1991, NATURE, V350, P347, DOI 10.1038/350347a0; BLOOMFIELD SA, 1992, INVEST OPHTH VIS SCI, V33, P1173; BORGGRAHAM L, 1991, SINGLE NEURON COMPUT; BRANDON C, 1987, BRAIN RES, V401, P385, DOI 10.1016/0006-8993(87)91426-0; BRECHA N, 1988, P NATL ACAD SCI USA, V85, P6187, DOI 10.1073/pnas.85.16.6187; FAMIGLIETTI EV, 1983, BRAIN RES, V261, P138, DOI 10.1016/0006-8993(83)91293-3; FAMIGLIETTI EV, 1991, J COMP NEUROL, V309, P40, DOI 10.1002/cne.903090105; KOCH C, 1982, PHILOS T R SOC B, V298, P227, DOI 10.1098/rstb.1982.0084; KOSAKA T, 1988, EXP BRAIN RES, V70, P605; LEVICK WR, 1983, PROGR RETINAL RES, V2, P267; MASLAND RH, 1976, J NEUROPHYSIOL, V39, P1220, DOI 10.1152/jn.1976.39.6.1220; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P121, DOI 10.1098/rspb.1984.0086; MASLAND RH, 1979, J CELL BIOL, V83, P159, DOI 10.1083/jcb.83.1.159; MILLER RF, 1983, P NATL ACAD SCI-BIOL, V80, P3069, DOI 10.1073/pnas.80.10.3069; OMALLEY DM, 1989, P NATL ACAD SCI USA, V86, P3414, DOI 10.1073/pnas.86.9.3414; OYSTER CW, 1968, J PHYSIOL-LONDON, V199, P613, DOI 10.1113/jphysiol.1968.sp008671; PEICHL L, 1979, J PHYSIOL-LONDON, V291, P117, DOI 10.1113/jphysiol.1979.sp012803; TAUCHI M, 1985, J NEUROSCI, V5, P2494; TAUCHI M, 1984, PROC R SOC SER B-BIO, V223, P101, DOI 10.1098/rspb.1984.0085; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; VANEY DI, 1988, BRAIN RES, V438, P369, DOI 10.1016/0006-8993(88)91366-2; VANEY DI, 1984, PROC R SOC SER B-BIO, V220, P501, DOI 10.1098/rspb.1984.0016; VANEY DI, 1989, NEUROBIOLOGY INNER R, P154; VANEY DI, 1990, PROGR RETINAL RES, V9, P1; WYATT HJ, 1975, J NEUROPHYSIOL, V38, P613, DOI 10.1152/jn.1975.38.3.613	31	75	78	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1949	1952		10.1126/science.1470920	http://dx.doi.org/10.1126/science.1470920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470920				2022-12-01	WOS:A1992KD08800036
J	ZHANG, Y; RAMOS, BF; JAKSCHIK, BA				ZHANG, Y; RAMOS, BF; JAKSCHIK, BA			NEUTROPHIL RECRUITMENT BY TUMOR-NECROSIS-FACTOR FROM MAST-CELLS IN IMMUNE-COMPLEX PERITONITIS	SCIENCE			English	Article							LEUKOCYTE ADHESION; MICE; INFLAMMATION; AUGMENTATION	During generalized immune complex-induced inflammation of the peritoneal cavity, two peaks of tumor necrosis factor (TNF) were observed in the peritoneal exudate of normal mice. In mast cell-deficient mice, the first peak was undetected, and the second peak of TNF and neutrophil influx were significantly reduced. Antibody to TNF significantly inhibited neutrophil infiltration in normal but not in mast cell-deficient mice. Mast cell repletion of the latter normalized TNF, neutrophil mobilization, and the effect of the antibody to TNF. Thus, in vivo, mast cells produce the TNF that augments neutrophil emigration.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031922] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS SI, 1991, J IMMUNOL, V146, P405; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; COCHRANE CG, 1984, SPRINGER SEMIN IMMUN, V7, P263, DOI 10.1007/BF01893023; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; KITAMURA Y, 1978, BLOOD, V52, P447; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; QURESHI R, 1988, J IMMUNOL, V141, P2090; RAMOS BF, 1992, J PHARMACOL EXP THER, V262, P559; RAMOS BF, 1991, J IMMUNOL, V147, P1636; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAMOS BF, UNPUB; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SUMMERS JB, 1988, J MED CHEM, V31, P3, DOI 10.1021/jm00396a002; VANDENBROEK MF, 1988, J RHEUMATOL, V15, P544; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, J IMMUNOL, V149, P2482; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385; ZHANG Y, 1992, IMMUNOLOGY, V77, P422	24	250	251	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 18	1992	258	5090					1957	1959		10.1126/science.1470922	http://dx.doi.org/10.1126/science.1470922			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD088	1470922				2022-12-01	WOS:A1992KD08800039
J	BALLEM, PJ; BELZBERG, A; DEVINE, DV; LYSTER, D; SPRUSTON, B; CHAMBERS, H; DOUBROFF, P; MIKULASH, K				BALLEM, PJ; BELZBERG, A; DEVINE, DV; LYSTER, D; SPRUSTON, B; CHAMBERS, H; DOUBROFF, P; MIKULASH, K			KINETIC-STUDIES OF THE MECHANISM OF THROMBOCYTOPENIA IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOMOSEXUAL MEN; HEMATOLOGIC MANIFESTATIONS; PATHO-PHYSIOLOGY; GLYCOPROTEIN-IB; HIV INFECTION; PURPURA; MEGAKARYOCYTES; PLATELETS; AUTOANTIBODIES; INTERLEUKIN-6	Background. Isolated thrombocytopenia accompanied by increased amounts of platelet-associated antibody is a common manifestation of human immunodeficiency virus (HIV) infection, and the thrombocytopenia often improves with zidovudine. It is not clear whether the mechanism of HIV-related thrombocytopenia primarily involves autoimmune destruction of platelets or reduced platelet production by megakaryocytes. Methods. We studied the survival of In-111-labeled autologous platelets and performed platelet imaging in 24 men with isolated HIV-related thrombocytopenia (1 6 who received no treatment and 8 who received zidovudine). We also studied 20 HIV-infected men with normal platelet counts (10 who received no treatment and 10 who received zidovudine) and studied 12 healthy seronegative men as controls. Results. Mean(+/-SD) platelet survival was significantly decreased in both the untreated and the zidovudine-treated patients with HIV-related thrombocytopenia (to 92+/-33 and 129+/-44 hours, respectively; both P<0.001), as compared with the normal controls (198+/-15 hours). Mean platelet survival was also significantly decreased in the HIV-infected patients with normal platelet counts (untreated, 162+/-23 hours, P<0.01; zidovudine-treated, 166+/-35 hours, P<0.05). Imaging studies, however, revealed no evidence of increased clearance of autologous platelets in the liver or spleen in any of these groups. Mean platelet production was significantly depressed in the untreated patients with thrombocytopenia (23,000+/-11,000 platelets per cubic millimeter per day, P<0.001) as compared with the healthy controls (45,000+/-6,000 per cubic millimeter per day). Mean platelet production was significantly increased, however, in the men treated with zidovudine, both in those with thrombocytopenia (60,000+/-31,000 platelets per cubic millimeter per day, P<0.01 vs. controls) and in those without thrombocytopenia (68,000+/-22,000 per cubic millimeter per day, P<0.01). Conclusions. Although there was a moderate reduction in platelet survival in HIV-infected persons, these patients, regardless of platelet counts, also had decreased production of platelets, possibly due to viral infection of the megakaryocytes. Zidovudine appears to improve platelet production.	ST PAULS HOSP, DEPT MED, VANCOUVER V6Z 1Y6, BC, CANADA; ST PAULS HOSP, DEPT NUCL MED, VANCOUVER V6Z 1Y6, BC, CANADA; ST PAULS HOSP, DEPT PATHOL, VANCOUVER V6Z 1Y6, BC, CANADA; CANADIAN RED CROSS SOC, BLOOD TRANSFUS SERV, VANCOUVER, BC, CANADA; UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA	St. Paul's Hospital; University of Saskatchewan; St. Paul's Hospital; University of Saskatchewan; St. Paul's Hospital; University of Saskatchewan; University of British Columbia								ABRAMS DI, 1984, AM J CLIN PATHOL, V81, P13, DOI 10.1093/ajcp/81.1.13; ABRAMS DI, 1986, ANN INTERN MED, V104, P47, DOI 10.7326/0003-4819-104-1-47; ASANO S, 1990, BLOOD, V75, P1602; BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BALLEM PJ, 1989, BLUT, V59, P111, DOI 10.1007/BF00320260; BASCH RS, 1990, P NATL ACAD SCI USA, V87, P8085, DOI 10.1073/pnas.87.20.8085; BEARDSLEY DS, 1984, J CLIN INVEST, V74, P1701, DOI 10.1172/JCI111587; BETTAIEB A, 1989, BRIT J HAEMATOL, V73, P241, DOI 10.1111/j.1365-2141.1989.tb00259.x; BIK T, 1982, BLOOD, V59, P482; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; CHOW FPR, 1991, BLOOD S, V78, pA148; COX LH, 1991, BLOOD, V77, P286; GERNSHEIMER T, 1989, NEW ENGL J MED, V320, P974, DOI 10.1056/NEJM198904133201505; HANSON SR, 1985, BLOOD, V66, P1105; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; HEYNS AP, 1985, PLATELET KINETICS IM, V2, P97; HILL RJ, 1990, J CLIN INVEST, V85, P1242, DOI 10.1172/JCI114559; HIRSCHEL B, 1988, ANN INTERN MED, V109, P718, DOI 10.7326/0003-4819-109-9-718; HIRSH J, 1966, BRIT J HAEMATOL, V12, P44, DOI 10.1111/j.1365-2141.1966.tb00125.x; HYMES KB, 1988, NEW ENGL J MED, V318, P516, DOI 10.1056/NEJM198802253180812; JERUSHALMY Z, 1963, P SOC EXP BIOL MED, V114, P687, DOI 10.3181/00379727-114-28771; KARPATKIN S, 1988, P NATL ACAD SCI USA, V85, P9763, DOI 10.1073/pnas.85.24.9763; KLAASSEN RJL, 1989, BLUT, V59, P75, DOI 10.1007/BF00320253; LEIDERMAN IZ, 1987, BLOOD, V70, P1267; LIPSON RL, 1959, AM J CLIN PATHOL, V32, P526; LOUACHE F, 1991, BLOOD, V78, P1697; MATHIAS CJ, 1984, SEMIN NUCL MED, V14, P118, DOI 10.1016/S0001-2998(84)80025-2; MONTANER JSG, 1990, J ACQ IMMUN DEF SYND, V3, P565; MONTE D, 1992, BLOOD, V79, P2670; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; MURPHY EA, 1971, THROMB DIATH HAEMOST, V25, P53, DOI 10.1055/s-0038-1654280; PENA JM, 1990, ACTA HAEMATOL-BASEL, V83, P86; PERKOCHA LA, 1988, AM J HEMATOL, V29, P94, DOI 10.1002/ajh.2830290207; POTTAGE JC, 1988, JAMA-J AM MED ASSOC, V260, P3045, DOI 10.1001/jama.260.20.3045; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SCADDEN DT, 1989, BLOOD, V74, P1455; SCOTT S, 1978, BLOOD, V52, P47; STELLA CC, 1987, J CLIN INVEST, V80, P286, DOI 10.1172/JCI113071; STELLA CC, 1988, HAEMATOLOGICA, V73, P25; STRATTON JR, 1989, J NUCL MED, V30, P629; SZATKOWSKI NS, 1986, BLOOD, V67, P310; TERADA H, 1966, BLOOD-J HEMATOL, V28, P213, DOI 10.1182/blood.V28.2.213.213; VANDERLELIE J, 1987, BRIT J HAEMATOL, V67, P109, DOI 10.1111/j.1365-2141.1987.tb02304.x; WALSH CM, 1984, NEW ENGL J MED, V311, P635, DOI 10.1056/NEJM198409063111004; WOODS VL, 1984, BLOOD, V63, P368; WOODS VL, 1984, BLOOD, V64, P156; ZAULI G, 1992, BLOOD, V79, P2680; ZON LI, 1987, BRIT J HAEMATOL, V66, P251, DOI 10.1111/j.1365-2141.1987.tb01307.x; ZUCKERFRANKLIN D, 1989, P NATL ACAD SCI USA, V86, P5595, DOI 10.1073/pnas.86.14.5595; ZUCKERFRANKLIN D, 1989, AM J PATHOL, V134, P1295; 1987, MMWR MORB MORTAL S1, V36, pS3	51	162	169	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1779	1784		10.1056/NEJM199212173272503	http://dx.doi.org/10.1056/NEJM199212173272503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1435932				2022-12-01	WOS:A1992KB97500003
J	BRUZIK, JP; MANIATIS, T				BRUZIK, JP; MANIATIS, T			SPLICED LEADER RNAS FROM LOWER EUKARYOTES ARE TRANSSPLICED IN MAMMALIAN-CELLS	NATURE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PRE-MESSENGER-RNA; 2'-OME RNA; C-ELEGANS; INVITRO; SEQUENCES; U2; OLIGONUCLEOTIDES; IDENTIFICATION; PRECURSORS	EXON sequences present on separate RNA molecules can be joined by trans-splicing in trypanosomatids, Euglena, and in the nematode and trematode worms1-3. Trans-splicing involves an interaction between a 5' splice site present in a spliced leader RNA and a 3' splice site located near the 5' end of pre-messenger RNAs. In vitro trans-splicing of artificial mammalian pre-mRNAs has been reported, but the efficiency of splicing appears to depend on sequence complementarity between the two substrates4-7. There has been speculation that some natural pre-mRNAs can be trans-spliced in mammalian cells in vivo8,9, but alternative interpretations have not been ruled out. Here we show that spliced leader RNAs can be accurately trans-spliced in mammalian cells in vivo and in vitro. Both nematode and mammalian 3' splice sites can function as acceptors for trans-splicing in vivo. These results reveal functional conservation in the splicing machinery between lower eukaryotes and mammals, and they directly demonstrate the potential for trans-splicing in mammalian cells.			BRUZIK, JP (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BEKTESH SL, 1988, NUCLEIC ACIDS RES, V16, P5692, DOI 10.1093/nar/16.12.5692; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BLENCOWE BJ, 1989, CELL, V59, P531, DOI 10.1016/0092-8674(89)90036-6; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; Huang X Y, 1992, Genet Eng (N Y), V14, P211; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SHARP PA, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90753-1; SHIMIZU A, 1989, P NATL ACAD SCI USA, V86, P8020, DOI 10.1073/pnas.86.20.8020; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	36	66	84	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					692	695		10.1038/360692a0	http://dx.doi.org/10.1038/360692a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465136				2022-12-01	WOS:A1992KD08200063
J	CAMPS, M; CAROZZI, A; SCHNABEL, P; SCHEER, A; PARKER, PJ; GIERSCHIK, P				CAMPS, M; CAROZZI, A; SCHNABEL, P; SCHEER, A; PARKER, PJ; GIERSCHIK, P			ISOZYME-SELECTIVE STIMULATION OF PHOSPHOLIPASE C-BETA-2 BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							ADENYLYL CYCLASE; SIGNAL TRANSDUCTION; RECEPTOR; CELLS	HYDROLYSIS by phospholipase C (PLC) of phosphatidylinositol 4,5-bisphosphate is a key mechanism by which many extracellular signalling molecules regulate functions of their target cells1,2. At least eight distinct isozymes of PLC are recognized in mammalian cells3,4. Receptor-controlled PLC is often regulated by G proteins, which can be modified by pertussis toxin in some cells but not in others5,6. In the latter cells, PLC-beta1, but not PLC-gamma1 or PLC-delta1, may be activated by members of the alpha(q)-subfamily of the G protein alpha-subunits7-10. An unidentified PLC in soluble fractions of cultured human HL-60 granulocytes is specifically stimulated by G protein betagamma subunits purified from retina and brain11. Identification of a second PLC-beta complementary DNA (PLC-beta2) in an HL-60 cell cDNA library9 prompted us to investigate the effect of purified G protein betagamma subunits on the activities of PLC-beta1 and PLC-beta2 transiently expressed in cultured mammalian cells. We report here that PLC-beta1 and PLC-beta2 were stimulated by free betagamma subunits and that PLC-beta2 was the most sensitive to betagamma stimulation. Thus stimulation of PLC by betagamma subunits is isozyme-selective and PLC-beta2 is a prime target of betagamma stimulation. Activation of PLC-beta2 by betagamma subunits may be an important mechanism by which pertussis toxin-sensitive G proteins stimulate PLC.	GERMAN CANC RES CTR, DIV MOLEC PHARMACOL, W-6900 HEIDELBERG, GERMANY; IMPERIAL CANC RES FUND, PROT PHOSPHORYLAT LAB, LONDON WC2A 3PX, ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Cancer Research UK			Parker, Peter j/D-5192-2013	Camps, Montserrat/0000-0002-9849-8657; parker, peter/0000-0002-6218-2933				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; LEE CH, 1992, J BIOL CHEM, V267, P16044; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PARK D, 1992, J BIOL CHEM, V267, P16048; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q	24	572	576	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					684	686		10.1038/360684a0	http://dx.doi.org/10.1038/360684a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465133				2022-12-01	WOS:A1992KD08200060
J	CHEN, J; KANAI, Y; COWAN, NJ; HIROKAWA, N				CHEN, J; KANAI, Y; COWAN, NJ; HIROKAWA, N			PROJECTION DOMAINS OF MAP2 AND TAU DETERMINE SPACINGS BETWEEN MICROTUBULES IN DENDRITES AND AXONS	NATURE			English	Article							POLARITY ORIENTATION; MOLECULAR-STRUCTURE; BINDING DOMAIN; PROTEIN TAU; EXPRESSION; BRAIN; CDNA; PHOSPHORYLATION; ORGANIZATION; SEQUENCES	NEURONS develop a highly polarized morphology consisting of dendrites and a long axon. Both axons and dendrites contain microtubules and microtubule-associated proteins (MAPs) with characteristic structures1. Among MAPs, MAP2 is specifically expressed in dendrites2 whereas MAP2C and tau are abundant in the axon2-5. But the influence of MAP2, MAP2C and tau on the organization of microtubule domains in dendrites versus axons is unknown. Both MAP2 and tau induce microtubule bundle formation in fibroblasts after transfection of complementary DNAs6,7 and a long process resembling an axon is extended in Sf9 cells infected with recombinant baculovirus expressing tau8,9. We have now expressed MAP2 and MAP2C in Sf9 cells in order to compare their morphology and the arrangement of their microtubules to that found in Sf9 cells expressing tau. We report here that the spacing between microtubules depends on the MAP expressed: in cells expressing MAP2, the distance is similar to that found in dendrites, whereas the spacing between microtubules in cells expressing MAP2C or tau is similar to that found in axons.	UNIV TOKYO,SCH MED,DEPT ANAT & CELL BIOL,BUNKYO KU,TOKYO 113,JAPAN; NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	University of Tokyo; New York University			Kanai, Yoshimitsu/W-3486-2019	Kanai, Yoshimitsu/0000-0002-0375-6853				AIZAWA H, 1988, J BIOL CHEM, V263, P7703; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; HEIDEMANN SR, 1981, J CELL BIOL, V91, P661, DOI 10.1083/jcb.91.3.661; HIROKAWA N, 1988, J CELL BIOL, V107, P1449, DOI 10.1083/jcb.107.4.1449; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1988, J NEUROSCI, V8, P285; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KNOPS J, 1991, J CELL BIOL, V114, P725, DOI 10.1083/jcb.114.4.725; KOSIK KS, 1989, NEURON, V2, P1389, DOI 10.1016/0896-6273(89)90077-9; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PAPANDRIKOPOULOU A, 1989, NATURE, V340, P650, DOI 10.1038/340650a0; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; TAKEUCHI M, 1992, J NEUROCHEM, V58, P1510, DOI 10.1111/j.1471-4159.1992.tb11372.x; UMEYAMA T, IN PRESS J CELL BIOL; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; WEBB NR, 1990, MAXBAC BACULOVIRUS E; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	28	477	495	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					674	676		10.1038/360674a0	http://dx.doi.org/10.1038/360674a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465130				2022-12-01	WOS:A1992KD08200056
J	CITRON, M; OLTERSDORF, T; HAASS, C; MCCONLOGUE, L; HUNG, AY; SEUBERT, P; VIGOPELFREY, C; LIEBERBURG, I; SELKOE, DJ				CITRON, M; OLTERSDORF, T; HAASS, C; MCCONLOGUE, L; HUNG, AY; SEUBERT, P; VIGOPELFREY, C; LIEBERBURG, I; SELKOE, DJ			MUTATION OF THE BETA-AMYLOID PRECURSOR PROTEIN IN FAMILIAL ALZHEIMERS-DISEASE INCREASES BETA-PROTEIN PRODUCTION	NATURE			English	Article							IDENTIFICATION; RECEPTOR; GENE	PROGRESSIVE cerebral deposition of the 39-43-amino-acid amyloid beta-protein (Abeta) is an invariant feature of Alzheimer's disease which precedes symptoms of dementia by years or decades. The only specific molecular defects that cause Alzheimer's disease which have been identified so far are missense mutations in the gene encoding the beta-amyloid precursor protein (beta-APP) in certain families with an autosomal dominant form of the disease (familial Alzheimer's disease, or FAD)1-5. These mutations are located within or immediately flanking the Abeta region of beta-APP, but the mechanism by which they cause the pathological phenotype of early and accelerated Abeta deposition is unknown. Here we report that cultured cells which express a beta-APP complementary DNA bearing a double mutation (Lys to Asn at residue 595 plus Met to Leu at position 596) found in a Swedish FAD family5 produce approximate 6-8-fold more Abeta than cells expressing normal beta-APP. The Met 596 to Leu mutation is principally responsible for the increase. These data establish a direct link between a FAD genotype and the clinicopathological phenotype. Further, they confirm the relevance of the continuous Abeta production by cultured cells6-8 for elucidating the fundamental mechanism of Alzheimer's disease.	ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080; HARVARD UNIV,SCH MED,NEUROSCI PROGRAM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	CITRON, M (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.							CHEN WJ, 1990, J BIOL CHEM, V265, P3116; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, IN PRESS J BIOL CHEM; HARLIN MCC, 1991, NATURE, V353, P844; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, IN PRESS NATURE; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	19	1553	1662	1	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					672	674		10.1038/360672a0	http://dx.doi.org/10.1038/360672a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465129				2022-12-01	WOS:A1992KD08200055
J	FOOR, F; PARENT, SA; MORIN, N; DAHL, AM; RAMADAN, N; CHREBET, G; BOSTIAN, KA; NIELSEN, JB				FOOR, F; PARENT, SA; MORIN, N; DAHL, AM; RAMADAN, N; CHREBET, G; BOSTIAN, KA; NIELSEN, JB			CALCINEURIN MEDIATES INHIBITION BY FK506 AND CYCLOSPORINE OF RECOVERY FROM ALPHA-FACTOR ARREST IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; CYCLOPHILIN; GENE; PROTEIN; CDNA	THE structurally unrelated immunosuppressants FK506 and cyclosporin A (CsA) act similarly, inhibiting a Ca2+-dependent signal required for interleukin-2 transcription and T-cell activation1. Each drug binds to its cytosolic receptor, FKBP-12 and cyclophilin, respectively, and the drug-receptor complexes inhibit the Ca2+/calmodulin-dependent protein phosphatase, calcineurin2-4. In yeast, calcineurin has been implicated in recovery from alpha-mating factor arrest5,6. Here we show that FK506 bound to yeast FKBP-12 appears to form a complex with yeast calcineurin. Moreover, recovery from mating factor arrest is highly sensitive to FK506 or CsA, and this sensitivity requires the presence of FKBP-12 or cyclophilin, respectively. These results define a key physiological target of an FK506- and CsA-sensitive signal pathway in yeast, suggest a high degree of mechanistic conservation with mammalian cells, and indicate that further examination of the yeast system should provide insight into the same process in T cells.	MERCK RES LABS,POB 2000,BLDG R80Y-2A97,RAHWAY,NJ 07065	Merck & Company								BARNES DA, 1986, MOL CELL BIOL, V6, P2828, DOI 10.1128/MCB.6.8.2828; BRIZUELA L, 1991, MOL CELL BIOL, V11, P4616, DOI 10.1128/MCB.11.9.4616; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; HAENDLER B, 1989, GENE, V83, P39, DOI 10.1016/0378-1119(89)90401-0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; NIELSEN JB, 1992, P NATL ACAD SCI USA, V89, P7471, DOI 10.1073/pnas.89.16.7471; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0	14	200	206	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					682	684						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1281518				2022-12-01	WOS:A1992KD08200059
J	HUGO, P; KAPPLER, JW; GODFREY, DI; MARRACK, PC				HUGO, P; KAPPLER, JW; GODFREY, DI; MARRACK, PC			A CELL-LINE THAT CAN INDUCE THYMOCYTE POSITIVE SELECTION	NATURE			English	Article							ANTIGEN-PRESENTING ABILITY; THYMIC EPITHELIAL-CELLS; T-CELLS; SELF-RECOGNITION; STROMAL CELL; DIFFERENTIATION; EXPRESSION; APPEARANCE; KINETICS; GROWTH	THE thymus positively selects thymocytes that bear T-cell receptors which recognize antigen presented by self major histocompatibility complex (MHC) proteins1,2. positive selection is usually driven by MHC products on radiation-resistant cortical epithelial cells3-5. It is unknown whether positive selection is mediated by all thymic epithelial cells or by some specialized subsets4. Here we introduce an H-2(b)-expressing thymic epithelial cell line into the thymuses of lethally irradiated H-2k animals reconstituted with H-2b/k F1 BM or fetal liver cells. I-A(b)-restricted T cells are found in these animals, demonstrating that selection occurs on the introduced epithelial cells.	DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	HUGO, P (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,HOWARD HUGHES MED INST,1400 JACKSON ST,DENVER,CO 80206, USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687; Godfrey, Dale/0000-0002-3009-5472				BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; Benoist C, 1989, Semin Immunol, V1, P117; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BERRIH S, 1985, J IMMUNOL, V135, P1165; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; FISCHER M, 1991, J IMMUNOL, V146, P3452; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; LO D, 1986, J IMMUNOL, V137, P1772; LONGO DL, 1983, J IMMUNOL, V130, P2525; MCDEVITT HO, 1972, J EXP MED, V135, P1259, DOI 10.1084/jem.135.6.1259; MONTGOMERY RA, 1991, J IMMUNOL, V147, P554; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NISHIMURA T, 1990, J IMMUNOL, V145, P4012; PARDOLL D, 1992, CURR OPIN IMMUNOL, V4, P162, DOI 10.1016/0952-7915(92)90006-Z; POTWOROWSKI EF, 1986, IN VITRO CELL DEV B, V22, P557; RANSOM J, 1991, CELL IMMUNOL, V134, P180, DOI 10.1016/0008-8749(91)90341-8; Shortman K, 1990, Semin Immunol, V2, P3; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882; ZLOTNIK A, 1983, J IMMUNOL, V131, P2814	25	101	101	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					679	682		10.1038/360679a0	http://dx.doi.org/10.1038/360679a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465132				2022-12-01	WOS:A1992KD08200058
J	KATZ, A; WU, DQ; SIMON, MI				KATZ, A; WU, DQ; SIMON, MI			SUBUNITS-BETA-GAMMA OF HETEROTRIMERIC G-PROTEIN ACTIVATE BETA-2 ISOFORM OF PHOSPHOLIPASE-C	NATURE			English	Article							ADENYLYL CYCLASE; RECEPTOR	THE activation of heterotrimeric G proteins results in the exchange of GDP bound to the alpha-subunit for GTP and the subsequent dissociation of a complex of the beta- and gamma-subunits (G(betagamma)). The alpha-subunits of different G proteins interact with a variety of effectors1-7, but less is known about the function of the free G(betagamma) complex. G(betagamma) has been implicated in the activation of a cardiac potassium channel8, a retinal phospholipase A2 (ref. 9) and a specific receptor kinase10, and in vitro reconstitution experiments indicate that the G(betagamma) complex can act with G(alpha) subunit to modulate the activity of different isoforms of adenylyl cyclase11. Of two phospholipase activities that can be separated in extracts of HL-60 cells, purified G(betagamma) is found to activate one of them12. Here we report that in co-transfection assays G(betagamma) subunits specifically activate the beta2 and not the beta1 isoform of phospholipase, which acts on phosphatidylinositol. We use transfection assays to show also that receptor-mediated release of G(betagamma) from G proteins that are sensitive to pertussis toxin can result in activation of the phospholipase. This effect may be the basis of the pertussis-toxin-sensitive phospholipase C activation seen in some cell systems (reviewed in refs 13 and 14).	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Katz, Arieh/F-5836-2012					ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DEVIVO M, 1990, ADP RIBOSYLATING TOX, P267; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAGA K, 1992, J BIOL CHEM, V267, P2222; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; LEE CH, 1992, J BIOL CHEM, V267, P16044; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PARK D, 1992, J BIOL CHEM, V267, P16048; PARKER EM, 1991, J BIOL CHEM, V266, P519; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; UI M, 1990, ADP RIBOSYLATING TOX, P45; WU DQ, 1992, J BIOL CHEM, V267, P1811; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	30	466	471	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					686	689		10.1038/360686a0	http://dx.doi.org/10.1038/360686a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465134				2022-12-01	WOS:A1992KD08200061
J	LAWN, RM; WADE, DP; HAMMER, RE; CHIESA, G; VERSTUYFT, JG; RUBIN, EM				LAWN, RM; WADE, DP; HAMMER, RE; CHIESA, G; VERSTUYFT, JG; RUBIN, EM			ATHEROGENESIS IN TRANSGENIC MICE EXPRESSING HUMAN APOLIPOPROTEIN(A)	NATURE			English	Article							LOW-DENSITY-LIPOPROTEIN; ATHEROSCLEROSIS SUSCEPTIBILITY; PLASMINOGEN ACTIVATION; HUMAN AORTA; QUANTIFICATION; LESIONS; FIBRIN; ACCUMULATION; MACROPHAGES; INHIBITION	ELEVATED plasma levels of the lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, myocardial infarction, stroke and restenosis (for reviews, see refs 1-3). Lp(a) differs from low-density lipoprotein by the addition of the glycoprotein apolipoprotein(a), a homologue of plasminogen that contains many tandemly repeated units which resemble the fourth kringle domain of plasminogen, and single homologues of its kringle-5 and protease domain4. As plasma Lp(a) concentration is strongly influenced by heritable factors and is refractory to most drug and dietary manipulation, the effects of modulating it are difficult to mimic experimentally. In addition, the absence of apolipoprotein(a) from virtually all species other than primates precludes the use of convenient animal models. Here we show that transgenic mice expressing human apolipoprotein(a) are more susceptible than control mice to the development of lipid-staining lesions in the aorta, and that apolipoprotein(a) co-localizes with lipid deposition in the artery walls.	UNIV TEXAS,SW MED SCH,HOWARD HUGHES MED INST,DALLAS,TX 75235; LAWRENCE BERKELEY LAB,DIV CELL & MOLEC BIOL,BERKELEY,CA 94720; UNIV TEXAS,SW MED SCH,DEPT MOLEC GENET,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LAWN, RM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CARDIOVASC MED,STANFORD,CA 94305, USA.		Chiesa, Giulia/G-8987-2012	Chiesa, Giulia/0000-0001-5553-1210				BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; CHIESA G, IN PRESS J BIOL CHEM; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MCCONATHY WJ, 1990, FASEB J, V4, pA1019; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; NIENDORF A, 1990, VIRCHOWS ARCH A, V417, P105, DOI 10.1007/BF02190527; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PEPIN JM, 1991, J LIPID RES, V32, P317; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROUY D, 1991, ARTERIOSCLER THROMB, V11, P629, DOI 10.1161/01.ATV.11.3.629; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SALONEN EM, 1989, EMBO J, V8, P4035, DOI 10.1002/j.1460-2075.1989.tb08586.x; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCANU AM, 1991, ANN INTERN MED, V115, P209, DOI 10.7326/0003-4819-115-3-209; SMITH EB, 1990, ATHEROSCLEROSIS, V84, P173, DOI 10.1016/0021-9150(90)90088-Z; STEWARTPHILLIPS JL, 1991, ATHEROSCLEROSIS, V90, P211, DOI 10.1016/0021-9150(91)90117-L; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZIONCHECK TF, 1991, J CLIN INVEST, V87, P767, DOI 10.1172/JCI115079	30	264	273	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					670	672		10.1038/360670a0	http://dx.doi.org/10.1038/360670a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465128				2022-12-01	WOS:A1992KD08200054
J	MOLLON, JD; BOWMAKER, JK				MOLLON, JD; BOWMAKER, JK			THE SPATIAL ARRANGEMENT OF CONES IN THE PRIMATE FOVEA	NATURE			English	Article							COLOR-VISION; MACACA-FASCICULARIS; SENSITIVE CONES; WORLD PRIMATE; PIGMENTS	THE retinae of Old World primates contain three classes of light-sensitive cone, which exhibit peak absorption in different spectral regions1-4. But how are the different types of cone arranged in the hexagonal mosaic of the fovea? This question has often been answered with artists' impressions5-7, but never with direct measurements. Staining for antibodies specific to the short-wave photopigment has revealed a sparse, semiregular array of cones8; but nothing is known about the arrangement of the more numerous long- and middle-wave cones. Are they randomly distributed, with chance aggregations of one type, as Hartridge postulated in these columns nearly 50 years ago9,10? Or do they exhibit a regular alternation, recalling the systematic mosaics seen in some non-mammalian species6,11? Or, conversely, is there positive clumping of particular cone types, as might be expected if local patches of cones were descended from a single precursor cell? We have made direct microspectrophotometric measurements of patches of foveal retina from Old World monkeys, and report here that the distribution of long- and middle-wave cones is locally random. These two cone types are present in almost equal numbers, and not in the ratio of 2:1 that has been postulated for the human fovea.	UNIV LONDON, INST OPHTHALMOL, BATH ST, LONDON EC1V 9EL, ENGLAND	University of London; University College London	MOLLON, JD (corresponding author), UNIV CAMBRIDGE, DEPT EXPTL PSYCHOL, CAMBRIDGE CB2 3EB, ENGLAND.		Mollon, John/C-3520-2009; Mollon, John/U-2631-2019	Mollon, John/0000-0001-8533-033X; Mollon, John/0000-0001-8533-033X				AHNELT PK, 1987, J COMP NEUROL, V255, P18, DOI 10.1002/cne.902550103; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BOWMAKER JK, 1987, VISION RES, V27, P2101, DOI 10.1016/0042-6989(87)90124-6; BOWMAKER JK, 1991, J EXP BIOL, V156, P1; BOWMAKER JK, 1980, J PHYSIOL-LONDON, V298, P131, DOI 10.1113/jphysiol.1980.sp013071; CICERONE CM, 1989, VISION RES, V29, P115, DOI 10.1016/0042-6989(89)90178-8; CURCIO CA, 1991, J COMP NEUROL, V312, P610, DOI 10.1002/cne.903120411; DEMONASTERIO FM, 1981, SCIENCE, V213, P1278, DOI 10.1126/science.7268439; DOBELLE WH, 1969, SCIENCE, V166, P1508, DOI 10.1126/science.166.3912.1508; HAROSI FI, 1987, J GEN PHYSIOL, V89, P717, DOI 10.1085/jgp.89.5.717; HARTRIDGE H, 1947, PHILOS T ROY SOC B, V232, P519, DOI 10.1098/rstb.1947.0004; HARTRIDGE H, 1946, NATURE, V157, P482, DOI 10.1038/157482b0; Hartridge H, 1944, NATURE, V153, P45, DOI 10.1038/153045a0; Knowles A., 1977, PHOTOBIOLOGY VISION; Lennie P., 1991, COMPUTATIONAL MODELS, P71, DOI [10.7551/mitpress/2002.003.0010, DOI 10.7551/MITPRESS/2002.003.0010]; LIEBMAN PA, 1964, J OPT SOC AM, V54, P1451, DOI 10.1364/JOSA.54.001451; Lythgoe J.N., 1979, ECOLOGY VISION; MARC RE, 1977, SCIENCE, V196, P454, DOI 10.1126/science.403607; MOLLON JD, 1989, J EXP BIOL, V146, P21; MOLLON JD, 1984, PROC R SOC SER B-BIO, V222, P373, DOI 10.1098/rspb.1984.0071; POKORNY J, 1991, PIGMENTS PERCEPTION; REID RC, 1992, NATURE, V356, P716, DOI 10.1038/356716a0; WALRAVEN PL, 1974, VISION RES, V14, P1339, DOI 10.1016/0042-6989(74)90007-8; WILLIAMS DR, 1991, PIGMENTS PERCEPTION	24	114	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 17	1992	360	6405					677	679		10.1038/360677a0	http://dx.doi.org/10.1038/360677a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465131				2022-12-01	WOS:A1992KD08200057
J	MOORE, K; WENDON, J; FRAZER, M; KARANI, J; WILLIAMS, R; BADR, K				MOORE, K; WENDON, J; FRAZER, M; KARANI, J; WILLIAMS, R; BADR, K			PLASMA ENDOTHELIN IMMUNOREACTIVITY IN LIVER-DISEASE AND THE HEPATORENAL-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FUNCTIONAL RENAL-FAILURE; VASCULAR-RESPONSES; CIRRHOSIS; VASOCONSTRICTOR; PROSTAGLANDIN-E2; KIDNEY; HEMODYNAMICS; EXCRETION; ASCITES; SODIUM	Background. Severe renal vasoconstriction is central to the pathogenesis of renal failure in the hepatorenal syndrome. Endothelin-1 and endothelin-3 are potent, long-acting vasoconstrictors, and endothelin-1 has selective potency as a renal vasoconstrictor. These properties suggest a role tor endothelins in the hepatorenal syndrome. Methods. We measured plasma endothelin-1 and endothelin-3 concentrations using specific radioimmunoassays in subjects with the hepatorenal syndrome, liver disease but normal renal function, chronic renal failure, acute renal failure, liver dysfunction and renal impairment, or normal liver and kidney function. Results. The patients with the hepatorenal syndrome had markedly elevated mean (+/-SE) plasma concentrations of endothelin-1 (36+/-5 ng per liter [14.5+/-1.8 pmol per liter]) and endothelin-3 (43+/-3 ng per liter [16.3+/-1.0 pmol per liter]) as compared with the normal subjects (endothelin-1, 4+/-1 ng per liter [1.7+/-0.2 pmol per liter]; and endothelin-3, 18+/-1 ng per liter [6.8+/-0.4 pmol per liter]; P<0.001) and with the patients in the other four groups (P<0.001 to P<0.05). The plasma endothelin-1, but not endothelin-3, concentrations in these four patient groups were significantly higher than in the normal subjects (P<0.001 to P<0.05). The concentrations of endothelin-1 in renal arterial plasma and renal venous plasma, measured in five patients with the hepatorenal syndrome and three with chronic liver disease and normal renal function, were 20+/-4 ng per liter (7.9+/-1.8 pmol per liter) and 24+/-4 ng per liter (9.5+/-1.5 pmol per liter), respectively (P<0.05). Conclusions. The increase in plasma endothelin-1 and endothelin-3 concentrations in patients with the hepatorenal syndrome is consistent with the hypothesis that these substances have a role in the pathogenesis of the disease.	UNIV LONDON KINGS COLL, SCH MED & DENT, INST LIVER STUDIES, LONDON WC2R 2LS, ENGLAND; VANDERBILT UNIV, DIV NEPHROL, NASHVILLE, TN 37240 USA; VANDERBILT UNIV, CTR KIDNEY & UROL DIS, NASHVILLE, TN 37240 USA	University of London; King's College London; Vanderbilt University; Vanderbilt University	MOORE, K (corresponding author), ROYAL POSTGRAD MED SCH, DEPT CLIN PHARMACOL, DU CANE RD, LONDON W12 0NN, ENGLAND.			opoku, anita/0000-0001-7243-8157				ARROYO V, 1983, EUR J CLIN INVEST, V13, P271, DOI 10.1111/j.1365-2362.1983.tb00100.x; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BADR KF, 1989, BIOCHEM BIOPH RES CO, V161, P776, DOI 10.1016/0006-291X(89)92667-3; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; CLARKE JG, 1989, AM J PHYSIOL, V257, pH2033, DOI 10.1152/ajpheart.1989.257.6.H2033; EMORI T, 1991, BIOCHEM BIOPH RES CO, V174, P228, DOI 10.1016/0006-291X(91)90510-E; EPSTEIN M, 1987, HEPATOLOGY, V7, P1359, DOI 10.1002/hep.1840070629; EPSTEIN M, 1970, AM J MED, V49, P175, DOI 10.1016/S0002-9343(70)80073-0; FERNANDEZSEARA J, 1989, GASTROENTEROLOGY, V97, P1304, DOI 10.1016/0016-5085(89)91704-6; HEMSEN A, 1991, ACTA PHYSIOL SCAND, V142, P1; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; KAUFMANN H, 1991, LANCET, V338, P1542, DOI 10.1016/0140-6736(91)92370-H; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; MOORE K, 1991, GASTROENTEROLOGY, V100, P1069, DOI 10.1016/0016-5085(91)90284-R; MOORE KP, 1990, J HEPATOL, V11, P263, DOI 10.1016/0168-8278(90)90123-9; MOREAU R, 1989, GASTROEN CLIN BIOL, V13, P978; MUNGER KA, 1991, CONT ISSUES NEPHROL, V23, P297; PERNOW J, 1990, ACTA PHYSIOL SCAND, V140, P311, DOI 10.1111/j.1748-1716.1990.tb09005.x; PERNOW J, 1988, ACTA PHYSIOL SCAND, V134, P573, DOI 10.1111/j.1365-201X.1988.tb10642.x; RIMOLA A, 1986, J HEPATOL, V3, P111, DOI 10.1016/S0168-8278(86)80154-4; RINGLARSEN H, 1977, SCAND J CLIN LAB INV, V37, P635, DOI 10.3109/00365517709100657; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; TOMITA K, 1989, NEW ENGL J MED, V321, P1127; WILKINSON SP, 1978, KIDNEY LIVER DISEASE, P113; ZIPSER RD, 1983, GASTROENTEROLOGY, V84, P697	26	319	325	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1774	1778		10.1056/NEJM199212173272502	http://dx.doi.org/10.1056/NEJM199212173272502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1435931				2022-12-01	WOS:A1992KB97500002
J	NIXON, PA; ORENSTEIN, DM; KELSEY, SF; DOERSHUK, CF				NIXON, PA; ORENSTEIN, DM; KELSEY, SF; DOERSHUK, CF			THE PROGNOSTIC VALUE OF EXERCISE TESTING IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE FATIGUE; FITNESS; MODELS; ADULTS	Background. Previous studies have shown female sex, impaired pulmonary function, older age, malnutrition, and colonization of the respiratory tract by Pseudomonas cepacia to be associated with a poor prognosis in patients with cystic fibrosis. We sought to determine the prognostic value of exercise testing in addition to the other prognostic factors. Methods. A total of 109 patients with cystic fibrosis, 7 to 35 years old, underwent pulmonary-function and exercise testing in the late 1970s. They were followed for eight years to determine the factors associated with subsequent mortality. Survival rates were calculated with standard life-table methods. Cox proportional-hazards regression models were used to determine crude relative risks of mortality and relative risks adjusted tor age, sex, body-mass index, forced expiratory volume in one second (FEV1), end-tidal partial pressure of carbon dioxide (PCO2) at peak exercise, and oxygen consumption at peak exercise (V(O2peak)). Results. Patients with the highest levels of aerobic fitness (V(O2peak), greater-than-or-equal-to 82 percent of predicted) had a survival rate of 83 percent at eight years, as compared with rates of 51 percent and 28 percent for patients with middle (V(O2peak), 59 to 81 percent of predicted) and lowest (V(O2peak), less-than-or-equal-to 58 percent of predicted) levels of fitness, respectively. After adjustment for other risk factors, patients with higher levels of aerobic fitness were more than three times as likely to survive than patients with lower levels of fitness. Colonization by P. cepacia was associated with a risk of dying that was increased fivefold. Age, sex, body-mass index, FEV1, and end-tidal PCO2 at peak exercise were not independently correlated with mortality. Conclusions. Higher levels of aerobic fitness in patients with cystic fibrosis are associated with a significantly lower risk of dying. Although better aerobic fitness may simply be a marker for less severe illness, measurement Of V(O2peak) appears to be valuable for predicting prognosis. Further research is warranted to determine whether improving aerobic fitness through exercise programs will result in a better prognosis.	UNIV PITTSBURGH, DEPT PEDIAT, DIV PULMONOL, PITTSBURGH, PA 15260 USA; CASE WESTERN RESERVE UNIV, DEPT PEDIAT, DIV PULMONOL & CYST FIBROSIS, CLEVELAND, OH 44106 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL35334] Funding Source: Medline; NIDDK NIH HHS [DK27651] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BACEVICE AE, 1976, 29TH P ANN C ENG MED, V18, P39; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; Bouchard C., 1986, SPORT HUMAN GENETICS, P59; COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2; COX DR, 1972, J R STAT SOC B, V34, P187; FLEISS JL, 1981, STATISTICAL METHODS, P138; GASKIN K, 1982, J PEDIATR-US, V100, P857, DOI 10.1016/S0022-3476(82)80501-5; GODFREY S, 1974, EXERCISE TESTING CHI, P30; HUANG NN, 1987, AM J MED, V82, P871, DOI 10.1016/0002-9343(87)90147-1; ISSEKUTZ B, 1962, J APPL PHYSIOL, V17, P47, DOI 10.1152/jappl.1962.17.1.47; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12, P168; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; MACKLEM PT, 1977, CLIN SCI MOL MED, V53, P419, DOI 10.1042/cs0530419; MACLEAN GL, 1985, S AFR J WILDL RES, V15, P1; MURCIANO D, 1984, NEW ENGL J MED, V311, P349, DOI 10.1056/NEJM198408093110601; ORENSTEIN D M, 1991, Respiratory Care, V36, P746; ORENSTEIN DM, 1981, CHEST, V80, P392, DOI 10.1378/chest.80.4.392; ORENSTEIN DM, 1989, CHEST, V95, P344, DOI 10.1378/chest.95.2.344; ORENSTEIN DM, IN PRESS HUMAN KINET; SALH W, 1989, THORAX, V44, P1006, DOI 10.1136/thx.44.12.1006; TABLAN OC, 1985, J PEDIATR-US, V107, P382, DOI 10.1016/S0022-3476(85)80511-4; WAGENER JS, 1989, PERSPECTIVES CYSTIC, P236; ZINMAN R, 1989, J PEDIATR-US, V114, P368, DOI 10.1016/S0022-3476(89)80553-0	25	470	473	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 17	1992	327	25					1785	1788		10.1056/NEJM199212173272504	http://dx.doi.org/10.1056/NEJM199212173272504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB975	1435933				2022-12-01	WOS:A1992KB97500004
J	ROZAKISADCOCK, M; MCGLADE, J; MBAMALU, G; PELICCI, G; DALY, R; LI, W; BATZER, A; THOMAS, S; BRUGGE, J; PELICCI, PG; SCHLESSINGER, J; PAWSON, T				ROZAKISADCOCK, M; MCGLADE, J; MBAMALU, G; PELICCI, G; DALY, R; LI, W; BATZER, A; THOMAS, S; BRUGGE, J; PELICCI, PG; SCHLESSINGER, J; PAWSON, T			ASSOCIATION OF THE SHC AND GRB2/SEM5 SH2-CONTAINING PROTEINS IS IMPLICATED IN ACTIVATION OF THE RAS PATHWAY BY TYROSINE KINASES	NATURE			English	Article							NERVE GROWTH-FACTOR; TRK PROTOONCOGENE; PC12 CELLS; RECEPTOR; DIFFERENTIATION; INHIBITION; AFFINITY; MUTATION; VECTORS	THE mammalian shc gene encodes two overlapping, widely expressed proteins of 46 and 52K, with a carboxy-terminal SH2 domain that binds activated growth factor receptors, and a more amino-terminal glycine/proline-rich region1. These shc gene products (Shc) are transforming when overexpressed in fibroblasts1. Shc proteins become phosphorylated on tyrosine in cells stimulated with a variety of growth factors1, and in cells transformed by v-src (ref. 2), suggesting that they are tyrosine kinase targets that control a mitogenic signalling pathway. Here we report that tyrosine-phosphorylated Shc proteins form a specific complex with a non-phosphorylated 23K polypeptide encoded by the grb2/sem-5 gene3,4. The grb2/sem-5 gene product itself contains an SH2 domain, which mediates binding to Shc, and is implicated in activation of the Ras guanine nucleotide-binding protein by tyrosine kinases in both Caenorhabditis elegans and mammalian cells3,4. Consistent with a role in signalling through Ras, shc overexpression induced Ras-dependent neurite outgrowth in PC12 cells. These results suggest that Shc tyrosine phosphorylation can couple tyrosine kinases to Grb2/Sem-5, through formation of a Shc-Grb2/Sem-5 complex, and thereby regulate the mammalian Ras signalling pathway.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology; University of Toronto; University of Perugia; New York University			Franzeck, Fabian C/B-5055-2011; Daly, Roger J/C-8179-2009; Pawson, Tony J/E-4578-2013; Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255; Daly, Roger/0000-0002-5739-8027				BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO K, 1990, ONCOGENE, V5, P921; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	23	941	978	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 17	1992	360	6405					689	692		10.1038/360689a0	http://dx.doi.org/10.1038/360689a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KD082	1465135				2022-12-01	WOS:A1992KD08200062
J	ALLEN, S; SERUFILIRA, A; BOGAERTS, J; VANDEPERRE, P; NSENGUMUREMYI, F; LINDAN, C; CARAEL, M; WOLF, W; COATES, T; HULLEY, S				ALLEN, S; SERUFILIRA, A; BOGAERTS, J; VANDEPERRE, P; NSENGUMUREMYI, F; LINDAN, C; CARAEL, M; WOLF, W; COATES, T; HULLEY, S			CONFIDENTIAL HIV TESTING AND CONDOM PROMOTION IN AFRICA - IMPACT ON HIV AND GONORRHEA RATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REPRESENTATIVE SAMPLE; CHILDBEARING WOMEN; AIDS; RISK; KNOWLEDGE; RWANDA; ATTITUDES; INFECTION; BEHAVIOR	Objective.-We evaluated the impact of human immunodeficiency virus (HIV) testing and counseling on self-reported condom and spermicide use and on corresponding HIV seroconversion and gonorrhea rates in urban Rwandan women. Design.-Prospective cohort study with 2 years of follow-up, comparison of outcome variables before and after an intervention, and condom use measured in a control group that did not receive the intervention. Setting.-Outpatient research clinic in Kigali, the capital of Rwanda. Participants.-One thousand four hundred fifty-eight childbearing women, 32% of whom were infected with HIV, were enrolled in a prospective study in 1988, and followed at 3- to 6-month intervals for 2 years. Follow-up was available for 95% of subjects at year 1 and 92% at year 2. Interventions.-An acquired immunodeficiency syndrome (AIDS) educational videotape, HIV testing and counseling, and free condoms and spermicide were provided to all participants and interested sexual partners. Main Outcome Measures.-Self-report of compliance with condom-spermicide use and observed incidence of HIV and gonorrhea. Results.-Only 7% of the women reported ever trying condoms before the intervention, but 22% reported condom use with good compliance 1 year later. Women who were HIV-positive were more likely to adopt condom use than HIV-negative women (36% vs 16%; P<.05). Independent predictors of condom use, both in HIV-positive and in HIV-negative women, included HIV testing and counseling of the male partner, having a nonmonogamous relationship, and believing condoms were not dangerous. Human immunodeficiency virus seroconversion rates decreased significantly (from 4.1 to 1.8 per 100 person-years; P<.04) in women whose partners were tested and counseled. The prevalence of gonorrhea decreased substantially (13% to 6%; P<.05) among HIV-positive women, with the greatest reduction among condom users (16% to 4%; P<.05). Conclusion.-A confidential HIV testing and counseling program was associated with increased use of condoms and reduced rates of gonorrhea and HIV in urban Rwandan women. The lack of risk reduction in HIV-negative women whose partner's serostatus was unknown was of concern. Interventions that promote HIV testing and counseling for both members of a couple should be considered in other high-prevalence areas.	WHO,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA 27,SWITZERLAND; PROJET SAN FRANCISCO,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; BELGIAN RWANDAN,KIGALI,RWANDA; MINIST HLTH,NATL AIDS CONTROL PROGRAM,KIGALI,RWANDA	World Health Organization; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALLEN, S (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94105, USA.		Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427	NIAID NIH HHS [R01 AI23980] Funding Source: Medline; NIMH NIH HHS [MH 42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADAMCHAK DJ, 1990, AIDS, V4, P245, DOI 10.1097/00002030-199003000-00011; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, BRIT MED J, V304, P1605, DOI 10.1136/bmj.304.6842.1605; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; ALLEN S, 1988, 14TH INT C AIDS STOC; BAJOS N, 1989, BEH, V11, P42; BECKER MH, 1988, AM J PUBLIC HEALTH, V78, P394, DOI 10.2105/AJPH.78.4.394; BOGAERTS J, 1989, SEX TRANSM DIS, V16, P123, DOI 10.1097/00007435-198907000-00001; Bradbeer C, 1990, Int J STD AIDS, V1, P233; CARAEL M, 1988, AIDS, V2, P201; CARAEL M, 1988, AIDS HLTH PROMOTION, P6; CARBALLO M, 1989, J SEX RES, V26, P287, DOI 10.1080/00224498909551516; CLEARY PD, 1991, AM J PUBLIC HEALTH, V81, P1586, DOI 10.2105/AJPH.81.12.1586; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; COATES TJ, 1988, AIDS, V2, pS239, DOI 10.1097/00002030-198800001-00037; COCHRAN SD, 1991, SOC SCI MED, V33, P25, DOI 10.1016/0277-9536(91)90447-K; FORSTER SJ, 1989, AIDS, V3, P147, DOI 10.1097/00002030-198903000-00005; GILLIES P, 1990, AIDS, V4, P943, DOI 10.1097/00002030-199010000-00001; GOLDBERG HI, 1989, B WORLD HEALTH ORGAN, V67, P85; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; KEGELES SM, 1990, AIDS, V4, P585, DOI 10.1097/00002030-199006000-00016; Kizer K. W., 1990, AIDS and Public Policy Journal, V5, P24; KONDELULE JK, 1989, AIDS, V3, P513, DOI 10.1097/00002030-198908000-00005; KREISS J, 1989, 5TH INT C AIDS MONTR; LINDAN C, 1991, AIDS, V5, P993, DOI 10.1097/00002030-199108000-00011; MANN J, 1987, NEW ENGL J MED, V316, P345; MAY JF, 1990, STUD FAMILY PLANN, V21, P20, DOI 10.2307/1966588; MBIZVO MT, 1989, CENT AFR J MED, V35, P519; MCKUSICK L, 1990, AM J PUBLIC HEALTH, V80, P978, DOI 10.2105/AJPH.80.8.978; MUSKA S, 1990, 6TH INT C AIDS SAN F; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; RWANDAN HIV, 1989, LANCET, V1, P941; SHEON A, 1989, 4TH INT C AIDS ASS C; SOLOMON MZ, 1989, AM J PUBLIC HEALTH, V79, P453, DOI 10.2105/AJPH.79.4.453; VANDEPERRE P, 1987, AIDS, V1, P207; Vermund Sten H., 1990, Annals of Epidemiology, V1, P141, DOI 10.1016/1047-2797(90)90005-D; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WILSON D, 1990, SOC SCI MED, V31, P609, DOI 10.1016/0277-9536(90)90097-C; WILSON D, 1988, CENT AFR J MED, V34, P95; WOFSY CB, 1988, WESTERN J MED, V149, P687; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238; 1990, MMWR, V39, P137; 1990, WHO AIDS SERIES, V8	45	199	199	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3338	3343		10.1001/jama.268.23.3338	http://dx.doi.org/10.1001/jama.268.23.3338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KB732	1453526				2022-12-01	WOS:A1992KB73200026
J	BARRETTCONNOR, E; HOLBROOK, TL				BARRETTCONNOR, E; HOLBROOK, TL			SEX-DIFFERENCES IN OSTEOPOROSIS IN OLDER ADULTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; ISCHEMIC-HEART-DISEASE; POSTMENOPAUSAL WOMEN; RISK-FACTORS; MEN; MASS; CALCIUM; STEROIDS; HORMONES; PREMENOPAUSAL	Objective.-To describe the association of non-insulin-dependent diabetes mellitus (NIDDM) with bone mineral density (BMD). Design.-A survey of men and women from an established epidemiologic cohort who were separately screened for diabetes by oral glucose tolerance test between 1984 and 1987 and for osteopenia by BMD measured in 1988-1989. Setting.-A community-based population of older adults, Rancho Bernardo, Calif. Participants.-The first 627 consecutively seen white men and women aged 55 to 88 years. Main Outcome Measures.-Bone density measured by single photon absorptiometry at the ultradistal wrist and midradius and by dual x-ray absorptiometry at the femoral neck and lumbar spine. Main Results.-Among the 236 men and 391 women, whose average age was 72 years, 41 men and 39 women had NIDDM, 56 men and 110 women had impaired glucose tolerance, and 139 men and 242 women had normal glucose tolerance. Men with diabetes had BMD levels similar to those men with normal glucose tolerance, whereas women with diabetes had significantly higher BMD levels at all sites than women with normal glucose tolerance. The increased bone density in diabetic women was unexplained by age, obesity, cigarette smoking, alcohol intake, regular physical activity, and the use of diuretics and estrogen. The multiply adjusted mean BMD in women with NIDDM compared with normoglycemic women was 0.600 g/cm2 vs 0.548 g/cm2 at the midradius; 0.265 g/cm2 vs 0.230 g/cm2 at the ultradistal wrist; 0.654 g/cm2 vs 0.610 g/cm2 at the femoral neck; and 0.962 g/cm2 vs 0.859 g/cm2 at the spine. The sex differences were unexplained by survivor bias, prior obesity, or duration of diabetes. Differences were seen in women (but not men) whose diabetes was first detected at the screening evaluation, ie, before drug or dietary treatment. Similarly, in women (but not men) without diabetes increasing BMD levels at all four sites were associated with increasing postchallenge glucose levels independent of age and body mass index. Conclusions.-Older women with NIDDM or hyperglycemia had better BMD than women with normal glucose tolerance, independent of differences in obesity and many other risk factors. No differences in bone density by diabetic status were observed in men. We hypothesize that the sex differences may be explained by the greater androgenicity reported in women with hyperglycemic and hyperinsulinemic conditions.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT COMMUNITY & FAMILY MED,9500 GILLMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; ANDO S, 1984, J ENDOCRINOL INVEST, V7, P21, DOI 10.1007/BF03348370; AUWERX J, 1988, DIABETES, V37, P8, DOI 10.2337/diabetes.37.1.8; BARRETTCONNOR E, 1990, AM J EPIDEMIOL, V132, P895, DOI 10.1093/oxfordjournals.aje.a115732; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BENNETT AE, 1984, J CLIN ENDOCR METAB, V59, P70; BRODY S, 1987, ACTA OBSTET GYN SCAN, V66, P357, DOI 10.3109/00016348709103653; DAVIDSON BJ, 1983, OBSTET GYNECOL, V61, P275; DELEEUW I, 1977, DIABETES, V26, P1130, DOI 10.2337/diabetes.26.12.1130; DEUTSCH S, 1987, INT J GYNECOL OBSTET, V25, P217, DOI 10.1016/0020-7292(87)90238-4; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FORESTA C, 1984, HORM RES, V19, P18, DOI 10.1159/000179855; FRANCIS RM, 1986, BONE, V7, P261, DOI 10.1016/8756-3282(86)90205-X; GARG A, 1990, J CLIN ENDOCR METAB, V70, P1007, DOI 10.1210/jcem-70-4-1007; GIACCA A, 1988, BONE, V9, P29, DOI 10.1016/8756-3282(88)90024-5; GREENSPAN SL, 1989, ANN INTERN MED, V110, P526, DOI 10.7326/0003-4819-110-7-526; HAFFNER SM, 1988, METABOLISM, V37, P683, DOI 10.1016/0026-0495(88)90091-1; HEATH H, 1979, J CLIN ENDOCR METAB, V49, P462, DOI 10.1210/jcem-49-3-462; HEATH H, 1980, NEW ENGL J MED, V303, P567, DOI 10.1056/NEJM198009043031008; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; ISAIA G, 1987, ACTA DIABETOL LAT, V24, P305, DOI 10.1007/BF02742962; JOHNSTON CC, 1985, METABOLISM, V34, P544, DOI 10.1016/0026-0495(85)90192-1; KELLY PJ, 1990, BRIT MED J, V300, P1361, DOI 10.1136/bmj.300.6736.1361; KHAW KT, 1991, CLIN SCI, V80, P199, DOI 10.1042/cs0800199; Kissebah AHK, 1985, METABOLIC COMPLICATI, P115; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; LEVY J, 1986, CALCIFIED TISSUE INT, V39, P316, DOI 10.1007/BF02555197; LICHTENSTEIN MJ, 1987, AM J EPIDEMIOL, V126, P647, DOI 10.1093/oxfordjournals.aje.a114704; MARSHALL DH, 1977, BRIT MED J, V2, P1177, DOI 10.1136/bmj.2.6096.1177; MCNAIR P, 1988, DAN MED BULL, V35, P109; MEEMA HE, 1967, CAN MED ASSOC J, V96, P132; MEIER DE, 1987, J AM GERIATR SOC, V35, P189, DOI 10.1111/j.1532-5415.1987.tb02308.x; PEDRAZZONI M, 1989, CALCIFIED TISSUE INT, V45, P331, DOI 10.1007/BF02556002; RICO H, 1989, CALCIFIED TISSUE INT, V45, P71, DOI 10.1007/BF02561404; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RINGE JD, 1976, AM J ROENTGENOL, V126, P1300, DOI 10.2214/ajr.126.6.1300; SCHEIDTNAVE C, 1991, MAY SAN DIEG EP RES; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SELBY PL, 1988, DIABETIC MED, V5, P423, DOI 10.1111/j.1464-5491.1988.tb01021.x; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SORENSEN OH, 1986, DIABETES 1985, P754; STANLEY HL, 1991, J AM GERIATR SOC, V39, P766, DOI 10.1111/j.1532-5415.1991.tb02698.x; STEINBERG KK, 1989, J CLIN ENDOCR METAB, V69, P533, DOI 10.1210/jcem-69-3-533; Verstraeten A, 1991, CLIN ORTHOP RELAT R, V264, P169; WEINSTOCK RS, 1989, J BONE MINER RES, V4, P97; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WINGARD D L, 1990, Diabetes Care, V13, P3; World Health Organization, 1985, DIAB MELL REP WHO ST, V727	49	147	155	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3333	3337						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1453525				2022-12-01	WOS:A1992KB73200025
J	DAGAN, R; ENGLEHARD, D; PICCARD, E				DAGAN, R; ENGLEHARD, D; PICCARD, E			EPIDEMIOLOGY OF INVASIVE CHILDHOOD PNEUMOCOCCAL INFECTIONS IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; SEROTYPE DISTRIBUTION; BACTERIAL-MENINGITIS; ANTIMICROBIAL RESISTANCE; POLYSACCHARIDE VACCINE; CEREBROSPINAL-FLUID; CHARLESTON COUNTY; RESPIRATORY-TRACT; SOUTH-CAROLINA; UNITED-STATES	Objective.-To study the epidemiology of childhood pneumococcal invasive infections in Israel as a background for immunization programs. Design.-A 2-year (October 1988 through September 1990) prospective, nationwide surveillance of all invasive pediatric pneumococcal infections. Setting.-All 25 medical centers hospitalizing children in Israel, including all laboratories performing blood cultures from pediatric patients. Patients.-Infants and children aged 0 to 12 years visiting the pediatric emergency department or hospitalized in pediatric departments were included if Streptococcus pneumoniae was isolated from blood or cerebrospinal fluid. Results.-Four hundred sixty-nine invasive infections were diagnosed. Pneumonia, bacteremia without apparent focus, meningitis, and cellulitis were found in 39%, 37%, 17%, and 3%, respectively. The annual incidence was 42 per 100 000 for children younger than 5 years of age (104 per 100 000 for those <12 months old). The two most common serotypes were 1 and 5, which are rare in Western 'Europe and North America. Eight groups comprised 82% of all invasive infections. Extrapolated to a population in which 100 000 live births occur yearly, the total annual hospitalizations for pneumococci infections was calculated to be 1928 days. The overall case-fatality rate was 2.2%, but it was 30% during the first month of life. Conclusions.-Pneumococcal invasive infections are common in children in Israel and carry considerable morbidity.	HADASSAH MED CTR,DEPT PEDIAT,JERUSALEM,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84105 BEER SHEVA,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Ben Gurion University	DAGAN, R (corresponding author), BEN GURION UNIV NEGEV,PEDIAT INFECT DIS UNIT,SOROKA MED CTR,POB 151,IL-84105 BEER SHEVA,ISRAEL.							ANDERSEN AH, 1989, IEEE T MED IMAGING, V8, P50, DOI 10.1109/42.20361; AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; BAIRD DR, 1976, LANCET, V2, P1344; BARKER J, 1989, J INFECT DIS, V159, P348, DOI 10.1093/infdis/159.2.348; Baron EJ, 1990, BAILEY SCOTTS DIAGNO, P333; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRIMBLECOMBE FSW, 1958, BRIT MED J, V1, P119, DOI 10.1136/bmj.1.5063.119; BURKE JP, 1971, AM J DIS CHILD, V121, P353, DOI 10.1001/archpedi.1971.02100150127021; BURMAN LA, 1986, SCAND J INFECT DIS, V18, P45, DOI 10.3109/00365548609032305; BURMAN LA, 1985, REV INFECT DIS, V7, P133; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; FENOLL A, 1991, REV INFECT DIS, V13, P56; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; GIEBINK GS, 1985, PEDIATR INFECT DIS J, V4, P343, DOI 10.1097/00006454-198507000-00001; GRAY BM, 1979, J INFECT DIS, V140, P979, DOI 10.1093/infdis/140.6.979; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; GREENWOOD BM, 1980, LANCET, V1, P360; GUIRGUIS N, 1983, B WORLD HEALTH ORGAN, V61, P517; ISTRE GR, 1987, J INFECT DIS, V156, P732, DOI 10.1093/infdis/156.5.732; JACOBS NM, 1979, PEDIATRICS, V64, P296; JETTE LP, 1989, J CLIN MICROBIOL, V27, P1; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KLUGMAN KP, 1988, J INFECT DIS, V158, P956, DOI 10.1093/infdis/158.5.956; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; LAFONG AC, 1988, J INFECTION, V16, P235, DOI 10.1016/S0163-4453(88)97556-1; LEIONEN M, 1986, PEDIAT INFECT DIS, V5, P39; LODA FA, 1975, J PEDIATR-US, V87, P1087, DOI 10.1016/S0022-3476(75)80120-X; LUND E, 1970, ACTA PATHOLOG MICROB, V78, P333; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; MUFSON MA, 1982, JAMA-J AM MED ASSOC, V248, P1486, DOI 10.1001/jama.248.12.1486; ONYEMELUKWE GC, 1983, J INFECTION, V5, P157; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; ROGOT E, 1976, AM J EPIDEMIOL, V103, P198, DOI 10.1093/oxfordjournals.aje.a112218; SARNAIK S, 1990, PEDIATR INFECT DIS J, V9, P181, DOI 10.1097/00006454-199003000-00007; SCHLECH WF, 1985, JAMA-J AM MED ASSOC, V253, P1749, DOI 10.1001/jama.253.12.1749; SCHWARZMANN SW, 1971, ARCH INTERN MED, V127, P1037, DOI 10.1001/archinte.127.6.1037; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; STATES SJ, 1977, INT J BIOMETEOROL, V21, P7, DOI 10.1007/BF01552962; TAKALA AK, 1992, 8TH ANN M EUR SOC PE; VERHAEGEN J, 1990, EUR J CLIN MICROBIOL, V9, P390, DOI 10.1007/BF01979467; 1991, PEDIATRICS, V88, P169; 1989, STATISTICAL ABSTRACT	44	147	154	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3328	3332		10.1001/jama.268.23.3328	http://dx.doi.org/10.1001/jama.268.23.3328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1364814				2022-12-01	WOS:A1992KB73200024
J	ESKOLA, J; TAKALA, AK; KELA, E; PEKKANEN, E; KALLIOKOSKI, R; LEINONEN, M				ESKOLA, J; TAKALA, AK; KELA, E; PEKKANEN, E; KALLIOKOSKI, R; LEINONEN, M			EPIDEMIOLOGY OF INVASIVE PNEUMOCOCCAL INFECTIONS IN CHILDREN IN FINLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPSULAR POLYSACCHARIDE VACCINE; STREPTOCOCCUS-PNEUMONIAE; ANTIBODY-RESPONSE; CONJUGATE VACCINE; B DISEASE; CHARLESTON COUNTY; SOUTH-CAROLINA; NEW-GUINEA; BACTEREMIA; INFANTS	Objective.-To study the epidemiologic characteristics of invasive infections in children caused by Streptococcus pneumoniae to provide background data for vaccination programs. Design.-A nationwide laboratory-based prospective surveillance of all invasive pneumococcal infections in children during 1985 through 1989. Setting.-A network of all microbiologic laboratories and pediatric wards in Finland. Patients.-Children aged 0 to 15 years who were admitted to a hospital with S pneumoniae isolated from blood, cerebrospinal fluid, or deep aspirate sample. Results.-Four hundred fifty-two invasive pneumococcal infections were diagnosed in 1985 through 1989. The annual incidence rate was 8.9 per 100 000 children less than 16 years of age (24.2 per 100 000 among children less than 5 years of age and 45.3 per 100 000 among those less than 2 years of age). The most common clinical entities were bacteremia without focus (310 cases), pneumonia (66 cases), and meningitis (51 cases), with other focal infections seen in 25 cases. The pneumococcal groups/types 14, 6, 19, 7, 18, and 23 comprised 78% of all invasive infections. Conclusions.-Streptococcus pneumoniae is a common cause of invasive infections in children in Finland. A pneumococcal conjugate vaccine containing the six most common groups/types could prevent up to 70% of invasive pneumococcal infections of children in Finland if fully protective in infancy.	NATL PUBL HLTH INST,DEPT BACTERIAL & RESP INFECT,SF-00280 HELSINKI 28,FINLAND	Finland National Institute for Health & Welfare	ESKOLA, J (corresponding author), NATL PUBL HLTH INST,DEPT INFECT DIS EPIDEMIOL,SF-00280 HELSINKI 28,FINLAND.							ANDERSEN AH, 1989, IEEE T MED IMAGING, V8, P50, DOI 10.1109/42.20361; BARKER J, 1989, J INFECT DIS, V159, P348, DOI 10.1093/infdis/159.2.348; BARRY MA, 1984, J INFECT DIS, V149, P449, DOI 10.1093/infdis/149.3.449; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BRILES DE, 1992, INFECT IMMUN, V60, P111, DOI 10.1128/IAI.60.1.111-116.1992; BURKE JP, 1971, AM J DIS CHILD, V121, P353, DOI 10.1001/archpedi.1971.02100150127021; BURMAN LA, 1985, REV INFECT DIS, V7, P133; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; DOUGLAS RM, 1983, J INFECT DIS, V148, P131, DOI 10.1093/infdis/148.1.131; ENGELHARD D, 1991, 31ST INT C ANT AG CH; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FATTOM A, 1990, INFECT IMMUN, V58, P2309, DOI 10.1128/IAI.58.7.2309-2312.1990; FILICE GA, 1980, AM J EPIDEMIOL, V112, P828, DOI 10.1093/oxfordjournals.aje.a113055; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; GUIRGUIS N, 1983, B WORLD HEALTH ORGAN, V61, P517; HANSMAN D, 1977, AUST NZ J MED, V7, P267, DOI 10.1111/j.1445-5994.1977.tb03684.x; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KOSKELA M, 1986, PEDIATR INFECT DIS J, V5, P45, DOI 10.1097/00006454-198601000-00009; LEINONEN M, 1986, PEDIATR INFECT DIS J, V5, P39, DOI 10.1097/00006454-198601000-00008; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MURPHY TV, 1991, 31ST INT C ANT AG CH; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016; ONYEMELUKWE GC, 1982, J INFECTION, V5, P157, DOI 10.1016/S0163-4453(82)91772-8; RILEY ID, 1986, LANCET, V2, P877; RILEY ID, 1977, LANCET, V1, P1338; RILEY ID, 1991, REV INFECT DIS, V13, P535; ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821; ROBBINS JB, 1983, J INFECT DIS, V148, P1136, DOI 10.1093/infdis/148.6.1136; SARNAIK S, 1990, PEDIATR INFECT DIS J, V9, P181, DOI 10.1097/00006454-199003000-00007; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; WEINBERG GA, 1988, J PEDIATR-US, V113, P621, DOI 10.1016/S0022-3476(88)80369-X; 1989, PEDIATR INFECT DIS J, V8, P21; 1985, NEW VACCINE DEV ESTA, V2, P44	36	201	214	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3323	3327		10.1001/jama.268.23.3323	http://dx.doi.org/10.1001/jama.268.23.3323			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1453524				2022-12-01	WOS:A1992KB73200023
J	STEINHART, R; REINGOLD, AL; TAYLOR, F; ANDERSON, G; WENGER, JD				STEINHART, R; REINGOLD, AL; TAYLOR, F; ANDERSON, G; WENGER, JD			INVASIVE HAEMOPHILUS-INFLUENZAE INFECTIONS IN MEN WITH HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; INTRAVENOUS DRUG-USERS; HEMOPHILUS-INFLUENZAE; BACTERIAL PNEUMONIA; AIDS; BACTEREMIA; ADULTS; SURVEILLANCE; DISEASE	Objective.-To determine the incidence of invasive Haemophilus influenzae disease in men with the acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV) infection and the proportion of disease due to serotype b. Design.-Population-based, active surveillance. Setting.-San Francisco (Calif) Department of Health. Participants.-All men 20 to 49 years of age with invasive H influenzae disease. Results.-The cumulative incidences of invasive H influenzae disease in men 20 to 49 years of age with AIDS and in HIV-infected men 20 to 49 years of age without AIDS were 79.2 and 14.6 per 100 000, respectively, but only 33% of cases were due to serotype b. The corresponding rates for invasive H influenzae b disease were 11.3 and 7.6 per 100 000. Conclusions.-Men with AIDS or HIV infection are at increased risk of invasive H influenzae infections, including H influenzae b, but such infections are still infrequent in this population.	UNIV CALIF BERKELEY,SCH PUBL HLTH,EPIDEMIOL PROGRAM,140 WARREN HALL,BERKELEY,CA 94720; BUR EPIDEMIOL & DIS CONTROL,SAN FRANCISCO,CA; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL,DEPT HLTH,ATLANTA,GA 30333	University of California System; University of California Berkeley; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BERNSTEIN LJ, 1985, PEDIATR INFECT DIS J, V4, P472, DOI 10.1097/00006454-198509000-00005; FARLEY MM, 1992, ANN INTERN MED, V116, P806, DOI 10.7326/0003-4819-116-10-806; GRANOFF DM, 1980, J INFECT DIS, V141, P40, DOI 10.1093/infdis/141.1.40; HECHT FM, 1991, NEW ENGL J MED, V326, P1569; MUSHER DM, 1983, ANN INTERN MED, V99, P444, DOI 10.7326/0003-4819-99-4-444; PELTOLA H, 1990, REV INFECT DIS, V12, P708; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; ROLSTON KVI, 1987, AM J MED, V83, P604, DOI 10.1016/0002-9343(87)90789-3; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SCHUCHAT A, 1991, JAMA-J AM MED ASSOC, V265, P3275, DOI 10.1001/jama.265.24.3275; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SIMBERKOFF M, 1989, 29TH INT C ANT AG CH, P174; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WALLACE RJ, 1981, J INFECT DIS, V144, P101, DOI 10.1093/infdis/144.2.101; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WHIMBEY E, 1986, ANN INTERN MED, V104, P511, DOI 10.7326/0003-4819-104-4-511; WHITE S, 1985, CHEST, V87, P486, DOI 10.1378/chest.87.4.486; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; 1988, MMWR, V37, P593	24	74	75	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1992	268	23					3350	3352						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB732	1453528				2022-12-01	WOS:A1992KB73200028
J	BERKMAN, LF; LEOSUMMERS, L; HORWITZ, RI				BERKMAN, LF; LEOSUMMERS, L; HORWITZ, RI			EMOTIONAL SUPPORT AND SURVIVAL AFTER MYOCARDIAL-INFARCTION - A PROSPECTIVE, POPULATION-BASED STUDY OF THE ELDERLY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; SOCIAL SUPPORT; ACTIVITIES OF DAILY LIVING; OUTCOME ASSESSMENT (HEALTH CARE); COMORBIDITY	SUDDEN CARDIAC DEATH; CORONARY HEART-DISEASE; SOCIAL SUPPORT; MULTIVARIATE-ANALYSIS; MORTALITY; PROGNOSIS; HEALTH; MEN; DETERMINANTS; ATTACK	Objective: To compare the survival of elderly patients hospitalized for acute myocardial infarction who have emotional support with that of patients who lack such support, while controlling for severity of disease, comorbidity, and functional status. Design: A prospective, community-based cohort study. Setting: Two hospitals in New Haven, Connecticut. Patients: Men (n = 100) and women (n = 94) 65 years of age or more hospitalized for acute myocardial infarction between 1982 and 1988. Measurements: Social support, age, gender, race, education, marital status, living arrangements, presence of depression, smoking history, weight, and physical function were assessed prospectively using questionnaires. The presence of congestive heart failure, pulmonary edema, and cardiogenic shock; the position of infarction; in-hospital complications; and history of myocardial infarction were assessed using medical records. Comorbidity was defined using an index based on the presence of eight conditions. Results: Of 194 patients, 76 (39%) died in the first 6 months after myocardial infarction. In multiple logistic regression analyses, lack of emotional support was significantly associated with 6-month mortality (odds ratio, 2.9; 95% Cl, 1.2 to 6.9) after controlling for severity of myocardial infarction, comorbidity, risk factors such as smoking and hypertension, and sociodemographic factors. Conclusions: When emotional support was assessed before myocardial infarction, it was independently related to risk for death in the subsequent 6 months.			BERKMAN, LF (corresponding author), YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, 60 COLL ST, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE ON AGING [N01AG002105] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02105] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERKMAN L, 1989, DEMOGRAPHY, V26, P661, DOI 10.2307/2061264; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BLAZER DG, 1982, AM J EPIDEMIOL, V115, P684, DOI 10.1093/oxfordjournals.aje.a113351; BRACKETT CD, 1988, AM J CARDIOL, V61, P979, DOI 10.1016/0002-9149(88)90110-5; CASE RB, 1992, JAMA-J AM MED ASSOC, V267, P515, DOI 10.1001/jama.267.4.515; Charlson ME, 1984, J CHRON DIS, V37, P369; COHEN S, 1988, HEALTH PSYCHOL, V7, P269, DOI 10.1037/0278-6133.7.3.269; CROOG SM, 1977, HEART PATIENT RECOVE; HARRELL FE, 1986, PHGLM PROCEDURE SUGI, P437; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; KAPLAN GA, 1988, AM J EPIDEMIOL, V128, P370, DOI 10.1093/oxfordjournals.aje.a114977; KAPLAN JR, 1982, ARTERIOSCLEROSIS, V2, P359, DOI 10.1161/01.ATV.2.5.359; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KRANTZ DS, 1980, J HUM STRESS, V6, P27, DOI 10.1080/0097840X.1980.9936096; LOWN B, 1987, CIRCULATION, V76, P186; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MAYOU R, 1984, J PSYCHOSOM RES, V28, P17, DOI 10.1016/0022-3999(84)90036-9; MEDALIE JH, 1976, AM J MED, V60, P910, DOI 10.1016/0002-9343(76)90921-9; MERMELSTEIN R, 1986, J CONSULT CLIN PSYCH, V54, P447, DOI 10.1037/0022-006X.54.4.447; NEREM RM, 1980, SCIENCE, V208, P1475, DOI 10.1126/science.7384790; ORTHGOMER K, 1987, J CHRON DIS, V40, P949, DOI 10.1016/0021-9681(87)90145-7; POWELL LH, 1985, J CHRON DIS, V38, P253, DOI 10.1016/0021-9681(85)90068-2; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; RUBERMAN W, 1983, J CHRON DIS, V36, P151, DOI 10.1016/0021-9681(83)90089-9; RUBERMAN W, 1992, JAMA-J AM MED ASSOC, V267, P559, DOI 10.1001/jama.267.4.559; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SEEMAN TE, 1987, PSYCHOSOM MED, V49, P341, DOI 10.1097/00006842-198707000-00003; SEEMAN TE, 1987, AM J EPIDEMIOL, V126, P714, DOI 10.1093/oxfordjournals.aje.a114711; SEEMAN TE, 1988, SOC SCI MED, V26, P737, DOI 10.1016/0277-9536(88)90065-2; SEEMAN TE, IN PRESS ANN EPIDEMI; SOKOLOW M, 1987, CLIN CARDIOLOGY; WELIN L, 1985, LANCET, V1, P915; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; 1971, WHO5TH REP	38	581	586	0	34	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					1003	1009		10.7326/0003-4819-117-12-1003	http://dx.doi.org/10.7326/0003-4819-117-12-1003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443968				2022-12-01	WOS:A1992KB98000005
J	BIKKINA, M; LARSON, MG; LEVY, D				BIKKINA, M; LARSON, MG; LEVY, D			PROGNOSTIC IMPLICATIONS OF ASYMPTOMATIC VENTRICULAR ARRHYTHMIAS - THE FRAMINGHAM HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						EXTRASYSTOLE; CORONARY DISEASE; ARRHYTHMIA; MYOCARDIAL INFARCTION	ACUTE MYOCARDIAL-INFARCTION; SUDDEN-DEATH; HEALTHY-SUBJECTS; DISEASE; HYPERTROPHY; FREQUENT; COMPLEX; ECTOPY; RISK; MASS	Objective: To evaluate the prevalence and prognostic significance of asymptomatic complex or frequent ventricular premature beats detected during ambulatory electrocardiographic (ECG) monitoring. Design: Cohort study with a follow-up period of 4 to 6 years. Setting: Population-based. Participants: Surviving patients of the original Framingham Heart Study cohort and offspring of original cohort members (2727 men and 3306 women). Measurements: One-hour ambulatory electrocardiography. Results: The age-adjusted prevalence of complex or frequent arrhythmia (more than 30 ventricular premature complexes per hour or multiform premature complexes, ventricular couplets, ventricular tachycardia, or R-on-T ventricular premature complexes) was 12% (95% Cl, 11% to 13%) in the 2425 men without clinically evident coronary heart disease and 33% (Cl, 24% to 42%) in the 302 men with coronary heart disease. The corresponding values in women (3064 without disease and 242 with disease) were 12% (Cl, 11 % to 13%) and 26% (Cl, 9% to 43%). After adjusting for age and traditional risk factors for coronary heart disease in a Cox proportional hazards model, men without coronary heart disease who had complex or frequent ventricular arrhythmias were at increased risk for both all-cause mortality (relative risk, 2.30; Cl, 1.65 to 3.20) and the occurrence of myocardial infarction or death from coronary heart disease (relative risk, 2.12; Cl, 1.33 to 3.38). In men with coronary heart disease and in women with and without coronary heart disease, complex or frequent arrhythmias were not associated with an increased risk for either outcome. Conclusions: In men who do not have clinically apparent coronary heart disease, the incidental detection of ventricular arrhythmias is associated with a twofold increase in the risk for all-cause mortality and myocardial infarction or death due to coronary heart disease. The preventive and therapeutic implications of these findings await further investigation.	FRAMINGHAM HEART DIS EPIDEMIOL STUDY, 5 THURBER ST, FRAMINGHAM, MA 01701 USA; NHLBI, BETHESDA, MD 20892 USA; BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Harvard University; Beth Israel Deaconess Medical Center			Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254				[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1973, JAMA, V223, P1116; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BIGGER JT, 1977, PROG CARDIOVASC DIS, V19, P255, DOI 10.1016/0033-0620(77)90005-6; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CATS VM, 1979, AM J CARDIOL, V44, P1257, DOI 10.1016/0002-9149(79)90438-7; CHIANG BN, 1969, ANN INTERN MED, V70, P1159, DOI 10.7326/0003-4819-70-6-1159; CONNOLLY SJ, 1992, AM J CARDIOL, V69, P308, DOI 10.1016/0002-9149(92)90225-N; Dawber, 1959, J CHRON DIS, V10, P186, DOI 10.1016/0021-9681(59)90002-5; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DESOYZA N, 1978, AM J MED, V64, P377, DOI 10.1016/0002-9343(78)90215-2; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; ELKON KB, 1977, S AFR MED J, V52, P564; FEIGENBAUM H, 1981, ECHOCARDIOGR-J CARD, P51; FISHER FD, 1973, CIRCULATION, V47, P712, DOI 10.1161/01.CIR.47.4.712; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; HORAN MJ, 1984, JAMA-J AM MED ASSOC, V251, P380; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KENNEDY HL, 1980, ANN INTERN MED, V92, P179, DOI 10.7326/0003-4819-92-2-179; KENNEDY HL, 1976, AM J CARDIOL, V38, P141, DOI 10.1016/0002-9149(76)90140-5; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KOPPES GM, 1980, AM J CARDIOL, V46, P322, DOI 10.1016/0002-9149(80)90079-X; KOTLER MN, 1973, CIRCULATION, V47, P959, DOI 10.1161/01.CIR.47.5.959; LEVY D, 1988, AM J CARDIOL, V62, P147, DOI 10.1016/0002-9149(88)91383-5; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1987, AM J CARDIOL, V59, P836, DOI 10.1016/0002-9149(87)91102-7; LEVY D, 1987, AM J CARDIOL, V60, P560, DOI 10.1016/0002-9149(87)90305-5; LICHSTEIN E, 1983, CIRCULATION, V67, P5; LIE KI, 1975, CIRCULATION, V52, P755, DOI 10.1161/01.CIR.52.5.755; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MIALL WE, 1983, BMJ-BRIT MED J, V287, P1249; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSS AJ, 1974, CIRCULATION, V49, P460, DOI 10.1161/01.CIR.49.3.460; MOSS AJ, 1980, PROG CARDIOVASC DIS, V23, P33, DOI 10.1016/0033-0620(80)90004-3; OLSSON G, 1984, CIRCULATION, V69, P1129, DOI 10.1161/01.CIR.69.6.1129; PELL S, 1961, JAMA-J AM MED ASSOC, V175, P463, DOI 10.1001/jama.1961.03040060037008; RABKIN SW, 1981, AM HEART J, V101, P135, DOI 10.1016/0002-8703(81)90655-4; RODSTEIN M, 1971, CIRCULATION, V44, P617, DOI 10.1161/01.CIR.44.4.617; RUBERMAN W, 1977, NEW ENGL J MED, V297, P750, DOI 10.1056/NEJM197710062971404; SWERDLOW CD, 1983, NEW ENGL J MED, V308, P1436, DOI 10.1056/NEJM198306163082402; TALAJIC M, 1991, CAN J CARDIOL, V7, P96; 1991, SAS P217 SAS I INC T; 1989, SAS STAT USERS GUIDE, V1; [No title captured]	51	147	155	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					990	996		10.7326/0003-4819-117-12-990	http://dx.doi.org/10.7326/0003-4819-117-12-990			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1280018				2022-12-01	WOS:A1992KB98000003
J	GINSBURG, KS; LIANG, MH; NEWCOMER, L; GOLDHABER, SZ; SCHUR, PH; HENNEKENS, CH; STAMPFER, MJ				GINSBURG, KS; LIANG, MH; NEWCOMER, L; GOLDHABER, SZ; SCHUR, PH; HENNEKENS, CH; STAMPFER, MJ			ANTICARDIOLIPIN ANTIBODIES AND THE RISK FOR ISCHEMIC STROKE AND VENOUS THROMBOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						ANTIBODIES, ANTICARDIOLIPIN; CEREBROVASCULAR DISORDERS; THROMBOPHLEBITIS; PULMONARY EMBOLISM; LUPUS ERYTHEMATOSUS, SYSTEMIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-CARDIOLIPIN ANTIBODIES; PRIMARY ANTIPHOSPHOLIPID SYNDROME; RETINAL VASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CEREBROVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; ANTICOAGULANT; ASSOCIATION; SLE	Objective: To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and venous thrombosis in healthy adult men. Design: A nested, case-control study in a prospective cohort. Setting. A nationwide study of physicians. Participants: The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22 071 male physicians. At entry, 68% of the participants submitted plasma samples that were subsequently frozen at -80-degrees-C. During 60.2 months of follow-up, follow-up for nonfatal outcomes was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus. Measurements: Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay. The mean anticardiolipin antibody titers of the case patients in the two diagnostic groups (ischemic stroke; venous thrombosis or pulmonary embolus) were compared with those of the control groups, and relative risks were calculated for patients in increasing percentile categories of anticardiolipin antibodies by conditional logistic regression. Results: The anticardiolipin antibody titers were higher in case patients with deep venous thrombosis and pulmonary embolus than in their matched controls (P = 0.01). Persons with anticardiolipin antibody titers above the 95th percentile had a relative risk for developing deep venous thrombosis or pulmonary embolus of 5.3 (95% Cl, 1.55 to 18.3; P = 0.01). The anticardiolipin antibody titers in case patients with ischemic stroke and controls were not significantly different (P > 0.2), and no clear trend of higher risks among those with elevated levels of anticardiolipin antibodies was observed. Conclusion: An anticardiolipin antibody level above the 95th percentile is an important risk factor for deep venous thrombosis or pulmonary embolus but not for ischemic stroke in healthy adult men.	BRIGHAM & WOMENS HOSP, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530, P60AR036308] Funding Source: NIH RePORTER; NCI NIH HHS [CA42182] Funding Source: Medline; NIAMS NIH HHS [AR36308, AR07530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; [Anonymous], 1988, NEW ENGL J MED; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1989, AM J MED, V86, P391, DOI 10.1016/0002-9343(89)90335-5; ASHERSON RA, 1986, ARTHRITIS RHEUM, V29, P1292, DOI 10.1002/art.1780291019; ASHERSON RA, 1989, Q J MED, V73, P1103; ASHERSON RA, 1987, ANN RHEUM DIS, V46, P605, DOI 10.1136/ard.46.8.605; ASHERSON RA, 1989, ANN RHEUM DIS, V48, P358, DOI 10.1136/ard.48.5.358; BOEY ML, 1983, BMJ-BRIT MED J, V287, P1021, DOI 10.1136/bmj.287.6398.1021; CARRERAS LO, 1981, LANCET, V1, P244; COLACO CB, 1983, ANN RHEUM DIS, V42, P228; COLACO CB, 1985, CLIN EXP IMMUNOL, V59, P449; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; COON WW, 1976, SURG GYNECOL OBSTET, V143, P385; COOPER RC, 1989, BRIT J RHEUMATOL, V28, P379; COULL BM, 1990, STROKE, V21, P1370, DOI 10.1161/01.STR.21.9.1370; CRONIN ME, 1988, J RHEUMATOL, V15, P795; DECATERINA R, 1990, AM J CARDIOL, V65, P922, DOI 10.1016/0002-9149(90)91439-D; DERKSEN RHWM, 1986, ARTHRITIS RHEUM, V29, P1295, DOI 10.1002/art.1780291021; DONALDSON MC, 1990, J VASC SURG, V11, P825, DOI 10.1067/mva.1990.20120; DREW P, 1987, ANN RHEUM DIS, V46, P612, DOI 10.1136/ard.46.8.612; FORT JG, 1987, ARTHRITIS RHEUM, V30, P752, DOI 10.1002/art.1780300705; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; HALL S, 1984, J RHEUMATOL, V11, P846; HAMSTEN A, 1986, LANCET, V1, P113; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1983, LANCET, V2, P1211; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; HARRIS EN, 1985, J CLIN LAB IMMUNOL, V16, P1; HARRIS EN, 1988, ANNU REV MED, V39, P261, DOI 10.1146/annurev.med.39.1.261; HASSELAAR P, 1990, J RHEUMATOL, V17, P186; ISENBERG DA, 1986, MEDICINE, V65, P46, DOI 10.1097/00005792-198601000-00003; KALUNIAN KC, 1988, AM J MED, V85, P602; KHAMASHTA MA, 1988, ANN RHEUM DIS, V47, P849, DOI 10.1136/ard.47.10.849; KLEMP P, 1988, CLIN EXP IMMUNOL, V74, P254; KUSHNER M, 1989, STROKE, V20, P225, DOI 10.1161/01.STR.20.2.225; LAVALLE C, 1990, J RHEUMATOL, V17, P34; LEVINE SR, 1987, ARCH NEUROL-CHICAGO, V44, P876, DOI 10.1001/archneur.1987.00520200078024; LOCKSHIN M D, 1991, Current Opinion in Rheumatology, V3, P797, DOI 10.1097/00002281-199110000-00008; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MCNEIL HP, 1990, CLIN EXP RHEUMATOL, V8, P525; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MEYER O, 1987, J RHEUMATOL, V14, P502; MORTON KE, 1986, LANCET, V2, P1353; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; OUT HJ, 1989, ANN RHEUM DIS, V48, P1023, DOI 10.1136/ard.48.12.1023; POPE JM, 1991, AM J MED, V90, P299, DOI 10.1016/0002-9343(91)90569-J; RUIZARGUELLES GJ, 1989, J RHEUMATOL, V16, P381; SAMMARITANO LR, 1990, SEMIN ARTHRITIS RHEU, V20, P81, DOI 10.1016/0049-0172(90)90021-7; SLETNES KE, 1992, LANCET, V339, P451, DOI 10.1016/0140-6736(92)91057-F; STURFELT G, 1987, ARTHRITIS RHEUM, V30, P382, DOI 10.1002/art.1780300404	52	453	464	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					997	1002		10.7326/0003-4819-117-12-997	http://dx.doi.org/10.7326/0003-4819-117-12-997			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443986				2022-12-01	WOS:A1992KB98000004
J	SLOAN, S; RADEMAKER, AW; KAHRILAS, PJ				SLOAN, S; RADEMAKER, AW; KAHRILAS, PJ			DETERMINANTS OF GASTROESOPHAGEAL JUNCTION INCOMPETENCE - HIATAL-HERNIA, LOWER ESOPHAGEAL SPHINCTER, OR BOTH	ANNALS OF INTERNAL MEDICINE			English	Article						ESOPHAGOGASTRIC JUNCTION; HERNIA, HIATAL; GASTROESOPHAGEAL REFLUX; MANOMETRY; FLUOROSCOPY	REFLUX ESOPHAGITIS; PRESSURE; MECHANISMS; DIAPHRAGM; SMOKING	Objective: To examine the effects of hiatal hernia and lower esophageal sphincter (LES) pressure on the competence of the gastroesophageal junction under conditions of abrupt increases in intra-abdominal pressure. Design: Acute experiments. Setting: University-hospital-based gastroenterology practice. Participants: Sixteen asymptomatic volunteers and 34 patients with endoscopic findings suggestive of hiatal hernia. Intervention: A series of eight provocative maneuvers entailing abrupt changes in intra-abdominal pressure. Measurements: Five radiographic measurements relevant to the presence and extent of hiatal hernia were made from videotaped barium-swallow examinations. Lower esophageal sphincter pressure was measured immediately before each maneuver. The percentage of maneuvers that resulted in gastroesophageal reflux was calculated as the reflux score. A stepwise regression analysis was then used to model the relation between measured variables of the gastroesophageal junction (manometric and radiographic) with reflux score. Results: Patients with hiatal hernia had substantially higher reflux scores and lower LES pressures than either patients without hernias or volunteers. In diminishing order of significance, the terms in the model of susceptibility to reflux were axial length of hernia measured between swallows; LES pressure; and an interaction term in which a progressive increase occurred in the risk for reflux associated with a hypotensive lower esophageal sphincter as hernia size increased. Conclusions: Gastroesophageal junction competence during abrupt increases in intra-abdominal pressure is compromised by both hiatal hernia and low LES pressure. These factors interact with each other to determine susceptibility to reflux.	NORTHWESTERN UNIV, SCH MED,DEPT MED,SUITE 1526,WESLEY TOWERS, 250 E SUPER ST, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000669] Funding Source: NIH RePORTER; NIDCD NIH HHS [1RO1DC00669-01] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BERSTAD A, 1986, SCAND J GASTROENTERO, V21, P55, DOI 10.3109/00365528609034622; BOYLE JT, 1987, AM J PHYSIOL, V253, pG315, DOI 10.1152/ajpgi.1987.253.3.G315; BOYLE JT, 1985, GASTROENTEROLOGY, V88, P723, DOI 10.1016/0016-5085(85)90143-X; COHEN S, 1971, NEW ENGL J MED, V284, P1053, DOI 10.1056/NEJM197105132841902; DEMEESTER TR, 1981, J THORAC CARDIOV SUR, V82, P547; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503; Dodds WJ, 1990, J GASTROINTEST MOTIL, V2, P79; JOHNSON LF, 1978, AM J DIG DIS, V23, P498, DOI 10.1007/BF01072693; KAHRILAS PJ, 1988, GASTROENTEROLOGY, V94, P73, DOI 10.1016/0016-5085(88)90612-9; KAHRILAS PJ, 1990, GUT, V31, P4, DOI 10.1136/gut.31.1.4; KAUL B, 1986, SCAND J GASTROENTERO, V21, P31, DOI 10.3109/00365528609034617; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P88; LEVINE MS, 1989, RADIOLOGY ESOPHAGUS, P256; MITTAL RK, 1990, AM J PHYSIOL, V258, pG624, DOI 10.1152/ajpgi.1990.258.4.G624; MITTAL RK, 1988, J CLIN INVEST, V81, P1182, DOI 10.1172/JCI113433; MITTAL RK, 1989, AM J PHYSIOL, V256, pG139, DOI 10.1152/ajpgi.1989.256.1.G139; OTT DJ, 1985, GASTROINTEST RADIOL, V10, P317, DOI 10.1007/BF01893120; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P246; SLOAN S, 1991, GASTROENTEROLOGY, V100, P596, DOI 10.1016/0016-5085(91)80003-R; SONTAG SJ, 1991, J CLIN GASTROENTEROL, V13, P628, DOI 10.1097/00004836-199112000-00006; WRIGHT RA, 1979, DIGEST DIS SCI, V24, P311, DOI 10.1007/BF01296546	22	201	210	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1992	117	12					977	982		10.7326/0003-4819-117-12-977	http://dx.doi.org/10.7326/0003-4819-117-12-977			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB980	1443984				2022-12-01	WOS:A1992KB98000001
J	CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; RITTER, JM				CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; RITTER, JM			IMPAIRED ENDOTHELIUM-DEPENDENT VASODILATION OF FOREARM RESISTANCE VESSELS IN HYPERCHOLESTEROLEMIA	LANCET			English	Article							NITRIC-OXIDE; CORONARY-ARTERIES; RELAXING FACTOR; ACETYLCHOLINE; RELEASE; RELAXATION; AORTA	Endothelium-dependent vasodilation in response to acetylcholine is impaired in the coronary microvasculature of hypercholesterolaemic subjects. Outside the coronary circulation, however, it has been suggested that hypercholesterolaemia results in a functional abnormality of vascular smooth muscle rather than in endothelial dysfunction. We examined vasodilator responses to acetylcholine, methacholine, and the endothelium-independent vasodilator sodium nitroprusside in the forearm resistance vessels of 12 men with primary hypercholesterolaemia and 12 normocholesterolaemic male controls. Endothelium-dependent vasodilation in response to acetylcholine was impaired in hypercholesterolaemic patients compared with controls: at the highest dose of drug (15 mug per min) mean blood flow in the forearms of the hypercholesterolaemic group was only 52% (95% CI 31-88%) of that in the control group. Responses to sodium nitroprusside and to methacholine in the two study groups were not significantly different. These results indicate that endothelial dysfunction in hypercholesterolaemic subjects is generalised and extends to vascular beds outside the coronary circulation. Selective impairment to acetylcholine suggests that, at a molecular level, the defect is limited to a specific pathway.	ST THOMAS HOSP,DEPT ENDOCRINOL,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT CHEM PATHOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT CLIN PHARMACOL,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	CHOWIENCZYK, PJ (corresponding author), ST THOMAS HOSP,DEPT CLIN PHARMACOL,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.			Watts, Gerald/0000-0003-2276-1524; Chowienczyk, Phil/0000-0003-4507-038X				BOSSALLER C, 1987, J CLIN INVEST, V79, P170, DOI 10.1172/JCI112779; BRAYDEN JE, 1985, CIRC RES, V56, P163; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; KATO T, 1990, HYPERTENSION, V15, P475, DOI 10.1161/01.HYP.15.5.475; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEILD TO, 1990, J PHYSIOL-LONDON, V420, P247, DOI 10.1113/jphysiol.1990.sp017910; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RALEVIC V, 1992, BRIT J PHARMACOL, V106, P650, DOI 10.1111/j.1476-5381.1992.tb14390.x; RUBANYI GM, 1987, J PHARMACOL EXP THER, V240, P802; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; VALLANCE P, 1989, LANCET, V2, P997; WHITNEY RJ, 1953, J PHYSIOL-LONDON, V121, P1	15	441	446	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1430	1432		10.1016/0140-6736(92)92621-L	http://dx.doi.org/10.1016/0140-6736(92)92621-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360559				2022-12-01	WOS:A1992KC28400003
J	CHRISTENSEN, J				CHRISTENSEN, J			PATHOPHYSIOLOGY OF THE IRRITABLE-BOWEL-SYNDROME	LANCET			English	Article							MYOELECTRICAL ACTIVITY; COLONIC MOTOR; SYMPTOMS; DIAGNOSIS; MOTILITY; DISEASE				CHRISTENSEN, J (corresponding author), UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.							ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7; BARKER LF, 1928, AM J MED SCI, V178, P606; Bockus HL, 1928, AM J MED SCI, V176, P813, DOI 10.1097/00000441-192812000-00006; CHAUDHARY NA, 1962, Q J MED, V31, P307; DINAN TG, 1990, J PSYCHOSOM RES, V34, P575, DOI 10.1016/0022-3999(90)90032-Y; ESLER MD, 1973, NEW ENGL J MED, V288, P16, DOI 10.1056/NEJM197301042880104; HISLOP IG, 1971, GUT, V12, P452, DOI 10.1136/gut.12.6.452; Hurst AF, 1935, LANCET, V1, P1483; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JORDAN SM, 1929, JAMA-J AM MED ASSOC, V93, P592; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KELLOW JE, 1992, SCAND J GASTROENTERO, V27, P53, DOI 10.3109/00365529209011167; KENDALL GPN, 1990, GUT, V31, P1062, DOI 10.1136/gut.31.9.1062; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; KUMAR D, 1985, LANCET, V2, P973; KUMAR D, 1990, DIGESTION, V45, P80, DOI 10.1159/000200227; LATIMER P, 1981, GASTROENTEROLOGY, V80, P893; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MCALLISTER C, 1990, BIOMED PHARMACOTHER, V44, P399, DOI 10.1016/0753-3322(90)90043-9; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; Ryle JA, 1928, LANCET, V2, P1115; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; SNAPE WJ, 1977, GASTROENTEROLOGY, V72, P383; SNAPE WJ, 1978, GASTROENTEROLOGY, V75, P373; TALLEY NJ, 1990, GASTROENTEROLOGY, V99, P327, DOI 10.1016/0016-5085(90)91012-U; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927, DOI 10.1016/0016-5085(91)90717-Y; THOMPSON WG, 1986, CAN MED ASSOC J, V134, P111; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; THOMPSON WG, 1979, IRRITABLE GUT FUNCTI; TROTMAN IF, 1986, LANCET, V2, P364; TROTMAN IF, 1988, GUT, V29, P218, DOI 10.1136/gut.29.2.218; White BV, 1940, ANN INTERN MED, V14, P854, DOI 10.7326/0003-4819-14-5-854; White WH, 1905, LANCET, V2, P1229; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1187, DOI 10.1016/0016-5085(90)90332-U; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0	35	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1444	1447						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360568				2022-12-01	WOS:A1992KC28400012
J	ECKEL, RH				ECKEL, RH			INSULIN RESISTANCE - AN ADAPTATION FOR WEIGHT MAINTENANCE	LANCET			English	Article							LIPOPROTEIN-LIPASE; PIMA-INDIANS; OBESE WOMEN; GLUCOSE; GAIN; RESPONSIVENESS; SENSITIVITY; METABOLISM; REDUCTION; RECEPTOR	Insulin resistance can be physiological, but most often is associated with metabolic disorders such as obesity and non-insulin dependent diabetes mellitus. The reduction in insulin action seen in insulin-resistant states affects metabolic fuel partitioning in a way that would prevent additional weight gain. Despite the potential adverse effects of cardiovascular risk factors that accompany insulin resistance, reductions in insulin action may well be necessary to prevent additional weight gain in those in whom excessive food intake is coupled with inactivity.			ECKEL, RH (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL, DENVER, CO 80262 USA.							BIELINSKI R, 1985, AM J CLIN NUTR, V42, P69, DOI 10.1093/ajcn/42.1.69; BLOCH CA, 1987, J PEDIATR-US, V110, P481, DOI 10.1016/S0022-3476(87)80522-X; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; DONAHUE RP, 1987, LANCET, V1, P821; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1987, J CLIN INVEST, V80, P992, DOI 10.1172/JCI113193; FARESE RV, 1991, METABOLISM, V40, P214, DOI 10.1016/0026-0495(91)90178-Y; FLATT JP, 1987, AM J CLIN NUTR, V45, P296, DOI 10.1093/ajcn/45.1.296; HAFFNER SM, 1989, ARTERIOSCLEROSIS, V9, P928, DOI 10.1161/01.ATV.9.6.928; HOLLENBECK CB, 1984, DIABETES, V33, P460, DOI 10.2337/diabetes.33.5.460; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOLTERMAN OG, 1981, J CLIN INVEST, V68, P957, DOI 10.1172/JCI110350; KRAMER FM, 1989, INT J OBESITY, V13, P123; LEBLANC J, 1982, METABOLISM, V31, P453, DOI 10.1016/0026-0495(82)90233-5; NEWMAN WP, 1983, METABOLISM, V32, P590, DOI 10.1016/0026-0495(83)90029-X; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; RANDLE PJ, 1963, LANCET, V1, P785; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSSINI AA, 1985, JOSLINS DIABETES MEL, P834; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TURNER RC, 1983, DIABETOLOGIA, V24, P404; WIGAND JP, 1979, DIABETES, V28, P287, DOI 10.2337/diabetes.28.4.287; ZURLO F, 1990, AM J PHYSIOL, V259, pE650	26	154	156	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1992	340	8833					1452	1453		10.1016/0140-6736(92)92633-Q	http://dx.doi.org/10.1016/0140-6736(92)92633-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360570				2022-12-01	WOS:A1992KC28400014
J	GUSTAFSSON, C; ASPLUND, K; BRITTON, M; NORRVING, B; OLSSON, B; MARKE, LA				GUSTAFSSON, C; ASPLUND, K; BRITTON, M; NORRVING, B; OLSSON, B; MARKE, LA			COST-EFFECTIVENESS OF PRIMARY STROKE PREVENTION IN ATRIAL-FIBRILLATION - SWEDISH NATIONAL PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective-To assess the potential effects of primary prevention with anticoagulants or aspirin in atrial fibrillation on Swedish population. Design-Analysis of cost effectiveness based on the following assumptions: about 83 000 people have atrial fibrillation in Sweden, of whom 22 000 would be potential candidates for treatment with anticoagulants and 55 000 for aspirin treatment; the annual 5% stroke rate is reduced by 64% (with anticoagulants) and 25% (with aspirin); incidence of intracranial haemorrhage of 0.3%, 1.3%, or 2.0% per year; direct and indirect costs of a stroke of Kr180 000 and Kr90 000; estimated annual cost of treatment is Kr5030 for anticoagulants and Kr100 for aspirin. Setting-Total Swedish population. Main outcome measures-Direct and indirect costs of stroke saved, number of strokes prevented, and cost of preventive treatment. Results-Depending on the rate of haemorrhagic complications 34 to 83 patients would need to be treated annually with anticoagulants to prevent one stroke; 83 patients would need to be treated with aspirin. Giving anticoagulant treatment only would reduce costs by Kr60 million if the incidence of intracranial haemorrhage were 0.3% but would imply a net expense if the complication rate exceeded 1.3%. The total savings from giving anticoagulant (22 000 patients) and aspirin (55 000 patients) treatment would be Kr175 million per year corresponding to 2 million Pounds per million inhabitants each year. Conclusions-Treatment with anticoagulants and, if contraindications exist, with aspirin is cost effective provided that the risk of serious haemorrhage complications due to anticoagulants is kept low.	UMEA REG HOSP,DEPT MED,UMEA,SWEDEN; ST GORANS UNIV HOSP,DEPT MED,S-11281 STOCKHOLM,SWEDEN; LUND HOSP,DEPT NEUROL,LUND,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; LUND HOSP,DEPT CARDIOL,LUND,SWEDEN	Saint Goran's Hospital	GUSTAFSSON, C (corresponding author), MARIESTAD HOSP,DEPT MED,BOX 411,S-54224 MARIESTAD,SWEDEN.			Norrving, Bo/0000-0002-8024-5096				ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CONOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDAHL S, 1984, EUR HEART J, V5, P326, DOI 10.1093/oxfordjournals.eurheartj.a061659; PETERSEN P, 1989, LANCET, V1, P175; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; 1991, CIRCULATION, V84, P527; 1988, BMJ, V296, P320; 1990, NEW ENGL J MED, V323, P1505	10	126	126	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1457	1460		10.1136/bmj.305.6867.1457	http://dx.doi.org/10.1136/bmj.305.6867.1457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493390	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992KC91800019
J	HARVEY, JM; HOWIE, AJ; LEE, SJ; NEWBOLD, KM; ADU, D; MICHAEL, J; BEEVERS, DG				HARVEY, JM; HOWIE, AJ; LEE, SJ; NEWBOLD, KM; ADU, D; MICHAEL, J; BEEVERS, DG			RENAL BIOPSY FINDINGS IN HYPERTENSIVE PATIENTS WITH PROTEINURIA	LANCET			English	Note								27 patients with hypertension and persistent proteinuria were investigated by renal biopsy. The 13 patients without structural glomerular abnormalities were younger and had less proteinuria than the other 14, but otherwise the two groups had similar clinical features. 6 of the 14 had diffuse glomerular abnormalities; the other 8 had segmental sclerosing lesions, which were mainly in the hilum of the glomeruli, as seen in states of glomerular overload. Glomeruli in all groups were larger than those in normotensive people. It is possible that hypertension causes glomerular enlargement, proteinuria, and segmental glomerular lesions because of loss of functioning glomeruli due to ischaemia.	DUDLEY RD GEN HOSP,DEPT MED,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT PATHOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,DEPT NEPHROL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								BULPITT CJ, 1986, J HYPERTENS, V4, P93, DOI 10.1097/00004872-198602000-00015; GIFFORD RW, 1969, MILBANK FUND Q, V47, P170, DOI 10.2307/3349261; GOSLING P, 1989, CLIN SCI, V76, P39, DOI 10.1042/cs0760039; HOWIE AJ, 1989, J PATHOL, V157, P141, DOI 10.1002/path.1711570209; KINCAIDSMITH PS, 1982, HYPERTENSION MECHANI, P94; NEWBOLD KM, 1990, J PATHOL, V162, P329, DOI 10.1002/path.1711620409; NEWBOLD KM, 1990, J PATHOL, V160, P255, DOI 10.1002/path.1711600312; TOBIAN L, 1987, AM J CARDIOL, V60, P421; TOMSON CRV, 1991, J HUM HYPERTENS, V5, P189; YOSHIDA Y, 1989, KIDNEY INT, V35, P654, DOI 10.1038/ki.1989.35	10	83	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1435	1436		10.1016/0140-6736(92)92624-O	http://dx.doi.org/10.1016/0140-6736(92)92624-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360561				2022-12-01	WOS:A1992KC28400005
J	HERD, RM; HUNTER, JAA; MCLAREN, KM; CHETTY, U; WATSON, ACH; GOLLOCK, JM				HERD, RM; HUNTER, JAA; MCLAREN, KM; CHETTY, U; WATSON, ACH; GOLLOCK, JM			EXCISION BIOPSY OF MALIGNANT-MELANOMA BY GENERAL-PRACTITIONERS IN SOUTH EAST SCOTLAND 1982-91	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To examine the management of patients who had a malignant melanoma excised initially by general practitioners in south east Scotland over the past 10 years and to assess the impact of the April 1990 contract on this. Design-A retrospective case-control study. Setting-South east Scotland. Subjects-All patients in south east Scotland who had malignant melanomas excised by general practitioners in 1982-91. Outcome measures-Demographic details of patients; Breslow thickness, clearance of excision. Results-42 patients had malignant melanomas excised by general practitioners in 1982-91: 15 in 1982-9 and 27 in 1990-1. These patients were significantly younger than those who had their tumours excised initially in hospital. Although the longest diameter of melanomas excised by general practitioners was significantly less than of those excised in hospital, the Breslow thicknesses were similar. Completeness of initial excision was doubtful or incomplete in nine (23%) general practitioner excisions compared with 4/o of hospital excisions, but the time interval between excision biopsy and wide excision was similar. Pathology requests accompanying excision biopsies mentioned melanoma as a possible diagnosis in 15% (6/40) of general practitioner cases compared with 79% of hospital cases. Thirty nine general practitioners responded to a questionnaire and only 12 had considered melanoma in the differential diagnosis. Conclusions-General practitioners need to think more often of malignant melanoma when they excise pigmented lesions and when they consider this tumour a possibility should perform an excision biopsy with a lateral clearance of at least 2 mm.	UNIV EDINBURGH, ROYAL INFIRM, DEPT PATHOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, DEPT SURG, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; ST JOHNS HOSP, PLAST SURG UNIT, Livingston, ENGLAND; BORDERS GEN HOSP, DEPT SURG, BORDERS, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	HERD, RM (corresponding author), UNIV EDINBURGH, ROYAL INFIRM, DEPT DERMATOL, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							BAGLEY FH, 1981, CANCER-AM CANCER SOC, V47, P2126, DOI 10.1002/1097-0142(19810501)47:9<2126::AID-CNCR2820470904>3.0.CO;2-C; BRAZIER JE, 1991, BRIT MED J, V303, P1472, DOI 10.1136/bmj.303.6815.1472-a; COX NH, 1992, BMJ-BRIT MED J, V304, P1177; ELLWOOD JM, 1988, PIGMENT CELL, V9, P118; HILLAN KJ, 1991, BRIT MED J, V303, P1180, DOI 10.1136/bmj.303.6811.1180; LANDTHALER M, 1989, CANCER-AM CANCER SOC, V64, P1612, DOI 10.1002/1097-0142(19891015)64:8<1612::AID-CNCR2820640810>3.0.CO;2-7; LEDERMAN JS, 1985, J AM ACAD DERMATOL, V13, P983, DOI 10.1016/S0190-9622(85)70249-6; Mackie R. M., 1989, MALIGNANT MELANOMA G; MCWILLIAM LJ, 1991, BRIT MED J, V303, P1177, DOI 10.1136/bmj.303.6811.1177; Pitcher R., 1991, BR J DERMATOL S38, V125, P93; RAMPEN FHJ, 1984, BRIT J DERMATOL, V111, P431, DOI 10.1111/j.1365-2133.1984.tb06605.x; SHRANK AB, 1991, BRIT J DERMATOL, V125, P599, DOI 10.1111/j.1365-2133.1991.tb14804.x; URIST MM, 1985, CUTANEOUS MELANOMA C, P71; WHIMSTER WF, 1991, BRIT MED J, V303, P1149, DOI 10.1136/bmj.303.6811.1149; WILLIAMS RB, 1991, BRIT MED J, V303, P1179, DOI 10.1136/bmj.303.6811.1179; 1989, GENERAL PRACTICE NAT	16	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 12	1992	305	6867					1476	1478		10.1136/bmj.305.6867.1476	http://dx.doi.org/10.1136/bmj.305.6867.1476			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493395	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992KC91800025
J	HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL				HOWARD, MR; CHAPMAN, CE; DUNSTAN, JA; MITCHELL, C; LLOYD, HL			REGIONAL TRANSFUSION CENTER PREOPERATIVE AUTOLOGOUS BLOOD DONATION PROGRAM - THE 1ST 2 YEARS	BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN	Objective-To assess the efficacy of a regional autologous blood donation programme. Design-Clinical and laboratory data were collected and stored prospectively. Transfusion data were collected retrospectively from hospital blood bank records. Setting-Northern Region Blood Transfusion Service and 14 hospitals within the Northern Regional Health Authority. Subjects-505 patients referred for autologous blood donation before elective surgery. Main outcome measures-Patient eligibility, adverse events from donation, autologous blood units provided, and autologous and allogeneic blood units transfused within 10 days of operation. Results-Of 505 patients referred, 354 donated at least one unit. 78 of 151 referred patients who did not donate were excluded at the autologous clinic, mostly because of anaemia or ischaemic heart disease. In 73 cases the patient, general practitioner, or hospital consultant decided against donation. 363 autologous procedures were undertaken. In 213 (59%) cases all requested units were provided. The most common reasons for incomplete provision were late referral or anaemia. Adverse events accompanied 24 of 928 donations (2.6%). Transfusion data were obtained for 357 of the 363 procedures. 281 donors were transfused; autologous blood only was given to 225, autologous and allogeneic blood was given to 52, and allogeneic blood only was given to four. 648 of 902 (72%) units of autologous blood were transfused. Complete provision of requested autologous units was followed by allogeneic transfusion in 12 of 208 procedures (5.8%). Incomplete provision was followed by allogeneic transfusion in 44 of 149 procedures (30%). Conclusions-This study shows the feasibility of a regional autologous transfusion programme. Autologous donors only infrequently received allogeneic transfusion. Patients should be appropriately selected and referred early.	NO REG BLOOD TRANSFUS CTR,NEWCASTLE TYNE,ENGLAND		HOWARD, MR (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							BACHON JPA, 1991, TRANSFUSION, V31, P513; BENOIT P, 1992, TRANSFUSION MED, V2, P75; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; GIBLETT ER, 1977, TRANSFUSION, V17, P299, DOI 10.1046/j.1537-2995.1977.17477216857.x; GOODNOUGH LT, 1989, NEW ENGL J MED, V321, P1163, DOI 10.1056/NEJM198910263211705; GRAF H, 1990, BRIT MED J, V300, P1627, DOI 10.1136/bmj.300.6740.1627; Gunson H H, 1991, CDR (Lond Engl Rev), V1, pR144; HICKMAN M, 1988, LANCET, V1, P1221; KRUSKALL MS, 1986, TRANSFUSION, V26, P335, DOI 10.1046/j.1537-2995.1986.26486262740.x; NELSON K, 1991, Transfusion (Bethesda), V31, p47S; PETERSEN LR, 1992, 5TH NAT FOR AIDS HEP, P37; PINDYCK J, 1987, JAMA-J AM MED ASSOC, V257, P1186, DOI 10.1001/jama.257.9.1186; POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x; SCHMIDT PJ, 1991, TRANSFUSION, V31, P681, DOI 10.1046/j.1537-2995.1991.31892023489.x; TASAKI T, 1992, LANCET, V339, P773, DOI 10.1016/0140-6736(92)91895-F; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; 1989, VOX SANG, V57, P278; 1986, JAMA-J AM MED ASSOC, V256, P2378; 1988, CLIN LAB HAEMATOL, V10, P193	22	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1470	1473		10.1136/bmj.305.6867.1470	http://dx.doi.org/10.1136/bmj.305.6867.1470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493393	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992KC91800022
J	LOCOCO, F; DIVERIO, D; PANDOLFI, PP; BIONDI, A; ROSSI, V; AVVISATI, G; RAMBALDI, A; ARCESE, W; PETTI, MC; MELONI, G; MANDELLI, F; GRIGNANI, F; MASERA, G; BARBUI, T; PELICCI, PG				LOCOCO, F; DIVERIO, D; PANDOLFI, PP; BIONDI, A; ROSSI, V; AVVISATI, G; RAMBALDI, A; ARCESE, W; PETTI, MC; MELONI, G; MANDELLI, F; GRIGNANI, F; MASERA, G; BARBUI, T; PELICCI, PG			MOLECULAR EVALUATION OF RESIDUAL DISEASE AS A PREDICTOR OF RELAPSE IN ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Note							LEUKEMIA	Acute promyelocytic leukaemia (APL) is characterised by a unique fusion transcript, PML/RARalpha. We tested for this transcript in 35 APL patients who were in apparent remission after various treatments. 11 of 13 patients who tested positive 4 months after achieving remission were in relapse 1-4 months later. All 22 patients who tested negative at 4 months were disease-free after a further 3 months to five years. The test may therefore prove useful in determining the need for additional treatment during clinical remission.	IST MARIO NEGRI,BERGAMO,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,I-06100 PERUGIA,ITALY; UNIV MILAN,PEDIAT CLIN,I-20122 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Perugia; University of Milan	LOCOCO, F (corresponding author), UNIV LA SAPIENZA,DEPT HUMAN BIOPATHOL,VIA BENEVENTO 6,I-00161 ROME,ITALY.		Biondi, Andrea/AAX-1865-2020; Rambaldi, Alessandro/P-2603-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Rambaldi, Alessandro/M-6172-2019; Biondi, Andrea/K-9997-2016	Biondi, Andrea/0000-0002-6757-6173; Rambaldi, Alessandro/0000-0002-3739-7502; Rambaldi, Alessandro/0000-0002-3739-7502; Avvisati, Giuseppe/0000-0002-5027-5868; , Xavier/0000-0002-8083-2127; ARCESE, WILLIAM/0000-0001-5697-366X				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BIONDI A, 1992, BLOOD, V80, P492; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; ROWLEY JD, 1977, LANCET, V1, P549; Sambrook J., 1989, MOL CLONING LAB MANU	6	206	208	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1437	1438		10.1016/0140-6736(92)92625-P	http://dx.doi.org/10.1016/0140-6736(92)92625-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360562				2022-12-01	WOS:A1992KC28400006
J	NI, HL; KNIGHT, AI; CARTWRIGHT, K; PALMER, WH; MCFADDEN, J				NI, HL; KNIGHT, AI; CARTWRIGHT, K; PALMER, WH; MCFADDEN, J			POLYMERASE CHAIN-REACTION FOR DIAGNOSIS OF MENINGOCOCCAL MENINGITIS	LANCET			English	Article							ACUTE BACTERIAL-MENINGITIS	Meningococcal disease is normally suspected on clinical grounds but confirmed by isolation of Neisseria meningitidis from blood or cerebrospinal fluid (CSF), or by detection of gram-negative diplococci in CSF. After parenteral antibiotics are started the isolation rate of meningococci from blood cultures drops from 50% to less than 5% and the chances of CSF being positive by culture or microscopy are also reduced. We used the polymerase chain reaction (PCR) in a blinded study to detect meningococcal DNA in 54 CSF samples from patients with meningococcal disease or from controls. The PCR primers were specific for the meningococcal insertion sequence IS1106. The sensitivity and specificity of this PCR for diagnosis of meningococcal meningitis were both 91%. Sensitivity was not affected by prior antibiotic treatment. The IS1106 PCR is a rapid and sensitive test for confirmation of the diagnosis of meningococcal meningitis.	UNIV SURREY, SCH BIOL SCI, MOLEC MICROBIOL GRP, GUILDFORD GU2 5XH, SURREY, ENGLAND; GLOUCESTERSHIRE ROYAL HOSP, PUBL HLTH LAB, GLOUCESTER, ENGLAND	University of Surrey; Gloucestershire Royal Hospital				McFadden, Johnjoe/0000-0003-2145-0046				BOHR V, 1983, J INFECTION, V7, P193, DOI 10.1016/S0163-4453(83)96980-3; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT KAV, 1986, LANCET, V2, P558; GOLDACRE MJ, 1977, ARCH DIS CHILD, V52, P501, DOI 10.1136/adc.52.6.501; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; KNIGHT AI, 1992, MOL MICROBIOL, V6, P1565, DOI 10.1111/j.1365-2958.1992.tb00878.x; KRISTIANSEN BE, 1991, LANCET, V337, P1568, DOI 10.1016/0140-6736(91)93262-8; NI H, 1992, EPIDEMIOL INFECT, V109, P227, DOI 10.1017/S0950268800050184; SABOOR SA, 1992, LANCET, V339, P1012, DOI 10.1016/0140-6736(92)90535-B; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; SWARTZ MN, 1965, NEW ENGL J MED, V272, P779, DOI [10.1056/NEJM196504152721506, 10.1056/NEJM196504222721607]; 1988, DHSS PLCMO882 DEP HL	14	106	112	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 12	1992	340	8833					1432	1434		10.1016/0140-6736(92)92622-M	http://dx.doi.org/10.1016/0140-6736(92)92622-M			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360560				2022-12-01	WOS:A1992KC28400004
J	PEANO, GM; FENOGLIO, LM; MENARDI, G; BALBO, R; MARENCHINO, D; FENOGLIO, S				PEANO, GM; FENOGLIO, LM; MENARDI, G; BALBO, R; MARENCHINO, D; FENOGLIO, S			HETEROSEXUAL TRANSMISSION OF HEPATITIS-C VIRUS IN FAMILY GROUPS WITHOUT RISK-FACTORS	BRITISH MEDICAL JOURNAL			English	Article							NON-B-HEPATITIS; SEXUAL TRANSMISSION; NON-A		OSPED S CROCE,SERV IMMUNOEMATOL & TRASFUSIONALE,USL 58,BLOOD BANK UNIT,MED STAFF,CUNEO,ITALY; UNIV TURIN,MED CLIN B,DIV MED GEN 1,I-10124 TURIN,ITALY	University of Turin	PEANO, GM (corresponding author), VIA Q SELLA 22,I-12100 CUNEO,ITALY.							ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; KIYOSAWA K, 1991, J MED VIROL, V33, P114, DOI 10.1002/jmv.1890330209; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; TEDDER RS, 1991, BRIT MED J, V302, P1299, DOI 10.1136/bmj.302.6788.1299	5	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1473	1474		10.1136/bmj.305.6867.1473	http://dx.doi.org/10.1136/bmj.305.6867.1473			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1283543	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992KC91800023
J	SANDERCOCK, P; BAMFORD, J; DENNIS, M; BURN, J; SLATTERY, J; JONES, L; BOONYAKARNKUL, S; WARLOW, C				SANDERCOCK, P; BAMFORD, J; DENNIS, M; BURN, J; SLATTERY, J; JONES, L; BOONYAKARNKUL, S; WARLOW, C			ATRIAL-FIBRILLATION AND STROKE - PREVALENCE IN DIFFERENT TYPES OF STROKE AND INFLUENCE ON EARLY AND LONG-TERM PROGNOSIS (OXFORDSHIRE COMMUNITY STROKE PROJECT)	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; RISK-FACTORS; THROMBOEMBOLIC COMPLICATIONS; BRAIN INFARCTION; FRAMINGHAM; REGISTRY; RECURRENCE; DURATION; EMBOLISM	Objective-To determine in patients with first ever stroke whether atrial fibrillation influences clinical features, the need to perform computed tomography, and prognosis. Design-Observational cohort study with maximum follow up of 6.5 years. Setting-Primary care, based on 10 general practices in urban and rural Oxfordshire. Subjects-Consecutive series of 675 patients with first ever stroke registered in the Oxfordshire community stroke project. Main outcome measures-Prevalence of atrial fibrillation by type of stroke; effect of atrial fibrillation on case fatality rate and risk of recurrent stroke, vascular death, and death from all causes. Results-Prevalence of atrial fibrillation was 17% (95% confidence interval 14% to 20%) for all stroke types (115/675), 18% (15% to 21%) for cerebral infarction (97/545), 11% (4% to 11%) for primary intercerebral haemorrhage (7/66), and 0% (0 to 11%) for subarachnoid haemorrhage (0/33). For patients with cerebral infarction the 30 day case fatality rate was significantly higher with atrial fibrillation (23%) than with sinus rhythm (8%); the risk of early recurrent stroke (within 30 days) was 1% with atrial fibrillation and 4% with sinus rhythm. In patients who survived at least 30 days the average annual risk of recurrent stroke was 8.2% (5.9% to 10.9%) with sinus rhythm and 11% (6.0% to 17.3%) with atrial fibrillation. Conclusions-After a first stroke atrial fibrillation was not associated with a definite excess risk of recurrent stroke, either within 30 days or within the first few years. Survivors with and without atrial fibrillation had a clinically important absolute risk of further serious vascular events.	ST JAMES UNIV HOSP,DEPT NEUROL,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT REHABIL MED,SOUTHAMPTON S09 4XY,ENGLAND; RADCLIFFE INFIRM,GIBSON LABS,DEPT COMMUNITY MED & GEN PRACTICE,OXFORD OX2 6HE,ENGLAND; RAJAVITHI HOSP,DEPT MED,DIV NEUROL,BANGKOK 10400,THAILAND	Saint James's University Hospital; University of Southampton; Radcliffe Infirmary; Rajavithi Hospital	SANDERCOCK, P (corresponding author), WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021	sandercock, peter/0000-0001-8484-0135; 				ARMITAGE P, 1971, STATISTICAL METHODS, P135; BAMFORD J, 1992, LANCET, V339, P400, DOI 10.1016/0140-6736(92)90085-H; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; BOGOUSSLAVSKY J, 1990, ACTA NEUROL SCAND, V82, P143; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; BRITTON M, 1985, STROKE, V16, P182, DOI 10.1161/01.STR.16.2.182; BRITTON M, 1979, ACTA MED SCAND, V205, P425; CAMDELISE L, 1991, STROKE, V22, P169; DARLING RC, 1967, SURG GYNECOL OBSTETR, V124, P106; DAVIS PH, 1987, ANN NEUROL, V22, P319, DOI 10.1002/ana.410220307; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; DIXON WJ, 1985, BMDP STATISTICAL SOF, P576; FISHER CM, 1979, GERIATRICS, V34, P59; FLEGEL KM, 1987, LANCET, V1, P878; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FRIEDMAN PJ, 1991, STROKE, V22, P209, DOI 10.1161/01.STR.22.2.209; GARDNER MJ, 1989, STATISTICS CONFIDENC; GUSTAFSSON C, 1986, ACTA NEUROL SCAND, V73, P520; HARRISON MJG, 1984, STROKE, V15, P441, DOI 10.1161/01.STR.15.3.441; HART RG, 1983, STROKE, V14, P827, DOI 10.1161/str.14.5.827a; HART RG, 1983, STROKE, V14, P688, DOI 10.1161/01.STR.14.5.688; HAYNES RB, 1985, EPIDEMIOLOGY SCI CLI; HIER DB, 1991, STROKE, V22, P155, DOI 10.1161/01.STR.22.2.155; KELLEY RE, 1984, NEUROLOGY, V34, P1285, DOI 10.1212/WNL.34.10.1285; KIPECKY SL, 1987, NEW ENGL J MED, V317, P669; KOLLER RL, 1982, NEUROLOGY, V32, P283; LOWE GDO, 1983, LANCET, V1, P784; MARQUARDSEN J, 1969, NATURAL HIST ACUTE C, P138; MOHR JP, 1978, NEUROLOGY, V28, P754, DOI 10.1212/WNL.28.8.754; OLSEN T, 1990, J NEUROL, V237, P139; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, STROKE, V21, P4, DOI 10.1161/01.STR.21.1.4; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RICCI S, 1989, STROKE, V20, P853, DOI 10.1161/01.STR.20.7.853; RICCI S, 1991, SALZBURG C CEREBROVA, P7; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SAGE JI, 1983, STROKE, V14, P537, DOI 10.1161/01.STR.14.4.537; SANTAMARIA J, 1983, NEUROLOGY, V33, P1104, DOI 10.1212/WNL.33.8.1104; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; VANMERWIJK G, 1990, J NEUROL, V237, P205; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1986, ARCH NEUROL-CHICAGO, V43, P71; 1989, ARCH NEUROL-CHICAGO, V46, P727; 1990, NEW ENGL J MED, V322, P863; 1990, NEW ENGL J MED, V323, P1505	53	188	192	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1460	1465		10.1136/bmj.305.6867.1460	http://dx.doi.org/10.1136/bmj.305.6867.1460			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493391	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992KC91800020
J	WEBER, FH; MCCALLUM, RW				WEBER, FH; MCCALLUM, RW			CLINICAL APPROACHES TO IRRITABLE-BOWEL-SYNDROME	LANCET			English	Article							DOUBLE-BLIND; DISORDERS; PLACEBO; DIAGNOSIS; MOTILITY; TRANSIT		UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA 22908	University of Virginia								BYRNE S, 1987, J CLIN PSYCHIAT, V48, P388; CAMILLERI M, 1989, AM J PHYSIOL, V257, pG284, DOI 10.1152/ajpgi.1989.257.2.G284; CHAUDHARY NA, 1962, Q J MED, V31, P307; DROSSMAN DA, 1990, ANN INTERN MED, V113, P828, DOI 10.7326/0003-4819-113-11-828; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; FIELDING JF, 1981, DIGESTION, V22, P155, DOI 10.1159/000198627; Froguel E., 1990, J GASTROINTEST MOTIL, V2, P176; GREENBAUM DS, 1987, DIGEST DIS SCI, V32, P257, DOI 10.1007/BF01297051; GUTHRIE E, 1991, GASTROENTEROLOGY, V100, P450, DOI 10.1016/0016-5085(91)90215-7; HARVEY RF, 1983, LANCET, V1, P632; HASLER W, 1992, Gastroenterology, V102, pA457; KEELING PWN, 1975, J IRISH COLL PHYS S, V4, P91; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KLEIN KB, 1988, GASTROENTEROLOGY, V95, P232, DOI 10.1016/0016-5085(88)90319-8; KREVSKY B, 1992, DIGEST DIS SCI, V37, P919, DOI 10.1007/BF01300391; LAVO B, 1987, SCAND J GASTROENTERO, V22, P77, DOI 10.3109/00365528709091003; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MATHIAS JR, 1989, DIGEST DIS SCI, V34, P761, DOI 10.1007/BF01540350; MAXTON DG, 1991, GUT, V32, P662, DOI 10.1136/gut.32.6.662; NANDA R, 1989, GUT, V30, P1099, DOI 10.1136/gut.30.8.1099; PASSARETTI S, 1989, ALIMENT PHARM THERAP, V3, P267; PASSARETTI S, 1987, PROG MED, V43, P121; PRIOR A, 1987, GUT, V28, P1510, DOI 10.1136/gut.28.11.1510; RITSEMA GH, 1991, CLIN RADIOL, V43, P113, DOI 10.1016/S0009-9260(05)81589-2; SASAKI D, 1986, GASTROINTEST ENDOSC, V32, P185, DOI 10.1016/S0016-5107(86)71801-4; SCHAFFSTEIN W, 1990, CURR THER RES CLIN E, V47, P136; SCIARRETTA G, 1987, GUT, V28, P970, DOI 10.1136/gut.28.8.970; SMITH RC, 1990, GASTROENTEROLOGY, V98, P293, DOI 10.1016/0016-5085(90)90817-K; STAFANINI GF, 1992, AM J GASTROENTEROL, V87, P55; STEADMAN C J, 1990, Gastroenterology, V98, pA394; SUTBBS JB, 1991, J NUCL MED, V32, P1375; TALLEY NJ, 1990, GUT, V31, P77, DOI 10.1136/gut.31.1.77; TALLEY NJ, 1987, LANCET, V2, P1144; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; VANOUTRYVE M, 1991, J CLIN GASTROENTEROL, V13, P49; WALSH P, 1986, BR J CLIN PRACT, V40, P292; WHITEHEAD WE, 1990, GASTROENTEROLOGY, V98, P1485, DOI 10.1016/0016-5085(90)91079-L; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423	39	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 12	1992	340	8833					1447	1452		10.1016/0140-6736(92)92632-P	http://dx.doi.org/10.1016/0140-6736(92)92632-P			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC284	1360569				2022-12-01	WOS:A1992KC28400013
J	WRIGHT, J; FORD, H				WRIGHT, J; FORD, H			LETTER FROM AFRICA - ANOTHER AFRICAN DISASTER	BRITISH MEDICAL JOURNAL			English	Article											WRIGHT, J (corresponding author), GOOD SHEPHERD HOSP,SITEKI,SWAZILAND.		Wright, John/H-1624-2012	Wright, John/0000-0001-9572-7293					0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 12	1992	305	6867					1479	1480		10.1136/bmj.305.6867.1479	http://dx.doi.org/10.1136/bmj.305.6867.1479			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KC918	1493396	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992KC91800027
J	ALLBRITTON, NL; MEYER, T; STRYER, L				ALLBRITTON, NL; MEYER, T; STRYER, L			RANGE OF MESSENGER ACTION OF CALCIUM-ION AND INOSITOL 1,4,5-TRISPHOSPHATE	SCIENCE			English	Article							DIFFUSION; OSCILLATIONS; INDICATORS; KINETICS; RECEPTOR; BINDING; MUSCLE; CELLS; CA-2+; PHOSPHATES	The range of messenger action of a point source of Ca2+ or inositol 1,4,5-trisphosphate (IP3) was determined from measurements of their diffusion coefficients in a cytosolic extract from Xenopus laevis oocytes. The diffusion coefficient (D) of [H-3]IP3 injected into an extract was 283 mum2/s. D for Ca2+ increased from 13 to 65 mum2/s when the free calcium concentration was raised from about 90 nM to 1 muM. The slow diffusion of Ca2+ in the physiologic concentration range results from its binding to slowly mobile or immobile buffers. The calculated effective ranges of free Ca2+ before it is buffered, buffered Ca2+, and IP3 determined from their diffusion coefficients and lifetimes were 0.1 mum, 5 mum, and 24 mum, respectively. Thus, for a transient point source of messenger in cells smaller than 20 mum, IP3 is a global messenger, whereas Ca2+ acts in restricted domains.	DUKE UNIV,DEPT CELL BIOL,DURHAM,NC 27710	Duke University	ALLBRITTON, NL (corresponding author), STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Meyer, Tobias/0000-0003-4339-3804	NIAID NIH HHS [5F32AI0814203] Funding Source: Medline; NIMH NIH HHS [MH45324] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHMED Z, 1988, CELL CALCIUM, V9, P57, DOI 10.1016/0143-4160(88)90025-5; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BLATTER LA, 1990, BIOPHYS J, V58, P1491, DOI 10.1016/S0006-3495(90)82494-2; BORSE N, 1992, SCIENCE, V256, P1021; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BURGESS GM, 1985, BIOCHEM J, V232, P237, DOI 10.1042/bj2320237; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; Cohen P, 1988, CALMODULIN; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CRANK J, 1975, MATH DIFFUSION, P12; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DONAHUE BS, 1987, CELL CALCIUM, V8, P437, DOI 10.1016/0143-4160(87)90027-3; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HODGKIN AL, 1957, J PHYSIOL-LONDON, V138, P253, DOI 10.1113/jphysiol.1957.sp005850; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KUSHMERICK MJ, 1969, SCIENCE, V166, P1297, DOI 10.1126/science.166.3910.1297; KUSHMERICK MJ, 1980, BIOPHYSICAL CHEM 2, P570; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MINTA A, 1989, J BIOL CHEM, V264, P8171; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NASI E, 1985, BIOPHYS J, V47, P735, DOI 10.1016/S0006-3495(85)83972-2; NEHR E, 1992, J PHYSL, V450, P273; PALMER S, 1989, CELL SIGNAL, V1, P147, DOI 10.1016/0898-6568(89)90004-1; PARYS JB, 1992, J BIOL CHEM, V267, P18776; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SALA F, 1990, BIOPHYS J, V57, P313, DOI 10.1016/S0006-3495(90)82533-9; SHAYMAN JA, 1988, BIOCHEM BIOPH RES CO, V151, P114, DOI 10.1016/0006-291X(88)90566-9; SULPICE JC, 1990, METHODS INOSITIDE RE, P45; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TIMMERMAN MP, 1986, FEBS LETT, V209, P1, DOI 10.1016/0014-5793(86)81073-0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WANG JH, 1952, J AM CHEM SOC, V74, P1611, DOI 10.1021/ja01126a524; WANG JH, 1953, J AM CHEM SOC, V75, P1769, DOI 10.1021/ja01103a539; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	48	881	892	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1812	1815		10.1126/science.1465619	http://dx.doi.org/10.1126/science.1465619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465619				2022-12-01	WOS:A1992KB96400044
J	BLACK, FL				BLACK, FL			WHY DID THEY DIE	SCIENCE			English	Editorial Material							HLA				BLACK, FL (corresponding author), YALE UNIV,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510, USA.							BAUR MP, 1982, HISTOCOMPATIBILITY T; BELICH MP, 1992, NATURE, V357, P326, DOI 10.1038/357326a0; BHATIA K, 1989, HUM BIOL, V61, P45; BLACK FL, 1971, J INFECT DIS, V124, P306, DOI 10.1093/infdis/124.3.306; BORST P, 1991, PARASITOL TODAY, V8, pA29; CATTANEO R, 1986, VIROLOGY, V154, P97, DOI 10.1016/0042-6822(86)90433-2; DEHAY C, 1987, TISSUE ANTIGENS, V30, P49; Denevan William M, 1992, NATIVE POPULATION AM; DUTOIT ED, 1990, TISSUE ANTIGENS, V36, P122, DOI 10.1111/j.1399-0039.1990.tb01812.x; FLEMINGMORAN M, 1991, HUM BIOL, V63, P835; FRIKEL P, 1963, REV MUS PAUL, V14, P11145; GARENNE M, 1990, J INFECT DIS, V161, P1088, DOI 10.1093/infdis/161.6.1088; HEDRICK PW, 1983, GENETICS, V104, P449; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KILLIAMS RC, 1981, AM J PHYS ANTHROPOL, V56, P291; LEE TD, 1988, TISSUE ANTIGENS, V32, P188, DOI 10.1111/j.1399-0039.1988.tb01656.x; MCCRUMB FR, 1963, AM J DIS CHILD, V101, P689; Salzano F. M., 1988, S AM INDIANS CASE ST; SULLIVAN PJ, 1992, SCIENCE, V256, P1743, DOI 10.1126/science.1520396; WATKINS DI, 1992, NATURE, V357, P329, DOI 10.1038/357329a0; [No title captured]	21	119	121	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1739	1741		10.1126/science.1465610	http://dx.doi.org/10.1126/science.1465610			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465610				2022-12-01	WOS:A1992KB96400023
J	CORBOY, JR; BUZY, JM; ZINK, MC; CLEMENTS, JE				CORBOY, JR; BUZY, JM; ZINK, MC; CLEMENTS, JE			EXPRESSION DIRECTED FROM HIV LONG TERMINAL REPEATS IN THE CENTRAL-NERVOUS-SYSTEM OF TRANSGENIC MICE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; CELL-LINES; GLIAL-CELLS; T-CELL; INFECTION; TYPE-1; BRAIN; GENE; TISSUE	Infection with the human immunodeficiency virus (HIV) is frequently accompanied by the AIDS (acquired immunodeficiency syndrome) dementia complex. The role of specific HIV genetic elements in the pathogenesis of central nervous system (CNS) disease is not clear. Transgenic mice were constructed that contained the long terminal repeats (LTRs) of two CNS-derived strains and a T cell tropic strain of HIV-1. Only mice generated with CNS-derived LTRs directed expression in the CNS, particularly in neurons. Thus, some strains of HIV-1 have a selective advantage for gene expression in the brain, and neurons can supply the cellular factors necessary for their transcription.	JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED NEUROL & MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV COMPARAT MED & PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027297, P30AI028748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007000] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27297, AI28748] Funding Source: Medline; NINDS NIH HHS [NS07000] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1987, LANCET, V2, P234; BUDKA H, 1987, ACTA NEUROPATHOL, V75, P185, DOI 10.1007/BF00687080; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFINIS G, 1987, AIDS, V1, P229; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CORBOY JR, UNPUB; EILBOTT DJ, 1989, P NATL ACAD SCI USA, V86, P3337, DOI 10.1073/pnas.86.9.3337; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; GRAY F, 1991, ACTA NEUROPATHOL, V82, P229, DOI 10.1007/BF00294450; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HAROUSE JM, 1989, J VIROL, V63, P2527, DOI 10.1128/JVI.63.6.2527-2533.1989; HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969; HO DD, 1985, NEW ENGL J MED, V313, P1494; Hogan B., 1986, MANIPULATING MOUSE E; HOLAND CA, 1985, J VIROL, V53, P152; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUNSCH C, 1989, J VIROL, V63, P5054, DOI 10.1128/JVI.63.12.5054-5061.1989; KURE K, 1990, ACTA NEUROPATHOL, V80, P393, DOI 10.1007/BF00307693; LANGLEY OK, 1984, HDB NEUROCHEMISTRY, pCH4; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LEONARD J, 1989, AIDS RES HUM RETROV, V5, P421, DOI 10.1089/aid.1989.5.421; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; LEVY JA, 1985, LANCET, V2, P586; LI XL, 1990, J VIROL, V64, P1383, DOI 10.1128/JVI.64.3.1383-1387.1990; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MANNOJI H, 1986, ACTA NEUROPATHOL, V71, P341, DOI 10.1007/BF00688060; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; MYERS G, 1991, HUMAN RETROVIRUSES A; NAVIA BA, 1986, ANN NEUROL, V19, P517, DOI 10.1002/ana.410190602; OVERBEEK PA, 1986, SCIENCE, V231, P1574, DOI 10.1126/science.3006249; POMERANTZ RJ, 1991, J VIROL, V65, P1041, DOI 10.1128/JVI.65.2.1041-1045.1991; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; POPOVIC M, 1984, LANCET, V2, P1472; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PUMAROLASUNE T, 1987, ANN NEUROL, V21, P490, DOI 10.1002/ana.410210513; ROSEN CA, 1985, J VIROL, V55, P862, DOI 10.1128/JVI.55.3.862-866.1985; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SKOWRONSKI J, 1991, J VIROL, V65, P754, DOI 10.1128/JVI.65.2.754-762.1991; SMALL JA, 1989, J VIROL, V63, P1891, DOI 10.1128/JVI.63.5.1891-1896.1989; STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360; VAZEUX R, 1987, AM J PATHOL, V126, P403; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WALKER DG, 1989, J NEUROL NEUROSUR PS, V52, P583, DOI 10.1136/jnnp.52.5.583; WARD JM, 1987, AM J PATHOL, V127, P199; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; WOLFS TFW, 1991, VIROLOGY, V185, P195, DOI 10.1016/0042-6822(91)90767-6	57	89	90	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1804	1808						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465618				2022-12-01	WOS:A1992KB96400042
J	DARMIENTO, J; DALAL, SS; OKADA, Y; BERG, RA; CHADA, K				DARMIENTO, J; DALAL, SS; OKADA, Y; BERG, RA; CHADA, K			COLLAGENASE EXPRESSION IN THE LUNGS OF TRANSGENIC MICE CAUSES PULMONARY-EMPHYSEMA	CELL			English	Article							CONNECTIVE-TISSUE; HEPATIC-FIBROSIS; ANIMAL-MODELS; PATHOGENESIS; ELASTASE; DISEASE; GENE; METALLOPROTEINASES; INHIBITORS; EFFICIENT	Transgenic mice were generated that expressed a human collagenase transgene in their lungs under the direction of the haptoglobin promoter. Histological analysis demonstrated disruption of the alveolar walls and coalescence of the alveolar spaces with no evidence of fibrosis or inflammation. This pathology is strikingly similar to the morphological changes observed in human emphysema and therefore implicates interstitial collagenase as a possible etiological agent in the disease process. Although elastase has been proposed as the primary enzyme responsible for emphysematous lung damage, this study provides evidence that other extracellular matrix proteases could play a role in emphysema. In addition, these transgenic mice are a defined genetic animal model system to study the pathogenesis of emphysema.	KANAZAWA UNIV, SCH MED, DEPT PATHOL, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University	DARMIENTO, J (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT BIOCHEM, PISCATAWAY, NJ 08854 USA.		Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755	NIGMS NIH HHS [GM 38731] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038731] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG RA, 1989, THERAPEUTIC APPROACHES TO INFLAMMATORY DISEASES, P84; BERMAN M, 1980, COLLAGENASE NORMAL P, P141; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; CLEWELL DB, 1972, J BACTERIOL, V110, P1135, DOI 10.1128/JB.110.3.1135-1146.1972; CORRIN B, 1990, LUNGS, V5, P167; EMONARD H, 1989, HEPATOLOGY, V10, P77, DOI 10.1002/hep.1840100116; Gibbs AR, 1984, OCCUPATIONAL LUNG DI, P129; GOLDRING IP, 1968, ARCH ENVIRON HEALTH, V16, P59, DOI 10.1080/00039896.1968.10665015; GROSS P, 1965, ARCH ENVIRON HEALTH, V11, P50, DOI 10.1080/00039896.1965.10664169; HANCE AJ, 1975, AM REV RESPIR DIS, V112, P657; HARRIS ED, 1974, NEW ENGL J MED, V291, P652, DOI 10.1056/NEJM197409262911305; HARRIS ED, 1977, MAMMALIAN COLLAGENAS, P249; Hogan B., 1986, MANIPULATING MOUSE E; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; HOIDAL JR, 1989, HDB ANIMAL MODELS PU; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; JANOFF A, 1985, AM REV RESPIR DIS, V132, P417; JOHANSON WG, 1972, J CLIN INVEST, V51, P288, DOI 10.1172/JCI106813; KARLINSKY JB, 1978, AM REV RESPIR DIS, V117, P1109; KESSLER S, 1975, LAB INVEST, V32, P71; KILBURN KH, 1971, ARCH INTERN MED, V127, P884, DOI 10.1001/archinte.127.5.884; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUSHNER I, 1987, DIS MARKERS, V5, P1; LAROS CD, 1976, RESPIRATION, V33, P325, DOI 10.1159/000193748; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MCLAUGHLIN RF, 1971, CHEST, V59, P592, DOI 10.1378/chest.59.6.592; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAELI D, 1974, CLIN IMMUNOL IMMUNOP, V3, P187, DOI 10.1016/0090-1229(74)90004-X; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; OKAZAKI I, 1974, NATURE, V252, P49, DOI 10.1038/252049a0; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; PINNELL SR, 1972, NEW ENGL J MED, V286, P1013, DOI 10.1056/NEJM197205112861901; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PUTT F, 1972, MANUAL HISTOPATHOLOG, P111; RILEY DJ, 1987, AM REV RESPIR DIS, V135, P441; RUBIN E, 1988, PATHOLOGY, P542; Sambrook J., 1989, MOL CLONING LAB MANU; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469, DOI 10.1164/arrd.1977.116.3.469; SNIDER GL, 1989, ANNU REV MED, V40, P411; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P149, DOI 10.1164/arrd.1986.133.1.149; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACEY A, 1988, NATURE, V332, P131, DOI 10.1038/332131a0; UITTO J, 1987, CONNECTIVE TISSUE DI, V12; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YU SY, 1978, EXP MOL PATHOL, V29, P37, DOI 10.1016/0014-4800(78)90024-2; [No title captured]	55	280	300	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					955	961		10.1016/0092-8674(92)90391-O	http://dx.doi.org/10.1016/0092-8674(92)90391-O			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458541				2022-12-01	WOS:A1992KB99000008
J	EISENLOHR, LC; BACIK, I; BENNINK, JR; BERNSTEIN, K; YEWDELL, JW				EISENLOHR, LC; BACIK, I; BENNINK, JR; BERNSTEIN, K; YEWDELL, JW			EXPRESSION OF A MEMBRANE PROTEASE ENHANCES PRESENTATION OF ENDOGENOUS ANTIGENS TO MHC CLASS I-RESTRICTED LYMPHOCYTES-T	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANGIOTENSIN-CONVERTING ENZYME; CELL-SURFACE EXPRESSION; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; INFLUENZA NUCLEOPROTEIN; VACCINIA VIRUS; RECOGNITION; MOLECULES	We find that expression of the membrane dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE) enhances presentation of certain endogenously synthesized peptides to major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes. ACE appears to function only in an intracellular secretory compartment of antigen-presenting cells. ACE-enhanced antigen presentation requires the expression of the putative antigenic peptide transporters, TAP1 and TAP2. These findings demonstrate that a protease can influence the processing of endogenously synthesized antigens and strongly suggest that longer peptides can be transported from the cytosol to a secretory compartment where trimming of antigenic peptides to the lengths preferred by MHC class I molecules can occur if the appropriate protease is present.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20906; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Emory University			yewdell, jyewdell@nih.gov jonathan/A-1702-2012					ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; BENNINK JR, 1986, J VIROL, V57, P786, DOI 10.1128/JVI.57.3.786-791.1986; BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER HC, 1988, CELL, V52, P253, DOI 10.1016/0092-8674(88)90514-4; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; EISENLOHR LC, 1992, J EXP MED, V175, P481, DOI 10.1084/jem.175.2.481; EISENLOHR LC, 1992, J IMMUNOL METHODS, V154, P131, DOI 10.1016/0022-1759(92)90220-N; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KOSLOWSKI S, 1992, J EXP MED, V175, P1417; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; NEELS HM, 1983, CLIN CHEM, V29, P1399; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SHERMAN LA, 1992, J EXP MED, V175, P1221, DOI 10.1084/jem.175.5.1221; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1988, J IMMUNOL, V141, P3324; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANPEL A, 1989, IMMUNOGENETICS, V29, P75; WEI L, 1991, J BIOL CHEM, V266, P5540; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033; YEWDELL JW, 1988, CELL, V52, P843, DOI 10.1016/0092-8674(88)90426-6; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	47	161	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					963	972		10.1016/0092-8674(92)90392-P	http://dx.doi.org/10.1016/0092-8674(92)90392-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333889				2022-12-01	WOS:A1992KB99000009
J	FREIJE, D; HELMS, C; WATSON, MS; DONISKELLER, H				FREIJE, D; HELMS, C; WATSON, MS; DONISKELLER, H			IDENTIFICATION OF A 2ND PSEUDOAUTOSOMAL REGION NEAR THE XQ AND YQ TELOMERES	SCIENCE			English	Article							HUMAN SEX-CHROMOSOMES; SHORT ARM; HUMAN SPERMATOCYTES; PAIRING REGION; DNA; SEQUENCES; HOMOLOGY; AMPLIFICATION; POLYMORPHISM; EVOLUTION	The telomeres of Xq and Yq have been observed to associate during meiosis, and in rare cases a short synaptonemal complex is present. Molecular cloning of loci from Xqter and Yqter has revealed that their sequence homology extends over 400 kilobases, which suggests the possibility of genetic exchange. This hypothesis was tested by the development of two highly informative microsatellite markers from yeast artificial chromosome clones that carried Xqter sequences and the following of their inheritance in a set of reference pedigrees from the Centre d'Etude du Polymorphisme Humain in Paris, France. From a total of 195 informative male meioses, four recombination events between these loci were observed. In three cases, paternal X alleles were inherited by male offspring, and in one case a female offspring inherited her father's Y allele. These data support the existence of genetic exchange at Xq-Yq, which defines a second pseudoautosomal region between the sex chromosomes.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV HUMAN MOLEC GENET,660 S EUCLID ST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHGRI NIH HHS [HG00100, HG00201] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AFFARA NA, 1986, NUCLEIC ACIDS RES, V14, P5353, DOI 10.1093/nar/14.13.5353; ANDERSSON M, 1986, SCIENCE, V233, P786, DOI 10.1126/science.3738510; ARVEILER B, 1989, GENOMICS, V4, P460, DOI 10.1016/0888-7543(89)90269-3; BENGTSSON BO, 1987, ANN HUM GENET, V51, P57, DOI 10.1111/j.1469-1809.1987.tb00865.x; BICKMORE WA, 1987, NUCLEIC ACIDS RES, V15, P6261, DOI 10.1093/nar/15.15.6261; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; CHANDLEY AC, 1984, CYTOGENET CELL GENET, V38, P241, DOI 10.1159/000132070; COOKE HJ, 1984, NATURE, V311, P259, DOI 10.1038/311259a0; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; EDWARDS A, 1991, AM J HUM GENET, V49, P746; FREIJE D, 1992, AM J HUM GENET, V51, P66; GREEN P, UNPUB CRI MAP VERSIO; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Koller PC, 1934, J GENET, V29, P159, DOI 10.1007/BF02982193; KRISHNAN BR, 1991, NUCLEIC ACIDS RES, V19, P1153, DOI 10.1093/nar/19.5.1153; LUTY JA, 1990, AM J HUM GENET, V46, P776; PAGE D C, 1987, Genomics, V1, P243, DOI 10.1016/0888-7543(87)90051-6; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PAGE DC, 1984, NATURE, V311, P119, DOI 10.1038/311119a0; PEDICINI A, 1991, GENOMICS, V11, P482, DOI 10.1016/0888-7543(91)90167-D; ROUYER F, 1986, NATURE, V319, P291, DOI 10.1038/319291a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SIMMLER MC, 1985, NATURE, V317, P692, DOI 10.1038/317692a0; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOLARI AJ, 1980, CHROMOSOMA, V81, P315, DOI 10.1007/BF00368145; SPEED RM, 1988, HUM GENET, V78, P260, DOI 10.1007/BF00291673; SPEED RM, 1990, HUM GENET, V84, P547; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R	31	152	156	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1784	1787		10.1126/science.1465614	http://dx.doi.org/10.1126/science.1465614			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465614				2022-12-01	WOS:A1992KB96400036
J	HANNON, GJ; MARONEY, PA; YU, YT; HANNON, GE; NILSEN, TW				HANNON, GJ; MARONEY, PA; YU, YT; HANNON, GE; NILSEN, TW			INTERACTION OF U6 SNRNA WITH A SEQUENCE REQUIRED FOR FUNCTION OF THE NEMATODE SL RNA IN TRANSSPLICING	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PRE-MESSENGER-RNA; LEADER RNA; CAENORHABDITIS-ELEGANS; TRANSSPLICING INVITRO; A-PROTEIN; U1 SNRNA; BINDING; SM; SITE	Nematode trans-spliced leader (SL) RNAs are composed of two domains, an exon [the 22-nucleotide spliced leader] and a small nuclear RNA (snRNA)-like sequence. Participation in vitro of the spliced leader RNA in trans-splicing reactions is independent of the exon sequence or size and instead depends on features contained in the snRNA-like domain of the molecule. Chemical modification interference analysis has revealed that two short sequence elements in the snRNA-like domain are necessary for SL RNA activity. These elements are sufficient for such activity because when added to a 72-nucleotide fragment of a nematode U1 snRNA, this hybrid RNA could participate in trans-splicing reactions in vitro. One of the critical sequence elements may function by base-pairing with U6 snRNA, an essential U snRNA for both cis- and trans-splicing.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Hannon, Gregory/AAB-3568-2019		NIAID NIH HHS [AI28799] Funding Source: Medline; NIGMS NIH HHS [GM31528] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH M, 1990, NUCLEIC ACIDS RES, V18, P449, DOI 10.1093/nar/18.3.449; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; Cao L, UNPUB; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; ENGLAND TE, 1978, NATURE, V275, P560, DOI 10.1038/275560a0; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JOSHUA GWP, 1991, MOL BIOCHEM PARASIT, V460, P209; LASALA D, UNPUB; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MARONEY PA, UNPUB; MATTAJ IW, 1988, STRUCTURE FUNCTION M, P100; NILSEN TW, 1989, MOL CELL BIOL, V9, P3543, DOI 10.1128/MCB.9.8.3543; PATTON JR, 1989, MOL CELL BIOL, V9, P3360, DOI 10.1128/MCB.9.8.3360; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SHAMBAUGH J, UNPUB; SHARP PA, 1987, CELL, V50, P147, DOI 10.1016/0092-8674(87)90207-8; SUROWY CS, 1989, MOL CELL BIOL, V9, P4179, DOI 10.1128/MCB.9.10.4179; TAKACS AM, 1988, P NATL ACAD SCI USA, V85, P7932, DOI 10.1073/pnas.85.21.7932; THOMAS J, 1990, NUCLEIC ACIDS RES, V18, P2633, DOI 10.1093/nar/18.9.2633; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; VANDOREN K, 1988, NATURE, V335, P556; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; ZENG WL, 1990, MOL CELL BIOL, V10, P2765, DOI 10.1128/MCB.10.6.2765	32	53	54	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1775	1780		10.1126/science.1465612	http://dx.doi.org/10.1126/science.1465612			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465612				2022-12-01	WOS:A1992KB96400034
J	JEGALIAN, BG; DEROBERTIS, EM				JEGALIAN, BG; DEROBERTIS, EM			HOMEOTIC TRANSFORMATIONS IN THE MOUSE INDUCED BY OVEREXPRESSION OF A HUMAN HOX3.3 TRANSGENE	CELL			English	Article							HUMAN HOMEOBOX GENES; SPINAL-CORD; DROSOPHILA; EXPRESSION; ANTENNAPEDIA; MURINE; ORGANIZATION; PROTEIN; SEQUENCE; HOX-1.1	A permanent transgenic mouse line was generated carrying 40 copies of the human Hox3.3 gene. The resulting mice express large amounts of Hox3.3 protein in posterior regions of the embryo where this homeodomain protein is normally not expressed. The transgene causes homeotic transformations of the skeleton, in particular the appearance of an extra pair of ribs in the lumbar region, transformation of the shape of posterior ribs into that of more anterior ones, and the joining of an additional pair of ribs to the sternum. The phenotype of this line resembles that obtained by the targeted loss-of-function mutation of Hox3.1 (Le Mouellic et al., 1992). In transient assays, the human Hox3.3 transgene leads to the formation of additional ribs in more posterior vertebrae as well.			JEGALIAN, BG (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.			De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD 21502-07] Funding Source: Medline; NIGMS NIH HHS [GM 08042-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021502, R01HD021502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acampora D, 1991, Oxf Surv Eukaryot Genes, V7, P1; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; CARRASCO AE, 1984, CELL, V37, P409, DOI 10.1016/0092-8674(84)90371-4; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1988, EMBO J, V7, P2139, DOI 10.1002/j.1460-2075.1988.tb03053.x; COLETTA PL, 1991, MECH DEVELOP, V35, P129, DOI 10.1016/0925-4773(91)90063-C; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ESTIBEIRO JP, 1990, POSTIMPLANTATION MAM, P173; GARBER RL, 1983, EMBO J, V2, P2027, DOI 10.1002/j.1460-2075.1983.tb01696.x; GAUNT SJ, 1988, DEVELOPMENT, V104, P169; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GILMAN M, 1989, CURRENT PROTOCOLS MO, P471; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Green EL, 1941, GENETICS, V26, P192; GREEN MC, 1989, GENETIC VARIANTS STR; HAFEN E, 1984, NATURE, V307, P287, DOI 10.1038/307287a0; HOGAN BLM, 1988, MANIPULATING MOUSE E; JEGALIAN BJ, 1992, IN PRESS MECH DEV; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KESSEL M, 1992, DEVELOPMENT, V115, P4487; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1984, CELL, V37, P403, DOI 10.1016/0092-8674(84)90370-2; OJEDA JL, 1970, STAIN TECHNOL, V45, P137; OLIVER G, 1989, GENE DEV, V3, P641, DOI 10.1101/gad.3.5.641; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; WRIGHT CVE, 1989, CELL, V59, P81, DOI 10.1016/0092-8674(89)90871-4	46	159	163	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					901	910		10.1016/0092-8674(92)90387-R	http://dx.doi.org/10.1016/0092-8674(92)90387-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1360874				2022-12-01	WOS:A1992KB99000004
J	KASSAVETIS, GA; JOAZEIRO, CAP; PISANO, M; GEIDUSCHEK, EP; COLBERT, T; HAHN, S; BLANCO, JA				KASSAVETIS, GA; JOAZEIRO, CAP; PISANO, M; GEIDUSCHEK, EP; COLBERT, T; HAHN, S; BLANCO, JA			THE ROLE OF THE TATA-BINDING PROTEIN IN THE ASSEMBLY AND FUNCTION OF THE MULTISUBUNIT YEAST RNA POLYMERASE-III TRANSCRIPTION FACTOR, TFIIIB	CELL			English	Article							HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; DNA; INVITRO; PROMOTER; SUBUNIT; BACTERIOPHAGE-T4; COMPONENTS; ACTIVATION; COMPLEXES	The Saccharomyces cerevisiae RNA polymerase III transcription factor (TF)IIIB has been assembled from three components. An assembly pathway of these polypeptides, which specifies their interactions, has been determined. The TATA-binding protein, TBP, and the TFIIB-related BRF1 gene product BRF, together reconstitute the transcription factor activity and TFIIIC-dependent DNA-binding activity of the B' component of TFIIIB. BRF alone weakly binds to a TFIIIC-tRNA gene complex; TBP greatly stabilizes this interaction. B" transcription factor actitivity is recovered with its previously identified 90 kd polypeptide from SDS-polyacrylamide gels. Incorporation of the 90 kd B" protein into the transcription complex requires TBP. The heparin-resistant TFIIIB-DNA complex retains all three of its constituent proteins, TBP, BRF, and B".	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of California System; University of California San Diego; Fred Hutchinson Cancer Center	KASSAVETIS, GA (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.		Pisano, Marina/C-3978-2015	Pisano, Marina/0000-0002-0649-1010	NHLBI NIH HHS [HL07312] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BRAUN BR, 1992, IN PRESS J BIOL CHEM; BRAUN BR, 1992, IN PRESS J MOL BIOL; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; COLBERT T, 1992, IN PRESS GENES DEV; CORMACK BP, 1992, CELL, V69, P665; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; KASSAVETIS GA, 1984, P NATL ACAD SCI-BIOL, V81, P5101, DOI 10.1073/pnas.81.16.5101; KUNKEL GR, 1991, BIOCHIM BIOPHYS ACTA, V1088, P1, DOI 10.1016/0167-4781(91)90146-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; OMAI L, 1992, CELL, V68, P965; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMMEN KA, 1992, J MOL BIOL, V223, P873, DOI 10.1016/0022-2836(92)90249-J; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WEIS L, 1992, IN PRESS FASEB J; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	41	218	218	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1055	1064		10.1016/0092-8674(92)90399-W	http://dx.doi.org/10.1016/0092-8674(92)90399-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458536				2022-12-01	WOS:A1992KB99000016
J	KIELECZAWA, J; DUNN, JJ; STUDIER, FW				KIELECZAWA, J; DUNN, JJ; STUDIER, FW			DNA SEQUENCING BY PRIMER WALKING WITH STRINGS OF CONTIGUOUS HEXAMERS	SCIENCE			English	Article							SINGLE-STRANDED-DNA; BACTERIOPHAGE-T7 DNA; ESCHERICHIA-COLI; BINDING-PROTEIN; HYBRIDIZATION; POLYMERASE	When template DNA is saturated with a single-stranded DNA binding protein (SSB), strings of three or four contiguous hexanucleotides (hexamers) can cooperate through base-stacking interactions to prime DNA synthesis specifically from the 3' end of the string. Under the same conditions, priming by individual hexamers is suppressed. Strings of three or four hexamers representing more than 200 of the 4096 possible hexamers primed easily readable sequence ladders at more than 75 different sites in single-stranded or denatured double-stranded templates 6.4 kilobases to 40 kilobase pairs long, with a success rate of 60 to 90 percent. A synthesis of 1 micromole of hexamer supplies enough material for thousands of primings, so multiple libraries of all 4096 hexamers could be distributed at a reasonable cost. Such libraries would allow rapid and economical sequencing. Automating this strategy could increase the speed and efficiency of large-scale DNA sequencing by at least an order of magnitude.			KIELECZAWA, J (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.							BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HUNKAPILLER T, 1991, SCIENCE, V254, P59, DOI 10.1126/science.1925562; Khrapko K R, 1991, DNA Seq, V1, P375, DOI 10.3109/10425179109020793; KHRAPKO KR, 1989, FEBS LETT, V256, P118, DOI 10.1016/0014-5793(89)81730-2; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; QUARTIN RS, 1989, BIOCHEMISTRY-US, V28, P1040, DOI 10.1021/bi00429a018; SHERMAN LA, 1970, J VIROL, V6, P841, DOI 10.1128/JVI.6.6.841-846.1970; STUDIER FW, 1989, P NATL ACAD SCI USA, V86, P6917, DOI 10.1073/pnas.86.18.6917; SZYBALSKI W, 1990, GENE, V90, P177, DOI 10.1016/0378-1119(90)90458-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1989, J BIOL CHEM, V264, P6447; VANWEZENBEEK PMGF, 1980, GENE, V11, P129, DOI 10.1016/0378-1119(80)90093-1; WBRIGHT R, 1992, GENE, V114, P81; WEISS B, 1971, METHODS ENZYMOLOGY D, V21, P319; 1990, UNDERSTANDING OUR GE	19	104	131	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1787	1791		10.1126/science.1465615	http://dx.doi.org/10.1126/science.1465615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465615				2022-12-01	WOS:A1992KB96400037
J	KITAJIMA, I; SHINOHARA, T; BILAKOVICS, J; BROWN, DA; XU, X; NERENBERG, M				KITAJIMA, I; SHINOHARA, T; BILAKOVICS, J; BROWN, DA; XU, X; NERENBERG, M			ABLATION OF TRANSPLANTED HTLV-I TAX-TRANSFORMED TUMORS IN MICE BY ANTISENSE INHIBITION OF NF-KAPPA-B	SCIENCE			English	Article							T-CELL LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTOR; TRANSGENIC MICE; RETROVIRUS; EXPRESSION; LYMPHOMA; PROTEIN; GENE; OLIGODEOXYNUCLEOTIDES	Mice transgenic for the human T cell leukemia virus (HTLV-1) Tax gene develop fibroblastic tumors that express NF-kappaB-inducible early genes. In vitro inhibition of NF-kappaB expression by antisense oligodeoxynucleotides (ODNs) inhibited growth of these culture-adapted Tax-transformed fibroblasts as well as an HTLV-I-transformed human lymphocyte line. In contrast, antisense inhibition of Tax itself had no apparent effect on cell growth. Mice treated with antisense to NF-kappaB ODNs showed rapid regression of transplanted fibrosarcomas. This suggests that NF-kappaB expression may be necessary for the maintenance of the malignant phenotype and provides a therapeutic approach for HTLV-I-associated disease.	Scripps Res Inst, DEPT NEUROPHARMACOL, CVN 10, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCI NIH HHS [CA50234] Funding Source: Medline; NIMH NIH HHS [MH47680] Funding Source: Medline; NINDS NIH HHS [NS01330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH047680] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V63, P1072; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; FELGNER PL, 1988, P NATL ACAD SCI USA, V85, P7413; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GOODCHILD J, 1988, P NATL ACAD SCI USA, V85, P5507, DOI 10.1073/pnas.85.15.5507; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, UNPUB; KITAJIMA I, IN PRESS J BIOL CHEM; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; MACGREGOR GR, 1989, METHODS MOL BIOL; MILLER PS, 1980, J BIOL CHEM, V255, P9659; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; Winer BJ., 1971, STAT PRINCIPLES EXPT; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	27	270	295	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1792	1795		10.1126/science.1299224	http://dx.doi.org/10.1126/science.1299224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1299224				2022-12-01	WOS:A1992KB96400038
J	KOCH, AE; POLVERINI, PJ; KUNKEL, SL; HARLOW, LA; DIPIETRO, LA; ELNER, VM; ELNER, SG; STRIETER, RM				KOCH, AE; POLVERINI, PJ; KUNKEL, SL; HARLOW, LA; DIPIETRO, LA; ELNER, VM; ELNER, SG; STRIETER, RM			INTERLEUKIN-8 AS A MACROPHAGE-DERIVED MEDIATOR OF ANGIOGENESIS	SCIENCE			English	Article							SYNOVIAL TISSUE MACROPHAGES; TUMOR NECROSIS FACTOR; MESSENGER-RNA; NEUTROPHIL; PEPTIDE; NEOVASCULARIZATION; PURIFICATION; INHIBITION; INDUCTION; MONOCYTES	Angiogenic factors produced by monocytes-macrophages are involved in the pathogenesis of chronic inflammatory disorders characterized by persistent angiogenesis. The possibility was tested that interleukin-8 (IL-8), which is a cytokine that is chemotactic for lymphocytes and neutrophils, is also angiogenic. Human recombinant IL-8 was potently angiogenic when implanted in the rat cornea and induced proliferation and chemotaxis of human umbilical vein endothelial cells. Angiogenic activity present in the conditioned media of inflamed human rheumatoid synovial tissue macrophages or lipopolysaccharide-stimulated blood monocytes was equally blocked by antibodies to either IL-8 or tumor necrosis factor-alpha. An IL-8 antisense oligonucleotide specifically blocked the production of monocyte-induced angiogenic activity. These data suggest a function for macrophage-derived IL-8 in angiogenesis-dependent disorders such as rheumatoid arthritis, tumor growth, and wound repair.	UNIV MICHIGAN,DEPT OPHTHALMOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT MED,DIV PULM,ANN ARBOR,MI 48109; LAKESIDE VET ADM MED CTR,CHICAGO,IL 60611; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; LOYOLA UNIV,MED CTR,DEPT SURG,MAYWOOD,IL 60153	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Loyola University Chicago	KOCH, AE (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ARTHRIT & CONNECT TISSUE DIS SECT,WARD BLDG 3-315,CHICAGO,IL 60611, USA.		Polverini, Peter/AAJ-8392-2020; Huang, H/E-9490-2010; Koch, Alisa E/B-6894-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692, R29AR041492] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39926] Funding Source: Medline; NIAMS NIH HHS [AR41492, AR30692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BRENNAN FM, 1990, EUR J IMMUNOL, V20, P2141, DOI 10.1002/eji.1830200938; DEMARCO D, 1991, BIOCHEM BIOPH RES CO, V174, P411, DOI 10.1016/0006-291X(91)91431-B; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1988, BIOCHEM BIOPH RES CO, V154, P205, DOI 10.1016/0006-291X(88)90671-7; KOCH AE, 1986, ARTHRITIS RHEUM, V29, P471, DOI 10.1002/art.1780290403; KOCH AE, 1991, J IMMUNOL, V147, P2187; KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233; KOCH AE, 1988, J RHEUMATOL, V15, P1058; KOCH AE, 1991, AGENTS ACTIONS, V34, P350, DOI 10.1007/BF01988728; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PEICHL P, 1992, ANN RHEUM DIS, V51, P19, DOI 10.1136/ard.51.1.19; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; POLVERINI PJ, 1989, CYTOKINES, P54; SCHRODER JM, 1986, J INVEST DERMATOL, V87, P53, DOI 10.1111/1523-1747.ep12523566; SELTZ M, 1991, J CLIN INVEST, V87, P463; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; STOECKLE M Y, 1990, New Biologist, V2, P313; VISSERS MCM, 1988, J IMMUNOL METHODS, V110, P203, DOI 10.1016/0022-1759(88)90104-4; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355	27	1852	1928	1	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1798	1801		10.1126/science.1281554	http://dx.doi.org/10.1126/science.1281554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1281554				2022-12-01	WOS:A1992KB96400040
J	LLOYD, AM; WALBOT, V; DAVIS, RW				LLOYD, AM; WALBOT, V; DAVIS, RW			ARABIDOPSIS AND NICOTIANA ANTHOCYANIN PRODUCTION ACTIVATED BY MAIZE REGULATOR-R AND REGULATOR-C1	SCIENCE			English	Article							TISSUE-SPECIFIC EXPRESSION; CHALCONE SYNTHASE; TRANSCRIPTIONAL ACTIVATORS; GENE; HOMOLOGY; MYB; TRANSFORMATION; INDUCTION; INFECTION; ELICITOR	Anthocyanin pathway-specific transcriptional activators Rand C1 from the monocot maize were expressed in two dicots, Arabidopsis thaliana and Nicotiana tabacum. Expression of R caused augmented anthocyanin pigmentation in both plant species and augmented trichome (hair) production in Arabidopsis. Alone, C1 had no effect. Hybrid transgenic Arabidopsis expressing both C1 and R produced anthocyanins in root, petal, and stamen tissues that normally never express anthocyanins. When R was expressed in the transparent testa glabrous (without anthocyanins and trichomes) mutant of Arabidopsis, the deficiency was complemented and both anthocyanins and trichomes were restored.	STANFORD UNIV,DEPT BIOL,STANFORD,CA 94305	Stanford University	LLOYD, AM (corresponding author), STANFORD UNIV,DEPT BIOCHEM,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32422] Funding Source: Medline; PHS HHS [R37-H600198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bateson W., 1901, J R HORT SOC, V26, P1; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; Coe E. H. Jr., 1988, Corn and corn improvement. Third edition., P81; DAMIANI RD, UNPUB; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; DRUMMHERREL H, 1981, PHOTOCHEM PHOTOBIOL, V33, P391, DOI 10.1111/j.1751-1097.1981.tb05435.x; FEINBAUM RL, 1988, MOL CELL BIOL, V8, P1985, DOI 10.1128/MCB.8.5.1985; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; HABEREDER H, 1989, PLANTA, V177, P58, DOI 10.1007/BF00392154; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; Hunt A. G., UNPUB; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Koornneef M., 1981, ARABID INF SERV, V18, P45; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KUBASEK W, UNPUB; LLOYD AL, UNPUB; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUDWIG SR, 1990, SCIENCE, V247, P449, DOI 10.1126/science.247.4941.449; McClure J. W, 1975, FLAVONOIDS, P970, DOI DOI 10.1007/978-1-4899-2909-9_18; MEHDY MC, 1987, EMBO J, V6, P1527, DOI 10.1002/j.1460-2075.1987.tb02396.x; Mendel JG., 1865, VERHANDLUNGEN NATURF, V4, P3, DOI DOI 10.1093/OXFORDJOURNALS.JHERED.A106151; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; RYDER TB, 1987, MOL GEN GENET, V210, P219, DOI 10.1007/BF00325687; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHIRLEY BW, 1992, PLANT CELL, V4, P333, DOI 10.1105/tpc.4.3.333; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201	30	404	451	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1773	1775		10.1126/science.1465611	http://dx.doi.org/10.1126/science.1465611			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465611				2022-12-01	WOS:A1992KB96400033
J	LOBO, SM; TANAKA, M; SULLIVAN, ML; HERNANDEZ, N				LOBO, SM; TANAKA, M; SULLIVAN, ML; HERNANDEZ, N			A TBP COMPLEX ESSENTIAL FOR TRANSCRIPTION FROM TATA-LESS BUT NOT TATA-CONTAINING RNA POLYMERASE-III PROMOTERS IS PART OF THE TFIIIB FRACTION	CELL			English	Article							HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; ACCURATE TRANSCRIPTION; MULTIPLE FACTORS; BINDING-PROTEIN; SNRNA PROMOTER; FACTOR-TAU; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; FACTOR-EPSILON	The TATA box-binding protein TBP directs transcription by all three eukaryotic RNA polymerases. In mammalian cells, TBP is found in at least three different complexes: SL1, D-TFIID, and B-TFIID. While SL1 and D-TFIID are involved in RNA polymerase I and II transcription, respectively, no unique function has been assigned to the B-TFIID complex. Here we show that the TFIIIB fraction required for RNA polymerase III transcription contains two separable components, one of which is a TBP-containing complex that may correspond to B-TFIID. For transcription of TATA-less RNA polymerase III genes such as the VAI, 5S, and 7SL genes, this complex cannot be replaced by either TBP alone or the D-TFIID complex. In contrast, TBP alone is active for basal transcription from the TATA-containing U6 promoter. This indicates different requirements for recruiting TBP to TATA-less and TATA-containing RNA polymerase III promoters.			LOBO, SM (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Hernandez, Nouria/0000-0003-1465-4585	NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [R01 GM38810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P2403, DOI 10.1093/nar/15.6.2403; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P583; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GEIDUSCHEK EP, 1992, IN PRESS TRANSCRIPTI; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HARLOW E, 1988, ANTIBODIES LABORATOR; HERNANDEZ N, 1992, IN PRESS COLD SPRING; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LITTLE RD, 1989, GENOMICS, V4, P376, DOI 10.1016/0888-7543(89)90345-5; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHASTRY BS, 1982, J BIOL CHEM, V257, P2979; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3584	65	147	148	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1029	1040		10.1016/0092-8674(92)90397-U	http://dx.doi.org/10.1016/0092-8674(92)90397-U			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458534				2022-12-01	WOS:A1992KB99000014
J	MIZOGUCHI, H; O'SHEA, JJ; LONGO, DL; LOEFFLER, CM; MCVICAR, DW; OCHOA, AC				MIZOGUCHI, H; O'SHEA, JJ; LONGO, DL; LOEFFLER, CM; MCVICAR, DW; OCHOA, AC			ALTERATIONS IN SIGNAL TRANSDUCTION MOLECULES IN LYMPHOCYTES-T FROM TUMOR-BEARING MICE	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; ZETA-CHAIN; FC-RECEPTORS; ACTIVATION; COMPLEX; PHOSPHORYLATION; GENERATION; EXPRESSION; CD4	Impaired immune responses occur frequently in cancer patients or in tumor-bearing mice, but the mechanisms of the tumor-induced immune defects remain poorly understood. In an in vivo murine colon carcinoma model (MCA-38), animals bearing a tumor longer than 26 days develop CD8+ T cells with impaired cytotoxic function, decreased expression of the tumor necrosis factor-alpha and granzyme B genes, and decreased ability to mediate an antitumor response in vivo. T lymphocytes from tumor-bearing mice expressed T cell antigen receptors that contained low amounts of CD3gamma and completely lacked CD3zeta, which was replaced by the Fc(epsilon) gamma-chain. Expression of the tyrosine kinases p56lck and p59fyn was also reduced. These changes could be the basis of immune defects in tumor-bearing hosts.	NCI, FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LABS, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Longo, Dan L./F-6022-2011; McVicar, Daniel/G-1970-2015		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; ALTMAN A, 1990, CRIT REV IMMUNOL, V10, P347; BRODER S, 1978, NEW ENGL J MED, V299, P1281, DOI 10.1056/NEJM197812072992305; BUFERNE M, 1992, J IMMUNOL, V148, P657; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERSH EM, 1965, NEW ENGL J MED, V273, P1006, DOI 10.1056/NEJM196511042731903; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; LOEFFLER CM, 1992, J IMMUNOL, V149, P949; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MIZOGUCHI H, UNPUB; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NORTH RJ, 1984, J EXP MED, V159, P1295, DOI 10.1084/jem.159.5.1295; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHMITTVERHULST AM, 1987, NATURE, V325, P628, DOI 10.1038/325628a0; SUSSMAN JJ, 1988, NATURE, V334, P625, DOI 10.1038/334625a0; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TAKASUGI M, 1977, CANCER RES, V37, P413; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WEISS A, 1990, J CLIN INVEST, V86, P1015, DOI 10.1172/JCI114803; Weissman A M, 1989, Year Immunol, V4, P74; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; YOUNG RC, 1972, AM J MED, V52, P63, DOI 10.1016/0002-9343(72)90008-3	45	623	655	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1795	1798		10.1126/science.1465616	http://dx.doi.org/10.1126/science.1465616			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465616				2022-12-01	WOS:A1992KB96400039
J	MOUNKES, LC; JONES, RS; LIANG, BC; GELBART, W; FULLER, MT				MOUNKES, LC; JONES, RS; LIANG, BC; GELBART, W; FULLER, MT			A DROSOPHILA MODEL FOR XERODERMA-PIGMENTOSUM AND COCKAYNES-SYNDROME - HAYWIRE ENCODES THE FLY HOMOLOG OF ERCC3, A HUMAN EXCISION REPAIR GENE	CELL			English	Article							AFFECT MICROTUBULE FUNCTION; IRRADIATED MAMMALIAN-CELLS; BETA-TUBULIN SUBUNIT; DNA-REPAIR; ULTRAVIOLET-LIGHT; MOLECULAR CHARACTERIZATION; INTERACTING GENES; HUMAN-FIBROBLASTS; UV IRRADIATION; RNA-SYNTHESIS	The haywire gene of Drosophila encodes a protein with 66% identity to the product of the human ERCC3 gene, associated with xeroderma pigmentosum B (XP-B) and Cockayne's syndrome (CS). XP is a human autosomal recessive disease characterized by extreme sensitivity to ultraviolet irradiation and marked susceptibility to skin cancer. In addition, XP and CS patients often exhibit a variety of defects, ranging f rom central nervous system disorders to hypogonadism. Phenotypes of haywire mutants mimic some of the effects of XP. Many haywire alleles are recessive lethal, viable alleles cause ultraviolet sensitivity, and flies expressing marginal levels of haywire display motor defects and reduced life span. Progeny of females carrying a maternal effect allele show central nervous system defects.	STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT GENET, STANFORD, CA 94305 USA; SO METHODIST UNIV, DEPT BIOL SCI, DALLAS, TX 75275 USA; HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA	Stanford University; Stanford University; Southern Methodist University; Harvard University	MOUNKES, LC (corresponding author), UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA.			Fuller, Margaret T/0000-0002-3804-4987	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007135] Funding Source: NIH RePORTER; NICHD NIH HHS [HD18127] Funding Source: Medline; NIGMS NIH HHS [5T32GM07135-15] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED FE, 1978, BIOCHIM BIOPHYS ACTA, V521, P805, DOI 10.1016/0005-2787(78)90319-2; ARLETT CF, 1978, DNA REPAIR MECHANISM, P633; BENHUR E, 1980, FEBS LETT, V120, P21, DOI 10.1016/0014-5793(80)81036-2; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; BONNER JJ, 1984, CELL, V37, P979; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUTLAG DL, 1990, COMPUT APPL BIOSCI, V6, P237; BUSCH DB, 1980, SOMAT CELL GENET, V6, P407, DOI 10.1007/BF01542792; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; COLE J, 1992, MUTAT RES, V273, P171, DOI 10.1016/0921-8777(92)90078-H; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DUPUY JM, 1982, J INVEST DERMATOL, V78, P356; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLETJER WL, 1992, P NATL ACAD SCI USA, V89, P261; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GIORNO R, 1976, CELL, V9, P775, DOI 10.1016/0092-8674(76)90140-9; GLOVER TW, 1979, P NATL ACAD SCI USA, V76, P3982, DOI 10.1073/pnas.76.8.3982; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HACKETT PB, 1975, J MOL BIOL, V91, P235, DOI 10.1016/0022-2836(75)90378-2; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JONES RS, 1990, GENETICS, V126, P185; KANTOR GJ, 1979, BIOPHYS J, V27, P359, DOI 10.1016/S0006-3495(79)85223-6; KAUFMANN WK, 1980, BIOCHIM BIOPHYS ACTA, V608, P191, DOI 10.1016/0005-2787(80)90147-1; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; KEMPHUES KJ, 1983, GENETICS, V105, P345; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEHMANN AR, 1979, CANCER RES, V39, P4237; LEHMANN AR, 1982, CANCER SURV, V1, P93; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MACINNES MA, 1990, PROG CLIN BIOL RES, V340, P265; MAHER VM, 1975, J NATL CANCER I, V54, P1287, DOI 10.1093/jnci/54.6.1287; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; MAYNE LV, 1982, CANCER RES, V42, P1473; MAYNE LV, 1982, MUTAT RES, V106, P179, DOI 10.1016/0027-5107(82)90200-7; MCCORMICK JJ, 1986, CANCER RES, V46, P489; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MICHALKE H, 1969, J MOL BIOL, V41, P1, DOI 10.1016/0022-2836(69)90122-3; MISMER D, 1987, GENETICS, V116, P565; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NOCENTINI S, 1976, BIOCHIM BIOPHYS ACTA, V454, P114, DOI 10.1016/0005-2787(76)90359-2; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; REGAN CL, 1990, GENETICS, V125, P77; REGAN CL, 1988, GENE DEV, V2, P82, DOI 10.1101/gad.2.1.82; ROBBINS JH, 1991, HUM GENET, V88, P242; ROBBINS JH, 1974, ANN INTERN MED, V80, P221, DOI 10.7326/0003-4819-80-2-221; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEFANINI M, 1982, SOMAT CELL GENET, V8, P635, DOI 10.1007/BF01542856; STICH HF, 1973, MUTAT RES, V17, P127, DOI 10.1016/0027-5107(73)90261-3; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TATES AD, 1989, MUTAT RES, V213, P73, DOI 10.1016/0027-5107(89)90033-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1991, NATURE, V350, P190, DOI 10.1038/350190a0; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0	70	120	122	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					925	937		10.1016/0092-8674(92)90389-T	http://dx.doi.org/10.1016/0092-8674(92)90389-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458540				2022-12-01	WOS:A1992KB99000006
J	PELLETIER, H; KRAUT, J				PELLETIER, H; KRAUT, J			CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN ELECTRON-TRANSFER PARTNERS, CYTOCHROME-C PEROXIDASE AND CYTOCHROME-C	SCIENCE			English	Article							SITE-DIRECTED MUTANTS; FERROCYTOCHROME-C; COMPOUND-I; 3-DIMENSIONAL STRUCTURE; PARAMAGNETIC RESONANCE; CHEMICAL MODIFICATION; ESCHERICHIA-COLI; BINDING DOMAINS; RADICAL SITE; RESOLUTION	The crystal structure of a 1:1 complex between yeast cytochrome c peroxidase and yeast iso-1-cytochrome c was determined at 2.3 angstrom resolution. This structure reveals a possible electron transfer pathway unlike any previously proposed for this extensively studied redox pair. The shortest straight line between the two hemes closely follows the peroxidase backbone chain of residues Ala194, Ala193, Gly192, and finally Trp191, the indole ring of which is perpendicular to, and in van der Waals contact with, the peroxidase heme. The crystal structure at 2.8 angstrom of a complex between yeast cytochrome c peroxidase and horse heart cytochrome c was also determined. Although crystals of the two complexes (one with cytochrome c from yeast and the other with cytochrome c from horse) grew under very different conditions and belong to different space groups, the two complex structures are closely similar, suggesting that cytochrome c interacts with its redox partners in a highly specific manner.			PELLETIER, H (corresponding author), UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA.				NIDDK NIH HHS [DK07233] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAND P, 1991, STRUCT BOND, V75, P1; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BOSSHARD HR, 1991, PEROXIDASES CHEM BIO, V2, pCH3; BRUNGER AT, 1990, XPLOR MANUAL; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CORIN AF, 1991, BIOCHEMISTRY-US, V30, P11585, DOI 10.1021/bi00113a014; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; FISHEL LA, 1991, BIOCHEMISTRY-US, V30, P1986, DOI 10.1021/bi00221a036; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GEREN L, 1991, BIOCHEMISTRY-US, V30, P9450, DOI 10.1021/bi00103a009; HAHM S, 1992, BIOCHEMISTRY-US, V31, P3472, DOI 10.1021/bi00128a022; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HILDEBRANDT P, 1992, BIOCHEMISTRY-US, V31, P2384, DOI 10.1021/bi00123a025; HOFFMAN BM, 1991, STRUCT BOND, V75, P85; KANG CH, 1978, J BIOL CHEM, V253, P6502; Keilin D, 1929, P R SOC LOND B-CONTA, V104, P206, DOI 10.1098/rspb.1929.0009; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; KIM KL, 1990, BIOCHEMISTRY-US, V29, P9150, DOI 10.1021/bi00491a008; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1465, DOI 10.1021/bi00704a023; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; LUM VR, 1987, PROTEIN STRUCTURE FO, V2, P143; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; MAUK AG, 1991, STRUCT BOND, V75, P131; MAURO JM, 1988, BIOCHEMISTRY-US, V27, P6243, DOI 10.1021/bi00417a008; MCLENDON G, 1991, STRUCT BOND, V75, P159; MILLER MA, 1988, BIOCHEMISTRY-US, V27, P9081, DOI 10.1021/bi00426a003; MILLER MA, 1992, BIOCHEMISTRY-US, V31, P2789, DOI 10.1021/bi00125a020; MOCHAN E, 1971, BIOCHEM J, V121, P69, DOI 10.1042/bj1210069; MOENCH SJ, 1992, BIOCHEMISTRY-US, V31, P3661, DOI 10.1021/bi00129a015; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; OCHI H, 1983, J MOL BIOL, V166, P407, DOI 10.1016/S0022-2836(83)80092-8; ONUCHIC JN, 1992, ANNU REV BIOPH BIOM, V21, P349, DOI 10.1146/annurev.biophys.21.1.349; PELLETIER H, 1992, THESIS U CALIFORNIA; POULOS TL, 1980, J BIOL CHEM, V255, P322; POULOS TL, 1987, J BIOL CHEM, V262, P13881; SALEMME FR, 1973, J BIOL CHEM, V248, P7701; SCHOLES CP, 1989, ISRAEL J CHEM, V29, P85; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SMITH L, 1965, BIOCHIM BIOPHYS ACTA, V105, P1, DOI 10.1016/S0926-6593(65)80170-9; TAKANO T, 1981, J MOL BIOL, V153, P79, DOI 10.1016/0022-2836(81)90528-3; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; YONETANI T, COMMUNICATION; [No title captured]; 1988, MERLOT MANUAL	47	720	723	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 11	1992	258	5089					1748	1755		10.1126/science.1334573	http://dx.doi.org/10.1126/science.1334573			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1334573				2022-12-01	WOS:A1992KB96400026
J	POLLOCK, RA; JAY, G; BIEBERICH, CJ				POLLOCK, RA; JAY, G; BIEBERICH, CJ			ALTERING THE BOUNDARIES OF HOX3.1 EXPRESSION - EVIDENCE FOR ANTIPODAL GENE-REGULATION	CELL			English	Article							CENTRAL NERVOUS-SYSTEM; TRANSGENIC MICE; HOMEODOMAIN PROTEIN; DROSOPHILA EMBRYOS; SUBMUCOSAL CYSTS; AUTO-REGULATION; RETINOIC ACID; HOMEOBOX; MOUSE; HOX-3.1	To investigate the function of region-specific patterns of mouse homeobox gene expression during embryogenesis, we programmed a minimal change in the distribution of Hox3.1 transcripts along the antero-posterior body axis in transgenic mice. Regulatory sequences from Hox1.4, a gene normally expressed more anteriorly than Hox3.1, were chosen to direct expression of a Hox3.1 transgene. Offspring of independent transgenic lines expressed the transgene more anteriorly than the Hox3.1 gene. Rather than predicted posterior transformations, we observed anterior transformations of vertebrae in newborn mice. Transgenic mice also developed profound gastrointestinal tissue malformations, which may provide a molecular explanation for human developmental disorders often involving these same two regions. Paradoxically, vertebral transformations in the transgenic mice were strikingly similar to those reported in mice homozygous for a null mutation of the Hox3.1 gene. This observation suggests that Hox genes may be regulated antipodally, with over- or underexpression resulting in similar phenotypes.			POLLOCK, RA (corresponding author), AMER RED CROSS, JEROME H HOLLAND LAB, ROCKVILLE, MD 20855 USA.		Jay, Gregory/C-6346-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD027943] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07522, HD27943] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKAM M, 1987, DEVELOPMENT, V101, P1; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; Bateson W., 1894, MAT STUDY VARIATION, DOI [10.5962/bhl.title.1348, DOI 10.5962/BHL.TITLE.1348]; BEARDMORE H E, 1958, Pediatr Clin North Am, P457; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIEBERICH C, 1987, MOL CELL BIOL, V7, P4003, DOI 10.1128/MCB.7.11.4003; BIEBERICH CJ, 1991, ANN NY ACAD SCI, V642, P346; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BREIER G, 1988, EMBO J, V7, P1329, DOI 10.1002/j.1460-2075.1988.tb02948.x; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; Danforth CH, 1930, AM J PHYS ANTHROPOL, V14, P463, DOI 10.1002/ajpa.1330140311; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; FERGUSONSMITH AC, 1989, GENOMICS, V5, P250, DOI 10.1016/0888-7543(89)90054-2; GALLIOT B, 1989, DEVELOPMENT, V107, P343; GAUNT SJ, 1988, DEVELOPMENT, V103, P135; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GORDON JW, 1990, J IN VITRO FERTIL EM, V7, P223, DOI 10.1007/BF01129523; GORDON JW, 1990, BIOL REPROD, V42, P869, DOI 10.1095/biolreprod42.6.869; GORDON JW, 1990, DEV BIOL, V137, P349, DOI 10.1016/0012-1606(90)90259-L; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; Green EL, 1941, GENETICS, V26, P192; GREEN EL, 1953, SCIENCE, V117, P81, DOI 10.1126/science.117.3030.81; GREGG BC, 1983, J EMBRYOL EXP MORPH, V73, P135; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUNEBERG H, 1950, J GENET, V50, P112, DOI 10.1007/BF02986799; IGNATIUS JA, 1970, GASTROENTEROLOGY, V59, P610; INOUYE M, 1976, Congenital Anomalies, V16, P171; IWANAGA T, 1975, CANCER, V36, P606, DOI 10.1002/1097-0142(197508)36:2<606::AID-CNCR2820360243>3.0.CO;2-V; JAMES R, 1991, J BIOL CHEM, V266, P3246; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEMOUELLIC H, 1988, GENE DEV, V2, P125, DOI 10.1101/gad.2.1.125; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCLETCHIE NGB, 1954, SURG GYNECOL OBSTET, V99, P135; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MOCHIZUKI Y, 1989, Stomach and Intestine (Tokyo), V24, P1057; NIIZAWA M, 1992, GASTROINTEST RADIOL, V17, P9, DOI 10.1007/BF01888497; PILLAY I, 1976, CANCER, V38, P915, DOI 10.1002/1097-0142(197608)38:2<915::AID-CNCR2820380239>3.0.CO;2-V; Ptashne M., 1986, A GENETIC SWITCH; PUSCHEL AW, 1990, DEVELOPMENT, V108, P435; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; Rotterdam H., 1989, PATHOLOGY STOMACH DU; RUBIO CA, 1989, PATHOL RES PRACT, V184, P418, DOI 10.1016/S0344-0338(89)80037-8; RUSSELL LB, 1956, J EXP ZOOL, V131, P329, DOI 10.1002/jez.1401310308; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHUGHART K, 1991, DEVELOPMENT, V112, P807; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHASHIKANT C S, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P207; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; Struthers J, 1874, J Anat Physiol, V9, P17; Thorington R.W. Jr, 1989, P125; Thorington R.W. Jr., 1972, Nemouria, VNo. 8, P1; THURSTON SE, 1984, CLIN PEDIATR, V23, P652, DOI 10.1177/000992288402301111; TOTH LE, 1987, P NATL ACAD SCI USA, V84, P6790, DOI 10.1073/pnas.84.19.6790; Washburn S, 1952, AM J PHYS ANTHROPOL, V10, P251; WEBER W, 1950, J GENET, V50, P174, DOI 10.1007/BF02986801; WESTERFIELD M, 1992, GENE DEV, V6, P591, DOI 10.1101/gad.6.4.591; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WIECZOREK RL, 1984, AM J GASTROENTEROL, V79, P597; WILLIS RA, 1962, BORDERLAND EMBRYOLOG; WOLGEMUTH DJ, 1989, NATURE, V337, P464, DOI 10.1038/337464a0; YAMAGIWA H, 1979, ACTA PATHOL JAPON, V29, P347; YASUDA Y, 1986, TERATOLOGY, V34, P37, DOI 10.1002/tera.1420340106; YOUNG WS, 1991, FOCUS, V13, P46; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	83	133	139	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					911	923		10.1016/0092-8674(92)90388-S	http://dx.doi.org/10.1016/0092-8674(92)90388-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1360875				2022-12-01	WOS:A1992KB99000005
J	SETTE, A; CEMAN, S; KUBO, RT; SAKAGUCHI, K; APPELLA, E; HUNT, DF; DAVIS, TA; MICHEL, H; SHABANOWITZ, J; RUDERSDORF, R; GREY, HM; DEMARS, R				SETTE, A; CEMAN, S; KUBO, RT; SAKAGUCHI, K; APPELLA, E; HUNT, DF; DAVIS, TA; MICHEL, H; SHABANOWITZ, J; RUDERSDORF, R; GREY, HM; DEMARS, R			INVARIANT CHAIN PEPTIDES IN MOST HLA-DR MOLECULES OF AN ANTIGEN-PROCESSING MUTANT	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I; BINDING SITE; T-CELLS; REGION; GENE; SPECIFICITY; MUTATIONS; MHC	Class II major histocompatibility complexes bind peptides in an endosome-like compartment. When the class II null cell line 721.174 was transfected with class II DR3 genes, DR molecules were produced in normal amounts. However, the DR molecules were abnormally conformed and unstable because deletion of an antigen-processing gene had impaired intracellular formation of most class II-peptide complexes. Yet, 70 percent of the DR molecules still bore peptides, 80 percent of which were 21- to 24-amino acid fragments of the class II-associated invariant chain. These peptides were rare on DR3 from control cells. Thus, a defect in the main antigen-processing pathway revealed a process in which DR molecules bind long peptides derived from proteins present in the same compartment.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; NCI,BETHESDA,MD 20892; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Virginia	SETTE, A (corresponding author), CYTEL,3525 JOHN HOPKINS COURT,SAN DIEGO,CA 92121, USA.		Sette, Alessandro/AFO-8916-2022; Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015486, R01AI018634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18634, AI15486] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; Brodsky F M, 1992, Trends Cell Biol, V2, P109, DOI 10.1016/0962-8924(92)90015-F; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; CEMAN S, 1992, J IMMUNOL, V149, P754; CEMAN S, UNPUB; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COTNER T, 1991, J IMMUNOL, V146, P414; DeMars R, 1992, Trends Cell Biol, V2, P81, DOI 10.1016/0962-8924(92)90077-Z; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEMARS R, 1983, HUM IMMUNOL, V8, P123, DOI 10.1016/0198-8859(83)90008-3; DENAGEL DC, 1992, IMMUNOL TODAY, V13, P86, DOI 10.1016/0167-5699(92)90147-Y; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; LAMB CA, 1992, J IMMUNOL, V148, P3478; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LONG EO, 1992, NEW BIOL, V4, P274; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; OSULLIVAN D, 1990, J IMMUNOL, V145, P1799; RIBERBY JM, 1992, J IMMUNOL, V148, P2856; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1992, IMMUNOL TODAY, V13, P43, DOI 10.1016/0167-5699(92)90131-P; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SIDNEY J, 1992, J IMMUNOL, V149, P2634; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; Teyton L, 1992, Trends Cell Biol, V2, P52, DOI 10.1016/0962-8924(92)90163-H; TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N; VANSCHOOTEN WCA, 1989, EUR J IMMUNOL, V19, P2075, DOI 10.1002/eji.1830191116; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	39	216	222	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1801	1804		10.1126/science.1465617	http://dx.doi.org/10.1126/science.1465617			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465617				2022-12-01	WOS:A1992KB96400041
J	SHUAI, K; SCHINDLER, C; PREZIOSO, VR; DARNELL, JE				SHUAI, K; SCHINDLER, C; PREZIOSO, VR; DARNELL, JE			ACTIVATION OF TRANSCRIPTION BY IFN-GAMMA - TYROSINE PHOSPHORYLATION OF A 91-KD DNA-BINDING PROTEIN	SCIENCE			English	Article							ALPHA-STIMULATED TRANSCRIPTION; INTERFERON-ALPHA; CYTOPLASMIC ACTIVATION; RECONSTITUTED INVITRO; GEL-ELECTROPHORESIS; POSITIVE REGULATOR; ISGF3; GENE; KINASE	Interferon-gamma (IFN-gamma) induces the transcription of the gene encoding a guanylate binding protein by activating a latent cytoplasmic factor, GAF (gamma-activated factor). GAF is translocated to the nucleus and binds a DNA element, the gamma-activated site. Through cross-linking and the use of specific antibodies GAF was found to be a 91-kilodalton DNA binding protein that was previously identified as one of four proteins in interferon-stimulated gene factor-3 (ISGF-3), a transcription complex activated by IFN-alpha. The IFN-gamma-dependent activation of the 91-kilodalton DNA binding protein required cytoplasmic phosphorylation of the protein on tyrosine. The 113-kilodalton ISGF-3 protein that is phosphorylated in response to IFN-alpha was not phosphorylated nor translocated to the nucleus in response to IFN-gamma. Thus the two different ligands result in tyrosine phosphorylation of different combinations of latent cytoplasmic transcription factors that then act at different DNA binding sites.			SHUAI, K (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.							CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1992, P NATL ACAD SCI USA, V89, P7846; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOWARD OMZ, 1992, ONCOGENE, V7, P895; HUTNER T, 1992, CELL, V70, P375; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KA, UNPUB; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, UNPUB; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P31; WALAAS SI, 1989, J MOL NEUROSCI, V1, P117, DOI 10.1007/BF02918897; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	27	708	730	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1808	1812		10.1126/science.1281555	http://dx.doi.org/10.1126/science.1281555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1281555				2022-12-01	WOS:A1992KB96400043
J	SPRENGER, F; NUSSLEINVOLHARD, C				SPRENGER, F; NUSSLEINVOLHARD, C			TORSO RECEPTOR ACTIVITY IS REGULATED BY A DIFFUSIBLE LIGAND PRODUCED AT THE EXTRACELLULAR TERMINAL REGIONS OF THE DROSOPHILA EGG	CELL			English	Article							FEMALE STERILE MUTATIONS; TYROSINE KINASE-ACTIVITY; DORSAL-VENTRAL POLARITY; TOLL GENE-PRODUCT; SIGNAL TRANSDUCTION; TRUNCATED RECEPTOR; CONSERVED FEATURES; EMBRYONIC TERMINI; RNA-POLYMERASE; 2ND CHROMOSOME	torso encodes a receptor tyrosine kinase (torso) required for anterior and posterior terminal development of the Drosophila embryo. Injecting eggs with in vitro synthesized torso mRNAs revealed that torso activation is governed by an extracellular molecule, presumably the torso ligand, produced at terminal regions of the egg during early embryogenesis. In the absence of torso, the ligand shows no apparent localization, indicating that it is diffusible and normally bound by an excess of torso receptor at the egg poles. Mutant ligand-binding torso proteins can suppress telson formation in a dominant negative manner, suggesting that the ligand is limited in amount. Analysis of torso mutations indicates that torso functions as a tyrosine kinase and that gain-of-function mutations causing ligand-independent activation are located in the extracellular domain.	MAX PLANCK INST ENTWICKLUNGSBIOL, GENET ABT, W-7400 TUBINGEN, GERMANY	Max Planck Society								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BERGER SL, 1987, GUIDE MOL CLONING TE, V152; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DICKSON B, 1992, IN PRESS GENES DEV, V6; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO C, 1991, DEVELOPMENT, V111, P1021; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEINE G, 1981, EUR J BIOCHEM, V116, P419; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1986, GENETICS, V113, P695; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PIGNONI F, 1992, DEV BIOL, V115, P221; Roberts D.B., 1986, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1989, GENETICS, V121, P101; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENS LM, 1991, CELL-CELL INTERACTIONS IN EARLY DEVELOPMENT, P145; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SZABAD J, 1989, GENETICS, V122, P823; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARN RM, 1982, DEV BIOL, V89, P540, DOI 10.1016/0012-1606(82)90344-X; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; Wieschaus E., 1986, P199; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	55	137	137	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					987	1001		10.1016/0092-8674(92)90394-R	http://dx.doi.org/10.1016/0092-8674(92)90394-R			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333890				2022-12-01	WOS:A1992KB99000011
J	STEMPLE, DL; ANDERSON, DJ				STEMPLE, DL; ANDERSON, DJ			ISOLATION OF A STEM-CELL FOR NEURONS AND GLIA FROM THE MAMMALIAN NEURAL CREST	CELL			English	Article							NERVE GROWTH-FACTOR; INTERMEDIATE FILAMENT PROTEIN; FORMING SCHWANN-CELLS; NGF-RECEPTOR; SYMPATHETIC NEURONS; PROGENITOR-CELL; CLONAL ANALYSIS; MOUSE EMBRYO; AVIAN EMBRYO; DORSAL-ROOT	We have isolated mammalian neural crest cells using a monoclonal antibody to the low affinity NGF receptor, and established conditions for the serial propagation of these cells in clonal culture to assess their developmental potential. This analysis indicates that, first, single mammalian neural crest cells are multipotent, able to generate at least neurons and Schwann cells like their avian counterparts. Second, multipotent neural crest cells generate multipotent progeny, indicating that they are capable of self-renewal and therefore are stem cells. Third, multipotent neural crest cells also generate some clonal progeny that form only neurons or glia, suggesting the production of committed neuroblasts and glioblasts. Manipulation of the substrate alters the fate of the multipotent cells. These findings have implications for models of neural crest development in vivo, and establish a system for studying the generation of cellular diversity by a multipotent stem cell in vitro.			STEMPLE, DL (corresponding author), CALTECH,HOWARD HUGHES MED INST,DIV BIOL 216-76,PASADENA,CA 91125, USA.		Pillay, Nischalan/F-9536-2012	Stemple, Derek/0000-0002-8296-9928				ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BERND P, 1986, DEV BIOL, V115, P415, DOI 10.1016/0012-1606(86)90261-7; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHEN AM, 1975, DEV BIOL, V46, P262, DOI 10.1016/0012-1606(75)90104-9; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; FRIEDMAN B, 1990, J COMP NEUROL, V295, P43, DOI 10.1002/cne.902950105; HALL PA, 1989, DEVELOPMENT, V106, P619; Hawrot E, 1979, Methods Enzymol, V58, P574; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HUSZAR D, 1991, DEVELOPMENT, V112, P131; JESSEN KR, 1990, DEVELOPMENT, V109, P91; JESSEN KR, 1987, J NEUROSCI, V7, P3362; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; LANDIS SC, 1983, DEV BIOL, V98, P349, DOI 10.1016/0012-1606(83)90365-2; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN N, 1991, GLIA, V4, P175; LEDOUARIN NM, 1980, NATURE, V286, P663, DOI 10.1038/286663a0; LEMKE G, 1988, DEVELOPMENT, V102, P499; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LORING J, 1982, DEV BIOL, V90, P165, DOI 10.1016/0012-1606(82)90222-6; MAXWELL GD, 1987, DEVELOPMENT, V101, P767; MAXWELL GD, 1990, DEV BIOL, V141, P233, DOI 10.1016/0012-1606(90)90118-3; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MIRSKY R, 1990, DEVELOPMENT, V109, P105; MIRSKY R, 1982, NEUROIMMUNOLOGY, P141; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; NEWGREEN D, 1980, CELL TISSUE RES, V211, P269; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROGERS SL, 1990, DEV BIOL, V141, P173, DOI 10.1016/0012-1606(90)90112-V; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SIEBERBLUM M, 1985, EXP CELL RES, V158, P267, DOI 10.1016/0014-4827(85)90450-1; SMITHTHOMAS LC, 1989, DEVELOPMENT, V105, P251; STEMPLE DL, 1991, NEUROSCI LETT, V124, P57, DOI 10.1016/0304-3940(91)90821-A; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TRAPP BD, 1981, J CELL BIOL, V90, P1, DOI 10.1083/jcb.90.1.1; TRAPP BD, 1979, P NATL ACAD SCI USA, V76, P3552, DOI 10.1073/pnas.76.7.3552; WOLINSKY EJ, 1985, J NEUROSCI, V5, P1497; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387	61	672	802	1	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					973	985		10.1016/0092-8674(92)90393-Q	http://dx.doi.org/10.1016/0092-8674(92)90393-Q			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458542				2022-12-01	WOS:A1992KB99000010
J	TAGGART, AKP; FISHER, TS; PUGH, BF				TAGGART, AKP; FISHER, TS; PUGH, BF			THE TATA-BINDING PROTEIN AND ASSOCIATED FACTORS ARE COMPONENTS OF POL-III TRANSCRIPTION FACTOR TFIIIB	CELL			English	Article							RNA POLYMERASE-III; HUMAN U6 GENE; DNA-BINDING; INVITRO TRANSCRIPTION; ACCURATE TRANSCRIPTION; PROMOTER; COMPLEXES; UPSTREAM; INITIATION; ACTIVATION	RNA polymerases I, II, and III require the TATA-binding protein (TBP) to initiate promoter-specific transcription. We have separated HeLa TBP into four phosphocellulose fractions that elicit polymerase specificity in supplying TBP activity to TBP-depleted pol II and pol III transcription reactions. Polymerase specificity might arise in part through distinct TBP-associated factors (TAFs), which have recently been identified in pol I and II transcription. However, the requirement for pol III TAFs has not been established. Here we show that classical pol III transcription involves a minimum of two novel TAFs: TAF-172 and TAF-L. Not only does TAF-172 activate pol III transcription, but it also inhibits the binding of TBP to the TATA box, thereby repressing pol II transcription. The TBP-TAF-172-TAF-L complex can replace TFIIIB both in transcription reactions reconstituted with TFIIIC and in template commitment assays. Thus SL1, TFIID, and TFIIIB might be functionally similar TBP-TAF complexes that direct pol I, II, and III transcription, respectively.			TAGGART, AKP (corresponding author), PENN STATE UNIV,DEPT MOLEC & CELL BIOL,CTR GENE REGULAT,UNIV PK,PA 16802, USA.				NIGMS NIH HHS [GM47855-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREDOW S, 1990, GENE, V86, P217, DOI 10.1016/0378-1119(90)90282-V; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CARLES C, 1991, J BIOL CHEM, V266, P24092; COLBERT T, 1992, IN PRESS GENES DEV; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY JW, 1991, J BIOL CHEM, V266, P17721; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORTES P, 1992, J MOL CELL BIOL, V12, P413; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOSTROZA JA, 1992, CELL, V70, P477; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MITCHELL MT, 1992, J BIOL CHEM, V267, P1995; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9163; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; Weinmann Roberto, 1992, Gene Expression, V2, P81; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	66	142	146	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1015	1028		10.1016/0092-8674(92)90396-T	http://dx.doi.org/10.1016/0092-8674(92)90396-T			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458533				2022-12-01	WOS:A1992KB99000013
J	TROELSTRA, C; VANGOOL, A; DEWIT, J; VERMEULEN, W; BOOTSMA, D; HOEIJMAKERS, JHJ				TROELSTRA, C; VANGOOL, A; DEWIT, J; VERMEULEN, W; BOOTSMA, D; HOEIJMAKERS, JHJ			ERCC6, A MEMBER OF A SUBFAMILY OF PUTATIVE HELICASES, IS INVOLVED IN COCKAYNES-SYNDROME AND PREFERENTIAL REPAIR OF ACTIVE GENES	CELL			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; NUCLEOTIDE EXCISION REPAIR; 7TH COMPLEMENTATION GROUP; STRAND-SPECIFIC REPAIR; CHINESE-HAMSTER CELLS; XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; ESCHERICHIA-COLI; CDNA CLONING	Cells from patients with the UV-sensitive nucleotide excision repair disorder Cockayne's syndrome (CS) have a specific defect in preferential repair of lesions from the transcribed strand of active genes. This system permits quick resumption of transcription after UV exposure. Here we report the characterization of ERCC6, a gene involved in preferential repair in eukaryotes. ERCC6 corrects the repair defect of CS complementation group B (CS-B). It encodes a protein of 1493 amino acids, containing seven consecutive domains conserved between DNA and RNA helicases. The entire helicase region bears striking homology to segments in recently discovered proteins involved in transcription regulation, chromosome stability, and DNA repair. Mutation analysis of a CS-B patient indicates that the gene is not essential for cell viability and is specific for preferential repair of transcribed sequences.			TROELSTRA, C (corresponding author), ERASMUS UNIV, CTR MED GENET, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS.		Hoeijmakers, Jan/AAX-6972-2021; van Gool, Alain J./L-4328-2015; Vermeulen, Wim/W-8708-2019; van Gool, Alain J/G-3806-2010	Vermeulen, Wim/0000-0003-3616-734X; van Gool, Alain/0000-0003-0010-5286				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS AD, 1978, J INVEST DERMATOL, V70, P237, DOI 10.1111/1523-1747.ep12541383; [Anonymous], 1985, DNA REPAIR; ARLETT CF, 1982, INDUCED MUTAGENESIS, P249; BANG DD, 1992, IN PRESS NUCL ACIDS; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BUDD M, 1982, MUTAT RES, V103, P19, DOI 10.1016/0165-7992(82)90080-X; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; CLARK MW, 1992, YEAST, V8, P133, DOI 10.1002/yea.320080208; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DEWEERDK.EA, 1972, NATURE-NEW BIOL, V238, P80, DOI 10.1038/newbio238080a0; DOMINSKI Z, 1992, MOL CELL BIOL, V12, P2108, DOI 10.1128/MCB.12.5.2108; DOMINSKI Z, 1991, MOL CELL BIOL, V11, P6075, DOI 10.1128/MCB.11.12.6075; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FLEJTER WL, 1992, P NATL ACAD SCI USA, V89, P261, DOI 10.1073/pnas.89.1.261; FRYNS JP, 1991, AM J MED GENET, V40, P343, DOI 10.1002/ajmg.1320400320; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HENDERSON EE, 1981, VIROLOGY, V115, P237, DOI 10.1016/0042-6822(81)90107-0; HIGGINS DR, 1983, P NATL ACAD SCI-BIOL, V80, P5680, DOI 10.1073/pnas.80.18.5680; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEHMANN A R, 1987, Cancer Reviews, V7, P82; LEHMANN AR, 1982, MUTAT RES, V106, P347, DOI 10.1016/0027-5107(82)90115-4; LOMMEL L, 1991, MUTAT RES, V255, P183, DOI 10.1016/0921-8777(91)90052-Q; MAYNE LV, 1986, EXP CELL RES, V162, P530, DOI 10.1016/0014-4827(86)90356-3; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NAUMOVSKI L, 1983, P NATL ACAD SCI-BIOL, V80, P4818, DOI 10.1073/pnas.80.15.4818; OH EY, 1987, P NATL ACAD SCI USA, V84, P3638, DOI 10.1073/pnas.84.11.3638; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBY SW, 1991, TRENDS GENET, V7, P79; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SAEKI T, 1980, MUTAT RES, V73, P251, DOI 10.1016/0027-5107(80)90192-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHILD D, 1992, YEAST, V8, P385, DOI 10.1002/yea.320080506; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIMPSON NE, 1990, CYTOGENET CELL GENET, V55, P142, DOI 10.1159/000133006; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1981, SOMAT CELL GENET, V7, P445, DOI 10.1007/BF01542989; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; THOMPSON LH, 1989, MUTAGENESIS, V4, P140, DOI 10.1093/mutage/4.2.140; THOMPSON LH, 1988, SOMAT CELL MOLEC GEN, V14, P605, DOI 10.1007/BF01535314; TROELSTRA C, 1992, GENOMICS, V12, P745, DOI 10.1016/0888-7543(92)90304-B; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, THESIS STATE U LEIDE; VERMEULEN W, 1986, MUTAT RES, V165, P199, DOI 10.1016/0167-8817(86)90055-6; VERMEULEN W, 1991, MUTAT RES, V255, P201, DOI 10.1016/0921-8777(91)90054-S; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WEN L, 1989, NUCLEIC ACIDS RES, V17, P1197, DOI 10.1093/nar/17.3.1197; WOOD CM, 1987, EXP CELL RES, V169, P543, DOI 10.1016/0014-4827(87)90214-X; YAGI T, 1983, MUTAT RES, V112, P59, DOI 10.1016/0167-8817(83)90024-X; YE RD, 1987, J BIOL CHEM, V262, P3718; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P165, DOI 10.1016/0167-8817(88)90018-1; ZELLE B, 1980, MUTAT RES, V72, P491, DOI 10.1016/0027-5107(80)90121-9	93	630	645	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 11	1992	71	6					939	953		10.1016/0092-8674(92)90390-X	http://dx.doi.org/10.1016/0092-8674(92)90390-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1339317	Green Published			2022-12-01	WOS:A1992KB99000007
J	WHITE, RJ; JACKSON, SP				WHITE, RJ; JACKSON, SP			MECHANISM OF TATA-BINDING PROTEIN RECRUITMENT TO A TATA-LESS CLASS-III PROMOTER	CELL			English	Article							RNA POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; HUMAN U6 GENE; ACCURATE TRANSCRIPTION; MULTIPLE FACTORS; TFIID COMPLEX; INITIATION; ACTIVATION; PURIFICATION; COMPONENTS	The TATA-binding protein (TBP) is required for transcription by RNA polymerase III (pol III), even though many pol III templates, such as the adenovirus VA(I) gene, lack a consensus TATA box. We show that TBP alone does not form a stable, productive interaction with VA(I) DNA. However, it can be incorporated into an initiation complex if the other class III basal factors, TFIIIB and TFIIIC, are also present. TFIIIB can associate with the evolutionarily conserved C-terminal domain of TBP in the absence of DNA or TFIIIC, suggesting that TFIIIB exists in solution as a complex with TBP. The stable association of TBP with an essential component of the pol III transcription apparatus may account for the ability of TATA-less class III genes to recruit TBP.			WHITE, RJ (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURKE DJ, 1985, J BIOL CHEM, V260, P816; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CAREY MF, 1986, J BIOL CHEM, V261, P4309; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, MOL CELL BIOL, V11, P63, DOI 10.1128/MCB.11.1.63; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WHITE RJ, 1992, IN PRESS J CELL SCI; Wolffe AP, 1991, CURR OPIN CELL BIOL, V3, P461, DOI 10.1016/0955-0674(91)90074-9; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	60	109	111	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1041	1053		10.1016/0092-8674(92)90398-V	http://dx.doi.org/10.1016/0092-8674(92)90398-V			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1458535				2022-12-01	WOS:A1992KB99000015
J	WORKMAN, JL; KINGSTON, RE				WORKMAN, JL; KINGSTON, RE			NUCLEOSOME CORE DISPLACEMENT INVITRO VIA A METASTABLE TRANSCRIPTION FACTOR NUCLEOSOME COMPLEX	SCIENCE			English	Article							POLYMERASE-II TRANSCRIPTION; XENOPUS-LAEVIS OOCYTES; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; POSITIONED NUCLEOSOMES; HYPERSENSITIVE SITES; DNA-REPLICATION; PHO5 PROMOTER; GAL4; ACTIVATION	In order to function, transcription factors must compete for DNA binding with structural components of chromatin, including nucleosomes. Mechanisms that could be used in this competition have been characterized with the use of the DNA binding domain of the yeast GAL4 protein. The binding of GAL4 to a nucleosome core resulted in a ternary complex containing GAL4, the core histone proteins, and DNA. This ternary complex was unstable; upon the addition of nonspecific competitor DNA, it dissociated into either the original nucleosome core particle or GAL4 bound to naked DNA. Nucleosome core destabilization by GAL4 did not require a transcriptional activation domain. These data demonstrate the displacement of nucleosome cores as a direct result of binding by a regulatory factor. Similar mechanisms might affect the establishment of factor occupancy of promoters and enhancers in vivo.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1989, TRENDS GENET, V5, P268, DOI 10.1016/0168-9525(89)90100-5; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chen H. M., UNPUB; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; JUAN LJ, UNPUB; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAPP M, 1990, J BIOL CHEM, V265, P9357; SCHMID A, IN PRESS CELL; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; STEIN A, 1988, J MOL BIOL, V203, P1029, DOI 10.1016/0022-2836(88)90127-1; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	36	171	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 11	1992	258	5089					1780	1784		10.1126/science.1465613	http://dx.doi.org/10.1126/science.1465613			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB964	1465613				2022-12-01	WOS:A1992KB96400035
J	WRANA, JL; ATTISANO, L; CARCAMO, J; ZENTELLA, A; DOODY, J; LAIHO, M; WANG, XF; MASSAGUE, J				WRANA, JL; ATTISANO, L; CARCAMO, J; ZENTELLA, A; DOODY, J; LAIHO, M; WANG, XF; MASSAGUE, J			TGF-BETA SIGNALS THROUGH A HETEROMERIC PROTEIN-KINASE RECEPTOR COMPLEX	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MOLECULAR-WEIGHT RECEPTOR; MEMBRANE PROTEOGLYCAN; CELL-PROLIFERATION; EXPRESSION CLONING; FIBROBLAST GROWTH; BINDING-PROTEINS; ACTIVIN RECEPTOR; IDENTIFICATION; TRANSDUCTION	Transforming growth factor beta (TGFbeta) binds with high affinity to the type II receptor, a transmembrane protein with a cytoplasmic serine/threonine kinase domain. We show that the type II receptor requires both its kinase activity and association with another TGFbeta-binding protein, the type I receptor, to signal growth inhibition and early gene responses. Receptors I and II associate as interdependent components of a heteromeric complex: receptor I requires receptor II to bind TGFbeta, and receptor II requires receptor I to signal. This mode of operation points to fundamental differences between this receptor and the protein-tyrosine kinase cytokine receptors.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Duke University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Wrana, Jeffrey/F-8857-2013	Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R37CA034610, R01CA034610] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEBKOWSKI JS, 1986, MOL CELL BIOL, V6, P1838, DOI 10.1128/MCB.6.5.1838; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN HY, 1992, CELL, V70; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELOCHE, 1992, MOL BIOL CELL, V3, P63; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PARALKAR VM, 1991, P NATL ACAD SCI USA, V88, P3397, DOI 10.1073/pnas.88.8.3397; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WRANA JL, 1991, BIOCHEM J, V273, P523, DOI 10.1042/bj2730523; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	1452	1502	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 11	1992	71	6					1003	1014		10.1016/0092-8674(92)90395-S	http://dx.doi.org/10.1016/0092-8674(92)90395-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KB990	1333888				2022-12-01	WOS:A1992KB99000012
J	DICKSON, B; SPRENGER, F; MORRISON, D; HAFEN, E				DICKSON, B; SPRENGER, F; MORRISON, D; HAFEN, E			RAF FUNCTIONS DOWNSTREAM OF RAS1 IN THE SEVENLESS SIGNAL TRANSDUCTION PATHWAY	NATURE			English	Article							RECEPTOR TYROSINE KINASE; DROSOPHILA-MELANOGASTER; PUTATIVE RECEPTOR; CELL FATE; PROTEIN; GENE; EYE; TORSO; REQUIREMENT; ACTIVATION	SPECIFICATION of the R7 cell fate in the developing Drosophila eye requires activation of the Sevenless (Sev) receptor tyrosine kinase, located on the surface of the R7 precursor cell, by its interaction with the Boss protein, expressed on the surface of the neighbouring R8 cell1-3. Four genes that participate in the intracellular transmission of this signal have so far been identified and molecularly characterized: Ras1, Sos, Gap1 and sina (refs 4-8). The Drosophila homologue of the mammalian Raf-1 serine/threonine kinase, which has been implicated in signal transduction pathways activated by many receptor tyrosine kinases (reviewed in refs 9 and 10), is encoded by the raf locus (also known as l(1)polehole11, Draf-1 12 or Draf13). Here we show that the Drosophila Raf serine/threonine kinase also plays a crucial role in the R7 pathway: the response to Sev activity is dependent on raf function, and a constitutively activated Raf protein can induce R7 cell development in the absence of sev function. We also present genetic evidence suggesting that Raf acts downstream of Ras1 and upstream of Sina in this signal transduction cascade.	MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,W-7400 TUBINGEN,GERMANY; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	DICKSON, B (corresponding author), UNIV ZURICH,INST ZOOL,WINTERTHORERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Dickson, Barry/0000-0003-0715-892X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; KARCH F, 1981, J MOL BIOL, V148, P219, DOI 10.1016/0022-2836(81)90536-2; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRAMERS PGN, 1983, MUTAT RES, V107, P187, DOI 10.1016/0027-5107(83)90162-8; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SPRENGER F, IN PRESS CELL; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	29	290	300	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					600	603		10.1038/360600a0	http://dx.doi.org/10.1038/360600a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461284				2022-12-01	WOS:A1992KB95900090
J	ELLERBROCK, TV; LIEB, S; HARRINGTON, PE; BUSH, TJ; SCHOENFISCH, SA; OXTOBY, MJ; HOWELL, JT; ROGERS, MF; WITTE, JJ				ELLERBROCK, TV; LIEB, S; HARRINGTON, PE; BUSH, TJ; SCHOENFISCH, SA; OXTOBY, MJ; HOWELL, JT; ROGERS, MF; WITTE, JJ			HETEROSEXUALLY TRANSMITTED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AMONG PREGNANT-WOMEN IN A RURAL FLORIDA COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUAL-BEHAVIOR; UNITED-STATES; TRANSMISSION; CRACK; RISK; EPIDEMIOLOGY; AIDS; HIV	Background. In the United States, an increasing proportion of women infected with the human immunodeficiency virus (HIV) live in nonmetropolitan areas. Little is known, however, about the risk factors for HIV transmission in women outside large cities. Methods. We interviewed and tested 1082 (99.8 percent) of 1084 consecutive pregnant women who registered for prenatal care at a public health clinic in western Palm Beach County, Florida. This rural agricultural area of about 36,000 people is known to have a high prevalence of HIV infection. Results. The seroprevalence of HIV was 5.1 percent (52 of 1011 women). Black women who were neither Haitian nor Hispanic had the highest rate of infection (8.3 percent [48 of 575]). Only 4 of 1009 women (0.4 percent) reported ever injecting drugs, and the 4 were HIV-sero-negative; however, 14 of 43 users of "crack" cocaine (33 percent) had HIV infection. At prenatal registration, 131 of 983 women (13 percent) tested positive for gonorrhea, chlamydial infection, or syphilis. By multivariate logistic-regression analysis, HIV infection was found to be independently associated with having used crack cocaine (odds ratio, 3.3; P<0.001), having had more than two sexual partners (odds ratio, 4.6; P<0.001), being black but neither Hispanic nor Haitian (odds ratio, 11; P<0.001), having had sexual intercourse with a high-risk partner (odds ratio, 5.6; P<0.001), and testing positive for syphilis (odds ratio, 3.1; P = 0.015). Nevertheless, 11 of the 52 HIV-infected women (21 percent) reported a total of only two to five sexual partners and no known high-risk partners, had never used crack cocaine, and had no positive tests for sexually transmitted disease. Conclusions. In the rural community we studied, most of the women with HIV infection acquired it through heterosexual contact. The increasing seroprevalence of HIV and the increasing incidence of syphilis and use of crack cocaine mean that other women may be at similar risk of acquiring heterosexually transmitted HIV infection.	FLORIDA STATE DEPT HLTH & REHABIL SERV,DIST 9 OFF,W PALM BEACH,FL; FLORIDA STATE DEPT HLTH & REHABIL SERV,AIDS PROGRAM,TALLAHASSEE,FL		ELLERBROCK, TV (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD NE,MAILSTOP E-45,ATLANTA,GA 30333, USA.							ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BOWEN GS, 1990, FAM PLANN PERSPECT, V22, P62, DOI 10.2307/2135510; CARLSON RG, 1991, J PSYCHOACTIVE DRUGS, V23, P11, DOI 10.1080/02791072.1991.10472570; CASTRO KG, 1988, SCIENCE, V239, P193, DOI 10.1126/science.3336781; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHIPHANGWI I, 1990, 6TH INT C AIDS SAN F, V1, P158; DARROW WW, 1988, 4TH P INT C AIDS STO, V1, P273; DEBUONO BA, 1990, NEW ENGL J MED, V322, P821, DOI 10.1056/NEJM199003223221206; DEHOVITZ J, 1991, 7TH INT C AIDS FLOR, V2, P320; EDLIN B, 1991, 7TH INT C AIDS FLOR, V2, P68; ELLERBROCK TV, 1991, JAMA-J AM MED ASSOC, V265, P2971, DOI 10.1001/jama.265.22.2971; FRIEDMAN SR, 1988, 4TH INT C AIDS ABSTR, V2, P396; FULLILOVE RE, 1990, JAMA-J AM MED ASSOC, V263, P851, DOI 10.1001/jama.263.6.851; LAGA M, 1990, 6TH INT C AIDS SAN F, V1, P158; LAZZARIN A, 1991, ARCH INTERN MED, V151, P2411, DOI 10.1001/archinte.151.12.2411; Lieb S, 1988, J Fla Med Assoc, V75, P301; MATI J, 1991, 7TH INT C AIDS FLOR, V2, P319; NARKUNAS JP, 1989, 5TH P INT C AIDS MON, P101; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; PUCCIO PS, 1991, DRUG OTHER SUBSTANCE; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P1432, DOI 10.1001/jama.264.11.1432; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; WASSER S, 1991, 119TH ANN M AM PUBL, P6; Wilkinson Alec., 1989, BIG SUGAR SEASONS CA; 1991, CENSUS POPULATION HO	25	104	105	1	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1704	1709		10.1056/NEJM199212103272402	http://dx.doi.org/10.1056/NEJM199212103272402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1308669	Bronze			2022-12-01	WOS:A1992KA89700002
J	HOSOBUCHI, M; KREIS, T; SCHEKMAN, R				HOSOBUCHI, M; KREIS, T; SCHEKMAN, R			SEC21 IS A GENE REQUIRED FOR ER TO GOLGI PROTEIN-TRANSPORT THAT ENCODES A SUBUNIT OF A YEAST COATOMER	NATURE			English	Article							SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; COATED VESICLES; CLATHRIN; STACK; COMPLEX; COMPLEMENTATION; IDENTIFICATION; BINDING; VECTORS	NON-CLATHRIN coated vesicles have been implicated in early steps of intercompartmental transport1-4. A distinct set of coat proteins are peripherally associated with the exterior of purified mammalian intra-Golgi transport vesicles5. The 'coatomer', a cytosolic complex containing a similar subunit composition to and sharing at least one subunit (beta-COP) with the coat found on vesicles, has been postulated to be the precursor of this non-clathrin coat6. Here we describe the characterization of SEC21, an essential gene required for protein transport from the endoplasmic reticulum to the Golgi in the yeast Saccharomyces cerevisiae. The 105K product of this gene, Sec21p, participates in a cytosolic complex that we show to be a yeast homologue of the mammalian coatomer. These observations demonstrate that a non-clathrin coat protein plays an essential role in intercompartmental transport.	UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV GENEVA, DEPT BIOL CELLULAIRE, CH-1211 GENEVA 4, SWITZERLAND	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	HOSOBUCHI, M (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, 401 BARKER HALL, BERKELEY, CA 94720 USA.							BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Duden R, 1991, Trends Cell Biol, V1, P14, DOI 10.1016/0962-8924(91)90064-G; DUNN B, 1989, CURRENT PROTOCOLS MO, V2; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; HARLOW E, 1988, ANTIBODIES LABORATOR, V98, P100; HARLOW E, 1988, ANTIBODIES LABORATOR, V98, P114; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PAYNE GS, 1987, MOL CELL BIOL, V7, P3888, DOI 10.1128/MCB.7.11.3888; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVEIRA LA, 1990, J CELL BIOL, V111, P1437, DOI 10.1083/jcb.111.4.1437; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	31	171	175	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 10	1992	360	6404					603	605		10.1038/360603a0	http://dx.doi.org/10.1038/360603a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461285				2022-12-01	WOS:A1992KB95900091
J	MANNING, CJ; WAKELAND, EK; POTTS, WK				MANNING, CJ; WAKELAND, EK; POTTS, WK			COMMUNAL NESTING PATTERNS IN MICE IMPLICATE MHC GENES IN KIN RECOGNITION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MATING PREFERENCES; SYSTEMS	HOUSE mice (Mus musculus domesticus) form communal nests and appear to nurse each other's pups indiscriminately. Communal nesting probably functions to reduce infanticide1, but it also makes females vulnerable to exploitation if nursing partners fail to provide their fair share of care. Kinship theory predicts that females will preferentially form communal nests with relatives to minimize exploitation and further increase inclusive fitness2-4. Here we provide evidence from seminatural populations that females prefer communal nesting partners that share allelic forms of major histocompatibility complex genes. Such behaviour would lead to the selection of close relatives as communal nesting partners5-7. Although criteria for the demonstration of kin recognition are currently embroiled in controversy8,9, this is the first vertebrate study to meet Grafen's restrictive requirements8,10: discrimination is based on genetic similarity at highly polymorphic loci, incidental correlations due to relatedness are experimentally controlled, and strong reasons exist for expecting the assayed behaviour to be kin-selected.	UNIV FLORIDA,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195	State University System of Florida; University of Florida; University of Washington; University of Washington Seattle	MANNING, CJ (corresponding author), UNIV FLORIDA,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610, USA.			Potts, Wayne/0000-0003-4137-0326				BARNARD C, 1991, TREND ECOL EVOL, V310, P312; BARNARD CJ, 1991, BIOL REV, V66, P377; BEAUCHAMP GK, 1990, CHEM SIGNAL, V5, P244; BEAUCHAMP GK, 1988, BEHAV GENET, V18, P537, DOI 10.1007/BF01065520; BEECHER MD, 1982, AM ZOOL, V22, P477; BROWN JL, 1983, ETHICAL QUESTIONS BR, P111; EGID K, 1989, ANIM BEHAV, V38, P548, DOI 10.1016/S0003-3472(89)80051-X; GETZ WM, 1981, J THEOR BIOL, V92, P209, DOI 10.1016/0022-5193(81)90288-5; GRAFEN A, 1990, ANIM BEHAV, V39, P42, DOI 10.1016/S0003-3472(05)80724-9; GROSBERG RK, 1986, NATURE, V322, P456, DOI 10.1038/322456a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HURST JL, 1992, BEHAV ECOL, V3, P196, DOI 10.1093/beheco/3.3.196; Klein J., 1986, NATURAL HIST MAJOR H; LACY RC, 1983, AM NAT, V121, P489, DOI 10.1086/284078; MANNING CJ, IN PRESS ANIM BEHAV; Oka H., 1970, PROFILES JAPANESE SC, P196; PACKER C, 1992, ANIM BEHAV, V43, P265, DOI 10.1016/S0003-3472(05)80222-2; PARTRIDGE L, 1988, PHILOS T R SOC B, V319, P525, DOI 10.1098/rstb.1988.0063; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; POTTS WK, 1990, TRENDS ECOL EVOL, V5, P181, DOI 10.1016/0169-5347(90)90207-T; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0; THOMAS L, 1975, IMMUNE SYSTEM INFECT, P2; Uyenoyama M. K., 1988, EVOLUTION SEX EXAMIN, P212; WILKINSON GS, 1988, ETHOLOGY, V77, P103; YAMAZAKI K, 1988, SCIENCE, V240, P1331, DOI 10.1126/science.3375818	25	197	210	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					581	583		10.1038/360581a0	http://dx.doi.org/10.1038/360581a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461279				2022-12-01	WOS:A1992KB95900083
J	MATSUMURA, K; ERVASTI, JM; OHLENDIECK, K; KAHL, SD; CAMPBELL, KP				MATSUMURA, K; ERVASTI, JM; OHLENDIECK, K; KAHL, SD; CAMPBELL, KP			ASSOCIATION OF DYSTROPHIN-RELATED PROTEIN WITH DYSTROPHIN-ASSOCIATED PROTEINS IN MDX MOUSE MUSCLE	NATURE			English	Article							SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; GLYCOPROTEIN COMPLEX; GENE; MICE; LOCALIZATION; SARCOLEMMA; EXPRESSION; FIBERS	DYSTROPHIN is associated with a complex of muscle membrane (sarcolemmal) glycoproteins that provide a linkage to the extracellular matrix protein, laminin1-8. The absence of dystrophin leads to a dramatic reduction of the dystrophin-associated proteins (156DAG, 59DAP, 50DAG, 43DAG and 35DAG) in the sarcolemma of patients with Duchenne muscular dystrophy and mdx mice2,6-8. Here we demonstrate that dystrophin-related protein (DRP, utrophin), an autosomal homologue of dystrophin9-17, is associated with an identical or antigenically similar complex of sarcolemmal proteins and that DRP and the dystrophin/DRP-associated proteins colocalize to the neuromuscular junction in Duchenne muscular dystrophy and mdx muscle. The DRP and dystrophin/DRP-associated proteins are found throughout the sarcolemma in small-calibre skeletal muscles and cardiac muscle of adult mdx mice. Because these muscles show minimal pathological changes18-20, our results could provide a basis for the upregulation of DRP as a potential therapeutic approach.	UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa	MATSUMURA, K (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Ervasti, James/AAZ-4786-2020	Campbell, Kevin/0000-0003-2066-5889; Ohlendieck, Kay/0000-0002-6266-4510; Kahl, Steven/0000-0001-7085-9556				BUCKLE VJ, 1990, HUM GENET, V85, P324; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MAN NT, 1991, J CELL BIOL, V115, P1695; MATSUMURA K, 1988, MUSCLE NERVE, V11, P97, DOI 10.1002/mus.880110202; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; OHLENDIECK K, IN PRESS NEUROLOGY; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; TAKEMITSU M, 1991, BIOCHEM BIOPH RES CO, V180, P1179, DOI 10.1016/S0006-291X(05)81320-8; TORRES LFB, 1987, BRAIN, V110, P269, DOI 10.1093/brain/110.2.269	21	450	456	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					588	591		10.1038/360588a0	http://dx.doi.org/10.1038/360588a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461282				2022-12-01	WOS:A1992KB95900086
J	MURAKAMI, Y; MATSUFUJI, S; KAMEJI, T; HAYASHI, S; IGARASHI, K; TAMURA, T; TANAKA, K; ICHIHARA, A				MURAKAMI, Y; MATSUFUJI, S; KAMEJI, T; HAYASHI, S; IGARASHI, K; TAMURA, T; TANAKA, K; ICHIHARA, A			ORNITHINE DECARBOXYLASE IS DEGRADED BY THE 26S-PROTEASOME WITHOUT UBIQUITINATION	NATURE			English	Article							RETICULOCYTE LYSATE; PEST HYPOTHESIS; MOUSE KIDNEY; 26S COMPLEX; DEGRADATION; PROTEINS; CELLS; PROTEASE; PURIFICATION; TURNOVER	ORNITHINE decarboxylase (ODC), a key enzyme in polyamine biosynthesis, is the most rapidly turned over mammalian enzyme1. We have shown that its degradation is accelerated by ODC antizyme2,3, an inhibitory protein induced by polyamines4,5. This is a new type of enzyme regulation and may be a model for selective protein degradation. Here we report the identification of the protease responsible for ODC degradation. Using a cell-free degradation system, we demonstrate that immunodepletion of proteasomes from cell extracts causes almost complete loss of ATP- and antizyme-dependent degradation of ODC. In addition, purified 26S proteasome complex, but not the 20S proteasome, catalyses ODC degradation in the absence of ubiquitin. These results strongly suggest that the 26S proteasome, widely viewed as specific for ubiquitin-conjugated proteins, is the main enzyme responsible for ODC degradation. The 26S proteasome may therefore have a second role in ubiquitin-independent proteolysis.	CHIBA UNIV,FAC PHARMACEUT SCI,CHIBA 260,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Chiba University; Tokushima University	MURAKAMI, Y (corresponding author), JIKEI UNIV,DEPT NUTR,MINATO KU,TOKYO 105,JAPAN.		Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556; Igarashi, Kazuei/0000-0003-3751-3187				ARMON T, 1990, J BIOL CHEM, V265, P20723; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V205, P9; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P47; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KAMEJI T, IN PRESS BIOCH J; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; LI X, 1992, MOL CELL BIOL, V12, P3356; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; NISHIYAMA M, 1988, PREP BIOCHEM, V18, P227, DOI 10.1080/00327488808062524; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROGRES S, 1986, SCIENCE, V234, P20; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V196, P647, DOI 10.1111/j.1432-1033.1991.tb15861.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEELY JE, 1982, J BIOL CHEM, V257, P7549; SHERMAN MY, 1992, EMBO J, V11, P71; TANAKA K, 1992, NEW BIOL, V4, P173; TANAKA K, 1988, J BIOL CHEM, V263, P16209	31	690	700	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					597	599		10.1038/360597a0	http://dx.doi.org/10.1038/360597a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1334232				2022-12-01	WOS:A1992KB95900089
J	PORCELLI, S; MORITA, CT; BRENNER, MB				PORCELLI, S; MORITA, CT; BRENNER, MB			CD1B RESTRICTS THE RESPONSE OF HUMAN CD4-8- LYMPHOCYTES-T TO A MICROBIAL ANTIGEN	NATURE			English	Article							GAMMA-DELTA CELLS; HLA CLASS-I; MONOCLONAL-ANTIBODIES; RECOGNITION; GENES; EXPRESSION; RECEPTOR; DIFFERENTIATION; THYMOCYTES; MOLECULES	MOLECULES encoded by the human CD1 locus on chromosome 1 (ref. 33) are recognized by selected CD4-8- T-cell clones expressing either alphabeta or gammadelta T-cell antigen receptors1,2. The known structural resemblance of CD1 molecules to antigen-presenting molecules encoded by major histocompatibility complex (MHC) genes on human chromosome 6 (refs 3, 4, 34, 35), suggested that CD1 may represent a family of antigen-presenting molecules separate from those encoded in the MHC1,5,6. Here we report that the proliferative and cytotoxic responses of human CD4-8-alphabetaTCR+ T cells specific for Mycobacterium tuberculosis can be restricted by CD1b, one of the four identified protein products of the CD1 locus. The responses of these T cells to M. tuberculosis seemed not to involve MHC encoded molecules, but were absolutely dependent on the expression of CD1b by the antigen-presenting cell and involved an antigen processing requirement similar to that seen in MHC class II-restricted antigen presentation. These results provide, to our knowledge, the first direct evidence for the proposed antigen-presenting function of CD1 molecules and suggest that the CD1 family plays a role in cell-mediated immunity to microbial pathogens.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	PORCELLI, S (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.		Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294				ALBERTSON DG, 1988, EMBO J, V7, P2801, DOI 10.1002/j.1460-2075.1988.tb03135.x; ANEGON I, 1991, J IMMUNOL, V147, P3973; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BLUESTONE JA, 1989, J IMMUNOL, V142, P1785; BOUMSELL L, 1989, LEUCOCYTE TYPING, V4, P251; BRODSKY FM, 1982, J IMMUNOL, V128, P129; CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211; CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0; CHESNUT RW, 1982, J IMMUNOL, V129, P2382; ERLICH H, 1986, HUM IMMUNOL, V16, P205, DOI 10.1016/0198-8859(86)90049-2; FAURE F, 1990, EUR J IMMUNOL, V20, P703, DOI 10.1002/eji.1830200336; FAVALORO EJ, 1986, DIS MARKERS, V4, P261; GLIMCHER LH, 1982, J EXP MED, V156, P640, DOI 10.1084/jem.156.2.640; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; LANIER LL, 1987, LEUKOCYTE TYPING, V3, P175; MARTIN LH, 1987, P NATL ACAD SCI USA, V84, P9189, DOI 10.1073/pnas.84.24.9189; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; MORITA CT, 1991, EUR J IMMUNOL, V21, P2999, DOI 10.1002/eji.1830211215; OLIVE D, 1984, IMMUNOGENETICS, V20, P253, DOI 10.1007/BF00364207; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PARHAM P, 1992, NATURE, V357, P193, DOI 10.1038/357193a0; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RONCAROLO MG, 1991, J IMMUNOL, V147, P781; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SHAW S, 1985, HUM IMMUNOL, V12, P191, DOI 10.1016/0198-8859(85)90336-2; SHIUE L, 1988, J EXP MED, V168, P1993, DOI 10.1084/jem.168.6.1993; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZENMOUR J, 1992, J IMMUNOL, V148, P1941; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	35	533	542	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					593	597		10.1038/360593a0	http://dx.doi.org/10.1038/360593a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1281285				2022-12-01	WOS:A1992KB95900088
J	RANDHAWA, PS; JAFFE, R; DEMETRIS, AJ; NALESNIK, M; STARZL, TE; CHEN, YY; WEISS, LM				RANDHAWA, PS; JAFFE, R; DEMETRIS, AJ; NALESNIK, M; STARZL, TE; CHEN, YY; WEISS, LM			EXPRESSION OF EPSTEIN-BARR VIRUS-ENCODED SMALL RNA (BY THE EBER-1 GENE) IN LIVER SPECIMENS FROM TRANSPLANT RECIPIENTS WITH POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSITU HYBRIDIZATION; DISORDERS; EBV; LYMPHOMAS; TISSUES; INDIVIDUALS; LYMPHOCYTES; PATHOLOGY; HEPATITIS; THERAPY	Background. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression. We postulated that the tissue expression of the small RNA transcribed by the EBER-1 gene during latent EBV infection would identify patients at risk for PTLD. Methods. We studied EBER-1 gene expression in liver specimens obtained from 24 patients 2 days to 22 months before the development of PTLD, using in situ hybridization with an oligonucleotide probe. Control specimens were obtained from 20 recipients of allografts with signs of injury due to organ retrieval, acute graft rejection, or viral hepatitis in whom PTLD had not developed 9 to 71 months after the biopsy. Results. Of the 24 patients with PTLD, 17 (71 percent) had specimens in which 1 to 40 percent of mononuclear cells were positive for the EBER-1 gene. In addition, 10 of these 17 patients (59 percent) had specimens with histopathological changes suggestive of EBV hepatitis. In every case, EBER-1-positive cells were found within the lymphoproliferative lesions identified at autopsy. Only 2 of the 20 controls (10 percent) had specimens with EBER-1-positive cells (P<0.001), and such cells were rare. Conclusions. EBER-1 gene expression in liver tissue precedes the occurrence of clinical and histologic PTLD. The possibility of identifying patients at risk by the method we describe here and preventing the occurrence of PTLD by a timely reduction of immunosuppression needs to be addressed by future prospective studies.	UNIV PITTSBURGH, DIV TRANSPLANTAT BIOL, PITTSBURGH, PA 15260 USA; PRESBYTERIAN UNIV HOSP, PITTSBURGH TRANSPLANT INST, PITTSBURGH, PA USA; PRESBYTERIAN UNIV HOSP, DEPT SURG, PITTSBURGH, PA USA; CHILDRENS HOSP PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA USA; CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City of Hope			Randhawa, Parmjeet/H-4285-2019		NCI NIH HHS [CA-50341] Funding Source: Medline; NHLBI NIH HHS [HL-13108] Funding Source: Medline; NIAAA NIH HHS [A-3176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA050341] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAMBER M, 1981, GUT, V22, P854, DOI 10.1136/gut.22.10.854; BUSH JL, 1989, LAB MED, V20, P318, DOI 10.1093/labmed/20.5.318; CROUSE CA, 1990, J CLIN MICROBIOL, V28, P1026, DOI 10.1128/JCM.28.5.1026-1032.1990; DEMETRIS AJ, 1987, PATHOL ANNU, V22, P347; Gowing N F, 1975, Pathol Annu, V10, P1; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; KATZ BZ, 1989, J INFECT DIS, V160, P589, DOI 10.1093/infdis/160.4.589; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; LOCKER J, 1989, AM J PATHOL, V135, P977; LUKES RJ, 1958, AM J PATHOL, V34, P586; MARKIN RS, 1987, GASTROENTEROLOGY, V93, P1210, DOI 10.1016/0016-5085(87)90246-0; NALESNIK MA, 1988, AM J PATHOL, V133, P173; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; RANDHAWA PS, 1990, AM J SURG PATHOL, V14, P538, DOI 10.1097/00000478-199006000-00004; RANDHAWA PS, 1991, AM J PATHOL, V138, P1027; ROONEY C, 1989, J VIROL, V63, P1531, DOI 10.1128/JVI.63.4.1531-1539.1989; SCHUURMAN HJ, 1989, AM J CLIN PATHOL, V91, P461, DOI 10.1093/ajcp/91.4.461; Sheibani K, 1984, Semin Diagn Pathol, V1, P235; SHIBATA D, 1991, BLOOD, V77, P1527; STARZL TE, 1984, LANCET, V1, P583; STRAUCH B, 1974, LANCET, V1, P234; SU IJ, 1991, BLOOD, V77, P799; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; WEISS LM, 1990, AM J PATHOL, V137, P979; WEISS LM, 1991, AM J PATHOL, V139, P1259; WEISS LM, 1991, J HISTOCHEM CYTOCHEM, V39, P1237, DOI 10.1177/39.9.1918942; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	30	160	161	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1710	1714		10.1056/NEJM199212103272403	http://dx.doi.org/10.1056/NEJM199212103272403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1331789	Green Accepted			2022-12-01	WOS:A1992KA89700003
J	ROYDEN, CS; BANKS, MS; CROWELL, JA				ROYDEN, CS; BANKS, MS; CROWELL, JA			THE PERCEPTION OF HEADING DURING EYE-MOVEMENTS	NATURE			English	Article							OPTICAL-FLOW; MOTION; IMAGE; DIRECTION	WHEN a person walks through a rigid environment while holding eyes and head fixed, the pattern of retinal motion flows radially away from a point, the focus of expansion (Fig. 1a)1,2. Under such conditions of translation, heading corresponds to the focus of expansion and people identify it readily3. But when making an eye/head movement to track an object off to the side, retinal motion is no longer radial (Fig. 1b)4. Heading perception in such situations has been modelled in two ways. Extra-retinal models monitor the velocity of rotational movements through proprioceptive or efference information from the extraocular and neck muscles and use that information to discount rotation effects5. Retinal-image models determine (and eliminate) rotational components from the retinal image alone6-12. These models have been tested13,14 by measuring heading perception under two conditions. First, observers judged heading while tracking a point on a simulated ground plane. Second, they fixated a stationary point and the How field simulated the effects of a tracking eye movement. Extra-retinal models5 predict poorer performance in the simulated condition because the eyes do not move. Retinal-image models6-12 predict no difference in performance because the two conditions produce identical patterns of retinal motion. Warren and Hannon13,14 observed similar performance and concluded that people do not require extra-retinal information to judge heading with eye/head movements present, but they used extremely slow tracking eye movements of 0.2-1.2 deg s-1; a moving observer frequently tracks objects at much higher rates (L. Stark, personal communication). Here we examine heading judgements at higher, more typical eye movement velocities and find that people require extra-retinal information about eye position15 to perceive heading accurately under many viewing conditions.	UNIV CALIF BERKELEY,SCH OPTOMETRY,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT PSYCHOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley								BRUSS AR, 1983, COMPUT VISION GRAPH, V21, P3, DOI 10.1016/S0734-189X(83)80026-7; DROULEZ J, 1990, BIOL CYBERN, V62, P211, DOI 10.1007/BF00198096; Gibson J.J., 1950, PERCEPTION VISUAL WO, DOI DOI 10.2307/1419017; Gibson J.J., 1966, SENSES CONSIDERED PE; HEEGER DJ, IN PRESS INT J COMP; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; LONGUETHIGGINS HC, 1981, NATURE, V293, P133, DOI 10.1038/293133a0; MATIN L, 1981, S STUDY MOTON PERCEP; REGAN D, 1982, SCIENCE, V215, P194, DOI 10.1126/science.7053572; RIEGER JH, 1985, J OPT SOC AM A, V2, P354, DOI 10.1364/JOSAA.2.000354; von Holst E, 1954, BRIT J ANIM BEHAV, V2, P89, DOI DOI 10.1016/S0950-5601(54)80044-X; WARREN WH, 1988, J EXP PSYCHOL HUMAN, V14, P646, DOI 10.1037/0096-1523.14.4.646; WARREN WH, 1990, J OPT SOC AM A, V7, P160, DOI 10.1364/JOSAA.7.000160; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0; WARREN WH, 1991, BIOL CYBERN, V65, P311, DOI 10.1007/BF00216964; WAXMAN AM, 1985, INT J ROBOT RES, V4, P72, DOI 10.1177/027836498500400306	16	261	262	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					583	587		10.1038/360583a0	http://dx.doi.org/10.1038/360583a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1461280				2022-12-01	WOS:A1992KB95900084
J	SELWYN, PA; ALCABES, P; HARTEL, D; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; DAVENNY, K; FRIEDLAND, GH				SELWYN, PA; ALCABES, P; HARTEL, D; BUONO, D; SCHOENBAUM, EE; KLEIN, RS; DAVENNY, K; FRIEDLAND, GH			CLINICAL MANIFESTATIONS AND PREDICTORS OF DISEASE PROGRESSION IN DRUG-USERS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; NEW-YORK-CITY; HIV-INFECTION; MAINTENANCE TREATMENT; BACTERIAL PNEUMONIA; CONTROLLED TRIAL; NATURAL-HISTORY; HOMOSEXUAL MEN; ZIDOVUDINE AZT; UNITED-STATES	Background and Methods. To examine the clinical course of human immunodeficiency virus (HIV) infection in injection-drug users, we conducted a prospective study of a cohort of patients in a methadone-treatment program in New York City from July 1985 through December 1990. The patients underwent standardized evaluations at base line and semiannually thereafter and received on-site primary medical care. Rates of progression to the acquired immunodeficiency syndrome (AIDS) and major outcomes before the development of AIDS were examined by univariate analyses; the risk of AIDS was also assessed by product-limit survival analysis and proportional-hazards regression. Results. Of 318 HIV-seropositive patients who did not yet have AIDS (171 men and 147 women), 90 were black, 179 were Hispanic, and 49 were white; the median age was 33 years. Over a median of 3.0 years of follow-up, 55 (17 percent) received a diagnosis of AIDS (incidence per 100 person-years, 5.8). Major outcomes before the development of AIDS included oral candidiasis (incidence per 100 person-years, 11.2), pyogenic bacterial infections including pneumonia and sepsis (8.0), pulmonary tuberculosis (1.2), multiple constitutional symptoms (13.6), and herpes zoster (1.3). There were 41 deaths from AIDS, and 13 seropositive patients without AIDS (4.1 percent) died of bacterial infections, as compared with only 1 of 411 seronegative patients studied (P<0.001). The incidence of AIDS was 62 percent lower among those who took zidovudine than among those who did not (P = 0.02). In the multivariate analysis, progression to AIDS was best predicted by low numbers and percentages of CD4+ lymphocytes, nonuse of zidovudine, and the presence of oral candidiasis, bacterial infections, or tuberculosis. There was no consistent relation between progression to disease and the continued use of injection drugs. Conclusions. HIV-infected injection-drug users have progression to AIDS at rates comparable to those of other HIV-infected groups, but they have substantial pre-AIDS morbidity and mortality, particularly from bacterial infections, which also appear to predict disease progression.	MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT INTERNAL MED, DIV INFECT DIS, BRONX, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine				Schoenbaum, Ellie/0000-0002-0878-284X	NIDA NIH HHS [DAO4347-05] Funding Source: Medline; PHS HHS [U64CCU200714] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1992, AIDS, V6, P421; [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BRETTLE RP, 1991, AIDS, V5, P125, DOI 10.1097/00002030-199102000-00001; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; CASABONA J, 1990, J ACQ IMMUN DEF SYND, V3, P272; Dowdle W R, 1989, MMWR Suppl, V38, P1; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; COATES RA, 1990, AM J EPIDEMIOL, V132, P717, DOI 10.1093/oxfordjournals.aje.a115713; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; FERNANDEZCRUZ E, 1990, AIDS, V4, P987, DOI 10.1097/00002030-199010000-00007; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GATES JR, 1991, 7TH INT C AIDS FLOR, V2, P377; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; JARLAIS DCD, 1987, AIDS, V1, P105; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MACDONELL KB, 1990, AM J MED, V89, P706, DOI 10.1016/0002-9343(90)90210-5; MARGOLICK JB, 1992, JAMA-J AM MED ASSOC, V267, P1631, DOI 10.1001/jama.267.12.1631; MIENTJES GH, 1992, AIDS, V6, P207, DOI 10.1097/00002030-199202000-00012; MIENTJES GH, 1991, AIDS, V5, P35, DOI 10.1097/00002030-199101000-00005; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PAYNE SF, 1990, AIDS, V4, P335, DOI 10.1097/00002030-199004000-00008; PERUCCI CA, 1991, AM J PUBLIC HEALTH, V81, P1307, DOI 10.2105/AJPH.81.10.1307; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PHILLIPS AN, 1991, LANCET, V337, P389; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; POLSKY B, 1986, ANN INTERN MED, V104, P38, DOI 10.7326/0003-4819-104-1-38; RAGNI MV, 1990, J ACQ IMMUN DEF SYND, V3, P708; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SCHRAGER LK, 1988, AIDS, V2, pS183, DOI 10.1097/00002030-198800001-00027; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SELWYN PA, 1991, 119TH ANN M AM PUBL, P153; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; WILLOCKS L, 1992, J INFECTION, V24, P37, DOI 10.1016/0163-4453(92)90898-G; WITT DJ, 1987, AM J MED, V82, P900, DOI 10.1016/0002-9343(87)90150-1; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; 1989, MMWR MORB MORTAL WKL, V38, P165; 1991, MMWR MORB MORTAL WKL, V40, P1; 1991, WKLY EPIDEMIOL REC, V66, P33; 1991, REPORT TWIN EPIDEMIC; 1991, MMWR MORB MORTAL WKL, V40, P891	64	299	300	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1697	1703		10.1056/NEJM199212103272401	http://dx.doi.org/10.1056/NEJM199212103272401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1359411				2022-12-01	WOS:A1992KA89700001
J	SMITH, RG; HAMILTON, S; HOFMANN, F; SCHNEIDER, T; NASTAINCZYK, W; BIRNBAUMER, L; STEFANI, E; APPEL, SH				SMITH, RG; HAMILTON, S; HOFMANN, F; SCHNEIDER, T; NASTAINCZYK, W; BIRNBAUMER, L; STEFANI, E; APPEL, SH			SERUM ANTIBODIES TO L-TYPE CALCIUM CHANNELS IN PATIENTS WITH AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTOR-NEURON DISEASE; EATON MYASTHENIC SYNDROME; GRAY-MATTER DISEASE; SKELETAL-MUSCLE; SPINAL-CORD; PROTEINS; SUBUNIT; AUTOANTIBODIES; IGG; AUTOIMMUNITY	Background and Methods. Sporadic amyotrophic lateral sclerosis is a chronic, progressive degenerative disease of the motor neurons of the spinal cord and motor cortex. The cause is unknown. Recent electrophysiologic studies in animals indicate that immunoglobulins from patients with this disease alter presynaptic voltage-dependent calcium currents and calcium-dependent release of neurotransmitters. To determine whether similar interactions might be identified biochemically, we used an enzyme-linked immunosorbent assay (ELISA) to detect the reaction of serum IgG with purified complexes of L-type voltage-gated calcium channels from rabbit skeletal muscle. The results from patients with amyotrophic lateral sclerosis were compared with those obtained from patients with other types of motor neuron disease, patients with autoimmune. and non-autoimmune neurologic diseases, and normal subjects. Results. Serum samples from 36 of 48 patients with sporadic amyotrophic lateral sclerosis (75 percent) contained IgG that reacted with L-type calcium-channel protein, and serum reactivity on ELISA correlated with the rate of disease progression (Spearman rank-correlation coefficient, 0.62). Reactive serum was present in only 1 of 25 normal subjects and 1 of 35 control patients with no motor neuron disease. Antibodies to L-type voltage-gated calcium channels were identified in 6 of 9 patients with Lambert-Eaton syndrome, and in 3 of 15 patients with Guillain-Barre syndrome. Conclusions. Antibodies to L-type voltage-gated calcium channels are present in the serum of patients with amyotrophic lateral sclerosis, and antibody titers correlate with the rate of disease progression. Together with previous data, these results suggest a role for autoimmune mechanisms in the pathogenesis of sporadic amyotrophic lateral sclerosis.	BAYLOR COLL MED,DEPT NEUROL,6501 FANNIN,NB 302,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV SAARLAND,W-6650 HOMBURG,GERMANY	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Saarland University				Hamilton, Susan/0000-0003-0241-9369				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; APPEL SH, 1986, ARCH NEUROL-CHICAGO, V43, P234, DOI 10.1001/archneur.1986.00520030026007; APPEL SH, 1991, P NATL ACAD SCI USA, V88, P647, DOI 10.1073/pnas.88.2.647; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; APPEL SH, 1991, CURRENT NEUROLOGY, V10, P287; APPEL V, 1987, ANN NEUROL, V22, P328, DOI 10.1002/ana.410220308; CRAWFORD GD, 1992, J NEUROSCI, V12, P3392; DELBONO O, 1991, AM J PHYSIOL, V260, pC1347, DOI 10.1152/ajpcell.1991.260.6.C1347; DELBONO O, 1991, J PHYSIOL-LONDON, V444, P723, DOI 10.1113/jphysiol.1991.sp018903; ENDO T, 1984, J IMMUNOL, V132, P1793; ENGEL AG, 1989, ANN NY ACAD SCI, V560, P278, DOI 10.1111/j.1749-6632.1989.tb24105.x; ENGELHARDT JI, 1989, ANN NEUROL, V26, P368, DOI 10.1002/ana.410260310; ENGELHARDT JI, 1990, ARCH NEUROL-CHICAGO, V47, P1210, DOI 10.1001/archneur.1990.00530110068019; ENGELHARDT JI, 1990, J NEUROIMMUNOL, V27, P21, DOI 10.1016/0165-5728(90)90132-7; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; HAMILTON SL, 1991, CELLULAR CALCIUM, P313; HAUSER SL, 1986, NEUROLOGY, V36, P1614, DOI 10.1212/WNL.36.12.1614; HORWICH MS, 1974, ARCH NEUROL-CHICAGO, V30, P332, DOI 10.1001/archneur.1974.00490340060015; HOU KC, 1986, BIOTECHNIQUES, V4, P358; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HULSIZER S C, 1991, Society for Neuroscience Abstracts, V17, P1159; INGVARMAEDER M, 1986, ACTA NEUROL SCAND, V74, P218, DOI 10.1111/j.1600-0404.1986.tb07858.x; KELEMEN J, 1983, ARCH NEUROL-CHICAGO, V40, P752, DOI 10.1001/archneur.1983.04050110070012; KIM YI, 1988, SCIENCE, V239, P405, DOI 10.1126/science.2447652; LANG B, 1987, J PHYSIOL-LONDON, V390, P257, DOI 10.1113/jphysiol.1987.sp016698; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; MAGNELLI V, IN PRESS J PHYSL LON; MEININGER V, 1990, Neurology, V40, P183; MINTZ IM, 1991, P NATL ACAD SCI USA, V88, P6628, DOI 10.1073/pnas.88.15.6628; MORTON ME, 1989, NEURON, V2, P1499, DOI 10.1016/0896-6273(89)90196-7; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; MULDER DW, 1969, CONT NEUROLOGY S, V2, P12; NAGAYAMA Y, 1991, J CLIN INVEST, V88, P336, DOI 10.1172/JCI115297; NASTAINCZYK W, 1990, GEN PHYSIOL BIOPHYS, V9, P321; NORMAN RI, 1989, ANN NY ACAD SCI, V560, P258, DOI 10.1111/j.1749-6632.1989.tb24103.x; OLDSTONE MBA, 1976, LANCET, V2, P169; ORDONEZ G, 1989, NEUROLOGY, V39, P683, DOI 10.1212/WNL.39.5.683; PALO J, 1978, LANCET, V1, P1270; PESTRONK A, 1989, ANN NEUROL, V25, P98, DOI 10.1002/ana.410250118; POWERS AC, 1985, ANNU REV MED, V36, P533; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROWLAND LP, 1984, TRENDS NEUROSCI, V7, P110, DOI 10.1016/S0166-2236(84)80236-2; SAKAMOTA J, 1991, PHYSIOLOGIST, V34, P109; SAWADA T, 1992, Biophysical Journal, V61, pA401; SCHNEIDER T, IN PRESS METHODS MOL, V13; SCOTT D, 1985, J BIOL CHEM, V260, P736; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SMITH R G, 1991, Society for Neuroscience Abstracts, V17, P1451; STEFANSSON K, 1985, SCIENCE, V228, P1117, DOI 10.1126/science.4039466; TAJTI J, 1991, J NEUROIMMUNOL, V34, P143, DOI 10.1016/0165-5728(91)90123-O; TOUZEAU G, 1986, NEUROLOGY, V36, P573, DOI 10.1212/WNL.36.4.573; VINCENT A, 1989, TRENDS NEUROSCI, V12, P496, DOI 10.1016/0166-2236(89)90109-4; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6; YOUNGER DS, 1990, NEUROLOGY, V40, P595, DOI 10.1212/WNL.40.4.595; [No title captured]	57	173	179	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	1992	327	24					1721	1728		10.1056/NEJM199212103272405	http://dx.doi.org/10.1056/NEJM199212103272405			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA897	1331790				2022-12-01	WOS:A1992KA89700005
J	WANG, MX; CHURCH, GM				WANG, MX; CHURCH, GM			A WHOLE GENOME APPROACH TO INVIVO DNA-PROTEIN INTERACTIONS IN ESCHERICHIA-COLI	NATURE			English	Article							MANNITOL MTL OPERON; ESCHERICHIA-COLI; RESTRICTION ENZYMES; BINDING-SITES; METHYLATION; SEQUENCE; GENE; METHYLTRANSFERASE; ENDONUCLEASE; RECOGNITION	THE increasingly rapid pace at which genomic DNA sequences are being determined has created a need for more efficient techniques to determine which parts of these sequences are bound in vivo by the proteins controlling processes such as gene expression, DNA replication and chromosomal mechanics. Here we describe a whole-genome approach to identify and characterize such DNA sequences. The method uses endogenous or artificially introduced methylases to methylate all genomic targets except those protected in vivo by protein or non-protein factors interfering with methylase action. These protected targets remain unmethylated in purified genomic DNA and are identified using methylation-sensitive restriction endonucleases. When the method was applied to the Escherichia coli genome, 0.1% of the endogenous adenine methyltransferase (Dam methylase) targets were found to be unmethylated. Five foreign methylases were examined by transfection. Database-matched DNA sequences flanking the in vivo-protected Dam sites all fell in the non-coding regions of seven E. coli operons (mtl, cdd, flh, gut, car, psp and fep). In the first four operons these DNA sequences closely matched the consensus sequence that binds to the cyclic AMP-receptor protein. The in vivo protection at the Dam site upstream of the car operon was correlated with a downregulation of car expression, as expected of a feedback repressor-binding model.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Jefferson University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	WANG, MX (corresponding author), THOMAS JEFFERSON UNIV,WILLS EYE HOSP,DIV RES,ONCOL RES LAB,PHILADELPHIA,PA 19107, USA.			church, george/0000-0001-6232-9969				BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BECKER MM, 1984, NATURE, V309, P682, DOI 10.1038/309682a0; BIRD AP, 1978, J MOL BIOL, V118, P27, DOI 10.1016/0022-2836(78)90242-5; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BRAATEN BA, 1992, P NATL ACAD SCI USA, V89, P4250, DOI 10.1073/pnas.89.10.4250; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAMPBELL JL, 1988, GENE, V74, P189, DOI 10.1016/0378-1119(88)90283-1; CARTWRIGHT IL, 1991, BIOTECHNIQUES, V11, P188; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DAVIS T, 1988, MOL MICROBIOL, V2, P405, DOI 10.1111/j.1365-2958.1988.tb00045.x; EBRIGHT R, 1982, MOL STRUCTURE BIOL A; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FEHER Z, 1989, CURR GENET, V16, P461, DOI 10.1007/BF00340726; GEIER GE, 1979, J BIOL CHEM, V254, P1408; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUNASEKERA A, 1990, NUCLEIC ACIDS RES, V18, P6853, DOI 10.1093/nar/18.23.6853; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JIANG W, 1990, MOL MICROBIOL, V4, P2003, DOI 10.1111/j.1365-2958.1990.tb02050.x; KWOH TJ, 1988, NUCLEIC ACIDS RES, V16, P11489, DOI 10.1093/nar/16.24.11489; LENGELER J, 1978, MOL GEN GENET, V164, P163, DOI 10.1007/BF00267381; LYONS SM, 1984, J BACTERIOL, V159, P421, DOI 10.1128/JB.159.1.421-423.1984; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; RAZIN A, 1980, NUCLEIC ACIDS RES, V8, P1783, DOI 10.1093/nar/8.8.1783; RINGQUIST S, 1992, P NATL ACAD SCI USA, V89, P4539, DOI 10.1073/pnas.89.10.4539; SABOURIN D, 1975, J BACTERIOL, V122, P338, DOI 10.1128/JB.122.1.338-340.1975; SALUZ HP, 1991, TRENDS GENET, V7, P207, DOI 10.1016/0168-9525(91)90366-X; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SILVERMAN M, 1974, J BACTERIOL, V120, P1196, DOI 10.1128/JB.120.3.1196-1203.1974; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; STORMO GD, 1989, P NATL ACAD SCI USA, V86, P1183, DOI 10.1073/pnas.86.4.1183; VALENTINHANSEN P, 1989, MOL MICROBIOL, V3, P1385, DOI 10.1111/j.1365-2958.1989.tb00120.x; VOVIS GF, 1977, J MOL BIOL, V115, P525, DOI 10.1016/0022-2836(77)90169-3; WILSON GG, 1988, GENE, V74, P281, DOI 10.1016/0378-1119(88)90304-6; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YMADA M, 1987, J BIOL CHEM, V265, P5455	36	56	58	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 10	1992	360	6404					606	610		10.1038/360606a0	http://dx.doi.org/10.1038/360606a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KB959	1334233				2022-12-01	WOS:A1992KB95900092
J	CHEN, YCJ; GUO, YL; HSU, CC; ROGAN, WJ				CHEN, YCJ; GUO, YL; HSU, CC; ROGAN, WJ			COGNITIVE-DEVELOPMENT OF YU-CHENG (OIL DISEASE) CHILDREN PRENATALLY EXPOSED TO HEAT-DEGRADED PCBS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYCHLORINATED-BIPHENYLS PCBS; BIRTH-DEFECTS; DIBENZOFURANS; CONTAMINANTS; DIOXINS; TAIWAN; BLOOD	Objective.-To compare the cognitive development in Taiwanese children who had been exposed prenatally to high levels of heat-degraded polychlorinated biphenyls (PCBs) with control children who were exposed to background levels. The disorder was called Yu-Cheng, "oil disease," in Taiwan. Design.-Matched-pair cohort study. Setting.-Communities in central Taiwan in which there had been a cooking-oil contamination and mass poisoning by heat-degraded PCBs in 1978 through 1979. Participants.-One hundred eighteen children born between June 1978 and March 1985 during or after their mothers' consumption of contaminated rice oil; 118 children matched for age, sex, neighborhood, maternal age, and parental education and occupational class; and 15 older siblings of exposed children, born before the poisoning. Main Outcome Measures.-Cognitive development measured from 1985 through 1990 using the Chinese versions of the Stanford-Binet test and the Wechsler Intelligence Scale for Children, Revised. Results.-The exposed children scored approximately 5 points lower on the Stanford-Binet test at the ages of 4 and 5 years and approximately 5 points lower on the Wechsler Intelligence Scale for Children, Revised, at the ages of 6 and 7 years. Children born up to 6 years after their mothers' exposure were as affected as children born within a year or two after exposure when examined at 6 and 7 years of age. Older siblings resembled the control children. Conclusion.-Children prenatally exposed to heat-degraded PCBs had poorer cognitive development than their matched controls. The effect persisted in the children up to the age of 7 years, and children born long after the exposure were still affected.	NATL CHENG KUNG UNIV,COLL MED,DEPT ENVIRONM HLTH,TAINAN,TAIWAN; NIEHS,RES TRIANGLE PK,NC 27709	National Cheng Kung University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	CHEN, YCJ (corresponding author), NATL CHENG KUNG UNIV,COLL MED,DEPT PSYCHIAT,138 SHENG LI RD,TAINAN 70428,TAIWAN.		Rogan, Walter/I-6034-2012	Rogan, Walter/0000-0002-9302-0160; GUO, Yue Leon/0000-0002-8530-4809				Anastasi A., 1982, PSYCHOL TESTING, V5th; CHEN CC, 1988, CHIN PSYCHIATRY, V2, P257; CHEN JH, 1979, MANUAL CHINESE VERSI; CHEN PH, 1981, CLIN MED TAIPEI, V7, P71; CHEN YC, 1989, CHIN PSYCHIATRY, V3, P89; CHEN YC, 1990, CHIN PSYCHIATRY, V4, P40; CHEN YCJ, IN PRESS J FORMOSAN; Crow K D, 1970, Trans St Johns Hosp Dermatol Soc, V56, P79; DEVOOGT P, 1989, TOPICS ENV HLTH, V4, P3; DYMENT PG, 1971, B ENVIRON CONTAM TOX, V6, P532, DOI 10.1007/BF01796861; ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; FUNATSU I, 1972, Kurume Medical Journal, V19, P43; GLADEN BC, 1991, J PEDIATR-US, V119, P58, DOI 10.1016/S0022-3476(05)81039-X; HARA I, 1985, ENVIRON HEALTH PERSP, V59, P85, DOI 10.2307/3429879; Harada M., 1976, B I CONSTITUTIONAL S, V25, P1; HSU CC, 1988, CHIN PSYCH, V2, P26; HSU CC, 1989, CHIN PSYCHIATRY S1, V3, P101; HSU ST, 1985, ENVIRON HEALTH PERSP, V59, P5, DOI 10.2307/3429867; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JENSEN AA, 1989, TOPICS ENV HLTH, V4, P345; KURATSUNE M, 1989, TOPICS ENV HLTH, V4, P381; LAN CF, 1981, CLIN MED TAIPEI, V7, P96; LIU SH, 1985, ANN REP BUREAU HLTH, V1, P269; MASTROIACOVO P, 1988, JAMA-J AM MED ASSOC, V259, P1668, DOI 10.1001/jama.259.11.1668; MASUDA Y, 1985, ENVIRON HEALTH PERSP, V59, P53, DOI 10.2307/3429874; NICHOLSON WJ, 1987, REV HUMAN HLTH EFFEC; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; ROGAN WJ, 1989, TOPICS ENV HLTH, V4, P401; SAFE S, 1990, CRIT REV TOXICOL, V21, P51, DOI 10.3109/10408449009089873; SAMUELSSON B, 1989, Neurofibromatosis, V2, P78; SHALAT SL, 1989, BRIT J IND MED, V46, P823; SVENSSON BG, 1991, NEW ENGL J MED, V324, P8, DOI 10.1056/NEJM199101033240102; TILSON HA, 1990, NEUROTOXICOL TERATOL, V12, P239, DOI 10.1016/0892-0362(90)90095-T; YEH TL, 1988, CHIN PSYCHIATRY, V2, P172; YU ML, 1991, NEUROTOXICOL TERATOL, V13, P195, DOI 10.1016/0892-0362(91)90011-K; 1977, MANUAL CHINESE 4TH V	36	208	217	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3213	3218		10.1001/jama.268.22.3213	http://dx.doi.org/10.1001/jama.268.22.3213			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433761				2022-12-01	WOS:A1992KA65400027
J	HEDBERG, CW; KORLATH, JA; DAOUST, JY; WHITE, KE; SCHELL, WL; MILLER, MR; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT				HEDBERG, CW; KORLATH, JA; DAOUST, JY; WHITE, KE; SCHELL, WL; MILLER, MR; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT			A MULTISTATE OUTBREAK OF SALMONELLA-JAVIANA AND SALMONELLA-ORANIENBURG INFECTIONS DUE TO CONSUMPTION OF CONTAMINATED CHEESE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEDDAR CHEESE	Objective.-To determine the source of an outbreak of Salmonella javiana and Salmonella oranienburg infections. Design.-Laboratory-based statewide surveillance for Salmonella infections and two separate case-control studies. Setting.-Community- and industry-based studies conducted from May through October 1989. Participants.-Thirty-one culture-confirmed outbreak-associated cases of S javiana infection and 60 community controls matched for telephone prefix, gender, and age in case-control study I; 50 cases, 100 community controls, and 64 family member controls in case-control study II. Results.-One hundred thirty-six culture-confirmed cases of S javiana infection and 11 cases of S oranienburg infection were associated with the outbreak in Minnesota. Outbreak-associated cases were also identified in Wisconsin (15 cases), and in Michigan and New York (one case each). Cases were more likely than controls to have consumed mozzarella cheese manufactured at a single cheese plant (plant X) or cheese that had been shredded at processing plants that also shredded cheese manufactured at plant X (odds ratio [OR], 7.2; 95% confidence interval [CI], 1.7 to 23.2; P<.01). The outbreak-associated strains of both serovars were isolated from two unopened 16-oz (0.45-kg) blocks of mozzarella cheese produced at plant X. The most probable numbers of Salmonella organisms in these samples were 0.36/100 g and 4.3/100 g. Conclusions.-The potential for bacterial pathogen contamination of cheese during manufacture and processing has important epidemiologic implications, particularly because cheese consumption has recently increased in the United States. Low-level contamination of a nationally distributed food product can cause geographically dispersed foodborne outbreaks that may be difficult to detect.	MINNESOTA DEPT HLTH,EPIDEMIOL FIELD SERV SECT,MINNEAPOLIS,MN; MINNESOTA DEPT HLTH,DIV PUBL HLTH LABS,MINNEAPOLIS,MN; HLTH & WELF CANADA,HLTH PROTECT BRANCH,SIR FG BANTING RES CTR,OTTAWA K1A 0L2,ONTARIO,CANADA; WISCONSIN DEPT HLTH & SOCIAL SERV,DIV HLTH,MADISON,WI; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA	HEDBERG, CW (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440, USA.							ANDREWS WH, 1984, BACTERIOLOGICAL ANAL, pCH7; BARRY AL, 1985, MANUAL CLIN MICROBIO, pCH102; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Breslow N.E., 1980, STAT METHODS CANC RE, P192; CHALKER RB, 1988, REV INFECT DIS, V10, P111; DAOUST JY, 1989, J FOOD PROTECT, V52, P906, DOI 10.4315/0362-028X-52.12.906; DAOUST JY, 1985, AM J EPIDEMIOL, V122, P717, DOI 10.1093/oxfordjournals.aje.a114151; Felip G. de, 1984, Microbiologie - Aliments - Nutrition, V2, P251; FONTAINE RE, 1980, AM J EPIDEMIOL, V111, P247, DOI 10.1093/oxfordjournals.aje.a112892; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; PUTNAM AJ, 1989, USDA STATISTICAL B, V773; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P84; ROTHMAN KJ, 1979, EPIDEMIOLOGIC ANAL P, P5; 1978, MFHPB20 HLTH WELF CA, P1	14	63	63	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3203	3207		10.1001/jama.268.22.3203	http://dx.doi.org/10.1001/jama.268.22.3203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433759				2022-12-01	WOS:A1992KA65400025
J	HEDBERG, CW; LEVINE, WC; WHITE, KE; CARLSON, RH; WINSOR, DK; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT				HEDBERG, CW; LEVINE, WC; WHITE, KE; CARLSON, RH; WINSOR, DK; CAMERON, DN; MACDONALD, KL; OSTERHOLM, MT			AN INTERNATIONAL FOODBORNE OUTBREAK OF SHIGELLOSIS ASSOCIATED WITH A COMMERCIAL AIRLINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMID	Objective.-To determine the source of an international outbreak of shigellosis associated with consumption of food served by a Minnesota-based airline. Design.-Cohort studies of players and staff of a Minnesota-based professional football team and passengers on flights with a confirmed case of outbreak-associated Shigella sonnei infection. Setting.-Community- and industry-based studies conducted from October through November 1988. Participants.-Sixty-five football team players and staff, and 725 airline passengers in the cohort studies. Results.-Twenty-one (32%) of 65 football players and staff developed shigellosis that was associated with consumption of cold sandwiches prepared at the airline flight kitchen (relative risk [RR], 17.1; 95% confidence interval [CI], 2.4 to 120; P<.001). Confirmed or probable shigellosis was identified among 240 passengers on 219 flights to 24 states, the District of Columbia, and four countries between September 14 and October 13. An outbreak-associated strain of S sonnei was isolated from football players and staff, airline passengers, and flight attendants. Thirty (4.1%) of 725 passengers on 13 flights with confirmed cases had confirmed or probable shigellosis. Illness was associated with consumption of cold food items served on the flights and prepared by hand at the airline flight kitchen (RR, 5.7; 95% CI, 1.4 to 23.5; P<.01). Conclusions.-This international outbreak of shigellosis was identified only because of the occurrence of an index outbreak involving a professional football team. Prevention of Shigella transmission in mass catering establishments may require reduction of hand contact in the preparation of cold food items or elimination of these items from menus.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ENTER DIS BRANCH,ATLANTA,GA; HENNEPIN CTY COMMUNITY HLTH DEPT,MINNEAPOLIS,MN; UNIV TEXAS,SCH MED,HOUSTON,TX 77025	Centers for Disease Control & Prevention - USA; University of Texas System	HEDBERG, CW (corresponding author), MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,POB 9441,MINNEAPOLIS,MN 55440, USA.							BARRY AL, 1985, MANUAL CLIN MICROBIO, pCH102; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BRYAN FL, 1981, FOOD TECHNOL-CHICAGO, V35, P78; LEE LA, 1991, J INFECT DIS, V164, P894, DOI 10.1093/infdis/164.5.894; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; ROTHMAN KJ, 1979, EPIDEMIOLOGIC ANAL P, P5; TAUXE RV, 1987, AM J EPIDEMIOL, V125, P150, DOI 10.1093/oxfordjournals.aje.a114498; WINSOR DK, 1988, J INFECT DIS, V158, P1108, DOI 10.1093/infdis/158.5.1108	9	67	67	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3208	3212		10.1001/jama.268.22.3208	http://dx.doi.org/10.1001/jama.268.22.3208			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433760				2022-12-01	WOS:A1992KA65400026
J	PEREZSTABLE, EJ; SABOGAL, F; OTEROSABOGAL, R; HIATT, RA; MCPHEE, SJ				PEREZSTABLE, EJ; SABOGAL, F; OTEROSABOGAL, R; HIATT, RA; MCPHEE, SJ			MISCONCEPTIONS ABOUT CANCER AMONG LATINOS AND ANGLOS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEXICAN-AMERICANS; UNITED-STATES; BREAST-CANCER; ACCULTURATION; HISPANICS; POPULATION; BEHAVIOR; SYMPTOMS; SMOKING; HEALTH	Objective.-To collect information regarding knowledge about and attitudes toward cancer in a sample of adult health plan members, self-identified as Latino or Anglo. Design.-Cross-sectional survey. Setting.-Prepaid health plan. Respondents.-A random sample of 844 Latinos (mean age, 50.5 years) and 510 Anglos (51.8 years) completed the interview. Main Outcome Measures and Results.-Latinos were significantly more likely than Anglos to think that sugar substitutes (58% vs 42%), bruises from being hit (53% vs 34%), microwave ovens (47% vs 23%), eating pork (31% vs 11%), eating spicy foods (15% vs 8%), breast-feeding (14% vs 6%), and antibiotics (32% vs 12%) could cause cancer (P<.001 for each). Compared with Anglos, Latinos more often misidentified constant dizziness (39% vs 25%) and arthralgias (35% vs 20%) as being symptoms of cancer. A higher proportion of Latinos believed that having cancer is like getting a death sentence (46% vs 26%), that cancer is God's punishment (7% vs 2%), that there is very little one can do to prevent getting cancer (26% vs 18%), that it is uncomfortable to touch someone with cancer (13% vs 8%), and that they would rather not know if they had incurable cancer (35% vs 23%; P<.001 for each). Latino ethnicity was a significant predictor of these knowledge and attitude items in multivariate logistic regression models adjusted for sex, education, age, employment, marital status, county of residence, and self-perceived health status. Conclusions.-We conclude that misconceptions about cancer are more prevalent among Latinos than Anglos and that selected attitudes about cancer among Latinos fit a cultural theme of fatalismo. These data can enable development of culturally appropriate cancer control interventions for Latinos.	KAISER PERMANENTE MED CARE PROGRAM, DIV RES, OAKLAND, CA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA	Kaiser Permanente; University of California System; University of California San Francisco			Hiatt, Robert/AAQ-1537-2021		NCI NIH HHS [CA 50030] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajzen I., 1980, UNDERSTANDING ATTITU; [Anonymous], 1980, ACCULTURATION THEORY; Brislin R.W., 1973, CROSS CULTURAL METHO; DALY MB, 1985, JNCI-J NATL CANCER I, V74, P753; HAFFNER SM, 1985, AM J CLIN NUTR, V42, P1266, DOI 10.1093/ajcn/42.6.1266; JEPSON C, 1991, AM J PUBLIC HEALTH, V81, P501, DOI 10.2105/AJPH.81.4.501; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; MARCUS AC, 1985, AM J PUBLIC HEALTH, V75, P169, DOI 10.2105/AJPH.75.2.169; MARIN G, 1989, AM J PUBLIC HEALTH, V79, P196, DOI 10.2105/AJPH.79.2.196; MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005; MARIN G, 1991, APPLIED SOCIAL RES M, V23, P130; MAURER JD, 1990, VITAL HLTH STAT, V20, P1; OTT L, 1988, INTRO STATISTICAL ME, P220; ROOT RK, 1987, WESTERN J MED, V146, P213; ROSENWAIKE I, 1987, AM J PUBLIC HEALTH, V77, P603, DOI 10.2105/AJPH.77.5.603; SABOGAL F, 1987, HISPANIC J BEHAV SCI, V9, P397, DOI 10.1177/07399863870094003; SAMET JM, 1988, J NATL CANCER I, V80, P432, DOI 10.1093/jnci/80.6.432; Sandoval M. C., 1986, CROSS CULTURAL TRAIN, P151; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; TREVINO FM, 1991, JAMA-J AM MED ASSOC, V265, P233, DOI 10.1001/jama.265.2.233; TRIANDIS HC, 1984, J PERS SOC PSYCHOL, V47, P1363, DOI 10.1037/0022-3514.47.6.1363; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; 1980, 1980 CENSUS POPULATI; 1986, SPSSX USERS GUIDE; 1992, MMWR, V41, P354; 1985, STUDY HISPANICS ATTI; 1984, CONDITIONS HISPANICS	27	223	223	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3219	3223		10.1001/jama.268.22.3219	http://dx.doi.org/10.1001/jama.268.22.3219			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433762				2022-12-01	WOS:A1992KA65400028
J	SUNDT, TM				SUNDT, TM			SURGERY FOR INTRACEREBRAL HEMORRHAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SUNDT, TM (corresponding author), MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3248	3248						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433770				2022-12-01	WOS:A1992KA65400035
J	WOOD, RC; MACDONALD, KL; OSTERHOLM, MT				WOOD, RC; MACDONALD, KL; OSTERHOLM, MT			CAMPYLOBACTER ENTERITIS OUTBREAKS ASSOCIATED WITH DRINKING RAW-MILK DURING YOUTH ACTIVITIES - A 10-YEAR REVIEW OF OUTBREAKS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							JEJUNI INFECTION; SURVEILLANCE; CONSUMPTION; DISEASE; ENGLAND	Objective.-To determine the incidence of recognized outbreaks of Campylobacter enteritis associated with drinking raw milk during youth activities. Design.-Retrospective survey of 51 state and territorial health departments. Setting.-The 50 United States and the Territory of Puerto Rico. Populations.-Persons in preschool through college. Measurement.-Information was obtained for all Campylobacter outbreaks associated with consumption of raw milk during youth activities from 1981 through 1990 that were investigated by state and territorial health departments. Results.-Twenty outbreaks were identified in 11 states. Four hundred fifty-eight outbreak-associated cases occurred among 1013 persons who drank raw milk, with an overall attack rate of 45%. At least one outbreak was reported for each year of the 10-year period. Fourteen outbreaks (70%) occurred among children in kindergarten through third grade, compared with one outbreak (5%) among fourth through sixth graders. The remaining five outbreaks (25%) occurred in mixed groups of children and teenagers. Only nine (60%) of 15 outbreaks identified from 1981 through 1988 were reported to the Campylobacter national surveillance system maintained by the Centers for Disease Control and Prevention. Conclusion.-Drinking raw milk on school field trips or other youth activities continues despite the occurrence of multiple Campylobacter outbreaks documented from this practice. Such illnesses can be prevented by educating dairy farmers and officials of schools and youth organizations about the hazards of drinking raw milk. Public health organizations need to develop and implement such educational programs.	MINNESOTA DEPT HLTH,DIV DIS PREVENT & CONTROL,ACUTE DIS EPIDEMIOL SECT,717 DELAWARE ST SE,MINNEAPOLIS,MN 55440	Minnesota Department of Health (MHD)								BIRKHEAD G, 1988, J INFECT DIS, V157, P1095, DOI 10.1093/infdis/157.5.1095; BLASER MJ, 1987, JAMA-J AM MED ASSOC, V257, P43, DOI 10.1001/jama.257.1.43; BLASER MJ, 1983, ANN INTERN MED, V98, P360, DOI 10.7326/0003-4819-98-3-360; DEMING MS, 1987, AM J EPIDEMIOL, V126, P526, DOI 10.1093/oxfordjournals.aje.a114685; FINCH MJ, 1984, ARCH INTERN MED, V144, P1610, DOI 10.1001/archinte.144.8.1610; FINCH MJ, 1985, AM J EPIDEMIOL, V122, P262, DOI 10.1093/oxfordjournals.aje.a114097; GALBRAITH NS, 1982, BMJ-BRIT MED J, V284, P1761, DOI 10.1136/bmj.284.6331.1761; HARRIS NV, 1986, AM J PUBLIC HEALTH, V76, P407, DOI 10.2105/AJPH.76.4.407; HOPKINS RS, 1984, AM J PUBLIC HEALTH, V74, P249, DOI 10.2105/AJPH.74.3.249; HUDSON SJ, 1990, LANCET, V335, P1160, DOI 10.1016/0140-6736(90)91162-4; JOSEPH C, 1990, EPIDEMIOL INFECT, V105, P419, DOI 10.1017/S0950268800048007; KLEIN BS, 1986, JAMA-J AM MED ASSOC, V255, P361, DOI 10.1001/jama.255.3.361; KORLATH JA, 1985, J INFECT DIS, V152, P592, DOI 10.1093/infdis/152.3.592; KORNBLATT AN, 1985, AM J EPIDEMIOL, V122, P884, DOI 10.1093/oxfordjournals.aje.a114171; LOVETT J, 1983, APPL ENVIRON MICROB, V46, P459, DOI 10.1128/AEM.46.2.459-462.1983; MARTIN ML, 1986, LANCET, V2, P1043; MCNAUGHTON RD, 1982, CAN MED ASSOC J, V126, P657; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; RILEY LW, 1985, J INFECT DIS, V151, P956, DOI 10.1093/infdis/151.5.956; ROBINSON DA, 1981, BRIT MED J, V282, P1374, DOI 10.1136/bmj.282.6273.1374; SKIRROW MB, 1990, LANCET, V336, P921, DOI 10.1016/0140-6736(90)92282-M; TACKET CO, 1985, JAMA-J AM MED ASSOC, V253, P2058, DOI 10.1001/jama.253.14.2058; TAUXE RV, 1987, AM J PUBLIC HEALTH, V77, P1219, DOI 10.2105/AJPH.77.9.1219; WALTNERTOEWS D, 1990, J FOOD PROTECT, V53, P258, DOI 10.4315/0362-028X-53.3.258; 1986, MMWR, V35, P311; 1986, MMWR, V37, P1; 1987, CAN DIS WKLY REP, V13, P5	28	43	43	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	1992	268	22					3228	3230		10.1001/jama.268.22.3228	http://dx.doi.org/10.1001/jama.268.22.3228			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA654	1433764				2022-12-01	WOS:A1992KA65400030
J	ADAM, R; BISMUTH, H; DIAMOND, T; DUCOT, B; MORINO, M; ASTARCIOGLU, I; JOHANN, M; AZOULAY, D; CHICHE, L; BAO, YM; CASTAING, D				ADAM, R; BISMUTH, H; DIAMOND, T; DUCOT, B; MORINO, M; ASTARCIOGLU, I; JOHANN, M; AZOULAY, D; CHICHE, L; BAO, YM; CASTAING, D			EFFECT OF EXTENDED COLD ISCHEMIA WITH UW SOLUTION ON GRAFT FUNCTION AFTER LIVER-TRANSPLANTATION	LANCET			English	Article							EURO-COLLINS SOLUTIONS; HYDROXYETHYL STARCH; PRESERVATION; STORAGE; METABOLISM; 24-HOUR; P-31	Studies in animals on the use of UW solution in liver transplantation have shown an inverse relation between cold ischaemia time (CIT) and graft function. There are few clinical data on this relation in human beings. We have investigated the effect of extended cold ischaemia in a prospective study. We assessed early graft function and subsequent outcome for 306 consecutive elective liver transplantations; for analyses, grafts were grouped according to CIT (< 12 h group A, greater-than-or-equal-to 12 h group B), since a preliminary study identified 12 h as a significant cut-off point. Initial graft function was better in group A than group B, as shown by maximum alanine aminotransferase activity (mean 623 [805] vs 946 [1148], p=0.02), bile production on days 1-3 (p<0.05), maximum serum bilirubin by day 10 (206 [166] vs 244 [163] mumol/l, p=0.04), and frequencies of primary non-function (1 [0.4%] vs 4 [7%], p=0.006) and hepatocyte necrosis on routine biopsy sample after reperfusion (18% vs 31%, p=0.04). Long-term outcome was also better in group A than group B; graft and patient survival rates were higher and fewer retransplantations were needed. These findings suggest that cold ischaemia in UW solution for longer than 12 h is a risk factor for graft function and patient survival. We recommend that the limit of the safe CIT be reconsidered.	HOP BICETRE,INSERM,U292,F-94270 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	ADAM, R (corresponding author), HOP PAUL BROUSSE,HEPATOBILIARY SURG & LIVER TRANSPLANT RES UNIT,F-94800 VILLEJUIF,FRANCE.		Morino, Mario/AAI-6437-2020; Azoulay, Daniel/Q-7887-2018	Morino, Mario/0000-0003-4540-1409; CHICHE, LAURENCE/0000-0001-9081-4750				ADAM R, 1990, TRANSPLANT P, V22, P499; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; BISMUTH H, 1984, SURGERY, V95, P367; BISMUTH H, 1989, BRIT J SURG, V76, P722, DOI 10.1002/bjs.1800760723; COFER JB, 1990, TRANSPLANTATION, V49, P1088, DOI 10.1097/00007890-199006000-00012; FURUKAWA H, 1991, TRANSPLANT P, V23, P1550; HOWARD TK, 1990, TRANSPLANTATION, V49, P103, DOI 10.1097/00007890-199001000-00023; JAMIESON NV, 1988, TRANSPLANTATION, V46, P512, DOI 10.1097/00007890-198810000-00009; JAMIESON NV, 1989, TRANSPLANT P, V21, P1292; KALAYOGLU M, 1988, LANCET, V1, P617; MORINO M, 1992, CLIN TRANSPLANT, V6, P97; NEDELEC JF, 1990, TRANSPLANT P, V22, P492; NEDELEC JF, 1989, TRANSPLANT P, V21, P1327; OLTHOFF KM, 1990, TRANSPLANTATION, V49, P284, DOI 10.1097/00007890-199002000-00012; SANCHEZURDAZPAL L, 1992, HEPATOLOGY, V16, P49, DOI 10.1002/hep.1840160110; STARZL TE, 1987, SURG GYNECOL OBSTET, V165, P343; STRATTA RJ, 1990, TRANSPLANTATION, V50, P438, DOI 10.1097/00007890-199009000-00015; TODO S, 1989, JAMA-J AM MED ASSOC, V261, P711, DOI 10.1001/jama.261.5.711; TODO S, 1989, CLIN TRANSPLANT, V3, P253; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002	20	178	181	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1373	1376		10.1016/0140-6736(92)92559-X	http://dx.doi.org/10.1016/0140-6736(92)92559-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360089				2022-12-01	WOS:A1992KB20200003
J	BRYDON, WG; FERGUSON, A				BRYDON, WG; FERGUSON, A			HEMOGLOBIN IN GUT LAVAGE FLUID AS A MEASURE OF GASTROINTESTINAL BLOOD-LOSS	LANCET			English	Note							DISEASE	To detect and measure occult gastrointestinal bleeding, we have measured haemoglobin concentrations (by HemoQuant) in the clear fluid obtained after whole-gut lavage. In subjects with healthy gastrointestinal tracts, lavage-fluid haemoglobin concentrations were 0.5-5.1 mg/L, equivalent to daily blood loss of 0.1-1.1 mL. High concentrations were found for patients with colorectal cancer, severe diverticular disease, and rectal varices, in seven of sixteen patients with active inflammatory bowel disease, and in four patients with iron-deficiency anaemia thought to be due to gastrointestinal bleeding. In these four patients, estimated blood loss ranged from 2.6-24.5 mL per day. This method could have various research and clinical applications.	WESTERN GEN HOSP,DEPT MED,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh								CAMERON AD, 1960, GUT, V1, P177, DOI 10.1136/gut.1.2.177; GASPARI MM, 1988, J IMMUNOL METHODS, V110, P85, DOI 10.1016/0022-1759(88)90086-5; HARDCASTLE JD, 1989, FAECAL OCCULT BLOOD; HERZOG P, 1982, GASTROENTEROLOGY, V83, P957; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; OMAHONY S, 1990, GUT, V31, P1341, DOI 10.1136/gut.31.12.1341; OMAHONY S, 1991, SCAND J GASTROENTERO, V26, P940, DOI 10.3109/00365529108996246; SALLAM J, 1992, LANCET, V339, P179; SCHWARTZ S, 1983, CLIN CHEM, V29, P2061	9	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1381	1382		10.1016/0140-6736(92)92562-T	http://dx.doi.org/10.1016/0140-6736(92)92562-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360092				2022-12-01	WOS:A1992KB20200006
J	DURANDZALESKI, I; BONNET, F; ROCHANT, H; BIERLING, P; LEMAIRE, F				DURANDZALESKI, I; BONNET, F; ROCHANT, H; BIERLING, P; LEMAIRE, F			USEFULNESS OF CONSENSUS CONFERENCES - THE CASE OF ALBUMIN	LANCET			English	Article							PRACTICE GUIDELINES; MEDICINE; TRIAL	The usefulness of consensus conferences has been questioned. We have assessed the impact of a 1989 consensus conference about the treatment of hypovolaemia on prescribing practice at our hospital. Data available from the blood bank enabled us to follow albumin use and costs by department between 1987 and 1991. Medical journals, direct mail, and meetings were used to disseminate the recommendations of the consensus conference, which were that the only indications for albumin are massive haemorrhage, plasmapheresis, massive hypoalbuminaemia, and volume expansion in pregnancy; for hypovolaemia caused by septic shock or vasoplegia, fluid gelatins and crystalloids should be used. In the year after the conference, and in subsequent years, albumin use and costs were 40% lower than before the conference, even though total medical expenditure continued to rise and numbers of patients admitted did not change. We believe that consensus conferences can be a useful means of improving medical practice. The features that ensured success in this programme were the small number of prescribers, the homogeneous setting, and the frequent restatement of the recommendations.	HOP HENRI MONDOR,SURG INTENS CARE UNIT,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,DEPT HAEMATOL,F-94010 CRETEIL,FRANCE; HOP HENRI MONDOR,MED INTENS CARE UNIT,F-94010 CRETEIL,FRANCE; CDTS,VAL DE MARNE,CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	DURANDZALESKI, I (corresponding author), HOP HENRI MONDOR,DEPT PUBL HLTH,51 AVE MARECHAL DE LATTRE DE TASSIGNY,F-94010 CRETEIL,FRANCE.							BLACKBURN GL, 1992, CRIT CARE MED, V20, P157; BROOK RH, 1989, JAMA-J AM MED ASSOC, V262, P3027, DOI 10.1001/jama.262.21.3027; CONSEILLER C, 1983, COMPENSATION PERTES, P49; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GROOTENDORST AF, 1988, INTENS CARE MED, V14, P554, DOI 10.1007/BF00263529; KANOUSE, 1989, CHANGING MED PRACTIS; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARTIN AR, 1980, NEW ENGL J MED, V303, P1330, DOI 10.1056/NEJM198012043032304; PERRIER JF, 1989, ANN FR ANESTH, V8, P204, DOI 10.1016/S0750-7658(89)80105-4; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P225, DOI 10.1001/jama.252.2.225; Stocking B, 1992, Qual Health Care, V1, P56, DOI 10.1136/qshc.1.1.56; THOMAS J, 1991, JAMA-J AM MED ASSOC, V65, P2202; 1989, REAN SOINS INTENS ME, V5, P295; 1985, JAMA-J AM MED ASSOC, V253, P551	15	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1388	1390		10.1016/0140-6736(92)92568-Z	http://dx.doi.org/10.1016/0140-6736(92)92568-Z			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360098				2022-12-01	WOS:A1992KB20200012
J	ELREFAEY, H; HINSHAW, K; HENSHAW, R; SMITH, N; TEMPLETON, A				ELREFAEY, H; HINSHAW, K; HENSHAW, R; SMITH, N; TEMPLETON, A			MEDICAL-MANAGEMENT OF MISSED ABORTION AND ANEMBRYONIC PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article									ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen				Hinshaw, Kim/0000-0003-0468-4326				NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; 1990, BRIT J OBSTET GYNAEC, V97, P480; 1990, FERTIL STERIL, V56, P132; 1989, HUM REPROD, V4, P718	4	63	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1399	1399		10.1136/bmj.305.6866.1399	http://dx.doi.org/10.1136/bmj.305.6866.1399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486304	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992KB85600022
J	EMERY, P; SALMON, M; BRADLEY, H; WORDSWORTH, P; TUNN, E; BACON, PA; WARING, R				EMERY, P; SALMON, M; BRADLEY, H; WORDSWORTH, P; TUNN, E; BACON, PA; WARING, R			GENETICALLY-DETERMINED FACTORS AS PREDICTORS OF RADIOLOGICAL CHANGE IN PATIENTS WITH EARLY SYMMETRICAL ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article							RHEUMATOID-ARTHRITIS; SUSCEPTIBILITY; SULFOXIDATION	Objective-To determine whether genetic factors associated with established rheumatoid arthritis could, in combination with rheumatoid factor, predict the development of radiological erosions in patients with early symmetrical (rheumatoid-like) arthritis. Design-Prospective study. Setting-Teaching hospital, early arthritis clinic. Subjects-Forty nine patients with symmetrical polyarthritis attending the early arthritis clinic. Main outcome measures-Conserved sequence of DRbeta third allelic hypervariable region, sulphoxidation capacity, rheumatoid factor, and development of radiologically determined bone erosions. Results-None of the 49 patients had radiological erosions at presentation but 25 developed these by four years. Patients with the conserved class II major histocompatibility complex (third allelic hypervariable of DRbeta1) genes associated with rheumatoid arthritis had a relative risk for the development of erosions of 1.9 (95% confidence interval 0.8 to 4.5). For poor sulphoxidation the risk was 2.5 (1.1 to 5.6) and for the presence of rheumatoid factor 1.8 (0.9 to 3.7). Of the 33 patients who had two or three of these risk factors, 24 developed erosions, with a relative risk of 11.6 (1.7 to 78.5) compared with only one of the 16 individuals with no or one risk factor. Conclusions-This preliminary study shows that by using these stable markers it is possible to make clinically useful predictions of outcome in patients with early symmetrical inflammatory arthritis.	UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Birmingham; University of Oxford	EMERY, P (corresponding author), UNIV BIRMINGHAM,DEPT RHEUMATOL,POB 363,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		emery, paul/B-3560-2013	Waring, Rosemary/0000-0001-6617-5856				EMERY P, 1992, ANN RHEUM DIS, V51, P318, DOI 10.1136/ard.51.3.318; EMERY P, 1984, J RHEUMATOL, V11, P626; GARDINER M, 1989, STATISTICS CONFIDENC; GREGERSEN PK, 1986, P NATL ACAD SCI USA, V83, P2642, DOI 10.1073/pnas.83.8.2642; Harris ED, 1989, TXB RHEUMATOLOGY; MITCHELL SC, 1984, BRIT J CLIN PHARMACO, V18, P507, DOI 10.1111/j.1365-2125.1984.tb02498.x; VANDERHEIJDE DMF, 1988, SEMIN ARTHRITIS RHEU, V17, P284; WILKENS RF, 1991, ARTHRITIS RHEUM, V34, P43; WINCHESTER RJ, 1988, SPRINGER SEMIN IMMUN, V10, P119, DOI 10.1007/BF01857219; WORDSWORTH BP, 1989, P NATL ACAD SCI USA, V86, P10049, DOI 10.1073/pnas.86.24.10049; WORDSWORTH BP, 1991, BRIT J RHEUMATOL, V30, P178; YOUNG A, 1991, ARTHRITIS RHEUM, V34, P93; YOUNG A, 1991, ARTHRITIS RHEUM, V34, P48	13	79	80	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1387	1389		10.1136/bmj.305.6866.1387	http://dx.doi.org/10.1136/bmj.305.6866.1387			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486300	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992KB85600018
J	KNEKT, P; HELIOVAARA, M; RISSANEN, A; AROMAA, A; AARAN, RK				KNEKT, P; HELIOVAARA, M; RISSANEN, A; AROMAA, A; AARAN, RK			SERUM ANTIOXIDANT VITAMINS AND RISK OF CATARACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL DISCHARGE DATA; SENILE CATARACT; PREVENTION; VALIDITY; AGE	Objective-To investigate serum concentrations of alpha tocopherol, beta carotene, retinol, and selenium for their prediction of end stage cataract. Design-A case-control study, nested within a cohort study, based on the linkage of records of subjects aged 40-83 from a health survey with those from the national Finnish hospital discharge register. Subjects-47 patients admitted to ophthalmological wards for senile cataract over 15 years and two controls per patient individually matched for sex, age, and municipality. Main outcome measure-Concentration of serum micronutrients, development of cataract according to whether operation was performed. Results-Low serum concentrations of antioxidant vitamins predicted the development of senile cataract, the odds ratio between the lowest third and the two higher thirds of the distribution of serum concentrations of alpha tocopherol and beta carotene being 1-9 (95% confidence interval 0.9 to 4.1) and 1.7 (0.8 to 3.8), respectively. Patients with both alpha tocopherol and beta carotene concentrations in the lowest third had an odds ratio of 2.6 (1.0 to 6.8) of cataract compared with subjects in the top two thirds. The associations were strengthened by adjustment for potential confounding factors such as occupation, smoking, blood pressure, serum cholesterol concentration, body mass index, and diabetes. No association was found between the serum concentrations of selenium, retinol, and retinol binding protein and the risk of cataract. Conclusions-Low serum concentrations of the antioxidant vitamins alpha tocopherol and beta carotene are risk factors for end stage senile cataract. Controlled trials of the role of antioxidant vitamins in cataract prevention are therefore warranted.	UNIV TAMPERE, DEPT BIOMED SCI, TAMPERE, FINLAND	Tampere University	KNEKT, P (corresponding author), SOCIAL INSURANCE INST, POB 78, SF-00381 HELSINKI, FINLAND.							AARAN RK, 1988, J PHARMACEUT BIOMED, V6, P853, DOI 10.1016/0731-7085(88)80101-8; ALFTHAN G, 1982, ANAL CHIM ACTA, V140, P221, DOI 10.1016/S0003-2670(01)95468-6; Breslow NE., 1980, IARC SCI PUBLICATION, V32; CHENG H, 1989, BRIT MED J, V298, P1470, DOI 10.1136/bmj.298.6686.1470; GERSTER H, 1989, Z ERNAHRUNGSWISS, V28, P56, DOI 10.1007/BF02025566; HELIOVAARA M, 1987, J CHRON DIS, V40, P251, DOI 10.1016/0021-9681(87)90161-5; HELIOVAARA M, 1984, ACTA MED SCAND, V216, P309; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; JACQUES PF, 1991, AM J CLIN NUTR, V53, pS352, DOI 10.1093/ajcn/53.1.352S; JACQUES PF, 1988, AM J CLIN NUTR, V48, P152, DOI 10.1093/ajcn/48.1.152; JACQUES PF, 1991, MICRONUTRIENTS HLTH, P359; KENNEDY RH, 1984, INVEST OPHTHALMOL  S, V25, P1; KNEKT P, 1988, AM J EPIDEMIOL, V127, P28, DOI 10.1093/oxfordjournals.aje.a114788; KNEKT P, 1988, SERUM ALPHA TOCOPHER, pML83; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; POIKOLAINEN K, 1983, DRUG ALCOHOL DEPEN, V12, P315, DOI 10.1016/0376-8716(83)90002-9; ROBERTSON JM, 1989, ANN NY ACAD SCI, V570, P372; SHETTY PS, 1979, LANCET, V2, P230; TEIKARI JM, 1987, ACTA OPHTHALMOL, V65, P589; 1985, WHO TECH REP SER, V727	21	126	129	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1392	1394		10.1136/bmj.305.6866.1392	http://dx.doi.org/10.1136/bmj.305.6866.1392			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486302	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992KB85600020
J	MOFFATT, CJ; FRANKS, PJ; OLDROYD, M; BOSANQUET, N; BROWN, P; GREENHALGH, RM; MCCOLLUM, CN				MOFFATT, CJ; FRANKS, PJ; OLDROYD, M; BOSANQUET, N; BROWN, P; GREENHALGH, RM; MCCOLLUM, CN			COMMUNITY CLINICS FOR LEG ULCERS AND IMPACT ON HEALING	BRITISH MEDICAL JOURNAL			English	Article							CHRONIC VENOUS ULCERS; COMPRESSION; TRIAL	Objective-To evaluate the effectiveness of community clinics for leg ulcers. Design-All patients with leg ulceration were invited to community clinics that offered treatment developed in a hospital research clinic. Patients without serious arterial disease (Doppler ankle/brachial index > 0.8) were treated with a high compression bandage of four layers. Setting-Six community clinics held in health centres in Riverside District Health Authority supported by the Charing Cross vascular surgical service. Patients-All patients referred to the community services with leg ulceration, irrespective of cause and duration of ulceration. Main outcome measures-Time to complete healing by the life table method. Results-550 ulcerated legs were seen in 475 patients of mean (SD) age 73.8 (11.9) years. There were 477 venous ulcers of median size 4.2 cm2 (range 0.1-117 cm2), 128 being larger than 10 cm2. These ulcers had been present for a median of three months (range one week to 63 years) with 150 present for over one year. Four layer bandaging in the community clinics achieved complete healing in 318 (69%) venous ulcers by 12 weeks and 375 (83%) by 24 weeks. There were 56 patients with an ankle/brachial arterial pressure index < 0.8, indicating arterial disease. The 50 patients with pressure index <0.8>0.5 were treated with reduced compression, and 24 (56%) healed by 12 weeks and 31 (75%) by 24 weeks. The figures for overall healing for all leg ulcers were 351/550 (67%) at 12 weeks and 417/550 (81%) at 24 weeks, compared with only 11/51 (22%) at 12 weeks before the community clinics were set up. Conclusions-Community clinics for venous ulcers offer an effective means of achieving healing in most patients with leg ulcers.	UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,DEPT SOCIAL POLICY,SURREY TW20 0EX,ENGLAND; W LONDON HOSP,RIVERSIDE DIST HLTH AUTHOR,FAMILY & COMMUNITY SERV UNIT,LONDON W6 7DQ,ENGLAND; UNIV HOSP S MANCHESTER,DEPT SURG,MANCHESTER M20 8LR,LANCS,ENGLAND	University of London; Royal Holloway University London; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	MOFFATT, CJ (corresponding author), CHARING CROSS HOSP,DEPT SURG,LONDON W6 8RF,ENGLAND.		Franks, Peter J/G-3592-2013	Franks, Peter J/0000-0002-9782-0181; Moffatt, Christine/0000-0002-2436-0129				BACKHOUSE CM, 1987, BRIT J SURG, V74, P626, DOI 10.1002/bjs.1800740732; BALE S, 1989, CARE, V7, P90; BLAIR SD, 1988, BRIT MED J, V297, P1159, DOI 10.1136/bmj.297.6657.1159; BLAIR SD, 1988, PHLEBOLOGY, V3, P129; CALLAM MJ, 1987, BRIT MED J, V295, P1382, DOI 10.1136/bmj.295.6610.1382; CALLAM MJ, 1985, BRIT MED J, V290, P1855, DOI 10.1136/bmj.290.6485.1855; COLGAN MP, 1990, BRIT MED J, V300, P972, DOI 10.1136/bmj.300.6730.972; CORNWALL JV, 1986, BRIT J SURG, V73, P693, DOI 10.1002/bjs.1800730905; POSKITT KR, 1987, BRIT MED J, V294, P674, DOI 10.1136/bmj.294.6573.674; WRIGHT D, 1987, Journal of Cardiovascular Surgery, V28, P97; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	11	191	193	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 5	1992	305	6866					1389	1392		10.1136/bmj.305.6866.1389	http://dx.doi.org/10.1136/bmj.305.6866.1389			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486301	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992KB85600019
J	REARDON, W; ROSS, RJM; SWEENEY, MG; LUXON, LM; PEMBREY, ME; HARDING, AE; TREMBATH, RC				REARDON, W; ROSS, RJM; SWEENEY, MG; LUXON, LM; PEMBREY, ME; HARDING, AE; TREMBATH, RC			DIABETES-MELLITUS ASSOCIATED WITH A PATHOGENIC POINT MUTATION IN MITOCHONDRIAL-DNA	LANCET			English	Article							MYOPATHY; GENE; FEATURES; ACIDOSIS; DISEASE; MELAS	Family studies of diabetes mellitus (DM) show that patients are more likely to have affected mothers than affected fathers. Since the inheritance of mitochondrial (mtDNA), unlike nuclear DNA, is exclusively maternal, could it be that defect(s) in mtDNA account for some cases of DM? Such defects have been associated with rare neurological syndromes, in some of which DM has been an accompanying feature. We have looked for glucose intolerance and for a previously known point mutation of mtDNA in a family, some of whose members have a multisystem disorder with DM but not neurological involvement. DNA samples were obtained from fourteen family members. The point mutation (affecting position 3243 in the tRNA leucine mitochondrial gene) was found in all three diabetic patients and post mortem tissues in the proband; it was also found in seven offspring of female patients. It was not found in the two children of the male proband. The contribution of this mutation to DM in general is not known but clinicians ought to be aware of the possibility, especially in families with multisystem disease and maternal transmission.	ST BARTHOLOMEWS HOSP, DEPT ENDOCRINOL, LONDON EC1, ENGLAND; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON WC1, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROOTOL, LONDON WC1, ENGLAND	University of London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	REARDON, W (corresponding author), INST CHILD HLTH, MOTHERCARE UNIT CLIN GENET & FETAL MED, LONDON WC1N 1EH, ENGLAND.		Ross, Richard/B-2672-2012	Ross, Richard/0000-0001-9222-9678; Trembath, Richard/0000-0003-0550-3400				ALCOLADO JC, 1991, BRIT MED J, V302, P1178, DOI 10.1136/bmj.302.6786.1178; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408; EVIATAR L, 1990, NEUROLOGY, V40, P1761, DOI 10.1212/WNL.40.11.1761; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7; HAMMANS SR, 1991, BRIT J HOSP MED, V46, P20; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HOLT IJ, 1990, AM J HUM GENET, V46, P428; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; PENROSE LS, 1945, P AM DIABETES ASSOC, V5, P163; PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915; POULTON J, 1989, LANCET, V1, P236; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VULIER C, 1991, NATURE, V354, P155; 1985, TECH REP SER WHO, V727	17	366	379	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1376	1379		10.1016/0140-6736(92)92560-3	http://dx.doi.org/10.1016/0140-6736(92)92560-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360090				2022-12-01	WOS:A1992KB20200004
J	SUN, XF; CARSTENSEN, JM; ZHANG, H; STAL, O; WINGREN, S; HATSCHEK, T; NORDENSKJOLD, B				SUN, XF; CARSTENSEN, JM; ZHANG, H; STAL, O; WINGREN, S; HATSCHEK, T; NORDENSKJOLD, B			PROGNOSTIC-SIGNIFICANCE OF CYTOPLASMIC-P53 ONCOPROTEIN IN COLORECTAL ADENOCARCINOMA	LANCET			English	Article							P53 EXPRESSION; BREAST-CANCER; ONCOGENE; TUMORS	Mutation of p53, a tumour-suppressor protein, leads to overexpression of the protein and loss of its tumour-suppressive properties. In some tumours (eg, breast) p53 expression is related to well-known prognostic factors, but findings in colorectal tumours are equivocal. We have used the polyclonal antibody CM1 to investigate nuclear and cytoplasmic p53 expression in colorectal tumours and to assess their relations with prognosis. Of 293 colorectal adenocarcinomas, 71 (24%) showed p53 expression in the nucleus alone, 30 (10%) showed p53 in the cytoplasm alone, and 43 (15%) showed both nuclear and cytoplasmic expression. Nuclear p53 expression showed no relation with survival or Dukes' stage of the tumour. However, the frequency of cytoplasmic expression increased with advancing Dukes' stage (chi2 for trend 11.18, 1 df, p=0.0008) and cytoplasmic expression was associated with poor survival (rate ratio 2.3 [95% Cl 1.6-3.3], p<0.0001). Among tumours of Dukes' stage A-C, cytoplasmic expression showed prognostic value independent of nuclear staining, grade of differentiation, and Dukes' stage (2.3 [1.4-3.7], p=0.0021). We conclude that cytoplasmic expression of p53 may be a useful biological indicator of prognosis in colorectal adenocarcinoma.	LINKOPING UNIV HOSP,DEPT PATHOL,S-58185 LINKOPING,SWEDEN	Linkoping University	SUN, XF (corresponding author), LINKOPING UNIV HOSP,DEPT ONCOL,S-58185 LINKOPING,SWEDEN.			Carstensen, John/0000-0003-2256-8089				ARMITAGE P, 1987, STATISTICAL METHODS; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANG K, 1991, J HISTOCHEM CYTOCHEM, V39, P1281, DOI 10.1177/39.9.1680897; COSSMAN J, 1991, J NATL CANCER I, V83, P980, DOI 10.1093/jnci/83.14.980; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIDOFF AM, 1991, SURGERY, V110, P259; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARRIS AL, 1990, J PATHOL, V162, P5, DOI 10.1002/path.1711620103; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; PURDIE CA, 1991, AM J PATHOL, V138, P807; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REMVIKOS Y, 1990, INT J CANCER, V45, P450, DOI 10.1002/ijc.2910450313; SCOTT N, 1991, BRIT J CANCER, V63, P317, DOI 10.1038/bjc.1991.74; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1991, ADV ONCOL, V7, P3	20	234	237	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1369	1373		10.1016/0140-6736(92)92558-W	http://dx.doi.org/10.1016/0140-6736(92)92558-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360088				2022-12-01	WOS:A1992KB20200002
J	TIMMONS, MJ				TIMMONS, MJ			MALIGNANT-MELANOMA EXCISION MARGINS - MAKING A CHOICE	LANCET			English	Editorial Material							RECURRENCE; WIDE				TIMMONS, MJ (corresponding author), ST LUKES HOSP,DEPT PLAST SURG,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.							ACKERMAN AB, 1983, HUM PATHOL, V14, P743, DOI 10.1016/S0046-8177(83)80298-6; Ames FC, 1992, CUTANEOUS MELANOMA, P287; BOULAY M, 1888, ARCH GEN MED, V2, P157; Butterworth T, 1934, J AMER MED ASSOC, V102, P739, DOI 10.1001/jama.1934.02750100005002; CASCINELLI N, 1980, EUR J CANCER, V16, P1079; DIETERICH P, 1887, ARCH KLIN CHIR BERLI, V35, P289; EVANS J, 1990, BRIT J PLAST SURG, V43, P426, DOI 10.1016/0007-1226(90)90007-M; FALLOWFIELD ME, 1990, HISTOPATHOLOGY, V17, P397, DOI 10.1111/j.1365-2559.1990.tb00758.x; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; GRIFFITHS RW, 1986, BRIT J SURG, V73, P349, DOI 10.1002/bjs.1800730507; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; Handley WS, 1907, LANCET, V1, P927; Handley WS, 1907, LANCET, V1, P996; KELLY JW, 1984, ANN SURG, V200, P759; Norris W., 1857, 8 CASES MELANOSIS PA; PACK GT, 1952, ANN SURG, V136, P905, DOI 10.1097/00000658-195212000-00001; RAMPEN F, 1981, EUR J CANCER, V17, P589, DOI 10.1016/0014-2964(81)90062-1; RAVEN RW, 1950, ANN ROY COLL SURG, V6, P28; TAYLOR BA, 1985, EUR J SURG ONCOL, V11, P7; VERONESI U, 1991, ARCH SURG-CHICAGO, V126, P438	20	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 5	1992	340	8832					1393	1395		10.1016/0140-6736(92)92570-6	http://dx.doi.org/10.1016/0140-6736(92)92570-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB202	1360100				2022-12-01	WOS:A1992KB20200014
J	VONMUTIUS, E; FRITZSCH, C; WEILAND, SK; ROLL, G; MAGNUSSEN, H				VONMUTIUS, E; FRITZSCH, C; WEILAND, SK; ROLL, G; MAGNUSSEN, H			PREVALENCE OF ASTHMA AND ALLERGIC DISORDERS AMONG CHILDREN IN UNITED GERMANY - A DESCRIPTIVE COMPARISON	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SULFUR-OXIDES; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; NEW-ZEALAND; HAY-FEVER; RESPONSIVENESS; ADOLESCENTS; POLLINOSIS; MORTALITY; MORBIDITY	Objectives-To compare the prevalence of asthma and allergic disorders among children in Munich, western Germany, and Letpzig, eastern Germany, where environmental exposure, particularly air concentrations of sulphur dioxide and particulate matter, and living conditions have differed over the past 45 years. Design-Prevalence surveys among school-children aged 9-11 years in Leipzig and Munich. Self completion of written questionnaire by the children's parents and lung function measurements. Subjects-1051 children in Leipzig and 5030 in Munich. Setting-Primary schools. Main outcome measures-Reported lifetime prevalence of asthma and allergic disorders, and bronchial hyperresponsiveness assessed by cold air inhalation challenge. Results-The lifetime prevalence of asthma diagnosed by a doctor was 7.3% (72) in Leipzig and 9.3% (435) in Munich; prevalences of wheezing were 20% (191) and 17% (786) respectively. The prevalence of diagnosed bronchitis was higher in Leipzig than Munich (30.9% (303) v 15.9% (739); p<0.01). A significant drop in forced expiratory volume (>9%) after cold air challenge was measured in 6.4% (57) of children in Leipzig and in 7.7% (345) of those in Munich. Hay fever (2.4% (24) v 8.6% (410); p<0.01) and typical symptoms of rhinitis (16.6% (171) v 19.7% (961); p<0.05) were reported less often in Leipzig than in Munich. Conclusions-No significant differences were seen in the lifetime prevalence of asthma, wheezing, and bronchial hyperresponsiveness between children in Leipzig and Munich. The lifetime prevalence of bronchitis was higher in Leipzig than in Munich. The lower prevalence rates of allergic disorders in Leipzig could point toward aetiological factors that are associated with Western lifestyle and living conditions.	CHILDRENS HOSP LEIPZIG, O-7050 LEIPZIG, GERMANY; RUHR UNIV BOCHUM, DEPT SOCIAL MED & EPIDEMIOL, W-4630 BOCHUM, GERMANY; GSF MEDIS INST, ENVIRONM & HUMAN HLTH RES CTR, W-8000 MUNICH, GERMANY; KRANKENHAUS GROSSHANSDORF HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, HAMBURG, GERMANY	Ruhr University Bochum	VONMUTIUS, E (corresponding author), UNIV MUNICH, CHILDRENS HOSP, DR VON HAUNERSCHE KINDERKLIN, W-8000 MUNICH 2, GERMANY.							ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; DODGE R, 1985, AM J EPIDEMIOL, V121, P720, DOI 10.1093/aje/121.5.720; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FLEISS JL, 1980, STATISTICAL METHODS; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRIDAY GA, 1988, PEDIATR CLIN N AM, V35, P1149; GORE AT, 1968, BR J PREV SOC MED, V12, P104; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JORRES R, 1990, EUR RESPIR J, V3, P132; KOENIG JQ, 1985, J ALLERGY CLIN IMMUN, V76, P813, DOI 10.1016/0091-6749(85)90754-7; LOGAN WPD, 1953, LANCET, V264, P336; LUNN JE, 1970, BRIT J PREV SOC MED, V24, P223; LUNN JE, 1967, BRIT J PREV SOC MED, V21, P7; MITCHELL EA, 1989, J ASTHMA, V26, P349, DOI 10.3109/02770908909073277; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; NICOLAI T, IN PRESS AM REV RESP; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEINBRUCK P, 1969, MONATSSCHR LUNGENKR, V12, P289; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VARONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P909; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; 1990, STATISTICAL ANAL VER	36	363	369	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1395	1399		10.1136/bmj.305.6866.1395	http://dx.doi.org/10.1136/bmj.305.6866.1395			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486303	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992KB85600021
J	VOSS, LD; MULLIGAN, J; BETTS, PR; WILKIN, TJ				VOSS, LD; MULLIGAN, J; BETTS, PR; WILKIN, TJ			POOR GROWTH IN SCHOOL ENTRANTS AS AN INDEX OF ORGANIC-DISEASE - THE WESSEX GROWTH STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHORT STATURE; HEIGHT; RELIABILITY; CHILDREN; NEED	Objective-To establish whether poor height or height velocity, assessed during the year of school entry, might identify children with previously undiagnosed organic disease. Design-Observation of a total population and their case controls. Setting-Community base. Subjects-All 14346 children in two health districts entering school during two consecutive years were screened for height by school nurses, and those whose height lay below the 3rd centile according to Tanner and Whitehouse standards (n=180) were identified. After excluding 32 with known organic disease, five from ethnic minorities, and three who refused to take part, the remaining 140 short normal children were matched with 140 age and sex matched controls of average height (10th-90th centile) and their height velocities over 12 months measured. Main outcome measures-Height, height velocity, previously diagnosed organic disease, and organic disease diagnosed as a result of blood tests and specialist examination. Results-Twenty five of the 180 short children (14%) were already known to have chronic organic disease which could explain their poor growth. Blood tests and specialist examination revealed a further seven with organic disease, which was acquired rather than congenital in three, and a second cause of short stature in one with known organic disease. These eight conditions had been missed at the school entry medical examination. The shorter the child, the more likely an underlying organic disorder, with seven of the 12 children whose heights were more than 3 standard deviations below the mean having some organic disease. Height velocity measured over 12 months, however, did not distinguish short normal children from those with disease or from their matched controls. Conclusions-Height, but not height velocity, is a useful index for identifying unrecognised organic disease at school entry. The shorter the stature the greater the prevalence of organic disease. The frequency of newly diagnosed remediable disease in this study (1 in 3-4000) is similar to that of neonatal hypothyroidism, which is routinely screened for. Routine investigation of all very short school entrants is recommended.			VOSS, LD (corresponding author), SOUTHAMPTON GEN HOSP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AYNSLEYGREEN A, 1983, ARCH DIS CHILD, V58, P535; BROOK CGD, 1991, ARCH DIS CHILD, V66, P85, DOI 10.1136/adc.66.1.85; BROOK CGD, 1989, CLIN PAEDIATRIC ENDO, P118; CHINN S, 1989, ARCH DIS CHILD, V64, P1545, DOI 10.1136/adc.64.11.1545; CROSS AW, 1985, J PEDIATR-US, V107, P653, DOI 10.1016/S0022-3476(85)80388-7; DONALD RA, 1984, ENDOCRINE DISORDERS; HINDMARSH PC, 1988, ACTA PAEDIATR SCAND, P73; KENNEDY FD, 1988, ARCH DIS CHILD, V63, P1261, DOI 10.1136/adc.63.10.1261; LACEY KA, 1974, LANCET, V1, P42; PARKIN JM, 1989, CLIN PAEDIATRIC ENDO, P96; SMITH GC, 1990, ARCH DIS CHILD, V65, P225, DOI 10.1136/adc.65.2.225; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; TANNER JM, 1986, HUMAN GROWTH COMPREH, V3, P95; VIMPANI GV, 1981, ARCH DIS CHILD, V56, P922, DOI 10.1136/adc.56.12.922; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; VOSS LD, 1987, LANCET, V2, P447; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340; ZERFAS AJ, 1986, HUMAN GROWTH, P490	19	73	75	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 5	1992	305	6866					1400	1402		10.1136/bmj.305.6866.1400	http://dx.doi.org/10.1136/bmj.305.6866.1400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KB856	1486305	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992KB85600023
J	FAHNESTOCK, ML; TAMIR, I; NARHI, L; BJORKMAN, PJ				FAHNESTOCK, ML; TAMIR, I; NARHI, L; BJORKMAN, PJ			THERMAL-STABILITY COMPARISON OF PURIFIED EMPTY AND PEPTIDE-FILLED FORMS OF A CLASS-I MHC MOLECULE	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; HLA-B-ANTIGENS; HEAVY-CHAIN; VIRAL PEPTIDES; LYMPHOCYTES-T; BETA-2-MICROGLOBULIN; CELLS; BINDING; SURFACE; EXPRESSION	A secreted form of a class I major histocompatibility complex (MHC) molecule was denatured and renatured in vitro in the absence of peptide. The resulting empty class I heterodimer was immunologically reactive and structurally similar to a heterodimer renatured in the presence of an appropriate restricted peptide. Thermal stability profiles indicated that the two forms of heterodimer differed in their resistance to denaturation by heat but that a significant portion of the empty class I heterodimers had a native conformation at physiological temperatures. Free energies calculated from these data gave a direct measure of the stabilization of the class I MHC molecule that resulted from peptide binding.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; AMGEN INC, BIOPHYS, THOUSAND OAKS, CA 91320 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Amgen					NIAID NIH HHS [AI28931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BENJAMIN RJ, 1991, NATURE, V351, P74, DOI 10.1038/351074a0; BERNABEU C, 1984, NATURE, V308, P642, DOI 10.1038/308642a0; BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; FAHNESTOCK ML, UNPUB; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; GASTINEL LN, UNPUB; GORGA JC, 1989, P NATL ACAD SCI USA, V86, P2321, DOI 10.1073/pnas.86.7.2321; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GROVES ML, 1982, J BIOL CHEM, V257, P2619; HARLOW E, 1982, ANTIBODIES LABORATOR, P522; HOCHMAN JH, 1988, J IMMUNOL, V140, P2322; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LUESCHER IF, 1991, NATURE, V351, P72, DOI 10.1038/351072a0; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; MCINTOSH K, 1982, J CLIN MICROBIOL, V16, P329, DOI 10.1128/JCM.16.2.329-333.1982; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARHAM P, 1983, J BIOL CHEM, V258, P6179; PARHAM P, 1979, J BIOL CHEM, V254, P8709; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RAGHAVAN M, UNPUB; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; ROTZSCHKE O, 1990, SCIENCE, V249, P283, DOI 10.1126/science.1695760; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YOKOYAMA K, 1985, BIOCHEMISTRY-US, V24, P3002, DOI 10.1021/bi00333a029	39	128	134	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1658	1662		10.1126/science.1360705	http://dx.doi.org/10.1126/science.1360705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360705				2022-12-01	WOS:A1992KA89600040
J	LU, ZL; WILLIAMSON, SJ; KAUFMAN, L				LU, ZL; WILLIAMSON, SJ; KAUFMAN, L			BEHAVIORAL LIFETIME OF HUMAN AUDITORY SENSORY MEMORY PREDICTED BY PHYSIOLOGICAL MEASURES	SCIENCE			English	Article								Noninvasive magnetoencephalography makes it possible to identify the cortical area in the human brain whose activity reflects the decay of passive sensory storage of information about auditory stimuli (echoic memory). The lifetime for decay of the neuronal activation trace in primary auditory cortex was found to predict the psychophysically determined duration of memory for the loudness of a tone. Although memory for the loudness of a specific tone is lost, the remembered loudness decays toward the global mean of all of the loudnesses to which a subject is exposed in a series of trials.	NYU,DEPT PHYS,NEW YORK,NY 10003; NYU,CTR NEURAL SCI,NEW YORK,NY 10003; NYU,DEPT PSYCHOL,NEW YORK,NY 10003	New York University; New York University; New York University								BERLINER JE, 1967, J ACOUST SOC AM, V61, P1577; CONRAD R, 1964, BRIT J PSYCHOL, V55, P75, DOI 10.1111/j.2044-8295.1964.tb00899.x; Crowder R., 1976, PRINCIPLES LEARNING; GLANZER M, 1966, J VERB LEARN VERB BE, V5, P351, DOI 10.1016/S0022-5371(66)80044-0; HARI R, 1980, EXP BRAIN RES, V40, P237, DOI 10.1007/BF00237543; HELSON H, 1964, ADAPTATION LEVEL THE; Hollingworth H.L., 1910, J PHILOS PSYCHOL SCI, V7, P461, DOI [DOI 10.2307/2012819, 10.2307/2012819]; IPSEN G, 1926, NEUE PSYCHOL STUD, V1, P279; IPSEN G, 1926, NEUE PSYCHOL STUD, V1, P171; KAUFMAN L, 1992, ELECTROEN CLIN NEURO, V82, P266, DOI 10.1016/0013-4694(92)90107-S; Lauenstein O, 1933, PSYCHOL FORSCH, V17, P130, DOI 10.1007/BF02411957; Lu Z., UNPUB; LU ZL, 1992, BRAIN RES, V572, P236, DOI 10.1016/0006-8993(92)90475-O; MASSARO DW, 1970, J EXP PSYCHOL, V85, P411, DOI 10.1037/h0029712; MASSARO DW, 1975, EXPT PSYCHOL INFORMA; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MURDOCK BB, 1969, J VERB LEARN VERB BE, V8, P665, DOI 10.1016/S0022-5371(69)80120-9; Needham JG, 1935, J EXP PSYCHOL, V18, P530, DOI 10.1037/h0056775; Neisser U., 2014, COGNITIVE PSYCHOL; PISONI DB, 1973, PERCEPT PSYCHOPHYS, V13, P253, DOI 10.3758/BF03214136; SPERLING G, 1960, PSYCHOL MONOGR, V74, P1, DOI 10.1037/h0093759; TREISMAN A, 1964, J VERB LEARN VERB BE, V3, P449, DOI 10.1016/S0022-5371(64)80015-3; WEINBERGER NM, 1987, PROG NEUROBIOL, V29, P1, DOI 10.1016/0301-0082(87)90014-1; WEINBERGER NM, 1990, CONCEPTS NEUROSCIENC, V1, P91; WESTENBERG IS, 1976, ELECTROEN CLIN NEURO, V40, P337, DOI 10.1016/0013-4694(76)90186-3; WICKELGR.WA, 1969, J MATH PSYCHOL, V6, P13, DOI 10.1016/0022-2496(69)90028-5; WILLIAMSON S J, 1991, Brain Topography, V4, P169, DOI 10.1007/BF01132773; Woodrow H, 1933, AM J PSYCHOL, V45, P391, DOI 10.2307/1415039; Woodworth R. S., 1938, EXPT PSYCHOL	29	207	208	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1668	1670		10.1126/science.1455246	http://dx.doi.org/10.1126/science.1455246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KA896	1455246				2022-12-01	WOS:A1992KA89600043
J	MENDELSON, NH				MENDELSON, NH			PRODUCTION AND INITIAL CHARACTERIZATION OF BIONITES - MATERIALS FORMED ON A BACTERIAL BACKBONE	SCIENCE			English	Article							BACILLUS-SUBTILIS; CELL-WALLS; BIOTECHNOLOGY; PRECIPITATION; GROWTH; THREAD	The addition of soluble metal salts of calcium, iron, or copper to cultures of Bacillus subtilis grown in web form nucleated precipitation at the surface of the bacterial cell walls. The mineralized cell filaments can be drawn into a fiber that when dried consists of a bacterial thread backbone carrying an inorganic solid. The ratios of organic to inorganic components (by weight) in the stiff brittle materials, called bionites, were: 1.08 for fe(2) bactonite, 1.8 for calbactonite, 2.3 for fe(3)bactonite, and 5 for cu(2)bactonite. X-ray photoelectron spectra suggest that the fe(3)bactonite contains Fe2O3, that calbactonite contains calcium carbonate, and that cu(2)bactonite contains CuCl (Cu I). Acid-base reactions of the bionites are compatible with these identifications. Burning out the organic phase of the febactonites yields a black magnetic material, presumably magnetite. The burnt cubactonite appears to yield elemental Cu(s). Calbactonite upon hydration was able to retain a genetically engineered enzymatic activity.			MENDELSON, NH (corresponding author), UNIV ARIZONA, DEPT MOLEC & CELLULAR BIOL, TUCSON, AZ 85721 USA.							ABELSON PH, 1983, SCIENCE, V219, P611, DOI 10.1126/science.6572016; BEVERIDGE TJ, 1980, J BACTERIOL, V141, P876, DOI 10.1128/JB.141.2.876-887.1980; BEVERIDGE TJ, 1989, SPEC PUBL SOC GEN MI, V26, P65; BEVERIDGE TJ, 1976, J BACTERIOL, V127, P1502, DOI 10.1128/JB.127.3.1502-1518.1976; CALVERT P, 1988, J MATER SCI, V23, P3801, DOI 10.1007/BF01106796; CHALOUPKA J, 1964, FOLIA MICROBIOL, V9, P9, DOI 10.1007/BF02875894; Doyle R.J., 1989, METAL IONS BACTERIA, P275; FERRIS FG, 1988, GEOLOGY, V16, P149, DOI 10.1130/0091-7613(1988)016<0149:MIBBBS>2.3.CO;2; HEUER AH, 1992, SCIENCE, V255, P1098, DOI 10.1126/science.1546311; HUGHES MN, 1989, METALS MICROORGANISM, P337; KOSHLAND DE, 1991, SCIENCE, V252, P1593, DOI 10.1126/science.252.5013.1593; Krumbein WE, 1986, BIOMINERALIZATION LO, P55; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; MANN S, 1986, BIOMINERALIZATION LO, P39; MARQUIS RE, 1976, CAN J MICROBIOL, V22, P975, DOI 10.1139/m76-142; MENDELSON NH, 1976, P NATL ACAD SCI USA, V73, P1740, DOI 10.1073/pnas.73.5.1740; MENDELSON NH, 1989, J BACTERIOL, V171, P1055, DOI 10.1128/jb.171.2.1055-1062.1989; MENDELSON NH, 1990, SCI PROG, V74, P425; MENDELSON NH, 1977, MICROBIOLOGY 1977, P5; MORITA RY, 1980, GEOMICROBIOL J, V2, P63, DOI 10.1080/01490458009377751; PAUTARD FGE, 1970, BIOL CALCIFICATION, P106; POOLEY HM, 1976, J BACTERIOL, V125, P1127, DOI 10.1128/JB.125.3.1127-1138.1976; POOLEY HM, 1976, J BACTERIOL, V125, P1139, DOI 10.1128/JB.125.3.1139-1147.1976; Rouxhet PG, 1991, MICROBIAL CELL SURFA, P173; SALHI B, 1991, THESIS U ARIZONA TUC; SWAISGOOD HE, 1985, ENZYMES IMMOBILIZED, P1; THWAITES JJ, 1991, ADV MICROB PHYSIOL, V32, P173, DOI 10.1016/S0065-2911(08)60008-9; THWAITES JJ, 1985, P NATL ACAD SCI USA, V82, P2163, DOI 10.1073/pnas.82.7.2163; ZIOLO RF, 1992, SCIENCE, V257, P219, DOI 10.1126/science.257.5067.219	29	27	27	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 4	1992	258	5088					1633	1636		10.1126/science.1455245	http://dx.doi.org/10.1126/science.1455245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1455245				2022-12-01	WOS:A1992KA89600031
J	MEZEY, E; PALKOVITS, M				MEZEY, E; PALKOVITS, M			LOCALIZATION OF TARGETS FOR ANTIULCER DRUGS IN CELLS OF THE IMMUNE-SYSTEM	SCIENCE			English	Article							ACETYLCHOLINE-RECEPTOR GENES; GASTRIC-ACID SECRETION; DUODENAL-ULCER; DOPAMINE AGONISTS; MOLECULAR-CLONING; PARIETAL-CELLS; RAT; CYSTEAMINE; PROPIONITRILE; EXPRESSION	The gastric mucosa consists of the epithelium, which lines the lumen, the lamina propria, and the muscularis mucosae. The targets of drugs used to treat stomach and duodenal ulcers are thought to be the acid-secreting parietal cells of the epithelium. However, immune cells in the lamina propria are the only cells that showed detectable messenger RNAs for histamine, muscarinic, gastrin, and dopamine receptors by in situ hybridization histochemistry. None of the epithelial cells expressed any of these messenger RNAs. Thus, the targets of antiulcer drugs seem to be cells of the immune system in the gut and not parietal cells, as generally believed. This conclusion may revise the thinking about ulcer formation and may shed light on the etiology of such chronic small intestinal diseases as Crohn's disease.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892; NINCDS,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	MEZEY, E (corresponding author), SEMMELWEIS UNIV MED,SCH MED,NEUROMORPHOL LAB,H-1085 BUDAPEST 8,HUNGARY.		Palkovits, Miklos/F-2707-2013; Mezey, Eva/A-8105-2008	Palkovits, Miklos/0000-0003-0578-0387; Mezey, Eva/0000-0002-5907-4691				BIENENSTOCK J, 1980, IMMUNOLOGY, V41, P249; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANDBORG LL, 1969, GASTROENTEROLOGY, V57, P191; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BRIMBLECOMBE RW, 1975, J INT MED RES, V3, P86, DOI 10.1177/030006057500300205; BRUNTON LL, 1990, PHARM BASE THERAPEUT, V1, P897; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CHUANG CN, 1991, SCAND J GASTROENTERO, V26, P95, DOI 10.3109/00365529109093184; CRABBE PA, 1966, GASTROENTEROLOGY, V51, P305; CRABBE PA, 1965, LAB INVEST, V14, P235; FIOCCHI C, 1990, IMMUNOLOGY IMMUNOPAT, P107; GALLAGHER G, 1987, J PHARMACOL EXP THER, V240, P883; GLAVIN GB, 1989, J PHARMACOL EXP THER, V251, P726; GLAVIN GB, 1990, DIGEST DIS SCI, V35, P1153, DOI 10.1007/BF01537589; GLAVIN GB, 1991, BRAIN RES REV, V16, P301, DOI 10.1016/0165-0173(91)90012-W; GLAVIN GB, 1987, LIFE SCI, V41, P1397, DOI 10.1016/0024-3205(87)90615-1; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; GUTH PH, 1966, GASTROENTEROLOGY, V50, P562; GUYTON AC, 1980, TXB MED PHYSL; HERNANDEZ DE, 1987, LIFE SCI, V41, P2717, DOI 10.1016/0024-3205(87)90464-4; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LAMOROUX A, 1987, EMBO J, V6, P3921; LETH R, 1987, AM J PHYSIOL, V253, pG497, DOI 10.1152/ajpgi.1987.253.4.G497; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MEZEY E, 1989, NUCLEIC ACIDS RES, V17, P2125, DOI 10.1093/nar/17.5.2125; MEZEY E, UNPUB; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; OISHI T, 1987, J PHARMACOL EXP THER, V240, P879; Roitt I.M., 1988, ESSENTIAL IMMUNOLOGY; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SIKIRIC P, 1991, DIGEST DIS SCI, V36, P905, DOI 10.1007/BF01297139; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SOLL AH, 1984, AM J PHYSIOL, V247, pG715, DOI 10.1152/ajpgi.1984.247.6.G715; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SZABO S, 1979, LANCET, V2, P880; SZABO S, 1987, J PHARMACOL EXP THER, V240, P871; SZABO S, 1988, TOXICOL PATHOL, V16, P205, DOI 10.1177/019262338801600213; SZABO S, 1987, CHRONOBIOL INT, V4, P31, DOI 10.3109/07420528709078506; SZABO S, 1979, DIGEST DIS SCI, V24, P471, DOI 10.1007/BF01299831; SZABO S, 1979, Gastroenterology, V76, P1257; SZABO S, 1982, ADV DOPAMINE RES, V37, P165; TOMASI TB, 1968, NEW ENGL J MED, V279, P1327, DOI 10.1056/NEJM196812122792408; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; YOUNG WS, 1986, MOL BRAIN RES, V1, P231, DOI 10.1016/0169-328X(86)90029-X	48	83	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1662	1665		10.1126/science.1333642	http://dx.doi.org/10.1126/science.1333642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1333642				2022-12-01	WOS:A1992KA89600041
J	YOSHINAGA, SK; PETERSON, CL; HERSKOWITZ, I; YAMAMOTO, KR				YOSHINAGA, SK; PETERSON, CL; HERSKOWITZ, I; YAMAMOTO, KR			ROLES OF SWI1, SWI2, AND SWI3 PROTEINS FOR TRANSCRIPTIONAL ENHANCEMENT BY STEROID-RECEPTORS	SCIENCE			English	Article							TUMOR VIRUS PROMOTER; MAMMALIAN GLUCOCORTICOID RECEPTOR; DEHYDROGENASE-II ISOZYME; YEAST HO GENE; SACCHAROMYCES-CEREVISIAE; DNA-BINDING; PREINITIATION COMPLEX; INVITRO TRANSCRIPTION; UPSTREAM ACTIVATION; CHROMATIN STRUCTURE	The SWI1, SWI2, and SWI3 proteins, which are required for regulated transcription of numerous yeast genes, were found also to be essential for rat glucocorticoid receptor function in yeast; the receptor failed to activate transcription in strains with mutations in the SWI1, SWI2, or SWI3 genes. Certain mutations in genes encoding components of chromatin, identified as suppressors of swi mutations, partially relieved the SWI- requirement for receptor function. Immunoprecipitation of glucocorticoid receptor derivatives from wild-type (SWI+) yeast extracts coprecipitated the SWI3 protein; such receptor-SWI3 complexes were not detected in swi1- or swi2- mutant strains, implying that a complex of multiple SWI proteins may associate with the receptor. Prior incubation of a Drosophila embryo transcription extract with the yeast SWI3-specific antibody inhibited receptor function in vitro whereas the antibody had no effect if added after initiation complex formation. Thus, positive regulation by the glucocorticoid receptor in vivo and in vitro appears to require its interaction, at an early step, with one or more SWI proteins.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BITTER GA, 1984, GENE, V32, P263, DOI 10.1016/0378-1119(84)90002-7; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ESTRUCH F, 1990, MOL CELL BIOL, V10, P2544, DOI 10.1128/MCB.10.6.2544; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GUARENTE L, 1992, TRENDS GENET, V8, P27, DOI 10.1016/0168-9525(92)90021-U; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; IMAI E, UNPUB; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, UNPUB; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MOAZED D, COMMUNICATION; NASMYTH K, COMMUNICATION; NEIGEBORN L, 1984, GENETICS, V108, P845; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKABE I, 1992, NUCLEIC ACIDS RES, V20, P4649, DOI 10.1093/nar/20.17.4649; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PERLMANN T, 1991, MOL CELL BIOL, V11, P5259, DOI 10.1128/MCB.11.10.5259; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PICARD D, 1990, GENE, V86, P257, DOI 10.1016/0378-1119(90)90287-2; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHENA M, 1991, P NATL ACAD SCI USA, V88, P10421, DOI 10.1073/pnas.88.23.10421; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TAGUCHI AKW, 1987, GENETICS, V116, P531; TAGUCHI AKW, 1987, GENETICS, V116, P523; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WINSTON F, IN PRESS TRENDS GENE; WOOLFORD J, 1986, MOL CELL BIOL, V6, P674; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; YOSHINAGA SK, 1991, MOL ENDOCRINOL, V5, P844, DOI 10.1210/mend-5-6-844; YOSHINAGA SK, UNPUB; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	74	434	439	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1598	1604		10.1126/science.1360703	http://dx.doi.org/10.1126/science.1360703			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1360703				2022-12-01	WOS:A1992KA89600021
J	YU, HT; ROSEN, MK; SHIN, TB; SEIDELDUGAN, C; BRUGGE, JS; SCHREIBER, SL				YU, HT; ROSEN, MK; SHIN, TB; SEIDELDUGAN, C; BRUGGE, JS; SCHREIBER, SL			SOLUTION STRUCTURE OF THE SH3 DOMAIN OF SRC AND IDENTIFICATION OF ITS LIGAND-BINDING SITE	SCIENCE			English	Article							COHERENCE TRANSFER SPECTROSCOPY; 3-DIMENSIONAL NMR-SPECTROSCOPY; MULTIPLE-QUANTUM COHERENCE; PROTEINS; SPECTRA; SIMPLIFICATION; ASSIGNMENTS; RECEPTOR; SYSTEMS; YEAST	The Src homology 3 (SH3) region is a protein domain of 55 to 75 amino acids found in many cytoplasmic proteins, including those that participate in signal transduction pathways. The solution structure of the SH3 domain of the tyrosine kinase Src was determined by multidimensional nuclear magnetic resonance methods. The molecule is composed of two short three-stranded anti-parallel beta sheets packed together at approximately right angles. Studies of the SH3 domain bound to proline-rich peptide ligands revealed a hydrophobic binding site on the surface of the protein that is lined with the side chains of conserved aromatic amino acids.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139	Harvard University; Takeda Pharmaceutical Company Ltd; Takeda Oncology				Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA27951] Funding Source: Medline; NCRR NIH HHS [1-S10-RR04870] Funding Source: Medline; NIGMS NIH HHS [GM44993] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027951, R01CA027951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARROWSMITH CH, 1990, BIOCHEMISTRY-US, V29, P6332, DOI 10.1021/bi00479a002; BAX A, 1981, J MAGN RESON, V43, P478, DOI 10.1016/0022-2364(81)90060-3; BOLTON PH, 1982, CHEM PHYS LETT, V89, P139, DOI 10.1016/0009-2614(82)83390-3; BOLTON PH, 1982, J MAGN RESON, V48, P336, DOI 10.1016/0022-2364(82)90288-8; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, XPLOR MANUAL; BRUNGER AT, 1992, XPLOR MANUAL 5 3 0; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; EICH G, 1982, J AM CHEM SOC, V104, P3731, DOI 10.1021/ja00377a036; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOYAMA S, UNPUB; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER B, COMMUNICATION; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMUTH SP, 1989, MOL CELL BIOL, V9, P1109; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PATTERSON Y, 1990, SCIENCE, V249, P755; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Potts W M, 1988, Oncogene Res, V3, P343; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SPITZFADEN C, 1992, FEBS LETT, V300, P291, DOI 10.1016/0014-5793(92)80866-F; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WAGNER G, 1983, J MAGN RESON, V55, P151, DOI 10.1016/0022-2364(83)90284-6; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZY, UNPUB; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	43	306	317	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 4	1992	258	5088					1665	1668		10.1126/science.1280858	http://dx.doi.org/10.1126/science.1280858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA896	1280858				2022-12-01	WOS:A1992KA89600042
J	BHASKAR, KR; GARIK, P; TURNER, BS; BRADLEY, JD; BANSIL, R; STANLEY, HE; LAMONT, JT				BHASKAR, KR; GARIK, P; TURNER, BS; BRADLEY, JD; BANSIL, R; STANLEY, HE; LAMONT, JT			VISCOUS FINGERING OF HCL THROUGH GASTRIC MUCIN	NATURE			English	Article							MUCUS-BICARBONATE BARRIER; MUCOSAL PROTECTION; PH GRADIENT; DIFFUSION; PATTERNS; ACID; GEL; GLYCOPROTEIN; SECRETION; VISCOSITY	THE HCl in the mammalian stomach is concentrated enough to digest the stomach itself, yet the gastric epithelium remains undamaged. One protective factor is gastric mucus, which forms a protective layer over the surface epithelium1-4 and acts as a diffusion barrier5,6 Bicarbonate ions secreted by the gastric epithelium7 are trapped in the mucus gel, establishing a gradient from pH 1-2 at the lumen to pH 6-7 at the cell surface8-10. How does HCl, secreted at the base of gastric glands by parietal cells, traverse the mucus layer without acidifying it? Here we demonstrate that injection of HCl through solutions of pig gastric mucin produces viscous fingering patterns11-18 dependent on pH, mucin concentration and acid flow rate. Above pH 4, discrete fingers are observed, whereas below pH 4, HCl neither penetrates the mucin solution nor forms fingers. Our in vitro results suggest that HCl secreted by the gastric gland can penetrate the mucus gel layer (pH 5-7) through narrow fingers, whereas HCl in the lumen (pH 2) is prevented from diffusing back to the epithelium by the high viscosity of gastric mucus gel on the luminal side.	BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215; BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215	Boston University; Boston University	BHASKAR, KR (corresponding author), BOSTON UNIV HOSP,MED CTR,GASTROENTEROL SECT,88 E NEWTON ST,BOSTON,MA 02218, USA.		Bansil, Rama/ABC-4452-2020	Bansil, Rama/0000-0003-1311-1749; Stanley, H./0000-0003-2800-4495				AGREN J, 1990, ACTA PHYSL SCAND, V140, pA36; ALLEN A, 1976, NATURE, V264, P88, DOI 10.1038/264088a0; ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; ALLEN A, 1980, GUT, V21, P249, DOI 10.1136/gut.21.3.249; Allen A., 1981, PHYSL GASTROINTESTIN, P617; BENJACOB E, 1990, NATURE, V343, P523, DOI 10.1038/343523a0; BHASKAR KR, 1991, AM J PHYSIOL, V261, pG827, DOI 10.1152/ajpgi.1991.261.5.G827; BLOOM W, 1966, TXB HISTOLOGY, P433; BUKA A, 1986, NATURE, V323, P424, DOI 10.1038/323424a0; CASTELL DO, 1987, ESOPHAGEAL MOTILITY, P21; FABRY T L, 1990, Gastroenterology, V98, pA42; FLEMSTROM G, 1987, PHYSL GASTROINTESTIN, P1011; GARIK P, 1991, PHYS REV LETT, V66, P1606, DOI 10.1103/PhysRevLett.66.1606; GONG DH, 1990, AM J PHYSIOL, V259, pG681, DOI 10.1152/ajpgi.1990.259.4.G681; HEATLEY NG, 1959, GASTROENTEROLOGY, V37, P313; Hele-Shaw H. S., 1898, NATURE, V58, P34, DOI DOI 10.1038/058034A0; HOLLANDER F, 1954, ARCH INTERN MED, V93, P107, DOI 10.1001/archinte.1954.00240250117009; HOLM L, 1990, J INTERN MED, V228, P91, DOI 10.1111/j.1365-2796.1990.tb01478.x; JOSEPH DD, 1990, EUR J MECH B-FLUID, V9, P565; KERSS S, 1982, CLIN SCI, V63, P185; LAL J, 1992, PHYSICA A, V186, P88, DOI 10.1016/0378-4371(92)90367-Y; MAKHLOUF GM, 1984, PHYSL GASTROINTESTIN, V1, P551; MAY SE, 1989, PHYS REV A, V40, P1723, DOI 10.1103/PhysRevA.40.1723; MURTY VLN, 1984, BIOCHEM BIOPH RES CO, V121, P521, DOI 10.1016/0006-291X(84)90213-4; NITTMANN J, 1985, NATURE, V314, P141, DOI 10.1038/314141a0; PATRONELLA CK, 1988, GASTROENTEROLOGY, V95, P612, DOI 10.1016/S0016-5085(88)80005-2; PFEIFFER CJ, 1981, AM J PHYSIOL, V240, pG176, DOI 10.1152/ajpgi.1981.240.2.G176; SEELIG LL, 1985, AM J ANAT, V174, P15, DOI 10.1002/aja.1001740103; SELLERS LA, 1987, BIORHEOLOGY, V24, P615; TAKEUCHI K, 1983, GASTROENTEROLOGY, V84, P331; WALLACE JL, 1989, AM J PHYSIOL, V256, pG31, DOI 10.1152/ajpgi.1989.256.1.G31; WILLIAMS SE, 1981, GUT, V22, P94, DOI 10.1136/gut.22.2.94; WILLIAMS SE, 1980, GASTROENTEROLOGY, V79, P299	33	174	174	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					458	461		10.1038/360458a0	http://dx.doi.org/10.1038/360458a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448168				2022-12-01	WOS:A1992KA79700058
J	BLOCK, SM				BLOCK, SM			MAKING LIGHT WORK WITH OPTICAL TWEEZERS	NATURE			English	Article							INFRARED-LASER BEAMS; MEMBRANE-GLYCOPROTEINS; FORCE; MANIPULATION; TRAP; PARTICLES; FIELDS		HARVARD UNIV, DEPT CELLULAR & DEV BIOL, CAMBRIDGE, MA 02138 USA	Harvard University	BLOCK, SM (corresponding author), ROWLAND INST SCI INC, 100 CAMBRIDGE PKWY, CAMBRIDGE, MA 02142 USA.							ASHKIN A, 1992, BIOPHYS J, V61, P569, DOI 10.1016/S0006-3495(92)81860-X; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; ASHKIN A, 1987, SCIENCE, V235, P1517, DOI 10.1126/science.3547653; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; ASHKIN A, 1989, P NATL ACAD SCI USA, V86, P7914, DOI 10.1073/pnas.86.20.7914; ASHKIN A, 1989, BER BUNSEN PHYS CHEM, V93, P254, DOI 10.1002/bbpc.19890930308; BARTON JP, 1989, J APPL PHYS, V66, P2800, DOI 10.1063/1.344207; BARTON JP, 1989, J APPL PHYS, V66, P4594, DOI 10.1063/1.343813; BARTON JP, 1988, J APPL PHYS, V64, P1632, DOI 10.1063/1.341811; Bems M. W., 1991, INT REV CYTOL, V129, P1; BEMS MW, 1989, P NATL ACAD SCI USA, V86, P4539; BEMS MW, 1992, EXP CELL RES, V198, P375; BERG HC, 1976, J THEOR BIOL, V56, P269, DOI 10.1016/S0022-5193(76)80074-4; BLOCK SM, 1991, CYTOMETRY, V12, P492, DOI 10.1002/cyto.990120605; BLOCK SM, 1989, NATURE, V338, P514, DOI 10.1038/338514a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOCK SM, 1990, NONINVASIVE TECHNIQU, V9, P375; BURNS MM, 1990, SCIENCE, V249, P749, DOI 10.1126/science.249.4970.749; CHARON NW, 1992, J BACTERIOL, V174, P832, DOI 10.1128/jb.174.3.832-840.1992; CHU S, 1992, SCI AM, V266, P70, DOI 10.1038/scientificamerican0292-70; DENK W, 1990, APPL OPTICS, V29, P2382, DOI 10.1364/AO.29.002382; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; HONG LA, 1991, EXP CELL RES, V197, P21, DOI 10.1016/0014-4827(91)90475-A; KUCIK DF, 1991, J CELL BIOL, V114, P1029, DOI 10.1083/jcb.114.5.1029; Kuo S C, 1992, Trends Cell Biol, V2, P116, DOI 10.1016/0962-8924(92)90016-G; KUO SC, 1990, BIOPHYS J, V57, pA399; MISAWA H, 1992, APPL PHYS LETT, V60, P310, DOI 10.1063/1.106695; SATO S, 1991, OPT LETT, V16, P282, DOI 10.1364/OL.16.000282; SCHUT TCB, 1991, CYTOMETRY, V12, P479, DOI 10.1002/cyto.990120603; SEEGER S, 1991, CYTOMETRY, V12, P497, DOI 10.1002/cyto.990120606; SHEPHERD GMG, 1990, P NATL ACAD SCI USA, V87, P8627, DOI 10.1073/pnas.87.21.8627; SIMMONS RM, 1992, MECHANISM MYOFILAMEN; SIMON A, 1992, PHYS REV LETT, V68, P3375, DOI 10.1103/PhysRevLett.68.3375; STEUBING RW, 1991, CYTOMETRY, V12, P505, DOI 10.1002/cyto.990120607; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; TADIR Y, 1990, FERTIL STERIL, V53, P944; VISSCHER K, 1992, OPTIK, V90, P57; VISSCHER K, 1992, J OPTIK, V89, P174; WAYNE D B, 1991, Journal of Cell Biology, V115, p102A; WEBER G, 1992, INT REV CYTOL, V133, P1, DOI 10.1016/S0074-7696(08)61857-4; WRIGHT WH, 1990, IEEE J QUANTUM ELECT, V26, P2148, DOI 10.1109/3.64351	42	139	149	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					493	495		10.1038/360493a0	http://dx.doi.org/10.1038/360493a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448176				2022-12-01	WOS:A1992KA79700071
J	BOUVET, P; BELASCO, JG				BOUVET, P; BELASCO, JG			CONTROL OF RNASE-E-MEDIATED RNA DEGRADATION BY 5'-TERMINAL BASE-PAIRING IN ESCHERICHIA-COLI	NATURE			English	Article							MESSENGER-RNA; ESCHERICHIA-COLI; RIBONUCLEASE-E; BACILLUS-SUBTILIS; PROCESSING ENZYME; PRIMER FORMATION; STABILITY; AMS; PLASMID; GENE	DESPITE the variety of messenger RNA half-lives in bacteria (0.5-30 min in Escherichia coli) and their importance in controlling gene expression, their molecular basis remains obscure. The life-time of an entire mRNA molecule can be determined by features near,its 5' end, but no 5' exoribonuclease has been identified in any prokaryotic organism1-6. A mutation that inactivates E. coli RNase E also increases the average lifetime of bulk E. coli mRNA and of many individual messages, suggesting that cleavage by this endonuclease may be the rate-determining step in the degradation of most mRNAs in E. coli7-16. We have investigated the substrate preference of RNase E in E. coli by using variants of RNA I, a small untranslated RNA whose swift degradation in vivo is initiated by RNase E cleavage at an internal site. We report here that RNase E has an unprecedented substrate specificity for an endoribonuclease, as it preferentially cleaves RNAs that have several unpaired nucleotides at the 5' end. The sensitivity of RNase E to 5'-terminal base pairing may explain how determinants near the 5' end can control rates of mRNA decay in bacteria.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; UNIV RENNES 1,BIOL & GENET DEV LAB,CNRS,UA 256,F-35042 RENNES,FRANCE	Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1			, Bouvet/AAC-8779-2020	Bouvet, Philippe/0000-0003-4524-2233				APIRION D, 1978, GENETICS, V90, P659; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; BECHHOFER DH, 1989, J BACTERIOL, V171, P5803, DOI 10.1128/jb.171.11.5803-5811.1989; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; CANNISTRARO VJ, 1985, J BACTERIOL, V161, P820, DOI 10.1128/JB.161.2.820-822.1985; CHEN LH, 1991, J BACTERIOL, V173, P4578, DOI 10.1128/jb.173.15.4578-4586.1991; DEUTSCHER MP, 1990, POSTTRANSCRIPTIONAL, P1; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; FORCHHAMMER J, 1972, J MOL BIOL, V71, P687, DOI 10.1016/S0022-2836(72)80032-9; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; GORSKI K, 1985, CELL, V43, P461, DOI 10.1016/0092-8674(85)90176-X; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MORIKAWA N, 1969, NATURE, V223, P37, DOI 10.1038/223037a0; MORITA M, 1979, EUR J BIOCHEM, V97, P435, DOI 10.1111/j.1432-1033.1979.tb13131.x; MORSE DE, 1969, NATURE, V223, P40, DOI 10.1038/223040a0; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; POLISKY B, 1988, CELL, V55, P929, DOI 10.1016/0092-8674(88)90235-8; ROY MK, 1983, BIOCHIM BIOPHYS ACTA, V747, P200, DOI 10.1016/0167-4838(83)90098-5; SANDLER P, 1989, J BACTERIOL, V171, P6680, DOI 10.1128/jb.171.12.6680-6688.1989; SANDLER P, 1988, J MOL BIOL, V203, P905, DOI 10.1016/0022-2836(88)90116-7; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TARASEVICIENE L, 1991, MOL MICROBIOL, V5, P851, DOI 10.1111/j.1365-2958.1991.tb00758.x; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; WU F, 1992, NUCLEIC ACIDS RES, V20, P811, DOI 10.1093/nar/20.4.811; YAMAMOTO T, 1975, J MOL BIOL, V92, P289, DOI 10.1016/0022-2836(75)90228-4	32	191	196	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					488	491		10.1038/360488a0	http://dx.doi.org/10.1038/360488a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280335				2022-12-01	WOS:A1992KA79700067
J	BOUVIER, M; SZATKOWSKI, M; AMATO, A; ATTWELL, D				BOUVIER, M; SZATKOWSKI, M; AMATO, A; ATTWELL, D			THE GLIAL-CELL GLUTAMATE UPTAKE CARRIER COUNTERTRANSPORTS PH-CHANGING ANIONS	NATURE			English	Article							RAT-BRAIN; ASPARTATE; RECEPTORS; COTRANSPORT; CALIBRATION; CEREBELLUM; TRANSPORT; POTASSIUM; RELEASE; NEURONS	UPTAKE into glial cells helps to terminate glutamate's neurotransmitter action and to keep its extracellular concentration, [Glu]o, below neurotoxic levels. The accumulative power of the uptake carrier stems from its transport of inorganic ions such as sodium (into the cell) and potassium (out of the cell)1-3. There is controversy over whether the carrier also transports a proton (or pH-changing anion)4,5. Here we show that the carrier generates an alkalinization outside and an acidification inside glial cells, and transports anions out of the cells, suggesting that there is a carrier cycle in which two Na+ accompany each glutamate anion into the cell, while one K+ and one OH- (or HCO3-) are transported out. This stoichiometry predicts a minimum [Glu]o of 0.6 muM normally (tonically activating presynaptic autoreceptors and postsynaptic NMDA receptors), and 370 muM during brain anoxia (high enough to kill neurons). Transport of OH-/HCO3- on the uptake carrier generates significant pH changes, and may provide a mechanism for neuron-glial interaction.	IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND	Imperial College London	BOUVIER, M (corresponding author), UNIV LONDON UNIV COLL,DEPT PHYSIOL,GOWER ST,LONDON WC1E 6BT,ENGLAND.		Attwell, David/ABE-6750-2020		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BERGER SJ, 1977, J NEUROCHEM, V28, P149, DOI 10.1111/j.1471-4159.1977.tb07720.x; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1987, J NEUROSCI, V7, P357; EDSALL JT, 1958, BIOPHYSICAL CHEM, P585; EIGEN M, 1958, PROC R SOC LON SER-A, V247, P505, DOI 10.1098/rspa.1958.0208; EISNER DA, 1989, PFLUG ARCH EUR J PHY, V413, P553, DOI 10.1007/BF00594188; ERECINSKA M, 1983, J BIOL CHEM, V258, P9069; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; KALIA K, 1990, J PHYSL, V427, P241; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KVAMME E, 1985, NEUROCHEM RES, V10, P993, DOI 10.1007/BF00964635; MOBBS P, 1968, BRAIN RES, V460, P235; NEWMAN EA, 1991, GLIA, V4, P424, DOI 10.1002/glia.440040411; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PUTNAM RW, 1986, J PHYSIOL-LONDON, V381, P205, DOI 10.1113/jphysiol.1986.sp016323; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SARANTIS M, 1990, BRAIN RES, V516, P322, DOI 10.1016/0006-8993(90)90935-5; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SCHOUSBOE A, 1975, J NEUROCHEM, V25, P909, DOI 10.1111/j.1471-4159.1975.tb04429.x; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Thomas R. C., 1978, ION SENSITIVE INTRAC	28	343	351	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					471	474		10.1038/360471a0	http://dx.doi.org/10.1038/360471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448171				2022-12-01	WOS:A1992KA79700062
J	DAVIES, K				DAVIES, K			IMPRINTING AND SPLICING JOIN TOGETHER	NATURE			English	Editorial Material																		BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; FISHER EM, 1991, CELL, V63, P1205; HAMABE J, 1991, AM J MED GENET, V41, P64, DOI 10.1002/ajmg.1320410117; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LEFF SE, 1992, NATURE, V2, P265; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WAGSTAFF J, 1991, AM J HUM GENET, V49, P330; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	12	4	4	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					492	492		10.1038/360492a0	http://dx.doi.org/10.1038/360492a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448175	Bronze			2022-12-01	WOS:A1992KA79700070
J	HILL, AVS; ELVIN, J; WILLIS, AC; AIDOO, M; ALLSOPP, CEM; GOTCH, FM; GAO, XM; TAKIGUCHI, M; GREENWOOD, BM; TOWNSEND, ARM; MCMICHAEL, AJ; WHITTLE, HC				HILL, AVS; ELVIN, J; WILLIS, AC; AIDOO, M; ALLSOPP, CEM; GOTCH, FM; GAO, XM; TAKIGUCHI, M; GREENWOOD, BM; TOWNSEND, ARM; MCMICHAEL, AJ; WHITTLE, HC			MOLECULAR ANALYSIS OF THE ASSOCIATION OF HLA-B53 AND RESISTANCE TO SEVERE MALARIA	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; T-CELL EPITOPES; MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOTOXIC LYMPHOCYTES-T; CLASS-I MOLECULES; CIRCUMSPOROZOITE PROTEIN; LIVER-STAGE; VACCINE DEVELOPMENT; SURFACE-ANTIGENS; VIRAL-ANTIGEN	The protective association between the human leukocyte antigen HLA-B53 and severe malaria was investigated by sequencing of peptides eluted from this molecule followed by screening of candidate epitopes from pre-erythrocytic-stage antigens of Plasmodium falciparum in biochemical and cellular assays. Among malaria-immune Africans, HLA-B53-restricted cytotoxic T lymphocytes recognized a conserved nonamer peptide from liver-stage-specific antigen-1 (LSA-1), but no HLA-B53-restricted epitopes were identified in other antigens. These findings indicate a possible molecular basis for this HLA-disease association and support the candidacy of liver-stage-specific antigen-1 as a malaria vaccine component.	UNIV OXFORD,DEPT BIOCHEM,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3QU,ENGLAND; MRC LABS,BANJUL,SENEGAMBIA; UNIV TOKYO,INST MED SCI,MINAMI KU,TOKYO 108,JAPAN	University of Oxford; University of Tokyo	HILL, AVS (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008; Takiguchi, Masafumi/E-7468-2013	Townsend, Alain/0000-0002-3702-0107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; Amiel J.L, 1967, HISTOCOMPAT TEST, V1967, P79; ARNOT D, 1989, PARASITOL TODAY, V5, P138, DOI 10.1016/0169-4758(89)90077-X; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BODMER HC, 1989, NATURE, V337, P653, DOI 10.1038/337653a0; CARRENO BM, 1992, J IMMUNOL, V148, P894; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLYDE DF, 1973, AM J MED SCI, V266, P398, DOI 10.1097/00000441-197312000-00001; COWAN G, 1992, LANCET, V339, P1412, DOI 10.1016/0140-6736(92)91229-2; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; DOOLAN DL, 1992, INFECT IMMUN, V60, P675, DOI 10.1128/IAI.60.2.675-682.1992; DOOLAN DL, 1991, INT IMMUNOL, V3, P511, DOI 10.1093/intimm/3.6.511; DOOLAN DL, 1991, INFECT IMMUN, V60, P765; DRUIHLE P, 1989, NEW STRATEGIES PARAS; ELLIS SA, 1985, HUM IMMUNOL, V13, P13, DOI 10.1016/0198-8859(85)90023-0; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; ELVIN J, IN PRESS J IMMUN MET; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GOOD MF, 1988, IMMUNOL TODAY, V9, P351, DOI 10.1016/0167-5699(88)91336-9; GOOD MF, 1988, P NATL ACAD SCI USA, V85, P1199, DOI 10.1073/pnas.85.4.1199; GUERINMARCHAND C, 1987, NATURE, V329, P164, DOI 10.1038/329164a0; HARRIS R, 1969, NATURE, V221, P1062, DOI 10.1038/2211062a0; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HAYASHI H, 1990, IMMUNOGENETICS, V32, P195, DOI 10.1007/BF02114973; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HOFFMAN SL, 1989, SCIENCE, V244, P1078, DOI 10.1126/science.2524877; HOLLINGDALE MR, 1990, IMMUNOL LETT, V25, P71, DOI 10.1016/0165-2478(90)90094-7; JACOBSON S, 1990, NATURE, V348, P245, DOI 10.1038/348245a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; KUMAR S, 1988, NATURE, V334, P258, DOI 10.1038/334258a0; LOCKYER M, 1990, PARASITOL TODAY, V6, P76, DOI 10.1016/0169-4758(90)90213-N; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MALIK A, 1991, P NATL ACAD SCI USA, V88, P3300, DOI 10.1073/pnas.88.8.3300; MCCUTCHAN TF, 1990, IMMUNOL LETT, V25, P23, DOI 10.1016/0165-2478(90)90085-5; MCGREGOR IA, 1968, MALARIA PRINCIPLES P, P559; MEIS JFGM, 1986, CELL TISSUE RES, V244, P345, DOI 10.1007/BF00219210; MELLOUK S, 1990, LANCET, V335, P721, DOI 10.1016/0140-6736(90)90832-P; MOELANS IIMD, 1991, MOL BIOCHEM PARASIT, V45, P193, DOI 10.1016/0166-6851(91)90086-L; NIXON DF, 1992, IMMUNOLOGY, V76, P515; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PERLMANN P, 1990, Immunology Letters, V25, P1; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SEDEGAH M, 1992, J IMMUNOL, V149, P966; SUHRBIER A, 1990, INFECT IMMUN, V58, P2834, DOI 10.1128/IAI.58.9.2834-2839.1990; SUHRBIER A, 1991, PARASITOL TODAY, V7, P160, DOI 10.1016/0169-4758(91)90120-D; SUTTON J, IN PRESS EUR J IMMUN; TIWARI JL, 1985, HLA DISEASE ASS; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; VANBLEEK GM, 1990, NATURE, V348, P213; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; WEISS WR, 1990, J EXP MED, V171, P1083; YAMAMOTO J, 1990, P NATL ACAD SCI USA, V87, P2583, DOI 10.1073/pnas.87.7.2583; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J; ZHU JD, 1991, MOL BIOCHEM PARASIT, V48, P223, DOI 10.1016/0166-6851(91)90117-O	65	596	618	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					434	439		10.1038/360434a0	http://dx.doi.org/10.1038/360434a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280333				2022-12-01	WOS:A1992KA79700049
J	JOHNSON, AM; WADSWORTH, J; WELLINGS, K; BRADSHAW, S; FIELD, J				JOHNSON, AM; WADSWORTH, J; WELLINGS, K; BRADSHAW, S; FIELD, J			SEXUAL LIFE-STYLES AND HIV RISK	NATURE			English	Editorial Material							BEHAVIOR		SOCIAL & COMMUNITY PLANNING RES, LONDON EC1V 0AX, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1NY, ENGLAND	Imperial College London	JOHNSON, AM (corresponding author), UCL, SCH MED, ACAD DEPT GENITOURINARY MED, LONDON W1N 8AA, ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; CARBALLO M, 1989, J SEX RES, V26, P2887; HILLIER H, 1988, SHORT TERM PREDICTIO, P48; JOHNSON AM, 1990, NATURE, V343, P109, DOI 10.1038/343109a0; MADDOX J, 1989, NATURE, V341, P181, DOI 10.1038/341181a0; RGERS SM, 1991, J SEX RES, V28, P491; SPIRA A, 1992, NATURE, V360, P407; Sundet J. M., 1988, GLOBAL IMPACT AIDS, P53; WADSWORTH J, 1991, J ROY STAT SOC A STA, V154, P367; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; 1990, CDR112; 1992, HLTH NATION STRATEGY; 1991, CDR, V1, pR69; 1989, GENERAL HOUSEHOLD SU; 1992, PP2 OPCS SER, V15; 1989, SHORT TERM PREDICTIO	16	197	199	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					410	412		10.1038/360410a0	http://dx.doi.org/10.1038/360410a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448163				2022-12-01	WOS:A1992KA79700022
J	KANAI, Y; HEDIGER, MA				KANAI, Y; HEDIGER, MA			PRIMARY STRUCTURE AND FUNCTIONAL-CHARACTERIZATION OF A HIGH-AFFINITY GLUTAMATE TRANSPORTER	NATURE			English	Article							EXCITATORY AMINO-ACIDS; GLIAL-CELLS; RAT-BRAIN; SEROTONIN TRANSPORTER; EXPRESSION CLONING; RECEPTORS; CARRIER; IDENTIFICATION; METABOLISM; ASPARTATE	GLUTAMATE transport across plasma membranes of neurons, glial cells and epithelial cells of the small intestine and kidney proceeds by high- and low-affinity transport systems1-5. High-affinity (K(m) 2-50 muM) transport systems have been described1,6,7 that are dependent on Na+ but not Cl- ions and have a preference for L-glutamate and D- and L-aspartate. In neurons high-affinity glutamate transporters are essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft6,7. We have isolated a complementary DNA encoding an electrogenic Na+- but not Cl--dependent high-affinity glutamate transporter (named EAAC1) from rabbit small intestine by expression in Xenopus oocytes. We find EAAC1 transcripts in specific neuronal structures in the central nervous system as well as in the small intestine, kidney, liver and heart. The function and pharmacology of the expressed protein are characteristic of the high-affinity glutamate transporter already identified in neuronal tissues. The abnormal glutamate transport that is associated with certain neurodegenerative diseases8 and which occurs during ischaemia and anoxia7 Could be due to abnormalities in the function of this protein.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Hediger, Matthias/0000-0003-1946-027X				BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; COX DWG, 1977, J NEUROCHEM, V29, P579, DOI 10.1111/j.1471-4159.1977.tb10707.x; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.bi.56.070187.003031; EIEN A, 1992, CAN J NEUROL SCI, V19, P117; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; FERKANY J, 1986, J NEUROSCI RES, V16, P491, DOI 10.1002/jnr.490160305; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1986, ANAL BIOCHEM, V159, P280, DOI 10.1016/0003-2697(86)90344-1; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; KANAI Y, IN PRESS AM J PHYSL; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KILTY J, 1991, SCIENCE, V254, P78; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROMANO PM, 1989, AM J PHYSIOL, V257, pR180, DOI 10.1152/ajpregu.1989.257.1.R180; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SCHWARTZ EA, 1990, J PHYSIOL-LONDON, V426, P43, DOI 10.1113/jphysiol.1990.sp018126; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SIESJO BK, 1990, NEWS PHYSIOL SCI, V5, P120; SILBERNAGL S, 1979, KLIN WOCHENSCHR, V57, P1009, DOI 10.1007/BF01479986; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TOLNER B, 1992, J BACTERIOL, V174, P2391, DOI 10.1128/JB.174.7.2391-2393.1992; WANG CD, 1991, MOL PHARMACOL, V40, P168; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WINGROVE TG, 1988, AM J PHYSIOL, V255, pC737, DOI 10.1152/ajpcell.1988.255.6.C737	43	1205	1233	0	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					467	471		10.1038/360467a0	http://dx.doi.org/10.1038/360467a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1280334				2022-12-01	WOS:A1992KA79700061
J	PORTER, SB; SANDE, MA				PORTER, SB; SANDE, MA			TOXOPLASMOSIS OF THE CENTRAL-NERVOUS-SYSTEM IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; MAINTENANCE THERAPY; CEREBRAL TOXOPLASMOSIS; AIDS PATIENTS; ENCEPHALITIS; PYRIMETHAMINE; CLINDAMYCIN; EFFICACY; COMBINATION	Background and Methods. Toxoplasmosis is the most common opportunistic infection of the central nervous system in patients with the acquired immunodeficiency syndrome (AIDS). To investigate its clinical course, we reviewed the records of 115 patients with AIDS and central nervous system toxoplasmosis treated at San Francisco General Hospital between 1981 and 1990. Results. The most common presenting symptoms were headache (in 55 percent), confusion (52 percent), and fever (47 percent). Focal neurologic deficits were present in 79 patients (69 percent). The median CD4 cell count at presentation was 50 per cubic millimeter (50x10(6) per liter). Thirteen of 80 patients with clinical toxoplasmosis (16 percent) and 4 of 18 patients with pathologically proved disease (22 percent) had undetectable antitoxoplasma IgG antibodies by indirect immunofluorescence assay. Of 103 patients, 94 (91 percent) had enhancing lesions on CT. Single lesions were seen in 28 of 103 patients (27 percent) on CT, and such lesions were seen in 3 of 21 patients (14 percent) on magnetic resonance imaging. Over 90 percent of patients who eventually had clinical and radiographic improvement had evidence of improvement by day 14 of therapy. Adverse drug reactions occurred in 71 patients (62 percent) and led to a change in therapy in 50 patients (43 percent). Among the patients who survived a first episode of toxoplasmosis, the median survival was 265 days. Conclusions. Toxoplasmosis occurs in advanced stages of human immunodeficiency virus infection, and the absence of antitoxoplasma antibodies on immunofluorescence assay does not exclude the diagnosis. The clinical and radiographic response to therapy is usually rapid, but treatment is frequently limited by adverse drug effects.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SANDE, MA (corresponding author), SAN FRANCISCO GEN HOSP,MED SERV,RM 5H22,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.							CARRAZANA EJ, 1989, CLIN NEUROL NEUROSUR, V91, P291, DOI 10.1016/0303-8467(89)90004-8; CIRICILLO SF, 1971, J NEUROSURG, V74, P1029; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; DINA TS, 1991, RADIOLOGY, V179, P823, DOI 10.1148/radiology.179.3.2027999; FOPPA CU, 1991, EUR J CLIN MICROBIOL, V10, P187, DOI 10.1007/BF01964458; GONZALEZCLEMENTE JM, 1990, MED CLIN-BARCELONA, V95, P441; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; KATLAMA C, 1991, EUR J CLIN MICROBIOL, V10, P189, DOI 10.1007/BF01964459; LEPORT C, 1989, J INFECT DIS, V160, P557, DOI 10.1093/infdis/160.3.557; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LEVY RM, 1988, J ACQ IMMUN DEF SYND, V1, P41; LUFT BJ, 1984, JAMA-J AM MED ASSOC, V252, P913, DOI 10.1001/jama.252.7.913; LUFT BJ, 1988, J INFECT DIS, V157, P1, DOI 10.1093/infdis/157.1.1; MILLER CN, 1990, 30TH INT C ANT AG CH; NAVIA BA, 1986, ANN NEUROL, V19, P224, DOI 10.1002/ana.410190303; PEDROL E, 1990, AIDS, V4, P511, DOI 10.1097/00002030-199006000-00003; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; WANKE C, 1987, AM J TROP MED HYG, V36, P509, DOI 10.4269/ajtmh.1987.36.509; WONG B, 1984, ANN INTERN MED, V100, P36, DOI 10.7326/0003-4819-100-1-36	20	454	466	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1643	1648		10.1056/NEJM199212033272306	http://dx.doi.org/10.1056/NEJM199212033272306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1359410				2022-12-01	WOS:A1992KA26000006
J	RIBERDY, JM; NEWCOMB, JR; SURMAN, MJ; BARBOSA, JA; CRESSWELL, P				RIBERDY, JM; NEWCOMB, JR; SURMAN, MJ; BARBOSA, JA; CRESSWELL, P			HLA-DR MOLECULES FROM AN ANTIGEN-PROCESSING MUTANT-CELL LINE ARE ASSOCIATED WITH INVARIANT CHAIN PEPTIDES	NATURE			English	Article							CLASS-II MOLECULES; ALLOANTIGENS; BINDING; PROTEOLYSIS; TRANSPORT	THE invariant chain, which associates with the major histocompatibility complex (MHC) class II molecules in the endoplasmic reticulum, serves two functions important in antigen processing. First, it prevents class II molecules from binding peptides in the early stages of intracellular transport1-3. Second, it contains a cytoplasmic signal that targets the class II-invariant chain complex to an acidic endosomal compartment4-6. Proteolytic cleavage and subsequent dissociation of the invariant chain then occurs7,8, allowing peptides derived from endocytosed proteins to bind to released class II molecules before their expression at the cell surface3. Certain human cell lines that are mutant in one or more MHC-linked genes are defective in class II-restricted antigen processing9-11. Here we show that in transfectants of one of these cell lines, T2, this deficiency results in the association of a large proportion of class II molecules with a nested set of invariant-chain-derived peptides (class II-associated invariant chain peptides, or CLIP). HLA-DR3 molecules isolated from T2 transfectants can be efficiently loaded with antigenic peptides by exposure to a low pH in vitro, perhaps reflecting the in vivo conditions in which peptides associate with class II molecules12-14. Addition of synthetic CLIP inhibits the loading process, indicating that CLIP may define the region of the invariant chain responsible for obstructing the class II binding site.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,310 CEDAR ST,NEW HAVEN,CT 06510; MILES RES CTR,INST INFLAMMAT & AUTOIMMUN,DEPT PRECLIN TECHNOL,W HAVEN,CT 06516	Howard Hughes Medical Institute; Yale University								BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BILLING RJ, 1976, J IMMUNOL, V117, P1589; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1977, EUR J IMMUNOL, V7, P636, DOI 10.1002/eji.1830070911; GELUK A, 1992, EUR J IMMUNOL, V22, P107, DOI 10.1002/eji.1830220117; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLIMCHER LH, 1987, J IMMUNOL, V138, P1519; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMPSON LA, 1980, J IMMUNOL, V125, P293; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, IN PRESS J IMMUN; NGUYEN QV, 1989, HUM IMMUNOL, V24, P153, DOI 10.1016/0198-8859(89)90056-6; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SPRINGER TA, 1977, J BIOL CHEM, V252, P6201; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	29	351	356	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					474	477		10.1038/360474a0	http://dx.doi.org/10.1038/360474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448172				2022-12-01	WOS:A1992KA79700063
J	SONG, KN; WANG, YQ; SASSOON, D				SONG, KN; WANG, YQ; SASSOON, D			EXPRESSION OF HOX-7.1 IN MYOBLASTS INHIBITS TERMINAL DIFFERENTIATION AND INDUCES CELL-TRANSFORMATION	NATURE			English	Article							HOMEOBOX GENE; GROWTH-FACTOR; EMBRYOGENESIS; MYOGENIN; FAMILY	THE terminal differentiation of myogenic cells initiates in the proximal portion of the limb bud whereas the distal region remains undifferentiated and proliferative1-3 . The apical ectodermal ridge maintains the progress zone in an undifferentiated state4 and induces proliferation of limb mesenchymal cells5. Hox-7.1, a homeobox-containing gene, is expressed throughout the limb bud when limb outgrowth begins, whereas transcripts are later restricted to distal limb mesenchyme6,7 which is the proposed site of positional specification2. Transplantation of proximal limb bud tissue into the distal portion of the limb results in a re-expression of Hox-7.1 in the transplanted mesenchyme8. Similar grafts result in a positional reassignment to distal structures9 as well as dedifferentiation of the grafted proximal tissue10. Because of the association of Hox-7.1 expression with proliferative and undifferentiated cells, we tested whether Hox-7.1 regulates differentiation by transfection of Hox-7.1 complementary DNA into determined myogenic cells which represent one mesenchymal lineage in the limb. Here we report that forced expression of Hox-7.1 blocks terminal differentiation and results in a corresponding decrease in steady-state levels of MyoD1. Consistent with the association of Hox-7.1 with proliferation, Hox-7.1-expressing cells also acquire a transformed phenotype. Forced expression of Hox-8.1, a related Hox-gene, does not affect terminal differentiation indicating that the effects of Hox-7.1 are specific.			SONG, KN (corresponding author), BOSTON UNIV, SCH MED, DEPT BIOCHEM, 80 E CONCORD ST, BOSTON, MA 02118 USA.		SASSOON, David A/G-2502-2013	SASSOON, David A/0000-0001-6074-048X				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM ME, 1984, MOL BIOL DEV, V19, P275; CHEVALLIER A, 1978, ROUX ARCH DEV BIOL, V184, P57, DOI 10.1007/BF00848669; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; HAMPE A, 1960, J EMBRYOL EXP MORPH, V8, P241; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HILL RE, 1989, GENE DEV, V3, P26, DOI 10.1101/gad.3.1.26; KIENY M, 1986, BIBL ANAT, V29, P65; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MOORE JW, 1991, DEVELOPMENT, V111, P741; OLWIN BB, 1988, J CELL BIOL, V107, P761, DOI 10.1083/jcb.107.2.761; ROBERT B, 1989, EMBO J, V8, P91, DOI 10.1002/j.1460-2075.1989.tb03352.x; Sambrook J., 1989, MOL CLONING LAB MANU; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SAUNDERS JW, 1959, DEV BIOL, V1, P281, DOI 10.1016/0012-1606(59)90030-2; SOLURSH M, 1981, DEV BIOL, V86, P471, DOI 10.1016/0012-1606(81)90205-0; SUMMERBELL D, 1972, NATURE-NEW BIOL, V239, P24, DOI 10.1038/newbio239024a0; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	21	202	204	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					477	481		10.1038/360477a0	http://dx.doi.org/10.1038/360477a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1360150				2022-12-01	WOS:A1992KA79700064
J	SPIRA, A; BAJOS, N; BEJIN, A; BELTZER, N; BOZON, M; DUCOT, B; DURANDEAU, A; FERRAND, A; GIAMI, A; GILLOIRE, A; GIRAUD, M; LERIDON, H; MESSIAH, A; LUDWIG, D; MOATTI, JP; MOUNNIER, L; OLOMUCKI, H; POPLAVSKY, J; RIANDEY, B; SPENCER, B; SZTALRYD, JM				SPIRA, A; BAJOS, N; BEJIN, A; BELTZER, N; BOZON, M; DUCOT, B; DURANDEAU, A; FERRAND, A; GIAMI, A; GILLOIRE, A; GIRAUD, M; LERIDON, H; MESSIAH, A; LUDWIG, D; MOATTI, JP; MOUNNIER, L; OLOMUCKI, H; POPLAVSKY, J; RIANDEY, B; SPENCER, B; SZTALRYD, JM			AIDS AND SEXUAL-BEHAVIOR IN FRANCE	NATURE			English	Editorial Material											SPIRA, A (corresponding author), HOP BICETRE,78 RUE GEN LECLERC,F-94275 LE KREMLIN BICETR,FRANCE.		Messiah, Antoine/GLT-9598-2022; Giami, Alain J./G-3676-2013; Messiah, Antoine/M-1984-2018; Bajos, Nathalie/M-4170-2018	Messiah, Antoine/0000-0003-4457-7381; Giami, Alain J./0000-0001-7639-3005; Messiah, Antoine/0000-0003-4457-7381; Bajos, Nathalie/0000-0001-8073-9056				ALDHOUS P, 1992, SCIENCE, V257, P225; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; BAJOS N, 1991, A ACSF SCI SOCIALES, V9, P58; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CZAJA R, 1988, INT Q COMMUN HLTH ED, V8, P23; FRANK O, 1990, RECHERCHES COMPORTEM; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; LAGRANGE H, 1991, POPULATION, V2, P249; LERIDON H, 1991, POPULATION, V2, P777; MCQUEEN DV, 1992, HEALTH EDUC RES, V7, P47, DOI 10.1093/her/7.1.47; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; POLLAK M, 1992, ASSESSING AIDS PREVE, P305; ROGERS SM, 1991, J SEX RES, V28, P491, DOI 10.1080/00224499109551621; Simon P, 1972, RAPPORT COMPORTEMENT; SUNDET JM, 1989, HLTH POLICY, V13, P160; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; WELLINGS K, 1990, NATURE, V348, P276, DOI 10.1038/348276a0; 1992, B METHOD SOCIOL, V35, P46; 1992, AIDS, V6, P315; 1992, AIDS, V6, P243	20	124	124	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 3	1992	360	6403					407	409						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	KA797	1448162				2022-12-01	WOS:A1992KA79700021
J	THEOBALD, M; NIERLE, T; BUNJES, D; ARNOLD, R; HEIMPEL, H				THEOBALD, M; NIERLE, T; BUNJES, D; ARNOLD, R; HEIMPEL, H			HOST-SPECIFIC INTERLEUKIN-2-SECRETING DONOR T-CELL PRECURSORS AS PREDICTORS OF ACUTE GRAFT-VERSUS-HOST DISEASE IN BONE-MARROW TRANSPLANTATION BETWEEN HLA-IDENTICAL SIBLINGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINOR HISTOCOMPATIBILITY ANTIGENS; LYMPHOCYTES-T; EFFECTOR MECHANISMS; FREQUENCY-ANALYSIS; INVITRO; HELPER; INDUCTION; LEUKEMIA; INVIVO; SKIN	Background. Acute graft-versus-host disease (GVHD) is a serious complication of allogeneic bone marrow transplantation from an HLA-identical sibling. There is no practical test before transplantation that gives sufficient information to predict the degree of allogeneic reactivity between HLA-identical siblings. Methods. We determined the frequency with which host-specific interleukin-2-secreting donor T-cell precursors occurred in 16 consecutive pairs of HLA-identical siblings before they underwent marrow grafting. The results were correlated with the development of acute GVHD after transplantation. Results. High frequencies of host-specific T-cell precursors (greater-than-or-equal-to 1 per 100,000) were detectable before transplantation in eight donors whose siblings later had severe (grade II or III) acute GVHD. Among the donors to eight patients with mild (grade 0 or I) acute GVHD, low frequencies (<1 per 100,000) were found. Conclusions. Analysis of the frequency of such cells before transplantation may be a useful predictor of severe acute GVHD in allogeneic bone marrow transplantation between HLA-identical siblings. It is possible that the patients at risk for serious acute GVHD after marrow grafting may benefit from some alternative form of immunosuppressive therapy.	UNIV HOSP ULM, DEPT INTERNAL MED 3, BONE MARROW TRANSPLANTAT UNIT, ULM, GERMANY	Ulm University								ALDACCAK R, 1990, LEUKEMIA, V4, P222; CHAMPLIN R, 1990, BLOOD, V76, P418; CLEVELAND MG, 1988, J IMMUNOL, V141, P3349; DEBUEGER M, 1991, EUR J IMMUNOL, V21, P2839, DOI 10.1002/eji.1830211127; DELMONTE L, 1982, TRANSPLANTATION, V34, P100; EIERMANN TH, 1991, TISSUE ANTIGENS, V38, P193; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HAMILTON BL, 1987, J IMMUNOL, V139, P2511; Hansen J A, 1984, Prog Clin Biol Res, V149, P299; HOLLER E, 1990, BLOOD, V75, P1011; JOHNSEN HE, 1992, SCAND J IMMUNOL, V35, P353, DOI 10.1111/j.1365-3083.1992.tb02868.x; KAMINSKI E, 1988, BONE MARROW TRANSPL, V3, P149; KAMINSKI E, 1989, TRANSPLANTATION, V48, P608; KORNGOLD R, 1987, TRANSPLANTATION, V44, P335, DOI 10.1097/00007890-198709000-00002; MCCARTHY PL, 1991, BLOOD, V78, P1915; PERREAULT C, 1990, BLOOD, V76, P1269; PIGUET PF, 1987, J EXP MED, V166, P1280, DOI 10.1084/jem.166.5.1280; PIGUET PF, 1990, GRAFT VS HOST DISEAS, P255; SHARROCK CEM, 1990, IMMUNOL TODAY, V11, P281, DOI 10.1016/0167-5699(90)90113-N; SPRENT J, 1986, IMMUNOL REV, V91, P195, DOI 10.1111/j.1600-065X.1986.tb01489.x; STORB R, 1989, BLOOD, V73, P1729; SYMINGTON FW, 1990, TRANSPLANTATION, V50, P518, DOI 10.1097/00007890-199009000-00033; TASWELL C, 1981, J IMMUNOL, V126, P1614; THEOBALD M, 1989, J IMMUNOL METHODS, V121, P19, DOI 10.1016/0022-1759(89)90415-8; THEOBALD M, 1990, TRANSPLANTATION, V50, P850, DOI 10.1097/00007890-199011000-00021; TRUITT RL, 1991, BONE MARROW TRANSPL, V8, P51; VANELS CACM, 1990, HUM IMMUNOL, V28, P39, DOI 10.1016/0198-8859(90)90101-T; VANELS CACM, 1990, TRANSPLANTATION, V50, P67, DOI 10.1097/00007890-199007000-00012; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; VOGELSANG GB, 1985, NEW ENGL J MED, V313, P645, DOI 10.1056/NEJM198509123131101; Waldmann H., 1979, LIMITING DILUTION AN	33	162	165	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	1992	327	23					1613	1617		10.1056/NEJM199212033272301	http://dx.doi.org/10.1056/NEJM199212033272301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA260	1435898				2022-12-01	WOS:A1992KA26000001
J	VAZEUX, R; HOFFMAN, PA; TOMITA, JK; DICKINSON, ES; JASMAN, RL; STJOHN, T; GALLATIN, WM				VAZEUX, R; HOFFMAN, PA; TOMITA, JK; DICKINSON, ES; JASMAN, RL; STJOHN, T; GALLATIN, WM			CLONING AND CHARACTERIZATION OF A NEW INTERCELLULAR-ADHESION MOLECULE ICAM-R	NATURE			English	Article							IMMUNOGLOBULIN; LFA-1; SUPERFAMILY; ACTIVATION; SEQUENCES; RECEPTOR; SYSTEM	THE human intercellular adhesion molecules ICAM-1, ICAM-2 and their counter-receptors, the beta2 or leukointegrins, mediate a variety of homotypic and heterotypic leukocyte and endothelial cell-cell adhesions central to immunocompetence1. It has been found2 that cell-cell adhesion which is dependent on expression of the leukocyte function-associated antigen LFA-1 is not always blocked completely by antibodies raised against ICAM-1 and ICAM-2. Other leukointegrin ligands therefore probably exist, such as a glycoprotein of M(r) 124K that binds LFA-1 and has been designated ICAM-3 on the basis of this function3. We have molecularly cloned a new member of the ICAM family, ICAM-R, which is related to ICAM-1 and ICAM-2. The complementary DNA encoding ICAM-R is 1,781 base pairs long and the protein has five extracellular immunoglobulin-family type domains. The mature cell-surface form of the ICAM-R protein has an M(r) which varies from 116 to 140K in a cell type-specific fashion. Overall identities in protein sequence with ICAM-1 and ICAM-2 are 48% and 31% respectively, with the degree of similarity varying between individual domains. The high level of expression of ICAM-R on resting leukocytes of all lineages and its lack of expression on either resting or cytokine-activated endothelial cells indicates a pattern of expression distinct from ICAM-1 and ICAM-2. In common with ICAM-1 and ICAM-2, ICAM-R is a ligand for the beta2-integrin CD11a/LFA-1 (CD18).	ICOS CORP, 22021 20TH AVE SE, BOTHELL, WA 98021 USA	Icos Corporation								AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; BAGNASCO M, 1990, CELL IMMUNOL, V128, P362, DOI 10.1016/0008-8749(90)90033-N; CLARK EA, 1986, HUM IMMUNOL, V16, P100, DOI 10.1016/0198-8859(86)90039-X; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MAKGOBA MW, 1988, EUR J IMMUNOL, V18, P637, DOI 10.1002/eji.1830180423; NOTTENBURG C, 1990, GENE, V95, P279, DOI 10.1016/0378-1119(90)90372-X; POBER JS, 1986, J IMMUNOL, V137, P1893; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	17	202	220	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 3	1992	360	6403					485	488		10.1038/360485a0	http://dx.doi.org/10.1038/360485a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KA797	1448174				2022-12-01	WOS:A1992KA79700066
J	BRANCATI, FL; WHITTLE, JC; WHELTON, PK; SEIDLER, AJ; KLAG, MJ				BRANCATI, FL; WHITTLE, JC; WHELTON, PK; SEIDLER, AJ; KLAG, MJ			THE EXCESS INCIDENCE OF DIABETIC END-STAGE RENAL-DISEASE AMONG BLACKS - A POPULATION-BASED STUDY OF POTENTIAL EXPLANATORY FACTORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESSENTIAL-HYPERTENSION; RACIAL-DIFFERENCES; BLOOD-PRESSURE; MARYLAND; MELLITUS; FAILURE; RACE; RISK	Objective.-To investigate whether the excess incidence of diabetic end-stage renal disease (ESRD) among African Americans could be explained by racial differences in putative ESRD risk factors. Design.-Population-based, ecologic study using the 1981 and 1982 Maryland Statewide Household Hypertension Survey for data on risk factor prevalence. Participants.-A total of 2.1 million adults residing within the boundaries of the Maryland Regional ESRD Registry, grouped by race and ZIP code into 26 subpopulations. Main Outcome Measure.-Incidence rates of treatment for diabetic ESRD between 1980 and 1985 from the Maryland Regional ESRD Registry by subpopulation. Results.-Between 1980 and 1985, 442 persons entered treatment for diabetic ESRD. At the level of the subpopulation, diabetic ESRD incidence was positively associated with black race (relative risk [RR], 3.42; 95% confidence interval [Cl], 2.84 to 4.13), prevalence of diabetes (RR, 2.35; 95% Cl, 1.92 to 2.87), prevalence of poorly controlled hypertension (RR, 1.80; 95% Cl, 1.45 to 1.86), lack of a regular source of health care (RR, 1.82; 95% Cl, 1.62 to 2.05), and lower socioeconomic status as indicated by lack of college education (RR, 1.41; 95% Cl, 1.32 to 1.52) (all, P<.0001). After adjusting for these risk factors, black race remained strongly associated with the overall incidence of diabetic ESRD (RR, 2.70; 95% Cl, 1.89 to 3.86; P<.0001). Further analyses suggested that this excess risk among blacks was confined to ESRD related to non-insulin-dependent diabetes (RR, 4.80; 95% Cl, 3.09 to 7.46; P<.0001); blacks were at no higher risk than were whites for ESRD related to insulin-dependent diabetes (RR, 0.90; 95% Cl, 0.52 to 1.55; P=.70). Conclusions.-These data suggest that the excess incidence of diabetic ESRD among blacks is not fully explained by a higher prevalence of diabetes or hypertension in blacks or by racial differences in age, socioeconomic status, or access to health care. Instead, they suggest an increased susceptibility to ESRD resulting from non-insulin-dependent diabetes among blacks as compared with whites.			BRANCATI, FL (corresponding author), JOHNS HOPKINS MED INST,WELCH CTR PREVENT EPIDEMIOL & CLIN RES,CARNEGIE 2,600 N WOLFE ST,BALTIMORE,MD 21287, USA.			Whittle, Jeff/0000-0002-9544-838X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722, M01RR000035] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00722, 5M01RR00035] Funding Source: Medline; NHLBI NIH HHS [HL07180] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RM, 1991, DIABETES CARE, V14, P605, DOI 10.2337/diacare.14.7.605; APOSTOLIDES AY, 1980, P SECTION SURVEY RES, V1, P692; BRESLOW NE, 1989, DESIGN ANAL COHORT S, V2, P119; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; DRIZD T, 1986, VITAL HLTH STAT, V234, P10; EBERHARDT MS, 1990, DIABETES S1, V39, pA205; ENTWISLE G, 1983, PREV MED, V12, P695, DOI 10.1016/0091-7435(83)90227-X; FERGUSON R, 1988, J CLIN EPIDEMIOL, V41, P1189, DOI 10.1016/0895-4356(88)90023-6; FROHLICH ED, 1984, MINER ELECTROL METAB, V10, P173; GOLD CH, 1982, S AFR MED J, V61, P263; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HARRIS MI, 1985, NIH851468 PUBL, P1; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; JAMEEL N, 1990, DIABETES S1, V39, pA39; KAPPEL DF, 1986, AM J KIDNEY DIS, V8, P234, DOI 10.1016/S0272-6386(86)80031-2; LEBOVITZ HE, 1990, DIABETES CARE, V13, P1186, DOI 10.2337/diacare.13.11.1186; LEVY SB, 1978, ANN INTERN MED, V88, P12, DOI 10.7326/0003-4819-88-1-12; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P290; MOORE RD, 1990, AM J HYPERTENS, V3, P1; Rettig BS, 1984, DIABETIC NEPHROPATHY, V3, P26; ROSEMAN JM, 1985, NIH851468 US DEP HLT, P1; STATIUS LW, 1988, DISEASES KIDNEY, P2561; STEWART JH, 1975, BMJ-BRIT MED J, V1, P440, DOI 10.1136/bmj.1.5955.440; TIERNEY WM, 1989, AM J KIDNEY DIS, V13, P485, DOI 10.1016/S0272-6386(89)80006-X; WARREN SE, 1980, AM J MED, V69, P425, DOI 10.1016/0002-9343(80)90015-7; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P289; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; 1989, USRDS1989 NIH NAT I; 1984, ZIP CODE PROFILE RAC	30	187	187	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3079	3084		10.1001/jama.268.21.3079	http://dx.doi.org/10.1001/jama.268.21.3079			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1433738				2022-12-01	WOS:A1992KA00200030
J	LISKOWSKY, DR				LISKOWSKY, DR			BIOLOGICAL RHYTHMS AND SHIFT WORK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LISKOWSKY, DR (corresponding author), US OFF TECHNOL ASSESSMENT,BIOL APPLICAT PROGRAM,WASHINGTON,DC, USA.							1989, SCAND J WORK ENV HEA, V15, P165; 1990, OCCUP MED, V5, P273; 1991, BIOL RHYTHMS IMPLICA	3	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	1992	268	21					3047	3047		10.1001/jama.268.21.3047	http://dx.doi.org/10.1001/jama.268.21.3047			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA002	1433723				2022-12-01	WOS:A1992KA00200005
J	AYUS, JC; WHEELER, JM; ARIEFF, AI				AYUS, JC; WHEELER, JM; ARIEFF, AI			POSTOPERATIVE HYPONATREMIC ENCEPHALOPATHY IN MENSTRUANT WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						HYPONATREMIA; ENCEPHALOPATHY, HYPONATREMIC; POSTOPERATIVE COMPLICATIONS; MENSTRUATION	HYPERTONIC SALINE; BRAIN-DAMAGE; WATER; SEIZURES; SURGERY; ARREST; RAT	Objectives: To determine factors associated with the development of encephalopathy and with its clinical course in patients with postoperative hyponatremia. Setting: Consultation and referral services of two university medical centers and community hospitals. Design: Case-control study (risk factors for encephalopathy) and cohort study (clinical course among patients with encephalopathy). Patients: Case patients included 65 adults with postoperative hyponatremic encephalopathy; controls included 674 adult patients who had postoperative hyponatremia without encephalopathy and who were selected from 76 678 consecutive adult surgical inpatients. Measurements: Age, gender, menstrual status, neurologic symptoms, time to development and degree of hyponatremia, arterial blood gas determinations, serum chemistries, morbidity and mortality. Results: Case patients included 40 women (62%) and 25 men (38%) (P > 0.05); controls included 367 women (54%) and 307 men (46%) (P > 0.1). Of the 34 case patients who developed permanent brain damage or died, 33 (97%) were women (P < 0.001). Among the women with brain damage, 25 (76%) were menstruant (P < 0.001). The relative risk for death or permanent brain damage from hyponatremic encephalopathy in women compared with men was 28 (95% CI, 5 to 141) and in menstruant women compared with postmenopausal women, 26 (CI, 11 to 62). Arterial PO2 at diagnosis was significantly lower in female than in male case patients (34 +/- 5 compared with 91 +/- 3 mm Hg; P < 0.001). Further, of the 38 case patients who had respiratory arrest before the diagnosis of hyponatremic encephalopathy, 36 (95%) were women. Extent of or time to development of hyponatremia did not correlate with subsequent brain damage (P > 0.1). Conclusions: Women and men are equally likely to develop hyponatremia and hyponatremic encephalopathy after surgery. However, when hyponatremic encephalopathy develops, menstruant women are about 25 times more likely to die or have permanent brain damage compared with either men or postmenopausal women.	BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA	Baylor College of Medicine; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIA NIH HHS [R01AG08575] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008575] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREOLI TE, 1992, CECIL TXB MED, P499; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7; AYUS JC, 1992, CLIN RES, V40, pA223; CHARLTON AJ, 1980, ANAESTHESIA, V35, P804, DOI 10.1111/j.1365-2044.1980.tb03922.x; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; DEUTSCH S, 1966, ANESTHESIOLOGY, V27, P250, DOI 10.1097/00000542-196627030-00003; FRASER CL, 1989, AM J PHYSIOL, V257, pE284, DOI 10.1152/ajpendo.1989.257.2.E284; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; FRASER CL, IN PRESS CLIN DISORD; GARCIA JH, 1980, BRAIN EDEMA PATHOLOG, P147; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; GUY AJ, 1987, BRIT J SURG, V74, P1027, DOI 10.1002/bjs.1800741123; HARRISON RH, 1956, J UROLOGY, V75, P95, DOI 10.1016/S0022-5347(17)66783-1; Helwig FC, 1935, J AMER MED ASSOC, V104, P1569, DOI 10.1001/jama.1935.02760180001001; HORNBEIN TF, 1989, NEW ENGL J MED, V321, P1714, DOI 10.1056/NEJM198912213212505; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; KOZAK LJ, 1989, DHHS PHS891250 DEP H; LEVINSKY NG, 1991, HARRISONS PRINCIPLES, P278; MELTON JE, 1983, AM J PHYSIOL, V244, pR724, DOI 10.1152/ajpregu.1983.244.5.R724; MORAN WH, 1964, SURGERY, V56, P99; NARINS RG, 1990, INTERNAL MED, P832; NATTIE EE, 1981, J APPL PHYSIOL, V51, P1086, DOI 10.1152/jappl.1981.51.5.1086; OELZ O, 1990, HYPOXIA ADAPTATIONS, P206; ROSOMOFF HL, 1963, ARCH NEUROL-CHICAGO, V9, P26, DOI 10.1001/archneur.1963.00460070036003; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P174; RYDER KW, 1984, J UROLOGY, V132, P995, DOI 10.1016/S0022-5347(17)49984-8; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; SCOTT JC, 1965, OBSTET GYNECOL, V26, P168; SHIMOJYO S, 1968, NEUROLOGY, V18, P127, DOI 10.1212/WNL.18.2.127; TIEN R, 1992, AM J MED, V92, P513, DOI 10.1016/0002-9343(92)90748-Z; VEXLER ZS, 1992, CLIN RES, V40, pA306; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168; ZIMMERMANN B, 1952, SURGERY, V31, P654; 1990, HLTH NUTRITION, P110; 1985, SAS USERS GUIDE BASI, P1290	39	328	334	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					891	897		10.7326/0003-4819-117-11-891	http://dx.doi.org/10.7326/0003-4819-117-11-891			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1443949				2022-12-01	WOS:A1992JZ27600003
J	COLEMAN, EA; FEUER, EJ				COLEMAN, EA; FEUER, EJ			BREAST-CANCER SCREENING AMONG WOMEN FROM 65 TO 74 YEARS OF AGE IN 1987-88 AND 1991	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; MAMMOGRAPHY; BREAST SELF-EXAMINATION; MASS SCREENING; PHYSICAL EXAMINATION	OLDER WOMEN; MAMMOGRAPHY; PHYSICIANS	Objective: To compare breast cancer screening rates from the 1991 survey with data from 1987-88 for women aged 65 to 74. Design: Surveys of women from five communities. Settings: Five control communities of the National Cancer Institute's Breast Cancer Screening Consortium. Participants: White, non-Hispanic women, ages 65 to 74; 499 in 1987-88 and 2156 in 1991. Response rates for the first survey wave ranged by area from 65% to 77% and for the second survey wave, from 62% to 85%. Main Outcome Measure: Mammogram and clinical breast examination during the past year and performance of monthly breast self examination, with the screening rates in wave 2 directly standardized to the income and education distribution of wave 1 in each area. Results: Mammography use between waves increased significantly (P < 0.05 after adjusting for education, income, and age) in all but one area (from 19% to 33% in wave 1 to 35% to 59% in wave 2). Among women who had a mammogram, the percent who also had a clinical breast examination decreased between waves from 95% to 85% (P = 0.001). Conclusions: Mammography in older women increased dramatically over 3 years, although the use of clinical breast examination may be decreasing.	NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	COLEMAN, EA (corresponding author), NCI, DCPC, APPL RES BRANCH, EPN 343, BETHESDA, MD 20892 USA.				DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085122] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CN-85122-01] Funding Source: Medline	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDA RF, 1990, AM J PREV MED, V6, P123, DOI 10.1016/S0749-3797(18)31016-X; BIRD RE, 1989, RADIOLOGY, V171, P87, DOI 10.1148/radiology.171.1.2494683; Burg M A, 1990, J Aging Health, V2, P514, DOI 10.1177/089826439000200406; COLL PP, 1989, J AM GERIATR SOC, V37, P957, DOI 10.1111/j.1532-5415.1989.tb07281.x; COSTANZA ME, 1991, ARCH INTERN MED, V151, P1851, DOI 10.1001/archinte.151.9.1851; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; LANE DS, 1992, AM J PUBLIC HEALTH, V82, P199, DOI 10.2105/AJPH.82.2.199; LERMAN C, 1990, PREV MED, V19, P279, DOI 10.1016/0091-7435(90)90028-I; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; RIES LAG, 1991, NIH912789 PUB; SICKLES EA, 1990, RADIOLOGY, V175, P323, DOI 10.1148/radiology.175.2.2326455; Sloane P D, 1991, Fam Med, V23, P40; VANOORTMARSSEN GJ, 1990, CANCER-AM CANCER SOC, V66, P1601, DOI 10.1002/1097-0142(19901001)66:7<1601::AID-CNCR2820660727>3.0.CO;2-O; WEINBERGER M, 1991, J AM GERIATR SOC, V39, P22, DOI 10.1111/j.1532-5415.1991.tb05901.x; ZAPKA JG, 1989, AM J PUBLIC HEALTH, V79, P1499, DOI 10.2105/AJPH.79.11.1499; ZAPKA JG, 1990, ADV CANCER CONTROL, V339, P259; 1990, JAMA-J AM MED ASSOC, V264, P54; 1990, FED REGISTER, V55, P53510	20	71	71	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					961	966		10.7326/0003-4819-117-11-961	http://dx.doi.org/10.7326/0003-4819-117-11-961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1443958				2022-12-01	WOS:A1992JZ27600012
J	KROENKE, K; LUCAS, CA; ROSENBERG, ML; SCHEROKMAN, B; HERBERS, JE; WEHRLE, PA; BOGGI, JO				KROENKE, K; LUCAS, CA; ROSENBERG, ML; SCHEROKMAN, B; HERBERS, JE; WEHRLE, PA; BOGGI, JO			CAUSES OF PERSISTENT DIZZINESS - A PROSPECTIVE-STUDY OF 100 PATIENTS IN AMBULATORY CARE	ANNALS OF INTERNAL MEDICINE			English	Article						DIZZINESS; AMBULATORY CARE; VESTIBULAR DISEASES; VERTIGO; PSYCHIATRIC STATUS RATING SCALES	DIAGNOSTIC INTERVIEW SCHEDULE; DIZZY PATIENT; GENERAL-POPULATION; MEDICAL OUTCOMES; CLINICAL METHODS; RELIABILITY; SYMPTOMS; VALIDITY; THERAPY; HYPERVENTILATION	Objective: To determine the causes of persistent dizziness in outpatients. Design: Consecutive adult outpatients presenting with a chief complaint of dizziness. Setting: Four clinics (internal medicine, walk-in, emergency room, and neurology) in a teaching hospital. Patients: Of 185 patients presenting during the 10-month study period, 51 (28%) had minimal or no dizziness at 2-week follow-up. Of the remaining 134 patients, 100 completed the study protocol (mean age, 62 years; range, 20 to 85 years). Measurements: Evaluation included a detailed study questionnaire, standardized physical examination, vestibular testing by a neuro-ophthalmologist, laboratory tests, audiometry, and a structured psychiatric interview. Data were abstracted onto a standard form and reviewed by three raters. Raters independently assigned diagnoses using explicit criteria, with the final cause determined by consensus. Results: Primary causes of dizziness included vestibular disorders (54 patients), psychiatric disorders (16 patients), presyncope (6 patients), dysequilibrium (2 patients), and hyperventilation (1 patient); dizziness was multicausal in 13 patients and of unknown cause in 8 patients. Many of those with a single primary cause, however, had at least one other condition contributing to their dizziness; only 52% of patients had a single "pure" cause. Thirty patients had a potentially treatable primary cause, the most common being benign positional vertigo (BPV) (16%) and psychiatric disorders (6%). Central vestibulopathies detected in 10 patients were presumably vascular or idiopathic in origin. No brain tumors or cardiac arrhythmias were found. Conclusions: Vestibular disease and psychiatric disorders are the most common causes of persistent dizziness in outpatients. In about 50% of patients with dizziness, more than one factor causes or aggravates symptoms. Life-threatening causes were rare, even in our elderly population.	UNIFORMED SERV UNIV HLTH SCI, DEPT NEUROL, BETHESDA, MD 20814 USA; WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	KROENKE, K (corresponding author), UNIFORMED SERV UNIV HLTH SCI, DEPT MED, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA.			Kroenke, Kurt/0000-0002-0114-4669				AFZELIUS LE, 1980, LARYNGOSCOPE, V90, P649; Baloh R.W., 1990, CLIN NEUROPHYSIOL; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BRANDT T, 1980, ARCH OTOLARYNGOL, V106, P484; Brandt T., 1991, VERTIGO ITS MULTISEN; CLARK PI, 1980, CHEST, V77, P722, DOI 10.1378/chest.77.6.722; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; FEINSTEIN AR, 1985, J CHRON DIS, V38, P619, DOI 10.1016/0021-9681(85)90016-5; HELZER JE, 1985, ARCH GEN PSYCHIAT, V42, P657; HELZER JE, 1987, ARCH GEN PSYCHIAT, V44, P1069; HERR RD, 1989, ANN EMERG MED, V18, P664, DOI 10.1016/S0196-0644(89)80524-4; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOLT PE, 1989, BEHAV RES THER, V27, P453, DOI 10.1016/0005-7967(89)90016-8; JOHNSON JE, 1988, MIL MED, V153, P21; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; KROENKE K, 1991, CLIN RES, V39, pA579; KROENKE K, 1989, JAMA-J AM MED ASSOC, V262, P914; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MADLONKAY DJ, 1985, J FAM PRACTICE, V21, P109; MAGARIAN GJ, 1982, MEDICINE, V61, P219, DOI 10.1097/00005792-198207000-00002; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; OJALA M, 1988, ACTA NEUROL SCAND, V78, P26, DOI 10.1111/j.1600-0404.1988.tb03614.x; Paik, 2003, STAT METHODS RATES P, P598; REILLY BM, 1991, PRACTICAL STRATEGIES, P162; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ROBINS LN, PSYCHIATRIC DISORDER, P991; SKIENDZIELEWSKI JJ, 1980, ANN EMERG MED, V9, P353, DOI 10.1016/S0196-0644(80)80111-9; SLOANE P, 1989, J AM GERIATR SOC, V37, P101, DOI 10.1111/j.1532-5415.1989.tb05867.x; SLOANE PD, 1989, J FAM PRACTICE, V29, P33; Spitzer R., 1988, STRUCTURED CLIN INTE; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914	36	187	192	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					898	904		10.7326/0003-4819-117-11-898	http://dx.doi.org/10.7326/0003-4819-117-11-898			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1443950				2022-12-01	WOS:A1992JZ27600004
J	REINUS, JF; LEIKIN, EL; ALTER, HJ; CHEUNG, L; SHINDO, M; JETT, B; PIAZZA, S; SHIH, JWK				REINUS, JF; LEIKIN, EL; ALTER, HJ; CHEUNG, L; SHINDO, M; JETT, B; PIAZZA, S; SHIH, JWK			FAILURE TO DETECT VERTICAL TRANSMISSION OF HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Article						MATERNAL-FETAL EXCHANGE; HEPATITIS-C; HEPATITIS ANTIBODIES; PREGNANCY COMPLICATIONS, INFECTIOUS	NON-B-HEPATITIS; MATERNAL-INFANT TRANSMISSION; CHRONIC NON-A; INFECTION; ANTIBODY; MOTHER; HIV	Objective: To search for transmission of hepatitis C virus (HCV) from infected mothers to their infants. Design: Prospective clinical, serologic, and molecular biologic follow-up (at least 3 months) of the infants of mothers with anti-HCV antibody. Setting: A county hospital providing primary and referral care in high-risk obstetrics (perinatology). Patients: Twenty-three mothers with anti-HCV antibody and their 24 infants. Methods: An enzyme-linked immunosorbent assay (EIA) and a four-antigen recombinant immunoblot assay (RIBA) were used to test for anti-HCV antibody; serum HCV RNA was measured in two independent laboratories by reverse transcription and polymerase chain reaction (PCR) using nested primers in the 5'-noncoding region. Infant samples were tested for HCV RNA by PCR at delivery and after 3 to 6 months of follow-up. Each sample was tested at least four times in two independent laboratories. Results: Twenty-nine of 648 mothers (4.5%; 95% CI, 3.0% to 6.4%) had anti-HCV antibody; these women had 30 babies. Twenty-three mothers and their 24 babies were followed at least 3 months (mean follow-up, 52 weeks). Of the 23 mothers, 21 (91%; CI, 72% to 99%) had a reactive RIBA; one woman had an indeterminate RIBA and was positive for HCV RNA by PCR. In 16 of 23 mothers (70%; CI, 47% to 87%), PCR yielded a positive result in both laboratories. The mean maternal alanine aminotransferase (ALT) level was 1.6 times the normal value. All the babies had anti-HCV antibody in cord-blood samples, but antibody disappeared or diminished in strength in interval samples, and no infant had evidence of active production of anti-HCV antibody. Only 1 of 24 (4%; CI, 0.1% to 21%) cord-blood samples was HCV RNA positive, and none of 24 (0%; CI, 0% to 14%) follow-up samples was positive for HCV RNA by PCR in either laboratory. Four mothers and one baby had antibody to HIV. Conclusions: Infant anti-HCV antibody is most likely acquired passively in utero, and vertical transmission of HCV is uncommon.			REINUS, JF (corresponding author), MONTEFIORE MED CTR, DIV GASTROENTEROL, 111 E 210TH ST, BRONX, NY 10467 USA.		Jett, Betsy/AAT-5154-2021					ALFORD CA, 1975, AM J DIS CHILD, V129, P455, DOI 10.1001/archpedi.1975.02120410043014; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1991, ANN INTERN MED, V115, P644, DOI 10.7326/0003-4819-115-8-644; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P410; BUSCH MP, 1992, NEW ENGL J MED, V326, P64, DOI 10.1056/NEJM199201023260114; CHEN DS, 1991, J INFECT DIS, V164, P428, DOI 10.1093/infdis/164.2.428; ESTEBAN R, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P413; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FORTUNY C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P418; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; JOUNG MK, 1991, 3RD P INT S HCV STRA, P96; KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; LEE SD, 1991, HEPATOLOGY, V13, P830, DOI 10.1016/0270-9139(91)90249-U; MCHUTCHISON JG, 1991, GASTROENTEROLOGY, V101, P1117, DOI 10.1016/0016-5085(91)90742-4; NOVATI R, 1992, J INFECT DIS, V165, P720, DOI 10.1093/infdis/165.4.720; ROUDOTTHORAVAL E, 1991, 3RD P INT S HCV STRA, P85; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SMOLEN P, 1983, J PEDIATR-US, V103, P917, DOI 10.1016/S0022-3476(83)80714-8; STEVENS CE, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P407; STEVENS CE, 1984, VIRAL HEPATITIS LIVE, P275; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TONG MJ, 1981, GASTROENTEROLOGY, V80, P999; WEJSTAL R, 1990, J MED VIROL, V30, P178, DOI 10.1002/jmv.1890300306	26	139	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					881	886		10.7326/0003-4819-117-11-881	http://dx.doi.org/10.7326/0003-4819-117-11-881			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1332561				2022-12-01	WOS:A1992JZ27600001
J	Wejstal, R; Widell, A; Mansson, AS; Hermodsson, S; Norkrans, G				Wejstal, R; Widell, A; Mansson, AS; Hermodsson, S; Norkrans, G			Mother-to-Infant Transmission of Hepatitis-C Virus	ANNALS OF INTERNAL MEDICINE			English	Article						Hyponatremia; Encephalopathy, Hyponatremic; Postoperative Complications; Menstruation	POLYMERASE CHAIN-REACTION; NON-B HEPATITIS; CHRONIC NON-A; VERTICAL TRANSMISSION; RNA; INFECTION	Objective: To describe the rate of perinatal transmission of hepatitis C virus (HCV). Design: Follow-up study of newborn children of mothers with chronic HCV infection. Setting: A university hospital in Sweden. Participants: Fourteen women with chronic HCV infection and their 21 newly born children. Main Outcome Measures: Detection of HCV RNA in serum by the polymerase chain reaction and detection of anti-HCV antibody by second generation assays. Results: All mothers were found to be positive for anti-HCV antibody both by second-generation enzyme-linked immunosorbent assay (ELISA) and by second-generation recombinant immunoblot assay (RIBA-2); all also had detectable serum HCV RNA. Two children had long-lasting alanine aminotransferase (ALT) elevations, and one of them became HCV RNA positive. None of the other children developed biochemical hepatitis. However, two additional children had temporary viremia. Only the child with biochemical and biopsy-proven hepatitis and detectable HCV RNA in multiple blood samples actively produced anti-HCV antibody. Conclusions: Mother-to-infant transmission of HCV infection from chronically infected women without human immunodeficiency virus (HIV) infection seems to be uncommon.	Gothenburg Univ, Ostra Hosp, Dept Infect Dis, S-41685 Gothenburg, SWEDEN; Gothenburg Univ, Sahlgrens Hosp, S-41345 Gothenburg, SWEDEN; Malmo Gen Hosp, S-21401 Malmo, SWEDEN; Univ Lund, S-22101 Lund, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Lund University	Wejstal, R (corresponding author), Gothenburg Univ, Ostra Hosp, Dept Infect Dis, S-41685 Gothenburg, SWEDEN.							[Anonymous], 1977, LANCET, V2, P914; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BUSCH MP, 1992, NEW ENGL J MED, V326, P64, DOI 10.1056/NEJM199201023260114; CHEN DS, 1991, J INFECT DIS, V164, P428, DOI 10.1093/infdis/164.2.428; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAXI A, 1991, LANCET, V337, P1354, DOI 10.1016/0140-6736(91)93037-A; CRISTIANO K, 1991, HEPATOLOGY, V14, P51, DOI 10.1002/hep.1840140109; ERCILLA M G, 1991, Journal of Hepatology, V13, pS26, DOI 10.1016/0168-8278(91)91092-U; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FORTUNY C, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P418; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; KUROKI T, 1991, J INFECT DIS, V164, P427, DOI 10.1093/infdis/164.2.427; NOVATI R, 1991, Journal of Hepatology, V13, pS56, DOI 10.1016/0168-8278(91)91213-Z; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; REESINK HW, 1990, LANCET, V335, P1216, DOI 10.1016/0140-6736(90)92734-Y; ROUDOTTHORAVAL F, 1991, HEPATOLOGY, V14, pA130; STEVENS CE, 1991, PERINATAL SEXUAL TRA, P407; TAYLOR PE, 1991, POST TRANSFUSION HEP, P441; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; TONG MJ, 1981, GASTROENTEROLOGY, V80, P999; VANDERPOEL CL, 1991, LANCET, V337, P317, DOI 10.1016/0140-6736(91)90942-I; WEINTRUB PS, 1990, HEPATOLOGY, V12, P850; WEJSTAL R, 1989, SCAND J INFECT DIS, V21, P485, DOI 10.3109/00365548909037875; WEJSTAL R, 1990, J MED VIROL, V30, P178, DOI 10.1002/jmv.1890300306; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409	25	145	144	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1992	117	11					887	890		10.7326/0003-4819-117-11-887	http://dx.doi.org/10.7326/0003-4819-117-11-887			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ276	1332562				2022-12-01	WOS:A1992JZ27600002
J	BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG				BRECKER, SJD; XIAO, HB; SPARROW, J; GIBSON, DG			EFFECTS OF DUAL-CHAMBER PACING WITH SHORT ATRIOVENTRICULAR DELAY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							PULSED DOPPLER ECHOCARDIOGRAPHY; LEFT-VENTRICULAR FUNCTION; CONGESTIVE HEART-FAILURE; COMPARATIVE SURVIVAL; HEMODYNAMIC BENEFIT; GAS-EXCHANGE; BLOCK; EXERCISE; REGURGITATION; PACEMAKERS	Mitral or tricuspid regurgitation of long duration may so shorten the ventricular filling time in dilated cardiomyopathy that stroke volume is limited. We assessed the effects of changing the atrioventricular interval during temporary or permanent dual-chamber DDD pacing in twelve dilated cardiomyopathy patients with short ventricular filling times due to regurgitation. We measured ventricular filling time and cardiac output with doppler echocardiography and exercise capacity on a treadmill, at baseline and with the best atrioventricular delay during pacing. The durations of both mitral and tricuspid regurgitation were significantly shorter at the shorter atrioventricular interval (mean reductions 85 [95% Cl 60-110] ms and 110 [75-150] ms, respectively; p<0.001 for both). There were consequent increases in left-ventricular and right-ventricular filling times (65 [35-95] ms and 90 [60-120] ms, p<0.001). For each 50 ms reduction in atrioventricular delay, left-ventricular filling time increased by 35 ms in six subjects with presystolic mitral regurgitation and right-ventricular filling time by 30 ms in nine subjects with presystolic tricuspid regurgitation. At the short atrioventricular interval, cardiac output was greater than baseline (by 1.1 [0.8-1.4] I/min, p<0.01) and there were rises in exercise duration (104 [45-165] s, p<0.05) and maximum oxygen consumption (2.1 [1.5-2.7]ml kg-1min-1, p<0.05). There was a decrease in the Likert visual analogue score of breathlessness at peak exercise (8.6 [SD 2.1] vs 4.9 [3.1], p<0.01 ). Although from a small sample, these findings suggest that DDD pacing with a short atrioventricular delay may have therapeutic potential in patients with dilated cardiomyopathy, even in the absence of conventional indications for pacemaker implantation.			BRECKER, SJD (corresponding author), ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT CARDIAC,SYDNEY ST,LONDON SW3 6NP,ENGLAND.							ALPERT MA, 1986, J AM COLL CARDIOL, V7, P925, DOI 10.1016/S0735-1097(86)80358-8; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; BULLER NP, 1988, BRIT HEART J, V59, P212; DAVIES NJH, 1979, RESP PHYSIOL, V36, P261, DOI 10.1016/0034-5687(79)90029-X; DICARLO LA, 1987, AM HEART J, V114, P746, DOI 10.1016/0002-8703(87)90784-8; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; LEE CH, 1991, BRIT HEART J, V65, P342; LIPKIN DP, 1985, BRIT HEART J, V54, P321; MBASSOUROUM M, IN PRESS BR HEART J; MEHTA D, 1989, BRIT HEART J, V61, P161; NG KSK, 1989, BRIT HEART J, V62, P246; OCCHETTA E, 1990, PACE, V13, P916, DOI 10.1111/j.1540-8159.1990.tb02129.x; OLDERSHAW PJ, 1983, BRIT HEART J, V49, P568; PANIDIS IP, 1986, J AM COLL CARDIOL, V7, P768, DOI 10.1016/S0735-1097(86)80335-7; REITER MJ, 1982, AM J CARDIOL, V49, P687, DOI 10.1016/0002-9149(82)91947-6; RITTER P, 1989, EUR HEART J, V10, P637, DOI 10.1093/oxfordjournals.eurheartj.a059541; ROKEY R, 1986, AM J CARDIOL, V57, P692, DOI 10.1016/0002-9149(86)90864-7; ROSENQVIST M, 1991, AM J CARDIOL, V67, P148, DOI 10.1016/0002-9149(91)90437-P; RUTISHAUSER W, 1966, CIRCULATION, V34, P807, DOI 10.1161/01.CIR.34.5.807; RYDEN L, 1988, PACE, V11, P1051, DOI 10.1111/j.1540-8159.1988.tb03951.x; SACHER HL, 1989, ANGIOLOGY, V40, P489, DOI 10.1177/000331978904000511; SCHNITTGER I, 1988, J AM COLL CARDIOL, V11, P83, DOI 10.1016/0735-1097(88)90170-2; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079; WISH M, 1987, AM J CARDIOL, V60, P566, DOI 10.1016/0002-9149(87)90306-7; XIAO HB, 1991, BRIT HEART J, V66, P443; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1983, J AM COLL CARDIOL, V2, P755	30	243	263	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1308	1312		10.1016/0140-6736(92)92492-X	http://dx.doi.org/10.1016/0140-6736(92)92492-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360034				2022-12-01	WOS:A1992KA26200003
J	FIGUERAS, A; MORALESOLIVAS, FJ; CAPELLA, D; PALOP, V; LAPORTE, JR				FIGUERAS, A; MORALESOLIVAS, FJ; CAPELLA, D; PALOP, V; LAPORTE, JR			BOVINE GANGLIOSIDES AND ACUTE MOTOR POLYNEUROPATHY	BRITISH MEDICAL JOURNAL			English	Article									UNIV AUTONOMA BARCELONA,CSU VALL DHEBRON,INST CATALA FARMACOL,SERV FARMACOL CLIN,E-08035 BARCELONA,SPAIN; UNIV VALENCIA,FAC MED,DEPT FARMACOL,VALENCIA,SPAIN; CTR FARMACOVIGILANCIA COMUNITAT VALENCIANA,VALENCIA,SPAIN	Autonomous University of Barcelona; University of Valencia			Laporte, Joan-Ramon/A-1302-2011; Figueras, Albert/H-7743-2012; Figueras, Albert/I-7421-2013	Figueras, Albert/0000-0002-2740-2013; Figueras, Albert/0000-0002-2740-2013				BRADLEY WG, 1990, MUSCLE NERVE, V13, P853; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; ROPPER AH, 1992, NEW ENGL J MED, V326, P1130, DOI 10.1056/NEJM199204233261706; SCHONHOFER PS, 1991, LANCET, V338, P757; 1985, LANCET, V1, P1137	5	70	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1330	1331		10.1136/bmj.305.6865.1330	http://dx.doi.org/10.1136/bmj.305.6865.1330			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1309191	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992KA77300022
J	GILLIS, CR; HOLE, DJ; LAMONT, DW; GRAHAM, AC; RAMAGE, S				GILLIS, CR; HOLE, DJ; LAMONT, DW; GRAHAM, AC; RAMAGE, S			THE INCIDENCES OF LUNG-CANCER AND BREAST-CANCER IN WOMEN IN GLASGOW	BRITISH MEDICAL JOURNAL			English	Article											GILLIS, CR (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,SCOTLAND.							DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P38, DOI 10.1136/jech.42.1.38; SCHOTTENFELD D, 1982, CANCER EPIDEMIOLOGY; [No title captured]	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1331	1331		10.1136/bmj.305.6865.1331	http://dx.doi.org/10.1136/bmj.305.6865.1331			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483078	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992KA77300023
J	PEAT, JK; HABY, M; SPIJKER, J; BERRY, G; WOOLCOCK, AJ				PEAT, JK; HABY, M; SPIJKER, J; BERRY, G; WOOLCOCK, AJ			PREVALENCE OF ASTHMA IN ADULTS IN BUSSELTON, WESTERN-AUSTRALIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; POPULATION; QUESTIONNAIRE; SCHOOLCHILDREN; METHACHOLINE; HISTAMINE; COMMUNITY; CHILDREN	Objective-To estimate whether the prevalence of asthma in adults increased over a nine year interval. Design-Serial cross sectional studies of the population with a protocol that included both subjective and objective measurements. Setting-Busselton, Western Australia. Subjects-A random sample of 553 subjects aged 18-55 years in 1981, and of 1028 subjects aged 18-55 years in 1990. Main outcome measures-Respiratory symptoms measured by self administered questionnaire, bronchial responsiveness measured by bronchial challenge with histamine, and allergy measured by skin prick tests. Results-Symptoms with increased prevalence were those with significant association with allergy in this population. Recent wheeze increased from 17.5% to 28.8% (p<0.001) and diagnosed asthma increased Erom 9.0% to 16.3% (p<0.001). The increase was greatest in subjects less than 30 years old. The prevalence of shortness of breath coming on at rest and of hay fever also increased significantly, but the prevalence of shortness of breath on exertion, chronic cough, bronchial hyperresponsiveness, current asthma (defined as recent wheeze plus bronchial hyperresponsiveness), and allergy did not increase. The severity of bronchial responsiveness did not change significantly in any symptom group. Conclusions-Young adults showed a significant increase in reporting of symptoms related to allergy but not in the prevalence of current asthma. The increase in symptoms may be due to increased awareness of asthma in this community, to changed treatment patterns, or to increased exposures to allergens.	UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA; UNIV SYDNEY, DEPT PUBL HLTH, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney; University of Sydney			Haby, Michelle/AGL-3386-2022	Haby, Michelle/0000-0001-6203-9195				ABRAMSON M, 1992, AUST NZ J MED, V22, P358, DOI 10.1111/j.1445-5994.1992.tb02148.x; ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CAMPBELL DA, 1989, AUST NZ J MED S, V19, P657; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; LEBOWITZ MD, 1976, AM REV RESPIR DIS, V113, P627; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEARCE N, 1991, CLIN EXP ALLERGY, V21, P401, DOI 10.1111/j.1365-2222.1991.tb01679.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P338, DOI 10.1164/ajrccm/144.2.338; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SAMET JM, 1978, AM J EPIDEMIOL, V108, P435, DOI 10.1093/oxfordjournals.aje.a112642; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1966, QUESTIONNAIRE RESPIR	23	157	157	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 28	1992	305	6865					1326	1329		10.1136/bmj.305.6865.1326	http://dx.doi.org/10.1136/bmj.305.6865.1326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483077	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992KA77300021
J	PRESS, RI; PEEBLES, CL; KUMAGAI, Y; OCHS, RL; TAN, EM				PRESS, RI; PEEBLES, CL; KUMAGAI, Y; OCHS, RL; TAN, EM			ANTINUCLEAR AUTOANTIBODIES IN WOMEN WITH SILICONE BREAST IMPLANTS	LANCET			English	Article							HUMAN ADJUVANT DISEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; AUGMENTATION MAMMOPLASTY; AUTOIMMUNE-DISEASE; RHEUMATIC DISEASES; SJOGRENS SYNDROME; SCLERODERMA; ANTIBODIES; SCLEROSIS	Clinical syndromes resembling autoimmune diseases have been reported in women who have had breast augmentation procedures. To see whether there is a humoral immune response in these diseases that is similar to the immune response in their idiopathic counterparts, we assessed the immunological specificity of antinuclear antibodies (ANAs) and certain epidemiological features in 24 patients, all of whom (with 1 exception) had received silicone gel breast implants. ANA specificities were identified by indirect immunofluorescence, immunodiffusion, western blot analysis, and immunoprecipitation of radiolabelled intracellular proteins. Of 11 patients who had symptoms and signs that met criteria for defined autoimmune diseases, 7 had scleroderma or subsets of this disorder and the others had systemic lupus erythematosus, rheumatoid arthritis, or overlapping autoimmune diseases. High ANA titres were present in 10 of these 11 patients and the ANA specificities were similar to those found in the idiopathic forms of the corresponding autoimmune diseases. Trauma, with resultant rupture of implants, accelerated onset of symptoms. 13 other patients had autoimmune disorders of a less clearly defined nature and low titres of ANAs whose specificities could not be identified. ANAs are associated with the development of autoimmune complications in women with silicone breast implants. Further studies are needed to see whether this relation is one of cause and effect and whether ANAs might be early serological markers preceding development of autoimmune symptoms.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, WM KECK AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA; IMAICHI HOSP, TOCHIGI 32112, JAPAN	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032063, R37AR032063] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00833] Funding Source: Medline; NIAMS NIH HHS [AR32063] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; ARNETT F C, 1987, Arthritis and Rheumatism, V30, pS17; BALDWIN CM, 1983, ANN PLAS SURG, V10, P270, DOI 10.1097/00000637-198304000-00002; BALLOU SP, 1986, MANUAL CLIN LABORATO, P740; BLACK CM, 1983, LANCET, V1, P53; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; BYRON MA, 1984, BRIT J RHEUMATOL, V23, P227; CHAN EKL, 1992, MANUAL CLIN LABORATO, P755; ENDO LP, 1987, SEMIN ARTHRITIS RHEU, V17, P112, DOI 10.1016/0049-0172(87)90033-3; FOCK KM, 1984, J RHEUMATOL, V11, P98; FRITZLER MJ, 1985, CLIN IMMUNOL IMMUNOP, V36, P120, DOI 10.1016/0090-1229(85)90045-5; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HAUSTEIN UF, 1985, INT J DERMATOL, V24, P147, DOI 10.1111/j.1365-4362.1985.tb05406.x; HOCHBERG MC, 1981, EPIDEMIOL REV, V3, P27, DOI 10.1093/oxfordjournals.epirev.a036238; KAISER W, 1990, ANN RHEUM DIS, V49, P937, DOI 10.1136/ard.49.11.937; KASAKAWAR, 1987, MIXED CONNECTIVE TIS, P41; KUMAGAI Y, 1984, ARTHRITIS RHEUM-US, V27, P1, DOI 10.1002/art.1780270101; MARIK PE, 1990, S AFR MED J, V77, P212; MEDSGER TA, 1985, EPIDEMIOLOGY RHEUMAT; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; MIYOSHI K, 1964, IJISHIMPO, V2122, P9; OKANO Y, 1984, ANN RHEUM DIS, V43, P520, DOI 10.1136/ard.43.3.520; REIMER G, 1987, J CLIN INVEST, V79, P65, DOI 10.1172/JCI112809; ROM WN, 1983, CHEST, V83, P515, DOI 10.1378/chest.83.3.515; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; VANVENROOIJ WJ, 1991, J IMMUNOL METHODS, V140, P181, DOI 10.1016/0022-1759(91)90369-Q; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; WEINER SR, 1986, PLAST RECONSTR SURG, V77, P185, DOI 10.1097/00006534-198602000-00001; WELSH KT, 1988, SYSTEMIC SCLEROSIS S; WILSON MR, 1986, MANUAL CLIN LABORATO, P750	34	143	143	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 28	1992	340	8831					1304	1307		10.1016/0140-6736(92)92491-W	http://dx.doi.org/10.1016/0140-6736(92)92491-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360033				2022-12-01	WOS:A1992KA26200002
J	RAVINE, D; WALKER, RG; GIBSON, RN; FORREST, SM; RICHARDS, RI; FRIEND, K; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; WALKER, RG; GIBSON, RN; FORREST, SM; RICHARDS, RI; FRIEND, K; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			PHENOTYPE AND GENOTYPE HETEROGENEITY IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Article							LINKAGE HETEROGENEITY; GENETIC-HETEROGENEITY; CHROMOSOME-16; LOCUS; PKD1; DIAGNOSIS; FAMILIES; MARKER	It is now clear that mutations of at least two genetic loci can lead to autosomal dominant polycystic kidney disease (ADPKD). We have compared the clinical features of ADPKD caused by mutations at the PKD1 locus (linked to the alpha-globin complex on chromosome 16) with those of disease not linked to the locus (non-PKD1). We identified 18 families (285 affected members) with mutations at PKD1 and 5 families (49 affected individuals) in which involvement of this locus could be dismissed. Non-PKD1 patients lived longer than PKD1 patients (median survival 71.5 vs 56.0 years), had a lower risk of progressing to renal failure (odds ratio 0.35, 95% Cl 0.13-0.92), were less likely to have hypertension (odds ratio adjusted for age and family of origin 0.29, 0.11-0.80), were diagnosed at an older age (median 69.1 vs 44.8 years), and had fewer renal cysts at the time of diagnosis. Although most of the PKD1 families were ascertained through clinics treating patients with renal impairment, no non-PKD1 family was identified through this source. Non-PKD1 ADPKD has a much milder phenotype than that linked to PKD1. Partly as a result of this difference in severity, the reported prevalence of this genotype is probably an underestimate.	ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT NEPHROL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA; ADELAIDE CHILDRENS HOSP INC,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital	RAVINE, D (corresponding author), UNIV HOSP WALES,INST MED GENET,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.		Richards, Robert/ABE-6423-2020; Ravine, David/A-6797-2008					BACHNER L, 1990, HUM GENET, V85, P221; BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BREUNING MH, 1990, NUCLEIC ACIDS RES, V18, P3106, DOI 10.1093/nar/18.10.3106-a; BREUNING MH, 1987, LANCET, V2, P1359; BREUNING MH, 1990, J MED GENET, V27, P603, DOI 10.1136/jmg.27.10.603; DISNEY APS, 1990, 13TH AUSTR NZ COMB D, P22; GAL A, 1989, CLIN GENET, V35, P13; HARRIS PC, 1991, LANCET, V338, P1484, DOI 10.1016/0140-6736(91)92300-Q; HYLAND VJ, 1990, HUM GENET, V84, P286; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIMBERLING WJ, 1990, KIDNEY INT, V37, P249; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, AM J HUM GENET, V42, P498; MANDICH P, 1990, AM J MED GENET, V35, P579, DOI 10.1002/ajmg.1320350426; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3122, DOI 10.1093/nar/16.7.3122; NAROD S, 1991, CLIN GENET, V39, P125; Norby S, 1989, Prog Clin Biol Res, V305, P83; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1987, HUM GENET, V76, P348, DOI 10.1007/BF00272443; ROMEO G, 1988, LANCET, V2, P8; SNIJDEWINT FGM, 1990, NUCLEIC ACIDS RES, V18, P3108, DOI 10.1093/nar/18.10.3108-a; THOMPSON AD, IN PRESS GENOMICS; TUFVESON G, NEPHROL DIAL TRANS S, V4, P5; WEEKS DE, 1989, AM J HUM GENET, V45, P819	28	170	174	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1330	1333		10.1016/0140-6736(92)92503-8	http://dx.doi.org/10.1016/0140-6736(92)92503-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360045				2022-12-01	WOS:A1992KA26200014
J	SEMPRINI, AE; LEVISETTI, P; BOZZO, M; RAVIZZA, M; TAGLIORETTI, A; SULPIZIO, P; ALBANI, E; ONETA, M; PARDI, G				SEMPRINI, AE; LEVISETTI, P; BOZZO, M; RAVIZZA, M; TAGLIORETTI, A; SULPIZIO, P; ALBANI, E; ONETA, M; PARDI, G			INSEMINATION OF HIV-NEGATIVE WOMEN WITH PROCESSED SEMEN OF HIV-POSITIVE PARTNERS	LANCET			English	Note								Many HIV-discordant couples want to have children so much that they are willing to abandon condom-protected sexual intercourse irrespective of the risks. Previous testing in our laboratory showed that gradient centrifugation followed by a swim-up procedure effectively removed HIV-1-infected cells from the semen of HIV-seropositive men. 85 HIV-discordant couples were screened for fertility; 29 women were found suitable for a timed in semination course with the processed semen of their HIV-seropositive partner. None of the inseminated women seroconverted, and 17 pregnancies were achieved in 15 women. All 10 babies born to these mothers remain HIV seronegative. The findings may help in the counselling of such couples and also give them hope of having healthy babies.			SEMPRINI, AE (corresponding author), UNIV MILAN,SCH MED,SAN PAOLO BIOMED INST,DEPT OBSTET & GYNAECOL,VIA RUDINI 8,I-21042 MILAN,ITALY.		Setti, Paolo Emanuele Levi/AAB-9718-2019; SEMPRINI, AUGUSTO ENRICO/S-6415-2017	SEMPRINI, AUGUSTO ENRICO/0000-0002-1113-2012; Levi-Setti, Paolo Emanuele/0000-0003-1024-4386				ANDERSON DJ, 1992, 48TH ANN M AM FERT S; ASHIDA ER, 1987, P NATL ACAD SCI USA, V84, P3395, DOI 10.1073/pnas.84.10.3395; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; SARACCO A, IN PRESS J ACQUIR IM; SEMPRINI AE, 1991, SUCCESSFUL REMOVAL H, P534; SEMPRINI AE, 1990, 6 INT C AIDS SAN FRA, P267; Semprini AE, 1987, C INSERM, V154, P462; WOLFF H, 1988, 4 INT C AIDS STOCKH; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1992, REPORT AIDS CASES	10	260	267	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1317	1319		10.1016/0140-6736(92)92495-2	http://dx.doi.org/10.1016/0140-6736(92)92495-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360037				2022-12-01	WOS:A1992KA26200006
J	VANACKER, BAC; KOOMEN, GCM; KOOPMAN, MG; DEWAART, DR; ARISZ, L				VANACKER, BAC; KOOMEN, GCM; KOOPMAN, MG; DEWAART, DR; ARISZ, L			CREATININE CLEARANCE DURING CIMETIDINE ADMINISTRATION FOR MEASUREMENT OF GLOMERULAR-FILTRATION RATE	LANCET			English	Article							MARKER; PHARMACOKINETICS; IMPROVES	Creatinine clearance inaccurately estimates true glomerular filtration rate (GFR) because of tubular secretion of creatinine. We studied the ability of oral cimetidine, a blocker of tubular creatinine secretion, to improve the accuracy of measuring creatinine clearance. Clearances of inulin and endogenous creatinine were simultaneously measured in 16 patients with renal disease before administration of cimetidine and during 8 successive 3 h clearance periods with cimetidine 400 mg as priming dose followed by 200 mg every 3 h. At baseline, creatinine relative to inulin clearance (Cl(C)/Cl(I)) ranged from 1.14 to 2.27. With cimetidine, Cl(C)/Cl(I) approached unity in 8 patients (mean 1.02 [SD 0.03]), but considerably exceeded unity in 8 others (1.33 [0.14]). Plasma cimetidine/creatinine ratio was smaller in this second group, due to significantly higher renal clearance of cimetidine (333 [136] vs 165 [89] ml/min, p=0.01). In a further study, cimetidine dose and, consequently plasma cimetidine concentration, was increased in 6 additional patients who had incomplete inhibition previously. This increased dose completely inhibited tubular creatinine secretion in the third until the sixth hour, so that creatinine clearance equalled GFR. Provided an adequate dose of cimetidine is given, 24 h creatinine clearance during administration of drug measures GFR accurately in patients with renal disease. However, because of the maximum daily dose of cimetidine that is advised, short clearance times (3 h) are recommended.	UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN CHEM,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VANACKER, BAC (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT MED,RENAL UNIT F4-215,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.							BAUER JH, 1982, AM J KIDNEY DIS, V2, P337, DOI 10.1016/S0272-6386(82)80091-7; BERLYNE GM, 1964, LANCET, V2, P874; BRATER C, 1992, KIDNEY PHYSL PATHOPH, P3597; BROWN P, 1977, CLIN CHIM ACTA, V76, P103, DOI 10.1016/0009-8981(77)90123-1; BURGESS E, 1982, RENAL PHYSIOL BIOCH, V5, P27; CARRIE BJ, 1980, AM J MED, V69, P177, DOI 10.1016/0002-9343(80)90376-9; GIOVANNETTI S, 1991, NEPHRON, V59, P11, DOI 10.1159/000186510; GISCLON LG, 1988, DRUG METAB DISPOS, V16, P331; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; HOOD B, 1971, Scandinavian Journal of Urology and Nephrology, V5, P154, DOI 10.3109/00365597109133594; KOOPMAN MG, 1989, CLIN SCI, V77, P105, DOI 10.1042/cs0770105; LEVINSKY NG, 1959, AM J PHYSIOL, V196, P549, DOI 10.1152/ajplegacy.1959.196.3.549; Miller BF, 1938, J CLIN INVEST, V17, P31, DOI 10.1172/JCI100925; PETRI M, 1988, KIDNEY INT, V34, P832, DOI 10.1038/ki.1988.257; ROUBENOFF R, 1990, ANN INTERN MED, V113, P501, DOI 10.7326/0003-4819-113-7-501; Shannon JA, 1935, J CLIN INVEST, V14, P403, DOI 10.1172/JCI100691; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; SOMOGYI A, 1983, CLIN PHARMACOKINET, V8, P463, DOI 10.2165/00003088-198308060-00001; VANACKER BAC, 1992, J LAB CLIN MED, V120, P400; VANGINNEKEN CAM, 1989, CLIN PHARMACOKINET, V16, P38, DOI 10.2165/00003088-198916010-00003; WEBER JA, 1991, CLIN CHEM, V37, P695; ZIEMNIAK JA, 1981, CLIN CHEM, V27, P272	22	138	138	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1326	1329		10.1016/0140-6736(92)92502-7	http://dx.doi.org/10.1016/0140-6736(92)92502-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360044				2022-12-01	WOS:A1992KA26200013
J	VINE, SJ; PRYSDAVIES, A; PEARSON, JF				VINE, SJ; PRYSDAVIES, A; PEARSON, JF			TRANSVERSE POSTERIOR CERVICOISTHMIC RUPTURE AFTER GEMEPROST PESSARIES FOR TERMINATION	BRITISH MEDICAL JOURNAL			English	Letter							VAGINAL PESSARIES; UTERINE RUPTURE; PREGNANCY				VINE, SJ (corresponding author), UNIV HOSP WALES,CARDIFF CF4 4XN,S GLAM,WALES.							BYRNE P, 1991, BRIT MED J, V302, P852, DOI 10.1136/bmj.302.6780.852-c; CAMERON IT, 1987, PROSTAGLANDINS, V34, P111, DOI 10.1016/0090-6980(87)90268-1; LOWENSOHN R, 1974, AM J OBSTET GYNECOL, V119, P1057, DOI 10.1016/0002-9378(74)90258-0; WENTZ AC, 1973, AM J OBSTET GYNECOL, V115, P1107, DOI 10.1016/0002-9378(73)90560-7; WIENER JJ, 1990, BRIT J OBSTET GYNAEC, V97, P1061, DOI 10.1111/j.1471-0528.1990.tb02484.x	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 28	1992	305	6865					1332	1332		10.1136/bmj.305.6865.1332	http://dx.doi.org/10.1136/bmj.305.6865.1332			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA773	1483081	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992KA77300024
J	WANG, RYH; SHIH, JWK; GRANDINETTI, T; PIERCE, PF; HAYES, MM; WEAR, DJ; ALTER, HJ; LO, SC				WANG, RYH; SHIH, JWK; GRANDINETTI, T; PIERCE, PF; HAYES, MM; WEAR, DJ; ALTER, HJ; LO, SC			HIGH-FREQUENCY OF ANTIBODIES TO MYCOPLASMA-PENETRANS IN HIV-INFECTED PATIENTS	LANCET			English	Article							AIDS; PROTEINS; AGENT	Mycoplasma penetrans, a novel mycoplasma isolated from HIV-1-infected patients with AIDS, has pathogenic properties associated with in-vivo virulence. Enzyme-linked immunosorbent assay and western blotting detected a more than 100 times higher frequency of antibodies to the mycoplasma in serum from HIV-1-infected patients with AIDS (40%) than from HIV-negative controls (0.3%). Serum from 20% of HIV-1-infected, symptom-free individuals also had M penetrans specific antibodies. The antibodies major immunoreactivity was directed against P35 and P38, the two main lipid-associated membrane protein antigens of the organism. Patients attending sexually transmitted disease clinics had a low frequency of antibody (0.9%). None of 178 HIV-negative patients with different non-AIDS diseases, many associated with immune dysfunction and/or low white cell counts, tested positive for the antibodies. M penetrans, apparently not a commensal and not a simple opportunist, is uniquely associated with HIV-1 infection and AIDS.	ARMED FORCES INST PATHOL,DEPT INFECT & PARASIT DIS PATHOL,AMER REGISTRY PATHOL,WASHINGTON,DC 20306; NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892; AMER RED CROSS,NATL CAPITAL CHAPTER,WASHINGTON,DC; GEORGETOWN UNIV HOSP,HIV CLIN PROGRAM,WASHINGTON,DC 20007	United States Department of Defense; National Institutes of Health (NIH) - USA; American Red Cross; Georgetown University					NIAID NIH HHS [AI-31830] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031830] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; COLE BC, 1985, MYCOPLASMAS, V4, P203; DELGIUDICE RA, 1985, INT J SYST BACTERIOL, V35, P285, DOI 10.1099/00207713-35-3-285; HAWKINS RE, 1992, J INFECT DIS, V165, P581, DOI 10.1093/infdis/165.3.581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAITRE M, 1992, INFECT IMMUN, V60, P742; LO SC, 1989, AM J TROP MED HYG, V40, P399, DOI 10.4269/ajtmh.1989.40.399; LO SC, 1989, AM J TROP MED HYG, V41, P364, DOI 10.4269/ajtmh.1989.41.364; LO SC, 1989, AM J TROP MED HYG, V40, P213, DOI 10.4269/ajtmh.1989.40.213; LO SC, 1991, LANCET, V338, P1415, DOI 10.1016/0140-6736(91)92721-D; LO SC, 1992, INT J SYST BACTERIOL, V42, P357, DOI 10.1099/00207713-42-3-357; LO SC, 1989, AM J TROP MED HYG, V41, P601, DOI 10.4269/ajtmh.1989.41.601; LO SC, 1991, SCIENCE, V251, P1074, DOI 10.1126/science.1705362; LO SC, 1991, MODERN PATHOL, V6, P750; MONTAGNIER L, 1990, RETROVIRUSES HUMAN A, P9; ROSENGARTEN R, 1990, SCIENCE, V247, P315, DOI 10.1126/science.1688663; RUUTH E, 1989, IMMUNOL REV, V112, P133, DOI 10.1111/j.1600-065X.1989.tb00556.x; Somerson N. L., 1979, MYCOPLASMAS, V2, P191; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WISE KS, 1987, J BACTERIOL, V169, P5546, DOI 10.1128/jb.169.12.5546-5555.1987; Wright K, 1990, Science, V248, P682, DOI 10.1126/science.2333519; 1991, LANCET, V337, P20	22	78	83	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 28	1992	340	8831					1312	1316		10.1016/0140-6736(92)92493-Y	http://dx.doi.org/10.1016/0140-6736(92)92493-Y			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KA262	1360035	Green Submitted			2022-12-01	WOS:A1992KA26200004
J	CHATTERJEE, S; JOHNSON, PR; WONG, KK				CHATTERJEE, S; JOHNSON, PR; WONG, KK			DUAL-TARGET INHIBITION OF HIV-1 INVITRO BY MEANS OF AN ADENOASSOCIATED VIRUS ANTISENSE VECTOR	SCIENCE			English	Article							TRANS-ACTIVATION; GENE-EXPRESSION; RNA; REPLICATION; CELLS; CLONING; DNA; TRANSDUCTION; INTEGRATION; RESISTANCE	An adeno-associated virus vector encoding an antisense RNA was used to transduce stable intracellular resistance to human immunodeficiency virus-1 (HIV-1) in human hemopoietic and non-hemopoietic cell lines. The antisense targets are present in all HIV-1 transcripts and include the TAR sequence, which is critical for transcription and virus replication, and the polyadenylation signal. Cell lines expressing antisense RNA showed up to 95 percent inhibition of gene expression directed by the HIV-1 long terminal repeat and greater than 99 percent reduction in infectious HIV-1 production, with no detectable cellular toxicity. Because of their efficient transcription and inability to recombine with HIV-1, adeno-associated virus vectors represent a promising form of anti-retroviral gene therapy.	NIAID,VIRAL DIS LAB,ROCKVILLE,MD 20852; GEORGETOWN UNIV,DEPT MICROBIOL,DIV MOLEC VIROL & IMMUNOL,ROCKVILLE,MD; NIAID,INFECT DIS LAB,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Johnson, Philip R/A-6892-2009					BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BERNS KI, 1987, ADV VIRUS RES, V32, P243, DOI 10.1016/S0065-3527(08)60479-0; CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599; CHATTERJEE S, UNPUB; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FENRICK R, 1989, J VIROL, V63, P5006, DOI 10.1128/JVI.63.12.5006-5012.1989; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GOLDSTEIN S, 1990, J ACQ IMMUN DEF SYND, V3, P98; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERMONAT PL, 1984, P NATL ACAD SCI-BIOL, V81, P6466, DOI 10.1073/pnas.81.20.6466; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOPE TJ, 1992, J VIROL, V66, P1849, DOI 10.1128/JVI.66.4.1849-1855.1992; Johnson V., 1990, TECHNIQUES HIV RES; JOSHI S, 1991, J VIROL, V65, P5524, DOI 10.1128/JVI.65.10.5524-5530.1991; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LAFACE D, 1988, VIROLOGY, V162, P483, DOI 10.1016/0042-6822(88)90491-6; LAUGHLIN CA, 1983, GENE, V23, P65, DOI 10.1016/0378-1119(83)90217-2; LEBKOWSKI JS, 1988, MOL CELL BIOL, V8, P3988, DOI 10.1128/MCB.8.10.3988; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MCLAUGHLIN SK, 1988, J VIROL, V62, P1963, DOI 10.1128/JVI.62.6.1963-1973.1988; MENDELSON E, 1992, VIROLOGY, V187, P453, DOI 10.1016/0042-6822(92)90447-W; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RHODES A, 1990, J GEN VIROL, V71, P1965, DOI 10.1099/0022-1317-71-9-1965; SAMULSKI RJ, 1982, P NATL ACAD SCI-BIOL, V79, P2077, DOI 10.1073/pnas.79.6.2077; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMADA T, 1991, Antiviral Chemistry and Chemotherapy, V2, P133; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SULLENGER BA, 1990, MOL CELL BIOL, V10, P6512, DOI 10.1128/MCB.10.12.6512; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WEEKS DL, 1983, MOL CELL BIOL, V3, P1222, DOI 10.1128/MCB.3.7.1222; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WILEY JA, 1989, AIDS, V3, pS71, DOI 10.1097/00002030-198901001-00011; WONG KL, UNPUB	37	183	229	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1485	1488		10.1126/science.1359646	http://dx.doi.org/10.1126/science.1359646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1359646	Green Submitted			2022-12-01	WOS:A1992JZ62500029
J	CLEMENTS, JD; LESTER, RAJ; TONG, G; JAHR, CE; WESTBROOK, GL				CLEMENTS, JD; LESTER, RAJ; TONG, G; JAHR, CE; WESTBROOK, GL			THE TIME COURSE OF GLUTAMATE IN THE SYNAPTIC CLEFT	SCIENCE			English	Article							METHYL-D-ASPARTATE; CULTURED HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; CENTRAL NERVOUS-SYSTEM; KINETIC-ANALYSIS; RAT HIPPOCAMPUS; ACID RECEPTORS; BINDING-SITES; CURRENTS; ACETYLCHOLINE	The peak concentration and rate of clearance of neurotransmitter from the synaptic cleft are important determinants of synaptic function, yet the neurotransmitter concentration time course is unknown at synapses in the brain. The time course of free glutamate in the cleft was estimated by kinetic analysis of the displacement of a rapidly dissociating competitive antagonist from N-methyl-D-aspartate (NMDA) receptors during synaptic transmission. Glutamate peaked at 1.1 millimolar and decayed with a time constant of 1.2 milliseconds at cultured hippocampal synapses. This time course implies that transmitter saturates postsynaptic NMDA receptors. However, glutamate dissociates much more rapidly from alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Thus, the time course of free glutamate predicts that dissociation contributes to the decay of the AMPA receptor-mediated postsynaptic current.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University	CLEMENTS, JD (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.		yasin, raiesa/F-9500-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH046613, R01MH046613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026494, R01NS026494, R01NS021419] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46613] Funding Source: Medline; NINDS NIH HHS [NS21419, NS26494] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTOL TM, 1991, BIOPHYS J, V59, P1209; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; BENVENISTE M, 1991, BRIT J PHARMACOL, V104, P207, DOI 10.1111/j.1476-5381.1991.tb12409.x; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; COLQUHOUN D, IN PRESS J PHYSL LON; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; EVANS RH, 1979, BRIT J PHARMACOL, V67, P591, DOI 10.1111/j.1476-5381.1979.tb08706.x; EVANS RH, 1978, BRAIN RES, V148, P536, DOI 10.1016/0006-8993(78)90744-8; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; GAGE PW, 1975, J PHYSIOL-LONDON, V244, P385, DOI 10.1113/jphysiol.1975.sp010805; HARRIS KM, 1986, NEUROSCIENCE, V19, P857, DOI 10.1016/0306-4522(86)90304-0; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KATZ B, 1973, J PHYSIOL-LONDON, V231, P549, DOI 10.1113/jphysiol.1973.sp010248; LAND BR, 1984, P NATL ACAD SCI-BIOL, V81, P1594, DOI 10.1073/pnas.81.5.1594; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P173, DOI 10.1113/jphysiol.1972.sp009840; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MCLENNAN H, 1979, BRAIN RES, V169, P83, DOI 10.1016/0006-8993(79)90375-5; MONAGHAN DT, 1988, P NATL ACAD SCI USA, V85, P9836, DOI 10.1073/pnas.85.24.9836; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; OLVERMAN HJ, 1988, NEUROSCIENCE, V26, P1, DOI 10.1016/0306-4522(88)90123-6; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; RIVEROS N, 1986, BRAIN RES, V386, P405, DOI 10.1016/0006-8993(86)90181-2; Salpeter MM, 1987, VERTEBRATE NEUROMUSC, V23, P1; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THEDINGA KH, 1989, NEUROSCI LETT, V104, P217, DOI 10.1016/0304-3940(89)90357-1; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121	36	817	850	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1498	1501		10.1126/science.1359647	http://dx.doi.org/10.1126/science.1359647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1359647				2022-12-01	WOS:A1992JZ62500033
J	FABER, DS; YOUNG, WS; LEGENDRE, P; KORN, H				FABER, DS; YOUNG, WS; LEGENDRE, P; KORN, H			INTRINSIC QUANTAL VARIABILITY DUE TO STOCHASTIC PROPERTIES OF RECEPTOR-TRANSMITTER INTERACTIONS	SCIENCE			English	Article							CENTRAL INHIBITORY SYNAPSE; LONG-TERM POTENTIATION; GLYCINE RECEPTORS; CENTRAL NEURON; NEUROMUSCULAR SYNAPSE; HIPPOCAMPAL SLICES; CHANNEL ACTIVATION; SPINAL-CORD; TRANSMISSION; ACETYLCHOLINE	Synaptic events at the neuromuscular junction are integer multiples of a quantum, the postsynaptic response to transmitter released from one presynaptic vesicle. At central synapses where quanta are small, it has been suggested they are invariant due to occupation of all postsynaptic receptors, a concept neglecting inherent fluctuations in channel behavior. If this did occur, the quantal release model would not apply there and could not be used to localize sites of synaptic modification. Monte Carlo simulations of quanta include transmitter diffusion and interactions with postsynaptic receptors that are treated probabilistically. These models suggest that when there are few postsynaptic channels available at a synapse, their stochastic behavior produces significant intrinsic variance in response amplitude and kinetics, and saturation does not occur. These results were confirmed by analysis of inhibitory quanta in embryonic and adult Mauthner cells involving a small and large number of channels, respectively. The findings apply to excitatory synapses as well.	SUNY BUFFALO, NEUROBIOL LAB, BUFFALO, NY 14214 USA; INST PASTEUR, INSERM, U261, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021848] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21848] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKAGI H, 1988, SCIENCE, V242, P270, DOI 10.1126/science.2845580; BARTOL TM, 1991, BIOPHYS J, V59, P1290, DOI 10.1016/S0006-3495(91)82344-X; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BUSCH C, 1990, COLD SPRING HARB SYM, V55, P69; DIAMOND J, 1973, J PHYSIOL-LONDON, V232, P113, DOI 10.1113/jphysiol.1973.sp010259; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; EDWARDS FR, 1976, J PHYSIOL-LONDON, V259, P689, DOI 10.1113/jphysiol.1976.sp011489; FABER DS, 1988, P NATL ACAD SCI USA, V85, P8708, DOI 10.1073/pnas.85.22.8708; FABER DS, 1985, P NATL ACAD SCI USA, V82, P3504, DOI 10.1073/pnas.82.10.3504; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; FABER DS, 1980, SCIENCE, V208, P612, DOI 10.1126/science.6245449; FABER DS, 1988, J NEUROPHYSIOL, V60, P1982, DOI 10.1152/jn.1988.60.6.1982; FABER DS, 1982, J NEUROPHYSIOL, V48, P654, DOI 10.1152/jn.1982.48.3.654; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; HARTZELL HC, 1975, J PHYSIOL-LONDON, V251, P427, DOI 10.1113/jphysiol.1975.sp011102; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P65, DOI 10.1113/jphysiol.1981.sp013972; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KORN H, 1990, J NEUROPHYSIOL, V63, P198, DOI 10.1152/jn.1990.63.1.198; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; KORN H, 1987, P NATL ACAD SCI USA, V84, P5981, DOI 10.1073/pnas.84.16.5981; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; Legendre P., 1992, Society for Neuroscience Abstracts, V18, P1357; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARGAROLI A, 1992, NATURE, V357, P134; ROBINSON HPC, 1991, BIOPHYS J, V59, P295, DOI 10.1016/S0006-3495(91)82223-8; ROPERT N, 1990, J PHYSIOL-LONDON, V428, P287; SEITANIDOU T, 1988, J NEUROSCI, V8, P4319; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; SOLODKIN M, 1991, J NEUROPHYSIOL, V65, P927, DOI 10.1152/jn.1991.65.4.927; TRILLER A, 1982, J NEUROPHYSIOL, V48, P708, DOI 10.1152/jn.1982.48.3.708; TWYMAN RE, 1991, J PHYSIOL-LONDON, V435, P303, DOI 10.1113/jphysiol.1991.sp018512; VRENSEN G, 1980, BRAIN RES, V184, P23, DOI 10.1016/0006-8993(80)90585-5; YOUNG AB, 1973, P NATL ACAD SCI USA, V70, P2832, DOI 10.1073/pnas.70.10.2832	43	155	155	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1992	258	5087					1494	1498		10.1126/science.1279813	http://dx.doi.org/10.1126/science.1279813			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279813				2022-12-01	WOS:A1992JZ62500032
J	GAUR, A; WIERS, B; LIU, A; ROTHBARD, J; FATHMAN, CG				GAUR, A; WIERS, B; LIU, A; ROTHBARD, J; FATHMAN, CG			AMELIORATION OF AUTOIMMUNE ENCEPHALOMYELITIS BY MYELIN BASIC-PROTEIN SYNTHETIC PEPTIDE INDUCED ANERGY	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; T-CELL TOLERANCE; MULTIPLE-SCLEROSIS; MONOCLONAL-ANTIBODY; ANTIGEN; DETERMINANT; EPITOPES; MICE; PREVENTION; REVERSAL	Experimental autoimmune encephalomyelitis (EAE), a demyelinating disease of the central nervous system that can be induced in susceptible strains of mice by immunization with myelin basic protein (MBP) or its immunodominant T cell determinants, serves as a model of human multiple sclerosis. Tolerance to MBP in adult mice was induced by intraperitoneal injection of synthetic peptides of immunodominant determinants of MBP and prevented MBP-induced EAE. Furthermore, tolerance-inducing regimens of peptides administered to mice after the disease had begun (10 days after induction with MBP) blocked the progression and decreased the severity of EAE. Peptide-induced tolerance resulted from the induction of anergy in proliferative, antigen-specific T cells.	STANFORD UNIV,MED CTR,SCH MED,DIV IMMUNOL & RHEUMATOL,STANFORD,CA 94305; IMMULOG PHARMACEUT CORP,PALO ALTO,CA 94304	Stanford University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027989] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; ALVORD EC, 1965, ANN NY ACAD SCI, V1220, P333; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; CAMPBELL B, 1973, ARCH NEUROL-CHICAGO, V29, P10, DOI 10.1001/archneur.1973.00490250028003; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; DEMAGISTRIS TM, 1992, CELL, V68, P625; DRISCOLL BF, 1976, J IMMUNOL, V117, P110; DRISCOLL BF, 1974, J IMMUNOL, V112, P392; EYLAR EH, 1972, NATURE, V236, P74, DOI 10.1038/236074a0; FRITZ RB, 1983, J IMMUNOL, V130, P191; GAMMON G, 1986, NATURE, V319, P413, DOI 10.1038/319413a0; HAFLER DA, 1988, J EXP MED, V167, P1313, DOI 10.1084/jem.167.4.1313; HASHIM GA, 1973, ARCH BIOCHEM BIOPHYS, V156, P287, DOI 10.1016/0003-9861(73)90367-6; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KONO DH, 1988, J EXP MED, V168, P213, DOI 10.1084/jem.168.1.213; MARTIN R, 1991, J EXP MED, V173, P19, DOI 10.1084/jem.173.1.19; MARTIN R, 1992, J IMMUNOL, V148, P1359; OKI A, 1985, J EXP MED, V161, P897, DOI 10.1084/jem.161.5.897; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; WISNIEWSKI HM, 1977, ANN NEUROL, V1, P144, DOI 10.1002/ana.410010207; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1988, J EXP MED, V167, P1586, DOI 10.1084/jem.167.5.1586; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	29	239	249	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1491	1494		10.1126/science.1279812	http://dx.doi.org/10.1126/science.1279812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279812				2022-12-01	WOS:A1992JZ62500031
J	GREEN, JBA; NEW, HV; SMITH, JC				GREEN, JBA; NEW, HV; SMITH, JC			RESPONSES OF EMBRYONIC XENOPUS CELLS TO ACTIVIN AND FGF ARE SEPARATED BY MULTIPLE DOSE THRESHOLDS AND CORRESPOND TO DISTINCT AXES OF THE MESODERM	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; AMPHIBIAN DEVELOPMENT; NEURAL INDUCTION; HOMEOBOX GENES; RETINOIC ACID; BODY PATTERN; LAEVIS; EXPRESSION; ORGANIZER; HOMOLOG	The potent mesoderm-inducing factors activin and FGF are present as maternally synthesized proteins in embryos of X. laevis. We show that activin can act on explanted blastomeres to induce at least five different cell states ranging from posterolateral mesoderm to dorsoanterior organizer mesoderm. Each state is induced in a narrow dose range bounded by sharp thresholds. By contrast, FGF induces only posterolateral markers and does so over relatively broad dose ranges. FGF can modulate the actions of activin, potentiating them and broadening the threshold-bounded dose windows. Our results indicate that orthogonal gradients of activin and FGF would be sufficient to specify the main elements of the body plan.			GREEN, JBA (corresponding author), NATL INST MED RES, OPHTHALMOL LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.		Green, Jeremy/F-3630-2010	Green, Jeremy/0000-0002-6102-2620; Smith, Jim/0000-0003-2413-9392				ALBANO RM, 1990, DEVELOPMENT, V110, P435; ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BOLCE ME, 1992, DEVELOPMENT, V115, P681; BOTERENBROOD EC, 1973, ROUX ARCH DEV BIOL, V173, P319, DOI 10.1007/BF00575837; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; COOKE J, 1989, DEVELOPMENT, V107, P229; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1981, NATURE, V290, P775, DOI 10.1038/290775a0; COOKE J, 1985, J EMBRYOL EXP MORPH, V88, P85; Dalcq A., 1937, Archives de Biologie Liege, V48, P669; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1990, CURR TOP DEV BIOL, V24, P31; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FRITZ A, 1988, NUCLEIC ACIDS RES, V16, P1453, DOI 10.1093/nar/16.4.1453; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; GURDON JB, 1984, CELL, V38, P691, DOI 10.1016/0092-8674(84)90264-2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAUSEN P, 1981, STAIN TECHNOL, V56, P287, DOI 10.3109/10520298109067329; JONAS EA, 1989, DEVELOPMENT, V106, P399; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; MOHUN T, 1988, J MOL BIOL, V202, P67, DOI 10.1016/0022-2836(88)90519-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SAHA MS, 1992, NEURON, V8, P1003, DOI 10.1016/0896-6273(92)90123-U; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	64	442	449	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					731	739		10.1016/0092-8674(92)90550-V	http://dx.doi.org/10.1016/0092-8674(92)90550-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423628				2022-12-01	WOS:A1992JZ63300004
J	HANVEY, JC; PEFFER, NJ; BISI, JE; THOMSON, SA; CADILLA, R; JOSEY, JA; RICCA, DJ; HASSMAN, CF; BONHAM, MA; AU, KG; CARTER, SG; BRUCKENSTEIN, DA; BOYD, AL; NOBLE, SA; BABISS, LE				HANVEY, JC; PEFFER, NJ; BISI, JE; THOMSON, SA; CADILLA, R; JOSEY, JA; RICCA, DJ; HASSMAN, CF; BONHAM, MA; AU, KG; CARTER, SG; BRUCKENSTEIN, DA; BOYD, AL; NOBLE, SA; BABISS, LE			ANTISENSE AND ANTIGENE PROPERTIES OF PEPTIDE NUCLEIC-ACIDS	SCIENCE			English	Article							TRIPLE-HELIX FORMATION; RNASE-H; INHIBITION; DNA; OLIGONUCLEOTIDES; TRANSCRIPTION; TRANSLATION; INVITRO	Peptide nucleic acids (PNAs) are polyamide oligomers that can strand invade duplex DNA, causing displacement of one DNA strand and formation of a D-loop. Binding of either a T10 PNA or a mixed sequence 15-mer PNA to the transcribed strand of a G-free transcription cassette caused 90 to 100 percent site-specific termination of pol II transcription elongation. When a T10 PNA was bound on the nontranscribed strand, site-specific inhibition never exceeded 50 percent. Binding of PNAs to RNA resulted in site-specific termination of both reverse transcription and in vitro translation, precisely at the position of the PNA . RNA heteroduplex. Nuclear microinjection of cells constitutively expressing SV40 large T antigen (T Ag) with either a 15-mer or 20-mer PNA targeted to the T Ag messenger RNA suppressed T Ag expression. This effect was specific in that there was no reduction in beta-galactosidase expression from a coinjected expression vector and no inhibition of T Ag expression after microinjection of a 10-mer PNA.	GLAXO INC,RES INST,DEPT CELL BIOL,5 MOORE DR,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT MED CHEM,RES TRIANGLE PK,NC 27709; HOOD COLL,DEPT BIOL,FREDERICK,MD 21701	GlaxoSmithKline; GlaxoSmithKline								BOIZIAU C, 1991, NUCLEIC ACIDS RES, V19, P1113, DOI 10.1093/nar/19.5.1113; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MAHER LJ, 1990, BIOCHEMISTRY-US, V29, P8820, DOI 10.1021/bi00489a045; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; TITUS DE, 1991, PROMEGA PROTOCOLS AP, P59; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WICKSTROM E, 1991, PROSPECTS ANTISENSE; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	19	463	570	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1481	1485		10.1126/science.1279811	http://dx.doi.org/10.1126/science.1279811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279811				2022-12-01	WOS:A1992JZ62500028
J	HASEGAWA, H; SKACH, W; BAKER, O; CALAYAG, MC; LINGAPPA, V; VERKMAN, AS				HASEGAWA, H; SKACH, W; BAKER, O; CALAYAG, MC; LINGAPPA, V; VERKMAN, AS			A MULTIFUNCTIONAL AQUEOUS CHANNEL FORMED BY CFTR	SCIENCE			English	Article							CYSTIC-FIBROSIS GENE; XENOPUS OOCYTES; CHLORIDE CHANNEL; MESSENGER-RNA; EXPRESSION; WATER; PERMEABILITY; CELLS	The cystic fibrosis gene product (CFTR) is a complex protein that functions as an adenosine 3,5-monophosphate (cAMP)-stimulated ion channel and possibly as a regulator of intracellular processes. In order to determine whether the CFTR molecule contains a functional aqueous pathway, anion, water, and urea transport were measured in Xenopus oocytes expressing CFTR. Cyclic AMP agonists induced a Cl- conductance of 94 microsiemens and an increase in water permeability of 4 x 10(-4) centimeter per second that was inhibited by a Cl- channel blocker and was dependent on anion composition. CFTR has a calculated single channel water conductance of 9 x 10(-13) cubic centimeter per second, suggesting a pore-like aqueous pathway. Oocytes expressing CFTR also showed cAMP-stimulated transport of urea but not the larger solute sucrose. Thus CFTR contains a cAMP-stimulated aqueous pore that can transport anions, water, and small solutes. The results also provide functional evidence for water movement through an ion channel.	UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CYST FIBROSIS RES CTR,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R01DK043840, R37DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAR CE, 1991, J BIOL CHEM, V266, P19142; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FINKELSTEIN A, 1987, DISTINGUISHED LECTUR, V4, pCH2; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GREEN ME, 1992, BIOPHYS J, V62, P101, DOI 10.1016/S0006-3495(92)81792-7; ILLINGER D, 1989, CELL BIOPHYS, V14, P17, DOI 10.1007/BF02797388; LEUCHTAG HR, 1992, BIOPHYS J, V62, P22, DOI 10.1016/S0006-3495(92)81766-6; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SKACH W, UNPUB; TILLY BC, 1992, J BIOL CHEM, V267, P9470; TSAI ST, 1991, BIOCHEMISTRY-US, V30, P2087, DOI 10.1021/bi00222a013; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; WANGEMANN P, 1986, PFLUG ARCH        S2, V407, P128; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26; ZHANG R, 1990, J BIOL CHEM, V265, P15375; ZHANG R, 1991, J CLIN INVEST, V88, P1553, DOI 10.1172/JCI115466; ZHANG R, IN PRESS J CELL BIOL	30	134	140	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1477	1479		10.1126/science.1279809	http://dx.doi.org/10.1126/science.1279809			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279809				2022-12-01	WOS:A1992JZ62500026
J	HUPP, TR; MEEK, DW; MIDGLEY, CA; LANE, DP				HUPP, TR; MEEK, DW; MIDGLEY, CA; LANE, DP			REGULATION OF THE SPECIFIC DNA-BINDING FUNCTION OF P53	CELL			English	Article							CASEIN-KINASE-II; CELLULAR TUMOR-ANTIGEN; HEAT-SHOCK PROTEINS; EPIDERMAL GROWTH-FACTOR; VIRUS-40 T-ANTIGEN; ESCHERICHIA-COLI; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; SV40-TRANSFORMED CELLS; NUCLEAR-LOCALIZATION	The DNA binding activity of p53 is required for its tumor suppressor function; we show here that this activity is cryptic but can be activated by cellular factors acting on a C-terminal regulatory domain of p53. A gel mobility shift assay demonstrated that recombinant wild-type human p53 binds DNA sequence specifically only weakly, but a monoclonal antibody binding near the C terminus activated the cryptic DNA binding activity stoichiometrically. p53 DNA binding could be activated by a C-terminal deletion of p53, mild proteolysis of full-length p53, E. coli dnaK (which disrupts protein-protein complexes), or casein kinase II (and coincident phosphorylation of a C-terminal site on p53). Activation of p53 DNA binding may be critical in regulation of its ability to arrest cell growth and thus its tumor suppressor function.			HUPP, TR (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADDISON C, 1990, ONCOGENE, V5, P423; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HALL PA, 1992, IN PRESS ONCOGENE; HARLOW E, 1988, ANTIBODIES LABORATOR; Hoekstra M F, 1992, Trends Cell Biol, V2, P153, DOI 10.1016/0962-8924(92)90022-F; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBARD TJP, 1991, PROTEIN ENG, V4, P711, DOI 10.1093/protein/4.7.711; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILARSKI KL, 1989, J CELL BIOL, V109, P1947, DOI 10.1083/jcb.109.5.1947; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1992, ONCOGENE, V7, P1515; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	92	968	994	1	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					875	886		10.1016/0092-8674(92)90562-Q	http://dx.doi.org/10.1016/0092-8674(92)90562-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423635				2022-12-01	WOS:A1992JZ63300016
J	LEONHARDT, H; PAGE, AW; WEIER, HU; BESTOR, TH				LEONHARDT, H; PAGE, AW; WEIER, HU; BESTOR, TH			A TARGETING SEQUENCE DIRECTS DNA METHYLTRANSFERASE TO SITES OF DNA-REPLICATION IN MAMMALIAN NUCLEI	CELL			English	Article							PRE-MESSENGER-RNA; MURINE ERYTHROLEUKEMIA-CELLS; INTRACELLULAR-LOCALIZATION; POLYMERASE-ALPHA; SATELLITE DNA; LIGASE-I; EXPRESSION; DOMAINS; HYBRIDIZATION; SPECIFICITY	Tissue-specific patterns of methylated deoxycytidine residues in the mammalian genome are preserved by postreplicative methylation of newly synthesized DNA. DNA methyltransferase (MTase) is here shown to associate with replication foci during S phase but to display a diffuse nucleoplasmic distribution in non-S phase cells. Analysis of DNA MTase-beta-galactosidase fusion proteins has shown that association with replication foci is mediated by a novel targeting sequence located near the N-terminus of DNA MTase. This sequence has the properties expected of a targeting sequence in that it is not required for enzymatic activity, prevents proper targeting when deleted, and, when fused to beta-galactosidase, causes the fusion protein to associate with replication foci in a cell cycle-dependent manner.	UNIV CALIF SAN FRANCISCO, DEPT LAB MED, DIV MOLEC CYTOMETRY, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	LEONHARDT, H (corresponding author), HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02115 USA.		Leonhardt, Heinrich/B-2791-2014		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043565] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17665] Funding Source: Medline; NIGMS NIH HHS [GM43565] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BECK JS, 1961, LANCET, V1, P1203; BENSCH KG, 1982, J BIOL CHEM, V257, P8391; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BRANCOLINI C, 1991, P NATL ACAD SCI USA, V88, P6936, DOI 10.1073/pnas.88.16.6936; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; DANDREA AD, 1983, NUCLEIC ACIDS RES, V11, P4753, DOI 10.1093/nar/11.14.4753; FOX MH, 1991, J CELL SCI, V99, P247; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MEIER UT, 1992, CELL, V70, P127; MILLS AD, 1989, J CELL SCI, V94, P471; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; NOGUCHI H, 1983, CELL, V32, P443, DOI 10.1016/0092-8674(83)90464-6; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; OTTIGER HP, 1984, P NATL ACAD SCI-BIOL, V81, P3993, DOI 10.1073/pnas.81.13.3993; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 1989, MOL CLONING LAB MANU; SAUNDERS WS, 1991, J CELL BIOL, V115, P919, DOI 10.1083/jcb.115.4.919; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TUBO RA, 1987, J BIOL CHEM, V262, P1148; VISSEL B, 1989, GENOMICS, V5, P407, DOI 10.1016/0888-7543(89)90003-7; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WEIER HU, 1991, BIOTECHNIQUES, V10, P498	52	836	853	1	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					865	873		10.1016/0092-8674(92)90561-P	http://dx.doi.org/10.1016/0092-8674(92)90561-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423634	Green Published			2022-12-01	WOS:A1992JZ63300015
J	MADHANI, HD; GUTHRIE, C				MADHANI, HD; GUTHRIE, C			A NOVEL BASE-PAIRING INTERACTION BETWEEN U2 AND U6 SNRNAS SUGGESTS A MECHANISM FOR THE CATALYTIC ACTIVATION OF THE SPLICEOSOME	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; GROUP-II INTRON; RIBONUCLEOPROTEIN-PARTICLES; SACCHAROMYCES-CEREVISIAE; SPLICING REACTION; SITE SELECTION; YEAST; U4; MUTATION	Prior to the chemical steps of mRNA splicing, the extensive base-pairing interaction between the U4 and U6 spliceosomal snRNAs is disrupted. Here, we use a mutational analysis in yeast to demonstrate a conserved base-pairing interaction between the U6 and U2 snRNAs that is mutually exclusive with the U4-U6 interaction. In this novel pairing, conserved sequences in U6 interact with a sequence in U2 that is immediately upstream of the branch point recognition region. Remarkably, the residues in U6 that can be consequently juxtaposed with the intron substrate include those that have been proposed previously to be catalytic. Both the first and second steps of splicing are inhibited when this base-paired structure is mutated. These observations, together with the high conservation of the U2-U6 structure, lead us to propose that it might be a component of the spliceosomal active site.			MADHANI, HD (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Madhani, Hiten/0000-0001-7400-6657	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21119] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BORDONNE R, 1992, NUCLEIC ACIDS RES, V20, P479, DOI 10.1093/nar/20.3.479; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMM J, 1989, EMBO J, V8, P4179, DOI 10.1002/j.1460-2075.1989.tb08603.x; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; KELLER EB, 1985, NUCLEIC ACIDS RES, V13, P4971, DOI 10.1093/nar/13.13.4971; KOCH JL, 1992, MOL CELL BIOL, V12, P1950, DOI 10.1128/MCB.12.5.1950; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MYSLINSKI E, 1990, SCIENCE, V247, P1213, DOI 10.1126/science.1690452; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; RINKE J, 1985, J MOL BIOL, V185, P721, DOI 10.1016/0022-2836(85)90057-9; ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHUSTER EO, 1990, NATURE, V345, P270, DOI 10.1038/345270a0; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SILICIANO PG, 1987, CELL, V50, P585, DOI 10.1016/0092-8674(87)90031-6; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	63	383	393	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					803	817		10.1016/0092-8674(92)90556-R	http://dx.doi.org/10.1016/0092-8674(92)90556-R			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423631				2022-12-01	WOS:A1992JZ63300010
J	MATTER, K; HUNZIKER, W; MELLMAN, I				MATTER, K; HUNZIKER, W; MELLMAN, I			BASOLATERAL SORTING OF LDL RECEPTOR IN MDCK CELLS - THE CYTOPLASMIC DOMAIN CONTAINS 2 TYROSINE-DEPENDENT TARGETING DETERMINANTS	CELL			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; DENSITY LIPOPROTEIN RECEPTOR; PLASMA-MEMBRANE PROTEINS; INFLUENZA-VIRUS HEMAGGLUTININ; LYMPHOCYTE FC-RECEPTORS; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEINS; MEDIATED ENDOCYTOSIS	In MDCK cells, transport of membrane proteins to the basolateral plasma membrane has been shown to require a distinct cytoplasmic domain determinant. Although the determinant is often related to signals used for localization in clathrin-coated pits, inactivation of the coated pit domain in the human LDL receptor did not affect basolateral targeting. By expressing mutant and chimeric LDL receptors, we have now identified two independently acting signals that are individually sufficient for basolateral targeting. The two determinants mediate basolateral sorting with different efficiencies, but both contain tyrosine residues critical for activity. The first determinant was colinear with, but distinct from, the coated pit domain of the receptor. The second was found in the C-terminal region of the cytoplasmic domain of the receptor and, although tyrosine-dependent, did not mediate endocytosis. The results suggest that membrane proteins can have functionally redundant signals for basolateral transport and that a tyrosine-containing motif may be a common feature of multiple intracellular sorting events.			MATTER, K (corresponding author), YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA.		Hunziker, Walter/GSM-8190-2022; Matter, Karl/C-4880-2008; Mellman, Ira/ABG-5896-2020; Hunziker, Walter/B-3140-2010	Matter, Karl/0000-0001-8026-7220; Hunziker, Walter/0000-0002-5265-4933				BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SA, 1985, J BIOL CHEM, V260, P9867; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Hauri H P, 1991, Semin Cell Biol, V2, P355; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1991, Semin Cell Biol, V2, P397; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Machamer C E, 1991, Trends Cell Biol, V1, P141, DOI 10.1016/0962-8924(91)90001-P; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RODRIGUEZBOULAN E, 1984, J CELL BIOL, V98, P308, DOI 10.1083/jcb.98.1.308; RODRIQUEZBOULAN E, 1992, IN PRESS ANN REV CEL; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WANDINGERNESS A, 1990, INTRACELLULAR TRAFFI, P575; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39	44	337	340	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					741	753		10.1016/0092-8674(92)90551-M	http://dx.doi.org/10.1016/0092-8674(92)90551-M			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423629				2022-12-01	WOS:A1992JZ63300005
J	MCPHEETERS, DS; ABELSON, J				MCPHEETERS, DS; ABELSON, J			MUTATIONAL ANALYSIS OF THE YEAST U2 SNRNA SUGGESTS A STRUCTURAL SIMILARITY TO THE CATALYTIC CORE OF GROUP-I INTRONS	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SELF-SPLICING RNA; RIBONUCLEOPROTEIN-PARTICLES; BINDING-SITE; CONSERVED NUCLEOTIDES; TRYPANOSOMA-BRUCEI; MAMMALIAN U2; U6 SNRNA; TETRAHYMENA	We have used an in vitro reconstitution system to determine the effects of a large number of mutations in the highly conserved 5' terminal domain of the yeast U2 snRNA on pre-mRNA splicing. Whereas many mutations have little or no functional consequence, base substitutions in two regions were found to have drastic effects on pre-mRNA splicing. A previously unrecognized function for the U2 snRNA in the second step of splicing was found by alteration of the absolutely conserved sequence AGA upstream of the branch point recognition sequence. The effects of these mutations suggest the formation of a structure involving the U2 snRNA similar to the guanosine-binding site found in the catalytic core of group I introns.			MCPHEETERS, DS (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032637, R01GM032637, F32GM012544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12544, GM32637] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; Ares M. Jr, 1989, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V94, P13; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BURKE JM, 1989, FEBS LETT, V250, P129, DOI 10.1016/0014-5793(89)80704-5; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GUPTA S, 1991, NUCLEIC ACIDS RES, V19, P2073, DOI 10.1093/nar/19.suppl.2073; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; KHELLIL S, 1991, NUCLEIC ACIDS RES, V19, P877, DOI 10.1093/nar/19.4.877; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MCNEIL JB, 1985, MOL CELL BIOL, V5, P3545, DOI 10.1128/MCB.5.12.3545; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MICHEL F, 1990, GENE DEV, V4, P777, DOI 10.1101/gad.4.5.777; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NELSON KK, 1989, GENE DEV, V3, P1562, DOI 10.1101/gad.3.10.1562; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PAN ZQ, 1989, GENE DEV, V3, P1887, DOI 10.1101/gad.3.12a.1887; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; REDDY R, 1990, NUCLEIC ACIDS RES, V18, P2231, DOI 10.1093/nar/18.suppl.2231; REDDY R, 1989, METHOD ENZYMOL, V180, P521; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHUMYATSKY G, 1992, NUCLEIC ACIDS RES, V20, P2159, DOI 10.1093/nar/20.suppl.2159; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU J, 1992, IN PRESS MOL CELL BI; YARUS M, 1989, NUCLEIC ACIDS RES, V17, P6969, DOI 10.1093/nar/17.17.6969; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1992, J MOL BIOL, V225, P945, DOI 10.1016/0022-2836(92)90095-2; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3; YARUS M, 1991, NUCLEIC ACIDS RES, V19, P1297, DOI 10.1093/nar/19.6.1297; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	70	94	95	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					819	831		10.1016/0092-8674(92)90557-S	http://dx.doi.org/10.1016/0092-8674(92)90557-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423632				2022-12-01	WOS:A1992JZ63300011
J	ROBERTS, RW; CROTHERS, DM				ROBERTS, RW; CROTHERS, DM			STABILITY AND PROPERTIES OF DOUBLE AND TRIPLE HELICES - DRAMATIC EFFECTS OF RNA OR DNA BACKBONE COMPOSITION	SCIENCE			English	Article							RIBONUCLEASE-H; HYBRID; INHIBITION; OLIGONUCLEOTIDE; TRANSCRIPTION; POLYMERASE; PROMOTER; BINDING; R(GCG)D(TATACGC); CLEAVAGE	Studies of a series of short oligonucleotide double and triple helices containing either all RNA, all DNA, or a mixture of the two show strand-dependent variation in their stability and structure. The variation in stability for both groups falls over a range of greater than 10 kilocalories per mole. In forming the triple helix, RNA is favored on both pyrimidine strands, whereas DNA is favored on the purine strand. In general, relatively unstable duplexes form particularly stable triplexes and vice versa. Structural data indicate that the strands in hybrid helices adopt a conformation that is intermediate between molecules containing all DNA and all RNA. Thus, RNA-DNA hybrids were not forced into the conformation of the RNA (A-form). The provocative stability of the triplex with an RNA third strand + DNA duplex points to novel antisense strategies and opens the possibility of an in vivo role of these structures. Overall, the data emphasize the fundamental role of sugars in determining the properties of nucleic acid complexes.			ROBERTS, RW (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511, USA.				NIAMS NIH HHS [GAR21966] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNOTT S, 1986, J MOL BIOL, V188, P631, DOI 10.1016/S0022-2836(86)80011-0; ARNOTT S, 1976, NUCLEIC ACIDS RES, V3, P2459, DOI 10.1093/nar/3.10.2459; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; CHAMBERLIN MJ, 1965, FED PROC, V24, P1446; CHOU SH, 1989, BIOCHEMISTRY-US, V28, P2435, DOI 10.1021/bi00432a014; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; GRAY DM, 1980, NUCLEIC ACIDS RES, V8, P3695, DOI 10.1093/nar/8.16.3695; HAASNOOT CAG, 1983, J BIOMOL STRUCT DYN, V1, P131, DOI 10.1080/07391102.1983.10507430; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HAUSEN P, 1970, EUR J BIOCHEM, V14, P278, DOI 10.1111/j.1432-1033.1970.tb00287.x; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEHRMAN EA, 1977, NUCLEIC ACIDS RES, V4, P1381, DOI 10.1093/nar/4.5.1381; MACAYA R, 1992, J MOL BIOL, V225, P755, DOI 10.1016/0022-2836(92)90399-5; MACAYA RF, 1992, J AM CHEM SOC, V114, P781, DOI 10.1021/ja00028a067; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MELLEMA JR, 1983, NUCLEIC ACIDS RES, V11, P5717, DOI 10.1093/nar/11.16.5717; MILLER HI, 1973, J BIOL CHEM, V248, P2621; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; ORSON FM, 1991, NUCLEIC ACIDS RES, V19, P3435, DOI 10.1093/nar/19.12.3435; PLUM GE, 1990, P NATL ACAD SCI USA, V87, P9436, DOI 10.1073/pnas.87.23.9436; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; ROBERTS RL, UNPUB; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023	39	443	474	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1463	1466		10.1126/science.1279808	http://dx.doi.org/10.1126/science.1279808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279808				2022-12-01	WOS:A1992JZ62500022
J	ROCA, J; WANG, JC				ROCA, J; WANG, JC			THE CAPTURE OF A DNA DOUBLE HELIX BY AN ATP-DEPENDENT PROTEIN CLAMP - A KEY STEP IN DNA TRANSPORT BY TYPE-II DNA TOPOISOMERASES	CELL			English	Article							NUCLEOTIDE-SEQUENCE; YEAST; GYRASE; SITE; COMPLEXES; HOMOLOGY; CLEAVAGE; MITOSIS; GENE	The binding of linear and circular forms of DNA to yeast DNA topoisomerase II or its complex with AMPPNP, the nonhydrolyzable beta,gamma-imido analog of ATP, was carried out to probe the ATP analog-induced conformational change of the enzyme. Binding of the ATP analog is shown to convert the enzyme to a circular clamp with an annulet, through which only a linear DNA can pass; subsequent circularization of the bound linear DNA forms a salt-stable catenane between the protein circular clamp and the DNA ring. Analysis of catenane formation between a small DNA ring originally bound to the topoisomerase and a large DNA ring subsequently added, under conditions such that the two do not exchange, supports a model in which a second DNA double-helix can enter the open jaws of a DNA-bound protein clamp, and the closure of the jaws upon ATP-binding traps the second duplex and transports it through an enzyme-operated gate in the first DNA duplex.			ROCA, J (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.		Roca, Joaquim/AAP-1077-2020	Roca, Joaquim/0000-0003-1462-954X	NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024544, R01GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CARON PR, 1992, IN PRESS 1991 INT S; DRLICA K, 1988, BIOCHEMISTRY-US, V27, P2253, DOI 10.1021/bi00407a001; GOTO T, 1982, J BIOL CHEM, V257, P5866; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; Hsieh TS, 1990, DNA TOPOLOGY ITS BIO, P243; HUANG WM, 1990, DNA TOPOLOGY ITS BIO, P265; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIZZUUCHI K, 1980, PNAS, V77, P1847; MORRISON A, 1980, J BIOL CHEM, V255, P2211; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; POMMIER Y, 1989, BIOCHEMISTRY-US, V28, P995, DOI 10.1021/bi00429a012; TAMURA JK, 1992, J BIOL CHEM, V267, P9214; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1980, MECHANISTIC STUDIES, P769; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YANAGIDA M, 1987, NUCLEIC ACIDS MOL BI, V1, P196; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	36	297	305	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					833	840		10.1016/0092-8674(92)90558-T	http://dx.doi.org/10.1016/0092-8674(92)90558-T			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330327				2022-12-01	WOS:A1992JZ63300012
J	SCHMID, A; FASCHER, KD; HORZ, W				SCHMID, A; FASCHER, KD; HORZ, W			NUCLEOSOME DISRUPTION AT THE YEAST PHO5 PROMOTER UPON PHO5 INDUCTION OCCURS IN THE ABSENCE OF DNA-REPLICATION	CELL			English	Article							RNA POLYMERASE-II; BETA-GLOBIN GENE; TRANSCRIPTIONALLY ACTIVE CHROMATIN; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; ACID-PHOSPHATASE; POSITIONED NUCLEOSOMES; HYPERSENSITIVE SITES; REGULATORY PROTEINS; MAJOR LATE	Activation of the PHO5 gene in S. cerevisiae by phosphate starvation was previously shown to be accompanied by the disappearance of four positioned nucleosomes from the promoter. To investigate the mechanism, we replaced the PHO80 gene, a negative regulator of PHO5, by a temperature-sensitive allele. As a consequence, PHO5 can be activated in the presence of phosphate by a temperature shift from 24-degrees-C to 37-degrees-C. Under these conditions, the promoter undergoes the same chromatin transition as in phosphate-starved cells. Disruption of the nucleosomes by the temperature shift also occurs when DNA replication is prevented. Nucleosomes re-form when the temperature is shifted from 37-degrees-C back to 24-degrees-C in nondividing cells. Glucose is required for the disruption of the nucleosomes during the temperature upshift, not for their re-formation during the temperature downshift. These experiments prove that DNA replication is not required for the transition between the nucleosomal and the non-nucleosomal state at the PHO5 promoter.			SCHMID, A (corresponding author), UNIV MUNICH,INST PHYS CHEM,SCHILLERSTR 44,W-8000 MUNICH 2,GERMANY.							ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BARBARIC S, 1992, NUCLEIC ACIDS RES, V20, P1031, DOI 10.1093/nar/20.5.1031; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BERBEN G, 1990, YEAST, V6, P451, DOI 10.1002/yea.320060510; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BURGLIN TR, 1988, CELL, V53, P339, DOI 10.1016/0092-8674(88)90153-5; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FASCHER KD, 1989, THESIS U MUNCHEN MUN; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FISHER F, 1991, ONCOGENE, V6, P1099; FOY HR, 1987, EMBO J, V6, P2321; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAGUENAUERTSAPIS R, 1984, MOL CELL BIOL, V4, P2668, DOI 10.1128/MCB.4.12.2668; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HANES SD, 1986, CRC CR REV BIOCH MOL, V21, P153, DOI 10.3109/10409238609113611; HAYASHI N, 1991, MOL CELL BIOL, V11, P785, DOI 10.1128/MCB.11.2.785; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANEKO Y, 1985, MOL CELL BIOL, V5, P248, DOI 10.1128/MCB.5.1.248; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; KOREN R, 1986, GENE, V41, P271, DOI 10.1016/0378-1119(86)90107-1; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KULAEV IS, 1983, ADV MICROB PHYSIOL, V24, P83, DOI 10.1016/S0065-2911(08)60385-9; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEMIRE JM, 1985, MOL CELL BIOL, V5, P2131, DOI 10.1128/MCB.5.8.2131; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LUCCHINI G, 1988, MOL GEN GENET, V212, P459, DOI 10.1007/BF00330850; MADDEN SL, 1990, MOL CELL BIOL, V10, P5950, DOI 10.1128/MCB.10.11.5950; MADDEN SL, 1988, NUCLEIC ACIDS RES, V16, P2625, DOI 10.1093/nar/16.6.2625; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MEYHACK B, 1982, EMBO J, V1, P675, DOI 10.1002/j.1460-2075.1982.tb01229.x; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PAVLOVIC B, 1988, MOL CELL BIOL, V8, P5513, DOI 10.1128/MCB.8.12.5513; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PHAM TA, 1991, J BIOL CHEM, V266, P18179; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; ROBERGE M, 1992, MOL MICROBIOL, V6, P419, DOI 10.1111/j.1365-2958.1992.tb01485.x; RUDOLPH H, 1987, P NATL ACAD SCI USA, V84, P1340, DOI 10.1073/pnas.84.5.1340; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; Toh-e A, 1986, Yeast, V2, P129, DOI 10.1002/yea.320020209; TOHE A, 1988, MOL GEN GENET, V214, P162, DOI 10.1007/BF00340196; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; UESONO Y, 1992, MOL GEN GENET, V231, P426, DOI 10.1007/BF00292712; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VENTER U, 1989, NUCLEIC ACIDS RES, V17, P1353, DOI 10.1093/nar/17.4.1353; VOGEL K, 1990, MOL MICROBIOL, V4, P2013, DOI 10.1111/j.1365-2958.1990.tb00560.x; VOGEL K, 1989, MOL CELL BIOL, V9, P2050, DOI 10.1128/MCB.9.5.2050; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WILLS C, 1990, CRIT REV BIOCHEM MOL, V25, P245, DOI 10.3109/10409239009090611; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YA MB, 1991, MOL CELL BIOL, V11, P3229; YANIV M, 1986, CRIT REV BIOCHEM MOL, V21, P1, DOI 10.3109/10409238609113607; YOSHIDA K, 1989, MOL GEN GENET, V217, P40, DOI 10.1007/BF00330940	89	139	141	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					853	864		10.1016/0092-8674(92)90560-Y	http://dx.doi.org/10.1016/0092-8674(92)90560-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1423633				2022-12-01	WOS:A1992JZ63300014
J	SCHUTZE, S; POTTHOFF, K; MACHLEIDT, T; BERKOVIC, D; WIEGMANN, K; KRONKE, M				SCHUTZE, S; POTTHOFF, K; MACHLEIDT, T; BERKOVIC, D; WIEGMANN, K; KRONKE, M			TNF ACTIVATES NF-KAPPA-B BY PHOSPHATIDYLCHOLINE-SPECIFIC PHOSPHOLIPASE-C-INDUCED ACIDIC SPHINGOMYELIN BREAKDOWN	CELL			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; ENHANCER-BINDING-PROTEIN; GH3 PITUITARY-CELLS; IMMUNODEFICIENCY VIRUS TYPE-1; NIEMANN-PICK DISEASE; HUMAN LYMPHOCYTES-T; FACTOR-ALPHA; TRANSCRIPTION FACTOR; MOLECULAR-CLONING	In this paper, we describe a phospholipid transmission pathway mediating tumor necrosis factor (TNF) activation of the nuclear transcription factor kappaB (NF-kappaB). Central to this TNF signaling route is the second messenger-like molecule ceramide, which is generated by sphingomyelin (SM) breakdown catalyzed by a sphingomyelinase (SMase). SMase activation is secondary to the generation of 1,2-diacylglycerol (DAG) produced by a TNF-responsive PC-specific phospholipase C (PC-PLC). The functional coupling of these two C type phospholipases is revealed by D609, a selective inhibitor of PC-PLC. SMase itself, or SMase-inducing regimens such as exogenous PLC or synthetic DAGs, induces NF-kappaB activation at pH 5.0, suggesting the operation of an acidic SMase. A model is proposed in which a TNF-responsive PC-PLC via DAG couples to an acidic SMase, resulting in the generation of ceramide, which eventually triggers rapid induction of nuclear NF-kappaB activity.	UNIV GOTTINGEN, ZENTRUM INNERE MED, HAMATOL ONKOL ABT, W-3400 GOTTINGEN, GERMANY	University of Gottingen	SCHUTZE, S (corresponding author), TECH UNIV MUNICH, INST MED MIKROBIOL & HYG, W-8000 MUNICH 80, GERMANY.		Schütze, Stefan/C-8596-2011					ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ATKINSON YH, 1990, IMMUNOLOGY, V70, P82; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EIBL H, 1969, ANAL BIOCHEM, V30, P51, DOI 10.1016/0003-2697(69)90372-8; FAURE R, 1992, J BIOL CHEM, V267, P11215; FERLINZ K, 1991, BIOCHEM BIOPH RES CO, V179, P1187, DOI 10.1016/0006-291X(91)91697-B; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GODFREY RW, 1987, BIOCHEM BIOPH RES CO, V142, P235, DOI 10.1016/0006-291X(87)90476-1; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAY DG, 1986, J BIOL CHEM, V261, P8473; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KORATCHER S, 1978, ENZYMES LIPID METABO, P221; KRONKE M, 1992, TUMOR NECROSIS FACTO, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LE JM, 1987, LAB INVEST, V56, P234; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OLD LJ, 1987, NATURE, V326, P330, DOI 10.1038/326330a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; RAO BG, 1976, J LIPID RES, V17, P506; RAO GR, 1981, BIOCHEM J, V198, P9, DOI 10.1042/bj1980009; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSTENBECK I, 1990, J CHROMATOGR-BIOMED, V525, P85, DOI 10.1016/S0378-4347(00)83381-2; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TOMITA M, 1990, J BIOCHEM-TOKYO, V108, P811, DOI 10.1093/oxfordjournals.jbchem.a123285; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZOU L, 1989, BIOTECHNOL APPL BIOC, V11, P217	72	1045	1060	2	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					765	776		10.1016/0092-8674(92)90553-O	http://dx.doi.org/10.1016/0092-8674(92)90553-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330325				2022-12-01	WOS:A1992JZ63300007
J	TAKAHAMA, Y; SINGER, A				TAKAHAMA, Y; SINGER, A			POSTTRANSCRIPTIONAL REGULATION OF EARLY T-CELL DEVELOPMENT BY T-CELL RECEPTOR SIGNALS	SCIENCE			English	Article							3' UNTRANSLATED REGION; CD8 GENE-EXPRESSION; MESSENGER-RNA; IMMATURE THYMOCYTES; ANTIGEN RECEPTOR; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; V(D)J RECOMBINATION; MURINE THYMOCYTES; TRANSGENIC MICE	During differentiation in the thymus, immature T cells progress through an ordered sequence of developmental stages that are best characterized by variable expression of the co-receptor molecules CD4 and CD8. Crosslinking of T cell receptor (TCR) molecules on precursor thymocytes was found to block their differentiation into CD4+CD8+ cells by eliminating messenger RNA's encoding two families of developmentally important molecules: the co-receptor molecules CD4 and CD8 and the recombination activating genes 1 and 2. TCR-induced post-transcriptional regulation in early thymocytes was specific for selective messenger RNA's, required protein synthesis, and was itself developmentally regulated. These data identify a post-transcriptional mechanism that is influenced by TCR signals and that regulates early thymocyte development.			TAKAHAMA, Y (corresponding author), NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA.		Takahama, Yousuke/A-5863-2010	Takahama, Yousuke/0000-0002-4992-9174				ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHENKIANG S, 1989, METHOD ENZYMOL, V180, P82; CLEVELAND D W, 1989, New Biologist, V1, P121; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; HUSMANN LA, 1988, J IMMUNOL, V141, P736; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUBO RT, 1989, J IMMUNOL, V142, P2736; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8633, DOI 10.1073/pnas.85.22.8633; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PAILLARD F, 1990, EMBO J, V9, P1867, DOI 10.1002/j.1460-2075.1990.tb08312.x; PARDOLL DM, 1987, J EXP MED, V165, P1624, DOI 10.1084/jem.165.6.1624; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PETRIE HT, 1990, EUR J IMMUNOL, V20, P2813, DOI 10.1002/eji.1830201243; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROYER HD, 1985, P NATL ACAD SCI USA, V82, P5510, DOI 10.1073/pnas.82.16.5510; Sambrook J., 1989, MOL CLONING LAB MANU; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCOLLAY R, 1988, IMMUNOL REV, V104, P81, DOI 10.1111/j.1600-065X.1988.tb00760.x; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHAMA Y, 1992, SCIENCE, V258, P653, DOI 10.1126/science.1357752; TAKAHAMA Y, 1991, J IMMUNOL, V147, P2883; TAKAHAMA Y, UNPUB; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WILKINSON MF, 1991, MOL IMMUNOL, V28, P57, DOI 10.1016/0161-5890(91)90087-Z; Wilson A, 1989, Int Immunol, V1, P605, DOI 10.1093/intimm/1.6.605; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0	63	96	96	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 27	1992	258	5087					1456	1462		10.1126/science.1439838	http://dx.doi.org/10.1126/science.1439838			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1439838				2022-12-01	WOS:A1992JZ62500021
J	THANOS, D; MANIATIS, T				THANOS, D; MANIATIS, T			THE HIGH MOBILITY GROUP PROTEIN HMG-I(Y) IS REQUIRED FOR NF-KAPPA-B-DEPENDENT VIRUS INDUCTION OF THE HUMAN IFN-BETA GENE	CELL			English	Article							DNA-BINDING PROTEIN; INTERFERON GENE; HMG-I; NUCLEAR FACTOR; CHROMOSOMAL-PROTEINS; REGULATORY ELEMENTS; INDUCIBLE ENHANCER; ESCHERICHIA-COLI; MAMMALIAN-CELLS; RNA-POLYMERASE	In this paper, we show that both NF-kappaB and the high mobility group protein I(Y) (HMG I(Y)) are required for virus induction of the human interferon-beta (IFN-beta) gene. NF-kappaB binds to the terminal regions of a 10 bp regulatory sequence through contacts in the major groove, while HMG I(Y) recognizes the central region of the same sequence through contacts in the minor groove. Mutations that interfere with binding of either protein decrease the level of virus induction, and activation of the gene can be blocked by either NF-kappaB or HMG I(Y) antisense RNA. HMG I(Y) stimulates the binding of NF-kappaB to the IFN-beta promoter, and it may also function as a promoter-specific accessory factor for NF-kappaB transcriptional activity.			THANOS, D (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1990, HORMONAL CONTROL REG, P423; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Demaeyer E., 1988, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FASHENA ST, 1991, MOL CELL BIOL, V12, P894; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GOODBOURN S, 1985, CELL, V41, P509, DOI 10.1016/S0092-8674(85)80024-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1992, IN PRESS INT REV EXP; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEHN DA, 1988, BIOCHEM INT, V16, P963; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Maniatis T., 1982, MOL CLONING; MANIATIS T, 1992, IN PRESS TRANSCRIPTI; MAUXION F, 1991, P NATL ACAD SCI USA, V88, P2141, DOI 10.1073/pnas.88.6.2141; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOLITOR JA, 1991, NEW BIOL, V3, P987; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; REEVES R, 1990, J BIOL CHEM, V265, P8573; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VILCEK J, 1990, HDB EXPT PHARM, V95, P1; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZABEL U, 1991, J BIOL CHEM, V266, P252	65	609	613	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 27	1992	71	5					777	789		10.1016/0092-8674(92)90554-P	http://dx.doi.org/10.1016/0092-8674(92)90554-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330326				2022-12-01	WOS:A1992JZ63300008
J	TRIAS, J; JARLIER, V; BENZ, R				TRIAS, J; JARLIER, V; BENZ, R			PORINS IN THE CELL-WALL OF MYCOBACTERIA	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; TUBERCULOSIS; INFECTION; MEMBRANE; BARRIER	The cell wall of mycobacteria is an efficient permeability barrier that makes mycobacteria naturally resistant to most antibiotics. Liposome swelling assays and planar bilayer experiments were used to investigate the diffusion process of hydrophilic molecules through the cell wall of Mycobacterium chelonae and identify the main hydrophilic pathway. A 59-kilodalton cell wall protein formed a water-filled channel with a diameter of 2.2 nanometers and an average single-channel conductance equal to 2.7 nanosiemens in 1 M potassium chloride. These results suggest that porins can be found in the cell wall of a Gram-positive bacterium. A better knowledge of the hydrophilic pathways should help in the design of more effective antimycobacterial agents.	UNIV PARIS 06,BACTERIOL VIROL LAB,F-75634 PARIS 13,FRANCE; UNIV WURZBURG,LEHRSTUHL BIOTECHNOL,W-8700 WURZBURG,GERMANY	UDICE-French Research Universities; Sorbonne Universite; University of Wurzburg				Benz, Roland/0000-0002-9510-9265				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1988, ANNU REV MICROBIOL, V42, P359, DOI 10.1146/annurev.mi.42.100188.002043; BLOOM BR, 1989, NATURE, V342, P115, DOI 10.1038/342115a0; DRAPER P, 1982, BIOL MYCOBACTERIA, P9; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; JARLIER V, 1991, ANTIMICROB AGENTS CH, V35, P1937, DOI 10.1128/AAC.35.9.1937; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Minnikin DE, 1987, CHEMOTHERAPY TROPICA, P19; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; TRIAS J, UNPUB; WHEELER PR, 1988, BRIT MED BULL, V44, P547, DOI 10.1093/oxfordjournals.bmb.a072267; YOSHIMURA F, 1983, J BIOL CHEM, V258, P2308; 1982, TUBERCLE, V63, P157	16	164	173	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 27	1992	258	5087					1479	1481		10.1126/science.1279810	http://dx.doi.org/10.1126/science.1279810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ625	1279810				2022-12-01	WOS:A1992JZ62500027
J	WEISSMAN, JS; KIM, PS				WEISSMAN, JS; KIM, PS			THE PRO REGION OF BPTI FACILITATES FOLDING	CELL			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROTEIN-DISULFIDE-ISOMERASE; NUCLEAR-MAGNETIC-RESONANCE; INTERMEDIATE; SEQUENCES; PATHWAY; DITHIOTHREITOL; POLYPEPTIDE; REQUIREMENT; MICROSOMES	The in vitro folding pathway of bovine pancreatic trypsin inhibitor (BPTI) has been described previously in terms of the disulfide-bonded intermediates that accumulate during folding of the protein. Folding is slow, occurring in hours at pH 7.3, 25-degrees-C. In addition, approximately half of the BPTI molecules become trapped as a dead-end, native-like intermediate. In vivo, BPTI is synthesized as a precursor protein that includes a 13 residue amino-terminal pro region. This pro region contains a cysteine residue. We find that, in vitro, both the rate of formation and the yield of properly folded BPTI are increased substantially in a recombinant model of pro-BPTI. The cysteine residue is necessary for this effect. Moreover, a single cysteine residue, tethered to the carboxy-terminal end of BPTI with a flexible linker of repeating Ser-Gly-Gly residues, is sufficient to assist in disulfide formation. Thus, the pro region appears to facilitate folding by providing a tethered, solvent-accessible, intramolecular thiol-disulfide reagent.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT PHYS, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	WEISSMAN, JS (corresponding author), MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02142 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041307] Funding Source: NIH RePORTER; NIAID NIH HHS [T32AI07348] Funding Source: Medline; NIGMS NIH HHS [GM41307] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHAU MH, 1991, FEBS LETT, V291, P296, DOI 10.1016/0014-5793(91)81305-R; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1987, J MOL BIOL, V194, P11, DOI 10.1016/0022-2836(87)90711-X; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1975, J MOL BIOL, V95, P167, DOI 10.1016/0022-2836(75)90389-7; CREIGHTON TE, 1988, BIOPHYS CHEM, V31, P155, DOI 10.1016/0301-4622(88)80021-8; DARBY NJ, 1992, J MOL BIOL, V224, P905, DOI 10.1016/0022-2836(92)90458-V; DEISENHOFER J, 1975, ACTA CRYSTALLOGR B, V31, P238, DOI 10.1107/S0567740875002415; DOERING D, 1992, THESIS MIT CAMBRIDGE; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; FIELDS C G, 1991, Peptide Research, V4, P95; FREEDMAN RB, 1991, CONFORMATIONS FORCES, P204; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HURLE MR, 1992, PROTEIN SCI, V1, P91; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.bi.59.070190.003215; KOSEN PA, 1992, BIOCHEMISTRY-US, V31, P5705, DOI 10.1021/bi00140a004; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIN TY, 1991, P NATL ACAD SCI USA, V88, P10573, DOI 10.1073/pnas.88.23.10573; NADERI HM, 1991, CONFORMATIONS FORCES, P86; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTHWARF DM, 1992, P NATL ACAD SCI USA, V89, P7944, DOI 10.1073/pnas.89.17.7944; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; STASSINOPOULOU CI, 1984, EUR J BIOCHEM, V145, P423, DOI 10.1111/j.1432-1033.1984.tb08571.x; STATES DJ, 1987, J MOL BIOL, V195, P731, DOI 10.1016/0022-2836(87)90192-6; STATES DJ, 1984, J MOL BIOL, V174, P411, DOI 10.1016/0022-2836(84)90345-0; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; VANMIERLO CPM, 1992, P NATL ACAD SCI USA, V89, P6775, DOI 10.1073/pnas.89.15.6775; VANMIERLO CPM, 1991, J MOL BIOL, V222, P373, DOI 10.1016/0022-2836(91)90217-T; VANMIERLO CPM, 1991, J MOL BIOL, V222, P353, DOI 10.1016/0022-2836(91)90216-S; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WLODAWER A, 1984, J MOL BIOL, V180, P301, DOI 10.1016/S0022-2836(84)80006-6; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	57	133	139	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					841	851		10.1016/0092-8674(92)90559-U	http://dx.doi.org/10.1016/0092-8674(92)90559-U			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1384990				2022-12-01	WOS:A1992JZ63300013
J	WINSLOW, GM; SCHERER, MT; KAPPLER, JW; MARRACK, P				WINSLOW, GM; SCHERER, MT; KAPPLER, JW; MARRACK, P			DETECTION AND BIOCHEMICAL-CHARACTERIZATION OF THE MOUSE MAMMARY-TUMOR VIRUS-7 SUPERANTIGEN (MLS-1(A))	CELL			English	Article							RECEPTOR V-BETA; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RESPONSES; STAPHYLOCOCCAL ENTEROTOXIN-B; DISPARATE STIMULATOR CELLS; MLS-MODIFIED PRODUCTS; BONE-MARROW CHIMERAS; OPEN READING FRAME; CLONAL DELETION; DENDRITIC CELLS	Mouse mammary tumor viruses encode superantigens that bind to class II major histocompatibility complex proteins and engage T cells that bear particular V(beta)s. Among these superantigens is the long known, but previously uncharacterized, Mls-1a product, encoded by Mtv-7. Using a monoclonal antibody, we detect the Mtv-7 superantigen on the surface of activated B cells, but not on T cells or resting B cells. The superantigen is synthesized as a 45 kd transmembrane glycoprotein precursor, but is proteolytically processed to yield an 18.5 kd surface protein that we suggest is the functional form of the superantigen.	UNIV COLORADO, HLTH SCI CTR, DEPT MICROBIOL & IMMUNOL & MED, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, DENVER, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WINSLOW, GM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DIV BASIC IMMUNOL, HOWARD HUGHES MED INST, DENVER, CO 80206 USA.		Marrack, Philippa/AHE-6316-2022	Marrack, Philippa/0000-0003-1883-3687	NIAID NIH HHS [AI 18785, AI 17134] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018785, R01AI018785, R01AI017134, R37AI017134, R56AI017134] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; ANDERSON GD, 1989, J IMMUNOL, V143, P3757; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEUTNER U, 1992, P NATL ACAD SCI USA, V89, P5432, DOI 10.1073/pnas.89.12.5432; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BRANDTCARLSON C, 1991, J VIROL, V65, P6051, DOI 10.1128/JVI.65.11.6051-6060.1991; CHOI YW, 1992, J EXP MED, V175, P847, DOI 10.1084/jem.175.3.847; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DEKRUYFF RH, 1986, J IMMUNOL, V137, P1109; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FIRESTONE GL, 1982, NATURE, V300, P221, DOI 10.1038/300221a0; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOLLOB KJ, 1991, J IMMUNOL, V147, P2447; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAINAUT P, 1990, CANCER RES, V50, P3754; HAMILOS DL, 1989, J IMMUNOL, V142, P1069; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HEDO JA, 1983, J BIOL CHEM, V258, P20; HELD W, 1992, J EXP MED, V175, P1623, DOI 10.1084/jem.175.6.1623; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HERMAN A, 1990, J EXP MED, V172, P709, DOI 10.1084/jem.172.3.709; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; Herrmann T, 1991, Curr Top Microbiol Immunol, V174, P21; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; JOUVINMARCHE E, 1992, P NATL ACAD SCI USA, V89, P3232, DOI 10.1073/pnas.89.8.3232; KAIN SR, 1992, J BIOL CHEM, V267, P8128; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KATZ ME, 1985, J IMMUNOL, V134, P2064; KING LB, 1990, MOL CELL BIOL, V10, P4211, DOI 10.1128/MCB.10.8.4211; KING LB, 1990, J IMMUNOL, V144, P3218; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KNIGHT AM, 1992, EUR J IMMUNOL, V22, P879, DOI 10.1002/eji.1830220339; KORMAN AJ, 1992, EMBO J, V11, P1901, DOI 10.1002/j.1460-2075.1992.tb05242.x; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KUBO RT, 1983, MOL IMMUNOL, V20, P67, DOI 10.1016/0161-5890(83)90106-2; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSONSCIARD EL, 1990, EUR J IMMUNOL, V20, P1223, DOI 10.1002/eji.1830200605; LIEGLER TJ, 1986, J VIROL, V59, P159, DOI 10.1128/JVI.59.1.159-162.1986; LYNCH DH, 1985, J IMMUNOL, V134, P2071; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARCHEJOUVIN E, 1992, P NATL ACAD SCI USA, V89, P3232; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MARRACK P, 1990, J EXP MED, V171, P455, DOI 10.1084/jem.171.2.455; MAZDA O, 1991, J EXP MED, V173, P539, DOI 10.1084/jem.173.3.539; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NANDI S, 1972, J NATL CANCER I, V48, P1085; NICOLAS JF, 1987, EUR J IMMUNOL, V17, P1561, DOI 10.1002/eji.1830171106; OZATO K, 1980, J IMMUNOL, V124, P533; PAPIERNIK M, 1992, J EXP MED, V175, P453, DOI 10.1084/jem.175.2.453; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; PULLEN AM, 1991, J EXP MED, V173, P1183, DOI 10.1084/jem.173.5.1183; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROBERTS JL, 1990, J EXP MED, V171, P935, DOI 10.1084/jem.171.3.935; ROSS SR, 1985, P NATL ACAD SCI USA, V82, P5880, DOI 10.1073/pnas.82.17.5880; RUDY CK, 1992, J EXP MED, V175, P1613, DOI 10.1084/jem.175.6.1613; SALMONS B, 1990, J VIROL, V64, P6355, DOI 10.1128/JVI.64.12.6355-6359.1990; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; SINGER PA, 1990, EMBO J, V9, P3641, DOI 10.1002/j.1460-2075.1990.tb07575.x; SPEISER DE, 1990, J EXP MED, V172, P1305, DOI 10.1084/jem.172.5.1305; SPEISER DE, 1989, J EXP MED, V170, P595, DOI 10.1084/jem.170.2.595; SPEISER DE, 1989, J EXP MED, V170, P2165, DOI 10.1084/jem.170.6.2165; TSUBURA A, 1988, CANCER RES, V48, P6555; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VACCHIO MS, 1990, J EXP MED, V172, P807, DOI 10.1084/jem.172.3.807; VANKLAVEREN P, 1988, J VIROL, V62, P4410, DOI 10.1128/JVI.62.11.4410-4413.1988; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WEBB SR, 1990, SCIENCE, V248, P1643; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1991, J EXP MED, V174, P1255, DOI 10.1084/jem.174.5.1255; YAGI JJ, 1990, J IMMUNOL, V144, P892	102	103	105	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					719	730		10.1016/0092-8674(92)90549-R	http://dx.doi.org/10.1016/0092-8674(92)90549-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330323				2022-12-01	WOS:A1992JZ63300003
J	ZANOLARI, B; RATHS, S; SINGERKRUGER, B; RIEZMAN, H				ZANOLARI, B; RATHS, S; SINGERKRUGER, B; RIEZMAN, H			YEAST PHEROMONE RECEPTOR ENDOCYTOSIS AND HYPERPHOSPHORYLATION ARE INDEPENDENT OF G PROTEIN-MEDIATED SIGNAL TRANSDUCTION	CELL			English	Article							ALPHA-FACTOR RECEPTOR; BETA-ADRENERGIC-RECEPTOR; TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; SACCHAROMYCES-CEREVISIAE; PEPTIDE PHEROMONE; INSULIN-RECEPTOR; GAMMA-SUBUNITS; EGF RECEPTOR; S-CEREVISIAE	When alpha factor binds to the yeast alpha factor receptor a signal is transmitted via a tripartite G protein that prepares the cell for conjugation. As a result of alpha factor binding the receptor also undergoes a regulated internalization and hyperphosphorylation. Using cells that lack activity of this tripartite G protein, we show that G protein-mediated pheromone signal transduction is not necessary for regulation of receptor internalization or hyperphosphorylation. Therefore, the processes of signal transduction and down regulation can be uncoupled. We propose that binding of alpha factor to its receptor results in a receptor conformation change that permits receptor hyperphosphorylation and interaction with the endocytic machinery.			ZANOLARI, B (corresponding author), UNIV BASEL, BIOCTR, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DULIC V, 1990, J CELL SCI, V97, P517; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; GASSER SM, 1982, J BIOL CHEM, V257, P3034; HAGEN DC, 1984, J MOL BIOL, V178, P835, DOI 10.1016/0022-2836(84)90314-0; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HARI J, 1987, J BIOL CHEM, V262, P15341; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JENNESS DD, 1986, CELL, V46, P345, DOI 10.1016/0092-8674(86)90655-0; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUVARD D, 1983, EMBO J, V2, P1655, DOI 10.1002/j.1460-2075.1983.tb01640.x; Maniatis T., 1982, MOL CLONING; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cb.07.110191.003411; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SINGER B, 1990, J CELL BIOL, V110, P1911, DOI 10.1083/jcb.110.6.1911; Sprague G F Jr, 1990, Adv Genet, V27, P33; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; TERNYNCK T, 1976, ANN INST PASTEUR IMM, VC127, P197; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; ZANOLARI B, 1991, MOL CELL BIOL, V11, P5251, DOI 10.1128/MCB.11.10.5251	49	70	70	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 27	1992	71	5					755	763		10.1016/0092-8674(92)90552-N	http://dx.doi.org/10.1016/0092-8674(92)90552-N			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JZ633	1330324				2022-12-01	WOS:A1992JZ63300006
J	ANNAS, GJ				ANNAS, GJ			HEALTH WARNINGS, SMOKING, AND CANCER - THE CIPOLLONE CASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				GOSTIN LO, 1991, JAMA-J AM MED ASSOC, V266, P3178, DOI 10.1001/jama.266.22.3178; GREENHOUSE L, 1992, NY TIMES        0301, P1; GREENHOUSE L, 1992, NY TIMES        0505, pB10; SLADE J, 1992, JAMA-J AM MED ASSOC, V268, P524, DOI 10.1001/jama.268.4.524; 1989, DHHS CDC898411 DEP H; 1991, DHHS PHS9150213 DEP	6	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1992	327	22					1604	1607		10.1056/NEJM199211263272219	http://dx.doi.org/10.1056/NEJM199211263272219			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ432	1435897				2022-12-01	WOS:A1992JZ43200027
J	AUVINEN, M; PAASINEN, A; ANDERSSON, LC; HOLTTA, E				AUVINEN, M; PAASINEN, A; ANDERSSON, LC; HOLTTA, E			ORNITHINE DECARBOXYLASE ACTIVITY IS CRITICAL FOR CELL-TRANSFORMATION	NATURE			English	Article							ROUS-SARCOMA VIRUS; POLYAMINE METABOLISM; GENE-EXPRESSION; TYROSINE; GROWTH; PHOSPHORYLATION; AMPLIFICATION; INDUCTION; KINASES; DNA	THE enzyme ornithine decarboxylase is the key regulator of the synthesis of polyamines1-3 which are essential for cell proliferation4,5. Expression of this enzyme is transiently increased upon stimulation by growth factors1-3, but becomes constitutively activated during cell transformation induced by carcinogens6,7, viruses8-10 or oncogenes11-14. To test whether ornithine decarboxylase could be a common mediator of transformation and oncogenic itself, we transfected NIH3T3 cells with expression vectors carrying the complementary DNA encoding human ornithine decarboxylase in sense and antisense orientations. The increased expression of the enzyme (50-100-times endogenous levels) induced not only cell transformation, but also anchorage-independent growth in soft agar and increased tyrosine phosphorylation of a protein of M(r) 130K. Expression of ornithine decarboxylase antisense RNA was associated with an epithelioid morphology and reduced cell proliferation. Moreover, blocking the endogenous enzyme using specific inhibitor or synthesizing antisense RNA prevented transformation of rat fibroblasts by temperature-sensitive v-src oncogene. Our results imply that the gene encoding ornithine decarboxylase is a proto-oncogene central for regulation of cell growth and transformation.	UNIV HELSINKI,DEPT PATHOL,HAARTMANINKATU 3,SF-00290 HELSINKI 29,FINLAND	University of Helsinki								BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; CHANG BK, 1988, BIOCHEM BIOPH RES CO, V157, P264, DOI 10.1016/S0006-291X(88)80042-1; DON S, 1975, CANCER RES, V35, P3618; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERIKSON RL, 1980, J CELL BIOL, V87, P319, DOI 10.1083/jcb.87.2.319; GAZDAR AF, 1976, NATURE, V262, P696, DOI 10.1038/262696a0; GILMOUR SK, 1987, CANCER RES, V47, P1221; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HADDOX MK, 1980, CANCER RES, V40, P604; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; JANNE OA, 1984, ANN NY ACAD SCI, V438, P72, DOI 10.1111/j.1749-6632.1984.tb38277.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; POHJANPELTO P, 1981, NATURE, V293, P475, DOI 10.1038/293475a0; Sambrook J., 1989, MOL CLONING LAB MANU; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEILER N, 1990, CANCER RES, V50, P5077; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEGLICH C, 1985, SOMAT CELL MOLEC GEN, V11, P11, DOI 10.1007/BF01534730; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONIN PN, 1989, ONCOGENE, V4, P1117; YUSPA SH, 1976, NATURE, V262, P402, DOI 10.1038/262402a0	34	640	657	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					355	358		10.1038/360355a0	http://dx.doi.org/10.1038/360355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280331				2022-12-01	WOS:A1992JZ63000055
J	BORDER, WA; NOBLE, NA; YAMAMOTO, T; HARPER, JR; YAMAGUCHI, Y; PIERSCHBACHER, MD; RUOSLAHTI, E				BORDER, WA; NOBLE, NA; YAMAMOTO, T; HARPER, JR; YAMAGUCHI, Y; PIERSCHBACHER, MD; RUOSLAHTI, E			NATURAL INHIBITOR OF TRANSFORMING GROWTH-FACTOR-BETA PROTECTS AGAINST SCARRING IN EXPERIMENTAL KIDNEY-DISEASE	NATURE			English	Article							EXPERIMENTAL GLOMERULONEPHRITIS; EXTRACELLULAR-MATRIX; RAT GLOMERULUS; FIBRONECTIN	THE central pathological feature of human kidney disease that leads to kidney failure is the accumulation of extracellular matrix in glomeruli. Overexpression of transforming growth factor-beta (TGF-beta) underlies the accumulation of pathological matrix in experimental glomerulonephritis1. Administration of an antibody raised against TGF-beta to glomerulonephritic rats suppresses glomerular matrix production and prevents matrix accumulation in the injured glomeruli2. One of the matrix components induced by TGF-beta, the proteoglycan decorin, can bind TGF-beta and neutralize its biological activity3, so decorin may be a natural regulator of TGF-beta (refs 3, 4). We tested whether decorin could antagonize the action of TGF-beta in vivo using the experimental glomerulonephritis model1. We report here that administration of decorin inhibits the increased production of extracellular matrix and attenuates manifestations of disease, confirming our hypothesis. On the basis of our results, decorin may eventually prove to be clinically useful in diseases associated with overproduction of TGF-beta.	TELIOS PHARMACEUT INC,SAN DIEGO,CA 92121; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute	BORDER, WA (corresponding author), UNIV UTAH,SCH MED,DIV NEPHROL,SALT LAKE CITY,UT 84132, USA.							BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; BORDER WA, 1988, KIDNEY INT, V34, P419, DOI 10.1038/ki.1988.197; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BORDER WA, 1990, KIDNEY INT, V37, P289; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065; COURTOY PJ, 1980, J CELL BIOL, V87, P691, DOI 10.1083/jcb.87.3.691; COURTOY PJ, 1982, J HISTOCHEM CYTOCHEM, V30, P874, DOI 10.1177/30.9.7130672; GINSBERG JM, 1992, J CLIN INVEST, V90, P1; KULOZIK M, 1990, J CLIN INVEST, V86, P917, DOI 10.1172/JCI114793; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; OOMURA A, 1989, VIRCHOWS ARCH A, V415, P151, DOI 10.1007/BF00784353; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; ROBERTS AB, 1989, HDB EXPT PHARM, P419; WANG A, 1991, J BIOL CHEM, V266, P15598; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	16	958	1012	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					361	364		10.1038/360361a0	http://dx.doi.org/10.1038/360361a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280332				2022-12-01	WOS:A1992JZ63000057
J	DONALDSON, JG; FINAZZI, D; KLAUSNER, RD				DONALDSON, JG; FINAZZI, D; KLAUSNER, RD			BREFELDIN-A INHIBITS GOLGI MEMBRANE-CATALYZED EXCHANGE OF GUANINE-NUCLEOTIDE ONTO ARF PROTEIN	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; TRANSPORT; APPARATUS; VESICLES; COFACTOR; COMPLEX; COP	THE fungal metabolite brefeldin A is a powerful tool for investigating membrane traffic in eukaryotic cells1. The effects of brefeldin A on traffic are partly explained by its ability to prevent binding of cytosolic coat proteins onto membranes2-5. The non-clathrin coatomer complex6,7 binds reversibly to Golgi membranes in a GTP-controlled cycle8-10. The low-molecular-mass GTP-binding protein ADP-ribosylation factor (ARF), which also associates reversibly with Golgi membranes11,12, is required for coatomer binding13 and probably accounts for the control by guanine nucleotide of the coatomer-membrane interaction. Brefeldin A prevents the assembly of coatomer onto the membrane by inhibiting the GTP-dependent interaction of ARF with the Golgi membrane13, but the nature of this interaction has not been established. Here we demonstrate that Golgi membranes can specifically catalyse the exchange of GTP onto ARF and that brefeldin A prevents this function.			DONALDSON, JG (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.		finazzi, dario/GYV-1567-2022	Finazzi, Dario/0000-0001-5176-2839				BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKUCHI A, 1992, J BIOL CHEM, V267, P14611; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; ORCI L, 1991, CELL, V64, P1183; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	26	637	647	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					350	352		10.1038/360350a0	http://dx.doi.org/10.1038/360350a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448151				2022-12-01	WOS:A1992JZ63000053
J	DOUGAN, S; DINARDO, S				DOUGAN, S; DINARDO, S			DROSOPHILA WINGLESS GENERATES CELL TYPE DIVERSITY AMONG ENGRAILED EXPRESSING CELLS	NATURE			English	Article							SEGMENT-POLARITY GENE; LARVAL EPIDERMIS; FUSHI-TARAZU; ZYGOTIC LOCI; MELANOGASTER; EMBRYOS; PATTERN; CUTICLE; CHROMOSOME; PROTEIN	DURING embryogenesis, body pattern is established in a stepwise process1. After specification of the body axis, the embryo is subdivided into smaller units. Within these units, a diverse array of cell types is then generated. The subdivisions of the Drosophila embryo, called parasegments2, are defined by the interface between cells expressing the homeoprotein Engrailed and cells expressing the secreted protein Wingless3-5. We have examined the generation of cell-type diversity within parasegments by focusing on the choice of cell fate made by the engrailed (en)-expressing cells. These cells differentiate as one of two alternative cell types6. We report here that this choice is mediated by wingless (wg), in a function distinct from its early role maintaining en expression7,8. Thus, en cells exhibit different responses to the wg signal at different developmental stages. Early wg input stabilizes the subdivision of the body axis by maintaining en expression, whereas later input generates cell-type diversity.			DOUGAN, S (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.		Dougan, Scott/B-8416-2008	Dougan, Scott/0000-0003-0214-4772; DiNardo, Stephen/0000-0003-4131-5511				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1985, NATURE, V313, P639; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HILLMAN R, 1970, J MORPHOL, V131, P383, DOI 10.1002/jmor.1051310403; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KASSIS JA, 1991, GENETICS, V128, P751; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	22	111	111	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					347	350		10.1038/360347a0	http://dx.doi.org/10.1038/360347a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1280330				2022-12-01	WOS:A1992JZ63000052
J	FUJITA, I; TANAKA, K; ITO, M; CHENG, K				FUJITA, I; TANAKA, K; ITO, M; CHENG, K			COLUMNS FOR VISUAL FEATURES OF OBJECTS IN MONKEY INFEROTEMPORAL CORTEX	NATURE			English	Article							TEMPORAL CORTEX; MACAQUE MONKEY; ORGANIZATION; NEURONS; VISION	AT early stages of the mammalian visual cortex, neurons with similar stimulus selectivities are vertically arrayed through the thickness of the cortical sheet and clustered in patches or bands across the surface. This organization, referred to as a 'column', has been found with respect to one-dimensional stimulus parameters such as orientation of stimulus contours1, eye dominance of visual inputs1, and direction of stimulus motion2. It is unclear, however, whether information with extremely high dimensions, such as visual shape, is organized in a similar columnar fashion or in a different manner in the brain. Here we report that the anterior inferotemporal area of the monkey cortex, the final station of the visual cortical stream crucial for object recognition3-8, consists of columns, each containing cells responsive to similar visual features of objects.	RIKEN INST PHYS & CHEM RES,INFORMAT SCI LAB,WAKO,SAITAMA 35101,JAPAN; RES DEV CORP JAPAN,PRECURSORY RES EMBRYON SCI & TECHNOL,WAKO,SAITAMA 35101,JAPAN	RIKEN; Japan Science & Technology Agency (JST)	FUJITA, I (corresponding author), RIKEN INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL INFORMAT PROC LAB,WAKO,SAITAMA 35101,JAPAN.		Cheng, Kang/A-6448-2016; Tanaka, Keiji/N-5917-2015	Tanaka, Keiji/0000-0002-1910-3427				ABELES M, 1970, J NEUROPHYSIOL, V33, P172, DOI 10.1152/jn.1970.33.1.172; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V51, P16, DOI 10.1152/jn.1984.51.1.16; BAYLIS GC, 1987, J NEUROSCI, V7, P330; DEAN P, 1982, ANAL VISUAL BEHAVIOR, P587; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GOCHIN PM, 1991, EXPL BRAIN RES, V66, P170; Gross C. G., 1973, HDB SENSORY PHYSIOLO, P451; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IWAI E, 1985, VISION RES, V25, P425, DOI 10.1016/0042-6989(85)90068-9; IWAI E, 1988, BRAIN RES, V444, P397, DOI 10.1016/0006-8993(88)90955-9; KAAS JH, 1990, SIGNAL SENSE LOCAL G, P67; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; Mountcastle V., 1978, MINDFUL BRAIN, P7; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PERRETT DI, 1985, BEHAV BRAIN RES, V16, P153, DOI 10.1016/0166-4328(85)90089-0; SAITO H, 1986, J NEUROSCI, V6, P145; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	22	465	467	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					343	346		10.1038/360343a0	http://dx.doi.org/10.1038/360343a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448150				2022-12-01	WOS:A1992JZ63000051
J	GARRY, DJ; CAPLAN, AL; VAWTER, DE; KEARNEY, W				GARRY, DJ; CAPLAN, AL; VAWTER, DE; KEARNEY, W			ARE THERE REALLY ALTERNATIVES TO THE USE OF FETAL TISSUE FROM ELECTIVE ABORTIONS IN TRANSPLANTATION RESEARCH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ECTOPIC PREGNANCY; MANAGEMENT; FETUS; DEATH				GARRY, DJ (corresponding author), UNIV MINNESOTA,MINNEAPOLIS,MN 55455, USA.							BOUE J, 1975, TERATOLOGY, V12, P11, DOI 10.1002/tera.1420120103; BRENNER PF, 1980, JAMA-J AM MED ASSOC, V243, P673, DOI 10.1001/jama.243.7.673; BUDOWICK M, 1980, FERTIL STERIL, V34, P169; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; ELIAS S, 1981, AM J OBSTET GYNECOL, V141, P698, DOI 10.1016/S0002-9378(15)33314-7; FERNANDEZ H, 1988, OBSTET GYNECOL, V71, P171; FUNG CHK, 1990, JAMA-J AM MED ASSOC, V264, P34, DOI 10.1001/jama.1990.03450010038015; KALTER H, 1987, AM J OBSTET GYNECOL, V156, P1243, DOI 10.1016/0002-9378(87)90156-6; LEACH RE, 1989, J REPROD MED, V34, P324; MARTIN JN, 1988, OBSTET GYNECOL, V71, P549; MORRISON I, 1985, AM J OBSTET GYNECOL, V152, P975, DOI 10.1016/0002-9378(85)90542-3; Nederlof K P, 1990, MMWR CDC Surveill Summ, V39, P9; NOLAN K, 1990, TRANSPLANT P, V22, P1028; PITKIN RM, 1987, AM J OBSTET GYNECOL, V157, P583, DOI 10.1016/S0002-9378(87)80011-X; POLAND BJ, 1976, TERATOLOGY, V14, P315, DOI 10.1002/tera.1420140306; RAYBURN W, 1985, OBSTET GYNECOL, V65, P637; ROCHESTER D, 1987, RADIOLOGY, V165, P843, DOI 10.1148/radiology.165.3.3317509; RUBIN GL, 1983, JAMA-J AM MED ASSOC, V249, P1725, DOI 10.1001/jama.249.13.1725; SIMPSON JL, 1982, GENETICS OBSTETRICS, P125; STAFFORD PA, 1988, AM J OBSTET GYNECOL, V159, P485, DOI 10.1016/S0002-9378(88)80115-7; STRATFORD BF, 1970, AM J OBSTET GYNECOL, V107, P1223, DOI 10.1016/S0002-9378(15)30373-2; STROBINO BA, 1987, AM J OBSTET GYNECOL, V157, P1150, DOI 10.1016/S0002-9378(87)80280-6; THORNE E D, 1989, Fetal Therapy, V4, P37; VAWTER DE, 1992, J LAB CLIN MED, V120, P30; WINTER RM, 1988, MALFORMED FETUS STIL, P14; 1985, JAMA-J AM MED ASSOC, V254, P1891; 1987, BUREAU CENSUS, P74; 1984, SPONTANEOUS ABORTION, V8, P34	28	21	21	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 26	1992	327	22					1592	1595		10.1056/NEJM199211263272211	http://dx.doi.org/10.1056/NEJM199211263272211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ432	1435888				2022-12-01	WOS:A1992JZ43200011
J	GUO, HC; JARDETZKY, TS; GARRETT, TPJ; LANE, WS; STROMINGER, JL; WILEY, DC				GUO, HC; JARDETZKY, TS; GARRETT, TPJ; LANE, WS; STROMINGER, JL; WILEY, DC			DIFFERENT LENGTH PEPTIDES BIND TO HLA-AW68 SIMILARLY AT THEIR ENDS BUT BULGE OUT IN THE MIDDLE	NATURE			English	Article							SELF-PEPTIDES; VIRAL PEPTIDES; LYMPHOCYTES-T; ANTIGENS; CRYSTALLOGRAPHY; SPECIFICITY; MOLECULES; HLA-B27; PROTEIN; CHAINS	WE report here the determination and refinement to 1.9 angstrom resolution by X-ray cryo-crystallography the structure of HLA-Aw68. The averaged image from the collection of bound, endogenous peptides clearly shows the atomic structure at the first three and last two amino acids in the peptides but no connected electron density in between. This suggests that bound peptides, held at both ends, take alternative pathways and could be of different lengths by bulging out in the middle. Peptides eluted from HLA-Aw68 include peptides of 9, 10 and 11 amino acids, a direct indication of the length heterogeneity of tightly bound peptides. Peptide sequencing shows relatively conserved 'anchor' residues at position 2 and the carboxy-terminal residue. Conserved binding sites for the peptide N and C termini at the ends of the class I major histocompatibility complex binding groove are apparently dominant in producing the long half-lives of peptide binding and the peptide-dependent stabilization of the class I molecule's structure.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	GUO, HC (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.							BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; ROBBINS PA, 1989, J IMMUNOL, V143, P4098; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SILVER ML, 1991, NATURE, V350, P619, DOI 10.1038/350619a0; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANBLEEK GM, 1990, NATURE, V348, P213; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	31	403	443	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					364	366		10.1038/360364a0	http://dx.doi.org/10.1038/360364a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448153				2022-12-01	WOS:A1992JZ63000058
J	HALLENBERGER, S; BOSCH, V; ANGLIKER, H; SHAW, E; KLENK, HD; GARTEN, W				HALLENBERGER, S; BOSCH, V; ANGLIKER, H; SHAW, E; KLENK, HD; GARTEN, W			INHIBITION OF FURIN-MEDIATED CLEAVAGE ACTIVATION OF HIV-1 GLYCOPROTEIN-GP160	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; ENDOPROTEOLYTIC CLEAVAGE; BIOSYNTHESIS; PRECURSOR; TRANSPORT; GP160; CELLS	THE envelope glycoprotein of human immunodeficiency virus (HIV) initiates infection1 by mediating fusion of the viral envelope with the cell membrane. Fusion activity requires proteolytic cleavage of the gp160 protein into gp120 and gp41 at a site containing several arginine and lysine residues2. Activation at basic cleavage sites is observed with many membrane proteins of cellular and viral origin. We have recently found that the enzyme activating the haemagglutinin of fowl plague virus (FPV), an avian influenza virus, is furin3. Furin, a subtilisin-like eukaryotic endoprotease4-6, has a substrate specificity for the consensus amino-acid sequence Arg-X-Lys/Arg-Arg at the cleavage site7. We show here that the glycoprotein of HIV-1, which has the same protease recognition motif as the FPV haemagglutinin, is also activated by furin.	DEUTSCH KREBSFORSCHUNGSZENTRUM HEIDELBERG,INST ANGEW TUMORVIROL,W-6900 HEIDELBERG 1,GERMANY; FRIEDRICH MIESCHER INST BASEL,CH-4002 BASEL,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Miescher Institute for Biomedical Research	HALLENBERGER, S (corresponding author), UNIV MARBURG,INST VIROL,ROBERT KOCHSTR 17,W-3550 MARBURG,GERMANY.							BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; GARTEN W, 1989, VIROLOGY, V172, P25, DOI 10.1016/0042-6822(89)90103-7; GUO HG, 1990, VIROLOGY, V174, P217, DOI 10.1016/0042-6822(90)90070-8; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MERGENER K, 1992, VIROLOGY, V186, P25, DOI 10.1016/0042-6822(92)90058-W; MYERS G, 1991, HUMAN RETROVIRUSES A; OWENS RJ, 1989, J VIROL, V63, P978, DOI 10.1128/JVI.63.2.978-982.1989; PRINCE AM, 1988, P NATL ACAD SCI USA, V85, P6944, DOI 10.1073/pnas.85.18.6944; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; VONDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664; WILK T, 1992, VIRUS GENES, V6, P229, DOI 10.1007/BF01702562; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; WILLEY RL, 1991, VIROLOGY, V184, P319, DOI 10.1016/0042-6822(91)90848-6; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9368	22	483	501	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					358	361		10.1038/360358a0	http://dx.doi.org/10.1038/360358a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1360148				2022-12-01	WOS:A1992JZ63000056
J	HARRIS, LJ; LARSON, SB; HASEL, KW; DAY, J; GREENWOOD, A; MCPHERSON, A				HARRIS, LJ; LARSON, SB; HASEL, KW; DAY, J; GREENWOOD, A; MCPHERSON, A			THE 3-DIMENSIONAL STRUCTURE OF AN INTACT MONOCLONAL-ANTIBODY FOR CANINE LYMPHOMA	NATURE			English	Article							SEGMENTAL FLEXIBILITY; CRYSTALLOGRAPHIC REFINEMENT; IMMUNOELECTRON MICROSCOPY; ROTATIONAL FLEXIBILITY; IMMUNOGLOBULIN-G; ATOMIC MODELS; MOLECULE KOL; FC FRAGMENT; FAB REGIONS; RESOLUTION	CRYSTAL structures of Fab antibody fragments determined by X-ray diffraction characteristically feature four-domain, beta-barrel arrangements1-3. A human antibody Fc fragment has also been found to have four beta-barrel domains4. The structures of a few intact antibodies have been solved5-8: in two myeloma proteins, the flexible hinge regions that connect the Fc to the Fab segments were deleted5,6 so the molecules were non-functional, structurally restrained, T-shaped antibodies; a third antibody, Kol, had no hinge residues missing but the Fc region was sufficiently disordered that it was not possible to relate its disposition accurately with respect to the Fab components7,8. Here we report the structure at 3.5 angstrom resolution of an IgG2a antitumour monoclonal antibody which contains an intact hinge region and was solved in a triclinic crystal by molecular replacement using known Fc and Fab fragments. The antibody is asymmetric, reflecting its dynamic character. There are two local, apparently independent, dyads in the molecule. One relates the heavy chains in the Fc, the other relates the constant domains of the Fabs. The variable domains are not related by this 2-fold axis because of the different Fab elbow angles of 159-degrees and 143-degrees. The Fc has assumed an asymmetric, oblique orientation with respect to loosely tethered yet almost collinear Fabs. Our study enables the two antigen-binding segments as well as the Fc portion of a functional molecule to be visualized and illustrates the flexibility of these immune response proteins.	IMMUNOPHARMACEUT INC, SAN DIEGO, CA 92127 USA		HARRIS, LJ (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.							ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COLMAN PM, 1976, J MOL BIOL, V100, P257, DOI 10.1016/S0022-2836(76)80062-9; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DANGL JL, 1988, EMBO J, V7, P1989, DOI 10.1002/j.1460-2075.1988.tb03037.x; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; JEGLUM KA, 1989, 7TH P ACVIM FOR SAN, P922; JONES TA, 1982, COMPUTATIONAL CRYSTA, P307; LAMY J, 1985, BIOCHEMISTRY-US, V24, P5532, DOI 10.1021/bi00341a038; LARSON S, 1991, J MOL BIOL, V222, P17, DOI 10.1016/0022-2836(91)90731-K; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; RAJAN SS, 1983, MOL IMMUNOL, V20, P797; ROSALES C, 1988, CELL IMMUNOL, V115, P420, DOI 10.1016/0008-8749(88)90194-3; ROUX KH, 1984, EUR J IMMUNOL, V14, P459, DOI 10.1002/eji.1830140514; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHNEIDER WP, 1988, P NATL ACAD SCI USA, V85, P2509, DOI 10.1073/pnas.85.8.2509; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; SILVERTON EW, 1977, P NATL ACAD SCI USA, V74, P5140, DOI 10.1073/pnas.74.11.5140; STEPLEWSKI Z, 1987, CANCER IMMUNOL IMMUN, V24, P197; WADE RH, 1989, J MOL BIOL, V206, P349, DOI 10.1016/0022-2836(89)90484-1; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WRIGLEY NG, 1983, J MOL BIOL, V169, P771, DOI 10.1016/S0022-2836(83)80170-3	29	181	187	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					369	372		10.1038/360369a0	http://dx.doi.org/10.1038/360369a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448155				2022-12-01	WOS:A1992JZ63000060
J	HELMS, JB; ROTHMAN, JE				HELMS, JB; ROTHMAN, JE			INHIBITION BY BREFELDIN-A OF A GOLGI MEMBRANE ENZYME THAT CATALYZES EXCHANGE OF GUANINE-NUCLEOTIDE BOUND TO ARF	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING-PROTEIN; COATED VESICLES; TRANSPORT; COMPLEX; IDENTIFICATION; PURIFICATION; ENDOSOMES; COFACTOR; CELLS	A WIDE variety of membrane transformations important in intracellular transport are inhibited by the fungal metabolite brefeldin A (refs 1-4), implying that the target for this drug is central to the formation and maintenance of subcellular compartments5. Brefeldin A added to cells causes the rapid and reversible dissociation of a Golgi-associated peripheral membrane protein (M(r) 110,000)6 which was found to be identical to one of the subunits of the coat of Golgi-derived (non-clathrin) coated vesicles, beta-COP7,8, implying that brefeldin A prevents transport by blocking the assembly of coats and thus the budding of enclosed vesicles9. In addition to the coatomer (a cytosol-derived complex of seven polypeptide chains, one of which is beta-COP10), the non-clathrin (COP) coat of Golgi-derived vesicles contains stoichiometric amounts of a small (M(r) approximately 20,000) GTP-binding protein, the ADP-ribosylation factor (ARF)11. Binding of ARF to Golgi membranes is necessary before coatomer/beta-COP can bind these membranes (ref. 12; and D. J. Palmer et al., manuscript submitted), so the primary effect of brefeldin A seems to be on the reaction responsible for ARF binding. Indeed, like beta-COP, ARF is dissociated from the Golgi complex by treatment with brefeldin A and brefeldin A prevents ARF from associating in vitro13, but the mechanism of this action by brefeldin A has been unclear. Here we report the discovery of an enzyme in a Golgi-enriched fraction that catalyses guanine nucleotide (GDP-GTP) exchange on ARF-1 protein, and which is inhibited by brefeldin A. We suggest that activation of ARF proteins for membrane localization by compartmentalized exchange enzymes is in general the first committed step in membrane transformation pathways.			HELMS, JB (corresponding author), SLOAN KETTERING MEM CANC CTR, ROCKEFELLER RES LAB, PROGRAM CELLULAR BIOCHEM & BIOPHYS, NEW YORK, NY 10021 USA.							ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; RANDAZZO PA, 1991, SCIENCE, V254, P850, DOI 10.1126/science.1658935; RANDAZZO PA, 1992, SCIENCE, V257, P862, DOI 10.1126/science.1323875; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCLEICHER M, FEBS LETT, V200, P156; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	31	623	636	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					352	354		10.1038/360352a0	http://dx.doi.org/10.1038/360352a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448152				2022-12-01	WOS:A1992JZ63000054
J	MATZUK, MM; FINEGOLD, MJ; SU, JGJ; HSUEH, AJW; BRADLEY, A				MATZUK, MM; FINEGOLD, MJ; SU, JGJ; HSUEH, AJW; BRADLEY, A			ALPHA-INHIBIN IS A TUMOR-SUPPRESSOR GENE WITH GONADAL SPECIFICITY IN MICE	NATURE			English	Article							MESSENGER RIBONUCLEIC-ACIDS; BETA-B; CELL TUMORS; ACTIVIN-A; SUBUNIT; EXPRESSION; HORMONE; EMBRYOGENESIS; PROLIFERATION; PROTOONCOGENE	The inhibins are alpha:beta heterodimeric growth factors that are members of the transforming growth factor-beta family. To understand the physiological roles of the inhibins in mammalian development and reproduction, a targeted deletion of the alpha-inhibin gene was generated by homologous recombination in mouse embryonic stem cells. Mice homozygous for the null allele (inhibin-deficient) initially develop normally but every mouse ultimately develops mixed or incompletely differentiated gonadal stromal tumours either unilaterally or bilaterally. Inhibin is thus a critical negative regulator of gonadal stromal cell proliferation and the first secreted protein identified to have tumour-suppressor activity.	BAYLOR COLL MED, DEPT PATHOL, HOUSTON, TX 77030 USA; STANFORD UNIV, DEPT GYNECOL OBSTET, DIV REPROD BIOL, STANFORD, CA 94305 USA	Baylor College of Medicine; Stanford University	MATZUK, MM (corresponding author), BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA.			Bradley, Allan/0000-0002-2349-8839				BARTON DE, 1989, GENOMICS, V5, P91, DOI 10.1016/0888-7543(89)90091-8; BHASIN S, 1989, ENDOCRINOLOGY, V124, P987, DOI 10.1210/endo-124-2-987; BRADLEY A, 1992, BIO-TECHNOL, V10, P534, DOI 10.1038/nbt0592-534; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; Cate R.L, 1990, PEPTIDE GROWTH FACTO, P179; CHIN TW, 1991, CANCER RES, V51, P2101; DEJONG FH, 1990, J STEROID BIOCHEM, V37, P863, DOI 10.1016/0960-0760(90)90433-L; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FRANCHIMONT P, 1981, ACTA ENDOCRINOL-COP, V98, P312, DOI 10.1530/acta.0.0980312; GALWAY AB, 1990, J CLIN ENDOCR METAB, V71, P907, DOI 10.1210/jcem-71-4-907; GARDNER WU, 1955, CANCER RES, V15, P109; HAMILTON TC, 1992, CURR PROB CANCER, V16, P5, DOI 10.1016/0147-0272(92)90047-R; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; KEENE JL, 1989, MOL ENDOCRINOL, V3, P2011, DOI 10.1210/mend-3-12-2011; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; LAPPOHN RE, 1989, NEW ENGL J MED, V321, P790, DOI 10.1056/NEJM198909213211204; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHER JP, 1990, ENDOCRINOLOGY, V127, P3206, DOI 10.1210/endo-127-6-3206; MAYO KE, 1986, P NATL ACAD SCI USA, V83, P5849, DOI 10.1073/pnas.83.16.5849; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; O WS, 1989, MOL CELL ENDOCRINOL, V62, P307; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; PIQUETTE GN, 1990, BIOL REPROD, V43, P1050, DOI 10.1095/biolreprod43.6.1050; RABINOVICI J, 1990, J CLIN ENDOCR METAB, V71, P1396, DOI 10.1210/jcem-71-5-1396; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTS VJ, 1991, ENDOCRINOLOGY, V128, P3122, DOI 10.1210/endo-128-6-3122; Scully R. E, 1979, TUMORS OVARY MALDEVE; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; Teilum G., 1976, SPECIAL TUMORS OVARY; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUCHIYA E, 1992, CANCER RES, V52, P2478; TWOMBLY GH, 1949, CANCER, V2, P884, DOI 10.1002/1097-0142(194909)2:5<884::AID-CNCR2820020522>3.0.CO;2-2; VALE W, 1990, PEPTIDE GROWTH FACTO, V2, P211; VANDISSELEMILIANI FMF, 1989, ENDOCRINOLOGY, V125, P1899, DOI 10.1210/endo-125-4-1898; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOODRUFF TK, 1992, ENDOCRINOLOGY, V130, P871, DOI 10.1210/en.130.2.871; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196; YOUNG RH, 1987, SEMIN DIAGN PATHOL, V4, P342	45	822	873	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					313	319		10.1038/360313a0	http://dx.doi.org/10.1038/360313a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448148				2022-12-01	WOS:A1992JZ63000041
J	STODDARD, BL; STRONG, RK; ARROTT, A; FARBER, GK				STODDARD, BL; STRONG, RK; ARROTT, A; FARBER, GK			MIR FOR THE CRYSTALLOGRAPHERS MONEY	NATURE			English	Editorial Material							PROTEIN CRYSTAL-GROWTH; SPACE-SHUTTLE; MICROGRAVITY; DIFFUSION		CALTECH,DIV BIOL,PASADENA,CA 91125; PAYLOAD SYST,CAMBRIDGE,MA 02139; PENN STATE UNIV,DAVEY LAB 152,DEPT CHEM,UNIV PK,PA 16802; PENN STATE UNIV,DAVEY LAB 152,DEPT MOLEC & CELL BIOL,UNIV PK,PA 16802	California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	STODDARD, BL (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BAIRD JK, 1986, J CRYST GROWTH, V76, P694, DOI 10.1016/0022-0248(86)90186-7; DELUCAS L J, 1990, Methods (Orlando), V1, P105, DOI 10.1016/S1046-2023(05)80153-7; DeLucas L J, 1991, Adv Space Biol Med, V1, P249; DELUCAS LJ, 1989, SCIENCE, V246, P651, DOI 10.1126/science.2510297; DELUCAS LJ, 1986, J CRYST GROWTH, V76, P681, DOI 10.1016/0022-0248(86)90185-5; DELUCAS LJ, 1991, J CRYST GROWTH, V110, P302, DOI 10.1016/0022-0248(91)90899-G; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; LITTKE W, 1986, J CRYST GROWTH, V76, P663, DOI 10.1016/0022-0248(86)90183-1; LITTKE W, 1984, SCIENCE, V225, P203, DOI 10.1126/science.225.4658.203; PLASSLINK A, 1988, J APPL MICROGRAVITY, V3, P123; SHLICHTA PJ, 1986, J CRYST GROWTH, V76, P656, DOI 10.1016/0022-0248(86)90182-X; SIBILLE L, 1991, J CRYST GROWTH, V110, P72, DOI 10.1016/0022-0248(91)90868-6; STODDARD BL, 1991, J CRYST GROWTH, V110, P312, DOI 10.1016/0022-0248(91)90900-P; STRONG RK, 1992, J CRYST GROWTH, V119, P200, DOI 10.1016/0022-0248(92)90672-6	14	14	14	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 26	1992	360	6402					293	294		10.1038/360293a0	http://dx.doi.org/10.1038/360293a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448142				2022-12-01	WOS:A1992JZ63000025
J	ZATORRE, RJ; JONESGOTMAN, M; EVANS, AC; MEYER, E				ZATORRE, RJ; JONESGOTMAN, M; EVANS, AC; MEYER, E			FUNCTIONAL LOCALIZATION AND LATERALIZATION OF HUMAN OLFACTORY CORTEX	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; TEMPORAL LOBECTOMY; BLOOD-FLOW; DISCRIMINATION; DEFICITS	ANATOMICAL and physiological investigations in monkeys indicate that olfaction is subserved by several cortical regions1,2. But the areas implicated in the human olfactory system have not been definitively identified by functional criteria. Behavioural evidence3,4 has suggested that laterally specialized mechanisms for odour processing may exist, but the neuroanatomical substrate remains unknown. We used positron emission tomography to study the cortical representation of human olfactory processing by comparing cerebral blood flow changes evoked during olfactory stimulation with those of a control task. We report here significant cerebral blood flow increases at the junction of the inferior frontal and temporal lobes bilaterally, corresponding to the piriform cortex, and unilaterally, in the right orbitofrontal cortex. The results complement and extend previous data implicating these regions in olfactory processing, and indicate that a functional asymmetry exists in the human brain favouring the right orbitofrontal area in olfaction.	MCGILL UNIV, DEPT NEUROL & NEUROSURG, MONTREAL H3A 2B4, QUEBEC, CANADA	McGill University	ZATORRE, RJ (corresponding author), MONTREAL NEUROL HOSP & INST, MCCONNELL BRAIN IMAGING CTR, MONTREAL H3A 2B4, QUEBEC, CANADA.							EICHENBAUM H, 1983, BRAIN, V106, P459, DOI 10.1093/brain/106.2.459; ENGEN T, 1965, J EXP PSYCHOL, V70, P611, DOI 10.1037/h0022685; ESKENAZI B, 1983, NEUROPSYCHOLOGIA, V21, P365, DOI 10.1016/0028-3932(83)90023-4; ESKENAZI B, 1986, NEUROPSYCHOLOGIA, V24, P553, DOI 10.1016/0028-3932(86)90099-0; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Evans A C, 1992, Neuroimage, V1, P43, DOI 10.1016/1053-8119(92)90006-9; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; HABERLY LB, 1989, TRENDS NEUROSCI, V12, P258, DOI 10.1016/0166-2236(89)90025-8; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; Mesulam M-M., 1985, CEREB CORTEX, P179, DOI DOI 10.1007/978-1-4757-9619-3_5; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; PRICE JL, 1991, OLFACTION, P101; RAICHLE ME, 1983, J NUCL MED, V24, P790; TAKAGI SF, 1991, CEREB CORTEX, V9, P133; TALAIIRACH J, 1988, COPLANAR STEREOTAXIC; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZATORRE RJ, 1992, SCIENCE, V256, P846, DOI 10.1126/science.1589767; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71	23	527	530	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 26	1992	360	6402					339	340		10.1038/360339a0	http://dx.doi.org/10.1038/360339a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JZ630	1448149				2022-12-01	WOS:A1992JZ63000049
J	CLAMAN, HN				CLAMAN, HN			THE BIOLOGY OF THE IMMUNE-RESPONSE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL RECEPTOR				CLAMAN, HN (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, DENVER, CO 80262 USA.							ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BIENENSTOCK J, 1984, ANNU REV MED, V35, P49, DOI 10.1146/annurev.me.35.020184.000405; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Demaeyer E., 1988, INTERFERONS OTHER RE; FAIRCHILD RL, 1988, J IMMUNOL, V141, P3342; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1; JERNE NK, 1984, IMMUNOL REV, V79, P5, DOI 10.1111/j.1600-065X.1984.tb00484.x; MARRACK P, 1990, SCIENCE, V162, P493; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; SHORTER RG, 1982, ADV INTERNAL MED, V27, P247; STREILEIN JW, 1983, J INVEST DERMATOL, V80, pS12, DOI 10.1111/1523-1747.ep12536743; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2	14	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2790	2796		10.1001/jama.268.20.2790	http://dx.doi.org/10.1001/jama.268.20.2790			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433694				2022-12-01	WOS:A1992JY66800002
J	FINK, JN; KELLY, KJ				FINK, JN; KELLY, KJ			IMMUNOLOGICAL ASPECTS OF GRANULOMATOUS AND INTERSTITIAL LUNG-DISEASES AND OF CYSTIC-FIBROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; INDUCED PULMONARY-DISEASE; LOWER RESPIRATORY-TRACT; CHRONIC INFLAMMATION; IMMUNE-COMPLEXES; UNKNOWN CAUSE; TOMOGRAPHY; ACTIVATION; FARMERS; DRUGS				FINK, JN (corresponding author), MED COLL WISCONSIN,ALLERGY IMMUNOL,MILWAUKEE,WI 53226, USA.			Kelly, Kevin/0000-0002-2954-6117				BANKS DE, 1986, ANN ALLERGY, V57, P389; CANLIN A, 1988, J LEUKOCYTE BIOL, V43, P299; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; CARROLL JL, 1989, IMMUNOLOGIC DISORDER, P475; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P488; COOPER JAD, 1986, AM REV RESPIR DIS, V133, P321; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P235, DOI 10.1056/NEJM198401263100406; CRYSTAL RG, 1984, NEW ENGL J MED, V310, P154, DOI 10.1056/NEJM198401193100304; DOLL NJ, 1981, J ALLERGY CLIN IMMUN, V68, P281; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; FEW F, 1986, J CLIN IMMUNOL, V6, P225; FINK JN, 1991, IMMUNOLOGICALLY MEDI, P399; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; GHOSE T, 1974, CLIN ALLERGY, V4, P119, DOI 10.1111/j.1365-2222.1974.tb01369.x; Gocke D J, 1971, J Exp Med, V134, P330; GREENBERGER PA, 1988, ALLERGY PRINCIPLES P, P1219; Hamman L, 1935, Trans Am Clin Climatol Assoc, V51, P154; HASLAM P, 1975, CLIN EXP IMMUNOL, V20, P379; KASAHARA K, 1989, CLIN IMMUNOL IMMUNOP, V51, P419, DOI 10.1016/0090-1229(89)90040-8; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KRAUSEHOOYMAN L, 1983, INT ARCH ALLER A IMM, V71, P245, DOI 10.1159/000233398; KUNKEL SL, 1984, J CLIN INVEST, V74, P514, DOI 10.1172/JCI111449; Liebow A, 1969, FRONTIERS PULMONARY, P102; LYNCH JP, 1991, IMMUNOLOGICALLY MEDI, P189; MARX JJ, 1990, AM J IND MED, V18, P263, DOI 10.1002/ajim.4700180304; MARX JJ, 1973, J IMMUNOL, V111, P590; MOSS RB, 1986, AM REV RESPIR DIS, V133, P648; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1206; NEELD DA, 1990, AM REV RESPIR DIS, V142, P1200, DOI 10.1164/ajrccm/142.5.1200; OLIVEIRA DBG, 1989, KIDNEY INT, V35, P923, DOI 10.1038/ki.1989.76; Parrillo J E, 1977, Trans Assoc Am Physicians, V90, P135; Pepys J, 1969, HYPERSENSITIVITY DIS; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSSMAN MD, 1991, IMMUNOLOGICALLY MEDI, P217; SALVAGGIO JE, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P435; SANS J, 1988, J BIOL CHEM, V263, P1374; Stankus RP, 1988, INTERSTITIAL LUNG DI, P111; WILSON MR, 1977, J ALLERGY CLIN IMMUN, V60, P218, DOI 10.1016/0091-6749(77)90133-6	38	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2874	2881		10.1001/jama.268.20.2874	http://dx.doi.org/10.1001/jama.268.20.2874			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433703				2022-12-01	WOS:A1992JY66800011
J	VALENTINE, MD				VALENTINE, MD			ANAPHYLAXIS AND STINGING INSECT HYPERSENSITIVITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IDIOPATHIC ANAPHYLAXIS; IMMUNOTHERAPY; VENOM				VALENTINE, MD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DIV ALLERGY, BALTIMORE, MD 21205 USA.							DESHAZO RD, 1990, NEW ENGL J MED, V323, P462, DOI 10.1056/NEJM199008163230707; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; GOLDEN DBK, 1983, J CLIN IMMUNOASSAY, V6, P172; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Portier P, 1902, CR SEANC SOC BIOL, V54, P170; Schick B., 1905, SERUM SICKNESS; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V73, P699, DOI 10.1016/0091-6749(84)90309-9; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1979, HDB SERIES CLIN LA F, VF, P71; WIGGINS CA, 1988, J ALLERGY CLIN IMMUN, V82, P849, DOI 10.1016/0091-6749(88)90089-9; WONG S, 1991, ANN INTERN MED, V114, P133, DOI 10.7326/0003-4819-114-2-133	15	24	24	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1992	268	20					2830	2833		10.1001/jama.268.20.2830	http://dx.doi.org/10.1001/jama.268.20.2830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY668	1433697				2022-12-01	WOS:A1992JY66800005
J	HUHTASAARI, F; ASPLUND, K; LUNDBERG, V; STEGMAYR, B; WESTER, PO				HUHTASAARI, F; ASPLUND, K; LUNDBERG, V; STEGMAYR, B; WESTER, PO			TOBACCO AND MYOCARDIAL-INFARCTION - IS SNUFF LESS DANGEROUS THAN CIGARETTES	BRITISH MEDICAL JOURNAL			English	Article							SMOKELESS TOBACCO; RISK-FACTORS; NICOTINE; SMOKING; CONSUMPTION; MECHANISMS; ABSORPTION; PATTERNS; CANCER	Objective-To estimate the risk of myocardial infarction in snuff users, cigarette smokers, and non-tobacco users in northern Sweden, where using snuff is traditional. Design-Case-control study. Setting-Northern Sweden. Subjects-All 35-64 year old men who had had a first myocardial infarction and a population based sample of 35-64 year old men who had not had an infarction in the same geographical area. Main outcome measure-Tobacco consumption (regular snuff dipping, regular cigarette smoking, non-tobacco use) and risk of acute myocardial infarction. Results-59 of 585 (10%) patients who had a first myocardial infarction and 87 of 589 (15%) randomly selected men without myocardial infarction were non-smokers who used snuff daily. The age adjusted odds ratio for myocardial infarction was 0.89 (95% confidence interval 0.62 to 1.29) for exposure to snuff and 1.87 (1.40 to 2.48) for cigarette smoking compared with non-tobacco users, showing an increased risk in smokers but not in snuff dippers. Regular cigarette smokers had a significantly higher risk of myocardial infarction than regular snuff dippers (age adjusted odds ratio 2.09; 1.39 to 3.15). Smoking, but not snuff dipping, predicted myocardial infarction in a multiple logistic regression model that included age and level of education. Conclusions-In middle aged men snuff dipping is associated with a lower risk of myocardial infarction than cigarette smoking.	UMEA UNIV HOSP,DEPT MED,S-90185 UMEA,SWEDEN; LULEA BODEN HOSP,DEPT MED,S-95128 LULEA,SWEDEN; KALIX HOSP,DEPT MED,S-95282 KALIX,SWEDEN	Umea University								ASPLUND K, IN PRESS CARDIOVASC; BENOWITZ NL, 1988, CLIN PHARMACOL THER, V44, P23, DOI 10.1038/clpt.1988.107; BOLINDER G, 1992, European Heart Journal, V13, P393; BOLINDER G, 1988, LAKARTIDNINGEN, V85, P1248; BROCKIE RE, 1990, SEMIN RESPIR MED, V11, P5, DOI 10.1055/s-2007-1006191; BROWNSON RC, 1990, PREV MED, V19, P170, DOI 10.1016/0091-7435(90)90018-F; CHRISTEN AG, 1987, AVIAT SPACE ENVIR MD, V58, P97; CONNOLLY GN, 1986, NEW ENGL J MED, V314, P1020, DOI 10.1056/NEJM198604173141605; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; ELIASSON M, 1991, J INTERN MED, V230, P17, DOI 10.1111/j.1365-2796.1991.tb00401.x; ERNSTER VL, 1989, NATL CANCER I MONOGR, V8, P87; GLOVER ED, 1989, AM J PUBLIC HEALTH, V79, P207, DOI 10.2105/AJPH.79.2.207; HATSUKAMI DK, 1987, CLIN PHARMACOL THER, V41, P103, DOI 10.1038/clpt.1987.17; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; NORDGREN P, 1990, BRIT J ADDICT, V85, P1107; ORLANDI MA, 1989, NCI MONOGRAPHS, V8, P5; Peterson J S, 1990, Arctic Med Res, V49 Suppl 2, P32; ROBERTSON D, 1988, AM HEART J, V115, P258, DOI 10.1016/0002-8703(88)90646-1; RUSSELL MAH, 1985, LANCET, V2, P1370; SCHEI E, 1990, PREV MED, V19, P667, DOI 10.1016/0091-7435(90)90063-P; SCHROEDER KL, 1988, ADDICT BEHAV, V13, P395, DOI 10.1016/0306-4603(88)90047-0; SCHROEDER KL, 1985, NEW ENGL J MED, V312, P919; SQUIRES WG, 1984, PREV MED, V13, P195, DOI 10.1016/0091-7435(84)90051-3; STAVENOW L, 1988, ARTERY, V15, P94; STEGMAYR B, 1991, HYGIEA, V100, P252; VENITT S, 1990, BRIT J ADDICT, V85, P1100; WEST R, 1990, BRIT J ADDICT, V85, P1097; WILKINSON L, 1989, SYSTAT SYSTEM STATIS; WILLIAMS RR, 1977, JNCI-J NATL CANCER I, V58, P525, DOI 10.1093/jnci/58.3.525; WRIGHT BM, 1970, LANCET, V1, P337; 1989, WORLD HLTH STATISTIC, P27; 1986, HLTH CONSEQUENCES US; 1976, PUBLIC HLTH EUROPE, V5; 1988, WHO TECH REPORTS SER, V773	35	122	124	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1252	1256		10.1136/bmj.305.6864.1252	http://dx.doi.org/10.1136/bmj.305.6864.1252			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477567	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JZ52100021
J	OCALLAGHAN, E; GIBSON, T; COLOHAN, HA; BUCKLEY, P; WALSHE, DG; LARKIN, C; WADDINGTON, JL				OCALLAGHAN, E; GIBSON, T; COLOHAN, HA; BUCKLEY, P; WALSHE, DG; LARKIN, C; WADDINGTON, JL			RISK OF SCHIZOPHRENIA IN ADULTS BORN AFTER OBSTETRIC COMPLICATIONS AND THEIR ASSOCIATION WITH EARLY ONSET OF ILLNESS - A CONTROLLED-STUDY	BRITISH MEDICAL JOURNAL			English	Article							PERINATAL COMPLICATIONS; PREGNANCY; DISORDER; PSYCHOSIS; DELIVERY; BIRTH; LIFE	Objective-To determine whether obstetric complications occur to excess in the early histories of individuals who go on to develop schizophrenia when compared with controls, and to seek clinical correlates of any such excess. Design-Contemporaneous maternity hospital records were identified and extracted verbatim, and these extracts evaluated for obstetric complications by two independent assessors who were blind to subjects' status. Subjects-65 patients having an ICD-9 diagnosis of schizophrenia, the records of the previous same sex live birth being deemed to be those of a control subject. Main outcome measure-Presence of one or more obstetric complications recorded in maternity notes of patients and controls. Results-When two recognised scales for specifying obstetric complications were used the patients with schizophrenia were significantly more likely than controls to have experienced at least one obstetric complication (odds ratio 2.44, 95% confidence interval 1.08 to 6.03). Patients also showed a greater number and severity of and total score for obstetric complications, fetal distress being the only complication to occur to significant individual excess (present in five (8%) patients, absent in controls). There was a marked sex effect, male patients being more vulnerable (odds ratio 4.24, 1.39 to 12.90) to such complications. Obstetric complications in patients were unrelated to family history or season of birth but were associated with a significantly younger age at onset of illness (mean difference -4.5 years, -1.2 to -7.8 years). Conclusions-Patients with schizophrenia, particularly males, have an excess of obstetric complications in their early developmental histories, and such complications are associated with a younger age at onset of their disease. Though the data are not conclusive, they also suggest that obstetric complications may be secondary to yet earlier events.	ST JOHN GOD PSYCHIAT SERV,BLACKROCK,DUBLIN,IRELAND; ROYAL COLL SURG IRELAND,DUBLIN 2,IRELAND	Royal College of Surgeons - Ireland								CHAMBERLAIN GVP, 1987, DEWHURSTS TXB OBSTET, P101; CHITKARA B, 1988, BRIT J PSYCHIAT, V152, P391, DOI 10.1192/bjp.152.3.391; DONE DJ, 1991, BRIT MED J, V302, P1576, DOI 10.1136/bmj.302.6792.1576; EAGLES JM, 1990, LANCET, V335, P1139, DOI 10.1016/0140-6736(90)91136-X; GARDNER MJ, 1989, BRIT MED J; GOLDSTEIN JM, 1990, SCHIZOPHRENIA BULL, V16, P179, DOI 10.1093/schbul/16.2.179; JACOBSEN B, 1980, ACTA PSYCHIAT SCAND, V62, P337, DOI 10.1111/j.1600-0447.1980.tb07709.x; KERWIN R, 1991, BRIT MED J, V303, P188, DOI 10.1136/bmj.303.6795.188-b; LANE EA, 1966, J PSYCHOL, V64, P227, DOI 10.1080/00223980.1966.10544847; LEWIS S, 1991, BRIT MED J, V303, P582, DOI 10.1136/bmj.303.6802.582-b; LEWIS SW, 1987, J PSYCHIAT RES, V21, P413, DOI 10.1016/0022-3956(87)90088-4; Lewis SW, 1989, SCHIZOPHRENIA, P56; McNeil TF, 1978, NATURE SCHIZOPHRENIA, P401; MURRAY RM, 1991, CONCEPTS OF MENTAL DISORDER, P48; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; OCALLAGHAN E, 1991, BRIT J PSYCHIAT, V158, P764, DOI 10.1192/bjp.158.6.764; OCALLAGHAN E, 1991, AM J PSYCHIAT, V148, P479; OCALLAGHAN E, 1990, BRIT J PSYCHIAT, V157, P578, DOI 10.1192/bjp.157.4.578; OCALLAGHAN E, 1990, PSYCHOL MED, V20, P89, DOI 10.1017/S0033291700013258; PARNAS J, 1982, BRIT J PSYCHIAT, V140, P416, DOI 10.1192/bjp.140.4.416; POLLACK M, 1966, AM J ORTHOPSYCHIAT, V36, P510, DOI 10.1111/j.1939-0025.1966.tb02394.x; POLLACK M, 1968, AM J ORTHOPSYCHIAT, V38, P94, DOI 10.1111/j.1939-0025.1968.tb00560.x; WADDINGTON JL, 1991, ARCH GEN PSYCHIAT, V48, P271; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; WILLIAMS MA, 1991, OBSTET GYNECOL, V78, P14; WOERNER MG, 1973, ACTA PSYCHIAT SCAND, V49, P712, DOI 10.1111/j.1600-0447.1973.tb04460.x; 1978, WHO ICD9; 1987, CENSUS 86	28	160	162	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1256	1259		10.1136/bmj.305.6864.1256	http://dx.doi.org/10.1136/bmj.305.6864.1256			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JZ521	1477568	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JZ52100022
J	PARKER, L; CRAFT, AW; DALE, G; BELL, S; COLE, M; MCGILL, AC; SEVIOUR, JA; SMITH, J				PARKER, L; CRAFT, AW; DALE, G; BELL, S; COLE, M; MCGILL, AC; SEVIOUR, JA; SMITH, J			SCREENING FOR NEUROBLASTOMA IN THE NORTH OF ENGLAND	BRITISH MEDICAL JOURNAL			English	Article							NEURO-BLASTOMA; CHILDHOOD NEUROBLASTOMA; SAPPORO CITY; JAPAN	Objective-To determine the feasibility of establishing a system of screening for neuroblastoma. Design-Prospective study of mass screening in four clearly defined geographical areas. Setting-Four health districts of the Northern region of England. Subjects-20 829 babies aged 6 months, 92% of target population. Interventions-Collection of urine on filter paper for analysis of content of homovanillic and vanillylmandelic acid in relation to urinary creatinine concentrations. Main outcome measures-Derivation of reference range. Identification of babies with homovanillic or vanillylmandelic acid >3 SD above the mean (positive cases). Investigation of positive cases for evidence of neuroblastoma. Results-The upper limit of normal (3 SD above the mean) for vanillylmandelic acid was 15 mumol/mmol creatinine and for homovanillic acid 24 mumol/mmol creatinine. Of the 20 829 babies screened, 2537 (12.2%) required a second sample to be taken because the first sample was inadequate. Of these, 527 (2.5%) provided a liquid urine specimen and 10 (0.04%) had positive results for neuroblastoma. Two of them had neuroblastoma (true positives) and eight did not (false positives). A further three children from the cohort were subsequently found to have neuroblastoma; they had raised homovanillic acid or vanillylmandelic acid values, or both, but screened negative at 6 months. Conclusions-Screening for neuroblastoma is possible in the health care system of the United Kingdom. Evaluation of the efficacy of screening in reducing the mortality from neuroblastoma requires a controlled trial.	NEWCASTLE GEN HOSP,DEPT CLIN BIOCHEM,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	PARKER, L (corresponding author), MED SCH NEWCASTLE UPON TYNE,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.			PARKER, LOUISE/0000-0002-5188-8113				BRODEUR GM, 1987, CANCER RES, V47, P4248; COLE M, 1992, MED PEDIATR ONCOL, V20, P84, DOI 10.1002/mpo.2950200119; COLE M, IN PRESS ARCH DIS CH; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; DALE G, 1988, ANN CLIN BIOCHEM, V25, P233, DOI 10.1177/000456328802500306; EVANS AE, 1987, CANCER, V59, P1853, DOI 10.1002/1097-0142(19870601)59:11<1853::AID-CNCR2820591102>3.0.CO;2-F; HANAWA Y, 1990, MED PEDIATR ONCOL, V18, P472, DOI 10.1002/mpo.2950180607; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MIZUTA M, 1988, JPN J PUBLIC HLTH, V35, P179; NISHI M, 1990, J PEDIATR SURG, V25, P545, DOI 10.1016/0022-3468(90)90570-Y; NISHI M, 1987, CANCER, V60, P433, DOI 10.1002/1097-0142(19870801)60:3<433::AID-CNCR2820600326>3.0.CO;2-H; NISHI M, 1989, PEDIATR RES, V26, P603, DOI 10.1203/00006450-198912000-00018; PARKER L, 1991, CANCER SCREENING, P337; RUTHVEN CRJ, 1979, CHEM DIAGNOSIS DISEA, P1239; SAWADA T, 1984, LANCET, V2, P271; SAWADA T, 1991, CANCER SCREENING, P337; SEVIOUR JA, 1988, J CHROMATOGR-BIOMED, V432, P273, DOI 10.1016/S0378-4347(00)80652-0; SHAFFORD EA, 1984, J CLIN ONCOL, V2, P742, DOI 10.1200/JCO.1984.2.7.742; TUCHMAN M, 1990, PEDIATRICS, V86, P765; TUCHMAN M, 1987, PEDIATRICS, V79, P203	20	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1260	1263		10.1136/bmj.305.6864.1260	http://dx.doi.org/10.1136/bmj.305.6864.1260			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1303649	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992JZ52100023
J	RUSHFORTH, JA; WILSON, N				RUSHFORTH, JA; WILSON, N			SHOULD GENERAL-PRACTITIONERS HAVE ACCESS TO PEDIATRIC CARDIOLOGISTS	BRITISH MEDICAL JOURNAL			English	Article									KILLINGBECK HOSP,LEEDS LS14 6UH,ENGLAND		RUSHFORTH, JA (corresponding author), GEN INFIRM,DEPT PAEDIATR,LEEDS LS2 9NS,ENGLAND.							NEWBURGER JW, 1983, NEW ENGL J MED, V308, P61, DOI 10.1056/NEJM198301133080201; WILSON N, 1986, RECENT ADV PAEDIATRI, V8, P87	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1264	1265		10.1136/bmj.305.6864.1264	http://dx.doi.org/10.1136/bmj.305.6864.1264			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477570	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JZ52100025
J	SAUNDERS, CJP				SAUNDERS, CJP			DRIVING AND DIABETES-MELLITUS	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,ACAD UNIT PUBL HLTH MED,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds								DAVIS TG, 1973, OKLAHOMA STATE MED A, V66, P322; DEKLERK NH, 1983, J EPIDEMIOL COMMUN H, V37, P232, DOI 10.1136/jech.37.3.232; FRIER BM, 1980, LANCET, V1, P1232; STEEL JM, 1981, LANCET, V2, P354; WILLIAMS DRR, 1990, DIABETIC MED, V7, P74, DOI 10.1111/j.1464-5491.1990.tb01312.x	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 21	1992	305	6864					1265	1265		10.1136/bmj.305.6864.1265	http://dx.doi.org/10.1136/bmj.305.6864.1265			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477571	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JZ52100026
J	SCHOLEFIELD, JH; HICKSON, WGE; SMITH, JHF; ROGERS, K; SHARP, F				SCHOLEFIELD, JH; HICKSON, WGE; SMITH, JHF; ROGERS, K; SHARP, F			ANAL INTRAEPITHELIAL NEOPLASIA - PART OF A MULTIFOCAL DISEASE PROCESS	LANCET			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN-REACTION; PREVALENCE; CERVIX; WARTS; WOMEN	Invasive carcinomas of the anogenital epithelium share a common aetiological facto-human papillomavirus (HPV) type 16. Although genital intraepithelial neoplasia may be multifocal, there have been no studies of the prevalence of anal intraepithelial neoplasia in women with intraepithelial neoplasia of the genital tract. We tested the hypothesis that women with high-grade cervical intraepithelial neoplasia are at higher risk of disease in the anus than are control women of similar age with no history of anogenital neoplasia. 29 (19%) of 152 women with cervical intraepithelial neoplasia grade III had histological evidence of anal intraepithelial neoplasia. Of the 29 patients, 11 had grade III anal lesions; 2 of those women had concomitant invasive anal squamous-cell carcinomas. Only 7% (8/115) women with high-grade lesions of the cervix alone had evidence of anal intraepithelial neoplasia; by contrast, 57% (21/37) of those with more than one focus of intraepithelial neoplasia (cervix plus vulva, vagina, or both) had anal lesions. HPV 16 DNA was identified in 18 (51%) of 35 anal biopsy samples in the study group. No evidence of anal intraepithelial neoplasia was found in the control group (50 women), although 2 patients had grade I cervical lesions. HPV 16 DNA was identified in 12 (24%) of biopsy samples from the cervix and 7 (14%) from the anus in the control group; all 7 women with anal HPV16 had concomitant cervical infection. The role of anal examination in the assessment of women with any focus of genital intraepithelial neoplasia requires further investigation.	NO GEN HOSP,CTR CLIN SCI,DEPT GYNAECOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT HISTOPATHOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	Northern General Hospital; Northern General Hospital	SCHOLEFIELD, JH (corresponding author), NO GEN HOSP,CTR CLIN SCI,DEPT SURG,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							Bancroft JD., 1982, THEORY PRACTICE HIST, P362; CAMPION MJ, 1986, LANCET, V2, P237; CORNELISSEN MTE, 1989, J GEN VIROL, V70, P2555, DOI 10.1099/0022-1317-70-10-2555; GOORNEY BP, 1987, GENITOURIN MED, V63, P216; HAUSEN HZ, 1987, MED ONCOL TUMOR PHAR, V4, P187; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PALMER JG, 1989, DIS COLON RECTUM, V32, P1016, DOI 10.1007/BF02553872; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1991, THESIS U LIVERPOOL; SHARP F, 1991, TEXT ATLAS INTEGRATE, P186; SONNEX C, 1991, BRIT MED J, V303, P1243, DOI 10.1136/bmj.303.6812.1243; WATERHOUSE J, 1982, CANCER INCIDENCE 5 C, P675; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14	16	98	101	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1271	1273		10.1016/0140-6736(92)92961-E	http://dx.doi.org/10.1016/0140-6736(92)92961-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359331				2022-12-01	WOS:A1992JZ23700015
J	SMITH, R				SMITH, R			USING A MOCK TRIAL TO MAKE A DIFFICULT CLINICAL DECISION	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Many clinical decisions have to be taken with inadequate scientific information. Reaching a consensus among experts has been tried as one response to this problem. Another, described here, is to use legal process to dissect a difficult question. In this case a mock trial-using barristers, expert witnesses, and a jury-was conducted on whether bone marrow transplantation should be offered to all children with symptomatic sickle cell disease. Transplantation seems to offer about a 90% cure rate for a condition that may kill 15% of children before they reach 20. But transplantation carries a 10% risk of death or severe disability, and doctors cannot predict which children will suffer severly from their sickle cell disease and which will suffer little or nothing. The jury eventually reached a majority decision that transplantation should not be offered now to all symptomatic children.										CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; DAVIES SC, 1992, IN PRESS SICKLE  JUN; SMITH R, 1992, J MED ETHICS, V18, P117, DOI 10.1136/jme.18.3.117; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; VERMYLEN C, 1991, ARCH DIS CHILD, V66, P1195, DOI 10.1136/adc.66.10.1195; VERMYLEN C, 1988, LANCET, V1, P1427	6	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 21	1992	305	6864					1284	1287		10.1136/bmj.305.6864.1284	http://dx.doi.org/10.1136/bmj.305.6864.1284			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ521	1477577	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JZ52100033
J	TAI, YT; BUT, PPH; YOUNG, K; LAU, CP				TAI, YT; BUT, PPH; YOUNG, K; LAU, CP			CARDIOTOXICITY AFTER ACCIDENTAL HERB-INDUCED ACONITE POISONING	LANCET			English	Note								Aconitine and its related alkaloids are known cardiotoxins with no therapeutic role in modern western medicine. The rootstocks of Aconitum plants, which contain aconite alkaloids, have been common components of Chinese herbal recipes. We have documented life-threatening intoxication in 17 Chinese subjects after accidental herb-induced aconite poisoning. All patients developed symptoms of aconite toxicity within 2 h of herb ingestion. Most developed tachyarrhythmias, including ventricular tachycardia and fibrillation from which 2 patients died. Toxicological evaluation revealed that aconites from the Aconitum rootstocks were the only plausible casual factor for intoxication. These cases point to the need for strict surveillance of herbal substances with low safety margins.	UNIV HONG KONG,DEPT MED,HONG KONG,HONG KONG; CHINESE UNIV HONG KONG,CHINESE MED MAT RES CTR,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT ANAESTHESIA & INTENS CARE,SHA TIN,HONG KONG; CHINESE UNIV HONG KONG,DEPT BIOL,SHA TIN,HONG KONG	University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong								BISSET NG, 1981, J ETHNOPHARMACOL, V4, P247, DOI 10.1016/0378-8741(81)90001-5; CHANG HM, 1987, PHARM APPLICATIONS C, V1; CHANG HM, 1987, PHARM APPLICATIONS C, V2; FATOVICH DM, 1992, ANN EMERG MED, V21, P309, DOI 10.1016/S0196-0644(05)80894-7; FIDDES FS, 1958, BRIT MED J, V2, P779, DOI 10.1136/bmj.2.5099.779; Hartung EF, 1930, J AMER MED ASSOC, V95, P1265, DOI 10.1001/jama.1930.27210170005010c; KAPOOR SC, 1969, INDIAN HEART J, V25, P329; PEPPER K, 1967, PFLUGGERS ARCH, V296, P328; REYNOLDS JEF, 1989, MARTINDALE EXTRA PHA, P1538; 1990, PHARMACOPOEIA PEOPLE, V1, P26; 1983, BRIT HERBAL PHARMACO, P12	11	148	153	3	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 21	1992	340	8830					1254	1256		10.1016/0140-6736(92)92951-B	http://dx.doi.org/10.1016/0140-6736(92)92951-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JZ237	1359321				2022-12-01	WOS:A1992JZ23700005
J	ARONDEL, V; LEMIEUX, B; HWANG, I; GIBSON, S; GOODMAN, HM; SOMERVILLE, CR				ARONDEL, V; LEMIEUX, B; HWANG, I; GIBSON, S; GOODMAN, HM; SOMERVILLE, CR			MAP-BASED CLONING OF A GENE CONTROLLING OMEGA-3-FATTY-ACID DESATURATION IN ARABIDOPSIS	SCIENCE			English	Article							POLYMORPHISM LINKAGE MAP; THALIANA; DNA; METABOLISM; MUTANTS; PLASMID; PLANTS	A gene from the flowering plant Arabidopsis thaliana that encodes an omega-3 desaturase was cloned on the basis of the genetic map position of a mutation affecting membrane and storage lipid fatty acid composition. Yeast artificial chromosomes covering the genetic locus were identified and used to probe a seed complementary DNA library. A complementary DNA clone for the desaturase was identified and introduced into roots of both wild-type and mutant plants by Ti plasmid-mediated transformation. Transgenic tissues of both mutant and wild-type plants had significantly increased amounts of the fatty acid produced by this desaturase.	MICHIGAN STATE UNIV, US DOE, PLANT RES LAB, E LANSING, MI 48824 USA; YORK UNIV, DEPT BIOL, N YORK M3J 1P3, ONTARIO, CANADA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA	Michigan State University; United States Department of Energy (DOE); York University - Canada; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Somerville, Christopher R/A-4048-2009	Somerville, Christopher R/0000-0003-4647-0094				BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BROWSE J, COMMUNICATION; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; MARTINEZZAPATER J, UNPUB; MOORE L, 1979, PLASMID, V2, P617, DOI 10.1016/0147-619X(79)90059-3; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NIYOGI KK, 1992, PLANT CELL, V4, P721, DOI 10.1105/tpc.4.6.721; OWENS LD, 1985, PLANT PHYSIOL, V77, P87, DOI 10.1104/pp.77.1.87; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; QUINN PJ, 1988, SYM SOC EXP BIOL, V42, P237; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SOMERVILLE C, 1991, SCIENCE, V252, P80, DOI 10.1126/science.252.5002.80; STEPONKUS PL, 1990, PHILOS T ROY SOC B, V326, P571, DOI 10.1098/rstb.1990.0032; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; WADA H, 1990, NATURE, V347, P200, DOI 10.1038/347200a0; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501	24	386	470	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1353	1355		10.1126/science.1455229	http://dx.doi.org/10.1126/science.1455229			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455229				2022-12-01	WOS:A1992JY95800037
J	BEVILACQUA, PC; KIERZEK, R; JOHNSON, KA; TURNER, DH				BEVILACQUA, PC; KIERZEK, R; JOHNSON, KA; TURNER, DH			DYNAMICS OF RIBOZYME BINDING OF SUBSTRATE REVEALED BY FLUORESCENCE-DETECTED STOPPED-FLOW METHODS	SCIENCE			English	Article							HELIX-COIL TRANSITION; INTERVENING SEQUENCE; RIBOSOMAL-RNA; TETRAHYMENA-THERMOPHILA; ACTIVE-SITE; KINETICS; MECHANISM; RECOGNITION; CLEAVAGE; THERMODYNAMICS	Fluorescence-detected stopped-flow and equilibrium methods have been used to study the mechanism for binding of pyrene (pyr)-labeled RNA oligomer substrates to the ribozyme (catalytic RNA) from Tetrahymena thermophila. The fluorescence of these substrates increases up to 25-fold on binding to the ribozyme. Stopped-flow experiments provide evidence that pyr experiences at least three different microenvironments during the binding process. A minimal mechanism is presented in which substrate initially base pairs to ribozyme and subsequently forms tertiary contacts in an RNA folding step. All four microscopic rate constants are measured for ribozyme binding of pyrCCUCU.	UNIV ROCHESTER, DEPT CHEM, ROCHESTER, NY 14627 USA; POLISH ACAD SCI, INST BIOORGAN CHEM, PL-60704 POZNAN, POLAND; PENN STATE UNIV, DEPT MOLEC & CELL BIOL, University Pk, PA 16802 USA	University of Rochester; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Schroeder, Susan/D-3946-2011	Bevilacqua, Philip/0000-0001-8074-3434; Kierzek, Ryszard/0000-0002-7644-0016	NIGMS NIH HHS [GM44613, GM 22939] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022939, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BENNUN M, 1992, J PHYS CHEM-US, V96, P1523, DOI 10.1021/j100183a004; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HE L, 1991, BIOCHEMISTRY-US, V30, P11124, DOI 10.1021/bi00110a015; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HIROMI K, 1979, KINETICS FAST ENZYME, P258; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KIERZEK R, UNPUB; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; LABUDA D, 1984, J MOL BIOL, V174, P587, DOI 10.1016/0022-2836(84)90085-8; LIN CT, 1976, J AM CHEM SOC, V98, P6536, DOI 10.1021/ja00437a020; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; NORTH AM, 1964, COLLISION THEORY CHE, pCH7; PETERSHEIM M, 1983, BIOCHEMISTRY-US, V22, P256, DOI 10.1021/bi00271a004; PORSCHKE D, 1973, BIOPOLYMERS, V12, P1313, DOI 10.1002/bip.1973.360120609; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SUGIMOTO N, 1989, NUCLEIC ACIDS RES, V17, P355, DOI 10.1093/nar/17.1.355; SULLIVAN FX, 1985, CELL, V42, P639, DOI 10.1016/0092-8674(85)90121-7; Turner DH, 1990, LANDOLTBORNSTEIN N C, V1, P201; WARING RB, 1983, J MOL BIOL, V167, P595, DOI 10.1016/S0022-2836(83)80100-4; WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2; WILLIAMS AP, 1989, BIOCHEMISTRY-US, V28, P4283, DOI 10.1021/bi00436a025; YOON K, 1976, NUCLEIC ACIDS RES, V3, P2233, DOI 10.1093/nar/3.9.2233; YOON K, 1975, J MOL BIOL, V99, P507, DOI 10.1016/S0022-2836(75)80169-0; YUAN RC, 1979, NUCLEIC ACIDS RES, V7, P2399, DOI 10.1093/nar/7.8.2399; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	35	189	190	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1355	1357		10.1126/science.1455230	http://dx.doi.org/10.1126/science.1455230			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455230				2022-12-01	WOS:A1992JY95800038
J	DAUBE, SS; VONHIPPEL, PH				DAUBE, SS; VONHIPPEL, PH			FUNCTIONAL TRANSCRIPTION ELONGATION COMPLEXES FROM SYNTHETIC RNA-DNA BUBBLE DUPLEXES	SCIENCE			English	Article							TERNARY COMPLEXES; CHAIN ELONGATION; POLYMERASE-II; BINDING; INITIATION; HOLOENZYME; TEMPLATE; PROTEIN; INVITRO; VIEW	A synthetic RNA-DNA bubble duplex construct intended to mimic the nucleic acid frame-work of a functional transcription elongation complex was designed and assembled. The construct consisted of a double-stranded DNA duplex of variable length (the template and nontemplate strands) containing an internal noncomplementary DNA "bubble" sequence. The 3' end of an RNA oligonucleotide that is partially complementary to the template DNA strand was hybridized within the DNA bubble to form an RNA-DNA duplex with a noncomplementary 5'-terminal RNA tail. The addition of either Escherichia coli or T7 RNA polymerase to this construct formed a complex that synthesized RNA with good efficiency from the hybridized RNA primer in a template-directed and processive manner, and displayed other features of a normal promoter-initiated transcription elongation complex. Other such constructs can be designed to examine many of the functional and regulatory properties of transcription systems.	UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon	DAUBE, SS (corresponding author), UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403, USA.			von Hippel, Peter H./0000-0003-2512-8097	NIGMS NIH HHS [GM-15792, GM-29158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R37GM015792, R01GM015792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; CHAMBERLIN MJ, 1973, J BIOL CHEM, V148, P2235; DAUBE SS, UNPUB; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEE DN, IN PRESS J MOL BIOL; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.biochem.54.1.171; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; REDDY MK, 1992, J BIOL CHEM, V267, P14157; RHODES G, 1974, J BIOL CHEM, V249, P6675; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SIPPEL A, 1968, BIOCHIM BIOPHYS ACTA, V157, P218, DOI 10.1016/0005-2787(68)90286-4; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WEBSTER KR, 1991, BIOTECHNIQUES, V11, P658; WHEELER AR, 1987, BIOCHEMISTRY-US, V26, P3322, DOI 10.1021/bi00386a012; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	28	93	109	4	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1320	1324		10.1126/science.1280856	http://dx.doi.org/10.1126/science.1280856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1280856				2022-12-01	WOS:A1992JY95800026
J	FRENCH, S				FRENCH, S			CONSEQUENCES OF REPLICATION FORK MOVEMENT THROUGH TRANSCRIPTION UNITS INVIVO	SCIENCE			English	Article							ESCHERICHIA-COLI CHROMOSOME; BIOTIN HOLOENZYME SYNTHETASE; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; CELL-CYCLE; BIRA-GENE; ORGANIZATION; OPERON; VISUALIZATION	To examine the basis for the evolutionary selection for codirectionality of replication and transcription in Escherichia coli, electron microscopy was used to visualize replication from an inducible ColE1 replication origin inserted into the Escherichia coli chromosome upstream (5') or downstream (3') of rrnB, a ribosomal RNA operon. Active rrnB operons were replicated either in the same direction in which they were transcribed or in the opposite direction. In either direction, RNA polymerases were dislodged during replication. When replication and transcription were codirectional, the rate of replication fork movement was similar to that observed in nontranscribed regions. When replication and transcription occurred in opposite directions, replication fork movement was reduced.			FRENCH, S (corresponding author), UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903, USA.				NIGMS NIH HHS [GM 21020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLMAN R, 1991, J BACTERIOL, V173, P7970, DOI 10.1128/jb.173.24.7970-7974.1991; BACKMAN K, 1978, COLD SPRING HARB SYM, V43, P69; BARKER DF, 1981, J MOL BIOL, V146, P469, DOI 10.1016/0022-2836(81)90043-7; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BREWER BJ, 1990, BACTERIAL CHROMOSOME, P61; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; COOPER S, 1985, J MOL BIOL, V163, P661; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRENCH SL, 1989, J BACTERIOL, V171, P4207, DOI 10.1128/JB.171.8.4207-4216.1989; GOTTA S, 1991, THESIS U VIRGINIA; GOTTA SL, 1991, J BACTERIOL, V173, P6647, DOI 10.1128/jb.173.20.6647-6649.1991; HELLER K, 1985, J BACTERIOL, V161, P904, DOI 10.1128/JB.161.3.904-908.1985; HELMSTETTER CE, 1968, J MOL BIOL, V31, P507, DOI 10.1016/0022-2836(68)90424-5; HIROSE S, 1983, MOL GEN GENET, V189, P422, DOI 10.1007/BF00325904; HOFMANN S, 1977, J BACTERIOL, V132, P718, DOI 10.1128/JB.132.2.718-722.1977; HOWARD PK, 1985, GENE, V35, P321, DOI 10.1016/0378-1119(85)90011-3; INOUE N, 1991, J BACTERIOL, V173, P1208, DOI 10.1128/jb.173.3.1208-1214.1991; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUNDRIGAN MD, 1991, P NATL ACAD SCI USA, V88, P1479, DOI 10.1073/pnas.88.4.1479; MCKNIGHT SL, 1978, THESIS U VIRGINIA; MKANIATIS T, 1982, MOL CLONING LABORATO, P68; NOMURA M, 1977, ANNU REV GENET, V11, P297, DOI 10.1146/annurev.ge.11.120177.001501; OSHEIM YN, 1988, MOL CELL BIOL, V8, P2811, DOI 10.1128/MCB.8.7.2811; PANAYOTATOS N, 1984, NUCLEIC ACIDS RES, V12, P2641, DOI 10.1093/nar/12.6.2641; RAHMOUNI R, 1992, J MOL BIOL, V223, P131; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X	33	206	209	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 20	1992	258	5086					1362	1365		10.1126/science.1455232	http://dx.doi.org/10.1126/science.1455232			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455232				2022-12-01	WOS:A1992JY95800040
J	LEHNER, T; BERGMEIER, LA; PANAGIOTIDI, C; TAO, L; BROOKES, R; KLAVINSKIS, LS; WALKER, P; WALKER, J; WARD, RG; HUSSAIN, L; GEARING, AJH; ADAMS, SE				LEHNER, T; BERGMEIER, LA; PANAGIOTIDI, C; TAO, L; BROOKES, R; KLAVINSKIS, LS; WALKER, P; WALKER, J; WARD, RG; HUSSAIN, L; GEARING, AJH; ADAMS, SE			INDUCTION OF MUCOSAL AND SYSTEMIC IMMUNITY TO A RECOMBINANT SIMIAN IMMUNODEFICIENCY VIRAL PROTEIN	SCIENCE			English	Article							VIRUS-LIKE PARTICLES; CHOLERA-TOXIN; MACAQUE MONKEYS; IGG ANTIBODIES; RETROVIRUS; VACCINE; ANTIGEN; AIDS; IMMUNIZATION; EXPRESSION	Heterosexual transmission through the cervico-vaginal mucosa is the principal route of human immunodeficiency virus (HIV) infection in Africa and is increasing in the United States and Europe. Vaginal immunization with simian immunodeficiency virus (SIV) had not yet been studied in nonhuman primates. Immune responses in macaques were investigated by stimulation of the genital and gut-associated lymphoid tissue with a recombinant, particulate SIV antigen. Vaginal, followed by oral, administration of the vaccine elicited three types of immunity: (i) gag protein p27-specific, secretory immunoglobulin A (IgA) and immunoglobulin G (IgG) in the vaginal fluid, (ii) specific CD4+ T cell proliferation and helper function in B cell p27-specific IgA synthesis in the genital lymph nodes, and (iii) specific serum IgA and IgG, with CD4+ T cell proliferative and helper functions in the circulating blood.	BRITISH BIOTECHNOL LTD, COWLEY OX4 5LY, OXON, ENGLAND		LEHNER, T (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DIV IMMUNOL, LONDON BRIDGE, LONDON SE1 9RT, ENGLAND.			Brookes, Roger/0000-0002-5361-0617; Klavinskis, Linda S./0000-0001-5828-6978				ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; ALMOND N, 1990, J VIROL METHODS, V28, P305, DOI 10.1016/0166-0934(90)90124-X; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BELL EB, 1967, NATURE, V214, P423, DOI 10.1038/214423a0; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; BURNS NR, 1990, J MOL BIOL, V216, P207, DOI 10.1016/S0022-2836(05)80308-0; BURNS NR, 1991, METHOD MOL BIOL, V8, P277; CULLITON BJ, 1991, NATURE, V352, P15, DOI 10.1038/352015a0; CZERKINSKY C, 1989, INFECT IMMUN, V57, P1072, DOI 10.1128/IAI.57.4.1072-1077.1989; DANIEL MD, 1987, J GEN VIROL, V68, P3183, DOI 10.1099/0022-1317-68-12-3183; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; ELSON CO, 1984, J IMMUNOL, V133, P2892; FELLOWES R, 1990, J IMMUNOL METHODS, V132, P165, DOI 10.1016/0022-1759(90)90026-R; GRIFFITHS JC, 1991, J VIROL, V65, P450, DOI 10.1128/JVI.65.1.450-456.1991; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; LANDE IJM, 1986, J REPROD IMMUNOL, V9, P57, DOI 10.1016/0165-0378(86)90025-2; Lehner T, 1992, VACCINE RES, V3, P319; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LYCKE N, 1986, IMMUNOLOGY, V59, P301; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MILLER MD, 1990, J IMMUNOL, V144, P122; MILLS KHG, 1991, J IMMUNOL, V147, P3560; MURPHEYCORB M, 1986, NATURE, V321, P435, DOI 10.1038/321435a0; OGRA PL, 1973, J IMMUNOL, V110, P1307; PARR EL, 1988, J REPROD IMMUNOL, V14, P165, DOI 10.1016/0165-0378(88)90067-8; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STURN B, 1978, MED MICROBIOL IMMUN, V165, P119, DOI 10.1007/BF02122747; WIRA CR, 1989, IMMUNOLOGY, V68, P24; WIRA CR, 1987, J IMMUNOL, V138, P4159; YANG SL, 1979, FERTIL STERIL, V32, P588	32	144	152	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1365	1369		10.1126/science.1360702	http://dx.doi.org/10.1126/science.1360702			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1360702				2022-12-01	WOS:A1992JY95800041
J	WATKINS, DC; JOHNSON, GL; MALBON, CC				WATKINS, DC; JOHNSON, GL; MALBON, CC			REGULATION OF THE DIFFERENTIATION OF TERATOCARCINOMA CELLS INTO PRIMITIVE ENDODERM BY G-ALPHA-I2	SCIENCE			English	Article							RETINOIC ACID; G-PROTEINS; STEM-CELLS; MODULATION; EXPRESSION; INDUCTION; SEQUENCES; CYCLASE; ASSAY; GI2	The amount of the heterotrimeric G protein subunit Galpha(i2) decreases after the induction of F9 teratocarcinoma cells to become primitive endoderm in the presence of retinoic acid (RA). The reduction of the Galpha(i2) protein in F9 cells by antisense RNA expression was associated with (i) loss of receptor-mediated inhibition of adenylyl cyclase; (ii) decreased cell doubling time; (iii) induction of a primitive, endoderm-like phenotype in the absence of RA; and (iv) production of the differentiation marker tissue-type plasminogen activator. Expression of a constitutively active, mutant Galpha(i2) blocked RA-induced differentiation. These data suggest the involvement of Galpha(i2) in the control of stem cell differentiation and provide insight into the involvement of G proteins in growth regulation.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; NATL JEWISH CTR IMMUNOL, DEPT PEDIAT & BASIC SCI, DENVER, CO 80206 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; National Jewish Health	WATKINS, DC (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA.		malbon, craig/ABF-3604-2020					ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; DARROW AL, 1990, METHOD ENZYMOL, V190, P110; GALVINPARTON P, UNPUB; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; KLEBE RJ, 1991, P NATL ACAD SCI USA, V88, P9588, DOI 10.1073/pnas.88.21.9588; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; Sambrook J., 1989, MOL CLONING LAB MANU; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DL, UNPUB; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	27	101	104	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 20	1992	258	5086					1373	1375		10.1126/science.1455234	http://dx.doi.org/10.1126/science.1455234			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY958	1455234				2022-12-01	WOS:A1992JY95800043
J	ABOULELA, F; MURCHIE, AIH; LILLEY, DMJ				ABOULELA, F; MURCHIE, AIH; LILLEY, DMJ			NMR-STUDY OF PARALLEL-STRANDED TETRAPLEX FORMATION BY THE HEXADEOXYNUCLEOTIDE D(TG4T)	NATURE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TELOMERIC DNA; PROTON RESONANCES; OLIGONUCLEOTIDES; SPECTROSCOPY; ASSIGNMENT; MISMATCH	MULTISTRANDED DNA structures based upon guanine association have been proposed to be important in the structure of chromosome telomeres1 and in immunoglobulin class switching2. Nucleic acids containing runs of guanine bases form a number of structures in vitro3-6, including fold-back structures (Fig. 1a)7-9 and parallel-stranded quadruplex structures in DNA2,10 and RNA11. The features of fold-back structures have now been determined at high-resolution12-14. The different structures are probably based on a tetrad of hydrogen-bonded guanine bases (Fig. 1b), with buffer conditions and sequence effects mediating isomerization between the different forms4,15-18. Here we use NMR spectroscopy to investigate the solution structure of the complex formed by the hexadeoxynucleotide d(TG4T) in the presence of sodium ions. We have observed the formation of a parallel-stranded quadruplex containing hydrogen-bonded tetrads of guanine. The parallel-stranded form differs significantly from the fold-back form, with individual nucleotide conformations being closer to those of B-form DNA.			ABOULELA, F (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND.		aboul-ela, fareed/C-2887-2011					BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FAZEKERLY GV, 1984, NUCLEIC ACIDS RES, V12, P8269; FORSTER M, 1989, J MOL GRAPHICS, V7, P196, DOI 10.1016/0263-7855(89)80002-5; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HARDIN CC, 1992, BIOCHEMISTRY-US, V31, P833, DOI 10.1021/bi00118a028; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HENDERSON ER, 1990, BIOCHEMISTRY-US, V29, P732, DOI 10.1021/bi00455a020; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LANE AN, 1991, BIOCHEM J, V279, P269, DOI 10.1042/bj2790269; LI Y, 1991, P NATL ACAD SCI USA, V88, P26, DOI 10.1073/pnas.88.1.26; LU M, 1992, BIOCHEMISTRY-US, V31, P2455, DOI 10.1021/bi00124a003; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P5263, DOI 10.1093/nar/19.19.5263; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PINNAVAIA TJ, 1975, J AM CHEM SOC, V97, P7198, DOI 10.1021/ja00857a059; RINKEL LJ, 1987, J BIOMOL STRUCT DYN, V4, P621, DOI 10.1080/07391102.1987.10507665; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SKLENAR V, 1986, FEBS LETT, V208, P94, DOI 10.1016/0014-5793(86)81539-3; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1991, J MOL BIOL, V222, P819, DOI 10.1016/0022-2836(91)90513-6; WANG Y, 1992, NATURE, V356, P126; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Wuthrich K., 1986, NMR PROTEINS NUCL AC	31	193	200	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					280	282		10.1038/360280a0	http://dx.doi.org/10.1038/360280a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436110				2022-12-01	WOS:A1992JY96000059
J	AGNELLO, V; CHUNG, RT; KAPLAN, LM				AGNELLO, V; CHUNG, RT; KAPLAN, LM			A ROLE FOR HEPATITIS-C VIRUS-INFECTION IN TYPE-II CRYOGLOBULINEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIXED CRYOGLOBULINEMIA; RHEUMATOID-FACTOR; CROSS-IDIOTYPE; ANTIBODIES; ASSOCIATION; INTERFERON; DISEASES; CHAINS; HEAVY; ALPHA	Background. Type II cryoglobulinemia is a vasculitis characterized by cryoglobulins consisting of complexes of polyclonal IgG and monoclonal IgM rheumatoid factors. The cause of these immune complexes is unknown, though both the hepatitis B (HBV) and C (HCV) viruses have been suspected. Methods. We studied 19 patients with Type II cryoglobulinemia for markers of HCV and HBV infection. Quantitative HCV antibody and RNA studies were performed on whole serum, cryoprecipitates, and supernatants. Results. Eight patients (42 percent) had HCV antibodies, and 16 (84 percent) had HCV RNA. Of the 19 patients, 5 (26 percent) had HBV markers, but only 1 had evidence of active HBV infection. Control serum samples from nine patients with Type I cryoglobulinemia were negative for HCV antibody and HCV RNA. There was a close, although not exclusive, association of one type of rheumatoid factor (WA) with HCV RNA. HCV antibody and HCV RNA were concentrated approximately 10-fold and 1000-fold, respectively, in the Type II cryoglobulins examined. Conclusions. Type II cryogiobulinemia is strongly associated with concomitant HCV infection and a high rate of false negative serologic tests. HCV virions and HCV antigen-antibody complexes are concentrated in the cryoprecipitates, most commonly in association with the WA type of rheumatoid factor, suggesting a role for HCV in the pathogenesis of mixed cryoglobulinemia.	MASSACHUSETTS GEN HOSP,DEPT MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; EDITH NOURSE ROGERS MEM VET AFFAIRS HOSP,BEDFORD,MA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	AGNELLO, V (corresponding author), LAHEY CLIN MED CTR,DEPT LAB MED,CLIN IMMUNOL LAB,41 MALL RD,BURLINGTON,MA 01805, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035487] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042189, T32DK007191] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35487] Funding Source: Medline; NIDDK NIH HHS [DK42189, 5T32DK07191] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNELLO V, 1986, J EXP MED, V164, P1809, DOI 10.1084/jem.164.5.1809; AGNELLO V, 1973, KIDNEY INT, V3, P90, DOI 10.1038/ki.1973.15; AGNELLO V, 1980, J EXP MED, V151, P1514, DOI 10.1084/jem.151.6.1514; AGNELLO V, 1981, ANN INTERN MED, V94, P266, DOI 10.7326/0003-4819-94-2-266; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BARNES JL, 1990, ARTHRITIS RHEUM-US, V33, P1710, DOI 10.1002/art.1780331115; BONOMO L, 1987, AM J MED, V83, P726, DOI 10.1016/0002-9343(87)90904-1; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; CASATO M, 1991, LANCET, V337, P1047, DOI 10.1016/0140-6736(91)92715-E; CHUNG RT, 1991, HEPATOLOGY, V14, pA65; COLTORTI M, 1991, 3RD INT S HCV STRASB; Dienstag J L, 1981, Semin Liver Dis, V1, P45, DOI 10.1055/s-2008-1063929; DIGHIERO G, 1986, ANN NY ACAD SCI, V475, P135, DOI 10.1111/j.1749-6632.1986.tb20863.x; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P621; FERRI C, 1991, INFECTION, V19, P417, DOI 10.1007/BF01726453; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; FERRI C, 1991, EUR J CANCER, V27, pS81, DOI 10.1016/0277-5379(91)90583-Y; GIUSTI G, 1980, B I SIEROTER MILAN, V59, P571; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; GOREVIC PD, 1980, AM J MED, V69, P287, DOI 10.1016/0002-9343(80)90390-3; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; IKEDA Y, 1990, LANCET, V335, P1345, DOI 10.1016/0140-6736(90)91228-3; KNOX TA, 1991, AM J MED, V91, P554, DOI 10.1016/0002-9343(91)90196-5; KUNKEL HG, 1973, J EXP MED, V137, P331, DOI 10.1084/jem.137.2.331; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; MAGGIORE Q, 1981, KIDNEY INT, V19, P579, DOI 10.1038/ki.1981.55; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MELTZER M, 1966, AM J MED, V40, P837, DOI 10.1016/0002-9343(66)90200-2; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PASCUAL V, 1992, ARTHRITIS RHEUM-US, V35, P11, DOI 10.1002/art.1780350103; PLAGEMANN PGW, 1991, ARCH VIROL, V120, P165, DOI 10.1007/BF01310473; REALDI G, 1974, Z IMMUNITATSFORSCH, V147, P114; SANZ I, 1989, J IMMUNOL, V142, P4054; TANAKA M, 1991, CLIN EXP RHEUMATOL, V9, P308	36	1209	1234	1	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1490	1495		10.1056/NEJM199211193272104	http://dx.doi.org/10.1056/NEJM199211193272104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1383822				2022-12-01	WOS:A1992JY16500004
J	BLOCKI, FA; SCHLIEVERT, PM; WACKETT, LP				BLOCKI, FA; SCHLIEVERT, PM; WACKETT, LP			RAT-LIVER PROTEIN LINKING CHEMICAL AND IMMUNOLOGICAL DETOXIFICATION SYSTEMS	NATURE			English	Article							GLUTATHIONE S-TRANSFERASES; MIGRATION INHIBITORY FACTOR; CELL HYBRIDOMA CLONE; MACROPHAGE-MIGRATION; MECHANISMS; ACID	MAMMALS have separate enzymatic and cellularly mediated detoxification systems. Glutathione S-transferases (GSTs) protect against xenobiotic chemicals which continuously enter the body, largely through mucous membranes1-5. These enzymes catalyse the conjugation of glutathione with a wide variety of electrophilic compounds rendering them non-toxic. Mammals also mount a cellular immunological response on entry of foreign cells, viruses or macromolecules into the body6-8. T lymphocytes mobilize at the site of foreign body entry and secrete protein messengers called lymphokines. Secondary to T lymphocytes, macrophages concentrate at the infection site and function in antigen processing and phagocytosis. In vitro, macrophage movement is arrested by one class of lymphokines known as macrophage migration inhibitory factors (MIFs). We report here the purification of milligram quantities of a unique multifunctional protein from rat liver which links enzymatic and immunological detoxification systems. This protein actuates both GST and MIF activity and matches the primary structure of a human MIF9 in 25 out of 26 amino-terminal amino acids. Primary structure comparisons revealed significant similarity between GSTs and MIF. The glutathione affinity chromatography purification described here yields a 100-fold increase in obtaining MIF9-11 and will aid understanding of its precise biological function.	UNIV MINNESOTA,DEPT MICROBIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,GRAY FRESHWATER BIOL INST,NAVARRE,MN 55392; UNIV MINNESOTA,DEPT BIOCHEM,NAVARRE,MN 55392	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota System				Schlievert, Patrick/0000-0001-8314-9369				ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; AHMED AE, 1978, BIOCHEM PHARMACOL, V27, P2021, DOI 10.1016/0006-2952(78)90061-8; ALLISON AC, 1978, IMMUNOL REV, V40, P3, DOI 10.1111/j.1600-065X.1978.tb00399.x; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; BOYER TD, 1989, HEPATOLOGY, V9, P486, DOI 10.1002/hep.1840090324; BOYER TD, 1983, ZAKIM BIOCH PHARM, V32, P297; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P73; DING GJF, 1985, J BIOL CHEM, V260, P3268; FJELLSTEDT TA, 1973, J BIOL CHEM, V248, P3702; GOUST JM, 1986, IMMUN SERIES, V28, P169; HARRINGTON JT, 1973, J IMMUNOL, V110, P752; HIROSE S, 1991, MICROBIOL IMMUNOL, V35, P235, DOI 10.1111/j.1348-0421.1991.tb01552.x; JAKOBY WB, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P87; KOHLERSTAUB D, 1985, J BACTERIOL, V162, P676, DOI 10.1128/JB.162.2.676-681.1985; LATHROP RH, 1989, ARIADNE MANUAL; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; OKI S, 1991, LYMPHOKINE CYTOK RES, V10, P273; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; RAJAPAKSE DA, 1970, NATURE, V226, P857, DOI 10.1038/226857a0; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P391, DOI 10.1093/infdis/147.3.391; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; ZHANG PH, 1991, J BIOL CHEM, V266, P19475	28	73	80	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					269	270		10.1038/360269a0	http://dx.doi.org/10.1038/360269a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436109				2022-12-01	WOS:A1992JY96000055
J	CAUX, C; DEZUTTERDAMBUYANT, C; SCHMITT, D; BANCHEREAU, J				CAUX, C; DEZUTTERDAMBUYANT, C; SCHMITT, D; BANCHEREAU, J			GM-CSF AND TNF-ALPHA COOPERATE IN THE GENERATION OF DENDRITIC LANGERHANS CELLS	NATURE			English	Article							COLONY-STIMULATING FACTOR; NECROSIS-FACTOR-ALPHA; IDENTIFICATION; PROLIFERATION; VIABILITY; BLOOD	DENDRITIC cells comprise a system of highly efficient antigen-presenting cells which initiate immune responses such as the sensitization of T cells restricted by major histocompatibility complex molecules, the rejection of organ transplants and the formation of T-cell-dependent antibodies. Dendritic cells are found in many non-lymphoid tissues, such as skin (Langerhans cells) and mucosa, and they migrate after antigen capture through the afferent lymph or the bloodstream to lymphoid organs, where they efficiently present antigen to T cells1. Dendritic cells are difficult to isolate and, although they originate from bone marrow2,3 their site of maturation and the conditions that direct their growth and differentiation are still poorly characterized. Granulocyte macrophage-colony stimulating factor (GM-CSF) favours the outgrowth of dendritic cells from mouse peripheral blood4. Here we extend this finding to man and demonstrate that cooperation between GM-CSF and tumour necrosis factor-alpha (TNF-alpha) is crucial for the generation of human dendritic/Langerhans cells from CD34+ haematopoietic progenitors. The availability of large numbers of these cells should now facilitate the understanding of their role in immunological regulation and disorder.	HOP EDOUARD HERRIOT, INSERM, U346, F-69437 LYON 03, FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	CAUX, C (corresponding author), SCHERING PLOUGH CORP, IMMUNOL RES LAB, 27 CHEMIN PEUPLIERS, BP 11, F-69571 DARDILLY, FRANCE.		dezutter-dambuyant, colette/F-5962-2013; Caux, Christophe/G-2851-2013	dezutter-dambuyant, colette/0000-0002-3866-4537; Caux, Christophe/0000-0003-2438-833X				CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAUX C, 1990, BLOOD, V75, P2292; CAUX C, 1991, BLOOD, V78, P635; CROW MK, 1982, CLIN EXP IMMUNOL, V49, P338; DEZUTTERDAMBUYANT C, 1989, HYBRIDOMA, V8, P199, DOI 10.1089/hyb.1989.8.199; DEZUTTERDAMBUYANT C, 1985, J INVEST DERMATOL, V84, P465, DOI 10.1111/1523-1747.ep12272371; DJEU JY, 1992, TUMOR NECROSIS FACTO, P531; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GHIARA P, 1987, J IMMUNOL, V139, P3676; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KNIGHT SC, 1991, ACCESSORY CELLS IN HIV AND OTHER RETROVIRAL INFECTIONS, P145; KOCH F, 1990, J EXP MED, V171, P159, DOI 10.1084/jem.171.1.159; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LUGER TA, 1989, ACTA DERM-VENEREOL, V69, P61; MALIK STA, 1992, TUMOR NECROSIS FACTO, P407; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; SORNASSE T, 1992, J EXP MED, V175, P15, DOI 10.1084/jem.175.1.15; STEINMAN RM, 1974, J EXP MED, V139, P1431, DOI 10.1084/jem.139.6.1431; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; VANDERIJN M, 1984, HUM IMMUNOL, V9, P201, DOI 10.1016/0198-8859(84)90025-9; VANVOORHIS WC, 1982, J EXP MED, V155, P1172, DOI 10.1084/jem.155.4.1172; VANVOORHIS WC, 1983, J EXP MED, V158, P174, DOI 10.1084/jem.158.1.174; WITMERPACK MD, 1987, J EXP MED, V166, P1484, DOI 10.1084/jem.166.5.1484	29	1425	1480	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					258	261		10.1038/360258a0	http://dx.doi.org/10.1038/360258a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279441				2022-12-01	WOS:A1992JY96000051
J	JONES, EY; DAVIS, SJ; WILLIAMS, AF; HARLOS, K; STUART, DI				JONES, EY; DAVIS, SJ; WILLIAMS, AF; HARLOS, K; STUART, DI			CRYSTAL-STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF A SOLUBLE FORM OF THE CELL-ADHESION MOLECULE CD2	NATURE			English	Article							ERYTHROCYTE RECEPTOR; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; ANTIGEN; PROTEIN; BINDING; RECOGNITION; EXPRESSION; FRAGMENT	The crystal structure of a soluble form of the T lymphocyte antigen CD2 provides the first complete view of the extracellular region of a cell adhesion molecule. The topology of the molecule, which comprises two immunoglobulin-like domains, is the same as that of the first two domains of CD4 but the relative domain orientation is altered by a fairly flexible linker region. The putative ligand-binding beta-sheet forms a flat surface towards the top of the molecule. Crystal contacts between these surfaces suggest a plausible model for the adhesive interaction.	UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, MRC, CELLULAR IMMUNOL UNIT, OXFORD OX1 3RE, ENGLAND	University of Oxford	JONES, EY (corresponding author), LAB MOLEC BIOPHYS, REX RICHARDS BLDG, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Jones, Yvonne/N-8111-2019; Jones, Yvonne/J-2293-2016	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Stuart, David/0000-0002-3426-4210				BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DAVIS SJ, IN PRESS PROTEIN ENG; DECKERT M, 1991, FASEB J, V5, pA614; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; DUSTIN ML, 1991, ANNU REV IMMUNOL, V9, P27, DOI 10.1146/annurev.iy.09.040191.000331; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HARLOS K, 1992, J APPL CRYSTALLOGR, V25, P536, DOI 10.1107/S0021889892002656; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; HUNIG T, 1985, J EXP MED, V162, P890, DOI 10.1084/jem.162.3.890; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1991, ACTA CRYSTALLOGR A, V47, P753, DOI 10.1107/S0108767391006839; JONES EY, 1991, ISOMORPHOUS REPLACEM, P39; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; McPherson A, 1982, PREPARATION ANAL PRO; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUL FA, 1978, J BIOL CHEM, V253, P585; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SPRINGER TA, 1991, NATURE, V353, P704, DOI 10.1038/353704a0; SPRUYT LL, 1991, J EXP MED, V174, P1407, DOI 10.1084/jem.174.6.1407; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STAUNTON DE, 1989, J EXP MED, V169, P1087, DOI 10.1084/jem.169.3.1087; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; YAGITA H, IN PRESS J EXP MED	49	307	315	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					232	239		10.1038/360232a0	http://dx.doi.org/10.1038/360232a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279440				2022-12-01	WOS:A1992JY96000042
J	MANDEL, MA; GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF				MANDEL, MA; GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF			MOLECULAR CHARACTERIZATION OF THE ARABIDOPSIS FLORAL HOMEOTIC GENE APETALA1	NATURE			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; LINKAGE MAP; YEAST; THALIANA; SRF	THE first step in flower development is the transition of an inflorescence meristem into a floral meristem. Each floral meristem differentiates into a flower consisting of four organ types that occupy precisely defined positions within four concentric whorls. Genetic studies in Arabidopsis thaliana and Antirrhinum majus have identified early-acting genes that determine the identity of the floral meristem, and late-acting genes that determine floral organ identity1-5. In Arabidopsis, at least two genes, APETALA1 and LEAFY, are required for the transition of an inflorescence meristem into a floral meristem1. We have cloned the APETALA1 gene and here we show that it encodes a putative transcription factor that contains a MADS-domain2. APETALA1 RNA is uniformly expressed in young flower primordia, and later becomes localized to sepals and petals. Our results suggest that APETALA1 acts locally to specify the identity of the floral meristem, and to determine sepal and petal development.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								BOWMAN JL, 1991, DEVELOPMENT, V112, P1; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	23	904	1010	4	123	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					273	277						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359429				2022-12-01	WOS:A1992JY96000057
J	MITCHELL, JM; SUNSHINE, JH				MITCHELL, JM; SUNSHINE, JH			CONSEQUENCES OF PHYSICIANS OWNERSHIP OF HEALTH-CARE FACILITIES - JOINT VENTURES IN RADIATION-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINANCIAL INCENTIVES; OFFICE PRACTICE; PREPAID; DEMAND	Background. Physicians are increasingly the owners of health care facilities to which they refer patients for services but at which they do not practice. We studied such ownership arrangements, known as "joint ventures," in the field of radiation therapy, examining their effects on access, use of services, costs, and quality. Methods. Because 44 percent of free-standing facilities providing radiation therapy in Florida in 1989 were joint ventures, as compared with 7 percent elsewhere (95 percent confidence interval, 3 to 10 percent), we compared data for Florida with comparable data for the remainder of the United States. We also compared radiation-therapy facilities in Florida that were established as joint ventures with those that were not. Since most data were derived from entire populations rather than from samples, any differences found were of necessity statistically significant. Results. No joint-venture facilities providing radiation therapy were located in inner-city neighborhoods or rural areas, but 11 percent of other free-standing facilities and hospital-based facilities were located in such areas. Among free-standing facilities, joint ventures received 39 percent of their revenues from patients with well-paying insurance coverage, as compared with 31 percent for facilities that were not joint ventures (P<0.01). The frequency and costs of radiation-therapy treatments at free-standing centers were 40 to 60 percent higher in Florida than in the rest of the United States; there was no below-average use of radiation therapy at hospitals or higher cancer rates that explained the higher rates of use or higher costs in Florida. Radiation physicists at joint-venture facilities (the principal personnel involved in quality control other than physicians) spent 18 percent less time with each patient over the course of treatment than did their counterparts at free-standing facilities that were not joint ventures (P<0.05). Mortality among patients with cancer in Florida was not lower than the U.S. average, even though joint ventures are much more common in that state. Conclusions. Joint ventures in radiation therapy appear to have adverse effects on patients' access to care. They also appear to increase the use of services and costs substantially. Some indicators show that joint ventures cause either no improvement in quality or a decline. Our results add to the evidence indicating that physicians' self-referral generally has negative consequences. We recommend legislation to ban ownership of joint ventures by referring physicians. Such legislation needs to be carefully designed in order to achieve its objectives and forestall new, financially abusive arrangements.	AMER COLL RADIOL,RES DEPT,RESTON,VA; FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306	American College of Radiology; State University System of Florida; Florida State University	MITCHELL, JM (corresponding author), GEORGETOWN UNIV,GRAD PUBL POLICY PROGRAM,3600 N ST NW,SUITE 200,WASHINGTON,DC 20007, USA.							EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; FUCHS VR, 1978, J HUM RESOUR, V13, P35, DOI 10.2307/145247; GRAY BH, 1986, FOR PROFIT ENTERPRIS, P151; HANKS G E, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P87; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; IGLEHART JK, 1989, NEW ENGL J MED, V321, P198, DOI 10.1056/NEJM198907203210327; KRAMER S, 1984, STAT MED, V3, P353, DOI 10.1002/sim.4780030411; KRAMER S, 1984, International Journal of Radiation Oncology, Biology, Physics, V10, P49; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, 1991 FLOR HLTH CAR C; Morrison DE., 1970, SIGNIFICANCE TEST CO; PEAR R, 1991, NY TIMES        1105, pA17; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RIES LAG, 1991, NCI NIH912789 PUBL; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; SCHROEDER SA, 1978, MED CARE, V16, P289, DOI 10.1097/00005650-197804000-00002; SUNSHINE JH, 1992, RADIOLOGY, V183, P535, DOI 10.1148/radiology.183.2.1561364; Waldholz Michael, 1989, WALL STREET J   0301, pA1; WILENSKY GR, 1983, MILBANK FUND Q, V61, P252, DOI 10.2307/3349907; 1990, PHYSICIANS CURRENT P; 1989, FINANCIAL ARRANGEMEN; 1989, FED REGISTER, V54, P8894; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1992, PRESIDENTS COMPREHEN, P68	28	99	99	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 19	1992	327	21					1497	1501		10.1056/NEJM199211193272106	http://dx.doi.org/10.1056/NEJM199211193272106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY165	1406881				2022-12-01	WOS:A1992JY16500006
J	MOMBAERTS, P; CLARKE, AR; RUDNICKI, MA; IACOMINI, J; ITOHARA, S; LAFAILLE, JJ; WANG, LL; ICHIKAWA, Y; JAENISCH, R; HOOPER, ML; TONEGAWA, S				MOMBAERTS, P; CLARKE, AR; RUDNICKI, MA; IACOMINI, J; ITOHARA, S; LAFAILLE, JJ; WANG, LL; ICHIKAWA, Y; JAENISCH, R; HOOPER, ML; TONEGAWA, S			MUTATIONS IN T-CELL ANTIGEN RECEPTOR GENES ALPHA-BLOCK AND BETA-BLOCK THYMOCYTE DEVELOPMENT AT DIFFERENT STAGES	NATURE			English	Article							MOUSE PGK-1 GENE; TRANSGENIC MICE; EXPRESSION; CHAIN; ORGANIZATION; DIVERSITY; ANTIBODY; SEQUENCE; PROMOTER; MUTANT	Analysis of mice carrying mutant T-cell antigen receptor (TCR) genes indicates that TCR-beta gene rearrangement or expression is critical for the differentiation of CD4-CD8- thymocytes to CD4+CD8+ thymocytes, as well as for the expansion of the pool of CD4+CD8+ cells. TCR-alpha is irrelevant in these developmental processes. The development of gammadelta T cells does not depend on either TCR-alpha or TCR-beta.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV EDINBURGH,AFRC,CTR GENOME RES,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV EDINBURGH,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Edinburgh; Massachusetts Institute of Technology (MIT); University of Edinburgh			Clarke, Alan R/A-6256-2008; Itohara, Shigeyoshi/I-8769-2012; clarke, alan r/P-2820-2014	Itohara, Shigeyoshi/0000-0002-2410-9989; Clarke, Alan/0000-0002-4281-426X				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HAAS W, 1992, CURR OPIN IMMUNOL, V4, P147, DOI 10.1016/0952-7915(92)90004-X; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; HOCKETT R D JR, 1989, New Biologist, V1, P266; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P293; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOMBAERTS P, 1991, P NATL ACAD SCI USA, V88, P3084, DOI 10.1073/pnas.88.8.3084; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; SHORTMAN K, 1992, CURR OPIN IMMUNOL, V4, P140, DOI 10.1016/0952-7915(92)90003-W; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1988, P NATL ACAD SCI USA, V85, P9729, DOI 10.1073/pnas.85.24.9729; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X	29	964	979	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					225	231		10.1038/360225a0	http://dx.doi.org/10.1038/360225a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359428				2022-12-01	WOS:A1992JY96000041
J	NABAVI, N; FREEMAN, GJ; GAULT, A; GODFREY, D; NADLER, LM; GLIMCHER, LH				NABAVI, N; FREEMAN, GJ; GAULT, A; GODFREY, D; NADLER, LM; GLIMCHER, LH			SIGNALING THROUGH THE MHC CLASS-II CYTOPLASMIC DOMAIN IS REQUIRED FOR ANTIGEN PRESENTATION AND INDUCES B7 EXPRESSION	NATURE			English	Article							CELL ACTIVATION ANTIGEN-B7; T-CELLS; COSTIMULATORY SIGNAL; RESTRICTED ANTIGEN; MOLECULES; RECEPTOR; TRANSLOCATION; INTERLEUKIN-2; INDUCTION; PROVIDES	CLASS II major histocompatibility complex (MHC) molecules function as antigen-presenting elements as well as signal transducers on B lymphocytes. We previously reported that a B lymphoma cell transfectant, 5C2, expressing genetically engineered I-A(k) molecules with truncated cytoplasmic domains was severely impaired in both antigen presentation and in anti-Ia-induced intracytoplasmic signalling1-5. These two functions could be restored by preculturing 5C2 cells with cyclic AMP analogues6,7. Here we demonstrate that impaired signal transduction by truncated class II molecules results in a deficiency in induction of the newly defined B-cell accessory molecule B7 (ref. 8), which can be reversed by restoration of B7 expression. These data imply that contact of the T-cell antigen receptor with MHC/antigen ligand results in signal transmission through the class II cytoplasmic domain. This signal, which can be mimicked by dibutyryl cAMP, induces expression of B7, resulting in effective antigen presentation. The fact that crosslinking of surface class II MHC also induces B7 expression on normal resting human B cells9 supports this contention.	HARVARD UNIV,SCH PUBL HLTH,665 HUNTINGTON AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; ROCHE RES CTR,DEPT IMMUNOPHARMACOL,NUTLEY,NJ 07110; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR BIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Roche Holding; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616; Godfrey, Dale/0000-0002-3009-5472				CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN ZZ, 1987, J IMMUNOL, V138, P2345; DAMLE NK, 1991, EUR J IMMUNOL, V21, P1277, DOI 10.1002/eji.1830210527; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FREEMAN GJ, 1991, J EXP MED, V174, P625, DOI 10.1084/jem.174.3.625; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; NABAVI N, 1989, J IMMUNOL, V142, P1444; POLLOK KE, 1991, J IMMUNOL, V146, P1633; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; STPIERRE Y, 1991, J IMMUNOL, V147, P2875; STPIERRE Y, 1989, J IMMUNOL, V143, P808; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; YOKOCHI T, 1982, J IMMUNOL, V128, P823	20	336	359	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					266	268		10.1038/360266a0	http://dx.doi.org/10.1038/360266a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1279442				2022-12-01	WOS:A1992JY96000054
J	NIWA, M; MACDONALD, CC; BERGET, SM				NIWA, M; MACDONALD, CC; BERGET, SM			ARE VERTEBRATE EXONS SCANNED DURING SPLICE-SITE SELECTION	NATURE			English	Article							MESSENGER-RNAS; POLY(A) SITE; POLYADENYLATION; SEQUENCES; INVITRO; DEFINITION; INTRON; MODEL	PAIRWISE recognition of splice sites as a result of a scanning mechanism is an attractive model to explain the coordination of vertebrate splicing1. Such a mechanism would predict a polarity-of-site recognition in the scanned unit, but no evidence for a polarity gradient across introns has been found2-4. We have suggested that the exon rather than the intron is the unit of recognition in vertebrates5 and that polyadenylation and splicing factors interact during recognition of 3'-terminal exons6-8. Interaction is reflected in maximal rates of in vitro polyadenylation. If scanning across the exon is operating during this interaction, then insertion of a 5' splice site should depress polyadenylation. Here we report recognition in vitro and in vivo of a 5' splice site situated within a 3'-terminal exon, and a concomitant depression of polyadenylation and ultraviolet crosslinking of a polyadenylation factor. Decreased crosslinking was only found when the 3' and 5' splice sites were within 300 nucleotides of each other. These results are consistent with an exon scanning mechanism for splice-site selection.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	NIWA, M (corresponding author), BAYLOR COLL MED,VERNA & MARRS MCCLEAN DEPT BIOCHEM,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			MacDonald, Clinton/0000-0003-3209-1982				ADAMI G, 1988, EMBO J, V7, P2107, DOI 10.1002/j.1460-2075.1988.tb03050.x; AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; BRADY HA, 1988, MOL CELL BIOL, V8, P3291, DOI 10.1128/MCB.8.8.3291; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; CUNNINGHAM SA, 1991, J MOL BIOL, V217, P265, DOI 10.1016/0022-2836(91)90541-D; EPERON LP, 1986, NATURE, V324, P280, DOI 10.1038/324280a0; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; KUHNE T, 1983, EMBO J, V2, P727, DOI 10.1002/j.1460-2075.1983.tb01492.x; LANG KM, 1983, SCIENCE, V220, P1351, DOI 10.1126/science.6304877; LEAR AL, 1990, J MOL BIOL, V211, P103, DOI 10.1016/0022-2836(90)90014-D; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NIWA M, 1991, GENE EXPRESSION, V1, P5; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112	19	117	118	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					277	280		10.1038/360277a0	http://dx.doi.org/10.1038/360277a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1359430				2022-12-01	WOS:A1992JY96000058
J	OBERHAUSER, AF; MONCK, JR; BALCH, WE; FERNANDEZ, JM				OBERHAUSER, AF; MONCK, JR; BALCH, WE; FERNANDEZ, JM			EXOCYTOTIC FUSION IS ACTIVATED BY RAB3A PEPTIDES	NATURE			English	Article							GTP-BINDING PROTEIN; PERITONEAL MAST-CELLS; CAPACITANCE MEASUREMENTS; MEMBRANE CAPACITANCE; SYNAPTIC VESICLES; GAMMA-S; TRANSPORT; ENDOCYTOSIS; SECRETION; MECHANISM	STUDIES of intracellular traffic in yeast and mammalian systems have implicated members of the Rab family of small GTP-binding proteins as regulators of membrane fusion1-10. We have used the patch clamp technique to measure exocytotic fusion events directly and investigate the role of GTP-binding proteins in regulating exocytosis in mast cells. Intracellular perfusion of mast cells with GTP-gammaS is sufficient to trigger complete exocytotic degranulation in the absence of other intracellular messengers11. Here we show that GTP is a potent inhibitor of GTP-gammaS-induced degranulation, indicating that sustained activation of a GTP-binding protein is sufficient for membrane fusion. We have found that synthetic oligopeptides, corresponding to part of the effector domain of Rab3a12, stimulate complete exocytotic degranulation, similar to that induced by GTP-gammaS. The response is selective for Rab3a sequence and is strictly dependent on Mg2+ and ATP. This suggests that sustained activation of a Rab3 protein causes exocytotic fusion. The peptide response can be accelerated by GDP-betaS, suggesting that Rab3a peptides compete with endogenous Rab3 proteins for a binding site on a target effector protein, which causes fusion on activation.	SCRIPPS RES INST, DEPT MOLEC & CELLULAR BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	OBERHAUSER, AF (corresponding author), MAYO CLIN & MAYO FDN, DEPT PHYSIOL & BIOPHYS, ROCHESTER, MN 55905 USA.			Oberhauser, Andres/0000-0001-7375-7109				ALMERS W, 1987, J PHYSIOL-LONDON, V386, P205, DOI 10.1113/jphysiol.1987.sp016530; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DETOLEDO GA, 1990, J CELL BIOL, V110, P1033, DOI 10.1083/jcb.110.4.1033; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; LINDAU M, 1987, FEBS LETT, V222, P317, DOI 10.1016/0014-5793(87)80393-9; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MONCK JR, 1990, P NATL ACAD SCI USA, V87, P7804, DOI 10.1073/pnas.87.20.7804; MONCK JR, IN PRESS J CELL BIOL; MOUSLI M, 1989, J PHARMACOL EXP THER, V250, P329; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; PADFIELD PJ, 1992, P NATL ACAD SCI USA, V89, P1656, DOI 10.1073/pnas.89.5.1656; PENNER R, 1987, BIOSCIENCE REP, V7, P313, DOI 10.1007/BF01121453; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SENYSHYN J, 1992, FEBS LETT, V309, P41, DOI 10.1016/0014-5793(92)80735-Y; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x	33	166	167	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					270	273		10.1038/360270a0	http://dx.doi.org/10.1038/360270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1331813				2022-12-01	WOS:A1992JY96000056
J	PERERA, FP; HEMMINKI, K; GRYZBOWSKA, E; MOTYKIEWICZ, G; MICHALSKA, J; SANTELLA, RM; YOUNG, TL; DICKEY, C; BRANDTRAUF, P; DEVIVO, I; BLANER, W; TSAI, WY; CHORAZY, M				PERERA, FP; HEMMINKI, K; GRYZBOWSKA, E; MOTYKIEWICZ, G; MICHALSKA, J; SANTELLA, RM; YOUNG, TL; DICKEY, C; BRANDTRAUF, P; DEVIVO, I; BLANER, W; TSAI, WY; CHORAZY, M			MOLECULAR AND GENETIC-DAMAGE IN HUMANS FROM ENVIRONMENTAL-POLLUTION IN POLAND	NATURE			English	Article							LUNG-CANCER; DNA ADDUCTS; BINDING	EXTREME environmental pollution such as that found in the highly industrialized Silesian region of Poland has been associated with increased risk of cancer and adverse reproductive outcomes1,2. Among the most prevalent carcinogenic and mutagenic air pollutants in Silesia are the polycyclic aromatic hydrocarbons (PAH) which are largely produced by industrial and residential combustion of coal1. Molecular epidemiology aims to prevent disease by using biological markers to identify risks well before clinicai onset to allow effective intervention3-7. Here, we use a battery of biological markers to measure molecular and genetic damage in peripheral blood samples from residents of Silesia and from persons living in a rural, less polluted area of Poland. The results show that their exposure to environmental pollution is associated with significant increases in carcinogen-DNA adducts (PAH-DNA and aromatic adducts), in sister chromatid exchange including high-frequency cells, and in chromosomal aberrations as well as a doubling in the frequency of ras oncogene overexpression. We found that aromatic adducts on DNA were significantly correlated with chromosomal mutation, providing us with a molecular link between environmental exposure and a genetic alteration relevant to cancer and reproductive risk.	KAROLINSKA INST,CNT,S-14152 HUDDINGE,SWEDEN; INST ONCOL,DEPT TUMOR BIOL,PL-44100 GLIWICE,POLAND; COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032; COLUMBIA UNIV,DIV BIOSTAT,NEW YORK,NY 10032	Karolinska Institutet; Maria Sklodowska-Curie National Research Institute of Oncology; Columbia University; Columbia University	PERERA, FP (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,DIV ENVIRONM SCI,60 HAVEN AVE,B1-109,NEW YORK,NY 10032, USA.			Perera, Frederica/0000-0002-1364-9250				BARTSCH H, 1988, METHODS DETECTING DN; BIERI JG, 1979, AM J CLIN NUTR, V32, P2500; BRANDTRAUF PW, 1992, FORD INT J CANCER, V51, P1; BRANDTRAUF PW, 1990, CURRENT ISSUES RESPI, V3, P4; CARRANO AV, 1988, MUTAT RES, V204, P379, DOI 10.1016/0165-1218(88)90036-5; FAORO R, 1991, AEROMETRIC INFORMATI; FRIEDMAN GD, 1986, AM J EPIDEMIOL, V123, P781, DOI 10.1093/oxfordjournals.aje.a114307; FUKINO H, 1982, MUTAT RES, V102, P237, DOI 10.1016/0165-1218(82)90133-1; HEMMINKI K, 1990, CARCINOGENESIS, V11, P1229, DOI 10.1093/carcin/11.7.1229; HENNEKENS CH, 1984, CANCER DETECT PREV, V7, P147; HERTZMAN C, 1990, HLTH POLICY RES UNIT, V90, pD2; JEDRYCHOWSKI W, 1990, J EPIDEMIOL COMMUN H, V44, P114, DOI 10.1136/jech.44.2.114; MAYER JL, IN PRESS MUTATION RE; MOON TE, NUTRITION CANCER PRE; MOORE DH, 1984, SISTER CHROMATID EXC, P469; MOTYKIEWICZ G, 1989, MUTAT RES, V223, P243, DOI 10.1016/0165-1218(89)90052-9; PERERA FP, 1988, CANCER RES, V48, P2288; PERERA FP, 1990, CA A CANCER J CLIN, V40, P227; PERERA FP, IN PRESS MOL EPIDEMI; PEZZUTO JM, 1986, P AM ASSOC CANC RES, V27, P126; WEI LJ, 1983, J AM STAT ASSOC, V78, P725; Wilcosky T. C., 1990, BIOL MARKERS EPIDEMI, P3; IN PRESS MONOGRAPH I	23	255	258	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 19	1992	360	6401					256	258		10.1038/360256a0	http://dx.doi.org/10.1038/360256a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436106				2022-12-01	WOS:A1992JY96000050
J	RICHARDSON, MA; GERLITZ, B; GRINNELL, BW				RICHARDSON, MA; GERLITZ, B; GRINNELL, BW			ENHANCING PROTEIN-C INTERACTION WITH THROMBIN RESULTS IN A CLOT-ACTIVATED ANTICOAGULANT	NATURE			English	Article							THROMBOMODULIN; COAGULATION; EXPRESSION; SUBSTITUTION; INHIBITION; INFUSION; SEQUENCE; MODEL	HUMAN protein C is a vitamin K-dependent plasma glycoprotein that circulates as an inactive zymogen. At the endothelial cell surface, thrombin in complex with the integral membrane protein thrombomodulin converts protein C to its active form by specific cleavage of an activation peptide1-3. The activated form of protein C has potent anticoagulant activity as a feedback regulator of thrombin generation (reviewed in refs 4-6), and also has profibrinolytic7-10, anti-ischaemic11 and anti-inflammatory properties12. Protein C is effective in the treatment of model and human thrombotic diseases4,13-16 but, except when it has been used to treat genetic or acquired deficiencies and microvascular thrombosis, it is administered as the activated enzyme, which has a short biological half-life. We have altered two putative inhibitory acidic residues near the thrombin cleavage site, which results in a 30-fold increase in substrate utilization by alpha-thrombin. We combined these changes with a genetically altered glycoform to generate a zymogen protein C with a 60-fold increased cleavage rate by free alpha-thrombin, independent of its cofactor thrombomodulin. We show that this 'proform' of protein C, unlike the natural circulating zymogen, can be activated by thrombin generated in clotting human plasma, resulting in an inhibition of further clot formation. Our data therefore show that we have engineered a site-activated agent, which only has anticoagulant activity when significant amounts of thrombin are being generated.	ELI LILLY & CO, LILLY RES LAB, LILLY CORP CTR, DEPT CARDIOVASC RES, INDIANAPOLIS, IN 46285 USA	Eli Lilly								BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; CHANG JY, 1985, EUR J BIOCHEM, V151, P271; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; COMP PC, 1981, J CLIN INVEST, V68, P1221, DOI 10.1172/JCI110368; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; EHRLICH HJ, 1989, J BIOL CHEM, V264, P14298; EHRLICH HJ, 1990, EMBO J, V9, P2367, DOI 10.1002/j.1460-2075.1990.tb07411.x; EMERICK SC, 1987, PHARM TOXICOLOGY PRO, P351; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1989, PROG HEMOST THROMB, V9, P29; ESMON NL, 1982, J BIOL CHEM, V257, P859; FENG FN, 1989, BIOCHEMISTRY-US, V28, P3094; GARDNER JE, 1983, HUMAN PROTEIN C THRO, P265; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; GRINNELL BW, 1987, BIO-TECHNOL, V5, P1189, DOI 10.1038/nbt1187-1189; GRINNELL BW, 1990, PROTEIN C RELATED AN, P13; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; GRUBER A, 1989, BLOOD, V73, P639; HEEB MJ, 1990, J BIOL CHEM, V265, P2365; KISIEL W, 1979, J CLIN INVEST, V64, P761, DOI 10.1172/JCI109521; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; OKAJIMA K, 1990, AM J HEMATOL, V33, P277, DOI 10.1002/ajh.2830330413; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; ROMISCH J, 1991, FIBRINOLYSIS, V5, P191, DOI 10.1016/0268-9499(91)90023-W; SNOW TR, 1991, CIRCULATION, V84, P293, DOI 10.1161/01.CIR.84.1.293; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; YE J, 1991, J BIOL CHEM, V266, P23016; ZOLTON R P, 1973, Thrombosis Research, V3, P23, DOI 10.1016/0049-3848(73)90123-0	33	47	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 19	1992	360	6401					261	264		10.1038/360261a0	http://dx.doi.org/10.1038/360261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JY960	1436107				2022-12-01	WOS:A1992JY96000052
J	BERKY, ZT; LUCIANO, WJ; JAMES, WD				BERKY, ZT; LUCIANO, WJ; JAMES, WD			LATEX GLOVE ALLERGY - A SURVEY OF THE UNITED-STATES-ARMY-DENTAL-CORPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CONTACT URTICARIA; RUBBER GLOVES; HOSPITAL PERSONNEL; ANAPHYLAXIS; DERMATITIS; HEALTH; VINYL	Objective.-To assess the prevalence of latex glove allergy in a population of health care providers (dentists) with a high occupational exposure to latex gloves. Design.-A survey instrument was distributed to all active-duty dental officers in the US Army (n=1628). The survey was designed to identify those individuals who had symptoms of allergy to latex gloves. Setting.-US Army dental facilities worldwide. Results.-The response rate to the survey was 64% (n=1043). There were 143 (13.7%) responses indicating latex glove allergy. If nonrespondents were assumed to be allergy-free, the prevalence rate would be 8.8%. Conclusion.-Latex allergy, as ascertained by self-report in this survey, appears to have a substantial prevalence in this health care provider population.	USA,DENT CLIN,FT RICHIE,MD; WALTER REED ARMY MED CTR,DERMATOL SERV,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	BERKY, ZT (corresponding author), CRAVEN DENT CLIN,FT KNOX,KY 40121, USA.							BAUER X, 1990, LANCET, V335, P912; BELSITO DV, 1990, DERMATOL CLIN, V8, P61, DOI 10.1016/S0733-8635(18)30523-0; CONDESALAZAR L, 1990, DERMATOL CLIN, V8, P49, DOI 10.1016/S0733-8635(18)30521-7; DOOMSGOOSSENS A, 1988, J AM ACAD DERMATOL, V18, P1360, DOI 10.1016/S0190-9622(88)80116-6; FISHER AA, 1991, CUTIS, V47, P301; GOLD M, 1991, J ALLERGY CLIN IMMUN, V87, P662, DOI 10.1016/0091-6749(91)90385-2; GONZALEZ E, 1988, J AM DENT ASSOC, V117, P467, DOI 10.1016/S0002-8177(88)73019-6; HEALEY MP, 1990, J AM DENT ASSOC, V121, P672, DOI 10.14219/jada.archive.1990.0273; KORNIEWICZ DM, 1990, J CLIN MICROBIOL, V28, P787, DOI 10.1128/JCM.28.4.787-788.1990; KOTILAINEN HR, 1989, ARCH INTERN MED, V149, P2749; LAWLOR K, IN PRESS CUTANEOUS S; MARCH PJ, 1988, J AM DENT ASSOC, V117, P590, DOI 10.14219/jada.archive.1988.0046; MASO MJ, 1990, J AM ACAD DERMATOL, V23, P733, DOI 10.1016/0190-9622(90)70283-N; MAYER R, 1988, JAMA-J AM MED ASSOC, V259, P3184; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb15107.x; PALMER C, 1989, ADA NEWS, V20, P1; RICH P, 1991, J AM ACAD DERMATOL, V24, P37, DOI 10.1016/0190-9622(91)70006-N; RUDZKI E, 1989, CONTACT DERMATITIS, V20, P247, DOI 10.1111/j.1600-0536.1989.tb03140.x; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SOCKIN S M, 1991, Journal of Allergy and Clinical Immunology, V87, P269, DOI 10.1016/0091-6749(91)91803-2; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TAYLOR JS, 1986, CONTACT DERMATITIS, P604; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, BRIT MED J, V297, P1029, DOI 10.1136/bmj.297.6655.1029; TURJANMAA K, 1989, CONTACT DERMATITIS, V20, P360, DOI 10.1111/j.1600-0536.1989.tb03173.x; TURJANMAA K, 1984, ALLERGY S2, V40, pS35; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; WRANGSJO K, 1986, CONTACT DERMATITIS, V15, P79, DOI 10.1111/j.1600-0536.1986.tb01281.x; WRANGSJO K, 1988, CONTACT DERMATITIS, V19, P264, DOI 10.1111/j.1600-0536.1988.tb02925.x; 1990, ARMY DEFENSE MATERIA; 1990, FDA DRUG B, V20, P2; 1988, FACTS AIDS DENTAL TE; 1988, MMWR, V379, P377	39	78	79	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2695	2697						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1433688				2022-12-01	WOS:A1992JX68000032
J	KATZ, DA; LITTENBERG, B; CRONENWETT, JL				KATZ, DA; LITTENBERG, B; CRONENWETT, JL			MANAGEMENT OF SMALL ABDOMINAL AORTIC-ANEURYSMS - EARLY SURGERY VS WATCHFUL WAITING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FACTORS AFFECTING SURVIVAL; CORONARY-ARTERY DISEASE; EXPANSION RATE; NATURAL-HISTORY; RISK-FACTORS; MORTALITY; RUPTURE; EXPERIENCE; VARIABLES; COMPLICATIONS	Objective.-To compare two clinical strategies for the management of small abdominal aortic aneurysms (AAAs) less than 5 cm in diameter: early surgery (repair small AAAs when diagnosed) and watchful waiting (measure AAA size every 6 months and repair when the diameter reaches 5 cm). Data Sources.-We reviewed data from an earlier longitudinal study of patients with small AAAs to estimate incidence rates of rupture or acute expansion. Estimates for other parameters in the model were obtained by searching the medical literature (MEDLINE, 1966 to present). Data Synthesis.-We constructed a Markov decision tree to compare early surgery with watchful waiting in patients with asymptomatic AAAs less than 5 cm in diameter, with respect to long-term survival in quality-adjusted life years. The average annual rates of rupture or acute expansion for AAAs with a maximal transverse diameter of less than 4.0, 4.0 to 4.9, and at least 5.0 cm, are 0, 3.3, and 14.4 events per 100 patient-years of observation, respectively. At an average rupture rate of 3.3 events per 100 patient-years and an average operative risk for elective surgery (4.6%, 30-day mortality), our model predicts that early surgery improves survival in patients who present with a 4-cm AAA. The benefit of early surgery decreases with increased age at presentation. If the average rupture rate for AAAs less than 5 cm is assumed to be low (eg, 0.4 event per 100 patient-years), watchful waiting is favored, particularly as operative risk increases. The decision in this subgroup, however, is sensitive to possible future increases in operative risk. Conclusions.-In the majority of scenarios that we examined, early surgery is preferred to watchful waiting for patients with AAAs less than 5 cm in diameter. Watchful waiting is generally favored, however, for patients with a low risk of AAA rupture or acute expansion, including those patients who present with very small AAAs (eg, <4 cm). More accurate data concerning the rupture risk of AAAs less than 5 cm would improve clinical decision making.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT MED,TECHNOL ASSESSMENT PROGRAM,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,VASC SURG SECT,HANOVER,NH 03756	Dartmouth College; Dartmouth College	KATZ, DA (corresponding author), VET ADM MED CTR,DEPT MED 111B,WHITE RIVER JCT,VT 05001, USA.			Katz, David/0000-0001-5348-6532; Littenberg, Benjamin/0000-0002-7647-1808				ABERNATHY CM, 1986, JAMA-J AM MED ASSOC, V256, P597; Amundsen S, 1989, Eur J Vasc Surg, V3, P405, DOI 10.1016/S0950-821X(89)80046-5; BAIRD RJ, 1978, CAN MED ASSOC J, V118, P1229; BALLARD DJ, 1990, ABDOMINAL AORTIC ANE, P1; BECK JR, 1983, MED DECIS MAKING, V3, P411; BERGQVIST D, 1990, ACTA CHIR SCAND, V156, P63; Berne T V, 1969, Am Surg, V35, P36; BERNSTEIN EF, 1984, ANN SURG, V200, P255, DOI 10.1097/00000658-198409000-00003; BICKERSTAFF LK, 1984, J VASC SURG, V1, P6, DOI 10.1067/mva.1984.avs0010006; BODILY KC, 1985, AM J SURG, V149, P580, DOI 10.1016/S0002-9610(85)80129-X; BRECKWOLDT WL, 1991, J VASC SURG, V13, P798, DOI 10.1016/0741-5214(91)90044-U; BUTLER MJ, 1978, BRIT J SURG, V65, P839, DOI 10.1002/bjs.1800651204; COLLIN J, 1990, ANGIOLOGY, V41, P53, DOI 10.1177/000331979004100108; CRONENWETT JL, 1985, SURGERY, V98, P472; CRONENWETT JL, 1990, J VASC SURG, V11, P260; DARLING RC, 1977, CIRCULATION, V56, P161; DEBAKEY ME, 1964, ANN SURG, V160, P622, DOI 10.1097/00000658-196410000-00007; DENT A, 1986, BRIT J SURG, V73, P318; DIEHL JT, 1983, ANN SURG, V197, P49, DOI 10.1097/00000658-198301001-00008; DONALDSON MC, 1985, J VASC SURG, V2, P564; FIELDING JWL, 1981, BRIT MED J, V283, P355, DOI 10.1136/bmj.283.6287.355; FOSTER JH, 1969, SURG GYNECOL OBSTETR, V129, P1; Glimaker H, 1991, Eur J Vasc Surg, V5, P125, DOI 10.1016/S0950-821X(05)80675-9; GUIRGUIS EM, 1991, AM J SURG, V162, P481, DOI 10.1016/0002-9610(91)90266-G; HOLLIER LH, 1984, J VASC SURG, V1, P290, DOI 10.1067/mva.1984.avs0010290; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; JOHANSEN K, 1991, J VASC SURG, V13, P240, DOI 10.1016/0741-5214(91)90216-H; Johansson G, 1990, Eur J Vasc Surg, V4, P497, DOI 10.1016/S0950-821X(05)80791-1; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; JOHNSON G, 1980, ARCH SURG-CHICAGO, V115, P51; JOHNSTON KW, 1989, J VASC SURG, V9, P437, DOI 10.1067/mva.1989.vs0090437; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1467; KREMER H, 1984, KLIN WOCHENSCHR, V62, P1120, DOI 10.1007/BF01782469; LAWRIE GM, 1979, SURGERY, V85, P483; LEDERLE FA, 1988, ARCH INTERN MED, V148, P1753, DOI 10.1001/archinte.148.8.1753; LIMET R, 1991, J VASC SURG, V14, P540, DOI 10.1016/0741-5214(91)90249-T; LITTOOY FN, 1989, ARCH SURG-CHICAGO, V124, P419; MCCABE CJ, 1981, ARCH SURG-CHICAGO, V116, P1025; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; MURPHY JL, 1990, CAN J SURG, V33, P201; NEVITT MP, 1989, NEW ENGL J MED, V321, P1009, DOI 10.1056/NEJM198910123211504; Olsen P S, 1990, Ann Vasc Surg, V4, P580, DOI 10.1016/S0890-5096(06)60843-1; OLSEN PS, 1991, J CARDIOVASC SURG, V32, P636; OURIEL K, 1990, J VASC SURG, V11, P493, DOI 10.1067/mva.1990.18639; PILCHER DB, 1980, AM J SURG, V139, P487, DOI 10.1016/0002-9610(80)90325-6; PLATE G, 1985, ARCH SURG-CHICAGO, V120, P590; PLATE G, 1988, ACTA CHIR SCAND, V154, P25; QUILL DS, 1989, SURG CLIN N AM, V69, P713; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SHACKLETON CR, 1987, J VASC SURG, V6, P583, DOI 10.1067/mva.1987.avs0060583; STERPETTI AV, 1991, SURG GYNECOL OBSTET, V173, P175; STERPETTI AV, 1985, AM J SURG, V150, P772, DOI 10.1016/0002-9610(85)90427-1; SULLIVAN CA, 1990, J VASC SURG, V11, P799; SZILAGYI DE, 1966, ANN SURG, V164, P678, DOI 10.1097/00000658-196610000-00014; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; THOMAS PRS, 1988, BRIT J SURG, V75, P733, DOI 10.1002/bjs.1800750804; 1987, VITAL STATISTICS US; 1990, USRDS1990 US REN DAT, P33	60	109	110	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2678	2686		10.1001/jama.268.19.2678	http://dx.doi.org/10.1001/jama.268.19.2678			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1433687				2022-12-01	WOS:A1992JX68000030
J	PHILLIPS, AN; ELFORD, J; SABIN, C; BOFILL, M; JANOSSY, G; LEE, CA				PHILLIPS, AN; ELFORD, J; SABIN, C; BOFILL, M; JANOSSY, G; LEE, CA			IMMUNODEFICIENCY AND THE RISK OF DEATH IN HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILIC COHORT; NATURAL-HISTORY; VIRUS-INFECTION; AIDS; COUNTS; PROGRESSION; PREDICTORS; MARKERS; TYPE-1; FOLLOW	Objective.-To describe the rate of development of immunodeficiency in human immunodeficiency virus (HIV) infection and to relate this to the risk of death. Design.-Inception cohort followed up for up to 12 years from HIV seroconversion until January 1, 1992. Setting.-A regional hemophilia center based in a major teaching hospital. Patients.-All 111 patients with hemophilia who seroconverted to HIV-1 between 1979 and 1985 were registered at the center. Patients have been closely followed up clinically and immunologically. Outcome Measures.-Development of immunodeficiency, defined by a CD4 lymphocyte count falling beneath 0.20 and 0.05 x 10(9)/L, and death. Results.-Kaplan-Meier estimates suggest that almost half (46%; 95% confidence interval [CI], 26% to 66%) of patients alive 12 years after seroconversion will have a CD4 lymphocyte count that has remained above 0.05 x 10(9)/L. Thirty-five percent (95% CI, 22% to 48%) remain above 0.20 x 10(9)/L. Thirty-seven patients died of HIV-related causes, and there was a 52% probability (95% CI, 35% to 69%) of HIV-related mortality by 12 years from seroconversion. Mortality risk was closely associated with severe immunodeficiency. There was only a 15% chance (95% CI, 6% to 25%) of HIV-related death occurring before a CD4 count of below 0.05 x 10(9)/L had been reached. There was an average of one HIV-related death per 96.7 patient-years of observation before the CD4 count had fallen below 0.05 x 10(9)/L, as compared with one death per 2.5 patient-years of observation after the CD4 count had fallen below this level (P<.0001). Conclusions.-In patients with HIV infection who are closely followed up, the risk of death is low before the CD4 lymphocyte count has fallen to 0.05 x 10(9)/L, a count many patients remain above up to 12 years after seroconversion.	UNIV LONDON ROYAL FREE HOSP,DEPT PUBL HLTH & PRIMARY CARE,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,DEPT IMMUNOL,LONDON,ENGLAND; UNIV LONDON ROYAL FREE HOSP,CTR HAEMOPHILIA,LONDON,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London	PHILLIPS, AN (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				CAMPANA D, 1987, J IMMUNOL, V138, P648; ESTEBAN JI, 1990, LANCET, V335, P1419; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; EYSTER ME, 1992, 7TH INT C AIDS AMST; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; JANOSSY G, 1985, CLIN EXP IMMUNOL, V59, P257; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LANGHON BE, 1991, J INFECT DIS, V164, P244; LEE C, 1992, BRIT J HAEMATOL, V81, P133, DOI 10.1111/j.1365-2141.1992.tb08191.x; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PHILLIPS AN, 1991, LANCET, V337, P389; PHILLIPS AN, 1992, J ACQ IMMUN DEF SYND, V5, P148; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; TEDDER RS, 1991, BRIT MED J, V302, P1299, DOI 10.1136/bmj.302.6788.1299; WAYNE WF, 1988, CYTOMETRY, V3, P23; WEBER R, 1990, BRIT MED J, V301, P1362, DOI 10.1136/bmj.301.6765.1362; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184; [No title captured]	25	70	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2662	2666		10.1001/jama.268.19.2662	http://dx.doi.org/10.1001/jama.268.19.2662			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX680	1359163				2022-12-01	WOS:A1992JX68000027
J	STONE, VE; SEAGE, GR; HERTZ, T; EPSTEIN, AM				STONE, VE; SEAGE, GR; HERTZ, T; EPSTEIN, AM			THE RELATION BETWEEN HOSPITAL EXPERIENCE AND MORTALITY FOR PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; ACQUIRED IMMUNODEFICIENCY SYNDROME; PROGNOSTIC FACTORS; NEW-YORK; VOLUME; SEVERITY; QUALITY; OUTCOMES; PERFECT; ILLNESS	Objective.-To determine whether there is an association between mortality and hospital acquired immune deficiency syndrome (AIDS) experience for all AIDS-related diagnoses, and to determine whether the association is explained by differences in severity of illness, earlier discharge of terminally ill patients, or differences in resource use. Design and Setting.-Population-based statewide cohort study. All hospitalizations identified for a cohort of AIDS patients diagnosed during 1987 in 40 Massachusetts hospitals were included. Patients.-All women and all male intravenous drug users (n=151), and a random sample of all male non-intravenous drug users diagnosed with AIDS during 1987 in Massachusetts (n=149). Main Outcome Measures.-Primary end points studied were (1) inpatient mortality and (2) 30-day mortality. Length of stay, cost, and intensive care unit use were also examined. Results.-In 806 hospitalizations at 40 hospitals inpatient mortality was 13.2%. Relative risk of mortality at low AIDS experience hospitals was 2.16 (95% confidence interval, 1.43 to 3.26) compared with high AIDS experience hospitals. When logistic regression was used to control for age, sex, race, human immunodeficiency virus transmission mode, severity, payer, admission type, hospital ownership, and teaching status, low hospital experience with AIDS remained a significant predictor of inpatient mortality (relative risk, 2.92; 95% confidence interval, 1.37 to 6.22). Comparisons of 30-day mortality by hospital AIDS experience yielded similar results. Length of stay and intensive care unit use were also significantly higher at low-experience hospitals after controlling for severity of illness (P<.05). Conclusions.-We conclude that mortality of AIDS patients is higher at hospitals with less AIDS experience. This finding is not because of greater severity of illness, differences in discharge patterns of the terminally ill, or less intensive use of resources.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BOSTON UNIV,BOSTON CITY HOSP,SCH MED,DEPT MED,INFECT DIS SECT,BOSTON,MA 02118; BOSTON UNIV,BOSTON CITY HOSP,SCH MED,DEPT MED,GEN INTERNAL MED SECT,BOSTON,MA 02118; BOSTON DEPT HLTH & HOSP,INST URBAN HLTH POLICY RES & EDUC,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Boston Medical Center; Boston University; Boston Medical Center; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Brigham & Women's Hospital					AHRQ HHS [1 RO3HS06150-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; BENNETT CL, 1990, ARCH INTERN MED, V150, P1447, DOI 10.1001/archinte.150.7.1447; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; COTTON DJ, 1989, JAMA-J AM MED ASSOC, V261, P3016, DOI 10.1001/jama.261.20.3016; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; ELSADR W, 1988, AM REV RESPIR DIS, V137, P1264, DOI 10.1164/ajrccm/137.6.1264; FINK A, 1989, MED CARE, V27, P315, DOI 10.1097/00005650-198904000-00001; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HARDY AM, 1987, PUBLIC HEALTH REP, V102, P386; HARTZ AJ, 1989, NEW ENGL J MED, V321, P1720, DOI 10.1056/NEJM198912213212506; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JUSTICE AC, 1989, NEW ENGL J MED, V320, P1388, DOI 10.1056/NEJM198905253202106; KAHN KL, 1988, JAMA-J AM MED ASSOC, V260, P3625, DOI 10.1001/jama.260.24.3625; KALES CP, 1987, ARCH INTERN MED, V147, P1413; KELLY JV, 1989, MED CARE, V27, P1085, DOI 10.1097/00005650-198912000-00001; LIPSITZ SR, 1990, COMPUT BIOMED RES, V23, P268, DOI 10.1016/0010-4809(90)90021-4; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; MATHEWS WC, 1989, J CLIN EPIDEMIOL, V42, P421, DOI 10.1016/0895-4356(89)90131-5; MOSKOWITZ MA, 1988, J AM GERIATR SOC, V36, P860, DOI 10.1111/j.1532-5415.1988.tb04272.x; ODDLEIFSON S, 1989, 5TH INT C AIDS MONTR; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; ROTHMAN DJ, 1990, NEW ENGL J MED, V323, P764, DOI 10.1056/NEJM199009133231129; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; TURNER BJ, 1989, MED CARE, V27, P423, DOI 10.1097/00005650-198904000-00009; WENGER JD, 1988, J GEN INTERN MED, V3, P464, DOI 10.1007/BF02595923; ZAMAN MK, 1988, AM REV RESPIR DIS, V137, P796, DOI 10.1164/ajrccm/137.4.796; 1987, MMWR S, V36, pS1; 1991, FED REGISTER, V56, P25178; 1987, MEDICARE B	36	99	99	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2655	2661		10.1001/jama.268.19.2655	http://dx.doi.org/10.1001/jama.268.19.2655			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX680	1433685				2022-12-01	WOS:A1992JX68000026
J	WEITZMAN, M; GORTMAKER, SL; SOBOL, AM; PERRIN, JM				WEITZMAN, M; GORTMAKER, SL; SOBOL, AM; PERRIN, JM			RECENT TRENDS IN THE PREVALENCE AND SEVERITY OF CHILDHOOD ASTHMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHANGING PATTERNS; BEHAVIOR PROBLEMS; NEW-ZEALAND; CHILDREN; MORTALITY; HOSPITALIZATION; RATES; HEALTH; RISKS	Objective.-To examine changes in the prevalence and distribution of childhood asthma and its relationship with various measures of children's health and functioning between 1981 and 1988. It was hypothesized that there would be an increase in the prevalence of asthma, especially among black children, and that available measures would suggest a deterioration in the health and functioning of children with asthma over this period. Design.-Analyses of data from the Child Health Supplements to the National Health Interview Survey. Setting and Sample.-Nationally representative random sample of 15 224 children aged 0 to 17 years in 1981 and 17 110 in 1988. Main Outcome Measures.-Changes in (1) the prevalence and distribution of asthma, and (2) among children with asthma, the percentage of children hospitalized, days spent in bed, school days lost in the year prior to survey, and parent ratings and reports of children's overall health status and behavior problems. Results.-The estimated prevalence of childhood asthma increased from 3.1% in 1981 to 4.3% in 1988 (P<.0001), with similar increases for children, adolescents, and both sexes. Increases occurred among white children (2.7% to 4.1%; P<.0001) but not black children (5.3% vs 5.1%; not significant). Among those with asthma in 1988 compared with 1981, there was better overall health status (11% vs 24% fair/poor; P<.0001) and fewer with 30 or more days spent in bed in the last year (3.9% vs 7.2%; P<.04). We also observed trends toward a lower rate of hospitalization in the last year (10% vs 14%; P=.07), fewer school days missed (2% vs 6% with >30 days; P=.08), and a lower rate of extreme behavior problem scores (13% vs 18%; P=.09) in 1988 compared with 1981. Reductions were similar among both black and white children. Conclusions.-These results indicate that the estimated prevalence of asthma among children in the United States increased by almost 40%, and that although the increase occurred exclusively among white children, the prevalence of asthma still remains higher in black children than in white children. There was no support for increasing asthma severity and functional impact among either black or white children with asthma in 1988 compared with 1981. These findings provide no evidence to support the beliefs that asthma prevalence is increasing largely among black children or that the severity of asthma among most children in the United States is increasing.	UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642; HARVARD UNIV,SCH PUBL HLTH,DEPT BEHAV SCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114	University of Rochester; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital				Perrin, James/0000-0002-1810-3708				ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172, DOI 10.1136/adc.64.1.172; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURT ML, 1989, ARCH DIS CHILD, V64, P1452; BURT ML, 1987, J EPIDEMIOL COMMUNIT, V41, P185; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CYPRESS BK, 1983, VITAL HLTH STAT 13, V75, P13; EVANS R, 1987, CHEST, V91, P652; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; HAAHTELA T, 1990, BRIT MED J, V301, P266, DOI 10.1136/bmj.301.6746.266; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; NEWACHECK PW, 1986, AM J PUBLIC HEALTH, V76, P178, DOI 10.2105/AJPH.76.2.178; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; PERRIN JM, 1991, AJDC, V145, P415; PETERSON JL, 1986, J MARRIAGE FAM, V48, P295, DOI 10.2307/352397; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SLY RM, 1988, ANN ALLERGY, V60, P433; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SUDMAN S, 1976, APPL SAMPLING, P69; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEITZMAN M, 1986, J CHRON DIS, V39, P799, DOI 10.1016/0021-9681(86)90082-2; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1992, PEDIATRICS, V90, P342; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; 1982, VITAL HLTH STAT 10, V14, P1; 1989, STATISTICAL ABSTRACT, P462; 1990, PHS901232 NAT CTR HL, P16; 1973, PHS DHEW HRA741511 P, P1	40	285	287	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1992	268	19					2673	2677		10.1001/jama.268.19.2673	http://dx.doi.org/10.1001/jama.268.19.2673			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX680	1304735				2022-12-01	WOS:A1992JX68000029
J	BARRETTCONNOR, E				BARRETTCONNOR, E			LOWER ENDOGENOUS ANDROGEN LEVELS AND DYSLIPIDEMIA IN MEN WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	ANNALS OF INTERNAL MEDICINE			English	Article						ANDROGENS; DIABETES-MELLITUS, NON-INSULIN-DEPENDENT; TESTOSTERONE; LIPOPROTEINS, HDL; CHOLESTEROL; TRIGLYCERIDES	DENSITY-LIPOPROTEIN CHOLESTEROL; HORMONE-BINDING GLOBULIN; PLASMA TESTOSTERONE LEVELS; SEX-HORMONES; GLUCOSE-INTOLERANCE; BOUND TESTOSTERONE; SERUM-LIPOPROTEINS; ADULT MEN; ESTRADIOL; RESISTANCE	Objective: To compare plasma androgen levels in diabetic and nondiabetic men and to determine their relation to diabetic dyslipidemia. Design: A population-based, case-control study. Setting: Community. Participants: Men 53 to 88 years of age from the Rancho Bernardo, California, cohort who were screened for diabetes using an oral glucose tolerance test. Measurements: Plasma androgen levels were compared in 44 men with untreated non-insulin-dependent diabetes mellitus and 88 age-matched men who had a normal glucose tolerance test. The relation of lipid and lipoprotein levels to androgen level and diabetic status was assessed before and after adjusting for covariates. Results: Men with diabetes had significantly lower plasma levels of free (4.96 nmol/L compared with 5.58 nmol/L) and total testosterone (14.7 nmol/L compared with 17.4 nmol/L), dihydrotestosterone (428 pg/mL compared with 533 pg/mL), and dehydroepiandrosterone sulfate (DHEA-S) (1.92 mumol/L compared with 2.42 mumol/L) than nondiabetic men. They also had significantly lower high-density lipoprotein (HDL) cholesterol and significantly higher triglyceride levels. Differences were not explained by obesity, alcohol use, or cigarette habit. Overall, the total testosterone level, but not the free testosterone level, was positively correlated with the HDL cholesterol level (P = 0.009) and negatively correlated with the triglyceride level (P = 0.0001). Similar associations were seen in analyses restricted to the men without diabetes. Conclusions: Lower levels of endogenous androgens are seen in older diabetic men, and low androgen levels are associated with diabetic dyslipidemia.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO, DEPT COMMUNITY & FAMILY MED, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.				NIA NIH HHS [AG07181] Funding Source: Medline; NIDDK NIH HHS [DK31801] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007181, R01AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTT WGH, 1987, DIABETES, V36, P897, DOI 10.2337/diabetes.36.8.897; ANDERSON DC, 1976, STEROIDS, V28, P179, DOI 10.1016/0039-128X(76)90108-2; ANDO S, 1984, J ENDOCRINOL INVEST, V7, P21, DOI 10.1007/BF03348370; BARRETTCONNOR E, 1990, AM J EPIDEMIOL, V132, P895, DOI 10.1093/oxfordjournals.aje.a115732; BREMNER WJ, 1983, J CLIN ENDOCR METAB, V56, P1278, DOI 10.1210/jcem-56-6-1278; COHEN JC, 1987, J CLIN ENDOCR METAB, V64, P960, DOI 10.1210/jcem-64-5-960; DAI WS, 1984, AM J CARDIOL, V53, P1259, DOI 10.1016/0002-9149(84)90075-4; DAI WS, 1981, AM J EPIDEMIOL, V114, P804, DOI 10.1093/oxfordjournals.aje.a113251; DUELL PB, 1990, ARCH INTERN MED, V150, P2317, DOI 10.1001/archinte.150.11.2317; FRIEDL KE, 1989, J CLIN ENDOCR METAB, V68, P971, DOI 10.1210/jcem-68-5-971; FRIEDL KE, 1990, METABOLISM, V39, P69, DOI 10.1016/0026-0495(90)90150-B; GODSLAND IF, 1986, CLIN SCI, V71, P665, DOI 10.1042/cs0710665; GUTAI J, 1981, AM J CARDIOL, V48, P897, DOI 10.1016/0002-9149(81)90356-8; HAMALAINEN E, 1986, METABOLISM, V35, P535, DOI 10.1016/0026-0495(86)90011-9; HELLER RF, 1983, ACTA ENDOCRINOL-COP, V104, P253, DOI 10.1530/acta.0.1040253; Khaw K T, 1992, Ann Epidemiol, V2, P675, DOI 10.1016/1047-2797(92)90012-F; KHAW KT, 1991, ARTERIOSCLER THROMB, V11, P489, DOI 10.1161/01.ATV.11.3.489; KIRKLAND RT, 1987, JAMA-J AM MED ASSOC, V257, P502, DOI 10.1001/jama.257.4.502; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LASKARZEWSKI PM, 1983, METABOLISM, V32, P262, DOI 10.1016/0026-0495(83)90191-9; LICHTENSTEIN MJ, 1987, AM J EPIDEMIOL, V126, P647, DOI 10.1093/oxfordjournals.aje.a114704; LINDHOLM J, 1982, AM J MED, V73, P648, DOI 10.1016/0002-9343(82)90405-3; MANNI A, 1985, J CLIN ENDOCR METAB, V61, P705, DOI 10.1210/jcem-61-4-705; MARIN P, IN PRESS OBESITY EUR; MENDOZA SG, 1981, METABOLISM, V30, P481, DOI 10.1016/0026-0495(81)90184-0; MILLER GJ, 1985, ATHEROSCLEROSIS, V55, P251, DOI 10.1016/0021-9150(85)90104-2; MORRISON JA, 1981, CIRCULATION, V64, P113; NORDOY A, 1979, ATHEROSCLEROSIS, V34, P431, DOI 10.1016/0021-9150(79)90067-4; OSTLUND RE, 1990, NEW ENGL J MED, V322, P229, DOI 10.1056/NEJM199001253220404; REBUFFESCRIVE M, 1992, INT J OBESITY, V2, P675; SEIDELL JC, 1990, METABOLISM, V39, P897, DOI 10.1016/0026-0495(90)90297-P; SEMMENS J, 1983, METABOLISM, V32, P428, DOI 10.1016/0026-0495(83)90002-1; SIMON D, 1992, DIABETOLOGIA, V35, P173, DOI 10.1007/BF00402551; SRINIVASAN SR, 1985, METABOLISM, V34, P861, DOI 10.1016/0026-0495(85)90111-8; STEFANICK ML, 1987, J CLIN ENDOCR METAB, V64, P723, DOI 10.1210/jcem-64-4-723; THOMPSON PD, 1989, JAMA-J AM MED ASSOC, V261, P1165, DOI 10.1001/jama.261.8.1165; TREMBLAY RR, 1974, CONTRACEPTION, V10, P599, DOI 10.1016/0010-7824(74)90099-7; WILSON JD, 1980, METABOLISM, V29, P1278, DOI 10.1016/0026-0495(80)90159-6; WINGARD D L, 1990, Diabetes Care, V13, P3; WOODARD TL, 1981, J CLIN ENDOCR METAB, V53, P905, DOI 10.1210/jcem-53-5-905; ZIMMET P, 1990, DIABETES RES CLIN PR, V10, pS167, DOI 10.1016/0168-8227(90)90158-P; 1985, WHO727 STUD GROUP DI; 1974, DHEW75628 NAT HEART	43	239	243	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					807	811		10.7326/0003-4819-117-10-807	http://dx.doi.org/10.7326/0003-4819-117-10-807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416554				2022-12-01	WOS:A1992JX83800002
J	GHALI, JK; LIAO, YL; SIMMONS, B; CASTANER, A; CAO, GC; COOPER, RS				GHALI, JK; LIAO, YL; SIMMONS, B; CASTANER, A; CAO, GC; COOPER, RS			THE PROGNOSTIC ROLE OF LEFT-VENTRICULAR HYPERTROPHY IN PATIENTS WITH OR WITHOUT CORONARY-ARTERY DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; VENTRICULAR FUNCTION, LEFT; HEART ENLARGEMENT; HYPERTENSION; ECHOCARDIOGRAPHY	HEART-DISEASE; ECHOCARDIOGRAPHIC ASSESSMENT; ESSENTIAL-HYPERTENSION; RISK-FACTORS; MASS; INFARCTION; MORTALITY; EVENTS; DEATH; SIZE	Objective: To examine the association between echocardiographically determined left ventricular hypertrophy and mortality in patients with and without coronary artery disease. Design: Cohort study with a mean follow-up period of 4 years. Setting: An inner-city public hospital in Chicago. Patients: A cohort of 785 patients, most of whom were black and had hypertension. Interventions: Coronary arteriography for presumed coronary artery disease and echocardiography. Main Outcome Measure: All-cause and cardiac mortality. Results: Left ventricular hypertrophy, based on left ventricular mass corrected for body surface area, was present in 194 of 381 patients (51%) with coronary artery disease and in 162 of 404 patients (40%) without coronary artery disease. Patients with left ventricular hypertrophy had worse survival than those without hypertrophy in both the group with coronary artery disease and the group without coronary artery disease. After adjustment was made for age at baseline, sex, and hypertension, the relative risk for death from any cause in patients with hypertrophy compared with patients without hypertrophy was 2.14 (95% Cl, 1.24 to 3.68) among those with coronary artery disease and 4.14 (Cl, 1.77 to 9.71) among those without coronary artery disease. Conclusions: Echocardiographically determined left ventricular hypertrophy is an important prognostic marker in patients with or without coronary artery disease. The effect of reversing ventricular hypertrophy in patients with and without coronary disease deserves further study.	LOYOLA UNIV, STRITCH SCH MED, DEPT PREVENT MED & EPIDEMIOL, MAYWOOD, IL 60153 USA; COOK CTY HOSP, CHICAGO, IL 60612 USA	Loyola University Chicago; John H Stroger Junior Hospital Cook County					NHLBI NIH HHS [R01HL 36723] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONOW WS, 1991, AM J CARDIOL, V67, P295, DOI 10.1016/0002-9149(91)90562-Y; BORHANI NO, 1987, AM J CARDIOL, V60, pI13; BORHANI NO, 1986, PROG CARDIOVASC DIS, V29, P55, DOI 10.1016/0033-0620(86)90034-4; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1987, HEART HYPERTENSION, P197; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; FROHLICH ED, 1988, J HYPERTENS, V6, pS2, DOI 10.1097/00004872-198812040-00002; FROHLICH ED, 1987, AM J CARDIOL, V59, pA91, DOI 10.1016/0002-9149(87)90183-4; GHALI JK, 1991, J AM COLL CARDIOL, V17, P1277, DOI 10.1016/S0735-1097(10)80135-4; Kannel W B, 1978, Ann N Y Acad Sci, V304, P128, DOI 10.1111/j.1749-6632.1978.tb25585.x; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KJELSBERG MO, 1985, AM J CARDIOL, V55, P1; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KOYANAGI S, 1982, CIRCULATION, V65, P1192, DOI 10.1161/01.CIR.65.6.1192; KOYANAGI S, 1982, CIRC RES, V50, P55, DOI 10.1161/01.RES.50.1.55; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; Marcus ML, 1983, CORONARY CIRCULATION, P285; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MOSER M, 1991, EUR HEART J, V12, P1034, DOI 10.1093/eurheartj/12.9.1034; PATTERSON JE, 1985, 1299286 DEP TREAS IN, P245; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1987, CIRCULATION, V75, P26; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SCHAIBLE TF, 1986, J APPL PHYSIOL, V60, P1435, DOI 10.1152/jappl.1986.60.4.1435; TROY BL, 1972, CIRCULATION, V45, P602, DOI 10.1161/01.CIR.45.3.602; WEBER KT, 1988, J APPL CARDIOL, V3, P37; ZEHENDER M, 1992, CIRCULATION, V85, P1808, DOI 10.1161/01.CIR.85.5.1808	34	384	388	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					831	836		10.7326/0003-4819-117-10-831	http://dx.doi.org/10.7326/0003-4819-117-10-831			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416558				2022-12-01	WOS:A1992JX83800006
J	SCHARSCHMIDT, BF; HELD, MJ; HOLLANDER, HH; READ, AE; LAVINE, JE; VEEREMAN, G; MCGUIRE, RF; THALER, MM				SCHARSCHMIDT, BF; HELD, MJ; HOLLANDER, HH; READ, AE; LAVINE, JE; VEEREMAN, G; MCGUIRE, RF; THALER, MM			HEPATITIS-B IN PATIENTS WITH HIV-INFECTION - RELATIONSHIP TO AIDS AND PATIENT SURVIVAL	ANNALS OF INTERNAL MEDICINE			English	Note						HEPATITIS-B; HUMAN IMMUNODEFICIENCY VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HUMAN IMMUNODEFICIENCY VIRUS; LONG TERMINAL REPEAT; HOMOSEXUAL MEN; PREVALENCE	Hepatitis B virus (HBV) infection is common in patients infected with human immunodeficiency virus (HIV). Experimental evidence suggests that chronic HBV infection may accelerate the course of HIV-related disease, but clinical data are lacking. Therefore, we assessed the relationship of serologic markers for HBV infection to the presence of AIDS and length of survival in 511 patients with HIV infection, 233 (46%) of whom had AIDS. Hepatitis B virus markers were more prevalent in patients with AIDS (89%) than in those without AIDS (80%; P < 0.02). Among the various markers, anti-HBs did not differ between the groups (62% compared with 61%), whereas HBsAg, a marker of chronic infection, was more than twice as common in the AIDS group (10.7% compared with 4.7%; P < 0.02). Survival was shorter in patients with AIDS than in patients without AIDS but was not influenced in either group by the presence of HBsAg. These findings indicate that chronic HBV infection among HIV-infected patients is more prevalent in patients with AIDS than those without AIDS, and that this association probably reflects a manifestation of AIDS rather than an effect of HBV on progression of HIV-related disease.			SCHARSCHMIDT, BF (corresponding author), UNIV CALIF SAN FRANCISCO, DIV GASTROENTEROL, 1120 HSW, SAN FRANCISCO, CA 94143 USA.				NIADDK NIH HHS [AM 26740] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COX DR, 1972, J R STAT SOC B, V34, P187; HIRSCHMAN SZ, 1988, J MED VIROL, V26, P145, DOI 10.1002/jmv.1890260206; HOMANN C, 1991, J ACQ IMMUN DEF SYND, V4, P416; HOUGHTON J, 1989, CLIN RES, V37, pA368; OUATTARA SA, 1990, J ACQ IMMUN DEF SYND, V3, P282; PERRILLO RP, 1986, ANN INTERN MED, V105, P382, DOI 10.7326/0003-4819-105-3-382; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; TWU JS, 1989, P NATL ACAD SCI USA, V86, P5168, DOI 10.1073/pnas.86.13.5168	9	83	84	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					837	838		10.7326/0003-4819-117-10-837	http://dx.doi.org/10.7326/0003-4819-117-10-837			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416559				2022-12-01	WOS:A1992JX83800007
J	SWERDLOW, DL; WOODRUFF, BA; BRADY, RC; GRIFFIN, PM; TIPPEN, S; DONNELL, HD; GELDREICH, E; PAYNE, BJ; MEYER, A; WELLS, JG; GREENE, KD; BRIGHT, M; BEAN, NH; BLAKE, PA				SWERDLOW, DL; WOODRUFF, BA; BRADY, RC; GRIFFIN, PM; TIPPEN, S; DONNELL, HD; GELDREICH, E; PAYNE, BJ; MEYER, A; WELLS, JG; GREENE, KD; BRIGHT, M; BEAN, NH; BLAKE, PA			A WATERBORNE OUTBREAK IN MISSOURI OF ESCHERICHIA-COLI-O157-H7 ASSOCIATED WITH BLOODY DIARRHEA AND DEATH	ANNALS OF INTERNAL MEDICINE			English	Article						ESCHERICHIA-COLI INFECTIONS; MISSOURI; DIARRHEA; WATER SUPPLY	ESCHERICHIA-COLI O157-H7; HEMOLYTIC-UREMIC SYNDROME; SHIGA-LIKE TOXIN; HEMORRHAGIC COLITIS; MONOCLONAL-ANTIBODIES; SEROTYPE O157-H7; NURSING-HOME; INFECTIONS; 0157-H7	Objective: To describe and determine the source of a large outbreak of Escherichia coli O157:H7 (ECO157) infections in Missouri. Design: A case-control study and a household survey. Setting: A small city in a rural Missouri township that had an unchlorinated water supply. Patients: Case patients were residents of or visitors to Burdine Township with bloody diarrhea or diarrhea and abdominal cramps occurring between 15 December 1989 and 20 January 1990. Measurements: Escherichia coli O157 was isolated from 21 stool specimens. All isolates were resistant to sulfisoxazole, tetracycline, and streptomycin; produced Shiga-like toxins I and II; and had one 60-megadalton plasmid. Results: Among the 243 case patients, 86 had bloody stools, 32 were hospitalized, 4 died, and 2 had the hemolytic uremic syndrome. In the case-control study, no food was associated with illness, but ill persons had drunk more municipal water than had controls (P = 0.04). The survey showed that, during the peak of the outbreak, bloody diarrhea was 18.2 times more likely to occur in persons living inside the city and using municipal water than in persons living outside the city and using private well water (P = 0.001). Shortly before the peak of the outbreak, 45 water meters were replaced, and two water mains ruptured. The number of new cases declined rapidly after residents were ordered to boil water and after chlorination of the water supply. Conclusions: This was the largest outbreak of ECO157 infections, the first due to a multiply resistant organism, and the first shown to be transmitted by water. System-wide chlorination as well as hyperchlorination during repairs might have prevented this outbreak. Both bloody and nonbloody diarrhea may be common manifestations of this infection, which is probably underdiagnosed because of the failure of routine stool cultures to identify the organism. Cities with deteriorating water systems using untreated water risk widespread illness from contaminated drinking water.	MISSOURI STATE DEPT HLTH, JEFFERSON CITY, MO 65102 USA; US EPA, RISK REDUCT ENGN LAB, CINCINNATI, OH 45268 USA	United States Environmental Protection Agency	SWERDLOW, DL (corresponding author), CTR DIS CONTROL, ENTER DIS BRANCH, MAILSTOP C-09, ATLANTA, GA 30333 USA.							[Anonymous], 1989, STANDARD METHODS EXA, V17th; Barry A., 1985, MANUAL CLIN MICROBIO, V4th; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOPP CA, 1987, J CLIN MICROBIOL, V25, P1486, DOI 10.1128/JCM.25.8.1486-1489.1987; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; DOWNES FP, 1988, INFECT IMMUN, V56, P1926, DOI 10.1128/IAI.56.8.1926-1933.1988; Duncan L., 1987, Canada Diseases Weekly Report, V13, P5; GELDREICH EE, 1992, WATER RES, V26, P1127, DOI 10.1016/0043-1354(92)90150-3; GREENE KD, 1991, 91ST ANN M AM SOC MI, P374; GRIFFIN PM, 1988, ANN INTERN MED, V109, P705, DOI 10.7326/0003-4819-109-9-705; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; KONOWALCHUK J, 1977, INFECT IMMUN, V18, P775, DOI 10.1128/IAI.18.3.775-779.1977; MARCH SB, 1986, J CLIN MICROBIOL, V23, P869, DOI 10.1128/JCM.23.5.869-872.1986; MCGOWAN KL, 1989, LANCET, V1, P967; MEYERS JA, 1976, J BACTERIOL, V127, P1529, DOI 10.1128/JB.127.3.1529-1537.1976; NAYLOR GRE, 1983, LANCET, V1, P864; NEILL MA, 1985, ARCH INTERN MED, V145, P2215, DOI 10.1001/archinte.145.12.2215; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; RADETSKY M, 1986, PEDIATR INFECT DIS J, V5, P230, DOI 10.1097/00006454-198603000-00015; RAGHUBEER EV, 1990, J CLIN MICROBIOL, V28, P803, DOI 10.1128/JCM.28.4.803-805.1990; RATNAM S, 1988, J CLIN MICROBIOL, V26, P2006, DOI 10.1128/JCM.26.10.2006-2012.1988; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROSE JB, 1990, INVESTIGATION PREVEN, P223; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1985, INFECT IMMUN, V50, P695, DOI 10.1128/IAI.50.3.695-700.1985; WELLS JG, 1983, J CLIN MICROBIOL, V18, P512, DOI 10.1128/JCM.18.3.512-520.1983	29	372	384	3	56	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					812	819		10.7326/0003-4819-117-10-812	http://dx.doi.org/10.7326/0003-4819-117-10-812			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416555				2022-12-01	WOS:A1992JX83800003
J	WEIDNER, G; CONNOR, SL; HOLLIS, JF; CONNOR, WE				WEIDNER, G; CONNOR, SL; HOLLIS, JF; CONNOR, WE			IMPROVEMENTS IN HOSTILITY AND DEPRESSION IN RELATION TO DIETARY CHANGE AND CHOLESTEROL LOWERING - THE FAMILY HEART-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CHOLESTEROL, DIETARY; DIET THERAPY; DEPRESSION; HOSTILITY; DIETARY FATS	RANDOMLY SELECTED FAMILIES; BODY-WEIGHT; MEN; WOMEN; BEHAVIOR; CHILDREN; DISEASE; TRIALS; LIPIDS; AGE	Objective: To describe changes in negative emotions among participants of a cholesterol-lowering study. Design: Cohort study. Quantitative evaluation of changes in negative emotions in relation to diet and plasma cholesterol levels before and after a 5-year dietary intervention program aimed at reducing plasma cholesterol levels. Setting: Community-dwelling families of the Family Heart Study, Portland, Oregon. Participants: One hundred forty-nine men and 156 women from 233 families (mean age, 37.7 years). Measurements: Changes in negative emotions including depression and aggressive hostility as measured by the Hopkins Symptom Checklist (SCL-90). Results: Improvement in overall emotional state was noted for the entire sample. Those who consumed a low-fat, high complex-carbohydrate diet at the end of the study showed significantly greater improvements in depression (P = 0.044; difference in improvement, 2.9 points) and aggressive hostility (P = 0.035; difference in improvement, 3.3 points) as well as a reduction in their plasma cholesterol levels (P = 0.024; difference in improvement, 2.7%) compared with those who ate a high-fat "American diet." Conclusions: Participation in a cholesterol-lowering program may not be associated with a worsening in emotional state. To the contrary, improvements in diet appear to be associated with reductions in depression and aggressive hostility as well as with lowered plasma cholesterol levels.	OREGON HLTH SCI UNIV, DEPT MED, PORTLAND, OR 97201 USA	Oregon Health & Science University	WEIDNER, G (corresponding author), SUNY STONY BROOK, DEPT PSYCHOL, STONY BROOK, NY 11794 USA.				NHLBI NIH HHS [HL40368, HL20910, HL25687] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025687, R01HL020910, R01HL040368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BECK AT, 1985, AM J PSYCHIAT, V142, P559; CONNOR SL, 1982, CIRCULATION, V65, P1290, DOI 10.1161/01.CIR.65.7.1290; CONNOR SL, 1984, CIRCULATION, V70, P76, DOI 10.1161/01.CIR.70.1.76; CONNOR SL, 1992, J AM DIET ASSOC, V92, P41; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; DEROGATIS LR, 1977, SCL 90 VERSION MANUA, V1; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HOLLIS JF, 1984, PREV MED, V13, P276, DOI 10.1016/0091-7435(84)90084-7; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; MURPHY CM, 1989, J CONSULT CLIN PSYCH, V57, P579, DOI 10.1037/0022-006X.57.5.579; PIERCE DK, 1984, PREV MED, V13, P390, DOI 10.1016/0091-7435(84)90030-6; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; WEIDNER G, 1987, PSYCHOSOM MED, V49, P136, DOI 10.1097/00006842-198703000-00004; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; [No title captured]	18	111	112	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					820	823		10.7326/0003-4819-117-10-820	http://dx.doi.org/10.7326/0003-4819-117-10-820			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416556				2022-12-01	WOS:A1992JX83800004
J	WEYAND, CM; HICOK, KC; CONN, DL; GORONZY, JJ				WEYAND, CM; HICOK, KC; CONN, DL; GORONZY, JJ			THE INFLUENCE OF HLA-DRB1 GENES ON DISEASE SEVERITY IN RHEUMATOID-ARTHRITIS	ANNALS OF INTERNAL MEDICINE			English	Article						ARTHRITIS, RHEUMATOID; HLA-DR1 ANTIGEN; RHEUMATOID NODULE; VASCULITIS	SHARED EPITOPE HYPOTHESIS; ASSOCIATION; THERAPY; SUSCEPTIBILITY; SPECIFICITIES	Objective: To explore the role of HLA-DRB1 genes in determining disease severity in rheumatoid arthritis. Design: Case series of patients with seropositive rheumatoid arthritis. Setting: The outpatient clinic of the Division of Rheumatology, Mayo Clinic. Patients: One hundred and two patients with seropositive, erosive rheumatoid arthritis and a minimum disease duration of 3 years. Measurements: Patients were genotyped for both HLA-DRB1 alleles and were categorized according to the expression of one or two disease-linked HLA-DRB1 alleles. Identification of HLA-DRB1 alleles was done by the polymerase chain reaction and subsequent oligonucleotide hybridization. Homozygosity for allelic variants was confirmed by sequence analysis. Immunogenetically defined patient subgroups were retrospectively evaluated for joint destruction and patterns of disease manifestation, including rheumatoid organ disease. Results: Of 102 patients, 98 (96%) expressed the disease-linked sequence polymorphism. Forty-seven patients (46%) carried a double dose of the relevant sequence stretch: Twenty-eight patients expressed HLA-DRB1*04 variants on both alleles, and 19 combined an HLA-DRB*04 variant with HLA-DRB1*0101 or DRB1*1402. Nodular disease was present in 100% of patients typed as HLA-DRB1*04/04 and in 59% of patients typed as HLA-DRB1 *04 and who had inherited only a single dose of the disease-linked sequence polymorphism (P < 0.0001). Major organ systems were involved in 61% and 11% of these two patient groups, respectively (P < 0.0001); and joint surgery was required in 61% and 25% (P < 0.002), respectively. Patients typed as HLA-DR*04/01 had intermediate clinical courses. Conclusion: Genotyping patients with rheumatoid arthritis for both HLA-DRB1 alleles identifies clinical subsets with distinct profiles of disease manifestations.			WEYAND, CM (corresponding author), MAYO CLIN & MAYO FDN, 401 GUGGENHEIM, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FUCHS HA, 1989, J RHEUMATOL, V16, P585; GORONZY J, 1986, J CLIN INVEST, V77, P1042, DOI 10.1172/JCI112358; GORONZY JJ, 1992, J IMMUNOL, V148, P604; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; JOHNSON K, 1990, J RHEUMATOL, V17, P34; KLIPPEL JH, 1990, J RHEUMATOL, V17, P1118; KUSHNER I, 1989, J RHEUMATOL, V16, P1; MARSH SGE, 1991, IMMUNOGENETICS, V33, P321, DOI 10.1007/BF00216691; Masi A T, 1976, Semin Arthritis Rheum, V4, P299; MCCARTY DJ, 1990, J RHEUMATOL, V17, P1115; NEPOM GT, 1987, J CLIN IMMUNOL, V7, P1, DOI 10.1007/BF00915418; NEPOM GT, 1986, LANCET, V2, P1002; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1986, J RHEUMATOL, V13, P841; SCHIFF B, 1982, ANN RHEUM DIS, V41, P403, DOI 10.1136/ard.41.4.403; SCOTT DL, 1987, LANCET, V1, P1108; SHARP JT, 1991, ARTHRITIS RHEUM, V34, P660, DOI 10.1002/art.1780340606; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; VOLLERTSEN RS, 1990, RHEUM DIS CLIN N AM, V16, P445; WALKER DJ, 1985, ANN RHEUM DIS, V44, P519, DOI 10.1136/ard.44.8.519; WESTEDT ML, 1986, ANN RHEUM DIS, V45, P534, DOI 10.1136/ard.45.7.534; WEYAND CM, 1992, J CLIN INVEST, V89, P2033, DOI 10.1172/JCI115814; WEYAND CM, 1991, J IMMUNOL, V147, P70; WEYAND CM, 1989, IMMUNOBIOLOGY HLA IM, V2, P422; WILLKENS RF, 1991, ARTHRITIS RHEUM, V34, P43, DOI 10.1002/art.1780340107; WILSKE KR, 1990, J RHEUMATOL, V17, P4; YOUNG A, 1984, ARTHRITIS RHEUM, V27, P20, DOI 10.1002/art.1780270104	33	421	435	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1992	117	10					801	806		10.7326/0003-4819-117-10-801	http://dx.doi.org/10.7326/0003-4819-117-10-801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX838	1416553				2022-12-01	WOS:A1992JX83800001
J	CAMPBELL, LV; ASHWELL, SM; BORKMAN, M; CHISHOLM, DJ				CAMPBELL, LV; ASHWELL, SM; BORKMAN, M; CHISHOLM, DJ			WHITE COAT HYPERGLYCEMIA - DISPARITY BETWEEN DIABETES CLINIC AND HOME BLOOD-GLUCOSE CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To identify patients with discrepantly high clinic blood glucose concentrations compared with self reported values and to assess whether such patients have errors in self monitoring technique. To determine whether, in patients with good technique, the discrepancy is a transient phenomenon related to clinic attendance. Design-Prospective study of diabetes clinic patients recruited over six months. Setting-Outpatient diabetes clinic of a teaching hospital. Subjects-34 consecutive patients with noninsulin dependent diabetes who had had at least two consecutive clinic blood glucose concentrations more than 5 mmol/l higher than the mean self reported concentration. Main outcome measures-Assessment of monitoring technique; presence of cognitive or physical impairment; serum fructosamine concentration; home and clinic blood glucose concentrations. Results-15 of 34 patients had errors in monitoring technique, 12 of whom had cognitive or physical impairment. In the remaining 19, the mean (SD) blood glucose concentrations of capillary and venous samples taken at home (10.2 (0.6) and 12.2 (1.1) mmol/l respectively) were significantly lower than in those taken at the clinic (16.8 (1.6) mmol/l, p<0.0002). The fructosamine concentration was significantly higher in patients with monitoring errors than those without (2.4 (0.4) v 1.8 (0.4) mmol/l, p<0.0001). Conclusions-"White coat" hyperglycaemia was detected in about half the patients but errors in technique accounted for the rest of the discrepancies. Patients' ability should be assessed before teaching self monitoring and the technique checked regularly.	ST VINCENTS HOSP,GARVAN INST MED RES,SYDNEY,NSW 2010,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney	CAMPBELL, LV (corresponding author), ST VINCENTS HOSP,CTR DIABET,SYDNEY,NSW 2010,AUSTRALIA.		Chisholm, Donald J/J-9332-2013; Campbell, Lesley V/B-2271-2008	Chisholm, Donald J/0000-0002-5349-5735; 				[Anonymous], 1987, DIABETES CARE, V10, P95; BURGESS E, 1991, DIABETOLOGIA, V34, P684, DOI 10.1007/BF00401000; CAMPBELL LV, 1991, DIABETES, V40, P140; FELL LR, 1985, AUST VET J, V62, P403, DOI 10.1111/j.1751-0813.1985.tb14120.x; Long J, 1990, Md Med J, V39, P555; MCLAY J, 1987 P AUSTR DIAB ED, pE3; MOLNAR GD, 1974, DIABETOLOGIA, V10, P139, DOI 10.1007/BF01219670; ROSE RM, 1981, TXB ENDOCRINOLOGY, P654; SCHLEICHER ED, 1990, CLIN CHEM, V36, P136; SURWIT RS, 1983, DIABETES CARE, V6, P176, DOI 10.2337/diacare.6.2.176	10	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1194	1196		10.1136/bmj.305.6863.1194	http://dx.doi.org/10.1136/bmj.305.6863.1194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467722	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JY77700021
J	CHATELAIN, P; MEIER, B; DELASERNA, F; MOLES, V; PANDE, AK; VERINE, V; URBAN, P				CHATELAIN, P; MEIER, B; DELASERNA, F; MOLES, V; PANDE, AK; VERINE, V; URBAN, P			SUCCESS WITH CORONARY ANGIOPLASTY AS SEEN AT DEMONSTRATIONS OF PROCEDURE	LANCET			English	Article							NATIONAL-HEART; OCCLUSION; REGISTRY; STENTS; LUNG	To assess the real-life results of coronary angioplasty, unidentified participants made notes on 104 cases demonstrated live at twelve international angioplasty courses in 1991. The initially planned procedure was successful in 73% with crossover to another device in 20% for an ultimate success rate of 93%. Interventions lasted an hour on average and two devices on average were used per artery tackled. Rates of success and of complication necessitating reintervention were, for balloon angioplasty (57 cases) 81% and 19%, for directional atherectomy (16 cases) 75% and 0%, for the Rotablator (12 cases) 42% and 42%, for stent implantation (10 cases) 100% and 0%, for excimer laser angioplasty (6 cases) 17% and 33%, and for Rotacs recanalisation (3 cases) 67% and 0%, respectively. The complications were occlusions (threatened, acute, or delayed) and they were usually treated by balloon angioplasty or a stent. No death or myocardial infarction was reported. The observer attending the demonstration tended to take a less favourable view of the outcome than the clinician doing the procedure and in general the results of coronary angioplasty seemed inferior to those reported in journals. Interventions done before an audience will be unusually stressful but this will be outweighed by the fact that difficult cases with a low probability of success are rarely tackled during live courses. This survey suggests that conventional balloon angioplasty, complemented by stent implantation in selected cases, is the treatment of choice.	UNIV GENEVA,HOP CANTONAL,CTR CARDIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva			DE LA SERNA, JAVIER/B-1735-2012	DE LA SERNA, JAVIER/0000-0003-3904-1101				DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; ERBEL R, 1986, CATHETER CARDIO DIAG, V12, P116, DOI 10.1002/ccd.1810120211; FOURRIER JL, 1989, J AM COLL CARDIOL, V14, P1278, DOI 10.1016/0735-1097(89)90428-2; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; HINOHARA T, 1990, CIRCULATION, V81, P79; HOLMES DR, 1990, TXB INTERVENTIONAL C, P223; KALTENBACH M, 1989, J INTERVEN CARDIOL, V2, P137; LITVACK F, 1989, LANCET, V1, P102; Meany T B, 1991, J Invasive Cardiol, V3, P19; MEIER B, 1992, JAMA-J AM MED ASSOC, V268, P741, DOI 10.1001/jama.268.6.741; SANBORN TA, 1991, J AM COLL CARDIOL, V17, P94, DOI 10.1016/0735-1097(91)90709-I; SCHATZ RA, 1991, CIRCULATION, V83, P148, DOI 10.1161/01.CIR.83.1.148; SCHATZ RA, 1989, CIRCULATION, V79, P445, DOI 10.1161/01.CIR.79.2.445; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; TOPOL E J, 1992, Journal of the American College of Cardiology, V19, p138A; UMANS V, 1992, EUR HEART J, V13, P918, DOI 10.1093/oxfordjournals.eurheartj.a060293; WEINTRAUB WS, 1990, AM J CARDIOL, V65, P183, DOI 10.1016/0002-9149(90)90082-C	18	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1202	1205		10.1016/0140-6736(92)92900-Z	http://dx.doi.org/10.1016/0140-6736(92)92900-Z			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359269				2022-12-01	WOS:A1992JY38600012
J	GOULD, TH; CROSBY, DL; HARMER, M; LLOYD, SM; LUNN, JN; REES, GAD; ROBERTS, DE; WEBSTER, JA				GOULD, TH; CROSBY, DL; HARMER, M; LLOYD, SM; LUNN, JN; REES, GAD; ROBERTS, DE; WEBSTER, JA			POLICY FOR CONTROLLING PAIN AFTER SURGERY - EFFECT OF SEQUENTIAL-CHANGES IN MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article							POSTOPERATIVE PAIN; SERVICE; ANALGESIA	Objective-To observe the effects of introducing an acute pain service to the general surgical wards of a large teaching hospital. Design-A study in seven stages: (1) an audit of current hospital practice succeeded by the sequential introduction to the general surgical wards of (2) pain assessment charts; (3) an algorithm to allow more frequent use of intramuscular analgesia; (4) increased use of local anaesthetic techniques of wound infiltration and nerve blocks; (5) an information sheet for patients about postoperative pain; (6) the introduction of patient controlled analgesia; (7) a repeat audit of hospital practice. Data were collected on each patient 24 hours after operation. Setting-University Hospital of Wales, which has both district general and tertiary referral functions. Patients-2035 patients over nine months from all surgical specialties (excluding cardiac) at the hospital. General surgical operations were studied in detail and separated into major, intermediate, and minor for data collection. Main outcome measures-A change in the median visual analogue pain scores 24 hours after surgery for pain during relaxation, pain on movement, and pain on deep inspiration at each stage of the study. Results-There was a reduction in median visual analogue scores during the study. The median (95% confidence interval) scores for pain during relaxation decreased from 45 (34 to 53) in stage 1 to 16 (10 to 20) in stage 7 for major surgical procedures. Pain on movement decreased from 78 (66 to 80) to 46 (38 to 48), and pain on deep inspiration decreased from 64 (48 to 78) to 36 (31 to 38). The reductions in median scores for intermediate and minor operative procedures showed similar patterns. Conclusions-The introduction of an acute pain service to the general surgical wards led to considerable improvement in the level of postoperative pain as assessed by visual analogue scores. Simple techniques of regular pain assessment and the more frequent use of intramuscular analgesia as a result of using an algorithm were particularly effective.	UNIV HOSP WALES,DEPT ANAESTHET,CARDIFF,WALES; UNIV WALES COLL MED,DEPT ANAESTHET,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University								BAHAR M, 1985, ANASTHESIA, V40, P5529; BANOS JE, 1989, METHOD FIND EXP CLIN, V11, P123; FELL D, 1982, BMJ, V283, P92; Lee A, 1990, ANAESTHESIA, V46, P1028; LEHMANN KA, 1985, PATIENT CONTROLLED A, P134; LIU WHD, 1991, BRIT J ANAESTH, V67, P768, DOI 10.1093/bja/67.6.768; MACINTYRE PE, 1990, MED J AUSTRALIA, V153, P417, DOI 10.5694/j.1326-5377.1990.tb125503.x; MAGNANI B, 1990, PATIENT CONTROLLED A, P85; MATHER LE, 1975, BRIT J ANAESTH, V47, P1269, DOI 10.1093/bja/47.12.1269; MELZACK R, 1975, PAIN, V1, P275; OWEN H, 1989, ANAESTHESIA, V44, P11, DOI 10.1111/j.1365-2044.1989.tb11088.x; READY LB, 1988, ANESTHESIOLOGY, V68, P100, DOI 10.1097/00000542-198801000-00016; REVILL SI, 1976, ANAESTHESIA, V31, P1191, DOI 10.1111/j.1365-2044.1976.tb11971.x; Siegel S, 1988, NONPARAMETRIC STAT B, P213, DOI DOI 10.1177/014662168901300212; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; Smith G., 1984, QUALITY CARE ANAESTH, P164; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; WHITE WD, 1979, BRIT MED J, V2, P166, DOI 10.1136/bmj.2.6183.166; ZAR JH, 1984, BIOSTAT ANAL, P219; 1990, WORKING PARTY PAIN S; 1991, CURRENT PROBLEMS, V31, P3	21	161	163	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 14	1992	305	6863					1187	1193		10.1136/bmj.305.6863.1187	http://dx.doi.org/10.1136/bmj.305.6863.1187			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467721	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JY77700020
J	JOBST, KA; SMITH, AD; SZATMARI, M; MOLYNEUX, A; ESIRI, ME; KING, E; SMITH, A; JASKOWSKI, A; MCDONALD, B; WALD, N				JOBST, KA; SMITH, AD; SZATMARI, M; MOLYNEUX, A; ESIRI, ME; KING, E; SMITH, A; JASKOWSKI, A; MCDONALD, B; WALD, N			DETECTION IN LIFE OF CONFIRMED ALZHEIMERS-DISEASE USING A SIMPLE MEASUREMENT OF MEDIAL TEMPORAL-LOBE ATROPHY BY COMPUTED-TOMOGRAPHY	LANCET			English	Article							CEREBRAL STRUCTURE; HIPPOCAMPAL; CT; DIAGNOSIS; VOLUME; BRAIN; MRI; AGE	The medial temporal lobe of the brain is important for normal cognitive function, notably for memory, and is the region with the most extensive pathological change in Alzheimer's disease (AD). We wanted to find out if atrophy of the medial temporal lobe could be detected in life in patients in whom a diagnosis of AD was subsequently established histopathologically. The minimum width of the medial temporal lobe, measured by temporal-lobe-oriented computed tomography (CT) about one year before death, in 44 patients with a histopathological diagnosis of AD (cases) was nearly half (0.56 of the median) that in 75 controls of the same age with no clinical evidence of dementia (95% confidence interval 0.51-0.61). There was little overlap between the distributions of measurements in cases and controls. A cut-off (< 0.79 MoM) selected to yield a 5% false-positive rate gave an expected detection rate of 92%. A cut-off selected to yield a false-positive rate of 1% (< 0.70 MoM) yielded a 79% detection rate. 20 of the 44 patients with histopathologically diagosed AD had been scanned more than once before death, and the test (cut-off < 0.79 MoM) was positive in all 20 more than a year before and in 9/10 more than 2 years before death. In 10 subjects with dementia but with histopathology excluding AD, the mean minimum width of the medial temporal lobe was significantly greater than that in the cases with AD, but was not significantly different from that in controls. Medial temporal lobe CT is a non-invasive, rapid, simple and effective test for AD which could have immediate application firstly in improving the accuracy of prevalence and incidence studies and, secondly, for the identification of groups of high-risk patients in the evaluation of novel treatments for AD. In the future, it could be applied as a screening test.	UNIV OXFORD, DEPT PHARMACOL, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; UNIV OXFORD, DEPT PSYCHIAT, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; UNIV OXFORD, DEPT CLIN NEUROL, OXFORD PROJECT INVESTIGATE MEMORY & AGEING, OXFORD, ENGLAND; ST BARTHOLOMEWS HOSP, COLL MED, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1A 7BE, ENGLAND; RADCLIFFE INFIRM, DEPT RADIOL, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, DEPT NEUROPATHOL, OXFORD OX2 6HE, ENGLAND	University of Oxford; University of Oxford; University of Oxford; University of London; Queen Mary University London; Radcliffe Infirmary; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010; Wald, Nicholas/AAY-8924-2021	Smith, Anthony D./0000-0002-1095-6722; 				ANDERSON JM, 1983, J NEUROL SCI, V58, P235, DOI 10.1016/0022-510X(83)90220-4; BOGERTS B, 1990, SCHIZOPHR RES, V3, P295, DOI 10.1016/0920-9964(90)90013-W; CASCINO GD, 1991, ANN NEUROL, V30, P31, DOI 10.1002/ana.410300107; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DUARA R, 1992, CLIN BRAIN IMAGING P, P294; ESIRI MM, 1989, DIAGNOSTIC NEUROPATH, P109; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GEORGE AE, 1990, AM J NEURORADIOL, V11, P101; JACK CR, 1992, NEUROLOGY, V42, P183, DOI 10.1212/WNL.42.1.183; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P68, DOI 10.1016/0006-3223(91)90211-4; JERNIGAN TL, 1991, BIOL PSYCHIAT, V29, P55, DOI 10.1016/0006-3223(91)90210-D; JOBST KA, 1992, J NEUROL NEUROSUR PS, V55, P190, DOI 10.1136/jnnp.55.3.190; KESSLAK JP, 1991, NEUROLOGY, V41, P51, DOI 10.1212/WNL.41.1.51; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KIDO DK, 1989, AM J NEURORADIOL, V10, P551; KUKULL WA, 1990, NEUROLOGY, V40, P1364, DOI 10.1212/WNL.40.9.1364; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; RAPOPORT SI, 1991, CEREBROVAS BRAIN MET, V3, P297; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SEAB JP, 1988, MAGN RESON MED, V8, P200, DOI 10.1002/mrm.1910080210; STRAITON JA, 1991, NEURORADIOLOGY, V33, P19, DOI 10.1007/BF00593327; 1987, DIAGNOSTIC STATISTIC	24	245	246	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1179	1183						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359259				2022-12-01	WOS:A1992JY38600002
J	LOK, ASF; KWAN, WK; MOECKLI, R; YARBOUGH, PO; CHAN, RT; REYES, GR; LAI, CL; CHUNG, HT; LAI, TST				LOK, ASF; KWAN, WK; MOECKLI, R; YARBOUGH, PO; CHAN, RT; REYES, GR; LAI, CL; CHUNG, HT; LAI, TST			SEROEPIDEMIOLOGICAL SURVEY OF HEPATITIS-E IN HONG-KONG BY RECOMBINANT-BASED ENZYME IMMUNOASSAYS	LANCET			English	Article							NON-B-HEPATITIS; TRANSMITTED NON-A; WATERBORNE NON-A; E VIRUS; IDENTIFICATION	The agent that causes the enterally transmitted form of non-A, non-B hepatitis has been cloned and called hepatitis E virus (HEV). We have carried out a seroepidemiological survey on the prevalence of hepatitis E in Hong Kong. In a retrospective study, serum from 394 patients with acute viral hepatitis and 355 healthy subjects was tested for antibodies to HEV (anti-HEV) with a recombinant-based enzyme immunoassay. 65 (16.5%) patients with hepatitis were positive for IgM anti-HEV and 23 (5.8%) were also positive for IgM anti-HEV. Of 18 patients diagnosed as having acute non-A, non-B, non-C hepatitis, 6 were IgM anti-HEV positive. 17 (6%) patients in whom acute hepatitis A was diagnosed were also infected with HEV. None of 70 patients with acute hepatitis B or C or exacerbation of chronic hepatitis B was IgM anti-HEV positive. 57 (16.1%) of the healthy subjects were positive for IgG anti-HEV. The prevalence of IgG anti-HEV was higher in subjects over 20 years old than in younger subjects (24% vs 4%, p < 0.0001). IgG anti-HEV was detected in 26% of subjects who were positive for IgG antibody to HAV and in 7% of those negative for that antibody (p < 0.0001). We demonstrated the validity of the recombinant-based enzyme immunoassays for the diagnosis of hepatitis E. Our results suggest that hepatitis E accounts for a third of non-A, non-B, non-C hepatitis in Hong Kong and that coinfection of hepatitis A and E can occur.	UNIV HONG KONG,QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG; PRINCESS MARGARET HOSP,INFECT DIS UNIT,HONG KONG,HONG KONG; PRINCESS MARGARET HOSP,MED UNIT,HONG KONG,HONG KONG; GENELABS INC,REDWOOD CITY,CA	University of Hong Kong			Lok, Anna/B-8292-2009; Lai, Ching Lung/C-4298-2009	Yang, Shuman/0000-0002-9638-0890; Lai, Ching-Lung/0000-0002-5927-2436				ARANKALLE VA, 1988, LANCET, V1, P550; BRADLEY D, 1988, J GEN VIROL, V69, P731, DOI 10.1099/0022-1317-69-3-731; CHIN KP, 1991, J MED VIROL, V34, P191, DOI 10.1002/jmv.1890340312; GOLDSMITH R, 1992, LANCET, V339, P328, DOI 10.1016/0140-6736(92)91647-Q; GUST ID, 1987, J INFECT DIS, V156, P630, DOI 10.1093/infdis/156.4.630; KRAWCZYNSKI K, 1989, J INFECT DIS, V159, P1042, DOI 10.1093/infdis/159.6.1042; RAMALINGASWAMI V, 1988, LANCET, V1, P571; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SKIDMORE SJ, 1992, J MED VIROL, V37, P58, DOI 10.1002/jmv.1890370110; SKIDMORE SJ, 1991, LANCET, V337, P1541, DOI 10.1016/0140-6736(91)93227-Z; SONG DY, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P528; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; VELAZQUEZ O, 1990, JAMA-J AM MED ASSOC, V263, P3281, DOI 10.1001/jama.263.24.3281; YARBOUGH PO, 1991, J VIROL, V65, P5790, DOI 10.1128/JVI.65.11.5790-5797.1991; 1990, LANCET, V336, P1158	15	104	105	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1205	1208		10.1016/0140-6736(92)92901-Q	http://dx.doi.org/10.1016/0140-6736(92)92901-Q			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359270				2022-12-01	WOS:A1992JY38600013
J	MARKUSSIS, V; BESHYAH, SA; FISHER, C; SHARP, P; NICOLAIDES, AN; JOHNSTON, DG				MARKUSSIS, V; BESHYAH, SA; FISHER, C; SHARP, P; NICOLAIDES, AN; JOHNSTON, DG			DETECTION OF PREMATURE ATHEROSCLEROSIS BY HIGH-RESOLUTION ULTRASONOGRAPHY IN SYMPTOM-FREE HYPOPITUITARY ADULTS	LANCET			English	Article							HUMAN GROWTH-HORMONE; CARDIOVASCULAR-DISEASE; CAROTID ATHEROSCLEROSIS; FOLLOW-UP; PROGRESSION; ARTERIOSCLEROSIS; REGRESSION; POPULATION; ULTRASOUND; MORTALITY	Retrospective analysis suggests that there is increased mortality from vascular disease in hypopituitary adults, but vascular status before death is unknown. High resolution B-mode ultrasonic imaging of both carotid and femoral arteries was therefore done in 34 adult hypopituitary patients on routine replacement therapy and was compared with that in 39 matched controls. Changes were related to risk factors for vascular disease. Carotid intima-media thickness was greater in patients than in controls (mean [SD] 0.74 [0.16] vs 0.65 [0.13] mm, p < 0.02). This difference was seen in middle-aged and elderly patients. More patients than controls had one or more atheromatous plaques (65% vs 41%, p < 0.05). The percentage of individual arteries with a plaque was also higher in patients (32% vs 18%, p < 0.005). In multiple regression analysis, patients' age was the dominant factor determining carotid intima-media thickness. Symptom-free adults with hypopituitarism show an increased prevalence of atherosclerosis.	ST MARYS HOSP, SCH MED, METAB MED UNIT, LONDON W2 1PG, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, SCH MED, IRVINE LAB, HARROW HA1 3UJ, MIDDX, ENGLAND; NORTHWICK PK HOSP & CLIN RES CTR, SCH MED, ACAD SURG UNIT, HARROW HA1 3UJ, MIDDX, ENGLAND	Imperial College London; Imperial College London; Imperial College London; Imperial College London			Beshyah, Salem A/I-1533-2019; Beshyah, Salem/H-3213-2016	Beshyah, Salem A/0000-0003-3650-9741; Beshyah, Salem/0000-0003-3650-9741				BELCARO G, 1990, CURR THER RES CLIN E, V48, P116; BLACKETT PR, 1982, METABOLISM, V31, P117, DOI 10.1016/0026-0495(82)90121-4; ERNST E, 1991, BRIT MED J, V303, P596, DOI 10.1136/bmj.303.6803.596; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULLER JH, 1983, BMJ-BRIT MED J, V287, P867, DOI 10.1136/bmj.287.6396.867; GARDNER MJ, 1989, STATISTICS CONFIDENC, P20; ISHIBASHI S, 1985, ACTA ENDOCRINOL-COP, V110, P456, DOI 10.1530/acta.0.1100456; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LIBBER SM, 1990, MEDICINE, V69, P46, DOI 10.1097/00005792-199001000-00004; MARGITIC SE, 1991, ARTERIOSCLER THROMB, V11, P443, DOI 10.1161/01.ATV.11.2.443; MERIMEE TJ, 1973, DIABETES, V22, P813, DOI 10.2337/diab.22.11.813; MERIMEE TJ, 1972, METABOLISM, V21, P1053, DOI 10.1016/0026-0495(72)90036-4; MERIMEE TJ, 1968, METABOLISM, V17, P1005, DOI 10.1016/0026-0495(68)90006-1; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; POLI A, 1988, ATHEROSCLEROSIS, V70, P253, DOI 10.1016/0021-9150(88)90176-1; RICOTTA JJ, 1987, J VASC SURG, V6, P512, DOI 10.1067/mva.1987.avs0060512; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; TEALE JD, 1986, ANN CLIN BIOCHEM, V23, P413, DOI 10.1177/000456328602300406; WARRICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; WUSTER C, 1991, KLIN WOCHENSCHR, V69, P769, DOI 10.1007/BF01797616	24	360	367	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1188	1192		10.1016/0140-6736(92)92892-J	http://dx.doi.org/10.1016/0140-6736(92)92892-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359261				2022-12-01	WOS:A1992JY38600004
J	RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA				RESTRICK, LJ; DAVIES, SW; NOONE, L; WEDZICHA, JA			AMBULATORY OXYGEN IN CHRONIC HEART-FAILURE	LANCET			English	Note							OBSTRUCTIVE AIRWAYS DISEASE; PORTABLE OXYGEN; EXERCISE CAPACITY	Ambulatory oxygen therapy may be of benefit in bicycle exercise tests. We have assessed the effects of ambulatory oxygen during walk tests in 12 patients with chronic heart failure. In 6 min walks with the patient breathing air, mean (SD) arterial oxygen saturation (SaO2) fell from 94.4 (3.7)% at rest to 90.1 (6.1)% (p = 0.014) on exercise. 2 l/min oxygen increased resting SaO2 from 93.7 (4.0)% (air cylinder) to 96.5 (3.0)% (p < 0.001) with no effect on minimum SaO2, distance, or breathlessness. During endurance walks, 4 l/min oxygen increased minimum SaO2 from 90.4 (5.6)% to 93.5 (4.7)% (p = 0.011) but also had no effect on breathlessness or distance. Ambulatory oxygen in currently available cylinders cannot be recommended for patients with chronic heart failure.	LONDON CHEST HOSP,DEPT THORAC MED,BONNER RD,LONDON E2 9JX,ENGLAND; LONDON CHEST HOSP,DEPT CARDIOL,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London								BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; COCKROFT AL, 1989, Q J MED, V268, P669; DAVIDSON AC, 1988, THORAX, V43, P965, DOI 10.1136/thx.43.12.965; DAVIES S W, 1992, Pharmaceutical Medicine (London), V5, P239; DAVIES SW, 1991, BRIT HEART J, V65, P179; LEGGETT RJE, 1977, BRIT MED J, V2, P84, DOI 10.1136/bmj.2.6079.84; LIPKIN DP, 1986, BRIT MED J, V292, P653, DOI 10.1136/bmj.292.6521.653; LOCK SH, 1991, RESP MED, V85, P407, DOI 10.1016/S0954-6111(06)80186-1; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; WATERHOUSE JC, 1983, THORAX, V38, P302, DOI 10.1136/thx.38.4.302	10	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1192	1193		10.1016/0140-6736(92)92893-K	http://dx.doi.org/10.1016/0140-6736(92)92893-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359262				2022-12-01	WOS:A1992JY38600005
J	ROSEVEAR, SK; HOLT, DW; LEE, TD; FORD, WCL; WARDLE, PG; HULL, MGR				ROSEVEAR, SK; HOLT, DW; LEE, TD; FORD, WCL; WARDLE, PG; HULL, MGR			SMOKING AND DECREASED FERTILIZATION RATES INVITRO	LANCET			English	Note							CIGARETTE-SMOKING; COTININE; NICOTINE; DISPOSITION; FLUID	To examine possible mechanisms for the association between cigarette smoking and reduced fertility, we have measured the concentration of the nicotine metabolite cotinine in ovarian follicular fluid collected at the time of oocyte recovery during treatment for in-vitro fertilisation. In a group of women in whom follicular fluid cotinine could not be detected (limit of accurate measurement 20 ng/ml) 116 oocytes were collected, of which 84 became fertilised (72%), whereas among women with cotinine concentration greater than 20 ng/ml 20/45 (44%) oocytes did so (p < 0.01). The median fertilisation rates for individuals (range 1-8 eggs each) in the high and low cotinine groups were 57% and 75%, respectively (p < 0.05). These findings suggest that infertile women should be advised to stop or reduce smoking generally, and especially before treatment by in-vitro fertilisation.	ST GEORGE HOSP, SCH MED, DEPT CARDIOL SCI, ANALYT UNIT, LONDON SW17 0RE, ENGLAND	St Georges University London	ROSEVEAR, SK (corresponding author), UNIV BRISTOL, ST MICHAELS HOSP, DEPT OBSTET & GYNAECOL, BRISTOL BS2 8EG, ENGLAND.							BAIRD DD, 1985, JAMA-J AM MED ASSOC, V253, P2979, DOI 10.1001/jama.253.20.2979; BARBIERI RL, 1986, FERTIL STERIL, V46, P232; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; HANSEL MC, 1986, ANN CLIN BIOCHEM, V23, P596, DOI 10.1177/000456328602300518; HOWE G, 1985, BRIT MED J, V290, P1697, DOI 10.1136/bmj.290.6483.1697; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; MCLACHLAN JA, 1976, FERTIL STERIL, V27, P1204; ROSENBERG J, 1980, CLIN PHARMACOL THER, V28, P517, DOI 10.1038/clpt.1980.196; WARDLE PG, 1986, HUM REPROD, V1, P455, DOI 10.1093/oxfordjournals.humrep.a136454; WEISS T, 1989, HUM REPROD, V4, P482, DOI 10.1093/oxfordjournals.humrep.a136931	11	79	81	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 14	1992	340	8829					1195	1196		10.1016/0140-6736(92)92895-M	http://dx.doi.org/10.1016/0140-6736(92)92895-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359264				2022-12-01	WOS:A1992JY38600007
J	THOMAS, JE; GIBSON, GR; DARBOE, MK; DALE, A; WEAVER, LT				THOMAS, JE; GIBSON, GR; DARBOE, MK; DALE, A; WEAVER, LT			ISOLATION OF HELICOBACTER-PYLORI FROM HUMAN FECES	LANCET			English	Note							INFECTION; CHILDHOOD	Helicobacter pylori is arguably the commonest chronic infection in man. However, its route of transmission is unknown. We have isolated viable H pylori from the faeces of an infected individual from The Gambia. The organism was cultured on selective media after concentration of faecal bacteria by centrifugation in a buffer equilibrated with a microaerophilic gas mixture. Growth characteristics, microscopic appearances, and enzyme activities were the same as those of a typical gastric isolate of H pylori. Protein preparations derived from the new isolate and the typical strain were antigenically similar, and had very similar electrophoretic profiles (including two major protein bands of 62 and 26 kDa, corresponding to the urease enzyme subunits). With the same technique, organisms with the colony morphology, growth requirements, enzyme activities, and microscopic appearances of H pylori were isolated from the faeces of 9 of 23 randomly selected childen aged 3-27 months from a Gambian village with a high prevalence of H pylori infection in early life. Faecal-oral transmission is probably important in the spread of infection in such communities.	MRC,DUNN NUTR CTR,BANJUL,SENEGAMBIA		THOMAS, JE (corresponding author), MRC,DUNN NUTR CTR,MILTON RD,CAMBRIDGE CB4 1XJ,ENGLAND.		Gibson, Glenn R/A-9595-2009					COSTAS M, 1991, SCAND J GASTROENTERO, V26, P20, DOI 10.3109/00365529109093204; HOLCOMBE C, 1992, AM J GASTROENTEROL, V87, P28; KLEIN PD, 1991, LANCET, V337, P1503, DOI 10.1016/0140-6736(91)93196-G; KLEIN PD, 1989, CAMPYLOBACTER PYLORI, P83; MAPSTONE NP, 1992, IRISH J MED SCI S10, V161, P29; MARSHALL B J, 1984, Microbios Letters, V25, P83; MILLER L, 1988, J BIOL CHEM, V263, P5668; SHAMES B, 1989, J CLIN MICROBIOL, V27, P2849, DOI 10.1128/JCM.27.12.2849-2850.1989; THOMAS JE, 1990, J CLIN MICROBIOL, V28, P2641, DOI 10.1128/JCM.28.12.2641-2646.1990; THOMAS JE, 1991, GUT, V32, pA1231	10	421	441	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 14	1992	340	8829					1194	1195		10.1016/0140-6736(92)92894-L	http://dx.doi.org/10.1016/0140-6736(92)92894-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY386	1359263				2022-12-01	WOS:A1992JY38600006
J	YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T				YOONG, AFE; LIM, J; HUDSON, CN; CHARD, T			AUDIT OF COMPLIANCE WITH ANTENATAL PROTOCOLS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES; PHYSICIANS; POLICIES; CARE	Objective-To assess the implementation of action protocols dictated by antenatal risk factors noted at the initial (booking) antenatal visit. Design-Retrospective study of 2000 women delivered between 1 March 1990 and 29 March 1991. Setting-Maternity department of a district general hospital supporting a multiethnic population in inner London. Main outcome measures-Comparison of clinical actions performed against those dictated by the department's protocols. Analysis according to clinical importance, gestation at booking, maternal age, parity, birth order, ethnic origin, and certainty of gestational age. Results-Interobserver agreement between the two auditors was good (chi statistic for risk factors detected, 0.78; for actions generated, 0.80). Of the 15 658 actions dictated by department protocols, 3673 (23.5%) were actually performed by the clinicians. The 63 combinations of risk factors and actions believed by consultants to be of particular clinical importance had an action rate of 28.3% compared with 18.6% for those considered less important (p < 0.001). Mothers who first visited the hospital antenatal clinic at or before 24 weeks' gestation had 25.2% of relevant protocols fulfilled (p < 0.001). Compliance was significantly improved in women aged 36 or over (32.4%), black women (24.9%), and cases of uncertain gestation (24.5%). Parity and birth order were not associated with an altered action rate. Ethnic origin deemed as "other" (than white, black, Asian, or oriental) or "unknown" was associated with poor compliance (19.3%). Conclusions-Compliance to a set of agreed protocols was poor even though a computer system was available and a protocol manual had been distributed. Protocols were more likely to be implemented in women who booked early and in some groups of women deemed at high risk including older mothers, black women, and those denoted as having uncertain gestational age.			YOONG, AFE (corresponding author), ST BARTHOLOMEWS HOSP & MED COLL, JOINT ACAD UNIT OBSTET GYNAECOL & REPROD PHYSIOL, LONDON EC1A 7BE, ENGLAND.							BARRETT JFR, 1990, LANCET, V336, P549, DOI 10.1016/0140-6736(90)92097-2; BODDY K, 1982, ROYAL COLLEGE OBSTET, P40; BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; CARROLL S, 1988, J OBSTET GYNAECOL, V8, P222, DOI 10.3109/01443618809012289; CHNG PK, 1980, BMJ-BRIT MED J, V281, P1184, DOI 10.1136/bmj.281.6249.1184; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1265, DOI 10.1001/jama.263.9.1265; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2239, DOI 10.1001/jama.263.16.2239; EDDY DM, 1982, NEW ENGL J MED, V307, P343, DOI 10.1056/NEJM198208053070604; GRILLI R, 1991, MED CARE, V29, P50, DOI 10.1097/00005650-199101000-00005; GUTHRIE KA, 1989, BRIT J OBSTET GYNAEC, V96, P552, DOI 10.1111/j.1471-0528.1989.tb03254.x; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; ODOWD TC, 1991, BRIT MED J, V303, P450, DOI 10.1136/bmj.303.6800.450; SHAW CD, 1990, BRIT MED J, V300, P649, DOI 10.1136/bmj.300.6725.649; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480	17	11	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 14	1992	305	6863					1184	1186		10.1136/bmj.305.6863.1184	http://dx.doi.org/10.1136/bmj.305.6863.1184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JY777	1467720	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992JY77700019
J	CANNONALBRIGHT, LA; GOLDGAR, DE; MEYER, LJ; LEWIS, CM; ANDERSON, DE; FOUNTAIN, JW; HEGI, ME; WISEMAN, RW; PETTY, EM; BALE, AE; OLOPADE, OI; DIAZ, MO; KWIATKOWSKI, DJ; PIEPKORN, MW; ZONE, JJ; SKOLNICK, MH				CANNONALBRIGHT, LA; GOLDGAR, DE; MEYER, LJ; LEWIS, CM; ANDERSON, DE; FOUNTAIN, JW; HEGI, ME; WISEMAN, RW; PETTY, EM; BALE, AE; OLOPADE, OI; DIAZ, MO; KWIATKOWSKI, DJ; PIEPKORN, MW; ZONE, JJ; SKOLNICK, MH			ASSIGNMENT OF A LOCUS FOR FAMILIAL MELANOMA, MLM, TO CHROMOSOME-9P13-P22	SCIENCE			English	Article							CUTANEOUS MALIGNANT-MELANOMA; DYSPLASTIC NEVUS SYNDROME; CYTOGENETIC ANALYSIS; SYNDROME DNS; HIGH-RISK; INHERITANCE; LINKAGE; CANCER; UPDATE	Linkage analysis of ten Utah kindreds and one Texas kindred with multiple cases of cutaneous malignant melanoma (CMM) provided evidence that a locus for familial melanoma susceptibility is in the chromosomal region 9p13-p22. The genetic markers analyzed reside in a candidate region on chromosome 9p21, previously implicated by the presence of homozygous deletions in melanoma tumors and by the presence of a germline deletion in an individual with eight independent melanomas. Multipoint linkage analysis was performed between the familial melanoma susceptibility locus (MLM) and two short tandem repeat markers, D9S126 and the interferon-alpha (IFNA) gene, which reside in the region of somatic loss in melanoma tumors. An analysis incorporating a partially penetrant dominant melanoma susceptibility locus places MLM near IFNA and D9S126 with a maximum location score of 12.71. Therefore, the region frequently deleted in melanoma tumors on 9p21 presumably contains a locus that plays a critical role in predisposition to familial melanoma.	UNIV UTAH,SCH MED,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; UNIV CHICAGO,MED CTR,DEPT MED,CHICAGO,IL 60637; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	Utah System of Higher Education; University of Utah; University of Texas System; UTMD Anderson Cancer Center; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Yale University; University of Chicago; University of Chicago Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	CANNONALBRIGHT, LA (corresponding author), UNIV UTAH,SCH MED,DEPT INTERNAL MED,SALT LAKE CITY,UT 84112, USA.		Lewis, Cathryn/M-8766-2019; Hegi, Monika/O-4796-2015; Lewis, Cathryn M/A-5225-2010	Lewis, Cathryn/0000-0002-8249-8476; Hegi, Monika/0000-0003-0855-6495; Lewis, Cathryn M/0000-0002-8249-8476; albright, lisa/0000-0003-2602-3668	NCI NIH HHS [CA 48711, CA 42014] Funding Source: Medline; NCRR NIH HHS [RR 00064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014, P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1991, ANTICANCER RES, V11, P433; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BALE SJ, 1989, J NATL CANCER I, V81, P70, DOI 10.1093/jnci/81.1.70; CANNONALBRIGHT LA, 1990, AM J HUM GENET, V46, P912; CLARK WH, 1978, ARCH DERMATOL, V114, P732, DOI 10.1001/archderm.114.5.732; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; EASTON D, 1990, CANCER SURV, V9, P395; EASTON DF, COMMUNICATION; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, GENOMICS, V14, P105, DOI 10.1016/S0888-7543(05)80290-3; FOUNTAIN JW, IN PRESS P NATL ACAD; FOUNTAIN JW, 1991, AM J HUM GENET, V49, P223; FREY C, 1991, J NATL CANCER I, V83, P170; GOLDGAR DE, 1991, J NATL CANCER I, V83, P1726, DOI 10.1093/jnci/83.23.1726; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GREENE MH, 1983, P NATL ACAD SCI-BIOL, V80, P6071, DOI 10.1073/pnas.80.19.6071; Greene MH., 1979, HEREDITARY VARIANT M; GRUIS NA, 1990, NEW ENGL J MED, V322, P853; HAPPLE R, 1982, J AM ACAD DERMATOL, V6, P540, DOI 10.1016/S0190-9622(82)80369-1; Hayward N., COMMUNICATION; JONASSON J, 1977, J CELL SCI, V24, P217; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; KWIATKOWSKI DJ, IN PRESS HUM MOL GEN; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; LYNCH HT, 1978, J MED GENET, V15, P352, DOI 10.1136/jmg.15.5.352; MACCLUER JW, 1992, CYTOGENET CELL GENET, V59, P148; NANCARROW DJ, 1992, GENOMICS, V12, P18, DOI 10.1016/0888-7543(92)90401-D; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1992, CANCER RES, V52, P2523; OLOPADE OI, 1991, P AM ASSOC CANC RES, V52, P1814; OLOPADE OI, 1990, P AM ASSOC CANC RES, V31, P1883; OTT J, 1985, ANAL HUMAN GENETIC L; PASCOE L, 1987, AM J HUM GENET, V40, P464; PETTY EM, UNPUB; PETTY EM, IN PRESS AM J MED GE; RODERICK TH, 1984, MOUSE NEWS LETT, V71, P8; SKOLNICK M, 1980, BANBURY REPORT, V4, P285; SOBER AJ, 1991, DERMATOL CLIN, V9, P617; SWERDLOW AJ, 1984, LANCET, V2, P168; TRAUPE H, 1989, AM J MED GENET, V32, P155, DOI 10.1002/ajmg.1320320203; VANHAERINGEN A, 1989, GENOMICS, V5, P61, DOI 10.1016/0888-7543(89)90086-4; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEEKS DE, 1992, AM J HUM GENET, V50, P859; WISEMAN RW, UNPUB; 1992, JAMA-J AM MED ASSOC, V268, P1314; 1988, 1987 ANN CANCER STAT; 1988, CANCER UTAH STATISTI	51	482	500	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1148	1152		10.1126/science.1439824	http://dx.doi.org/10.1126/science.1439824			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439824				2022-12-01	WOS:A1992JX85200032
J	CATANIA, JA; COATES, TJ; STALL, R; TURNER, H; PETERSON, J; HEARST, N; DOLCINI, MM; HUDES, E; GAGNON, J; WILEY, J; GROVES, R				CATANIA, JA; COATES, TJ; STALL, R; TURNER, H; PETERSON, J; HEARST, N; DOLCINI, MM; HUDES, E; GAGNON, J; WILEY, J; GROVES, R			PREVALENCE OF AIDS-RELATED RISK-FACTORS AND CONDOM USE IN THE UNITED-STATES	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; SEXUAL-BEHAVIOR; TRANSMISSION; WOMEN; PREVENTION; FREQUENCY; PROMOTION; BIAS	A national probability survey of human immunodeficiency virus (HIV)-related risk factors among the general heterosexual population, the National AIDS (acquired immunodeficiency syndrome) Behavioral Surveys, has obtained data from 10,630 respondents. Data are presented on the prevalence of HIV-related risks in the general heterosexual population, on the distribution of the three largest risk groups across social strata, and on the prevalence and distribution of condom use among heterosexuals reporting a risk factor. Between 15 and 31 percent of heterosexuals nationally and 20 and 41 percent in cities with a high prevalence of AIDS reported an HIV risk factor. Condom use was relatively low. Only 17 percent of those with multiple sexual partners, 12.6 percent of those with risky sexual partners, and 10.8 percent of untested transfusion recipients used condoms all the time. Overall, the results suggest that current HIV prevention programs have, to a very limited extent, reached those heterosexuals with multiple sexual partners but have failed to reach many other groups of the heterosexual population at risk for HIV. New public health strategies may be needed for these specific risk groups.	UNIV CALIF SAN FRANCISCO, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA; UNIV NEW HAMPSHIRE, DEPT SOCIOL & ANTHROPOL, DURHAM, NH 03824 USA; SUNY STONY BROOK, DEPT SOCIOL, STONY BROOK, NY 11794 USA; UNIV CALIF BERKELEY, SURVEY RES CTR, BERKELEY, CA 94720 USA; UNIV MICHIGAN, DEPT SOCIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, INST SOCIAL RES, ANN ARBOR, MI 48109 USA; US BUR CENSUS, WASHINGTON, DC 20233 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University System Of New Hampshire; University of New Hampshire; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of California System; University of California Berkeley; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	CATANIA, JA (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, SAN FRANCISCO, CA 94143 USA.				NIMH NIH HHS [MH46240, MH43892] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043892, R01MH046240] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTER MJ, 1986, JAMA-J AM MED ASSOC, V256, P1307, DOI 10.1001/jama.256.10.1307; BAJOS N, 1991, SEXUAL BEHAVIOR FRAN, P405; BRADBURN NM, 1979, IMPROVING INTERVIEW, V42; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; CATANIA JA, 1990, EVAL PROGRAM PLANN, V13, P19, DOI 10.1016/0149-7189(90)90005-H; CATANIA JA, 1989, GERONTOLOGIST, V29, P373, DOI 10.1093/geront/29.3.373; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CATANIA JA, UNPUB; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P565; COATES T, 1990, AIDS 2ND DECADE; COATES T, 1989, 1989 AIDS CLIN REV; DONEGAN E, 1988, JAMA-J AM MED ASSOC, V260, P922; ECHENBERG D, 1985, MMWR-MORBID MORTAL W, V34, P573; FELDBLUM PJ, 1991, AIDS, V5, P1265, DOI 10.1097/00002030-199110000-00020; Fowler F. J., 1988, SURVEY RES METHODS; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; GOEDERT JJ, 1984, LANCET, V2, P711; GUYDISH J, 1991, PREVENTING AIDS DRUG, P28; GUYDISH JR, 1990, AM J PUBLIC HEALTH, V80, P995, DOI 10.2105/AJPH.80.8.995; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HANNAN J, 1991, HEMOPHILIA HIV RISK; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HINGSON R, 1989, PREV MED, V18, P806, DOI 10.1016/0091-7435(89)90016-9; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KANOUSE D, 1991, AIDS RELATED KNOWLED; KEETER S, 1988, AM J PREV MED, V4, P146, DOI 10.1016/S0749-3797(18)31187-5; KINSEY AC, 1953, SEXUAL BEHAVIOR HUMA; LANGE WR, 1988, AM J PUBLIC HEALTH, V78, P443, DOI 10.2105/AJPH.78.4.443; LAVRAKAS PJ, 1987, TELEPHONE SURVEY MET; LINDENBAUM S, 1991, EVALUATING AIDS PREV, P223; MCQUEEN D, 1989, STUDY LIFESTYLE HLTH; MILLER HG, 1990, AIDS 2 DECADE; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; PADIAN N, 1990, CONRAD W S, P25; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SHELTON JD, 1990, CONRAD W S, P327; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; SORENSEN J, 1991, PREVENTING AIDS DRUG, P62; STALL R, 1989, AIDS AGING SOC WHAT, P77; SYRJANEN K, 1984, BRIT J VENER DIS, V60, P243; THORNBERRY OT, 1988, WILEY S PRO, P25; TURNER CF, 1989, AIDS SEXUAL BEHAVIOR; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WATKINS JD, 1988, REPORT PRESIDENTIAL; WEDDINGTON W, 1990, MMWR-MORBID MORTAL W, V39, P274; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V77, P685, DOI 10.2105/AJPH.77.6.685; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; 1991, HIV AIDS SURVEILLANC; 1982, COUNCIL AM SURVEY RE	49	273	274	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1101	1106		10.1126/science.1439818	http://dx.doi.org/10.1126/science.1439818			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439818				2022-12-01	WOS:A1992JX85200018
J	CHAN, AC; IWASHIMA, M; TURCK, CW; WEISS, A				CHAN, AC; IWASHIMA, M; TURCK, CW; WEISS, A			ZAP-70 - A 70 KD PROTEIN-TYROSINE KINASE THAT ASSOCIATES WITH THE TCR ZETA-CHAIN	CELL			English	Article							CELL ANTIGEN RECEPTOR; AMINO-ACID SEQUENCE; T-CELL; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; ETA-CHAIN; PHYSICAL ASSOCIATION; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; GAMMA-CHAIN	Protein-tyrosine kinases (PTKs) play an integral role in T cell activation. Stimulation of the T cell antigen receptor (TCR) results in tyrosine phosphorylation of a number of cellular substrates. One of these is the TCR zeta chain, which can mediate the transduction of extracellular stimuli into cellular effector functions. We have recently identified a 70 kd tyrosine phosphoprotein (ZAP-70) that associates with zeta and undergoes tyrosine phosphorylation following TCR stimulation. Here we report the isolation of a cDNA clone encoding ZAP-70. ZAP-70 represents a novel PTK and is expressed in T and natural killer cells. Moreover, tyrosine phosphorylation and association of ZAP-70 with zeta require the presence of src family PTKs and provide a potential mechanism by which the src family PTKs and ZAP-70 may interact to mediate TCR signal transduction.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	CHAN, AC (corresponding author), UNIV CALIF SAN FRANCISCO, DIV RHEUMATOL, SAN FRANCISCO, CA 94143 USA.				NIAMS NIH HHS [AR20684] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BANIYASH M, 1989, J BIOL CHEM, V264, P13252; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BUFERNE M, 1992, J IMMUNOL, V148, P657; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Frank S J, 1990, Semin Immunol, V2, P89; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GEISLER C, 1992, J IMMUNOL, V148, P2437; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; Innis MA, 1990, PCR PROTOCOLS GUIDE; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LITTMAN DR, 1987, NATURE, V326, P85, DOI 10.1038/326085a0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NORMENT AM, 1989, J IMMUNOL, V142, P3312; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; Sambrook J., 1989, MOL CLONING LAB MANU; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	77	964	996	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					649	662		10.1016/0092-8674(92)90598-7	http://dx.doi.org/10.1016/0092-8674(92)90598-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423621				2022-12-01	WOS:A1992JY67600012
J	FUCHS, EJ; MATZINGER, P				FUCHS, EJ; MATZINGER, P			B-CELLS TURN OFF VIRGIN BUT NOT MEMORY T-CELLS	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; MIXED LEUKOCYTE REACTION; DENDRITIC CELLS; LYMPHOCYTES-B; BLOOD-TRANSFUSIONS; ACTIVE ENHANCEMENT; PRIMING INVIVO; SKIN-GRAFT; TOLERANCE; INDUCTION	There are three possible outcomes when a T cell recognizes a cell bearing a self or foreign antigen. (i) The T cell is not sufficiently signaled and is unaffected. (ii) The T cell is activated. (iii) The T cell is turned off. The differentiation state of the T cell is critical to the outcome. Although both virgin and memory T cells can be activated by antigens presented by "professional" antigen-presenting cells such as dendritic cells, they differ in their responses to B cells. Experienced T cells respond to antigen presented by B cells, whereas virgin T cells are rendered tolerant. These findings may relate to the phenomena of low- and high-zone tolerance, neonatal tolerance, and the beneficial effect of blood transfusions on allograft survival.	NIH,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								ASHWELL JD, 1988, J IMMUNOL, V141, P2536; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BELL EB, 1990, NATURE, V348, P163, DOI 10.1038/348163a0; BIKOFF E, 1986, J IMMUNOL, V137, P28; BILLINGHAM RE, 1956, PHILOS T R SOC B, V239, P357, DOI 10.1098/rstb.1956.0006; BOOG CJP, 1985, NATURE, V318, P59, DOI 10.1038/318059a0; BURAKOFF SJ, 1978, J EXP MED, V148, P1414, DOI 10.1084/jem.148.5.1414; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; CHESNUT RW, 1982, J IMMUNOL, V128, P1764; CLAVERIE JM, 1986, ANN INST PASTEUR IMM, VD137, P425; COBBOLD SP, 1990, EUR J IMMUNOL, V20, P2747, DOI 10.1002/eji.1830201232; EYNON EE, 1991, TRANSPLANT P, V23, P729; EYNON EE, 1992, J EXP MED, V175, P131, DOI 10.1084/jem.175.1.131; GOLOB K, UNPUB; GORDON RD, 1975, J EXP MED, V142, P1108, DOI 10.1084/jem.142.5.1108; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GUERDER S, 1992, J EXP MED, V176, P553, DOI 10.1084/jem.176.2.553; GUERDER S, 1989, COLD SPRING HARB SYM, V54, P799; HAWRYLOWICZ CM, 1988, J IMMUNOL, V141, P4083; HORI S, 1989, J IMMUNOL, V143, P1447; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JENKINSON EJ, 1985, TRANSPLANTATION, V39, P331, DOI 10.1097/00007890-198503000-00030; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAKIUCHI T, 1983, J IMMUNOL, V131, P109; KRIEGER JI, 1986, J IMMUNOL, V137, P3117; KRIEGER JI, 1985, J IMMUNOL, V135, P2937; KURTJONES EA, 1988, J IMMUNOL, V140, P3773; LAFFERTY KJ, 1980, IMMUNOL REV, V51, P279, DOI 10.1111/j.1600-065X.1980.tb00325.x; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LASSILA O, 1988, NATURE, V334, P253, DOI 10.1038/334253a0; LAUCHART W, 1980, TRANSPLANTATION, V29, P259, DOI 10.1097/00007890-198003000-00020; LIU Y, 1991, INT IMMUNOL, V3, P323, DOI 10.1093/intimm/3.4.323; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MCKEAN DJ, 1981, J EXP MED, V154, P1419, DOI 10.1084/jem.154.5.1419; METLAY JP, 1989, J EXP MED, V169, P239, DOI 10.1084/jem.169.1.239; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; OPELZ G, 1973, TRANSPLANT P, V5, P253; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; RAMMENSEE HG, 1991, BONE MARROW TRANSPL, V7, P26; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; RON Y, 1987, J IMMUNOL, V138, P2848; RYAN JJ, 1984, J IMMUNOL, V133, P2343; SHIMONKEVITZ RP, 1988, J EXP MED, V168, P143, DOI 10.1084/jem.168.1.143; STROM TB, 1977, TRANSPL P, V9, P965; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; VANROOD JJ, 1990, SCIENCE, V248, P1388, DOI 10.1126/science.1972596; WEBB SR, 1985, EUR J IMMUNOL, V15, P92, DOI 10.1002/eji.1830150118; WEBB SR, 1989, J EXP MED, V169, P1, DOI 10.1084/jem.169.1.1; WEISS S, 1989, P NATL ACAD SCI USA, V86, P282, DOI 10.1073/pnas.86.1.282	56	544	557	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1156	1159		10.1126/science.1439825	http://dx.doi.org/10.1126/science.1439825			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439825	Green Submitted			2022-12-01	WOS:A1992JX85200034
J	GEISLER, R; BERGMANN, A; HIROMI, Y; NUSSLEINVOLHARD, C				GEISLER, R; BERGMANN, A; HIROMI, Y; NUSSLEINVOLHARD, C			CACTUS, A GENE INVOLVED IN DORSOVENTRAL PATTERN-FORMATION OF DROSOPHILA, IS RELATED TO THE I-KAPPA-B GENE FAMILY OF VERTEBRATES	CELL			English	Article							P-ELEMENT TRANSPOSASE; DNA-BINDING SUBUNIT; DORSAL PROTEIN; TRANSMEMBRANE PROTEIN; EMBRYONIC POLARITY; SEQUENCE; REL; TRANSCRIPTION; TOLL; DIFFERENTIATION	Among the maternally active genes of Drosophila, cactus is the only one whose loss of function mutations specifically produce ventralized embryos. Its product inhibits nuclear translocation of the dorsal morphogen in the dorsal region of the embryo. Here we report the cloning of cactus and the sequencing of its maternal transcript. The identity of our clones was verified by induction of phenocopies with antisense RNA and rescue of the mutant phenotype with sense RNA. cactus is predicted to encode an acidic, cytoplasmic protein with seven ankyrin repeats. The sequence has similarity to the IkappaB proteins that inhibit the vertebrate transcription factor NF-kappaB. In analogy to results obtained with IkappaB and NF-kappaB, bacterially expressed cactus protein can inhibit DNA binding of dorsal protein in vitro.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GEISLER, R (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,GENET ABT,SPEMANNSTR 35-III,W-7400 TUBINGEN,GERMANY.		Geisler, Robert/K-6201-2013	Geisler, Robert/0000-0002-3909-8311				ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYLE H, 1989, THESIS COLUMBIA U NE; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; IP YT, 1991, CELL, V64, P439; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NAUBER U, 1991, ANTISENSE NUCLEIC AC, P113; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAY RP, 1991, DEVELOPMENT, V113, P35; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBERTSON HM, 1988, GENETICS, V118, P461; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	50	221	227	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					613	621		10.1016/0092-8674(92)90595-4	http://dx.doi.org/10.1016/0092-8674(92)90595-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423618				2022-12-01	WOS:A1992JY67600009
J	GIESE, KP; MARTINI, R; LEMKE, G; SORIANO, P; SCHACHNER, M				GIESE, KP; MARTINI, R; LEMKE, G; SORIANO, P; SCHACHNER, M			MOUSE P(0) GENE DISRUPTION LEADS TO HYPOMYELINATION, ABNORMAL EXPRESSION OF RECOGNITION MOLECULES, AND DEGENERATION OF MYELIN AND AXONS	CELL			English	Article							CELL-ADHESION MOLECULES; IMMUNOELECTRON MICROSCOPIC LOCALIZATION; L3 CARBOHYDRATE STRUCTURES; PERIPHERAL NERVOUS-SYSTEM; N-CAM; SCIATIC-NERVE; SCHWANN-CELLS; PROTEIN-ZERO; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODIES	We have used homologous recombination in embryonic stem cells to generate mice carrying a mutation in the gene encoding P0, an immunoglobulin-related recognition molecule and the major protein of peripheral nervous system myelin. These mice are deficient in normal motor coordination and exhibit tremors and occasional convulsions. Axons in their peripheral nerves are severely hypomyelinated and a subset of myelin-like figures and axons degenerate. The mutation leads to an abnormal regulation of some, but not all, molecules involved in myelination. These results demonstrate that P0 is essential for the normal spiraling, compaction, and maintenance of the peripheral myelin sheath and the continued integrity of associated axons. They further suggest that this protein conveys a signal that regulates Schwann cell gene expression.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; BAYLOR COLL MED, INST MOLEC GENET, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Salk Institute; Baylor College of Medicine; Howard Hughes Medical Institute	GIESE, KP (corresponding author), SWISS FED INST TECHNOL, DEPT NEUROBIOL, CH-8093 ZURICH, SWITZERLAND.		Giese, Karl P/A-3112-2011; Soriano, Philippe M/E-5797-2015	Giese, Karl P/0000-0003-4503-7344; Soriano, Philippe M/0000-0002-0427-926X; Martini, Rudolf/0000-0002-5463-5592	NICHD NIH HHS [HD 24875, HD 25326] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD025326, R01HD024875, R01HD025326] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIXBY JL, 1990, J CELL BIOL, V111, P2725, DOI 10.1083/jcb.111.6.2725; BOLLENSEN E, 1987, NEUROSCI LETT, V82, P77, DOI 10.1016/0304-3940(87)90174-1; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CERVELLO M, 1991, P NATL ACAD SCI USA, V88, P10548, DOI 10.1073/pnas.88.23.10548; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; DURSO D, 1990, NEURON, V4, P449, DOI 10.1016/0896-6273(90)90057-M; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FAHRIG T, 1990, EUR J NEUROSCI, V2, P153, DOI 10.1111/j.1460-9568.1990.tb00407.x; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FILBIN MT, 1990, NATURE, V344, P871, DOI 10.1038/344871a0; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; ISHAQUE A, 1980, CAN J BIOCHEM CELL B, V58, P913, DOI 10.1139/o80-125; JESSEN KR, 1990, DEVELOPMENT, V109, P91; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUCHERER A, 1987, J CELL BIOL, V104, P1597, DOI 10.1083/jcb.104.6.1597; KUHN R, 1990, J NEUROSCI, V10, P205; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINI R, 1991, J NEUROSCI RES, V28, P261, DOI 10.1002/jnr.490280214; MARTINI R, 1990, J NEUROCYTOL, V19, P601, DOI 10.1007/BF01257247; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MARTINI R, 1988, DEV BIOL, V129, P330, DOI 10.1016/0012-1606(88)90380-6; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIRSKY R, 1986, J NEUROCYTOL, V15, P799, DOI 10.1007/BF01625196; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NEUMANN H, 1990, THESIS U WURZBURG GE; NIEKE J, 1985, DIFFERENTIATION, V30, P141, DOI 10.1111/j.1432-0436.1985.tb00525.x; NORONHA AB, 1986, BRAIN RES, V385, P237, DOI 10.1016/0006-8993(86)91069-3; OWENS GC, 1991, DEVELOPMENT, V112, P639; Palay S.L., 1974, CEREBELLAR CORTEX CY; POLLERBERG GE, 1987, CELL TISSUE RES, V250, P227, DOI 10.1007/BF00214676; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; POTTER NT, 1988, J NEUROIMMUNOL, V18, P49, DOI 10.1016/0165-5728(88)90134-8; PUCKETT C, 1987, J NEUROSCI RES, V18, P511, DOI 10.1002/jnr.490180402; RATHJEN FG, 1984, EMBO J, V3, P1; REICHARDT LF, 1990, COLD SPRING HARB SYM, V55, P341; SCHACHNER M, 1991, NERVE GROWTH CONE, P237; Schachner M., 1990, SEMIN NEUROSCI, V2, P497; SCHNEIDERSCHAULIES J, 1990, J NEUROSCI RES, V27, P286, DOI 10.1002/jnr.490270307; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SWASH M, 1991, CLIN NEUROLOGY, P1177; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TRAPP BD, 1981, J CELL BIOL, V90, P1, DOI 10.1083/jcb.90.1.1; VONBOHLEN, 1992, IN PRESS EUR J NEURO; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOU KH, 1991, GENOMICS, V9, P751, DOI 10.1016/0888-7543(91)90370-T; ZIMMER A, 1992, ANNU REV NEUROSCI, V15, P115, DOI 10.1146/annurev.neuro.15.1.115	63	429	430	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					565	576		10.1016/0092-8674(92)90591-Y	http://dx.doi.org/10.1016/0092-8674(92)90591-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1384988				2022-12-01	WOS:A1992JY67600005
J	GU, Y; NAKAMURA, T; ALDER, H; PRASAD, R; CANAANI, O; CIMINO, G; CROCE, CM; CANAANI, E				GU, Y; NAKAMURA, T; ALDER, H; PRASAD, R; CANAANI, O; CIMINO, G; CROCE, CM; CANAANI, E			THE T(4-11) CHROMOSOME-TRANSLOCATION OF HUMAN ACUTE LEUKEMIAS FUSES THE ALL-1 GENE, RELATED TO DROSOPHILA-TRITHORAX, TO THE AF-4 GENE	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; FUSION MESSENGER-RNA; DNA-BINDING DOMAIN; TRANSCRIPTION FACTOR; BITHORAX COMPLEX; BCR SEQUENCES; CELL-LINE; RAR-ALPHA; EXPRESSION; LOCUS	The ALL-1 gene located at human chromosome 11 band q23 is rearranged in acute leukemias with interstitial deletions or reciprocal translocations between this region and chromosomes 1, 4, 6, 9, 10, or 19. The gene spans approximately 100 kb of DNA and contains at least 21 exons. It encodes a protein of more than 3910 amino acids containing three regions with homology to sequences within the Drosophila trithorax gene, including cysteine-rich regions that can be folded into six zinc finger-like domains. The breakpoint cluster region within ALL-1 spans 8 kb and encompasses several small exons, most of which begin in the same phase of the open reading frame. The t(4;11) chromosome translocation results in two reciprocal fusion products coding for chimeric proteins derived from ALL-1 and from a gene on chromosome 4. This suggests that each 11q23 abnormality gives rise to a specific oncogenic fusion protein.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University	GU, Y (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; CIMINO, Giuseppe/0000-0002-7781-0816	NCI NIH HHS [CA39860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P6322; CAPDEVILA MP, 1981, ROUX ARCH DEV BIOL, V190, P339, DOI 10.1007/BF00863271; CHU ML, 1990, EMBO J, V9, P985; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; COHEN A, 1991, BLOOD, V78, P94; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HEIM S, 1987, CANCER CYTOGENETICS; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; INGHAM PW, 1985, COLD SPRING HARB SYM, V50, P201, DOI 10.1101/SQB.1985.050.01.026; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LANGE B, 1987, BLOOD, V70, P192; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCKEON J, 1991, ROUX ARCH DEV BIOL, V199, P387, DOI 10.1007/BF01705848; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOZER BA, 1989, P NATL ACAD SCI USA, V86, P3738, DOI 10.1073/pnas.86.10.3738; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RABBITT RH, 1991, CELL, V67, P641; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STONG RC, 1985, BLOOD, V66, P439; STONG RC, 1986, BLOOD, V67, P391; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; WEDEEN C, 1986, CELL, V44, P739, DOI 10.1016/0092-8674(86)90840-8; WEI S, 1990, CANCER GENET CYTOGEN, V46, P1, DOI 10.1016/0165-4608(90)90002-R; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	39	832	876	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					701	708		10.1016/0092-8674(92)90603-A	http://dx.doi.org/10.1016/0092-8674(92)90603-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423625				2022-12-01	WOS:A1992JY67600017
J	HANDELI, S; WEINTRAUB, H				HANDELI, S; WEINTRAUB, H			THE TS41 MUTATION IN CHINESE-HAMSTER CELLS LEADS TO SUCCESSIVE S PHASES IN THE ABSENCE OF INTERVENING G2, M, AND G1	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; DNA-REPLICATION; PROTEIN-KINASE; NEGATIVE CONTROL; FISSION YEAST; CYCLE CONTROL; MITOSIS; COMPLEX; CHECKPOINTS; EXPRESSION	The ts41 mutation of Chinese hamster cells was first isolated and characterized by Hirschberg and Marcus (1982) who showed that at nonpermissive temperature, cells accumulate up to 16C equivalents of DNA. Here we show that the mutation is recessive and at nonpermissive temperature, cells replicate their genome normally, but instead of going on into G2, M, and G1, they pass directly into a second S phase. Entry into a second S phase does not require serum nor is it inhibited by G2 checkpoints or mitotic inhibitors. Temperature-shift experiments suggest that the ts41 gene product participates in two functions in the cell cycle: entry into mitosis and inhibition of entry into S phase. The ts41 mutation seems to define a class of cell cycle mutant that couples the sequential events of DNA replication and mitosis.			HANDELI, S (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,SEATTLE,WA 98104, USA.							ANDEREASSEN PR, 1991, J CELL SCI, V100, P299; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BREWER EN, 1968, EXP CELL RES, V49, P79, DOI 10.1016/0014-4827(68)90521-1; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CHARRON M, 1990, BIOCHEMISTRY-US, V29, P9531, DOI 10.1021/bi00493a006; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DAS M, 1981, P NATL ACAD SCI-BIOL, V78, P5677, DOI 10.1073/pnas.78.9.5677; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1989, J CELL SCI S, V12, P21; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAINSOD A, 1987, MOL CELL BIOL, V7, P775, DOI 10.1128/MCB.7.2.775; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HANKS SK, 1980, J CELL BIOL, V87, P285, DOI 10.1083/jcb.87.1.285; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRAI K, 1971, J VIROL, V8, P828, DOI 10.1128/JVI.8.6.828-835.1971; HIRSCHBERG J, 1982, J CELL PHYSIOL, V113, P159, DOI 10.1002/jcp.1041130125; HOLLIDAY R, 1990, New Biologist, V2, P719; HORAN PK, 1974, INT J CANCER, V14, P514, DOI 10.1002/ijc.2910140411; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; JACOBS JP, 1970, NATURE, V227, P168, DOI 10.1038/227168a0; KLEVECZ RR, 1982, EXP CELL RES, V140, P307, DOI 10.1016/0014-4827(82)90119-7; KULKA RG, 1988, J BIOL CHEM, V263, P15726; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LEHMAN JM, 1970, J VIROL, V6, P738, DOI 10.1128/JVI.6.6.738-749.1970; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; RAO AP, 1976, J NATL CANCER I, V57, P11399; Rao P.N., 1982, PREMATURE CHROMOSOME, P1; REED SI, 1980, GENETICS, V95, P561; ROBERTS JM, 1986, CELL, V46, P741, DOI 10.1016/0092-8674(86)90350-8; ROBERTS JM, 1988, CELL, V52, P397, DOI 10.1016/S0092-8674(88)80032-1; SHAMANSKI FL, 1991, CELL, V66, P1289, DOI 10.1016/0092-8674(91)90050-9; SHERLINE P, 1984, EXP CELL RES, V153, P109, DOI 10.1016/0014-4827(84)90453-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH AV, 1991, DEVELOPMENT, V112, P997; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VARSHAVSKY A, 1983, MECHANISMS DNA REPLI, P463; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZETTERBERG A, 1991, COLD SH Q B, V56, P137	59	87	89	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					599	611		10.1016/0092-8674(92)90594-3	http://dx.doi.org/10.1016/0092-8674(92)90594-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423617				2022-12-01	WOS:A1992JY67600008
J	HEGINBOTHAM, L; ABRAMSON, T; MACKINNON, R				HEGINBOTHAM, L; ABRAMSON, T; MACKINNON, R			A FUNCTIONAL CONNECTION BETWEEN THE PORES OF DISTANTLY RELATED ION CHANNELS AS REVEALED BY MUTANT K+ CHANNELS	SCIENCE			English	Article							POTASSIUM CHANNEL; SELECTIVE CONDUCTANCE; COMPLEMENTARY-DNA; ACTIVATED CHANNEL; CALCIUM CHANNELS; SODIUM-CHANNEL; DROSOPHILA-EAG; RETINAL RODS; TEA BLOCKADE; SHAKER	The overall sequence similarity between the voltage-activated K+ channels and cyclic nucleotide-gated ion channels from retinal and olfactory neurons suggests that they arose from a common ancestor. On the basis of sequence comparisons, mutations were introduced into the pore of a voltage-activated K+ channel. These mutations confer the essential features of ion conduction in the cyclic nucleotide-gated ion channels; the mutant K+ channels display little selectivity among monovalent cations and are blocked by divalent cations. The property of K+ selectivity is related to the presence of two amino acids that are absent from the pore-forming region of the cyclic nucleotide-gated channels. These data demonstrate that very small differences in the primary structure of an ion channel can account for extreme functional diversity, and they suggest a possible connection between the pore-forming regions of K+, Ca2+, and cyclic nucleotide-gated ion channels.			HEGINBOTHAM, L (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400, R01GM043949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400, GM43949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; DELGADO R, 1991, P NATL ACAD SCI USA, V88, P557, DOI 10.1073/pnas.88.2.557; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hille B., 1991, IONIC CHANNELS EXCIT; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAMB A, 1987, CELL, V50, P405, DOI 10.1016/0092-8674(87)90494-6; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289; YAU KW, 1981, NATURE, V292, P502, DOI 10.1038/292502a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZIMMERMAN AL, 1992, J PHYSIOL-LONDON, V449, P759, DOI 10.1113/jphysiol.1992.sp019112; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	42	372	380	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1152	1155		10.1126/science.1279807	http://dx.doi.org/10.1126/science.1279807			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1279807				2022-12-01	WOS:A1992JX85200033
J	HENDRIX, RW; DUDA, RL				HENDRIX, RW; DUDA, RL			BACTERIOPHAGE-LAMBDA PAPA - NOT THE MOTHER OF ALL LAMBDA-PHAGES	SCIENCE			English	Article							EVEN-TYPE BACTERIOPHAGES; TAIL FIBER PROTEIN; ESCHERICHIA-COLI; RECEPTOR; COMPONENT; SEQUENCE; ENCODES; GENOME; GENE	The common laboratory strain of bacteriophage lambda-lambda wild type or lambdaPaP-carries a frameshift mutation relative to Ur-lambda, the original isolate. The Ur-lambda virions have thin, jointed tail fibers that are absent from lambda wild type. Two novel proteins of Ur-lambda constitute the fibers: the product of stf, the gene that is disrupted in lambda wild type by the frameshift mutation, and the product of gene tfa, a protein that is implicated in facilitating tail fiber assembly. Relative to lambda wild type, Ur-lambda has expanded receptor specificity and adsorbs to Escherichia coli cells more rapidly.			HENDRIX, RW (corresponding author), UNIV PITTSBURGH, DEPT BIOL SCI, PITTSBURGH, PA 15260 USA.			Duda, Robert/0000-0002-9517-2731	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047795] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047795, GM47795] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; DICKSON RC, 1973, J MOL BIOL, V79, P633, DOI 10.1016/0022-2836(73)90068-5; DOVE WF, 1969, VIROLOGY, V38, P349, DOI 10.1016/0042-6822(69)90378-X; DREXLER K, 1991, J MOL BIOL, V219, P655, DOI 10.1016/0022-2836(91)90662-P; GEORGE DG, 1983, BIOCHEM BIOPH RES CO, V115, P1061, DOI 10.1016/S0006-291X(83)80043-6; HAGGARDLJUNGQUIST E, 1992, J BACTERIOL, V174, P1462, DOI 10.1128/jb.174.5.1462-1477.1992; Hendrix R. W., 1971, BACTERIOPHAGE LAMBDA, P355; HENDRIX RW, UNPUB; IIDA S, 1984, VIROLOGY, V134, P421, DOI 10.1016/0042-6822(84)90309-X; JACOB F, 1954, ANN I PASTEUR PARIS, V87, P653; KAISER AD, 1957, VIROLOGY, V3, P42, DOI 10.1016/0042-6822(57)90022-3; KAISER AD, COMMUNICATION; KAR S, 1983, THESIS U PITTSBURGH; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KOCH C, 1987, PHAGE MU, P75; LEDERBERG EM, 1951, GENETICS, V36, P560; MICHEL CJ, 1986, GENE, V44, P147, DOI 10.1016/0378-1119(86)90055-7; MONTAG D, 1987, J BACTERIOL, V169, P5884, DOI 10.1128/jb.169.12.5884-5886.1987; MONTAG D, 1987, J MOL BIOL, V196, P165, DOI 10.1016/0022-2836(87)90519-5; MONTAG D, 1989, J BACTERIOL, V171, P4378, DOI 10.1128/JB.171.8.4378-4384.1989; MOUNT DWA, 1968, VIROLOGY, V35, P134, DOI 10.1016/0042-6822(68)90313-9; POPA MP, 1991, J VIROL, V65, P3227, DOI 10.1128/JVI.65.6.3227-3237.1991; RANDALLH.L, 1973, J BACTERIOL, V116, P1436, DOI 10.1128/JB.116.3.1436-1446.1973; REEVE JN, 1979, MOL GEN GENET, V172, P243, DOI 10.1007/BF00271723; RIEDE I, 1987, J MOL BIOL, V194, P23, DOI 10.1016/0022-2836(87)90712-1; SAIGO K, 1978, VIROLOGY, V85, P422, DOI 10.1016/0042-6822(78)90449-X; SANDMEIER H, 1992, J BACTERIOL, V174, P3936, DOI 10.1128/jb.174.12.3936-3944.1992; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SHINAGAW.H, 1966, BIKEN J, V9, P135; THIRION JP, 1972, GENETICS, V71, P207; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WARD S, 1971, J MOL BIOL, V62, P479, DOI 10.1016/0022-2836(71)90149-5; WOOD WB, 1983, BACTERIOPHAGE T4, P259; [No title captured]	34	98	102	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1145	1148		10.1126/science.1439823	http://dx.doi.org/10.1126/science.1439823			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439823				2022-12-01	WOS:A1992JX85200031
J	HOWARD, PK; SEFTON, BM; FIRTEL, RA				HOWARD, PK; SEFTON, BM; FIRTEL, RA			ANALYSIS OF A SPATIALLY REGULATED PHOSPHOTYROSINE PHOSPHATASE IDENTIFIES TYROSINE PHOSPHORYLATION AS A KEY REGULATORY PATHWAY IN DICTYOSTELIUM	CELL			English	Article							LEUKOCYTE-COMMON ANTIGEN; ANTERIOR-LIKE CELLS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; GENE-EXPRESSION; RAS GENE; DISCOIDEUM; RECEPTOR; ENCODES	We have cloned a Dictyostelium phosphotyrosine phosphatase (PTP1) with a catalytic domain showing approximately 38%-50% amino acid identity to those of other PTPs. PTP1 contains an approximately 99 amino acid insert and bacterially produced PTP1 possesses PTP activity. PTP1 is expressed at a very low level in vegetative cells, induced by 4 hr, and maximally expressed at the tight aggregate stage. PTP1-lacZ studies indicate that PTP1 is spatially localized to prestalk and anterior-like cell types. PTP1 gene disruptants show accelerated development, whereas strains overexpressing PTP1 to a high level fail to aggregate. Strains overexpressing moderate levels exhibit severe morphological defects following aggregation, including multiply tipped aggregates and morphologically aberrant fruiting bodies. Western blot analysis using anti-phosphotyrosine antibodies shows specific changes in the mutant strains when compared with wild-type cells. The results indicate that reversible protein-tyrosine phosphorylation and PTP1 play important regulatory roles during Dictyostelium development.	SALK INST BIOL SCI,SAN DIEGO,CA 92186	Salk Institute	HOWARD, PK (corresponding author), UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093, USA.							AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BURKI E, 1991, GENE, V102, P57, DOI 10.1016/0378-1119(91)90538-M; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DEVINE KM, 1985, DEV BIOL, V107, P364, DOI 10.1016/0012-1606(85)90318-5; DINGERMANN T, 1990, DEV GENET, V11, P410, DOI 10.1002/dvg.1020110514; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; ESCH RK, 1991, GENE DEV, V5, P9, DOI 10.1101/gad.5.1.9; FIRTEL RA, 1991, TRENDS GENET, V7, P381, DOI 10.1016/0168-9525(91)90260-W; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; KAMPS MP, 1988, ONCOGENE, V2, P305; Kimmel AR, 1991, CURR OPIN GENET DEV, V1, P383, DOI 10.1016/S0959-437X(05)80304-1; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUSPA A, 1992, GENOMICS, V13, P49, DOI 10.1016/0888-7543(92)90201-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MANN SKO, 1992, IN PRESS P NATL ACAD; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; NELLEN W, 1985, GENE, V39, P155, DOI 10.1016/0378-1119(85)90309-9; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OTTILIE S, 1991, P NATL ACAD SCI USA, V88, P3455, DOI 10.1073/pnas.88.8.3455; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; REYMOND CD, 1986, NATURE, V323, P340, DOI 10.1038/323340a0; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWEIGER A, 1990, FEBS LETT, V268, P199, DOI 10.1016/0014-5793(90)81007-B; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Williams JG, 1991, CURR OPIN GENET DEV, V1, P358, DOI 10.1016/S0959-437X(05)80300-4; WILLIAMS JG, 1989, CELL, V59, P1157, DOI 10.1016/0092-8674(89)90771-X; WILLIAMS JG, 1989, DEVELOPMENT, V7, P91; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	55	66	67	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					637	647		10.1016/0092-8674(92)90597-6	http://dx.doi.org/10.1016/0092-8674(92)90597-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423620				2022-12-01	WOS:A1992JY67600011
J	JOHNSON, RS; SPIEGELMAN, BM; PAPAIOANNOU, V				JOHNSON, RS; SPIEGELMAN, BM; PAPAIOANNOU, V			PLEIOTROPIC EFFECTS OF A NULL MUTATION IN THE C-FOS PROTOONCOGENE	CELL			English	Article							TRANSFORMED-CELL LINE; EMBRYONIC STEM-CELLS; ANTISENSE RNA; DNA-BINDING; GENE-EXPRESSION; TRANSGENIC MICE; GLUCOCORTICOID RECEPTOR; TARGETED DISRUPTION; MOLECULAR-CLONING; NERVOUS-SYSTEM	The c-fos proto-oncogene has been implicated as a central regulatory component of the nuclear response to mitogens and other extracellular stimuli. Embryonic stem cells targeted at the c-fos locus have been used to generate chimeric mice that have transmitted the mutated allele through the germline. Homozygous mutants show reduced placental and fetal weights and significant loss of viability at birth. Approximately 40% of the homozygous mutants survive and grow at normal rates until severe osteopetrosis, characterized by foreshortening of the long bones, ossification of the marrow space, and absence of tooth eruption, begins to develop at approximately 11 days. Among other abnormalities, these mice show delayed or absent gametogenesis, lymphopenia, and altered behavior. Despite these defects, many live as long as their wild-type or heterozygous littermates (currently 7 months). These data indicate that c-fos is not required for the growth of most cell types but is involved in the development and function of several distinct tissues.	TUFTS UNIV, SCH VET MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Tufts University; Tufts University; Harvard University; Harvard Medical School	JOHNSON, RS (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Papaioannou, Virginia/0000-0001-7558-8601	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926, R01HD027295] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24926, HD27295] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADAMSON ED, 1985, EMBO J, V4, P941, DOI 10.1002/j.1460-2075.1985.tb03722.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BARKA T, 1989, EXP CELL RES, V185, P419, DOI 10.1016/0014-4827(89)90312-1; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BIGGERS JD, 1991, J IN VITRO FERTIL EM, V8, P352, DOI 10.1007/BF01133028; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; FARRAR WL, 1989, CRIT REV THER DRUG, V5, P229; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HASTY P, 1991, MOL CELL BIOL, V11, P4509, DOI 10.1128/MCB.11.9.4509; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KOUSVELARI E, 1988, EXP CELL RES, V179, P194, DOI 10.1016/0014-4827(88)90358-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LEVI BZ, 1988, CELL DIFFER DEV, V25, P95, DOI 10.1016/0922-3371(88)90105-0; LEVI BZ, 1989, P NATL ACAD SCI USA, V86, P2262, DOI 10.1073/pnas.86.7.2262; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1985, NATURE, V314, P546, DOI 10.1038/314546a0; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKUNO H, 1991, ONCOGENE, V6, P1491; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEARLE AG, 1954, J GENET, V52, P68, DOI 10.1007/BF02981491; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	61	581	591	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					577	586		10.1016/0092-8674(92)90592-Z	http://dx.doi.org/10.1016/0092-8674(92)90592-Z			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423615				2022-12-01	WOS:A1992JY67600006
J	KASTAN, MB; ZHAN, QM; ELDEIRY, WS; CARRIER, F; JACKS, T; WALSH, WV; PLUNKETT, BS; VOGELSTEIN, B; FORNACE, AJ				KASTAN, MB; ZHAN, QM; ELDEIRY, WS; CARRIER, F; JACKS, T; WALSH, WV; PLUNKETT, BS; VOGELSTEIN, B; FORNACE, AJ			A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA	CELL			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; DNA DAMAGE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; PROTEIN; GENE; CANCER; INDUCTION; REPLICATION; DEGRADATION	Cell cycle checkpoints can enhance cell survival and limit mutagenic events following DNA damage. Primary murine fibroblasts became deficient in a G1 checkpoint activated by ionizing radiation (IR) when both wild-type p53 alleles were disrupted. In addition, cells from patients with the radiosensitive, cancer-prone disease ataxia-telangiectasia (AT) lacked the IR-induced increase in p53 protein levels seen in normal cells. Finally, IR induction of the human GADD45 gene, an induction that is also defective in AT cells, was dependent on wild-type p53 function. Wild-type but not mutant p53 bound strongly to a conserved element in the GADD45 gene, and a p53-containing nuclear factor, which bound this element, was detected in extracts from irradiated cells. Thus, we identified three participants (AT gene(s), p53, and GADD45) in a signal transduction pathway that controls cell cycle arrest following DNA damage; abnormalities in this pathway probably contribute to tumor development.	NCI,MOLEC PHARMACOL LAB,BETHESDA,MD 20892; MIT,CTR CANC RES,CAMBRIDGE,MA 02139	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Massachusetts Institute of Technology (MIT)	KASTAN, MB (corresponding author), JOHNS HOPKINS ONCOL CTR,600 N WOLFE ST,BALTIMORE,MD 21287, USA.		Carrier, France/C-3063-2008; Fornace, Albert J/A-7407-2008; El-Deiry, Wafik/AAJ-6080-2020	Fornace, Albert J/0000-0001-9695-085X; El-Deiry, Wafik/0000-0002-9577-8266; Carrier, France/0000-0002-5517-5284	NCI NIH HHS [CA 09071, CA 43460] Funding Source: Medline; NIEHS NIH HHS [ES 05777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043460, T32CA009071, R37CA043460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005777, R01ES005777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doll R., 1981, J NATL CANCER I, V66, P1192; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1989, EXP CELL RES, V182, P61, DOI 10.1016/0014-4827(89)90279-6; FORNACE AJ, 1991, RADIAT RES, P213; FORNACE AJ, 1992, IN PRESS ANN NY ACAD; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GIRARDI AJ, 1966, ANN MED EXP BIOL FEN, V44, P242; HARTWELL LH, 1989, SCIENCE, V246, P6229; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YUNIS JJ, 1990, ADV ONCOL, V6, P3; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	56	3151	3237	1	137	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					587	597		10.1016/0092-8674(92)90593-2	http://dx.doi.org/10.1016/0092-8674(92)90593-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423616				2022-12-01	WOS:A1992JY67600007
J	KIDD, S				KIDD, S			CHARACTERIZATION OF THE DROSOPHILA CACTUS LOCUS AND ANALYSIS OF INTERACTIONS BETWEEN CACTUS AND DORSAL PROTEINS	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; TOLL GENE-PRODUCT; DORSOVENTRAL PATTERN; EMBRYONIC POLARITY; VENTRAL POLARITY; MESSENGER-RNA; NOTCH LOCUS; SEQUENCE; TRANSCRIPTION	An oligonucleotide based on the cdc10/SWI6 repeats of the Drosophila Notch protein was used to isolate other Drosophila genes with these repeats. One of these genes is the cactus locus, 1 of 11 genes required maternally for the establishment in embryos of a gradient of nuclear localization of dorsal protein, a rel-like transcription factor. Previous work showed that in cactus mutants more dorsal protein enters the nucleus in dorsal regions, resulting in a ventralized phenotype. It is now shown that the cactus locus produces two proteins that differ at their carboxy termini; both contain six cdc10/SWI6 repeats that are sufficient for binding to dorsal and for inhibiting the ability of dorsal to bind DNA. The site on dorsal to which cactus binds was localized to the rel homology domain, where it overlaps with, or is adjacent to, the nuclear localization signal. In vivo the bulk of the cactus protein associated with dorsal is phosphorylated. This, or the association with dorsal, appears to stabilize the maternal cactus protein.			KIDD, S (corresponding author), ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM25103] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025103] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKUSJARVI G, 1979, CELL, V16, P841, DOI 10.1016/0092-8674(79)90099-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; GEISLER R, 1992, CELL, V71; GERTTULA S, 1988, GENETICS, V119, P123; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; IP YT, 1991, CELL, V64, P439; ISODA K, 1992, GENE DEV, V6, P619, DOI 10.1101/gad.6.4.619; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; LIEBER T, 1992, IN PRESS NEURON, V9; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; NORRIS JL, 1992, GENE DEV, V6, P1657; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUSHLOW CA, 1990, CELL BIOL, V1, P173; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEEN JY, 1988, BIOTECHNIQUES, V6, P942; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1984, NATURE, V311, P262, DOI 10.1038/311262a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; WULCZYN GF, 1992, NATURE, V358, P597; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	59	220	223	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					623	635		10.1016/0092-8674(92)90596-5	http://dx.doi.org/10.1016/0092-8674(92)90596-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423619				2022-12-01	WOS:A1992JY67600010
J	MAIN, AL; HARVEY, TS; BARON, M; BOYD, J; CAMPBELL, ID				MAIN, AL; HARVEY, TS; BARON, M; BOYD, J; CAMPBELL, ID			THE 3-DIMENSIONAL STRUCTURE OF THE 10TH TYPE-III MODULE OF FIBRONECTIN - AN INSIGHT INTO RGD-MEDIATED INTERACTIONS	CELL			English	Article							CELL-BINDING DOMAIN; NUCLEAR-MAGNETIC-RESONANCE; SITE-DIRECTED MUTAGENESIS; PROTEIN STRUCTURES; ADHESIVE FUNCTION; CRYSTAL-STRUCTURE; HUMAN CD4; SPECTROSCOPY; RECOGNITION; SEQUENCES	The solution structure of the tenth type III module of fibronectin has been determined using nuclear magnetic resonance techniques. The molecule has a fold similar to that of immunoglobulin domains, with seven beta strands forming two antiparallel beta sheets, which pack against each other. Both beta sheets contribute conserved hydrophobic residues to a compact core. The topology is more similar to that of domain 2 of CD4, PapD, and the extracellular domain of the human growth hormone receptor than to that of immunoglobulin C domains. The module contains an Arg-Gly-Asp sequence known to be involved in cell adhesion. This tripeptide is solvent exposed and lies on a conformationally mobile loop between strands F and G, consistent with its cell adhesion function.			MAIN, AL (corresponding author), UNIV OXFORD, DEPT BIOCHEM, S PARKS RD, OXFORD OX1 3QU, ENGLAND.		Harvey, Timothy S/F-9863-2013	Harvey, Timothy S/0000-0001-6270-1943				ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; AOTA S, 1991, J BIOL CHEM, V266, P15938; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BARTON GJ, 1990, METHOD ENZYMOL, V183, P403; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, XPLOR MANUAL; CONSTANTINE KL, 1991, BIOCHEMISTRY-US, V30, P1663, DOI 10.1021/bi00220a032; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOWNING AK, 1992, J MOL BIOL, V225, P821, DOI 10.1016/0022-2836(92)90403-7; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOMMEL U, 1992, IN PRESS J MOL BIOL; Hynes R. O., 1990, FIBRONECTINS; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; MARION D, 1988, J MAGN RESON, V80, P528, DOI 10.1016/0022-2364(88)90250-8; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mosher DF, 1989, FIBRONECTIN; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RICHARDSON JS, 1978, P NATL ACAD SCI USA, V75, P2574, DOI 10.1073/pnas.75.6.2574; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; WANG HM, 1992, J BIOL CHEM, V267, P979; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YAMADA KM, 1991, J BIOL CHEM, V266, P12809	51	450	487	1	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 13	1992	71	4					671	678		10.1016/0092-8674(92)90600-H	http://dx.doi.org/10.1016/0092-8674(92)90600-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423622				2022-12-01	WOS:A1992JY67600014
J	PELISKA, JA; BENKOVIC, SJ				PELISKA, JA; BENKOVIC, SJ			MECHANISM OF DNA STRAND TRANSFER-REACTIONS CATALYZED BY HIV-1 REVERSE-TRANSCRIPTASE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ROUS-SARCOMA VIRUS; RETROVIRAL RECOMBINATION; GENETIC-RECOMBINATION; RNASE-H; POLYMERASE; REPLICATION; SUBSTITUTIONS; MUTAGENESIS; HYDROLYSIS	Two DNA strand transfer reactions occur during retroviral reverse transcription. The mechanism of the first, minus strand strong-stop DNA, transfer has been studied in vitro with human immunodeficiency virus 1 reverse transcriptase (HIV-1 RT) and a model template-primer system derived from the HIV-1 genome. The results reveal that HIV-1 RT alone can catalyze DNA strand transfer reactions. Two kinetically distinct ribonuclease (RNase) H activities associated with HIV-1 RT are required for removal of RNA fragments annealed to the nascent DNA strand. Examination of the binding of DNA . RNA duplex and single-stranded RNA to HIV-1 RT during strand transfer supports a model where the enzyme accommodates both the acceptor RNA template and the nascent DNA strand before the transfer event is completed. The polymerase activity incorporated additional bases beyond the 5' end of the RNA template, resulting in a base misincorporation upon DNA strand transfer. Such a process occurring in vivo during retroviral homologous recombination could contribute to the hypermutability of the HIV-1 genome.			PELISKA, JA (corresponding author), PENN STATE UNIV, DEPT CHEM, University Pk, PA 16802 USA.				NIAID NIH HHS [AI08275] Funding Source: Medline; NIGMS NIH HHS [GM13306] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008275] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; COLLETT MS, 1978, NATURE, V272, P181, DOI 10.1038/272181a0; DARLIX JL, 1977, J VIROL, V23, P659, DOI 10.1128/JVI.23.3.659-668.1977; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, IN PRESS P NATL ACAD; GUISER RG, 1991, J BIOL CHEM, V266, P13103; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HUBER HE, 1989, J BIOL CHEM, V264, P4669; Jencks W.P., 1987, CATALYSIS CHEM ENZYM; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MIZRAHI V, 1990, NUCLEIC ACIDS RES, V18, P5359, DOI 10.1093/nar/18.18.5359; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; RICHTERCOOK NJ, 1992, J BIOL CHEM, V267, P15952; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sambrook J, 1989, MOL CLONING; SOBOL RW, 1991, BIOCHEMISTRY-US, V30, P10623, DOI 10.1021/bi00108a004; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; Varmus H. E., 1982, RNA TUMOR VIRUSES, P369; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; YU H, 1992, J BIOL CHEM, V267, P10888	49	306	312	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1112	1118		10.1126/science.1279806	http://dx.doi.org/10.1126/science.1279806			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1279806				2022-12-01	WOS:A1992JX85200020
J	ROBERT, D; AMOROSO, J; HOY, RR				ROBERT, D; AMOROSO, J; HOY, RR			THE EVOLUTIONARY CONVERGENCE OF HEARING IN A PARASITOID FLY AND ITS CRICKET HOST	SCIENCE			English	Article							EUPHASIOPTERYX-OCHRACEA; SEXUAL DIFFERENCES; SENSITIVITY	Parasitism is a widespread and diverse life strategy that connects species throughout the animal kingdom. Female parasitoid flies of the genus Ormia must find a specific cricket host on which to deposit their parasitic maggots. To reproduce, female flies must perform the same task as female crickets: find a singing male cricket. These flies have evolved a unique hearing organ that allows them to detect and locate singing male crickets. Through evolutionary convergence, these flies possess a hearing organ that much more resembles a cricket's ear than a typical fly's ear, allowing these parasitoids to take advantage of the sensory ecological niche of their host.	CORNELL UNIV, NEUROBIOL & BEHAV SECT, ITHACA, NY 14853 USA; UNIV FLORIDA, DEPT ENTOMOL & NEMATOL, GAINESVILLE, FL 32611 USA	Cornell University; State University System of Florida; University of Florida					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000103] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC00103] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BAILEY WJ, 1991, J COMP PHYSIOL A, V169, P349; BENNETCLARK HC, 1968, J EXP BIOL, V49, P117; CADE W, 1975, SCIENCE, V190, P1312, DOI 10.1126/science.190.4221.1312; CARDONE B, 1988, PHYSIOL ENTOMOL, V13, P9, DOI 10.1111/j.1365-3032.1988.tb00903.x; Ewing AW, 1989, ARTHROPOD BIOACOUSTI; GRAY E. G., 1960, PHIL TRANS ROY SOC LONDON SER B BIOL SCI, V243, P75, DOI 10.1098/rstb.1960.0005; HALL JC, 1985, COMPREHENSIVE INSECT, V9, P287; LAKESHARLAN R, 1992, NATURWISSENSCHAFTEN, V79, P224, DOI 10.1007/BF01227133; MANGOLD JR, 1978, FLA ENTOMOL, V61, P57, DOI 10.2307/3494638; Michelsen A., 1985, COMPREHENSIVE INSECT, P495; MOISEFF A, 1983, J COMP PHYSIOL, V152, P155, DOI 10.1007/BF00611181; Moulins M, 1976, STRUCTURE FUNCTION P, P387; NARINS PM, 1976, SCIENCE, V192, P378, DOI 10.1126/science.1257772; ROTH LM, 1948, AM MIDL NAT, V40, P265, DOI 10.2307/2421604; Sokal R., 1981, BIOMETRY; WALKER TJ, 1986, FLA ENTOMOL, V69, P678, DOI 10.2307/3495213; WALKER TJ, 1962, EVOLUTION, V16, P407, DOI 10.2307/2406176; YAGER DD, 1990, J ZOOL, V221, P517, DOI 10.1111/j.1469-7998.1990.tb04017.x; YAGER DD, 1986, SCIENCE, V231, P727, DOI 10.1126/science.3945806	19	147	154	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 13	1992	258	5085					1135	1137		10.1126/science.1439820	http://dx.doi.org/10.1126/science.1439820			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439820				2022-12-01	WOS:A1992JX85200027
J	SCRUTTON, NS; DEONARAIN, MP; BERRY, A; PERHAM, RN				SCRUTTON, NS; DEONARAIN, MP; BERRY, A; PERHAM, RN			COOPERATIVITY INDUCED BY A SINGLE MUTATION AT THE SUBUNIT INTERFACE OF A DIMERIC ENZYME - GLUTATHIONE-REDUCTASE	SCIENCE			English	Article							ESCHERICHIA-COLI; ASPARTATE TRANSCARBAMOYLASE; DIRECTED MUTAGENESIS; DISULFIDE BRIDGE; RESOLUTION; DEHYDROGENASE; SPECIFICITY; COENZYME; SITE	When glycine418 of Escherichia coli glutathione reductase, which is in a closely packed region of the dimer interface, is replaced with a bulky tryptophan residue, the enzyme becomes highly cooperative (Hill coefficient 1.76) for glutathione binding. The cooperativity is lost when the mutant subunit is hybridized with a wild-type subunit to create a heterodimer. The mutation appears to disrupt atomic packing at the dimer interface, which induces a change of kinetic mechanism. A single mutation in a region of the protein remote from the active site can thus act as a molecular switch to confer cooperativity on an enzyme.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND	University of Cambridge				Berry, Alan/0000-0003-3502-0426				BERGER SA, 1990, NATURE, V343, P575, DOI 10.1038/343575a0; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; DEMBOWSKI NJ, 1990, BIOCHEMISTRY-US, V29, P3716, DOI 10.1021/bi00467a018; DEONARAIN MP, 1990, P ROY SOC B-BIOL SCI, V241, P179, DOI 10.1098/rspb.1990.0083; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1491, DOI 10.1021/bi00120a028; DEONARAIN MP, 1992, BIOCHEMISTRY-US, V31, P1498, DOI 10.1021/bi00120a029; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9601; ERMLER U, 1991, PROTEINS, V9, P174, DOI 10.1002/prot.340090303; GREER S, 1986, BIOCHEMISTRY-US, V25, P2736, DOI 10.1021/bi00357a069; HENDERSON GB, 1991, P NATL ACAD SCI USA, V88, P8769, DOI 10.1073/pnas.88.19.8769; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO LC, 1989, SCIENCE, V245, P522, DOI 10.1126/science.2667139; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P8764, DOI 10.1073/pnas.88.19.8764; MATTEVI A, 1991, J MOL BIOL, V220, P975, DOI 10.1016/0022-2836(91)90367-F; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PAI EF, 1983, J BIOL CHEM, V258, P1751; PERHAM RN, 1991, BIOESSAYS, V13, P515, DOI 10.1002/bies.950131005; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCRUTTON NS, 1988, FEBS LETT, V241, P46, DOI 10.1016/0014-5793(88)81028-7; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Segel IH, 1975, ENZYME KINETICS, P460; STEBBINS JW, 1992, BIOCHEMISTRY-US, V31, P2328, DOI 10.1021/bi00123a017; VANVLIET F, 1991, P NATL ACAD SCI USA, V88, P9180, DOI 10.1073/pnas.88.20.9180; WENTE SR, 1991, J BIOL CHEM, V266, P20833; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; WONG KK, 1988, BIOCHEMISTRY-US, V27, P7091, DOI 10.1021/bi00418a063	29	47	46	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1140	1143		10.1126/science.1439821	http://dx.doi.org/10.1126/science.1439821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439821				2022-12-01	WOS:A1992JX85200029
J	SMITH, SB; FINZI, L; BUSTAMANTE, C				SMITH, SB; FINZI, L; BUSTAMANTE, C			DIRECT MECHANICAL MEASUREMENTS OF THE ELASTICITY OF SINGLE DNA-MOLECULES BY USING MAGNETIC BEADS	SCIENCE			English	Article							GEL-ELECTROPHORESIS; FLUORESCENCE MICROSCOPY; MANIPULATION; FLEXIBILITY; DYNAMICS; BINDING; DAPI	Single DNA molecules were chemically attached by one end to a glass surface and by their other end to a magnetic bead. Equilibrium positions of the beads were observed in an optical microscope while the beads were acted on by known magnetic and hydrodynamic forces. Extension versus force curves were obtained for individual DNA molecules at three different salt concentrations with forces between 10(-14) and 10(-11) newtons. Deviations from the force curves predicted by the freely jointed chain model suggest that DNA has significant local curvature in solution. Ethidium bromide and 4',6-diamidino-2-phenylindole had little effect on the elastic response of the molecules, but their extent of intercalation was directly measured. Conversely, the effect of bend-inducing cis-diamminedichloroplatinum (II) was large and supports the hypothesis of natural curvature in DNA.	UNIV OREGON,INST MICROBIOL,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon				Bustamante, Carlos/0000-0002-2970-0073	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032543, R01GM032543] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERMAN B, 1989, BIOPOLYMERS, V28, P1541, DOI 10.1002/bip.360280906; BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BUECHE F, 1962, PHYSICAL PROPERTIES, P37; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.biophys.20.1.415; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P557; CASSASA EF, 1967, POLYM LETT, V5, P773; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DIMARZIO EA, 1965, J CHEM PHYS, V42, P2101, DOI 10.1063/1.1696251; Flory P, 1989, STATISTICAL MECHANIC, P307; HAGERMAN PJ, 1981, BIOPOLYMERS, V20, P1503, DOI 10.1002/bip.1981.360200710; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; Johnson N.P., 1989, PROG CLIN BIOCH MED, V10, P1, DOI [10.1007/978-3-642-74760-1_1, DOI 10.1007/978-3-642-74760-1_1]; KASEVICH M, 1990, 12TH P INT C AT PHYS, P53; Lorentz H. A., 1907, ABHANDLUNGEN THEORET, P23; MACQUET JP, 1978, BIOCHIMIE, V60, P901, DOI 10.1016/S0300-9084(78)80574-4; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P226; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; SOBEL ES, 1991, BIOPOLYMERS, V31, P1559, DOI 10.1002/bip.360311311; STIGTER D, 1991, BIOPOLYMERS, V31, P169, DOI 10.1002/bip.360310205; Trifonov E.N., 1987, STRUCTURE EXPRESSION, P243; VOLLENWEIDER HJ, 1978, BIOCHEMISTRY-US, V75, P710; WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0; ZIMM BH, IN PRESS Q REV BIOPH	28	1474	1643	9	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1122	1126		10.1126/science.1439819	http://dx.doi.org/10.1126/science.1439819			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439819				2022-12-01	WOS:A1992JX85200022
J	SZE, JY; WOONTNER, M; JAEHNING, JA; KOHLHAW, GB				SZE, JY; WOONTNER, M; JAEHNING, JA; KOHLHAW, GB			INVITRO TRANSCRIPTIONAL ACTIVATION BY A METABOLIC INTERMEDIATE - ACTIVATION BY LEU3 DEPENDS ON ALPHA-ISOPROPYLMALATE	SCIENCE			English	Article							REGULATORY GENE LEU3; YEAST LEU4; EXPRESSION; BINDING; BIOSYNTHESIS; DELETION; PROTEINS; PRODUCT; ELEMENT; REGION	In the absence of the leucine biosynthetic precursor alpha-isopropylmalate (alpha-IPM), the yeast LEU3 protein (Leu3p) binds DNA and acts as a transcriptional repressor in an in vitro extract. Addition of alpha-IPM resulted in a dramatic increase in Leu3p-dependent transcription. The presence of alpha-IPM was also required for Leu3p to compete effectively with another transcriptional activator, GAL4/VP16, for limiting transcription factors. Therefore, the addition of alpha-IPM appears to convert a transcriptional repressor into an activator. This represents an example in eukaryotes of direct transcriptional regulation by a small effector molecule.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; INDIANA UNIV,INST MOLEC & CELLULAR BIOL,BLOOMINGTON,IN 47405; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038101] Funding Source: NIH RePORTER; NIAID NIH HHS [K04 AI 00874] Funding Source: Medline; NIGMS NIH HHS [GM15102, R01 GM38101] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAI YL, 1991, NUCLEIC ACIDS RES, V19, P5991, DOI 10.1093/nar/19.21.5991; BAICHWAL VR, 1983, CURR GENET, V7, P369, DOI 10.1007/BF00445877; BELTZER JP, 1986, J BIOL CHEM, V261, P5160; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; CALVO JM, 1970, METHODS ENZYMOLOGY A, V17, P791; CHANG LFL, 1984, GENETICS, V108, P91; FRIDEN P, 1989, MOL CELL BIOL, V9, P4056, DOI 10.1128/MCB.9.9.4056; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GARDNER KH, 1991, BIOCHEMISTRY-US, V30, P11292, DOI 10.1021/bi00111a015; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KOHLHAW GB, 1983, AMINO ACIDS BIOSYNTH, P285; LITSKEPETERSEN JG, 1986, NUCLEIC ACIDS RES, V14, P961; MARTINEZARIAS A, 1984, NATURE, V307, P740, DOI 10.1038/307740b0; PETERS MH, 1990, ARCH BIOCHEM BIOPHYS, V276, P294, DOI 10.1016/0003-9861(90)90041-V; POLACCO JC, 1973, GENETICS, V74, P443; SZE JY, UNPUB; WOONTNER M, UNPUB; ZHOU K, 1987, NUCLEIC ACIDS RES, V15, P5261, DOI 10.1093/nar/15.13.5261; ZHOU K, 1990, J BIOL CHEM, V265, P17409; ZHOU KM, 1990, NUCLEIC ACIDS RES, V18, P291, DOI 10.1093/nar/18.2.291	24	87	88	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 13	1992	258	5085					1143	1145		10.1126/science.1439822	http://dx.doi.org/10.1126/science.1439822			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX852	1439822				2022-12-01	WOS:A1992JX85200030
J	THEUNISSEN, O; RUDT, F; GUDDAT, U; MENTZEL, H; PIELER, T				THEUNISSEN, O; RUDT, F; GUDDAT, U; MENTZEL, H; PIELER, T			RNA AND DNA-BINDING ZINC FINGERS IN XENOPUS TFIIIA	CELL			English	Article							TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; 5S RIBOSOMAL-RNA; LAEVIS OOCYTES; FUNCTIONAL DOMAINS; GENE PROMOTER; 5S-RNA GENE; PROTEIN; PARTICLE; SITE	The nine tandem zinc finger repeats in the 5S gene-specific transcription factor IIIA (TFIIIA) from Xenopus mediate specific binding to 5S DNA as well as to 5S ribosomal RNA. A comparative functional analysis of a systematic set of TFIIIA zinc finger combinations reveals that most, if not all, participate in both DNA and RNA binding. Minimal sets of fingers sufficient for DNA and RNA recognition are different. In RNA binding, most finger elements are found to be functionally equivalent. However, the nonessential finger 6 exhibits RNA binding characteristics distinct from the other eight modules. The secondary/tertiary structure of the central domain in 5S RNA, not its primary sequence, is found to carry the essential structural information for TFIIIA binding in Xenopus oocytes. Taken together, our findings suggest that RNA and DNA binding are overlapping, though separable functions of the nine zinc finger elements in TFIIIA, occurring via fundamentally different molecular mechanisms.			THEUNISSEN, O (corresponding author), MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,IHNESTR 73,W-1000 BERLIN 33,GERMANY.							BAUDIN F, 1991, J MOL BIOL, V218, P69, DOI 10.1016/0022-2836(91)90874-6; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; FAIRALL L, 1986, J MOL BIOL, V192, P577, DOI 10.1016/0022-2836(86)90278-0; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; JOHO KE, 1990, CELL, V61, P293, DOI 10.1016/0092-8674(90)90809-S; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; KRAMER A, 1983, J BIOL CHEM, V258, P1915; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MAJOWSKI K, 1987, EMBO J, V6, P3057, DOI 10.1002/j.1460-2075.1987.tb02612.x; Maniatis T, 1989, DECONTAMINATION DILU; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NIETFELD W, 1989, J MOL BIOL, V208, P639, DOI 10.1016/0022-2836(89)90155-1; NIETFELD W, 1990, EMBO J, V9, P399; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1983, FEBS LETT, V157, P283, DOI 10.1016/0014-5793(83)80562-6; PIELER T, 1985, EMBO J, V4, P1847, DOI 10.1002/j.1460-2075.1985.tb03859.x; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PIELER T, 1984, NUCLEIC ACIDS RES, V12, P8393, DOI 10.1093/nar/12.22.8393; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; SAKONJU S, 1981, CELL, V23, P665, DOI 10.1016/0092-8674(81)90429-3; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1797, DOI 10.1093/nar/19.8.1797; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1791, DOI 10.1093/nar/19.8.1791; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	43	148	149	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					679	690		10.1016/0092-8674(92)90601-8	http://dx.doi.org/10.1016/0092-8674(92)90601-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423623				2022-12-01	WOS:A1992JY67600015
J	TKACHUK, DC; KOHLER, S; CLEARY, ML				TKACHUK, DC; KOHLER, S; CLEARY, ML			INVOLVEMENT OF A HOMOLOG OF DROSOPHILA-TRITHORAX BY 11Q23 CHROMOSOMAL TRANSLOCATIONS IN ACUTE LEUKEMIAS	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA-BINDING PROTEIN; BITHORAX COMPLEX; HMG-I; CLONING; MOTIF; GENES; IDENTIFICATION; BREAKPOINTS	We have identified a human homolog of the Drosophila trithorax protein that is structurally altered by 11q23 translocations in acute leukemias. Human trithorax (HRX) is a predicted 431 kd protein containing two potential DNA-binding motifs consisting of zinc fingers conserved with the fly protein and nonconserved amino-terminal "AT hook" motifs related to the DNA-binding motifs in HMG proteins. 11q23 translocations disrupt the HRX gene between these two motifs, and in a t(11;19)-carrying cell line fusion transcripts are expressed from both derivative chromosomes. The more abundant derivative 11 transcript codes for a chimeric protein containing the AT hook motifs fused to a previously undescribed protein (ENL) from chromosome 19. These data suggest a novel role for a trithorax-homologous protein in multilineage human leukemias that may be mediated by DNA binding within the minor groove at AT-rich sites, implicated to play an important role in bacterial IHF-, yeast datin-, and mammalian HMG-mediated gene activation.			TKACHUK, DC (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.				NATIONAL CANCER INSTITUTE [R01CA055029, R01CA042971, R37CA042971] Funding Source: NIH RePORTER; NCI NIH HHS [CA42971, CA55029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; CASTELLIGAIR JE, 1990, EMBO J, V9, P4267, DOI 10.1002/j.1460-2075.1990.tb07875.x; CHEN CS, 1991, BLOOD, V78, P2498; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; HARRIS BN, 1988, CANCER GENET CYTOGEN, V30, P171, DOI 10.1016/0165-4608(88)90108-2; HAYASHI Y, 1985, LEUKEMIA RES, V9, P1467, DOI 10.1016/0145-2126(85)90038-4; HEIM S, 1987, CANCER CYTOGENETICS; INGHAM PW, 1985, COLD SPRING HARB SYM, V50, P201, DOI 10.1101/SQB.1985.050.01.026; INGHAM PW, 1983, NATURE, V306, P591, DOI 10.1038/306591a0; JACOBS G, 1990, New Biologist, V2, P583; KANEKO Y, 1988, LEUKEMIA, V2, P672; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MANIATIS T, 1992, TRANSCRIPTIONAL REGU; MAZO AM, 1990, P NATL ACAD SCI USA, V87, P2112, DOI 10.1073/pnas.87.6.2112; MITELMAN F, 1987, CATALOG CHROMOSOME A; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MORINAGA T, 1991, MOL CELL BIOL, V11, P6041, DOI 10.1128/MCB.11.12.6041; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAIMONDI SC, 1989, BLOOD, V73, P1627; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SHIMIZU H, 1989, AM J PEDIAT HEMATOL, V11, P162; SMITH SD, 1989, BLOOD, V73, P2182; Smith T. F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; THOMPSON LH, 1985, SOMAT CELL MOLEC GEN, V11, P87, DOI 10.1007/BF01534738; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZIEMINVANDERPOE.S, 1991, P NATL ACAD SCI USA, V86, P10735	46	889	929	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					691	700		10.1016/0092-8674(92)90602-9	http://dx.doi.org/10.1016/0092-8674(92)90602-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1423624				2022-12-01	WOS:A1992JY67600016
J	WANG, GH; SEEGER, C				WANG, GH; SEEGER, C			THE REVERSE-TRANSCRIPTASE OF HEPATITIS-B VIRUS ACTS AS A PROTEIN PRIMER FOR VIRAL-DNA SYNTHESIS	CELL			English	Article							P-GENE-PRODUCT; RNA ENCAPSIDATION; TERMINAL PROTEIN; POLYMERASE; GENOME; INITIATION; SEQUENCE; IDENTIFICATION; REPLICATION; WOODCHUCK	Hepatitis B viruses (hepadnaviruses) replicate their DNA genomes by reverse transcription of an RNA intermediate. Efforts to examine the biochemical mechanism for viral DNA synthesis have been hampered by the failure to solubilize the reverse transcriptase from virions and to express the polymerase in heterologous systems in an enzymatically active form. Here, we demonstrate that the polymerase of a hepadnavirus synthesized in an in vitro translation reaction exhibits reverse transcriptase activity. Furthermore, our results show that the polymerase acts as a primer for DNA synthesis and remains covalently linked to nascent DNA, a feature that is not known to exist in any other RNA-directed DNA polymerases. Priming of DNA synthesis requires viral RNA but occurs independently of other viral components. The ability to express the hepadnavirus reverse transcriptase in an enzymatically active form will allow detailed biochemical and functional analyses of this complex enzyme, and may facilitate the identification of inhibitors required for antiviral therapy.			WANG, GH (corresponding author), FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111, USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024972, R01AI030544, R01AI024972] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIAID NIH HHS [AI-30544, AI-24972] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHANG LJ, 1989, NATURE, V337, P364, DOI 10.1038/337364a0; CONDREAY LD, 1992, VIROLOGY, V188, P208, DOI 10.1016/0042-6822(92)90751-A; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GERLICH WH, 1980, CELL, V21, P801, DOI 10.1016/0092-8674(80)90443-2; HELGSTRAND E, 1978, SCIENCE, V201, P819, DOI 10.1126/science.210500; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P550; JUNKERNIEPMANN M, 1990, EMBO J, V9, P3389, DOI 10.1002/j.1460-2075.1990.tb07540.x; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KHUDYAKOV YE, 1989, FEBS LETT, V243, P115, DOI 10.1016/0014-5793(89)80110-3; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIEN JM, 1987, J VIROL, V61, P3832, DOI 10.1128/JVI.61.12.3832-3840.1987; MANDART E, 1984, J VIROL, V49, P782, DOI 10.1128/JVI.49.3.782-792.1984; Mason W. S., 1987, Hepadna viruses. Proceedings of a Director's Sponsors-UCLA Symposium. Held at Keystone, Colorado, March 29-April 3, 1987, P3; MOLNARKIMBER KL, 1983, J VIROL, V45, P165, DOI 10.1128/JVI.45.1.165-172.1983; PUGH JC, 1988, J VIROL, V62, P3513, DOI 10.1128/JVI.62.9.3513-3516.1988; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; ROYCHOUDHURY S, 1991, J VIROL, V65, P3617, DOI 10.1128/JVI.65.7.3617-3624.1991; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SEEGER C, 1991, J VIROL, V65, P5190, DOI 10.1128/JVI.65.10.5190-5195.1991; SEEGER C, 1990, J VIROL, V64, P16, DOI 10.1128/JVI.64.1.16-23.1990; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; WIMMER E, 1982, CELL, V28, P199, DOI 10.1016/0092-8674(82)90335-X; WU TT, 1991, J VIROL, V65, P2155, DOI 10.1128/JVI.65.5.2155-2163.1991	32	313	329	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 13	1992	71	4					663	670		10.1016/0092-8674(92)90599-8	http://dx.doi.org/10.1016/0092-8674(92)90599-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JY676	1384989				2022-12-01	WOS:A1992JY67600013
J	ARNOLD, D; DRISCOLL, J; ANDROLEWICZ, M; HUGHES, E; CRESSWELL, P; SPIES, T				ARNOLD, D; DRISCOLL, J; ANDROLEWICZ, M; HUGHES, E; CRESSWELL, P; SPIES, T			PROTEASOME SUBUNITS ENCODED IN THE MHC ARE NOT GENERALLY REQUIRED FOR THE PROCESSING OF PEPTIDES BOUND BY MHC CLASS-I MOLECULES	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LINKED LMP; GENE; HLA; EXPRESSION; REGION; HEAVY; IDENTIFICATION; TRANSPORTER; DETERMINANT	ANTIGEN processing provides major histocompatibility complex (MHC) class I molecules with short peptides, which they selectively bind and present to cytotoxic T lymphocytes1-4. The proteolytic system generating these peptides in the cytosol is unidentified, but their delivery into the endoplasmic reticulum is mediated by the TAP1-TAP2 transporter encoded in the MHC class II region5-9. Closely linked to TAP1 and TAP2 are genes for the LMP2 and LMP7 proteins10, which resemble components of proteasomes11-13, proteolytic complexes known to degrade cytosolic proteins14. This association has led to the common assumption that proteasomes function in this immunological pathway (discussed in ref. 15). We now show that the expression of stably assembled class I molecules and apparently normal peptide processing can be completely restored in the absence of LMP2 and LMP7 in the human lymphoblastoid cell line mutant 721.174 (refs 16, 17). The identity of LMP7 is directly confirmed by reconstitution of a proteasomal subunit after gene transfer. These results therefore dispute the hypothetical involvement of proteasomes in antigen processing, although a more subtle effect of LMP2 and LMP7 cannot be ruled out.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Yale University	ARNOLD, D (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,44 BINNEY ST,BOSTON,MA 02115, USA.			Driscoll, James/0000-0001-8364-0617				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BRODSKY FM, 1979, EUR J IMMUNOL, V9, P536, DOI 10.1002/eji.1830090709; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FRUH K, 1992, J BIOL CHEM, V267, P22131; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAYNES BF, 1982, HUM IMMUNOL, V4, P273, DOI 10.1016/0198-8859(82)90001-5; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LJUNGGREN HG, 1990, NATURE, V346, P478; LONG EO, 1991, HUM IMMUNOL, V31, P229, DOI 10.1016/0198-8859(91)90092-N; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MONACO JJ, 1982, P NATL ACAD SCI-BIOL, V79, P3001, DOI 10.1073/pnas.79.9.3001; OZATO K, 1981, J IMMUNOL, V126, P317; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; WAYS JP, 1986, J IMMUNOL, V137, P217; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	36	221	226	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					171	174		10.1038/360171a0	http://dx.doi.org/10.1038/360171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436094				2022-12-01	WOS:A1992JX75200064
J	BEAM, KG; ADAMS, BA; NIIDOME, T; NUMA, S; TANABE, T				BEAM, KG; ADAMS, BA; NIIDOME, T; NUMA, S; TANABE, T			FUNCTION OF A TRUNCATED DIHYDROPYRIDINE RECEPTOR AS BOTH VOLTAGE SENSOR AND CALCIUM-CHANNEL	NATURE			English	Article							DYSGENIC SKELETAL-MUSCLE; 2 SIZE FORMS; CHARGE MOVEMENT; ALPHA-1; PHOSPHORYLATION; SUBUNITS; CELLS; CDNAS; ACID; RAT	THE skeletal muscle dihydropyridine (DHP) receptor serves dual functions, as a voltage sensor for excitation-contraction coupling and as an L-type calcium channel1-3. Biochemical analysis indicates the presence of two forms of the DHP receptor polypeptide in skeletal muscle, a full-length translation product present as a minor species and a much more abundant form that has a truncated carboxy-terminus4-6. On the basis of these and other observations7, it has been proposed8 that, in skeletal muscle, only the full-length DHP receptor can function as a calcium channel and that the truncated form can only function as a voltage sensor for excitation-contraction coupling. To resolve this issue, we have now constructed a complementary DNA (pC6DELTA1) encoding a protein corresponding to the truncated DHP receptor in skeletal muscle. Expression of pC6DELTA1 in dysgenic myotubes fully restores both excitation-contraction coupling and calcium current, consistent with the idea that a single class of DHP receptors performs both functions.	KYOTO UNIV,FAC MED,DEPT MED CHEM,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MOLEC GENET,KYOTO 606,JAPAN	Kyoto University; Kyoto University	BEAM, KG (corresponding author), COLORADO STATE UNIV,COLL VET MED & BIOMED SCI,DEPT PHYSIOL,FT COLLINS,CO 80523, USA.		Tuluc, Petronel/C-2527-2011					ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1972, BIOCHIM BIOPHYS ACTA, V267, P605, DOI 10.1016/0005-2728(72)90194-6; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LAI Y, 1990, J BIOL CHEM, V265, P20839; LAMB GD, 1987, J PHYSIOL-LONDON, V393, P595, DOI 10.1113/jphysiol.1987.sp016843; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1991, NATURE, V352, P800, DOI 10.1038/352800a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	18	95	95	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					169	171		10.1038/360169a0	http://dx.doi.org/10.1038/360169a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1331811				2022-12-01	WOS:A1992JX75200063
J	BOCSKEI, Z; GROOM, CR; FLOWER, DR; WRIGHT, CE; PHILLIPS, SEV; CAVAGGIONI, A; FINDLAY, JBC; NORTH, ACT				BOCSKEI, Z; GROOM, CR; FLOWER, DR; WRIGHT, CE; PHILLIPS, SEV; CAVAGGIONI, A; FINDLAY, JBC; NORTH, ACT			PHEROMONE BINDING TO 2 RODENT URINARY PROTEINS REVEALED BY X-RAY CRYSTALLOGRAPHY	NATURE			English	Article							NASAL-MUCOSA; RESOLUTION; REFINEMENT; CRYSTALLIZATION; SEQUENCE; REGION	THE principal protein excreted in male rat urine, urinary alpha2-globulin and the homologous mouse protein, major urinary protein, have been well characterized, although their functions remain unclear. Male rat urine affects the behaviour and sexual response of female rats1, leading to the proposal that rodent urinary proteins are responsible for binding pheromones and their subsequent release from drying urine2. Urinary alpha2-globulin is also involved in hyaline droplet nephropathy, an important toxicological syndrome in male rats resulting from exposure to a number of industrial chemicals and characterized by the accumulation of liganded urinary alpha2-globulin in lysosomes in the kidney, followed by the induction of renal cancer3. We now report the three-dimensional structures of mouse major urinary protein (at 2.4 angstrom resolution) and rat urinary alpha2-globulin (at 2.8 angstrom resolution). The results corroborate the role of these proteins in pheromone transport and elaborate the structural basis of ligand binding.	UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV PARMA,IST FISIOL UMANA,I-43100 PARMA,ITALY	University of Leeds; University of Parma			Flower, Darren/F-1263-2010	Flower, Darren/0000-0002-8542-7067; Phillips, Simon/0000-0001-8922-0250; Groom, Colin/0000-0001-8921-9575	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACCHINI A, IN PRESS EXPERIMENTI; BOCSKEI Z, 1991, J MOL BIOL, V218, P699, DOI 10.1016/0022-2836(91)90258-8; BORGHOFF SJ, 1990, ANNU REV PHARMACOL, V30, P349, DOI 10.1146/annurev.pa.30.040190.002025; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVAGGIONI A, 1990, COMP BIOCHEM PHYS B, V96, P513, DOI 10.1016/0305-0491(90)90049-Y; CAVAGGIONI A, 1987, FEBS LETT, V212, P225, DOI 10.1016/0014-5793(87)81349-2; CHERFILS J, 1988, J APPL CRYSTALLOGR, V21, P985, DOI 10.1107/S002188988800932X; CLARK AJ, 1985, EMBO J, V4, P3159, DOI 10.1002/j.1460-2075.1985.tb04059.x; CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; Cowley J. J., 1978, Biological determinants of sexual behaviour., P87; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1991, J MOL GRAPHICS, V9, P257, DOI 10.1016/0263-7855(91)80021-Q; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; ICHIYOSHI Y, 1987, BIOCHIM BIOPHYS ACTA, V910, P43, DOI 10.1016/0167-4781(87)90093-5; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KIMURA H, 1991, J BIOL CHEM, V266, P5963; NORTH ACT, 1991, BIOCH SOC S, V57, P35; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PARRYSMITH DJ, 1991, COMPUT APPL BIOSCI, V7, P233; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; TIRINDELLI R, 1989, EUR J BIOCHEM, V185, P569, DOI 10.1111/j.1432-1033.1989.tb15151.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90	27	354	365	2	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					186	188		10.1038/360186a0	http://dx.doi.org/10.1038/360186a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1279439				2022-12-01	WOS:A1992JX75200069
J	DRICKAMER, K				DRICKAMER, K			ENGINEERING GALACTOSE-BINDING ACTIVITY INTO A C-TYPE MANNOSE-BINDING PROTEIN	NATURE			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SITE; RAT; HOMOLOGY; LECTIN	CALCIUM-DEPENDENT or C-type carbohydrate-recognition domains are homologous protein modules found in a variety of animal lectins1. Selective binding of sugars by these domains is essential for glycoprotein clearance, cell-cell adhesion and pathogen neutralization. Although various C-type carbohydrate-recognition domains share sequence identity ranging from 20 to 55%, their sugar-binding characteristics vary widely. The structure of a mannose-binding carbohydrate-recognition domain in complex with a saccharide ligand suggests that two glutamic acid-asparagine pairs are essential determinants of ligand binding by this domain2. In C-type lectins that bind galactose with higher affinity than mannose, one of these pairs is replaced by glutamine-aspartic acid. Here we shift the sequence of the mannose-binding protein to correspond to that found in galactose-binding domains in order to test the importance of these residues in sugar-binding selectivity. This simple switch in the position of a single amide group alters the binding activity of the domain so that galactose becomes the preferred ligand.			DRICKAMER, K (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1991, J BIOL CHEM, V266, P4810; Maniatis T., 1982, MOL CLONING; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SIKDER SK, 1983, J BIOL CHEM, V258, P2520; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	18	443	467	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					183	186		10.1038/360183a0	http://dx.doi.org/10.1038/360183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1279438				2022-12-01	WOS:A1992JX75200068
J	GOODRICH, DW; LEE, WH				GOODRICH, DW; LEE, WH			ABROGATION BY C-MYC OF G1 PHASE ARREST INDUCED BY RB PROTEIN BUT NOT BY P53	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; BINDING; DIFFERENTIATION; MICROINJECTION; TRANSFORMATION; SUPPRESSION; ONCOGENE; DOMAINS; GROWTH	INACTIVATING mutations of the retinoblastoma gene (RB) are found in a wide variety of tumour cells1. Replacement of wild-type RB can suppress the tumorigenicity of some of these cells, suggesting that the RB protein (Rb) may negatively regulate cell growth2-4. As activation of c-myc expression promotes cell proliferation and blocks differentiation, it may positively regulate cell growth5-9. The c-myc protein is localized in the nucleus and can physically associate with RB protein in vitro10, hence c-myc may functionally antagonize RB function. Microinjection of Rb in G1 phase reversibly arrests cell-cycle progression11. Here we co-inject RB protein with c-myc, EJ-ras, c-fos or c-jun protein. Co-injection of c-myc, but not EJ-ras, c-fos or c-jun, inhibits the ability of Rb to arrest the cell cycle. The c-myc does not inhibit the activity of another tumour supressor, p53 (ref. 12). Thus, c-myc and RB specifically antagonize one another in the cell.			GOODRICH, DW (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.							BARNER M, 1992, CELL GROWTH DIFFER, V3, P183; Bishop JM, 1982, RNA TUMOR VIRUSES, P999; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPOLLA JS, 1986, NATURE, V320, P760; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOIODRICH DW, 1992, CAN RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAMATA T, 1990, MOL CELL BIOL, V10, P880, DOI 10.1128/MCB.10.3.880; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1991, COLD SPRING HARB SYM, V56, P211; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MILLER CW, 1990, CANCER RES, V50, P7950; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PREDERGAST GC, 1992, TRENDS GENET, V8, P91; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	33	107	110	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					177	179		10.1038/360177a0	http://dx.doi.org/10.1038/360177a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436095				2022-12-01	WOS:A1992JX75200066
J	HERRERO, I; MIRASPORTUGAL, MT; SANCHEZPRIETO, J				HERRERO, I; MIRASPORTUGAL, MT; SANCHEZPRIETO, J			POSITIVE FEEDBACK OF GLUTAMATE EXOCYTOSIS BY METABOTROPIC PRESYNAPTIC RECEPTOR STIMULATION	NATURE			English	Article							PROTEIN-KINASE-C; ISOLATED NERVE-TERMINALS; LONG-TERM POTENTIATION; RAT CEREBROCORTICAL SYNAPTOSOMES; AMINO-ACID RECEPTORS; DIRECT ACTIVATION; DENTATE GYRUS; RELEASE; CA-2+; 4-AMINOPYRIDINE	GLUTAMATE is important in several forms of synaptic plasticity such as long-term potentiation, and in neuronal cell degeneration1,2. Glutamate activates several types of receptors, including a metabotropic receptor that is sensitive to trans-1-amino-cyclo-penthyl-1,3-dicarboxylate, coupled to G protein(s) and linked to inositol phospholipid metabolism3-6. The activation of the metabotropic receptor in neurons generates inositol 1,4,5-trisphosphate, which causes the release of Ca2+ from intracellular stores and diacylglycerol, which activates protein kinase C7-9. In nerve terminals, the activation of presynaptic protein kinase C with phorbol esters enhances glutamate release10. But the presynaptic receptor involved in this protein kinase C-mediated increase in the release of glutamate has not yet been identified. Here we demonstrate the presence of a presynaptic glutamate receptor of the metabotropic type that mediates an enhancement of glutamate exocytosis in cerebrocortical nerve terminals. Interestingly, this potentiation of glutamate release is observed only in the presence of arachidonic acid, which may reflect that this positive feedback control of glutamate exocytosis operates in concert with other pre- or postsynaptic events of the glutamatergic neurotransmission that generate arachidonic acid. This presynaptic glutamate receptor may have a physiological role in the maintenance of long-term potentiation where there is an increase in glutamate release mediated by postsynaptically generated arachidonic acid11.	UNIV COMPLUTENSE MADRID, FAC VET, DEPT BIOQUIM, E-28040 MADRID, SPAIN	Complutense University of Madrid			Miras-Portugal, Maria Teresa/L-7137-2014	Sanchez-Prieto, Jose/0000-0002-8513-3501				BARRIE AP, 1991, J NEUROCHEM, V57, P1398, DOI 10.1111/j.1471-4159.1991.tb08306.x; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1988, NEUROLOGY NEUROBIOLO, V35, P3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERRERO I, 1991, J NEUROCHEM, V57, P718, DOI 10.1111/j.1471-4159.1991.tb03805.x; HERRERO I, 1991, NEUROSCI LETT, V126, P41, DOI 10.1016/0304-3940(91)90366-2; HERRERO I, 1992, FEBS LETT, V296, P317, DOI 10.1016/0014-5793(92)80312-5; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; LYNCH MA, 1989, NEUROSCIENCE, V30, P693, DOI 10.1016/0306-4522(89)90162-0; MANZONI OJJ, 1990, NEUROSCI LETT, V109, P146, DOI 10.1016/0304-3940(90)90553-L; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCMAHON HT, 1991, J NEUROCHEM, V56, P86, DOI 10.1111/j.1471-4159.1991.tb02566.x; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; MURPHY SN, 1988, P NATL ACAD SCI USA, V85, P8737, DOI 10.1073/pnas.85.22.8737; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; NICHOLLS DG, 1978, BIOCHEM J, V170, P511, DOI 10.1042/bj1700511; NICOLETTI F, 1988, NEUROPHARMACOLOGY, V27, P551, DOI 10.1016/0028-3908(88)90174-8; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; RUBIO I, 1991, J NEUROCHEM, V57, P1159, DOI 10.1111/j.1471-4159.1991.tb08274.x; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; SCHOEPP D D, 1990, Society for Neuroscience Abstracts, V16, P618; SCHOEPP DD, 1989, J NEUROCHEM, V53, P273, DOI 10.1111/j.1471-4159.1989.tb07324.x; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; VERHAGE M, 1989, J NEUROCHEM, V53, P1188, DOI 10.1111/j.1471-4159.1989.tb07413.x	34	355	374	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					163	166		10.1038/360163a0	http://dx.doi.org/10.1038/360163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1359425				2022-12-01	WOS:A1992JX75200061
J	KADLUBAR, FF				KADLUBAR, FF			DETECTION OF HUMAN DNA CARCINOGEN ADDUCTS	NATURE			English	Article							SENSITIVITY				KADLUBAR, FF (corresponding author), US FDA,NATL CTR TOXICOL RES,JEFFERSON,AR 72079, USA.							Carson R., 1962, SILENT SPRING; GAYLOR DW, IN PRESS ENV HLTH PE; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; GUPTA RC, 1985, CANCER RES, V45, P5656; MILLER JA, 1983, ENVIRON HEALTH PERSP, V49, P3, DOI 10.2307/3429574; RANDERATH K, 1981, P NATL ACAD SCI-BIOL, V78, P6126, DOI 10.1073/pnas.78.10.6126; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	8	6	6	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					189	189		10.1038/360189a0	http://dx.doi.org/10.1038/360189a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436097				2022-12-01	WOS:A1992JX75200070
J	LISBERGER, SG; SEJNOWSKI, TJ				LISBERGER, SG; SEJNOWSKI, TJ			MOTOR LEARNING IN A RECURRENT NETWORK MODEL BASED ON THE VESTIBULOOCULAR REFLEX	NATURE			English	Article							ELECTRO-PHYSIOLOGICAL OBSERVATIONS; TERM ADAPTIVE-CHANGES; FLOCCULUS; MONKEYS; INTEGRATION; ADAPTATION; PLASTICITY; PATHWAYS; NEURONS	MOST models of neural networks have assumed that neurons process information on a timescale of milliseconds and that the long-term modification of synaptic strengths underlies learning and memory1. But neurons also have cellular mechanisms that operate on a timescale of tens or hundreds of milliseconds, such as a gradual rise in firing rate in response to injection of constant current2 or a rapid rise followed by a slower adaptation3. These dynamic properties of neuronal responses are mediated by ion channels that are subject to modulation4. We demonstrate here how a neural network with recurrent feedback connections can convert long-term modulation of neural responses that occur over these intermediate timescales into changes in the amplitude of the steady output from the system. This general principle may be relevant to many feedback systems in the brain. Here it is applied to the vestibulo-ocular reflex, whose amplitude is subject to long-term adaptive modification by visual inputs5. The model reconciles apparently contradictory data on the neural locus of the cellular mechanisms that mediate this simple form of learning and memory.	UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143; HOWARD HUGHES MED INST,SALK INST BIOL SCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Francisco; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	LISBERGER, SG (corresponding author), UNIV CALIF SAN FRANCISCO,WM KECK FDN,CTR INTEGRAT NEUROSCI,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.		Sejnowski, Terrence/AAV-5558-2021					BRADLEY K, 1961, J PHYSIOL-LONDON, V156, P75, DOI 10.1113/jphysiol.1961.sp006659; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; FUCHS AF, 1975, J NEUROPHYSIOL, V38, P1140, DOI 10.1152/jn.1975.38.5.1140; GONSHOR A, 1976, J PHYSIOL-LONDON, V256, P381, DOI 10.1113/jphysiol.1976.sp011330; ITO M, 1972, BRAIN RES, V40, P81, DOI 10.1016/0006-8993(72)90110-2; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; LISBERGER SG, 1986, J NEUROSCI, V6, P346; LISBERGER SG, 1988, SCIENCE, V242, P771, DOI 10.1126/science.3142040; LISBERGER SG, 1988, SCIENCE, V242, P728, DOI 10.1126/science.3055293; LISBERGER SG, 1992, 9201 U CAL I NEUR CO; MILES FA, 1980, J NEUROPHYSIOL, V43, P1477, DOI 10.1152/jn.1980.43.5.1477; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; STORM JF, 1988, NATURE, V336, P379, DOI 10.1038/336379a0; STRONG JA, 1987, NEUROMODULATION BIOC; WATANABE E, 1984, BRAIN RES, V297, P169, DOI 10.1016/0006-8993(84)90555-9	16	101	101	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					159	161		10.1038/360159a0	http://dx.doi.org/10.1038/360159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436091				2022-12-01	WOS:A1992JX75200059
J	MARTIN, P; LEWIS, J				MARTIN, P; LEWIS, J			ACTIN CABLES AND EPIDERMAL MOVEMENT IN EMBRYONIC WOUND-HEALING	NATURE			English	Article							SCANNING ELECTRON-MICROSCOPY; EPITHELIAL-CELLS; GENE-EXPRESSION; MIGRATION; XENOPUS; VISUALIZATION; MICROFILAMENT; MORPHOGENESIS; CULTURE	SKIN wounds in embryos heal rapidly and perfectly. Even though the epidermis appears to be stretched taut over the surface of a structure such as a growing limb bud, its response to wounding is to close over the lesion, rather than to gape more widely. In adult wounds, the epidermis seems to migrate by means of lamellipodia, crawling over the exposed connective tissue1-5. But in embryonic wounds we do not see lamellipodia. The epidermis at the edge of the wound looks smooth, as though under a circumferential tension. Here we show that a cable of filamentous actin appears to run continuously around most of the wound margin. It is confined to the single row of basal cells at the free edge of the epidermis. We suggest that the actin cable acts as a contractile 'purse string' to close up the embryonic wound.	UNIV OXFORD,DEPT ZOOL,IMPERIAL CANC RES FUND,DEV BIOL UNIT,OXFORD OX1 3PS,ENGLAND	University of Oxford	MARTIN, P (corresponding author), UNIV OXFORD,DEPT HUMAN ANAT,OXFORD OX1 3QX,ENGLAND.		Lewis, Julian H/E-8733-2010	Martin, Paul/0000-0002-2665-5086				Bard J. B. L., 1990, MORPHOGENESIS CELLUL; BELOUSSOV LV, 1975, J EMBRYOL EXP MORPH, V34, P559; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; Bereiter-Hahn J., 1986, P443; BUCK RC, 1979, INVEST OPHTH VIS SCI, V18, P767; DIPASQUALE A, 1975, EXP CELL RES, V94, P191, DOI 10.1016/0014-4827(75)90545-5; FRISTROM D, 1988, TISSUE CELL, V20, P645, DOI 10.1016/0040-8166(88)90015-8; Gabbiani G, 1977, Int Rev Cytol, V48, P187, DOI 10.1016/S0074-7696(08)61745-3; GEIGER B, 1987, J CELL SCI S, V8, P251; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; MARTIN P, 1992, MECH DEVELOP, V38, P209, DOI 10.1016/0925-4773(92)90054-N; MAUPINSZAMIER P, 1978, J CELL BIOL, V77, P738; MCDONALD K, 1984, J ULTRA MOL STRUCT R, V86, P107, DOI 10.1016/S0022-5320(84)80051-9; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; ODLAND G, 1968, J CELL BIOL, V39, P135, DOI 10.1083/jcb.39.1.135; PANG SC, 1978, AM J ANAT, V153, P177, DOI 10.1002/aja.1001530202; RADICE GP, 1980, DEV BIOL, V76, P26, DOI 10.1016/0012-1606(80)90360-7; SHERRATT JA, IN PRESS B MATH BIOL; SMEDLEY MJ, 1984, J EMBRYOL EXP MORPH, V83, P109; STANISSTREET M, 1982, J EMBRYOL EXP MORPH, V67, P195; STANISSTREET M, 1980, J EMBRYOL EXP MORPH, V59, P341; THEVENET A, 1981, ARCH ANAT MICROSC MO, V70, P227; Trinkaus J.P., 1984, CELLS ORGANS; VAUGHAN RB, 1966, J CELL SCI, V1, P407; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	28	349	354	6	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					179	183		10.1038/360179a0	http://dx.doi.org/10.1038/360179a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436096				2022-12-01	WOS:A1992JX75200067
J	MOMBURG, F; ORTIZNAVARRETE, V; NEEFJES, J; GOULMY, E; VANDEWAL, Y; SPITS, H; POWIS, SJ; BUTCHER, GW; HOWARD, JC; WALDEN, P; HAMMERLING, GJ				MOMBURG, F; ORTIZNAVARRETE, V; NEEFJES, J; GOULMY, E; VANDEWAL, Y; SPITS, H; POWIS, SJ; BUTCHER, GW; HOWARD, JC; WALDEN, P; HAMMERLING, GJ			PROTEASOME SUBUNITS ENCODED BY THE MAJOR HISTOCOMPATIBILITY COMPLEX ARE NOT ESSENTIAL FOR ANTIGEN PRESENTATION	NATURE			English	Article							CLASS-II REGION; MULTICATALYTIC PROTEINASE; LINKED LMP; HUMAN MHC; GENE; MOLECULES; ANTIBODY; TRANSPORTERS; INVITRO	MAJOR histocompatibility complex (MHC) class I molecules bind and deliver peptides derived from endogenously synthesized proteins to the cell surface for survey by cytotoxic T lymphocytes. It is believed that endogenous antigens are generally degraded in the cytosol, the resulting peptides being translocated into the endoplasmic reticulum where they bind to MHC class I molecules. Transporters containing an ATP-binding cassette encoded by the MHC class II region seem to be responsible for this transport1-8. Genes coding for two subunits of the '20S' proteasome (a multicatalytic proteinase) have been found in the vicinity of the two transporter genes in the MHC class II region, indicating that the proteasome could be the unknown proteolytic entity in the cytosol involved in the generation of MHC class I-binding peptides9-13. By introducing rat genes encoding the MHC-linked transporters into a human cell line lacking both transporter and proteasome subunit genes, we show here that the MHC-encoded proteasome subunits are not essential for stable MHC class I surface expression, or for processing and presentation of antigenic peptides from influenza virus and an intracellular protein.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; AFRC,INST ANIM PHYSIOL & GENET RES,DEPT IMMUNOL,CAMBRIDGE CB2 4AT,ENGLAND; MAX PLANCK INST BIOL,W-7400 TUBINGEN,GERMANY	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Max Planck Society	MOMBURG, F (corresponding author), GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.		Neefjes, Jacques J.C./H-8780-2017; Ortiz-Navarrete, Vianney/H-1932-2016	Neefjes, Jacques J.C./0000-0001-6763-2211; Howard, Jonathan/0000-0003-2756-5143; Powis, Simon/0000-0003-4218-2984; Ortiz-Navarrete, Vianney/0000-0001-6546-9713				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; GOULMY E, 1988, TRANSPLANT REV, V2, P29, DOI DOI 10.1016/S0955-470X(88)80005-3; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HORAI S, 1992, IMMUNOGENETICS, V16, P135; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MULLER C, 1983, HUM IMMUNOL, V6, P189, DOI 10.1016/0198-8859(83)90092-7; MULLER C, 1985, HUM IMMUNOL, V14, P333, DOI 10.1016/0198-8859(85)90241-1; MULLER C, 1981, HUM IMMUNOL, V5, P269; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0	32	267	274	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 12	1992	360	6400					174	177		10.1038/360174a0	http://dx.doi.org/10.1038/360174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1299222	Green Submitted			2022-12-01	WOS:A1992JX75200065
J	ROSENBERG, RL; EAST, JE				ROSENBERG, RL; EAST, JE			CELL-FREE EXPRESSION OF FUNCTIONAL SHAKER POTASSIUM CHANNELS	NATURE			English	Article							PROTEIN TRANSLOCATION; XENOPUS OOCYTES; K+ CHANNELS; RECEPTORS; GLYCOSYLATION; INACTIVATION; DROSOPHILA; REGION; LOCUS; GENE	THE functional activity of ion channels and other membrane proteins requires that the proteins be correctly assembled in a transmembrane configuration. Thus, the functional expression of ion channels, neurotransmitter receptors and complex membrane-limited signalling mechanisms from complementary DNA has required the injection of messenger RNA or transfection of DNA into Xenopus oocytes or other target cells that are capable of processing newly translated protein into the surface membrane1-4. These approaches, combined with voltage-clamp analysis of ion channel currents, have been especially powerful in the identification of structure-function relationships in ion channels5-7. But oocytes express endogenous ion channels8,9, neurotransmitter receptors10 and receptor-channel subunits11, complicating the interpretation of results in mRNA-injected eggs. Furthermore, it is difficult to control experimentally the membrane lipids and post-translational modifications that underlie the regulation and modulation of ion channels in intact cells. A cell-free system for ion channel expression is ideal for good experimental control of protein expression and modulatory processes. Here we combine cell-free protein translation, microsomal membrane processing12-14 of nascent channel proteins, and reconstitution of newly synthesized ion channels into planar lipid bilayers15 to synthesize, glycosylate, process into membranes, and record in vitro the activity of functional Shaker potassium channels.	UNIV N CAROLINA, DEPT PHYSIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	ROSENBERG, RL (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, CHAPEL HILL, NC 27599 USA.							ALBERTS B, 1991, MOL BIOL CELL; BOURINET E, 1992, FEBS LETT, V299, P5, DOI 10.1016/0014-5793(92)80087-W; BULLER AL, 1990, MOL PHARMACOL, V37, P423; DAS RC, 1980, J BIOL CHEM, V255, P7933; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FLUHARTY SJ, 1991, J NEUROCHEM, V56, P1307, DOI 10.1111/j.1471-4159.1991.tb11426.x; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; Hille B., 1992, IONIC CHANNELS EXCIT; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; IVERSON LE, 1988, P NATL ACAD SCI USA, V85, P5723, DOI 10.1073/pnas.85.15.5723; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; KOBILKA BK, 1990, J BIOL CHEM, V265, P7610; LESTER HA, 1988, SCIENCE, V241, P1057, DOI 10.1126/science.2457947; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; Miller C., 1986, ION CHANNEL RECONSTI; NUMA S, 1989, HARVEY LECT, V83, P121; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; ROSENBERG RL, 1991, J GEN PHYSIOL, V97, P1207, DOI 10.1085/jgp.97.6.1207; SCHWARZ TL, 1988, NATURE, V331, P137, DOI 10.1038/331137a0; SCHWARZ TL, 1990, NEURON, V4, P119, DOI 10.1016/0896-6273(90)90448-O; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; YANG XC, 1992, J NEUROSCI, V12, P268; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZONA C, 1990, PROC R SOC SER B-BIO, V239, P119, DOI 10.1098/rspb.1990.0011	30	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					166	169		10.1038/360166a0	http://dx.doi.org/10.1038/360166a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436093				2022-12-01	WOS:A1992JX75200062
J	WEIS, WI; DRICKAMER, K; HENDRICKSON, WA				WEIS, WI; DRICKAMER, K; HENDRICKSON, WA			STRUCTURE OF A C-TYPE MANNOSE-BINDING PROTEIN COMPLEXED WITH AN OLIGOSACCHARIDE	NATURE			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; ASPARAGINE-LINKED OLIGOSACCHARIDES; PULMONARY SURFACTANT APOPROTEIN; SOLUTION CONFORMATION; 3-DIMENSIONAL STRUCTURES; CELL-ADHESION; LECTIN DOMAIN; RECEPTOR; RAT; REFINEMENT	C-type (Ca2+-dependent) animal lectins such as mannose-binding proteins mediate many cell-surface carbohydrate-recognition events. The crystal structure at 1.7 angstrom resolution of the carbohydrate-recognition domain of rat mannose-binding protein complexed with an oligomannose asparaginyl-oligosaccharide reveals that Ca2+ forms coordination bonds with the carbohydrate ligand. Carbohydrate specificity is determined by a network of coordination and hydrogen bonds that stabilizes the ternary complex of protein, Ca2+ and sugar. Two branches of the oligosaccharide crosslink neighbouring carbohydrate-recognition domains in the crystal, enabling multivalent binding to a single oligosaccharide chain to be visualized directly.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150				ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BILDERBACK D, 1988, NUCL INSTRUM METH A, V266, P636, DOI 10.1016/0168-9002(88)90457-3; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3671, DOI 10.1021/bi00284a021; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P1362, DOI 10.1021/bi00275a007; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR MANUAL; BRUNGER AT, 1992, ANTURE, V355, P472; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HOMANS SW, 1986, BIOCHEMISTRY-US, V25, P6342, DOI 10.1021/bi00368a076; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6649, DOI 10.1021/bi00395a014; IKEDA K, 1987, J BIOL CHEM, V262, P7451; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE YC, 1982, GLYCOCONJUGATES, V4, P57; PETERS D, 1981, J MOL STRUCT, V85, P107; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; SIEGELMAN M, 1991, Current Biology, V1, P125, DOI 10.1016/0960-9822(91)90299-C; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPRINGER TA, 1991, ANTURE, V349, P196; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WRIGHT CS, 1992, J BIOL CHEM, V267, P14345; 1979, SUITE PROGRAMS PROTE	49	853	891	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 12	1992	360	6400					127	134		10.1038/360127a0	http://dx.doi.org/10.1038/360127a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JX752	1436090				2022-12-01	WOS:A1992JX75200049
J	WIGGINS, S; WHYTE, P; HUGGINS, M; ADAM, S; THEILMANN, J; BLOCH, M; SHEPS, SB; SCHECHTER, MT; HAYDEN, MR				WIGGINS, S; WHYTE, P; HUGGINS, M; ADAM, S; THEILMANN, J; BLOCH, M; SHEPS, SB; SCHECHTER, MT; HAYDEN, MR			THE PSYCHOLOGICAL CONSEQUENCES OF PREDICTIVE TESTING FOR HUNTINGTONS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DNA MARKERS; GENE	Background. Advances in molecular genetics have led to the development of tests that can predict the risk of inheriting the genes for several adult-onset diseases. However, the psychological consequences of such testing are not well understood. Methods. The 135 participants in the Canadian program of genetic testing to predict the risk of Huntington's disease were followed prospectively in three groups according to their test results: the increased-risk group (37 participants), the decreased-risk group (58 participants), and the group with no change in risk (the no-change group) (40 participants). All the participants received counseling before and after testing. Standard measures of psychological distress (the General Severity Index of the Symptom Check List 90-R), depression (the Beck Depression Inventory), and well-being (the General Well-Being Scale) were administered before genetic testing and again at intervals of 7 to 10 days, 6 months, and 12 months after the participants received their test results. Results. At each follow-up assessment, the decreased-risk group had lower scores for distress than before testing (P<0.001). The increased-risk group showed no significant change from base line on any follow-up measure, but over the year of study there were small linear declines (P<0.023) for distress and depression. The no-change group had scores lower than at base line on the index of general well-being at each follow-up (P less-than-or-equal-to 0.045). At the 12-month follow-up, both the increased-risk group and the decreased-risk group had lower scores for depression and higher scores for well-being than the no-change group (P less-than-or-equal-to 0.049). Conclusions. Predictive testing for Huntington's disease has potential benefits for the psychological health of persons who receive results that indicate either an increase or a decrease in the risk of inheriting the gene for the disease.	UNIV BRITISH COLUMBIA,DEPT MED GENET,RM 416,2125 E MALL,VANCOUVER V6T 1Z4,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia; University of British Columbia			Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Schechter, Martin/0000-0001-6063-2155; Adam, Shelin/0000-0002-4401-6157				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLOCH M, 1992, AM J MED GENET, V42, P499, DOI 10.1002/ajmg.1320420416; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; CRAUFURD D, 1989, LANCET, V2, P603; DEROGATIS LR, 1983, SCL90R ADM SCORING P; DUPUY H, 1969, PSYCHOL EXAMINATION; FOLSTEIN SE, 1983, NEUROBEH TOXICOL TER, V5, P605; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; HUGGINS M, 1992, AM J MED GENET, V42, P508, DOI 10.1002/ajmg.1320420417; KESSLER S, 1987, AM J MED GENET, V26, P259, DOI 10.1002/ajmg.1320260204; KESSLER S, 1987, AM J ORTHOPSYCHIAT, V57, P212, DOI 10.1111/j.1939-0025.1987.tb03531.x; SKRAASTAD MI, 1991, AM J MED GENET, V38, P217; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; WARE JE, 1979, R19873HEW RAND REP; WINER BJ, 1971, STATISTICAL PRINCIPL, P177	18	338	338	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 12	1992	327	20					1401	1405		10.1056/NEJM199211123272001	http://dx.doi.org/10.1056/NEJM199211123272001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JX479	1406858				2022-12-01	WOS:A1992JX47900001
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ALERT ON CHANGES IN STANDARDIZED CAT ALLERGEN EXTRACT PRODUCTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-01	WOS:A1992JW61600006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL TO PROVIDE MORE PEDIATRIC USE INFORMATION IN DRUG LABELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1902, FED REG         1016, V57, P47427	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-01	WOS:A1992JW61600004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			1ST DRUG AVAILABLE UNDER PARALLEL TRACK POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2491	2491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1328699				2022-12-01	WOS:A1992JW61600005
J	SPERA, RV; FARBER, BF				SPERA, RV; FARBER, BF			MULTIPLY-RESISTANT ENTEROCOCCUS-FAECIUM - THE NOSOCOMIAL PATHOGEN OF THE 1990S	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VANCOMYCIN		N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV INFECT DIS & IMMUNOL,MANHASSET,NY 11030	Cornell University; Northwell Health; North Shore University Hospital								HANDWERGER S, 1992, CLIN INFECT DIS, V14, P655, DOI 10.1093/clinids/14.3.655; JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; MURRAY BE, 1991, J INFECT DIS, V163, P1185, DOI 10.1093/infdis/163.6.1185; RAMPHAL R, 1992, ANTIMICROB AGENTS CH, V36, P1062, DOI 10.1128/AAC.36.5.1062; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; UTTLEY AHC, 1989, EPIDEMIOL INFECT, V103, P173, DOI 10.1017/S0950268800030478; VANDERAUWERA P, 1990, 30TH INT C ANT AG CH; WADE J, 1991, LANCET, V337, P1616, DOI 10.1016/0140-6736(91)93320-9	12	75	78	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2563	2564		10.1001/jama.268.18.2563	http://dx.doi.org/10.1001/jama.268.18.2563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1308665				2022-12-01	WOS:A1992JW61600030
J	UDVARHELYI, IS; GATSONIS, C; EPSTEIN, AM; PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ				UDVARHELYI, IS; GATSONIS, C; EPSTEIN, AM; PASHOS, CL; NEWHOUSE, JP; MCNEIL, BJ			ACUTE MYOCARDIAL-INFARCTION IN THE MEDICARE POPULATION - PROCESS OF CARE AND CLINICAL OUTCOMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; PROGNOSIS; WOMEN; MEN; MANAGEMENT; MORTALITY; MORBIDITY; SURVIVAL; TRIALS	Objective.-To describe the process of care and clinical outcomes associated with acute myocardial infarction (AMI) in the Medicare population, and to examine differences in process of care and outcome of care as a function of patient age, gender, and race. Design.-Retrospective cohort study using a longitudinal database created from Medicare utilization and administrative files. Patient Populations.-A cohort of AMI patients covered by Medicare in 1987 and a random sample of Medicare patients without AMI. Main Process and Outcome Measurements.-(1) The use of coronary angiography, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty during the first 90 days after a new AMI; (2) mortality at 30 days, 1 year, and 2 years; (3) reinfarction rates; and (4) reoperation rates for coronary artery bypass graft surgery and percutaneous transluminal coronary angioplasty. Main Results.-Mortality rates were high: 26% at 30 days, 40% at 1 year, and 47% at 2 years. They varied greatly by age, less so by gender and race, and were high even among patients who survived the first 30 days. Compared with mortality, reinfarction was uncommon, occurring in 7.3% of patients. During the first 90 days, 23% of all patients underwent angiography and 13% underwent coronary revascularization (coronary artery bypass graft surgery, 8%; percutaneous transluminal coronary angioplasty, 5%). The use of all three procedures decreased with age and was less common among women and blacks than among men and whites. Differential use by age and race was greater for angiography than for revascularization procedures. Conclusions.-The prognosis following AMI in patients aged 65 years and above is much worse than is commonly realized. Procedure use in these patients varies as a function of gender and race, even though mortality does not. Further research is needed to reduce the mortality of elderly patients with AMI and to understand the significance of differences in procedure use on the basis of sociodemographic characteristics.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University			Newhouse, Joseph/AGJ-5632-2022		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON GM, 1989, NEW ENGL J MED, V321, P1443, DOI 10.1056/NEJM198911233212105; [Anonymous], 1982, EPIDEMIOLOGIC RES; ANTMANEM, 1992, JAMA-J AM MED ASSOC, V268, P240; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BRAUNWALD E, 1988, HEART DISEASE TXB CA; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER LD, 1985, CIRCULATION, V72, P110; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GRAVES EJ, 1990, PUBLICATION NATIONAL, V185; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HURST JW, 1989, HEART ARTERIES VEINS; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEW EA, 1990, MED RISKS TRENDS MOR, pCH5; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; PELL S, 1985, NEW ENGL J MED, V312, P1005, DOI 10.1056/NEJM198504183121601; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YUSUF S, 1990, CIRCULATION, V82, P117; 1989, INT CLASSIFICATION D	26	210	213	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	1992	268	18					2530	2536		10.1001/jama.268.18.2530	http://dx.doi.org/10.1001/jama.268.18.2530			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW616	1404820				2022-12-01	WOS:A1992JW61600024
J	CELERMAJER, DS; SORENSEN, KE; GOOCH, VM; SPIEGELHALTER, DJ; MILLER, OI; SULLIVAN, ID; LLOYD, JK; DEANFIELD, JE				CELERMAJER, DS; SORENSEN, KE; GOOCH, VM; SPIEGELHALTER, DJ; MILLER, OI; SULLIVAN, ID; LLOYD, JK; DEANFIELD, JE			NONINVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADULTS AT RISK OF ATHEROSCLEROSIS	LANCET			English	Article							CORONARY-ARTERY DISEASE; CAROTID-ARTERY; MEN; ACETYLCHOLINE; FLOW; RELAXATION; SMOKING; CHOLESTEROL; REGRESSION; THICKNESS	Endothelial dysfunction is an early event in experimental studies of atherogenesis, preceding formation of plaques. We have devised a non-invasive method for testing endothelial function, to find out whether abnormalities are present in symptom-free children and young adults at high risk of atherosclerosis. With high-resolution ultrasound, we measured the diameter of the superficial femoral and brachial arteries at rest, during reactive hyperaemia (with increased flow causing endothelium-dependent dilatation), and after sublingual glyceryl trinitrate (GTN; causing endothelium-independent dilatation) in 100 subjects-50 controls without vascular risk factors (aged 8-57 years), 20 cigarette smokers (aged 17-62 years), 10 children with familial hypercholesterolaemia (FH; aged 8-16 years), and 20 patients with established coronary artery disease (CAD). Adequate scans were obtained in all but 6 cases. Flow-mediated dilatation was observed in arteries from all control subjects. Dilatation was inversely related to baseline vessel diameter (r=-0.81, p<0.0001); in arteries of 6.0 mm or less, mean dilatation was 10 (SE 2)%. In smokers, FH children, and adults with CAD, flow-mediated dilatation was much reduced or absent (p<0.001 for comparison with each relevant control group). Dilatation in response to GTN was present in all groups. Endothelial dysfunction is present in children and adults with risk factors for atherosclerosis, such as smoking and hypercholesterolaemia, before anatomical evidence of plaque formation in the arteries studied. This may be an important early event in atherogenesis.	HOSP SICK CHILDREN,MED UNIT,LONDON WC1N 3JH,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; MRC Biostatistics Unit	CELERMAJER, DS (corresponding author), HOSP SICK CHILDREN,CARDIOTHORAC UNIT,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.		Tanaka, Gohichi/A-1684-2010; Deanfield, John E/C-5178-2008	Deanfield, John/0000-0001-8806-6052				ANDERSON EA, 1989, CIRCULATION, V79, P93, DOI 10.1161/01.CIR.79.1.93; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARNTZENIUS AC, 1985, NEW ENGL J MED, V312, P805, DOI 10.1056/NEJM198503283121301; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CHAVEAU M, 1985, CARDIOVASC RES, V19, P700; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; COOKE JP, 1991, CIRCULATION, V83, P1057, DOI 10.1161/01.CIR.83.3.1057; ENOS WF, 1953, JAMA-J AM MED ASSOC, V152, P1090, DOI 10.1001/jama.1953.03690120006002; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; KWITEROVICH PO, 1990, PEDIATR CLIN N AM, V37, P1489; LAURENT S, 1990, AM J PHYSIOL, V258, pH1004, DOI 10.1152/ajpheart.1990.258.4.H1004; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MCGILL HC, 1988, AM HEART J, V115, P250, DOI 10.1016/0002-8703(88)90645-X; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MCLENACHAN JM, 1990, CIRCULATION, V82, P1169, DOI 10.1161/01.CIR.82.4.1169; NABEL EG, 1990, J AM COLL CARDIOL, V16, P349, DOI 10.1016/0735-1097(90)90584-C; OLSSON AG, 1991, CIRCULATION, V83, P698, DOI 10.1161/01.CIR.83.2.698; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; RENEMAN RS, 1986, ULTRASOUND MED BIOL, V12, P465, DOI 10.1016/0301-5629(86)90218-8; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1115; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; STARY HC, 1989, ARTERIOSCLEROSIS, V99, pI19; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; WENDELHAG I, 1991, CLIN PHYSIOL, V11, P565, DOI 10.1111/j.1475-097X.1991.tb00676.x	29	3820	4389	3	170	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1111	1115		10.1016/0140-6736(92)93147-F	http://dx.doi.org/10.1016/0140-6736(92)93147-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359209	Bronze			2022-12-01	WOS:A1992JX13400001
J	FUGHBERMAN, A; EPSTEIN, S				FUGHBERMAN, A; EPSTEIN, S			TAMOXIFEN - DISEASE PREVENTION OR DISEASE SUBSTITUTION	LANCET			English	Editorial Material							BONE-MINERAL CONTENT; BREAST-CANCER; ADJUVANT TAMOXIFEN; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR RISK; SERUM-LIPOPROTEINS; TRIAL; DENSITY; TUMORS		UNIV ILLINOIS,SCH PUBL HLTH,BOX 6998,CHICAGO,IL 60680; NATL WOMENS HLTH NETWORK,WASHINGTON,DC	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Fugh-Berman, Adriane/0000-0002-1717-7617				BRUNING PF, 1988, BRIT J CANCER, V58, P497, DOI 10.1038/bjc.1988.248; BUSH TL, 1988, CLIN CHEM, V34, pB60; CHING CK, 1992, LANCET, V339, P940, DOI 10.1016/0140-6736(92)90991-B; FENDL KC, 1992, CANCER RES, V52, P235; FENTIMAN IS, 1989, BRIT J CANCER, V60, P262, DOI 10.1038/bjc.1989.266; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1990, J CLIN ONCOL, V8, P1019, DOI 10.1200/JCO.1990.8.6.1019; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GOTFREDSEN A, 1984, CANCER, V53, P853, DOI 10.1002/1097-0142(19840215)53:4<853::AID-CNCR2820530406>3.0.CO;2-M; JORDAN VC, 1992, J NATL CANCER I, V84, P231, DOI 10.1093/jnci/84.4.231; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; LOVE RR, 1988, BREAST CANCER RES TR, V12, P279; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOGUCHI M, 1987, BRIT J SURG, V74, P586, DOI 10.1002/bjs.1800740714; PAVLIDIS NA, 1992, CANCER, V69, P2961, DOI 10.1002/1097-0142(19920615)69:12&lt;2961::AID-CNCR2820691215&gt;3.0.CO;2-W; POWLES TJ, 1989, BRIT J CANCER, V60, P126, DOI 10.1038/bjc.1989.235; RALOFF J, 1992, SCI NEWS, V141, P266; ROSSNER S, 1984, ATHEROSCLEROSIS, V52, P339, DOI 10.1016/0021-9150(84)90064-9; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SHULTZ MM, 1985, YALE LAW J, V95, P219, DOI 10.2307/796352; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; WOLTER J, 1988, P AN M AM SOC CLIN, V7, P10; 1987, FDA ADVERSE REACTION	25	71	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1143	1145		10.1016/0140-6736(92)93161-F	http://dx.doi.org/10.1016/0140-6736(92)93161-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359220				2022-12-01	WOS:A1992JX13400013
J	HORAK, ER; LEEK, R; KLENK, N; LEJEUNE, S; SMITH, K; STUART, N; GREENALL, M; STEPNIEWSKA, K; HARRIS, AL				HORAK, ER; LEEK, R; KLENK, N; LEJEUNE, S; SMITH, K; STUART, N; GREENALL, M; STEPNIEWSKA, K; HARRIS, AL			ANGIOGENESIS, ASSESSED BY PLATELET ENDOTHELIAL-CELL ADHESION MOLECULE ANTIBODIES, AS INDICATOR OF NODE METASTASES AND SURVIVAL IN BREAST-CANCER	LANCET			English	Article							TUMOR ANGIOGENESIS; ANTIGEN	Animal models suggest a role for new vessel formation (angiogenesis) in tumours with metastatic potential, and there is some evidence that this is true for human tumours. What is needed is a sensitive and specific label for endothelial cells, and one candidate would be a monoclonal antibody to platelet/endothelial cell adhesion molecule (PECAM). We have counted microvessels in 103 primary breast cancers using the JC70 antibody to PECAM (or CD31). We compared our findings with various pathological indicators (lymph node status and tumour grade, size, and type and markers (oestrogen receptor, and c-erbB-2 expression and detection of mutant p53). Tumours showed significantly higher vascularisation than normal breast tissue and the number of blood vessels/mm2 was significantly associated with node metastasis. Only 2 out of 50 tumours with 99 vessel/mm2 or less were node positive whereas 31 out of 39 tumours with counts above 140/mm2 were positive (p<0.0001). Tumour size and grade also correlated with node metastasis and vascularisation also increased with the size of the primary and with poor differentiation. However, within each subgroup of size or differentiation tumours without node involvement had much lower vascular counts, and multivariate analysis showed that vascular count alone explains the association of size and grade with node metastasis. Other markers, conventional or novel, did not correlate with vascularisation. Even with the short follow-up in this series, vascular counts correlated with early death. These results suggest that angiogenesis is closely linked to metastasis, that it is acquired at a critical density of vessels, and that this process occurs as tumours enlarge or become more poorly differentiated. Counting of newly formed microvessels stained with endothelium-specific antibodies may prove to be a useful tool in the early detection of metastatic potential and in the selection of patients for whom anti-angiogenesis drugs might be beneficial.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND,MOLEC ONCOL LAB,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND; IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC1,ENGLAND	University of Oxford; University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Stepniewska, Kasia/0000-0002-1713-6209				ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GANNON JV, 1990, EMBO J, V9, P3927; Gatter KC, 1984, RECENT ADV HISTOPATH, P35; Goldmann E, 1907, LANCET, V2, P1236; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HORAK E, 1991, ONCOGENE, V6, P2277; JENSEN HM, 1982, SCIENCE, V218, P293, DOI 10.1126/science.6181563; KUZU I, 1992, J CLIN PATHOL, V45, P143, DOI 10.1136/jcp.45.2.143; LIOTTA LA, 1974, CANCER RES, V34, P997; MAHADEVAN V, 1990, ACTA ONCOL, V29, P97, DOI 10.3109/02841869009089997; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; NICHOLSON S, 1989, LANCET, V1, P182; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690; SCHMIDT JG, 1992, LANCET, V339, P810, DOI 10.1016/0140-6736(92)91937-4; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; STARKEY JR, 1988, INT J CANCER, V42, P48, DOI 10.1002/ijc.2910420110; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	21	810	868	0	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1120	1124		10.1016/0140-6736(92)93150-L	http://dx.doi.org/10.1016/0140-6736(92)93150-L			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1279332				2022-12-01	WOS:A1992JX13400003
J	KANIS, JA; JOHNELL, O; GULLBERG, B; ALLANDER, E; DILSEN, G; GENNARI, C; VAZ, AAL; LYRITIS, GP; MAZZUOLI, G; MIRAVET, L; PASSERI, M; CANO, RP; RAPADO, A; RIBOT, C				KANIS, JA; JOHNELL, O; GULLBERG, B; ALLANDER, E; DILSEN, G; GENNARI, C; VAZ, AAL; LYRITIS, GP; MAZZUOLI, G; MIRAVET, L; PASSERI, M; CANO, RP; RAPADO, A; RIBOT, C			EVIDENCE FOR EFFICACY OF DRUGS AFFECTING BONE METABOLISM IN PREVENTING HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; WOMEN; RISK; ESTROGEN; DIET	Objective-To examine the effects of taking drugs affecting bone metabolism on the risk of hip fracture in women aged over 50 years. Design-Retrospective, population based, case-control study by questionnaire. Setting-14 centres in six countries in southern Europe. Subjects-2086 women with hip fracture and 3532 control women matched for age. Main outcome measures-Number of drugs affecting bone metabolism taken and length taken for. Results-Women taking drugs affecting bone metabolism had a significantly decreased risk of hip fracture. After adjustment for differences in other risk factors, the relative risk of hip fractures was 0.55 (95% confidence interval 0.31 to 0.85) in women taking oestrogens, 0.75 (0.60 to 0.94) in those taking calcium, and 0.69 (0.51 to 0.92) in those taking calcitonin. The fall in risk was not significant for anabolic steroids (0.6 (0.29 to 1.22)). Neither vitamin D nor fluorides were associated with a significant decrease in the risk of hip fracture. The effect on hip fracture risk increased significantly with increasing duration of exposure (risk ratio 0.8 (0.61 to 1.05) for less than median exposure v 0.66 (0.5 to 0.88) for greater than median exposure). Drugs were equally effective in older and younger women, with the exception of oestrogen. Conclusions-Oestrogen, calcium, and calcitonins significantly decrease the risk of hip fracture. Short term intervention late in the natural course of osteoporosis may have significant effects on the incidence of hip fracture.	MALMO GEN HOSP,ORTHOPAED,S-21401 MALMO,SWEDEN; MALMO GEN HOSP,MED STAT,S-21401 MALMO,SWEDEN; HUDDINGE UNIV HOSP,DEPT SOCIAL MED,S-14186 HUDDINGE,SWEDEN; ISTANBUL UNIV,FAK CAPA TIP,ISTANBUL,TURKEY; UNIV SIENA,I-53100 SIENA,ITALY; ACCIDENT HOSP,T GAROFALIDIS RES,GR-14561 KIFISIA,GREECE; POLICLIN UMBERTO 1,MED CLIN 2,I-00161 ROME,ITALY; CTR ANDRE LICHTWITZ,INSERM,U18,F-75010 PARIS,FRANCE; IST CLIN MED GEN TERAPIA MED,I-43100 PARMA,ITALY; FDN JIMENEZ DIAZ,DEPT INTERNAL MED,E-28040 MADRID,SPAIN; CHU TOULOUSE PURPAN,SERV ENDOCRINOL,F-31059 TOULOUSE,FRANCE	Karolinska Institutet; Istanbul University; University of Siena; Sapienza University Rome; University Hospital Sapienza Rome; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	KANIS, JA (corresponding author), UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,WHO,COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; CHESNUT CH, 1983, METABOLISM, V32, P571, DOI 10.1016/0026-0495(83)90027-6; COOPER C, 1988, BRIT MED J, V297, P1443, DOI 10.1136/bmj.297.6661.1443; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DEQUEKER J, 1991, CLIN RHEUMATOL, V10, P49, DOI 10.1007/BF02208033; DEQUEKER J, 1991, CLIN RHEUMATOL, P54; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; GEUSENS P, 1977, OSTEOPOROSIS, P966; Hosmer D, 2013, APPL LOGISTIC REGRES; HUTCHINSON TA, 1979, LANCET, V2, P705; Kanis J A, 1991, Osteoporos Int, V1, P182, DOI 10.1007/BF01625451; KANIS JA, 1991, CALCIFIED TISSUE INT, V49, pS33, DOI 10.1007/BF02555086; KANIS JA, 1989, BRIT MED J, V298, P137, DOI 10.1136/bmj.298.6667.137; KANIS JA, 1989, BRIT MED J, V298, P205, DOI 10.1136/bmj.298.6668.205; KANIS JA, 1984, LANCET, V1, P27; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MACINTYRE I, 1988, LANCET, V1, P900; NAESSEN T, 1990, ANN INTERN MED, V113, P95, DOI 10.7326/0003-4819-113-2-95; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; 1991, OSTEOPOROSIS INT, V1, P114	24	262	268	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1124	1128		10.1136/bmj.305.6862.1124	http://dx.doi.org/10.1136/bmj.305.6862.1124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463947	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JX84100021
J	KATO, H; INOUE, O; KAWASAKI, T; FUJIWARA, H; WATANABE, T; TOSHIMA, H				KATO, H; INOUE, O; KAWASAKI, T; FUJIWARA, H; WATANABE, T; TOSHIMA, H			ADULT CORONARY-ARTERY DISEASE PROBABLY DUE TO CHILDHOOD KAWASAKI-DISEASE	LANCET			English	Note							ANEURYSMS	We have surveyed adult survivors of childhood Kawasaki disease (KD) who had coronary artery disease that could be ascribed to KD. In response to questionnaires sent to cardiologists throughout Japan, 21 patients (1 7 men, 4 women, aged 20-63 years) with coronary lesions and a definite (2) or suspected (19) history of KD were reported. 5 patients had presented with acute myocardial infarction, 6 previous myocardial infarction, 9 angina pectoris, and 1 dilated cardiomyopathy. 16 patients had obstructions in two or more coronary arteries. 3 had died and 18 were alive with serious sequelae (mitral regurgitation, arrhythmias, congestive heart failure). Childhood KD should be included in the differential diagnosis of coronary artery disease in young adults.	KURUME UNIV,SCH MED,DEPT INTERNAL MED,KURUME,FUKUOKA 830,JAPAN; KAWASAKI DIS RES INFORMAT CTR,KAWASAKI,JAPAN; KYOTO UNIV,SCH MED,DEPT INTERNAL MED,KYOTO 606,JAPAN; AICHI MED SCH,DEPT INTERNAL MED,AICHI,JAPAN	Kurume University; Kyoto University; Aichi Medical University	KATO, H (corresponding author), KURUME UNIV,SCH MED,DEPT PEDIAT,67 ASAHI-MACHI,KURUME,FUKUOKA 830,JAPAN.							ISHIWATA S, 1992, AM J CARDIOL, V69, P692, DOI 10.1016/0002-9149(92)90168-X; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KATO H, 1986, J PEDIATR-US, V108, P923, DOI 10.1016/S0022-3476(86)80928-3; KATO H, 1975, J PEDIATR-US, V86, P892, DOI 10.1016/S0022-3476(75)80220-4; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; SAKAI Y, 1988, ANGIOLOGY, V39, P625, DOI 10.1177/000331978803900711	6	128	128	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1127	1129		10.1016/0140-6736(92)93152-D	http://dx.doi.org/10.1016/0140-6736(92)93152-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359212				2022-12-01	WOS:A1992JX13400005
J	LLOYD, BW; ALI, MH				LLOYD, BW; ALI, MH			HOW USEFUL DO PARENTS FIND HOME PEAK FLOW MONITORING FOR CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,COMMUNITY CHILD HLTH,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	LLOYD, BW (corresponding author), N MIDDLESEX HOSP,NATL HLTH SERV TRUST,LONDON N18 1QX,ENGLAND.							[Anonymous], 1990, BMJ, V301, P797; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; 1990, BRIT MED J, V301, P651	3	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1128	1129		10.1136/bmj.305.6862.1128	http://dx.doi.org/10.1136/bmj.305.6862.1128			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463948	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JX84100022
J	MACFARLANE, GJ; BOYLE, P; SCULLY, C				MACFARLANE, GJ; BOYLE, P; SCULLY, C			ORAL-CANCER IN SCOTLAND - CHANGING INCIDENCE AND MORTALITY	BRITISH MEDICAL JOURNAL			English	Article							TOBACCO; ALCOHOL; PHARYNX; TONGUE; CAVITY; DIET	Objectives-To determine the incidence of oral cancer in Scotland between 1960 and 1989 and oral cancer mortality from 1911 to 1989. Setting-Data were obtained on oral cancer incidence from the information and statistics division of the Common Services Agency of the Scottish Health Service and mortality data from the office of the registrar general for Scotland. Results-Mortality from intraoral cancers in Scotland substantially declined throughout this century until the mid-1970s. This trend, however, was then reversed, and fourfold increases in incidence were observed in younger age groups after 1960. Death rates in these younger age groups increased to levels previously recorded in the 1940s. These increases seemed to be cohort based and may therefore continue into the future. Conclusions-Reasons for increasing rates among younger age groups are speculative and rely on combining knowledge about risk factors and available ecological data. Though increases in incidence at younger ages do not result in a large change in the number of cases diagnosed, possible similar increases continuing into older ages, when oral cancer is more common, will correspond to a much larger increase in the actual number of cases. Given that such a large attributable risk is associated with tobacco and alcohol, however, these increases may be preventable.	BRISTOL DENT HOSP & SCH,DEPT ORAL MED SURG & PATHOL,CTR STUDY ORAL DIS,BRISTOL BS1 2LY,ENGLAND	University of Bristol	MACFARLANE, GJ (corresponding author), EUROPEAN INST ONCOL,DIV EPIDEMIOL & BIOSTAT,VIA RIPAMONTI 332-10,I-20141 MILAN,ITALY.		Boyle, Peter/A-4380-2014; Macfarlane, Gary J/I-9521-2014	Boyle, Peter/0000-0001-6251-0610; Macfarlane, Gary J/0000-0003-2322-3314				[Anonymous], 1988, IARC MONOGR EVAL CAR, V44, P41; [Anonymous], 1990, ANN REPORT; BINNIE WH, 1972, OPCS STUDIES MED POP; BLOT WJ, 1988, CANCER RES, V48, P3282; BRUGERE J, 1986, CANCER, V57, P391, DOI 10.1002/1097-0142(19860115)57:2<391::AID-CNCR2820570235>3.0.CO;2-Q; CASE RAM, 1976, SERIAL MORTALITY TAB, V4; DAVIS S, 1987, LANCET, V1, P910; DEPUE RH, 1986, NEW ENGL J MED, V315, P647; DOLL R, 1967, INT J CANCER, V2, P269, DOI 10.1002/ijc.2910020310; DOLL R, 1966, CANCER INCIDENCE 5 C, V1; Easson E C, 1976, Clin Oncol, V2, P191; GRAHAM S, 1977, J NATL CANCER I, V59, P1611, DOI 10.1093/jnci/59.6.1611; HAKULINEN T, 1986, ACTA PATHOLOGIC S228, V94, P30; KELLER AZ, 1965, AM J PUBLIC HEALTH N, V55, P1578, DOI 10.2105/AJPH.55.10.1578; LAVECCHIA C, 1992, EUR J CANCER, V28A, P132; MACFARLANE GJ, 1987, LANCET, V2, P1912; MERLETTI F, 1989, CANCER RES, V49, P4919; MOLLER H, 1989, J ORAL PATHOL MED, V18, P224, DOI 10.1111/j.1600-0714.1989.tb00767.x; MUIR C, 1987, IARC SCI PUBLICATION, V88; RUSSELL MH, 1955, BRIT MED J, V2, P823, DOI 10.1136/bmj.2.4943.823; SCHIFFLERS E, 1985, STAT MED, V4, P63, DOI 10.1002/sim.4780040110; SPRING JA, 1977, NATURE, V270, P567, DOI 10.1038/270567a0; SVEJDA J, 1971, NEOPLASMA, V18, P193; TAN K N, 1969, Australian Dental Journal, V14, P50; WALD NJ, 1985, CANCER RISKS PREVENT, P44; WINN DM, 1981, NEW ENGL J MED, V304, P745, DOI 10.1056/NEJM198103263041301; WYNDER EL, 1957, CANCER, V10, P1300, DOI 10.1002/1097-0142(195711/12)10:6&lt;1300::AID-CNCR2820100628&gt;3.0.CO;2-2; [No title captured]	28	82	84	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1121	1123		10.1136/bmj.305.6862.1121	http://dx.doi.org/10.1136/bmj.305.6862.1121			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463946	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JX84100020
J	OSTERGAARD, JR; KRAFT, M				OSTERGAARD, JR; KRAFT, M			NATURAL COURSE OF BENIGN COITAL HEADACHE	BRITISH MEDICAL JOURNAL			English	Article									PRIVATE CLIN NEUROL,NEUROL,DK-8240 RIISKOV,DENMARK		OSTERGAARD, JR (corresponding author), AARHUS UNIV HOSP,DEPT PEDIAT A,DK-8000 AARHUS,DENMARK.							JOHS DR, 1986, ARCH NEUROL-CHICAGO, V43, P1158; KRITZ K, 1970, CESK NEUROL NEUROCHI, V33, P162; LANCE JW, 1976, J NEUROL NEUROSUR PS, V39, P1226, DOI 10.1136/jnnp.39.12.1226; PAULSON GW, 1974, HEADACHE, V13, P181, DOI 10.1111/j.1526-4610.1974.hed1304181.x; 1988, CEPHALALGIA S7, V8, P1	5	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 7	1992	305	6862					1129	1129		10.1136/bmj.305.6862.1129	http://dx.doi.org/10.1136/bmj.305.6862.1129			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX841	1463949	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JX84100023
J	REDD, SC; BLOLAND, PB; KAZEMBE, PN; PATRICK, E; TEMBENU, R; CAMPBELL, CC				REDD, SC; BLOLAND, PB; KAZEMBE, PN; PATRICK, E; TEMBENU, R; CAMPBELL, CC			USEFULNESS OF CLINICAL CASE-DEFINITIONS IN GUIDING THERAPY FOR AFRICAN CHILDREN WITH MALARIA OR PNEUMONIA	LANCET			English	Article							PRIMARY HEALTH-CARE; PERENNIAL TRANSMISSION; PLASMODIUM-FALCIPARUM; EARLY-CHILDHOOD; DIAGNOSIS; POPULATION; INFECTIONS; EFFICACY; DISEASE; INTENSE	The World Health Organisation has developed disease-specific clinical case-definitions to guide management of children with fever or cough, the cardinal signs of malaria and pneumonia. To assess the usefulness of the case-definitions and to investigate their interaction, we studied children with fever or cough brought to a hospital in Lilongwe, Malawi. For all children, a thick blood smear was examined for Plasmodium falciparum parasites. Chest radiography was done only for children with parasitaemia and those who satisfied the clinical case-definition for pneumonia; others were assumed to have normal chest radiographs. Of 1599 enrolled children, 566 (35%) had parasitaemia and 116 had radiographic evidence of pneumonia; 43 had both pneumonia and parasitaemia. Of the 471 children who met the clinical definition for pneumonia, 449 (95%) also met the malaria clinical definition. Among children with radiographic evidence of pneumonia, the clinical definition for malaria was not predictive of parasitaemia (sensitivity 93%, specificity 5%). Whether malaria parasitaemia was present or absent, the pneumonia clinical definition distinguished children with and without radiographic evidence of pneumonia (sensitivity and specificity >60%). Children who satisifed the pneumonia clinical definition were more likely to have radiographic evidence of pneumonia (odds ratio 10.4, 95% confidence interval 5.2-20.7), parasitaemia (1.6, 1.2-2.2), or both at the same time (4.2, 2.1-8.4) than were children who did not meet the definition. Children who satisfy the malaria and pneumonia clinical definitions need treatment for both disorders. Scarce diagnostic methods, especially microscopy, are needed for more specific treatment of children with fever and cough.	CTR DIS CONTROL,INT HLTH PROGRAM OFF,ATLANTA,GA 30333; MALAWI MINIST HLTH,LILONGWE,MALAWI; EMORY UNIV,SCH MED,DEPT RADIOL,ATLANTA,GA 30322	Centers for Disease Control & Prevention - USA; Emory University	REDD, SC (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,MAILSTOP F12,ATLANTA,GA 30333, USA.							BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; CAMPBELL H, 1988, LANCET, V2, P742; CAMPBELL H, 1988, LANCET, V2, P1182; DARAMOLA OO, 1991, T R SOC TROP MED HYG, V84, P345; FREUND RJ, 1982, SAS SYSTEM LINEAR MO, P9; GREENWOOD BM, 1987, ANN TROP PAEDIATR, V7, P91, DOI 10.1080/02724936.1987.11748482; HARARI M, 1991, LANCET, V338, P928, DOI 10.1016/0140-6736(91)91785-S; HENDRICKSE RG, 1971, ANN TROP MED PARASIT, V65, P1; HEYMANN DL, 1987, T ROY SOC TROP MED H, V81, P722, DOI 10.1016/0035-9203(87)90005-8; KEELEY DJ, 1990, B WORLD HEALTH ORGAN, V68, P185; KHOROMANA CO, 1986, AM J TROP MED HYG, V35, P465, DOI 10.4269/ajtmh.1986.35.465; MASTRO TD, 1991, LANCET, V337, P156, DOI 10.1016/0140-6736(91)90813-5; ROUGEMONT A, 1991, LANCET, V338, P1292, DOI 10.1016/0140-6736(91)92592-P; RUEBUSH TK, 1986, REV INFECT DIS, V8, P454; SARMA PS, 1989, ANN INTERN MED, V111, P336, DOI 10.7326/0003-4819-111-4-336; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; TRAPE JF, 1987, AM J EPIDEMIOL, V126, P193, DOI 10.1093/aje/126.2.193; TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P435, DOI 10.1016/0035-9203(85)90054-9; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; 1990, SUPERVISORY SKILLS M; 1990, WHOARI905 WORLD HLTH; 1986, SUGI SUPPLEMENTAL LI, P269; 1986, WHO TECH REP SER, V375	23	64	65	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 7	1992	340	8828					1140	1143		10.1016/0140-6736(92)93160-O	http://dx.doi.org/10.1016/0140-6736(92)93160-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JX134	1359219	Bronze			2022-12-01	WOS:A1992JX13400012
J	JOHAL, GS; BRIGGS, SP				JOHAL, GS; BRIGGS, SP			REDUCTASE-ACTIVITY ENCODED BY THE HM1 DISEASE RESISTANCE GENE IN MAIZE	SCIENCE			English	Article							HELMINTHOSPORIUM-CARBONUM; HC-TOXIN; DETOXIFICATION	The HM1 gene in maize controls both race-specific resistance to the fungus Cochliobolus carbonum race 1 and expression of the NADPH (reduced form of nicotinamide adenine dinucleotide phosphate)-dependent HC toxin reductase (HCTR), which inactivates HC toxin, a cyclic tetrapeptide produced by the fungus to permit infection. Several HM1 alleles were generated and cloned by transposon-induced mutagenesis. The sequence of wild-type HM1 shares homology with dihydroflavonol-4-reductase genes from maize, petunia, and snapdragon. Sequence homology is greatest in the betaalphabeta-dinucleotide binding fold that is conserved among NADPH- and NADH (reduced form of nicotinamide adenine dinucleotide)dependent reductases and dehydrogenases. This indicates that HM1 encodes HCTR.			JOHAL, GS (corresponding author), PIONEER HI BRED INT INC,DEPT BIOTECHNOL RES,JOHNSTON,IA 50131, USA.		Johal, Guri/F-5056-2017	Johal, Guri/0000-0001-8101-8410				ANZAI H, 1989, MOL GEN GENET, V219, P492, DOI 10.1007/BF00259626; ATHMA P, 1991, GENETICS, V128, P163; BARKAN A, 1991, P NATL ACAD SCI USA, V88, P3502, DOI 10.1073/pnas.88.8.3502; BEAVIS WD, 1991, THEOR APPL GENET, V82, P636, DOI 10.1007/BF00226803; BELD M, 1989, PLANT MOL BIOL, V13, P491, DOI 10.1007/BF00027309; BRIGGS SP, 1987, CURR TOP PLANT BIOCH, V6, P59; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONE KC, 1988, PLANT TRANSPOSABLE E; DELLAPORTA SL, 1983, PLANT MOL BIOL REP, V1, P18; GROSS ML, 1982, TETRAHEDRON LETT, V23, P5381; HENRY RJ, 1991, PLANT MOL BIOL REP, V9, P139; JOHAL GS, 1990, MAIZE GENETICS COOPE, V64, P37; JOHAL GS, UNPUB; KAWAI M, 1983, BIOCHEM BIOPH RES CO, V111, P398, DOI 10.1016/0006-291X(83)90319-4; LIESCH JM, 1982, TETRAHEDRON, V38, P45, DOI 10.1016/0040-4020(82)85043-6; MEELEY RB, 1992, PLANT CELL, V4, P71, DOI 10.1105/tpc.4.1.71; MEELEY RB, 1991, PLANT PHYSIOL, V97, P1080, DOI 10.1104/pp.97.3.1080; MEYEROWITZ EM, 1982, CELL, V28, P165, DOI 10.1016/0092-8674(82)90386-5; MIAO VPW, 1992, APPL ENVIRON MICROB, V58, P801, DOI 10.1128/AEM.58.3.801-808.1992; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; PERHAM RN, 1991, BIOESSAYS, V13, P515, DOI 10.1002/bies.950131005; RASMUSSEN JB, 1988, PHYSIOL MOL PLANT P, V32, P283, DOI 10.1016/S0885-5765(88)80023-7; ROBERTSON D, COMMUNICATION; SCHEFFER RP, 1965, PHYTOPATHOLOGY, V55, P1037; SHAH D M, 1983, Journal of Molecular and Applied Genetics, V2, P111; SISCO P, COMMUNICATION; WALTON JD, 1982, BIOCHEM BIOPH RES CO, V107, P785, DOI 10.1016/0006-291X(82)90592-7; WOLF SJ, 1991, PLANT SCI, V70, P127; YODER OC, 1980, ANNU REV PHYTOPATHOL, V18, P103, DOI 10.1146/annurev.py.18.090180.000535	31	342	440	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					985	987		10.1126/science.1359642	http://dx.doi.org/10.1126/science.1359642			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359642				2022-12-01	WOS:A1992JW79600032
J	MARTIN, J; HORWICH, AL; HARTL, FU				MARTIN, J; HORWICH, AL; HARTL, FU			PREVENTION OF PROTEIN DENATURATION UNDER HEAT-STRESS BY THE CHAPERONIN HSP60	SCIENCE			English	Article							ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; SHOCK PROTEINS; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; ATP HYDROLYSIS; COMPLEX; IMPORT; GROE; RECONSTITUTION	The increased synthesis of heat shock proteins is a ubiquitous physiological response of cells to environmental stress. How these proteins function in protecting cellular structures is not yet understood. The mitochondrial heat shock protein 60 (Hsp60) has now been shown to form complexes with a variety of polypeptides in organelles exposed to heat stress. The Hsp60 was required to prevent the thermal inactivation in vivo of native dihydrofolate reductase (DHFR) imported into mitochondria. In vitro, Hsp60 bound to DHFR in the course of thermal denaturation, preventing its aggregation, and mediated its adenosine triphosphate-dependent refolding at increased temperatures. These results suggest a general mechanism by which heat shock proteins of the Hsp60 family stabilize preexisting proteins under stress conditions.	SLOAN KETTERING MEM CANC CTR,ROCKEFELLER RES LABS,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Memorial Sloan Kettering Cancer Center; Yale University; Howard Hughes Medical Institute; Yale University			Hartl, F. Ulrich/Y-8206-2019					APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DAUM G, 1982, J BIOL CHEM, V257, P3075; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GARVEY EP, 1989, BIOCHEMISTRY-US, V28, P2083, DOI 10.1021/bi00431a018; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.biophys.21.1.293; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KITTCHEL BB, 1978, BIOCHIM BIOPHYS ACTA, V534, P89; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Martin J., UNPUB; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN MY, 1992, EMBO J, V11, P71; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; TEINTZE M, 1982, J BIOL CHEM, V257, P364; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Welch WJ., 1990, STRESS PROTEINS BIOL, P223; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	39	251	255	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					995	998		10.1126/science.1359644	http://dx.doi.org/10.1126/science.1359644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359644				2022-12-01	WOS:A1992JW79600035
J	SCHULTE, RJ; CAMPBELL, MA; FISCHER, WH; SEFTON, BM				SCHULTE, RJ; CAMPBELL, MA; FISCHER, WH; SEFTON, BM			TYROSINE PHOSPHORYLATION OF CD22 DURING B-CELL ACTIVATION	SCIENCE			English	Article							ANTIGEN RECEPTOR COMPLEX; LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PHOSPHOLIPASE-C; KINASE; PHOSPHOTYROSINE; STIMULATION	Ligation of the antigen receptor on B cells induces the rapid phosphorylation of tyrosine on a number of cellular proteins. A monoclonal antibody that recognized a tyrosine-phosphorylated cell surface protein that was present in activated B cells was generated. Amino acid sequence analysis showed that this 140-kilodalton protein was CD22, a B cell-specific cell surface glycoprotein and putative extracellular ligand of the protein tyrosine phosphatase CD45. Tyrosine phosphorylation of CD22 may be important in B cell signal transduction, possibly through regulation of the adhesiveness of activated B cells.	SALK INST,MOLEC BIOL & VIROL LAB,SAN DIEGO,CA 92186; SALK INST,PEPTIDE BIOL LAB,SAN DIEGO,CA 92186	Salk Institute; Salk Institute					NATIONAL CANCER INSTITUTE [R01CA017289, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA17289] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESMARTINEZ JE, 1992, EUR J IMMUNOL, V22, P845, DOI 10.1002/eji.1830220332; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CARTER RH, 1991, J IMMUNOL, V147, P3663; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; DIMINNO G, 1983, BLOOD, V61, P140; DORKEN B, 1986, J IMMUNOL, V136, P4470; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PEZZUTTO A, 1988, J IMMUNOL, V140, P1791; PEZZUTTO A, 1987, J IMMUNOL, V138, P98; PEZZUTTO A, 1987, LEUKOCYTE TYPING, V3, P361; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; ROSS AH, 1981, NATURE, V294, P654, DOI 10.1038/294654a0; SCHULTE RJ, UNPUB; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1992, CELL, V68, P1003, DOI 10.1016/0092-8674(92)90071-J; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEINANDS J, 1990, EMBO J, V9, P449; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	51	139	140	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					1001	1004		10.1126/science.1279802	http://dx.doi.org/10.1126/science.1279802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1279802				2022-12-01	WOS:A1992JW79600037
J	WETTERAU, JR; AGGERBECK, LP; BOUMA, ME; EISENBERG, C; MUNCK, A; HERMIER, M; SCHMITZ, J; GAY, G; RADER, DJ; GREGG, RE				WETTERAU, JR; AGGERBECK, LP; BOUMA, ME; EISENBERG, C; MUNCK, A; HERMIER, M; SCHMITZ, J; GAY, G; RADER, DJ; GREGG, RE			ABSENCE OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN INDIVIDUALS WITH ABETALIPOPROTEINEMIA	SCIENCE			English	Article							APOLIPOPROTEIN-B GENE; CHOLESTERYL ESTER; DISULFIDE ISOMERASE; HYPOBETALIPOPROTEINEMIA; TRIACYLGLYCEROL; COMPLEX; DISEASE; CELLS	Abetalipoproteinemia is a human genetic disease that is characterized by a defect in the assembly or secretion of plasma very low density lipoproteins and chylomicrons. The microsomal triglyceride transfer protein (MTP), which is located in the lumen of microsomes isolated from the liver and intestine, has been proposed to function in lipoprotein assembly. MTP activity and the 88-kilodalton component of MTP were present in intestinal biopsy samples from eight control individuals but were absent in four abetalipoproteinemic subjects. This finding suggests that a defect in MTP is the basis for abetalipoproteinemia and that MTP is indeed required for lipoprotein assembly.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 07,INSERM,U327,F-75018 PARIS,FRANCE; HOP ST NICOLAS,SERV MED INTERNE,F-55107 VERDUN,FRANCE; HOP EDOUARD HERRIOT,MED INFANTILE CLIN B,F-69437 LYON,FRANCE; HOP ROBERT DEBRE,SERV GASTROENTEROL NUTR PEDIAT,F-75019 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,DEPT PEDIAT,F-75730 PARIS 15,FRANCE; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	WETTERAU, JR (corresponding author), BRISTOL MYERS SQUIBB,DEPT METABOL DIS,PRINCETON,NJ 08543, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOUMA ME, 1986, J CLIN INVEST, V78, P398, DOI 10.1172/JCI112590; GAY G, 1990, REV MED INTERNE, V11, P273, DOI 10.1016/S0248-8663(05)80857-4; HIGGINS JA, 1984, J LIPID RES, V25, P1295; HUANG LS, 1990, AM J HUM GENET, V46, P1141; IHM J, 1982, J BIOL CHEM, V257, P4818; JANERO DR, 1983, J BIOL CHEM, V258, P4496; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; LACAILLE F, 1989, ARCH FR PEDIATR, V46, P491; LACKNER KJ, 1986, J CLIN INVEST, V78, P1707, DOI 10.1172/JCI112766; LOWRY OH, 1951, J BIOL CHEM, V193, P265; SCOAZEC JY, 1992, GUT, V33, P414, DOI 10.1136/gut.33.3.414; TALMUD PJ, 1988, J CLIN INVEST, V82, P1803, DOI 10.1172/JCI113795; WETTERAU J, UNPUB; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006	19	597	624	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					999	1001						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1439810				2022-12-01	WOS:A1992JW79600036
J	WOLLE, D; DEAN, DR; HOWARD, JB				WOLLE, D; DEAN, DR; HOWARD, JB			NUCLEOTIDE IRON-SULFUR CLUSTER SIGNAL TRANSDUCTION IN THE NITROGENASE IRON-PROTEIN - THE ROLE OF ASP(125)	SCIENCE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; AZOTOBACTER-VINELANDII; FE-PROTEIN; ADENOSINE 5'-TRIPHOSPHATE; KLEBSIELLA-PNEUMONIAE; BINDING; MGATP; MECHANISM; LIGANDS	Electron transfer in nitrogenase involves a gating process initiated by MgATP (magnesium adenosine triphosphate) binding to Fe-protein. The redox site, an 4Fe:4S cluster, is structurally separated from the MgATP binding site. For MgATP hydrolysis to be coupled to electron transfer, a signal transduction mechanism is proposed that is similar to that in guanosine triphosphatase proteins. Based on the three-dimensional structure of Fe-protein, Asp125 is likely to be part of a putative transduction path. Altered Fe-protein with Glu replacing Asp has been prepared and retains the ability for the initial nucleotide-dependent conformational change. However, either MgADP or MgATP can induce the shift and Mg binding to the nucleotide is no longer essential.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061	Virginia Polytechnic Institute & State University								BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Burgess B. K., 1984, Advances in nitrogen fixation research, P103; DEITS TL, 1989, J BIOL CHEM, V264, P6619; ENNOR AH, 1957, METHOD ENZYMOL, V3, P850, DOI 10.1016/S0076-6879(57)03460-6; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1980, BIOCHEMISTRY-US, V19, P2333, DOI 10.1021/bi00552a009; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HIROSE M, 1971, BIOCHIM BIOPHYS ACTA, V251, P376, DOI 10.1016/0005-2795(71)90125-5; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; IMPERIAL J, 1988, NITROGEN FIXATION 10, P128; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWE D, 1984, MOLYBDENUM ENZYMES, P222; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NORMAND P, 1989, J MOL EVOL, V29, P436, DOI 10.1007/BF02602914; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Press WH, 1986, NUMERICAL RECIPES AR, P521; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROBSON RL, 1984, FEBS LETT, V173, P394, DOI 10.1016/0014-5793(84)80812-1; SEEFELDT LC, 1992, J BIOL CHEM, V267, P6680; STEPHENS PJ, 1979, P NATL ACAD SCI USA, V76, P2585, DOI 10.1073/pnas.76.6.2585; THORNELEY RNF, 1989, BIOCHEM J, V264, P657, DOI 10.1042/bj2640657; THORNELEY RNF, 1991, BIOCHEM J, V277, P735, DOI 10.1042/bj2770735; TSO MYW, 1973, BIOCHIM BIOPHYS ACTA, V309, P263, DOI 10.1016/0005-2744(73)90024-7; WALKER G, 1974, BIOCHEMISTRY-US, V13, P1872; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATT GD, 1986, BIOCHEMISTRY-US, V25, P8156, DOI 10.1021/bi00373a005; WOLLE D, 1992, J BIOL CHEM, V267, P3667; YATES G, 1992, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1973, BIOCHIM BIOPHYS ACTA, V292, P413, DOI 10.1016/0005-2728(73)90047-9	33	75	75	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 6	1992	258	5084					992	995		10.1126/science.1359643	http://dx.doi.org/10.1126/science.1359643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW796	1359643				2022-12-01	WOS:A1992JW79600034
J	BALASUBRAMANIAN, MK; HELFMAN, DM; HEMMINGSEN, SM				BALASUBRAMANIAN, MK; HELFMAN, DM; HEMMINGSEN, SM			A NEW TROPOMYOSIN ESSENTIAL FOR CYTOKINESIS IN THE FISSION YEAST S-POMBE	NATURE			English	Article							CELL-DIVISION CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; GENETIC-CONTROL; F-ACTIN; PROTEINS; MUSCLE	MUTATIONS in the Schizosaccharomyces pombe cdc8 gene impair cytokinesis1. Here we clone cdc8+ and find that it encodes a novel tropomyosin. Gene disruption results in lethal arrest of the cell cycle, but spore germination, cell growth, DNA replication and mitosis are all unaffected. Haploid cdc8 gene disruptants are rescued by expression of a fibroblast tropomyosin complementary DNA. Immunofluorescence microscopy of wild type and cdc8 gene distruptants indicates that cdc8 tropomyosin is present in two distinct cellular distributions: in dispersed patches, and during cytokinesis as a transient medial band. Collectively these results indicate that cdc8 tropomyosin has a specialized role which, we suggest, is to form part of the F-actin contractile ring at cytokinesis. These results establish the basis for further genetic studies of cytokinesis and of contractile protein function in S. pombe.	NATL RES COUNCIL CANADA, INST PLANT BIOTECHNOL, SASKATOON S7N 0W9, SASKATCHEWAN, CANADA; UNIV SASKATCHEWAN, DEPT MICROBIOL, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA	National Research Council Canada; University of Saskatchewan			Helfman, David M./C-2058-2011	Balasubramanian, Mohan/0000-0002-1292-8602				ALFA CE, 1990, J CELL SCI, V96, P71; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; HAGAN IM, 1988, J CELL SCI, V89, P343; JOCHOVA J, 1991, CELL BIOL INT REP, V15, P607, DOI 10.1016/0309-1651(91)90007-6; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; LIU HP, 1989, P NATL ACAD SCI USA, V86, P90, DOI 10.1073/pnas.86.1.90; MARKS J, 1992, J CELL SCI, V101, P801; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; SCHROEDER TE, 1990, ANN NY ACAD SCI, V582, P78; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATTS FZ, 1987, EMBO J, V6, P3499, DOI 10.1002/j.1460-2075.1987.tb02675.x; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X	22	204	205	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					84	87		10.1038/360084a0	http://dx.doi.org/10.1038/360084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436080				2022-12-01	WOS:A1992JW71700062
J	BRODY, H				BRODY, H			ASSISTED DEATH - A COMPASSIONATE RESPONSE TO A MEDICAL FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; SUICIDE; ETHICS				BRODY, H (corresponding author), MICHIGAN STATE UNIV, DEPT FAMILY PRACTICE, CTR CLIN B100, E LANSING, MI 48824 USA.		Brody, Howard/GQA-6310-2022					ADMIRAAL PV, 1984, JUSTIFIED EUTHANASIA; [Anonymous], 1992, HARVARD LAW REV, V105, P2021; [Anonymous], 1988, MED GOALS AGEING SOC; ARRAS JD, 1991, J MED PHILOS, V16, P29, DOI 10.1093/jmp/16.1.29; Battin M, 1992, Law Med Health Care, V20, P133; Benjamin M., 1990, SPLITTING DIFFERENCE; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; Brody H., 1987, STORIES SICKNESS; BRODY H, 1992, HEALERS POWER; CALLAHAN D, 1977, HASTINGS CENT REP, V7, P32, DOI 10.2307/3560692; CALLAHAN D, 1991, COMMONWEAL S    0809, P12; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; CRANFORD RE, 1984, I ETHICS COMMITTEES; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Drane JF, 1988, BECOMING GOOD DOCTOR; DUFFY TP, 1992, NEW ENGL J MED, V326, P933, DOI 10.1056/NEJM199204023261406; FENIGSEN R, 1991, ISSUES LAW MED, V7, P339; FOLEY KM, 1991, J PAIN SYMPTOM MANAG, V6, P289, DOI 10.1016/0885-3924(91)90052-6; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; GOMEZ CF, 1991, COMMONWEAL S, P5; Hampshire S., 1983, MORALITY CONFLICT; Humphry D, 1991, FINAL EXIT PRACTICAL; Jonsen Albert., 1988, ABUSE CASUISTRY HIST; JONSEN AR, 1991, THEOR MED, V12, P295, DOI 10.1007/BF00489890; JONSEN AR, 1991, COMMONWEAL S, P2; KANOTI GA, 1987, HLTH CARE ETHICS GUI, P293; KASS LR, 1989, PUBLIC INTEREST, P25; KASS LR, 1991, COMMONWEAL S, P8; KEVORKIAN J, 1991, PRESCRIPTION MEDICID; LADD J, 1980, LANCET, V2, P1127; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; May W E, 1987, Issues Law Med, V3, P203; Miller R J, 1992, Law Med Health Care, V20, P127, DOI 10.1111/j.1748-720X.1992.tb01179.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2365, DOI 10.1001/jama.263.17.2365; Pellegrino E D, 1992, J Clin Ethics, V3, P95; Pellegrino ED., 1988, PATIENTS GOOD RESTOR; Pellegrino EdmundD., 1981, PHILOS BASIS MED PRA; PENCE GE, 1988, AM J MED, V84, P139, DOI 10.1016/0002-9343(88)90022-8; PUTNAM H, 1983, NOT SOLVE ETHICAL PR; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J., 1986, END LIFE EUTHANASIA; SHAFFER CD, 1986, COLUMBIA LAW REV, V86, P348, DOI 10.2307/1122707; Shelp E. E., 1985, VIRTUE MED EXPLORATI; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANCE R, 1985, PERSPECT BIOL MED, V28, P282; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, EUTHANASIA REPORT RE	54	108	108	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1384	1388		10.1056/NEJM199211053271912	http://dx.doi.org/10.1056/NEJM199211053271912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1383820				2022-12-01	WOS:A1992JW07700012
J	DAVIES, K				DAVIES, K			MESSAGE IN A BOTTLE	NATURE			English	Editorial Material																		COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HASTBACKA J, 1990, P NATL ACAD SCI USA, V87, P8056, DOI 10.1073/pnas.87.20.8056; HASTBACKA J, 1991, GENOMICS, V11, P968, DOI 10.1016/0888-7543(91)90021-6; Luria SE, 1943, GENETICS, V28, P491	5	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					90	90		10.1038/360090a0	http://dx.doi.org/10.1038/360090a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436083	Bronze			2022-12-01	WOS:A1992JW71700064
J	IINO, M; ENDO, M				IINO, M; ENDO, M			CALCIUM-DEPENDENT IMMEDIATE FEEDBACK-CONTROL OF INOSITOL 1,4,5-TRISPHOSPHATE-INDUCED CA2+ RELEASE	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CHANNELS; TRISPHOSPHATE; OSCILLATIONS; PHOSPHATES; CEREBELLUM	THE temporal and spatial distribution of increases in intracellular Ca2+ concentration is an important factor in cellular signal transduction1. Inositol 1,4,5-trisphosphate (InsP3) plays a key part in agonist-induced Ca2+ release1, which can take place abruptly2 and in a confined space3 by a mechanism that is not fully understood. Here we analyse the kinetics of InsP3-induced Ca2+ release following flash photolysis4-7 of Caged InsP3 or caged Ca2+, and demonstrate that Ca2+-dependent immediate feedback control is an important determinant of the time course of Ca2+ release. The positive feedback mechanism is also important for the 'loading dependence' of InsP3-induced Ca2+ release8. Furthermore, our results support the operation of positive cooperativity in channel opening9 and feedback control augments the steep InsP3 concentration-Ca2+ release relation. These inherent properties of InsP3-induced Ca2+ release are expected to give rise to temporally abrupt and/or spatially confined Ca2+ release within the cell.			IINO, M (corresponding author), UNIV TOKYO, FAC MED, DEPT PHARMACOL, BUNKYO KU, TOKYO 113, JAPAN.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLATT MR, 1990, NATURE, V346, P766, DOI 10.1038/346766a0; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; IINO M, 1991, J GEN PHYSIOL, V98, P681, DOI 10.1085/jgp.98.4.681; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; INO M, 1989, J GEN PHYSIOL, V94, P363, DOI 10.1085/jgp.94.2.363; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; KAPLAN JH, 1990, ANNU REV PHYSIOL, V52, P897; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.bb.18.060189.001323; MEYER T, 1991, CELL, V64, P675, DOI 10.1016/0092-8674(91)90496-L; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MINTA A, 1989, J BIOL CHEM, V264, P8171; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; SOMLYO AP, 1990, REV PHYSL, V52, P857; WATRAS J, 1991, J NEUROSCI, V11, P3239	24	266	269	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					76	78		10.1038/360076a0	http://dx.doi.org/10.1038/360076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1331809				2022-12-01	WOS:A1992JW71700059
J	KRAUSS, S; MADEN, M; HOLDER, N; WILSON, SW				KRAUSS, S; MADEN, M; HOLDER, N; WILSON, SW			ZEBRAFISH PAX[B] IS INVOLVED IN THE FORMATION OF THE MIDBRAIN HINDBRAIN BOUNDARY	NATURE			English	Article							DEVELOPING EXCRETORY SYSTEM; BOX-CONTAINING GENE; INT-1 PROTOONCOGENE; FUSHI-TARAZU; NEURAL-TUBE; DROSOPHILA; EXPRESSION; MUTATION; PROTEIN; WNT-1	AMONG the genes thought to be involved in patterning the nervous system are a family of developmentally regulated paired box-containing (Pax) genes. Mutations in some of these Pax genes lead to severe developmental abnormalities. Zebrafish pax[b] (pax[zf-b]) is a member of the Pax gene family that is expressed in the presumptive posterior midbrain from the end of gastrulation and, at later stages, in other localized regions of the developing embryo1. Here we show that injection of antibodies raised against the pax[b] protein causes a localized malformation at the mid-brain-hinbrain boundary. In situ hybridizations demonstrate that antibody injection causes downregulation of pax[b] transcripts in the posterior midbrain and alteration of wnt-1 and eng-2 expression in this area. The data demonstrate an involvement of pax[b] in the formation of the midbrain-hindbrain junction.	UNIV LONDON KINGS COLL,RANDALL INST,DEV BIOL RES CTR,DIV BIOMED SCI,LONDON WC2B 5RL,ENGLAND	University of London; King's College London			Wilson, Stephen W/B-9404-2008	Wilson, Stephen W/0000-0002-8557-5940; Krauss, Stefan/0000-0001-6992-8091				BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUNWALD DJ, 1988, DEV BIOL, V126, P115, DOI 10.1016/0012-1606(88)90245-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; JOSTES B, 1991, MECH DEVELOP, V33, P27; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MIKKOLA J, 1992, J NEUROBIOL, V23, P933; MOLVEN A, 1991, EMBO J, V10, P799, DOI 10.1002/j.1460-2075.1991.tb08012.x; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PLACHOV D, 1990, DEVELOPMENT, V110, P643; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TSSEBEHJI M, 1992, NATURE, V355, P635; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435	32	122	124	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					87	89		10.1038/360087a0	http://dx.doi.org/10.1038/360087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436081				2022-12-01	WOS:A1992JW71700063
J	LANDSBERG, JP; MCDONALD, B; WATT, F				LANDSBERG, JP; MCDONALD, B; WATT, F			ABSENCE OF ALUMINUM IN NEURITIC PLAQUE CORES IN ALZHEIMERS-DISEASE	NATURE			English	Article							SENILE PLAQUES; DRINKING-WATER; MICROPROBE; BRAIN	CONTROVERSY exists over whether aluminium has a role in the aetiology of Alzheimer's disease. Alzheimer's disease is neuropathologically characterized by the occurrence of a minimum density of neurofibrillary tangles and neuritic plaques in the hippocampus and the association cortex of the brain1,2. The purported association of aluminium with Alzheimer's disease is based on: (1) the experimental induction of fibrillary changes in the neurons of animals by the injection of aluminium salts into brain tissue3,4; (2) reported detection of aluminium in neuritic plaques5-8 and tangle-bearing neurons9,10; (3) epidemiological studies linking aluminium levels in the environment, notably water supplies, with an increased prevalence of dementia11-14; and (4) a reported decrease in the rate of disease progression following the administration of desferroxamine, an aluminium chelator, to clinically diagnosed sufferers of Alzheimer's disease15. Here we use nuclear microscopy, a new analytical technique involving million-volt nuclear particles, to identify and analyse plaques in post-mortem tissue from patients with Alzheimer's disease without using chemical staining techniques and fail to demonstrate the presence of aluminium in plaque cores in untreated tissue.	RADCLIFFE INFIRM, DEPT NEUROPATHOL, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary	LANDSBERG, JP (corresponding author), UNIV OXFORD, NUCL PHYS LAB, SCANNING PROTON MICROPROBE UNIT, OXFORD OX1 3RH, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTAXO P, 1990, NUCL INSTRUM METH B, V49, P383, DOI 10.1016/0168-583X(90)90280-8; BENCH GS, 1989, NUCL INSTRUM METH B, V40-1, P655, DOI 10.1016/0168-583X(89)91069-0; CANDY J, 1988, INTERDISCIPL TOPICS, V25, P140; CANDY JM, 1986, LANCET, V1, P354; Candy JM, 1985, SENILE DEMENTIA ALZH, P183; CHAFI AH, 1991, NEUROSCI LETT, V123, P61, DOI 10.1016/0304-3940(91)90158-P; Chu W. K., 1978, BACKSCATTERING SPECT, DOI 10.1016/B978-0-12-173850-1.50008-9; DUCKETT S, 1976, CR ACAD SCI D NAT, V282, P393; DUCKETT S, 1980, J NEUROPATH EXP NEUR, V39, P350, DOI 10.1097/00005072-198005000-00048; EDWARDSON JA, 1990, ENVIRON GEOCHEM HLTH, V12, P94, DOI 10.1007/BF01734057; FLATEN TP, 1990, ENVIRON GEOCHEM HLTH, V12, P152, DOI 10.1007/BF01734064; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; JACOBS RW, 1989, CAN J NEUROL SCI, V16, P498, DOI 10.1017/S0317167100029838; Johansson S., 1988, PIXE NOVEL TECHNIQUE; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KLATZO I, 1965, J NEUROPATH EXP NEUR, V24, P187, DOI 10.1097/00005072-196504000-00002; LANDSBERG JP, 1991, NUCL INSTRUM METH B, V54, P180, DOI 10.1016/0168-583X(91)95510-K; MARTYN CN, 1989, LANCET, V1, P59; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MICHEL P, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P387; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; NERI LC, 1991, LANCET, V338, P390, DOI 10.1016/0140-6736(91)90531-S; NIKAIDO T, 1972, ARCH NEUROL-CHICAGO, V27, P549, DOI 10.1001/archneur.1972.00490180085017; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; SCHOFIELD RMS, 1988, NUCL INSTRUM METH B, V30, P398, DOI 10.1016/0168-583X(88)90032-8; STERN AJ, 1986, J NEUROPATH EXP NEUR, V45, P361, DOI 10.1097/00005072-198605000-00140; TERRY RD, 1965, J NEUROPATH EXP NEUR, V24, P200, DOI 10.1097/00005072-196504000-00003; WATT F, 1987, PRINCIPLES APPLICATI; WATT F, 1992, XRAY MICROANALYSIS B	30	242	245	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 5	1992	360	6399					65	68		10.1038/360065a0	http://dx.doi.org/10.1038/360065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436075				2022-12-01	WOS:A1992JW71700055
J	LARKMAN, A; HANNAY, T; STRATFORD, K; JACK, J				LARKMAN, A; HANNAY, T; STRATFORD, K; JACK, J			PRESYNAPTIC RELEASE PROBABILITY INFLUENCES THE LOCUS OF LONG-TERM POTENTIATION	NATURE			English	Article							QUANTAL ANALYSIS; HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; LTP; NEURONS	THE quantal hypothesis proposes that chemical synaptic transmission involves the probabilistic release of multimolecular packets of transmitter1. Analysis of the resulting trial-to-trial fluctuations in postsynaptic response can provide estimates both of the number of quanta released and of the size of their postsynaptic effect. This in turn permits the quantification of the relative contributions of pre- and postsynaptic factors to the strength of a given synapse. Quantal analysis of excitatory synapses in the hippocampus has proved difficult2-6 and has led to contradictory conclusions when applied to long-term potentiation7-14. Here we report the use of a combination of quantal analysis procedures to provide evidence that both pre- and postsynaptic changes can contribute substantially to the maintenance of long-term potentiation in the CA1 region of the hippocampus. The initial setting of the presynaptic release mechanism seems to determine their relative importance.			LARKMAN, A (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.			Hannay, Timo/0000-0002-5941-3390	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LARKMAN A, 1991, NATURE, V353, P396, DOI 10.1038/353396b0; MAGLEBY KL, 1981, J PHYSIOL-LONDON, V311, P267, DOI 10.1113/jphysiol.1981.sp013584; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; VORONIN LL, 1983, NEUROSCIENCE, V10, P1051, DOI 10.1016/0306-4522(83)90099-4	20	192	192	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					70	73		10.1038/360070a0	http://dx.doi.org/10.1038/360070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1331808				2022-12-01	WOS:A1992JW71700057
J	MULTIGNER, L; GAGNON, J; VANDORSSELAER, A; JOB, D				MULTIGNER, L; GAGNON, J; VANDORSSELAER, A; JOB, D			STABILIZATION OF SEA-URCHIN FLAGELLAR MICROTUBULES BY HISTONE-H1	NATURE			English	Article							CHLAMYDOMONAS ALPHA-TUBULIN; DOUBLET MICROTUBULES; STOP PROTEIN; TAU-PROTEIN; M-PHASE; CELLS; SPERM; ORIGIN; ASSOCIATION; STABILITY	Complex microtubule assemblies are essential components of eukaryotic cilia and flagella. They are extremely stable and are not affected by agents that normally induce polymer disassembly. The molecular basis of this microtubular stability is unknown, and it is not related to any feature of the constitutive tubulin. In sea urchin sperm flagella, axonemal microtubules are found to be stabilized by a protein identical to histone H1, a result that defines a new role for this histone and provides evidence for a concerted evolution of chromatin and microtubular structures.	INST BIOL STRUCT,F-38027 GRENOBLE 1,FRANCE; FAC CHIM STRASBOURG,SPECTROMETRIE MASSE BIOORGAN LAB,F-67008 STRASBOURG,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	MULTIGNER, L (corresponding author), CEN,INSERM,UNITE 244,DEPT BIOL MOLEC & STRUCT,CYTOSQUELETTE LAB,BP 85X,F-38041 GRENOBLE,FRANCE.		Multigner, Luc/I-2926-2015; Multigner, Luc/AAA-6214-2020; Gagnon, Jean/C-3136-2008	Multigner, Luc/0000-0003-3205-8568; Multigner, Luc/0000-0003-3205-8568; Gagnon, Jean/0000-0002-0177-824X				Behnke O, 1970, Int Rev Exp Pathol, V9, P1; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cavalier- Smith T, 1981, SOC GEN MICROBIOL S, V32, P33; CAVALIERSMITH T, 1988, BIOESSAYS, V9, P72, DOI 10.1002/bies.950090209; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CAVALIERSMITH T, 1975, NATURE, V256, P463, DOI 10.1038/256463a0; DRUBIN D, 1986, ANN NY ACAD SCI, V466, P257, DOI 10.1111/j.1749-6632.1986.tb38398.x; Dustin P., 1984, MICROTUBULES; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; ESPONDA P, 1980, CELL BIOL INT REP, V4, P549, DOI 10.1016/0309-1651(80)90020-X; FARRELL KW, 1982, METHOD CELL BIOL, V24, P61; FARRELL KW, 1978, J MOL BIOL, V121, P393, DOI 10.1016/0022-2836(78)90371-6; GIBBONS IR, 1972, J CELL BIOL, V54, P365, DOI 10.1083/jcb.54.2.365; GUNDERSEN GG, 1986, EUR J CELL BIOL, V42, P288; HARRISON A, 1990, J CELL SCI, V96, P347; Hnilica L.S., 1972, STRUCTURE BIOL FUNCT; IZANT JG, 1982, NATURE, V295, P248, DOI 10.1038/295248a0; JOB D, 1985, J CELL BIOL, V101, P1680, DOI 10.1083/jcb.101.5.1680; JOHNS EW, 1964, BIOCHEM J, V92, P55, DOI 10.1042/bj0920055; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LEFEBVRE PA, 1986, ANNU REV CELL BIOL, V2, P517, DOI 10.1146/annurev.cellbio.2.1.517; LHERNAULT SW, 1983, J CELL BIOL, V97, P258, DOI 10.1083/jcb.97.1.258; LINCK RW, 1987, J CELL BIOL, V104, P1069, DOI 10.1083/jcb.104.4.1069; LINCK RW, 1976, J CELL SCI, V20, P405; MARGOLIS RL, 1990, EMBO J, V9, P4095, DOI 10.1002/j.1460-2075.1990.tb07631.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PATURLE L, 1989, BIOCHEMISTRY-US, V28, P2698, DOI 10.1021/bi00432a050; PIROLLET F, 1989, BIOCHEMISTRY-US, V28, P835, DOI 10.1021/bi00428a064; PIROLLET F, 1987, EMBO J, V6, P3247, DOI 10.1002/j.1460-2075.1987.tb02642.x; Revzin A., 1990, BIOL NONSPECIFIC DNA; SCHULZE E, 1987, J CELL BIOL, V105, P2167, DOI 10.1083/jcb.105.5.2167; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; STEFFEN W, 1989, CELL MOTIL CYTOSKEL, V14, P359, DOI 10.1002/cm.970140306; STEPHENS R E, 1970, Journal of Molecular Biology, V47, P353, DOI 10.1016/0022-2836(70)90307-4; STEPHENS RE, 1989, J CELL SCI, V92, P403; STEPHENS RE, 1992, J CELL SCI, V101, P837; Stollar B D, 1978, Methods Cell Biol, V18, P105; STRICKLAND WN, 1980, EUR J BIOCHEM, V104, P567, DOI 10.1111/j.1432-1033.1980.tb04460.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VACQUIER VD, 1986, METHOD CELL BIOL, V27, P15, DOI 10.1016/S0091-679X(08)60340-4	42	61	61	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					33	39		10.1038/360033a0	http://dx.doi.org/10.1038/360033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436071				2022-12-01	WOS:A1992JW71700045
J	MUST, A; JACQUES, PF; DALLAL, GE; BAJEMA, CJ; DIETZ, WH				MUST, A; JACQUES, PF; DALLAL, GE; BAJEMA, CJ; DIETZ, WH			LONG-TERM MORBIDITY AND MORTALITY OF OVERWEIGHT ADOLESCENTS - A FOLLOW-UP OF THE HARVARD GROWTH STUDY OF 1922 TO 1935	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR-DISEASE; SERUM-LIPIDS; RISK FACTOR; OBESITY; WOMEN; WEIGHT; LIPOPROTEINS; CHILDREN; HEALTH; DEATH	Background. Overweight in adults is associated with increased morbidity and mortality. In contrast, the long-term effect of overweight in adolescence on morbidity and mortality is not known. Methods. We studied the relation between overweight and morbidity and mortality in 508 lean or overweight adolescents 13 to 18 years old who participated in the Harvard Growth Study of 1922 to 1935. Overweight adolescents were defined as those with a body-mass index that on two occasions was greater than the 75th percentile in subjects of the same age and sex in a large national survey. Lean adolescents were defined as those with a body-mass index between the 25th and 50th percentiles. Subjects who were still alive were interviewed in 1988 to obtain information about their medical history, weight, functional capacity, and other risk factors. For those who had died, information on the cause of death was obtained from death certificates. Results. Overweight in adolescent subjects was associated with an increased risk of mortality from all causes and disease-specific mortality among men, but not among women. The relative risks among men were 1.8 (95 percent confidence interval, 1.2 to 2.7; P = 0.004) for mortality from all causes and 2.3 (95 percent confidence interval, 1.4 to 4.1; P = 0.002) for mortality from coronary heart disease. The risk of morbidity from coronary heart disease and atherosclerosis was increased among men and women who had been overweight in adolescence. The risk of colorectal cancer and gout was increased among men and the risk of arthritis was increased among women who had been overweight in adolescence. Overweight in adolescence was a more powerful predictor of these risks than overweight in adulthood. Conclusions. Overweight in adolescence predicted a broad range of adverse health effects that were independent of adult weight after 55 years of follow-up.	GRAND VALLEY STATE UNIV, ALLENDALE, MI USA; TUFTS UNIV, USDA, HUMAN NUTR RES CTR, DIV BIOSTAT, BOSTON, MA 02111 USA; NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	Grand Valley State University; Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center	MUST, A (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR, EPIDEMIOL PROGRAM, 711 WASHINGTON ST, BOSTON, MA 02111 USA.							ABRAHAM S, 1971, HEALTH SERV REP, V86, P273, DOI 10.2307/4594149; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; COMSTOCK GW, 1986, AM J EPIDEMIOL, V124, P180, DOI 10.1093/oxfordjournals.aje.a114376; CRONK CE, 1982, AM J CLIN NUTR, V35, P347, DOI 10.1093/ajcn/35.2.347; DAVIS MA, 1990, SEMIN ARTHRITIS RHEU, V20, P34, DOI 10.1016/0049-0172(90)90045-H; DEARBORN WF, 1938, MONOGR SOC RES CHILD, V3; DEUTSCH MI, 1985, ANN HUM BIOL, V12, P275, DOI 10.1080/03014468500007781; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONAHUE RP, 1985, AM J EPIDEMIOL, V122, P458, DOI 10.1093/oxfordjournals.aje.a114127; FELSON DT, 1990, SEMIN ARTHRITIS RHEU, V20, P42, DOI 10.1016/0049-0172(90)90046-I; HARTZ AJ, 1986, J CHRON DIS, V39, P311, DOI 10.1016/0021-9681(86)90053-6; HAUST M D, 1990, Pediatric Pathology, V10, P253; HENRY RR, 1986, DIABETES, V35, P155, DOI 10.2337/diabetes.35.2.155; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; HOFFMANS MDAF, 1989, J CLIN EPIDEMIOL, V42, P513, DOI 10.1016/0895-4356(89)90147-9; KANNEL WB, 1984, J AM COLL NUTR, V3, P139; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LAPIDUS L, 1990, BRIT MED J, V10, P253; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1989, AM J EPIDEMIOL, V130, P833; MOSSBERG HO, 1989, LANCET, V2, P491; MUELLER WH, 1982, SOC SCI MED, V16, P191, DOI 10.1016/0277-9536(82)90022-3; PAFFENBARGER RS, 1973, AM J EPIDEMIOL, V97, P314, DOI 10.1093/oxfordjournals.aje.a121511; PAFFENBARGER RS, 1969, AM J EPIDEMIOL, V90, P527, DOI 10.1093/oxfordjournals.aje.a121099; SCOTT EC, 1982, HUM BIOL, V54, P501; SORENSEN TIA, 1977, J CHRON DIS, V30, P359, DOI 10.1016/0021-9681(77)90030-3; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; VANITALLIE TB, 1979, AM J CLIN NUTR, V32, P2723, DOI 10.1093/ajcn/32.12.2723; VOORS AW, 1982, ARTERIOSCLEROSIS, V2, P346, DOI 10.1161/01.ATV.2.4.346; WAALER HT, 1984, ACTA MED SCAND, P1; WEBBER LS, 1983, J CHRON DIS, V36, P647, DOI 10.1016/0021-9681(83)90081-4; WEBBER LS, 1991, AM J EPIDEMIOL, V133, P884, DOI 10.1093/oxfordjournals.aje.a115968; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; WILLETT W, 1990, MONOGRAPHS EPIDEMIOL, V15, P231; WYLIE CM, 1984, J AM GERIATR SOC, V32, P670, DOI 10.1111/j.1532-5415.1984.tb02258.x; 1990, NUTRITION YOUR HLTH; 1990, SAS STAT USERS GUIDE; 1980, INT CLASSIFICATION D; 1990, DHHS PHS901148 PUBL; 1990, NATIONAL HLTH NUTRIT, V3	44	1584	1638	1	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1350	1355		10.1056/NEJM199211053271904	http://dx.doi.org/10.1056/NEJM199211053271904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406836				2022-12-01	WOS:A1992JW07700004
J	NAGEL, G; HWANG, TC; NASTIUK, KL; NAIRN, AC; GADSBY, DC				NAGEL, G; HWANG, TC; NASTIUK, KL; NAIRN, AC; GADSBY, DC			THE PROTEIN KINASE-A-REGULATED CARDIAC CL- CHANNEL RESEMBLES THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR	NATURE			English	Article							CFTR CHLORIDE CHANNEL; AUTONOMIC REGULATION; MYOCYTES; GENE; EXPRESSION; CELLS; PHOSPHORYLATION; IDENTIFICATION; ADRENALINE; ACID	STIMULATION of beta-adrenoceptors in cardiac ventricular myocytes activates a strong chloride ion conductance1-5 as a result of phosphorylation by cyclic AMP-dependent protein kinase (PKA)2,4. This Cl- conductance, which is time- and voltage-independent1-5, counters2,5 the tendency of the simultaneously enhanced Ca2+ channel current to prolong the ventricular action potential. Using inside-out giant patches6 excised from guinea-pig myocytes, we show here that phosphorylation by the PKA catalytic subunit plus Mg-ATP elicits discrete Cl- channel currents. In almost symmetrical Cl- solutions (approximately 150 mM), unitary current amplitude scales with membrane potential, and reverses sign near 0 mV, to yield a single channel conductance of approximately 12 pS. Opening of the phosphorylated channels requires hydrolysable nucleoside triphosphate, indicating that phosphorylation by PKA is necessary, but not sufficient, for channel activation. The properties of these PKA-regulated cardiac Cl- channels are very similar, if not identical, to those of the cystic fibrosis transmembrane conductance regulator (CFTR)7, the epithelial cell Cl- channel whose regulation is defective in patients with cystic fibrosis. The full cardiological impact of these Cl- channels and of their possible malfunction in patients with cystic fibrosis remains to be determined.	ROCKEFELLER UNIV,CARDIAC MEMBRANE PHYSIOL LAB,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC & CELLULAR NEUROSCI LAB,NEW YORK,NY 10021	Rockefeller University; Rockefeller University				Nairn, Angus/0000-0002-7075-0195; Nagel, Georg/0000-0001-8174-8712				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; BENSON LN, 1984, AM REV RESPIR DIS, V130, P987; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CHERON G, 1984, ACTA PAEDIATR SCAND, V73, P697, DOI 10.1111/j.1651-2227.1984.tb09999.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; EHARA T, 1990, NATURE, V347, P284, DOI 10.1038/347284a0; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; Hilgemann D, 1991, SODIUM PUMP RECENT D, P543; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; Hwang Tzyh-Chang, 1992, Journal of General Physiology, V100, p69A; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; MATSUOKA S, 1990, J PHYSIOL-LONDON, V425, P579, DOI 10.1113/jphysiol.1990.sp018119; OVERHOLT J L, 1992, Biophysical Journal, V61, pA442; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 1989, MOL CLONING LAB MANU; SULLIVAN MM, 1986, CHEST, V90, P239, DOI 10.1378/chest.90.2.239; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417	30	162	165	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					81	84		10.1038/360081a0	http://dx.doi.org/10.1038/360081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1279437				2022-12-01	WOS:A1992JW71700061
J	NIKOLOV, DB; HU, SH; LIN, J; GASCH, A; HOFFMANN, A; HORIKOSHI, M; CHUA, NH; ROEDER, RG; BURLEY, SK				NIKOLOV, DB; HU, SH; LIN, J; GASCH, A; HOFFMANN, A; HORIKOSHI, M; CHUA, NH; ROEDER, RG; BURLEY, SK			CRYSTAL-STRUCTURE OF TFIID TATA-BOX BINDING-PROTEIN	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; CONSERVED DOMAIN; YEAST; GENE; INITIATION; CLONING	The structure of a central component of the eukaryotic transcriptional apparatus, a TATA-box binding protein (TBP or TFIIDtau) from Arabidopsis thaliana, has been determined by X-ray crystallography at 2.6 angstrom resolution. This highly symmetric alpha/beta structure contains a new DNA-binding fold, resembling a molecular 'saddle' that sits astride the DNA. The DNA-binding surface is a curved, antiparallel beta-sheet. When bound to DNA, the convex surface of the saddle would be presented for interaction with other transcription initiation factors and regulatory proteins.	ROCKEFELLER UNIV,MOLEC BIOPHYS LABS,1230 YORK AVE,NEW YORK,NY 10021; ROCKEFELLER UNIV,PLANT MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University				Burley, Stephen/0000-0002-2487-9713				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; FIKES JD, 1990, NATURE, V346, P291, DOI 10.1038/346291a0; GABRIELSEN OS, 1991, TRENDS BIOCHEM SCI, V16, P412, DOI 10.1016/0968-0004(91)90166-S; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; HAASS MM, 1992, FEBS LETT, V301, P294, DOI 10.1016/0014-5793(92)80260-N; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOFFMANN A, 1990, GENE DEV, V4, P1141, DOI 10.1101/gad.4.7.1141; HOLDSWORTH MJ, 1992, PLANT MOL BIOL, V19, P455, DOI 10.1007/BF00023393; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAGIRI F, 1992, TRENDS GENET, V8, P22, DOI 10.1016/0168-9525(92)90020-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MUHICH ML, 1990, P NATL ACAD SCI USA, V87, P9148, DOI 10.1073/pnas.87.23.9148; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REEDER RH, 1990, TRENDS GENET, V6, P390, DOI 10.1016/0168-9525(90)90298-K; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STUCKA R, 1990, FEBS LETT, V261, P223, DOI 10.1016/0014-5793(90)80558-Z; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKADA R, IN PRESS P NATN ACAD; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P58144; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	67	355	358	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					40	46		10.1038/360040a0	http://dx.doi.org/10.1038/360040a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1436073				2022-12-01	WOS:A1992JW71700046
J	QUILL, TE; CASSEL, CK; MEIER, DE				QUILL, TE; CASSEL, CK; MEIER, DE			CARE OF THE HOPELESSLY ILL - PROPOSED CLINICAL-CRITERIA FOR PHYSICIAN-ASSISTED SUICIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; DEATH; RESPONSIBILITY; NETHERLANDS		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; CUNY MT SINAI SCH MED, NEW YORK, NY 10029 USA	University of Rochester; University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BRAHAMS D, 1990, LANCET, V335, P591; Broadfield L, 1988, J Palliat Care, V4, P21; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CHARLSON ME, 1987, J GEN INTERN MED, V2, P359, DOI 10.1007/BF02596176; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; GEST T, 1990, US NEWS WORLD R 0709, P22; Glantz L H, 1987, Law Med Health Care, V15, P231; GLOVER J, 1977, CAUSING DEATH SAVING, P182; Gomez Carlos F., 1991, REGULATING DEATH EUT; HEILIG S, 1988, SAN FRANCISCO MED, V24, P34; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; LACHS J, 1976, NEW ENGL J MED, V294, P838, DOI 10.1056/NEJM197604082941513; LEENEN HJJ, 1990, BRIT MED J, V300, P69; MALCOLM A, 1990, NY TIMES        0614, pA6; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; NEWMAN SA, 1991, U PITT LAW REV, V53, P153; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2229; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; OVERMYER M, 1991, PHYSICIANS MANAGE, V31, P40; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; RACHELS J, 1975, NEW ENGL J MED, V292, P78, DOI 10.1056/NEJM197501092920206; REICHEL W, 1989, LANCET, V2, P1321; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; Schonwetter R S, 1990, Hosp J, V6, P65; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VAUX KL, 1988, JAMA-J AM MED ASSOC, V259, P2140, DOI 10.1001/jama.259.14.2140; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Weir R F, 1992, Law Med Health Care, V20, P116, DOI 10.1111/j.1748-720X.1992.tb01178.x; WOLF SM, 1989, HASTINGS CENT REP, V19, pS13; 1988, WITHHOLDING WITHDRAW; 1990, 1990 ROPER POLL PHYS; 1988, 1987 SURVEY CALIFORN; 1991, 1991 ROPER POLL W CO	42	221	220	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 5	1992	327	19					1380	1384		10.1056/NEJM199211053271911	http://dx.doi.org/10.1056/NEJM199211053271911			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW077	1406842				2022-12-01	WOS:A1992JW07700011
J	QUINTON, PM; REDDY, MM				QUINTON, PM; REDDY, MM			CONTROL OF CFTR CHLORIDE CONDUCTANCE BY ATP LEVELS THROUGH NONHYDROLYTIC BINDING	NATURE			English	Article							CYSTIC-FIBROSIS GENE; CHANNEL	SITE-SPECIFIC mutation1 and membrane reconstitution2 experiments provide compelling evidence that the product of the gene which is at fault in the disease cystic fibrosis, termed the cystic fibrosis transmembrane conductance regulator (CFTR)3, is a small-conductance chloride channel activated by phosphorylation4. As transport of chloride ions is passive, the predicted presence of two nucleotide-binding domains in CFTR seems as puzzling as a report5 that ATP hydrolysis is essential to activate the channel. We now find that in the sweat duct, which expresses high levels of CFTR6 and has a very high Cl- conductance7, intracellular concentrations of ATP must be about normal (5 mM)8 for activation of this conductance, apparently by a non-hydrolytic, perhaps allosteric, mechanism. This passive dependence on ATP should mean that even a modest depletion of cell energy levels will significantly lower the energy demands of electrolyte transport by decreasing chloride conductance. We believe this direct coupling between cellular ATP levels and chloride channel activity is an adaptive mechanism to protect the tissue from damage resulting from excessive energy depletion9.			QUINTON, PM (corresponding author), UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521, USA.							ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ATKINSON DE, 1977, METABOLISM ITS REGUL; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; KARTNER N, IN PRESS NATURE GENE; QUINTON PM, 1991, ADV EXP MED BIOL, V290, P159; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; THOMAS PJ, 1992, J BIOL CHEM, V267, P5727; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4	17	164	165	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 5	1992	360	6399					79	81		10.1038/360079a0	http://dx.doi.org/10.1038/360079a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JW717	1279436				2022-12-01	WOS:A1992JW71700060
J	BURSTIN, HR; LIPSITZ, SR; BRENNAN, TA				BURSTIN, HR; LIPSITZ, SR; BRENNAN, TA			SOCIOECONOMIC-STATUS AND RISK FOR SUBSTANDARD MEDICAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; HEALTH-INSURANCE; PREVENTIVE CARE; HEART-DISEASE; MASSACHUSETTS; AGE; PATTERNS; ACCESS; BOSTON	Objective.-To assess whether the socioeconomic status of the patient was associated with the risk of adverse events, defined as medical injuries caused by medical management, and the proportion of these events that resulted from substandard care. Setting.-51 hospitals in New York State. Methods.-Rates of medical injury and substandard care by gender, race, income, and payer status were developed from reviews of 30195 medical records in New York in 1984. We evaluated these socioeconomic parameters in a multivariate analysis, while controlling for hospital-level factors. Results.-We found that uninsured patients (odds ratio, 2.35; 95% confidence interval, 1.40 to 3.95) were at greater risk for substandard care. The characteristics of the hospitals to which patients were admitted did not affect this result. Race, gender, and income were not independently associated with risk for medical injury or substandard care in multivariate analyses. Conclusion.-Our findings suggest that the uninsured are at greater risk for suffering medical injury due to substandard medical care.	BRIGHAM & WOMENS HOSP,DIV GEN MED,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health								AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BENNETT CL, 1991, CANCER, V67, P2633, DOI 10.1002/1097-0142(19910515)67:10<2633::AID-CNCR2820671039>3.0.CO;2-9; BINDMAN AB, 1990, JAMA-J AM MED ASSOC, V264, P2899, DOI 10.1001/jama.264.22.2899; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BOMBARDIER C, 1977, NEW ENGL J MED, V297, P699, DOI 10.1056/NEJM197709292971305; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BRENNAN TA, 1991, JUST DOCTORING MED E; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; GREENBERGER NJ, 1991, BRIT MED J, V303, P1216, DOI 10.1136/bmj.303.6812.1216; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HELLER TA, 1984, J AM GERIATR SOC, V32, P782, DOI 10.1111/j.1532-5415.1984.tb06297.x; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LAMMER EJ, 1989, JAMA-J AM MED ASSOC, V261, P1757, DOI 10.1001/jama.261.12.1757; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; SHAH BV, 1981, SESUDAAN STANDARD ER; SHAH BV, 1984, RTI LOGIT PROCEDURE; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, STATEWIDE PLANNING R; 1985, AM HOSPITAL ASS GUID; 1984, 1984 SOURCEBOOK ZIP	32	193	192	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2383	2387		10.1001/jama.268.17.2383	http://dx.doi.org/10.1001/jama.268.17.2383			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404794				2022-12-01	WOS:A1992JV69400023
J	RECKER, RR; DAVIES, KM; HINDERS, SM; HEANEY, RP; STEGMAN, MR; KIMMEL, DB				RECKER, RR; DAVIES, KM; HINDERS, SM; HEANEY, RP; STEGMAN, MR; KIMMEL, DB			BONE GAIN IN YOUNG-ADULT WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL-CONTRACEPTIVE USE; MOTHER-DAUGHTER PAIRS; BIRTH-CONTROL PILLS; MINERAL CONTENT; PHYSICAL-ACTIVITY; LUMBAR SPINE; GENETIC-DETERMINANTS; PREMENOPAUSAL WOMEN; CALCIUM BALANCE; NORMAL-CHILDREN	Objective.-To test whether bone mass increases in healthy nonpregnant white women during early adult life after cessation of linear growth; and to test whether various self-chosen levels of physical activity and nutrient intake or use of oral contraceptives influences this increase in bone mass. Design.-Longitudinal prospective study of up to 5 years of 156 healthy college-aged women full-time students attending professional schools in universities in the Omaha, Neb, area. Setting.-University medical center. Participants.-A convenience sample of healthy women students from Omaha-area professional schools. Any candidate with an illness, condition, or medication (except oral contraceptives) thought to affect general health or bone mass was excluded. Interventions.-None. Outcome Measures.-Clinical and family histories of disease, particularly osteoporosis; oral contraceptive use; bone mineral densities of the spine, forearm, and total body by dual- and single-photon absorptiometry; estimates of nutrient intake by repeated 7-day diet diaries; and measures of physical activity using a physical activity monitor. Results.-The median gain in bone mass for the third decade of life, expressed as a percentage per decade, was 4.8% for the forearm, 5.9% for lumbar bone mineral content, 6.8% for lumbar bone mineral density, and 12.5% for total body bone mass (P<.0001 in all cases). By both bivariate and multiple regression analysis the rate of gain in bone density of the spine was negatively correlated with age and positively correlated with calcium/protein intake ratio and physical activity (multiple r=.31; P=.004). Bivariate analysis showed that use of oral contraceptives was associated with greater gain in total body bone mass (r=.31, P=.01). The estimated age when mineral acquisition ceased ranged from 28.3 years to 29.5 years at the several study sites. Conclusions.-Gain in bone mass occurs in healthy young women during the third decade of life. Physical activity and dietary calcium intake both exert a positive effect on this bone gain. Use of oral contraceptives exerts a further independent positive effect. Changes in life-style among college-aged women, involving relatively modest increases in physical activity and calcium intake, may significantly reduce the risk of osteoporosis late in life.			RECKER, RR (corresponding author), CREIGHTON UNIV,SCH MED,CTR HARD TISSUE RES,601 N 30TH ST,OMAHA,NE 68131, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032462] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-32462] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALOIA JF, 1985, J LAB CLIN MED, V106, P630; BLACK DM, 1992, J BONE MINER RES, V7, P639; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BUCHANAN JR, 1988, J BONE MINER RES, V3, P673, DOI 10.1002/jbmr.5650030613; BUCHANAN JR, 1988, J BONE MINER RES, V3, P583; CAMERON J, 1964, SCIENCE, V142, P27; COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, CLIN ORTHOPAEDICS, V252, P163; DAVEE AM, 1990, J BONE MINER RES, V5, P245, DOI 10.1002/jbmr.5650050307; DEQUEKER J, 1987, BONE, V8, P207, DOI 10.1016/8756-3282(87)90166-9; ELDERS PJM, 1989, BONE MINER, V7, P289, DOI 10.1016/0169-6009(89)90085-8; EPKER B. N., 1965, CLIN ORTHOP RELAT RES, V41, P198; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Garn S.M., 1970, EARLIER GAIN LATER L; GEUSENS P, 1986, J NUCL MED, V27, P1540; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; GLASTRE C, 1990, J CLIN ENDOCR METAB, V70, P1330, DOI 10.1210/jcem-70-5-1330; HEANEY RP, 1982, J LAB CLIN MED, V99, P46; HRESHCHYSHYN MM, 1988, AM J OBSTET GYNECOL, V159, P318, DOI 10.1016/S0002-9378(88)80075-9; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1985, GROWTH, V49, P34; JOHANSEN JS, 1989, BONE MINER, V6, P77, DOI 10.1016/0169-6009(89)90025-1; KANDERS B, 1988, J BONE MINER RES, V3, P145; Kelly P J, 1990, Osteoporos Int, V1, P56, DOI 10.1007/BF01880417; KLESGES RC, 1985, AM J EPIDEMIOL, V122, P400, DOI 10.1093/oxfordjournals.aje.a114121; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LANDIN L, 1981, ACTA PAEDIATR SCAND, V70, P919, DOI 10.1111/j.1651-2227.1981.tb06251.x; LINDSAY R, 1986, CONTRACEPTION, V34, P333, DOI 10.1016/0010-7824(86)90086-7; LLOYD T, 1989, AM J OBSTET GYNECOL, V160, P402, DOI 10.1016/0002-9378(89)90457-2; LUTZ J, 1986, AM J CLIN NUTR, V44, P99, DOI 10.1093/ajcn/44.1.99; LUTZ J, 1990, AM J CLIN NUTR, V52, P872, DOI 10.1093/ajcn/52.5.872; MALLETTE LE, 1989, J BONE MINER RES, V4, P143; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; MELTON LJ, 1986, AM J EPIDEMIOL, V124, P254, DOI 10.1093/oxfordjournals.aje.a114383; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MILER J, 1991, J BONE MINER RES S, V6, P136; MOLLER M, 1978, CALC TISS RES, V25, P197, DOI 10.1007/BF02010768; MONTOYE HJ, 1983, MED SCI SPORT EXER, V15, P403; NILAS L, 1988, BONE MINER, V4, P95; PICARD D, 1988, BONE MINER, V4, P299; POCOCK NA, 1988, J BONE MINER RES, V3, P601; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; POLLITZER WS, 1989, AM J CLIN NUTR, V50, P1244, DOI 10.1093/ajcn/50.6.1244; Recker R R, 1990, J Bone Miner Res, V5, P307; RECKER RR, 1992, J BONE MINER RES, V7, P857; RIGGS BL, 1986, J CLIN INVEST, V77, P1487, DOI 10.1172/JCI112462; RIGGS BL, 1981, J CLIN INVEST, V67, P326; RODIN A, 1990, BONE, V11, P1, DOI 10.1016/8756-3282(90)90064-6; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SNOWHARTER C, 1990, J BONE MINER RES, V5, P589; STEGMAN M, IN PRESS OSTEOPOROSI; TYLAVSKY FA, 1989, CALCIFIED TISSUE INT, V45, P265, DOI 10.1007/BF02556017; WAHNER HW, 1985, RADIOLOGY, V156, P203, DOI 10.1148/radiology.156.1.4001406; WASHBURN RA, 1988, RES Q EXERCISE SPORT, V59, P83, DOI 10.1080/02701367.1988.10605479	60	599	612	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2403	2408		10.1001/jama.268.17.2403	http://dx.doi.org/10.1001/jama.268.17.2403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV694	1404797				2022-12-01	WOS:A1992JV69400026
J	WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM				WEISSMAN, JS; GATSONIS, C; EPSTEIN, AM			RATES OF AVOIDABLE HOSPITALIZATION BY INSURANCE STATUS IN MASSACHUSETTS AND MARYLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CASE-MIX; HEALTH; MORTALITY; QUALITY; AREA; INTERVENTION; SERVICES; DISTRICT; PAYMENT	Objective.-To determine whether uninsured and Medicaid patients have higher rates of avoidable hospitalizations than do insured patients. Design.-We used 1987 computerized hospital discharge data to select a cross-sectional sample of hospitalized patients. Population estimates from the Current Population Survey were used to estimate rates of admission, standardized for age and sex. Setting.-Nonfederal acute care hospitals in Massachusetts and Maryland. Patients.-All patients under 65 years of age who were uninsured, privately insured, or insured by Medicaid. Hospitalizations for obstetric and psychiatric conditions were excluded. Main Outcome Measures.-Relative risk of admission for 12 avoidable hospital conditions (AHCs) identified by a physician panel. Results.-Uninsured and Medicaid patients were more likely than insured patients to be hospitalized for AHCs. Rates for uninsured patients were significantly greater than for privately insured patients in Massachusetts for 10 of 12 individual AHCs, and in Maryland for five of 12 AHCs. After adjustment for baseline utilization, the results were statistically significant for 10 of 12 AHCs in Massachusetts and seven of 12 AHCs in Maryland. For Medicaid patients, rates were significantly greater than for privately insured patients for all AHCs in each state before adjustment, and for nine of 12 and seven of 12 AHCs in each state, respectively, after adjustment for baseline utilization. Conclusion.-Our findings suggest that patients who are uninsured or who have Medicaid coverage have higher rates of hospitalization for conditions that can often be treated out of hospital or avoided altogether. Our approach is potentially useful for routine monitoring of access and quality of care for selected groups of patients.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					AHRQ HHS [R01 HS06235] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; Brown E R, 1989, Med Care Rev, V46, P349, DOI 10.1177/107755878904600402; BUCK C, 1986, INT J HEALTH SERV, V16, P553, DOI 10.2190/QWWN-518N-5VFC-6272; CARR W, 1988, SERIES UNITED HOSPIT, V8, P5; CHARLTON JRH, 1983, LANCET, V1, P691; CHRISTOFFERSSON J, 1986, DRG MONITOR, V6, P1; Craddick J W, 1979, QRB Qual Rev Bull, V5, P2; DIEHR P, 1990, HEALTH SERV RES, V24, P741; GARFINKEL S, 1986, 20213 DEP HLTH HUM B; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; Howell E M, 1991, Health Care Financ Rev, V12, P1; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARTINI CJM, 1977, INT J HEALTH SERV, V7, P293, DOI 10.2190/XFYT-R576-0R6C-RJ4M; MOYER ME, 1989, HEALTH AFFAIR, V8, P102, DOI 10.1377/hlthaff.8.2.102; NEWHOUSE JP, 1991, HLTH SERVICES RES KE, P161; PERLOFF JD, 1987, J HEALTH POLIT POLIC, V12, P221, DOI 10.1215/03616878-12-2-221; Roos N P, 1988, Health Care Financ Rev, V9, P53; RUNDALL T, 1991, 119TH ANN M AM PUBL; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; RUTSTEIN DD, 1977, NEW ENGL J MED, V297, P508; SCHWARTZ E, 1990, INT J EPIDEMIOL, V19, P591, DOI 10.1093/ije/19.3.591; SOLBERG LI, 1990, INQUIRY-J HEALTH CAR, V27, P359; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOLHANDLER S, 1985, INT J HEALTH SERV, V15, P1, DOI 10.2190/90P3-LEFF-WNU0-GLY6; YERGAN J, 1988, MED CARE, V26, P1111, DOI 10.1097/00005650-198811000-00009; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1989, INT CLASSIFICATION D; 1987, SPECIAL REPORT ACCES, P2; 1989, CURRENT POPULATION S	37	515	519	2	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	1992	268	17					2388	2394		10.1001/jama.268.17.2388	http://dx.doi.org/10.1001/jama.268.17.2388			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV694	1404795				2022-12-01	WOS:A1992JV69400024
J	TARAGIN, MI; WILLETT, LR; WILCZEK, AP; TROUT, R; CARSON, JL				TARAGIN, MI; WILLETT, LR; WILCZEK, AP; TROUT, R; CARSON, JL			THE INFLUENCE OF STANDARD OF CARE AND SEVERITY OF INJURY ON THE RESOLUTION OF MEDICAL MALPRACTICE CLAIMS	ANNALS OF INTERNAL MEDICINE			English	Article						MALPRACTICE; SEVERITY OF ILLNESS INDEX; INSURANCE, LIABILITY; JURISPRUDENCE; PROFESSIONAL PRACTICE	PHYSICIANS	Objective: To explore how frequently physicians lose medical malpractice cases despite providing standard care and to assess whether severity of patient injury influences the frequency of plaintiff payment. Design: Retrospective cohort study. Setting: Physicians from the state of New Jersey insured by one insurance company from 1977 to 1992. Participants: A total of 12 829 physicians involved in 8231 closed malpractice cases. Measurements: Physician care and claim severity were prospectively determined by the insurance company using a standard process. Results: Physician care was considered defensible in 62% of the cases and indefensible in 25% of the cases, in almost half of which the physician admitted error. In the remaining 13% of cases, it was unclear whether physician care was defensible. The plaintiff received a payment in 43% of all cases. Payment was made 21 % of the time if physician care was considered defensible, 91% if considered indefensible, and 59% if considered unclear. The severity of the injury was classified as low, medium, or high in 28%, 47%, and 25% of the cases, respectively. Severity of injury had a small but significant association (P < 0.001) with the frequency of plaintiff payment (low severity, 39%; medium severity, 43%; and high severity, 47%). The severity of injury was not associated with the payment rate in cases resolved by a jury (low severity, 23%; medium severity, 25%; and high severity, 23%). Conclusions: In malpractice cases, physicians provide care that is usually defensible. The defensibility of the case and not the severity of patient injury predominantly influences whether any payment is made. Even in cases that require a jury verdict, the severity of patient injury has little effect on whether any payment is made. Our findings suggest that unjustified payments are probably uncommon.	UNIV MED & DENT NEW JERSEY, COOK COLL, NEW BRUNSWICK, NJ 08903 USA; NEW JERSEY MED INTERINSURANCE EXCHANGE, LAWRENCEVILLE, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	TARAGIN, MI (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DIV GEN INTERNAL MED, 97 PATERSON ST, NEW BRUNSWICK, NJ 08903 USA.							Boggs J S, 1987, J Fla Med Assoc, V74, P767; BOVBJERG RR, 1991, JAMA-J AM MED ASSOC, V265, P2836, DOI 10.1001/jama.265.21.2836; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; CHENEY FW, 1989, JAMA-J AM MED ASSOC, V261, P1599, DOI 10.1001/jama.261.11.1599; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; SAMUEL FE, 1986, LIABILITY THREAT SLO; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SLOAN FA, 1990, LAW SOC REV, V24, P997, DOI 10.2307/3053617; TARAGIN MI, 1992, IN PRESS AM J MED, P93; WEISS BD, 1986, J FAM PRACTICE, V23, P55; 1987, CONTINUING NEED LEGI; 1987, GAOHRD8755 GEN ACC O; 1989, AM MED NEWS     0106; 1987, GAOHRD8721 GEN ACC O; 1984, PHYSICIAN CHARACTERI; 1986, GAOHRD8650 GEN ACC O	18	118	118	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					780	784		10.7326/0003-4819-117-9-780	http://dx.doi.org/10.7326/0003-4819-117-9-780			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1308760				2022-12-01	WOS:A1992JV42400013
J	WILLIAMS, JW; SIMEL, DL; ROBERTS, L; SAMSA, GP				WILLIAMS, JW; SIMEL, DL; ROBERTS, L; SAMSA, GP			CLINICAL-EVALUATION FOR SINUSITIS - MAKING THE DIAGNOSIS BY HISTORY AND PHYSICAL-EXAMINATION	ANNALS OF INTERNAL MEDICINE			English	Article						SINUSITIS; TRANSILLUMINATION; RHINITIS; DIAGNOSIS, DIFFERENTIAL; TOOTHACHE	ACUTE MAXILLARY SINUSITIS; BACTERIAL SINUSITIS	Objective: To identify the most useful clinical examination findings for the diagnosis of acute and subacute sinusitis. Design: Prospective comparison of clinical findings with radiographs. Setting: General medicine clinics at a university-affiliated Veterans Affairs Medical Center. Patients: Two hundred forty-seven consecutive adult men with rhinorrhea (51%), facial pain (22%), or self-suspected sinusitis (27%) (median age, 50 years; median duration of symptoms, 11.5 days). Measurements: Patients were examined by a principal investigator (86%) or by a staff general internist, internal medicine resident (postgraduate year 2 or 3), or physician assistant, all blinded to radiographic results. All examiners recorded the presence or absence of 16 historical items, 5 physical examination items, and the clinical impression for sinusitis (high, intermediate, or low probability). The criterion standard was paranasal sinus radiographs (4 views), which were interpreted by radiologists blinded to clinical findings. Results: Thirty-eight percent of patients meeting entrance criteria had sinusitis. Sensitivity, specificity, and likelihood ratios were measured for clinical items. Logistic regression analysis showed five independent predictors of sinusitis: maxillary toothache (odds ratio, 2.9), transillumination (odds ratio, 2.7), poor response to nasal decongestants or antihistamines (odds ratio, 2.4), colored nasal discharge reported by the patient (odds ratio, 2.2), or mucopurulence seen during examination (odds ratio, 2.9). The overall clinical impression was more accurate than any single finding: high probability (likelihood ratio, 4.7), intermediate (likelihood ratio, 1.4), low probability (likelihood ratio, 0.4). Conclusions: General internists, focusing on five clinical findings and their overall clinical impression, can effectively stratify male patients with sinus symptoms as having a high, intermediate, or low probability of sinusitis.	VET ADM MED CTR, DURHAM, NC 27705 USA; DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University of Texas System; University of Texas Health San Antonio	WILLIAMS, JW (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR, 11C, 7400 MERTON MINTER BLVD, SAN ANTONIO, TX 78284 USA.		Williams, John W/A-3696-2008; Williams, John/AAM-4572-2020	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558				AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; AXELSSON A, 1983, ANN OTO RHINOL LARYN, V92, P75, DOI 10.1177/000348948309200118; AXELSSON A, 1974, AM J ROENTGENOL, V122, P621, DOI 10.2214/ajr.122.3.621; BALLINGER PW, 1991, MERRILLS ATLAS RADIO, P364; BATES B, 1991, PHYSICAL EXAMINATION, P189; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FLEISS JL, 1981, STATISTICAL METHODS, P112; GLECKMAN RA, 1986, HOSP PRACT, V21, P92; GLECKMAN RA, 1986, HOSPITAL PRACT, V21, P100; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1990, SAS STAT USERS GUIDE, P175; HARVEY BS, 1987, PRIMARY CARE MED, P883; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; Hosmer D., 1989, APPL LOGISTIC REGRES, P82; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MEYERS BR, 1984, J FAM PRACTICE, V18, P117; NORRBY R, 1983, SCAND J INFECT DIS, P14; Ramsey P G, 1985, Emerg Med Clin North Am, V3, P143; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; WALD ER, 1986, PEDIATRICS, V77, P795; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WILLIAMS JW, 1992, IN PRESS J GEN INTER, P6; YARINGTON CT, 1979, OTOLARYNG CLIN N AM, V12, P447	32	180	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1992	117	9					705	710		10.7326/0003-4819-117-9-705	http://dx.doi.org/10.7326/0003-4819-117-9-705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV424	1416571				2022-12-01	WOS:A1992JV42400001
J	BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH				BRANGER, PJ; VANDERWOUDEN, JC; SCHUDEL, BR; VERBOOG, E; DUISTERHOUT, JS; VANDERLEI, J; VANBEMMEL, JH			ELECTRONIC COMMUNICATION BETWEEN PROVIDERS OF PRIMARY AND SECONDARY CARE	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; SPECIALISTS	Objective-To study the effects of the introduction of electronic data interchange between primary and secondary care providers on speed of communication, efficiency of data handling, and satisfaction of general practitioners with communication. Design-Comparison of traditional paper based communication for laboratory reports and admission-discharge reports between hospital and general practitioners and electronic data interchange. Setting-Twenty-seven general practitioners whose offices were equipped with a practice information system and two general hospitals. Outcome measures-Paper based communication was evaluated by questionnaire responses from and interviews with care providers; electronic communication was evaluated by measuring time intervals between generation and delivery of messages and by assessing doctors' satisfaction with electronic data interchange by questionnaire. Results-Via paper mail admission-discharge reports took a median of 2-4 days, and laboratory reports 2 days, to reach general practitioners. With electronic data interchange almost all admission-discharge reports were available to general practitioners within one hour of generation. When samples were analysed on the day of collection (as was the case for 174/542 samples in one hospital and 443/854 in the other) the laboratory reports were also available to the general practitioner the same day via electronic data interchange. Fifteen general practitioners (of the 24 who returned the questionnaire) reported that the use of electronic admission-discharge reports provided more accurate and complete information about the care delivered to their patients. Ten general practitioners reported that electronic laboratory reports lessened the work of processing the data. Conclusion-Electronic communication between primary and secondary care providers is a feasible option for improving communication.	ERASMUS UNIV,DEPT GEN PRACTICE,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	BRANGER, PJ (corresponding author), ERASMUS UNIV,DEPT MED INFORMAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		van der Wouden, Johannes C/O-5109-2019; van der Wouden, Johannes C/C-2597-2009; Greiver, Michelle/N-8764-2015	van der Wouden, Johannes C/0000-0001-6639-6050; Greiver, Michelle/0000-0001-8957-0285				AMENT A, 1990, LECTURE NOTES MED IN, V40, P130; DOELEMAN F, 1987, FAM PRACT, V4, P176, DOI 10.1093/fampra/4.3.176; DUISTERHOUT JS, 1991, TELEMATICS IN MEDICINE, P151; HULL FM, 1986, BRIT MED J, V293, P311, DOI 10.1136/bmj.293.6542.311; JACOBS LGH, 1990, BRIT MED J, V301, P470, DOI 10.1136/bmj.301.6750.470; KINKHORST OM, 1991, TELEMATICS IN MEDICINE, P313; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; SANDLER DA, 1987, BRIT MED J, V295, P1523, DOI 10.1136/bmj.295.6612.1523; TULLOCH AJ, 1975, BRIT MED J, V4, P443, DOI 10.1136/bmj.4.5994.443; WALKER RJ, 1989, 1ST STEPS EDI; WESTERHOF HP, 1987, LECTURE NOTES MED IN, P1; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445; WILLIAMS EI, 1990, BRIT MED J, V300, P159, DOI 10.1136/bmj.300.6718.159; 1988, ISO9735 UN EC COMM E	14	76	77	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1068	1070		10.1136/bmj.305.6861.1068	http://dx.doi.org/10.1136/bmj.305.6861.1068			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467688	Bronze, Green Published			2022-12-01	WOS:A1992JW70100021
J	BROWN, MM; HUMPHREY, PRD				BROWN, MM; HUMPHREY, PRD			CAROTID ENDARTERECTOMY - RECOMMENDATIONS FOR MANAGEMENT OF TRANSIENT ISCHEMIC ATTACK AND ISCHEMIC STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANGIOGRAPHY		WALTON HOSP, DEPT NEUROL, LIVERPOOL L9 1AE, MERSEYSIDE, ENGLAND	Walton Centre	BROWN, MM (corresponding author), ST GEORGE HOSP, SCH MED, DIV CLIN NEUROSCI, LONDON SW17 0RE, ENGLAND.		Brown, Martin M/B-3288-2009	Brown, Martin M/0000-0002-3273-1356				BORGSTEIN RL, 1991, CLIN RADIOL, V44, P402, DOI 10.1016/S0009-9260(05)80659-2; CAPLAN LR, 1991, AM J NEURORADIOL, V12, P593; DENNIS M, 1991, BRIT MED J, V303, P636, DOI 10.1136/bmj.303.6803.636; DENNIS MS, 1989, STROKE, V20, P333, DOI 10.1161/01.STR.20.3.333; HANKEY GJ, 1990, BMJ-BRIT MED J, V300, P1485, DOI 10.1136/bmj.300.6738.1485; HUMPHREY P, 1990, J NEUROL NEUROSUR PS, V53, P966, DOI 10.1136/jnnp.53.11.966; KRETSCHMER G, 1990, ANN SURG, V211, P317, DOI 10.1097/00000658-199003000-00002; MURIE J, 1991, HOSPTIAL UPDATE  JUL, P557; MURIE JA, 1986, BRIT J SURG, V73, P867, DOI 10.1002/bjs.1800731103; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; 1988, BMJ, V296, P320	12	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 31	1992	305	6861					1071	1074		10.1136/bmj.305.6861.1071	http://dx.doi.org/10.1136/bmj.305.6861.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467689	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JW70100022
J	DEMORAES, JC; PERKINS, BA; CAMARGO, MCC; HIDALGO, NTR; BARBOSA, HA; SACCHI, CT; GRAL, IML; GATTAS, VL; VASCONCELOS, HD; PLIKAYTIS, BD; WENGER, JD; BROOME, CV				DEMORAES, JC; PERKINS, BA; CAMARGO, MCC; HIDALGO, NTR; BARBOSA, HA; SACCHI, CT; GRAL, IML; GATTAS, VL; VASCONCELOS, HD; PLIKAYTIS, BD; WENGER, JD; BROOME, CV			PROTECTIVE EFFICACY OF A SEROGROUP-B MENINGOCOCCAL VACCINE IN SAO-PAULO, BRAZIL	LANCET			English	Article							DISEASE	Serogroup B Neisseria meningitidis is the most common cause of epidemic meningococcal disease in developed countries. Until recently no vaccine has been available for prevention of infection with this organism. In an attempt to control epidemic serogroup B meningococcal disease in greater Sao Paulo, Brazil, during 1989 and 1990, a Cuban-produced outer-membrane-protein-based serogroup B meningococcal vaccine was given to about 2.4 million children aged from 3 months to 6 years. We have done a case-control study to estimate the efficacy of the vaccine in greater Sao Paulo. Microbiologically confirmed cases of serogroup B meningococcal disease were identified through hospital-based surveillance. Controls were matched by neighbourhood and age. Vaccination status was confirmed by inspection of vaccination cards. Between June, 1990, and June, 1991, 112 patients and 409 matched controls with confirmed vaccine status were enrolled. Estimated vaccine efficacy varied by age: 48 months or older = 74% (95% CI 16 to 92%), 24 to 47 months = 47% (-72 to 84%), and less than 24 months = -37% (< - 100 to 73%). Our results suggest that the Cuban-produced vaccine may be effective for prevention of serogroup B meningococcal disease in older children and adults.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,BLDG 1,ROOM 4409,ATLANTA,GA 30333; CTR DIS CONTROL,OFF DIRECTOR,ATLANTA,GA 30333; SAO PAULO STATE DEPT HLTH,CTR EPIDEMIOL SURVEILLANCE,SAO PAULO,BRAZIL; SAO PAULO DEPT HLTH,ADOLFO LUTZ INST,SAO PAULO,BRAZIL	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Universidade Estadual Paulista; Instituto Adolfo Lutz			Gattas, Vera Lucia/B-7956-2018; MORAES, JOSE C/H-6788-2012	Gattas, Vera Lucia/0000-0001-5032-4570; Tavares Sacchi, Claudio/0000-0002-5686-7979				[Anonymous], 1982, EPIDEMIOLOGIC RES; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; Frasch CE, 1983, MED TROP, V43, P177; FRASCH CE, 1983, MED MICROBIOLOGY, V2, P115; NOVO MV, 1991, ENFERMEDAD MENINGOCO; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; PELTOLA H, 1983, REV INFECT DIS, V5, P71; PINNER RW, 1991, J INFECT DIS, V164, P368, DOI 10.1093/infdis/164.2.368; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; SIERRA VG, 1991, 7TH P INT PATH NEISS; ZOLLINGER W D, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P211; 1989, MMWR, V38, P205; 1985, MMWR, V34, P255; 1989, MMWR, V38, P219	18	279	308	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1074	1078						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357461				2022-12-01	WOS:A1992JV77500011
J	EMSON, HE				EMSON, HE			A RIGHT TO REPRODUCE	LANCET			English	Editorial Material											EMSON, HE (corresponding author), ROYAL UNIV HOSP SASKATOON,DEPT PATHOL,SASKATOON S7N 0X0,SASKATCHEWAN,CANADA.							[Anonymous], 1992, LANCET, V339, P1515; EMSON HE, 1992, J APPL PHILOS, V9, P3	2	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1083	1083		10.1016/0140-6736(92)93089-6	http://dx.doi.org/10.1016/0140-6736(92)93089-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357463				2022-12-01	WOS:A1992JV77500013
J	FORSBLOM, CM; GROOP, PH; EKSTRAND, A; GROOP, LC				FORSBLOM, CM; GROOP, PH; EKSTRAND, A; GROOP, LC			PREDICTIVE VALUE OF MICROALBUMINURIA IN PATIENTS WITH INSULIN-DEPENDENT DIABETES OF LONG DURATION	BRITISH MEDICAL JOURNAL			English	Article							NEPHROPATHY	Objective-To investigate the predictive value of microalbuminuria (albumin excretion rate 30-300 mg/24 h) as a risk factor for overt diabetic nephropathy in patients with longstanding insulin dependent diabetes. Design-10 year follow up of patients with normoalbuminuria (albumin excretion rate < 30 mg/24 h), microalbuminuria (30-300 mg/24 h), and macroalbuminuria (> 300 mg/24 h) based on two out of three timed overnight urine samples. Setting-Outpatient clinic of Helsinki University Hospital. Subjects-72 consecutive patients who had had insulin dependent diabetes for over 15 years. Main outcome measures-Urinary albumin excretion rate, mortality, and prevalence of diabetic complications after 10 years. Results-56 patients were re-examined at 10 year follow up, 10 had died, five were lost to follow up, and one was excluded because of non-diabetic kidney disease. At initial screening 22 patients had macroalbuminuria, 18 had microalbuminuria, and 26 had normal albumin excretion. Only five (28%, 95% confidence interval 10% to 54%) of the microalbuminuric patients developed macroalbuminuria during the 10 year follow up and none developed end stage renal failure. Two (8%, 1% to 25%) normoalbuminuric patients developed macroalbuminuria and four (15%, 4% to 35%) became microalbuminuric. Seven (32%, 14% to 55%) of the macroalbuminuric patients developed end stage renal failure and six (27%, 11% to 50%) died of cardiovascular complications. Conclusion-Microalbuminuria is not a good predictor of progression to overt nephropathy in patients with longstanding insulin dependent diabetes.	HELSINKI UNIV HOSP,DEPT MED 4,UNIONINKATU 38,SF-00170 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital								ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; TEPPO AM, 1982, CLIN CHEM, V28, P1359; VIBERTI GC, 1982, LANCET, V1, P1430	6	137	140	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1051	1053		10.1136/bmj.305.6861.1051	http://dx.doi.org/10.1136/bmj.305.6861.1051			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467683	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JW70100016
J	MATSUMURA, Y; TARIN, D				MATSUMURA, Y; TARIN, D			SIGNIFICANCE OF CD44 GENE-PRODUCTS FOR CANCER-DIAGNOSIS AND DISEASE EVALUATION	LANCET			English	Article							CELLS	With increasing emphasis on the early detection of cancer, the search is on for reliable markers that will be clinically helpful in the diagnosis of small tumours and in the assessment of their metastatic potential. This report presents evidence that an abnormal pattern of activity of the CD44 gene is a promising candidate for both of these purposes in various types of malignancy. By a mechanism known as alternative splicing this gene can produce different messenger RNA molecules (transcripts) which are detectable, after amplification, as separate bands in electrophoretic gels. In neoplasia many abnormal variant transcripts are produced. A previous finding in animal experiments, that one such variant might be important in metastasis, prompted our study of human tumour tissue, benign and malignant, and of corresponding normal tissues. We studied tumour tissue from 34 patients with neoplastic disease (mostly breast or colon cancer) and normal or non-malignant diseased breast or colonic tissue from 11 patients and peripheral blood leucocytes from 4 healthy volunteers. CD44 gene activity was studied by amplifying messenger RNA with the polymerase chain reaction (PCR) followed by electrophoresis and blot hybridisation. In malignant tissues there was gross overproduction of each of 9 or more alternatively-spliced large molecular variants in all samples, whereas in the control samples only the standard product was routinely detected with occasional minimal quantities of one or two small variants. Furthermore, the band pattern permitted differentiation between the 23 cases with metastatic tumours of the breast or colon and the 8 with no detectable metastases. Calibration studies seeding blood with tumour cells showed that the technique can detect as few as 10 tumour cells among 10(7) leucocytes (1 ml of blood). Analysis of CD44 splice variants may prove to have applications not just to the early detection of metastatic potential in surgical biopsy specimens but also, if our findings are confirmed, in readily available bodily fluids, to the early diagnosis of cancer in screening programmes, to the assessment of remaining disease in the body and to the early detection of recurrences.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT PATHOL,OXFORD OX3 9DU,ENGLAND	University of Oxford			Matsumura, Yasuhiro/N-4472-2016					BIRCH M, 1991, CANCER RES, V51, P6660; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROST P, 1992, LANCET, V339, P1458, DOI 10.1016/0140-6736(92)92040-M; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HOFMANN M, 1991, CANCER RES, V51, P5292; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859	11	452	480	1	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1053	1058		10.1016/0140-6736(92)93077-Z	http://dx.doi.org/10.1016/0140-6736(92)93077-Z			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357452				2022-12-01	WOS:A1992JV77500002
J	NAYLOR, JA; GREEN, PM; RIZZA, CR; GIANNELLI, F				NAYLOR, JA; GREEN, PM; RIZZA, CR; GIANNELLI, F			FACTOR-VIII GENE EXPLAINS ALL CASES OF HEMOPHILIA-A	LANCET			English	Note							HEMOPHILIA-A; MUTATIONS; HALF	Using an mRNA-based method to examine haemophilia A mutations we provide an explanation for the puzzling report that half of the mutations causing severe disease are not detected by analysis of the putative promoter, exons, and most exon/intron boundaries of the factor VIII gene. An unusual cluster of mutations involving regions of intron 22 not examined earlier leads to defective joining of exons 22 and 23 in the mRNA and caused haemophilia A in 10/24 severely affected UK patients.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LJ,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford								GITSCHIER J, 1991, THROMB HAEMOSTASIS, V65, P662; HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; MONTANDON AJ, 1989, NUCLEIC ACIDS RES, V17, P3347, DOI 10.1093/nar/17.9.3347; NAYLOR JA, 1991, LANCET, V337, P635, DOI 10.1016/0140-6736(91)92450-G; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P1612, DOI 10.1001/jama.266.12.1612; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331	7	71	72	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1066	1067		10.1016/0140-6736(92)93080-7	http://dx.doi.org/10.1016/0140-6736(92)93080-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357455				2022-12-01	WOS:A1992JV77500005
J	RIMPELA, AH; RIMPELA, MK; KOSUNEN, EAL				RIMPELA, AH; RIMPELA, MK; KOSUNEN, EAL			USE OF ORAL-CONTRACEPTIVES BY ADOLESCENTS AND ITS CONSEQUENCES IN FINLAND 1981-91	BRITISH MEDICAL JOURNAL			English	Article							TEENAGE PREGNANCY; UNITED-STATES; WOMEN; COUNTRIES; DISEASE; AGE	Objectives-To study use of oral contraceptives among Finnish teenagers during 1981-91 and how abortions, childbirths, sexually transmitted diseases, and cardiovascular diseases changed during this period. Design-Biannual cross sectional surveys with mailed questionnaires from 1981 onwards and analysis of national statistics. Setting-Finland. Subjects-A nationwide sample of 14, 16, and 18 year olds. Sample size varied from 1249 to 3887 and response rate from 85% to 94%. Main outcome measures-Proportion taking oral contraceptive, fertility and abortion rates, hospital discharge rates, rates of sexually transmitted diseases. Results-The proportion of teenagers taking oral contraceptives increased steadily. In 1991 the percentages among 14, 16, and 18 year olds were 2%, 18%, and 41%,compared with 0.2%, 7% and 22% in 1981. Most users had a steady partner (80% of 16 year olds and 85% of 18 year olds). By 1989 rates of abortion had fallen from 12/1000 to 9.3/1000 in 16 year olds and from 25/1000 to 19.2/1000 in 18 year olds; fertility rates had fallen from 4.5/1000 to 2.3/1000 and from 23.5/1000 to 15.3/1000 respectively. Rates in 14 year olds fell only slightly. Gonorrhoea infection fell and HIV infection remained rare. Rates of hospital discharge after thromboembolic venous disease rose slightly. Conclusions-The increased use of oral contraceptives is the most likely explanation for decreasing abortion and fertility rates among teenagers. Increased reliance on the condom because of the threat of AIDS may increase unwanted pregnancies.	UNIV HELSINKI,DEPT PUBL HLTH,SF-00250 HELSINKI,FINLAND; UNIV TURKU,DEPT PUBL HLTH,SF-20520 TURKU 52,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,SF-33101 TAMPERE,FINLAND	University of Helsinki; University of Turku; Tampere University			Rimpela, Arja/J-3910-2014					ARMITAGE P, 1971, STATISTICAL METHODS; BERAL V, 1988, LANCET, V2, P1331; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; BROOKSGUNN J, 1991, B NY ACAD MED, V76, P527; DAVANZO J, 1991, JAMA-J AM MED ASSOC, V265, P2692; DEBUONO BA, 1990, NEW ENGL J MED, V322, P821, DOI 10.1056/NEJM199003223221206; HARRIS C, 1983, NEW ENGL J MED, V308, P1181, DOI 10.1056/NEJM198305193082001; HIRVONEN E, 1990, AM J OBSTET GYNECOL, V163, P281, DOI 10.1016/0002-9378(90)90568-R; HOFMANN A D, 1984, Bulletin of the World Health Organization, V62, P331; Holmgren K, 1990, Nord Med, V105, P46; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; KONTULA O, 1992, HEALTH EDUC RES, V7, P69, DOI 10.1093/her/7.1.69; KONTULA O, 1988, HLTH ED SERIES ORIGI, V9; KONTULA O, 1991, SUKUPUOLIELAMAN ALOI; MAKKONEN K, 1991, SCAND J SOC MED, V19, P32, DOI 10.1177/140349489101900106; Mandelin M, 1990, Nord Med, V105, P41; PIKE MC, 1983, LANCET, V2, P926; REDFIELD RR, 1985, JAMA-J AM MED ASSOC, V254, P2094, DOI 10.1001/jama.254.15.2094; RIMPELA M, 1988, HLTH BEHAVIOUR RES H; RUUSUVAARA L, 1983, THESIS U HELSINKI HE; SHAW RW, 1987, BRIT J OBSTET GYNAEC, V94, P724, DOI 10.1111/j.1471-0528.1987.tb03716.x; THOROGOOD M, 1990, AM J OBSTET GYNECOL, V163, P274, DOI 10.1016/0002-9378(90)90567-Q; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; Tikkanen J, 1988, Hygie, V7, P28; TURETSKY RA, 1983, CLIN PEDIATR, V22, P337, DOI 10.1177/000992288302200503; TYRER L B, 1977, Clinical Obstetrics and Gynecology, V20, P651, DOI 10.1097/00003081-197709000-00013; WALLACE HM, 1989, J ADOLESCENT HEALTH, V10, P231, DOI 10.1016/0197-0070(89)90239-8; 1987, OFFICIAL STATISTICS, P4; 1991, HLTH STATISTICS NORD, P36; 1980, OFFICIAL STATISTIC A, V4, P145; 1990, OFFICIAL STATISTICS, P1; OFFICIAL STATISTICS, V11, P77; 1980, OFFICIAL STATISTIC B, V6, P136; 1991, TILASTOJULKAISU 1991; 1988, POPULATION STUDIES, V109, P1	35	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1053	1057		10.1136/bmj.305.6861.1053	http://dx.doi.org/10.1136/bmj.305.6861.1053			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467684	Green Submitted, Bronze, Green Published			2022-12-01	WOS:A1992JW70100017
J	SWAI, AB; KITANGE, HM; MASUKI, G; KILIMA, PM; ALBERTI, KGMM; MCLARTY, DG				SWAI, AB; KITANGE, HM; MASUKI, G; KILIMA, PM; ALBERTI, KGMM; MCLARTY, DG			IS DIABETES-MELLITUS RELATED TO UNDERNUTRITION IN RURAL TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; PROTEIN-CALORIE MALNUTRITION; INSULIN-SECRETION; PREVALENCE; COMMUNITY; CHILDREN; FETAL	Objective-To investigate the relation between undernutrition and diabetes. Design-Survey of glucose tolerance in rural Tanzania. Setting-Eight villages in three widely separated regions of Tanzania. Subjects-8581 people aged 15 and above: 3705 men and 4876 women. Main outcome measures-Oral glucose tolerance, body mass index, height, and low haemoglobin and cholesterol concentrations. Results-In the eight villages 42.7-56.9% of all men and 30.0-45.2% of all women had a body mass index below 20 kg/m2; the lowest quintile was 18.2 kg/m2 in men and 18.6 kg/m2 in women. The prevalence of diabetes did not change significantly from the lowest to the highest fifths of body mass index in men (lowest 1.6% (95% confidence interval 0.8% to 2.9%) v highest 1.3% (0.7% to 2.5%)) or women (1.1% (0.6% to 2.1%) v 0.5% (0.2% to 1.2%)). In men and in women prevalence of impaired glucose tolerance was greater in the lowest fifths of height (8.2% (6.3% to 10.6%), and 11.1% (9.2% to 13.3%)) respectively and body mass index (9.6% (7.5% to 12.1%), and 8.4% (6.7% to 10.5%)) than in the highest fifths (impaired glucose tolerance 4.7% (3.4% to 6.5%); and 5.1% (3.9% to 6.7%); body mass index 5.1% (3.7% to 7.0%), and 7.7% (6.2% to 9.6%). Conclusion-Rates of diabetes were not significantly associated with low body mass index or height, but overall rates were much lower than those in well nourished Western populations. Increased impaired glucose tolerance in the most malnourished people may reflect the larger glucose load per kilogram weight. The role of undernutrition in the aetiology of diabetes must be questioned.	UNIV NEWCASTLE UPON TYNE,CTR HUMAN DIABET & METAB RES,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,DAR ES SALAAM,TANZANIA; MINIST HLTH,DAR ES SALAAM,TANZANIA	Newcastle University - UK; University of Dar es Salaam								ABOUBAKARE A, 1986, LANCET, V1, P1135; ALBERTI K G M M, 1988, Diabetes Research and Clinical Practice, V5, pS449; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BAJAJ JS, 1984, DIABETES MELLITUS; BECKER DJ, 1971, DIABETES, V20, P542, DOI 10.2337/diab.20.8.542; BENNETT PH, 1992, INT TXB DIABETES MEL, P147; COOK GC, 1967, NATURE, V215, P1295, DOI 10.1038/2151295a0; DAVIES JNP, 1948, LANCET, V1, P317; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; FLEMING A. F., 1984, PRINCIPLES MED AFRIC, P705; GOPALAN C., 1952, Indian Journal of Medical Sciences, V6, P277; GUPTA OP, 1976, EXCERPTA MED INT C S, V390, P23; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HEARD CRC, 1967, DIABETES, V16, P96, DOI 10.2337/diab.16.2.96; Himsworth H. P., 1949, P ROY SOC MED, V62, P323; KEEN H, 1984, BRIT MED BULL, V40, P359, DOI 10.1093/oxfordjournals.bmb.a072005; KHARDORI R, 1985, DIABETES CARE, V8, P302, DOI 10.2337/diacare.8.3.302a; KIMATI VP, 1985, E AFR MED J, V62, P105; LESTER FT, 1984, IDF B, V29, P14; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MCLARTY DG, 1990, DIABETIC MED, V7, P670, DOI 10.1111/j.1464-5491.1990.tb01470.x; MCLARTY DG, 1989, LANCET, V1, P871; McMillan D E, 1979, Diabetes Care, V2, P202, DOI 10.2337/diacare.2.2.202; MRISHO F, 1986, MALNUTRITION TANZANI, P7; NORUSIS MJ, 1986, SPSS PC SPSS IBM PC; NWOKOLO C, 1980, LANCET, V1, P457; OLURIN EO, 1969, BMJ-BRIT MED J, V4, P534, DOI 10.1136/bmj.4.5682.534; PITCHUMONI CS, 1988, PANCREAS, V3, P220, DOI 10.1097/00006676-198804000-00018; RAO RH, 1988, ENDOCR REV, V9, P67, DOI 10.1210/edrv-9-1-67; RAO RH, 1984, DIABETES CARE, V7, P595, DOI 10.2337/diacare.7.6.595; SHAPER AG, 1960, LANCET, V1, P1223; SMITH SR, 1975, METABOLISM, V24, P1073, DOI 10.1016/0026-0495(75)90101-8; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; SWAI ABM, 1991, DIABETES, V40, P516, DOI 10.2337/diabetes.40.4.516; SWAI ABM, IN PRESS DIABETES CA; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; TANNER JM, 1956, ARCH DIS CHILD, V31, P372, DOI 10.1136/adc.31.159.372; TANNER M, 1987, ACTA TROP, V44, P137; WALKER M, 1988, J EPIDEMIOL COMMUN H, V42, P299, DOI 10.1136/jech.42.3.299; WEST KM, 1971, DIABETES, V20, P99, DOI 10.2337/diab.20.2.99; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P231; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P74; WHINCUP PH, 1988, BMJ, V197, P980; 1987, PRELIMINARY REPORT H; 1989, ARCH INTERN MED, V149, P2650; [No title captured]	47	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 31	1992	305	6861					1057	1062		10.1136/bmj.305.6861.1057	http://dx.doi.org/10.1136/bmj.305.6861.1057			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JW701	1467685	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JW70100018
J	THOROGOOD, M; COWEN, P; MANN, J; MURPHY, M; VESSEY, M				THOROGOOD, M; COWEN, P; MANN, J; MURPHY, M; VESSEY, M			FATAL MYOCARDIAL-INFARCTION AND USE OF PSYCHOTROPIC-DRUGS IN YOUNG-WOMEN	LANCET			English	Note								We have observed an unexpected 17-fold increase in risk of total myocardial infarction (relative risk 16.9, 95% confidence interval 3.9-72.8) associated with current use of psychotropic drugs. This incidental finding, in a case-control study of cardiovascular mortality in women aged 16-39 not designed to test any hypothesis about psychotropic drugs, should be treated cautiously. There is, however, evidence of a relation between psychiatric morbidity and cardiovascular disease and the association recorded here requires further investigation.	LITTLEMORE HOSP,MRC,PSYCHOPHARMACOL RES UNIT,OXFORD,ENGLAND; UNIV OTAGO,DEPT HUMAN NUTR,DUNEDIN,NEW ZEALAND; UK OFF POPULAT CENSUSES & SURVEYS,HLTH STAT UNIT,LONDON WC2,ENGLAND; UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Otago; University of Oxford	THOROGOOD, M (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Cowen, Philip/0000-0001-5518-6138				AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; BRESLOW NE, STATISTICAL METHODS, V1; CARNEY RM, 1990, PSYCHOSOM MED, V52, P603, DOI 10.1097/00006842-199011000-00001; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; HAINES AP, 1987, BRIT MED J, V295, P297, DOI 10.1136/bmj.295.6593.297; TALBOTT E, 1981, AM J EPIDEMIOL, V114, P671, DOI 10.1093/oxfordjournals.aje.a113238; THOROGOOD M, 1991, BRIT J OBSTET GYNAEC, V98, P1245, DOI 10.1111/j.1471-0528.1991.tb15397.x; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, IN PRESS AM J EPIDEM; WEISSMAN MM, 1990, AM J PSYCHIAT, V147, P1504	10	69	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 31	1992	340	8827					1067	1068		10.1016/0140-6736(92)93081-W	http://dx.doi.org/10.1016/0140-6736(92)93081-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357456				2022-12-01	WOS:A1992JV77500006
J	[Anonymous]				[Anonymous]			POLIOVACCINE AND AIDS ORIGIN LINK VERY UNLIKELY	LANCET			English	Editorial Material																		CURTIS T, 1992, ROLLING STONE M 0319; KYLE WS, 1992, LANCET, V339, P600, DOI 10.1016/0140-6736(92)90876-5	2	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 31	1992	340	8827					1090	1091						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV775	1357471				2022-12-01	WOS:A1992JV77500017
J	BRAUN, T; RUDNICKI, MA; ARNOLD, HH; JAENISCH, R				BRAUN, T; RUDNICKI, MA; ARNOLD, HH; JAENISCH, R			TARGETED INACTIVATION OF THE MUSCLE REGULATORY GENE MYF-5 RESULTS IN ABNORMAL RIB DEVELOPMENT AND PERINATAL DEATH	CELL			English	Article							MYOGENIC DETERMINATION FACTORS; LOOP-HELIX PROTEINS; MYOSIN HEAVY-CHAIN; MOUSE EMBRYO; SKELETAL-MUSCLE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX; ALPHA-ACTIN; MYOD FAMILY	The Myf-5 gene, a member of the myogenic basic HLH factor family, has been inactivated in mice after homologous recombination in ES cells. Mice lacking Myf-5 were unable to breathe and died immediately after birth, owing to the absence of the major distal part of the ribs. Other skeletal abnormalities, except for complete ossification of the sternum, were not apparent. Histological examination of skeletal muscle from newborn mice revealed no morphological abnormalities. Northern blot analysis demonstrated normal levels of muscle-specific mRNAs including MyoD, myogenin, and Myf-6. However, the appearance of myotomal cells in early somites was delayed by several days. These results suggest that while Myf-5 plays a crucial role in the formation of lateral sclerotome derivatives, Myf-5 is dispensable for the development of skeletal muscle, perhaps because other members of the myogenic HLH family substitute for Myf-5 activity.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	BRAUN, T (corresponding author), UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,W-2000 HAMBURG 13,GERMANY.		Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNOLD HH, 1992, ADV DEV BIOCHM; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bancroft JD, 1990, THEORY PRACTICE HIST; BENFIELD PA, 1984, J BIOL CHEM, V259, P4979; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRADLEY A, 1987, PRODUCTION ANAL CHIM; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1991, EUR J BIOCHEM, V198, P187, DOI 10.1111/j.1432-1033.1991.tb16000.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; DRAKE CJ, 1991, DEV BIOL, V143, P418, DOI 10.1016/0012-1606(91)90092-H; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; Hall BK, 1977, ADV ANATOMY EMBRYOLO, V53, P1; HAUB O, 1991, DEVELOPMENT, V112, P397; HOFFMANN E, 1988, NUCLEIC ACIDS RES, V16, P2353, DOI 10.1093/nar/16.5.2353; Holtzer H., 1968, EPITHELIAL MESENCHYM, P152; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LYONS KM, 1990, DEVELOPMENT, V109, P833; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V20, P5755; Miller J B, 1991, Neuromuscul Disord, V1, P7, DOI 10.1016/0960-8966(91)90038-T; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RONG PM, 1992, DEVELOPMENT, V115, P657; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; RUGH R, 1990, MOUSE ITS REPRODUCTI; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS EJ, 1988, DIFFERENTIATION, V39, P34, DOI 10.1111/j.1432-0436.1988.tb00078.x; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SEIDEL U, 1989, J BIOL CHEM, V264, P16109; SOLURSH M, 1979, J EMBRYOL EXP MORPH, V54, P75; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WINTER B, 1992, EMBO J, V11, P1843, DOI 10.1002/j.1460-2075.1992.tb05236.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	71	577	592	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					369	382		10.1016/0092-8674(92)90507-9	http://dx.doi.org/10.1016/0092-8674(92)90507-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423602				2022-12-01	WOS:A1992JW43500004
J	BROCKDORFF, N; ASHWORTH, A; KAY, GF; MCCABE, VM; NORRIS, DP; COOPER, PJ; SWIFT, S; RASTAN, S				BROCKDORFF, N; ASHWORTH, A; KAY, GF; MCCABE, VM; NORRIS, DP; COOPER, PJ; SWIFT, S; RASTAN, S			THE PRODUCT OF THE MOUSE XIST GENE IS A 15 KB INACTIVE X-SPECIFIC TRANSCRIPT CONTAINING NO CONSERVED ORF AND LOCATED IN THE NUCLEUS	CELL			English	Article							POSITION-EFFECT VARIEGATION; CPG-RICH ISLANDS; CHROMOSOME INACTIVATION; MESSENGER-RNA; CONTROLLING ELEMENTS; H19 GENE; DNA; METHYLATION; EXPRESSION; REGION	The Xist gene maps to the X inactivation center region in both mouse and human, and previous analysis of the 3' end of the gene has demonstrated inactive X-specific expression, suggesting a possible role in X inactivation. We have now analyzed the entire mouse Xist gene. The mature inactive X-specific transcript is 15 kb in length and contains no conserved ORF. The Xist sequence contains a number of regions comprised of tandem repeats. Comparison with the human XIST gene demonstrates significant conservation of sequence and gene structure. Xist RNA is not associated with the translational machinery of the cell and is located almost exclusively in the nucleus. Together with conservation of inactive X-specific expression, these findings support a role for Xist in X inactivation, possibly as a functional RNA or as a chromatin organizer region.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	BROCKDORFF, N (corresponding author), MRC,CTR CLIN RES,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND.		Kay, Graham F/A-4130-2011	Brockdorff, Neil/0000-0003-4838-2653				ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROCKDORFF N, 1989, NUCLEIC ACIDS RES, V17, P1315, DOI 10.1093/nar/17.4.1315; BROCKDORFF N, 1991, GENOMICS, V10, P17, DOI 10.1016/0888-7543(91)90478-W; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CJ, 1990, AM J HUM GENET, V46, P273; Cattanach B. M., 1989, MOUSE NEWS LETT, V83, P165; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; CATTANACH BM, 1983, MOUSE NEWS LETT, V69, P24; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOVER GA, 1989, TRENDS GENET, V5, P100, DOI 10.1016/0168-9525(89)90038-3; FINI ME, 1989, J CELL BIOL, V6, P2045; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GOMEZMARQUEZ J, 1985, J BIOL CHEM, V260, P3490; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HERMAN GE, 1991, GENOMICS, V10, P961, DOI 10.1016/0888-7543(91)90186-I; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KANDA N, 1973, EXP CELL RES, V80, P463, DOI 10.1016/0014-4827(73)90324-8; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEE SY, 1971, BIOCHEMISTRY-US, V10, P510, DOI 10.1021/bi00779a025; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LIEBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241; LYON MF, 1961, NATURE, V190, P373; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; NORRIS DP, 1991, MAMM GENOME, V1, P78, DOI 10.1007/BF02443782; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POIRIER F, 1991, DEVELOPMENT, V113, P1105; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RASTAN S, 1982, GENET RES, V40, P139, DOI 10.1017/S0016672300019017; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1980, NATURE, V288, P172, DOI 10.1038/288172a0; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHERER SE, 1988, NUCLEIC ACIDS RES, V16, P1593, DOI 10.1093/nar/16.4.1593; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SHAPIRO LJ, 1979, SCIENCE, V204, P1224, DOI 10.1126/science.156396; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11262; VANDEPUTTE P, 1980, NATURE, V286, P218, DOI 10.1038/286218a0; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9	59	814	855	3	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					515	526		10.1016/0092-8674(92)90519-I	http://dx.doi.org/10.1016/0092-8674(92)90519-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423610				2022-12-01	WOS:A1992JW43500016
J	BURGOYNE, PS; MAHADEVAIAH, SK; SUTCLIFFE, MJ; PALMER, SJ				BURGOYNE, PS; MAHADEVAIAH, SK; SUTCLIFFE, MJ; PALMER, SJ			FERTILITY IN MICE REQUIRES X-Y PAIRING AND A Y-CHROMOSOMAL SPERMIOGENESIS GENE-MAPPING TO THE LONG ARM	CELL			English	Article							SEX-REVERSED MICE; SXR MALE-MICE; AUTOSOME REARRANGEMENT; CYTOLOGICAL EVIDENCE; DETERMINING REGION; PARTIAL DELETION; MALE-STERILITY; MOUSE; SPERMATOGENESIS; ANTIGEN	There is accumulating evidence that the mammalian Y chromosome, in addition to its testis-determining function, may have other male limited functions, particularly in spermatogenesis. We have previously shown that the short arm of the mouse Y carries information needed for spermatogonial proliferation. This information, together with the testis-determining gene Sry, is contained within the Y-derived sex reversal factor Sxr(a). XO males carrying a copy of Sxr(a) attached to the X chromosome are nevertheless sterile owing to an almost complete arrest during the meiotic metaphase stages. Here we show that this meiotic block can be overcome by providing a meiotic pairing partner (with no Y-specific DNA) for the XSxr(a) chromosome. However, this does not restore fertility because the sperm produced all have abnormal heads. It is concluded that the Y-specific region of the mouse Y chromosome long arm includes information essential for the normal development of the sperm head.			BURGOYNE, PS (corresponding author), MRC,MAMMALIAN DEV UNIT,WOLFSON HOUSE,4 STEPHENSON WAY,LONDON NW1 2HE,ENGLAND.		Palmer, Stephen/F-2822-2013	Palmer, Stephen/0000-0002-4907-4719				BISHOP CE, 1987, NUCLEIC ACIDS RES, V15, P2959, DOI 10.1093/nar/15.7.2959; BURGOYNE PS, 1986, NATURE, V320, P170, DOI 10.1038/320170a0; BURGOYNE PS, 1982, HUM GENET, V61, P85, DOI 10.1007/BF00274192; BURGOYNE PS, 1984, CONTROLLING EVENTS M, P349; CATTANACH BM, 1990, GENET RES, V56, P121, DOI 10.1017/S0016672300035199; CATTANACH BM, 1971, CYTOGENETICS, V10, P318, DOI 10.1159/000130151; CHANDLEY AC, 1980, CHROMOSOMA, V81, P9, DOI 10.1007/BF00292419; CHANDLEY AC, 1987, CHROMOSOMA, V95, P345, DOI 10.1007/BF00293181; EICHER EM, 1991, CYTOGENET CELL GENET, V57, P221, DOI 10.1159/000133152; EICHER EM, 1983, RECOMBINANT DNA MED, P57; EVANS EP, 1980, CHROMOSOMA, V81, P19, DOI 10.1007/BF00292420; EVANS EP, 1964, CYTOGENETICS, V3, P289, DOI 10.1159/000129818; EVANS EP, 1975, NATURE, V256, P40, DOI 10.1038/256040a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HALE DW, 1991, CYTOGENET CELL GENET, V57, P231, DOI 10.1159/000133153; HANNAPPEL E, 1979, HORM METAB RES, V11, P682, DOI 10.1055/s-0028-1092800; HOWELL WM, 1980, EXPERIENTIA, V36, P1014, DOI 10.1007/BF01953855; KOT MC, 1990, J EXP ZOOL, V256, P92, DOI 10.1002/jez.1402560112; KRZANOWSKA H, 1969, GENET RES, V13, P17, DOI 10.1017/S0016672300002706; KRZANOWSKA H, 1986, J REPROD FERTIL, V77, P265, DOI 10.1530/jrf.0.0770265; KRZANOWSKA H, 1976, GENET RES, V28, P189, DOI 10.1017/S0016672300016864; LEVY ER, 1986, CYTOGENET CELL GENET, V42, P159, DOI 10.1159/000132269; MAHADEVAIAH S, 1986, CYTOGENET CELL GENET, V41, P169, DOI 10.1159/000132222; MAHADEVAIAH S, 1988, CHROMOSOMA, V97, P145, DOI 10.1007/BF00327371; MAHADEVAIAH SK, 1993, IN PRESS J REPROD FE; MATSUDA Y, 1991, P NATL ACAD SCI USA, V88, P4850, DOI 10.1073/pnas.88.11.4850; MCLAREN A, 1988, P NATL ACAD SCI USA, V85, P6442, DOI 10.1073/pnas.85.17.6442; MCLAREN A, 1982, NATURE, V300, P446, DOI 10.1038/300446a0; MCLAREN A, 1983, GENET RES, V42, P345, DOI 10.1017/S0016672300021820; MCLAREN A, 1984, NATURE, V312, P552, DOI 10.1038/312552a0; MIKLOS GLG, 1974, CYTOGENET CELL GENET, V13, P558, DOI 10.1159/000130307; MONK M, 1987, P139; ROBERTS C, 1988, P NATL ACAD SCI USA, V85, P6446, DOI 10.1073/pnas.85.17.6446; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; STYRNA J, 1991, J REPROD FERTIL, V92, P187, DOI 10.1530/jrf.0.0920187; STYRNA J, 1991, GENET RES, V57, P195, DOI 10.1017/S0016672300029268; SUTCLIFFE MJ, 1991, MOL REPROD DEV, V30, P81, DOI 10.1002/mrd.1080300202; SUTCLIFFE MJ, 1989, DEVELOPMENT, V107, P373; TEASE C, 1989, CHROMOSOMA, V97, P390, DOI 10.1007/BF00292766	39	157	159	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					391	398		10.1016/0092-8674(92)90509-B	http://dx.doi.org/10.1016/0092-8674(92)90509-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423603				2022-12-01	WOS:A1992JW43500006
J	FERGUSON, EL; ANDERSON, KV				FERGUSON, EL; ANDERSON, KV			DECAPENTAPLEGIC ACTS AS A MORPHOGEN TO ORGANIZE DORSAL-VENTRAL PATTERN IN THE DROSOPHILA EMBRYO	CELL			English	Article							CELL-SHAPE CHANGES; GENE-PRODUCT; ACTIVIN-A; PROTEIN; MELANOGASTER; POLARITY; HOMOLOG; FATE; AXIS; GASTRULATION	Zygotic expression of the Drosophila TGFbeta family member decapentaplegic (dpp) is required for the development of the dorsal embryonic structures. By injecting dpp transcripts into young embryos, we find that 2- to 4-fold increases in the concentration of injected RNA elicit progressively more dorsal cell fates: only low levels of dpp permit development of ventral ectoderm, intermediate dpp levels drive dorsal epidermal development, and high dpp levels drive cells to differentiate as the most dorsal pattern element, the amnioserosa. Localized dpp RNA injections into embryos that lack all known maternal and zygotic dorsal-ventral polarity indicate that dpp can both define embryonic polarity and organize detailed patterning within the ectoderm. We infer that dpp acts as an extracellular morphogen and that the graded activity of dpp specifies the pattern of ectodermal cell fates in the Drosophila embryo.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV GENET, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Ferguson, Edwin/0000-0003-4125-4253	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035437] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07299] Funding Source: Medline; NIGMS NIH HHS [GM 35437] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P174; ANDERSON KV, 1989, GENES EMBRYOS, P1; ARORA K, 1992, DEVELOPMENT, V114, P1003; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FERGUSON EL, 1991, CURR TOP DEV BIOL, V25, P17; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; IP YT, 1991, CELL, V64, P439; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAY RP, 1991, DEVELOPMENT, V113, P35; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW C, 1987, GENE DEV, V1, P1268, DOI 10.1101/gad.1.10.1268; Rushlow C, 1990, Adv Genet, V27, P277; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHUPBACH T, 1989, GENETICS, V121, P101; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STEIN D, 1991, CELL, V65, P725, DOI 10.1016/0092-8674(91)90381-8; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Wieschaus E., 1986, P199; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; ZUSMAN SB, 1988, DEV BIOL, V129, P417, DOI 10.1016/0012-1606(88)90389-2	40	429	437	0	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					451	461		10.1016/0092-8674(92)90514-D	http://dx.doi.org/10.1016/0092-8674(92)90514-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423606				2022-12-01	WOS:A1992JW43500011
J	GEORGOPOULOS, K; MOORE, DD; DERFLER, B				GEORGOPOULOS, K; MOORE, DD; DERFLER, B			IKAROS, AN EARLY LYMPHOID-SPECIFIC TRANSCRIPTION FACTOR AND A PUTATIVE MEDIATOR FOR T-CELL COMMITMENT	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; CD3-DELTA GENE; YOLK-SAC; EXPRESSION; PRECURSORS; ONTOGENY; MOUSE	In a screen for transcriptional regulators that control differentiation into the T cell lineage, a complementary DNA was isolated encoding a zinc finger protein (Ikaros) related to the Drosophila gap protein Hunchback. The Ikaros protein binds to and activates the enhancer of a gene encoding an early T cell differentiation antigen, CD3delta. During development, Ikaros messenger RNA was first detected in the mouse fetal liver and the embryonic thymus when hematopoietic and lymphoid progenitors initially colonize these organs; no expression was observed in the spleen or the bone marrow. The pattern of Ikaros gene expression and its ability to stimulate CD3delta transcription support the model that Ikaros functions in the specification and maturation of the T lymphocyte.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MOLEC BIOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital	GEORGOPOULOS, K (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114, USA.							AUERBACH R, 1981, FORTS ZOOL, V26, P287; AUSSUBEL F, 1991, CURRENT PROTOCOLS MO; BARKER JE, 1968, DEV BIOL, V15, P14; CAPEL B, 1989, P NATL ACAD SCI USA, V86, P4564, DOI 10.1073/pnas.86.12.4564; FURLEY AJ, 1986, CELL, V46, P75, DOI 10.1016/0092-8674(86)90861-5; GALSON D, UNPUB; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GEORGOPOULOS K, UNPUB; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LIU CP, 1991, DEVELOPMENT, V113, P1315; LIU CP, 1991, EUR J IMMUNOL, V21, P1849, DOI 10.1002/eji.1830210811; METCALF D, 1987, MOL CONTROL BLOOD CE; MOORE MAS, 1967, J EXP MED, V126, P715, DOI 10.1084/jem.126.4.715; Owen J J, 1981, Prog Allergy, V29, P1; RUGH R, 1991, MOUSE ITS REPRODUCTI, P272; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SZILVASSY SJ, 1989, P NATL ACAD SCI USA, V86, P8798, DOI 10.1073/pnas.86.22.8798; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	26	373	392	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					808	812		10.1126/science.1439790	http://dx.doi.org/10.1126/science.1439790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439790				2022-12-01	WOS:A1992JV69200041
J	GIBBS, RA; TAYLOR, S; BENKOVIC, SJ				GIBBS, RA; TAYLOR, S; BENKOVIC, SJ			ANTIBODY-CATALYZED REARRANGEMENT OF THE PEPTIDE-BOND	SCIENCE			English	Article							PROTEINS; DEAMIDATION; ASPARAGINYL; RESIDUES	The generation of antibodies from a bifunctional cyclic phosphinate transition-state analog provided agents capable of efficiently catalyzing both steps of the overall conversion of a substrate containing an asparaginyl-glycyl sequence through a succinimide intermediate to the products aspartyl-glycyl and the rearranged isoaspartyl-glycyl sequence. This reaction provides a potential means in addition to amide cleavage for the deactivation of protein or peptide biological functions in vivo.			GIBBS, RA (corresponding author), PENN STATE UNIV,DEPT CHEM,152 DAVEY LAB,UNIV PK,PA 16802, USA.							AHERN TJ, 1985, SCIENCE, V228, P1280, DOI 10.1126/science.4001942; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; GIBBS RB, UNPUB; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; KOSSIAKOFF AA, 1988, SCIENCE, V240, P191, DOI 10.1126/science.3353715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MODRITZER K, 1975, SYN REACT INORG MET, V5, P45; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; NIMAN HL, 1980, P NATL ACAD SCI-BIOL, V77, P4524, DOI 10.1073/pnas.77.8.4524; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; Quin L. D., 1981, HETEROCYCLIC CHEM PH; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3092; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6	17	35	36	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					803	805		10.1126/science.1439788	http://dx.doi.org/10.1126/science.1439788			3	Multidisciplinary Sciences	Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439788				2022-12-01	WOS:A1992JV69200039
J	GOLDFARB, LG; PETERSEN, RB; TABATON, M; BROWN, P; LEBLANC, AC; MONTAGNA, P; CORTELLI, P; JULIEN, J; VITAL, C; PENDELBURY, WW; HALTIA, M; WILLS, PR; HAUW, JJ; MCKEEVER, PE; MONARI, L; SCHRANK, B; SWERGOLD, GD; AUTILIOGAMBETTI, L; GAJDUSEK, DC; LUGARESI, E; GAMBETTI, P				GOLDFARB, LG; PETERSEN, RB; TABATON, M; BROWN, P; LEBLANC, AC; MONTAGNA, P; CORTELLI, P; JULIEN, J; VITAL, C; PENDELBURY, WW; HALTIA, M; WILLS, PR; HAUW, JJ; MCKEEVER, PE; MONARI, L; SCHRANK, B; SWERGOLD, GD; AUTILIOGAMBETTI, L; GAJDUSEK, DC; LUGARESI, E; GAMBETTI, P			FATAL FAMILIAL INSOMNIA AND FAMILIAL CREUTZFELDT-JAKOB DISEASE - DISEASE PHENOTYPE DETERMINED BY A DNA POLYMORPHISM	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; HUMAN PRION PROTEIN; ALZHEIMERS-DISEASE; SPONGIFORM ENCEPHALOPATHY; SICKLING HEMOGLOBIN; MUTATION; BIOLOGY; VARIANT	Fatal familial insomnia (FFI) and a subtype of familial Creutzfeldt-Jakob disease (CJD), two clinically and pathologically distinct diseases, are linked to the same mutation at codon 178 (Asn178) of the prion protein gene. The possibility that a second genetic component modified the phenotypic expression of the Asn178 mutation was investigated. FFI and the familial CJD subtype segregated with different genotypes determined by the Asn178 mutation and the methionine-valine polymorphism at codon 129. The Met129, Asn178 allele segregated with FFI in all 15 affected members of five kindreds whereas the Val129, Asn178 allele segregated with the familial CJD subtype in all 15 affected members of six kindreds. Thus, two distinct disease phenotypes linked to a single pathogenic mutation can be determined by a common polymorphism.	CASE WESTERN RESERVE UNIV,INST PATHOL,DIV NEUROPATHOL,CLEVELAND,OH 44106; NINCDS,CENT NERVOUS SYST STUDIES LAB,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892; UNIV BOLOGNA,INST NEUROL,I-40126 BOLOGNA,ITALY; UNIV BORDEAUX,SCH MED,DEPT NEUROL,BORDEAUX,FRANCE; UNIV BORDEAUX,SCH MED,DEPT PATHOL,BORDEAUX,FRANCE; UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405; UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; UNIV AUCKLAND,DEPT PHYS,AUCKLAND,NEW ZEALAND; LAB NEUROPATHOL R ESCOUROLLE,PARIS,FRANCE; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48104; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Bologna; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; University of Vermont; University of Helsinki; University of Auckland; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; University of Michigan System; University of Michigan; Washington University (WUSTL)			Petersen, Robert/B-5075-2011; Wills, Peter R./B-9611-2012; Cortelli, Pietro/K-6063-2016	Petersen, Robert/0000-0002-3154-0072; Wills, Peter R./0000-0002-2670-7624; Cortelli, Pietro/0000-0002-3633-8818	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG008012] Funding Source: NIH RePORTER; NIA NIH HHS [AG-08012-02, 1 R01 AGNS08155-02] Funding Source: Medline; NINDS NIH HHS [NS 14509-13] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER HF, 1991, LANCET, V337, P1286, DOI 10.1016/0140-6736(91)92953-Y; BOOKCHIN RM, 1967, J BIOL CHEM, V242, P248; BROWN P, 1992, ANN NEUROL, V31, P282, DOI 10.1002/ana.410310309; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; BROWN PN, UNPUB; BUGE A, 1978, REV NEUROL, V134, P165; CASTANO EM, 1988, LAB INVEST, V58, P122; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; GAJDUSEK DC, 1990, VIROLOGY; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDFARB L G, 1989, American Journal of Human Genetics, V45, pA189; GOLDFARB LG, 1991, LANCET, V337, P425, DOI 10.1016/0140-6736(91)91198-4; GOLDFARB LG, 1992, ANN NEUROL, V31, P274, DOI 10.1002/ana.410310308; GOOSSENS M, 1975, FEBS LETT, V58, P149, DOI 10.1016/0014-5793(75)80246-8; GUIDON G, 1978, THESIS U RENNES; HALTIA M, 1979, Journal of the Neurological Sciences, V42, P381, DOI 10.1016/0022-510X(79)90171-0; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HSAIO K, 1992, NAT GENET, V1, P68; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LANGDOWN JV, 1989, BRIT J HAEMATOL, V71, P443; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LITTLE BW, 1986, ANN NEUROL, V20, P231, DOI 10.1002/ana.410200209; MANETTO V, 1992, NEUROLOGY, V42, P312, DOI 10.1212/WNL.42.2.312; MASTERS CL, 1978, BRAIN, V101, P333, DOI 10.1093/brain/101.2.333; MASTERS CL, 1981, BRAIN, V104, P559, DOI 10.1093/brain/104.3.559; MAY WW, 1968, ARCH NEUROL-CHICAGO, V19, P137, DOI 10.1001/archneur.1968.00480020023002; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MEDORI R, 1992, NEUROLOGY, V42, P669, DOI 10.1212/WNL.42.3.669; MONPLAISIR N, 1986, P NATL ACAD SCI USA, V83, P9363, DOI 10.1073/pnas.83.24.9363; MOOPENN WF, 1977, EUR J BIOCHEM, V77, P561, DOI 10.1111/j.1432-1033.1977.tb11699.x; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PENDLEBURY W, UNPUB; PETERSEN RB, 1992, PRION DISEASE HUMANS; PETERSEN RB, IN PRESS NEUROLOGY; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; TANAKA MT, 1992, ACTA NEUROL SCAND, V85, P327; YSOHIDA K, 1992, ANN NEUROL, V31, P328	40	587	615	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					806	808		10.1126/science.1439789	http://dx.doi.org/10.1126/science.1439789			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439789				2022-12-01	WOS:A1992JV69200040
J	GORLICH, D; PREHN, S; HARTMANN, E; KALIES, KU; RAPOPORT, TA				GORLICH, D; PREHN, S; HARTMANN, E; KALIES, KU; RAPOPORT, TA			A MAMMALIAN HOMOLOG OF SEC61P AND SECYP IS ASSOCIATED WITH RIBOSOMES AND NASCENT POLYPEPTIDES DURING TRANSLOCATION	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; INTEGRAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; MICROSOMAL-MEMBRANES; SEQUENCE RECEPTOR; SECRETORY PROTEIN; ROUGH MICROSOMES; BINDING-ACTIVITY; 4.5S RNA	SEC61p is essential for protein translocation across the endoplasmic reticulum membrane of S. cerevisiae. We have found a mammalian homolog that shows more than 50% sequence identity with the yeast protein. Moreover, several regions of SEC61p have significant similarities with corresponding ones of SecYp of bacteria, indicating a strong evolutionary conservation of the mechanism of protein translocation. Mammalian Sec61p, like the yeast protein, is located in the immediate vicinity of nascent polypeptides during their membrane passage. It is tightly associated with membrane-bound ribosomes, suggesting that the nascent chain passes directly from the ribosome into a protein-conducting channel. These results define Sec61p as a ubiquitous key component of the protein translocation apparatus.	HUMBOLDT UNIV,INST BIOCHEM,O-1040 BERLIN,GERMANY	Humboldt University of Berlin	GORLICH, D (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,O-1115 BERLIN,GERMANY.		Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 				ADELMAN MR, 1973, J CELL BIOL, V56, P206, DOI 10.1083/jcb.56.1.206; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; ARNDT E, 1992, BIOCHIM BIOPHYS ACTA, V1130, P13; AUER J, 1991, BIOCHIMIE, V73, P683, DOI 10.1016/0300-9084(91)90048-6; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLOBEL G, 1976, BIOCHEM BIOPH RES CO, V68, P1, DOI 10.1016/0006-291X(76)90001-2; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; COLLINS PG, 1991, J CELL BIOL, V114, P639, DOI 10.1083/jcb.114.4.639; CONNOLLY T, 1986, J CELL BIOL, V103, P2253, DOI 10.1083/jcb.103.6.2253; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; ITO K, 1983, CELL, V32, P789, DOI 10.1016/0092-8674(83)90065-X; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOIVULA T, 1991, FEBS LETT, V288, P114, DOI 10.1016/0014-5793(91)81015-Z; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER DI, 1982, NATURE, V297, P503; MICHALOWSKI CB, 1990, MOL GEN GENET, V224, P222, DOI 10.1007/BF00271555; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; NUNNARI JM, 1991, NATURE, V352, P638, DOI 10.1038/352638a0; OHKUBO S, 1987, MOL GEN GENET, V210, P314, DOI 10.1007/BF00325700; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TSCHAUDER S, 1992, IN PRESS MOL GEN GEN; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; ZIMMERMANN R, 1986, TRENDS BIOCHEM SCI, V11, P512, DOI 10.1016/0968-0004(86)90085-X	56	381	388	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					489	503		10.1016/0092-8674(92)90517-G	http://dx.doi.org/10.1016/0092-8674(92)90517-G			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423609				2022-12-01	WOS:A1992JW43500014
J	HART, MJ; MARU, Y; LEONARD, D; WITTE, ON; EVANS, T; CERIONE, RA				HART, MJ; MARU, Y; LEONARD, D; WITTE, ON; EVANS, T; CERIONE, RA			A GDP DISSOCIATION INHIBITOR THAT SERVES AS A GTPASE INHIBITOR FOR THE RAS-LIKE PROTEIN CDC42HS	SCIENCE			English	Article							BINDING PROTEIN; REGULATORY PROTEIN; ACTIVATING PROTEIN; DEPENDENT MANNER; HUMAN ONCOGENE; BCR; GENE; IDENTIFICATION; PRODUCT; REGION	Members of the family of Ras-related guanosine triphosphate (GTP) binding proteins appear to take part in the regulation of a number of biological processes, including cell growth and differentiation. Three different classes of proteins that regulate the GTP binding and GTP hydrolytic activities of the Ras family members have been identified. These different regulatory proteins inhibit guanosine diphosphate (GDP) dissociation (designated as GDIs), stimulate GDP dissociation and GDP-GTP exchange (designated as GDSs), or stimulate GTP hydrolysis (designated as GAPs). In the case of the Ras-like protein CDC42Hs, which is the human homolog of a Saccharomyces cerevisiae cell division cycle protein, the GDI protein also inhibited both the intrinsic and GAP-stimulated hydrolysis of GTP. These findings establish an additional role for the GDI protein-namely, as a guanosine triphosphatase (GTPase) inhibitory protein for a Ras-like GTP binding protein.	CORNELL UNIV,DEPT BIOCHEM CELL & MOLEC BIOL,SCHURMAN HALL,ITHACA,NY 14853; CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,INST MOLEC BIOL,LOS ANGELES,CA 90024; GENENTECH INC,DEPT CELL BIOL,SAN FRANCISCO,CA 94080	Cornell University; Cornell University; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Roche Holding; Genentech				Hart, Matthew/0000-0002-2683-480X				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS JM, 1992, ONCOGENE, V7, P611; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARBO A, 1991, J BIOL CHEM, V266, P23577; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CERIONE RA, 1990, RECEPTOR EFFECTOR CO, P69; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1991, J BIOL CHEM, V266, P20840; HART MJ, UNPUB; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEONARD D, IN PRESS J BIOL CHEM; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; UEDA T, 1990, J BIOL CHEM, V265, P9373	28	151	152	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					812	815		10.1126/science.1439791	http://dx.doi.org/10.1126/science.1439791			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439791				2022-12-01	WOS:A1992JV69200042
J	HERZ, J; CLOUTHIER, DE; HAMMER, RE				HERZ, J; CLOUTHIER, DE; HAMMER, RE			LDL RECEPTOR-RELATED PROTEIN INTERNALIZES AND DEGRADES UPA-PAI-1 COMPLEXES AND IS ESSENTIAL FOR EMBRYO IMPLANTATION	CELL			English	Article							LOW-DENSITY-LIPOPROTEIN; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; APOLIPOPROTEIN-E; MEDIATED INTERNALIZATION; ENDOTHELIAL-CELLS; BOUND UROKINASE; CULTURED-CELLS; HIGH-AFFINITY; STEM-CELLS	The low density lipoprotein receptor-related protein (LRP) is a large multifunctional clearance receptor that has been implicated in the hepatic uptake of chylomicron remnants and in the removal of protease-inhibitor complexes from the circulation and from the extracellular space. Disruption of the LRP gene in mice blocks development of LRP-I- embryos around the implantation stage. The expression pattern of LRP in the postimplantation stage embryo is identical to that of urokinase, a plasminogen activator that confers invasive properties to migrating cells. We demonstrate that LRP mediates uptake and degradation of urokinase-type plasminogen activator-plasminogen activator inhibitor 1 complexes and propose that the inability of the giant cells to remove the inactive protease complexes from their surfaces interferes with implantation of the embryo.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	HERZ, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Clouthier, David/A-7062-2009		NHLBI NIH HHS [HL 20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APPELLA E, 1987, J BIOL CHEM, V262, P4437; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; EATON GJ, 1963, GENETICA, V34, P155, DOI 10.1007/BF01664187; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; HILLIKER C, 1992, GENOMICS, V13, P472, DOI 10.1016/0888-7543(92)90276-X; JENSEN PH, 1988, PLACENTA, V9, P463, DOI 10.1016/0143-4004(88)90019-7; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MYKLEBOST O, 1989, GENOMICS, V5, P65, DOI 10.1016/0888-7543(89)90087-6; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLOUG M, 1991, SEMIN THROMB HEMOST, V17, P183, DOI 10.1055/s-2007-1002608; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Sambrook J., 1989, MOL CLONING LAB MANU; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHI WK, 1984, J EMBRYOL EXP MORPH, V81, P143; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0	55	532	544	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					411	421		10.1016/0092-8674(92)90511-A	http://dx.doi.org/10.1016/0092-8674(92)90511-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423604				2022-12-01	WOS:A1992JW43500008
J	KAYE, J; ELLENBERGER, DL				KAYE, J; ELLENBERGER, DL			DIFFERENTIATION OF AN IMMATURE T-CELL LINE - A MODEL OF THYMIC POSITIVE SELECTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTOR TRANSGENIC MICE; INTERCELLULAR-ADHESION MOLECULE-1; RESTRICTED ANTIGEN RECEPTOR; LYT-2 POLYPEPTIDES ARISE; NEGATIVE SELECTION; CD4+8+ THYMOCYTES; DNA FRAGMENTATION; SUSPENSION-CULTURE; MURINE THYMOCYTES	Thymocyte differentiation is dependent upon recognition of major histocompatibility complex (MHC) molecules on thymic stroma, a process called positive selection. Here we describe an immature CD4+8+ T cell line derived from a TCR transgenic mouse that differentiates into CD4+8- cells in response to antigen and nonthymic antigen-presenting cells. When injected intrathymically, these cells differentiate in the absence of antigen. The ability of immature T cells to recognize MHC molecules in the absence of foreign antigen in the thymus can thus be attributed to a unique property of thymic antigen-presenting cells. These studies also demonstrate the phenotypic and functional changes associated with TCR-mediated T cell maturation and establish an in vitro model system of positive selection.			KAYE, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HLO-07195] Funding Source: Medline; NIAID NIH HHS [AI31231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031231, R01AI031231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BILL J, 1989, NATURE, V341, P649, DOI 10.1038/341649a0; BLACKMAN MA, 1989, SCIENCE, V244, P214, DOI 10.1126/science.2784868; BLUE ML, 1989, J IMMUNOL, V142, P2714; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BORN W, 1987, J IMMUNOL, V138, P999; BOYER PD, 1988, J IMMUNOL, V140, P2886; CARLOW DA, 1992, J IMMUNOL, V148, P1595; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; COHEN JJ, 1984, J IMMUNOL, V132, P38; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, J IMMUNOL, V138, P2013; CRISPE IN, 1987, J IMMUNOL, V139, P3585; DUSTIN ML, 1986, J IMMUNOL, V137, P245; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FINE JS, 1991, J IMMUNOL, V147, P2852; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HARVEY JE, 1990, IMMUNOLOGY, V70, P203; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; HUNIG T, 1991, J EXP MED, V173, P561, DOI 10.1084/jem.173.3.561; JAMESON SC, 1991, J IMMUNOL, V147, P3185; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1992, J IMMUNOL, V148, P3342; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KIZAKI H, 1989, J IMMUNOL, V143, P1790; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEPESANT H, 1990, INT IMMUNOL, V2, P1021, DOI 10.1093/intimm/2.11.1021; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1988, J IMMUNOL, V140, P2508; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MATHIESON BJ, 1984, IMMUNOL REV, V82, P141, DOI 10.1111/j.1600-065X.1984.tb01121.x; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MERCEP M, 1989, J IMMUNOL, V142, P4085; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NONOYAMA S, 1989, EUR J IMMUNOL, V19, P1631, DOI 10.1002/eji.1830190917; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; REICHERT RA, 1986, J IMMUNOL, V136, P3521; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; Sambrook J., 1989, MOL CLONING LAB MANU; SCOTT B, 1989, NATURE, V338, P591, DOI 10.1038/338591a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SINGER KH, 1990, J IMMUNOL, V144, P2931; SIU G, 1989, J IMMUNOL, V143, P3813; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPEISER DE, 1992, J EXP MED, V175, P1277, DOI 10.1084/jem.175.5.1277; SPRENT J, 1978, J EXP MED, V147, P1838, DOI 10.1084/jem.147.6.1838; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TAGAWA M, 1986, P NATL ACAD SCI USA, V83, P3422, DOI 10.1073/pnas.83.10.3422; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; ZAMOYSKA R, 1985, CELL, V43, P153, DOI 10.1016/0092-8674(85)90020-0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1989, NATURE, V338, P76, DOI 10.1038/338076a0	94	63	63	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					423	435		10.1016/0092-8674(92)90512-B	http://dx.doi.org/10.1016/0092-8674(92)90512-B			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423605				2022-12-01	WOS:A1992JW43500009
J	KINGSLEY, DM; BLAND, AE; GRUBBER, JM; MARKER, PC; RUSSELL, LB; COPELAND, NG; JENKINS, NA				KINGSLEY, DM; BLAND, AE; GRUBBER, JM; MARKER, PC; RUSSELL, LB; COPELAND, NG; JENKINS, NA			THE MOUSE SHORT-EAR SKELETAL MORPHOGENESIS LOCUS IS ASSOCIATED WITH DEFECTS IN A BONE MORPHOGENETIC MEMBER OF THE TGF-BETA SUPERFAMILY	CELL			English	Article							TRANSFORMING GROWTH-FACTOR; MESODERM-INDUCING FACTOR; GENETIC-LINKAGE MAP; MESSENGER-RNA; EMBRYONIC-DEVELOPMENT; OSTEOGENIC PROTEIN; PATTERN-FORMATION; RETINOIC ACID; GERM LAYERS; ACTIVIN-A	The mouse short ear gene is required for normal growth and patterning of skeletal structures, and for repair of bone fractures in adults. We have carried out an extensive chromosome walk in the chromosome region that surrounds this locus. Here we show that the short ear region contains the gene for a TGFbeta-related protein called bone morphogenetic protein 5 (Bmp-5). This gene is deleted or rearranged in several independent mutations at the short ear locus. Mice homozygous for large deletions of the Bmp-5 coding region are viable and fertile. Mutations at the short ear locus provide an important new tool for defining the normal functions of BMPs in mammals. The specific skeletal defects seen in short-eared animals, which occur against a background of otherwise normal skeletal structures, suggest that particular aspects of skeletal morphology may be determined by individual members of a family of signaling factors that can induce the formation of cartilage and bone in vivo.	OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	United States Department of Energy (DOE); Oak Ridge National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	KINGSLEY, DM (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,BECKMAN CTR B300,STANFORD,CA 94305, USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANO RM, 1990, DEVELOPMENT, V110, P435; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BATCHELOR AL, 1966, MUTAT RES, V3, P218, DOI 10.1016/0027-5107(66)90063-7; BUCHBERG AM, 1988, ONCOGENE RES, V2, P149; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DICKINSON ME, 1990, GENOMICS, V6, P673; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; GELBART WM, 1989, DEVELOPMENT, V107, P65; Green EL, 1942, J MORPHOL, V70, P1, DOI 10.1002/jmor.1050700102; GREEN EL, 1946, AM NAT, V80, P619, DOI 10.1086/281482; GREEN JD, 1951, AM J ANAT, V88, P1; GREEN MARGARET C., 1957, JOUR HEREDITY, V48, P205; GREEN MARGARET C., 1952, OHIO JOUR SCI, V52, P31; GREEN MC, 1958, J EXP ZOOL, V137, P75, DOI 10.1002/jez.1401370105; GREEN MC, 1968, J EXP ZOOL, V167, P129, DOI 10.1002/jez.1401670202; Green MC., 1989, GENETIC VARIANTS STR, P12; Hinchliffe J. R., 1980, DEV VERTEBRATE LIMB; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES CM, 1991, DEVELOPMENT, V111, P531; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KINGSLEY DM, 1990, EMBO J, V9, P395, DOI 10.1002/j.1460-2075.1990.tb08123.x; KINGSLEY DM, 1989, GENETICS, V123, P165; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lynch CJ, 1921, AM NAT, V55, P421, DOI 10.1086/279826; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; NESBITT MN, 1973, MOUSE NEWS LETT, V49, P23; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PETRAGLIA F, 1989, P NATL ACAD SCI USA, V86, P5114, DOI 10.1073/pnas.86.13.5114; RAY RP, 1991, DEVELOPMENT, V113, P35; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; REUTER R, 1990, DEVELOPMENT, V110, P1031; RINCHIK EM, 1986, GENETICS, V112, P321; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RUSSELL LB, 1989, P NATL ACAD SCI USA, V86, P3704, DOI 10.1073/pnas.86.10.3704; RUSSELL LB, 1971, MUTAT RES, V11, P107, DOI 10.1016/0027-5107(71)90036-4; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; RUSSELL WL, 1951, COLD SPRING HARB SYM, V16, P327, DOI 10.1101/SQB.1951.016.01.024; Sambrook J., 1989, MOL CLONING LAB MANU; SEARLE AG, 1989, GENETIC VARIANTS STR, P582; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	66	421	438	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					399	410		10.1016/0092-8674(92)90510-J	http://dx.doi.org/10.1016/0092-8674(92)90510-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1339316				2022-12-01	WOS:A1992JW43500007
J	LAMPL, M; VELDHUIS, JD; JOHNSON, ML				LAMPL, M; VELDHUIS, JD; JOHNSON, ML			SALTATION AND STASIS - A MODEL OF HUMAN GROWTH	SCIENCE			English	Article							LONGITUDINAL BONE-GROWTH; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; LINEAR GROWTH; FACTOR-I; CHILDREN; HORMONE; PROTEIN; CHONDROCYTES; VELOCITY	Human growth has been viewed as a continuous process characterized by changing velocity with age. Serial length measurements of normal infants were assessed weekly (n = 10), semiweekly (n = 18), and daily (n = 3) (19 females and 12 males) during their first 21 months. Data show that growth in length occurs by discontinuous, aperiodic saltatory spurts. These bursts were 0.5 to 2.5 centimeters in amplitude during intervals separated by no measurable growth (2 to 63 days duration). These data suggest that 90 to 95 percent of normal development during infancy is growth-free and length accretion is a distinctly saltatory process of incremental bursts punctuating background stasis.	UNIV VIRGINIA, HLTH SCI CTR, NATL SCI FDN, CTR BIOL TIMING, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, DIV ENDOCRINOL & METAB, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHARMACOL, CHARLOTTESVILLE, VA 22908 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia; University of Virginia; University of Virginia	LAMPL, M (corresponding author), UNIV PENN, DEPT ANTHROPOL, PHILADELPHIA, PA 19104 USA.		Lampl, Michelle L/B-1619-2013		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000634] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NICHD NIH HHS [KO4HD00634] Funding Source: Medline; NIDDK NIH HHS [DK 38942] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTSSONWIKLAND K, 1988, J CLIN ENDOCR METAB, V67, P493, DOI 10.1210/jcem-67-3-493; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BORTELL R, 1990, J CELL BIOCHEM, V44, P81, DOI 10.1002/jcb.240440203; BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; BUTLER GE, 1990, ANN HUM BIOL, V17, P177, DOI 10.1080/03014469000000952; Cameron N., 1986, HUMAN GROWTH, V3, P3; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; Gordon CC, 1988, ANTHROPOMETRIC STAND, P3; Hamill PV, 1977, VITAL HLTH STAT 11, V11, P1; HARRISON GA, 1990, ANN HUM BIOL, V17, P407, DOI 10.1080/03014469000001182; HEALY MJR, 1988, NESTLE NUTRITION WOR, V14, P41; HERMANUSSEN M, 1988, ANN HUM BIOL, V15, P103, DOI 10.1080/03014468800009521; HERMANUSSEN M, 1986, ACTA PAEDIATR SCAND, V75, P601, DOI 10.1111/j.1651-2227.1986.tb10258.x; HUNZIKER EB, 1989, J PHYSIOL-LONDON, V414, P55, DOI 10.1113/jphysiol.1989.sp017676; KARLBERG J, 1987, STAT MED, V6, P185, DOI 10.1002/sim.4780060210; LAMPL M, UNPUB; LLOYD D, 1986, CELL CYCLE CLOCKS, P27; MARSHALL WA, 1971, ARCH DIS CHILD, V46, P414, DOI 10.1136/adc.46.248.414; MARTHA PM, 1989, J CLIN ENDOCR METAB, V69, P563, DOI 10.1210/jcem-69-3-563; MARTORELL R, 1975, AM J PHYS ANTHROPOL, V43, P347, DOI 10.1002/ajpa.1330430308; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAURAS N, 1987, J CLIN ENDOCR METAB, V64, P596, DOI 10.1210/jcem-64-3-596; Meredith HV, 1936, CHILD DEV, V7, P262; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; POLYCHRONAKOS C, 1988, EUR J PEDIATR, V147, P582, DOI 10.1007/BF00442467; ROCHE AF, 1980, AM J CLIN NUTR, V33, P2041, DOI 10.1093/ajcn/33.9.2041; Scammon RE, 1927, AM J PHYS ANTHROPOL, V10, P329, DOI 10.1002/ajpa.1330100303; SCHEVEN BAA, 1991, ACTA ENDOCRINOL-COP, V124, P602, DOI 10.1530/acta.0.1240602; SCHOLL D. A., 1954, DYNAMICS GROWTH PROC, P224; SMITH DW, 1976, J PEDIATR-US, V89, P225, DOI 10.1016/S0022-3476(76)80453-2; STEVENSON S, 1990, J ORTHOPAED RES, V8, P132, DOI 10.1002/jor.1100080117; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454; TANNER JM, 1990, FETUS MAN PHYSICAL G; TOGO M, 1982, ANN HUM BIOL, V9, P425, DOI 10.1080/03014468200005961; VALK IM, 1983, GROWTH, V47, P53; VANDERLINDEN FP, 1970, GROWTH, V34, P385; VELDHUIS JD, 1992, METHOD ENZYMOL, V210, P539; WALES JKH, 1987, ARCH DIS CHILD, V62, P166, DOI 10.1136/adc.62.2.166; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIT JM, 1987, ACTA PAEDIATR SCAND, P40; [No title captured]	46	233	238	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1992	258	5083					801	803		10.1126/science.1439787	http://dx.doi.org/10.1126/science.1439787			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439787				2022-12-01	WOS:A1992JV69200038
J	LEONE, G; MAYBAUM, L; LEE, PWK				LEONE, G; MAYBAUM, L; LEE, PWK			THE REOVIRUS CELL ATTACHMENT PROTEIN POSSESSES 2 INDEPENDENTLY ACTIVE TRIMERIZATION DOMAINS - BASIS OF DOMINANT NEGATIVE EFFECTS	CELL			English	Article							HEPTAD REPEAT REGION; WILD-TYPE P53; MUTANT P53; FUNCTIONAL DOMAINS; COLON CANCER; COILED-COIL; 3 SEROTYPES; SIGMA-1; IDENTIFICATION; GENE	The reovirus cell attachment protein, sigma1, is a homotrimer with an N-terminal fibrous tail and a C-terminal globular head. By cotranslating full-length and various truncated sigma1 proteins in vitro, we show that the N- and C-terminal halves of sigma1 possess independent trimerization and folding domains. Trimerization of sigma1 is initiated at the N-terminus by the formation of a "loose," protease-sensitive, three-stranded, alpha-helical coiled coil. This serves to bring the three unfolded C-termini into close proximity to one another, facilitating their subsequent trimerization and cooperative folding. Concomitant with, but independent of, this latter process, the N-terminal fiber further matures into a more stable and protease-resistant structure. The coordinated folding of sigma1 trimers exemplifies the dominant negative effects of mutant subunits in oligomeric complexes.			LEONE, G (corresponding author), UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY T2N 4N1,ALBERTA,CANADA.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300				ARMSTRONG GD, 1984, VIROLOGY, V138, P37, DOI 10.1016/0042-6822(84)90145-4; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BANERJEA AC, 1990, VIROLOGY, V179, P460, DOI 10.1016/0042-6822(90)90315-I; BASSELDUBY R, 1985, NATURE, V315, P421, DOI 10.1038/315421a0; BOURNE HR, 1991, NATURE, V353, P696, DOI 10.1038/353696b0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURSTIN SJ, 1982, VIROLOGY, V117, P146, DOI 10.1016/0042-6822(82)90514-1; CASHDOLLAR LW, 1985, P NATL ACAD SCI USA, V82, P24, DOI 10.1073/pnas.82.1.24; CASHDOLLAR LW, 1989, VIROLOGY, V168, P183, DOI 10.1016/0042-6822(89)90420-0; COOHAN JP, 1992, VIROLOGY, V186, P409; DUNCAN R, 1990, VIROLOGY, V174, P399, DOI 10.1016/0042-6822(90)90093-7; DUNCAN R, 1991, VIROLOGY, V182, P810, DOI 10.1016/0042-6822(91)90622-I; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; GANNON JV, 1990, EMBO J, V9, P1591; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEONE G, 1991, VIROLOGY, V182, P346, DOI 10.1016/0042-6822(91)90678-5; LEONE G, 1991, VIROLOGY, V182, P336, DOI 10.1016/0042-6822(91)90677-4; LEONE G, 1991, VIROLOGY, V184, P758, DOI 10.1016/0042-6822(91)90447-J; MAH DCW, 1990, VIROLOGY, V179, P95, DOI 10.1016/0042-6822(90)90278-Y; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NAGATA L, 1987, VIROLOGY, V160, P162, DOI 10.1016/0042-6822(87)90056-0; NAGATA L, 1984, NUCLEIC ACIDS RES, V12, P8699, DOI 10.1093/nar/12.22.8699; NIBERT ML, 1990, J VIROL, V64, P2976, DOI 10.1128/JVI.64.6.2976-2989.1990; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAUL RW, 1987, VIROLOGY, V159, P94, DOI 10.1016/0042-6822(87)90351-5; ROVINSKI B, 1988, ONCOGENE, V2, P445; SEMISOTNOV GV, 1987, FEBS LETT, V224, P9, DOI 10.1016/0014-5793(87)80412-X; SHARPE AH, 1985, NEW ENGL J MED, V312, P486, DOI 10.1056/NEJM198502213120806; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TURNER DL, 1992, VIROLOGY, V186, P219, DOI 10.1016/0042-6822(92)90076-2; WEINER HL, 1978, VIROLOGY, V86, P581, DOI 10.1016/0042-6822(78)90099-5; YEUNG MC, 1989, VIROLOGY, V170, P62, DOI 10.1016/0042-6822(89)90352-8; YEUNG MC, 1987, VIROLOGY, V156, P377, DOI 10.1016/0042-6822(87)90417-X	45	39	42	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 30	1992	71	3					479	488		10.1016/0092-8674(92)90516-F	http://dx.doi.org/10.1016/0092-8674(92)90516-F			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423608				2022-12-01	WOS:A1992JW43500013
J	LJUNGDAHL, PO; GIMENO, CJ; STYLES, CA; FINK, GR				LJUNGDAHL, PO; GIMENO, CJ; STYLES, CA; FINK, GR			SHR3 - A NOVEL COMPONENT OF THE SECRETORY PATHWAY SPECIFICALLY REQUIRED FOR LOCALIZATION OF AMINO-ACID PERMEASES IN YEAST	CELL			English	Article							NITROGEN CATABOLITE REPRESSION; MEMBRANE-SPANNING PROTEINS; CYCLOPHILIN HOMOLOG NINAA; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; GENE; TRANSPORT	Mutations in SHR3 block amino acid uptake into yeast by reducing the levels of multiple amino acid permeases within the plasma membrane. SHR3 is a novel integral membrane protein component of the endoplasmic reticulum (ER). shr3 null mutants specifically accumulate amino acid permeases in the ER; other plasma membrane proteins, secretory proteins, and vacuolar proteins are processed and targeted correctly. Our findings suggest that SHR3 interacts with a structural domain shared by amino acid permeases, an interaction required for permease-specific processing and transport from the ER. Even in the presence of excess amino acids, shr3 mutants exhibit starvation responses. shr3 mutants constitutively express elevated levels of GCN4, and mutant shr3/shr3 diploids undergo dimorphic transitions that result in filamentous growth at enhanced frequencies.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	LJUNGDAHL, PO (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Ljungdahl, Per O/M-5258-2013	Ljungdahl, Per O/0000-0002-6625-3540	NIGMS NIH HHS [GM12038, GM40266, GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035010, R01GM040266, R01GM035010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLE GF, 1985, P NATL ACAD SCI USA, V82, P3756, DOI 10.1073/pnas.82.11.3756; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COURCHESNE WE, 1983, MOL CELL BIOL, V3, P672, DOI 10.1128/MCB.3.4.672; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; FINERMOORE J, 1989, PREDICTION PROTEIN S, P719; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GARRETT JM, 1989, J GEN MICROBIOL, V135, P2429; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GREEN GN, 1989, J CELL SCI, P109; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GRENSON M, 1971, J BACTERIOL, V105, P477, DOI 10.1128/JB.105.2.477-482.1971; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; HORAK J, 1986, BIOCHIM BIOPHYS ACTA, V864, P223, DOI 10.1016/0304-4157(86)90001-8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1990, EUR J BIOCHEM, V190, P39, DOI 10.1111/j.1432-1033.1990.tb15542.x; KIM JM, 1990, GENETICS, V126, P799; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO PF, 1981, J BACTERIOL, V148, P241, DOI 10.1128/JB.148.1.241-247.1981; LINK AJ, 1991, GENETICS, V127, P681; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1990, MOL CELL BIOL, V10, P2941, DOI 10.1128/MCB.10.6.2941; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; PORUCHYNSKY MS, 1988, J CELL BIOL, V107, P1697, DOI 10.1083/jcb.107.5.1697; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSE M, 1981, P NATL ACAD SCI-BIOL, V78, P2460, DOI 10.1073/pnas.78.4.2460; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; RYTKA J, 1975, J BACTERIOL, V121, P562, DOI 10.1128/JB.121.2.562-570.1975; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SIKORSKI RS, 1989, GENETICS, V122, P19; SILVE S, 1991, MOL CELL BIOL, V11, P1114, DOI 10.1128/MCB.11.2.1114; SORSOLI WA, 1964, J BACTERIOL, V88, P20, DOI 10.1128/JB.88.1.20-24.1964; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SURDIN Y, 1965, BIOCHIM BIOPHYS ACTA, V107, P546, DOI 10.1016/0304-4165(65)90199-6; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; VANDENBOL M, 1989, GENE, V83, P153, DOI 10.1016/0378-1119(89)90413-7; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEBER E, 1988, J MOL EVOL, V27, P341, DOI 10.1007/BF02101197; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	82	180	183	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					463	478		10.1016/0092-8674(92)90515-E	http://dx.doi.org/10.1016/0092-8674(92)90515-E			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1423607				2022-12-01	WOS:A1992JW43500012
J	MCGARRY, JD				MCGARRY, JD			WHAT IF MINKOWSKI HAD BEEN AGEUSIC - AN ALTERNATIVE ANGLE ON DIABETES	SCIENCE			English	Article							FREE FATTY-ACID; HEPATIC GLUCOSE-PRODUCTION; CARNITINE PALMITOYLTRANSFERASE; PLASMA-GLUCOSE; INSULIN; MELLITUS; MECHANISMS; RESISTANCE; INHIBITION; OXIDATION	Despite decades of intensive investigation, the basic pathophysiological mechanisms responsible for the metabolic derangements associated with diabetes mellitus have remained elusive. Explored here is the possibility that traditional concepts in this area might have carried the wrong emphasis. It is suggested that the phenomena of insulin resistance and hyperglycemia might be more readily understood if viewed in the context of underlying abnormalities of lipid metabolism.	UNIV TEXAS, SW MED CTR, CTR DIABET RES, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MCGARRY, JD (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK011313, R37DK018573, R01DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK11313, DK18573] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY CJ, 1990, NEW ANTIDIABETIC DRU, P231; BALASSE EO, 1973, METABOLISM, V22, P1193, DOI 10.1016/0026-0495(73)90207-2; BALASSE EO, 1974, EUR J CLIN INVEST, V4, P247, DOI 10.1111/j.1365-2362.1974.tb02342.x; CHEN YDI, 1987, J CLIN ENDOCR METAB, V64, P17, DOI 10.1210/jcem-64-1-17; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FALHOLT K, 1988, DIABETIC MED, V5, P27, DOI 10.1111/j.1464-5491.1988.tb00936.x; MARBAN SL, 1992, DIABETES, V41, pA145; MCGARRY D, 1979, DIABETES, V28, P517; MCGARRY JD, 1973, J CLIN INVEST, V52, P877, DOI 10.1172/JCI107252; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; PONTIROLI AE, 1992, DIABETOLOGIA, V35, P294, DOI 10.1007/BF00400934; RANDLE PJ, 1988, DIABETES METAB REV, V4, P623, DOI 10.1002/dmr.5610040702; RATHEISER K, 1991, METABOLISM, V40, P1185, DOI 10.1016/0026-0495(91)90214-H; REAVEN GM, 1988, DIABETES, V37, P28, DOI 10.2337/diabetes.37.1.28; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; SALORANTA C, 1991, DIABETOLOGIA, V34, P409, DOI 10.1007/BF00403179; SCHUMACHER MC, 1992, DIABETES, V41, P416, DOI 10.2337/diabetes.41.4.416; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; UNGER RH, 1983, HDB EXPT PHARM, V2, P431; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WITITSUWANNAKUL D, 1977, J BIOL CHEM, V252, P7812; WOLF HPO, 1990, NEW ANTIDIABETIC DRU, P217; YOUNG AA, 1991, FEBS LETT, V287, P203, DOI 10.1016/0014-5793(91)80051-4; ZARJEVSKI N, 1992, ENDOCRINOLOGY, V130, P1564, DOI 10.1210/en.130.3.1564	27	544	557	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1992	258	5083					766	770		10.1126/science.1439783	http://dx.doi.org/10.1126/science.1439783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439783				2022-12-01	WOS:A1992JV69200026
J	RUDNICKI, MA; BRAUN, T; HINUMA, S; JAENISCH, R				RUDNICKI, MA; BRAUN, T; HINUMA, S; JAENISCH, R			INACTIVATION OF MYOD IN MICE LEADS TO UP-REGULATION OF THE MYOGENIC HLH GENE MYF-5 AND RESULTS IN APPARENTLY NORMAL MUSCLE DEVELOPMENT	CELL			English	Article							EMBRYONAL CARCINOMA-CELLS; CREATINE-KINASE GENE; MOUSE EMBRYO; ACTIN GENE; EXPRESSION; FAMILY; DIFFERENTIATION; MEMBER; IDENTIFICATION; ENHANCER	The myogenic basic HLH transcription factor family of genes, composed of MyoD, myogenin, Myf-5, and Myf-6, are thought to regulate skeletal muscle differentiation. To understand the role of MyoD in myogenesis, we have introduced a null mutation of MyoD into the germline of mice. Surprisingly, mice lacking MyoD are viable and fertile. Histological examination of skeletal muscle failed to reveal any morphological abnormalities in these mice. Furthermore, Northern analysis revealed normal levels of skeletal muscle-specific mRNAs. Significantly, Myf-5 mRNA levels are elevated in postnatal mutant mice. Normally, Myf-5 expression becomes markedly reduced at day 12 of gestation when MyoD mRNA first appears. This suggests that Myf-5 expression is repressed by MyoD. Our results indicate that MyoD is dispensable for skeletal muscle development in mice, revealing some degree of functional redundancy in the control of the skeletal myogenic developmental program.	MIT, WHITEHEAD INST, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA; UNIV HAMBURG, SCH MED, DEPT TOXICOL, W-2000 HAMBURG 13, GERMANY	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Hamburg			Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NCI NIH HHS [5R35 CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bancroft JD, 1990, THEORY PRACTICE HIST; BLOCK NE, 1992, MOL CELL BIOL, V12, P2484, DOI 10.1128/MCB.12.6.2484; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHEN L, 1992, SCIENCE, V256, P240, DOI 10.1126/science.1314423; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Maniatis T., 1982, MOL CLONING; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MILLER JB, 1991, NEUROMUSCULAR DISORD, V61, P7; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PATERSON BM, 1991, P NATL ACAD SCI USA, V88, P3782, DOI 10.1073/pnas.88.9.3782; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUDNICKI MA, 1989, DEVELOPMENT, V107, P361; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; RUDNICKI MA, 1991, GENOME ANAL, V2, P13; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	48	813	848	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					383	390		10.1016/0092-8674(92)90508-A	http://dx.doi.org/10.1016/0092-8674(92)90508-A			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1330322				2022-12-01	WOS:A1992JW43500005
J	SHERMAN, LA; HESSE, SV; IRWIN, MJ; LAFACE, D; PETERSON, P				SHERMAN, LA; HESSE, SV; IRWIN, MJ; LAFACE, D; PETERSON, P			SELECTING T-CELL RECEPTORS WITH HIGH-AFFINITY FOR SELF-MHC BY DECREASING THE CONTRIBUTION OF CD8	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOTOXIC LYMPHOCYTES-T; TRANSGENIC MICE; ALPHA-3 DOMAIN; ANTIGEN RECEPTOR; I MOLECULES; POSITIVE SELECTION; RECOGNITION; HLA-A2; THYMUS	Selective events during T cell repertoire development in the thymus include both the positive selection of cells whose receptors recognize self-major histocompatibility complex (MHC) molecules and negative selection (tolerance) of cells whose interaction with self-MHC is of high affinity. The affinity of T cell interactions with class I MHC molecules includes contributions by both the T cell receptor and the CD8 coreceptor. Therefore, by decreasing the affinity of the interaction with CD8, T cells whose receptors have relatively high affinities for self-MHC may survive negative selection. Such T cells were generated and those T cells reactive with self-MHC plus antigen also displayed low affinity for self.			SHERMAN, LA (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.			Sherman, Linda/0000-0001-6422-7069	NCI NIH HHS [CA 25803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DUKE RC, 1989, J EXP MED, V170, P59, DOI 10.1084/jem.170.1.59; ENGELHARD VH, 1991, J IMMUNOL, V146, P1226; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; IRWIN MJ, 1989, J EXP MED, V170, P1091, DOI 10.1084/jem.170.4.1091; KALINKE U, 1990, NATURE, V348, P642, DOI 10.1038/348642a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KISELOW P, 1988, NATURE, V335, P730; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAFACE D, 1992, FASEB J, V6, pA1709; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MACDONALD HR, 1988, NATURE, V336, P73; POTTER TA, 1989, NATURE, V337, P73, DOI 10.1038/337073a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMBERG NL, 1989, EUR J IMMUNOL, V19, P2349, DOI 10.1002/eji.1830191225; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VITIELLO A, 1983, J IMMUNOL, V131, P1635; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	30	97	111	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					815	818		10.1126/science.1439792	http://dx.doi.org/10.1126/science.1439792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439792				2022-12-01	WOS:A1992JV69200043
J	VACHON, G; COHEN, B; PFEIFLE, C; MCGUFFIN, ME; BOTAS, J; COHEN, SM				VACHON, G; COHEN, B; PFEIFLE, C; MCGUFFIN, ME; BOTAS, J; COHEN, SM			HOMEOTIC GENES OF THE BITHORAX COMPLEX REPRESS LIMB DEVELOPMENT IN THE ABDOMEN OF THE DROSOPHILA EMBRYO THROUGH THE TARGET GENE DISTAL-LESS	CELL			English	Article							SEGMENT-POLARITY GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ULTRABITHORAX PROTEINS; HOMEODOMAIN PROTEINS; IMAGINAL DISKS; FUSHI-TARAZU; MELANOGASTER; EXPRESSION; WINGLESS	Homeotic genes encode transcription factors that are thought to specify segmental identity by regulating expression of subordinate genes. Limb development is repressed in the abdominal segments of the Drosophila embryo by the hometic genes of the Bithorax complex (BX-C). Localized expression of the homeobox gene Distal-less (DII) is required for leg development in thoracic segments. We have identified a minimal cis-regulatory enhancer element that directs DII expression in the larval leg primordia. We present evidence that the BX-C proteins repress DII expression in abdominal segments by binding to a small number of specific sites in this element. Mutating these sites eliminates BX-C protein binding and renders the element insensitive to BX-C-mediated repression in vivo. Repression of limb development in the abdomen appears to be controlled at the DII enhancer. Thus DII may serve as a downstream target gene through which the homeotic genes control abdominal segment identity in the Drosophila embryo.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	VACHON, G (corresponding author), BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA.		Cohen, Stephen M/G-9930-2011	Cohen, Stephen M/0000-0003-2858-9163				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; CASANOVA J, 1987, EMBO J, V6, P3103, DOI 10.1002/j.1460-2075.1987.tb02619.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HUNT P, 1991, CELL, V66, P1075, DOI 10.1016/0092-8674(91)90029-X; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SAMSON ML, 1989, CELL, V57, P1045, DOI 10.1016/0092-8674(89)90342-5; SIMCOX AA, 1989, DEVELOPMENT, V107, P715; SIMCOX AA, 1991, MECH DEVELOP, V34, P11, DOI 10.1016/0925-4773(91)90087-M; STUART JJ, 1991, NATURE, V350, P72, DOI 10.1038/350072a0; SUNKEL CE, 1987, ROUX ARCH DEV BIOL, V196, P124, DOI 10.1007/BF00402034; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THALI M, 1988, NATURE, V336, P598, DOI 10.1038/336598a0; THUMMEL C, 1992, IN PRESS DROS INF SE; TREISMAN J, 1989, CELL, V59, P553; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wieschaus E., 1986, P199; WINSLOW GM, 1989, CELL, V57, P1017, DOI 10.1016/0092-8674(89)90340-1; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	57	317	326	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					437	450		10.1016/0092-8674(92)90513-C	http://dx.doi.org/10.1016/0092-8674(92)90513-C			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1358457				2022-12-01	WOS:A1992JW43500010
J	WANG, J; BEDZYK, MJ; CAFFREY, M				WANG, J; BEDZYK, MJ; CAFFREY, M			RESONANCE-ENHANCED X-RAYS IN THIN-FILMS - A STRUCTURE PROBE FOR MEMBRANES AND SURFACE-LAYERS	SCIENCE			English	Article							STANDING WAVES; INTERFACE; FLUORESCENCE; DIFFRACTION	An x-ray resonance effect in an organic thin film on an x-ray reflecting mirror is reported. The resonance effect is the result of interference between reflected and refracted x-rays at the air-organic thin film interface and occurs at incident angles slightly above the critical angle of the film. In excellent agreement with theory, the primary resonant x-ray electric field that is confined in the organic thin film is approximately 20 times as intense as the electric field of the incident beam when measured at a position close to the center of the film. Resonance-enhanced x-rays can be used to characterize the internal structure of Langmuir-Blodgett thin film membranes. This effect may also find use in x-ray-based thin film devices and in the structural analysis of adlayers and surfaces that have thus far proved difficult, if not impossible, to study because of sensitivity limitations.	OHIO STATE UNIV,CHEM PHYS PROGRAM,COLUMBUS,OH 43210; NORTHWESTERN UNIV,DEPT MAT SCI & ENGN,EVANSTON,IL 60208; ARGONNE NATL LAB,ARGONNE,IL 60439	University System of Ohio; Ohio State University; Northwestern University; United States Department of Energy (DOE); Argonne National Laboratory	WANG, J (corresponding author), OHIO STATE UNIV,DEPT CHEM,COLUMBUS,OH 43210, USA.		Bedzyk, Michael J/B-7503-2009; Bedzyk, Michael J/K-6903-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R23DK036849, R01DK045295, R01DK036849] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36849, DK 45295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER RS, 1983, PHYS REV LETT, V50, P153, DOI 10.1103/PhysRevLett.50.153; BEDZYK MJ, 1990, SCIENCE, V248, P52, DOI 10.1126/science.2321026; BEDZYK MJ, 1989, PHYS REV LETT, V62, P1376, DOI 10.1103/PhysRevLett.62.1376; BEDZYK MJ, 1988, SCIENCE, V241, P1788, DOI 10.1126/science.3175619; BLOCH JM, 1985, PHYS REV LETT, V54, P1039, DOI 10.1103/PhysRevLett.54.1039; BOMMARITO GM, 1987, THESIS CORNELL U ITH; Born M., 1991, PRINCIPLES OPTICS; Compton A.H., 1935, XRAYS THEORY EXPT; DEBOER DKG, 1991, PHYS REV B, V44, P498, DOI 10.1103/PhysRevB.44.498; EISENBERGER P, 1981, PHYS REV LETT, V46, P1081, DOI 10.1103/PhysRevLett.46.1081; MARRA WC, 1979, J APPL PHYS, V50, P6927, DOI 10.1063/1.325845; PARRATT LG, 1954, PHYS REV, V95, P359, DOI 10.1103/PhysRev.95.359; WANG J, 1991, NATURE, V354, P377, DOI 10.1038/354377a0	13	127	129	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 30	1992	258	5083					775	778		10.1126/science.1439784	http://dx.doi.org/10.1126/science.1439784			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV692	1439784				2022-12-01	WOS:A1992JV69200028
J	XIONG, Y; ZHANG, H; BEACH, D				XIONG, Y; ZHANG, H; BEACH, D			D-TYPE CYCLINS ASSOCIATE WITH MULTIPLE PROTEIN-KINASES AND THE DNA-REPLICATION AND REPAIR FACTOR PCNA	CELL			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; S-PHASE; AUXILIARY PROTEIN; POLYMERASE-DELTA; CDC2; MITOSIS; ACTIVATION; GENE	Human cyclin D1 has been associated with a wide variety of proliferative diseases but its biochemical role is unknown. In diploid fibroblasts we find that cyclin D1 is complexed with many other cellular proteins. Among them are protein kinase catalytic subunits CDK2, CDK4 (previously called PSK-J3), and CDK5 (also called PSSALRE). In addition, polypeptides of 21 kd and 36 kd are identified in association with cyclin D1. We show that the 36 kd protein is the proliferating cell nuclear antigen, PCNA. Cyclin D3 also associates with multiple protein kinases, p21 and PCNA. It is proposed that there exists a quaternary complex of D cyclin, CDK, PCNA, and p21 and that many combinatorial variations (cyclin D1, D3, CDK2, 4, and 5) may assemble in vivo. These findings link a human putative G1 cyclin that is associated with oncogenesis with a well-characterized DNA replication and repair factor.			XIONG, Y (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA.				NIGMS NIH HHS [GM39620-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039620] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1984, EMBO J, V3, P3177, DOI 10.1002/j.1460-2075.1984.tb02276.x; BUENO A, 1991, CELL, V66, P149, DOI 10.1016/0092-8674(91)90147-Q; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARLOW E, 1988, ANTIBODIES LABORATOR; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WON KA, 1992, IN PRESS P NATL ACAD; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	49	1014	1056	12	155	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 30	1992	71	3					505	514		10.1016/0092-8674(92)90518-H	http://dx.doi.org/10.1016/0092-8674(92)90518-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JW435	1358458				2022-12-01	WOS:A1992JW43500015
J	BAGHURST, PA; MCMICHAEL, AJ; WIGG, NR; VIMPANI, GV; ROBERTSON, EF; ROBERTS, RJ; TONG, SL				BAGHURST, PA; MCMICHAEL, AJ; WIGG, NR; VIMPANI, GV; ROBERTSON, EF; ROBERTS, RJ; TONG, SL			ENVIRONMENTAL EXPOSURE TO LEAD AND CHILDRENS INTELLIGENCE AT THE AGE OF 7 YEARS - THE PORT-PIRIE COHORT STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-LEVEL EXPOSURE; BLOOD-LEAD; IRON-DEFICIENCY; EARLY-CHILDHOOD; SOCIAL-CLASS; PERFORMANCE; ATTAINMENT; BEHAVIOR; IQ	Background. Exposure to lead in early childhood is thought to result in delayed neuropsychological development. As yet there is little longitudinal evidence to establish whether these effects persist into later childhood. Methods. We measured IQ scores in 494 seven-year-old children from the lead-smelting community of Port Pirie, Australia, in whom developmental deficits associated with elevated blood lead concentrations had already been reported at the ages of two and four years. Exposure to lead was estimated from the lead concentrations in maternal blood samples drawn antenatally and at delivery and from blood samples drawn from the children at birth (umbilical-cord blood), at the ages of 6 and 15 months and 2 years, and annually thereafter. Data relating to known covariates of child development were collected systematically for each child throughout the first seven years of life. Results. We found inverse relations between IQ at the age of seven years and both antenatal and postnatal blood lead concentrations. After adjustment by multiple regression for sex, parents' level of education, maternal age at delivery, parents' smoking status, socioeconomic status, quality of the home environment, maternal IQ, birth weight, birth order, feeding method (breast, bottle, or both), duration of breast-feeding, and whether the child's natural parents were living together, the relation with lead exposure was still evident for postnatal blood samples, particularly within the age range of 15 months to 4 years. For an increase in blood lead concentration from 10 mug per deciliter (0.48 mumol per liter) to 30 mug per deciliter (1.45 mumol per liter), expressed as the average of the concentrations at 15 months and 2, 3, and 4 years, the estimated reduction in the IQ of the children was in the range of 4.4 points (95 percent confidence interval, 2.2 to 6.6) to 5.3 points (95 percent confidence interval, 2.8 to 7.8). This reduction represents an approximate deficit in IQ of 4 to 5 percent. Conclusions. Low-level exposure to lead during early childhood is inversely associated with neuropsychological development through the first seven years of life.	CHILD ADOLESCENT & FAMILY HLTH SERV,ADELAIDE,SA,AUSTRALIA; ADELAIDE CTR WOMENS & CHILDRENS HLTH,DEPT CHEM PATHOL,ADELAIDE,SA,AUSTRALIA; NATL HLTH EDUC INST,DEPT SPECIAL PROGRAMMES,BEIJING,PEOPLES R CHINA; UNIV ADELAIDE,DEPT COMMUNITY MED,ADELAIDE,SA 5001,AUSTRALIA; FLINDERS UNIV,SCH NURSING,ADELAIDE,SA,AUSTRALIA; UNIV NEWCASTLE,FAC MED,NEWCASTLE,NSW 2308,AUSTRALIA	University of Adelaide; Flinders University South Australia; University of Newcastle	BAGHURST, PA (corresponding author), CSIRO,DIV HUMAN NUTR,POB 10041,GOUGER ST,ADELAIDE,SA 5000,AUSTRALIA.							BAGHURST P, 1985, ENVIRON RES, V38, P24, DOI 10.1016/0013-9351(85)90069-6; BAGHURST PA, 1992, ARCH ENVIRON HEALTH, V47, P203, DOI 10.1080/00039896.1992.9938350; BELLINGER D, 1989, INT J EPIDEMIOL, V18, P180, DOI 10.1093/ije/18.1.180; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BINDER S, 1991, STRATEGIC PLAN ELIMI; BRADLEY RH, 1979, AM J MENT DEF, V84, P235; COONEY GH, 1989, NEUROTOXICOL TERATOL, V11, P95, DOI 10.1016/0892-0362(89)90047-0; DANIEL A, 1984, COMMUNITY HEALTH ST, V8, P218; DIETRICH KN, 1987, PEDIATRICS, V80, P721; ERNHART CB, 1988, SCI TOTAL ENVIRON, V71, P453, DOI 10.1016/0048-9697(88)90218-5; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; FULTON M, 1987, LANCET, V1, P1221; GILBERT SG, 1987, TOXICOL APPL PHARM, V91, P484, DOI 10.1016/0041-008X(87)90070-6; HARVEY PG, 1984, SCI TOTAL ENVIRON, V40, P45, DOI 10.1016/0048-9697(84)90341-3; HATZAKIS A, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P211; Kaufman A.S., 1979, INTELLIGENT TESTING; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; LEE WR, 1990, BMJ-BRIT MED J, V301, P504, DOI 10.1136/bmj.301.6751.504; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MCMICHAEL AJ, 1985, MED J AUSTRALIA, V143, P499, DOI 10.5694/j.1326-5377.1985.tb119911.x; MCMICHAEL AJ, 1988, NEW ENGL J MED, V319, P468, DOI 10.1056/NEJM198808253190803; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1989, LEAD EXPOSURE AND CHILD DEVELOPMENT, P293; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NEEDLEMAN HL, 1991, ANNU REV PUBL HEALTH, V12, P111, DOI 10.1146/annurev.pu.12.050191.000551; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SMITH RE, 1983, SOIL SCI SOC AM J, V47, P1; WALTER T, 1989, PEDIATRICS, V84, P7; Wechsler D, 1981, ADULT INTELLIGENCE S; Wechsler D, 1974, WECHSLER ADULT INTEL; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755; 1988, JAMA-J AM MED ASSOC, V260, P1523; 1986, EPA600883028AF ENV C; 1985, 27871985 STAND ASS A	38	406	412	0	34	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1279	1284		10.1056/NEJM199210293271805	http://dx.doi.org/10.1056/NEJM199210293271805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1383818				2022-12-01	WOS:A1992JV25900005
J	IRWIN, MJ; HUDSON, KR; FRASER, JD; GASCOIGNE, NRJ				IRWIN, MJ; HUDSON, KR; FRASER, JD; GASCOIGNE, NRJ			ENTEROTOXIN RESIDUES DETERMINING T-CELL RECEPTOR V-BETA BINDING-SPECIFICITY	NATURE			English	Article							STAPHYLOCOCCAL-ENTEROTOXIN; STIMULATION; SUPERANTIGENS; MOLECULE; CHAIN	SUPERANTIGENS such as the staphylococcal enterotoxins bind to major histocompatibility complex (MHC) class II molecules and activate T cells through a specific interaction between the Vbeta region of the T-cell antigen receptor (TCR) and the toxin1-4. The TCR beta-chain alone is sufficient to produce the interaction with the enterotoxin-class II complex5. Identification of the regions of enterotoxins that interact with TCR has so far proved equivocal because of difficulties in distinguishing between direct effects on T-cell recognition and indirect effects resulting from alteration of binding to class II. For example, amino-terminal truncations of SEB abrogated T-cell stimulation whereas carboxy-terminal truncation of SEA stopped its mitogenic activity10,11. The most comprehensive study to date, accounting for both enterotoxin binding to class II and enterotoxin interactions with the TCR, identified two functionally important regions for SEB binding to TCR12. Although the amino-acid sequences of staphylococcal enterotoxins A and E are 82% identical6, they activate T cells bearing different Vbeta elements. We have assayed the binding of cells coated with these enterotoxins to soluble secreted TCR beta-chain protein and find that Vbeta3 binds enterotoxin A but not E, whereas Vbeta11 binds enterotoxin but not A. To map the amino-acid residues responsible for these different binding specificities, we prepared a series of hybrids between the two staphylococcal enterotoxins. We report that just two amino-acid residues near the carboxy terminus of the enterotoxins are responsible for the discrimination between these molecules by Vbeta3 and Vbeta11. The crystal structure of staphylococcal enterotoxin B (ref. 12) indicates that these form part of the outer rim of the site recognizing TCR.	Scripps Res Inst, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA; UNIV AUCKLAND, DEPT MOLEC MED, AUCKLAND, NEW ZEALAND	Scripps Research Institute; University of Auckland								BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BUELOW R, 1992, J IMMUNOL, V148, P1; CALLAHAN JE, 1990, J IMMUNOL, V144, P2473; COUCH JL, 1988, J BACTERIOL, V170, P2954, DOI 10.1128/jb.170.7.2954-2960.1988; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GASCOIGNE NR, IN PRESS J SEMIN IMM; GASCOIGNE NRJ, 1990, J BIOL CHEM, V265, P9296; GASCOIGNE NRJ, 1991, P NATL ACAD SCI USA, V88, P613, DOI 10.1073/pnas.88.2.613; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HUFNAGLE WO, 1991, INFECT IMMUN, V59, P2126, DOI 10.1128/IAI.59.6.2126-2134.1991; JOHNSON HM, 1991, FASEB J, V5, P2706, DOI 10.1096/fasebj.5.12.1916093; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KUBO RT, 1989, J IMMUNOL, V142, P2736; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; PALMER MS, 1989, NUCLEIC ACIDS RES, V17, P2353, DOI 10.1093/nar/17.6.2353; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; SINGH BR, 1989, J BIOL CHEM, V264, P4404; SMITH HP, 1992, J IMMUNOL, V149, P887; Summers MD, 1987, TEXAS AGR EXPT STATI; SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0; TAKIMOTO H, 1990, EUR J IMMUNOL, V20, P617, DOI 10.1002/eji.1830200323; VACCHIO MS, 1992, J EXP MED, V175, P1405, DOI 10.1084/jem.175.5.1405	23	77	80	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					841	843		10.1038/359841a0	http://dx.doi.org/10.1038/359841a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436060				2022-12-01	WOS:A1992JV77700067
J	KOUTSKY, LA; HOLMES, KK; CRITCHLOW, CW; STEVENS, CE; PAAVONEN, J; BECKMANN, AM; DEROUEN, TA; GALLOWAY, DA; VERNON, D; KIVIAT, NB				KOUTSKY, LA; HOLMES, KK; CRITCHLOW, CW; STEVENS, CE; PAAVONEN, J; BECKMANN, AM; DEROUEN, TA; GALLOWAY, DA; VERNON, D; KIVIAT, NB			A COHORT STUDY OF THE RISK OF CERVICAL INTRAEPITHELIAL NEOPLASIA GRADE-2 OR GRADE-3 IN RELATION TO PAPILLOMAVIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-1; CANCER; WOMEN; HERPES; ANTIBODIES	Background Human papillomavirus (HPV) has been associated with cervical intraepithelial neoplasia, but the temporal relation between the infection and the neoplasia remains unclear, as does the relative importance of the specific type of HPV, other sexually transmitted diseases, and other risk factors. Methods. We studied prospectively a cohort of 241 women who presented for evaluation of sexually transmitted disease and had negative cervical cytologic tests. The women were followed every four months with cytologic and colposcopic examinations of the uterine cervix and tests for HPV DNA and other sexually transmitted diseases. Results. Cervical intraepithelial neoplasia grade 2 or 3 was confirmed by biopsy in 28 women. On the basis of survival analysis, the cumulative incidence of cervical intraepithelial neoplasia at two years was 28 percent among women with a positive test for HPV and 3 percent among those without detectable HPV DNA. The risk was highest among those with HPV type 16 or 18 infection (adjusted relative risk as compared with that in women without HPV infection, 11; 95 percent confidence interval, 4.6 to 26; attributable risk, 52 percent). All 24 cases of cervical intraepithelial neoplasia grade 2 or 3 among HPV-positive women were detected within 24 months after the first positive test for HPV. After adjustment for the presence of HPV infection, the development of cervical intraepithelial neoplasia was also associated with younger age at first intercourse, the presence of serum antibodies to Chlamydia trachomatis, the presence of serum antibodies to cytomegalovirus, and cervical infection with Neisseria gonorrhoeae. Conclusions. Cervical intraepithelial neoplasia is a common and apparently early manifestation of cervical infection by HPV, particularly types 16 and 18.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT OBSTET & GYNECOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA; FRED HUTCHINSON CANC RES CTR, DEPT TUMOR BIOL, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center			, Holmes/K-6215-2019		NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024756, P01AI012192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 34493] Funding Source: Medline; NIAID NIH HHS [AI 12192, AI 24756] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; Breslow N E, 1987, IARC Sci Publ, P1; CAMPION MJ, 1986, LANCET, V2, P237; CUZICK J, 1989, BRIT J CANCER, V60, P238, DOI 10.1038/bjc.1989.261; DEVILLIERS EM, 1987, LANCET, V2, P703; DONNAN SPB, 1989, INT J EPIDEMIOL, V18, P32, DOI 10.1093/ije/18.1.32; HARRIS RWC, 1980, BRIT J CANCER, V42, P359, DOI 10.1038/bjc.1980.246; KIVIAT NB, 1989, J INFECT DIS, V159, P293, DOI 10.1093/infdis/159.2.293; KIVIAT NB, 1992, INT J GYNECOL PATHOL, V11, P197, DOI 10.1097/00004347-199207000-00005; Koss L. G, 1979, DIAGNOSTIC CYTOLOGY; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LORINCZ A, 1990, SEXUALLY TRANSMITTED, P953; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LORINCZ AT, 1990, AM J OBSTET GYNECOL, V162, P645, DOI 10.1016/0002-9378(90)90974-C; LORINCZ AT, 1986, VIRAL ETIOLOGY CERVI, P225; MCDOUGALL JK, 1986, CIBA F SYMP, V120, P86; Paavonen J, 1988, Obstet Gynecol Surv, V43, P373, DOI 10.1097/00006254-198807000-00001; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; PRATILI M A, 1986, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V15, P45; REEVES WC, 1987, INT J CANCER, V40, P450, DOI 10.1002/ijc.2910400403; REID R, 1987, AM J OBSTET GYNECOL, V156, P212, DOI 10.1016/0002-9378(87)90241-9; RITTER DB, 1988, AM J OBSTET GYNECOL, V159, P1517, DOI 10.1016/0002-9378(88)90587-X; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SLATTERY ML, 1989, AM J EPIDEMIOL, V130, P248, DOI 10.1093/oxfordjournals.aje.a115331; SMILEY L, 1990, SEXUALLY TRANSMITTED, P415; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; STAMM WE, 1990, SEXUALLY TRANSMITTED, P917; SYRJANEN K, 1987, PAPILLOMAVIRUSES, V5, P281; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; ZANINETTI P, 1986, INT J EPIDEMIOL, V15, P477, DOI 10.1093/ije/15.4.477; ZUNZUNEGUI MV, 1986, AM J EPIDEMIOL, V123, P302, DOI 10.1093/oxfordjournals.aje.a114238	33	762	794	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1272	1278		10.1056/NEJM199210293271804	http://dx.doi.org/10.1056/NEJM199210293271804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1328880				2022-12-01	WOS:A1992JV25900004
J	LIPSHULTZ, SE; ORAV, EJ; SANDERS, SP; HALE, AR; MCINTOSH, K; COLAN, SD				LIPSHULTZ, SE; ORAV, EJ; SANDERS, SP; HALE, AR; MCINTOSH, K; COLAN, SD			CARDIAC STRUCTURE AND FUNCTION IN CHILDREN WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION TREATED WITH ZIDOVUDINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTOLIC WALL STRESS; MITOCHONDRIAL-DNA; HIV-INFECTION; AIDS PATIENTS; RAT HEARTS; MYOPATHY; THERAPY; DYSFUNCTION; HYPERTROPHY; MECHANICS	Background. Abnormalities of cardiac structure and function are common in children infected with the human immunodeficiency virus (HIV). It is unclear, however, whether these abnormalities are attributable to the disease itself, associated infections, or possible cardiotoxic effects of the most commonly used treatment, zidovudine. Methods. We performed echocardiography in 24 children with symptomatic HIV infection immediately before they started zidovudine therapy and a mean of 1.32 years after therapy began. Sixteen of these children were also studied a mean of 1.26 years before starting zidovudine treatment. Comparison groups included 27 age-matched children with symptomatic HIV infection who had not received zidovudine and 191 normal children. Results. As compared with the normal children, the children treated with zidovudine had progressive left ventricular dilatation and an increase in ventricular-wall stress at end-systole (a measure of ventricular afterload); dilatation and stress were significantly elevated both before and during zidovudine treatment. The ratio of ventricular thickness to internal dimension was below normal before zidovudine treatment began (P<0.001). After treatment with zidovudine, however, overall left ventricular mass was increased (P = 0.02), as was peak wall stress (a stimulus to ventricular hypertrophy) (P = 0.01). Ventricular contractility remained normal, but fractional shortening of the left ventricle was decreased (P = 0.004). No statistically significant differences were detected at follow-up in any of these measurements between HIV-infected children treated with zidovudine and those not so treated. Conclusions. Progressive left ventricular dilatation occurred in children with symptomatic HIV infection. Compensatory hypertrophy also occurred but was inadequate to maintain peak systolic wall stress within the normal range. The progressive elevation of ventricular afterload due to dilatation resulted in depressed ventricular performance, but intrinsic ventricular contractility remained normal. Zidovudine did not appear to worsen or ameliorate these cardiac changes.	CHILDRENS HOSP MED CTR,DIV INFECT DIS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BOSTON CITY HOSP,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Boston Medical Center; Boston University	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP MED CTR,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NCRR NIH HHS [5M01RR02172] Funding Source: Medline; NHLBI NIH HHS [R01HL48012-01] Funding Source: Medline; NIAID NIH HHS [U01AI25934] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025934] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDEN PB, 1987, NUTRITION HEART DISE, V2, P71; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; CALDWELL B, 1991, 7TH P INT C AIDS FLO, V2, P362; COHEN AJ, 1990, AIDS, V4, P807, DOI 10.1097/00002030-199008000-00014; COLAN SD, 1987, J AM COLL CARDIOL, V9, P776, DOI 10.1016/S0735-1097(87)80232-2; COLAN SD, 1984, J AM COLL CARDIOL, V4, P715, DOI 10.1016/S0735-1097(84)80397-6; COLAN SD, 1987, J AM COLL CARDIOL, V10, P1085, DOI 10.1016/S0735-1097(87)80350-9; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CONNOR E, 1991, SEMIN PEDIATR INFECT, V2, P285; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; DALAKAS M, 1990, NEW ENGL J MED, V323, P994; DALAKAS MC, 1991, NEW ENGL J MED, V325, P1487, DOI 10.1056/NEJM199111213252107; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEYTON LR, 1989, NEW ENGL J MED, V321, P1246, DOI 10.1056/NEJM198911023211806; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GLANTZ S, 1990, PRIMER APPL REGRESSI, P294; GREENE MG, 1991, HARRIET LANE HDB, P42; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311; HSIA J, 1991, CIRCULATION S2, V84, P3; LAMPERTH L, 1991, LAB INVEST, V65, P742; LEWIS W, 1991, LAB INVEST, V65, P228; Lewis W, 1992, Cardiovasc Pathol, V1, P53, DOI 10.1016/1054-8807(92)90007-B; LIPSHULTZ SE, 1990, CIRCULATION, V82, P118; LIPSHULTZ SE, 1990, AM J CARDIOL, V66, P246, DOI 10.1016/0002-9149(90)90603-X; LIPSHULTZ SE, 1989, AM J CARDIOL, V63, P1489, DOI 10.1016/0002-9149(89)90014-3; LIPSHULTZ SE, 1989, PEDIATR RES, V25, pA183; LIPSHULTZ SE, 1989, CIRCULATION S2, V80, P322; LIPSHULTZ SE, 1991, CIRCULATION, V84, P660; MCKINNEY RE, 1991, NEW ENGL J MED, V324, P1018, DOI 10.1056/NEJM199104113241503; MHIRI C, 1991, ANN NEUROL, V29, P606, DOI 10.1002/ana.410290607; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; SALGO M, 1991, CARDIOMYOPATHY CONGE; SCHUNKERT H, 1991, P NATL ACAD SCI USA, V88, P11480, DOI 10.1073/pnas.88.24.11480; SIMPSON DM, 1991, AIDS, V5, P917, DOI 10.1097/00002030-199108000-00001; SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1; STEIN KM, 1991, AM J CARDIOL, V68, P1091, DOI 10.1016/0002-9149(91)90502-C; WALTER EB, 1991, J PEDIATR-US, V119, P152, DOI 10.1016/S0022-3476(05)81057-1; WHARTON JM, 1987, AM J MED, V83, P571, DOI 10.1016/0002-9343(87)90774-1; WILKINS CE, 1989, TEX HEART I J, V16, P44; Zar JH., 1999, BIOSTAT ANAL, V4; 1987, MMWR MORB MORTAL WKL, V36, P225	43	79	79	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1992	327	18					1260	1265		10.1056/NEJM199210293271802	http://dx.doi.org/10.1056/NEJM199210293271802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV259	1406818	Bronze			2022-12-01	WOS:A1992JV25900002
J	LUFKIN, T; MARK, M; HART, CP; DOLLE, P; LEMEUR, M; CHAMBON, P				LUFKIN, T; MARK, M; HART, CP; DOLLE, P; LEMEUR, M; CHAMBON, P			HOMEOTIC TRANSFORMATION OF THE OCCIPITAL BONES OF THE SKULL BY ECTOPIC EXPRESSION OF A HOMEOBOX GENE	NATURE			English	Article							VERTEBRAL COLUMN; DROSOPHILA; DISRUPTION; DEFECTS; HOX-1.1; MICE	MURINE Hox genes have been postulated to play a role in patterning of the embryonic body plan1-3. Gene disruption studies have suggested that for a given Hox complex, patterning of cell identity along the antero-posterior axis is directed by the more 'posterior' (having a more posterior rostral boundary of expression) Hox proteins expressed in a given cell4-6. This supports the 'posterior prevalence' model2, which also predicts that ectopic expression of a given Hox gene would result in altered structure only in regions anterior to its normal domain of expression. To test this model further, we have expressed the Hox-4.2 gene more rostrally than its normal mesoderm anterior boundary of expression, which is at the level of the first cervical somites. This ectopic expression results in a homeotic transformation of the occipital bones towards a more posterior phenotype into structures that resemble cervical vertebrae, whereas it has no effect in regions that normally express Hox-4.2. These results are similar to the homeotic posteriorization phenomenon generated in Drosophila by ectopic expression of genes of the homeotic complex HOM-C (refs 7-10; reviewed in ref. 3).	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dolle, Pascal/A-8037-2010; Lufkin, Thomas/AAG-7476-2019; Lufkin, Thomas/B-5352-2011	Dolle, Pascal/0000-0002-9294-9090; Lufkin, Thomas/0000-0002-7902-4771; Lufkin, Thomas/0000-0002-7902-4771; Hart, Charles/0000-0003-4440-726X				BAGNALL KM, 1988, DEVELOPMENT, V103, P69; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; de Beer G.R, 1971, DEV VERTEBRATE SKULL; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; EVANS FRANCIS GAYNOR, 1939, ANN NEW YORK ACAD SCI, V39, P29, DOI 10.1111/j.1749-6632.1939.tb55370.x; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FERGUSON MWJ, 1978, J ANAT, V125, P555; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gruss P, 1991, CURR OPIN GENET DEV, V1, P204, DOI 10.1016/S0959-437X(05)80071-1; Hogan B., 1986, MANIPULATING MOUSE E; JENKINS FA, 1969, ANAT REC, V164, P173, DOI 10.1002/ar.1091640205; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KURIORA MA, 1988, CELL, V55, P477; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NODEN DM, 1988, DEVELOPMENT, V103, P121; PIVETEAU J, 1954, TRAITE ZOOLOGIE, V12; Remak R., 1855, UNTERSUCHUNGEN ENTWI; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; THEILER K, 1988, ADV ANAT EMBRYOL CEL, V112, P1; VERBOUT AJ, 1985, ADV ANAT EMBRYOL CEL, V90, P1; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	31	247	252	1	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					835	841		10.1038/359835a0	http://dx.doi.org/10.1038/359835a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1359423				2022-12-01	WOS:A1992JV77700066
J	MUSACCHIO, A; NOBLE, M; PAUPTIT, R; WIERENGA, R; SARASTE, M				MUSACCHIO, A; NOBLE, M; PAUPTIT, R; WIERENGA, R; SARASTE, M			CRYSTAL-STRUCTURE OF A SRC-HOMOLOGY-3 (SH3) DOMAIN	NATURE			English	Article							PHOSPHOLIPASE-C; ALPHA-SPECTRIN; PROTEIN; SRC; SIMILARITY; REFINEMENT; SEQUENCES; ELEMENTS; ERRORS; BRAIN	THE Src-homologous SH3 domain is a small domain present in a large number of proteins that are involved in signal transduction, such as the Src protein tyrosine kinase, or in membrane-cytoskeleton interactions, but the function of SH3 is still unknown (reviewed in refs 1-3). Here we report the three-dimensional structure at 1.8 angstrom resolution of the SH3 domain of the cytoskeletal protein spectrin expressed in Escherichia coli. The domain is a compact beta-barrel made of five antiparallel beta-strands. The amino acids that are conserved in the SH3 sequences are located close to each other on one side of the molecule. This surface is rich in aromatic and carboxylic amino acids, and is distal to the region of the molecule where the N and C termini reside and where SH3 inserts into the alpha-spectrin chain. We suggest that a protein ligand binds to this conserved surface of SH3.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Musacchio, Andrea/0000-0003-2362-8784; Noble, Martin/0000-0002-3595-9807				ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; Bennett V, 1990, CURR OPIN CELL BIOL, V2, P51, DOI 10.1016/S0955-0674(05)80030-4; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1988, ONCOGENE, V3, P491; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SAHR KE, 1990, J BIOL CHEM, V265, P4434; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; 1979, CCP4 PACKAGE	35	413	424	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					851	855		10.1038/359851a0	http://dx.doi.org/10.1038/359851a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279434				2022-12-01	WOS:A1992JV77700071
J	NOTTEBOHM, E; DAMBLYCHAUDIERE, C; GHYSEN, A				NOTTEBOHM, E; DAMBLYCHAUDIERE, C; GHYSEN, A			CONNECTIVITY OF CHEMOSENSORY NEURONS IS CONTROLLED BY THE GENE POXN IN DROSOPHILA	NATURE			English	Article							CENTRAL NERVOUS-SYSTEM; SENSORY NEURONS; TRANSFORMATION; MELANOGASTER; PROJECTIONS; CUT	THE function of the nervous system depends on the formation of a net of appropriate connections, but little is known of the genetic program underlying this process. In Drosophila two genes that specify different types of sense organs have been identified: cut (ct)1,2, which specifies the formation of external sense organs as opposed to chordotonal organs, and pox-neuro (poxn)3, which specifies the formation of poly-innervated (chemosensory) organs as opposed to mono-innervated (mechanosensory) organs. Whether these genes are also involved in specifying the connectivity of the corresponding neurons is not known. The larval sense organs are unsuitable for analysis of the axonal pathway and connections and so we have investigated the effect of poxn on the adult. Here we show that overexpression of poxn induces the morphological transformation of mechanosensory into chemosensory bristles on the legs and that the neurons innervating the morphologically transformed bristles follow pathways and establish connections that are appropriate for chemosensory bristles.			NOTTEBOHM, E (corresponding author), UNIV LIBRE BRUXELLES,NEUROBIOL & GENET LAB,67 RUE CHEVAUX,B-1640 RHODE ST GENESE,BELGIUM.							BATE CM, 1976, HDB SENSORY PHYSL, V11; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DETHIER VG, 1965, PHYSL INSECT SENSES, P126; GHYSEN A, 1980, DEV BIOL, V78, P521, DOI 10.1016/0012-1606(80)90351-6; GHYSEN A, 1978, NATURE, V274, P869, DOI 10.1038/274869a0; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HELD LI, 1990, ROUX ARCH DEV BIOL, V199, P31, DOI 10.1007/BF01681531; MURPHEY RK, 1989, J NEUROSCI, V9, P3209; TEUGELS E, 1983, PROG BRAIN RES, V58, P305, DOI 10.1016/S0079-6123(08)60032-1; TOBLER H, 1973, EXPERIENTIA, V29, P170; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594	13	50	50	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					829	832		10.1038/359829a0	http://dx.doi.org/10.1038/359829a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436059				2022-12-01	WOS:A1992JV77700064
J	PALABRICA, T; LOBB, R; FURIE, BC; ARONOVITZ, M; BENJAMIN, C; HSU, YM; SAJER, SA; FURIE, B				PALABRICA, T; LOBB, R; FURIE, BC; ARONOVITZ, M; BENJAMIN, C; HSU, YM; SAJER, SA; FURIE, B			LEUKOCYTE ACCUMULATION PROMOTING FIBRIN DEPOSITION IS MEDIATED INVIVO BY P-SELECTIN ON ADHERENT PLATELETS	NATURE			English	Article							GRANULE MEMBRANE-PROTEIN; WEIBEL-PALADE BODIES; ACTIVATED PLATELETS; MONOCLONAL-ANTIBODY; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; GMP-140; NEUTROPHILS; RECEPTOR	THE glycoprotein P-selectin is a cell adhesion molecule of stimulated platelets and endothelial cells, which mediates the interaction of these cells with neutrophils and monocytes1,2. It is a membrane component of cell storage granules3-6, and is a member of the selectin family which includes E-selectin and L-selectin7,8. P-selectin recognizes both lineage-specific carbohydrate ligands on monocytes and neutrophils, including the Lewis x antigen, sialic acid, and a protein component9-12. In inflammation and thrombosis, P-selectin may mediate the interaction of leukocytes with platelets bound in the region of tissue injury and with stimulated endothelium1,2. To evaluate the role of P-selectin in platelet-leukocyte adhesion in vivo, the accumulation of leukocytes within an experimental thrombus was explored in an arteriovenous shunt model in baboons13. A Dacron graft implanted within an arteriovenous shunt is thrombogenic, accumulating platelets and fibrin within its lumen. These bound platelets express P-selectin14. Here we show that antibody inhibition of leukocyte binding to P-selectin expressed on platelets immobilized on the graft blocks leukocyte accumulation and inhibits the deposition of fibrin within the thrombus. These results indicate that P-selectin is an important adhesion molecule on platelets, mediating platelet-leukocyte binding in vivo, that the presence of leukocytes in thrombi is mediated by P-selectin, and that these leukocytes promote fibrin deposition.	NEW ENGLAND MED CTR,DIV CARDIOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; BIOGEN INC,CAMBRIDGE,MA 02142; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Biogen; Tufts University	PALABRICA, T (corresponding author), NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.							BAUMAN J M, 1986, Journal of Nuclear Medicine Technology, V14, P15; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BONFANTI R, 1989, BLOOD, V73, P1109; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; HSULIN SC, 1984, J BIOL CHEM, V259, P9121; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAMOYI E, 1986, METHOD ENZYMOL, V121, P652; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LERNER EA, 1981, YALE J BIOL MED, V54, P377; LOBB RR, 1991, J IMMUNOL, V147, P124; MACKEY WC, 1984, J SURG RES, V37, P112, DOI 10.1016/0022-4804(84)90170-7; MCAFEE JG, 1976, J NUCL MED, V17, P408; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; NIEMETZ J, 1972, J CLIN INVEST, V51, P307, DOI 10.1172/JCI106815; PALABRICA TM, 1989, P NATL ACAD SCI USA, V86, P1036, DOI 10.1073/pnas.86.3.1036; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROSEBROUGH SF, 1988, J NUCL MED, V29, P1212; SAUVAGE LR, 1976, HEALING ARTERIAL PRO; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; THAKAU ML, 1977, J NUCL MED, V518, P1022; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	26	701	734	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					848	851		10.1038/359848a0	http://dx.doi.org/10.1038/359848a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279433				2022-12-01	WOS:A1992JV77700070
J	PLATE, KH; BREIER, G; WEICH, HA; RISAU, W				PLATE, KH; BREIER, G; WEICH, HA; RISAU, W			VASCULAR ENDOTHELIAL GROWTH-FACTOR IS A POTENTIAL TUMOR ANGIOGENESIS FACTOR IN HUMAN GLIOMAS INVIVO	NATURE			English	Article							METASTASIS; FEATURES; MITOGEN; FAMILY	CLINICAL and experimental studies suggest that angiogenesis is a prerequisite for solid tumour growth1,2. Several growth factors with mitogenic or chemotactic activity for endothelial cells in vitro have been described, but it is not known whether these mediate tumour vascularization in vivo3,4. Glioblastoma, the most common and most malignant brain tumour in humans, is distinguished from astrocytoma by the presence of necroses and vascular proliferations5,6. Here we show that expression of an endothelial cell-specific mitogen, vascular endothelial growth factor (VEGF), is induced in astrocytoma cells but is dramatically upregulated in two apparently different subsets of glioblastoma cells. The high-affinity tyrosine kinase receptor for VEGF, flt, although not expressed in normal brain endothelium, is upregulated in tumour endothelial cells in vivo. These observations strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify VEGF as a potential tumour angiogenesis factor in vivo.	MAX PLANCK INST PSYCHIAT,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; UNIV FREIBURG,INST MOLEK ZELLBIOL,W-7800 FREIBURG,GERMANY; MAX PLANCK INST PHYSIOL & CLIN RES,W-6350 BAD NAUHEIM,GERMANY	Max Planck Society; University of Freiburg; Max Planck Society			Breier, Georg/E-3580-2016	Breier, Georg/0000-0002-9467-780X				BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; BREIER G, 1992, DEVELOPMENT, V114, P521; BREM SS, 1990, AM J PATHOL, V137, P1121; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1991, BIOL THERAPY CANCER, P743; GERMANO IM, 1989, J NEUROSURG, V70, P701, DOI 10.3171/jns.1989.70.5.0701; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JAIN RK, 1988, CANCER RES, V48, P2641; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLAGSBRUN M, 1990, HDB EXPT PHARM, V95, P549; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; PLATE KH, 1992, LAB INVEST, V67, P529; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; RISAU W, IN PRESS GROWTH FACT; Russell D., 1989, PATHOLOGY TUMORS NER; Scherer HJ, 1935, VIRCHOWS ARCH A, V294, P823, DOI 10.1007/BF01889141; SHIBUYA M, 1990, ONCOGENE, V5, P519; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4	31	2103	2215	3	87	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					845	848		10.1038/359845a0	http://dx.doi.org/10.1038/359845a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279432				2022-12-01	WOS:A1992JV77700069
J	SCHIAVO, G; BENFENATI, F; POULAIN, B; ROSSETTO, O; DELAURETO, PP; DASGUPTA, BR; MONTECUCCO, C				SCHIAVO, G; BENFENATI, F; POULAIN, B; ROSSETTO, O; DELAURETO, PP; DASGUPTA, BR; MONTECUCCO, C			TETANUS AND BOTULINUM-B NEUROTOXINS BLOCK NEUROTRANSMITTER RELEASE BY PROTEOLYTIC CLEAVAGE OF SYNAPTOBREVIN	NATURE			English	Article							INTEGRAL MEMBRANE-PROTEIN; SMALL SYNAPTIC VESICLES; CHROMAFFIN CELLS; DISTINCT SITES; SYNAPSIN-I; EXOCYTOSIS; TOXIN; CHAINS; GENES; BIND	CLOSTRIDIAL neurotoxins, including tetanus toxin and the seven serotypes of botulinum toxin (A-G), are produced as single chains and cleaved to generate toxins with two chains joined by a single disulphide bond (Fig. 1). The heavy chain (M(r) 100,000 (100K)) is responsible for specific binding to neuronal cells and cell penetration of the light chain (50K), which blocks neurotransmitter release1-9. Several lines of evidence have recently suggested that clostridial neurotoxins could be zinc endopeptidases2,10-14. Here we show that tetanus and botulinum toxins serotype B are zinc endopeptidases, the activation of which requires reduction of the interchain disulphide bond. The protease activity is localized on the light chain and is specific for synaptobrevin, an integral membrane protein of small synaptic vesicles. The rat synaptobrevin-2 isoform is cleaved by both neurotoxins at the same single site, the peptide bond Gln 76-Phe 77, but the isoform synaptobrevin-1, which has a valine at the corresponding position, is not cleaved. The blocking of neurotransmitter release of Aplysia neurons injected with tetanus toxin or botulinum toxin serotype B is substantially delayed by peptides containing the synaptobrevin-2 cleavage site. These results indicate that tetanus and botulinum B neurotoxins block neurotransmitter release by cleaving synaptobrevin2, a protein that, on the basis of our results, seems to play a key part in neurotransmitter release.	UNIV PADUA,CRIBI,I-35131 PADUA,ITALY; UNIV MODENA,INST FISIOL UMANA,I-41100 MODENA,ITALY; CNRS,NEUROBIOL MOLEC & CELLULAIRE LAB,F-91118 GIF SUR YVETTE,FRANCE; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706	University of Padua; Universita di Modena e Reggio Emilia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Wisconsin System; University of Wisconsin Madison	SCHIAVO, G (corresponding author), UNIV PADUA,CNR,CTR BIOMEMBRANE,DIPARTIMENTO SCI BIOMED,75 VIA TRIESTE,I-35131 PADUA,ITALY.		rossetto, ornella/AAC-3866-2022	rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745	Telethon [170] Funding Source: Medline	Telethon(Fondazione Telethon)		ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; DECAMILLI P, REV PHYSL, V52, P625; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FONTANA A, 1983, METHOD ENZYMOL, V91, P311; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOCHWESER J, 1982, NEW ENGL J MED, V306, P214; MOLGO J, 1990, J PHYSIOLOGY PARIS, V84, P152; MONTECUCCO C, 1986, TRENDS BIOCHEM SCI, V11, P314, DOI 10.1016/0968-0004(86)90282-3; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; POULAIN B, 1990, J PHYSIOL-PARIS, V84, P247; POULAIN B, 1992, J BIOL CHEM, V11, P3577; POULAIN B, 1991, J BIOL CHEM, V266, P1; SCHIAVO G, 1990, INFECT IMMUN, V58, P4136, DOI 10.1128/IAI.58.12.4136-4141.1990; SCHIAVO G, IN PRESS J BIOL CHEM; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, REV NEUROSCI, V14, P93; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; [No title captured]; [No title captured]	31	1407	1466	3	123	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					832	835		10.1038/359832a0	http://dx.doi.org/10.1038/359832a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1331807				2022-12-01	WOS:A1992JV77700065
J	SHWEIKI, D; ITIN, A; SOFFER, D; KESHET, E				SHWEIKI, D; ITIN, A; SOFFER, D; KESHET, E			VASCULAR ENDOTHELIAL GROWTH-FACTOR INDUCED BY HYPOXIA MAY MEDIATE HYPOXIA-INITIATED ANGIOGENESIS	NATURE			English	Article							PERMEABILITY FACTOR; CELL MITOGEN; GLIOBLASTOMA-MULTIFORME; MESSENGER-RNA; EXPRESSION; GENE; SECRETE; PROTEIN; TUMORS; LINE	INEFFICIENT vascular supply and the resultant reduction in tissue oxygen tension often lead to neovascularization in order to satisfy the needs of the tissue1. Examples include the compensatory development of collateral blood vessels in ischaemic tissues that are otherwise quiescent for angiogenesis and angiogenesis associated with the healing of hypoxic wounds2. But the presumptive hypoxia-induced angiogenic factors that mediate this feedback response have not been identified. Here we show that vascular endothelial growth factor (VEGF; also known as vascular permeability factor) probably functions as a hypoxia-inducible angiogenic factor. VEGF messenger RNA levels are dramatically increased within a few hours of exposing different cell cultures to hypoxia and return to background when normal oxygen supply is resumed. In situ analysis of tumour specimens undergoing neovascularization show that the production of VEGF is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci (presumably hypoxic regions) and the clustering of capillaries alongside VEGF-producing cells.	HADASSAH HEBREW UNIV HOSP,MED CTR,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL; HADASSAH HEBREW UNIV HOSP,MED CTR,DEPT PATHOL,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	SHWEIKI, D (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MOLEC BIOL,IL-91010 JERUSALEM,ISRAEL.		Keshet, Eli/GQR-0445-2022					ADAIR TH, 1990, AM J PHYSIOL, V259, pR393, DOI 10.1152/ajpregu.1990.259.3.R393; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HIRANO A, 1975, HUM PATHOL, V6, P611, DOI 10.1016/S0046-8177(75)80045-1; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; JELLINGER K, 1978, ACTA NEUROCHIR, V42, P5, DOI 10.1007/BF01406628; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KINASEWITZ GT, 1986, J APPL PHYSIOL, V61, P554, DOI 10.1152/jappl.1986.61.2.554; KNIGHTON D, 1987, CURRENT COMMUNICATIO, P150; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OLSEN SP, 1986, BRAIN RES, V368, P24; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x	30	3720	3909	7	285	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					843	845		10.1038/359843a0	http://dx.doi.org/10.1038/359843a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1279431				2022-12-01	WOS:A1992JV77700068
J	SWAMINATHAN, S; FUREY, W; PLETCHER, J; SAX, M				SWAMINATHAN, S; FUREY, W; PLETCHER, J; SAX, M			CRYSTAL-STRUCTURE OF STAPHYLOCOCCAL ENTEROTOXIN-B, A SUPERANTIGEN	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; USE PREDICTS REACTIVITY; MLSA-ENCODED ANTIGENS; T-CELL RECOGNITION; CLASS-II MOLECULES; BINDING SITE; TOLERANCE; CRYSTALLOGRAPHY; STIMULATION; REQUIREMENT	The three-dimensional structure of staphylococcal enterotoxin B, which is both a toxin and a super-antigen, has been determined to a resolution of 2.5 angstrom. The unusual main-chain fold containing two domains may represent a general motif adopted by all staphylococcal enterotoxins. The T-cell receptor binding site encompasses a shallow cavity formed by both domains. The MHCII molecule binds to an adjacent site. Another cavity with possible biological activity was also identified.			SWAMINATHAN, S (corresponding author), VET AFFAIRS MED CTR,BIOCRYSTALLOG LAB,POB 12055,UNIV DR C,PITTSBURGH,PA 15240, USA.							BERDOLL MS, 1985, STAPHYLOCOCCI, P247; Bergdoll M.S., 1979, FOOD BORNE INFECTION, P443; BERGDOLL MS, 1970, MICROBIAL TOXINS, P265; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLANCO L, 1990, INFECT IMMUN, V58, P3020, DOI 10.1128/IAI.58.9.3020-3028.1990; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSSON R, 1988, J IMMUNOL, V140, P2484; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEREWENDA Z, 1989, J APPL CRYSTALLOGR, V22, P123, DOI 10.1107/S0021889888012348; FLEISCHER B, 1988, J EXP MED, V167, P1697, DOI 10.1084/jem.167.5.1697; FUREY W, 1990, AM CRYSTALLOGR ASS M; HERMAN A, 1991, P NATL ACAD SCI USA, V88, P9954, DOI 10.1073/pnas.88.22.9954; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IRWIN MJ, 1992, NATURE, V359, P841, DOI 10.1038/359841a0; JANEWAY CA, 1989, IMMUNOL REV, V107, P61, DOI 10.1111/j.1600-065X.1989.tb00003.x; JOHNSON HM, 1992, SCI AM           APR, P92; JONES CL, 1986, J BACTERIOL, V166, P29, DOI 10.1128/jb.166.1.29-33.1986; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1992, J EXP MED, V175, P387, DOI 10.1084/jem.175.2.387; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; LANGFORD MP, 1978, INFECT IMMUN, V22, P62, DOI 10.1128/IAI.22.1.62-68.1978; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUSSELL JK, 1991, P NATL ACAD SCI USA, V88, P7228, DOI 10.1073/pnas.88.16.7228; SCHEUBER PH, 1985, INFECT IMMUN, V50, P869, DOI 10.1128/IAI.50.3.869-876.1985; SPERO L, 1978, J BIOL CHEM, V253, P8787; STEIMA GN, 1982, BIOCHEM BIOPH RES CO, V105, P121; SWAMINATHAN S, 1988, J MOL BIOL, V199, P397, DOI 10.1016/0022-2836(88)90326-9; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X	45	292	317	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					801	806		10.1038/359801a0	http://dx.doi.org/10.1038/359801a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436058				2022-12-01	WOS:A1992JV77700054
J	WEISSENBACH, J; GYAPAY, G; DIB, C; VIGNAL, A; MORISSETTE, J; MILLASSEAU, P; VAYSSEIX, G; LATHROP, M				WEISSENBACH, J; GYAPAY, G; DIB, C; VIGNAL, A; MORISSETTE, J; MILLASSEAU, P; VAYSSEIX, G; LATHROP, M			A 2ND-GENERATION LINKAGE MAP OF THE HUMAN GENOME	NATURE			English	Article							INVITRO AMPLIFICATION; DNA; GENE; OLIGONUCLEOTIDES; REPEAT; SINGLE	A linkage map of the human genome has been constructed based on the segregation analysis of 814 newly characterized polymorphic loci containing short tracts of (C-A)n repeats in a panel of DNAs from eight large families. Statistical linkage analysis placed 813 of the markers into 23 linkage groups corresponding to the 22 autosomes and the X chromosome; 605 show a heterozygosity above 0.7 and 553 could be ordered with odds ratios above 1,000:1. The distance spanned corresponds to approximately 90% of the estimated length of the human genome.	INST PASTEUR,UNITE GENET MOLEC HUMAINE,CNRS,URA 1445,F-75724 PARIS,FRANCE; CHU LAVAL,CTR ETUD POLYMORPHISME HUMAIN,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; CHU LAVAL,RESEAU MED GENET,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; INSERM,U358,F-75010 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Laval University; Laval University; Institut National de la Sante et de la Recherche Medicale (Inserm)	WEISSENBACH, J (corresponding author), GENETHON,1 RUE INT,F-91000 EVRY,FRANCE.		Vignal, Alain/I-6253-2017	Vignal, Alain/0000-0002-6797-2125				BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BISHOP DT, 1990, AM J HUM GENET, V46, P254; CHURCH GM, 1988, SCIENCE, V240, P185, DOI 10.1126/science.3353714; DIETRICH W, 1992, GENETICS, V131, P423; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1991, STAT METH BIOL MED S, V8, P81; LATHROP GM, 1988, GENOMICS, V2, P157; LITT M, 1989, AM J HUM GENET, V44, P397; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; OTT J, 1992, AM J HUM GENET, V51, P283; RISCH N, 1990, AM J HUM GENET, V46, P242; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; VERGNAUD G, 1991, ELECTROPHORESIS, V12, P134, DOI 10.1002/elps.1150120207; VIGINAL A, IN PRESS METHODS MOL, V1; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHITE R, 1990, GENETICS MAPS LOCUS; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727; 1991, CYTOGENET CELL GENET, V58, P1	24	1913	1999	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 29	1992	359	6398					794	801		10.1038/359794a0	http://dx.doi.org/10.1038/359794a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JV777	1436057				2022-12-01	WOS:A1992JV77700053
J	BOBAK, M; LEON, DA				BOBAK, M; LEON, DA			AIR-POLLUTION AND INFANT-MORTALITY IN THE CZECH REPUBLIC, 1986-88	LANCET			English	Article							RESPIRATORY HEALTH; PARTICLES; CHILDREN	An ecological study of infant mortality and air pollution was conducted in the Czech Republic. Routinely collected data on infant mortality and air pollution in the period 1986-88 were analysed for the 46 of the 85 districts in the republic for which both were available. The independent effects of total suspended particulates (TSP-10), sulphur dioxide (SO2), and oxides of nitrogen (NO(x)) adjusted for district socioeconomic characteristics, such as income, car ownership, and abortion rate, were estimated by logistic regression. We found weak positive associations between neonatal mortality and quintile of TSP-10 and SO2. Stronger adjusted effects were seen for postneonatal mortality, with a consistent increase in risk from the lowest to the highest TSP-10 quintile (p<0.001). Weaker and less consistent evidence of a positive association with NO(x) (p = 0.061) was observed. The strongest effects were seen for postneonatal respiratory mortality, which increased consistently from lowest to highest TSP-10 quintile (p = 0.013). There was also a suggestion of a positive association with SO2 (p = 0.062). The highest to lowest quintile risk ratios for postneonatal respiratory mortality were 2.41 (95% Cl 1.10-5.28) for TSP-10, 3.91 (0.90-16.9) for SO2, and 1.20 (0.37-3.91) NO(x). The specificity of the association between air pollution quintile (especially TSP-10) and postneonatal respiratory mortality is consistent with the known effects of air pollution on respiratory disease morbidity in children. These ecological associations require confirmation in an individually based study.	CHARLES UNIV, FAC MED 3, DEPT EPIDEMIOL, CS-11636 PRAGUE 1, CZECHOSLOVAKIA	Charles University Prague	BOBAK, M (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT SCI, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762; Bobak, Martin/0000-0002-2633-6851	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRESLOW NE, 1987, IARC SCI PUBL, V82; COLLINS JJ, 1971, AM J EPIDEMIOL, V93, P10, DOI 10.1093/oxfordjournals.aje.a121224; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; HOLLAND WW, 1979, AM J EPIDEMIOL, V110, P525, DOI 10.1093/oxfordjournals.aje.a112836; Lave LB, 1977, AIR POLLUTION HUMAN; Penna M L, 1991, Bull Pan Am Health Organ, V25, P47; PHILLIPS AN, 1992, STAT MED, V11, P953, DOI 10.1002/sim.4780110712; READ C, 1991, AIR POLLUTION CHILD; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; 1987, AIR QUALITY GUIDELIN; 1990, ENV CZECH REPUBLIC; 1988, EGRET USERS MANUAL	12	137	140	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					1010	1014		10.1016/0140-6736(92)93017-H	http://dx.doi.org/10.1016/0140-6736(92)93017-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357409				2022-12-01	WOS:A1992JV01400011
J	DAYSON, D; GOOCH, C; THORNICROFT, G				DAYSON, D; GOOCH, C; THORNICROFT, G			THE TAPS PROJECT .16. DIFFICULT TO PLACE, LONG-TERM PSYCHIATRIC-PATIENTS - RISK-FACTORS FOR FAILURE TO RESETTLE LONG STAY PATIENTS IN COMMUNITY FACILITIES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To identify patients who could not be resettled in the community as part of the closure plans of two psychiatric hospitals and to determine their numbers and risk factors for failure. Design and setting-Prospective study of the closure of Friern and Claybury psychiatric hospitals. Patients-The first third (369) of long stay psychiatric patients to be resettled. Outcome measures-Reasons for patients being readmitted to hospital and not leaving the patients' service needs. Results-22-6% of both hospitals' long stay patients-were not successfully resettled in the community. Eighteen continuing care places per 100 000 of catchment area population seem to be required for this group. Patients whose placements were unsuccessful were usually readmitted because of a deterioration of their mental state and aggressive behavior, both of which persisted and necessitated their continuing stay in hospital, often in a locked ward. Risk factors associated with failure were a high level of psychosis; a diagnosis of paranoid psychosis; incontinence; and being male. But having a social network, especially a large one, seemed to aid successful placement in the community. Conclusion-Rehabilitation efforts should be focused on the characteristics of these patients that put them at risk of failing to succeed in community placements.	INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London	DAYSON, D (corresponding author), FRIERN HOSP,TAPS RES UNIT,LONDON N11 3BP,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				ANDERSON J, IN PRESS BR J PSYCHI; CHRISTIEBROWN JRW, 1977, PSYCHOL MED, V7, P113; COID JW, 1991, BRIT MED J, V302, P603, DOI 10.1136/bmj.302.6777.603; DAYSON D, IN PRESS BR J PSYCHI; DUNN M, 1990, BRIT J PSYCHIAT, V157, P842, DOI 10.1192/bjp.157.6.842; HERXHEIMER A, 1991, DRUG THERAPEUTIC B, V29, P41; KENDELL RE, 1989, BRIT MED J, V299, P1237, DOI 10.1136/bmj.299.6710.1237; LEFF J, 1990, BRIT J PSYCHIAT, V157, P848, DOI 10.1192/bjp.157.6.848; STURT E, 1986, BRIT J PSYCHIAT, V148, P1; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; THORNICROFT G, IN PRESS TAPS PROJEC; WING JK, 1990, BRIT J PSYCHIAT, V157, P822, DOI 10.1192/bjp.157.6.822; Wing JK, 1974, DESCRIPTION CLASSIFI; 1992, HLTH NATION; 1991, HLTH NATION	15	26	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					993	995		10.1136/bmj.305.6860.993	http://dx.doi.org/10.1136/bmj.305.6860.993			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458147	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JV77600027
J	EKBOM, A; TRICHOPOULOS, D; ADAMI, HO; HSIEH, CC; LAN, SJ				EKBOM, A; TRICHOPOULOS, D; ADAMI, HO; HSIEH, CC; LAN, SJ			EVIDENCE OF PRENATAL INFLUENCES ON BREAST-CANCER RISK	LANCET			English	Article							PREGNANCY; BIRTH; ASSOCIATIONS; HYPOTHESIS; EXCRETION; ESTROGENS; AGE	Intrauterine exposure to high concentrations of endogenous pregnancy oestrogens may be important in the aetiology of breast cancer. In a nested case-control study we have assessed the relation between breast cancer risk and indicators of pregnancy oestrogen concentrations; preeclampsia/eclampsia is negatively related and measures of fetal size are positively related to oestrogen concentrations. Standard records for women born at Uppsala University Hospital between 1874 and 1954 were linked with records of invasive breast cancer cases, identified through their unique national registration numbers in the Swedish Cancer Registry during 1958-90. For each breast cancer case, we selected as potential controls female offspring of the first three mothers admitted to the hospital after the case's mother; only controls still living in Sweden and free from breast cancer when it was diagnosed in the case were finally included. Conditional logistic regression analysis was done for 458 breast cancer cases and 1197 matched controls. Pre-eclampsia/eclampsia was associated with a breast cancer rate ratio of 0.24 (95% confidence interval 0.09-0.70, p = 0.01). Linear trends for breast cancer incidence with increasing birth weight, birth length, and placental weight were positive but not significant. Thus, prenatal factors are important in breast carcinogenesis. Concentrations of pregnancy oestrogens may be one such factor, but other prenatal or perinatal factors cannot be excluded.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	EKBOM, A (corresponding author), UNIV HOSP UPPSALA, CANC EPIDEMIOL UNIT, S-75185 UPPSALA, SWEDEN.							ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; BERSTEIN LM, 1988, ADV CANCER RES, V50, P231, DOI 10.1016/S0065-230X(08)60439-X; BRESLOW NE, 1980, IARC SCI PUBL, V32, P192; COLE P, 1969, LANCET, V1, P604; DAVIES AM, 1983, OBSTETRICAL EPIDEMIO, P167; DEWAARD F, 1988, INT J CANCER, V41, P666, DOI 10.1002/ijc.2910410505; EKBOM A, 1991, AM J EPIDEMIOL, V134, P876, DOI 10.1093/oxfordjournals.aje.a116162; GANT NF, 1971, AM J OBSTET GYNECOL, V111, P555, DOI 10.1016/0002-9378(71)90472-8; GAROFF L, 1976, AM J OBSTET GYNECOL, V126, P1027, DOI 10.1016/0002-9378(76)90696-7; GERHARD I, 1987, EUR J OBSTET GYN R B, V26, P313, DOI 10.1016/0028-2243(87)90129-8; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; Gluckman P.D., 1986, OXF REV REPROD BIOL, V8, P1; HSIEH CC, 1991, CANCER CAUSE CONTROL, V2, P95, DOI 10.1007/BF00053127; HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; KELSEY JL, 1983, BREAST GYNECOLOGIC C, P5; KLOPPER A, 1975, J STEROID BIOCHEM, V6, P651, DOI 10.1016/0022-4731(75)90047-3; LONG PA, 1979, AM J OBSTET GYNECOL, V135, P344, DOI 10.1016/0002-9378(79)90702-6; LUNDE AS, 1980, PHS801358 DEP HLTH H, P5; MARSHALL JR, 1989, STAT MED, V8, P1041, DOI 10.1002/sim.4780080904; MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x; PANAGIOTOPOULOU K, 1990, CANCER CAUSE CONTROL, V1, P119, DOI 10.1007/BF00053162; Petridou E, 1990, Epidemiology, V1, P247, DOI 10.1097/00001648-199005000-00011; ROSING U, 1984, GYNECOL OBSTET INVES, V18, P199, DOI 10.1159/000299081; SANDSON TA, 1992, LANCET, V339, P523, DOI 10.1016/0140-6736(92)90341-Y; TAMBYRAJA RL, 1981, TWIN RES 3 A, V69, P189; THOMPSON JA, 1990, EPIDEMIOLOGY, V1, P101; THOMPSON WD, 1989, JNCI-J NATL CANCER I, V81, P1571, DOI 10.1093/jnci/81.20.1571; Thomson AM, 1983, OBSTETRICAL EPIDEMIO, P89; Tomatis L, 1989, IARC Sci Publ, P1; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0; YEN SSC, 1989, MATERNAL FETAL MED P, P375; 1990, CANCER INCIDENCE SWE	35	299	303	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					1015	1018		10.1016/0140-6736(92)93019-J	http://dx.doi.org/10.1016/0140-6736(92)93019-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357410				2022-12-01	WOS:A1992JV01400012
J	FOWKES, FGR; LENG, GC; DONNAN, PT; DEARY, IJ; RIEMERSMA, RA; HOUSLEY, E				FOWKES, FGR; LENG, GC; DONNAN, PT; DEARY, IJ; RIEMERSMA, RA; HOUSLEY, E			SERUM-CHOLESTEROL, TRIGLYCERIDES, AND AGGRESSION IN THE GENERAL-POPULATION	LANCET			English	Article							RISK; DISEASE; HEALTH; MEN	A higher than expected number of violent deaths and suicides in coronary prevention trials has provoked interest in the possibility that low serum cholesterol concentrations are associated in the general population with personality characteristics predisposing to aggressive and suicidal behaviour. We have investigated this possibility in the Edinburgh Artery Study. We measured serum lipid concentrations in blood samples taken from fasting subjects and assessed personality characteristics on the Bedford Foulds Personality Deviance Scales in a random sample of 1592 men and women aged 55-74 years, selected from age-sex registers of ten general practices in Edinburgh. Serum cholesterol concentration was not significantly associated with aggression in men, but it was associated in multivariate analysis (though not univariate analysis) with denigratory attitudes towards others among women. However, serum triglyceride concentration was related, especially in men, to hostile acts (r = 0.13, p < 0.001) and domineering attitude (r = 0.12, p < 0.001) independently of age, total and HDL cholesterol, cigarette smoking, and alcohol consumption. Subjects taking part in prevention trials have higher triglyceride concentrations than the general population and the relation between serum triglyceride concentration and aggression merits further investigation.	UNIV EDINBURGH, DEPT PSYCHOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, CARDIOVASC RES UNIT, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	FOWKES, FGR (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PUBL HLTH SCI, WOLFSON UNIT PREVENT PERIPHERAL VASC DIS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X				BEDFORD A, 1978, PERSONALITY DEVIANCE; BOLTONSMITH C, 1991, INT J EPIDEMIOL, V20, P95, DOI 10.1093/ije/20.1.95; Brown MS, 1990, PHARMACOL BASIS THER, P874; BRUNNER E, 1992, LANCET, V339, P1001; Caine TM, 1967, MANUAL HOSTILITY DIR; CHAIT A, 1981, DIABETES CARE, V4, P343, DOI 10.2337/diacare.4.3.343; DAYTON S, 1969, CIRCULATION S2, V39, P1; DIXON WJ, 1989, BMDP STATISTICAL SOF; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEILMAN KM, 1974, ARCH NEUROL-CHICAGO, V31, P67, DOI 10.1001/archneur.1974.00490370093018; KROMHOUT D, 1992, LANCET, V340, P317, DOI 10.1016/0140-6736(92)92415-C; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATHEW NT, 1976, EUR NEUROL, V14, P370, DOI 10.1159/000114761; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; VIKKUNEN M, 1984, BIOL PSYCHIAT, V19, P435; VIKKUNEN M, 1979, NEUROPSYCHOBIOLOGY, V5, P27; ZUCKERMAN M, 1991, PSYCHOBIOLOGY PERSON, P205; 1930, ANN REPORTS REGISTRA; 1990, SCOTTISH HLTH STATIS; 1986, SPSSX USERS GUIDE	30	76	77	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 24	1992	340	8826					995	998		10.1016/0140-6736(92)93009-C	http://dx.doi.org/10.1016/0140-6736(92)93009-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357449				2022-12-01	WOS:A1992JV01400003
J	GARDINER, AJS; FOREY, BA; LEE, PN				GARDINER, AJS; FOREY, BA; LEE, PN			AVIAN EXPOSURE AND BRONCHOGENIC-CARCINOMA	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the association between bird keeping and risk of lung cancer. Design-Case-control study asking detailed questions on exposure to domestic birds and other pets, smoking, and various demographic and potentially confounding variables. Setting-District general hospital; current admissions interviewed in hospital or recent admissions interviewed at home. Patients-143 patients with lung cancer, 143 controls with heart disease, and 143 controls with orthopaedic conditions individually matched for age, sex, date of admission, and current or past admission. Main outcome measures-Odds ratios for lung cancer in relation to various aspects of bird keeping, after adjustment for smoking and other relevant confounding variables. Results-Risk of lung cancer was not significantly associated with household exposure to pet birds at any time or at various specific periods in life, or to keeping large numbers of birds. For specific types of birds no association was seen for living in households with budgerigars or canaries but risk was significantly associated with keeping pigeons (odds ratio 3.53, 95% confidence interval 1.56 to 7.98). This remained significant after regression analysis to account for confounding variables (3.9, 1.2 to 12.62) in both sexes and all age groups. Conclusion-Bird keeping may confer some risk of lung cancer but the relation is not as strong as previously reported.	PN LEE STAT & COMP,SUTTON SM2 5DA,SURREY,ENGLAND	PN Lee Statistics & Computing Ltd	GARDINER, AJS (corresponding author), MONKLANDS DIST GEN HOSP,MED UNIT,AIRDRIE ML6 0JS,LANARK,SCOTLAND.			Lee, Peter/0000-0002-8244-1904				BRESLOW N. E., 1980, STATISTICAL METHODS; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; HOLST PAJ, 1988, BIRD KEEPING SOURCE	3	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					989	992		10.1136/bmj.305.6860.989	http://dx.doi.org/10.1136/bmj.305.6860.989			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458146	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JV77600026
J	GARNER, P; KRAMER, MS; CHALMERS, I				GARNER, P; KRAMER, MS; CHALMERS, I			MIGHT EFFORTS TO INCREASE BIRTH-WEIGHT IN UNDERNOURISHED WOMEN DO MORE HARM THAN GOOD	LANCET			English	Editorial Material							LOW BIRTH-WEIGHT; INFANT-MORTALITY; GESTATIONAL-AGE; DETERMINANTS; PREGNANCY; PRETERM; RISK		MCGILL UNIV,FAC MED,DEPT PEDIAT,MONTREAL H3A 2T5,QUEBEC,CANADA; MCGILL UNIV,FAC MED,DEPT EPIDEMIOL & BIOSTAT,MONTREAL H3A 2T5,QUEBEC,CANADA; RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND	McGill University; McGill University; Radcliffe Infirmary; University of Oxford	GARNER, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH POLICY UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			Osmond, Clive/0000-0002-9054-4655; Garner, Paul/0000-0002-0607-6941; Fall, Caroline/0000-0003-4402-5552				BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; BREMS S, 1989, 1988 1989 M ADV GROU; CHALMERS I, 1979, LANCET, V2, P1063; CNATTINGIUS S, 1988, BMJ-BRIT MED J, V297, P258, DOI 10.1136/bmj.297.6643.258; Fleming AF, 1985, BR J OBSTET GYNAE S5, V92, P32; HABICHT JP, 1973, NUTR REP INT, V7, P533; HARRISON KA, 1985, BR J OBSTET GYNAE S5, V92, P100; Kramer M S, 1990, Paediatr Perinat Epidemiol, V4, P381, DOI 10.1111/j.1365-3016.1990.tb00661.x; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; KRAMER MS, IN PRESS OXFORD DATA; LOMAS J, 1989, EFFECTIVE CARE PREGN, P1182; LUMLEY J, 1992, OXFORD DATABASE PERI; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; NAEYE RL, 1979, AM J OBSTET GYNECOL, V135, P3; PUFFER RR, 1987, SCI PUBLICATION PAN, V504; SAMMSVAUGHAN ME, 1990, J TROP PEDIATRICS, V36, P171, DOI 10.1093/tropej/36.4.171; TAFFEL S, 1986, DHHS PHS861922 NAT C; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VICTORA CG, 1987, INT J EPIDEMIOL, V16, P239, DOI 10.1093/ije/16.2.239; Villar J, 1982, Obstet Gynecol Surv, V37, P499, DOI 10.1097/00006254-198208000-00001; VILLAR J, 1984, PEDIATRICS, V74, P783; 1985, REPORT COMMITTEE STU; 1990, GESTATIONAL WEIGHT G	24	43	43	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1021	1023		10.1016/0140-6736(92)93022-F	http://dx.doi.org/10.1016/0140-6736(92)93022-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357412				2022-12-01	WOS:A1992JV01400014
J	KOHLMEIER, L; ARMINGER, G; BARTOLOMEYCIK, S; BELLACH, B; REHM, J; THAMM, M				KOHLMEIER, L; ARMINGER, G; BARTOLOMEYCIK, S; BELLACH, B; REHM, J; THAMM, M			PET BIRDS AS AN INDEPENDENT RISK FACTOR FOR LUNG-CANCER - CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERSENSITIVITY PNEUMONITIS; FANCIERS LUNG; OCCUPATION; PATHOLOGY; BREEDERS; SMOKING	Objective-To test the hypothesis that exposure to pct birds increases risk of developing lung cancer. Design-Case-control study. Computerised interviews were used to assess previous exposure to pets and other risk factors for lung cancer. Setting-Three major hospitals treating respiratory disease in former West Berlin. Subjects-All people newly diagnosed as having primary malignant neoplasm of the trachea, bronchi, or lung who were 65 or younger and control subjects matched for age and sex from the general population of former West Berlin. 279 cases and 635 controls qualified for the study; 239 cases and 429 controls participated. Main outcome measures-Odds ratio of developing lung cancer according to whether or not pet birds were kept and the duration of keeping pet birds. Results-In addition to the risk of lung cancer imposed by smoking, passive smoking, and occupational exposure to carcinogens, an increased relative risk of 2.14 (95% confidence interval 1.35 to 3.40) was found among people exposed to pet birds. The adjusted odds ratio for exposures longer than 10 years was 3.19 (1.48 to 8.21). Conclusions-Avian exposure seems to carry a risk of lung cancer. Until the pathogenesis is understood, long term exposure to pet birds in living areas should be avoided, especially among people at high risk of developing lung cancer.	UNIV GESAMTHSCH WUPPERTAL, W-5600 WUPPERTAL 1, GERMANY	University of Wuppertal	KOHLMEIER, L (corresponding author), BUNDESGESUNDHEITSAMT, INST SOCIAL MED & EPIDEMIOL, POSTFACH 330013, W-1000 BERLIN 33, GERMANY.		Rem, Jürgen/H-1309-2011					ALLEN DH, 1976, AM REV RESPIR DIS, V114, P555; [Anonymous], 1986, ENV TOBACCO SMOKE ME; AXELSON O, 1990, ANN NY ACAD SCI, V609, P165; BALASUBRAMANIAM SK, 1987, CLIN PEDIATR, V26, P174, DOI 10.1177/000992288702600402; BOURKE SJ, 1989, CLIN EXP ALLERGY, V19, P629, DOI 10.1111/j.1365-2222.1989.tb02758.x; BOURKE SJ, 1990, AM REV RESPIR DIS, V142, P1168, DOI 10.1164/ajrccm/142.5.1168; CARSTENSEN JM, 1990, ANN NY ACAD SCI, V609, P159; FEHR R, 1983, BERUFSSPEZIFISCHE KR, P137; FINK JN, 1968, ANN INTERN MED, V68, P1205, DOI 10.7326/0003-4819-68-6-1205; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V85, P655, DOI 10.1016/0091-6749(90)90107-F; HAGMAR L, 1990, AM J IND MED, V17, P77; HOLST PA, 1988, BRIT MED J, V297, P1319, DOI 10.1136/bmj.297.6659.1319; JAMES JM, 1987, CLIN EXP IMMUNOL, V68, P397; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; MENCK HR, 1976, J OCCUP ENVIRON MED, V18, P797, DOI 10.1097/00043764-197612000-00005; MILNE KL, 1983, AM J IND MED, V4, P565, DOI 10.1002/ajim.4700040410; OSTERGAARD JR, 1989, ACTA PAEDIATR SCAND, V78, P145, DOI 10.1111/j.1651-2227.1989.tb10906.x; PUKKALA E, 1983, INT J EPIDEMIOL, V12, P290, DOI 10.1093/ije/12.3.290; REED CE, 1965, J AMER MED ASSOC, V193, P261, DOI 10.1001/jama.1965.03090040005001; ROSENSTOCK L, 1986, CLIN OCCUPATIONAL ME; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SCHLUETER DP, 1969, ANN INTERN MED, V70, P457, DOI 10.7326/0003-4819-70-3-457; SCHMIDT CD, 1988, CHEST, V93, P359, DOI 10.1378/chest.93.2.359; SMITH JH, 1990, J PARASITOL, V76, P59, DOI 10.2307/3282628; Staib F, 1986, Prax Klin Pneumol, V40, P86; Staib F., 1987, AIDS-Forschung, V2, P363; Staib F, 1968, Mykosen, V11, P619; Staib F., 1989, AIDS-Forschung, V4, P649; STAIB F, 1985, ZBL BAKT MIK HYG B, V180, P567; STAIB F, 1987, INDOOR AIR 87, V1, P694; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEGENER HH, 1983, ZBL BAKT-INT J MED M, V256, P231; 1991, EGRET, P1; 1988, HLTH RISKS RADON OTH; 1989, GESUNDHEITSWESEN F 4; 1988, INT KLASSIFIKATION K; 1984, ABESTIFORM FIBERS NO	37	31	31	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1992	305	6860					986	989		10.1136/bmj.305.6860.986	http://dx.doi.org/10.1136/bmj.305.6860.986			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458145	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JV77600025
J	NEEDHAM, PR; DALEY, AG; LENNARD, RF				NEEDHAM, PR; DALEY, AG; LENNARD, RF			STEROIDS IN ADVANCED CANCER - SURVEY OF CURRENT PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									ST JOSEPHS HOSP,LONDON E8 4SA,ENGLAND		NEEDHAM, PR (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT CLIN PHARMACOL & THERAPEUT,LONDON E1 2AD,ENGLAND.							HANKS GW, 1983, POSTGRAD MED J, V59, P702, DOI 10.1136/pgmj.59.697.702; HERXHEIMER A, 1974, DRUG THER B, V16, P63; MOERTEL CG, 1974, CANCER-AM CANCER SOC, V33, P1607, DOI 10.1002/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V; WEISSMAN DE, 1988, J CLIN ONCOL, V6, P543, DOI 10.1200/JCO.1988.6.3.543; WILLOX JC, 1984, BRIT MED J, V288, P27, DOI 10.1136/bmj.288.6410.27	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					999	999		10.1136/bmj.305.6860.999	http://dx.doi.org/10.1136/bmj.305.6860.999			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV776	1458150	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JV77600030
J	ROTHSTEIN, JD; GUIDOTTI, A; TINUPER, P; CORTELLI, P; AVONI, P; PLAZZI, G; LUGARESI, E; SCHOCH, P; MONTAGNA, P				ROTHSTEIN, JD; GUIDOTTI, A; TINUPER, P; CORTELLI, P; AVONI, P; PLAZZI, G; LUGARESI, E; SCHOCH, P; MONTAGNA, P			ENDOGENOUS BENZODIAZEPINE RECEPTOR LIGANDS IN IDIOPATHIC RECURRING STUPOR	LANCET			English	Note								"Endozepines" are endogenous ligands for the benzodiazepine recognition sites on gamma-aminobutyric acid A receptors in the nervous system. Idiopathic recurring stupor (IRS) is a syndrome of spontaneous stupor or coma that is not associated with known metabolic, toxic, or structural abnormalities but can be reversed by flumazenil, a pure benzodiazepine antagonist. We measured endozepine-2 and endozepine-4 by high-performance liquid chromatography and radioreceptor assay in serum and cerebrospinal fluid from three patients with IRS. During episodes of stupor there was a large (up to 300-fold compared with control patients) increase of endozepine-4 content in cerebrospinal fluid and serum, but a return to normal concentrations between attacks. Endozepine-4 may contribute to, or be the cause of, IRS. The reasons for abnormal concentrations of endozepine in blood and brain are unknown.	GEORGETOWN UNIV,FIDIA GEORGETOWN INST NEUROSCI,WASHINGTON,DC 20057; UNIV BOLOGNA,INST NEUROL,I-40126 BOLOGNA,ITALY; HOFFMANN LA ROCHE AG,DIV PHARMA,PRECLIN RES,BASEL,SWITZERLAND	Georgetown University; University of Bologna; Roche Holding	ROTHSTEIN, JD (corresponding author), JOHNS HOPKINS UNIV,DEPT NEUROL,MEYER 5-119,600 N WOLFE ST,BALTIMORE,MD 21205, USA.		Cortelli, Pietro/K-6063-2016; Avoni, Patrizia/AAC-1879-2020; rothstein, jeffrey d/C-9470-2013; Tinuper, Paolo/AAB-7760-2020; Plazzi, Giuseppe/AAB-9627-2020	Cortelli, Pietro/0000-0002-3633-8818; tinuper, paolo/0000-0002-0588-3063; AVONI, PATRIZIA/0000-0003-0719-6803; Plazzi, Giuseppe/0000-0002-1051-0472	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001355] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01355] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COSTA E, 1987, PSYCHOPHARMACOLOGY 3, P425; GRIMM G, 1988, LANCET, V1, P1292; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P260, DOI 10.1016/0165-6147(91)90567-C; MENNINI T, 1983, ADV BIOCHEM PSYCHOPH, V38, P189; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; NUTT DJ, 1990, ARCH GEN PSYCHIAT, V47, P917; OLASMAA M, 1990, J NEUROCHEM, V55, P2015, DOI 10.1111/j.1471-4159.1990.tb05790.x; ROTHSTEIN JD, 1992, J NEUROCHEM, V58, P2102, DOI 10.1111/j.1471-4159.1992.tb10952.x; TINUPER P, 1992, ANN NEUROL, V31, P503, DOI 10.1002/ana.410310507; UNSELD E, 1989, BIOCHEM PHARMACOL, V38, P2473, DOI 10.1016/0006-2952(89)90091-9	10	47	47	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					1002	1004		10.1016/0140-6736(92)93011-B	http://dx.doi.org/10.1016/0140-6736(92)93011-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357403				2022-12-01	WOS:A1992JV01400005
J	STACEYCLEAR, A; MCCARTHY, KA; HALL, DA; PILESPELLMAN, E; WHITE, G; HULKA, C; WHITMAN, GJ; MAHONEY, E; KOPANS, DB				STACEYCLEAR, A; MCCARTHY, KA; HALL, DA; PILESPELLMAN, E; WHITE, G; HULKA, C; WHITMAN, GJ; MAHONEY, E; KOPANS, DB			BREAST-CANCER SURVIVAL AMONG WOMEN UNDER AGE 50 - IS MAMMOGRAPHY DETRIMENTAL	LANCET			English	Article							SCREENING TRIAL; MORTALITY; REDUCTION	Great uncertainty exists about the benefit of detecting breast cancer by mammography in women under 50 years of age. We have reviewed the survival of patients aged 49 years or less whose cancers were detected by mammography alone. 117 women under the age of 50 years were diagnosed with breast cancer between 1978 and 1991 based only on an abnormal mammogram. Ductal carcinoma in-situ (DCIS) was found in 47 (40%) of these women, whilst 70 (60%) had infiltrating ductal or infiltrating lobular carcinomas. During the same interval, 928 women in this age group presented with palpable breast cancer. DCIS was diagnosed in 82 (9%) of these women, whilst 846 (91%) had infiltrating carcinoma. Among the infiltrating cancers detected by mammography alone, 50% were stage I, whilst only 30% of the women with palpable cancers were stage I. Five-year survival for all mammographically detected cancer patients was 95%, whereas for women with palpable cancers the survival was 74% (p < 0.00005). If DCIS is not included, the corresponding survivals are 91% for mammographically detected infiltrating cancers and 72% for palpable infiltrating cancers. Only 1 woman who died among those with palpable cancer had had a mammogram before diagnosis. Our data contradict the suggestion that women under 50 are put at a survival disadvantage by undergoing mammography. We believe that investigators who have reported negative results in this age group must examine other causes for their results.	MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV SURG ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; JOENSUU H, 1992, LANCET, V339, P315, DOI 10.1016/0140-6736(92)91396-P; KOPANS DB, IN PRESS SCREENING M; MARTIN JE, 1979, AM J ROENTGENOL, V132, P737, DOI 10.2214/ajr.132.5.737; MILLER BA, 1991, J NATL CANCER I, V83, P678; MOSKOWITZ M, 1992, RADIOL CLIN N AM, V30, P221; MOSKOWITZ M, 1982, AM J ROENTGENOL, V138, P911, DOI 10.2214/ajr.138.5.911; MUIR BB, 1984, RADIOLOGY, V151, P39, DOI 10.1148/radiology.151.1.6701330; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; SEIDMAN H, 1987, CA-CANCER J CLIN, V37, P258, DOI 10.3322/canjclin.37.5.258; Shapiro S, 1988, PERIODIC SCREENING B; STOMPER PC, 1989, HEMATOL ONCOL CLIN N, V3, P611, DOI 10.1016/S0889-8588(18)30523-9; TABAR L, 1985, DIAGN IMAG CLIN MED, V54, P158; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; WATMOUGH DJ, 1992, LANCET, V340, P122, DOI 10.1016/0140-6736(92)90451-8; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546; 1991, LANCET, V337, P1575	21	36	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1357448				2022-12-01	WOS:A1992JV01400002
J	THORNICROFT, G; GOOCH, C; DAYSON, D				THORNICROFT, G; GOOCH, C; DAYSON, D			THE TAPS PROJECT .17. READMISSION TO HOSPITAL FOR LONG-TERM PSYCHIATRIC-PATIENTS AFTER DISCHARGE TO THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							REVOLVING-DOOR PATIENTS; NATION-WIDE COHORT; DEINSTITUTIONALIZATION; PATTERNS; SAMPLE; STAY	Objective-To identify risk factors which increase the likelihood of readmission for long stay psychiatric patients after discharge from hospital. Design-Follow up for five years of all long stay patients discharged from two large psychiatric hospitals to compare patients readmitted and not readmitted. Setting-Friern and Claybury Hospitals in north London and their surrounding catchment areas. Most patients were discharged to staffed or unstaffed group homes. Subjects-357 psychiatric patients who had been in hospital for over one year, of whom 118 were "new" long stay and 239 "old" long stay patients. Main outcome measures-Readmission to hospital and length of subsequent stay. Results-Of all discharged patients 97 (27%) were readmitted at some time during the follow up period, 57 (16%) in the first year after discharge, and 31 (9%) then remained in hospital for over a year. The best explanatory factors for readmission were: male sex, younger age group, high number of previous admissions, higher levels of symptomatic and social behavioural disturbance, a diagnosis of manic-depressive psychosis, and living in a non-staffed group home. Conclusions-During the closure of psychiatric hospitals, facilities need to be preserved for acute relapses among long term, and especially younger, discharged patients. Staffed group homes may help prevent relapse and reduce the number of admission beds required.			THORNICROFT, G (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				AVISON WR, 1987, AM J PSYCHIAT, V144, P10; BEISER M, 1985, AM J PSYCHIAT, V142, P1047; BLUMENTAHL S, 1988, PSYCHIATR PRAX, V154, P96; CHAMBERS M, 1990, BRIT MED J, V301, P1134, DOI 10.1136/bmj.301.6761.1134; CLARKE A, 1990, BRIT MED J, V301, P1136, DOI 10.1136/bmj.301.6761.1136; COLENDA C C, 1989, Psychiatric Quarterly (New York), V60, P227, DOI 10.1007/BF01064798; DAYSON D, 1992, BRIT MED J, V305, P993, DOI 10.1136/bmj.305.6860.993; DRAKE RE, 1989, HOSP COMMUNITY PSYCH, V40, P46; FERNANDO MLD, 1990, CAN J PSYCHIAT, V35, P71, DOI 10.1177/070674379003500111; GELLER JL, 1990, AM J PSYCHIAT, V147, P988; HAEFNER H, 1989, BRIT J PSYCHIAT, V155, P12; JONES K, 1986, BRIT J PSYCHIAT, V149, P537, DOI 10.1192/bjp.149.5.537; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P80, DOI 10.1111/j.1600-0447.1987.tb02865.x; KASTRUP M, 1987, ACTA PSYCHIAT SCAND, V76, P552, DOI 10.1111/j.1600-0447.1987.tb02918.x; LERNER Y, 1989, SOC PSYCH PSYCH EPID, V24, P121, DOI 10.1007/BF01788020; LEWIS T, 1990, ACTA PSYCHIAT SCAND, V82, P130, DOI 10.1111/j.1600-0447.1990.tb01369.x; MILNE R, 1990, BRIT MED J, V301, P1139, DOI 10.1136/bmj.301.6761.1139; OKIN RL, 1990, AM J PSYCHIAT, V147, P1596; POKORNY AD, 1983, AM J PSYCHIAT, V140, P1598; SETZE PJ, 1985, HOSP COMMUNITY PSYCH, V36, P521; THORNICROFT G, 1989, BRIT J PSYCHIAT, V155, P739, DOI 10.1192/bjp.155.6.739; WAN TTH, 1991, COMMUNITY MENT HLT J, V27, P3, DOI 10.1007/BF00752711; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1; ZILBER N, 1990, SOC PSYCH PSYCH EPID, V25, P144, DOI 10.1007/BF00782743; 1990, 5TH ANN TAPS C LOND	26	36	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1992	305	6860					996	998		10.1136/bmj.305.6860.996	http://dx.doi.org/10.1136/bmj.305.6860.996			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV776	1458148	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JV77600028
J	TIENARI, PJ; WIKSTROM, J; SAJANTILA, A; PALO, J; PELTONEN, L				TIENARI, PJ; WIKSTROM, J; SAJANTILA, A; PALO, J; PELTONEN, L			GENETIC SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS LINKED TO MYELIN BASIC-PROTEIN GENE	LANCET			English	Article							LENGTH POLYMORPHISM; DNA; AMPLIFICATION; TRANSCRIPTION; POLYMERASE; CRITERIA; MOUSE; RISK; MRI	Genetic factors have been implicated in the aetiology of multiple sclerosis (MS), but the genes conferring susceptibility to MS have not been identified. We carried out genetic linkage and association analyses by studying polymorphism of the myelin basic protein (MBP) gene on chromosome 18, a candidate gene for MS, in 21 MS families, 51 additional unrelated patients with definite MS, and 85 controls. All subjects were Finnish, and 14 of the families were from an area with an exceptional familial clustering of MS. Magnetic resonance imaging (MRI) was used to examine subclinical disease in symptom-free family members. In the association analysis, the allele frequencies between MS patients and controls differed significantly, p = 0.000049), the difference being attributable mainly to a higher frequency of a 1.27 kb allele among patients. In the linkage analysis, based on an autosomal dominant model and penetrance 0.05, a maximum LOD score of 3.42 (theta = 0.00) was obtained when patients with optic neuritis and their symptom-free siblings with abnormal MRI findings were classified as "affected". When these subjects were classified as "unknown" the maximum LOD scores ranged from 2.99 to 3.25 (theta = 0.00). The results suggest that in this population genetic predisposition to MS is closely linked to the MBP gene and that polymorphism at the MBP locus or an adjacent locus has a role in the aetiology of MS.	UNIV HELSINKI,DEPT NEUROL,SF-00100 HELSINKI 10,FINLAND	University of Helsinki	TIENARI, PJ (corresponding author), NATL PUBL HLTH INST,DEPT HUMAN MOLEC GENET,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.		Sajantila, Antti/AAY-9084-2021; Tienari, Pentti J/A-4893-2012	Sajantila, Antti/0000-0003-4117-5248				Alvord EC, 1984, EXPT ALLERGIC ENCEPH; BOYLAN KB, 1990, GENOMICS, V6, P16, DOI 10.1016/0888-7543(90)90443-X; BOYLAN KB, 1987, AM J HUM GENET, V40, P387; BOYLAN KB, 1990, ANN NEUROL, V27, P291, DOI 10.1002/ana.410270311; COMPSTON A, 1986, P56; EBERS GC, 1982, LANCET, V2, P88; FAZEKAS F, 1988, NEUROLOGY, V38, P1822, DOI 10.1212/WNL.38.12.1822; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; KAMHOLZ J, 1987, AM J HUM GENET, V40, P365; KASAI K, 1990, J FORENSIC SCI, V35, P1196; KINNUNEN E, 1983, ACTA NEUROL SCAND, V67, P255, DOI 10.1111/j.1600-0404.1983.tb04574.x; KURTZKE JF, 1983, MULTIPLE SCLEROSIS P, P47; MCDONALD WI, 1986, J NEUROL NEUROSUR PS, V49, P434; MCFARLAND HF, 1989, CLIN IMMUNOL IMMUNOP, V50, pS96, DOI 10.1016/0090-1229(89)90116-5; NEVANLINNA HR, 1972, HEREDITAS-GENETISK A, V71, P195; OKANO H, 1988, EMBO J, V7, P77, DOI 10.1002/j.1460-2075.1988.tb02785.x; Ott J., 1991, ANAL HUMAN GENETIC L; PATY DW, 1988, NEUROLOGY, V38, P180, DOI 10.1212/WNL.38.2.180; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RIZZO JF, 1988, NEUROLOGY, V38, P185, DOI 10.1212/WNL.38.2.185; ROACH A, 1985, CELL, V42, P149, DOI 10.1016/S0092-8674(85)80110-0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; Sambrook J., 1989, MOL CLONING; SANDBERG-WOLLHEIM M, 1990, Annals of Neurology, V27, P386, DOI 10.1002/ana.410270406; TIENARI PJ, IN PRESS J NEUROL NE; VISSCHER BR, 1979, NEUROLOGY, V29, P1354, DOI 10.1212/WNL.29.10.1354; WIKSTROM J, 1975, ACTA NEUROL SCAND, V51, P173, DOI 10.1111/j.1600-0404.1975.tb07598.x; WIKSTROM J, 1984, Neuroepidemiology, V3, P74, DOI 10.1159/000110844	29	141	141	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 24	1992	340	8826					987	991		10.1016/0140-6736(92)93007-A	http://dx.doi.org/10.1016/0140-6736(92)93007-A			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JV014	1383661				2022-12-01	WOS:A1992JV01400001
J	COSSON, P; BONIFACINO, JS				COSSON, P; BONIFACINO, JS			ROLE OF TRANSMEMBRANE DOMAIN INTERACTIONS IN THE ASSEMBLY OF CLASS-II MHC MOLECULES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE-PROTEINS; RECEPTOR; EXPRESSION; PRODUCTS; DISTINCT; COMMON; GENES; MODEL; CLONE	Evidence is presented that suggests a role for transmembrane domain interactions in the assembly of class II major histocompatibility complex (MHC) molecules. Mutations in the transmembrane domains of the class II MHC alpha or beta chains resulted in proteins that did not generate complexes recognized by conformation-dependent antibodies and that were largely retained in the endoplasmic reticulum. Insertion of the alpha and beta transmembrane domains into other proteins allowed the chimeric proteins to assemble, suggesting a direct interaction of the alpha and beta transmembrane domains. The interactions were mediated by a structural motif involving several glycine residues on the same face of a putative alpha helix.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Bonifacino, Juan S./0000-0002-5673-6370				BISHOP GA, 1988, IMMUNOGENETICS, V28, P184, DOI 10.1007/BF00375858; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; COSSON P, UNPUB; CRESSWELL P, 1987, CRIT REV IMMUNOL, V7, P31; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ESTESS P, 1986, P NATL ACAD SCI USA, V83, P3594, DOI 10.1073/pnas.83.11.3594; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; KABAT EA, 1991, SEQUENCES PROTEINS I, P816; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NIELSEN LK, 1990, J IMMUNOL, V144, P2915; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PIERRES M, 1980, EUR J IMMUNOL, V10, P950, DOI 10.1002/eji.1830101211; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P79; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TRAVERS P, 1984, NATURE, V310, P235, DOI 10.1038/310235a0; VANDENELSEN P, 1985, NATURE, V314, P542, DOI 10.1038/314542a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	33	191	208	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					659	662		10.1126/science.1329208	http://dx.doi.org/10.1126/science.1329208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329208				2022-12-01	WOS:A1992JU74500060
J	GAO, JL; XIA, XF				GAO, JL; XIA, XF			A PRIORI EVALUATION OF AQUEOUS POLARIZATION EFFECTS THROUGH MONTE-CARLO QM-MM SIMULATIONS	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; REACTION FIELD-THEORY; FREE-ENERGY; ELECTRONIC-PROPERTIES; COMPUTER-SIMULATION; POTENTIAL FUNCTIONS; LIQUID WATER; SOLVATION; MODEL; PROTEINS	A Monte Carlo quantum mechanical-molecular mechanical (QM-MM) simulation method was used to determine the contributions of the solvent polarization effect to the total interaction energies between solute and solvent for amino acid side chains and nucleotide bases in aqueous solution. In the present AM1-TIP3P approach, the solute molecule is characterized by valence electrons and nucleus cores with Hartree-Fock theory incorporating explicit solvent effects into the total Hamiltonian, while the solvent is approximated by the three-point charge TIP3P model. The polarization energy contributes 10 to 20 percent of the total electrostatic energy in these systems. The performance of the hybrid AM1-TIP3P model was further validated by consideration of bimolecular complexes with water and by computation of the free energies of solvation of organic molecules using statistical perturbation theory. Excellent agreement with ab initio 6-31G(d) results and experimental solvation free energies was obtained.			GAO, JL (corresponding author), SUNY BUFFALO,DEPT CHEM,BUFFALO,NY 14214, USA.							Allen M. P., 1987, COMPUTER SIMULATIONS; BARNES P, 1979, NATURE, V282, P459, DOI 10.1038/282459a0; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; BASH PA, 1987, J AM CHEM SOC, V109, P8192; BENNAIM A, 1984, J CHEM PHYS, V81, P2016, DOI 10.1063/1.447824; Bernal JD, 1933, J CHEM PHYS, V1, P515, DOI 10.1063/1.1749327; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BOTTCHER CJF, 1973, THEORY ELECTRIC POLA; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CEPERLEY D, 1986, SCIENCE, V231, P555, DOI 10.1126/science.231.4738.555; CRAMER CJ, 1991, J AM CHEM SOC, V113, P8305, DOI 10.1021/ja00022a017; CRAMER CJ, 1992, SCIENCE, V256, P213, DOI 10.1126/science.256.5054.213; CRAMER CJ, 1991, J AM CHEM SOC, V113, P8552, DOI 10.1021/ja00022a069; DANG LX, 1991, J AM CHEM SOC, V113, P2481, DOI 10.1021/ja00007a021; DEWAR MJS, 1990, J COMPUT CHEM, V11, P541, DOI 10.1002/jcc.540110413; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; FLORIS F, 1989, J COMPUT CHEM, V10, P616, DOI 10.1002/jcc.540100504; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; GAO J, 1992, MCQUB; GAO JL, 1992, J AM CHEM SOC, V114, P1912, DOI 10.1021/ja00031a073; GAO JL, 1992, J PHYS CHEM-US, V96, P537, DOI 10.1021/j100181a009; Hehre J., 1986, AB INITIO MOL ORBITA; HWANG JK, 1988, J AM CHEM SOC, V110, P5297, DOI 10.1021/ja00224a011; John D.L.B., 1970, APPROXIMATE MOL ORBI; JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; JORGENSEN WL, 1991, BOSS; KARELSON MM, 1989, J ORG CHEM, V54, P6030, DOI 10.1021/jo00287a012; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; Kirkwood JG, 1934, J CHEM PHYS, V2, DOI 10.1063/1.1749489; KOLLMAN PA, 1990, ACCOUNTS CHEM RES, V23, P246, DOI 10.1021/ar00176a002; LUZHKOV V, 1992, J COMPUT CHEM, V13, P199, DOI 10.1002/jcc.540130212; McCammon JA., 1987, DYNAMICS PROTEINS NU; MCCREERY JH, 1976, J AM CHEM SOC, V98, P7191, DOI 10.1021/ja00439a015; MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2; MURRAY TJ, 1992, J AM CHEM SOC, V114, P4010, DOI 10.1021/ja00036a079; Onsager L, 1936, J AM CHEM SOC, V58, P1486, DOI 10.1021/ja01299a050; PEARSON RG, 1986, J AM CHEM SOC, V108, P6109, DOI 10.1021/ja00280a002; PERUTZ MF, 1990, MECHANISMS COOPERATI; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; PRANATA J, 1991, J AM CHEM SOC, V113, P2810, DOI 10.1021/ja00008a002; SHARP K, 1992, J PHYS CHEM-US, V96, P3822, DOI 10.1021/j100188a047; SMYTH CP, 1955, DIELECTRIC BEHAVIOR; STEWART JJP, 1990, J COMPUT CHEM, V11, P543, DOI 10.1002/jcc.540110414; STEWART JJP, 1986, MOPAC VERSION 5 QCPE, V6, P455; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; TAPIA O, 1990, J CHIM PHYS PCB, V87, P875, DOI 10.1051/jcp/1990870875; TAPIA O, 1980, J PHYS CHEM-US, V84, P2646, DOI 10.1021/j100457a034; THOLE BT, 1982, CHEM PHYS, V71, P211, DOI 10.1016/0301-0104(82)87020-1; VANBELLE D, 1987, J MOL BIOL, V198, P721, DOI 10.1016/0022-2836(87)90213-0; VANGUNSTEREN WF, 1990, ANGEW CHEM INT EDIT, V29, P992, DOI 10.1002/anie.199009921; WAHSHEL A, 1972, J AM CHEM SOC, V94, P5612; WANG ISY, 1973, J AM CHEM SOC, V95, P8160, DOI 10.1021/ja00805a033; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WARSHEL A, 1991, COMPUTER MODELING CH; WASZKOWYCZ B, 1991, J CHEM SOC PERK T 2, P225, DOI 10.1039/p29910000225; WEINER SJ, 1986, P NATL ACAD SCI USA, V83, P649, DOI 10.1073/pnas.83.3.649; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; WONG MW, 1991, J AM CHEM SOC, V113, P4776, DOI 10.1021/ja00013a010; ZHENG C, 1988, NATURE, V334, P726, DOI 10.1038/334726a0; ZWANZIG RW, 1954, J CHEM PHYS, V22, P1420, DOI 10.1063/1.1740409	65	582	588	3	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					631	635		10.1126/science.1411573	http://dx.doi.org/10.1126/science.1411573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411573				2022-12-01	WOS:A1992JU74500052
J	JOHNSON, SW; SEUTIN, V; NORTH, RA				JOHNSON, SW; SEUTIN, V; NORTH, RA			BURST FIRING IN DOPAMINE NEURONS INDUCED BY N-METHYL-D-ASPARTATE - ROLE OF ELECTROGENIC SODIUM-PUMP	SCIENCE			English	Article							VENTRAL TEGMENTAL AREA; FREELY MOVING RATS; PARKINSONS-DISEASE; ELECTROPHYSIOLOGICAL PROPERTIES; IMPULSE FLOW; INVITRO; SYSTEM; INVIVO; MIDBRAIN; DRUGS	Dopamine-containing neurons of the mammalian midbrain are required for normal behavior and movements. In vivo they fire action potentials in bursts, but in vitro they discharge regularly spaced action potentials. Burst firing in vitro has now been shown to be robustly induced by the glutamate agonist N-methyl-D-aspartate (NMDA) although not by the non-NMDA agonists kainate or quisqualate. The hyperpolarization between bursts of action potentials results from electrogenic sodium ion extrusion by a ouabain-sensitive pump. This mechanism of burst generation in mammalian neurons may be important in the pathophysiology of schizophrenia and Parkinson's disease.	OREGON HLTH SCI UNIV, DEPT NEUROL, PORTLAND, OR 97201 USA	Oregon Health & Science University	JOHNSON, SW (corresponding author), OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA.		North, Richard/GQA-6156-2022					ADAMS WB, 1985, J PHYSIOL-LONDON, V360, P69, DOI 10.1113/jphysiol.1985.sp015604; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; Bjorklund A, 1984, HDB CHEM NEUROANAT 1, V2, P55; CHARLETY PJ, 1991, ACTA PHYSIOL SCAND, V142, P105, DOI 10.1111/j.1748-1716.1991.tb09134.x; CHRISTIE MJ, 1985, BRAIN RES, V333, P169, DOI 10.1016/0006-8993(85)90140-4; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; DEWEER P, 1988, ANNU REV PHYSIOL, V50, P225, DOI 10.1146/annurev.physiol.50.1.225; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; FREEMAN AS, 1985, LIFE SCI, V36, P1983, DOI 10.1016/0024-3205(85)90448-5; GONON FG, 1988, NEUROSCIENCE, V24, P19, DOI 10.1016/0306-4522(88)90307-7; GONON FG, 1985, NEUROSCIENCE, V14, P765, DOI 10.1016/0306-4522(85)90141-1; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRACE AA, 1984, J NEUROSCI, V4, P2877; GRACE AA, 1989, J NEUROSCI, V9, P3463; GREENAMYRE JT, 1991, ARCH NEUROL-CHICAGO, V48, P977, DOI 10.1001/archneur.1991.00530210109030; JAHNSEN H, 1984, J PHYSIOL-LONDON, V349, P227, DOI 10.1113/jphysiol.1984.sp015154; JOHNSON SW, 1992, J PHYSIOL-LONDON, V450, P455, DOI 10.1113/jphysiol.1992.sp019136; KRAMER RH, 1985, J PHYSIOL-LONDON, V362, P131, DOI 10.1113/jphysiol.1985.sp015667; LACEY MG, 1988, J PHYSIOL-LONDON, V406, pP18; LACEY MG, 1989, J NEUROSCI, V9, P1233; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Luria AR, 1969, HDB CLINICAL NEUROLO, P725; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; ROMO R, 1990, J NEUROPHYSIOL, V63, P592, DOI 10.1152/jn.1990.63.3.592; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; RUSSELL WR, 1948, LANCET, V254, P356; SANGHERA MK, 1984, NEUROSCIENCE, V12, P793, DOI 10.1016/0306-4522(84)90171-4; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULTZ W, 1986, J NEUROPHYSIOL, V56, P1439, DOI 10.1152/jn.1986.56.5.1439; SEEMAN P, 1975, SCIENCE, V188, P1217, DOI 10.1126/science.1145194; SHEPARD PD, 1991, EXP BRAIN RES, V86, P141, DOI 10.1007/BF00231048; SMITH TG, 1975, NATURE, V253, P450, DOI 10.1038/253450a0; SNYDER SH, 1976, AM J PSYCHIAT, V133, P197; STRECKER RE, 1985, BRAIN RES, V361, P339, DOI 10.1016/0006-8993(85)91304-6; SVENSSON TH, 1989, ACTA PHYSIOL SCAND, V136, P135, DOI 10.1111/j.1748-1716.1989.tb08640.x; WHITTAM R, 1962, BIOCHEM J, V82, P205, DOI 10.1042/bj0820205; WISE RA, 1988, ANN NY ACAD SCI, V537, P228; YUNG WH, 1991, J PHYSIOL-LONDON, V436, P643, DOI 10.1113/jphysiol.1991.sp018571	44	378	386	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					665	667		10.1126/science.1329209	http://dx.doi.org/10.1126/science.1329209			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329209				2022-12-01	WOS:A1992JU74500062
J	MAKITA, Z; VLASSARA, H; RAYFIELD, E; CARTWRIGHT, K; FRIEDMAN, E; RODBY, R; CERAMI, A; BUCALA, R				MAKITA, Z; VLASSARA, H; RAYFIELD, E; CARTWRIGHT, K; FRIEDMAN, E; RODBY, R; CERAMI, A; BUCALA, R			HEMOGLOBIN-AGE - A CIRCULATING MARKER OF ADVANCED GLYCOSYLATION	SCIENCE			English	Article							GLUCOSE-MODIFIED PROTEINS; DIABETES-MELLITUS; END-PRODUCTS; NONENZYMATIC GLYCOSYLATION; HUMAN COLLAGEN; AMINOGUANIDINE; TISSUE; NEPHROPATHY; RAT; FLUORESCENCE	Advanced glycosylation end products (AGEs) form spontaneously from glucose-derived Amadori products and accumulate on long-lived tissue proteins. AGEs have been implicated in the pathogenesis of several of the complications of aging and diabetes, including atherosclerosis and renal disease. With the use of recently developed AGE-specific antibodies, an AGE-modified form of human hemoglobin has been identified. Termed hemoglobin-AGE (Hb-AGE), this modified species accounts for 0.42 percent of circulating hemoglobin in normal individuals but increases to 0.75 percent in patients with diabetes-induced hyperglycemia. In a group of diabetic patients treated with the advanced glycosylation inhibitor aminoguanidine, Hb-AGE levels decreased significantly over a 1-month period. Hemoglobin-AGE measurements may provide an index of long-term tissue modification by AGEs and prove useful in assessing the contribution of advanced glycosylation to a variety of diabetic and age-related complications.	ALTEON INC, NORTHVALE, NJ 07647 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA; SUNY DOWNSTATE MED CTR, BROOKLYN, NY 11203 USA	Rush University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19655-15] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOOKCHIN RM, 1968, BIOCHEM BIOPH RES CO, V32, P86, DOI 10.1016/0006-291X(68)90430-0; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; ELLIS EN, 1991, METABOLISM, V40, P1016, DOI 10.1016/0026-0495(91)90122-D; ESPOSITO C, 1989, J EXP MED, V170, P1387, DOI 10.1084/jem.170.4.1387; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HOGAN M, IN PRESS J CLIN INVE; KIRSTEIN M, 1990, P NATL ACAD SCI USA, V87, P9010, DOI 10.1073/pnas.87.22.9010; KOENIG RJ, 1977, J BIOL CHEM, V252, P2992; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; KOHN RR, 1984, DIABETES, V33, P57, DOI 10.2337/diabetes.33.1.57; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LEWIS BS, 1990, EXP EYE RES, V50, P463, DOI 10.1016/0014-4835(90)90033-Q; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKITA Z, 1991, DIABETOLOGIA, V34, P40, DOI 10.1007/BF00404023; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, UNPUB; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; NICHOLLS K, 1989, LAB INVEST, V60, P486; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; NJOROGE FG, 1988, J BIOL CHEM, V263, P10646; ODETTI PR, 1990, DIABETES, V39, P796, DOI 10.2337/diabetes.39.7.796; PETERSON CM, 1985, DIABETES ANN, V1, P178; PONGOR S, 1984, P NATL ACAD SCI-BIOL, V81, P2684, DOI 10.1073/pnas.81.9.2684; SCHNIDER SL, 1981, J CLIN INVEST, V67, P1630, DOI 10.1172/JCI110198; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; VLASSARA H, 1985, P NATL ACAD SCI USA, V82, P5588, DOI 10.1073/pnas.82.17.5588; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47	36	256	272	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					651	653		10.1126/science.1411574	http://dx.doi.org/10.1126/science.1411574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411574				2022-12-01	WOS:A1992JU74500057
J	SCHELLENBERG, GD; BIRD, TD; WIJSMAN, EM; ORR, HT; ANDERSON, L; NEMENS, E; WHITE, JA; BONNYCASTLE, L; WEBER, JL; ALONSO, ME; POTTER, H; HESTON, LL; MARTIN, GM				SCHELLENBERG, GD; BIRD, TD; WIJSMAN, EM; ORR, HT; ANDERSON, L; NEMENS, E; WHITE, JA; BONNYCASTLE, L; WEBER, JL; ALONSO, ME; POTTER, H; HESTON, LL; MARTIN, GM			GENETIC-LINKAGE EVIDENCE FOR A FAMILIAL ALZHEIMERS-DISEASE LOCUS ON CHROMOSOME-14	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; C-FOS; MAMMALIAN BRAIN; MUTATION; MARKERS; HETEROGENEITY; KINDREDS; SEQUENCE; DEMENTIA; INDICATE	Linkage analysis was used to search the genome for chromosomal regions harboring familial Alzheimer's disease genes. Markers on chromosome 14 gave highly significant positive lod scores in early-onset non-Volga German kindreds; a Z(max) of 9.15 (theta = 0.01) was obtained with the marker D14S43 at 14q24.3. One early-onset family yielded a lod score of 4.89 (theta = 0.0). When no assumptions were made about age-dependent penetrance, significant results were still obtained (Z(max) = 5.94, theta = 0.0), despite the loss of power to detect linkage under these conditions. Results for the Volga German families were either negative or nonsignificant for markers in this region. Thus, evidence indicates a familial Alzheimer's disease locus on chromosome 14.	VET AFFAIRS MED CTR, DIV NEUROL, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, DIV MED GENET, SEATTLE, WA 98195 USA; MARSHFIELD MED RES FDN, MARSHFIELD, WI 54449 USA; NATL INST NEUROL & NEUROSURG, MEXICO CITY, MEXICO; WASHINGTON INST MENTAL ILLNESS RES & TRAINING, DEPT PSYCHIAT, STEILACOOM, WA 98494 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA; UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT PSYCHIAT, MINNEAPOLIS, MN 55455 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle	SCHELLENBERG, GD (corresponding author), UNIV WASHINGTON, DEPT MED, DIV NEUROL, SEATTLE, WA 98195 USA.			Orr, Harry/0000-0001-6118-741X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008017] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00248] Funding Source: Medline; NIA NIH HHS [AG08017] Funding Source: Medline; NIMH NIH HHS [R01MH43240] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERGEM ALM, NEUROBIOL AGING, V13, pS66; BIRD TD, 1989, ANN NEUROL, V25, P12, DOI 10.1002/ana.410250104; BIRD TD, 1988, ANN NEUROL, V23, P25, DOI 10.1002/ana.410230106; BREITNER JCS, NEUROBIOL AGING, V13, pS66; BROWN IR, 1990, J NEUROSCI RES, V27, P247, DOI 10.1002/jnr.490270302; CHARTIERHARLIN MC, 1991, NEUROSCI LETT, V129, P134, DOI 10.1016/0304-3940(91)90738-F; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COX DW, 1985, NATURE, V316, P79, DOI 10.1038/316079a0; CRAWFORD F, 1991, NEUROSCI LETT, V133, P1, DOI 10.1016/0304-3940(91)90042-R; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOUDSMIT J, 1981, J NEUROL SCI, V49, P79, DOI 10.1016/0022-510X(81)90190-8; HESTON LL, 1991, AM J MED GENET, V40, P449, DOI 10.1002/ajmg.1320400415; HODGE SE, 1983, AM J HUM GENET, V35, P1139; JORDAN SA, 1959, NUCLEIC ACIDS RES, V19, P1722; KAMINO K, 1992, AM J HUM GENET, V51, P998; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MOHS RC, 1987, ARCH GEN PSYCHIAT, V44, P405; MORTON NE, 1956, AM J HUM GENET, V8, P80; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; NEE LE, 1987, NEUROLOGY, V37, P359, DOI 10.1212/WNL.37.3.359; NUKIWA T, 1988, AM J HUM GENET, V43, P322; NUKIWA T, 1986, J BIOL CHEM, V261, P5989; Ott J., 1991, ANAL HUMAN GENETIC L; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; RAPOPORT SI, 1991, NEUROLOGY, V41, P1549, DOI 10.1212/WNL.41.10.1549; RISCH N, 1991, AM J HUM GENET, V48, P1058; RUPPERT C, 1987, MOL BRAIN RES, V2, P51, DOI 10.1016/0169-328X(87)90020-9; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SCHELLENBERG G, 1992, Neurobiology of Aging, V13, pS67; SCHELLENBERG GD, 1991, AM J HUM GENET, V49, P511; SCHELLENBERG GD, 1988, SCIENCE, V241, P1507, DOI 10.1126/science.3420406; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHELLENBERG GD, 1992, ANN NEUROL, V31, P223, DOI 10.1002/ana.410310214; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1722, DOI 10.1093/nar/19.7.1722; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMITH CAB, 1961, 2ND P INT C HUM GEN, V1, P212; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; TANZI RE, 1987, NATURE, V329, P156, DOI 10.1038/329156a0; TANZI RE, 1991, J BIOL CHEM, V266, P20579; TANZI RE, 1992, AM J HUM GENET, V51, P273; VALENCIA LG, 1986, REV INVEST CLIN, V38, P261; VAN BROECKHOVEN C, 1987, NATURE, V329, P153; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; VANDUIJN CM, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91611-W; WANG ZY, 1992, GENOMICS, V13, P532, DOI 10.1016/0888-7543(92)90121-8; WEITKAMP LR, 1983, AM J HUM GENET, V35, P443; WILLIAMSON R, 1991, CYTOGENET CELL GENET, V58, P1190, DOI 10.1159/000133727; YOSHIOKA K, 1991, BIOCHEM BIOPH RES CO, V178, P1141, DOI 10.1016/0006-291X(91)91011-Z; ZHANG P, 1992, NEUROSCIENCE, V46, P9, DOI 10.1016/0306-4522(92)90004-L	55	819	847	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					668	671		10.1126/science.1411576	http://dx.doi.org/10.1126/science.1411576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411576				2022-12-01	WOS:A1992JU74500063
J	TAKAHAMA, Y; SHORES, EW; SINGER, A				TAKAHAMA, Y; SHORES, EW; SINGER, A			NEGATIVE SELECTION OF PRECURSOR THYMOCYTES BEFORE THEIR DIFFERENTIATION INTO CD4+CD8+ CELLS	SCIENCE			English	Article							RECEPTOR TRANSGENIC MICE; BETA-T-CELL; IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; CLONAL ELIMINATION; CD4+8+ THYMOCYTES; ANTIGEN RECEPTOR; INVIVO; INTERMEDIATE; GENERATION	Thymic selection of the developing T cell repertoire is thought to occur at the CD4+CD8+ stage of differentiation and to be determined by the specificity of the T cell receptors (TCRs) that CD4+CD8+ thymocytes express. However, TCR signals can inhibit the differentiation of precursor thymocytes into CD4+CDB+ cells, which suggests that selection might occur earlier than thought. Indeed, in a negatively selecting male thymus, CD4-CD8(lo) precursor thymocytes that express a transgenic TCR to male antigen are developmentally arrested as a consequence of antigen encounter and fail to become CD4+CD8+. Thus, negative selection can occur before the CD4+CD8+ stage of differentiation.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Takahama, Yousuke/A-5863-2010	Takahama, Yousuke/0000-0002-4992-9174				BENOIST C, 1989, CELL, V58, P1027, DOI 10.1016/0092-8674(89)90501-1; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; Maniatis T., 1982, MOL CLONING; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NIKOLICZUGIC J, 1989, EUR J IMMUNOL, V19, P1957, DOI 10.1002/eji.1830191030; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETRIE HT, 1990, J EXP MED, V172, P1583, DOI 10.1084/jem.172.6.1583; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORTMAN K, 1988, CELL IMMUNOL, V113, P462, DOI 10.1016/0008-8749(88)90042-1; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TAKAHAMA Y, UNPUB; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; THEILER K, 1989, HOUSE MOUSE; VASQUEZ NJ, 1992, J EXP MED, V175, P1307, DOI 10.1084/jem.175.5.1307; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	31	108	109	2	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1992	258	5082					653	656		10.1126/science.1357752	http://dx.doi.org/10.1126/science.1357752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1357752				2022-12-01	WOS:A1992JU74500058
J	WILLIAMS, TL				WILLIAMS, TL			PHASE COUPLING BY SYNAPTIC SPREAD IN CHAINS OF COUPLED NEURONAL OSCILLATORS	SCIENCE			English	Article							LAMPREY SPINAL-CORD; CENTRAL PATTERN GENERATOR; LOCOMOTION; INTERNEURONS; FREQUENCY; MODEL	Many neural systems behave as arrays of coupled oscillators, with characteristic phase coupling. For example, the rhythmic activation patterns giving rise to swimming in fish are characterized by a rostral-to-caudal phase delay in ventral root activity that is independent of the cycle duration. This produces a traveling wave of curvature along the body of the animal with a wavelength approximately equal to the body length. Here a simple mechanism for phase coupling in chains of equally activated oscillators is postulated: the synapses between the cells making up a "unit oscillator" are simply repeated in neighboring segments, with a reduced synaptic strength. If such coupling is asymmetric in the rostral and caudal directions, traveling waves of activity are produced. The intersegmental phase lag that develops is independent of the coupling strength over at least a tenfold range. Furthermore, for the unit oscillator believed to underlie central pattern generation in the lamprey spinal cord, such coupling can result in a phase lag that is independent of frequency.			WILLIAMS, TL (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PHYSIOL,LONDON SW17 0RE,ENGLAND.							BUCHANAN JT, 1982, J NEUROPHYSIOL, V47, P948, DOI 10.1152/jn.1982.47.5.948; BUCHANAN JT, 1982, J NEUROPHYSIOL, V47, P961, DOI 10.1152/jn.1982.47.5.961; BUCHANAN JT, 1987, SCIENCE, V236, P312, DOI 10.1126/science.3563512; BUCHANAN JT, 1992, BIOL CYBERN, V66, P367, DOI 10.1007/BF00203673; COHEN AH, 1982, J MATH BIOL, V13, P345, DOI 10.1007/BF00276069; COHEN AH, 1987, J NEUROSCI METH, V21, P113, DOI 10.1016/0165-0270(87)90109-9; COHEN AH, 1980, EXP BRAIN RES, V41, P11; DALE N, 1986, J NEUROSCI, V6, P2662, DOI 10.1523/jneurosci.06-09-02662.1986; EKEBERG O, 1991, BIOL CYBERN, V65, P81, DOI 10.1007/BF00202382; ERMENTROUT GB, 1984, SIAM J MATH ANAL, V15, P215, DOI 10.1137/0515019; ERMENTROUT GB, 1991, J MATH BIOL, V29, P155; GRILLNER S, 1974, EXP BRAIN RES, V20, P459; GRILLNER S, 1988, NEUROSCI LETT, V89, P31, DOI 10.1016/0304-3940(88)90476-4; Grillner S., 1976, NEURAL CONTROL LOCOM, P181; KOPELL N, 1990, SIAM J APPL MATH, V50, P1014, DOI 10.1137/0150062; KOPELL N, 1988, MATH BIOSCI, V90, P87, DOI 10.1016/0025-5564(88)90059-4; KOPELL N, 1986, COMMUN PUR APPL MATH, V39, P623, DOI 10.1002/cpa.3160390504; KOPELL N, 1991, SIAM J APPL MATH, V51, P1397, DOI 10.1137/0151070; MATSUSHIMA T, 1992, J NEUROPHYSIOL, V67, P373, DOI 10.1152/jn.1992.67.2.373; ROVAINEN CM, 1974, J COMP NEUROL, V154, P189, DOI 10.1002/cne.901540206; ROVAINEN CM, 1989, J NEUROPHYSIOL, V54, P959; Sigvardt K.A., 1992, Seminars in the Neurosciences, V4, P37, DOI 10.1016/1044-5765(92)90032-W; SIGVARDT K A, 1991, Society for Neuroscience Abstracts, V17, P122; SIGVARDT KA, 1989, AM ZOOL, V29, P19; SZEKELY G, 1965, ACTA PHYSIOL HUNG, V27, P285; WALLEN P, 1984, J PHYSIOL-LONDON, V347, P225, DOI 10.1113/jphysiol.1984.sp015063; WALLEN P, IN PRESS J NEUROPHYS; WILLIAMS TL, 1990, J NEUROPHYSIOL, V64, P862, DOI 10.1152/jn.1990.64.3.862; WILLIAMS TL, 1989, J EXP BIOL, V143, P559; WILLIAMS TL, 1992, NEURAL COMPUT, V4, P546, DOI 10.1162/neco.1992.4.4.546	30	107	107	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					662	665		10.1126/science.1411575	http://dx.doi.org/10.1126/science.1411575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1411575				2022-12-01	WOS:A1992JU74500061
J	ZIEGELSTEIN, RC; CHENG, L; CAPOGROSSI, MC				ZIEGELSTEIN, RC; CHENG, L; CAPOGROSSI, MC			FLOW-DEPENDENT CYTOSOLIC ACIDIFICATION OF VASCULAR ENDOTHELIAL-CELLS	SCIENCE			English	Article							DEPOLARIZATION-INDUCED ALKALINIZATION; INTRACELLULAR PH REGULATION; LYMPHOCYTE VOLUME REGULATION; ACTIVATING FACTOR PRODUCTION; ESTER INDUCED ACTIVATION; BOVINE AORTIC-CELLS; CHICK HEART-CELLS; NA+-H+ EXCHANGE; SHEAR-STRESS; PROXIMAL TUBULES	Hemodynamic shear stress affects endothelial cell structure and function, but little is known about the signal transduction mechanisms involved in these processes. The effect of laminar shear stress on cytosolic pH (pH(i)) was examined in rat aortic endothelial cells cultured in glass capillary tubes. Shear stress forces led to a rapid decrease in pH(i) (maximal effect 0.09 pH unit at 13.4 dynes per square centimeter). Removal of specific ions or addition of exchange inhibitors suggests that in vascular endothelial cells shear stress forces activate both an alkali extruder, sodium ion-independent chloride-bicarbonate ion exchange, and an acid extruder, sodium-hydrogen ion exchange; the net effect in physiologic buffer with the bicarbonate ion is a decrease in pH(i).	NIA,FAMILY PRACTICE RES CTR,CARDIOVASC SCI LAB,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,DIV CARDIOL,BALTIMORE,MD 21205	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLANK PS, 1992, AM J PHYSIOL, V263, pH276, DOI 10.1152/ajpheart.1992.263.1.H276; BLANK PS, AM J PHYSL; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; CAPOGROSSI MC, UNPUB; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLE OF, 1986, CELL BIOL INT REP, V10, P399, DOI 10.1016/0309-1651(86)90034-2; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; DULL RO, 1991, AM J PHYSIOL, V261, pH149, DOI 10.1152/ajpheart.1991.261.1.H149; ESCOBALES N, 1990, AM J PHYSIOL, V259, pC640, DOI 10.1152/ajpcell.1990.259.4.C640; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GLEESON D, 1990, AM J PHYSIOL, V258, pG299, DOI 10.1152/ajpgi.1990.258.2.G299; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; KITAZONO T, 1988, BIOCHEM BIOPH RES CO, V152, P1304, DOI 10.1016/S0006-291X(88)80427-3; LANSMAN JB, 1988, NATURE, V331, P481, DOI 10.1038/331481a0; LIU S, 1990, J GEN PHYSIOL, V96, P1247, DOI 10.1085/jgp.96.6.1247; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; NAKACHE M, 1988, P NATL ACAD SCI USA, V85, P1841, DOI 10.1073/pnas.85.6.1841; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF342, DOI 10.1152/ajprenal.1989.256.2.F342; SIEBENS AW, 1989, AM J PHYSIOL, V256, pF354, DOI 10.1152/ajprenal.1989.256.2.F354; THOMAS RC, 1989, NATURE, V337, P601, DOI 10.1038/337601a0; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; WHITAKER JE, 1991, ANAL BIOCHEM, V194, P330, DOI 10.1016/0003-2697(91)90237-N; ZIEGELSTEIN RC, UNPUB; ZIEGELSTEIN RC, 1991, AM J PHYSIOL, V260, pH1698	34	110	111	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 23	1992	258	5082					656	659		10.1126/science.1329207	http://dx.doi.org/10.1126/science.1329207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU745	1329207				2022-12-01	WOS:A1992JU74500059
J	BURGARD, M; MAYAUX, MJ; BLANCHE, S; FERRONI, A; GUIHARDMOSCATO, ML; ALLEMON, MC; CIRARUVIGNERON, N; FIRTION, G; FLOCH, C; GUILLOT, F; LACHASSINE, E; VIAL, M; GRISCELLI, C; ROUZIOUX, C				BURGARD, M; MAYAUX, MJ; BLANCHE, S; FERRONI, A; GUIHARDMOSCATO, ML; ALLEMON, MC; CIRARUVIGNERON, N; FIRTION, G; FLOCH, C; GUILLOT, F; LACHASSINE, E; VIAL, M; GRISCELLI, C; ROUZIOUX, C			THE USE OF VIRAL CULTURE AND P24-ANTIGEN TESTING TO DIAGNOSE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION IN NEONATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; INFANTS BORN; HIV-1 INFECTION; CHILDREN; TYPE-1; ANTIBODIES; PROTEINS; MOTHERS; ASSAY; FETUS	Background. Early diagnosis of human immunodeficiency virus (HIV) infection in infants born to infected mothers is important for the infants' medical care, but the presence of maternal antibodies makes serologic tests uninformative. Methods. In a cohort study of 181 infants born to HIV-infected mothers, we assessed the diagnostic value of HIV viral culture and testing for the presence of p24 antigen. The infants were tested at birth, again during the first 3 months, then followed and tested at the age of at least 18 months. Results. Of the 181 infants, 3 died of HIV infection and 37 were seropositive after the age of 18 months. Viral cultures at birth were positive in 19 of the 40 infected infants and in none of the uninfected infants, yielding a sensitivity of 48 percent (95 percent confidence interval, 32 to 63 percent) and a specificity of 100 percent (95 percent confidence interval, 97 to 1 00 percent). By the age of three months, 30 of the 40 infants (75 percent) had positive cultures; again, there were no false positive results among the infants who were tested a second time, of the 141 who remained uninfected. The sensitivity of testing for p24 antigen at birth was only 18 percent, with a specificity of 100 percent. The presence of p24 antigen at birth was associated with the development of early and severe HIV-related disease (P<0.04). Conclusions. Viral culture at birth can correctly identify about half of newborns with HIV infection. The fact that this usually sensitive technique fails to identify about half the ultimately infected neonates suggests that vertical transmission of HIV may occur late in pregnancy or during delivery.	HOP NECKER ENFANTS MALAD,MICROBIOL LAB,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,IMMUNOL & HEMATOL UNIT,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,INSERM,U132,PARIS,FRANCE; HOP BICETRE,INSERM,U292,F-94270 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)								AMADORI A, 1988, LANCET, V1, P852; ARCHIBALD DW, 1990, AIDS, V4, P417, DOI 10.1097/00002030-199005000-00006; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; CANDOTTI D, 1991, AIDS, V5, P1003, DOI 10.1097/00002030-199108000-00012; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CZERKINSKY C, 1988, J IMMUNOL METHODS, V115, P31, DOI 10.1016/0022-1759(88)90306-7; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; FEORINO P, 1987, J CLIN MICROBIOL, V25, P2344, DOI 10.1128/JCM.25.12.2344-2346.1987; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; JOVAISAS E, 1985, LANCET, V2, P1129; LAURE F, 1988, LANCET, V2, P538; MAINLAND D, 1956, STATISTICAL TABLES U; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MOK JQ, 1987, LANCET, V1, P1164; PEUCHMAUR M, 1991, AIDS, V5, P741, DOI 10.1097/00002030-199106000-00015; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; ROUZIOUX C, 1992, AIDS, V6, P373, DOI 10.1097/00002030-199204000-00003; ROUZIOUX C, 1991, VIRAL QUANTITATION IN HIV INFECTION, P187; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SPRECHER S, 1986, LANCET, V2, P288; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; 1987, MMWR MORB MORTAL WKL, V36, P225	26	167	168	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1192	1197		10.1056/NEJM199210223271702	http://dx.doi.org/10.1056/NEJM199210223271702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406792				2022-12-01	WOS:A1992JU39300002
J	DAN, Y; POO, MM				DAN, Y; POO, MM			QUANTAL TRANSMITTER SECRETION FROM MYOCYTES LOADED WITH ACETYLCHOLINE	NATURE			English	Article							MUSCLE-CELL MEMBRANE; NEUROMUSCULAR-JUNCTION; SYNAPTIC VESICLES; RELEASE; RECEPTORS; CULTURE; EXOCYTOSIS	IT is well known that transmitter secretion requires specialized secretory organelles, the synaptic vesicles, for the packaging, storage and exocytotic release of the transmitter1,2. Here we report that when acetylcholine (ACh) is loaded into an isolated Xenopus myocyte, there is spontaneous quantal release of ACh from the myocyte which results in activation of its own surface ACh channels and the appearance of membrane currents resembling miniature endplate currents. This myocyte secretion probably reflects Ca2+-regulated exocytosis of ACh-filled cytoplasmic compartments. Furthermore, step depolarization of the myocyte membrane triggers evoked ACh release from the myocyte with a weak excitation-secretion coupling. These findings suggest that quantal transmitter secretion does not require secretory pathways unique to neurons and that the essence of presynaptic differentiation may reside in the provision of transmitter supply and modification of the preexisting secretion pathway.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University				Dan, Yang/0000-0002-3818-877X				ADLER EM, 1991, J NEUROSCI, V11, P1496; ANDERSON MJ, 1977, J PHYSIOL-LONDON, V268, P731, DOI 10.1113/jphysiol.1977.sp011879; BUCHANAN J, 1989, J NEUROSCI, V9, P1540; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; ENOMOTO K, 1988, EUR J PHARMACOL, V147, P209; EVERS J, 1989, J NEUROSCI, V9, P1523; HAMILL OP, 1981, PFLUGERS ARCH, V391, P80; HEUSER JE, 1979, J CELL BIOL, V81, P275, DOI 10.1083/jcb.81.2.275; ISRAEL M, 1979, PROG NEUROBIOL, V13, P237, DOI 10.1016/0301-0082(79)90017-0; Jessell T., 1991, PRINCIPLES NEURAL SC; KATZ B, 1977, PROC R SOC SER B-BIO, V196, P59, DOI 10.1098/rspb.1977.0029; Katz B., 1969, RELEASE NEURAL TRANS; KUFFLER SW, 1975, J PHYSIOL-LONDON, V251, P465, DOI 10.1113/jphysiol.1975.sp011103; MARSHALL IG, 1990, J PHYSIOL-LONDON, V424, pP52; MARSHALL IG, 1987, TRENDS NEUROSCI, V10, P174, DOI 10.1016/0166-2236(87)90044-0; MINTA A, 1989, J BIOL CHEM, V264, P8171; MOREL N, 1978, J NEUROCHEM, V30, P1553, DOI 10.1111/j.1471-4159.1978.tb10492.x; ORIDA N, 1978, NATURE, V275, P31, DOI 10.1038/275031a0; POO MM, 1982, NATURE, V295, P332, DOI 10.1038/295332a0; POULAIN B, 1986, J PHYSIOL-PARIS, V81, P270; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUN YA, 1985, J NEUROSCI, V5, P634; TABTI N, 1986, ACTA PHYSIOL SCAND, V128, P429, DOI 10.1111/j.1748-1716.1986.tb07996.x; Tabti N., 1991, CULTURING NERVE CELL, P137; TAKAHASHI T, 1987, J NEUROSCI, V7, P473; TRIMBLE AW, 1991, REV NEUROSCI, V14, P93; WHITTAKER VP, 1972, BIOCHEM J, V128, P833, DOI 10.1042/bj1280833; YOUNG SH, 1983, NATURE, V304, P161, DOI 10.1038/304161a0	30	81	82	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					733	736		10.1038/359733a0	http://dx.doi.org/10.1038/359733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436036				2022-12-01	WOS:A1992JU65000057
J	DERRICK, JP; WIGLEY, DB				DERRICK, JP; WIGLEY, DB			CRYSTAL-STRUCTURE OF A STREPTOCOCCAL PROTEIN-G DOMAIN BOUND TO AN FAB FRAGMENT	NATURE			English	Article							BINDING DOMAIN; IGG; RECOGNITION; REFINEMENT; SITES	PROTEIN G is a cell-surface protein from Streptococcus1,2 which binds to IgG molecules from a wide range of species with an affinity comparable to that of antigen3,4. The high affinity of protein G for the Fab portion of IgG poses a particular challenge in molecular recognition, given the variability of heavy chain subclass, light chain type and complementarity-determining regions. Here we report the crystal structure of a complex between a protein G domain and an immunoglobulin Fab fragment. An outer beta-strand in the protein G domain forms an antiparallel interaction with the last beta-strand in the constant heavy chain domain of the immunoglobulin, thus extending the beta-sheet into the protein G. The interaction between secondary structural elements in Fab and protein G provides an ingenious solution to the problem of maintaining a high affinity for many different IgG molecules. The structure also contrasts with Fab-antigen complexes, in which all contacts with antigen are mediated by the variable regions of the antibody, and to our knowledge provides the first details of interaction of the constant regions of Fab with another protein.	UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of York - UK	DERRICK, JP (corresponding author), UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, ENGLAND.			Derrick, Jeremy/0000-0002-4350-5354	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BJORCK L, 1990, P113; BJORCK L, 1984, J IMMUNOL, V133, P969; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DERRICK JP, 1992, J MOL BIOL, V227, P1253, DOI 10.1016/0022-2836(92)90535-R; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB, V1, P133; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES AT, 1978, J APPL CRYSTALLOGR A, V43, P489; LIAN LY, 1991, BIOCHEMISTRY-US, V30, P5335, DOI 10.1021/bi00236a002; MYHRE E B, 1990, P243; SAWYER JR, 1991, PROTEIN ENG, V4, P947, DOI 10.1093/protein/4.8.947; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; STONE GC, 1989, J IMMUNOL, V143, P565	19	153	167	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					752	754		10.1038/359752a0	http://dx.doi.org/10.1038/359752a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436040				2022-12-01	WOS:A1992JU65000064
J	FUJIMURA, T; RIBAS, JC; MAKHOV, AM; WICKNER, RB				FUJIMURA, T; RIBAS, JC; MAKHOV, AM; WICKNER, RB			POL OF GAG-POL FUSION PROTEIN REQUIRED FOR ENCAPSIDATION OF VIRAL-RNA OF YEAST L-A-VIRUS	NATURE			English	Article							HEPATITIS-B VIRUS; SACCHAROMYCES-CEREVISIAE; GENOMIC RNA; INVITRO; REPLICATION; POLYMERASE; TRANSCRIPTION; MATURATION; PARTICLES	DOUBLE-STRANDED RNA viruses have an RNA-dependent RNA polymerase activity associated with the viral particles which is indispensable for their replication cycle. Using the yeast L-A double-stranded RNA virus we have investigated the mechanism by which the virus encapsidates its genomic RNA and RNA polymerase. The L-A gag gene encodes the principal viral coat protein and the overlapping pol gene is expressed as a gag-pol fusion protein which is formed by a -1 ribosomal frameshift1-3. Here we show that Gag alone is sufficient for virus particle formation, but that it fails to package the viral single-stranded RNA genome. Encapsidation of the viral RNA requires only a part of the Pol region (the N-terminal quarter), which is presumably distinct from the RNA polymerase domain. Given that the Pol region has single-stranded RNA-binding activity, these results are consistent with our LA virus encapsidation model1: the Pol region of the fusion protein binds specifically to the viral genome (+) strand, and the N-terminal gag-encoded region primes polymerization of Gag to form the capsid, thus ensuring the packaging of both the viral genome and the RNA polymerase.	NIDDKD,BIOCHEM PHARMACOL LAB,GENET SIMPLE EUKARYOTES SECT,BETHESDA,MD 20892; NIAMSD,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	FUJIMURA, T (corresponding author), UNIV SALAMANCA,CSIC,DEPT MICROBIOL & GENET,INST MICROBIOL BIOQUIM,E-37071 SALAMANCA,SPAIN.		Ribas, Juan C/C-9864-2015; Fujimura, Tsutomu/K-5807-2014	Ribas, Juan C/0000-0001-6430-0895; Fujimura, Tsutomu/0000-0002-9457-6769				BARTENSCHLAGER R, 1990, J VIROL, V64, P5324, DOI 10.1128/JVI.64.11.5324-5332.1990; BIRNBAUM F, 1990, J VIROL, V64, P3319, DOI 10.1128/JVI.64.7.3319-3330.1990; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COFFIN J M, 1991, P645; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; FUJIMURA T, 1992, J BIOL CHEM, V267, P2708; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1986, P NATL ACAD SCI USA, V83, P4433, DOI 10.1073/pnas.83.12.4433; FUJIMURA T, 1987, MOL CELL BIOL, V7, P420, DOI 10.1128/MCB.7.1.420; HERRING AJ, 1977, NATURE, V268, P464, DOI 10.1038/268464a0; HIRSCH RC, 1990, NATURE, V344, P552, DOI 10.1038/344552a0; HOPPER JE, 1977, J BIOL CHEM, V252, P9010; ICHO T, 1989, J BIOL CHEM, V264, P6716; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; OERTLE S, 1990, J VIROL, V64, P5757, DOI 10.1128/JVI.64.12.5757-5763.1990; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; WELSH JD, 1980, NUCLEIC ACIDS RES, V8, P2365, DOI 10.1093/nar/8.11.2365; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1980, CELL, V21, P217, DOI 10.1016/0092-8674(80)90129-4; WICKNER RB, 1991, MOL BIOL YEAST SACCH, V1, P263	25	71	72	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					746	749		10.1038/359746a0	http://dx.doi.org/10.1038/359746a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436038				2022-12-01	WOS:A1992JU65000062
J	HAHN, K; DEBIASIO, R; TAYLOR, DL				HAHN, K; DEBIASIO, R; TAYLOR, DL			PATTERNS OF ELEVATED FREE CALCIUM AND CALMODULIN ACTIVATION IN LIVING CELLS	NATURE			English	Article							SWISS 3T3 FIBROBLASTS; FLUORESCENT ANALOG; LEADING-EDGE; MYOSIN; ACTIN; STIMULATION; TRANSPORT; BINDING	THE temporal and spatial dynamics of intracellular signals and protein effectors are being defined as a result of imaging using fluorescent reagents within living cells1-5. We have described a new class of fluorescent analogues2 termed optical biosensors6, which sense chemical or molecular events through their effects on protein transducers7. One example of this new class of indicators is MeroCaM, an environmentally sensitive fluorophore which when it is attached to calmodulin reflects the activation of calmodulin by calcium in vitro2. We report here that the rise in free calcium and MeroCaM activation occur in the same period during serum stimulation of quiescent fibroblasts. MeroCaM activation also correlates with the spatial pattern of increased free calcium and the contraction of transverse fibres during wound healing1,8-10. Finally, migrating fibroblasts in the later stages of wound-healing exhibit an increasing gradient of free calcium and MeroCaM activation from the front to the rear.	CARNEGIE MELLON UNIV, CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT BIOL SCI, PITTSBURGH, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University				Taylor, D. Lansing/0000-0001-6947-1343; Hahn, Klaus/0000-0002-1970-7562				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BRIGHT GR, 1989, METHOD CELL BIOL, V30, P157; BRIGHT GR, 1989, J CELL PHYSIOL, V141, P410, DOI 10.1002/jcp.1041410223; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BYRON KL, 1989, J BIOL CHEM, V264, P18234; Cohen P, 1988, CALMODULIN; CONRAD PA, 1989, CELL MOTIL CYTOSKEL, V14, P527, DOI 10.1002/cm.970140410; DEBIASIO RL, 1988, J CELL BIOL, V107, P2631, DOI 10.1083/jcb.107.6.2631; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; GIULIANO KA, 1990, CELL MOTIL CYTOSKEL, V16, P14, DOI 10.1002/cm.970160104; HAHN KM, 1990, J BIOL CHEM, V265, P20335; HAHN KM, IN PRESS FLUORESCENT; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOLEGA J, 1991, CURR TOP MEMBR, V38, P187; LUBYPHELPS K, 1985, J CELL BIOL, V101, P1245, DOI 10.1083/jcb.101.4.1245; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; MILLS JS, 1988, BIOCHEMISTRY-US, V27, P991, DOI 10.1021/bi00403a023; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Sellers JR, 1987, ENZYMES, V18, ppp381, DOI 10.1016/S1874-6047(08)60264-4; TAYLOR DL, 1992, AM SCI, V80, P322; TAYLOR DL, 1980, J CELL BIOL, V86, P599, DOI 10.1083/jcb.86.2.599; TAYLOR DL, 1989, CELL STRUCT FUNCT, P297; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; ZAVORTINK M, 1983, EXP CELL RES, V149, P375, DOI 10.1016/0014-4827(83)90350-6	26	156	164	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					736	738		10.1038/359736a0	http://dx.doi.org/10.1038/359736a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436037				2022-12-01	WOS:A1992JU65000058
J	KOKAME, K; FUKADA, Y; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y				KOKAME, K; FUKADA, Y; YOSHIZAWA, T; TAKAO, T; SHIMONISHI, Y			LIPID MODIFICATION AT THE N-TERMINUS OF PHOTORECEPTOR G-PROTEIN ALPHA-SUBUNIT	NATURE			English	Article							NH2-TERMINAL BLOCKING GROUP; AMINO-ACID-SEQUENCE; ROD OUTER SEGMENTS; MYRISTIC ACID; BETA-GAMMA; SUBSTRATE-SPECIFICITY; CDNA SEQUENCE; TRANSDUCIN; MYRISTOYLTRANSFERASE; BINDING	MYRISTATE is a fatty acid (fourteen-carbon chain with no double bonds, C14:0) linked to the amino-terminal glycine of several proteins 1-7, including alpha-subunits of heterotrimeric (alpha/betagamma) G proteins8,9. We report here a novel modification at the N terminus of the alpha-subunit of the photoreceptor G protein transducin, Talpha, with heterogeneous fatty acids composed of laurate (C12:0), unsaturated C14:2 and C14:1 fatty acids, and a small amount (approximately 5%) of myristate. Both the GTPase activity of Talpha/Tbetagamma and the Tbetagamma-dependent ADP-ribosylation of Talpha catalysed by pertussis toxin were inhibited by the lauroylated and myristoylated N-terminal peptide of Talpha. The myristoylated peptide gave 50% inhibition at a 3.5 to approximately 4.5-fold lower concentration than the lauroylated peptide in each assay, indicating that the strength of the interaction between Talpha and Tbetagamma is altered by heterogeneous fatty acids linked to Talpha. This suggests that a looser subunit interaction in transducin which is due to an abundance of N-linked fatty acids other than myristate would favour the rapid turnover and catalysis essential for the visual excitation in photoreceptor cells.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; UNIV ELECTROCOMMUN,DEPT APPL PHYS & CHEM,CHOFU,TOKYO 182,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Kyoto University; University of Electro-Communications - Japan; Osaka University			吉孝, 深田/G-5090-2014	Kokame, Koichi/0000-0002-9654-6299				AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; OZOLS J, 1984, J BIOL CHEM, V259, P3349; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SHULTZ AM, 1985, SCIENCE, V227, P427; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TOMER KB, 1983, J AM CHEM SOC, V105, P5487, DOI 10.1021/ja00354a055; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	29	189	192	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					749	752		10.1038/359749a0	http://dx.doi.org/10.1038/359749a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436039				2022-12-01	WOS:A1992JU65000063
J	KWAK, LW; CAMPBELL, MJ; CZERWINSKI, DK; HART, S; MILLER, RA; LEVY, R				KWAK, LW; CAMPBELL, MJ; CZERWINSKI, DK; HART, S; MILLER, RA; LEVY, R			INDUCTION OF IMMUNE-RESPONSES IN PATIENTS WITH B-CELL LYMPHOMA AGAINST THE SURFACE-IMMUNOGLOBULIN IDIOTYPE EXPRESSED BY THEIR TUMORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVE-SPECIFIC IMMUNOTHERAPY; TRANSPLANTATION RESISTANCE; RANDOMIZED TRIAL; IMMUNIZATION; VACCINATION; ANTIBODIES; MELANOMA; CYCLOPHOSPHAMIDE; COMBINATION	Background. The idiotypic determinants of the surface immunoglobulin of a B-cell lymphoma can serve as a clonal tumor-specific marker, which may have implications for immunotherapy. We sought to determine whether idiotype-specific immune responses against this autologous antigen could be induced in patients with B-cell lymphoma. Methods. Nine patients were selected who had minimal residual disease or a complete remission after chemotherapy. Each received a series of subcutaneous injections of the immunoglobulin derived from his or her tumor cells (immunoglobulin-idiotype protein), which had been conjugated to a protein carrier and mixed with an immunologic adjuvant. Results. In seven of the nine patients the injections induced sustained idiotype-specific immunologic responses of the humoral type (two patients), the cell-mediated type (four patients), or both (one patient). The use of an adjuvant was essential for these immune responses. The induced antibodies bound specifically to autologous immunoglobulin idiotype, inhibited the binding of murine monoclonal antiidiotype antibodies, and bound autologous tumor cells. Cell-mediated responses were demonstrated by the specific proliferation of immune peripheral-blood mononuclear cells to the soluble immunoglobulin-idiotype protein in vitro. The tumors of both of the patients with measurable disease regressed completely. Toxicity associated with the vaccine was minimal and consisted only of mild reactions at the site of intramuscular injection. Conclusions. These results demonstrate that autologous immunoglobulin idiotype can be formulated into an immunogenic, tumor-specific antigen in humans with B-cell lymphoma, and they provide the background for large-scale trials of active specific immunotherapy of this disease.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV ONCOL,STANFORD,CA 94305	Stanford University				Kwak, Larry/0000-0002-1884-5349; Levy, Ronald/0000-0003-2061-0650	NATIONAL CANCER INSTITUTE [R37CA033399, R01CA033399] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON AC, 1986, J IMMUNOL METHODS, V95, P157, DOI 10.1016/0022-1759(86)90402-3; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BRIDGES SH, 1978, J IMMUNOL, V121, P479; BROWN SL, 1989, BLOOD, V73, P651; BYSTRYN JC, 1988, CANCER, V61, P1065, DOI 10.1002/1097-0142(19880315)61:6<1065::AID-CNCR2820610602>3.0.CO;2-L; Campbell M J, 1989, Int Rev Immunol, V4, P251, DOI 10.3109/08830188909044782; CAMPBELL MJ, 1988, J IMMUNOL, V141, P3227; CAMPBELL MJ, 1990, J IMMUNOL, V145, P1029; CAMPBELL MJ, 1987, J IMMUNOL, V139, P2825; CARROLL WL, 1986, J IMMUNOL METHODS, V89, P61, DOI 10.1016/0022-1759(86)90032-3; CHAIN B, 1987, J IMMUNOL METHODS, V99, P221, DOI 10.1016/0022-1759(87)90131-1; DALEY MJ, 1978, J IMMUNOL, V120, P1620; FREEDMAN PM, 1976, J NATL CANCER I, V56, P735, DOI 10.1093/jnci/56.4.735; GEORGE AJT, 1988, J IMMUNOL, V141, P2168; GEORGE AJT, 1987, J IMMUNOL, V138, P628; HOON DSB, 1990, CANCER RES, V50, P5358; HOOVER HC, 1985, CANCER, V55, P1236, DOI 10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#; JORGENSEN T, 1980, SCAND J IMMUNOL, V11, P29, DOI 10.1111/j.1365-3083.1980.tb00205.x; KAMINSKI MS, 1987, J IMMUNOL, V138, P1289; MEEKER T, 1985, NEW ENGL J MED, V312, P1658, DOI 10.1056/NEJM198506273122602; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITCHELL MS, 1990, J CLIN ONCOL, V8, P856, DOI 10.1200/JCO.1990.8.5.856; SIRISINHA S, 1971, P NATL ACAD SCI USA, V68, P3130, DOI 10.1073/pnas.68.12.3130; STEVENSON FK, 1983, J IMMUNOL, V130, P970; STEVENSON GT, 1975, NATURE, V254, P714, DOI 10.1038/254714a0; STEVENSON GT, 1977, FED PROC, V36, P2268; SUGAI S, 1974, Journal of Experimental Medicine, V140, P1547, DOI 10.1084/jem.140.6.1547	28	489	550	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1209	1215		10.1056/NEJM199210223271705	http://dx.doi.org/10.1056/NEJM199210223271705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406793	Bronze			2022-12-01	WOS:A1992JU39300005
J	LUIRINK, J; HIGH, S; WOOD, H; GINER, A; TOLLERVEY, D; DOBBERSTEIN, B				LUIRINK, J; HIGH, S; WOOD, H; GINER, A; TOLLERVEY, D; DOBBERSTEIN, B			SIGNAL-SEQUENCE RECOGNITION BY AN ESCHERICHIA-COLI RIBONUCLEOPROTEIN COMPLEX	NATURE			English	Article							4.5S RNA; NASCENT PREPROLACTIN; PARTICLE; PROTEINS; MEMBRANE; TRANSLOCATION; POLYPEPTIDE; INSERTION; DOMAIN; ER	HYDROPHOBIC signal-sequences direct the transfer of secretory proteins across the inner membrane of prokaryotes and the endoplasmic reticulum membranes of eukaryotes1. In mammalian cells, signal-sequences are recognized by the 54K protein (M(r) 54,000) of the signal recognition particle (SRP)2,3 which is believed to hold the nascent chain in a translocation-competent conformation until it contacts the endoplasmic reticulum membrane4. The SRP consists of a 7S RNA and six different polypeptides. The 7S RNA and the 54K signal-sequence-binding protein (SRP54) of mammalian SRP exhibit strong sequence similarity to the 4.5S RNA and P48 protein (Ffh) of Escherichia coli5-7 which form a ribonucleoprotein particle. Depletion of 4.5S RNA or overproduction of P48 causes the accumulation of the beta-lactamase precursor, although not of other secretory proteins8,9. Whether 4.5S RNA and P48 are part of an SRP-like complex with a role in protein export is controversial. Here we show that the P48/4.5S RNA ribonucleoprotein complex interacts specifically with the signal sequence of a nascent secretory protein and therefore is a signal recognition particle.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Luirink, Joen/AAB-8658-2021; Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; High, Stephen/0000-0002-4532-8152				BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BROWN S, 1991, NEW BIOL, V3, P430; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201	19	158	161	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					741	743		10.1038/359741a0	http://dx.doi.org/10.1038/359741a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1279430	Green Submitted			2022-12-01	WOS:A1992JU65000060
J	PHILLIPS, GJ; SILHAVY, TJ				PHILLIPS, GJ; SILHAVY, TJ			THE ESCHERICHIA-COLI FFH-GENE IS NECESSARY FOR VIABILITY AND EFFICIENT PROTEIN EXPORT	NATURE			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI; 4.5S RNA; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOPROTEIN; SEQUENCE; SUBUNIT	HOMOLOGUES of the gene encoding the 54K (M(r) 54,000) subunit of the mammalian signal recognition particle have been identified in different organisms1-5. The Escherichia coli homologue, termed ffh (for fifty-four homologue), specifies a protein (Ffh) that shares many properties with its eukaryotic counterpart, including association with mammalian 7S RNA6 and the ability to bind signal sequences specifically7,8. Ffh also associates with E. coli 4.5S RNA, showing that it can form a ribonucleoprotein complex in prokaryotes6,9,10. These results are intriguing because extensive genetic and biochemical characterization of E. coli failed to identify a signal recognition particle-like mechanism for protein export11 Here we address this issue directly by construction of a strain in which ffh expression is arabinose-dependent. Results of depletion experiments indicate that Ffh is important in protein translocation.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	PHILLIPS, GJ (corresponding author), COLL WILLIAM & MARY,DEPT BIOL,WILLIAMSBURG,VA 23185, USA.			Silhavy, Thomas/0000-0001-7672-5153				BASSFORD P, 1991, CELL, V65, P367, DOI 10.1016/0092-8674(91)90453-6; BERNSTEIN HD, 1989, CELL, V58, P1017, DOI 10.1016/0092-8674(89)90497-2; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN HN, UNPUB; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BROWN S, 1991, NEW BIOL, V3, P430; BYSTROM AS, 1983, EMBO J, V2, P899, DOI 10.1002/j.1460-2075.1983.tb01519.x; DAVIS RW, 1986, ADV BACTERIAL GENETI; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; KOHL J, 1990, NUCLEIC ACIDS RES, V18, P1069, DOI 10.1093/nar/18.4.1069; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Silhavy T.J., 1984, EXPT GENE FUSIONS; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	23	237	240	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					744	746		10.1038/359744a0	http://dx.doi.org/10.1038/359744a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331806				2022-12-01	WOS:A1992JU65000061
J	SHULL, MM; ORMSBY, I; KIER, AB; PAWLOWSKI, S; DIEBOLD, RJ; YIN, MY; ALLEN, R; SIDMAN, C; PROETZEL, G; CALVIN, D; ANNUNZIATA, N; DOETSCHMAN, T				SHULL, MM; ORMSBY, I; KIER, AB; PAWLOWSKI, S; DIEBOLD, RJ; YIN, MY; ALLEN, R; SIDMAN, C; PROETZEL, G; CALVIN, D; ANNUNZIATA, N; DOETSCHMAN, T			TARGETED DISRUPTION OF THE MOUSE TRANSFORMING GROWTH FACTOR-BETA-1 GENE RESULTS IN MULTIFOCAL INFLAMMATORY DISEASE	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MUCOSAL IMMUNE-SYSTEM; NECROSIS FACTOR-ALPHA; FACTOR-BETA; EXPRESSION PATTERNS; LYMPHOCYTES-B; TGF BETA-1; CELLS; INHIBITION; EMBRYO	Transforming growth factor-beta1 (TGF-beta1) is a multifunctional growth factor that has profound regulatory effects on many developmental and physiological processes. Disruption of the TGF-beta1 gene by homologous recombination in murine embryonic stem cells enables mice to be generated that carry the disrupted allele. Animals homozygous for the mutated TGF-beta1 allele show no gross developmental abnormalities, but about 20 days after birth they succumb to a wasting syndrome accompanied by a multifocal, mixed inflammatory cell response and tissue necrosis, leading to organ failure and death. TGF-beta1-deficient mice may be valuable models for human immune and inflammatory disorders, including autoimmune diseases, transplant rejection and graft versus host reactions.	UNIV CINCINNATI, COLL MED, DEPT PATHOL & LAB MED, DIV COMPARAT PATHOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati	SHULL, MM (corresponding author), UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA.				NICHD NIH HHS [R01 HD026471] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026471] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOTTAZZO GF, 1983, LANCET, V2, P1115; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; BRANDTZAEG P, 1989, CURR TOP MICROBIOL, V146, P13; CHIN YH, 1992, J IMMUNOL, V148, P1106; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; COX DA, 1991, EUR J BIOCHEM, V197, P353, DOI 10.1111/j.1432-1033.1991.tb15918.x; CRONIN ME, 1988, PRIMER RHEUMATIC DIS, P120; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; ESPEVIK T, 1987, J EXP MED, V166, P571, DOI 10.1084/jem.166.2.571; ESPEVIK T, 1988, J IMMUNOL, V140, P2312; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; GAMBLE JR, 1988, SCIENCE, V242, P97; GATHERER D, 1990, DEVELOPMENT, V110, P445; GLODE LM, 1976, J IMMUNOL, V117, P2061; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; JOHNS LD, 1991, J IMMUNOL, V147, P1792; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KEHRL JH, 1991, J IMMUNOL, V146, P4016; KILSHAW PJ, 1991, EUR J IMMUNOL, V21, P2591, DOI 10.1002/eji.1830211041; KURUVILLA AP, 1991, P NATL ACAD SCI USA, V88, P2918, DOI 10.1073/pnas.88.7.2918; LEBMAN DA, 1990, J IMMUNOL, V144, P952; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LONDEI M, 1984, NATURE, V312, P639, DOI 10.1038/312639a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; ORTALDO JR, 1991, J IMMUNOL, V146, P3791; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEVELOPMENT, V110, P609; RACKE MK, 1991, J IMMUNOL, V146, P3012; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; RISTOW HJ, 1986, P NATL ACAD SCI USA, V83, P5531, DOI 10.1073/pnas.83.15.5531; ROBERTS AB, 1909, PEPTIDE GROWTH FACTO, V1, P419; ROOK AH, 1986, J IMMUNOL, V136, P3916; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; TALAL N, 1988, PRIMER RHEUMATIC DIS, P136; TAUTZ D, 1992, BIOESSAYS, V14, P263, DOI 10.1002/bies.950140410; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; TOKUYAMA H, 1989, CELL BIOL INT REP, V13, P251, DOI 10.1016/0309-1651(89)90147-1; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1988, J IMMUNOL, V140, P3026; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415	52	2546	2652	2	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					693	699		10.1038/359693a0	http://dx.doi.org/10.1038/359693a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436033	Green Accepted			2022-12-01	WOS:A1992JU65000045
J	STRYNADKA, NCJ; ADACHI, H; JENSEN, SE; JOHNS, K; SIELECKI, A; BETZEL, C; SUTOH, K; JAMES, MNG				STRYNADKA, NCJ; ADACHI, H; JENSEN, SE; JOHNS, K; SIELECKI, A; BETZEL, C; SUTOH, K; JAMES, MNG			MOLECULAR-STRUCTURE OF THE ACYL-ENZYME INTERMEDIATE IN BETA-LACTAM HYDROLYSIS AT 1.7 ANGSTROM RESOLUTION	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; BACILLUS-LICHENIFORMIS 749/C; REFINED CRYSTAL-STRUCTURE; MECHANISM; PENICILLIN; CATALYSIS; MUTANTS; RESISTANCE; SINGLE; PC1	The X-ray crystal structure of the molecular complex of penicillin G with a deacylation-defective mutant of the RTEM-1 beta-lactamase from Escherichia coli shows how these antibiotics are recognized and destroyed. Penicillin G is covalently bound to Ser 70 O(gamma) as an acyl-enzyme intermediate. The deduced catalytic mechanism uses Ser 70 O(gamma) as the attacking nucleophile during acylation. Lys 73 N(zeta) acts as a general base in abstracting a proton from Ser 70 and transferring it to the thiazolidine ring nitrogen atom via Ser 130 O(gamma). Deacylation is accomplished by nucleophilic attack on the penicilloyl carbonyl carbon by a water molecule assisted by the general base, Glu 166.	UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, ALBERTA, CANADA; DESY, EUROPEAN MOLEC BIOL LAB, W-2000 HAMBURG 52, GERMANY; UNIV ALBERTA, DEPT MICROBIOL, EDMONTON T6G 2E9, ALBERTA, CANADA; UNIV TOKYO, COLL ARTS & SCI, DEPT PURE & APPL SCI, MEGURO KU, TOKYO 153, JAPAN	University of Alberta; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Alberta; University of Tokyo			Jensen, Susan/C-8701-2013; Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019				Abraham EP, 1940, NATURE, V146, P837, DOI 10.1038/146837a0; ADACHI H, 1991, J BIOL CHEM, V266, P3186; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CARTWRIGHT SJ, 1989, BIOCHEM J, V263, P905, DOI 10.1042/bj2630905; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; Crowfoot D., 1949, CHEM PENICILLIN, P310; DALBADIEMCFARLAND G, 1986, BIOCHEMISTRY-US, V25, P332, DOI 10.1021/bi00350a008; DEXTER DD, 1978, J CHEM SOC, V185, P110; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; ESCOBAR WA, 1991, BIOCHEMISTRY-US, V30, P10783, DOI 10.1021/bi00108a025; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; FRERE JM, 1985, CRC CR REV MICROBIOL, V11, P299; GHUYSEN JM, 1991, ANNU REV MICROBIOL, V45, P37, DOI 10.1146/annurev.mi.45.100191.000345; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; GREEN DW, 1954, PROC R SOC LON SER-A, V225, P287, DOI 10.1098/rspa.1954.0203; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; Hendrickson W. A., 1980, COMPUTING CRYSTALLOG; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HERZBERG O, 1991, J MOL BIOL, V217, P701, DOI 10.1016/0022-2836(91)90527-D; Herzberg O, 1991, CURR OPIN STRUC BIOL, V1, P946, DOI 10.1016/0959-440X(91)90090-G; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JACOB F, 1990, PROTEIN ENG, V4, P79, DOI 10.1093/protein/4.1.79; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; JAMES MNG, 1968, NATURE, V220, P168, DOI 10.1038/220168a0; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KNAP AK, 1991, BIOCHEM J, V273, P85, DOI 10.1042/bj2730085; KNOWLES JR, 1985, ACCOUNTS CHEM RES, V18, P97, DOI 10.1021/ar00112a001; KNOX JR, 1991, J MOL BIOL, V220, P435, DOI 10.1016/0022-2836(91)90023-Y; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; MARTIN MT, 1988, BIOCHEM J, V254, P923, DOI 10.1042/bj2540923; MATTHEW M, 1976, J BACTERIOL, V125, P713, DOI 10.1128/JB.125.2.713-718.1976; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; OTWINOWSKI Z, 1990, AM CRYSTALLOGR ASS A; READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROSSMAN MG, 1972, INT SCI REV, V13; SWEET RM, 1970, J AM CHEM SOC, V92, P5489, DOI 10.1021/ja00721a032; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIRDEN R, 1990, BIOCHEMISTRY-US, V29, P145, DOI 10.1021/bi00453a018; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	49	540	545	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					700	705		10.1038/359700a0	http://dx.doi.org/10.1038/359700a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436034				2022-12-01	WOS:A1992JU65000046
J	SWARTZ, SM; BENNETT, MB; CARRIER, DR				SWARTZ, SM; BENNETT, MB; CARRIER, DR			WING BONE STRESSES IN FREE FLYING BATS AND THE EVOLUTION OF SKELETAL DESIGN FOR FLIGHT	NATURE			English	Article							INVIVO STRESS; HORSE EQUUS; STRAIN; MECHANICS; LOCOMOTION; RADIUS; SPEED; TIBIA; GAIT	THE primary mechanical functions of limb bones are to resist deformation, and hence provide stiff levers against which muscles can act, and to be sufficiently strong to prevent breaking under static or dynamic loads which arise from normal and accidental activities1. if bones perform these functions with a minimum amount of material, the energetic costs associated with building, maintaining and transporting the skeleton will be minimized2. Appropriate skeletal architecture for minimizing mass while maximizing strength depends on forces imposed on structural elements. In the evolutionary acquisition of flight in the bat lineage, the forelimb skeleton must have come to experience locomotor-forces that differed from those engendered by the terrestrial locomotion of non-flying bat relatives. Here we successfully measure in vivo strain on the wing bones of flying mammals. Our data demonstrate that torsion and shear are unique and crucial features of skeletal biomechanics during flight, and suggest that the evolution of skeletal design in bats and other flying vertebrates may be driven b the need to resist these loads.	UNIV QUEENSLAND, DEPT ANAT SCI, BRISBANE 4072, AUSTRALIA	University of Queensland	SWARTZ, SM (corresponding author), BROWN UNIV, PROGRAM ECOL & EVOLUT BIOL, PROVIDENCE, RI 02912 USA.		Swartz, Sharon/B-9309-2011; Bennett, Michael/A-7218-2012; Bennett, Michael/L-4483-2019	Swartz, Sharon/0000-0001-5762-7435; Bennett, Michael/0000-0001-8051-0040				ALEXANDER RM, 1981, SCI PROGRESS-UK, V67, P109; ALEXANDER RM, 1990, J ZOOL, V222, P471, DOI 10.1111/j.1469-7998.1990.tb04045.x; BERTRAM JEA, 1988, J THEOR BIOL, V131, P75, DOI 10.1016/S0022-5193(88)80122-X; BIEWENER AA, 1986, CALCIFIED TISSUE INT, V39, P390, DOI 10.1007/BF02555177; BIEWENER AA, 1986, J EXP BIOL, V123, P383; BIEWENER AA, 1983, J ZOOL, V201, P67, DOI 10.1111/j.1469-7998.1983.tb04261.x; BIEWENER AA, 1988, J ZOOL, V214, P547, DOI 10.1111/j.1469-7998.1988.tb03759.x; CARTER DR, 1978, J BIOMECH, V11, P199, DOI 10.1016/0021-9290(78)90013-1; CURREY JD, 1985, J ZOOL, V206, P453; Lanyon L E, 1976, Acta Orthop Belg, V42 Suppl 1, P98; Nordin M, 1989, BASIC BIOMECHANICS M, P3; PENNYCUICK CJ, 1967, J EXP BIOL, V46, P219; POUGH FH, 1985, VERTEBRATE LIFE; PRANGE HD, 1979, AM NAT, V113, P103, DOI 10.1086/283367; Rayner J.M.V., 1987, P23; RUBIN CT, 1982, J EXP BIOL, V101, P187; RUBIN CT, 1984, J THEOR BIOL, V107, P321, DOI 10.1016/S0022-5193(84)80031-4	17	136	138	8	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1992	359	6397					726	729		10.1038/359726a0	http://dx.doi.org/10.1038/359726a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1436035				2022-12-01	WOS:A1992JU65000055
J	THIGPEN, AE; DAVIS, DL; GAUTIER, T; IMPERATOMCGINLEY, J; RUSSELL, DW				THIGPEN, AE; DAVIS, DL; GAUTIER, T; IMPERATOMCGINLEY, J; RUSSELL, DW			THE MOLECULAR-BASIS OF STEROID 5-ALPHA-REDUCTASE DEFICIENCY IN A LARGE DOMINICAN KINDRED	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MALE PSEUDOHERMAPHRODITISM; 5ALPHA-REDUCTASE DEFICIENCY; DNA; POLYMERASE; POLYMORPHISMS; FORM		UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235; NATL UNIV PEDRO HENRIQUEZ URENA,DEPT PEDIAT,SANTO DOMINGO,DOMINICAN REP; CORNELL UNIV,SCH MED,DEPT MED,NEW YORK,NY 10021	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universidad Nacional Pedro Henriquez Urena; Cornell University				Russell, David/0000-0002-0277-403X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD009421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043753] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-07504, HD-09421] Funding Source: Medline; NIGMS NIH HHS [GM-43753] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DIAMOND JM, 1987, NATURE, V329, P105, DOI 10.1038/329105a0; GAJDUSEK DC, 1977, CIBA F S, V49, P69; GRIFFIN JE, 1981, J BIOL CHEM, V256, P3662; GRIFFIN JE, 1989, METABOLIC BASIS INHE, V2, P1919; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; IMPERATOMCGINLE.J, 1992, CECIL TXB MED, P1320; IMPERATOMCGINLEY J, 1979, NEW ENGL J MED, V300, P1233, DOI 10.1056/NEJM197905313002201; IMPERATOMCGINLEY J, 1985, J CLIN ENDOCR METAB, V60, P553, DOI 10.1210/jcem-60-3-553; IMPERATOMCGINLEY J, 1979, J STEROID BIOCHEM, V11, P637, DOI 10.1016/0022-4731(79)90093-1; IMPERATOMCGINLEY J, 1986, TRENDS GENET, V2, P130, DOI 10.1016/0168-9525(86)90202-7; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; LEE JS, 1991, DNA CELL BIOL, V10, P67, DOI 10.1089/dna.1991.10.67; LESHIN M, 1978, J CLIN INVEST, V62, P685, DOI 10.1172/JCI109176; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PETERSON RE, 1977, AM J MED, V62, P170, DOI 10.1016/0002-9343(77)90313-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; THIGPEN AE, 1992, J BIOL CHEM, V267, P8577; WALSH PC, 1974, NEW ENGL J MED, V291, P944, DOI 10.1056/NEJM197410312911806	24	104	110	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1992	327	17					1216	1219		10.1056/NEJM199210223271706	http://dx.doi.org/10.1056/NEJM199210223271706			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU393	1406794				2022-12-01	WOS:A1992JU39300006
J	VUKMANOVIC, S; GRANDEA, AG; FAAS, SJ; KNOWLES, BB; BEVAN, MJ				VUKMANOVIC, S; GRANDEA, AG; FAAS, SJ; KNOWLES, BB; BEVAN, MJ			POSITIVE SELECTION OF LYMPHOCYTES-T INDUCED BY INTRATHYMIC INJECTION OF A THYMIC EPITHELIAL-CELL LINE	NATURE			English	Article							PEPTIDE BINDING; VIRAL PEPTIDES; ANTIGEN; MHC; SELF; RECOGNITION; REPERTOIRE; THYMOCYTES; MOLECULES; MUTATIONS	T LYMPHOCYTES recognize antigens as peptide fragments associated with molecules encoded by the major histocompatibility complex (MHC) and expressed on the surface of antigen-presenting cells'. In the thymus, T cells bearing alphabeta receptors that react with the MHC molecules expressed by radioresistant stromal elements are positively selected for maturation2-5. In (A x B --> A) bone marrow chimaeras, T cells restricted to the MHC-A haplotype are positively selected, whereas MHC-B-reactive thymocytes are not. We investigated whether the introduction of particular thymic stromal elements bearing MHC-B molecules could alter the fate of B-reactive T cells in these (A x B --> A) chimaeras. Thymic epithelial cell (TEC) lines expressing H-2b were introduced by intrathymic injection into (H-2b/s --> H2s) bone marrow chimaeras and we measured their ability to generate H-2b-restricted cytotoxic T-lymphocytes (CTLs). We report here that one TEC line, 427.1, was able positively to select CTLs specific for influenza and vesicular stomatitis virus antigens in association with class I H-2b molecules. In addition, line 427.1 can process cytoplasmic proteins for presentation to H-2K(b)- and H-2D(b)-restricted CTLs. Thus, a TEC line capable of normal class I MHC antigen processing and presentation in vitro can induce positive selection after intrathymic injection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; WISTAR INST,PHILADELPHIA,PA 19104; UNIV PENN,PHILADELPHIA,PA 19104	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; The Wistar Institute; University of Pennsylvania	VUKMANOVIC, S (corresponding author), UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195, USA.			Vukmanovic, Stanislav/0000-0003-3547-8349; Knowles, Barbara B./0000-0002-2597-5619	Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI019335-19, R01 AI019335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; DENNERT G, 1980, CELL IMMUNOL, V53, P350, DOI 10.1016/0008-8749(80)90335-4; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; FINK PJ, 1988, IMMUNOL TODAY, V9, P377, DOI 10.1016/0167-5699(88)91238-8; GOLDSCHNEIDER I, 1986, J EXP MED, V163, P1, DOI 10.1084/jem.163.1.1; GRANDEA AG, 1992, P NATL ACAD SCI USA, V89, P2794, DOI 10.1073/pnas.89.7.2794; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; MARRACK P, 1988, IMMUNOL TODAY, V9, P308, DOI 10.1016/0167-5699(88)91324-2; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MIZUOCHI T, 1992, J EXP MED, V175, P1601, DOI 10.1084/jem.175.6.1601; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; NIKOLICZUGIC J, 1990, EUR J IMMUNOL, V20, P2431, DOI 10.1002/eji.1830201111; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; NUCHTERN JG, 1989, NATURE, V339, P23; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPRENT J, 1978, J EXP MED, V146, P1838; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YEWDELL JW, IN PRESS ADV IMMUN; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	32	104	106	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					729	732		10.1038/359729a0	http://dx.doi.org/10.1038/359729a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331804	Green Accepted			2022-12-01	WOS:A1992JU65000056
J	WANG, JX; BEST, PM				WANG, JX; BEST, PM			INACTIVATION OF THE SARCOPLASMIC-RETICULUM CALCIUM-CHANNEL BY PROTEIN-KINASE	NATURE			English	Article							PURIFIED RYANODINE RECEPTOR; RABBIT SKELETAL-MUSCLE; RELEASE CHANNEL; CA-2+ CHANNELS; FIBERS; PHOSPHORYLATION; SARCOBALLS; EXPRESSION; SYSTEM	THE ryanodine receptor protein of skeletal muscle sarcoplasmic reticulum (SR) membranes is a calcium ion channel which allows movement of calcium from the SR lumen into the cytoplasm during muscle activation1-5. Gating of this channel is modulated by a number of physiologically important substances including calcium. Interestingly, calcium has both activating and inactivating effects which are concentration- and tissue-specific. In skeletal muscle, calcium-dependent inactivation of calcium release occurs at concentrations reached physiologically, suggesting that calcium may modulate the release process by a negative feedback mechanism6-9. To determine the cellular mechanism responsible for calcium-dependent inactivation, we have investigated the ability of protein phosphorylation to affect single channel gating behaviour using the patch clamp technique. Here we demonstrate that the ryanodine receptor protein/calcium release channel of skeletal muscle SR is inactivated under conditions permissive for protein phosphorylation. This inactivation is reversed by the application of phosphatase and prevented by a peptide inhibitor specific for calcium/calmodulin-dependent protein kinase II. The results provide evidence for an endogenous protein kinase which is closely associated with the ryanodine receptor protein and regulates channel gating.	UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,524 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801; UNIV ILLINOIS,SCH MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign				Wang, Jixin/0000-0001-9285-1002				BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; CAMPBELL KP, 1982, J BIOL CHEM, V257, P1238; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; HALS GD, 1989, J GEN PHYSIOL, V93, P385, DOI 10.1085/jgp.93.3.385; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; KIM DH, 1986, J BIOL CHEM, V261, P1674; KWOK WM, 1991, PFLUG ARCH EUR J PHY, V419, P166, DOI 10.1007/BF00373003; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LUTTGAU HC, 1968, J PHYSIOL-LONDON, V194, P51; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORII H, 1987, J BIOCHEM-TOKYO, V102, P263, DOI 10.1093/oxfordjournals.jbchem.a122050; SCHNEIDER MF, 1988, J PHYSIOL-LONDON, V405, P727, DOI 10.1113/jphysiol.1988.sp017358; SIMON BJ, 1991, J GEN PHYSIOL, V97, P437, DOI 10.1085/jgp.97.3.437; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; STEIN P, 1988, BIOPHYS J, V54, P357, DOI 10.1016/S0006-3495(88)82967-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	23	119	120	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1992	359	6397					739	741		10.1038/359739a0	http://dx.doi.org/10.1038/359739a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JU650	1331805				2022-12-01	WOS:A1992JU65000059
J	COTE, TR; BIGGAR, RJ; DANNENBERG, AL				COTE, TR; BIGGAR, RJ; DANNENBERG, AL			RISK OF SUICIDE AMONG PERSONS WITH AIDS - A NATIONAL ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ACQUIRED IMMUNODEFICIENCY SYNDROME; IOWA RECORD-LINKAGE; MORTALITY; DISORDERS	Objective.-We sought to describe the rate, risk, trends, methods, and distribution of suicide among persons with the acquired immunodeficiency syndrome (AIDS) in the United States. Design.-We used National Center for Health Statistics multiple-cause mortality data from 1987 through 1989 to identify suicides among persons with AIDS (PWAs) and public-access AIDS surveillance data to determine person-years of observation of PWAs. Patients.-Residents of the United States with death certificates indicating suicide. Main Outcome Measure.-Death certificates indicating both AIDS and suicide. Results.-In 1987 through 1989, a total of 165 suicides among PWAs occurred in 45 states and the District of Columbia. All but one case were male. Among males the rate was 165 per 100 000 person-years of observation, 7.4-fold higher than among demographically similar men in the general population. Self-poisoning with drugs was both the most common method (35%) and the method with the highest standardized mortality ratio (35). Suicide risk for PWAs decreased significantly (P<.05) from 1987 to 1989. Conclusion.-Persons with AIDS have an increased risk of suicide, and assessment of such risk should be a standard practice in their care. These assessments should be carefully considered when potentially lethal medications are prescribed. The declining trend in suicide rates between 1987 and 1989 is encouraging; possible causes include emerging therapies for human immunodeficiency virus/AIDS, better psychiatric care for these patients, and lessened social stigma against PWAs.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY PREVENT, BALTIMORE, MD 21218 USA	Johns Hopkins University	COTE, TR (corresponding author), NCI, VIRAL EPIDEMIOL SECT, 6130 EXECUT PLAZA, EPN-434, ROCKVILLE, MD 20852 USA.							ABRAM HS, 1971, AM J PSYCHIAT, V127, P1199, DOI 10.1176/ajp.127.9.1199; BERKELMAN RL, 1989, AM J MED, V86, P761, DOI 10.1016/0002-9343(89)90470-1; BLACK D, 1985, ARCHIT DIGEST, V42, P82; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P71; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P78; BUEHLER JW, 1990, AM J PUBLIC HEALTH, V80, P1080, DOI 10.2105/AJPH.80.9.1080; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; GOODMAN RA, 1987, SOUTH MED J, V82, P1128; GROW M, 1989, VERSICHERUNGSMEDIZIN, V41, P188; HOLLAND JC, 1985, ANN INTERN MED, V103, P760, DOI 10.7326/0003-4819-103-5-760; ISRAEL RA, 1986, AM J EPIDEMIOL, V124, P161, DOI 10.1093/oxfordjournals.aje.a114375; KIZER KW, 1988, JAMA-J AM MED ASSOC, V260, P1881, DOI 10.1001/jama.1988.03410130075021; MARSHALL JR, 1983, SUICIDE LIFE-THREAT, V13, P15; MARZUK PM, 1988, JAMA-J AM MED ASSOC, V259, P1333, DOI 10.1001/jama.259.9.1333; MOYER LA, 1989, AM J EPIDEMIOL, V130, P1024, DOI 10.1093/oxfordjournals.aje.a115403; SCHOENFELD M, 1986, AM J MED GENET, V24, P305; 1991, DHHS PHS911260 US DE	18	77	77	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2066	2068		10.1001/jama.268.15.2066	http://dx.doi.org/10.1001/jama.268.15.2066			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404744				2022-12-01	WOS:A1992JT52000031
J	LEE, IM; PAFFENBARGER, RS				LEE, IM; PAFFENBARGER, RS			CHANGE IN BODY-WEIGHT AND LONGEVITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK FACTOR; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; CORONARY-DISEASE; RELATIVE WEIGHT; COLLEGE ALUMNI; MORTALITY; FRAMINGHAM; HEALTH; MEN	Objective.-To investigate the effect of body weight change on longevity. Design.-Cohort analytic study, following men from 1977 through 1988. Setting.-The study was conducted among Harvard University alumni with mean age of 58 years. Patients.-Alumni, free of cardiovascular disease and cancer, completed questionnaires on weight, height, cigarette habit, and physical activities in 1962 or 1966 and in 1977 (n=11 703). We assessed weight change between questionnaires, based on self-reported weights. Main Outcome Measure.-Mortality from all causes (n=1441), coronary heart disease (n=345), and cancer (n=459), determined from death certificates. Results.-Lowest all-cause mortality was among alumni maintaining stable weight (+/-1 kg). With this category as referent (relative risk=1.00), relative risks of death associated with losing more than 5 kg, losing between 1 and 5 kg, (more than 1 kg and up to 5 kg) gaining between 1 and 5 kg (more than 1 kg and up to 5 kg), and gaining more than 5 kg were 1.57 (95% confidence interval, 1.34 to 1.84), 1.26 (1.10 to 1.46), 1.06 (0.90 to 1.24), and 1.36 (1.11 to 1.66), respectively. For coronary heart disease mortality, relative risks were 1.75 (1.26 to 2.43), 1.43 (1.05 to 1.93), 1.28 (0.91 to 1.80), and 2.01 (1.36 to 2.97), respectively. Weight change did not predict cancer mortality. Findings were not explained by cigarette habit, physical activity, or body mass index. We observed similar trends for follow-up between 1977 and 1982 and between 1983 and 1988. Those losing or gaining more weight also reported greater total lifetime weight loss, which may indicate weight cycling. Conclusions.-Both body weight loss and weight gain are associated with significantly increased mortality from all causes and from coronary heart disease but not from cancer.	STANFORD UNIV, MED CTR, SCH MED, DIV EPIDEMIOL, STANFORD, CA 94305 USA	Stanford University	LEE, IM (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.		Lee, I-Min/ABD-5409-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034174] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09001] Funding Source: Medline; NHLBI NIH HHS [HL 34174] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; AVONS P, 1983, LANCET, V1, P1104; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; BOUCHARD C, 1991, NEW ENGL J MED, V324, P1887, DOI 10.1056/NEJM199106273242609; COX DR, 1972, J R STAT SOC B, V34, P187; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HEYDEN S, 1971, ARCH INTERN MED, V128, P956, DOI 10.1001/archinte.128.6.956; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEE IM, 1992, AM J EPIDEMIOL, V135, P169, DOI 10.1093/oxfordjournals.aje.a116269; LEE IM, 1991, J NATL CANCER I, V83, P1324, DOI 10.1093/jnci/83.18.1324; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PALTA M, 1982, AM J EPIDEMIOL, V115, P223, DOI 10.1093/oxfordjournals.aje.a113294; PHINNEY SD, 1991, AM J CLIN NUTR, V53, P1404, DOI 10.1093/ajcn/53.6.1404; RHOADS GG, 1983, LANCET, V1, P492; RODIN J, 1990, INT J OBESITY, V14, P303; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P41; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; SNEDECOR GW, 1980, STATISTICAL METHODS, P215; SONNICHSEN AC, 1990, INT J OBESITY, V14, P487; STEVENS J, 1990, INT J OBESITY, V14, P385; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; WANNAMETHEE G, 1990, POSTGRAD MED J, V66, P910, DOI 10.1136/pgmj.66.781.910; Willet W, 1990, NUTR EPIDEMIOLOGY, P245; [No title captured]; 1983, VITAL HLTH STAT 11, V230; 1960, STAT B METROP INSUR, V41, P1; 1987, VITAL HLTH STAT 11, V238	39	215	219	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2045	2049		10.1001/jama.268.15.2045	http://dx.doi.org/10.1001/jama.268.15.2045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404740				2022-12-01	WOS:A1992JT52000027
J	MITCHELL, JM; SCOTT, E				MITCHELL, JM; SCOTT, E			PHYSICIAN OWNERSHIP OF PHYSICAL THERAPY SERVICES - EFFECTS ON CHARGES, UTILIZATION, PROFITS, AND SERVICE CHARACTERISTICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICTS	Objective.-To evaluate the effects of physician ownership of freestanding physical therapy and rehabilitation facilities on utilization, charges, profits, and three measures of service characteristics for physical therapy treatments. Design.-Statistical comparison by physician joint venture ownership status of freestanding physical therapy and comprehensive rehabilitation facilities providing physical therapy treatments in Florida. Participants.-A total of 118 outpatient physical therapy facilities and 63 outpatient comprehensive rehabilitation facilities providing services in Florida during 1989. The data from the facilities were collected under a legislative mandate. Main Outcome Measures.-Visits per patient, average revenue per patient, percent operating income, percent markup, profits per patient, licensed therapist time per visit, and licensed and nonlicensed medical worker time per visit. Results.-Visits per patient were 39% to 45% higher in joint venture facilities. Both gross and net revenue per patient were 30% to 40% higher in facilities owned by referring physicians. Percent operating income and percent markup were significantly higher in joint venture physical therapy and rehabilitation facilities. Licensed physical therapists and licensed therapist assistants employed in nonjoint venture facilities spend about 60% more time per visit treating physical therapy patients than licensed therapists and licensed therapist assistants working in joint venture facilities. Joint ventures also generate more of their revenues from patients with well-paying insurance. Conclusion.-Our results indicate that utilization, charges per patient, and profits are higher when physical therapy and rehabilitation facilities are owned by referring physicians. With respect to service characteristics, joint venture firms employ proportionately fewer licensed therapists and licensed therapist assistants to perform physical therapy, so that licensed professionals employed in joint venture businesses spend significantly less time per visit treating patients. These results should be of interest to the medical profession, third-party payers, and policymakers, all of whom are concerned about the consequences of physician self-referral arrangements.	FLORIDA STATE UNIV,DEPT ECON,TALLAHASSEE,FL 32306; FLORIDA STATE UNIV,DEPT FINANCE,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University; State University System of Florida; Florida State University								BURDA D, 1992, MOD HEALTHCARE  0629, V23, P3; CRANE TS, 1992, JAMA-J AM MED ASSOC, V268, P85, DOI 10.1001/jama.268.1.85; DOBSON R, 1986, NEW ENGL J MED, V314, P250; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; MITCHELL JM, 1992, JAMA-J AM MED ASSOC, V268, P80, DOI 10.1001/jama.268.1.80; MITCHELL JM, 1991, JOINT VENTURES HLTH, V2; MORREIM EH, 1989, JAMA-J AM MED ASSOC, V262, P390, DOI 10.1001/jama.262.3.390; PEAR R, 1992, NY TIMES        0406, pA2; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P98, DOI 10.1001/jama.268.1.98; Waldholz Michael, 1989, WALL STREET J   0301, pA6; Waldholz Michael, 1989, WALL STREET J   0301, pA1; ZIMMERMAN M, 1989, COMMUNICATION    MAY; 1989, FINANCIAL ARRANGEMEN; 1991, FINAL OCCUPATIONAL S; 1991, 91390 US DEP LAB PUB; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1986, FOR PROFIT ENTERPRIS, P153; 1992, SOURCES HLTH INSURAN	21	89	89	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2055	2059		10.1001/jama.268.15.2055	http://dx.doi.org/10.1001/jama.268.15.2055			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1404742				2022-12-01	WOS:A1992JT52000029
J	WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; COLDITZ, G; MANSON, JE; SPIEGELMAN, D; ROSNER, B; HENNEKENS, CH; SPEIZER, FE				WILLETT, WC; HUNTER, DJ; STAMPFER, MJ; COLDITZ, G; MANSON, JE; SPIEGELMAN, D; ROSNER, B; HENNEKENS, CH; SPEIZER, FE			DIETARY-FAT AND FIBER IN RELATION TO RISK OF BREAST-CANCER - AN 8-YEAR FOLLOW-UP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; CONSUMPTION; DISEASE; CARCINOGENESIS; QUESTIONNAIRE; REDUCTION; NUTRITION; HEALTH; RATS	Objective.-To address the hypotheses that dietary fat increases and fiber decreases the risk of breast cancer. Design.-Prospective cohort study with dietary assessment at baseline, using a validated, self-administered food frequency questionnaire. Setting/Participants.-89 494 women in the Nurses' Health Study who were 34 through 59 years of age in 1980 and who were followed up for 8 years (>95% complete). Results.-1439 incident cases of breast cancer were diagnosed, including 774 among postmenopausal women. After adjustment for age, established risk factors, and total energy intake, we observed no evidence of any positive association between total fat intake and breast cancer incidence (relative risks [RRs] for increasing quintiles of fat intake were 1.0, 0.85, 0.96, 0.91, and 0.90; 95% confidence interval for highest vs lowest quintile, 0.77 to 1.07). Among postmenopausal women alone, corresponding RRs were 1.0, 0.89, 1.00, 0.95, and 0.91. Comparing extreme deciles of total fat intake (greater-than-or-equal-to 49% vs <29% of total energy intake), the RR was 0.86 (95% confidence interval, 0.67 to 1.08). A similar absence of any positive association was observed without adjustment for energy intake; for tumors less than 2 cm as well as 2 cm or greater in diameter; for saturated, monounsaturated, and polyunsaturated fat; and after excluding the first 4 years of follow-up. Also, we found no suggestion of any positive association when using a more detailed and precise dietary questionnaire completed in 1984 (666 subsequent cases), even when women consuming less than 25% of energy from fat were used as the comparison group. No suggestion of a protective effect of dietary fiber was observed (RRs for increasing quintiles were 1.0, 0.95, 0.93, 1.02, and 1.02). Conclusions.-These data provide evidence against both an adverse influence of fat intake and a protective effect of fiber consumption by middle-aged women on breast cancer incidence over 8 years. Nevertheless, the positive association between intake of animal fat and risk of colon cancer observed in many studies provides ample reason to limit this source of energy.	HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University	WILLETT, WC (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356, CA50597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050597, R01CA040356, R37CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appleton B S, 1986, Adv Exp Med Biol, V206, P99; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Birt D F, 1986, Adv Exp Med Biol, V206, P69; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; BOYAR AP, 1988, NUTR CANCER, V11, P93, DOI 10.1080/01635588809513975; COHEN LA, 1991, JNCI-J NATL CANCER I, V83, P496, DOI 10.1093/jnci/83.7.496; COHEN LA, 1990, MED HYPOTHESES, V31, P83, DOI 10.1016/0306-9877(90)90002-V; FREEDMAN LS, 1990, CANCER RES, V50, P5710; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V134, P714; GOLDIN BR, 1982, NEW ENGL J MED, V307, P1542, DOI 10.1056/NEJM198212163072502; GOODWIN PJ, 1987, JNCI-J NATL CANCER I, V79, P473; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; HEBERT JR, 1988, AM J CLIN NUTR, V47, P1068, DOI 10.1093/ajcn/47.6.1068; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HUNTER DJ, 1991, AM J EPIDEMIOL, V134, P715; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KNEKT P, 1990, AM J CLIN NUTR, V52, P903, DOI 10.1093/ajcn/52.5.903; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; MICOZZI MS, 1985, YEARB PHYS ANTHROPOL, V28, P175; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE R, 1990, J NATL CANCER I, V82, P129, DOI 10.1093/jnci/82.2.129; PRENTICE RL, 1988, JNCI-J NATL CANCER I, V80, P802, DOI 10.1093/jnci/80.11.802; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; ROELS OA, 1958, J NUTR, V65, P115, DOI 10.1093/jn/65.1.115; ROSE DP, 1987, JNCI-J NATL CANCER I, V78, P623; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; STRYKER WS, 1991, J AM DIET ASSOC, V91, P172; SUN M, 1988, SCIENCE, V239, P17, DOI 10.1126/science.3336770; SWANSON CA, 1988, CANCER RES, V48, P5363; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; WELSCH CW, 1983, J NATL CANCER I, V70, P215; WELSCH CW, 1992, CANCER RES, V52, pS2040; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, NUTRITIONAL EPIDEMIO; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1990, CANCER CAUSE CONTROL, V1, P103, DOI 10.1007/BF00053190; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1989, DIET HLTH; 1963, DEPT AGR HDB, V8	47	352	356	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1992	268	15					2037	2044		10.1001/jama.268.15.2037	http://dx.doi.org/10.1001/jama.268.15.2037			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT520	1328696				2022-12-01	WOS:A1992JT52000026
J	COOPER, SJ; KELLY, CB; KING, DJ				COOPER, SJ; KELLY, CB; KING, DJ			5-HYDROXYINDOLEACETIC ACID IN CEREBROSPINAL-FLUID AND PREDICTION OF SUICIDAL-BEHAVIOR IN SCHIZOPHRENIA	LANCET			English	Note							MONOAMINE METABOLITES; CSF; 5-HIAA	Low concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) are associated with suicidal behaviour in patients with depressive illness, but studies of the relation between CSF 5-HIAA and suicide in schizophrenia have been inconclusive and have not included long-term follow-up. In a prospective study, we measured 5-HIAA in CSF taken from 30 schizophrenic patients in a drug-free state, and followed these patients for 11 years. 10 patients made suicide attempts during follow-up. Suicide attempters had significantly lower concentrations of CSF 5-HIAA at initial evaluation than non-attempters (mean [SE] 6.7 [2.2] vs 23.6 [5.6] ng/ml, p < 0.05). Our findings provide further evidence of the relation between serotoninergic dysfunction and suicide, and suggest a role for drugs with serotoninergic effects in schizophrenia.	QUEENS UNIV BELFAST, DEPT THERAPEUT & PHARMACOL, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND; HOLYWELL HOSP, ANTRIM, NORTH IRELAND	Queens University Belfast	COOPER, SJ (corresponding author), QUEENS UNIV BELFAST, DEPT MENTAL HLTH, 97 LISBURN RD, BELFAST BT9 7BL, ANTRIM, NORTH IRELAND.							ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193; BANKI CM, 1984, J AFFECT DISORDERS, V6, P341, DOI 10.1016/S0165-0327(84)80012-9; DRAKE RE, 1985, COMPR PSYCHIAT, V26, P90, DOI 10.1016/0010-440X(85)90053-7; FEIGHNER JP, 1972, ARCH GEN PSYCHIAT, V26, P57, DOI 10.1001/archpsyc.1972.01750190059011; LEMUS CZ, 1990, BIOL PSYCHIAT, V27, P923, DOI 10.1016/0006-3223(90)90475-H; NINAN PT, 1984, AM J PSYCHIAT, V141, P566; ROY A, 1989, ARCH GEN PSYCHIAT, V46, P609; ROY A, 1985, PSYCHOL MED, V15, P335, DOI 10.1017/S0033291700023618; TRASKMAN L, 1981, ARCH GEN PSYCHIAT, V38, P631; VANPRAAG HM, 1983, LANCET, V2, P977	10	84	85	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1992	340	8825					940	941		10.1016/0140-6736(92)92819-2	http://dx.doi.org/10.1016/0140-6736(92)92819-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1383659				2022-12-01	WOS:A1992JT82300005
J	CZEISLER, CA; DUMONT, M; DUFFY, JF; STEINBERG, JD; RICHARDSON, GS; BROWN, EN; SANCHEZ, R; RIOS, CD; RONDA, JM				CZEISLER, CA; DUMONT, M; DUFFY, JF; STEINBERG, JD; RICHARDSON, GS; BROWN, EN; SANCHEZ, R; RIOS, CD; RONDA, JM			ASSOCIATION OF SLEEP-WAKE HABITS IN OLDER-PEOPLE WITH CHANGES IN OUTPUT OF CIRCADIAN PACEMAKER	LANCET			English	Article							BRIGHT LIGHT; SUPRACHIASMATIC NUCLEI; TEMPERATURE RHYTHMS; HUMAN-BRAIN; AGE; EXPOSURE; DEMENTIA; MEN; SEX	Many elderly people complain of disturbed sleep patterns but there is no evidence that the need to sleep decreases with age; it seems rather that the timing and consolidation of sleep change. We tried to find out whether there is a concurrent change in the output of the circadian pacemaker with age. The phase and amplitude of the pacemaker's output were assessed by continuous measurement of the core body temperature during 40 h ot sustained wakefulness under constant behavioural and environmental conditions. 27 young men (18-31 years) were compared with 21 older people (65-85 years; 11 men, 10 women); all were healthy and without sleep complaints. The mean amplitude of the endogenous circadian temperature oscillation (ECA) was 40% greater in young men than in the older group. Older men had a lower mean temperature ECA than older women. The minimum of the endogenous phase of the circadian temperature oscillation (ECP) occurred 1 h 52 min earlier in the older than in the young group. Customary bedtimes and waketimes were also earlier in the older group, as was their daily alertness peak. There was a close correlation between habitual waketime and temperature ECP in young men, which may lose precision with age, especially among women. These findings provide evidence for systematic age-related changes in the output of the human circadian pacemaker. We suggest that these changes may underlie the common complaints of sleep disturbance among elderly people. These changes could reflect the observed age-related deterioration of the hypothalmic nuclei that drive mammalian circadian rhythms.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	CZEISLER, CA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV ENDOCRINOL,BOSTON,MA 02115, USA.		Duffy, Jeanne F./AAJ-4845-2020	Duffy, Jeanne F./0000-0003-4177-4179	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006072, P01AG009975] Funding Source: NIH RePORTER; NIA NIH HHS [1-P01-AG09975, 1-RO1-AG06072] Funding Source: Medline; NIMH NIH HHS [H5-ROI-MH45130] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BROWN EN, IN PRESS J BIOL RHYT; Campbell S. S, 1991, SLEEP RES, V20, P448; CAMPBELL SS, 1988, PHYSIOL BEHAV, V42, P141, DOI 10.1016/0031-9384(88)90289-2; COBLENTZ JM, 1973, ARCH NEUROL-CHICAGO, V29, P299, DOI 10.1001/archneur.1973.00490290039003; CZEISLER CA, 1980, SCIENCE, V210, P1264, DOI 10.1126/science.7434029; CZEISLER CA, 1990, NEW ENGL J MED, V322, P1253, DOI 10.1056/NEJM199005033221801; CZEISLER CA, 1989, SCIENCE, V244, P1328, DOI 10.1126/science.2734611; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; CZEISLER CA, 1978, THESIS STANFORD U ST; DAVIS FC, 1984, J COMP PHYSIOL, V154, P221, DOI 10.1007/BF00604987; Dement W, 1985, HDB BIOL AGING, P692; DUMONT M, 1990, SLEEP RES, V19, P217; DUMONT M, 1990, 2ND M SOC RES BIOL R, P66; HOFMAN MA, 1988, J ANAT, V160, P127; HORNE J A, 1976, International Journal of Chronobiology, V4, P97; JEWETT ME, 1991, NATURE, V350, P59, DOI 10.1038/350059a0; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MANT A, 1988, COMMUNITY HEALTH ST, V12, P192; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; MINORS D S, 1984, Chronobiology International, V1, P205, DOI 10.3109/07420528409063897; MOE KE, 1991, J AM GERIATR SOC, V39, P383, DOI 10.1111/j.1532-5415.1991.tb02904.x; Monk TH, 1992, J GERONTOL PSYCH SCI, V47, P221; MORIN LP, 1988, J BIOL RHYTHM, V3, P237, DOI 10.1177/074873048800300302; PICKARD GE, 1985, J COMP PHYSIOL A, V156, P803, DOI 10.1007/BF00610832; PITTENDRIGH CS, 1974, SCIENCE, V186, P548, DOI 10.1126/science.186.4163.548; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; VITIELLO MV, 1986, NEUROBIOL AGING, V7, P97, DOI 10.1016/0197-4580(86)90146-6; WEITZMAN ED, 1982, NEUROBIOL AGING, V3, P299, DOI 10.1016/0197-4580(82)90018-5; WELSH DK, 1986, J GERONTOL, V41, P579, DOI 10.1093/geronj/41.5.579; Wever RA., 1979, CIRCADIAN SYSTEM MAN, DOI 10.1007/978-1-4612-6142-1	30	312	314	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					933	936		10.1016/0140-6736(92)92817-Y	http://dx.doi.org/10.1016/0140-6736(92)92817-Y			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357348				2022-12-01	WOS:A1992JT82300003
J	DEGRAAF, MJM				DEGRAAF, MJM			40 YEARS OF BEING TREATED FOR NOCTURNAL ENURESIS	LANCET			English	Editorial Material											DEGRAAF, MJM (corresponding author), UNIV LIMBURG,ACAD HOSP,POB 5800,6202 AZ MAASTRICHT,NETHERLANDS.							GILRUSHTON H, 1989, J PEDIATR, V114, P691; NORGAARD JP, 1985, J UROLOGY, V134, P1029, DOI 10.1016/S0022-5347(17)47581-1; RITTIG S, 1989, AM J PHYSIOL, V256, P664	3	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					957	958		10.1016/0140-6736(92)92828-4	http://dx.doi.org/10.1016/0140-6736(92)92828-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357357				2022-12-01	WOS:A1992JT82300014
J	GOODE, HF; BURNS, E; WALKER, BE				GOODE, HF; BURNS, E; WALKER, BE			VITAMIN-C DEPLETION AND PRESSURE SORES IN ELDERLY PATIENTS WITH FEMORAL-NECK FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; DIETARY SUPPLEMENTATION; PLASMA; ZINC; FEMUR	Objective-To evaluate the contribution of specific nutritional deficiencies (as indicated by zinc; vitamin A, C, and E; albumin; and haemoglobin concentrations) to the risk of pressure sores. Design-Observational cohort study. Setting-St James's University Hospital, Leeds. Subjects-21 elderly patients presenting consecutively to the orthopaedic unit with femoral neck fracture. Main outcome measure-Full thickness epidermal break over a pressure bearing surface. Results-10 patients (48%) developed a pressure sore during their hospital stay. Indices of zinc status and concentrations of albumin, haemoglobin, and vitamins A and E were similar in patients who developed a pressure sore and those who did not. Mean leucocyte vitamin C concentration, however, was 6.3 (SD 2.2) mug/10(8) cells in patients who developed a pressure sore as compared with 12.8 (4.6) mug/10(8) cells in patients who did not. Conclusions-Low concentrations of leucocyte vitamin C appear to be associated with subsequent development of pressure sores in elderly patients with femoral neck fractures.	GEN INFIRM,DEPT MED ELDERLY,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	GOODE, HF (corresponding author), ST JAMES UNIV HOSP,MED,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							AGREN MS, 1990, THESIS LINKOPING U L; Allman R M, 1989, Decubitus, V2, P30; BARRETT JD, 1988, J HYPERTENS, V6, P49; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; Breslow R, 1991, Decubitus, V4, P16; BROWN KM, IN PRESS P NUTR SOC; CATIGNANI GL, 1983, CLIN CHEM, V29, P708; DELMI M, 1990, LANCET, V335, P1013, DOI 10.1016/0140-6736(90)91073-J; DENSON KW, 1961, CLIN SCI, V21, P157; GOODE HF, 1991, AGE AGEING, V20, P345, DOI 10.1093/ageing/20.5.345; GOODE HF, 1990, CLIN SCI, V79, P247, DOI 10.1042/cs0790247; GOODE HF, 1989, ANN CLIN BIOCHEM, V26, P89, DOI 10.1177/000456328902600114; HUGHES AW, 1986, INJURY, V17, P19, DOI 10.1016/0020-1383(86)90007-0; MACHLIN LJ, 1984, HDB VITAMINS NUTRITI; MORGAN AG, 1975, INT J VITAM NUTR RES, V45, P448; PENN ND, 1991, AGE AGEING, V20, P169, DOI 10.1093/ageing/20.3.169; SCHORAH CJ, 1986, ANN CLIN BIOCHEM, V23, P566, DOI 10.1177/000456328602300513; TAYLOR TV, 1974, LANCET, V2, P544; VERSLUYSEN M, 1986, BRIT MED J, V292, P1311, DOI 10.1136/bmj.292.6531.1311; 1990, LANCET, V335, P1311	20	40	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1992	305	6859					925	927		10.1136/bmj.305.6859.925	http://dx.doi.org/10.1136/bmj.305.6859.925			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU649	1458073	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JU64900021
J	MARTIN, BC; WARRAM, JH; KROLEWSKI, AS; BERGMAN, RN; SOELDNER, JS; KAHN, CR				MARTIN, BC; WARRAM, JH; KROLEWSKI, AS; BERGMAN, RN; SOELDNER, JS; KAHN, CR			ROLE OF GLUCOSE AND INSULIN RESISTANCE IN DEVELOPMENT OF TYPE-2 DIABETES-MELLITUS - RESULTS OF A 25-YEAR FOLLOW-UP-STUDY	LANCET			English	Article							BETA-CELL; FAT DISTRIBUTION; PIMA-INDIANS; SENSITIVITY; MUSCLE; NIDDM; TRANSPORTERS; TOLERANCE; INVIVO; RISK	Type 2 diabetes mellitus is characterised by resistance of peripheral tissues to insulin and a relative deficiency of insulin secretion. To find out which is the earliest or primary determinant of disease, we used a minimum model of glucose disposal and insulin secretion based on intravenous glucose tolerance tests to estimate insulin sensitivity (S(I)), glucose effectiveness (ie, insulin-independent glucose removal rate, S(G)), and first-phase and second-phase beta-cell responsiveness in normoglycaemic offspring of couples who both had type 2 diabetes. 155 subjects from 86 families were followed-up for 6-25 years. More than 10 years before the development of diabetes, subjects who developed the disease had lower values of both S(I) (mean 3.2 [SD 2.4] vs 8.1 [6.7] 10(-3) l min-1 pmol-1 insulin; p < 0.0001) and S(G) (1.6 [0.9] vs 2.3 [1.2] 10(-2) min-1, p < 0.0001) than did those who remained normoglycaemic). For the subjects with both S(I) and SG below the group median, the cumulative incidence of type 2 diabetes during the 25 years was 76% (95% confidence interval 54-99). By contrast, no subject with both S(I) and S(G) above the median developed the disease. Subjects with low S(I)/high S(G) or high S(I)/low S(G) had intermediate risks. Insulin secretion, especially first phase, tended to be increased rather than decreased in this prediabetic phase and was appropriate for the level of insulin resistance. The development of type 2 diabetes is preceded by and predicted by defects in both insulin-dependent and insulin- independent glucose uptake; the defects are detectable when the patients are normoglycaemic and in most cases more than a decade before diagnosis of disease.	HARVARD UNIV,SCH PUBL HLTH,JOSLIN DIABET CTR 1 JOSLIN PL,DEPT EPIDEMIOL,DIV RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; UNIV ZURICH,INST SOCIAL & PREVENT MED,CH-8006 ZURICH,SWITZERLAND; UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,LOS ANGELES,CA 90033	Harvard University; Harvard T.H. Chan School of Public Health; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Zurich; University of Southern California			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; Bergman, Richard/0000-0003-1539-4471	NIDDK NIH HHS [DK-29867, DK-33201, DK-36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK033201, R01DK029867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARON AD, 1985, J CLIN INVEST, V76, P1782, DOI 10.1172/JCI112169; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERGMAN RN, 1989, DIABETES, V38, P1512, DOI 10.2337/diabetes.38.12.1512; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; BERGMAN RN, 1981, J CLIN INVEST, V68, P1456, DOI 10.1172/JCI110398; BERGSTROM RW, 1990, DIABETES, V39, P104, DOI 10.2337/diabetes.39.1.104; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FREYMOND D, 1988, J CLIN INVEST, V82, P1503, DOI 10.1172/JCI113758; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HANSEN IL, 1985, DIABETES, V34, P751, DOI 10.2337/diabetes.34.8.751; Hoffman WS, 1937, J BIOL CHEM, V120, P51; JOHNSTON C, 1990, DIABETIC MED, V7, P119, DOI 10.1111/j.1464-5491.1990.tb01345.x; KADISH AH, 1968, CLIN CHEM, V14, P116; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LEE ET, 1980, STATISTICAL METHODS; LESLIE RDG, 1986, BRIT MED J, V293, P840, DOI 10.1136/bmj.293.6551.840; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MENEILLY GS, 1989, J CLIN ENDOCR METAB, V63, P566; PORTE D, 1989, DIABETES, V38, P1333, DOI 10.2337/diabetes.38.11.1333; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICH SS, 1990, DIABETES, V39, P1315, DOI 10.2337/diabetes.39.11.1315; ROBERTSON RP, 1989, DIABETES, V38, P1501, DOI 10.2337/diabetes.38.12.1501; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P286; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; 1979, DIABETES, V28, P1039	31	950	973	1	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					925	929		10.1016/0140-6736(92)92814-V	http://dx.doi.org/10.1016/0140-6736(92)92814-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357346				2022-12-01	WOS:A1992JT82300001
J	MOSS, SF; LEGON, S; BISHOP, AE; POLAK, JM; CALAM, J				MOSS, SF; LEGON, S; BISHOP, AE; POLAK, JM; CALAM, J			EFFECT OF HELICOBACTER-PYLORI ON GASTRIC SOMATOSTATIN IN DUODENAL-ULCER DISEASE	LANCET			English	Article							CAMPYLOBACTER PYLORI; GENE-EXPRESSION; ACID SECRETION; ANTRAL GASTRIN; G-CELL; SEQUENCE; BASAL	Infection of the gastric antrum by Helicobacter pylori is associated with recurrent duodenal ulcer disease but the mechanism of ulcerogenesis is unclear. Since pathways inhibiting gastric secretion are defective in patients with duodenal ulcers, we investigated whether H pylori interferes with the normal gastric inhibition that is mediated by somatostatin. We studied 28 patients with active duodenal ulcers in whom H pylori was eradicated successfully. In 18 patients, we measured the density of antral somatostatin-immunoreactive cells and in a further 10 subjects, the amount of somatostatin mRNA before and after eradication of H pylori was determined. After eradication, the median density of somatostatin-immunoreactive cells increased significantly from 9 (range 3-47) to 19 (6-57) cells per mm muscularis mucosa (p=0.025). The median somatostatin mRNA/rRNA ratio increased from 50 (25-160) to 95 (40-180) (p=0.01). The number of gastrin cells and quantity of gastrin mRNA did not change significantly. Our results suggest that in duodenal ulcer disease, gastric secretory function is disinhibited through the suppression Of mucosal somatostatin.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0NN,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CHEM PATHOL,LONDON W12 0NN,ENGLAND	Imperial College London; Imperial College London	MOSS, SF (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,LONDON W12 0NN,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAIR AJ, 1987, J CLIN INVEST, V79, P582, DOI 10.1172/JCI112850; BRAND SJ, 1988, J CLIN INVEST, V82, P1059, DOI 10.1172/JCI113662; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER RG, 1985, GUT, V26, P232, DOI 10.1136/gut.26.3.232; DOCKRAY GJ, 1991, GASTROENTEROLOGY, V100, P1187; GOLODNER E H, 1992, Gastroenterology, V102, pA630; GRAHAM D Y, 1991, Gastroenterology, V100, pA75; HOWARD A, 1992, BIOCHEM BIOPH RES CO, V183, P499, DOI 10.1016/0006-291X(92)90510-R; ITO R, 1984, P NATL ACAD SCI-BIOL, V81, P4662, DOI 10.1073/pnas.81.15.4662; KANEKO H, 1992, DIGEST DIS SCI, V37, P409, DOI 10.1007/BF01307736; KING W W, 1992, Gastroenterology, V102, pA646; KIRKPATRICK PM, 1980, GASTROENTEROLOGY, V79, P4; LEVI S, 1989, BRIT MED J, V299, P1504, DOI 10.1136/bmj.299.6714.1504; LEVI S, 1989, LANCET, V1, P1167; MALAGELADA JR, 1977, GASTROENTEROLOGY, V73, P989; MCCOLL KEL, 1989, LANCET, V2, P499; MOSS S, 1992, GUT, V33, P289, DOI 10.1136/gut.33.3.289; MOSS SF, 1992, GUT, V33, pS28; SHEN LP, 1982, P NATL ACAD SCI-BIOL, V79, P4575, DOI 10.1073/pnas.79.15.4575; SOLCIA E, 1988, DIGESTION, V41, P185, DOI 10.1159/000199786; TARNASKY P R, 1991, Gastroenterology, V100, pA845; WALSH JH, 1975, J CLIN INVEST, V55, P462, DOI 10.1172/JCI107952; WU V, 1991, GASTROENTEROLOGY, V101, P1552, DOI 10.1016/0016-5085(91)90391-W	23	276	280	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 17	1992	340	8825					930	932		10.1016/0140-6736(92)92816-X	http://dx.doi.org/10.1016/0140-6736(92)92816-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT823	1357347				2022-12-01	WOS:A1992JT82300002
J	SHELDRICK, JH; VERNON, SA; WILSON, A; READ, SJ				SHELDRICK, JH; VERNON, SA; WILSON, A; READ, SJ			DEMAND INCIDENCE AND EPISODE RATES OF OPHTHALMIC DISEASE IN A DEFINED URBAN-POPULATION	BRITISH MEDICAL JOURNAL			English	Article							EYE DISEASE; OUTPATIENT; COMMUNITY; CASUALTY	Objectives-To estimate demand incidence and episode rates of ophthalmic disease in a defined urban population over one year. Design-Study of patients presenting with eye problems to general practice and eye casualty department. Setting-General practice and ophthalmic services in west Nottingham. Subjects-36018 people from the combined practice lists of 17 Nottingham general practitioners. Main outcome measures-Ophthalmic disorder, age and sex of patient, and where presented. Results-2587 consultations were recorded for ophthalmic problems, 1771 with general practitioners and 816 with eye casualty. Most consultations to general practice were by females (1066 (60%)), whereas men aged 15-44 accounted for most work in eye casualty. These men commonly presented with trauma. Infective conjunctivitis, the commonest condition, had an episode rate of 13.5/1000 population/year. Demand incidence for cataracts was 1.9/1000 population/year. Demand incidence for chronic conditions increased with age. Conclusions-As the average age of the population increases demand for ophthalmic services will rise. Planning and provision of resources to meet this increased demand should be considered now.	UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2RD,ENGLAND; UNIV NOTTINGHAM,ACAD UNIT OPHTHALMOL,NOTTINGHAM NG7 2RD,ENGLAND	University of Nottingham; University of Nottingham								BANKES JLK, 1968, BRIT MED J, V1, P791, DOI 10.1136/bmj.1.5595.791; BRENNANME, 1975, COMMUNITY HLTH, V7, P13; Brittain G P, 1988, Health Trends, V20, P43; DART JKG, 1986, BRIT MED J, V293, P1477, DOI 10.1136/bmj.293.6560.1477; DUKEELDER S, 1965, SYSTEM OPHTHALMOLOGY, V8, P444; EDWARDS RS, 1987, BRIT J OPHTHALMOL, V71, P938, DOI 10.1136/bjo.71.12.938; Fraser R C, 1981, J R Coll Gen Pract, V31, P410; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; Hughes A. M., 1976, MINISTRY AGR FISHERI, V9; JAY JL, 1990, EYE, V4, P127, DOI 10.1038/eye.1990.16; JONES NP, 1986, BRIT MED J, V292, P188, DOI 10.1136/bmj.292.6514.188; KHAN HA, 1977, AM J EPIDEMIOL, V106, P17; MORRELL DC, 1971, BRIT MED J, V2, P454, DOI 10.1136/bmj.2.5759.454; PAGECHIAPELLA A, 1985, BR J OPHTHALMOL, V69, P865; PODOGOR MJ, 1983, AM J EPIDEMIOL, V118, P206; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; PORT MJA, 1988, OPHTHAL PHYSL OPT, V8, P323, DOI 10.1016/0275-5408(88)90182-2; SHAW DE, 1986, ARCH OPHTHALMOL-CHIC, V104, P1843; SHELDRICK JH, 1992, BRIT MED J, V304, P1096, DOI 10.1136/bmj.304.6834.1096; VERNON SA, 1983, J ROY SOC MED, V76, P279, DOI 10.1177/014107688307600408; WARDEN J, 1990, BMJ, V300, P1990; 1962, MORBIDITY STATISTICS; 1974, MORBIDITY STATISTICS; 1986, MORBIDITY STATISTICS; 1991, GLOBAL POPULATION ES, P364	26	30	33	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1992	305	6859					933	936		10.1136/bmj.305.6859.933	http://dx.doi.org/10.1136/bmj.305.6859.933			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JU649	1458075	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JU64900024
J	ADAMS, DE; SHEKHTMAN, EM; ZECHIEDRICH, EL; SCHMID, MB; COZZARELLI, NR				ADAMS, DE; SHEKHTMAN, EM; ZECHIEDRICH, EL; SCHMID, MB; COZZARELLI, NR			THE ROLE OF TOPOISOMERASE-IV IN PARTITIONING BACTERIAL REPLICONS AND THE STRUCTURE OF CATENATED INTERMEDIATES IN DNA-REPLICATION	CELL			English	Article							ESCHERICHIA-COLI; TN3 RESOLVASE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; SALMONELLA-TYPHIMURIUM; NUCLEOID SEGREGATION; RECOMBINATION; MUTANTS; SITES; DECATENATION	Mutants in bacterial topoisomerase (topo) IV are deficient in chromosomal partitioning. To investigate the basis of this phenotype, we examined plasmid DNA topology in conditionally lethal topo IV mutants. We found that dimeric catenated plasmids accumulated in vivo after topo IV inhibition. The catenanes were supercoiled, contained from 2 to >32 nodes, and were the products of DNA synthesis. Electron microscopy and recombination tests proved that the catenanes have the unique structure predicted for replication intermediates. These data provide strong evidence for a model in which unlinking of the double helix can occur in two stages during DNA replication and for the critical role of topo IV in the second stage. The interlocks in the catenanes appear to be sequestered from DNA gyrase, perhaps by compartmentalization in an enzyme complex dedicated to partitioning.	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Princeton University	ADAMS, DE (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Zechiedrich, Elizabeth Lynn/S-4720-2019	Zechiedrich, Lynn/0000-0003-0533-1637	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014574] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14574-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; BENJAMIN HW, 1990, J BIOL CHEM, V265, P6441; BENYAJATI C, 1976, CELL, V9, P393, DOI 10.1016/0092-8674(76)90084-2; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DROGE P, 1992, METHOD ENZYMOL, V212, P120; FIELDSBERRY SC, 1989, NUCLEIC ACIDS RES, V17, P3261, DOI 10.1093/nar/17.8.3261; GARRARD WT, 1990, NUCLEIC ACIDS MOL BI, V4, P163; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHII S, 1991, J BACTERIOL, V173, P5551, DOI 10.1128/jb.173.17.5551-5553.1991; KANAAR R, 1989, CELL, V58, P147, DOI 10.1016/0092-8674(89)90411-X; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Kornberg A., 1992, DNA REPLICATION; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LUTTINGER AL, 1991, NEW BIOL, V3, P687; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RYAN KA, 1988, P NATL ACAD SCI USA, V85, P5844, DOI 10.1073/pnas.85.16.5844; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID MB, 1990, J BACTERIOL, V172, P5416, DOI 10.1128/jb.172.9.5416-5424.1990; SHELINE C, 1989, MOL CELL BIOL, V9, P169, DOI 10.1128/MCB.9.1.169; STECK TR, 1984, CELL, V36, P1081, DOI 10.1016/0092-8674(84)90058-8; STECK TR, 1984, J BACTERIOL, V158, P397, DOI 10.1128/JB.158.2.397-403.1984; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079; Yanagida M, 1990, DNA TOPOLOGY ITS BIO, P299; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	41	282	291	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					277	288		10.1016/0092-8674(92)90356-H	http://dx.doi.org/10.1016/0092-8674(92)90356-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330320				2022-12-01	WOS:A1992JU39500013
J	BREWER, BJ; LOCKSHON, D; FANGMAN, WL				BREWER, BJ; LOCKSHON, D; FANGMAN, WL			THE ARREST OF REPLICATION FORKS IN THE RDNA OF YEAST OCCURS INDEPENDENTLY OF TRANSCRIPTION	CELL			English	Article							RNA POLYMERASE-I; BACILLUS-SUBTILIS CHROMOSOME; ESCHERICHIA-COLI CHROMOSOME; DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL DNA; TERMINATOR PROTEIN; S-PHASE; PLASMID; SEQUENCE	Replication forks, moving opposite to the direction of transcription, are arrested at the 3' ends of the 35S transcription units in the rDNA locus of S. cerevisiae. Because of its position and polarity, we tested the hypothesis that this replication fork barrier (RFB) results from the act of transcription. Three results contradict this hypothesis. First, the RFB persists in a strain containing a disruption of the gene for the 135 kd subunit of RNA polymerase I. Second, the RFB causes a polar arrest of replication forks when transplanted to a plasmid. Third, transcription by RNA polymerase II of a plasmid copy of the 35S transcription unit lacking the RFB does not generate a barrier. We propose that replication forks are arrested in a directional manner through the binding of one or more proteins to two closely spaced sites in the RFB.			BREWER, BJ (corresponding author), UNIV WASHINGTON,DEPT GENET,SK-50,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018926, R37GM018926] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1987, MOL GEN GENET, V208, P127, DOI 10.1007/BF00330433; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1988, J BACTERIOL, V170, P662, DOI 10.1128/jb.170.2.662-668.1988; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON SP, 1989, MOL CELL BIOL, V9, P4986, DOI 10.1128/MCB.9.11.4986; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1989, EMBO J, V8, P2435, DOI 10.1002/j.1460-2075.1989.tb08374.x; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LIN YH, 1991, GENETICS, V127, P31; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Maniatis T., 1982, MOL CLONING; MORROW BE, 1989, J BIOL CHEM, V264, P9061; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; SAFFER LD, 1986, MOL CELL BIOL, V6, P1148, DOI 10.1128/MCB.6.4.1148; SANDERSON KE, 1988, MICROBIOL REV, V52, P485, DOI 10.1128/MMBR.52.4.485-532.1988; VANDERSANDE CAFM, 1989, NUCLEIC ACIDS RES, V17, P9127, DOI 10.1093/nar/17.22.9127; VOELKELMEIMAN K, 1987, CELL, V48, P1071, DOI 10.1016/0092-8674(87)90714-8; WANG HM, 1990, MOL CELL BIOL, V10, P1743, DOI 10.1128/MCB.10.4.1743; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5; ZEIGLER DR, 1990, GENETICS, V125, P703	38	216	219	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					267	276		10.1016/0092-8674(92)90355-G	http://dx.doi.org/10.1016/0092-8674(92)90355-G			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423594				2022-12-01	WOS:A1992JU39500012
J	BURATOWSKI, S; ZHOU, H				BURATOWSKI, S; ZHOU, H			A SUPPRESSOR OF TBP MUTATIONS ENCODES AN RNA POLYMERASE-III TRANSCRIPTION FACTOR WITH HOMOLOGY TO TFIIB	CELL			English	Article							TATA-BINDING-PROTEIN; WHOLE-CELL EXTRACT; HUMAN U6 GENE; SACCHAROMYCES-CEREVISIAE; ACCURATE INITIATION; ESCHERICHIA-COLI; YEAST; DNA; ACTIVATION; COMPLEXES	The TDS4 gene of S. cerevisiae was isolated as an allele-specific high copy suppressor of mutations within the basic region of the TATA-binding protein (TBP). The gene is essential for viability and encodes a 596 aa protein. The first 300 aa of the TDS4 protein exhibit significant sequence similarity to the RNA polymerase II transcription factor TFIIB. However, TDS4 is required for RNA polymerase III transcription in vivo and in vitro. Antibodies specific for TDS4 or TBP react with the TFIIIB complex, indicating that both proteins are components of the RNA polymerase III initiation complex. These findings suggest that the RNA polymerase II and III initiation mechanisms are extremely similar, and they explain how the TATA-binding protein can function in both systems.			BURATOWSKI, S (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DALBERG JE, 1991, SCIENCE, V254, P1462; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GUTHRIE C, 1991, METH ENZYMOL, V194; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LUE NF, 1990, J BIOL CHEM, V265, P18091; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MONCOLLIN V, 1992, P NATL ACAD SCI USA, V89, P397, DOI 10.1073/pnas.89.1.397; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WILLIS I, 1989, EMBO J, V8, P4281, DOI 10.1002/j.1460-2075.1989.tb08614.x; WOONTNER M, 1990, J BIOL CHEM, V265, P8979	52	141	142	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					221	230		10.1016/0092-8674(92)90351-C	http://dx.doi.org/10.1016/0092-8674(92)90351-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423590				2022-12-01	WOS:A1992JU39500008
J	CAREY, JR; LIEDO, P; OROZCO, D; VAUPEL, JW				CAREY, JR; LIEDO, P; OROZCO, D; VAUPEL, JW			SLOWING OF MORTALITY-RATES AT OLDER AGES IN LARGE MEDFLY COHORTS	SCIENCE			English	Article							MEDITERRANEAN FRUIT-FLY; DROSOPHILA-MELANOGASTER; CERATITIS-CAPITATA; MORBIDITY; COMPRESSION; POPULATION; HOST	It is generally assumed for most species that mortality rates increase monotonically at advanced ages. Mortality rates were found to level off and decrease at older ages in a population of 1.2 million medflies maintained in cages of 7,200 and in a group of approximately 48,000 adults maintained in solitary confinement. Thus, life expectancy in older individuals increased rather than decreased with age. These results cast doubt on several central concepts in gerontology and the biology of aging: (i) that senescence can be characterized by an increase in age-specific mortality, (ii) that the basic pattern of mortality in nearly all species follows the same unitary pattern at older ages, and (iii) that species have absolute life-span limits.	CTR INVEST ECOL SURESTE,TAPACHULA 30700,CHIAPAS,MEXICO; PROGRAMA MOSCAMED,METAPA 30820,CHIAPAS,MEXICO; ODENSE UNIV,DK-5230 ODENSE,DENMARK; DUKE UNIV,CTR DEMOG STUDIES,DURHAM,NC 27706	University of Southern Denmark; Duke University	CAREY, JR (corresponding author), UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616, USA.		Orozco-Davila, Dina/T-5369-2019; Orozco-Davila, Dina/B-3236-2016; Orozco-Davila, Dina/B-4050-2016; Orozco-Davila, Dina/AAJ-2862-2021; Liedo, Pablo/E-9313-2010	Orozco-Davila, Dina/0000-0002-6806-0945; Orozco-Davila, Dina/0000-0002-6806-0945; Liedo, Pablo/0000-0002-0004-1721; Vaupel, James/0000-0003-0783-3905	NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER; NIA NIH HHS [AG08761-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIGAKI T, 1984, EXP GERONTOL, V19, P267, DOI 10.1016/0531-5565(84)90022-6; BEARD RE, 1971, BIOL ASPECTS DEMOGRA, P75; BIRCH LC, 1948, J ANIM ECOL, V17, P15, DOI 10.2307/1605; CAREY JR, 1986, ENTOMOL EXP APPL, V42, P159, DOI 10.1007/BF00343543; CAREY JR, 1992, APPLIED DEMOGRAPHY B; CHIANG CL, 1984, LIFE TABLES ITS APPL, P116; Collatz K-G., 1986, INSECT AGING STRATEG; Comfort A., 1979, BIOL SENESCENCE; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; DEEVEY ES, 1947, Q REV BIOL, V22, P283, DOI 10.1086/395888; ECONOMOS AC, 1979, AGE, V2, P74, DOI 10.1007/BF02432250; Economos AC, 1982, ARCH GERONTOL GERIAT, V1, P3, DOI [10.1016/0167-4943(82)90003-6, DOI 10.1016/0167-4943(82)90003-6]; Finch CE, 1990, LONGEVITY SENESCENCE, P12; FRIES JF, 1983, MILBANK FUND Q, V61, P397, DOI 10.2307/3349864; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1987, GERONTOLOGICA PERSPE, V1, P5; GAVRILOV LA, 1991, BIOL LIFE SPAN QUANT, P129; GAVRILOV LA, 1991, BIOL LIFE SPAN QUANT, P128; GOMPERTZ B, 1977, MATH DEMOGRAPHY SELE, P279; HAZZARD DG, 1991, EXP GERONTOL, V26, P411, DOI 10.1016/0531-5565(91)90028-K; KANNISTO V, 1988, POP STUD-J DEMOG, V42, P389, DOI 10.1080/0032472031000143546; KRAINACKER DA, 1987, OECOLOGIA, V73, P583, DOI 10.1007/BF00379420; KRAINACKER DA, 1986, THESIS U CALIFORNIA; Leslie PH, 1940, J ANIM ECOL, V9, P27, DOI 10.2307/1425; Luckinbill LS, 1988, EVOL ECOL, V2, P85, DOI 10.1007/BF02071591; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; MERTZ DB, 1975, PHYSIOL ZOOL, V48, P1; MIQUEL J, 1976, MECH AGEING DEV, V5, P347, DOI 10.1016/0047-6374(76)90034-8; PARTRIDGE L, 1990, J INSECT PHYSIOL, V36, P419, DOI 10.1016/0022-1910(90)90059-O; Pearl R, 1927, AM NAT, V61, P289, DOI 10.1086/280154; Pearl R, 1935, Q REV BIOL, V10, P60, DOI 10.1086/394476; Pearl R, 1923, AM NAT, V57, P153, DOI 10.1086/279913; Pearl R, 1924, AM NAT, V58, P71, DOI 10.1086/279956; PROMISLOW DEL, 1991, EVOLUTION, V45, P1869, DOI 10.1111/j.1558-5646.1991.tb02693.x; RAGLAND SS, 1973, EXP GERONTOL, V8, P135, DOI 10.1016/0531-5565(73)90003-X; ROCKSTEIN M, 1959, GERONTOLOGY, V3, P23, DOI 10.1159/000210828; ROGERS A, 1992, DEMOGRAPHY, V29, P31, DOI 10.2307/2061361; SCHWARZ AJ, 1985, FLA ENTOMOL, V68, P467, DOI 10.2307/3495135; SMITH JM, 1958, J EXP BIOL, V35, P832; SOHAL RS, 1981, EXP GERONTOL, V16, P157, DOI 10.1016/0531-5565(81)90040-1; TATAR M, UNPUB; THATCHER AR, 1982, J I ACTUARIES, V109, P346; Vargas R., 1989, FRUIT FLIES THEIR B, V3B, P141; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; VAUPEL JW, 1979, DEMOGRAPHY, V16, P3; VAUPEL JW, 1988, MATH POPUL STUD, V1, P21, DOI DOI 10.1080/08898488809525259	46	455	462	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					457	461						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411540				2022-12-01	WOS:A1992JT77500033
J	CREWS, CM; ALESSANDRINI, A; ERIKSON, RL				CREWS, CM; ALESSANDRINI, A; ERIKSON, RL			THE PRIMARY STRUCTURE OF MEK, A PROTEIN-KINASE THAT PHOSPHORYLATES THE ERK GENE-PRODUCT	SCIENCE			English	Article							NUCLEOTIDE-SEQUENCE; FISSION YEAST; CELL-CYCLE; DIACYLGLYCEROL; RESISTANCE; CEREVISIAE; PROGRESS; CASCADES; ENCODES; FUS3	Mitogen-activated protein (MAP) kinases, also known as extracellular signal-regulated kinases (ERKs), are thought to act at an integration point for multiple biochemical signals because they are activated by a wide variety of extracellular signals, rapidly phosphorylated on threonine and tyrosine, and highly conserved. A critical protein kinase lies upstream of MAP kinase and stimulates the enzymatic activity of MAP kinase. The structure of this protein kinase, denoted MEK1, for MAP kinase or ERK kinase, was elucidated from a complementary DNA sequence an shown to be a protein of 393 amino acids (43,500 daltons) that is related most closely in size and sequence to the product encoded by the Schizosaccharomyces pombe byr1 gene. The MEK gene was highly expressed in murine brain, and the product expressed in bacteria phosphorylated the ERK gene product.			CREWS, CM (corresponding author), HARVARD UNIV,DEPT CELLULAR & DEV BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Crews, Craig M./ABH-9346-2020	Crews, Craig M./0000-0002-8456-2005	NATIONAL CANCER INSTITUTE [R35CA042580] Funding Source: NIH RePORTER; NCI NIH HHS [CA42580] Funding Source: Medline; NIGMS NIH HHS [GM07620-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; Alessandrini A., UNPUB; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Maniatis T., 1982, MOL CLONING; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NIELSEN O, 1992, EMBO J, V11, P1391, DOI 10.1002/j.1460-2075.1992.tb05184.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; SEGER R, 1992, J BIOL CHEM, V267, P14373; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	37	858	909	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					478	480		10.1126/science.1411546	http://dx.doi.org/10.1126/science.1411546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411546				2022-12-01	WOS:A1992JT77500040
J	CURTSINGER, JW; FUKUI, HH; TOWNSEND, DR; VAUPEL, JW				CURTSINGER, JW; FUKUI, HH; TOWNSEND, DR; VAUPEL, JW			DEMOGRAPHY OF GENOTYPES - FAILURE OF THE LIMITED LIFE-SPAN PARADIGM IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							MORTALITY; DYNAMICS; HETEROGENEITY; COMPRESSION; LONGEVITY; SELECTION	Experimental systems that are amenable to genetic manipulation can be used to address fundamental questions about genetic and nongenetic determinants of longevity. Analysis of large cohorts of ten genotypes of Drosophila melanogaster raised under conditions that favored extended survival has revealed variation between genotypes in both the slope and location of age-specific mortality curves. More detailed examination of a single genotype showed that the mortality trajectory was best fit by a two-stage Gompertz model, with no age-specific increase in mortality rates beyond 30 days after emergence. These results are contrary to the limited life-span paradigm, which postulates well-defined, genotype-specific limits on life-span and brief periods of intense and rapidly accelerating mortality rates at the oldest ages.	ODENSE UNIV,SCH MED,DK-5230 ODENSE,DENMARK; DUKE UNIV,CTR DEMOG STUDIES,DURHAM,NC 27706	University of Southern Denmark; Duke University	CURTSINGER, JW (corresponding author), UNIV MINNESOTA,DEPT ECOL EVOLUT & BEHAV,MINNEAPOLIS,MN 55455, USA.			Vaupel, James/0000-0003-0783-3905	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K04HD000638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG08761] Funding Source: Medline; NICHD NIH HHS [KO4 HD 00638] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CRAPO LM, 1981, VITALITY AGING IMPLI; ECONOMOS AC, 1979, AGE, V2, P74, DOI 10.1007/BF02432250; Economos AC, 1982, ARCH GERONTOL GERIAT, V1, P3, DOI [10.1016/0167-4943(82)90003-6, DOI 10.1016/0167-4943(82)90003-6]; ECONOMOS AC, 1987, ARCH GERONTOL GERIAT, V1, P3; Falconer D. S, 1981, INTRO QUANTITATIVE G; Finch CE., 1990, LONGEVITY SENESCENCE; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1987, GERONTOL PERSPECTA, V1, P54; FRIES JF, 1987, GERONTOLOGICA PERSPE, V1, P5; Gavrilov L.A., 1991, BIOL LIFE SPAN QUANT; GURALNICK M, 1987, GERONTOL PERSPECT, V1, P65; LUCKINBILL LS, 1985, HEREDITY, V55, P9, DOI 10.1038/hdy.1985.66; LUCKINBILL LS, 1986, HEREDITY, V56, P329, DOI 10.1038/hdy.1986.54; Manton K. G., 1987, GERONTOL PERSPECTA, V1, P23; MYERS GC, 1984, GERONTOLOGIST, V24, P346, DOI 10.1093/geront/24.4.346; PARSONS PA, 1977, EXP GERONTOL, V12, P241, DOI 10.1016/0531-5565(77)90012-2; RAMLAUHANSEN H, 1983, ANN STAT, V11, P453, DOI 10.1214/aos/1176346152; RAMLAUHANSEN H, 1983, SCAND ACTUAR J, V66, P165; Rose MR, 1991, EVOLUTIONARY BIOL AG; VAUPEL JW, 1979, DEMOGRAPHY, V16, P439, DOI 10.2307/2061224; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; VAUPEL JW, 1985, SOCIOLOGICAL METHODO; WITTEN M, 1988, MECH AGEING DEV, V46, P175, DOI 10.1016/0047-6374(88)90124-8	24	322	328	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					461	463		10.1126/science.1411541	http://dx.doi.org/10.1126/science.1411541			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411541				2022-12-01	WOS:A1992JT77500034
J	FISHMANLOBELL, J; HABER, JE				FISHMANLOBELL, J; HABER, JE			REMOVAL OF NONHOMOLOGOUS DNA ENDS IN DOUBLE-STRAND BREAK RECOMBINATION - THE ROLE OF THE YEAST ULTRAVIOLET REPAIR GENE RAD1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; EXCISION; INCISION; LOCUS	Double-strand breaks (DSBs) in Saccharomyces cerevisiae can be repaired by gene conversions or by deletions resulting from single-strand annealing between direct repeats of homologous sequences. Although rad1 mutants are resistant to x-rays and can complete DSB-mediated mating-type switching, they could not complete recombination when the ends of the break contained approximately 60 base pairs of nonhomology. Recombination was restored when the ends of the break were made homologous to donor sequences. Additionally, the absence of RAD1 led to the frequent appearance of a previously unobserved type of recombination product. These data suggest RAD1 is required to remove nonhomologous DNA from the 3' ends of recombining DNA, a process analogous to the excision of photodimers during repair of ultraviolet-damaged DNA.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University; Brandeis University				Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020056, R37GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM01722, GM20056] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CONNOLLY B, 1988, MOL CELL BIOL, V8, P2342, DOI 10.1128/MCB.8.6.2342; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; FISHMANLOBELL J, UNPUB; FISHMANLOBELL J, 1992, THESIS BRANDEIS U; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; KLEIN HL, 1988, GENETICS, V120, P367; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; RAY BL, 1991, MOL CELL BIOL, V11, P5372, DOI 10.1128/MCB.11.10.5372; REYNOLDS RJ, 1981, J BACTERIOL, V146, P692, DOI 10.1128/JB.146.2.692-704.1981; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; RUDIN N, 1989, GENETICS, V122, P519; SCHIESTL RH, 1988, MOL CELL BIOL, V8, P3619, DOI 10.1128/MCB.8.9.3619; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P6516; SNOW R, 1968, MUTAT RES, V6, P409, DOI 10.1016/0027-5107(68)90058-4; SOKAL RR, 1969, BIOMETRY, P599; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; THOMAS BJ, 1989, GENETICS, V123, P725; WEIFFENBACH B, 1983, P NATL ACAD SCI-BIOL, V80, P3401, DOI 10.1073/pnas.80.11.3401; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WILCOX DR, 1981, J BACTERIOL, V148, P618, DOI 10.1128/JB.148.2.618-623.1981; ZEHFUS BR, 1990, GENETICS, V126, P41	24	313	323	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					480	484		10.1126/science.1411547	http://dx.doi.org/10.1126/science.1411547			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411547				2022-12-01	WOS:A1992JT77500041
J	FRESKGARD, PO; BERGENHEM, N; JONSSON, BH; SVENSSON, M; CARLSSON, U				FRESKGARD, PO; BERGENHEM, N; JONSSON, BH; SVENSSON, M; CARLSSON, U			ISOMERASE AND CHAPERONE ACTIVITY OF PROLYL ISOMERASE IN THE FOLDING OF CARBONIC-ANHYDRASE	SCIENCE			English	Article							CIS-TRANS ISOMERASE; BINDING; CYCLOPHILIN; AGGREGATION; CATALYSIS; PROTEINS; MODELS; SITE	Several proteins have been discovered that either catalyze slow protein-folding reactions or assist folding in the cell. Prolyl isomerase, which has been shown to accelerate rate-limiting cis-trans peptidyl-proline isomerization steps in the folding pathway, can also participate in the protein-folding process as a chaperone. This function is exerted on an early folding intermediate of carbonic anhydrase, which is thereby prevented from aggregating, whereas the isomerase activity is performed later in the folding process.	LINKOPING UNIV,DEPT CHEM,INST FYS MATTEKN K,S-58183 LINKOPING,SWEDEN; UMEA UNIV,DEPT BIOCHEM,S-90187 UMEA,SWEDEN	Linkoping University; Umea University			Freskgård, Per-Ola/AAY-4194-2021					BERGENHEM N, 1989, INT J PEPT PROT RES, V33, P140; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARLSSON U, 1975, EUR J BIOCHEM, V52, P25, DOI 10.1111/j.1432-1033.1975.tb03969.x; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; DRAKENBERG T, 1972, J PHYS CHEM-US, V76, P2178, DOI 10.1021/j100659a020; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.biochem.60.1.321; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRANSSON C, 1992, FEBS LETT, V296, P90, DOI 10.1016/0014-5793(92)80410-I; FRESKGARD PO, 1991, FEBS LETT, V289, P117, DOI 10.1016/0014-5793(91)80922-P; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P1684, DOI 10.1021/bi00459a003; HENDERSON LE, 1973, ANAL BIOCHEM, V51, P288, DOI 10.1016/0003-2697(73)90477-6; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V9, P11; KALLEN J, 1991, NATURE, V353, P276, DOI 10.1038/353276a0; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; KIEFHABER T, 1990, BIOCHEMISTRY-US, V29, P3061, DOI 10.1021/bi00464a024; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PTITSYN OB, 1991, FEBS LETT, V285, P176, DOI 10.1016/0014-5793(91)80799-9; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; WOLFENDEN R, 1991, CHEMTRACTS BIOCH MOL, V2, P52	26	187	200	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					466	468		10.1126/science.1357751	http://dx.doi.org/10.1126/science.1357751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1357751				2022-12-01	WOS:A1992JT77500036
J	GAVIS, ER; LEHMANN, R				GAVIS, ER; LEHMANN, R			LOCALIZATION OF NANOS RNA CONTROLS EMBRYONIC POLARITY	CELL			English	Article							POSTERIOR DETERMINANT NANOS; SEGMENTATION GENE HUNCHBACK; EARLY DROSOPHILA EMBRYO; MATERNAL MESSENGER-RNA; ABDOMINAL SEGMENTATION; ANTERIOR LOCALIZATION; SEQUENCE SIMILARITY; PATTERN-FORMATION; BICOID PROTEIN; KRUPPEL GENE	Anterior-posterior polarity of the Drosophila embryo is initiated during oogenesis through differential maternal RNA localization. The RNA of the anterior morphogen bicoid is localized to the anterior pole of the embryo, where bicoid protein controls head and thorax development. The RNA of the posterior morphogen nanos is localized to the posterior pole, where nanos protein is required for abdomen formation. Here we show that the nanos 3' untranslated region, like that of the bicoid RNA, is sufficient for RNA localization. We have used the bicoid RNA localization signal to mislocalize nanos, producing embryos with two sources of nanos protein. Such embryos form two abdomens with mirror image symmetry. Embryos with nanos RNA localized only to the anterior have greater nanos gene activity than embryos with nanos RNA localized posteriorly. We propose a role for RNA localization in regulating nanos activity.			GAVIS, ER (corresponding author), MIT, DEPT BIOL, HOWARD HUGHES MED INST, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02139 USA.			Gavis, Elizabeth/0000-0003-0251-0760				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLACKMAN RK, 1986, J MOL BIOL, V188, P499, DOI 10.1016/S0022-2836(86)80001-8; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1987, GENE DEV, V1, P880, DOI 10.1101/gad.1.8.880; FROHNHOIFER HG, 1987, THESIS EBERHARD KARL; GAUL U, 1987, CELL, V51, P549, DOI 10.1016/0092-8674(87)90124-3; GAUL U, 1989, DEVELOPMENT, V107, P651; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KAUFMAN PD, 1989, CELL, V59, P359, DOI 10.1016/0092-8674(89)90297-3; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; LANTZ V, 1992, DEVELOPMENT, V115, P75; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1989, DEVELOPMENT, V107, P21; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; Lindsley D.L., 1992, GENOME DROSOPHILA ME; Lipshitz HD, 1991, CURR OPIN CELL BIOL, V3, P966, DOI 10.1016/0955-0674(91)90115-F; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MISMER D, 1987, GENETICS, V116, P565; MOHLER J, 1986, GENETICS, V112, P803; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; NUSSLEINVOLHARD C, 1977, ROUX ARCH DEV BIOL, V183, P249, DOI 10.1007/BF00867325; PIGNONI F, 1992, DEVELOPMENT, V115, P239; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RAFF JW, 1990, DEVELOPMENT, V110, P1249; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDER K, 1988, NATURE, V335, P68, DOI 10.1038/335068a0; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wieschaus E., 1986, P199; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	66	309	314	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					301	313		10.1016/0092-8674(92)90358-J	http://dx.doi.org/10.1016/0092-8674(92)90358-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423595				2022-12-01	WOS:A1992JU39500015
J	HOWE, LR; LEEVERS, SJ; GOMEZ, N; NAKIELNY, S; COHEN, P; MARSHALL, CJ				HOWE, LR; LEEVERS, SJ; GOMEZ, N; NAKIELNY, S; COHEN, P; MARSHALL, CJ			ACTIVATION OF THE MAP KINASE PATHWAY BY THE PROTEIN-KINASE RAF	CELL			English	Article							C-MYC; ONCOGENE PRODUCT; GROWTH; PHOSPHORYLATION; REQUIREMENT; EXPRESSION; MUTANT; SUBSTRATE; CASCADE; INSULIN	Both MAP kinases and the protein kinase p74raf-1 are activated by many growth factors in a c-ras-dependent manner and by oncogenic p21ras. We were therefore interested in determining the relationship between MAP kinases and raf. The MAP kinase ERK2 is activated by expression of oncogenically activated raf, independently of cellular ras. Overexpressed p74raf-1 potentiates activation of ERK2 by EGF and TPA. MAP kinase kinase inactivated by phosphatase 2A treatment is phosphorylated and reactivated by incubation with p74raf-1 immunoprecipitated from phorbol ester-treated cells. We conclude that raf protein kinase is upstream of MAP kinases and is either a MAP kinase kinase kinase or a MAP kinase kinase kinase kinase.	UNIV DUNDEE,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	HOWE, LR (corresponding author), INST CANC RES,CHESTER BEATTY LABS,LONDON,ENGLAND.		Gomez, Nestor/I-2522-2015	Gomez, Nestor/0000-0002-1348-2737; Howe, Louise/0000-0002-1468-7136				AHN NG, 1991, J BIOL CHEM, V266, P4220; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANCOCK JF, 1988, ONCOGENE, V3, P187; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRIS JDH, 1989, ONCOGENE, V4, P27; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SETH A, 1991, J BIOL CHEM, V266, P23521; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, IN PRESS ONCOGENE; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	44	802	811	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					335	342		10.1016/0092-8674(92)90361-F	http://dx.doi.org/10.1016/0092-8674(92)90361-F			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1330321				2022-12-01	WOS:A1992JU39500018
J	JENKINS, TM; SAXENA, JK; KUMAR, A; WILSON, SH; ACKERMAN, EJ				JENKINS, TM; SAXENA, JK; KUMAR, A; WILSON, SH; ACKERMAN, EJ			DNA POLYMERASE-BETA AND DNA-SYNTHESIS IN XENOPUS OOCYTES AND IN A NUCLEAR EXTRACT	SCIENCE			English	Article							TEMPLATE BINDING DOMAIN; SINGLE-STRANDED-DNA; REPAIR SYNTHESIS; HUMAN-CELLS; ALPHA; REPLICATION; LAEVIS; DELTA; EGGS; IDENTIFICATION	The identities of the DNA polymerases required for conversion of single-strand (ss) M13 DNA to double-strand (ds) M13 DNA were examined both in injected Xenopus laevis oocytes and in an oocyte nuclear extract. Inhibitors and antibodies specific to DNA polymerases alpha and beta were used. In nuclear extracts, inhibition by the antibody to polymerase beta could be reversed by purified polymerase beta. The polymerase beta inhibitors, dideoxythymidine triphosphate (ddTTP) and dideoxycytidine triphosphate (ddCTP), also blocked DNA synthesis and indicated that polymerase beta is invoLved in the conversion of ssDNA to dsDNA. These results also may have particular significance for emerging evidence of an ssDNA replication mode in eukaryotic cells.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				BJURSELL G, 1979, NATURE, V280, P420, DOI 10.1038/280420a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUZIO LO, 1981, MOL APPROACHES GENE, P149; Colman A., 1984, TRANSCRIPTION TRANSL, P49; CORTESE R, 1980, P NATL ACAD SCI-BIOL, V77, P4147, DOI 10.1073/pnas.77.7.4147; COX LS, 1990, J CELL SCI, V97, P177; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FORD CC, 1975, DEV BIOL, V43, P189, DOI 10.1016/0012-1606(75)90140-2; FRY M, 1986, ANIMAL CELL DNA POLY, P103; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; JENKINS TC, UNPUB; JOENJE H, 1978, J BIOL CHEM, V253, P2640; KAISERMAN HB, 1990, EUKARYOTIC NUCLEUS M, V2, P783; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGERSKI RJ, 1987, MOL CELL BIOL, V7, P4317, DOI 10.1128/MCB.7.12.4317; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; MECHALI M, 1982, CELL, V30, P93, DOI 10.1016/0092-8674(82)90015-0; NELSON EM, 1983, DEV BIOL, V96, P11, DOI 10.1016/0012-1606(83)90306-8; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SWACK JA, 1985, ANAL BIOCHEM, V147, P10, DOI 10.1016/0003-2697(85)90003-X; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERVLIET PC, 1990, EUKARYOTIC NUCLEUS, V1, P1; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; WANG TSF, 1990, EUKARYOTIC NUCLEUS M, V1, P147; WEISER T, 1991, J BIOL CHEM, V266, P10420; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; WIST E, 1979, BIOCHIM BIOPHYS ACTA, V562, P62, DOI 10.1016/0005-2787(79)90126-6	39	52	53	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					475	478		10.1126/science.1411545	http://dx.doi.org/10.1126/science.1411545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411545				2022-12-01	WOS:A1992JT77500039
J	KUO, CF; MCREE, DE; FISHER, CL; OHANDLEY, SF; CUNNINGHAM, RP; TAINER, JA				KUO, CF; MCREE, DE; FISHER, CL; OHANDLEY, SF; CUNNINGHAM, RP; TAINER, JA			ATOMIC-STRUCTURE OF THE DNA-REPAIR [4FE-4S] ENZYME ENDONUCLEASE-III	SCIENCE			English	Article							ALDEHYDIC ABASIC SITES; ESCHERICHIA-COLI; MACROMOLECULAR CRYSTALLOGRAPHY; ELECTROSTATIC POTENTIALS; CRYSTAL-STRUCTURE; OXIDATIVE DAMAGE; APURINIC SITES; PROTEIN; BINDING; RESOLUTION	The crystal structure of the DNA repair enzyme endonuclease III, which recognizes and cleaves DNA at damaged bases, has been solved to 2.0 angstrom resolution with an R factor of 0.185. This iron-sulfur [4Fe-4S] enzyme is elongated and bilobal with a deep cleft separating two similarly sized domains: a novel, sequence-continuous, six-helix domain (residues 22 to 132) and a Greek-key, four-helix domain formed by the amino-terminal and three carboxyl-terminal helices (residues 1 to 21 and 133 to 211) together with the [4Fe-4S] cluster. The cluster is bound entirely within the carboxyl-terminal loop with a ligation pattern (Cys-X6-Cys-X2-Cys-X5-Cys) distinct from all other known [4Fe-4S] proteins. Sequence conservation and the positive electrostatic potential of conserved regions identify a surface suitable for binding duplex B-DNA across the long axis of the enzyme, matching a 46 angstrom length of protected DNA. The primary role of the [4Fe-4S] cluster appears to involve positioning conserved basic residues for interaction with the DNA phosphate backbone. The crystallographically identified inhibitor binding region, which recognizes the damaged base thymine glycol, is a seven-residue beta-hairpin (residues 113 to 119). Location and side chain orientation at the base of the inhibitor binding site implicate Glu112 in the N-glycosylase mechanism and Lys120 in the beta-elimination mechanism. Overall, the structure reveals an unusual fold and a new biological function for [4Fe-4S]clusters and provides a structural basis for studying recognition of damaged DNA and the N-glycosylase and apurinic/apyrimidinic-lyase mechanisms.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SUNY ALBANY, DEPT BIOL SCI, CTR BIOCHEM & BIOPHYS, ALBANY, NY 12222 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; O'Handley, Suzanne/0000-0001-8373-0065	NHLBI NIH HHS [HL07695] Funding Source: Medline; NIGMS NIH HHS [GM 46312] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AHERN H, 1991, ASM NEWS, V57, P627; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; [Anonymous], 1985, DNA REPAIR; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; AUGUSTINE ML, 1991, BIOCHEMISTRY-US, V30, P8052, DOI 10.1021/bi00246a025; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BICKELHAUPT FM, 1990, INORG CHEM, V29, P350, DOI 10.1021/ic00327a039; BOERRIGTER PM, 1988, INT J QUANTUM CHEM, V33, P87, DOI 10.1002/qua.560330204; BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMMACK R, 1991, ADV INORG CHEM, V38, P1; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chen J., UNPUB; CHIRLIAN LE, 1987, J COMPUT CHEM, V8, P894, DOI 10.1002/jcc.540080616; CHOTHIA C, 1990, ANNU REV BIOCHEM, V59, P1007, DOI 10.1146/annurev.bi.59.070190.005043; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DAVIS ME, 1990, CHEM REV, V90, P509, DOI 10.1021/cr00101a005; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DOETSCH PW, 1987, MOL CELL BIOL, V7, P26, DOI 10.1128/MCB.7.1.26; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FU WG, 1992, J BIOL CHEM, V267, P16135; GOSSETT J, 1988, BIOCHEMISTRY-US, V27, P2629, DOI 10.1021/bi00407a054; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HELLAND DE, 1986, MOL CELL BIOL, V6, P1983, DOI 10.1128/MCB.6.6.1983; HENDERSON R, 1990, J MOL BIOL, V213, P899, DOI 10.1016/S0022-2836(05)80271-2; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JORGENSEN TJ, 1987, BIOCHEMISTRY-US, V26, P6436, DOI 10.1021/bi00394a021; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KUO CF, 1992, J MOL BIOL, V227, P347, DOI 10.1016/0022-2836(92)90703-M; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Lindahl T, 1979, Prog Nucleic Acid Res Mol Biol, V22, P135; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; MANNING GS, 1983, BIOPOLYMERS, V22, P689, DOI 10.1002/bip.360220211; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; OHANDLEY S, UNPUB; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PASCARELLA S, 1992, PROTEIN ENG, V5, P121, DOI 10.1093/protein/5.2.121; RAVENEK W, 1989, SCI COMPUTING SUPERC, P201; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RICHARDSON JS, 1988, PROTEINS, V4, P229, DOI 10.1002/prot.340040402; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHARDSON JS, 1990, PREDICTION PROTEIN S, P2; SCHWARTZ A, 1989, J MOL BIOL, V207, P445, DOI 10.1016/0022-2836(89)90266-0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; SWITZER R L, 1989, Biofactors, V2, P77; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WILLIAMS TV, 1982, THESIS U N CAROLINA; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017	67	283	286	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					434	440		10.1126/science.1411536	http://dx.doi.org/10.1126/science.1411536			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411536				2022-12-01	WOS:A1992JT77500027
J	LEUNGHAGESTEIJN, CY; SPENCE, AM; STERN, BD; ZHOU, YW; SU, MW; HEDGECOCK, EM; CULOTTI, JG				LEUNGHAGESTEIJN, CY; SPENCE, AM; STERN, BD; ZHOU, YW; SU, MW; HEDGECOCK, EM; CULOTTI, JG			UNC-5, A TRANSMEMBRANE PROTEIN WITH IMMUNOGLOBULIN AND THROMBOSPONDIN TYPE-1 DOMAINS, GUIDES CELL AND PIONEER AXON MIGRATIONS IN C-ELEGANS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GROWTH CONES; CIRCUMSPOROZOITE PROTEIN; NEURITE OUTGROWTH; MEMBRANE-PROTEINS; ATTACHMENT SITE; PHOSPHOLIPASE-C; M2 PROTEIN; GENE; SEQUENCE	The unc-5 gene is required for guiding pioneering axons and migrating cells along the body wall in C. elegans. In mutants, dorsal migrations are disrupted, but ventral and longitudinal movements are largely unaffected. The gene was tagged for molecular cloning by transposon insertions. Based on genomic and cDNA sequencing, the gene encodes UNC-5, a transmembrane protein of 919 aa. The predicted extracellular N-terminus comprises two immunoglobulin and two thrombospondin type 1 domains. Except for an SH3-like motif, the large intracellular C-terminus is novel. Mosaic analysis shows that unc-5 acts in migrating cells and pioneering neurons. We propose that UNC-5 is a transmembrane receptor expressed on the surface of motile cells and growth cones to guide dorsal movements.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND; ROCHE INST MOLEC BIOL, DEPT CELL & DEV BIOL, NUTLEY, NJ 07110 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ONTARIO, CANADA	MRC Laboratory Molecular Biology; Johns Hopkins University; University of Toronto	LEUNGHAGESTEIJN, CY (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC IMMUNOL & NEUROBIOL, TORONTO M5G 1X5, ONTARIO, CANADA.		Culotti, Joseph/G-6467-2013	Culotti, Joseph/0000-0001-6325-4612	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026295, R01NS026295] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; Bray D., 1992, CELL MOVEMENTS; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; CONRAD R, 1991, MOL CELL BIOL, V11, P1921, DOI 10.1128/MCB.11.4.1921; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GOLDBERG DJ, 1989, TRENDS NEUROSCI, V12, P503, DOI 10.1016/0166-2236(89)90110-0; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HERMAN RK, 1989, NEUROGENETICS, V5, P1; HOLT GD, 1990, J BIOL CHEM, V265, P2852; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; ISHII N, UNPUB LAMININ RELATE; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Maniatis T., 1982, MOL CLONING; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; MORI I, 1988, GENETICS, V120, P397; NAEVE CW, 1990, EMBO J, V9, P3857, DOI 10.1002/j.1460-2075.1990.tb07604.x; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; OSHEA KS, 1990, J CELL BIOL, V110, P1275, DOI 10.1083/jcb.110.4.1275; OSHEA KS, 1991, NEURON, V7, P231, DOI 10.1016/0896-6273(91)90261-W; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Rathjen FG, 1991, CURR OPIN CELL BIOL, V3, P992, DOI 10.1016/0955-0674(91)90119-J; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; RUAN KS, 1984, P NATL ACAD SCI-BIOL, V81, P4018, DOI 10.1073/pnas.81.13.4018; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGRUE RJ, 1990, VIROLOGY, V179, P51, DOI 10.1016/0042-6822(90)90272-S; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	78	347	366	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					289	299		10.1016/0092-8674(92)90357-I	http://dx.doi.org/10.1016/0092-8674(92)90357-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1384987				2022-12-01	WOS:A1992JU39500014
J	LUO, Y; FUJII, H; GERSTER, T; ROEDER, RG				LUO, Y; FUJII, H; GERSTER, T; ROEDER, RG			A NOVEL B-CELL DERIVED COACTIVATOR POTENTIATES THE ACTIVATION OF IMMUNOGLOBULIN PROMOTERS BY OCTAMER-BINDING TRANSCRIPTION FACTORS	CELL			English	Article							HEAVY-CHAIN PROMOTER; POU-DOMAIN; GENE-TRANSCRIPTION; PROTEIN-BINDING; HELA-CELLS; EXPRESSION; OCT-1; DNA; ELEMENTS; INVITRO	A novel B cell-restricted activity, required for high levels of octamer/Oct-dependent transcription from an immunoglobulin heavy chain (IgH) promoter, was detected in an in vitro system consisting of HeLa cell-derived extracts complemented with fractionated B cell nuclear proteins. The factor responsible for this activity was designated Oct coactivator from B cells (OCA-B). OCA-B stimulates the transcription from an IgH promoter in conjunction with either Oct-1 or Oct-2 but shows no significant effect on the octamer/Oct-dependent transcription of the ubiquitously expressed histone H2B promoter and the transcription of USF- and Sp1-regulated promoters. Taken together, our results suggest that OCA-B is a tissue-, promoter-, and factor-specific coactivator and that OCA-B may be a major determinant for B cell-specific activation of immunoglobulin promoters. In light of the evidence showing physical and functional interactions between Oct factors and OCA-B, we propose a mechanism of action for OCA-B and discuss the implications of OCA-B for the transcriptional regulation of other tissue-specific promoters.			LUO, Y (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.							COCKERILL PN, 1990, MOL CELL BIOL, V10, P1293, DOI 10.1128/MCB.10.3.1293; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUS M, 1987, EMBO J, V6, P1685, DOI 10.1002/j.1460-2075.1987.tb02418.x; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JOHNSON DG, 1990, MOL CELL BIOL, V10, P982, DOI 10.1128/MCB.10.3.982; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LUO Y, 1991, MOL CELL BIOL, V11, P3660, DOI 10.1128/MCB.11.7.3660; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MIZUSHIMASUGANO J, 1986, P NATL ACAD SCI USA, V83, P8511, DOI 10.1073/pnas.83.22.8511; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MULLERIMMERGLUCK MM, 1990, EMBO J, V9, P1625, DOI 10.1002/j.1460-2075.1990.tb08282.x; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844	49	247	251	1	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					231	241		10.1016/0092-8674(92)90352-D	http://dx.doi.org/10.1016/0092-8674(92)90352-D			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423591				2022-12-01	WOS:A1992JU39500009
J	MATSUSHIME, H; EWEN, ME; STROM, DK; KATO, JY; HANKS, SK; ROUSSEL, MF; SHERR, CJ				MATSUSHIME, H; EWEN, ME; STROM, DK; KATO, JY; HANKS, SK; ROUSSEL, MF; SHERR, CJ			IDENTIFICATION AND PROPERTIES OF AN ATYPICAL CATALYTIC SUBUNIT (P34(PSK-J3)/CDK4) FOR MAMMALIAN-D TYPE-G1 CYCLINS	CELL			English	Article							STIMULATING FACTOR-I; RETINOBLASTOMA SUSCEPTIBILITY GENE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; G1 CYCLINS; M-PHASE; YEAST; EXPRESSION; FAMILY	Murine D type cyclins associate with a catalytic subunit (p34PSK-J3 with properties distinct from known cyclin-dependent kinases (cdks). Mouse p34PSK-J3 shows less than 50% amino acid identity to p34cdc2, p33cdk2, and p36cdk3, lacks a PSTAIRE motif, and does not bind to p13suc1. Cyclin D1-p34PSK-J3 complexes accumulate in macrophages during G1 and decline in S phase, whereas complexes involving cyclins D2 and D3 form in proliferating T cells. Although histone H1 kinase activity is not detected in cyclin D or PSK-J3 immunoprecipitates, cyclin D-p34PSK-J3 complexes assembled in vitro stably bind and phosphorylate the retinoblastoma gene product (pRb) and an Rb-like protein (p107) but do not interact with pRb mutants that are functionally inactive. Thus, p34PSK-J3 is a cyclin D-regulated catalytic subunit that acts as an Rb (but not H1) kinase.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, SCH MED, NASHVILLE, TN 37232 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Vanderbilt University	MATSUSHIME, H (corresponding author), ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA.		Roussel, Martine F/F-1469-2016; Sherr, Charles J/N-8074-2018	Roussel, Martine F/0000-0002-1740-8139; Sherr, Charles J/0000-0002-5516-6206	NATIONAL CANCER INSTITUTE [P30CA021765, R35CA047064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038793] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA47064, P01-CA21765] Funding Source: Medline; NIGMS NIH HHS [R29-GM38793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1992, IN PRESS ONCOGENE; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Summers M.D., 1987, B TEXAS AGR EXPT STA, V1555; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	61	911	941	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					323	334		10.1016/0092-8674(92)90360-O	http://dx.doi.org/10.1016/0092-8674(92)90360-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423597				2022-12-01	WOS:A1992JU39500017
J	MERBS, SL; NATHANS, J				MERBS, SL; NATHANS, J			ABSORPTION-SPECTRA OF THE HYBRID PIGMENTS RESPONSIBLE FOR ANOMALOUS COLOR-VISION	SCIENCE			English	Article							MOLECULAR-GENETICS; GENES; GREEN; BLUE; XQ28	Unequal homologous recombination events between green and red cone pigment genes produce the red-green or green-red hybrid pigment genes found in many individuals with variant color vision. Photobleaching difference absorption spectroscopy of hybrid pigments produced in cultured cells shows that the spectral sensitivity of each hybrid pigment is intermediate between the parental green and red pigment sensitivities. Amino acids encoded by exons 2, 3, 4, and 5 produce spectral shifts at the wavelength of maximal absorbance of 0 to 4, 0 to 4, 3 to 4, and 15 to 21 nanometers, respectively, the exact value depending on the identities ot amino acids elsewhere in the hybrid.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	MERBS, SL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Nathans, Jeremy/0000-0001-8106-5460				ALPERN M, 1979, J PHYSIOL-LONDON, V288, P85; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P613, DOI 10.1113/jphysiol.1977.sp011785; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P595, DOI 10.1113/jphysiol.1977.sp011784; ALPERN M, 1977, J PHYSIOL-LONDON, V266, P647, DOI 10.1113/jphysiol.1977.sp011786; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; CHAN T, 1992, J BIOL CHEM, V267, P9478; Dartnall H.J.A., 1983, COLOUR VISION PHYSL, P69; DEEB SS, IN PRESS AM J HUM GE; FEIL R, 1990, GENOMICS, V6, P367, DOI 10.1016/0888-7543(90)90578-I; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0; MERBS SL, UNPUB; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NEITZ J, 1989, NATURE, V342, P679, DOI 10.1038/342679a0; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; PIANTANIDA TP, 1973, VISION RES, V13, P2049, DOI 10.1016/0042-6989(73)90181-8; PIANTANIDA TP, 1973, VISION RES, V13, P2033, DOI 10.1016/0042-6989(73)90180-6; POKORNY J., 1979, CONGENITAL ACQUIRED; RUSHTON W A H, 1972, Journal of Physiology (Cambridge), V220, P1; RUSHTON WAH, 1973, VISION RES, V13, P2017, DOI 10.1016/0042-6989(73)90179-X; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827; WILLIAMS AJ, 1992, EMBO J, V11, P2039, DOI 10.1002/j.1460-2075.1992.tb05261.x; WINDERICKX J, 1992, NATURE, V356, P431, DOI 10.1038/356431a0	27	148	151	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					464	466		10.1126/science.1411542	http://dx.doi.org/10.1126/science.1411542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411542				2022-12-01	WOS:A1992JT77500035
J	NADLER, SG; TEPPER, MA; SCHACTER, B; MAZZUCCO, CE				NADLER, SG; TEPPER, MA; SCHACTER, B; MAZZUCCO, CE			INTERACTION OF THE IMMUNOSUPPRESSANT DEOXYSPERGUALIN WITH A MEMBER OF THE HSP70 FAMILY OF HEAT-SHOCK PROTEINS	SCIENCE			English	Article							CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CYCLOSPORIN-A; 15-DEOXYSPERGUALIN; CYCLOPHILIN; RECEPTOR; INVITRO; CELLS; LYMPHOCYTES; EXPRESSION	Deoxyspergualin (DSG) is a potent immunosuppressant whose mechanism of action remains unknown. To elucidate its mechanism of action, an intracellular DSG binding protein was identified. DSG has now been shown to bind specifically to Hsc70, the constitutive or cognate member of the heat shock protein 70 (Hsp70) protein family. The members of the Hsp70 family of heat shock proteins are important for many cellular processes, including immune responses, and this finding suggests that heat shock proteins may represent a class of immunosuppressant binding proteins, or immunophilins, distinct from the previously identified cis-trans proline isomerases. DSG may provide a tool for understanding the function of heat shock proteins in immunological processes.	BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,WALLINGFORD,CT 06492	Bristol-Myers Squibb								BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; DICKNEITE G, 1987, INT J IMMUNOPHARMACO, V9, P559, DOI 10.1016/0192-0561(87)90123-8; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FUJII H, 1989, J ANTIBIOT, V42, P788, DOI 10.7164/antibiotics.42.788; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HANSEN LK, 1991, EXP CELL RES, V192, P587, DOI 10.1016/0014-4827(91)90080-E; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; ISHIBASHI M, 1989, TRANSPLANT P, V21, P1854; JIANG H, 1990, TRANSPLANT P, V22, P1633; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MAEDA K, 1992, 3RD INT C DRUG RES I; NEMOTO K, 1987, J ANTIBIOT, V40, P561, DOI 10.7164/antibiotics.40.561; NISHIMURA K, 1989, IMMUNOLOGY, V68, P66; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TAKAHARA S, 1992, TRANSPLANTATION, V53, P914, DOI 10.1097/00007890-199204000-00037; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TAKEUCHI T, 1981, J ANTIBIOT, V34, P1619, DOI 10.7164/antibiotics.34.1619; TEPPER MA, 1991, TRANSPLANT P, V23, P328; VANBUSKIRK A, 1989, J EXP MED, V170, P1799, DOI 10.1084/jem.170.6.1799; VANBUSKIRK AM, 1991, J IMMUNOL, V146, P500; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; YEM AW, 1992, J BIOL CHEM, V267, P2868	34	218	223	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					484	486		10.1126/science.1411548	http://dx.doi.org/10.1126/science.1411548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411548				2022-12-01	WOS:A1992JT77500042
J	NEVINS, JR				NEVINS, JR			E2F - A LINK BETWEEN THE RB TUMOR SUPPRESSOR PROTEIN AND VIRAL ONCOPROTEINS	SCIENCE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; CELLULAR TRANSCRIPTION FACTOR; DNA-BINDING ACTIVITY; HUMAN MYC PROMOTER; HUMAN CYCLIN-A; TRANS-ACTIVATION; CARCINOMA-CELLS; INFECTED CELLS; T-ANTIGEN	The cellular transcription factor E2F, previously identified as a component of early adenovirus transcription, has now been shown to be important in cell proliferation control. E2F appears to be a functional target for the action of the tumor suppressor protein Rb that is encoded by the retinoblastoma susceptibility gene. The disruption of this E2F-Rb interaction, as well as a complex involving E2F in association with the cell cycle-regulated cyclin A-cdk2 kinase complex, may be a common mechanism of action for the oncoproteins encoded by the DNA tumor viruses.			NEVINS, JR (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, GENET SECT, DURHAM, NC 27710 USA.							BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; COBRINIK D, COMMUNICATION; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DULBECCO R, 1965, P NATL ACAD SCI USA, V53, P403, DOI 10.1073/pnas.53.2.403; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREARSON PM, 1965, CANCER RES, V25, P737; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GIORDANO A, 1991, ONCOGENE, V6, P481; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT S, UNPUB; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KIT S, 1965, VIROLOGY, V27, P453, DOI 10.1016/0042-6822(65)90133-9; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRAUS VB, IN PRESS MOL CELL BI; KRAUS VB, UNPUB; LEDINKO N, 1967, CANCER RES, V27, P1459; LEES E, IN PRESS GENES DEV; LEES JA, UNPUB; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; Nevins J R, 1990, Semin Cancer Biol, V1, P59; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHWARZ JH, UNPUB; SHENK T, 1991, ADV CANCER RES, V57, P47; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TAKAHASH.M, 1966, P SOC EXP BIOL MED, V122, P740; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TOOZE J, 1984, DNA TUMOR VIRUSES; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YODER SS, 1983, MOL CELL BIOL, V3, P819, DOI 10.1128/MCB.3.5.819; ZIMMERMAN JE, 1970, VIROLOGY, V42, P1147, DOI 10.1016/0042-6822(70)90365-X	100	1540	1586	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					424	429						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411535				2022-12-01	WOS:A1992JT77500025
J	OWENHUGHES, TA; PAVITT, GD; SANTOS, DS; SIDEBOTHAM, JM; HULTON, CSJ; HINTON, JCD; HIGGINS, CF				OWENHUGHES, TA; PAVITT, GD; SANTOS, DS; SIDEBOTHAM, JM; HULTON, CSJ; HINTON, JCD; HIGGINS, CF			THE CHROMATIN-ASSOCIATED PROTEIN H-NS INTERACTS WITH CURVED DNA TO INFLUENCE DNA TOPOLOGY AND GENE-EXPRESSION	CELL			English	Article							HISTONE-LIKE PROTEINS; OSMOREGULATED PROU PROMOTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; OSMOTIC REGULATION; BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; PROLINE TRANSPORT; GLYCINE BETAINE; RNA-POLYMERASE	H-NS is an abundant structural component of bacterial chromatin and influences many cellular processes, including recombination, transposition, and transcription. We have studied the mechanism of action of H-NS at the osmotically regulated proU promoter. The interaction of H-NS with a curved DNA element located downstream of the proU promoter is required for normal regulation of expression. Heterologous curved sequences can replace the regulatory role of the proU curve. Hence, the luxAB and lacZ reporter genes, which differ in the presence or absence of a curve, can indicate very different patterns of transcription. H-NS interacts preferentially with these curved DNA elements in vitro. Furthermore, in vivo the interaction of H-NS with curved DNA participates in the control of plasmid linking number. The data suggest that H-NS-dependent changes in DNA topology play a role in the osmoregulation of proU expression.			OWENHUGHES, TA (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND.		Hinton, Jay/AAZ-1253-2021; Pavitt, Graham D/A-1363-2010; Santos, Diógenes/A-6647-2008; Hinton, Jay C. D./B-2142-2008	Hinton, Jay/0000-0003-2671-6026; Pavitt, Graham D/0000-0002-8593-2418; Santos, Diógenes/0000-0003-4971-463X; Hinton, Jay C. D./0000-0003-2671-6026; Owen-Hughes, Tom/0000-0002-0618-8185				BALBAS P, 1986, GENE, V50, P3, DOI 10.1016/0378-1119(86)90307-0; BHRIAIN NN, 1989, MOL MICROBIOL, V3, P933, DOI 10.1111/j.1365-2958.1989.tb00243.x; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CALLADINE CR, 1991, J MOL BIOL, V221, P981, DOI 10.1016/0022-2836(91)80187-Y; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DATTANANDA CS, 1991, J BACTERIOL, V173, P7481, DOI 10.1128/jb.173.23.7481-7490.1991; DAYN A, 1991, J BACTERIOL, V173, P2658, DOI 10.1128/jb.173.8.2658-2664.1991; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DORMAN CJ, 1990, NATURE, V344, P789, DOI 10.1038/344789a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DRUGERLIOTTA J, 1986, J BACTERIOL, V169, P2449; DUNLAP VJ, 1985, J BACTERIOL, V163, P296, DOI 10.1128/JB.163.1.296-304.1985; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FALCONI M, 1988, MOL MICROBIOL, V2, P323, DOI 10.1111/j.1365-2958.1988.tb00035.x; FALCONI M, 1991, NEW BIOL, V3, P615; FIGUEROA N, 1991, EMBO J, V10, P941, DOI 10.1002/j.1460-2075.1991.tb08028.x; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P777, DOI 10.1093/nar/16.2.777; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; GOWRISHANKAR J, 1985, J BACTERIOL, V164, P434, DOI 10.1128/JB.164.1.434-445.1985; GUALERZI CO, 1986, BACTERIAL CHROMATIN, P101; HIGGINS CF, 1990, MOL MICROBIOL, V4, P2007, DOI 10.1111/j.1365-2958.1990.tb00559.x; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HINTON JCD, 1992, MOL MICROBIOL, V6, P2327, DOI 10.1111/j.1365-2958.1992.tb01408.x; HSIEH LS, 1991, J BACTERIOL, V173, P3914, DOI 10.1128/JB.173.12.3914-3917.1991; HULTON CSJ, 1990, CELL, V63, P631, DOI 10.1016/0092-8674(90)90458-Q; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LEJEUNE P, 1990, P NATL ACAD SCI USA, V87, P360, DOI 10.1073/pnas.87.1.360; LUCHT JM, 1991, J BACTERIOL, V173, P801, DOI 10.1128/jb.173.2.801-809.1991; MAY G, 1990, MOL GEN GENET, V224, P81, DOI 10.1007/BF00259454; MAY G, 1986, MOL GEN GENET, V205, P225, DOI 10.1007/BF00430432; MAY G, 1989, MOL MICROBIOL, V3, P1521, DOI 10.1111/j.1365-2958.1989.tb00138.x; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Miller JH., 1972, EXPT MOL GENETICS; OVERDIER DG, 1989, J BACTERIOL, V171, P4694, DOI 10.1128/jb.171.9.4694-4706.1989; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; PARK SF, 1989, MOL MICROBIOL, V3, P1011, DOI 10.1111/j.1365-2958.1989.tb00252.x; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; RIMSKY S, 1990, BIOCHEMISTRY-US, V29, P3765, DOI 10.1021/bi00467a024; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; STIRLING DA, 1989, MOL MICROBIOL, V3, P1025, DOI 10.1111/j.1365-2958.1989.tb00253.x; SUTHERLAND L, 1986, J BACTERIOL, V168, P805, DOI 10.1128/jb.168.2.805-814.1986; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA K, 1991, MOL GEN GENET, V226, P367, DOI 10.1007/BF00260648; TRAVERS A, 1987, NATURE, V327, P280, DOI 10.1038/327280a0; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; Travers AA, 1991, CURR OPIN STRUC BIOL, V1, P114, DOI 10.1016/0959-440X(91)90019-P; WEREL W, 1991, EMBO J, V10, P2589, DOI 10.1002/j.1460-2075.1991.tb07800.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YAMADA H, 1990, J BIOCHEM-TOKYO, V108, P420, DOI 10.1093/oxfordjournals.jbchem.a123216; ZASLOFF M, 1978, NUCLEIC ACIDS RES, V5, P1139, DOI 10.1093/nar/5.4.1139; ZINKEL SS, 1991, J MOL BIOL, V219, P201, DOI 10.1016/0022-2836(91)90562-K; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	62	265	273	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					255	265		10.1016/0092-8674(92)90354-F	http://dx.doi.org/10.1016/0092-8674(92)90354-F			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423593				2022-12-01	WOS:A1992JU39500011
J	PLUMP, AS; SMITH, JD; HAYEK, T; AALTOSETALA, K; WALSH, A; VERSTUYFT, JG; RUBIN, EM; BRESLOW, JL				PLUMP, AS; SMITH, JD; HAYEK, T; AALTOSETALA, K; WALSH, A; VERSTUYFT, JG; RUBIN, EM; BRESLOW, JL			SEVERE HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS IN APOLIPOPROTEIN-E-DEFICIENT MICE CREATED BY HOMOLOGOUS RECOMBINATION IN ES CELLS	CELL			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; III HYPERLIPOPROTEINEMIA; E POLYMORPHISM; MESSENGER-RNA; STOP CODON; RAT-LIVER; A-I; MOUSE; GENE	apoE-deficient mice have been created by homologous recombination in ES cells. On a low fat, low cholesterol chow diet these animals have plasma cholesterol levels of 494 mg/dl compared with 60 mg/dl in control animals, and when challenged with a high fat Western-type diet, these animals have plasma cholesterol levels of 1821 mg/dl compared with 132 mg/dl in controls. This marked hypercholesterolemia is primarily due to elevated levels of very low and intermediate density lipoproteins. At 10 weeks of age, apoE-deficient mice have already developed atherosclerotic lesions in the aorta and coronary and pulmonary arteries. apoE-deficient mice are a promising small animal model to help understand the role of apoE in vivo and the genetic and environmental determinants of atherosclerosis.	LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	PLUMP, AS (corresponding author), ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA.		Breslow, Jan L/B-7544-2008; Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X	NHLBI NIH HHS [HL-33714, HL-32435] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033714, R01HL032435] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbey M., 1992, CURR OPIN LIPIDOL, V3, P12, DOI [10.1097/00041433-199202000-00003, DOI 10.1097/00041433-199202000-00003]; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HIXSON JE, 1991, ARTERIOSCLER THROMB, V11, P1237, DOI 10.1161/01.ATV.11.5.1237; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HORIUCHI K, 1989, J BIOCHEM-TOKYO, V106, P98, DOI 10.1093/oxfordjournals.jbchem.a122828; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; KATES M, 1966, BIOCHEMISTRY-US, V5, P4092, DOI 10.1021/bi00876a044; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SMITH JD, 1990, J BIOL CHEM, V265, P14709; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UTERMANN G, 1982, HUM GENET, V60, P344, DOI 10.1007/BF00569216; WALSH A, 1989, J BIOL CHEM, V264, P6488; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059; ZANNIS VI, 1982, J LIPID RES, V23, P911; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0; 1987, NATIONAL HLTH NUTRIT	43	1869	1994	1	127	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1992	71	2					343	353		10.1016/0092-8674(92)90362-G	http://dx.doi.org/10.1016/0092-8674(92)90362-G			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423598				2022-12-01	WOS:A1992JU39500019
J	RICE, NR; MACKICHAN, ML; ISRAEL, A				RICE, NR; MACKICHAN, ML; ISRAEL, A			THE PRECURSOR OF NF-KAPPA-B P50 HAS I-KAPPA-B-LIKE FUNCTIONS	CELL			English	Article							REL ONCOGENE PRODUCT; DNA-BINDING SUBUNIT; TRANSFORMED LYMPHOID-CELLS; V-REL; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTION FACTORS; CELLULAR PROTEINS; PHORBOL ESTER; 65-KD SUBUNIT; INHIBITION	The C-terminal half of the p105 precursor of the NF-kappaB p50 subunit contains ankyrin-like repeats similar to those in IkappaB molecules, which are known to retain NF-kappaB complexes in the cytoplasm. We demonstrate that in various cell lines p105 is found associated with either c-rel or p65 in the cytoplasm and serves IkappaB-like functions. p105 retains c-rel or p65 in the cytoplasm in cotransfection experiments in COS cells. It also inhibits DNA binding by c-rel in gel retardation assays. Stable interaction of p105 with c-rel or p65 requires the putative dimerization domain in the conserved rel homology region of p105, as well as a second contact with the IkappaB-related C-terminal part of p105. Pulse-chase experiments indicate that cytoplasmic complexes of p105 with c-rel or p65 give rise to cytoplasmic as well as nuclear p50-c-rel and p50-p65, respectively, probably through processing of p105. Thus, p105, like the IkappaBs, controls the subcellular localization and hence the transcriptional activity of at least two other members of the rel/NF-kappaB family.	STANFORD UNIV,PROGRAM CANC BIOL,STANFORD,CA 94305; INST PASTEUR,UNITE BIOL MOLEC EXPRESS GENIQUE,F-75724 PARIS 15,FRANCE	Stanford University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	RICE, NR (corresponding author), FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MOLEC VIROL & CARCINOGENESIS LAB,FREDERICK,MD 21702, USA.				NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, 5T32 CA 09302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BECKWITH M, 1990, J NATL CANCER I, V82, P501, DOI 10.1093/jnci/82.6.501; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DAVIS N, 1990, ONCOGENE, V5, P1105; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOCHEL T, 1991, ONCOGENE, V6, P615; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RICHARDSON PM, 1991, NATURE, V350, P625; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	39	419	423	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					243	253		10.1016/0092-8674(92)90353-E	http://dx.doi.org/10.1016/0092-8674(92)90353-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423592				2022-12-01	WOS:A1992JU39500010
J	RUTZ, JM; LIU, J; LYONS, JA; GORANSON, J; ARMSTRONG, SK; MCINTOSH, MA; FEIX, JB; KLEBBA, PE				RUTZ, JM; LIU, J; LYONS, JA; GORANSON, J; ARMSTRONG, SK; MCINTOSH, MA; FEIX, JB; KLEBBA, PE			FORMATION OF A GATED CHANNEL BY A LIGAND-SPECIFIC TRANSPORT PROTEIN IN THE BACTERIAL OUTER-MEMBRANE	SCIENCE			English	Article							ESCHERICHIA-COLI K-12; FERRIC ENTEROBACTIN RECEPTOR; AFFECT VITAMIN-B12 TRANSPORT; REGION TONB BOX; SALMONELLA-TYPHIMURIUM; POINT MUTATIONS; PORIN CHANNELS; IRON TRANSPORT; ENTEROCHELIN; NUCLEOTIDE	The ferric enterobactin receptor (FepA) is a high-affinity ligand-specific transport protein in the outer membrane of Gram-negative bacteria. Deletion of the cell-surface ligand-binding peptides of FepA generated mutant proteins that were incapable of high-affinity uptake but that instead formed nonspecific, passive channels in the outer membrane. Unlike native FepA, these pores acted independently of the accessory protein TonB, which suggests that FepA is a gated porin and that TonB acts as its gatekeeper by facilitating the entry of ligands into the FepA channel. The sequence homology among TonB-dependent proteins suggests that all ligand-specific outer membrane receptors may function by this gated-porin mechanism.	MED COLL WISCONSIN,DEPT MICROBIOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOPHYS,MILWAUKEE,WI 53226; E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858; UNIV MISSOURI,SCH MED,DEPT MOLEC MICROBIOL & IMMUNOL,COLUMBIA,MO 65212	Medical College of Wisconsin; Medical College of Wisconsin; University of North Carolina; East Carolina University; University of Missouri System; University of Missouri Columbia			Liu, Jun/AAC-9209-2019	Liu, Jun/0000-0002-0522-6733	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022608] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022923, R01GM022923, R01GM040565] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22608] Funding Source: Medline; NIGMS NIH HHS [GM22923, GM40565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG SK, 1990, J BIOL CHEM, V265, P14536; BAUMLER AJ, 1992, MOL MICROBIOL, V6, P1309, DOI 10.1111/j.1365-2958.1992.tb00852.x; BENSON SA, 1988, J MOL BIOL, V203, P961, DOI 10.1016/0022-2836(88)90121-0; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; DIMASI DR, 1973, J BACTERIOL, V115, P56; ECKER DJ, 1986, J BACTERIOL, V167, P666, DOI 10.1128/jb.167.2.666-673.1986; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; GUDMUNDSDOTTIR A, 1989, J BACTERIOL, V171, P6526, DOI 10.1128/jb.171.12.6526-6533.1989; GUTERMAN SK, 1973, J BACTERIOL, V114, P1217, DOI 10.1128/JB.114.3.1217-1224.1973; GUTERMAN SK, 1973, J BACTERIOL, V114, P1225, DOI 10.1128/JB.114.3.1225-1230.1973; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KOSTER W, 1986, MOL GEN GENET, V204, P435, DOI 10.1007/BF00331021; LEONG J, 1976, J BACTERIOL, V126, P823, DOI 10.1128/JB.126.2.823-830.1976; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MCINTOSH M, UNPUB; MILLER JH, 1978, EXPT MOL GENETICS, P104; MURPHY CK, 1990, J BACTERIOL, V172, P2736, DOI 10.1128/jb.172.5.2736-2746.1990; MURPHY CK, 1989, J BACTERIOL, V171, P5894, DOI 10.1128/jb.171.11.5894-5900.1989; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEILANDS JB, 1982, ANNU REV MICROBIOL, V36, P285, DOI 10.1146/annurev.mi.36.100182.001441; NEILANDS JB, 1981, ANNU REV NUTR, V1, P27, DOI 10.1146/annurev.nu.01.070181.000331; NEILANDS JB, 1952, J AM CHEM SOC, V74, P4846, DOI 10.1021/ja01139a033; NEILANDS JB, 1966, STRUCT BOND, V1, P59; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1981, J GEN PHYSIOL, V77, P121, DOI 10.1085/jgp.77.2.121; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; OZENBERGER BA, 1987, J BACTERIOL, V169, P3638, DOI 10.1128/jb.169.8.3638-3646.1987; POSTLE K, 1979, J MOL BIOL, V131, P619, DOI 10.1016/0022-2836(79)90011-1; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; PUGSLEY AP, 1976, J BACTERIOL, V126, P1052, DOI 10.1128/JB.126.3.1052-1062.1976; RUTZ JM, 1991, J BACTERIOL, V173, P5694; WANG CC, 1969, J BACTERIOL, V98, P1135, DOI 10.1128/JB.98.3.1135-1141.1969; WAYNE R, 1975, J BACTERIOL, V121, P497, DOI 10.1128/JB.121.2.497-503.1975; WAYNE R, 1976, J BACTERIOL, V126, P7, DOI 10.1128/JB.126.1.7-12.1976; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	42	155	160	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					471	475		10.1126/science.1411544	http://dx.doi.org/10.1126/science.1411544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411544				2022-12-01	WOS:A1992JT77500038
J	SHIVER, JW; SU, LS; HENKART, PA				SHIVER, JW; SU, LS; HENKART, PA			CYTOTOXICITY WITH TARGET DNA BREAKDOWN BY RAT BASOPHILIC LEUKEMIA-CELLS EXPRESSING BOTH CYTOLYSIN AND GRANZYME-A	CELL			English	Article							TOXIC LYMPHOCYTE-T; SERINE PROTEASE; PERFORIN; FRAGMENTATION; GRANULES; CLONING; LYSIS; ANTIBODY; BINDING; FAMILY	The noncytotoxic rat mast cell tumor line RBL was transfected with genes for the cytotoxic lymphocyte granule proteins cytolysin (perforin) and granzyme A, giving transfectants with mRNA and protein expression levels comparable with cloned cytotoxic T lymphocytes. Both RBL-cytolysin and RBL-cytolysin-granzyme A transfectants showed extremely potent killing of red cell targets and lysed 20%-60% of EL4 lymphoma targets at an effector-to-target ratio of 30. RBL transfectants expressing only granzyme A were not cytotoxic. Significant EL4 DNA breakdown accompanying lysis was observed only with RBL that was transfected with both cytolysin and granzyme A. These results support the granule-exocytosis model for lymphocyte cytotoxicity and show that effector granzyme A plays a role in target cell DNA breakdown.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,STANFORD,CA 94305	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University								BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BRUNET JF, 1988, IMMUNOL REV, V103, P21, DOI 10.1111/j.1600-065X.1988.tb00747.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON MM, 1988, ENDOCRINOLOGY, V122, P2158, DOI 10.1210/endo-122-5-2158; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; Fewtrell C, 1981, Kroc Found Ser, V14, P295; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERSHENFELD HK, 1986, SCIENCE, V232, P854, DOI 10.1126/science.2422755; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; HAYES MP, 1989, J EXP MED, V170, P933, DOI 10.1084/jem.170.3.933; HENKART PA, 1984, J EXP MED, V160, P75, DOI 10.1084/jem.160.1.75; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HUDIG D, 1991, J IMMUNOL, V147, P1360; ISHIKAWA H, 1989, J IMMUNOL, V143, P3069; KRAMER MD, 1987, IMMUNOL TODAY, V8, P140, DOI 10.1016/0167-5699(87)90141-1; LICHTENHELD MG, 1988, NATURE, V335, P448, DOI 10.1038/335448a0; LIU FT, 1980, J IMMUNOL, V124, P2728; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MUNGER WE, 1988, IMMUNOL REV, V103, P99, DOI 10.1111/j.1600-065X.1988.tb00752.x; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; SELLINS KS, 1991, J IMMUNOL, V147, P795; Serafin W E, 1990, Monogr Allergy, V27, P31; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHINKAI Y, 1988, NATURE, V334, P525, DOI 10.1038/334525a0; SHIVER JW, 1991, CELL, V64, P1174; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	35	237	240	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 16	1992	71	2					315	322		10.1016/0092-8674(92)90359-K	http://dx.doi.org/10.1016/0092-8674(92)90359-K			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JU395	1423596				2022-12-01	WOS:A1992JU39500016
J	WAKABAYASHI, K; TOKUNAGA, M; KOHNO, I; SUGIMOTO, Y; HAMANAKA, T; TAKEZAWA, Y; WAKABAYASHI, T; AMEMIYA, Y				WAKABAYASHI, K; TOKUNAGA, M; KOHNO, I; SUGIMOTO, Y; HAMANAKA, T; TAKEZAWA, Y; WAKABAYASHI, T; AMEMIYA, Y			SMALL-ANGLE SYNCHROTRON X-RAY-SCATTERING REVEALS DISTINCT SHAPE CHANGES OF THE MYOSIN HEAD DURING HYDROLYSIS OF ATP	SCIENCE			English	Article							ADENOSINE-TRIPHOSPHATASE; ACTIN-FILAMENTS; SKELETAL-MUSCLE; SUBFRAGMENT-1; SITE; EQUILIBRIUM; COMPLEXES; RADIATION; DOMAINS; ION	In the energy transduction of muscle contraction, it is important to know the nature and extent of conformational changes of the head portion of the myosin molecules. In the presence of magnesium adenosine triphosphate (MgATP), fairly large conformational changes of the myosin head [subfragment-1 (S1)] in solution were observed by small-angle x-ray scattering with the use of synchrotron radiation as an intense and stable x-ray source. The presence of MgATP reduced the radius of gyration of the molecule by about 3 angstrom units and the maximum chord length by about 10 angstroms, showing that the shape of S1 becomes more compact or round during hydrolysis of MgATP. Comparison with various nucleotide-bound S1 complexes that correspond to the known intermediate states during ATP hydrolysis indicates that the shape of S1 in a key intermediate state, S1-bound adenosine diphosphate (ADP) and phosphate [S1**.ADP.P(i)], differs significantly from the shape in the other intermediate states of the Sl adenosine triphosphatase cycle as well as that of nucleotide-free S1.	UNIV TOKYO, FAC SCI, DEPT PHYS, BUNKYO KU, TOKYO 113, JAPAN; NATL LAB HIGH ENERGY PHYS, PHOTON FACTORY, TSUKUBA, IBARAKI 305, JAPAN	University of Tokyo; High Energy Accelerator Research Organization (KEK)	WAKABAYASHI, K (corresponding author), OSAKA UNIV, FAC ENGN SCI, DEPT BIOPHYS ENGN, TOYONAKA, OSAKA 560, JAPAN.		Amemiya, Yoshiyuki/M-7147-2018	Amemiya, Yoshiyuki/0000-0003-3306-3772; Tokunaga, Makio/0000-0003-4586-8922				AGUIRRE R, 1989, BIOCHEMISTRY-US, V28, P799, DOI 10.1021/bi00428a058; AMEMIYA Y, 1988, TOP CURR CHEM, V147, P121, DOI 10.1007/3-540-19040-6_13; AMEMIYA Y, 1983, NUCL INSTRUM METHODS, V208, P471, DOI 10.1016/0167-5087(83)91170-5; BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; Bevington P. R., 1969, DATA REDUCTION ERROR; CRAIG R, 1985, P NATL ACAD SCI USA, V82, P3247, DOI 10.1073/pnas.82.10.3247; CURMI PMG, 1988, J MOL BIOL, V203, P781, DOI 10.1016/0022-2836(88)90209-4; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; Feigin LA, 1987, STRUCTURE ANAL SMALL; GEEVES MA, 1982, BIOCHEMISTRY-US, V21, P2782, DOI 10.1021/bi00540a032; GLATTER O, 1981, SMALL ANGLE SCATTERI, P119; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; GOODY R S, 1980, Journal of Muscle Research and Cell Motility, V1, P101, DOI 10.1007/BF00711928; Guinier A., 1955, SMALL ANGLE SCATTERI; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; HIGHSMITH S, 1990, BIOCHEMISTRY-US, V29, P4087, DOI 10.1021/bi00469a010; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KRETZSCHMAR KM, 1978, BIOCHEMISTRY-US, V17, P2314, DOI 10.1021/bi00605a009; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MARGOSSIAN SS, 1981, BIOCHEMISTRY-US, V20, P2151, DOI 10.1021/bi00511a012; MENDELSON R, 1980, BIOCHEMISTRY-US, V19, P4103, DOI 10.1021/bi00558a031; MENDELSON RA, 1991, ADV BIOPHYS, V27, P145; SHRIVER JW, 1984, TRENDS BIOCHEM SCI, V9, P322, DOI 10.1016/0968-0004(84)90303-7; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; STONE DB, 1986, BIOPHYS J, V49, pA444; Tokunaga M, 1991, Adv Biophys, V27, P157, DOI 10.1016/0065-227X(91)90015-6; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAKABAYASHI K, 1991, HDB SYNCHROTRON RAD, V4, P597; WALKER M, 1988, J MUSCLE RES CELL M, V9, P359, DOI 10.1007/BF01773879; WELLS C, 1984, J MUSCLE RES CELL M, V5, P97, DOI 10.1007/BF00713154; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701	34	140	140	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					443	447		10.1126/science.1411537	http://dx.doi.org/10.1126/science.1411537			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411537				2022-12-01	WOS:A1992JT77500029
J	WEINSTEIN, JN; KOHN, KW; GREVER, MR; VISWANADHAN, VN; RUBINSTEIN, LV; MONKS, AP; SCUDIERO, DA; WELCH, L; KOUTSOUKOS, AD; CHIAUSA, AJ; PAULL, KD				WEINSTEIN, JN; KOHN, KW; GREVER, MR; VISWANADHAN, VN; RUBINSTEIN, LV; MONKS, AP; SCUDIERO, DA; WELCH, L; KOUTSOUKOS, AD; CHIAUSA, AJ; PAULL, KD			NEURAL COMPUTING IN CANCER DRUG DEVELOPMENT - PREDICTING MECHANISM OF ACTION	SCIENCE			English	Article							TUMOR-CELL-LINES; ARTIFICIAL-INTELLIGENCE; NETWORKS; DIAGNOSIS; RECOGNITION; FEASIBILITY; BINDING; ERRORS; SITES; ASSAY	Described here are neural networks capable of predicting a drug's mechanism of action from its pattern of activity against a panel of 60 malignant cell lines in the National Cancer Institute's drug screening program. Given six possible classes of mechanism, the network misses the correct category for only 12 out of 141 agents (8.5 percent), whereas linear discriminant analysis, a standard statistical technique, misses 20 out of 141 (14.2 percent). The success of the neural net indicates several things. (i) The cell line response patterns are rich in information about mechanism. (ii) Appropriately designed neural networks can make effective use of that information. (iii) Trained networks can be used to classify prospectively the more than 10,000 agents per year tested by the screening program. Related networks, in combination with classical statistical tools, will help in a variety of ways to move new anticancer agents through the pipeline from in vitro studies to clinical application.	NCI,DIV CANC BIOL DIAG & CTR,MATH BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,INFORMAT TECHNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	WEINSTEIN, JN (corresponding author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,MOLEC PHARMACOL LAB,BLDG 37,ROOM 5C-25,BETHESDA,MD 20892, USA.			Weinstein, John/0000-0001-9401-6908; Rubinstein, Lawrence/0000-0002-9720-9737				ALLEY MC, 1988, CANCER RES, V48, P589; ASADA N, 1990, RADIOLOGY, V177, P857, DOI 10.1148/radiology.177.3.2244001; BAI R, 1991, J BIOL CHEM, V266, P15882; BOONE JM, 1990, MED PHYS, V17, P234, DOI 10.1118/1.596501; Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1; BRUNAK S, 1990, NUCLEIC ACIDS RES, V18, P4797, DOI 10.1093/nar/18.16.4797; DAPONTE JS, 1991, COMPUT MED IMAG GRAP, V15, P3, DOI 10.1016/0895-6111(91)90100-A; Dayhoff, 1990, NEURAL NETWORK ARCHI; DEMELER B, 1991, NUCLEIC ACIDS RES, V19, P1593, DOI 10.1093/nar/19.7.1593; DYTCH HE, 1990, ANAL QUANT CYTOL, V12, P379; Hand D. J, 1981, WILEY SERIES PROBABI; HOLLEY LH, 1989, P NATL ACAD SCI USA, V86, P152, DOI 10.1073/pnas.86.1.152; JAYARAM HN, 1992, BIOCHEM BIOPH RES CO, V186, P1600, DOI 10.1016/S0006-291X(05)81591-8; KHANNA T, 1991, F NEURAL NETWORKS; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KUROGI S, 1991, BIOL CYBERN, V64, P243, DOI 10.1007/BF00201985; LUKASHIN AV, 1989, J BIOMOL STRUCT DYN, V6, P1123, DOI 10.1080/07391102.1989.10506540; MANN NH, 1991, ORTHOP CLIN N AM, V22, P303; MCGREGOR MJ, 1989, PROTEIN ENG, V2, P521, DOI 10.1093/protein/2.7.521; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; ONEILL MC, 1991, NUCLEIC ACIDS RES, V19, P313, DOI 10.1093/nar/19.2.313; PAULL KD, 1988, P AM ASSOC CANC RES, V29, P488; PAULL KD, 1992, CANCER RES, V52, P3892; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PAULL KD, IN PRESS CANCER CHEM; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SHOEMAKER RH, 1988, PREDICTION RESPONSE, P265; Szu H. H., 1990, Telematics and Informatics, V7, P403, DOI 10.1016/S0736-5853(05)80017-6; WIED GL, 1990, ANAL QUANT CYTOL, V12, P417; WOLBERG WH, 1990, ANAL QUANT CYTOL, V12, P314; 1990, STATISTICAL ANAL SYS, V1	34	253	263	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 16	1992	258	5081					447	451		10.1126/science.1411538	http://dx.doi.org/10.1126/science.1411538			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411538				2022-12-01	WOS:A1992JT77500030
J	ZHANG, SH; REDDICK, RL; PIEDRAHITA, JA; MAEDA, N				ZHANG, SH; REDDICK, RL; PIEDRAHITA, JA; MAEDA, N			SPONTANEOUS HYPERCHOLESTEROLEMIA AND ARTERIAL LESIONS IN MICE LACKING APOLIPOPROTEIN-E	SCIENCE			English	Article							CORONARY HEART-DISEASE; E DEFICIENCY; PLASMA-LIPOPROTEINS; ATHEROSCLEROSIS; SUSCEPTIBILITY; SERUM; HYPERLIPOPROTEINEMIA; QUANTITATION; TRANSPORT	Apolipoprotein E (apoE) is a ligand for receptors that clear remnants of chylomicrons and very low density lipoproteins. Lack of apoE is, therefore, expected to cause accumulation in plasma of cholesterol-rich remnants whose prolonged circulation should be atherogenic. ApoE-deficient mice generated by gene targeting were used to test this hypothesis and to make a mouse model for spontaneous atherosclerosis. The mutant mice had five times normal plasma cholesterol, and developed foam cell-rich depositions in their proximal aortas by age 3 months. These spontaneous lesions progressed and caused severe occlusion of the coronary artery ostium by 8 months. The severe yet viable phenotype of the mutants should make them valuable for investigating genetic and environmental factors that modify the atherogenic process.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, PROGRAM MOLEC BIOL & BIOTECHNOL, CHAPEL HILL, NC 27599 USA; TEXAS A&M UNIV SYST, DEPT VET ANAT & PUBL HLTH, COLL STN, TX 77840 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Texas A&M University System; Texas A&M University College Station					NHLBI NIH HHS [HL42630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERG K, 1983, PROG MED GENET, V5, P35; BRESLOW JL, 1991, ANNU REV MED, V42, P357, DOI 10.1146/annurev.me.42.020191.002041; CAMUS MC, 1983, J LIPID RES, V24, P1210; DEMACKER PNM, 1978, CLIN CHEM, V24, P1439; FRANCE DS, 1989, J LIPID RES, V30, P1997; GETZ GS, 1988, ARCH PATHOL LAB MED, V112, P1048; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; GRUNDY SM, 1991, ARTERIOSCLER THROMB, V11, P1619, DOI 10.1161/01.ATV.11.6.1619; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KUROSAKA D, 1991, ATHEROSCLEROSIS, V88, P15, DOI 10.1016/0021-9150(91)90252-X; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LUSIS AJ, 1988, J LIPID RES, V29, P397; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MORRISETT JD, 1982, ARTERIOSCLEROSIS, V2, P312, DOI 10.1161/01.ATV.2.4.312; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Roberts A, 1976, Adv Exp Med Biol, V67, P313; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SHENG J, 1990, METABOLISM, V39, P155, DOI 10.1016/0026-0495(90)90069-O; Utermann G, 1986, Adv Exp Med Biol, V201, P261; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WEIBUST RS, 1973, GENETICS, V73, P303; Zhang S., UNPUB	26	1835	1927	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1992	258	5081					468	471		10.1126/science.1411543	http://dx.doi.org/10.1126/science.1411543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT775	1411543				2022-12-01	WOS:A1992JT77500037
J	BERG, AT; SHINNAR, S; HAUSER, WA; ALEMANY, M; SHAPIRO, ED; SALOMON, ME; CRAIN, EF				BERG, AT; SHINNAR, S; HAUSER, WA; ALEMANY, M; SHAPIRO, ED; SALOMON, ME; CRAIN, EF			A PROSPECTIVE-STUDY OF RECURRENT FEBRILE SEIZURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM DIAZEPAM PROPHYLAXIS; NATIONAL COHORT; CONVULSIONS; EPILEPSY; PREDICTORS; CHILDHOOD; LIFE; RISK	Background. Febrile seizures occur in 2 to 4 percent of all children, approximately one third of whom will have recurrent febrile seizures. Little is known about predictors of recurrence. Methods. In this prospective study, we identified 347 children (1 month to 10 years of age) who presented with a first febrile seizure at one of four pediatric emergency departments. Information about these children was collected from medical records and interviews with the parents, and the children were followed for a median of 20 months to ascertain whether febrile seizures recurred. Results. Recurrent febrile seizures occurred in 94 of the 347 children (27 percent) with a cumulative risk of 25 percent at one year and 30 percent at two years. The duration of fever before the initial seizure was associated with the risk of recurrence at one year: for fever lasting less than 1 hour, the risk of recurrence was 44 percent; for fever lasting 1 to 24 hours, 23 percent; and for fever lasting more than 24 hours, 13 percent (P<0.001). With each degree of increase in temperature (in degrees Fahrenheit), from 101-degrees-F (38.3-degrees-C) to greater-than-or-equal-to 105-degrees-F (40.6-degrees-C), the risk of recurrence at one year declined, from 35 percent to 30, 26, 20, and 13 percent (P for trend = 0.024). An age of less than 18 months and a family history of febrile seizures were also associated with an increased risk of recurrence. A family history of epilepsy, complex febrile seizures, and neurodevelopmental abnormalities did not increase the risk of recurrent febrile seizures. Conclusions. A shorter duration of fever before the initial febrile seizure and a lower temperature are associated with an increased risk of recurrence in children who have febrile seizures.	MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT NEUROL, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, DEPT PEDIAT, BRONX, NY 10467 USA; MONTEFIORE MED CTR, ALBERT EINSTEIN COLL MED, MONTEFIORE EINSTEIN EPILEPSY MANAGEMENT, BRONX, NY 10467 USA; COLUMBIA UNIV COLL PHYS & SURG, GERTRUDE SERGIEVSKY CTR, NEW YORK, NY 10032 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Columbia University	BERG, AT (corresponding author), YALE UNIV, SCH MED, DEPT PEDIAT, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.		Hauser, W Allen/AAB-5277-2020		NINDS NIH HHS [1R29 NS27728, 1R01 NS26151] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS027728, R01NS026151] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1990, EPILEPSY RES, V5, P209, DOI 10.1016/0920-1211(90)90040-3; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1980, Pediatrics, V66, P1009; Berg A T, 1992, Paediatr Perinat Epidemiol, V6, P145, DOI 10.1111/j.1365-3016.1992.tb00756.x; BERG A T, 1991, Epilepsia, V32, P84; BERG AT, 1992, EPILEPSIA, V33, P661, DOI 10.1111/j.1528-1157.1992.tb02344.x; BERG AT, 1990, J PEDIATR-US, V116, P329, DOI 10.1016/S0022-3476(05)82816-1; BREG W R, 1962, Pediatr Clin North Am, V9, P101; CAMFIELD CS, 1979, J PEDIATR-US, V95, P361, DOI 10.1016/S0022-3476(79)80507-7; CAMFIELD PR, 1980, J PEDIATR-US, V97, P16, DOI 10.1016/S0022-3476(80)80122-3; COX DR, 1972, J R STAT SOC B, V34, P187; DIXON WJ, 1985, BMDP STATISTICAL SOF, P555; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELRADHI AS, 1986, CLIN PEDIATR, V25, P311; FREEMAN JM, 1990, PEDIATRICS, V86, P624; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, MONOGRPAHS EPIDEMIOL, V1, P293; KNUDSEN FU, 1985, ARCH DIS CHILD, V60, P1045, DOI 10.1136/adc.60.11.1045; KNUDSEN FU, 1985, J PEDIATR-US, V106, P487, DOI 10.1016/S0022-3476(85)80688-0; Lennox MA, 1946, RES PUBL ASSOC RES N, V26, P342; LENNOX WG, 1953, PEDIATRICS, V11, P341; LENNOXBUCHTHAL MA, 1975, ACTA NEUROL SCAND, P77; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; OFFRINGA M, 1992, DEV MED CHILD NEUROL, V34, P15; POLLACK MA, 1978, AM J DIS CHILD, V132, P87, DOI 10.1001/archpedi.1978.02120260089021; PRUITT AW, 1985, PEDIATRICS, V76, P644; ROSMAN NP, 1992, CONT PEDIATR, V9, P12; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; SHINNAR S, 1990, CURRENT THERAPY NEUR, P29; SHIRTS SB, 1987, EPILEPSIA, V28, P625; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; WOLF SM, 1978, PEDIATRICS, V61, P728; WOLF SM, 1989, ACTA PAEDIATR SCAND, V78, P291, DOI 10.1111/j.1651-2227.1989.tb11072.x; WOLF SM, 1977, PEDIATRICS, V59, P378	37	168	172	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1122	1127		10.1056/NEJM199210153271603	http://dx.doi.org/10.1056/NEJM199210153271603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528207				2022-12-01	WOS:A1992JT15300003
J	BLATTER, EE; EBRIGHT, YW; EBRIGHT, RH				BLATTER, EE; EBRIGHT, YW; EBRIGHT, RH			IDENTIFICATION OF AN AMINO ACID-BASE CONTACT IN THE GCN4-DNA COMPLEX BY BROMOURACIL-MEDIATED PHOTO-CROSS-LINKING	NATURE			English	Article							LAC REPRESSOR PROTEIN; GENE-CONTROL REGIONS; LEUCINE ZIPPER; DNA-BINDING; GEL-ELECTROPHORESIS; ACTIVATOR PROTEIN; OPERATOR DNA; RECOGNITION; SITE; BROMODEOXYURIDINE	THE bZIP DNA-binding proteins are characterized by a 50-amino-acid DNA binding and dimerization motif, consisting of a highly basic DNA-binding region ('b') followed by a leucine zipper dimerization region ('ZIP')1. The best characterized bZIP DNA-binding protein is GCN4, a yeast transcriptional activator2-6. GCN4 binds to a 9-base-pair two-fold-symmetric DNA site, 5'-A-4T-3G-2A-1C0T+1C+2A+3T+4-3' (refs 7-10). A detailed model known as the 'induced helical fork' model has been proposed for the structure of the GCN4-DNA complex4. Using a site-specific bromouracil-mediated photocrosslinking method, we show here that the alanine at position 238 of GCN4 contacts, or is close to, the thymine 5-methyl of A.T at position +3 of the DNA site in the GCN4-DNA complex. Our results strongly support the induced helical fork model4. Our site-specific bromouracil-mediated photocrosslinking method requires no prior information regarding the structure of the protein or the structure of the protein-DNA complex and should be generalizable to DNA-binding proteins that interact with the DNA major groove11,12.	RUTGERS STATE UNIV,DEPT CHEM,NEW BRUNSWICK,NJ 08855; RUTGERS STATE UNIV,WAKSMAN INST,NEW BRUNSWICK,NJ 08855	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140				ALLEN TD, 1991, J BIOL CHEM, V266, P6113; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; FISHER EF, 1979, NUCLEIC ACIDS RES, V7, P401, DOI 10.1093/nar/7.2.401; FLIESS A, 1988, NUCLEIC ACIDS RES, V16, P11781, DOI 10.1093/nar/16.24.11781; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GOEDDEL DV, 1978, J MOL BIOL, V123, P661, DOI 10.1016/0022-2836(78)90211-5; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; HAYAKAWA T, 1988, NUCLEIC ACIDS RES, V16, P4761, DOI 10.1093/nar/16.11.4761; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HUTCHINSON F, 1973, Q REV BIOPHYS, V6, P201, DOI 10.1017/S0033583500001141; LIN SY, 1974, P NATL ACAD SCI USA, V71, P947, DOI 10.1073/pnas.71.3.947; MAVROTHALASSITIS G, 1990, DNA CELL BIOL, V9, P783, DOI 10.1089/dna.1990.9.783; OGATA R, 1977, P NATL ACAD SCI USA, V74, P4973, DOI 10.1073/pnas.74.11.4973; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PU WT, 1992, NUCLEIC ACIDS RES, V20, P771, DOI 10.1093/nar/20.4.771; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; STRUHL K, IN PRESS TRANSCRIPTI; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WHARTON RP, 1987, NATURE, V326, P888, DOI 10.1038/326888a0; WICK KL, 1991, J BIOL CHEM, V266, P6106	30	79	83	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					650	652		10.1038/359650a0	http://dx.doi.org/10.1038/359650a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406998				2022-12-01	WOS:A1992JT82400062
J	CHRISCHILLES, EA; SEGAR, ET; WALLACE, RB				CHRISCHILLES, EA; SEGAR, ET; WALLACE, RB			SELF-REPORTED ADVERSE DRUG-REACTIONS AND RELATED RESOURCE USE - A STUDY OF COMMUNITY-DWELLING PERSONS 65 YEARS OF AGE AND OLDER	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERSE DRUG REACTION REPORTING SYSTEMS; GERIATRICS; HEALTH RESOURCES; DRUG TOXICITY; HEALTH STATUS	GENERAL-PRACTICE	Objective: To describe the incidence and health resource consequences of self-reported adverse drug reactions (ADRs) and their relation to self-perceived health, number of medications used, and age in a geographically based population 65 years of age and older. Design: A survey of a defined population. Participants: Three thousand, one hundred seventy noninstitutionalized persons 65 years of age and older residing in two Iowa counties. Measurements: Reports of ADRs (elicited using an open-ended questionnaire); names of drugs involved; descriptions of reactions and related health resource use; self-perceived health status (at the first annual follow-up); and number of medications (from the baseline interview). Results: Ten percent (95% Cl, 8.97 to 11.09) of respondents reported one or more ADRs. Three quarters of respondents who reported ADRs contacted a physician. Of these, half indicated that a laboratory test had been ordered, and 7% reported a hospitalization due to the reaction. Advanced age alone was associated with decreased risk in women; a similar trend in men was not statistically significant. However, persons with poorer health status and those who reported the greatest prior use of medications were most likely to report reactions. Conclusions: In this study of noninstitutionalized elderly persons, advanced age did not appear to be associated with increased risk for self-reported ADRs. We could not determine whether the decrease in ADR reports among the oldest respondents represented true diminished ADR occurrence or altered ADR detection and reporting capabilities. When projected to the elderly community-dwelling U.S. population, 2.2 million annual physician visits, 1.1 million laboratory tests, and 146 000 hospitalizations may result from ADRs.			CHRISCHILLES, EA (corresponding author), UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA.			Chrischilles, Elizabeth/0000-0002-1843-1955				Campbell W H, 1978, J Community Health, V3, P205, DOI 10.1007/BF01349383; CHRISCHILLES EA, 1989, PHARMACOEPIDEMIOLOGY; CHRISCHILLES EA, 1992, IN PRESS J GERONTOL; CICCOLUNGHI SN, 1975, J CLIN PHARMACOL, V15, P496, DOI 10.1002/j.1552-4604.1975.tb01471.x; COL N, 1990, ARCH INTERN MED, V150, P841, DOI 10.1001/archinte.150.4.841; Colsher Patricia L., 1991, Annals of Epidemiology, V1, P215; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; CURB J D, 1985, American Journal of Preventive Medicine, V1, P36; DOWNING RW, 1970, J CLIN PHARM     SEP, P289; German P S, 1989, J Aging Health, V1, P4, DOI 10.1177/089826438900100102; GRYMONPRE RE, 1988, J AM GERIATR SOC, V36, P1092, DOI 10.1111/j.1532-5415.1988.tb04395.x; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; HELLING DK, 1987, J AM GERIATR SOC, V35, P4, DOI 10.1111/j.1532-5415.1987.tb01312.x; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; HUSKISSON EC, 1974, BRIT MED J, V29, P698; HUTCHINSON TA, 1986, J CHRON DIS, V39, P533, DOI 10.1016/0021-9681(86)90198-0; IREY NS, 1976, AM J PATHOL, V82, P617; KARCH FE, 1977, CLIN PHARMACOL THER, V21, P247; KELLAWAY GS, 1973, NEW ZEAL MED J, V78, P525; KLEIN LE, 1984, ARCH INTERN MED, V144, P1185, DOI 10.1001/archinte.144.6.1185; KOCH H, 1987, PHS871250 US DEP HLT; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LUMLEY C E, 1986, Pharmaceutical Medicine (London), V1, P205; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARTYS CR, 1979, BMJ-BRIT MED J, V2, P1194, DOI 10.1136/bmj.2.6199.1194; MCEVOY GK, 1990, AHFS DRUG INFORMATIO; MICHOCKI RJ, 1988, J AM GERIATR SOC, V36, P79, DOI 10.1111/j.1532-5415.1988.tb03439.x; MOELLER J, 1989, PHS893448 US DEP HLT; MULROY R, 1973, BRIT MED J, V2, P407, DOI 10.1136/bmj.2.5863.407; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NOLAN L, 1988, J AM GERIATR SOC, V36, P142, DOI 10.1111/j.1532-5415.1988.tb01785.x; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; SMIDT NA, 1972, NEW ZEAL MED J, V76, P397; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART RB, 1971, JOHNS HOPKINS MED J, V129, P319; STEWART RB, 1988, THERAPEUTICS ELDERLY; VENULET J, 1980, INT J CLIN PHARM TH, V18, P381; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1990, PHYSICIANS DESK REFE; 1979, HLTH INTERVIEW SURVE	41	104	106	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					634	640		10.7326/0003-4819-117-8-634	http://dx.doi.org/10.7326/0003-4819-117-8-634			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530194				2022-12-01	WOS:A1992JR86100002
J	COX, J; NAYLOR, CD				COX, J; NAYLOR, CD			THE CANADIAN-CARDIOVASCULAR-SOCIETY GRADING SCALE FOR ANGINA-PECTORIS - IS IT TIME FOR REFINEMENTS	ANNALS OF INTERNAL MEDICINE			English	Review						ANGINA PECTORIS; SEVERITY OF ILLNESS INDEX; CANADIAN-CARDIOVASCULAR-SOCIETY; CHEST PAIN; CLINIMETRICS	CORONARY-ARTERY DISEASE; CHRONIC STABLE ANGINA; SILENT MYOCARDIAL ISCHEMIA; HEART-DISEASE; CHEST PAIN; UNSTABLE ANGINA; NATURAL-HISTORY; ELECTROCARDIOGRAPHIC CHANGES; PROGNOSTIC IMPORTANCE; FUNCTIONAL STATUS	Objective: To appraise the measurement properties of the Canadian Cardiovascular Society (CCS) classification of stable angina pectoris. Data Sources: Relevant articles were identified through a MEDLINE search (1976 to November 1991). Bibliographies of retrieved articles were also reviewed. Study Selection: Studies chosen directly addressed the validity and reliability of the CCS scale. Recent studies and reviews of related topics (for example, silent ischemia) are selectively cited. Data Synthesis: No data address the scale's applicability, that is, how clinicians typically assign angina grades in practice. Comprehensiveness would be improved by coverage of the patient's perceptions of symptom burden; mixed exertional and rest symptoms; episodic or changing symptoms; and modifying factors. Reliability was assessed in one study with two clinicians; the interobserver, chance-corrected agreement on patient grading was 60%. Content validity (the ability of the scale to measure what it claims) is threatened by the unproven assumption of symptomatic or physiologic equivalence among diverse levels of different activities within any given grade of angina. Construct validity is uncertain, given weak relations between angina grade and noninvasive markers of ischemia, anatomical disease, or prognosis. The scale's responsiveness (the ability to detect the smallest clinically important changes) is limited by the reliance on four coarse gradations based on only ambulation or stair-climbing. Conclusions: The CCS scale for stable angina might be made more useful by developing measurements for patients' self-rated symptom burden and the changes they deem important; by adding items on clinical instability (that is, progressive symptoms or pain at rest); and by empirically testing the current scale to eliminate redundant or inconsistent elements.	SUNNYBROOK HLTH SCI CTR, CLIN EPIDEMIOL UNIT, A443, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA; DALHOUSIE UNIV, HALIFAX B3H 4H2, NS, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Dalhousie University; University of Toronto				Cox, Jafna/0000-0001-7908-5323				ALLISON RB, 1963, CIRCULATION, V27, P170, DOI 10.1161/01.CIR.27.2.170; ASSEY ME, 1988, AM J CARDIOL, V61, pF19; BIAGINI A, 1981, CLIN CARDIOL, V4, P315, DOI 10.1002/clc.4960040602; BURGGRAF GW, 1975, CIRCULATION, V51, P146, DOI 10.1161/01.CIR.51.1.146; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CALLAHAM PR, 1989, J AM COLL CARDIOL, V14, P1175, DOI 10.1016/0735-1097(89)90413-0; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHASSIN MR, 1986, INDICATIONS SELECTED; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; COHN PF, 1981, AM J CARDIOL, V47, P233, DOI 10.1016/0002-9149(81)90391-X; COHN PF, 1986, AM J MED, V81, P2, DOI 10.1016/0002-9343(86)90971-X; COLE JP, 1978, AM J CARDIOL, V41, P227, DOI 10.1016/0002-9149(78)90161-3; DEHMER GJ, 1982, CURRENT PROBLEMS CAR, V12, P213; DETRE K, 1981, CIRCULATION, V63, P1329, DOI 10.1161/01.CIR.63.6.1329; DEYO RA, 1984, CONTROL CLIN TRIALS, V5, P223, DOI 10.1016/0197-2456(84)90026-6; DUNCAN B, 1976, BRIT MED J, V1, P981, DOI 10.1136/bmj.1.6016.981; EGSTRUP K, 1987, ACTA MED SCAND, V222, P301; EPSTEIN SE, 1988, NEW ENGL J MED, V318, P1038, DOI 10.1056/NEJM198804213181606; FARHI JI, 1986, AM J CARDIOL, V58, P547, DOI 10.1016/0002-9149(86)90031-7; FEINSTEIN AR, 1986, ANN INTERN MED, V105, P413, DOI 10.7326/0003-4819-105-3-413; FEINSTEIN AR, 1977, AM HEART J, V93, P172, DOI 10.1016/S0002-8703(77)80308-6; Feinstein AR., 1987, CLINIMETRICS; FINDLAY I N, 1988, European Heart Journal, V9, P2; GARBER CE, 1991, J AM COLL CARDIOL, V17, P1256, DOI 10.1016/S0735-1097(10)80132-9; GOLDMAN L, 1982, J CHRON DIS, V35, P763, DOI 10.1016/0021-9681(82)90087-X; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOTTLIEB S O, 1987, American Journal of Cardiology, V60, p33J, DOI 10.1016/0002-9149(87)90681-3; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P403, DOI 10.1016/0895-4356(89)90128-5; HAGMAN M, 1977, ACTA MED SCAND, V201, P571; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HAUSMANN D, 1991, AM J CARDIOL, V67, P465, DOI 10.1016/0002-9149(91)90005-6; HEYDEN S, 1971, ARCH INTERN MED, V128, P961, DOI 10.1001/archinte.128.6.961; HLATKY MA, 1989, J CLIN EPIDEMIOL, V42, P381, DOI 10.1016/0895-4356(89)90125-X; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HUMPHRIE.JO, 1974, CIRCULATION, V49, P489, DOI 10.1161/01.CIR.49.3.489; ISKANDRIAN AS, 1984, AM J CARDIOL, V53, P1239, DOI 10.1016/0002-9149(84)90071-7; JAFFE MD, 1980, LANCET, V2, P934; JOHNSON SM, 1982, AM HEART J, V103, P4, DOI 10.1016/0002-8703(82)90522-1; KANNEL WB, 1972, AM J CARDIOL, V29, P154, DOI 10.1016/0002-9149(72)90624-8; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KOSSMANN CE, 1964, DISEASES HEART BLOOD, P112; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; MAHMARIAN JJ, 1990, CIRCULATION, V82, P1305, DOI 10.1161/01.CIR.82.4.1305; MARK DB, 1989, J AM COLL CARDIOL, V14, P885, DOI 10.1016/0735-1097(89)90459-2; MASERI A, 1980, BRIT HEART J, V43, P648; MASERI A, 1986, AM J MED, V80, P48, DOI 10.1016/0002-9343(86)90452-3; MCLENACHAN JM, 1991, CIRCULATION, V83, P1263, DOI 10.1161/01.CIR.83.4.1263; MEDALIE JH, 1973, AM J MED, V55, P583, DOI 10.1016/0002-9343(73)90179-4; MIRANDA CP, 1991, ANN INTERN MED, V114, P649, DOI 10.7326/0003-4819-114-8-649; MYERS WO, 1989, J THORAC CARDIOV SUR, V97, P487; MYERS WO, 1987, ANN THORAC SURG, V44, P471, DOI 10.1016/S0003-4975(10)62104-2; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NIXON PGF, 1987, AM HEART J, V114, P1542, DOI 10.1016/0002-8703(87)90583-7; PERMANYERMIRALDA G, 1991, J CLIN EPIDEMIOL, V44, P779, DOI 10.1016/0895-4356(91)90130-2; PROUDFIT W L, 1986, Canadian Journal of Cardiology, V2, P62; PROUDFIT WL, 1978, PROG CARDIOVASC DIS, V21, P53, DOI 10.1016/S0033-0620(78)80004-8; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; PUPITA G, 1989, AM HEART J, V118, P539, DOI 10.1016/0002-8703(89)90270-6; QUYYUMI AA, 1985, BRIT HEART J, V54, P22; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P123; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; ROSE G, 1968, BRIT J PREV SOC MED, V22, P12; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; SCHANG SJ, 1977, AM J CARDIOL, V39, P396, DOI 10.1016/S0002-9149(77)80095-7; SELZER A, 1972, AM J CARDIOL, V30, P306, DOI 10.1016/0002-9149(72)90079-3; SHUB C, 1990, MAYO CLIN PROC, V65, P233, DOI 10.1016/S0025-6196(12)65018-6; SMITH WCS, 1990, BRIT HEART J, V64, P295; SPIEKERMAN RE, 1962, CIRCULATION, V25, P57, DOI 10.1161/01.CIR.25.1.57; TAKARO T, 1982, CIRCULATION, V65, P60, DOI 10.1161/01.CIR.65.7.60; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; VASSILIADIS IV, 1991, AM HEART J, V121, P1403, DOI 10.1016/0002-8703(91)90145-8; WARTAK J, 1984, AM HEART J, V107, P402, DOI 10.1016/0002-8703(84)90401-0; WATERS DD, 1985, J AM COLL CARDIOL, V6, P1011, DOI 10.1016/S0735-1097(85)80302-8; WEBSTER JS, 1974, AM J CARDIOL, V33, P195, DOI 10.1016/0002-9149(74)90274-4; WEINBLATT E, 1968, J CHRON DIS, V21, P231, DOI 10.1016/0021-9681(68)90060-X; WEINER DA, 1987, AM J CARDIOL, V59, P725, DOI 10.1016/0002-9149(87)91081-2; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINER DA, 1978, AM HEART J, V96, P458, DOI 10.1016/0002-8703(78)90155-2; WIKLUND I, 1991, CLIN CARDIOL, V14, P204, DOI 10.1002/clc.4960140306	82	54	59	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					677	683		10.7326/0003-4819-117-8-677	http://dx.doi.org/10.7326/0003-4819-117-8-677			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530200				2022-12-01	WOS:A1992JR86100009
J	EPSTEIN, NR				EPSTEIN, NR			FRAME AND FOCUS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ALZHEIMERS DISEASE; PHYSICIAN-PATIENT RELATIONS		A physician meets with an Alzheimer patient and the patient's wife. In the process, an examination is done, and the wife and physician discuss her ability to cope with her difficult responsibilities. They digress into her memories of past travels with her husband, and of the onset of his disease. The physician grapples with questions of bis own vulnerability and ponders some disquieting possibilities.											0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1992	117	8					690	690		10.7326/0003-4819-117-8-690	http://dx.doi.org/10.7326/0003-4819-117-8-690			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JR861	1530201				2022-12-01	WOS:A1992JR86100011
J	HEMMATIBRIVANLOU, A; MELTON, DA				HEMMATIBRIVANLOU, A; MELTON, DA			A TRUNCATED ACTIVIN RECEPTOR INHIBITS MESODERM INDUCTION AND FORMATION OF AXIAL STRUCTURES IN XENOPUS EMBRYOS	NATURE			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; MESSENGER-RNA; BODY AXIS; NEURAL INDUCTION; EARLY RESPONSE; EXPRESSION; ANTERIOR; HOMOLOG; LAEVIS; CELLS	Activins can induce mesoderm in embryonic explants and have been proposed as the natural inducer in Xenopus. A mutant activin receptor that inhibits activin signalling is used to show that activin is required for the induction of mesoderm in vivo and the patterning of the embryonic body plan. Blocking the activin signal transduction pathway also reveals autonomous induction of a neural marker and unmasks a relationship between activin and fibroblast growth factor.			HEMMATIBRIVANLOU, A (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA ARI, 1990, TRENDS GENET, V6, P57; ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BOLCE M, IN PRESS; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CONDIE BG, 1987, DEVELOPMENT, V101, P93; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1991, METHODS CELL BIOL; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; Harland RM, 1991, METHODS CELL BIOL; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLO.A, IN PRESS; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONAS EA, 1989, DEVELOPMENT, V106, P399; JONES CM, 1992, DEVELOPMENT, V115, P639; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER R, 1991, METHODS CELL BIOL; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1991, DEVELOPMENT, V113, P1495; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIVE HL, 1989, CELL, V58, P171, DOI 10.1016/0092-8674(89)90413-3; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; SYMES K, 1987, DEVELOPMENT, V101, P185; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VIZE PD, 1991, XENOPUS LAEVIS PRACT, P361; WILSON PA, 1989, DEVELOPMENT, V105, P155	56	500	530	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					609	614		10.1038/359609a0	http://dx.doi.org/10.1038/359609a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328888				2022-12-01	WOS:A1992JT82400047
J	KEYSE, SM; EMSLIE, EA				KEYSE, SM; EMSLIE, EA			OXIDATIVE STRESS AND HEAT-SHOCK INDUCE A HUMAN GENE ENCODING A PROTEIN-TYROSINE PHOSPHATASE	NATURE			English	Article							SIGNAL TRANSDUCTION; IONIZING-RADIATION; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; SKIN FIBROBLASTS; POSITIVE CONTROL; HEME OXYGENASE; ACTIVATION; CELLS; PURIFICATION	REACTIVE oxygen species have been implicated both in the ageing process and in degenerative diseases, including arthritis and cancer1,2. Bacteria adapt to the lethal effects of oxidants such as hydrogen peroxide by inducing the expression of protective stress genes3,4 . Analogous responses have been identified in human cells. For example, haem oxygenase is a major stress protein in human cells treated with oxidants5, and reactive oxygen intermediates activate NF-kappaB, a transcriptional regulator of genes involved in inflammatory and acute-phase responses6. We report here the isolation and characterization of a novel complementary DNA (CL100) corresponding to a messenger RNA that is highly inducible by oxidative stress and heat shock in human skin cells. The cDNA contains an open reading frame specifying a protein of M(r) 39.3K with the structural features of a non-receptor-type protein-tyrosine phosphatase7 and which has significant amino-acid sequence similarity to a Tyr/Ser-protein phosphatase encoded by the late gene H1 of vaccinia virus8. The purified protein encoded by the CL100 open reading frame expressed in bacteria has intrinsic phosphatase activity. Given the relationship between the levels of protein-tyrosine phosphorylation, receptor activity, cellular proliferation and cell-cycle control, the induction of this gene may play an important regulatory role in the human cellular response to environmental stress.			KEYSE, SM (corresponding author), UNIV EDINBURGH,IMPERIAL CANC RES FUND,DEPT BIOCHEM,MOLEC PHARMACOL UNIT,HUGH ROBSON BLDG,EDINBURGH EH8 9XD,SCOTLAND.		Keyse, Stephen M./B-9575-2009	Keyse, Stephen M./0000-0002-5150-8221	Cancer Research UK [12053] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		AMES BN, 1985, GENETIC TOXICOLOGY E, P11; BAIROCH A, 1991, PROSITE DICT PROTEIN; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARLES CH, 1992, ONCOGENE, V7, P187; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CLAASSEN LA, 1991, J BIOL CHEM, V266, P11380; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967, DOI 10.1128/MCB.10.9.4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; Maniatis T., 1982, MOL CLONING; MILLAR BA, 1992, CELL, V68, P407; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; TYRRELL RM, 1986, CANCER RES, V46, P2665; ZIEGLERSKYLAKAKIS K, 1987, MUTAT RES, V192, P65, DOI 10.1016/0165-7992(87)90127-8	31	590	617	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					644	647		10.1038/359644a0	http://dx.doi.org/10.1038/359644a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406996				2022-12-01	WOS:A1992JT82400060
J	KOBAYASHI, T; STORRIE, B; SIMONS, K; DOTTI, CG				KOBAYASHI, T; STORRIE, B; SIMONS, K; DOTTI, CG			A FUNCTIONAL BARRIER TO MOVEMENT OF LIPIDS IN POLARIZED NEURONS	NATURE			English	Article							DEPENDENT SODIUM-CHANNELS; HIPPOCAMPAL-NEURONS; PLASMA-MEMBRANE; EPITHELIAL-CELL; INFLUENZA-VIRUS; TIGHT JUNCTIONS; GOLGI-APPARATUS; MAMMALIAN SPERM; MDCK CELLS; DOMAINS	IN polarized neurons, axons and dendrites perform different functions, which are reflected in their different molecular organization. Studies on the sorting of viral and endogenous glycoproteins in epithelial cells and hippocampal neurons suggest that there may be similarities in the mechanism of sorting in these two cell types1-3. The mechanisms that maintain the distinct composition of the two plasma membrane domains in these two cell types must, however, be different. We have proposed the existence of a functional barrier at the axonal hillock/initial segment which prevents the intermixing of membrane constituents1,2. Here we test this hypothesis by fusing liposomes containing fluorescent phospholipids into the plasma membrane of polarized hippocampal cells in culture. Fusion was induced by lowering the pH and mediated by influenza virus haemagglutinin expressed on the axonal surface of neurons infected with fowl plague virus. Labelling was found exclusively on axons after fusion. Although the fused lipids were mobile on the axonal membrane, no labelling was detected on the cell body and dendritic surfaces. These results suggest that there is a diffusion barrier at the axonal hillock/initial segment which maintains the compositional differences between the axonal and somatodendritic domains.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM, BLACKSBURG, VA 24061 USA	European Molecular Biology Laboratory (EMBL); Virginia Polytechnic Institute & State University			KOBAYASHI, TOSHIHIDE/S-8313-2019; Dotti, Carlos G/I-5533-2015; Kobayashi, Toshihide/B-6298-2015	KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Dotti, Carlos G/0000-0003-4052-1719; Kobayashi, Toshihide/0000-0002-4811-7270; Simons, Kai/0000-0002-9231-9996				ANGELIDES KJ, 1988, J CELL BIOL, V106, P1911, DOI 10.1083/jcb.106.6.1911; Banker G, 1991, CULTURING NERVE CELL; COWAN AE, 1987, J CELL BIOL, V104, P917, DOI 10.1083/jcb.104.4.917; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FRIEND DS, 1974, J CELL BIOL, V63, P641, DOI 10.1083/jcb.63.2.641; GILULA NB, 1972, J CELL BIOL, V53, P494, DOI 10.1083/jcb.53.2.494; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; HUNNICUTT GR, 1990, J CELL BIOL, V111, P1605, DOI 10.1083/jcb.111.4.1605; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; VAN MEER G, 1985, BIOCHEMISTRY-US, V24, P3593, DOI 10.1021/bi00335a030; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; WEISS RL, 1977, J CELL BIOL, V72, P133, DOI 10.1083/jcb.72.1.133; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x	25	127	129	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	1992	359	6396					647	650		10.1038/359647a0	http://dx.doi.org/10.1038/359647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1406997				2022-12-01	WOS:A1992JT82400061
J	MENIKOFF, JA; SACHS, GA; SIEGLER, M				MENIKOFF, JA; SACHS, GA; SIEGLER, M			BEYOND ADVANCE DIRECTIVES - HEALTH-CARE SURROGATE LAWS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SELF-DETERMINATION ACT; LIVING WILLS; INTERVENTIONS; ATTITUDES; PROXY; LIFE				MENIKOFF, JA (corresponding author), UNIV CHICAGO, CHICAGO, IL 60637 USA.							ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; Areen J, 1991, Law Med Health Care, V19, P91; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; CAPLAN AL, 1991, GERONTOLOGIST, V31, P582; CAPRON AM, 1990, HASTINGS CENT REP, V20, P35, DOI 10.2307/3562537; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; COHENMANSFIELD J, 1991, ARCH INTERN MED, V151, P289, DOI 10.1001/archinte.151.2.289; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Goldman G M, 1989, Law Med Health Care, V17, P298; GRECO PJ, 1991, ANN INTERN MED, V115, P639, DOI 10.7326/0003-4819-115-8-639; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; HIGH DM, 1991, GERONTOLOGIST, V31, P611, DOI 10.1093/geront/31.5.611; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; Portman R M, 1991, J Health Hosp Law, V24, P311; RHODEN NK, 1988, HARVARD LAW REV, V102, P375, DOI 10.2307/1341384; Rouse F, 1991, Law Med Health Care, V19, P83; ROWLAND M, 1990, NY TIMES        1111, V3, P17; Sachs G.A., 1991, J CRIT ILLNESS, V6, P348; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	23	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1992	327	16					1165	1169		10.1056/NEJM199210153271612	http://dx.doi.org/10.1056/NEJM199210153271612			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JT153	1528214				2022-12-01	WOS:A1992JT15300012
J	MIICK, SM; MARTINEZ, GV; FIORI, WR; TODD, AP; MILLHAUSER, GL				MIICK, SM; MARTINEZ, GV; FIORI, WR; TODD, AP; MILLHAUSER, GL			SHORT ALANINE-BASED PEPTIDES MAY FORM 3(10)-HELICES AND NOT ALPHA-HELICES IN AQUEOUS-SOLUTION	NATURE			English	Article							RIBONUCLEASE-A; PROTEINS; RESONANCE; SPECTRA; ANALOG	SHORT alanine peptides, containing 16 or 17 residues, appear to form alpha-helices in aqueous solution1-4. But the main spectroscopic analyses used on helical peptides (circular dichroism5 and nuclear magnetic resonance6-8) cannot distinguish between an alpha-helix (in which the ith residue is hydrogen-bonded to residue i + 4; ref. 9) a nd the next most common peptide helix, the 3(10)-helix10 (i --> i + 3 hydrogen-bonding). To address this problem we have designed single and doubly spin-labelled analogues of alanine-based peptides in which the nitroxide spin label forms an unbranched side chain extending from the sulphur atom of a cysteine residue. Here we report the circular dichroism, Fourier-transform infrared and electron-spin resonance spectra of these peptides under helix-forming conditions. The infrared absorbance gives an amide I' band with a frequency that is substantially different from that observed for alpha-helices. The electron-spin resonance spectra of doubly labelled helices show that the ranking of distances between side chains, around a single turn (residues 4-8), is inconsistent with an alpha-helical structure. Our experiments suggest that the more likely peptide geometry is a 3(10)-helix.	UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064	University of California System; University of California Santa Cruz								BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P2025, DOI 10.1002/bip.360231016; FALLE HR, 1966, MOL PHYS, V11, P49, DOI 10.1080/00268976600100841; GAUTAM B, 1991, BIOPOLYMERS, V31, P1763; KARLE IL, 1990, BIOCHEMISTRY-US, V29, P6747, DOI 10.1021/bi00481a001; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; KRYSTEK SR, 1992, FEBS LETT, V299, P255, DOI 10.1016/0014-5793(92)80127-3; LEMAIRE H, 1968, MOL PHYS, V14, P441, DOI 10.1080/00268976800100551; LUCKHURST GR, 1976, SPIN LABELING THEORY, pCH4; MALCOLM BR, 1983, BIOPOLYMERS, V22, P319, DOI 10.1002/bip.360220140; MANNING MC, 1991, BIOPOLYMERS, V31, P569, DOI 10.1002/bip.360310511; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P7511, DOI 10.1021/bi00484a021; MIICK SM, 1991, BIOCHEMISTRY-US, V30, P9498, DOI 10.1021/bi00103a016; OSTERHOUT JJ, 1989, BIOCHEMISTRY-US, V28, P7059, DOI 10.1021/bi00443a042; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009; TODD AP, 1991, BIOCHEMISTRY-US, V30, P5515, DOI 10.1021/bi00236a026; TONIOLO C, 1991, TRENDS BIOCHEM SCI, V16, P350; Voet D, 1990, BIOCHEMISTRY; WURTHRICH K, 1986, NMR PROTEINS NUCLEIC	25	213	213	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1992	359	6396					653	655		10.1038/359653a0	http://dx.doi.org/10.1038/359653a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JT824	1328890				2022-12-01	WOS:A1992JT82400063
